<SEC-DOCUMENT>0001819790-24-000063.txt : 20240508
<SEC-HEADER>0001819790-24-000063.hdr.sgml : 20240508
<ACCEPTANCE-DATETIME>20240508161242
ACCESSION NUMBER:		0001819790-24-000063
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240508
DATE AS OF CHANGE:		20240508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tarsus Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001819790
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				814717861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39614
		FILM NUMBER:		24926203

	BUSINESS ADDRESS:	
		STREET 1:		15440 LAGUNA CANYON ROAD
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		(949) 409-9820

	MAIL ADDRESS:	
		STREET 1:		15440 LAGUNA CANYON ROAD
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tars-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a12c9650-c665-4945-913e-9e9f011ed114,g:485e89bc-d27f-4026-942d-5c7ac04342fe,d:99aefa27e57f4135a048e6322fd4812b-->
<html xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:tars="http://tarsusrx.com/20240331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>tars-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0001819790</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-28">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-30">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-49" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-311">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-59" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-330">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-104" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="f-460">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="tars-20240331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>tars:segment</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>tars:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="warrant"><xbrli:measure>tars:warrant</xbrli:measure></xbrli:unit><xbrli:unit id="security"><xbrli:measure>tars:security</xbrli:measure></xbrli:unit><xbrli:unit id="contract"><xbrli:measure>tars:contract</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>tars:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:A2023ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-21</xbrli:startDate><xbrli:endDate>2023-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-05</xbrli:startDate><xbrli:endDate>2024-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-05</xbrli:startDate><xbrli:endDate>2024-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:A2023ATMProspectusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-21</xbrli:startDate><xbrli:endDate>2023-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:A2023ATMProspectusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">tars:IntangibleAssetsMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:CustomerEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:FiveCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-14</xbrli:startDate><xbrli:endDate>2024-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:CommonStockInLianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:MilestoneDeterminedByTheCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:GrandpharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:GrandpharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityFirstAmendmentTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-15</xbrli:startDate><xbrli:endDate>2023-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-15</xbrli:startDate><xbrli:endDate>2023-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tars:LineOfCreditSVBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-15</xbrli:startDate><xbrli:endDate>2023-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tars:LineOfCreditSVBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-15</xbrli:startDate><xbrli:endDate>2023-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-30</xbrli:startDate><xbrli:endDate>2024-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-30</xbrli:startDate><xbrli:endDate>2024-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-19</xbrli:startDate><xbrli:endDate>2024-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-19</xbrli:startDate><xbrli:endDate>2024-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-19</xbrli:startDate><xbrli:endDate>2024-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-19</xbrli:startDate><xbrli:endDate>2024-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">tars:BobakAzamianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">tars:BobakAzamianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">tars:JoseTrevejoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">tars:JoseTrevejoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i99aefa27e57f4135a048e6322fd4812b_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:110%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:110%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:110%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:15pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March&#160;31, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">or</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:9pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the transition period from _____</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%;text-decoration:underline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">to ____</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%;text-decoration:underline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#160;</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:  <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39614</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">TARSUS PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:48.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">81-4717861</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:48.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">15440 Laguna Canyon Road, Suite 160</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Irvine</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">92618</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">(949)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">418-1801</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.216%"><tr><td style="width:1.0%"/><td style="width:40.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.161%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">TARS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The Nasdaq Global Market LLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq Global Select Market</ix:nonNumeric>)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> &#9746;  No &#9744;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> &#9746;  No &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric>  No &#9746;</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of May 2, 2024, the number of outstanding shares of the registrant's common stock, par value $0.0001 per share, was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">37,781,693</ix:nonFraction>.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks and uncertainties associated with our business, many of which are beyond our control. Some of the more significant risks associated with our business include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a commercial-stage biopharmaceutical company with a limited operating history and a single product approved for commercial sale. We have incurred significant losses and negative cash flows from operations since our inception and anticipate that we will continue to incur significant expenses and losses for the foreseeable future.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Due to the recently initiated commercialization of XDEMVY and our continued development of our pipeline of product candidates through clinical trials and other indications, our capital requirements are difficult to predict and may change. We may need to obtain substantial additional funding to achieve our goals and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, reduce or eliminate our product development programs, commercialization efforts or other operations.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have only recently obtained regulatory approval for XDEMVY in the U.S. and we have limited experience as a commercial company generating revenue from product sales. If the commercial launch of XDEMVY is unsuccessful or any future approved products are unsuccessful, we may never be profitable.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are heavily dependent on the successful commercialization of XDEMVY and the development, regulatory approval, and commercialization of our current and future product candidates. XDEMVY remains subject to ongoing post-marketing review and extensive regulation.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in educating eye care providers ("ECPs"), and the market about the need for treatments specifically for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis and other diseases or conditions targeted by XDEMVY or our product candidates. XDEMVY or other product candidates that we may develop may fail to achieve market acceptance by ECPs, other healthcare providers and patients, or adequate formulary coverage, pricing or reimbursement by third-party payers and others in the medical community, and the market opportunity for these products may be smaller than we estimate. XDEMVY and any product candidates for which we obtain marketing approval may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The sizes of the market opportunity for XDEMVY for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis and TP-03 for the treatment of Meibomian Gland Disease ("MGD"), as well as our other product or product candidates, have not been established with precision and may be smaller than we estimate, possibly materially. If our estimates of the sizes overestimate these markets, our sales growth may be adversely affected. We may also not be able to grow the markets for our product candidates as intended or at all.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The development and commercialization of our products, including XDEMVY, for the treatment of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis, TP-03 for the potential treatment of MGD, TP-04 for the potential treatment of rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction, is dependent on intellectual property we license from Elanco Tiergesundheit AG ("Elanco"). </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to expand our development, regulatory and operational capabilities, and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We contract with third parties for the commercial manufacture of XDEMVY and for the manufacture of our product candidates for preclinical studies, clinical trials and for eventual commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of XDEMVY or our product candidates or compounds or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our commercialization or development efforts.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical drug development is a lengthy, expensive and risky process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future results. If clinical trials of our product candidates do not meet safety or efficacy endpoints or are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any termination or suspension of, or delays in the commencement or completion of, our planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain sufficient intellectual property protection for XDEMVY or our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent terms may be inadequate to protect our competitive position on our product candidates and preclinical programs for an adequate amount of time.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:94.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_10">Part I - Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_13">Item 1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_67">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_67">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_73">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_73">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_76">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_76">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_79">Part II - Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_79">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_82">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_82">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_85">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_85">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_88">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_88">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_91">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_91">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_94">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_94">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_97">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_97">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_100">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_100">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_103">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i99aefa27e57f4135a048e6322fd4812b_103">104</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i99aefa27e57f4135a048e6322fd4812b_13"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item I. Financial Statements (Unaudited)</span></div><div id="i99aefa27e57f4135a048e6322fd4812b_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO THE FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:93.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.025%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pages</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_19">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_22">Condensed Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_25">Condensed Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_28">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_31">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-6</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and par value amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.885%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-31">193,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-32">224,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">104,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">29,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">16,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-37">4,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-38">3,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">6,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">7,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">340,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">256,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-45">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-46">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-47">3,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-48">3,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-49">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-50">1,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="3" id="f-51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermInvestments" scale="3" id="f-52">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-55">349,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-56">265,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">36,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">23,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">5,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">13,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">42,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">36,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">29,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">29,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-67">74,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-68">68,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-69"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-70"/></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-71"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-72">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-73"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-74">10,000,000</ix:nonFraction></ix:nonFraction> authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-75"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-76"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-78">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-81"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-82">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-84">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-85"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-86">37,749,468</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2024 (unaudited); <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-87"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-88">34,211,190</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-89">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-90">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-91">555,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-92">441,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-93">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-94">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-95">280,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-96">244,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">275,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-98">196,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-99">349,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-100">265,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.885%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-101">24,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees and collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-103">2,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-104">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-105">27,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-106">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-107">1,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="f-108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">12,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">12,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">51,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-112">15,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-113">65,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-114">27,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations before other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-115">37,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-116">24,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-117">3,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-118">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-119">983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-120">684</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-121">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-122">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="f-123">585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="f-124">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity warrants issued by licensee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="f-125">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="f-126">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income, net </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">1,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-129">35,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">23,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) gain on marketable securities and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-131">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-132">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-133">35,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-134">23,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-135"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-136">1.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-137"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-138">0.88</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-139"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-140">35,300,655</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-141"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-142">26,742,023</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-143">34,211,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-144">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-145">441,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-146">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-147">244,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-148">196,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">35,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">35,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of stock-based compensation expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-151">5,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-152">5,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-153">6.7</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-154">3,281,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-155">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-156">98,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-157">98,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of pre-funded warrants, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="tars:ClassOfWarrantOrRightPaymentsOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-158">0.6</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-159">9,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-160">9,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-161">49,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-162">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-163">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon the vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-164">207,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-165">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-166">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-167">37,749,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-168">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">555,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-170">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">280,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">275,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-173">26,727,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-174">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-175">301,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-176">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-177">108,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-178">192,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-179">23,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-180">23,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-181">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-182">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-183">6,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-184">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-185">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon the vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-186">66,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-187">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-188">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-189">26,800,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-190">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">305,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-192">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">132,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">173,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.885%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-195">35,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-196">23,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-197">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-198">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-199">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of term loan-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-201">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-202">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-203">5,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-204">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="tars:OperatingLeaseNoncashExpense" scale="3" id="f-205">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="tars:OperatingLeaseNoncashExpense" scale="3" id="f-206">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="f-207">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="f-208">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization/accretion on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-209">290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-210">1,484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity warrants issued by licensee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="f-211">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="f-212">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain from transactions denominated in a foreign currency</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:fixed-zero" scale="3" id="f-213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-214">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-215">13,264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-216">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-217">929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="f-219">383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-220">3,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-221">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-222">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-223">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-224">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-225">12,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-226">1,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-227">7,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-228">1,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-229">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-230">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-231">37,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-232">21,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-233">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-234">40,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-235">104,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-236">28,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-237">174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-238">340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-239">102,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-240">11,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of paid issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-241">98,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of pre-funded warrants, net of paid issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-243">9,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-245">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-246">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-248">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-249">108,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-250">5,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-251">31,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-252">5,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents &#8212; beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-253">224,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-254">71,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents &#8212; end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-255">193,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-256">65,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Disclosures Noncash Investing and Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset obtained in exchange for operating lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-257">384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-258">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense paid in cash</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-259">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-260">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offering costs included within accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" scale="3" id="f-261">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="f-262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_31"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i99aefa27e57f4135a048e6322fd4812b_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-263" continuedAt="f-263-1" escape="true">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="f-263-1" continuedAt="f-263-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221; or the &#8220;Company&#8221;) is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The Company launched XDEMVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis, in August 2023, after receiving United States ("U.S.") Food and Drug Administration ("FDA") approval in July 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-On Public Offerings</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company completed a follow-on public offering under its shelf registration statement on Form S-3 (the "2021 Shelf Registration Statement") of <ix:nonFraction unitRef="shares" contextRef="c-36" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-264">5,714,285</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-37" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-265">17.50</ix:nonFraction> per share. In September 2023, the underwriters partially exercised the underwriters option to purchase additional shares resulting in the Company's issuance of an additional <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-266">355,164</ix:nonFraction> shares of common stock at the public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-39" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-267">17.50</ix:nonFraction> per share. The aggregate net proceeds received by the Company were $<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-268">99.3</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions, and other offering-related expenses.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company filed a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission ("SEC") on November 21, 2023, (the "2023 Shelf Registration Statement"), which replaced the 2021 Shelf Registration Statement, and permits the Company to offer up to $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="tars:SaleOfStockConsiderationAmountAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-269">300.0</ix:nonFraction>&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company filed an automatic shelf registration on Form S-3 ASR (the "2024 Shelf Registration Statement"). On March 5, 2024 the Company completed an underwritten follow-on public offering under the 2024 Shelf Registration Statement of <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-270">2,812,500</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-271">0.0001</ix:nonFraction> per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-272">312,500</ix:nonFraction> shares of its common stock (the &#8220;March 2024 Public Offering&#8221;). The price to the public was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-43" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-273">32.00</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-43" decimals="INF" name="tars:ClassOfWarrantOrRightSalePrice" scale="0" id="f-274">31.9999</ix:nonFraction> per pre-funded warrant, which was the price to the public of each share of common stock sold in the March 2024 Public Offering, minus the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-43" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-275">0.0001</ix:nonFraction> exercise price per pre-funded warrant. The pre-funded warrants are exercisable, subject to certain beneficial ownership restrictions, at any time after their original issuance and will not expire; as of March&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="tars:ClassOfWarrantOrRightReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-276">312,500</ix:nonFraction> of pre-funded warrants are exercisable. The Company also granted the underwriters a 30-day option to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-277">468,750</ix:nonFraction> additional shares of its common stock at the public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-278">32.00</ix:nonFraction> per share, which the underwriters exercised in full and was completed on March 5, 2024. The aggregate net proceeds received by the Company were $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-279">107.7</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Market Sales Agreement</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the 2023 Shelf Registration Statement, the Company concurrently filed a sales agreement prospectus covering the sale of up to $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="tars:SaleOfStockConsiderationAmountAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-280">100.0</ix:nonFraction>&#160;million of common stock pursuant to an Open Market Sale Agreement (the "2023 ATM Prospectus") with Jefferies LLC ("Jefferies"), which replaced the November 1, 2021 Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the "2021 ATM Prospectus"). Under the terms of the 2023 ATM Prospectus, Jefferies will act as the Company's sales agent and is entitled to compensation for its services equal to <ix:nonFraction unitRef="number" contextRef="c-46" decimals="2" name="tars:SaleOfStockSalesAgentFeePercentageOfGrossProceeds" scale="-2" id="f-281">3</ix:nonFraction>% of the gross proceeds of any shares of common stock sold. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, there were no sales of the Company's common stock pursuant to the 2023 ATM Prospectus. During the year ended December 31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-282">1,000,000</ix:nonFraction> shares of common stock under the 2023 ATM Prospectus for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-283">19.2</ix:nonFraction>&#160;million, after deducting broker commissions and offering-related expenses.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-263-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a limited operating history, limited history of product sales and has accumulated losses and negative cash flows from operations since inception. The Company has funded its inception-to-date operations through its Initial Public Offering ("IPO"), subsequent follow-on public offerings, and the 2023 ATM Prospectus, as well as from proceeds from product sales, the development and license agreement (the "China Out-License") with LianBio Ophthalmology Limited ("LianBio"), and draws on the loan and security agreements with Hercules Capital, Inc. ("Hercules") and Silicon Valley Bank, a division of First-Citizens Bank &amp; Trust Company ("SVB") (the "Credit Facility"). The Company estimates that its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the issuance date of the accompanying Condensed Financial Statements that have been prepared on a going-concern basis. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company plans to fund its operations, capital funding and other liquidity needs using existing cash and investments and, to the extent available, cash generated from commercial operations. Management expects the Company to continue to incur operating losses for the foreseeable future and may be required to raise additional capital to fund its ongoing operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own and/or enter into collaborations and other arrangements to address its liquidity needs, which could materially and adversely affect its business and financial prospects, or even its ability to remain a going concern.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Segment  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-284" escape="true">The Company operates <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-285"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-286">one</ix:nonFraction></ix:nonFraction> reportable operating segment focused on the development and commercialization of therapeutics. To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purpose of evaluating financial performance and the allocation of capital and personnel resources. The Company&#8217;s chief operating decision-maker, its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance.</ix:nonNumeric> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.</span></div></ix:continuation><div id="i99aefa27e57f4135a048e6322fd4812b_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-287" continuedAt="f-287-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-288" continuedAt="f-288-1" escape="true"><ix:continuation id="f-287-1" continuedAt="f-287-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the SEC. Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on February&#160;27, 2024.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of March&#160;31, 2024, the Condensed Statements of Operations and Comprehensive Loss, and the Condensed Statements of Stockholders&#8217; Equity for the three months ended March&#160;31, 2024 and 2023, and the Condensed Statements of Cash Flows for the three months ended March&#160;31, 2024 and 2023 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, </span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-287-2" continuedAt="f-287-3"><ix:continuation id="f-288-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December&#160;31, 2023 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2024 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2024 or any other interim or annual period.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-289" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these Condensed Financial Statements and Notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, expected demand for inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions used in the preparation of the accompanying Condensed Financial Statements under different assumptions and conditions.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Condensed Financial Statements as of and for the three months ended March 31, 2024, reflect the Company&#8217;s estimates of the impact of the macroeconomic and geopolitical environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies and estimates that most significantly impact the presented amounts within these accompanying Condensed Financial Statements are further described below:</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="f-290" continuedAt="f-290-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-290-1">Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-291" continuedAt="f-291-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities and Long-Term Investments</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist primarily of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are recorded at fair value with unrealized gains and losses reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-287-3" continuedAt="f-287-4"><ix:continuation id="f-291-1" continuedAt="f-291-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized gains and losses as well as credit losses, if any, on marketable securities identified on a specific identification basis are included in other income (expense) on the accompanying Condensed Statements of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other-than-temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-291-2">As of March&#160;31, 2024, the Company's holdings of common stock in the parent company of LianBio was included as marketable securities. As of December&#160;31, 2023, this LianBio common stock was classified as long-term investments due to the Company's intent at that time to hold these shares for longer than one year. These equity securities are designated as available-for-sale with associated unrealized gains or losses reported in other income (expense) within the Condensed Statements of Operations and Comprehensive Loss for each reported period.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-292" continuedAt="f-292-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-292-1">Accounts receivable generally consists of amounts due from the Company's customers, which includes pharmaceutical wholesalers and specialty pharmacy providers related to product sales of XDEMVY in the U.S. Payment terms are typically 30-60 days following delivery to customers. Accounts receivable are recorded net of discounts, chargebacks, allowances and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so it can properly assess and respond to changes in their credit profile. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company did not record a reserve for estimated credit losses during the three months ended March 31, 2024.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-293" continuedAt="f-293-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-293-1">Inventory is valued at the lower-of-cost or net realizable value, with cost determined on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and adjusts the value for any excess and obsolete inventory to net realizable value in the period in which the impairment is first identified and such charges are recorded as a component of cost of sales in the Condensed Statements of Operations and Comprehensive Loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Product that may be used in clinical development programs are excluded from inventory and the costs are charged to research and development expense in the Condensed Statements of Operations and Comprehensive Loss as incurred, as long as they do not have an alternative use. Prior to FDA approval of XDEMVY in July 2023, costs related to the production of inventory were recorded as research and development expense on the Condensed Statements of Operations and Comprehensive Loss in the period incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-294" continuedAt="f-294-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-294-1" continuedAt="f-294-2">Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow. </ix:continuation>The carrying value of intangible assets as a result of achieving certain commercial milestones was $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-295">4.0</ix:nonFraction>&#160;million as of March&#160;31, 2024, and are amortized to cost of sales over their useful life of <ix:nonNumeric contextRef="c-48" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-296">10</ix:nonNumeric> years from the date of first commercial sale (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Amortization expense for the three months ended March 31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-297">0.1</ix:nonFraction> million; <ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-298">no</ix:nonFraction> amortization expense was recorded for the three months ended March 31, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-287-4" continuedAt="f-287-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-299" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the expected future amortization expense for the Company's intangible assets is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="f-300">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="f-301">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="f-302">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="f-303">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-304">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="tars:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-305">1,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-306">3,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:continuation id="f-294-2"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including intangibles, are evaluated for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in the Condensed Statements of Operations and Comprehensive Loss. There have been <ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-307"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-308">no</ix:nonFraction></ix:nonFraction> impairments of intangible assets for the three months ended March 31, 2024 and 2023.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-309" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash, cash equivalents, accounts receivable, net, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-310" continuedAt="f-310-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from <span style="-sec-ix-hidden:f-311">three</span> to <ix:nonNumeric contextRef="c-50" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-312">five years</ix:nonNumeric>. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-287-5" continuedAt="f-287-6"><ix:continuation id="f-310-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in circumstances of the business indicate that the asset&#8217;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March&#160;31, 2024 and 2023.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-313" continuedAt="f-313-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Right-of-Use assets (&#8220;ROU assets&#8221;) represent the Company&#8217;s right to control an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the initial non-cancelable lease term, unless there is a renewal option that is reasonably certain to be exercised. The Company uses its incremental borrowing rate at the lease commencement date in determining the discount rate utilized to present value the future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable. The Company has lease agreements with both lease and non-lease components, which are accounted for as a single component for all asset classes. Lease expense for the Company's operating leases are recognized on a straight-line basis over the lease term.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-313-1">The Company's variable lease costs, consisting primarily of real estate taxes, insurance costs, and common area maintenance, are expensed as incurred and excluded from the reported ROU assets and lease liabilities amounts presented in the accompanying Condensed Balance Sheets. The current and noncurrent portion of the operating lease liability are included in accounts payable and other accrued liabilities and other long-term liabilities, respectively, in the accompanying Condensed Balance Sheets. Rent expense is allocated to research and development and general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-314" continuedAt="f-314-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration Risk </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company maintains cash held on deposit at financial institutions in the U.S., including SVB. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. The Company invests its excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. <ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-315" continuedAt="f-315-1" escape="true">The following table summarizes the percentage of the Company's product sales from its largest customers:</ix:nonNumeric></span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-287-6" continuedAt="f-287-7"><ix:continuation id="f-314-1"><ix:continuation id="f-315-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.983%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-51" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-316">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-52" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-317">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-53" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-318">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-54" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-319">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-55" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-320">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, amounts due from these five customers each exceeded 10% of gross accounts receivable and accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-56" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-321">100</ix:nonFraction>% of the accounts receivable balance on a combined basis.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Major Suppliers</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not currently own manufacturing facilities and depends on an outsourced manufacturing strategy for the production of XDEMVY for commercial use and for the production of its other product candidates for clinical trials. The Company enters into agreements with third-party manufacturers that are approved for the commercial production of XDEMVY and third-party suppliers that are approved for XDEMVY's active pharmaceutical ingredient. Although there are potential sources of supply other than the Company's existing manufacturers and suppliers, any new supplier would be required to qualify under applicable regulatory requirements. The loss of certain manufacturers and third-party suppliers could result in a temporary disruption of the Company&#8217;s commercialization efforts.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-322" continuedAt="f-322-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Product Sales, Net</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes product sales, net of XDEMVY when a customer obtains control of promised goods or services, which occurs at a point in time, typically upon delivery of the Company's product to the customer. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as each performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells XDEMVY to customers in the U.S., which became available for commercial sale during the third quarter of 2023. The Company sells XDEMVY to a limited number of specialty pharmacies and distributors (i.e., its customers) who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. Revenue from product sales is primarily recognized upon physical delivery of the product (when the customer obtains control of the product), in return for agreed-upon consideration. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or the transaction price, which may include fixed or variable consideration for (i) invoice discounts for prompt payment and distribution service fees, (ii) government and private payer rebates, chargebacks, discounts and fees, (iii) product returns and (iv) costs of co-pay assistance programs for patients, as well as other incentives. Estimates of variable consideration are calculated based on the actual product sales each reporting period and the nature of the variable consideration related to those sales. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates reflect the Company&#8217;s best estimate of the amount of consideration to which the Company expects to be entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ materially from </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-322-1" continuedAt="f-322-2"><ix:continuation id="f-287-7" continuedAt="f-287-8"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect product sales, net and earnings in the period such variances are adjusted. The Company categorizes product sales deduction estimates as follows:</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Service Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Pay Discounts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's customers are contractually permitted to return the product within the contractual allowable time before and after the applicable expiration date. In the initial sales period, the Company estimates its provision for returns based on industry data and adjusts the transaction price at the time of the product sale to the customer. Once sufficient history has been collected for product returns, the Company will utilize that history to inform its returns estimate. Once the product is returned, it is destroyed since it cannot be resold.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A chargeback is the difference between the Company's invoice price to the wholesaler and the wholesaler&#8217;s customer's contract price. The wholesaler tracks these sales and charges back the Company for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price and accounts receivable at the time of sale of the product to the customer.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company&#8217;s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer.</span></div><div style="margin-top:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ii) License Fees and Collaboration Revenue</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">China Out-License </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss has historically primarily related to the China Out-License that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-322-2" continuedAt="f-322-3"><ix:continuation id="f-287-8" continuedAt="f-287-9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kong, Macau, and Taiwan (the "China Territory")&#8212; see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract; (b) the contract&#8217;s transaction price for allocation (including variable consideration); (c) the stand-alone selling price for each identified performance obligation; and (d) the timing and amount of revenue recognition in each period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment; (ii) equity-based consideration; (iii) sales-based royalties; (iv) sales-based threshold milestones; (v) one-time payment for executing a drug supply agreement; (vi) development milestone payments; (vii) regulatory milestone payments; and (viii) a one-time termination payment to transition the rights to develop and commercialize TP-03 in China for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis to Xi An Grand Chang An Pharmaceutical Co., Ltd  ("GrandPharma"). Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#8217;s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-287-9" continuedAt="f-287-10"><ix:continuation id="f-322-3" continuedAt="f-322-4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Threshold Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other License Fees and Collaboration Revenue</span></div></ix:continuation><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-322-4">License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-323"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-324">no</ix:nonFraction></ix:nonFraction> revenue recognized under this arrangement for the three months ended March 31, 2024 and 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-325" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, freight, third-party royalties payable on the Company&#8217;s product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon FDA approval of XDEMVY in July 2023. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses in the Condensed Statements of Operations and Comprehensive Loss. Therefore, cost of sales of XDEMVY will reflect a lower average per unit cost until the related inventory is sold.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-326" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative costs consist of salaries, benefits, stock-based compensation and other personnel-related costs for the Company's executive, finance, sales and marketing, and other administrative functions. Selling, general and administrative expenses also include sales and marketing costs to support our commercial launch, consulting fees, legal services, rent and other facilities costs, patient assistance donations, and other general operating expenses not otherwise classified as research and development expenses. Advertising costs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-327" continuedAt="f-327-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including the costs of salaries, payroll taxes, employee benefit and other employee-related costs (including stock-based compensation expense), license fees, materials, supplies and the cost of services provided by outside contractors to conduct nonclinical studies, clinical trials and contract manufacturing activities. All costs associated with research and development are expensed as incurred. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-287-10" continuedAt="f-287-11"><ix:continuation id="f-327-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company's license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense in the Condensed Statements of Operations and Comprehensive Loss when paid or become payable, provided there is no alternative future use of rights in other research and development projects.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-328" continuedAt="f-328-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-329">100</ix:nonFraction>% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company&#8217;s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's common stock on the date preceding the award grant date.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock awards granted typically have <span style="-sec-ix-hidden:f-330">one</span> to <ix:nonNumeric contextRef="c-60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-331">four-year</ix:nonNumeric> service conditions and a contractual term of <ix:nonNumeric contextRef="c-61" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-332">10</ix:nonNumeric> years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including (a) the fair value of the Company&#8217;s common stock on the date of the option grant for all awards granted prior to the IPO, (b) the expected term of the stock option until its exercise by the recipient, (c) stock price volatility over the expected term, (d) the prevailing risk-free interest rate over the expected term, and (e) expected dividend payments over the expected term.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within cost of sales, research and development expense or selling, general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including:</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-287-11" continuedAt="f-287-12"><ix:continuation id="f-328-1"><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s expected term represents the period that the Company&#8217;s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s expected dividend yield is <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-333">zero</ix:nonFraction> because it has never paid cash dividends and does not expect to for the foreseeable future.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-334" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain due to the Company&#8217;s historical operating performance and recorded cumulative net losses in prior fiscal periods. A valuation allowance is recorded to reduce deferred tax assets, because based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when the Company were to determine that deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase the net income in the period that such determination was made.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-335" continuedAt="f-335-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-287-12"><ix:continuation id="f-335-1"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to net losses in all periods presented, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals diluted net loss per share.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-336" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-337" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued or Effective Accounting Standards</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Outside of the pronouncement below, other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2023-09"). ASU 2023-09 requires annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold and a disaggregation of income taxes paid, net of refunds. The standard also eliminates certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities and is effective for the Company beginning with the 2025 Annual Report on Form 10-K. Early adoption is permitted. ASU 2023-09 should be applied prospectively. Retrospective adoption is permitted. The Company is currently assessing the impact this standard will have on the Company's financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i99aefa27e57f4135a048e6322fd4812b_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-338" continuedAt="f-338-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="f-339" continuedAt="f-339-1" escape="true"><ix:continuation id="f-338-1" continuedAt="f-338-2"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-340">186,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-343">186,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-344">31,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-347">31,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-349">30,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-351">30,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-353">25,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-355">25,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-357">23,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-359">23,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="f-360">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="f-363">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-364">218,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-365">79,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-367">298,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">This balance includes cash requirements settled on a nightly basis.</span></div></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-338-2" continuedAt="f-338-3"><ix:continuation id="f-339-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-368">224,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-371">224,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-373">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-375">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="f-376">631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="f-379">631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="f-382">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="f-383">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-384">225,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-385">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-386">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-387">228,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">This balance includes cash requirements settled on a nightly basis.</span></div></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds and U.S. Treasury Securities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded with readily-available market prices that are publicly observable and independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper, Corporate Debt Securities and Government-related Debt Securities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper, corporate debt securities and government-related debt securities were valued using Level 2 inputs that utilized industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The Company reviews trading activity and pricing for these investments as of each measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LianBio Common Stock and Equity Warrants</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, contemporaneous with the China Out-License transaction, the Company and LianBio, executed a warrant agreement for the Company to purchase, in <ix:nonFraction unitRef="tranche" contextRef="c-96" decimals="INF" name="tars:WarrantAgreementNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-388">three</ix:nonFraction> tranches, common shares in LianBio at an exercise price equal to common stock par value, which converted into warrants of the parent company of LianBio (a pharmaceutical company focused on the Greater China and other Asian markets; Nasdaq: LIAN; any references to common stock or warrants of LianBio shall refer to common stock or warrants of the publicly-traded parent of LianBio) in connection with LianBio's previous Initial Public Offering. The first <ix:nonFraction unitRef="warrant" contextRef="c-26" decimals="INF" name="tars:NumberOfVestedWarrants" format="ixt-sec:numwordsen" scale="0" id="f-389">two</ix:nonFraction> tranches were vested exercised, and converted into <ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="tars:EquitySecuritiesFVNINumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-390">156,746</ix:nonFraction> shares of LianBio common stock as of December 31, 2022 and are recognized at fair value within long-term investments in the Condensed Balance Sheets as of March&#160;31, 2024 and December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2024, LianBio announced its plan to wind down its operations. On March 14, 2024, LianBio's Board of Directors made a special cash dividend payment to the Company for $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-391">0.7</ix:nonFraction>&#160;million (equivalent to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-97" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-392">4.80</ix:nonFraction> per share), which was recorded to other income (expense) in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024, and cash and cash equivalents in the Condensed Balance Sheets as of March&#160;31, 2024. LianBio was delisted from NASDAQ in March 2024 and now trades on the over-the-counter markets. As of March&#160;31, 2024 and December 31, 2023, LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2024, the Company executed an agreement with LianBio to terminate the unvested third warrant tranche (the "Warrant Termination Agreement") for a cancellation payment of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="tars:ProceedsFromCancellationOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-393">0.4</ix:nonFraction>&#160;million (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Upon execution of the Warrant Termination Agreement the Company recorded the final change in fair value of the equity warrant to other income (expense) in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024, and removed the equity warrant from other assets in the Condensed Balance Sheet as of March&#160;31, 2024. The third tranche of the equity warrant was classified as Level 3 in the fair value hierarchy and presented within other assets in the accompanying Condensed Balance Sheets as of December&#160;31, 2023. The most significant assumptions used in the option pricing valuation model as of each balance sheet date to determine its fair value included observable and unobservable inputs: LianBio common stock volatility (based on the historical volatility of similar companies); the probability of regulatory milestone achievement for vesting; and the application of an assumed discount rate.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-338-3" continuedAt="f-338-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-394" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the equity warrants were remeasured each reporting period with adjustments reported within other income (expense) on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised, expired or terminated. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:83.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="f-395">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants prior to termination</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="f-396">201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination of equity warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="3" id="f-397">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="f-398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="f-399">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="f-400">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="f-401">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="f-402" continuedAt="f-402-1" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and available-for-sale investments by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-403">186,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-404">186,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-405">3,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-406">3,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-407">3,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-409">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-410">3,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-411">193,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-413">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-414">193,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-415">28,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-417">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-418">28,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-419">27,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-421">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-422">27,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-423">25,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-425">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-426">25,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-427">23,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-428">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-429">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-430">23,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-431">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-433">1,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-434">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-435">105,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-436">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-437">1,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-438">104,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-439">224,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-440">224,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-441">224,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-442">224,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-443">2,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-445">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-446">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-447">2,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-449">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-450">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="3" id="f-451">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="3" id="f-453">477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="f-454">631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="3" id="f-455">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="3" id="f-457">477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="f-458">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-338-4"><ix:continuation id="f-402-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1 ) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, substantially all available-for-sale debt securities had a maturity of 12 months or less. <ix:nonFraction unitRef="security" contextRef="c-3" decimals="INF" name="tars:DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" format="ixt-sec:numwordsen" scale="0" id="f-459">Four</ix:nonFraction> securities have a contractual maturity between <span style="-sec-ix-hidden:f-460">one</span> and <ix:nonNumeric contextRef="c-105" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="f-461">two years</ix:nonNumeric>, with an estimated fair market value of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-462">20.6</ix:nonFraction>&#160;million and amortized cost of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-463">20.6</ix:nonFraction>&#160;million. As of December&#160;31, 2023, all available-for-sale debt securities had a maturity of 12 months or less. As of March&#160;31, 2024 and December&#160;31, 2023, the Company had <ix:nonFraction unitRef="contract" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt-sec:numwordsen" scale="0" id="f-464">twenty-six</ix:nonFraction> available-for-sale debt securities and <ix:nonFraction unitRef="contract" contextRef="c-4" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt-sec:numwordsen" scale="0" id="f-465">one</ix:nonFraction> available-for-sale debt security, respectively, in a continuous gross unrealized loss position for less than one year. As of March&#160;31, 2024 and December&#160;31, 2023, unrealized credit losses on these securities were not material. Further, the Company does not intend to sell these investments prior to maturity and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis. Accordingly, the Company did not recognize any other-than-temporary impairment losses.</span></div></ix:continuation><div id="i99aefa27e57f4135a048e6322fd4812b_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-466" continuedAt="f-466-1" escape="true">BALANCE SHEET ACCOUNT DETAIL</ix:nonNumeric></span></div><ix:continuation id="f-466-1"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-467" escape="true"><div style="margin-top:12pt;padding-left:72pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-468">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-469">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="f-470">677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="f-471">392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="f-472">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="f-473">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-474">4,036</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-475">3,107</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-476" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-477">1,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-478">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-479">681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-480">660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-481">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-482">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-483">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-484">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-485">2,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-486">2,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-487">1,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-488">1,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-489">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-490">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March 31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-491">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-492">0.1</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Other Accrued Liabilities&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-493" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other accrued liabilities consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:68.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="3" id="f-494">19,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="3" id="f-495">18,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product sales deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" format="ixt:num-dot-decimal" scale="3" id="f-496">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" format="ixt:num-dot-decimal" scale="3" id="f-497">4,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="tars:AccruedClinicalStudiesCurrent" scale="3" id="f-498">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="tars:AccruedClinicalStudiesCurrent" scale="3" id="f-499">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-500">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-501">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-502">36,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-503">23,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_49"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-504" continuedAt="f-504-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-504-1" continuedAt="f-504-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Outstanding and Reserves for Future Issuance</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-505"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-506">37,749,468</ix:nonFraction></ix:nonFraction> shares of common stock issued and outstanding, which excludes <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="tars:ClassOfWarrantOrRightReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-507">312,500</ix:nonFraction> of pre-funded warrants that remain exercisable at period end and are reserved for future issuance. As of December&#160;31, 2023 the Company had <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-508"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-509">34,211,190</ix:nonFraction></ix:nonFraction> shares of common stock issued and outstanding, respectively. Each share of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="c-3" decimals="INF" name="tars:CommonStockNumberOfVotes" format="ixt-sec:numwordsen" scale="0" id="f-510">one</ix:nonFraction> vote.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-511" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="f-512">7,435,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="f-513">7,054,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="f-514">2,859,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="f-515">2,859,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-516">5,217,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-517">4,760,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="f-518">1,981,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="f-519">1,708,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-520">17,494,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-521">16,382,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-522" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.885%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-523">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-525">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-526">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-527">3,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-528">2,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-529">5,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-530">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-531" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-532">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-533">6.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-534">4.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-535">4.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-536">71.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-537">71.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per stock option</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-540">35.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-541">15.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-542" continuedAt="f-542-1" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity during the three months ended March 31, 2024 was as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-504-2"><ix:continuation id="f-542-1"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-543">4,760,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-544">16.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-103" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-545">7.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-546">34,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-547">633,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-548">35.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-549">49,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-550">16.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-551">127,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-552">18.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:fixed-zero" scale="0" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-555">5,217,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-556">18.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-557">7.46</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-558">96,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable&#8212; March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-559">2,972,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-560">15.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-561">6.41</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-562">65,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested&#8212;March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-563">2,245,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-564">23.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-565">8.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-566">30,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of March&#160;31, 2024.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-567">33.0</ix:nonFraction>&#160;million of unrecognized compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average period of <ix:nonNumeric contextRef="c-121" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-568">2.6</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-569" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity during the three months ended March 31, 2024 was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-570">1,708,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-571">16.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-572">596,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-573">36.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-123" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-574">207,718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-575">16.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-123" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-576">116,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-577">17.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-578">1,981,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-579">22.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-580">41.0</ix:nonFraction>&#160;million of unrecognized compensation expense related to unvested restricted stock units, which the Company expects to recognize over a weighted average period of <ix:nonNumeric contextRef="c-123" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-581">3.5</ix:nonNumeric> years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan ("ESPP")</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to the ESPP was $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-582">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-583">0.1</ix:nonFraction> million, respectively, for the three months ended March 31, 2024 and 2023.</span></div></ix:continuation><div id="i99aefa27e57f4135a048e6322fd4812b_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-584" continuedAt="f-584-1" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-585" escape="true"><ix:continuation id="f-584-1" continuedAt="f-584-2"><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-586">35,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-587">23,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding&#8212;basic and diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-588"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-589">35,300,655</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-590"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-591">26,742,023</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share&#8212;basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-592"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-593">1.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-594"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-595">0.88</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Weighted-average shares outstanding includes pre-funded warrants issued on March 5, 2024.</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-596" escape="true"><ix:continuation id="f-584-2"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised&#8212;vested and unvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-597">5,217,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-598">4,596,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units&#8212;unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-599">1,981,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-600">1,128,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-601">7,199,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-602">5,724,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i99aefa27e57f4135a048e6322fd4812b_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-603" continuedAt="f-603-1" escape="true">COMMITMENTS&#160;&amp; CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-603-1" continuedAt="f-603-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the ordinary course of business, the Company enters into lease agreements with unaffiliated third parties for its facilities and office equipment. On March 20, 2024, the Company executed an amendment for an additional office suite. This amendment was accounted for as a lease modification and resulted in the recognition of an operating lease right-of-use asset valued at $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-604">0.4</ix:nonFraction>&#160;million as of the execution date. As of March&#160;31, 2024, the Company had <ix:nonFraction unitRef="contract" contextRef="c-3" decimals="INF" name="tars:LesseeOperatingLeaseNumberOfLeaseContracts" format="ixt-sec:numwordsen" scale="0" id="f-605">six</ix:nonFraction> active leases for adjacent office and laboratory suites in Irvine, California with a lease term through January 2027. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-606" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The below table summarizes the components of total lease expense:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-607">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-608">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-609">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-610">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-611">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-612">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company's facility leases had a remaining lease term of <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-613">2.8</ix:nonNumeric> years and a weighted-average incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="c-3" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-614">10</ix:nonFraction>%. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-615" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-616">660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-617">961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-618">994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-619">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="f-620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-621">2,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-622">343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="tars:LesseeOperatingLeaseLiabilityTenantImprovementAllowance" scale="3" id="f-623">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-624">2,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-625">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-626">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-627">2,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-603-2" continuedAt="f-603-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-License Agreements for Lotilaner</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elanco In-License Agreement for Skin and Eye Disease or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company executed a license agreement with Elanco Tiergesundheit AG (&#8220;Elanco&#8221;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, a clinical milestone was triggered to Elanco under the Eye and Derm Elanco Agreement upon enrollment of the first patient in the Phase 2a Galatea trial, evaluating the potential treatment of rosacea. The related milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-628">1.0</ix:nonFraction>&#160;million was included in research and development expense in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made cash payments to Elanco under the Eye and Derm Elanco Agreement comprised of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="tars:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-629">1.0</ix:nonFraction>&#160;million upfront upon contract execution in January 2019 and a total of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-630">4.0</ix:nonFraction>&#160;million for three specified clinical milestone achievements in September 2020, April 2021, and March 2023, which were all recorded in research and development expense in the Condensed Statements of Operations and Comprehensive Loss. During 2023, a milestone of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-631">4.0</ix:nonFraction>&#160;million was achieved and paid to Elanco upon the first commercial sale of XDEMVY in the U.S., which was recorded as an intangible asset in the Balance Sheet as of December 31, 2023. The Company is amortizing the intangible asset to cost of sales over its useful life of <ix:nonNumeric contextRef="c-48" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-632">10</ix:nonNumeric> years from the date of the first commercial sale.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make further cash payments to Elanco of $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="tars:CollaborativeArrangementFutureCashPayments" format="ixt:num-dot-decimal" scale="6" id="f-633">2.0</ix:nonFraction> million under the Eye and Derm Elanco Agreement upon achievement of the last clinical milestone in the treatment of human skin diseases using lotilaner and a maximum of $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-634">75.0</ix:nonFraction> million for various commercial and sales threshold milestones for the treatment of human skin diseases and the treatment of blepharitis in humans using lotilaner. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company received certain types of payments from its sublicensees, it was obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license, which occurred in July 2023 with FDA approval of XDEMVY. As a result of the commercialization of XDEMVY, the Company began accruing royalties payable to Elanco during the third quarter of 2023, which are recorded to cost of sales in the accompanying Condensed Statement of Operations and Comprehensive Loss for the three months ended March 31, 2024, and accounts payable and other accrued liabilities in the accompanying Condensed Balance Sheets as of March&#160;31, 2024. Royalty expense during the three months ended March 31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="f-635">1.2</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elanco In-License Agreement for All Other Diseases or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company executed a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement"). In September 2020, the Company issued Elanco <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-636">222,460</ix:nonFraction> shares of its common stock with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="f-637">3.1</ix:nonFraction> million ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-638">14.0003</ix:nonFraction> per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash payments under the All Human Uses Elanco Agreement of $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-639">0.5</ix:nonFraction> million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the potential treatment of Lyme disease. The Company is required to make further cash payments under this agreement upon the achievement of various clinical milestones up to an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-640">4.0</ix:nonFraction> million and various commercial and sales threshold milestones for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-641">77.0</ix:nonFraction> million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its product sales, net. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-603-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements, including severance and change in control agreements, with <ix:nonFraction unitRef="contract" contextRef="c-3" decimals="INF" name="tars:NumberOfEmploymentArrangementsWithExecutiveOfficers" format="ixt-sec:numwordsen" scale="0" id="f-642">six</ix:nonFraction> of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnities and Guarantees</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities varies, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.</span></div></ix:continuation><div id="i99aefa27e57f4135a048e6322fd4812b_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-643" continuedAt="f-643-1" escape="true">OUT-LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="f-643-1" continuedAt="f-643-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License of TP-03 Commercial Rights in the China Territory in March 2021</span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into the China Out-License agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the China Territory for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis and Meibomian Gland Disease. LianBio was contractually responsible for all clinical development and commercialization activities and costs within the China Territory.</span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed this arrangement and identified the following material promises under the arrangement: (i) the exclusive license to research, develop, manufacture, commercialize, make, offer for sale, sell, and import TP-03 in the China Territory; and (ii) the research and development services in the form of clinical study materials for the respective Phase 2b/3 trial ("Saturn-1") and Phase 3 ("Saturn-2") TP-03 trials. The promises to provide research and development services for Saturn-1 and Saturn-2 clinical trials were evaluated and determined to be distinct promises in the contract and each of the two clinical trials are separate performance obligations apart from the promise to provide the license.</span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assessment of the initial transaction price for the China Out-License agreement included an analysis of amounts the Company expected to receive, which at contract inception consisted of: (i) the upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-644">15.0</ix:nonFraction>&#160;million; (ii) a second cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="tars:RevenueRemainingPerformanceObligationAdditionalCashPayment" format="ixt:num-dot-decimal" scale="6" id="f-645">10.0</ix:nonFraction>&#160;million; (iii) a $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-646">10.0</ix:nonFraction>&#160;million milestone that was determined to be within the control of the Company; and (iv) $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="f-647">1.2</ix:nonFraction>&#160;million representing the initial fair value of the equity warrant. </span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for each performance obligation as follows: </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License</span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that this license was distinct based on an evaluation of the delivery of the functional license that was in the later stages of development, and it met the criteria for being distinct from the research and development services required under the China Out-License agreement. The Company determined the standalone selling price of this license using a discounted projected sales model and recognized as license fees and collaboration revenue the total allocated transaction price at contract inception, upon delivery of the license.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-643-2" continuedAt="f-643-3"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Services </span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standalone selling price of these performance obligations was determined using the adjusted market assessment approach. The Company analyzed costs expected to be incurred for each of the clinical trials through completion to estimate the price that a customer would be willing to pay for these services in order to benefit from the clinical trials. The Company determined that LianBio simultaneously benefited from the research and development services that are satisfied over time, as they were able to request and access the clinical trial data at any point through the trial completion. Therefore, the Company recognized the amounts allocated to the respective research and development performance obligations for Saturn-1 and Saturn-2 within license fees and collaboration revenue as the research and development services were provided using an input method, based on the costs incurred for each clinical trial and the total costs expected to be incurred to satisfy each performance obligation. The Company believes this method most faithfully depicted its performance in transferring the promised services during the expected period of time that each clinical trial was ongoing. The Company monitored the expected completion dates for each clinical trial and updated its estimated time to completion at each reporting period, as necessary.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2023, a specified milestone event was triggered based upon the signing of an agreement for which the Company has no ongoing obligations, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-648">2.5</ix:nonFraction>&#160;million recognized as license fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023.  </span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2024, LianBio announced its plan to wind down its operations and on March 14, 2024 made a special cash dividend payment to the Company for $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-649">0.7</ix:nonFraction>&#160;million (equivalent to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-97" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-650">4.80</ix:nonFraction> per share - see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). On March 26, 2024, the Company executed an agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. ("GrandPharma"), a subsidiary of Grand Pharmaceutical Group Limited, and LianBio to transition the rights to develop and commercialize TP-03 in China for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis from LianBio to GrandPharma (the "Novation Agreement"). Upon execution of the Novation Agreement, the China Out-License agreement with LianBio was assigned to GrandPharma and a one-time payment of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-651">2.5</ix:nonFraction>&#160;million (the "Termination Payment) was triggered and due to the Company from LianBio within <ix:nonNumeric contextRef="c-98" name="tars:TerminationPaymentPeriodDue" format="ixt-sec:durwordsen" id="f-652">fifteen days</ix:nonNumeric>. This Termination Payment was recorded to license fees and collaboration revenue in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and to other receivables in the Condensed Balance Sheets as of March&#160;31, 2024, as the $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-653">2.5</ix:nonFraction>&#160;million cash payment was not yet received by the Company until April 5, 2024. The Novation Agreement amended the $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-654">15.0</ix:nonFraction>&#160;million future development milestone payable on China regulatory approval of the China Out-License agreement with a combined condition of patent issuance related to TP-03 in China.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the execution of the Novation Agreement, the Company entered into an agreement with LianBio to terminate the unvested third tranche of the equity warrants related to the purchase of <ix:nonFraction unitRef="shares" contextRef="c-147" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-655">78,373</ix:nonFraction> shares of LianBio common stock for a total cancellation payment of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="tars:ProceedsFromCancellationOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-656">0.4</ix:nonFraction>&#160;million (the "Warrant Cancellation Payment"). This Warrant Cancellation Payment was recorded to license fees and collaboration revenue in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and other receivables in the Condensed Balance Sheets as of March&#160;31, 2024.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March&#160;31, 2024, the Company received aggregate payments from LianBio totaling $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-657">83.2</ix:nonFraction>&#160;million, comprised of (i) initial consideration of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="tars:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-658">15.0</ix:nonFraction>&#160;million, (ii) $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-659">67.5</ix:nonFraction>&#160;million for the achievement of specified milestones, and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-660">0.7</ix:nonFraction>&#160;million related to a special cash dividend.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-643-3">As of March&#160;31, 2024 the Company is eligible to receive further consideration from GrandPharma upon the achievement of additional TP-03 events, including: (i) additional regulatory and/or patent milestones of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-661">20.0</ix:nonFraction>&#160;million; (ii) China-based TP-03 sales threshold milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-662">100.0</ix:nonFraction>&#160;million; and (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales.</ix:continuation> </span></div><div id="i99aefa27e57f4135a048e6322fd4812b_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-663" continuedAt="f-663-1" escape="true">CREDIT FACILITY AGREEMENT</ix:nonNumeric></span></div><ix:continuation id="f-663-1" continuedAt="f-663-2"><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company executed the Credit Facility with Hercules and SVB that expires on February 2, 2027. As security for the obligations under the agreement, the Company granted a continuing security interest in substantially all of the Company's assets, excluding intellectual property on which there is a negative pledge. Concurrent with the execution of the Credit Facility, the Company made a $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-664">20.0</ix:nonFraction>&#160;million draw.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-663-2" continuedAt="f-663-3"><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2023, the Company entered into an amendment to the loan and security agreement (the "First Amendment"). The First Amendment set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions, including an extended period for the Company to drawdown the $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-665">25.0</ix:nonFraction>&#160;million tranche associated with the New Drug Application ("NDA") submission from March 15, 2023 to March 15, 2024, provided at least $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="tars:LineOfCreditFacilityDrawDownIncrements" format="ixt:num-dot-decimal" scale="6" id="f-666">5.0</ix:nonFraction>&#160;million was drawn on or before March 15, 2023 and at least an additional $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="tars:LineOfCreditFacilityDrawDownIncrements" format="ixt:num-dot-decimal" scale="6" id="f-667">5.0</ix:nonFraction>&#160;million was drawn on or before September 15, 2023. The Company did not incur any lender fees as part of this First Amendment. </span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2023, the Company entered into a second amendment to the loan and security agreement (the "Second Amendment"). The Second Amendment updated the terms of the amount and proportion of the Company&#8217;s cash required to be maintained at SVB or affiliates of SVB. The Company did not incur any lender fees as part of this Second Amendment.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2023 and September 15, 2023, respectively, the Company made separate draws of $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-668"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-669">5.0</ix:nonFraction></ix:nonFraction>&#160;million (including SVB's commitment of $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-4" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-670"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-4" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-671">1.25</ix:nonFraction></ix:nonFraction>&#160;million) from the $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-672">25.0</ix:nonFraction>&#160;million tranche that became available upon submission of the NDA. On March 15, 2024, the $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-673">15.0</ix:nonFraction>&#160;million tranche related to the Company's NDA submission with the FDA for TP-03 in September 2022 and the $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-674">35.0</ix:nonFraction>&#160;million tranche related to the FDA approval of XDEMVY in July 2023 both expired and were no longer available to be drawn as of period end. As of March&#160;31, 2024, the Credit Facility provides for a remaining aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-675">75.0</ix:nonFraction>&#160;million with tranched availability as follows: $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-676">50.0</ix:nonFraction>&#160;million available upon achievement of product sales, net thresholds; and $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-677">25.0</ix:nonFraction>&#160;million available upon lender approval.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these tranches may be drawn down in $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="tars:LineOfCreditFacilityDrawDownIncrements" format="ixt:num-dot-decimal" scale="6" id="f-678">5.0</ix:nonFraction>&#160;million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Amendment, the outstanding principal draws accrue interest at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus <ix:nonFraction unitRef="number" contextRef="c-167" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-679">4.45</ix:nonFraction>% with an aggregate cap of <ix:nonFraction unitRef="number" contextRef="c-168" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-680">11.45</ix:nonFraction>%, or (ii) <ix:nonFraction unitRef="number" contextRef="c-166" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-681">8.45</ix:nonFraction>%. At the execution date of the Credit Facility, the WSJ prime rate was <ix:nonFraction unitRef="number" contextRef="c-154" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="f-682">3.25</ix:nonFraction>% and increased to <ix:nonFraction unitRef="number" contextRef="c-169" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="f-683">8.50</ix:nonFraction>% as of March&#160;31, 2024.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay a specified fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="6" id="f-684">1.4</ix:nonFraction> million was derived by multiplying <ix:nonFraction unitRef="number" contextRef="c-166" decimals="4" name="tars:LineOfCreditFacilityPeriodicPaymentInterestRate" scale="-2" id="f-685">4.75</ix:nonFraction>% by the $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-686">30.0</ix:nonFraction>&#160;million outstanding principal balance as of March&#160;31, 2024 and is accreted to interest expense through maturity.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and 2023, the effective interest rate for the full term of the Credit Facility was <ix:nonFraction unitRef="number" contextRef="c-163" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-687">11.96</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-170" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-688">12.12</ix:nonFraction>%, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="f-689" continuedAt="f-689-1" escape="true">The Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:</ix:nonNumeric></span></div><ix:continuation id="f-689-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="f-690">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="f-691">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-692">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-693">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-694">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-695">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="f-696">983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="f-697">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Credit Facility consists of principal outstanding less legal and administrative issuance costs that were recorded as a debt discount to the term loan, net and will continue to be accreted to interest expense using the effective interest method during its term. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-698" continuedAt="f-698-1" escape="true">The principal balance of this Credit Facility and related accretion and amortization are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-698-1"><ix:continuation id="f-663-3"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-699">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-700">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="3" id="f-701">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="3" id="f-702">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="f-703">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="f-704">438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedAmortizationDeferredFinanceCosts" scale="3" id="f-705">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedAmortizationDeferredFinanceCosts" scale="3" id="f-706">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-707">29,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-708">29,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i99aefa27e57f4135a048e6322fd4812b_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-709" continuedAt="f-709-1" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="f-709-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consulting Agreements</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a preexisting consulting agreement with a board member who was appointed in December 2021. During the year ended December 31, 2023, this consulting agreement provided for annual cash compensation of approximately $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="tars:RelatedPartyTransactionAnnualCashCompensation" format="ixt:num-dot-decimal" scale="6" id="f-710">0.2</ix:nonFraction>&#160;million and option grants to purchase <ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-711">45,134</ix:nonFraction> shares of the Company&#8217;s common stock, with exercise prices ranging from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-173" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-712">2.01</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-174" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-713">34.72</ix:nonFraction> per share.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2024, this consulting agreement with the board member was amended to provide for annual cash compensation of approximately $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="tars:RelatedPartyTransactionAnnualCashCompensation" format="ixt:num-dot-decimal" scale="6" id="f-714">0.4</ix:nonFraction>&#160;million and an additional option grant to purchase <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-715">10,000</ix:nonFraction> shares of the Company&#8217;s common stock, with exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-716">27.49</ix:nonFraction> per share. This amended consulting agreement may be terminated by either party with <ix:nonNumeric contextRef="c-176" name="tars:RelatedPartTransactionTerminationNoticePeriod" format="ixt-sec:durwordsen" id="f-717">ten days</ix:nonNumeric>' notice and contains standard confidentiality, indemnification, and intellectual property assignment provisions in favor of the Company.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-718">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-719">0.1</ix:nonFraction>&#160;million, respectively, of selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss related to this amended consulting agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sponsorship Activities </span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, a board member of the Company was appointed president of the American Society of Cataract and Refractive Surgery ("ASCRS"), a society dedicated to meeting the needs of anterior segment ophthalmic surgeons.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-720">0.1</ix:nonFraction>&#160;million of selling, general and administrative expenses in the accompanying Condensed Statement of Operations and Comprehensive Loss for sponsorship and event-related activities associated with ASCRS.</span></div></ix:continuation><div id="i99aefa27e57f4135a048e6322fd4812b_856"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-721" continuedAt="f-721-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="f-721-1" continuedAt="f-721-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility with Pharmakon Advisors, LP</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2024, the Company executed a loan and security agreement (the "Pharmakon Credit Facility") with funds associated with Pharmakon Advisors, LP. The Company drew $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-722">75.0</ix:nonFraction>&#160;million in the initial tranche of the term loan in April 2024, a portion of which was utilized to repay all outstanding indebtedness on the existing Credit Facility term loan, resulting in total net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:ProceedsFromRepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-723">39.8</ix:nonFraction>&#160;million. The agreement provides for <ix:nonFraction unitRef="contract" contextRef="c-182" decimals="INF" name="tars:DebtInstrumentNumberOfPotentialAdditionalTranches" format="ixt-sec:numwordsen" scale="0" id="f-724">three</ix:nonFraction> potential additional term loan tranches in principal amounts up to $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-725">25.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-726">50.0</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-727">50.0</ix:nonFraction>&#160;million, respectively, subject to customary conditions to funding and, in the case of the last <ix:nonFraction unitRef="contract" contextRef="c-182" decimals="INF" name="tars:DebtInstrumentNumberOfTranchesWithMilestoneRequirements" format="ixt-sec:numwordsen" scale="0" id="f-728">two</ix:nonFraction> tranches, achieving minimum net sales milestones. The three potential additional term loan tranches may be requested on or prior to December 31, 2024, June 30, 2025 and December 31, 2025, respectively. The Pharmakon Credit Facility matures on April 19, 2029.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan bears interest at a floating rate based upon the secured overnight financing rate ("SOFR"), plus a margin of <ix:nonFraction unitRef="number" contextRef="c-186" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-729">6.75</ix:nonFraction>% per annum, and the SOFR is subject to a <ix:nonFraction unitRef="number" contextRef="c-186" decimals="4" name="tars:DebtInstrumentFloorInterestRate" scale="-2" id="f-730">3.75</ix:nonFraction>% floor. The agreement contains representations and warranties, and affirmative and negative covenants in each case. There is also no warrant coverage to the lenders and no financial covenants associated with the financing.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="f-721-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investment in Privately-held Eye Care Company</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2024, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participated in an equity round of an early clinical-stage private eye care company. Pursuant to the terms of a Preferred Stock Purchase Agreement the Company purchased</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-731">3.0</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of preferred stock. Drs. Azamian and Link are board members and the Company's former director, Michael Ackermann, is an executive and board member of this private company. The Company owns a small minority of this private company.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note Regarding Forward-Looking Statements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains certain forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, future revenue, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these terms or other similar expressions are intended to identify forward-looking statements. Factors that may cause actual results to differ from expected results, include, among others:</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize XDEMVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, formerly known as TP-03, for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis and the size of the market opportunity for XDEMVY;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing XDEMVY and our product candidates, if approved, including commercialization timelines and sales strategy;</span></div><div style="padding-left:56.25pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any statements regarding our ability to achieve distribution and patient access for our products including XDEMVY and timing and breadth of payer coverage; our expectations of the potential market size, pricing, gross-to-net yields, eye care provider and patient acceptance of our product and product candidates, opportunity and patient populations for our product and product candidates, including XDEMVY;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of XDEMVY and our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and progress of our current clinical trials and timing of initiation of our future clinical trials, and the reporting of data from our current and future trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approval for our product candidates </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our ability to meet existing or future regulatory standards or comply with post-approval requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the clinical development of our current and future product candidates, including the size, number and disease areas to be evaluated;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of health epidemics on our business and operations;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of unfavorable global and geopolitical economic conditions on our business and operations;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients in the United States ("U.S.") or globally, as applicable, who suffer from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis, Meibomian Gland Disease ("MGD"), rosacea, Lyme disease and malaria and the number of patients that will enroll in our clinical trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product and our product candidates to meet existing or future regulatory standards;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development and manufacturing of our product and product candidates, including additional indications for which we may pursue;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected potential benefits of strategic collaborations with third parties (including, for example, the receipt of payments, achievement and timing of milestones under license agreements, and the ability of our third party collaborators to commercialize our product candidates in the territories under license) and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existing regulations and regulatory developments in the U.S. and other jurisdictions;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel and our ability to attract and retain such personnel;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"); and</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of our existing resources and the proceeds from our initial public offering ("IPO, our subsequent follow-on public offerings in May 2022 (the "May 2022 Public Offering"), August 2023 (the "August 2023 Public Offering"), and March 2024 (the "March 2024 Public Offering", collectively the &#8220;Follow-On Public Offerings&#8221;), as well as proceeds from our sales agreement prospectus (the "2023 ATM Prospectus"), and drawdowns from our loan and security agreement (the "Pharmakon Credit Facility") with funds associated with Pharmakon Advisors, LP ("Pharmakon").</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and growth prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section titled &#8220;Risk Factors&#8221; elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, advancements, discoveries, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this report and the documents that we reference in this report and have filed with the Securities and Exchange Commission ("SEC") as exhibits to this report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product, XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was approved by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration ("FDA") in July 2023 for the treatment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">blepharitis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused by the infestation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mites, which is referred to as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis. Blepharitis ("Blephar" is a reference to eyelid and &#8220;itis&#8221; is a reference to inflammation) is an ophthalmic lid margin disease characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis. Poorly controlled and progressive blepharitis can lead to corneal damage over time and, in extreme cases, blindness. There may be as many as approximately 25&#160;million people in the U.S. who suffer from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis. XDEMVY is the first and only therapeutic approved by the FDA and we believe is the definitive standard of care for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XDEMVY targets and eradicates the root cause of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mite infestation. The active pharmaceutical ingredient ("API") of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GABA-Cl") channels with no GABA-Cl inhibition in humans.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have completed seven clinical trials that include a Phase 3 Saturn-2 trial, a Phase 2b/3 Saturn-1 trial, four Phase 2 trials, and a Phase 1 trial for XDEMVY in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis, all of which met their primary, secondary and/or certain exploratory endpoints, with the drug well tolerated throughout each trial. We have also completed, and/or have ongoing clinical trials for TP-03 for the potential treatment of MGD, TP-04 for the potential treatment of rosacea and TP-05 for potential Lyme disease prophylaxis, among others.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to further advance our pipeline with the lotilaner API to address several diseases in human medicine, including eye care, dermatology, and infectious disease prevention. We are investigating the development of our product candidates to address targeted diseases with high unmet medical needs, which currently include TP-03 for the potential treatment of MGD, TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Business and Clinical Highlights </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">XDEMVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In July 2023, XDEMVY was approved by the FDA as the first and only approved therapeutic for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis. XDEMVY targets the root cause of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis and in pivotal trials demonstrated significant improvement in eyelids (reduction of collarettes, the pathognomonic sign of the disease, to no more than two collarettes per upper lid), mite eradication (mite density of zero mites per lash) and erythema cure (grade zero). We launched XDEMVY on August 24, 2023.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the first quarter of 2024 we recognized $24.7 million in net product sales, an increase of 89% compared to the fourth quarter of 2023.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approximately 26,000 bottles of XDEMVY were delivered to patients during the first quarter of 2024, an increase of 65% compared to the fourth quarter of 2023.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approximately 8,000 ECPs have started patients on XDEMVY with more than 50% of ECPs prescribing XDEMVY to multiple patients as of May 3, 2024.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gross-to-net discounts remained consistent at approximately 55% given the impact of expected first quarter dynamics on net sales.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We launched the "Mite Party" campaign, dynamic, multi-channel campaigns for XDEMVY, that was designed to elevate consumer awareness of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">blepharitis through relatable messaging and compelling visuals.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continued to expand payer coverage of XDEMVY.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Secured several contracts, including two major commercial plans with approximately 18 million covered lives that placed XDEMVY on preferred status, and expect to begin recognizing the benefits of these contracts in the second quarter of 2024.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to be actively engaged in contracting discussions with all the key commercial and Medicare accounts and we remain on track for expected broad commercial coverage by the end of 2024 and broad Medicare coverage beginning in 2025.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On track with plans to deploy approximately 50 additional sales force representatives and leaders by the end of the third quarter of 2024.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Two additional independent meta-analyses of randomized controlled trials (Akhtar et al. and Talha et al.), demonstrating the efficacy of XDEMVY were published in peer-reviewed journals. To date, we are aware of four independent meta-analyses in total that have been published.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TP-03 Meibomian Gland Disease, Ersa Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In December 2023, we announced positive topline results of the Ersa Phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) administered twice daily or three times a day for 12 weeks for the treatment of MGD in patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mites. TP-03 demonstrated statistically significant and clinically meaningful improvements compared to baseline in two objective measures of the disease &#8211; the presence and quality </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of liquid secretion as measured by the Meibomian Gland Secretion Score and the number of glands secreting normal (clear) liquid and was well tolerated. We plan to discuss and determine the potential regulatory path with the FDA by the end of 2024.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TP-04 Rosacea, Galatea Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On February 27, 2024, we announced positive topline results from the Galatea trial evaluating TP-04, a novel gel formulation of lotilaner, for the treatment of rosacea which demonstrated statistically significant improvements (p&lt;0.05) in inflammatory lesions and Investigator's Global Assessment score (change in baseline and success rate) were observed compared to vehicle at week 12. TP-04 was generally well tolerated. We plan to discuss and determine the potential regulatory path with the FDA by the end of 2024.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TP-05 Lyme Disease, Carpo Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On </span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 22, 2024, we announced positive topline results from the Carpo trial, which demonstrated statistical significance in the mortality of ticks compared to vehicle (p&lt;0.001), regardless of treatment arm, and was well tolerated. The Carpo trial is designed to evaluate TP-05, a novel investigative oral, non-vaccine pharmacological prophylactic for the potential prevention of Lyme disease in humans. The Carpo trial evaluated the efficacy of TP-05 in killing lab grown, non-disease carrying ticks after they have attached to the skin of healthy volunteers, as well as confirm the safety, tolerability, and blood concentration of TP-05. We plan to discuss and determine the potential regulatory path with the FDA by the end of 2024.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe TP-05 is currently the only non-vaccine, drug-based prophylaxis in development that targets ticks, and potentially prevents Lyme disease transmission. It is designed to rapidly and durably provide systemic blood levels of lotilaner potentially sufficient to kill infected ticks attached to the human body before they can transmit the Borrelia bacteria that causes Lyme disease. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TP-03 China Territory Out-License</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On February 13, 2024, LianBio Ophthalmology Limited ("LianBio") announced its plan to wind down its operations. On March 14, 2024, LianBio's Board of Directors made a special cash dividend payment to the Company of $0.7&#160;million (equivalent to $4.80 per share, the fair value of the LianBio common stock).</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2024, we executed an agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. ("GrandPharma"), a subsidiary of Grand Pharmaceutical Group Limited, and LianBio to transition the rights to develop and commercialize TP-03 in China for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis (the "Novation Agreement"). Upon execution of the Novation Agreement, the development and license agreement with LianBio (the "China Out-License"), was assigned to GrandPharma and a one-time payment of $2.5&#160;million (the "Termination Payment") was triggered, which was received on April 5, 2024. Additionally, the Novation Agreement amended the $15.0&#160;million future development milestone related to the approval of TP-03 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis in the China Territory, as defined in the China Out-License, with a combined condition of issuance of a patent related to TP-03. All references to the China Out-License in this Quarterly Report on Form 10-Q shall refer to the China Out-License, as assigned from LianBio to GrandPharma, pursuant to the Novation Agreement.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the execution of the Novation Agreement, we entered into an agreement with LianBio to terminate the third tranche of the equity warrants related to the purchase of 78,373 shares of LianBio common stock for a total cancellation payment of $0.4&#160;million (the "Warrant Termination Payment"), which was received on April 5, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and Financial Overview</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated as a Delaware corporation in November 2016, and our headquarters are located in Irvine, California. Since our inception, we have devoted substantially all of our resources to organizing and staffing our company, acquiring intellectual property, clinical development of our product candidates, commercializing XDEMVY, building our research and development capabilities, raising capital, and enhancing our corporate infrastructure.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have financed our operations through private placements of preferred stock, convertible promissory notes, net proceeds from issuance of common stock in our IPO, our subsequent follow-on public offerings in May 2022, August 2023, and March 2024, and our 2023 sales agreement prospectus, as well as proceeds from net product sales, our China Out-License, and drawdowns from the Credit Facility and the Pharmakon Credit Facility.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net operating losses in every year since our inception and expect to continue to incur significant operating expenses as we commercialize XDEMVY for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis and as we advance our other product candidates through clinical trials, regulatory submissions, and potential commercialization. Our net loss was $35.7 million and $23.4 million for the three months ended March 31, 2024 and 2023, respectively. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. We anticipate that our operating expenses will increase significantly as we:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize XDEMVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our other products for which we obtain regulatory approvals;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain regulatory approval for XDEMVY and seek regulatory approval for our other product candidates that successfully complete clinical development, if any;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance the clinical development of TP-03 for the potential treatment of MGD, TP-04 for the potential treatment of rosacea and TP-05 for the potential Lyme disease prophylaxis;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage with contract manufacturers to ensure a sufficient supply chain capacity to provide commercial quantities of XDEMVY and any other products for which we may obtain marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional staff, including clinical, scientific, technical, regulatory, marketing, operations, financial, and other support personnel, to execute our business plan; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add information systems and personnel to support our product development and commercialization efforts, and to enable us to operate as a public company.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began generating product sales during the three months ended September 30, 2023 following the FDA approval of XDEMVY in July 2023 and our subsequent commercial launch in August 2023. Our reported revenue within license fees and collaboration revenue is from our China Out-License and clinical supply agreement; we expect to report additional revenue under this caption in future periods from GrandPharma related to the Novation Agreement.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate significant revenue from product sales and achieve profitability, if ever, we expect to finance our operations through public equity or debt financings, or collaborations, strategic alliances, or licensing arrangements with third parties. Adequate funding may not be available to us when needed on acceptable terms, or at all. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital or enter into such agreements as and when needed, we could be forced to significantly delay, scale back, or discontinue our product development and/or commercialization plans, which would negatively and adversely affect our financial condition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate significant revenue from product sales, net we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, our aggregate cash, cash equivalents and marketable securities was $298.5 million &#8211; see the section below titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations &#8212; Liquidity and Capital Resources.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of the Macroeconomic Environment</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the economy has experienced downward pressure, and together with high rates of inflation and energy supply issues experienced in certain regions, war and geopolitical conflicts, have led to regional and/or global macroeconomic challenges, the effects of which may be of an extended duration.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be exposed to credit risk on deposits at financial institutions to the extent our account balances exceed the amount insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). We maintain cash held in deposit at financial institutions in the U.S., including SVB, a division of First Citizens Bank. While these deposits are insured by the FDIC in an amount up to $250,000 for any depositor, to the extent we hold cash deposits in amounts that exceed the FDIC insurance limitation, we may incur a loss in the event of a failure of any of the financial institutions where we maintain deposits. We invest our excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. We believe the Company is not exposed to significant credit risk due to the financial position of the depository institution and the types of accounts we hold, but we will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the section titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Item 1A of Part II of this Quarterly Report on Form 10-Q, for a further discussion of the potential adverse impact of unfavorable global and geopolitical economic conditions on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees and collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations before other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,684)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,952)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(983)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity warrants issued by licensee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income, net </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,731)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,419)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,312)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Not meaningful for further disclosure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2024 we recognized revenue of $24.7 million from product sales, net of rebates, chargebacks, discounts, and other adjustments driven by approximately 26,000 prescriptions of XDEMVY to patients. During the three months ended March 31, 2023, there were no product sales, net recognized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Fees and Collaboration Revenue </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, we recognized $2.9 million of license fees and collaboration revenue including (i) $2.5 million for the Termination Payment related to the Novation Agreement and (ii) $0.4 million for the Warrant Termination Payment. During three months ended March 31, 2023 we recognized $2.5 million related to the achievement of a contractual milestone under the China Out License. These allocated amounts represented the satisfaction of the transfer of license rights to LianBio and the completion of related performance obligations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will recognize additional license fees and collaboration revenue under the Novation Agreement to the extent other events occur, specifically related to (i) milestone achievement of certain regulatory events in the China Territory, and (ii) royalties and milestones from our licensee's product sales of TP-03 in the China Territory. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024, we recognized $1.7 million in cost of sales for XDEMVY. Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, and freight-in, as well as third-party royalties payable on our product sales, net and amortization of capitalized intangible assets associated with XDEMVY. During the three months ended March&#160;31, 2023, there were no cost of sales recognized.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Direct external expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TP-03 program</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TP-04 program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TP-05 program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other early-stage programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indirect expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation and personnel-related </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elanco milestone expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,356&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased by $0.3 million for the three months ended March&#160;31, 2024, as compared to the prior year period. This decrease was primarily due to (i) $1.6 million of decreased TP-05 program expenses including $1.0 million for the food effect study and $0.5 million for the Carpo trial, and (ii) $1.0 million of prior period milestone expense related to our in-license agreement with Elanco. These decreases were partially offset by (i) $1.5 million of increased payroll and personnel-related costs (including increased stock-based compensation expense of $0.3 million) related to 20 employee additions period over period to drive our product development initiatives, (ii) $0.5 million of other indirect expenses, and (iii) $0.5 million of increased TP-03 program expenses primarily due to Phase 4 studies, which was partially offset by completion of the Ersa Phase 2a trial. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Selling, general and administrative expenses increased by $36.5 million for the three months ended March&#160;31, 2024, as compared to the prior year period. The increase was primarily due to (i) $11.3 million of increased payroll and personnel-related costs (including increased stock-based compensation expense of $1.2 million) for 122 corporate employee additions, period over period, to support our business growth and commercial leadership hires for our recent commercial launch of XDEMVY, (ii) $12.2 million of increased commercial and market research costs as we continued our commercial expansion for the recent commercial launch of XDEMVY, and (iii) $12.7 million of increased IT applications, legal, professional and other corporate expenses. We expect our field sales headcount and associated vendor expenses to continue to increase during 2024 due to further growth and expansion of our commercial activities for XDEMVY.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income, net increased by $0.4 million primarily due to (i) $0.8 million of increased interest income earned on our cash, cash equivalents and marketable securities, and (ii) $0.6 million of other income, net substantially related to dividend income from LianBio. These increases were partially offset by decreases in other income, net including (i) $0.5 million change in fair value of the LianBio common stock (ii) increased interest expense of $0.3 million on the Credit Facility, and (iii) $0.2 million change in fair value related to the final mark-to-market adjustment on the unvested third tranche equity warrant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have financed our operations substantially through private placements of preferred stock, net proceeds from the issuance of common stock through our IPO, Follow-on Public Offerings, and the 2023 ATM Prospectus, as well as proceeds from net product sales, the China Out-License, and drawdowns from the Credit Facility and the Pharmakon Credit Facility. As of March&#160;31, 2024, we had cash, cash equivalents and marketable securities of $298.5&#160;million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-On Public Offerings</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we completed the August 2023 Public Offering in which 5,714,285 shares of our common stock were sold at a public offering price of $17.50 per share. In September 2023, the underwriters partially exercised an option to purchase an additional 355,164 shares of our common stock at the public offering price of $17.50 per share. After giving effect </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the exercise of the underwriters' option, we sold a total of 6,069,449 shares and received aggregate net proceeds of $99.3 million, after deducting underwriting discounts, commissions, and other offering-related expenses.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we filed an automatic shelf registration statement on Form S-3 ASR (the "2024 Shelf Registration Statement"). On March 5, 2024 we completed an underwritten follow-on public offering under the 2024 Shelf Registration Statement on Form S-3 of 2,812,500 shares of our common stock, par value $0.0001 per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of our common stock (the &#8220;March 2024 Public Offering&#8221;). The price to the public was $32.00 per share and $31.9999 per pre-funded warrant, which was the price to the public of each share of common stock sold in the March 2024 Public Offering, minus the $0.0001 exercise price per pre-funded warrant. We also granted the underwriters a 30-day option to purchase up to 468,750 additional shares of its common stock at the public offering price of $32.00 per share, which the underwriters exercised in full on March 1, 2024. We received approximately $107.7&#160;million in aggregate net proceeds, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Market Sales Agreement</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, we sold 1,000,000 shares of our common stock for $20.00 per share under a sales agreement prospectus filed in November 2023, pursuant to the 2023 Shelf Registration Statement (defined below) covering the sale of up to $100.0 million of our common stock pursuant to an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "2023 ATM Prospectus") with Jefferies LLC ("Jefferies"). This resulted in net proceeds of $19.2 million, after deducting broker commissions and offering related expenses.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, there were no sales of our common stock pursuant to the 2023 ATM Prospectus.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">China Out-License</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, we have received $86.1&#160;million of total proceeds in connection with our China Out-License comprised of (i) $15.0&#160;million of initial consideration, (ii) $67.5&#160;million for the achievement of specified milestones, (iii) $0.7 million related to a special cash dividend, (iv) $2.5&#160;million related to the Novation Agreement, and (v) $0.4&#160;million related to the Warrant Termination Agreement.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 the Company is eligible to receive further consideration from GrandPharma upon the achievement of additional TP-03 events, including: (i) $20.0&#160;million of potential future regulatory and/or patent milestones; (ii) $100.0&#160;million of potential future China-Based TP-03 sales threshold milestones; and (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we executed the Credit Facility with Hercules and SVB. Concurrent with the execution of the Credit Facility we drew $20.0&#160;million. This Credit Facility was amended in January 2023 and August 2023. The Credit Facility, as amended, set a maximum interest rate, updated the terms of prepayment under the Credit Facility and includes an extended period to drawdown the tranche associated with the New Drug Application("NDA") submission, from March 15, 2023 to March 15, 2024 provided at least $5.0 million was drawn on or before March 15, 2023 and at least an additional $5.0 million was drawn on or before September 15, 2023. On March 15, 2023 and September 15, 2023, respectively, we made draws of $5.0 million (including SVB's commitment of $1.25 million) from the $25.0&#160;million tranche associated with the NDA submission of TP-03. The balance on the Credit Facility was $29.9&#160;million as of March&#160;31, 2024 and included a four-year period of interest-only payments. The agreement was extendable for a fifth year to February 2027 maturity, upon our expected achievement of required conditions. As of March&#160;31, 2024, we had $75.0&#160;million of remaining tranched availability. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2024 the Company executed the Pharmakon Credit Facility with Pharmakon. The Pharmakon Credit Facility provides a $75.0&#160;million initial term loan which was drawn in April 2024, a portion of which was utilized to repay all outstanding indebtedness associated with the prior Credit Facility, for total net proceeds of $39.8&#160;million. The Pharmakon Credit Facility provides for three potential additional term loan tranches in principal amounts up to $25.0&#160;million, $50.0&#160;million, and $50.0&#160;million, respectively, subject to customary conditions to funding and, in the case of the last two tranches,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achieving minimum net sales milestones. The three additional tranches may be requested on or prior to December 31, 2024, June 30, 2025 and December 31, 2025, respectively. The Pharmakon Credit Facility matures on April 19, 2029.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Credit Facility will bear interest at a floating rate based upon the secured overnight financing rate (&#8220;SOFR&#8221;), plus a margin of 6.75% per annum. The SOFR is subject to a 3.75% floor. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Credit Facility contains representations and warranties, affirmative and negative covenants in each case. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also no warrant coverage to the lenders and no financial covenants associated with the financing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenditures currently consist of cost of sales, research and development costs (including activities within our preclinical, clinical, regulatory, and drug manufacturing initiatives) and selling, general and administrative costs. Our use of cash is impacted by the timing and extent of payments for each of these activities and other business requirements. We have incurred significant losses and negative cash flows from operations since our inception and had an accumulated deficit of $280.4&#160;million as of March&#160;31, 2024. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that our cash, cash equivalents and marketable securities of $298.5&#160;million as of March&#160;31, 2024 is sufficient to fund our current and planned operations for at least the next twelve months from this Quarterly Report on Form 10-Q. We also anticipate having additional availability from our Pharmakon Credit Facility of at least $25.0&#160;million on or prior to December 31, 2024 and another $100 million contingent on reaching certain sales milestones. Our cash runway estimate is predicated on current assumptions for future revenue, operating expenses, and debt availability and may require future adjustments. Accordingly, we may be required to raise additional capital earlier than we currently expect based on our cash requirements and market dynamics. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we filed the 2024 Shelf Registration Statement, which permits us to offer and sell from time to time, in one or more series of issuances and on terms that we will determine at the time of the offering, our common stock, preferred stock, debt securities, warrants, units or any combination of such securities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we filed a shelf registration statement on Form S-3 that was declared effective by the SEC on November 21, 2023, (the "2023 Shelf Registration Statement"), which replaced the November 2021 Shelf Registration Statement, as defined below, and permits us to offer up to $300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the 2023 Shelf Registration Statement, we concurrently filed the 2023 ATM Prospectus with Jefferies. Under the terms of the 2023 ATM Prospectus, Jefferies will act as the Company's sales agent and is entitled to compensation for its services equal to 3% of the gross proceeds of any shares of common stock sold. In December 2023, we sold 1,000,000 shares of our common stock under the 2023 ATM Prospectus for $20.00 per share and received net proceeds of $19.2 million, after deducting broker commission and offering-related expenses.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2021, we filed a shelf registration statement on Form S-3 that was declared effective by the SEC on November 5, 2021 (the &#8220;2021 Shelf Registration Statement&#8221;), which permitted us to offer up to $300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time. The 2023 Shelf Registration Statement replaced the 2021 Shelf Registration Statement.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as part of the 2021 Shelf Registration Statement, we concurrently filed a sales agreement prospectus covering the sale of up to $100.0 million of our common stock pursuant to an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;2021 ATM Prospectus&#8221;) with Jefferies LLC. We did not sell any shares of our common stock under the 2021 ATM Prospectus. On July 31, 2023, in connection with the August 2023 Public Offering, we terminated the sales agreement prospectus relating to the 2021 ATM Prospectus.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Liquidity Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant operating losses for the foreseeable future, and for these losses to further increase, as we expand our clinical development programs for our other product candidates and given the recent commercial launch of XDEMVY. We may also encounter unforeseen expenses, difficulties, complications, delays and other currently unknown factors that could adversely affect our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional capital to fully develop our product candidates and to execute our business strategy. Our requirements of a future capital raise will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenue received from commercial sales of XDEMVY or our product candidates, should any of our product candidates receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing associated with commercializing XDEMVY or our product candidates, if they receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of clinical programs we decide to pursue;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and costs of development and commercial manufacturing activities;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time and availability of our Pharmakon Credit Facility;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our implementation of various computerized information systems;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of health epidemics on our clinical development or operations; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate funding may not be available to us on acceptable terms or at all. Our potential inability to raise capital when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds as required, we may need to delay, reduce, or terminate some or all development programs and clinical trials. We may also be required to sell or license our rights to product candidates in certain territories or indications that we would otherwise prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to address our liquidity needs, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially and adversely affect our business and financial prospects. See the section titled &#8220;Risk Factors&#8221; in this report for additional risks associated with our substantial capital requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Statements of Cash Flows</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,789)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,970)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,771&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,242)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,663)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $37.8 million for the three months ended March 31, 2024, which primarily consisted of our net loss of $35.7 million and a net decrease in net operating assets and liabilities of $8.6 million, partially offset by a net increase in non-cash and other changes of $6.5&#160;million. The net decrease in net operating assets and liabilities was primarily due to an increase in accounts receivable of $13.3 million and a decrease in accrued payroll and benefits of $7.3 million, partially offset by an increase in accounts payable and other accrued liabilities of $12.3 million. The net non-cash and other charges were primarily related to stock-based compensation expense of $5.5&#160;million and unrealized loss on equity investments of $0.6&#160;million.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $22.0 million for the three months ended March 31, 2023, which primarily consisted of our net loss of $23.4&#160;million and net decrease in net operating assets and liabilities of $1.4&#160;million, partially offset by a net increase in non-cash and other changes of $2.9&#160;million. The net decrease in net operating assets and liabilities was primarily due to an increase in accounts receivable of $2.5&#160;million, a decrease in accrued payroll and benefits of $1.3&#160;million, and a decrease in accounts payable and other accrued liabilities of $1.0&#160;million, partially offset by a decrease in other receivables of $3.2&#160;million. The net increase in non-cash and other charges were primarily related to stock-based compensation expense of $3.9&#160;million, partially offset by net amortization/accretion on marketable securities of $1.5&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Provided by Investing Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $102.2 million for the three months ended March 31, 2024, and primarily relates to $104.6 million of purchased investments and $0.2 million of purchased furniture, fixtures, office equipment and leasehold improvements for our laboratory and administrative offices, partially offset by $2.5 million of proceeds from maturities of investments.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $11.3 million for the three months ended March&#160;31, 2023, and primarily related to $40.3 million of proceeds from maturities of investments, partially offset by $28.7 million of purchased investments and $0.3 million of purchased furniture, fixtures and leasehold improvements for our laboratory and administrative offices.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $108.8 million for the three months ended March 31, 2024, and primarily relates to $98.6 million of net proceeds from the issuance of common stock and $9.4 million of net proceeds from the issuance of pre-funded warrants related to the March 2024 Public Offering, and $0.8 million of proceeds from employee stock option exercises.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $5.0 million for the three months ended March 31, 2023, which substantially relates to proceeds from the Credit Facility.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management's discussion and analysis of financial condition and results of operations is based on our Condensed Financial Statements, which have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP"). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of these Condensed Financial Statements, as well as the reported revenue earned and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in our filed Annual Report on Form 10-K for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in the notes to our financial statements also included in this Annual Report on Form 10-Q, we believe these critical accounting policies are the most important to understanding and evaluating our reported financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in the notes to which they relate within these accompanying Condensed Financial Statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law and in accordance with our bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. We are also party to indemnification agreements with our officers and directors. We believe the fair value of the indemnification rights and agreements is minimal. Accordingly, we have not recorded any liabilities for these indemnification rights and agreements as of March&#160;31, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The JOBS Act permits an emerging growth company such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected to opt out of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">earliest of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1)&#160;December 31, 2025, which is the last day of our first fiscal year following the fifth anniversary of the completion of our IPO, (2) the last day of our first fiscal year (a)&#160;in which we have total annual gross revenues of at least $1.235&#160;billion or (b)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700&#160;million, as of the prior June 30th and (3)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period.</span></div><div id="i99aefa27e57f4135a048e6322fd4812b_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and are not required to provide the information required under this item.</span></div><div id="i99aefa27e57f4135a048e6322fd4812b_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a system of disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act, is processed, recorded, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. These disclosure controls and procedures include, among other processes, controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), as appropriate, to allow for timely decisions regarding required disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March&#160;31, 2024. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March&#160;31, 2024, the Company's disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined by Exchange Act Rule 13a-15(f) and 15d-15(f) during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i99aefa27e57f4135a048e6322fd4812b_82"></div><div style="margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span></div><div id="i99aefa27e57f4135a048e6322fd4812b_85"></div><div style="margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Investing in our common stock is speculative and involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks described below, together with the other information contained in this Quarterly Report on Form 10-Q, including our financial statements and the related notes. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. The risks described below are not the only ones we face. Additional risks that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business and Operations</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early commercial-stage biopharmaceutical company with a limited operating history and a single product approved for commercial sale. We have incurred significant losses and negative cash flows from operations since our inception and anticipate that we will continue to incur significant expenses and losses for the foreseeable future.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have one product, XDEMVY, which recently obtained FDA approval for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Demode</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">x blepharitis in the U.S. in July 2023. We have incurred net losses each year since our company&#8217;s formation in 2016. We have funded our operations primarily from the sale and issuance of redeemable convertible preferred stock, convertible promissory notes and the sale of our common stock in our IPO, subsequent Follow-On Public Offerings, and under our 2023 ATM Prospectus, as well as proceeds from product sales, net, our China Out-License and draws from our Credit Facility and Pharmakon Credit Facility. For the three months ended March 31, 2024 and 2023 our net losses were $35.7 million and $23.4 million, respectively. As of March&#160;31, 2024 and December&#160;31, 2023, we had an accumulated deficit of $280.4 million and $244.7 million, respectively. Additionally, the net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indicator of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. We initiated sales and marketing activities to commercialize XDEMVY in August 2023. We expect to incur operating losses over the next several years and for the foreseeable future until our revenue from product sales from XDEMVY and any other approved products exceeds expenses, which may never occur. We may never achieve profitability and, even if we do, we may not be able to sustain or increase our profitability. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our accumulated deficit and working capital.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to continue incurring significant expenses and increasing operating losses for the foreseeable future. We expect that our expenses will increase substantially if and as we:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to commercialize XDEMVY and any other products for which we may obtain marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enhance our product development and planned future commercialization efforts of our product candidates, including through hiring additional clinical, regulatory, quality control and scientific personnel;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals and reimbursement for our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prepare for and initiate additional preclinical, clinical and other studies for our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change or add additional manufacturers or suppliers, some of which may require additional permits or other governmental approvals;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create additional infrastructure to support our operations as a public company, including adding operational, financial and management information systems and personnel;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify, assess, acquire or develop additional product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make milestone or other payments in connection with the development or approval of our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, protect, enforce and expand our intellectual property portfolio; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter issues with any of the above.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses could increase beyond our expectations if, among other things:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">there are any delays in establishing appropriate manufacturing arrangements for or completing the development of any of our product candidates; </span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we are required by regulatory authorities to perform clinical trials or studies in addition to, or different than, those that we currently expect; or</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to continue to expend substantial resources in connection with our commercialization efforts. If we are successful in commercializing more product candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional product candidates or to expand the approved indications of any marketed product. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We expect to expand our development, regulatory, operational, sales, marketing, and distribution capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> As we advance our research and development programs and commercialization efforts, we expect to experience continued growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, quality, regulatory affairs, manufacturing, quality control, sales, marketing, and distribution. To manage our anticipated future growth, we must:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">identify, recruit, integrate, maintain and motivate additional qualified personnel;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our development efforts effectively, including the initiation and execution of clinical trials for our product candidates; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improve our operational, financial and management controls, reporting systems and procedures.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future financial performance and our ability to develop, manufacture and commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities. If we do not effectively manage the expansion of our operations, we could experience weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The expansion of our operations also could lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain third-party contract organizations, advisors and consultants to provide certain services, including assuming substantial responsibilities for the conduct of our clinical trials and the manufacture of our product candidates. We cannot assure you that the services of such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">third-party contract organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by our vendors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to successfully commercialize XDEMVY, obtain marketing approval of our product candidates or otherwise advance our business. We cannot assure you that we will be able to properly manage our existing vendors or consultants or find other competent outside vendors and consultants on economically reasonable terms, or at all.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of the biotechnology and pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. If we are unable to continue to attract and retain high quality personnel and consultants, the rate and success at which we can discover and develop product candidates and operate our business will be limited. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are highly dependent on the expertise of our executive officers, as well as the other members of our scientific and clinical teams and certain advisors to develop and soundly execute our business strategy. Although we have employment offer letters with each of our executive officers, each of them may terminate their employment with us at any time. We do not maintain key person insurance for any of our executives or employees.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Recruiting and retaining qualified scientific, clinical, and sales and marketing personnel, are critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval for and commercialize our product candidates. Competition to hire qualified personnel in our industry is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited, and our business, prospects, financial condition and results of operations may be adversely affected.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our employees have become or will become vested in a substantial amount of our common stock or a number of common stock options. Our employees may be more likely to leave us if the shares they own have significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the market price of our common stock. Our future success also depends on our ability to continue to attract and retain additional executive officers and other key employees.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our information technology systems, or those of our third-party contract research organizations ("CROs") or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of XDEMVY and our product candidates&#8217; development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality, availability and integrity of such confidential information. We also have outsourced elements of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our operations to third parties, and as a result we manage a number of third-party contractors who have access to our confidential information.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs, contract manufacturing organization ("CMO"), and other contractors and consultants are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, interruptions or cyber incidents resulting from the conflict between Russia and Ukraine, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to data leakage. Further, due to the political uncertainty involving Russia and Ukraine, there is an increased likelihood that escalation of tensions could result in cyber attacks that could either directly or indirectly impact our operations. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the commercial operations of XDEMVY and further development of our product candidates could be delayed.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we have not experienced any such system failure, accident or security breach to date, we cannot assure you that our data protection efforts and our investment in information technology and cybersecurity will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. Our inability to use or access our information systems at critical points in time could adversely affect the timely and efficient operation of our business. Any delayed sales, significant costs or lost customers resulting from these technology failures could adversely affect our business, operations, and financial results. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption to our commercial operations of XDEMVY and further development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, including private lawsuits or class actions under the California Consumer Privacy Act ("CCPA"), which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain specific coverage to mitigate losses associated with certain cybersecurity incidents that impact our or our third parties&#8217; systems, networks, and technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities, could divert our resources and could limit or delay our commercialization of XDEMVY or any product candidates that we may develop.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face an inherent risk of product liability exposure related to the commercialization of XDEMVY and the testing of our product candidates in human clinical trials and will continue to face risk if we commercially sell any future products we may develop. The sale of XDEMVY and any approved products in the future as well as the use of product candidates by us in clinical trials may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that XDEMVY or our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the inability or delay of our efforts to commercialize XDEMVY or any products that we may develop;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased demand for XDEMVY or any product candidates or products that we may develop;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">withdrawal of regulatory approval, recall, restriction on the approval or a black box warning or contraindication for XDEMVY or any future product candidates, if approved;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delay, variation or termination of clinical trials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial subjects or challenges with clinical trial enrollment;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation and diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to study subjects or patients;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or new labeling requirements, marketing or promotional restrictions; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as our product candidates advance through clinical trials. Insurance coverage is increasingly expensive, thus we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful product or clinical trial liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our employees, independent contractors, including our CROs and CMOs, commercial partners, consultants, suppliers, service providers, and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to the risk that our employees, independent contractors, including our CROs and CMOs, commercial partners, consultants, suppliers, service providers, and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar foreign regulatory authorities, including those laws that require the reporting of true, complete, and accurate information to such foreign regulatory authorities; manufacturing standards; U.S. federal and state healthcare fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete, and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our nonclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, imprisonment, other sanctions, contractual damages, reputational harm, future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Health epidemics may affect our ability to initiate and complete preclinical studies and clinical trials, disrupt regulatory activities, disrupt our manufacturing and supply chain or have other adverse effects on our business and operations. In addition, health epidemics could cause substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could result in adverse effects on our business and operations.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business, operations and clinical development timelines could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of CROs upon whom we rely. Moreover, our clinical development timelines and plans could be affected by health epidemics as we and the third-party manufacturers and clinical research organizations that we engage may face disruptions. Site initiation and patient enrollment could be delayed or suspended due to prioritization of hospital resources toward the health epidemics or patients not having a desire to enroll in clinical trials due to concerns. In addition, some patients may not be able to comply with clinical trial protocols and the ability to conduct follow up visits with treated patients may be limited if patients do not want to participate in follow up visits due to concerns regarding health epidemics or if quarantines </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">impede patient movement or interrupt healthcare services. There may be shortages in the raw materials used in the manufacturing of our product candidates or laboratory supplies for our preclinical studies and clinical trials, in each case, because of ongoing efforts to address the outbreak.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure that the inability to collect such clinical data would not have an adverse impact on our clinical trial results. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to health epidemics could be adversely impacted.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may experience disruptions that could severely impact our business, preclinical studies, and clinical trials, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials, including receiving any required investigational new drug ("IND");</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling and retaining patients in our clinical trials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing disruptions;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in the transport of clinical trial materials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in local regulations as part of a response to a health epidemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties recruiting or retaining patients for our planned clinical trials if patients are affected by the virus or are fearful of visiting or traveling to clinical trial sites because of the outbreak;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of or changes in key clinical trial activities, such as clinical trial site monitoring, implementation of virtual monitoring, use of local testing labs, or home delivery of study drugs, due to limitations on travel imposed or recommended by federal or state governments, employers and others, use of new digital technologies for subject visits or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk that participants enrolled in our clinical trials will acquire a particular disease related to a health epidemic while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays in the operations of the FDA which may impact review and approval timelines;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in regulatory approvals for our product candidates due to the FDA focusing on clinical trials related to therapies and vaccines targeting health epidemics;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to accept data, including from clinical trials in affected geographies or failure to comply with updated FDA guidance and expectations related to the conduct of clinical trials during a health epidemic; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays to our sourced discovery and clinical activities.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The response to a health epidemic may redirect resources with respect to regulatory matters in a way that would adversely impact our ability to pursue marketing approvals. In addition, we may face impediments to regulatory meetings and potential approvals due to measures intended to limit in-person interactions. Furthermore, third parties, including manufacturers, medical institutions, clinical investigators, CROs and consultants with whom we conduct business, are similarly adjusting their operations and assessing their capacity in light of a health epidemic. If these third parties continue to experience shutdowns or business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The extent to which the health epidemic impacts our business, clinical trials, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration of the pandemic, its severity, the actions to contain the virus or address its impact, and how quickly and to what extent government orders and mandates are lifted and normal economic and operating activities can resume. Further, while the potential economic impact of any health epidemic may be difficult to assess or predict, it could result in significant disruptions of global financial markets, which could reduce our ability to access capital, which could in the future negatively affect our liquidity. To the extent a health epidemic adversely affects our business, clinical trials, results of operations and financial condition, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section. The ultimate impact of a health epidemic is highly uncertain and subject to change.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or the third parties upon whom we depend on may be adversely affected by earthquakes, fires or other natural disasters, or geopolitical events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any unplanned event, such as earthquakes, fires, flood, explosion, extreme weather, health epidemics, pandemics, power outages, telecommunication failures, war or other military conflict, terrorist activities or other natural or manmade accidents or incidents could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unfavorable global and geopolitical economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-align:justify;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our results of operations could be adversely affected by general conditions in the global and geopolitical economy and in the global financial markets. Financial pressures may cause government or other third-party payers to more aggressively seek cost containment measures in healthcare and other settings. As a result of global economic conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships (including inflation) may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. We believe such conditions have led and could continue to lead to reduced demand for our products, which could have a material adverse effect on our product sales, net, business and results of operations. The current inflationary environment related to increased aggregate demand, supply chain constraints and the effects from the armed conflict in Ukraine (including the effects of the sanctions that were implemented in response to the conflict and the resulting impacts on the commodity market and supply chains) and Israel have also increased our operating expenses and may continue to affect our operating expenses. Our operational costs, including the cost of energy, materials, labor, distribution and our other operational and facilities costs are subject to market conditions and are being adversely affected by inflationary pressures. Global and geopolitical economic conditions may also adversely affect the ability of our distributors, customers and suppliers to obtain the liquidity required to buy inventory or raw materials and to perform their obligations under agreements with us, which could disrupt our operations. Although we monitor our distributors&#8217;, customers&#8217; and suppliers&#8217; financial condition and their liquidity to mitigate our business risks, some of our distributors, customers and suppliers may become insolvent, which could have a material adverse effect on our product sales, business and results of operations. A significant worsening of global and geopolitical economic conditions could precipitate or materially amplify the other risks described herein.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We maintain a significant portfolio of investments disclosed as cash equivalents and marketable securities on our accompanying Balance Sheets. The value of our investments may be adversely affected by interest rate fluctuations, inflation, downgrades in credit ratings, illiquidity in the capital markets, health epidemics and other factors that may result in other-than-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">temporary declines in the value of our investments. Any of those events could cause us to record impairment charges with respect to our investment portfolio or to realize losses on sales of investments.</span></div><div style="text-align:justify;text-indent:48.95pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Development and Commercialization</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have only recently obtained regulatory approval for XDEMVY in the U.S. and commenced the commercial launch of XDEMVY. We have limited experience as a commercial company and generating revenue from product sales. If the commercial launch of XDEMVY is unsuccessful or any future approved products are unsuccessful, we may never be profitable.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recently received approval by the FDA for XDEMVY for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> blepharitis in the U.S. and began generating revenue from product sales during the third quarter of 2023. Our ability to become and remain profitable is heavily dependent on our ability to continue to generate revenue from XDEMVY. The success of our commercialization will depend on a number of factors, including, among others, the continued development of our commercial organization, including our internal sales and marketing team and distribution capabilities, our ability to navigate the significant expenses and risks involved with the development and management of such capabilities, satisfying any post-marketing regulatory requirements, our ability to secure and maintain adequate healthcare coverage and the acceptance of XDEMVY by patients, ECPs and third-party payers. Further, our commercial success is dependent on our ability to educate ECPs, patients and others in the medical community about </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> blepharitis. If XDEMVY, or any other future approved product, does not achieve an adequate level of acceptance, coverage, pricing or reimbursement, we may not generate significant revenue from product sales and we may not be profitable. Even if we successfully commercialize XDEMVY in the U.S., we may be unable to achieve or maintain profitability, unless XDEMVY is approved in other jurisdictions or for additional indications. Because of the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the timing and amount of revenues from product sales of XDEMVY, or any future approved products, or if or when we might achieve profitability.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unsuccessful in accomplishing our objectives, or if our commercialization efforts do not develop as planned, we may not be able to successfully commercialize XDEMVY or any future approved products, we may require significant additional capital and financial resources, we may not become profitable, and we may not be able to compete against more established companies in our industry. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on the successful commercialization of XDEMVY and the development, regulatory approval, and commercialization of our current and future product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have one product approved for commercial sale, XDEMVY (lotilaner ophthalmic solution) 0.25%, which was approved by the FDA in July 2023 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">blepharitis in the U.S. The success of our business, including our ability to generate revenue from product sales in the future, will primarily depend on the successful commercialization of XDEMVY and the successful development, regulatory approvals and commercialization of our product candidates in one or more jurisdictions. Our ability to generate revenue and achieve profitability depends significantly on our ability, or any future collaborator&#8217;s ability, to achieve a number of challenging objectives, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">timely receipt of regulatory approvals from applicable regulatory authorities for our product candidates for which we successfully complete clinical development;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">successful and timely completion of preclinical and clinical development of our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">successfully educating ECPs about </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">blepharitis and related diagnosis;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">successful commercial launch following any regulatory approval, including leveraging our commercial infrastructure in-house or with one or more collaborators;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">commercial acceptance of XDEMVY and any of our other product candidates by patients, the medical community and third-party payers;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining relationships with CROs and clinical sites for the clinical development, both in the U.S. and internationally, of our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making any required post-marketing approval commitments to applicable regulatory authorities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for product candidates that we develop, if approved;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining an IND prior to commencing clinical trials in the U.S. for drug for a particular indication, such as TP-04 for the potential treatment of rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety and efficacy profile both prior to and following any marketing approval of our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, assessing and developing new product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the U.S. and internationally;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting our rights in our intellectual property portfolio;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defending against third-party interference or infringement claims, if any;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining favorable terms in any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our existing or acquired product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining coverage and adequate reimbursement for customers and patients from government and third-party payers for XDEMVY and other potential product candidates that we develop;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing therapies and technological and market developments; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring and retaining qualified personnel.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may never be successful in achieving our objectives and, even if we do, may never generate significant revenue that is large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business, retain key employees and continue our operations.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be successful in educating ECPs and the market about the need for treatments specifically for Demodex blepharitis and other diseases or conditions targeted by XDEMVY or our product candidates. XDEMVY or other product candidates that we may develop may fail to achieve market acceptance by ECPs, other healthcare providers and patients, or adequate formulary coverage, pricing or reimbursement by third-party payers and others in the medical community, and the market opportunity for these products may be smaller than we estimate.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XDEMVY, or any current or future product candidate that receives marketing approval, may fail to gain sufficient market acceptance by ECPs or other healthcare providers, patients, third-party payers and others in the medical community. Before the approval of XDEMVY, there was no approved prescription therapeutic for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">blepharitis and the only other current treatments include over-the-counter and off-label remedies such as tea tree oil, lid wipes and artificial tears, as well as off-label prescription products. Efforts to educate the medical community, patients and third-party payers on the benefits of XDEMVY and our other product candidates may require significant resources and may not be successful.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although XDEMVY is approved for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis, ECPs and potential patients may not have sufficient information about, or recognize the need for a treatment specifically targeting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis. It is possible that ECPs may continue to rely on other treatments for treating symptoms consistent with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis. A key tenet of our continued commercialization strategy is to educate ECPs on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis and how to diagnose it with a simple slit lamp examination as well as raise patient awareness of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis. However, our efforts may prove to be unsuccessful, and we may not be able to develop this new market for XDEMVY. We may still not achieve success in promotional efforts for XDEMVY, and ECPs may continue to use existing treatments rather than XDEMVY or any other product candidate and potential patients may not inquire as to XDEMVY. It is also possible that ECPs and patients may not be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">willing to adopt XDEMVY for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis because of the possibility that the disease will recur despite mite eradication and the potential for periodic use of XDEMVY.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if generic versions of any products that compete with XDEMVY or any of our product candidates are approved for marketing by the FDA or comparable foreign regulatory authorities, they could be offered at a substantially lower price than we expect to offer for XDEMVY or our other product candidates, if approved. As a result, ECPs, patients and third-party payers may choose to rely on such products rather than XDEMVY or our product candidates, if approved.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If XDEMVY or any other product candidate that we develop does not achieve an adequate level of acceptance, formulary coverage, pricing or reimbursement we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of XDEMVY or any other product candidate that we develop, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the efficacy, safety and potential advantages of XDEMVY, or our product candidates, if approved, compared to alternative treatments, including the existing standard-of-care, and the perceptions by members of the healthcare community of the same;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products for sale at competitive prices, particularly in light of the lower cost of alternative treatments;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which the product is approved;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of ECPs to prescribe these therapies;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength and effectiveness of our marketing and distribution support, which may be adversely impacted by health epidemics;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity concerning our products or competing products and treatments;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of competitive products;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception by patients or physicians that the diseases we are targeting, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis, are not burdensome;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for our competitors to limit our access to the market through anti-competitive contracts or other arrangements;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party formulary coverage and adequate reimbursement;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products, if approved, together with other medications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The sales, marketing, and distribution of XDEMVY or any future approved products may be unsuccessful or less successful than anticipated. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market XDEMVY or any future approved products on acceptable terms, we may be unable to successfully commercialize XDEMVY or any future approved products.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recently began commercializing our first product, XDEMVY, in the U.S. The success of our commercialization efforts for XDEMVY and any future approved products is subject to the effective execution of our business plan, including, among others, the continued development of our internal sales, marketing and distribution capabilities. For example, we have established an internal infrastructure as well as an ECP-focused sales and distribution infrastructure to market XDEMVY and our product candidates in the U.S., and have completed hiring in areas to support commercialization, including sales management, sales representatives, marketing, access and reimbursement, sales support and distribution. There are significant risks involved with establishing our own sales, marketing, and distribution capabilities, including our ability to hire, retain and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">appropriately incentivize qualified individuals, provide adequate training to sales and marketing personnel, and effectively manage geographically dispersed sales and marketing teams to generate sufficient demand. Any failure or delay in the development of these capabilities could or negatively affect the success of our commercialization efforts and business. For example, the commercialization of XDEMVY may not develop as planned or anticipated, which may require us to, among other items, adjust or amend our business plan and incur significant expenses. </span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, given our lack of experience commercializing products, we do not have a track record of successfully executing on the commercialization of an approved product. If we are unsuccessful in accomplishing our objectives and executing on our business plan, or if the commercialization of XDEMVY or any future approved products does not develop as planned, we may require significant additional capital and financial resources, we may not become profitable, and we may not be able to compete against more established companies in our industry. </span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in order to continue to commercialize XDEMVY or commercialize any product candidates, if approved, we must continue to build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell and market our product candidates. We may not be successful in accomplishing these required tasks.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The sizes of the market opportunities for our product or product candidates, particularly XDEMVY for the treatment of Demodex blepharitis and TP-03 for the treatment of MGD, have not been established with precision and may be smaller than we estimate, possibly materially. If our estimates of the sizes overestimate these markets, our sales growth may be adversely affected. We may also not be able to grow the markets for our product candidates as intended or at all.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our assessment of the potential market opportunity for XDEMVY and other product candidates that we develop is based on industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties and our own internal epidemiology and market research studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Similarly, although the studies we have conducted are based on information that we believe to be complete and reliable, we cannot guarantee that such information is accurate or complete. The potential market opportunities for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis and for the treatment of MGD is difficult to precisely estimate, because patients often have multiple ocular surface diseases and the symptoms have significant overlap, leading to frequent misdiagnosis of the various conditions. Therefore, our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and our own epidemiology studies and market research, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions and the bases of the studies and research we have conducted are reasonable, no independent source has verified such assumptions or bases. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for XDEMVY or any of our other product candidates may be smaller than we expect, and as a result our revenue from product sales may be limited and it may be more difficult for us to achieve or maintain profitability.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the patients presenting at ECP clinics with multiple ocular surface diseases, there is overlap in market size estimates for blepharitis and MGD. Therefore, if XDEMVY receives regulatory approval for the treatment of both </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis and MGD, our opportunity could be less than our forecasts because the actual market for XDEMVY might be significantly smaller than our estimates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Even though we obtained regulatory approval with respect to XDEMVY for Demodex blepharitis, we may not be able to obtain regulatory approval for additional indications, such as MGD, or we may be required to conduct additional trials, which would limit our ability to realize the full market potential of XDEMVY or increase the costs of developing TP-03 for MGD.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exploring the therapeutic potential for TP-03 in MGD as an additional indication. If we are successful, the indication for use of TP-03 could potentially be broadened beyond the treatment of Demodex blepharitis to include MGD as an additional indication. However, there can be no assurance that we will obtain approval for any other indication, including MGD or for any broadened indication beyond the treatment of Demodex blepharitis. If we fail to maintain required approvals for these additional or broadened indications, or if regulatory approvals are delayed, we will not realize the full market potential of TP-03. Additionally, the FDA or other comparable foreign regulatory authority may require us to conduct additional clinical trials before seeking regulatory approval. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted. XDEMVY and our product candidates, if approved, will also compete with existing branded, generic and off-label products.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The development and commercialization of new drug products is highly competitive. We face competition with respect to XDEMVY and our product candidates that we may seek to develop or commercialize in the future, from many different sources, including major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide and existing treatments. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our products. Our competitors also may obtain FDA approval or other regulatory authority approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our ability to compete may be affected in many cases by insurers or other third-party payers, particularly Medicare and the competent authorities of the individual European Union Member States (collectively the "EU Member States"), seeking to encourage the use of generic products. Generic products are currently being used for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, while XDEMVY is approved for the treatment of blepharitis or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis specifically, a number of other treatments are currently available for blepharitis in the U.S. Current treatments for blepharitis in the U.S. include over the counter remedies such as tea tree oil, lid wipes and artificial tears, as well as off-label prescription products. If ECPs were to continue to prescribe these other existing treatments instead of XDEMVY, our business would be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we obtained FDA approval of XDEMVY, and even if we obtain FDA approval of any of our product candidates, we may never obtain approval or authorization for such product candidates, including XDEMVY, in any other jurisdiction or commercialize such product candidates in the U.S. or in any other jurisdiction, which would limit our ability to realize their full market potential.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In order to market any products, including XDEMVY, outside of the U.S., we will need to comply with additional onerous but varying regulatory requirements of other countries regarding safety and efficacy on a country-by-country basis. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Approval by the FDA in the U.S. does not ensure approval by comparable regulatory authorities in other countries or jurisdictions nor does it ensure that we will be able to successfully commercialize XDEMVY or any other approved products in the U.S. or in other jurisdictions. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Further, successful commercialization in the U.S. does not guarantee successful commercialization in other jurisdictions. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we, or our collaboration partners, fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our ability to realize the full market potential of our products will be harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future product candidates may cause significant adverse events, toxicities or other undesirable side effects which may delay or prevent marketing approval or cause us to abandon or limit further clinical development or commercialization of those product candidates. In addition, significant adverse events, toxicities or other undesirable side effects may be identified during post-marketing surveillance for XDEMVY, or future approved products, which could result in regulatory action or negatively affect our ability to market the product.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the European Commission or other comparable foreign regulatory authorities.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the conduct of clinical trials, subjects report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our understanding of the relationship between our product candidates and these adverse events may change as we gather more information, and additional unexpected adverse events or an increase in adverse event rates may occur. If additional clinical experience indicates that any of our product candidates have side effects or causes serious or life-threatening side effects, participant recruitment for trials and the ability of enrolled subjects to complete trials could be negatively impacted, and the development of the product candidate may fail or be delayed, which would severely harm our business, prospects, operating results and financial condition.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, if we or others later identify undesirable side effects or adverse events caused by XDEMVY or one of our product candidates that receives marketing approval, a number of potentially significant negative consequences could result, including, but not limited to:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such product or require additional warnings on the label such as a black box warning, a contraindication or other limitations on the product's approved use, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may be seized by regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be a recall of the product;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create and implement a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, including ECPs, and/or other elements to assure safe use;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer and there may be resulting harm to physician or patient acceptance of our product.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">As we participate in the Medicaid Drug Rebate Program and other governmental pricing programs, failure to comply with obligations under these programs could result in additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Medicaid Drug Rebate program, a participating manufacturer is required to pay a rebate to each state Medicaid program for its covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by the state Medicaid program as a condition of having federal funds being made available for drugs under Medicaid and Medicare Part B. Those rebates are based on pricing data reported by the manufacturer on a monthly and quarterly basis to the Centers for Medicare and Medicaid Services ("CMS"). These data include the average manufacturer price and, in the case of innovator products, the best price for each drug, which, in general, represents the lowest price available from the manufacturer to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity in the U.S. in any pricing structure, calculated to include all sales and associated rebates, discounts, and other price concessions. If we fail to pay the required rebate amount or report pricing data on a timely basis, we may be subject to civil monetary penalties and/or termination from the Medicaid Drug Rebate program. Additionally, civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit the required price data on a timely basis, or if we misclassify or misreport product information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS could also decide to terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act of 2010 ("ACA") (addressed further above in the section on &#8220;Business &#8211; Government Regulatory &#8211; Coverage and Reimbursement&#8221;) made significant changes to the Medicaid Drug Rebate Program, and CMS issued a final regulation to implement the changes to the Medicaid Drug Rebate Program under the ACA. CMS also issued a final regulation that modified prior Medicaid Drug Rebate Program regulations to permit reporting multiple best price figures with regard to value based purchasing arrangements; and provide definitions for &#8220;line extension,&#8221; &#8220;new formulation,&#8221; and related terms, with the practical effect of expanding the scope of drugs considered to be line extensions that are subject to an alternative rebate formula. While the regulatory provisions that purported to affect the applicability of the best price and average manufacturer price exclusions of manufacturer-sponsored patient benefit programs, in the context of pharmacy benefit managers ("PBM") &#8220;accumulator&#8221; programs were invalidated by a court, such programs may continue to negatively affect us in other ways. Our failure to comply with these price reporting and rebate payment options, as well as PBM &#8220;accumulator&#8221; programs, could negatively impact our financial results.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that a manufacturer also participate in the 340B Drug Pricing program ("340B program") in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. The 340B program requires participating manufacturers to agree to charge no more than the 340B &#8220;ceiling price&#8221; ("340B ceiling price") for the manufacturer&#8217;s covered outpatient drugs to a specified &#8220;covered entities,&#8221; including community health centers and other entities that receive certain federal grants, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program. If we are found to have knowingly and intentionally charged 340B covered entities more than the statutorily mandated ceiling price, we could be subject to significant civil monetary penalties and/or such failure also could be grounds for Health Resources and Services Administration to terminate our agreement to participate in the 340B program, in which case our covered outpatient drugs would no longer be eligible for federal payment under the Medicaid or Medicare Part B program.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Inflation Reduction Act of 2022 ("IRA") establishes a Medicare Part D inflation rebate scheme (the first rebate period is in fourth quarter 2022 through third quarter 2023) and a drug price negotiation program, with the first </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negotiated prices to take effect in 2026. It also makes several changes to the Medicare Part D benefit, including the creation of a new manufacturer discount program in place of the current coverage gap discount program (beginning in 2025). Manufacturers may be subject to civil monetary penalties for certain violations of the negotiation and inflation rebate provisions and an excise tax during a noncompliance period under the negotiation program. Drug manufacturers may also be subject to civil monetary penalties with respect to their compliance with the new Medicare Part D manufacturer drug discount program.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations are complex, vary across products and programs, and are often subject to interpretation by the manufacturer, governmental agencies, and courts. A manufacturer that becomes aware that its Medicaid reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, is obligated to resubmit corrected data up to three years after those data originally were due. Restatements and recalculations increase the costs for complying with the laws and policies governing the Medicaid Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. They also may affect the 340B ceiling price and therefore liability under the 340B program.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company&#8217;s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual rebates vary from estimates, due to government invoicing delays or otherwise, the Company may need to adjust accruals, potentially adversely, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer. </span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, in order to be eligible to have its products paid for with federal funds under the Medicaid and Medicare programs and purchased by the Department of Veterans Affairs (&#8220;VA&#8221;), Department of Defense (&#8220;DoD&#8221;), Public Health Service, and Coast Guard (collectively, the &#8220;Big Four agencies&#8221;) and certain federal grantees, a manufacturer is required to participate in the VA Federal Supply Schedule (&#8220;FSS&#8221;) pricing program, established under Section 603 of the Veterans Health Care Act of 1992. Under this program, the manufacturer is obligated to make its covered drugs available for procurement on an FSS contract and charge a price to the Big Four agencies that is no higher than the Federal Ceiling Price (&#8220;FCP&#8221;), which is a price calculated pursuant to a statutory formula. The FCP is derived from a calculated price point called the &#8220;non-federal average manufacturer price&#8221; (&#8220;Non FAMP&#8221;), which the manufacturer calculates and reports to the VA on a quarterly and annual basis. Pursuant to applicable law, knowing provision of false information in connection with a Non FAMP filing can subject a manufacturer to significant penalties for each item of false information. The FSS contract also contains extensive disclosure and certification requirements. If we overcharge the government in connection with the FSS contract or Tricare Retail Pharmacy Rebate Program, whether due to a misstated FCP or otherwise, we will be required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and any response to government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 703 of the National Defense Authorization Act for Fiscal Year 2008, the manufacturer is required to pay quarterly rebates to DoD on utilization of its innovator products that are dispensed through DoD&#8217;s Tricare network pharmacies to Tricare beneficiaries. The rebates are calculated as the difference between the annual Non FAMP and FCP for the calendar year that the product was dispensed. A manufacturer that overcharges the government in connection with the FSS contract or Tricare Retail Pharmacy Rebate Program, whether due to a misstated FCP or otherwise, is required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources on the commercialization of XDEMVY for the treatment of Demodex blepharitis and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our product candidates on the potential treatment of certain indications. We are currently focused on the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">commercialization, of XDEMVY for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on the most viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for TP-03 and other product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for XDEMVY, TP-03 for other indications and other product candidates, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The terms of approvals and ongoing regulation of XDEMVY and any other current product candidates or product candidates we develop could require substantial expenditure of resources and may limit how we manufacture and market our products, which could materially impair our ability to generate revenue from product sales.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XDEMVY, and any other product candidate for which we obtain regulatory approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising, and promotional activities for such product, will be subject to continual requirements of and review by the FDA, the European Medical Agency ("EMA") and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, current good manufacturing practice ("cGMP") requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. Even if regulatory approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, we and our contract manufacturers will continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, and quality control for XDEMVY and any other approved products. If we are not able to comply with post-approval regulatory requirements, we could have the regulatory approvals for our products, including XDEMVY, withdrawn by regulatory authorities and our ability to market XDEMVY or any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial condition, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If XDEMVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">or any of our product candidates that are approved for marketing are found to have been improperly promoted for off-label uses by us, or if ECPs misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA and other foreign regulatory authorities strictly regulate the marketing of and promotional claims that are made about drug products. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other foreign regulatory authorities as reflected in the product&#8217;s approved labeling. Any regulatory approval that the FDA or a foreign regulatory authority grants is limited to those specific diseases and indications for which a product is deemed to be safe and effective. For example, the FDA-approved label for XDEMVY is limited to the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis, and we are not permitted to promote XDEMVY for any other uses, unless and until such uses are approved.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, although we believe XDEMVY and our product candidates may exhibit a lower risk of side effects or more favorable tolerability profile or better symptomatic improvement than other products for the indications we are studying, without head-to-head data, we will be unable to make comparative claims for XDEMVY or our product candidates, if approved. If we receive regulatory approval for any of our products and are found to have promoted XDEMVY or any of our products or product candidates, if approved, for off-label uses, we may become subject to significant liability, which would materially harm our business. Both federal and state governments have levied large civil and criminal fines against companies for alleged improper promotion and have enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, our management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our brand and reputation could be damaged. The FDA has also previously requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine, or criminal penalties. It is also possible that other federal, state, or foreign enforcement authorities might take action if they determine our business activities constitute promotion of an off-label use, which could result in significant penalties, including criminal, civil or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations. We </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">cannot, however, prevent an ECP from using XDEMVY or our product candidates in ways that fall outside the scope of the approved indications, as he or she may deem appropriate in his or her medical judgment. ECPs may also misuse XDEMVY or our product candidates, if approved, or use improper techniques, which may lead to adverse results, side effects or injury and, potentially, subsequent product liability claims. Furthermore, the use of XDEMVY or our product candidates, if approved, for indications other than those approved by the FDA and/or other regulatory authorities may not effectively treat such conditions, which could harm our brand and reputation among ECPs and patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development is a lengthy, expensive and risky process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future results. If clinical trials of our product candidates do not meet safety or efficacy endpoints or are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. The research and development of drugs is an extremely risky industry. Only a small percentage of product candidates that enter the development process ever receive marketing approval. Failure or delay can occur at any time during the clinical trial process. To date, we have focused substantially all of our efforts and financial resources on identifying, acquiring, and developing our product candidates, including conducting preclinical studies and clinical trials. Clinical testing is expensive and can take many years to complete, and we cannot be certain that any clinical trials will be conducted as planned or completed on schedule, if at all. Furthermore, product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials. Our inability to successfully complete preclinical and clinical development could result in additional costs to us and negatively impact our ability to generate revenue. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize product candidates. We currently generate revenue from product sales for one product, and we may never be able to develop or commercialize additional marketable products.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The results of preclinical and early clinical trials of our product candidates and other products with the same mechanism of action may not be predictive of the results of later-stage clinical trials. For example, we may not be able to replicate the safety and efficacy results of our Phase 2b/3 clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> blepharitis in clinical trials for other indications in the future. Clinical trial failure may result from a multitude of factors including flaws in trial design, dose selection, placebo effect, patient enrollment criteria and other challenges with enrolling and maintaining trial subjects, relatively smaller sample size in earlier trials, and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval. Furthermore, as more product candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and preliminary or interim results of a clinical trial do not necessarily predict final results. For example, our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials. The failure of any of our product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product candidates or cause regulatory authorities to require additional testing before approving any of our product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to complete preclinical or clinical trials of current or future product candidates, due to safety concerns, or if the results of these trials are not satisfactory to convince regulatory authorities of their safety or efficacy, we will not be able to obtain marketing approval for commercialization. Even if we are able to obtain marketing approvals for any of our product candidates, those approvals may be for indications that are not as broad as desired or may contain other limitations that would adversely affect our ability to generate revenue from sales of those products. Moreover, if we are not able to differentiate our product against other approved products within the same class of drugs, or if any of the other circumstances described above occur, our business would be materially harmed and our ability to generate revenue from that class of drugs would be severely impaired.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each of our product candidates will require additional clinical development, management of clinical, preclinical (for some of our product candidates) and/or manufacturing activities, regulatory approval in multiple jurisdictions, achieving and maintaining commercial-scale supply, building of a commercial organization, substantial investment and significant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We may experience delays in our ongoing clinical trials, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Any recommendations by the FDA regarding our applications or clinical trials could cause delay of any regulatory approval by the FDA and cause our expenses to increase. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, or any other product candidates that we may develop, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may experience delays in or failure to reach agreement on acceptable terms with prospective CROs, vendors and clinical sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs, vendors and trial sites;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to obtain sufficient enrollment in our clinical trials, our enrollment needs may grow larger than we anticipate, or participants may fail to complete our clinical trials at a higher rate than we anticipate;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide, or regulators or institutional review boards ("IRBs) or ethics committees may require us, to suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or IRBs or ethics committees may not authorize us or our investigators to commence a clinical trial at a prospective clinical trial site or at all or may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain regulatory approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate, and we may need to delay or suspend one or more trials until we complete additional financing transactions or otherwise receive adequate funding;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate or may be delayed;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs or ethics committees to suspend or terminate trials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may determine that the planned design of our clinical trials is flawed or inadequate;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend or withdraw their approval of a product or impose restrictions on its distribution;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to timely or at all obtain INDs for a product candidate;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may modify a preclinical study or clinical trial protocol;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to establish clinical endpoints that applicable regulatory authorities consider clinically meaningful, or, if we seek accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities consider likely to predict clinical benefit;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays due to the outbreak of health epidemics, including with respect to the conduct of ongoing clinical trials, receipt of product candidates or other materials, submission of NDAs, filing of INDs, and starting any clinical trials for other indications or programs; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience manufacturing delays due to health epidemics in our supply chain caused by a shortage of raw materials, a lack of employees on site at our suppliers due to illness, or a lack of productivity at our suppliers due to local or national government quarantine restrictions on coming to the workplace.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">incur unplanned costs;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain marketing approval at all;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain marketing approval in some countries and not in others;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the product removed from the market after obtaining marketing approval.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot be certain whether any of our planned clinical trials will begin on schedule or any preclinical studies we plan to initiate will begin on our intended schedule, or whether any such studies or clinical trials will need to be restructured or will be completed on schedule, or at all. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, or are unable to achieve clinical endpoints due to unforeseen events, such as health epidemics, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to generate additional revenue from product sales. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates and impair our ability to commercialize our product candidates and may harm our business and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our product candidates still require significant testing. We only recently began clinical trials to test TP-04 and TP-05 in humans and, as a company, we have limited experience in this area.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are early in our development efforts for our product candidates and indications, including TP-03 for the treatment of MGD, TP-04 for the treatment of rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction. The risk of failure for product candidates in early development is high. Extensive clinical trials are necessary to demonstrate the safety and efficacy of such product candidates in humans. Clinical trials may fail to demonstrate that such product candidates are safe for humans and effective for indicated uses. Further, we intend to leverage data from the TP-03 preclinical studies and clinical safety assessments for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> blepharitis to satisfy the preclinical study requirements for TP-03 for the treatment of MGD, and TP-04 and TP-05 and other indications. For MGD, we announced the enrollment of our first patient in the Phase 2a Ersa trial studying TP-03 for the potential treatment of MGD and in December 2023 reported positive topline results. For rosacea, we conducted the Phase 1 Galatea trial with TP-04 and initiated the Phase 2a Galatea trial, for the treatment of rosacea in March 2023. In February 2024, we announced positive topline results and plan to discuss and determine the potential regulatory path with the FDA. With respect to Lyme disease, in December 2022 we announced positive topline results from the completed Callisto trial and enrollment of the first patient in the Carpo trial. The Carpo trial, evaluating TP-05, a novel investigative oral, non-vaccine pharmacological prophylactic for the potential prevention of Lyme disease in humans is a randomized, double-blind, placebo-controlled trial that evaluated the efficacy of TP-05 in killing lab grown, non-disease carrying ticks after they have attached to the skin of healthy volunteers, as well as confirm the safety, tolerability, and blood concentration of TP-05. In February 2024, we announced positive topline results from the Carpo trial and plan to discuss and determine the potential regulatory path with the FDA. The FDA may reject our use of data from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TP-03 preclinical studies for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> blepharitis for other indications or require additional studies to augment the data to advance for clinical development. The FDA may also reject our use of data from preclinical studies conducted by third parties for Lyme disease and require us to conduct additional preclinical studies before advancing to additional clinical trials. In addition, data from preclinical studies conducted by third parties may not be as reliable as data from studies conducted by us and since we did not conduct the studies, there may be weaknesses in the studies design or results that we may not be aware of.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In part because of our limited infrastructure, experience conducting clinical trials as a company and regulatory interactions, we cannot be certain that our clinical trials will be completed on time, that our planned clinical trials will be initiated on time, if at all, that our planned development programs would be acceptable to the FDA or other comparable foreign regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have and may continue to encounter difficulties or delays enrolling patients in our clinical trials, which could cause delays in or adverse effects of our clinical development activities.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have and may continue to experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We have and may continue to experience difficulties in patient enrollment in our clinical trials for a variety of reasons. For example, we recently experienced delays related to our Carpo trial with topline results pushed out to February 2024 as a result of patient enrollment delays. The enrollment of patients depends on many factors, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the patient eligibility criteria defined in the protocol;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity of patients to study sites;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the trial;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patient consents;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to, or lack of adequate compensation for, prospective patients;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties of enrolling patients or patients continuing to participate in follow-up visits due to ongoing or new health epidemics; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition would reduce the number and types of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. Moreover, potential patients and their doctors may be inclined to use existing therapies rather than enroll patients in any future clinical trial.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Any termination or suspension of, or delays in the commencement or completion of, our planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue from product sales and adversely affect our commercial prospects.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before we can initiate clinical trials in the U.S. for our product candidates, we must submit the results of preclinical testing and any previous clinical studies to the FDA along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND. The initiation of clinical trials in the EU Member States will be subject to similar requirements concerning approval by competent national authorities and the receipt of a positive opinion from the relevant ethics committees. We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities placing the clinical trial on hold;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjects failing to enroll or remain in our trial at the rate we expect;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjects choosing an alternative treatment or other product candidates, or participating in competing clinical trials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjects experiencing severe or unexpected drug-related adverse effects;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to demonstrate efficacy of the product;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any interruptions or delays in the supply of our product candidates for our clinical trials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any failure or delay in reaching an agreement with CROs, vendors and clinical trial sites;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices ("GCP") or regulatory requirements or other third parties not performing data collection or analysis in a timely or accurate manner;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors becoming debarred, disqualified or suspended or otherwise penalized by the FDA or other comparable foreign regulatory authorities for violations of applicable regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one or more IRBs, other ethics committees refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial; or</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements and policies, which may require us to amend clinical trial protocols to comply with these changes and resubmit our clinical trial protocols to IRBs or ethics committees for reexamination.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize the commercial prospects of our product candidates and our ability to generate revenue from product sales.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. For example, if we make manufacturing or formulation changes to our product candidates, we may need to conduct </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">additional studies to bridge our modified product candidates to earlier versions. Further, if one or more clinical trials are delayed, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly. Any termination of any clinical trial of our product candidates will harm our commercial prospects and our ability to generate revenue from product sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our future profitability may depend, in part, on our ability to commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties, such as our China Out-License. We are evaluating the opportunities for the development and commercialization of our product candidates in other foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approvals in other countries we may be required to comply with numerous and varying regulatory requirements of such countries regarding the safety and efficacy of our product candidates and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to additional risks and uncertainties, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our customers&#8217; ability to obtain reimbursement for our product candidates in foreign markets;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to directly control commercial activities if we are relying on third parties;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different medical practices and customs in foreign countries affecting acceptance in the marketplace;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">import or export licensing requirements;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer accounts receivable collection times;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer lead times for shipping;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">language barriers for technical training and the need for language translations;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection of intellectual property rights in some foreign countries;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the existence of additional potentially relevant third-party intellectual property rights;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency exchange rate fluctuations; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, the pharmaceutical industry in the China Territory is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. In recent years, the regulatory framework in the China Territory regarding the pharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful development of TP-03 by GrandPharma under the China Out-License and reduce the current benefits we believe are available to us. The China Territory authorities have become increasingly vigilant in enforcing laws in the pharmaceutical industry and any failure by GrandPharma or our other partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our partner&#8217;s business activities in the China Territory. Additionally, to the extent that we enter into collaborations with third parties for development and/or commercialization of our products or product candidates in foreign markets, we will be unable to directly control development and commercial activities or whether such third parties continue to develop or commercialize such products or product candidates. For example, on February 13, 2024, LianBio announced its completion of a comprehensive strategic review and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares, deregistration under Section 12(b) of the Exchange Act, and workforce reductions. In March 2024, we executed the Novation Agreement with GrandPharma and LianBio to transition the rights to develop and commercialize TP-03 in China for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">blepharitis. As of the date of this filing, it is uncertain if and when we will receive any future milestone consideration under the China Out-License.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another example of the changing regulatory requirements is that in the European Union ("EU"), the European Commission has presented a proposal to reform the current EU pharmaceutical legislation. The proposal intends to reduce the regulatory data protection period and orphan market exclusivity period for new medicinal products. It is currently uncertain if the proposal will be adopted in its current form and it is uncertain if and when the revised legislation would enter into force.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. In some countries, particularly the countries in Europe, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have conducted a number of our completed clinical trials for our product candidates at sites outside the U.S., and the FDA may not accept data from trials conducted in such locations.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the FDA may accept data from clinical trials conducted outside the U.S., acceptance of this data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with certain ethical and policy principles, including GCP standards. Among other requirements, the trial data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with certain U.S. laws and regulations. There can be no assurance the FDA will accept data from clinical trials conducted outside of the U.S. There can also be no assurance that the comparable foreign regulatory authority in any jurisdiction in which we seek regulatory approval for our product candidates will accept data from clinical trials conducted outside such jurisdiction. If the FDA or any such foreign regulatory authority does not accept the data from any trial that we have conducted outside the U.S., it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, there are risks inherent in conducting clinical trials in multiple jurisdictions, inside and outside of the U.S. and if we conduct trials outside of the U.S., we may face risks, such as:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct our clinical trials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign exchange rate fluctuations;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, customs, shipment and storage requirements;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cultural or legal differences in the standards for medical practice and clinical research;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminished protection of intellectual property in some countries;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different cultural attitudes to self-reported adverse events (such as burning, stinging, blurry vision) leading to a different safety profile; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Managing our obligations under our in-license and out-license agreements and other strategic agreements may divert management time and attention, causing delays or disruptions to our business.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into two license agreements with Elanco: (i) a license agreement for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 ("Eye and Derm Elanco Agreement") and (ii) a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement" and with the Eye and Derm Elanco Agreement, the "Elanco Agreements"), and have also entered into the China Out-License as discussed elsewhere herein. We also may in the future enter into in-license or out-license agreements with multiple licensors and strategic agreements, which, subject us to various obligations, including diligence obligations, reporting and notification obligations, payment obligations for achievement of certain milestone as well as other material obligations. We may need to devote substantial time and attention to ensuring that we successfully integrate these transactions into our existing operations and are compliant with our obligations under these agreements, which may divert management&#8217;s time and attention away from our research and development programs or other day-to-day activities.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our in-license, out-license, and strategic agreements are also complex and certain provisions in those agreements may be susceptible to multiple interpretations. In the event of any disagreement about the interpretation of these provisions, our management may need to devote a disproportionate amount of its attention to resolving these disagreements. Such disruptions may cause delays in our research and development programs and other business objectives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operating activities may be restricted by certain covenants in our license and other strategic agreements, which could limit our development and commercial opportunities.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with our in-license, out-license, or other collaborations or strategic alliances, we may agree to and be bound by negative covenants which may limit our development and commercial opportunities. For example, pursuant to the Elanco Agreements, we made certain covenants to only engage with third party suppliers previously approved by Elanco, and only under certain circumstances. These provisions may inhibit our development efforts, prevent us from forming strategic collaborations to develop and potentially commercialize any other product candidates and may materially harm our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interim top-line and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim top-line or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Position and Need for Additional Capital</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We commenced activities in 2016. Our limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability. Our operations to date have been limited to organizing our company, raising capital, identifying and developing product candidates, establishing licensing arrangements and/or acquiring necessary technology, undertaking research, preclinical studies and clinical trials of our product candidates, establishing arrangements for the manufacture of XDEMVY and other product candidates and longer-term planning for commercialization efforts of XDEMVY and our other potential product candidates. Our prospects must be considered in light of the uncertainties, risks, expenses and difficulties frequently encountered by companies in their early stages of operations. We have limited experience in obtaining marketing approvals, manufacturing commercial scale product or arranging for a third party to do so on our behalf, or conducting sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing, obtaining marketing approval for and commercializing products. In addition, as our business grows, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles. We may not be successful as we transition from a company with a research and development focus to a company capable of supporting commercial activities.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Due to the recently initiated commercialization of XDEMVY and our continued development of our pipeline of product candidates through clinical trials and other indications, our capital requirements are difficult to predict and may change. We may need to obtain substantial additional funding to achieve our goals and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, reduce or eliminate our product development programs, commercialization efforts or other operations.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since our inception, we have funded our operations through private placements of preferred stock, convertible promissory notes, the sale of our common stock in our IPO and the Follow-On Public Offerings, and the 2023 ATM Prospectus, as well as proceeds from product sales, net, our China Out-License, and draws on our Credit Facility and Pharmakon Credit Facility. We expect our expenses to increase substantially and we will require a larger amount of capital to fund our commercialization efforts, the development of our product candidates and the maintenance and expansion of our operations and capabilities. These expenditures will include costs associated with marketing and selling any products approved for sale, including XDEMVY, conducting non-clinical studies and clinical trials, obtaining regulatory approvals, securing manufacturing and supply of product candidates, costs associated with in-licensing assets consistent with our core strategy and other unanticipated costs. Further, as a public company, we incur significant legal, accounting and other costs associated with operating as a public company.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our cash, cash equivalents and marketable securities of $298.5 million as of March&#160;31, 2024 and expected sales of XDEMVY is sufficient to fund our current and planned operations for at least the next twelve months from the date of filing this Quarterly Report on Form 10-Q. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will need to raise substantial additional capital to complete the development and commercialization of XDEMVY and our other product candidates through one or more of: equity offerings, draws from our Pharmakon Credit Facility, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the complexities of our transition to a commercial-stage company, it is challenging to estimate the actual amounts necessary to successfully commercialize any products approved for sale. We may need to raise additional funds earlier than currently anticipated if we choose to pursue additional indications for our product candidates, acquire new product candidates or otherwise expand our business more rapidly than we presently planned. We have based these estimates on assumptions that may prove to be incorrect or require adjustment because of our ongoing business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing, receipt and amount of sales and marketing capabilities of any current and future products, including the success of our commercialization efforts involving XDEMVY;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our current and future products, including XDEMVY, and the impact of any competing products;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for any current or future products;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and costs of manufacturing development and commercial manufacturing activities and our ability to scale them up;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the scope, rate of progress, costs and results of our drug discovery, preclinical development activities, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of clinical programs we decide to pursue;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of regulatory review of our product candidates, including the potential for regulatory authorities to require that we conduct more studies and trials than those that we currently expect to conduct and the costs of post-marketing studies or risk evaluation and mitigation strategies that could be required by regulatory authorities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspensions or delays in enrollment of our ongoing and future clinical trials, issues with data collection, or changes to the number of subjects we decide to enroll in clinical trials, including as a result of health pandemics, competing trials, or otherwise; </span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities for any current or future products that are approved for sale, including marketing, sales, and distribution costs, and any discounts or rebates to obtain access;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential changes in the regulatory environment and enforcement rules;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy our outstanding debt obligations;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the sales and marketing activities associated with the commercialization of our products, including XDEMVY, and the development of our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential changes in pharmaceutical pricing and reimbursement infrastructure;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs related to any future collaboration or licensing partners upon the achievement of negotiated milestones; </span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with any product liability or other lawsuits related to our products; </span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense needed to attract and retain skilled personnel; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization efforts of any current or future products, including our commercialization efforts involving XDEMVY, identifying potential product candidates and conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for our product candidates. In addition, our product candidates, if approved, may not achieve adequate product sales or commercial success. Although we initiated commercialization of XDEMVY for the treatment of Demodex blepharitis in August 2023, we will need to continue to sustain our existing capital resources to fund our future operating expenses and capital expenditure requirements. Adequate additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market conditions. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, limit, reduce or eliminate our research and development programs or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. In addition, attempting to secure additional financing may divert the time and attention of management from day-to-day activities and distract from our research and development efforts. Alternatively, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time we can generate substantial revenue from product sales, including from XDEMVY, our only approved product, we expect to finance our cash needs through possible combinations of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. For example, in May 2022, August 2023, and March 2024, we completed the Follow-On Public Offerings, in which we received total net proceeds of $74.2 million, $99.3 million, and $107.7 million, respectively (after deducting underwriting discounts, commissions and other estimated offering-related expenses) through the issuance of 5,889,832 shares of our common stock in the May 2022 Public Offering, 6,069,449 shares of our common stock in the August 2023 Public Offering, and 2,812,500 shares of common stock, and in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of our common stock in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 2024 Public Offering. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions. For example, the Pharmakon Credit Facility restricts our ability to pursue certain transactions that we may believe to be in our best interests without the prior written consent of Pharmakon, including but not limited to: disposing of assets, engaging in mergers, acquisitions, and similar transactions, incurring additional indebtedness, granting liens, making investments, paying dividends or making distributions or certain other restricted payments in respect of equity, prepaying other indebtedness, entering into restrictive agreements, undertaking fundamental changes or amending certain material contracts, in each case subject to certain customary exceptions and negotiated carve outs.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we raise funds through research grants, we may be subject to certain requirements, which may limit our ability to use the funds or require us to share information from our research and development. Raising additional capital through any of these or other means could adversely affect our business and the holdings or rights of our stockholders, and may cause the market price of our shares to decline. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or continued and future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business and our financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC, as receiver, and SVB was subsequently transferred into a new entity, SVBB. On March 12, 2023, the Department of the Treasury, the Federal Reserve, and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception. Such parties also announced, among other items, that Silicon Valley Bridge Bank has assumed the obligations and commitments of former SVB and commitments to advance under existing credit agreements with former SVB will be honored by SVBB in accordance with and pursuant to the terms of such credit agreements. In March 2023, First Citizens Bank assumed all of SVBB&#8217;s obligations and commitments, and SVBB began operating as SVB, a division of First Citizens Bank. Unless otherwise noted herein, all references to SVB or Silicon Valley Bank shall refer to Silicon Valley Bank, a division of First Citizens Bank. In light of the foregoing, the Company does not believe it has exposure to loss as a result of SVB&#8217;s receivership. </span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently maintain cash held on deposit at financial institutions in the U.S., including at SVB. These deposits are insured by the FDIC in an amount up to $250,000 for any depositor. To the extent we hold cash deposits in amounts that exceed the FDIC insurance limitation, we may incur a loss in the event of a failure of any of the financial institutions where we maintain deposits, to the extent such loss exceeds the FDIC insurance limitation, and such a failure could have a material adverse effect upon our liquidity, operations and our results of operations. </span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we and other parties with whom we conduct business may be unable to access funds in such deposit account or other accounts, including money market funds, held with a financial institution or lending arrangements with such a financial institution. Our ability and any of our counter-party&#8217;s ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected. In this regard, counterparties to SVB credit agreements and arrangements, and third parties such as beneficiaries of letters of credit (among others), may experience direct impacts from financial institutions in the future and uncertainty remains over liquidity concerns in the broader financial services industry. </span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing indebtedness may limit our flexibility in financing and operating our business and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2024 we entered into the Pharmakon Credit Facility with Pharmakon. The Pharmakon Credit Facility provides a $75.0 million initial term loan which was drawn in April 2024, a portion of which was utilized to repay all outstanding indebtedness, for total net proceeds of $39.8 million. The Pharmakon Credit Facility provides for three potential additional term loan tranches in principal amounts up to $25.0 million, $50.0 million, and $50.0 million, respectively, subject to customary conditions to funding and, in the case of the last two tranches, achieving minimum net sales milestones, which may be requested on or prior to December 31, 2024, June 30, 2025 and December 31, 2025, respectively. The Pharmakon Credit Facility contains representations and warranties, affirmative and negative covenants in each case, which is customary for financings of this type. However, there are no financial covenants. The Pharmakon Credit Facility contains representations and warranties, affirmative and negative covenants in each case customary for financings of this type. Certain of the customary negative covenants limit our ability to, among other things, dispose of assets, engage in mergers, acquisitions, and similar transactions, incur additional indebtedness, grant liens, make investments, pay dividends or make distributions or certain other restricted payments in respect of equity, prepay other indebtedness, enter into restrictive agreements, undertake fundamental changes or amend certain material contracts, in each case subject to certain customary exceptions and negotiated carve outs. However, there are no financial covenants.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Such restrictions could limit our ability to take certain actions and could reduce our flexibility to run and manage our business which could have an adverse effect on our results of operations. Our obligations under the Pharmakon Credit Facility are secured by a lien in substantially all of our assets, subject to certain exclusions. If we were unable to repay amounts due under the Pharmakon Credit Facility, Pharmakon could proceed against such assets. Any declaration by Pharmakon of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may engage in acquisitions or strategic partnerships that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, cause or to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the future, we may enter into transactions to acquire other businesses, products or technologies or enter into strategic partnerships, including licensing. If we do identify suitable acquisition or partnership candidates, we may not be able to make such acquisitions or partnerships on favorable terms, or at all. Any acquisitions or partnerships we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. For example, our Pharmakon Credit Facility may restrict our ability to pursue certain mergers, acquisitions or consolidations without obtaining the prior consent of Pharmakon or repaying our outstanding loan amounts. </span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We could incur losses resulting from undiscovered liabilities of the acquired business or partnership that are not covered by the indemnification we may obtain from the seller or our partner. In addition, we may not be able to successfully integrate any acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions or partnerships may also divert management attention from day-to-day responsibilities, lead to a loss of key personnel, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or partnerships or the effect that any such transactions might have on our operating results.</span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred substantial losses during our history which we expect to continue, we do not expect to become profitable in the near future, and we may never achieve profitability. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards (&#8220;NOLs&#8221;), and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have not yet completed an ownership change analysis. If a requisite ownership change occurs, the amount of remaining tax attribute carryforwards available to offset taxable income and reduce income tax expense in future years may be restricted or eliminated. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state, and local income taxation are complex and are constantly under review by legislators, the U.S. Department of Treasury, and the Internal Revenue Service. Changes to tax laws (which may have retroactive application) have occurred and are likely to continue to occur in the future, which could adversely affect our shareholders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Reliance on Third Parties</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not have the ability to independently conduct our clinical trials. We currently rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our current and planned clinical trials of TP-03, TP-04 and TP-05 and other product candidates, and we expect to continue to rely upon third parties to conduct additional clinical trials of potential future product candidates. Third parties have a significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These third parties are not our employees, and except for remedies available to us under our agreements with such third party, we have limited ability to control the amount or timing of resources that any such third party will devote to our clinical trials. Some of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements with a third party, it would delay our development activities.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our reliance on these third parties for such development activities will reduce our control over these activities but will not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCP standards, regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The EC also requires us to comply with similar standards. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EC or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP or other applicable regulations. In addition, our clinical trials must be conducted with product produced under current applicable cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the marketing approval process. We also are required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The third parties we rely on for these services may also have relationships with other entities, some of which may be our competitors. In addition, the operations of our CROs and other third-party service providers may be constrained or disrupted by health epidemics. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays can occur, which could materially impact our ability to meet our desired clinical development timelines. Although we plan to carefully manage our relationships with our CROs, investigators and other third parties, we may nonetheless encounter challenges or delays in the future, which could have a material and adverse impact on our business, financial condition and prospects.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of any product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We contract with third parties for the commercial manufacture of XDEMVY and for the manufacture of our product candidates for preclinical studies, clinical trials and eventual commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of XDEMVY or our product candidates or compounds or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our commercialization or development efforts.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We do not have any, and have no plans to acquire any, manufacturing facilities. We produce in our laboratory relatively small quantities of compounds for evaluation in our research programs. We rely, and expect to continue to rely, on third parties for the commercial manufacture of XDEMVY and the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture of our product candidates, if approved. We currently have limited manufacturing arrangements and expect that XDEMVY and each of our product candidates will only be covered by single source suppliers for the foreseeable future. For example, we purchase our API for XDEMVY, lotilaner, from Elanco, who sources through a single source supplier. This reliance increases the risk that we will not have sufficient quantities of XDEMVY or our product candidates or any future approved products, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our commercialization or development efforts.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, all entities involved in the preparation of XDEMVY for commercial sale or other therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for XDEMVY and our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of XDEMVY, investigational products and future products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of XDEMVY or our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA on a timely basis and must adhere to the FDA&#8217;s Good Laboratory Practice regulations and cGMP regulations enforced by the FDA through its facilities inspection program. Foreign regulatory authorities, including the European Commission and the competent authorities of the EU Member States, may require compliance with similar requirements. The facilities and quality systems of our third-party contractor manufacturers must pass a pre-approval inspection for compliance with the applicable regulations as a condition of marketing approval of our product candidates. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMP regulations. We have little or no control over the production processes of third-party manufacturers, CMOs or other suppliers. The third-party manufacturing facilities used in the production of API and our drug products are located outside of the U.S. and require FDA approval, which our third-party manufacturers may have limited experience with obtaining. Our CMOs and other suppliers are subject to inspection by the FDA and may receive observations that they may not be able to resolve in a timely or effective manner, which could impact whether our products can be approved on a timely basis, if at all. </span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of XDEMVY, components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture XDEMVY or other materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture XDEMVY or our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture XDEMVY or our product candidates. If we elect to or are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. If any of our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture XDEMVY or our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer. </span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our or a third party&#8217;s failure to execute on our manufacturing requirements, to do so on commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to meet commercial demands for XDEMVY or any other future product that is approved; </span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to cease development or to recall batches of XDEMVY or our product candidates; </span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">an inability to initiate or continue clinical trials of our product candidates under development;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of the cooperation of an existing or future collaborator, including by Elanco Agreements; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities.</span></div><div><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XDEMVY, our product candidates and any future products that we may develop may compete with other products and product candidates for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could prevent or delay commercialization efforts of XDEMVY or any future products, if approved, clinical development of product candidates or marketing approval of current or future product candidates.</span></div><div style="margin-top:12pt;text-indent:55.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our third-party manufacturers may encounter shortages in the raw materials or API necessary to produce XDEMVY or our product candidates in the quantities needed in sufficient quantities for our commercialization or to meet an increase in demand, or for our clinical trials, as a result of capacity constraints or delays or disruptions in the market for the raw materials or APIs, including shortages caused by the purchase of such raw materials or APIs by our competitors or others. The failure of us or our third-party manufacturers to obtain the raw materials or APIs necessary to manufacture sufficient quantities of XDEMVY or our product candidates, may have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We, or our third-party manufacturers, may be unable to successfully scale-up manufacturing of XDEMVY or our product candidates in sufficient quality and quantity, which would delay or prevent us from commercializing, conducting clinical trials and developing our product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In order to successfully commercialize XDEMVY and to conduct clinical trials of our product candidates, we will need to manufacture XDEMVY and our product candidates in large quantities. We, or our manufacturing partners, may be unable to maintain or successfully increase the manufacturing capacity for XDEMVY or any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we, or our manufacturing partners, are unable to successfully scale up the manufacture of XDEMVY or our product candidates in sufficient quality and quantity, the commercialization of XDEMVY or the development, testing and clinical trials of that product candidate may be delayed or become infeasible, and commercialization of XDEMVY or marketing approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As product candidates progress through preclinical to late stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Intellectual Property</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect XDEMVY or our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the U.S. could increase the uncertainties and costs. Recent patent reform legislation in the U.S. and other countries, including the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) during patent prosecution and additional procedures to attack the validity of a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> review, and derivation proceedings. After March 2013, under the Leahy-Smith Act, the U.S. transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The U.S. federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a nonexclusive, nontransferable, irrevocable, paid-up license for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights&#8221;. March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a nonexclusive, partially exclusive, or exclusive license to a responsible applicant or applicants. If the patent owner refuses to do so, the government may grant the license itself. If, in the future, we co-own or license in technology that is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, the new unitary patent system that came into effect in Europe in June 2023 has increased the complexity and uncertainty of European patent laws and would significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (&#8220;UPC&#8221;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The development and commercialization of our products, including our lead product XDEMVY, for the treatment of Demodex blepharitis, TP-03 for the potential treatment of MGD, TP-04 for the potential treatment of rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction, is dependent on intellectual property we license from Elanco. If we breach our agreements with Elanco or the agreements are terminated, we could lose license rights that are important to our business.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Elanco Agreements we acquired exclusive, worldwide, sublicensable licenses to certain intellectual property of Elanco for the development, marketing and commercialization of lotilaner for (i) the treatment, prevention, palliation or cure of any eye or skin disease or condition in humans and (b) all other applications in humans, respectively. The Elanco Agreements impose various development, regulatory, commercial diligence, financial and other obligations on us. If we fail to comply with our obligations under the Elanco Agreements, or otherwise materially breach either Elanco Agreement, and fail to remedy such failure or cure such breach within 60 days, Elanco will have the right to terminate the applicable Elanco Agreement. If we fail to meet any milestones by the achievement deadlines set forth in either Elanco Agreement for any reason other than those outside of our reasonable control, and such milestones remain unmet for 120 days after Elanco notifies us thereof, Elanco may terminate the applicable Elanco Agreement.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> If either Elanco Agreement is terminated or if our field of use in the Eye and Derm Elanco Agreement is reduced to eye and skin conditions only by Elanco, we would lose our applicable license in the country where such license was terminated and all rights therein to the licensed intellectual property would revert to Elanco. The loss of the license from Elanco would prevent us from developing and commercializing TP-03, TP-04 and TP-05 in any country where the license is terminated and could subject us to claims of breach of contract and patent infringement by Elanco if any continued research, development, manufacture or commercialization of TP-03, TP-04 or TP-05 is covered by the affected patents. If Elanco terminates the Eye and Derm Elanco Agreement for our failure to achieve a development milestone by the specified achievement deadline, then we must grant Elanco a non-exclusive, sublicensable, royalty-free license to our patents and know-how relating to lotilaner to develop, manufacture and commercialize lotilaner and any licensed products for the treatment, palliation, prevention or cure of any eye or skin disease or condition in humans. If Elanco terminates the All Human Uses Elanco Agreement for our failure to achieve a development milestone by the specified achievement deadline, then we must grant Elanco a non-exclusive, sublicensable, royalty-free license to our patents and know-how relating to lotilaner to develop, manufacture and commercialize </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lotilaner and any licensed products for all applications in humans other than the treatment, palliation, prevention or cure of any eye or skin disease or condition. Accordingly, the loss of our license or the termination of our license for skin diseases and conditions or of our license for other use in humans with Elanco would materially harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to obtain and maintain sufficient intellectual property protection for XDEMVY or our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to XDEMVY, our development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to XDEMVY, our product candidates and research programs. We seek to protect our proprietary position by filing patent applications in the U.S. and abroad related to our novel discoveries and technologies that are important to our business. Our pending and future patent applications may not result in patents being issued that protect XDEMVY or our product candidates or their intended uses or that effectively prevent others from commercializing competitive technologies, products or product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce and defend the patents, covering technology that we license from third parties. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including U.S. Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the scope of patent protection outside of the U.S. is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the U.S., or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing or will pursue will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. As noted above, the Novation Agreement amended the $15.0 million future development milestone payable on China regulatory approval of the China Out-License agreement with a combined condition of patent issuance related to TP-03 in China. If we are not able to obtain the aforementioned patent issuance in China, the likelihood we achieve the associated milestone, as well as commercialization in the China Territory would be substantially decreased. </span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, we may not be aware of all third-party intellectual property rights potentially relating to XDEMVY or our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our ability to commercialize our products, is highly uncertain. Because we have not yet conducted a formal patent landscape analysis related to XDEMVY or our product candidates, we may not be aware of issued patents that a third party might assert are infringed by XDEMVY or one of our current or future product candidates, which could materially impair our ability to commercialize XDEMVY or our product candidates. Even if we diligently search third-party patents for potential infringement by our products or product candidates, including XDEMVY, TP-03, TP-04 or TP-05, we may not successfully find patents that our products or product candidates, including XDEMVY, TP-03, TP-04 or TP-05, may infringe. If we are unable to confirm that our products do not infringe third-party patents, others could preclude us from commercializing XDEMVY or our product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing or, in some cases, not published at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our patents or pending patent applications may be challenged in the courts or patent offices in the U.S. and abroad. For example, we may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in post-grant review or interference procedures, oppositions, derivations, revocations, reexaminations, or inter partes review proceedings, in the U.S. or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize XDEMVY or our current or future product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our owned and licensed patent estate includes patent applications, many of which are at an early stage of prosecution. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or ability to sell our products without infringing third-party patents or patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned and in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, while we seek to protect the trademarks we use in the U.S. and in other countries, we may be unsuccessful in obtaining registrations and/or otherwise protecting these trademarks. If that were to happen, we may be prevented from using our names, brands and trademarks unless we enter into appropriate royalty, license or coexistence agreements, which may not be available or may not be available on commercially reasonable terms. Over the long term, if we are unable to establish name recognition based on our trademarks, trade names, service marks and domain names, then we may not be able to compete effectively, resulting in a material adverse effect on our business. Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted or declared generic, or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trademarks and trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be sought in every country in which our products are made available. Any name we propose to use for our products in the U.S. must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, that does not infringe the existing rights of third parties and that is acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications relating to XDEMVY or our product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">candidates, our competitive position, business, financial condition, results of operations and prospects would be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our products.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the U.S. and abroad that is relevant to or necessary for the commercialization of XDEMVY or our product candidates in any jurisdiction. Because we have not yet conducted a formal patent landscape analysis related to XDEMVY or our product candidates, we may not be aware of issued patents that a third party might assert are infringed by one of XDEMVY or our current or future product candidates, which could materially impair our ability to commercialize XDEMVY or our product candidates. Even if we diligently search third-party patents for potential infringement by our products, including XDEMVY, or product candidates, we may not successfully find patents that our products or product candidates may infringe. If we are unable to confirm that our products, including XDEMVY, do not infringe third-party patents, others could preclude us from commercializing XDEMVY or our product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market XDEMVY or our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products, including XDEMVY.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may wish to acquire rights to future assets through in-licensing or may attempt to form collaborations in the future with respect to XDEMVY or our product candidates, but may not be able to do so, which may cause us to alter or delay our commercialization or development plans.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The commercialization of XDEMVY and the development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. In 2019 and 2020, we entered into the Eye and Derm Elanco Agreement and the All Human Uses Elanco Agreement, respectively. We plan to utilize these license rights in developing and marketing XDEMVY, and our TP-03,TP-04 and TP-05 product candidates. We may, in the future, decide to collaborate with other biopharmaceutical companies for the development and potential commercialization of XDEMVY in other jurisdictions or our product candidates. We will face significant competition in seeking appropriate collaborators. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for the commercialization of XDEMVY in other jurisdictions or the development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of XDEMVY or that product candidate to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the following:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the potential market for the product candidate;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and complexities of manufacturing and delivering such product candidate to patients;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design or results of clinical trials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of approval by the FDA or comparable foreign regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential of competing products;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the existence of uncertainty with respect to our ownership of technology or other rights, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">industry and market conditions generally.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for XDEMVY or our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collaborations that we have entered into and may enter in the future may not be successful, and any success will depend heavily on the efforts and activities of such collaborators. Collaborations pose a number of risks, including the following:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development of our product candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that divert resources or create competing priorities;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue commercialization of any product or product candidates that achieve marketing approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that may divert resources or create competing priorities;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates on a discretionary basis;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with XDEMVY or our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator may seek to renegotiate or terminate their relationship with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve marketing approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collaboration agreements may not lead to development or commercialization of our products or product candidates in the most efficient manner, or at all. If any collaborations that we enter into do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this report also apply to the activities of our collaborators.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms or we may fail to comply with our obligations under such agreements and our business could be harmed.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the Elanco Agreements, from time to time we may be required to license technology from additional third parties to further develop or commercialize our product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations and prospects significantly.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, if we fail to comply with our obligations under any license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain those licenses. In each of the Elanco Agreements, Elanco retains, and future licensors could retain, the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our licensors to obtain, maintain and enforce such licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. If our licensors do not adequately protect such licensed intellectual property, competitors may be able to use such intellectual property and erode or negate any competitive advantage we may have, which could materially harm our business, negatively affect our position in the marketplace, limit our ability to commercialize our products and product candidates and delay or render impossible our achievement of profitability. Further, entering into such license agreements could impose various diligence, commercialization, royalty or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek to terminate our license, which could adversely affect our competitive business position and harm our business prospects.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the above risks, intellectual property rights that we license in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation related issues;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that our patents or patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we have pending U.S. and foreign patent applications in our portfolio, we cannot predict:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">if and when patents may issue based on our patent applications;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection of any patent issuing based on our patent applications;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether the claims of any patent issuing based on our patent applications will provide protection against competitors;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not third parties will find ways to invalidate or circumvent our patent rights;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not others will obtain patents claiming aspects similar to those claimed in our patents and patent applications;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; and/or</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether the patent applications that we own or in-license will result in issued patents with claims that cover our products or product candidates or uses thereof in the U.S. or in other foreign countries.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot be certain that the claims in our pending patent applications directed to our products or product candidates and/or technologies will be considered patentable by the USPTO or by patent offices in foreign countries. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our product candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the U.S. or foreign countries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time consuming and, even if resolved in our favor, are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is a substantial amount of intellectual property litigation in the biotechnology and biopharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates. Third parties may assert infringement claims against us based on existing or future intellectual property rights, regardless of merit. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents are directed to various types of products or methods of use. As the pharmaceutical and biotechnology industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties. The scope of patents is subject to interpretation by the courts, and the interpretation is not always uniform. The legal threshold for initiating litigation or contested proceedings is low, so even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">able to do this. Proving invalidity may be difficult. For example, in the U.S., proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S., the term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-U.S. jurisdictions to extend the term of a patent that covers an approved drug. While we may apply for patent term extensions on patents covering XDEMVY and other product candidates that may receive FDA approval, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the U.S. or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Competitors may infringe, misappropriate or otherwise violate our patents, trademarks, copyrights or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product. To counter infringement or unauthorized use, we may be required to file infringement or other intellectual property-related claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from making, using, or selling the invention at issue. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from making, using or selling the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There also could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the U.S. could increase the uncertainties and costs. Recent patent reform legislation in the U.S. and other countries, including the Leahy-Smith Act signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> review, and derivation proceedings. After March 2013, under the Leahy-Smith Act, the U.S. transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The U.S. federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a nonexclusive, nontransferable, irrevocable, paid-up license for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights&#8221;. March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a nonexclusive, partially exclusive, or exclusive license to a responsible applicant or applicants. If the patent owner refuses to do so, the government may grant the license itself. If, in the future, we co-own or license in technology that is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents are of national or regional effect, and filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. As such, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Further, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceuticals or biologics, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment. As such, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Furthermore, certain foreign and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may rely on trade secret and proprietary know how which can be difficult to trace and enforce, and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to seeking patents for some of our technology and product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Elements of our product candidate, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade secrets and know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We further seek to protect our potential trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. While it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing an enforceable agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Despite these efforts, our assignment agreements may not be self-executing and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If we fail in bringing or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could materially, and adversely affect our business, financial condition, results of operations, and growth prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees. The assignment risks of this paragraph could also pertain to any intellectual property licensed-in to us. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We employ individuals who were previously employed at other biotechnology or biopharmaceutical companies, or at research institutions. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators, and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We or our licensors may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Supreme Court, other U.S. federal courts, U.S. Congress, the USPTO or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our or our licensors&#8217; patents;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file&#160;a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file&#160;a patent covering such intellectual property;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent terms may be inadequate to protect our competitive position on our product candidates and preclinical programs for an adequate amount of time.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patent rights are of limited duration. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. A patent term extension based on regulatory delay may be available in the U.S. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Government Regulation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our industry is highly regulated by the FDA and comparable foreign regulatory authorities. We must comply with extensive, strictly enforced regulatory requirements to develop, obtain, and maintain marketing approval for XDEMVY or any of our product candidates, if approved.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XDEMVY and any product candidates we develop and the activities associated with their development and commercialization, including their design, testing, manufacturing, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution are very heavily regulated. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and have relied and expect to continue to rely on third-party CROs to assist us in this process. Securing FDA or comparable foreign regulatory approval such as a marketing authorization from the European Commission or the competent authorities of the individual EU Member States requires the submission of extensive preclinical and clinical data and supporting information for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy for its intended use. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. It takes years to complete the testing of a new drug and development delays and/or failure can occur at any stage of testing. Any of our present and future clinical trials may be delayed, halted, not authorized, or approval of any of our products may be delayed or may not be obtained due to any of the following:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any preclinical study or clinical trial may fail to produce safety and efficacy results satisfactory to the FDA or comparable foreign regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from a preclinical study or clinical trial or adverse events during a clinical trial could cause a preclinical study or clinical trial to be repeated or a development program to be terminated, even if </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other studies or trials relating to the development program are ongoing or have been completed and were successful;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities can place a clinical hold on a trial if, among other reasons, it finds that subjects enrolled in the trial are or would be exposed to an unreasonable and significant risk of illness or injury;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the facilities that we utilize, or the processes or facilities of third-party vendors, including without limitation the contract manufacturers who are or will be manufacturing drug substance and drug product for us or any potential collaborators, may not satisfactorily complete inspections by the FDA or comparable foreign regulatory authorities; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may encounter delays or rejections based on changes in FDA regulations, standards or policies or the regulations, standards or policies of comparable foreign regulatory authorities during the period in which we develop a product candidate or the period required for review of any final marketing approval before we are able to market any product candidate.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, information generated during the clinical trial process is susceptible to varying interpretations that could delay, limit, or prevent marketing approval at any stage of the approval process.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, early positive preclinical or clinical trial results may not be replicated in later clinical trials. As more product candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Failure to demonstrate adequately the quality, safety and efficacy of any of our product candidates would delay or prevent marketing approval of the applicable product candidate. We cannot assure you that if clinical trials are completed, either we or our potential collaborators will submit applications for required authorizations to manufacture or market potential products or that any such application will be reviewed and approved by appropriate regulatory authorities in a timely manner, if at all. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S. and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could restrict or regulate post-approval activities, impact pricing and reimbursement and affect our ability to profitably sell XDEMVY or any other product candidates for which we obtain marketing approval and prevent or delay marketing approval of product candidates. Among policy makers and payers both federally and on the state level in the U.S. and elsewhere, including in the European Union, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ACA substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things: (i) introduced a new average manufacturer price definition for drugs and biologics that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies; (ii) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and expanded rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well; (iii) established a branded prescription drug fee that pharmaceutical manufacturers of branded prescription drugs must pay to the federal government; (iv) expanded the list of covered entities eligible to participate in the 340B program; (v) established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased from 50% in 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D (which, under the IRA, will be replaced by a new manufacturer discount program starting in 2025); (vi) expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability; (vii) created a licensure framework for follow on biologic products; and (viii) established a Center for Medicare &amp; Medicaid Innovation, at the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since its enactment, there have been judicial challenges to certain aspects of the ACA, as well as efforts by Congress to modify, and agencies to alter the implementation of, certain aspects of the ACA. For example, Congress eliminated the tax penalty for not complying with the ACA&#8217;s individual mandate to carry health insurance. Further, the Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D to close the coverage gap in most Medicare drug plans, commonly referred to as the "donut hole" (which, under the IRA, will be replaced by a new manufacturer discount program starting in 2025). In the future, Congress may consider other legislation to modify elements of the ACA or other health care reform measures, agencies may further alter their implementation of elements of the ACA or other such measures, and other judicial challenges to elements of the ACA or other such measures may be brought. The extent to which any such changes may impact our business or financial condition is uncertain.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the ACA, as currently enacted or may be amended in the future, as well as other healthcare reform measures including those that may be adopted in the future, may result in more rigorous coverage criteria, and less favorable payment methodologies, or other downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement or restriction on coverage under Medicare or other government programs may result in a similar reduction or restriction by private payers.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011 and subsequent laws. Subsequent legislation extended the 2% reduction, generally to 2031.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sequestration is currently set at 2% and will increase to 2.25% for the first half of fiscal year 2030, to 3% for the second half of fiscal year 2030, and to 4% for the remainder of the sequestration period that lasts through the first six months of fiscal year 2031. The American Taxpayer Relief Act of 2012 among other things, also reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially adversely affect customer demand and affordability for our products and related services and, accordingly, the results of our financial operations. Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015 which first affected physician payment in 2019. It is unclear how the introduction of the Medicare quality payment program will impact our business.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA introduces several changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs and a change in manufacturer liability under the program which could negatively affect the profitability of our product candidates. The IRA sunsets the current Part D coverage gap discount program starting in 2025 and replaces it with a new manufacturer discount program. Failure to pay a discount under this new program will be subject to a civil monetary penalty. In addition, the IRA establishes a Medicare Part B inflation rebate scheme and a Medicare Part D inflation rebate scheme, under which, generally speaking, manufacturers will owe rebates if the price of a Part B or Part D drug increases faster than the pace of inflation. Failure to timely pay a Part B or D inflation rebate is subject to a civil monetary penalty. The IRA also creates a drug price negotiation program under which the prices for Medicare units of certain high Medicare spend drugs and biologics without generic or biosimilar competition will be capped by reference to, among other things, a specified Non FAMP starting in 2026. Failure to comply with requirements under the drug price negotiation program is subject to an excise tax and/or a civil monetary penalty. This or any other legislative change could impact the market conditions for our products. </span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the European Commission has published a proposal that intends to reduce the regulatory data protection period and orphan market exclusivity period for new medicinal products. Although it is currently uncertain if the proposal will be adopted in its current form and it is uncertain if and when the revised legislation would enter into force, this reform can impact our product candidates in the EU.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several Congressional inquiries and proposed bills and initiatives, as well as state efforts, designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the U.S. have become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Additionally, states have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">established Prescription Drug Affordability Boards (or similar entities) to review high-cost drugs and, in some cases, set upper payment limits.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that these and other healthcare reform measures in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may hinder us in generating revenue, attaining profitability or commercializing our drugs, once marketing approval is obtained.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, the European Commission has published a proposal that intends to reduce the regulatory data protection period for new medicinal products, which would allow generic competitors to obtain marketing authorization for generic products relying on our data earlier than under the current laws and we may be faced with earlier generic competition and lower prices for our product on the EU market. The legislative process for this reform is expected to take several years. Although it is currently uncertain if the proposal will be adopted in its current form and it is uncertain if and when the revised legislation would enter into force, this reform could impact our product candidates in the EU.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the European Union, coverage and reimbursement status of any product candidates for which we obtain regulatory approval are provided for by the national laws of EU Member States. The requirements may differ across the EU Member States. In markets outside of the U.S. and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Also, at the national level, actions have been taken to enact transparency laws regarding payments between pharmaceutical companies and health care professionals.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the U.S., the European Union or any other jurisdiction. If we or any third parties we may engage with are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our employees, independent contractors, clinical trial investigators, contract research organizations, consultants, vendors and any potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, consultants, vendors and any potential commercial partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA laws and regulations or those of comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information, (ii) manufacturing standards, (iii) federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency reporting requirements, and other healthcare laws and regulations in the U.S. and abroad or (iv) laws that require the true, complete and accurate reporting of financial information or data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. We adopted a code of conduct applicable to all of our employees immediately following the completion of our IPO, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we maintain general liability insurance as well as workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, with respect to the operations of our current and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products. In addition, our supply chain may be adversely impacted if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance with environmental, health and safety laws and regulations. For example, we source our API for XDEMVY, lotilaner, from Elanco, who sources through a single source supplier. If such manufacturers become subject to such injunctions or sanctions due to non-compliance, it could delay, prevent or impair our commercialization efforts, which could have an adverse effect on our business. </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The pharmaceutical legislation reform as proposed by the European Commission in April 2023 would, if adopted, also impose stricter rules regarding the &#8216;Environmental Risk Assessment&#8217; that pharmaceutical manufacturers are obliged to perform. Under the proposal for new legislation, non-compliance with the Environmental Risk Assessment requirements could result in the withdrawal or refusal of a marketing authorization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to federal, state and foreign healthcare and abuse laws and false claims laws, as well as information privacy and security laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties, criminal sanctions, contractual damages, reputational harm, and diminished profits and future earnings.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ECPs and third-party payers will play a primary role in the recommendation and prescription of XDEMVY and any future product candidates we may develop and any product candidates for which we obtain marketing approval. Our arrangements with ECPs, patients, third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may affect our business or financial arrangements and relationships through which we market, sell and distribute our products. As a biopharmaceutical company, federal and state healthcare laws and regulations pertaining to fraud and abuse are applicable to our business and may affect our ability to operate. These laws are further described in the section titled &#8220;Business - Government Regulation - Other Regulatory Matters.&#8221;</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have entered into consulting and scientific advisory board arrangements with physicians and other ECPs, including some who could influence the use of XDEMVY or our product candidates, if approved. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering of and use of XDEMVY or our product candidates, if approved, to be in violation of applicable laws.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Various state and federal regulatory and enforcement agencies continue actively to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">investigate violations of health care laws and regulations, and the U.S. Congress continues to strengthen the arsenal of enforcement tools. Responding to investigations can be time- and resource-consuming and can divert management&#8217;s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Efforts to ensure that our collaborations or business arrangements with third parties, and our business generally, comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other current or future governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgements, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disruptions at the FDA and other agencies may also slow the time necessary for new products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which we collectively refer to as "Trade Laws", prohibit, among other things, companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">For XDEMVY, or if we receive marketing approval for another product candidate, we are and will continue being subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to restrictions, withdrawal from the market, or penalties if we fail to comply with applicable regulatory requirements or if we experience unanticipated problems with our product candidates, when and if approved.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Obtaining coverage and reimbursement approval for a product from a government or other third-party payer is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payer. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the U.S.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Third-party payers often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Coverage and reimbursement by a third-party payer may depend upon a number of factors, including the third-party payer&#8217;s determination that use of a product is:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot be sure that reimbursement will be available for XDEMVY or any other product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payers for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reimbursement may impact the demand for, and the price of, XDEMVY or any other product for which we obtain marketing approval. Assuming we obtain coverage for XDEMVY or another given product by a third-party payer, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payers to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to experience pricing pressures in connection with the sale of XDEMVY or any of our other product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outside of the U.S., many countries require approval of the sale price of a product before it can be marketed and the pricing review period only begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), significant fines, private litigation, and/or adverse publicity and could negatively affect our financial condition, operating results and business.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and any potential collaborators may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the U.S., numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission ("FTC")), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"). Though we are not directly subject to HIPAA information privacy and security provisions &#8211; other than with respect to providing certain employee benefits, depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements. For example, in California, the CCPA, as amended by the California Privacy Rights Act ("CPRA"), creates transparency requirements, grants to California consumers (as that term is broadly defined) several rights with regard to their personal information, and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide disclosures to California consumers, and provides such consumers with ways to opt-out of certain sales of personal information. The CPRA introduced significant amendments to the CCPA and established and funded the CPPA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The amendments introduced by the CPRA went into effect on January 1, 2023, and implementing regulations continue to be introduced by the CPPA. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or potential statutory or actual damages. In addition, California residents have the right to bring a private right of action in connection with certain types of incidents. These claims may result in significant liability and potential damages. Other states including Virginia, Colorado, Utah, Indiana, Iowa, Tennessee, Montana, Texas, and Connecticut, have enacted privacy laws similar to the CCPA that impose new obligations or limitations in areas affecting our business and we continue to assess the impact of these state legislations on our business as additional information and guidance becomes available. Similarly, there are a number of legislative proposals in the U.S, at both the federal and state level, that could impose new obligations or limitations in areas affecting our business. The CCPA and other state laws could impact our business activities depending on how they are interpreted and exemplify the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and have been proposed and enacted in other states.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FTC also sets expectations for failing to take appropriate steps to keep consumers&#8217; personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section 5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#8217; personal information; any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Activities outside of the U.S. require adherence to local and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for non-compliance. EU Member States and the United Kingdom (&#8220;UK&#8221;), as well as other jurisdictions where we may in the future operate, have adopted data protection laws and regulations, which impose significant compliance obligations. For example, the EU General Data Protection Regulation (&#8220;GDPR&#8221;) imposes certain obligations and restrictions on the ability to collect, analyze, use, store, disclose, transfer, or otherwise process personal data, including health-related information from clinical trial subjects. The GDPR imposes a broad range of obligations and restrictions relating to the processing and protection of personal data, including obligations to having a legal basis for processing personal data (which may result in some instances in obtaining the consent of the individuals to whom the personal data relates), providing detailed information about the processing activities disclosed to the individuals, dealing with restrictions on sharing of personal data with third parties, and the transferring of personal data out of the EU, having contractual arrangements in place where required (such as with clinical trial sites and vendors), reporting in certain instances </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">personal data breaches to data protection authorities and/or affected individuals, appointing data protection officers, conducting data protection impact assessments, responding to privacy rights requests, and keeping records of processing activities. The GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers, or to alleviate problems caused by such breaches. This may be onerous and if our efforts to comply with the GDPR or other applicable EU laws and regulations are not successful, it could adversely affect our business. Recent scrutiny and reevaluation of legal mechanisms to allow for the transfer of personal data from the European Economic Area ("EEA"), Switzerland, or UK to the U.S. may impact our ability to transfer personal data or otherwise may cause us to incur significant costs to do so legally. Although there are legal mechanisms to allow for the transfer of personal data from the EEA, Switzerland, and the UK to the U.S., uncertainty about compliance with EU data protection laws remains and data protection authorities from the different EU Member States may interpret the GDPR differently, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data in the EU. Enforcement by EU and UK regulators is generally active, and failure to comply with the GDPR or applicable Member State/UK local law may result in substantial fines, amongst other things (such as notices requiring compliance within a certain timeframe). The GDPR provides for fines and other administrative penalties in the event of any non-compliance, including fines of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious offenses. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with data protection authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Further, the UK Government may amend/update UK data protection laws, which may result in changes to our business operations and potentially incur commercial cost. </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, European/UK data protection laws, including the GDPR, generally restrict the transfer of personal data from the EEA (including the EU), UK, and Switzerland, to the U.S. and most other countries (except those deemed to be adequate by the European Commission/UK Secretary of State as applicable) unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. This may cause us to incur significant compliance costs for implementing lawful transfer mechanisms, conducting data transfer impact assessments, and implementing additional measures where necessary to ensure that personal data transferred are adequately protected in a manner essentially equivalent to the EU. The GDPR provides different transfer mechanisms we can use to lawfully transfer personal data from the EU to countries outside the EU. An example is relying on adequacy decisions of the European Commission, such as the EU-U.S. Data Privacy Framework which was adopted by the European Commission in 2023 ("EU-U.S. Data Privacy Framework"). The adequacy decision concludes that the U.S. ensures an adequate level of protection (compared to that of the EU) for personal data transferred from the EU to U.S. companies participating in the EU-U.S. Data Privacy Framework. The adequacy decisions of the European Commission are subject to periodic reviews and may be amended or withdrawn. Another example of a lawful transfer mechanism under the GDPR is using the EU Standard Contractual Clauses (&#8220;EU SCCs&#8221;) as approved by the European Commission in 2021. In order to use the EU Standard Contractual Clauses mechanism, the exporter and the importer must ensure that the importer may guarantee a level of personal data protection in the importing country&#8217;s level of protection must be adequate that is essentially equivalent to that of the EEA. It follows from case law of the Court of Justice of the European Union and the European Data Protection Board that compliance with EU data transfer obligations involves conducting transfer impact assessments, which includes documenting detailed analyses of data access and protection laws in the countries in which data importers are located, which can be costly and time-consuming.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Data importers must also expend resources in analyzing their ability to comply with transfer obligations, including implementing new safeguards and controls to further protect personal data In the UK, international transfer mechanisms have been approved, including: the International Data Transfer Agreement and the International Data Transfer Addendum to the EU SCCs. The UK Information Commissioner&#8217;s Office has issued and maintains guidance on how to approach undertaking risk assessments for transfers of UK data to non-adequate countries outside the UK.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lack of valid transfer mechanisms for data subject to EU/UK data protection laws could increase exposure to enforcement actions as described above, and may affect our business operations and require commercial cost (including potentially limiting our ability to collaborate/work with certain third parties and/or requiring an increase in our data processing capabilities in the EU/UK). Further, the European/UK data protection laws (including laws on international data transfers as set out above) may also be updated/revised, accompanied by new guidance and/or judicial/regulatory interpretations, which could entail further impacts on our compliance efforts and increased cost. </span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), significant fines, private litigation, and/or adverse publicity and could negatively affect our financial condition, operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain personal data, as well as the providers who share this personal data with us, may contractually limit our ability to use and disclose the personal data. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. We cannot </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assure you that our third-party service providers with access to our or our customers&#8217;, suppliers&#8217;, trial patients&#8217; and employees&#8217; personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy and data protection laws and regulations and/or which could in turn adversely affect our business, results of operations and financial condition. We cannot assure you that our contractual measures and our own privacy and security- related safeguards will protect us from the risks associated with the third-party processing, storage and transmission of such information. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Ownership of our Common Stock </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The stock price of our common stock may be volatile or may decline regardless of our operating performance and you could lose all or part of your investment.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our failure to achieve product development or commercialization goals or regulatory approval milestones in the timeframe we announce;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operating performance and the performance of other similar companies;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results from our ongoing clinical trials and future clinical trials with our current and future product candidates or of our competitors;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in the commencement, enrollment and the ultimate completion of clinical trials;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions with respect to our product or product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the U.S. and other countries;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to future product candidates or clinical development programs;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in hospital or ECP practices;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruitment or departure of key personnel;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the economy as a whole and market conditions in our industry;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or the financial results of companies that are perceived to be similar to us;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financing or other corporate transactions, or inability to obtain additional funding;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expiration of market standoff or contractual lock-up agreements;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of our market float; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other factors discussed in this report.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many biopharmaceutical companies. Stock prices of many biopharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If securities or industry analysts cease coverage of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are an "emerging growth company" and "smaller reporting company" and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are an emerging growth company as defined in the JOBS and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the option to present only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements of Section&#160;404(b) of the Sarbanes-Oxley Act of 2002, as amended (the "Sarbanes-Oxley Act");</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee compensation; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to submit certain executive compensation matters to stockholder advisory votes, such as "say-on-pay," "say-on-frequency," and "say-on-golden parachutes."</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The JOBS Act permits an emerging growth company such as us, to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected to opt out of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) December 31, 2025, the last day of the fiscal year following the fifth anniversary of the completion of our IPO, (b) the last day of the fiscal year (a) in which we have total annual gross revenue of at least $1.235 billion or (b) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investors may find our common stock less attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may decline or become more volatile.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of a substantial number of shares of our common stock in the public market could cause the price of our common stock to fall.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to decline. Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. As of March&#160;31, 2024, we had 37,749,468 shares of common stock outstanding. Shares held by directors, executive officers and other affiliates will be subject to volume limitations under Rule 144 under the Securities Act of 1933 (the Securities Act")  and various vesting agreements.</span></div><div style="margin-top:12pt;text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of our outstanding warrant or options, or the perception that such sales may occur, could adversely affect the market price of our common stock. We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, including pursuant to our ATM program, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. For example, in March 2024 we completed a follow-on public offering of 2.8 million shares of our common stock at a public offering price of $32.00 per share and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of our common stock at a price of $31.9999 per pre-funded warrant, for aggregate net proceeds of approximately $107.7 million (after deducting underwriting discounts, commissions and other estimated offering-related expenses) and in the fourth quarter of 2023 we raised approximately $19.2&#160;million, after deducting broker commissions and fees, through sales under our ATM program. To the extent that additional capital is raised through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our officers, directors and holders of more than 5% of our outstanding common stock acting together, will, due to their holdings of our common stock, have significant influence over all matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders oppose them. This concentration of ownership might also have the effect of delaying or preventing a change of control of our company that other stockholders may view as beneficial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Requirements associated with being a public company will increase our costs significantly, as well as divert significant company resources and management attention.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a public company, we are subject to the reporting requirements of the Exchange Act, or the other rules and regulations of the SEC, or any securities exchange relating to public companies. Compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of management and we will incur significant legal, accounting and other expenses. We cannot assure you that we will satisfy our obligations as a public company on a timely basis.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as a public company, it may be more difficult or more costly for us to obtain certain types of insurance, including directors&#8217; and officers&#8217; liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">difficult for us to attract and retain qualified personnel to serve on our board of directors, our board committees or as executive officers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could result in sanctions or other penalties that would harm our business.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of The Nasdaq Global Market LLC. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. We must perform system and process design evaluation and testing of the effectiveness of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Therefore, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engaging outside consultants, continue to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. This requires us to incur substantial professional fees and internal costs to maintain compliance.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities including equivalent foreign authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We do not intend to pay dividends for the foreseeable future.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have never declared nor paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Pharmakon Credit Facility also contains a negative covenant that prohibits us from paying dividends subject to limited exceptions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consequently, stockholders must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We could be subject to securities class action litigation.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. Our operating results may fluctuate due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the cost of manufacturing XDEMVY or our other product candidates, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the level of demand for XDEMVY or our product candidates should they receive approval, which may vary significantly;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk/benefit profile, cost and reimbursement policies with respect to XDEMVY or our product candidates, if approved, and existing and potential future drugs that compete with our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the gross-to-net yields for XDEMVY or our other product candidates, if approved;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully recruit patients for preclinical studies and clinical trials, and any delays caused by difficulties in such recruitment efforts;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approval for our product candidates, and the timing and scope of any such approvals we may receive;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract, hire and retain qualified personnel;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures that we will or may incur to develop additional product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the changing and volatile U.S., European and global economic environments, including the impact of current or future health pandemics; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirement for the affirmative vote of holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation or our amended and restated bylaws, which may inhibit the ability of an acquiror to effect such amendments to facilitate an unsolicited takeover attempt; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div><div><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the U.S. federal district courts are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws or any action asserting a claim against us that is governed by the internal affairs doctrine.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our certificate of incorporation will further provide that the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:48.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</span></div><div id="i99aefa27e57f4135a048e6322fd4812b_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Proceeds from Initial Public Offering</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There has been no material change in the planned use of proceeds from our IPO as described in the Registration Statement on Form S-1 (File No. 333-249076), declared effective by the SEC on October 15, 2020, and the related final prospectus, dated October 15, 2020, filed with the SEC on October 16, 2020, pursuant to Rule 424(b) of the Securities Act.</span></div><div id="i99aefa27e57f4135a048e6322fd4812b_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div id="i99aefa27e57f4135a048e6322fd4812b_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div id="i99aefa27e57f4135a048e6322fd4812b_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Securities <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-732"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-733"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-734">Trading Plans</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> of Directors and Executive Officers</span></div><ix:nonNumeric contextRef="c-188" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-735" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, <ix:nonNumeric contextRef="c-188" name="ecd:TrdArrIndName" id="f-736">Bobak Azamian</ix:nonNumeric>, <ix:nonNumeric contextRef="c-188" name="ecd:TrdArrIndTitle" id="f-737">Chief Executive Officer</ix:nonNumeric>, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-738">291,000</ix:nonFraction> shares of common stock held by Dr. Azamian between August 23, 2023 and July 24, 2024. Dr. Azamian <ix:nonNumeric contextRef="c-188" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-739">terminated</ix:nonNumeric> the trading plan effective <ix:nonNumeric contextRef="c-188" name="ecd:TrdArrTerminationDate" id="f-740">January 8, 2024</ix:nonNumeric>.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-190" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-741" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, <ix:nonNumeric contextRef="c-190" name="ecd:TrdArrIndName" id="f-742">Jose Trevejo</ix:nonNumeric>, <ix:nonNumeric contextRef="c-190" name="ecd:TrdArrIndTitle" id="f-743">former Chief Medical Officer</ix:nonNumeric>, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-191" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-744">6,107</ix:nonFraction> shares of common stock held by Dr. Trevejo between August 17, 2023 and May 16, 2024. Dr. Trevejo <ix:nonNumeric contextRef="c-190" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-745">terminated</ix:nonNumeric> the trading plan effective <ix:nonNumeric contextRef="c-190" name="ecd:TrdArrTerminationDate" id="f-746">January 12, 2024</ix:nonNumeric>.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.479%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.751%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">ep</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">a</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">ation Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">21</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">, 2024, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">by and between Registr</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">ant and Jose Trevejo</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="josetrevejo-tarsussepara.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-33124.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-33124.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-33124.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-33124.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Tarsus Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i99aefa27e57f4135a048e6322fd4812b_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i99aefa27e57f4135a048e6322fd4812b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TARSUS PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bobak Azamian, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bobak Azamian, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Chairman</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Director)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey Farrow</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Farrow</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Strategy Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                         </span></div><div style="margin-top:12pt;text-align:right;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                         </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1#
<SEQUENCE>2
<FILENAME>josetrevejo-tarsussepara.htm
<DESCRIPTION>EX-10.1#
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>josetrevejo-tarsussepara</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- josetrevejo-tarsussepara001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">1  Separation Agreement  The following agreement (&#8220;Agreement&#8221;) between Jos&eacute; M. Trevejo (&#8220;you&#8221;) and Tarsus Pharmaceuticals,  Inc. (the &#8220;Company&#8221; and, together with you, the &#8220;Parties&#8221;) confirms your separation from employment and  offers you certain benefits to which you would not otherwise be entitled, conditioned upon your provision  of a general release of claims and the obligations set forth in this Agreement.   WHEREAS, you have served as the Chief Medical Officer of the Company since February 7, 2022;  WHEREAS, the Company notified you on January 11, 2024 that you would be separating from the  Company; and  WHEREAS, you desire to fully and finally resolve any and all disputes and to set forth your complete  agreement and release of claims.   NOW, THEREFORE, with the intent to be legally bound hereby, and in consideration of the mutual  promises contained herein, the receipt and adequacy of which is hereby acknowledged, the Parties agree as  follows:  1. Separation from Employment:  Your last day of employment with the Company will be February 17, 2024 (the &#8220;Separation Date&#8221;).  2. Final Pay and Benefits:  You acknowledge and agree that the Company has provided you with your final pay, less lawful deductions (the &#8220;Final Pay&#8221;) through the Separation Date, in a timely  manner and in accordance with your state&#8217;s or commonwealth&#8217;s law.  Whether or not you execute this  Agreement, you will be entitled to, and are not releasing your rights to, any benefits required to be provided  to you pursuant to any employee benefit plans in which you are a participant. You may also have rights to  continue your group health coverage under the federal law commonly called &#8220;COBRA,&#8221; or a state or  commonwealth law equivalent.  3. Severance Benefits: a. Severance Pay: The Company will pay you severance in the form of a lump sum cash severance payment equal to twelve (12) months of your current annualized salary (&#8220;Severance Pay&#8221;).  The payments will be made pursuant to the Company&#8217;s standard payroll procedures within fourteen (14)  calendar days of the Effective Date (defined below). The Severance Pay will be treated as taxable  compensation, but is not intended by either party to be treated, and will not be treated, as compensation for  purposes of eligibility or benefits under any benefit plan of the Company. The Company will apply standard  tax and other applicable withholdings to payments made to you.  b. Severance Bonus: The Company will also pay your 2023 annual target bonus, based 90% on the fiscal year 2023 Company performance score, and based 10% on individual performance  in the Company&#8217;s complete and absolute discretion (the &#8220;Severance Bonus&#8221;) approved by the  Compensation Committee (the &#8220;Committee&#8221;) of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). This  Severance Bonus will be paid in a lump sum by March 22, 2024. The determinations of the Board or the  Committee with respect to the 2023 Bonus Amount will be final and binding. The Severance Bonus will be  treated as taxable compensation, but is not intended by either party to be treated, and will not be treated, as  compensation for purposes of eligibility or benefits under any benefit plan of the Company. The Company  will apply standard tax and other applicable withholdings to payments made to you.  DocuSign Envelope ID: 1E8C611B-1CC2-44DE-A435-3A51619055196DD3AC07-AC3A-4C96-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  2    c. COBRA Premiums: The Company will also pay the COBRA premiums for you  and, if applicable, your dependents, for your continued group health coverage to the appropriate health  insurer, for up to twelve (12) months after your Separation Date, provided you elect COBRA coverage.  However, the Company will discontinue any such payment of COBRA premiums upon the earlier of (i) the  date when you become eligible for substantially equivalent health insurance in connection with new  employment, or (ii) the expiration of your continuation coverage under COBRA. You agree to immediately  notify the Company in the event of (i) above.     d. Additional Equity Benefits: The Company will provide the additional equity  benefits described in the Equity paragraph below.    e. Paid Administrative Leave: The Company will place you on paid garden leave  from January 18, 2024, to February 17, 2024. During this period, the Company will continue to pay your  full salary and the employer portion of your health insurance or COBRA premiums, and you will continue  to vest in your equity awards. Further, during this period, you will be expected to provide services to assist  in the transition of your responsibilities as reasonably requested by the Company (the &#8220;Garden Leave  Services&#8221;).  f. Acknowledgement &amp; Consideration: You acknowledge the above benefits  (&#8220;Severance Benefits&#8221;) include some benefit you would not have been entitled to if had you not signed this  Agreement.   4. Equity:   a. Stock Options. You were granted the options set forth in the table below (each, an &#8220;Option&#8221;  and collectively, the &#8220;Options&#8221;) to purchase shares of the Company&#8217;s common stock (&#8220;Common Stock&#8221;)  under the Company&#8217;s 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;).  You acknowledge and agree that  vesting of your Options will cease as of your Separation Date, and your rights to exercise your Options will  be in accordance with the 2020 Plan and your Stock Option Agreements.  The table below sets forth the  number of vested and unvested shares subject to each Option as of your Separation Date.  As consideration  for entering into this Agreement, the Company will accelerate the vesting of your Options such that  following the Effective Date, you will be vested in an additional number of shares subject to each of the  Options as if you remained in continuous service with the Company through March 31, 2024 (as further set  forth in the table below).    Date of  Grant  Number  of Option  Shares  Granted  Exercise  Price Per  Share  Vested  Option  Shares  Outstanding  as of the  Separation  Date  Unvested  Option  Shares  Outstanding  as of the  Separation  Date  Number of  Option  Shares  Eligible for  Acceleration  Remaining  Unvested  Option  Shares Post- Acceleration  2/1/2022 116,424 $20.64 58,212 58,212 2,425 55,787  3/8/2023 45,459 $15.00 0 45,459 11,364 34,095    All unvested shares subject to the Options that are not eligible for acceleration as set forth in the  table above will be forfeited to the Company on the Separation Date, in accordance with the terms and  conditions set forth in the Stock Option Agreement governing each of the Options.    DocuSign Envelope ID: 1E8C611B-1CC2-44DE-A435-3A51619055196DD3AC07-AC3A-4C96-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  3    As additional consideration, your Options, to the extent vested as of the Separation Date or which  are eligible for vesting acceleration as of the Effective Date and as set forth in the table above, will remain  exercisable until the 12-month anniversary of your Separation Date, subject to their earlier termination in  accordance with the 2020 Plan.  To the extent the extension of the post-termination exercise period applies  to an Option that is an incentive stock option with an exercise price that is lower than the current fair market  value of the Company&#8217;s Common Stock, you understand that the effect of the extension will be to disqualify  the Option as an incentive stock option.  To the extent the extension of the post-termination exercise period  applies to an Option that is an incentive stock option with an exercise price that is equal to or greater than  the current fair market value of the Company&#8217;s Common Stock, the extension will not immediately  disqualify the Option as an incentive stock option; however, such Option will automatically become a  nonstatutory stock option three (3) months after the Separation Date.  If you exercise an Option that is not  an incentive stock option at the time of exercise, you will be required to make arrangements satisfactory to  the Company to satisfy all applicable withholding obligations.  The Stock Option Agreements governing the Options will remain in full force and effect, and you  agree to remain bound by those agreements.   b. Restricted Stock Units. You were granted the awards of restricted stock units (&#8220;RSUs&#8221;) set  forth in the table below pursuant to the 2020 Plan. You acknowledge and agree that vesting of your RSUs  will cease as of your Separation Date.  The table below sets forth the number of vested and unvested shares  subject to each award of RSUs as of your Separation Date.    Date of  Grant  Number of RSUs  Granted  Number of RSUs  Vested as of the  Separation Date  Number of RSUs  Unvested as of the  Separation Date  2/1/2022 30,197 7,549 22,648  3/8/2023 30,792 0 30,792    All unvested RSUs will be forfeited to the Company on the Separation Date, in accordance with  the terms and conditions set forth in the Restricted Stock Unit Agreement governing each of the awards of  RSUs.  c. Except as set forth in (a) and (b) above, you acknowledge and agree that you do not have  any other rights to receive, acquire, possess or vest into any additional shares of Common Stock or any  other shares, warrants, securities, derivative securities or other class of capital stock of the Company or any  of its parent, subsidiary or affiliated entities, in connection with your service with the Company.  5. Employee Representations:  You acknowledge that the Company relies on these  representations by you entering into this Agreement:  a. You do not have any claim against the Company or the Releasees (defined below),  or otherwise have not made internal, administrative, or judicial complaints, claims, or actions against or  regarding the Company or the Releasees, for claims you are releasing in this Agreement;  b. You have reported to the Company any work-related injuries or occupational  illnesses sustained by you during your employment with the Company;  c. To your knowledge, you have been properly provided any leaves of absence  requested and available to you based on your or your family members&#8217; health or medical condition or  DocuSign Envelope ID: 1E8C611B-1CC2-44DE-A435-3A51619055196DD3AC07-AC3A-4C96-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  4    military service, and have not been subjected to any improper treatment, conduct, or actions due to a request  for or taking such leave;  d. You have received all compensation due to date because of services you performed  for the Company;  e. You have been properly provided paid time off and, consistent with the Company&#8217;s  non-accrual vacation policy, you will not have any accrued, but unused vacation time or paid time off as of  the Separation Date for which you are entitled to payment; and    f. You are not aware of any conduct by any person that violates Company policy or  the Company&#8217;s legal, compliance, or regulatory obligations, or any other suspected ethical or compliance  issues by the Company or the other Releasees, which you have not brought to the attention of the Company.   6. Return of Company Property: You acknowledge and agree that as a condition precedent for  the Severance Benefits, you must return to the Company all of its property and data of any type in your  possession, custody, or control including, but not limited to keys, access codes or devices, physical or  electronically stored documents or files, computer equipment, cell phone, and passwords.  You further agree  to return all the Company&#8217;s property and data in substantially the same working condition in which they  were issued to you, normal wear and tear excepted. Notwithstanding the foregoing, (i) an inadvertent failure  by you to return such property, if immaterial, will not constitute a breach of this Agreement; and (ii) you  may retain compensation-related and personnel documents pertaining to your employment, and materials  distributed to shareholders generally.      7. Proprietary Information:  You acknowledge that you are bound and continue to be bound  by the Company&#8217;s Proprietary Information and Inventions Agreement (the &#8220;Confidentiality Agreement&#8221;),  a copy of which is attached as Exhibit A.    8. General Release and Waiver of Claims by You:  To the fullest extent permitted by law, you  on behalf of yourself, your heirs, family members, executors, estates, agents and assigns, or any controlled  affiliate and any trust or other entity of which you or your heirs, estates or family directly or indirectly hold  a majority beneficial interest, fully, finally, and forever release and discharge the Company and its owners,  agents, officers, shareholders, employees, directors, attorneys, subsidiaries, affiliates, successors, investors,  and assigns (collectively &#8220;Releasees&#8221;), of and from all claims and potential claims, which may legally be  waived by private agreement, whether known or unknown, which you have asserted or could assert against  the Company, arising out of or relating in any way to acts, circumstances, facts, transactions, or omissions  based on facts, occurring up to and including the date you sign this Agreement (the &#8220;Released Claims&#8221;).  The Released Claims specifically include, but are not limited to: claims under common law or equity; claims  for additional compensation or benefits arising out of your employment or your separation from  employment; wage and hour claims; unlawful discharge; breach of contract; breach of the covenant of good  faith and fair dealing; fraud; violation of public policy; defamation; physical injury; emotional distress;  negligence; claims under Title VII of the 1964 Civil Rights Act; the Age Discrimination in Employment  Act (&#8220;ADEA&#8221;); Older Workers Benefit Protection Act (&#8220;OWBPA&#8221;); the Employee Retirement Income  Security Act of 1974 (&#8220;ERISA&#8221;); the Americans with Disabilities Act; the Workers Adjustment and  Retraining Notification Act; the Equal Pay Act; the Family Medical Leave Act; the Civil Rights Act of  1866; the Pregnancy Discrimination Act; the Massachusetts Wage Act, the Massachusetts Fair Employment  Practices Act; the California Fair Employment and Housing Act, or the California Labor Code, and any  other federal, state, or local laws, constitution, rule, ordinance, order, and/or regulations, including their  amendments and respective implementing regulations. Notwithstanding the foregoing, nothing in this  Agreement is a waiver of any claims (i) to enforce this Agreement; (ii) for any obligation of the Company  pursuant to this Agreement; or (iii) regarding any rights of indemnification, rights to receipt of legal fees  DocuSign Envelope ID: 1E8C611B-1CC2-44DE-A435-3A51619055196DD3AC07-AC3A-4C96-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  5    and expenses, rights of insurance coverage, or rights to obtain contribution in the event of the entry of a  judgment against you as a result of any act or failure to act for which both you and the Company are jointly  responsible, to which you may be entitled.  By signing below, you expressly waive any benefits of Section 1542 of the Civil Code of the State  of California, which provides:  A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR  RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR  AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER,  WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE  DEBTOR OR RELEASED PARTY.  9. Protected Rights:    a. You understand that nothing in this Agreement limits your ability to file a charge  or complaint with, to provide documents or information voluntarily or in response to a subpoena or other  information request to, or to participate in an investigation or proceeding conducted by, the Equal  Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and  Health Administration, the Securities and Exchange Commission, or any other federal, state, or local  government agency or commission (each, a &#8220;Government Agency&#8221;).  You further understand this  Agreement does not limit your ability to communicate with any Government Agency or otherwise  participate in any investigation or proceeding that may be conducted by any Government Agency, including  providing documents or other information, without notice to the Company.  This Agreement does not limit  your right to receive an award for information provided to any Government Agency.  You understand that nothing in this Agreement: (i) applies to claims for unemployment or workers&#8217;  compensation benefits; (ii) applies to claims arising after the date you sign this Agreement; (iii) applies to  claims for reimbursement of expenses under the Company&#8217;s expense reimbursement policies; (iv) applies  to claims for any vested rights under the Company&#8217;s ERISA-covered employee benefit plans as applicable  on the date you sign this Agreement; (v) applies to claims that controlling law clearly states may not be  released by private agreement; (vi) limits or affects your right, if any, to challenge the validity of this  Agreement under the ADEA or the OWBPA; (vii) applies to a non-disclosure or non-disparagement clause  agreed to before a dispute arises involving a nonconsensual sexual act or sexual contact, including when  the victim lacks capacity to consent, or relating to conduct that is alleged to constitute sexual harassment;  (viii) precludes you from exercising your rights, if any, under Section 7 of the National Labor Relations Act  (&#8220;NLRA&#8221;) or under similar state law to engage in protected, concerted activity with other employees,  including discussing your compensation or terms and conditions of employment; or (ix) prevents you from  discussing or disclosing information about unlawful or criminal acts in the workplace, such as harassment  or discrimination or any other conduct that you have reason to believe is unlawful or waives your right to  testify in an administrative, legislative, or judicial proceeding concerning alleged criminal conduct or  alleged sexual harassment on the part of the Company, or on the part of the agents or employees of the  Company, when you have been required or requested to attend such a proceeding pursuant to a court order,  subpoena, or written request from an administrative agency or the legislature. However, by signing this  Agreement, you are waiving your right to recover any individual relief, including any backpay, frontpay,  reinstatement or other legal or equitable relief, in any charge, complaint, or lawsuit or other proceeding  brought by you or on your behalf by any third party, except for any right you may have to receive a payment  or award from a Government Agency (and not the Company) for information provided to said Government  Agency and except as provided under applicable law.    DocuSign Envelope ID: 1E8C611B-1CC2-44DE-A435-3A51619055196DD3AC07-AC3A-4C96-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  6    b. Notwithstanding your confidentiality obligations to the Company under the  Confidentiality Agreement, this Agreement, and otherwise, you understand that as provided by the Federal  Defend Trade Secrets Act, you will not be held criminally or civilly liable under any federal or state trade  secret law for the disclosure of a trade secret made: (i) in confidence to a federal, state, or local government  official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating  a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or other proceeding,  if such filing is made under seal.  c. You understand that upon the Effective Date, this Agreement will be final and  binding.  You promise not to pursue any claim released by this Agreement.  If approached by anyone for  counsel or assistance in the presentation or prosecution of any disputes, differences, grievances, claims,  charges, or complaints against the Releasees, you shall do no more than simply say you cannot provide  counsel or assistance.  If you break this promise, or otherwise breach your obligations under the Agreement,  you agree to pay the Company&#8217;s costs and expenses, including reasonable attorneys&#8217; fees, related to the  defense of any claims covered by this Agreement or any Releasee&#8217;s efforts to enforce this Agreement.   Notwithstanding the foregoing, although you are releasing claims you may have under the ADEA and the  OWBPA, you may challenge the knowing and voluntary nature of this release before a court, the Equal  Employment Opportunity Commission, or any other Government Agency charged with the enforcement of  any employment laws.  10. Confidentiality:  Except as required by law and subject to the Protected Rights paragraph  above, you must keep the existence, contents, terms, and conditions of this Agreement confidential and may  not disclose them except to your immediate family, accountant(s), attorneys, financial or tax advisers, or  under subpoena or court order.  If asked for information about this Agreement, you will simply respond that  you and the Company have separated on agreed terms.  Any breach of this Confidentiality paragraph shall  be deemed a material breach of this Agreement.    11. Cooperation:  You agree to reasonably cooperate with the Company relating to matters  within your knowledge or responsibility. Without limiting this commitment, you agree (i) to meet with  Company representatives, its counsel, or other designees at mutually convenient times and places with  respect to any items within the scope of this provision; (ii) to provide truthful testimony regarding same to  any court, agency, or other adjudicatory body; and (iii) to provide the Company with notice of contact by  any non-governmental adverse party or such adverse party&#8217;s representative, except as may be required by  law. The Company will reimburse you for reasonable expenses in connection with the cooperation described  in this paragraph. Any request for cooperation by the Company pursuant to this paragraph will not interfere  with your pursuit, acceptance, or performance of duties in respect of other employment (including self- employment). In connection with any cooperation pursuant to this paragraph, the Parties shall each use their  good-faith best efforts to reconcile and accommodate any conflicts in scheduling related to such  cooperation, and the Company shall minimize, to the extent reasonably possible, the time required of you  in connection with such requested cooperation.  12. No Disparagement:  Subject to the Protected Rights paragraph above, you agree that you  will never make any disparaging, defamatory, or negative statements public or privately, online or offline,  orally or in writing about the Company or its directors, officers, products, services or business practices,  your employment with the Company, or the termination of that employment. Similarly, the Company shall  instruct the Company&#8217;s current executive team members: Bobak Azamian, Jeff Farrow, Aziz Mottiwala,  Sesha Neervannan, Dianne Whitfield, Bryan Wahl, and Cara Miller to not make any disparaging,  defamatory, or negative statements, public or privately, online or offline, orally or in writing, about you,  your employment with the Company, or the termination of that employment. Notwithstanding the  foregoing, nothing in this Agreement prohibits you from (i) providing truthful testimony or information  necessary to enforce any agreement between you and the Company or pursuant to a subpoena, court order  DocuSign Envelope ID: 1E8C611B-1CC2-44DE-A435-3A51619055196DD3AC07-AC3A-4C96-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  7    or other legal process; (ii) correcting or refuting any incorrect, defamatory, disparaging, or derogatory  statements, made against you; or (iii) making truthful non-defamatory, non-disparaging, or non-derogatory  statements in the context of seeking new employment or as part of your employment with any succeeding  employer during normal competition.    13. No Admission of Liability: This Agreement shall not be construed or contended by you to  be an admission or evidence of any wrongdoing, unlawful conduct, or liability by the Company or the  Releasees. This Agreement shall be afforded the maximum protection allowable under Federal Rule of  Evidence 408 and/or any other state or federal law of similar effect. However, the Parties agree that this  Agreement may be used as evidence in a subsequent proceeding in which any of the Parties allege a breach  of this Agreement or as a complete defense to any lawsuit brought by any party.  14. Headings; Sub-Headings:  Headings and sub-headings of the paragraphs and sub- paragraphs of this Agreement are intended solely for convenience of reference and no provision of this  Agreement is to be construed based upon the heading or sub-heading of any paragraph or sub-paragraph.       15. Complete and Voluntary Agreement:  This Agreement, including its exhibits, constitutes  the entire agreement between you and the Company regarding the subject hereof and supersedes all prior  negotiations and agreements, whether written or oral, relating to such subject.  Notwithstanding the  foregoing, this Agreement shall not supersede obligations you may have under any agreements with the  Company regarding the non-disclosure of trade secrets and confidential or proprietary information,  prohibiting solicitation of customers, suppliers, or employees, prohibiting competition with the Company,  assigning intellectual property, or providing for a dispute resolution mechanism.  You acknowledge that  neither the Company, the Releasees, nor their agents or attorneys have made any promise, representation or  warranty, either express or implied, written or oral, which is not contained in this Agreement to induce you  to execute the Agreement. You acknowledge that you have executed this Agreement in reliance only upon  the promises, representations and warranties herein, and that you are executing this Agreement voluntarily  and free of any duress or coercion. This Agreement is binding on and is for the benefit of the Parties and  their respective successors, assigns, heirs, personal representatives, executors, administrators, and other  legal representatives.  16. Severability:  The provisions of this Agreement are severable, and if any part of the  Agreement is found to be invalid or unenforceable, the other parts shall remain valid and enforceable.   17. Modification; Counterparts; Electronic/PDF Signatures:  You agree this Agreement may  not be altered, amended, modified, or otherwise changed, except by another written agreement that  specifically refers to this Agreement, executed by authorized representatives of each party to this  Agreement.  This Agreement may be executed in several counterparts, each of which shall constitute an  original and all of which together shall constitute the same instrument.  Counterparts may be delivered via  facsimile, electronic mail, or other electronic transmission method, and may be executed using any  electronic signature method complying with the United States ESIGN Act of 2000 (e.g.,  www.docusign.com).  Any such counterpart so delivered shall be deemed to have been duly and validly  delivered and be valid and effective for all purposes.    18. Interpretation and Construction of Agreement: This Agreement shall be construed and  interpreted under the laws of the state or commonwealth where you were last employed by the Company  (Massachusetts) without regard to conflict-of-laws principles.  Moreover, this Agreement shall not be  construed against either Party as the author or drafter of the Agreement.   DocuSign Envelope ID: 1E8C611B-1CC2-44DE-A435-3A51619055196DD3AC07-AC3A-4C96-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  8    19. Review of Separation Agreement; Effective Date:  You understand that you must sign this  agreement no earlier than your Separation Date (February 17, 2024) and deliver it to me at email  bobby@tarsusrx.com no later than February 23, 2024 (the &#8220;Consideration Period&#8221;). You also agree that  you have had at least twenty-one (21) calendar days to consider this Agreement, and that changes to this  Agreement, whether material or immaterial, do not toll or restart the Consideration Period.  If you choose  to sign this Agreement before the Consideration Period ends, you represent: (i) you freely chose to do so  after carefully considering its terms; (ii) you are knowingly and voluntarily waiving the remainder of the  Consideration Period; and (iii) your decision to waive the remainder of the Consideration Period was not  induced by the Company through fraud, misrepresentation, or a threat to withdraw or alter the offer prior  to the expiration of the Consideration Period, or by providing different terms to you for signing this  Agreement prior to the expiration of the Consideration Period.  You affirm that you were advised to consult  with an attorney before signing this Agreement. You also understand you may revoke this Agreement within  seven (7) calendar days of signing (the &#8220;Revocation Period&#8221;) and that the Company will only provide you  with the Severance Benefits after that Revocation Period has expired.  Any revocation must be made in  writing and delivered to me at email bobby@tarsusrx.com. This Agreement is effective on the eighth (8th)  calendar day after you sign it, provided that you have not revoked it (the &#8220;Effective Date&#8221;).  (Remainder of Page Intentionally Left Blank; Signatures Follow Below)     DocuSign Envelope ID: 1E8C611B-1CC2-44DE-A435-3A51619055196DD3AC07-AC3A-4C96-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  9    The Parties have read this agreement and understand its legal and binding effect.  The Parties are  acting voluntarily, deliberately, and of their own free will in signing this agreement.       By:______________________________________  Bobak Azamian  Chief Executive Officer  Tarsus Pharmaceuticals, Inc.    Date:  __________________________          _______________________________   Jos&eacute; M. Trevejo    Date:  __________________________    *** Do not sign before February 17, 2024 ***      Exhibit  Exhibit A: Confidentiality Agreement        DocuSign Envelope ID: 1E8C611B-1CC2-44DE-A435-3A5161905519 2/20/2024 6DD3AC07-AC3A-4C96-B3D1-C704959A028D 2/21/2024 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    EXHIBIT A  Confidentiality Agreement    DocuSign Envelope ID: 1E8C611B-1CC2-44DE-A435-3A51619055196DD3AC07-AC3A-4C96-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  GDSVF&amp;H\3797916.1     PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT  The following confirms and memorializes an agreement that Tarsus  Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;) and I (Jos&eacute; Trevejo) have had  since the commencement of my employment (which term, for purposes of this agreement, shall be  deemed to include any relationship of service to the Company that I may have had prior to actually  becoming an employee) with the Company in any capacity and that is and has been a material part  of the consideration for my employment by Company:  1. I have not entered into, and I agree I will not enter into, any agreement either  written or oral in conflict with this Agreement or my employment with Company.  I will not violate  any agreement with or rights of any third party or, except as expressly authorized by Company in  writing hereafter, use or disclose my own or any third party&#8217;s confidential information or  intellectual property when acting within the scope of my employment or otherwise on behalf of  Company.  Further, I have not retained anything containing any confidential information of a prior  employer or other third party, whether or not created by me.  2. Company shall own all right, title and interest (including patent rights,  copyrights, trade secret rights, mask work rights, sui generis database rights and all other  intellectual property rights of any sort throughout the world) relating to any and all inventions  (whether or not patentable), works of authorship, mask works, designs, know-how, ideas and  information made or conceived or reduced to practice, in whole or in part, by me during the term  of my employment with Company to and only to the fullest extent allowed by California Labor  Code Section 2870 (which is attached as Appendix A) (collectively &#8220;Inventions&#8221;) and I will  promptly disclose all Inventions to Company.  Without disclosing any third party confidential  information, I will also disclose anything I believe is excluded by Section 2870 so that the  Company can make an independent assessment.  I hereby make all assignments necessary to  accomplish the foregoing.  I shall further assist Company, at Company&#8217;s expense, to further  evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce, and  defend any rights specified to be so owned or assigned.  I hereby irrevocably designate and appoint  Company as my agent and attorney-in-fact, coupled with an interest and with full power of  substitution, to act for and in my behalf to execute and file any document and to do all other  lawfully permitted acts to further the purposes of the foregoing with the same legal force and effect  as if executed by me. If anything created by me prior to my employment relates to Company&#8217;s  actual or proposed business, I have listed it on Appendix B in a manner that does not violate any  third party rights or disclose any confidential information.  Without limiting Section 1 or  Company&#8217;s other rights and remedies, if, when acting within the scope of my employment or  otherwise on behalf of Company, I use or disclose my own or any third party&#8217;s confidential  information or intellectual property (or if any Invention cannot be fully made, used, reproduced,  distributed and otherwise exploited without using or violating the foregoing), Company will have  and I hereby grant Company a perpetual, irrevocable, worldwide royalty-free, non-exclusive,  sublicensable right and license to exploit and exercise all such confidential information and  intellectual property rights.   3. I grant permission to Company (inclusive of any person or entity acting in  the Company&#8217;s behalf) to take and use visual and/or audio images (&#8220;Images&#8221;) of me. Images  include any type of recording, including but not limited to photographs, digital images, drawings,  DocuSign Envelope ID: 4E8AC6F3-813B-4439-91B1-B2748BAB94001 C611B 1CC2- DE-A435-3A51619055196DD3AC07-AC3A- C 6-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">2  GDSVF&amp;H\3797916.1   renderings, voices, sounds, video recordings, audio clips or accompanying written descriptions, in  any tangible form. Company shall own the Images and all rights relating thereto, and I hereby  assign all right, title, and interest to the foregoing to the Company. I shall further assist Company,  at Company&#8217;s expense, to further evidence, record and perfect such assignments, and to perfect,  obtain, maintain, enforce, and defend any rights specified to be so owned or assigned.  I hereby  irrevocably designate and appoint Company as my agent and attorney-in-fact, coupled with an  interest and with full power of substitution, to act for and in my behalf to execute and file any  document and to do all other lawfully permitted acts to further the purposes of the foregoing with  the same legal force and effect as if executed by me. The Images may be used for any legal purpose,  and in any manner or media without notifying me, non-limiting examples of which include  Company websites, publications, promotions, broadcasts, advertisements, social media, posters  and theater slides. I waive any right to inspect or approve the finished images or any printed or  electronic matter that may be used with them, or to be compensated for them. I release Company  and its employees and agents, including any entity authorized to publish, broadcast and/or  distribute a finished product containing the Images, from any claims, damages, or liability which  I may ever have in connection with the taking, use, or distribution of the Images.  4. To the extent allowed by law, paragraphs 2 and 3 includes all rights of  paternity, integrity, disclosure and withdrawal and any other rights that may be known as or  referred to as &#8220;moral rights,&#8221; &#8220;artist&#8217;s rights,&#8221; &#8220;droit moral,&#8221; or the like (collectively &#8220;Moral  Rights&#8221;).  To the extent I retain any such Moral Rights under applicable law, I hereby ratify and  consent to any action that may be taken with respect to such Moral Rights by or authorized by  Company and agree not to assert any Moral Rights with respect thereto.  I will confirm any such  ratifications, consents and agreements from time to time as requested by Company.      5. I agree that all Inventions and all other business, technical and financial  information (including, without limitation, the identity of and information relating to customers or  employees) I develop, learn or obtain during the term of my employment that relate to Company  or the business or demonstrably anticipated business of Company or that are received by or for  Company in confidence, constitute &#8220;Proprietary Information.&#8221;  I will hold in confidence and not  disclose or, except within the scope of my employment, use any Proprietary Information.   However, I shall not be obligated under this paragraph with respect to information I can document  is or becomes readily publicly available without restriction through no fault of mine.  Upon  termination of my employment, I will promptly return to Company all items containing or  embodying Proprietary Information (including all copies), except that I may keep my personal  copies of (i) my compensation records, (ii) materials distributed to shareholders generally and  (iii) this Agreement.  I also recognize and agree that I have no expectation of privacy with respect  to Company&#8217;s telecommunications, networking or information processing systems (including,  without limitation, stored computer files, email messages and voice messages) and that my activity  and any files or messages on or using any of those systems may be monitored at any time without  notice.    6. Until one year after the term of my employment, I will not encourage or  solicit any employee or consultant of Company to leave Company for any reason (except for the  bona fide firing of Company personnel within the scope of my employment).    DocuSign Envelope ID: 4E8AC6F3-813B-4439-91B1-B2748BAB94001 C611B 1CC2- DE-A435-3A51619055196DD3AC07-AC3A- C 6-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara013.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara013.jpg" title="slide13" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">3  GDSVF&amp;H\3797916.1   7. I agree that during the term of my employment with Company (whether or  not during business hours), I will not engage in any activity that is in any way competitive with  the business or demonstrably anticipated business of Company, and I will not assist any other  person or organization in competing or in preparing to compete with any business or demonstrably  anticipated business of Company.      8. I agree that this Agreement is not an employment contract for any particular  term and that I have the right to resign and Company has the right to terminate my employment at  will, at any time, for any or no reason, with or without cause.  In addition, this Agreement does  not purport to set forth all of the terms and conditions of my employment, and, as an employee of  Company, I have obligations to Company which are not set forth in this Agreement.  However,  the terms of this Agreement govern over any inconsistent terms and can only be changed by a  subsequent written agreement signed by the President of Company.  9. I agree that my obligations under paragraphs 2, 3, 4, 5 and 6 of this  Agreement shall continue in effect after termination of my employment, regardless of the reason  or reasons for termination, and whether such termination is voluntary or involuntary on my part,  and that Company is entitled to communicate my obligations under this Agreement to any future  employer or potential employer of mine.  My obligations under paragraphs 2, 3, 4 and 5 also shall  be binding upon my heirs, executors, assigns, and administrators and shall inure to the benefit of  Company, its subsidiaries, successors and assigns.    10. Any dispute in the meaning, effect or validity of this Agreement shall be  resolved in accordance with the laws of the State of California without regard to the conflict of  laws provisions thereof.  I further agree that if one or more provisions of this Agreement are held  to be illegal or unenforceable under applicable California law, such illegal or unenforceable  portion(s) shall be limited or excluded from this Agreement to the minimum extent required so  that this Agreement shall otherwise remain in full force and effect and enforceable in accordance  with its terms.  This Agreement is fully assignable and transferable by Company, but any purported  assignment or transfer by me is void.  I also understand that any breach of this Agreement will  cause irreparable harm to Company for which damages would not be an adequate remedy, and,  therefore, Company will be entitled to injunctive relief with respect thereto in addition to any other  remedies and without any requirement to post bond.   NOTICE: This agreement does not affect any immunity under 18 USC Sections 1833(b) (1) or (2),  which read as follows (note that for purposes of this statute only, individuals performing work as  contractors or consultants are considered to be employees):  (1)  An individual shall not be held criminally or civilly liable under any Federal  or State trade secret law for the disclosure of a trade secret that (A) is made (i) in  confidence to a Federal, State, or local government official, either directly or  indirectly, or to an attorney; and (ii) solely for the purpose of reporting or  investigating a suspected violation of law; or (B) is made in a complaint or other  document filed in a lawsuit or other proceeding, if such filing is made under seal.  (2)  An individual who files a lawsuit for retaliation by an employer for reporting  a suspected violation of law may disclose the trade secret to the attorney of the  DocuSign Envelope ID: 4E8AC6F3-813B-4439-91B1-B2748BAB94001 C611B 1CC2- DE-A435-3A51619055196DD3AC07-AC3A- C 6-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara014.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara014.jpg" title="slide14" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">4  GDSVF&amp;H\3797916.1   individual and use the trade secret information in the court proceeding, if the  individual (A) files any document containing the trade secret under seal; and (B)  does not disclose the trade secret, except pursuant to court order.     DocuSign Envelope ID: 4E8AC6F3-813B-4439-91B1-B2748BAB94001 C611B 1CC2- DE-A435-3A51619055196DD3AC07-AC3A- C 6-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara015.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara015.jpg" title="slide15" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">5  GDSVF&amp;H\3797916.1   I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND  AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT  RESERVATION.  NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO  ME TO INDUCE ME TO SIGN THIS AGREEMENT.  I SIGN THIS AGREEMENT  VOLUNTARILY AND FREELY, IN DUPLICATE, WITH THE UNDERSTANDING  THAT THE COMPANY WILL RETAIN ONE COUNTERPART AND THE OTHER  COUNTERPART WILL BE RETAINED BY ME.  Date:                                            Employee:            Signature              Name (Printed)  Accepted and Agreed to:  TARSUS PHARMACEUTICALS, INC.  By:     Name:    Title:        DocuSign Envelope ID: 4E8AC6F3-813B-4439-91B1-B2748BAB9400 1/18/2022 Jose Trevejo CEO Bobby Azamian 1 C611B 1CC2- DE-A435-3A51619055196DD3AC07-AC3A- C 6-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara016.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara016.jpg" title="slide16" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  GDSVF&amp;H\3797916.1   APPENDIX  A  California Labor Code Section 2870.  Application of provision providing that  employee shall assign or offer to assign rights in invention to employer.  (a) Any provision in an employment agreement which provides that an  employee shall assign, or offer to assign, any of his or her rights in an invention to his or her  employer shall not apply to an invention that the employee developed entirely on his or her own  time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information  except for those inventions that either:  (1) Relate at the time of conception or reduction to practice of the  invention to the employer&#8217;s business, or actual or demonstrably anticipated research or  development of the employer; or  (2) Result from any work performed by the employee for his employer.  (b) To the extent a provision in an employment agreement purports to require  an employee to assign an invention otherwise excluded from being required to be assigned under  subdivision (a), the provision is against the public policy of this state and is unenforceable.         DocuSign Envelope ID: 4E8AC6F3-813B-4439-91B1-B2748BAB94001 C611B 1CC2- DE-A435-3A51619055196DD3AC07-AC3A- C 6-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- josetrevejo-tarsussepara017.jpg -->
<DIV style="padding-top:2em;">
<IMG src="josetrevejo-tarsussepara017.jpg" title="slide17" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  GDSVF&amp;H\3797916.1   APPENDIX  B    PRIOR MATTER        DocuSign Envelope ID: 4E8AC6F3-813B-4439-91B1-B2748BAB94001 C611B 1CC2- DE-A435-3A51619055196DD3AC07-AC3A- C 6-B3D1-C704959A028D </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311-33124.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ide5ac0edadc04427a4766864bdb03833_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I, Bobak Azamian, M.D., Ph.D., certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.    I have reviewed this Quarterly Report on Form 10-Q of Tarsus Pharmaceuticals, Inc&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.    The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.    The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.452%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; May&#160;8, 2024</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;text-indent:0.9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Bobak Azamian, M.D., Ph.D.</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President, Chief Executive Officer and Board Chairman</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312-33124.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7cbcf29b1dbc415a8b78af0392c861e4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I, Jeffrey Farrow, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.    I have reviewed this Quarterly Report on Form 10-Q of Tarsus Pharmaceuticals, Inc&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.    The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.    The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.452%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; May&#160;8, 2024</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:right;text-indent:0.9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Jeffrey Farrow</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jeffrey Farrow</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer and Chief Strategy Officer</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Principal Financial Officer and Principal Accounting Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321-33124.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1e9954de800d4bc1821a4f0df6339b57_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.1 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Bobak Azamian, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:32.05pt"><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1) &#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:32.05pt"><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.&#160;&#160;&#160;&#160;</font></div><div style="text-indent:32.05pt"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.551%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; May&#160;8, 2024</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Bobak Azamian, M.D., Ph.D.</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President, Chief Executive Officer and Board Chairman</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit322-33124.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7e89220150ed473885343c00a80813fc_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jeffrey Farrow, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:32.05pt"><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:32.05pt"><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.371%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; May&#160;8, 2024</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Jeffrey Farrow</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jeffrey Farrow</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer and Chief Strategy Officer</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>tars-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a12c9650-c665-4945-913e-9e9f011ed114,g:485e89bc-d27f-4026-942d-5c7ac04342fe-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tars="http://tarsusrx.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://tarsusrx.com/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://tarsusrx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://tarsusrx.com/role/CondensedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofStockholdersEquity" roleURI="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Condensed Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlows" roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofStockholdersEquityParenthetical" roleURI="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandPresentationofFinancialStatements" roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements">
        <link:definition>0000008 - Disclosure - Description of Business and Presentation of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimates" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://tarsusrx.com/role/FairValueMeasurements">
        <link:definition>0000010 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetail" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetail">
        <link:definition>0000011 - Disclosure - Balance Sheet Account Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://tarsusrx.com/role/StockBasedCompensation">
        <link:definition>0000012 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://tarsusrx.com/role/NetLossPerShare">
        <link:definition>0000013 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingencies" roleURI="http://tarsusrx.com/role/CommitmentContingencies">
        <link:definition>0000014 - Disclosure - Commitment &amp; Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutLicenseAgreements" roleURI="http://tarsusrx.com/role/OutLicenseAgreements">
        <link:definition>0000015 - Disclosure - Out-License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreement" roleURI="http://tarsusrx.com/role/CreditFacilityAgreement">
        <link:definition>0000016 - Disclosure - Credit Facility Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://tarsusrx.com/role/RelatedPartyTransactions">
        <link:definition>0000017 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://tarsusrx.com/role/SubsequentEvent">
        <link:definition>0000018 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesTables" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://tarsusrx.com/role/FairValueMeasurementsTables">
        <link:definition>9954473 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailTables" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailTables">
        <link:definition>9954474 - Disclosure - Balance Sheet Account Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://tarsusrx.com/role/StockBasedCompensationTables">
        <link:definition>9954475 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://tarsusrx.com/role/NetLossPerShareTables">
        <link:definition>9954476 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesTables" roleURI="http://tarsusrx.com/role/CommitmentContingenciesTables">
        <link:definition>9954477 - Disclosure - Commitment &amp; Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementTables" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementTables">
        <link:definition>9954478 - Disclosure - Credit Facility Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandPresentationofFinancialStatementsDetails" roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails">
        <link:definition>9954479 - Disclosure - Description of Business and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails">
        <link:definition>9954480 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails">
        <link:definition>9954481 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails">
        <link:definition>9954482 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails">
        <link:definition>9954483 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Product Sales from Each of our Largest Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails">
        <link:definition>9954484 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>9954485 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails">
        <link:definition>9954486 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails">
        <link:definition>9954487 - Disclosure - Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailInventoriesDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails">
        <link:definition>9954488 - Disclosure - Balance Sheet Account Detail - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails">
        <link:definition>9954489 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>9954490 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>9954491 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSharesReservedforIssuanceDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails">
        <link:definition>9954492 - Disclosure - Stock-Based Compensation - Shares Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpenseDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails">
        <link:definition>9954493 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsofStockOptionsDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails">
        <link:definition>9954494 - Disclosure - Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>9954495 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>9954496 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://tarsusrx.com/role/NetLossPerShareDetails">
        <link:definition>9954497 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>9954498 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesLeaseAgreementsDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails">
        <link:definition>9954499 - Disclosure - Commitment &amp; Contingencies - Lease Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesLeaseCostDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails">
        <link:definition>9954500 - Disclosure - Commitment &amp; Contingencies - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails">
        <link:definition>9954501 - Disclosure - Commitment &amp; Contingencies - Summary of Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails_1" roleURI="http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails_1">
        <link:definition>9954501 - Disclosure - Commitment &amp; Contingencies - Summary of Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesInLicenseAgreementforLotilanerDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails">
        <link:definition>9954502 - Disclosure - Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesEmploymentArrangementsDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails">
        <link:definition>9954503 - Disclosure - Commitment &amp; Contingencies - Employment Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutLicenseAgreementsDetails" roleURI="http://tarsusrx.com/role/OutLicenseAgreementsDetails">
        <link:definition>9954504 - Disclosure - Out-License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementDetails" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementDetails">
        <link:definition>9954505 - Disclosure - Credit Facility Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementSummaryofInterestExpenseDetails" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails">
        <link:definition>9954506 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails">
        <link:definition>9954507 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://tarsusrx.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9954508 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://tarsusrx.com/role/SubsequentEventDetails">
        <link:definition>9954509 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="tars_LineOfCreditSVBMember" abstract="true" name="LineOfCreditSVBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" abstract="false" name="NumberOfEmploymentArrangementsWithExecutiveOfficers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_DebtInstrumentFloorInterestRate" abstract="false" name="DebtInstrumentFloorInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="tars_ElancoMember" abstract="true" name="ElancoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_A2023ATMProspectusMember" abstract="true" name="A2023ATMProspectusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ClassOfWarrantOrRightReservedForFutureIssuance" abstract="false" name="ClassOfWarrantOrRightReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_DevelopmentAndRegulatoryMilestoneMember" abstract="true" name="DevelopmentAndRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_DebtInstrumentNumberOfPotentialAdditionalTranches" abstract="false" name="DebtInstrumentNumberOfPotentialAdditionalTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_CommonStockInLianBioMember" abstract="true" name="CommonStockInLianBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_WarrantAgreementNumberOfTranches" abstract="false" name="WarrantAgreementNumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_PharmakonCreditFacilityTrancheFourMember" abstract="true" name="PharmakonCreditFacilityTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_SaleOfStockConsiderationAmountAuthorized" abstract="false" name="SaleOfStockConsiderationAmountAuthorized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_NumberOfVestedWarrants" abstract="false" name="NumberOfVestedWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_PharmakonCreditFacilityMember" abstract="true" name="PharmakonCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ProceedsFromCancellationOfWarrants" abstract="false" name="ProceedsFromCancellationOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_LicenseAndCollaborationOtherMember" abstract="true" name="LicenseAndCollaborationOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_RelatedPartyTransactionAnnualCashCompensation" abstract="false" name="RelatedPartyTransactionAnnualCashCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CreditFacilityFirstAmendmentTrancheTwoMember" abstract="true" name="CreditFacilityFirstAmendmentTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_AccruedClinicalStudiesCurrent" abstract="false" name="AccruedClinicalStudiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_TerminationPaymentPeriodDue" abstract="false" name="TerminationPaymentPeriodDue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements" abstract="false" name="DebtInstrumentNumberOfTranchesWithMilestoneRequirements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockSalesAgentFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_OperatingLeaseNoncashExpense" abstract="false" name="OperatingLeaseNoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CreditFacilityTrancheThreeMember" abstract="true" name="CreditFacilityTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CreditFacilityTrancheFourMember" abstract="true" name="CreditFacilityTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" abstract="true" name="ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_CommercialAndSalesMilestonesMember" abstract="true" name="CommercialAndSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_EquityIncentivePlan2016Member" abstract="true" name="EquityIncentivePlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_RelatedPartTransactionTerminationNoticePeriod" abstract="false" name="RelatedPartTransactionTerminationNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_MilestoneDeterminedByTheCompanyMember" abstract="true" name="MilestoneDeterminedByTheCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_EquityWarrantsFairValueDisclosure" abstract="false" name="EquityWarrantsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_BobakAzamianMember" abstract="true" name="BobakAzamianMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_CreditFacilityTrancheOneMember" abstract="true" name="CreditFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" abstract="true" name="AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_PharmakonCreditFacilityTrancheThreeMember" abstract="true" name="PharmakonCreditFacilityTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts" abstract="false" name="ClassOfWarrantOrRightPaymentsOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CollaborativeArrangementMaximumMilestonePayment" abstract="false" name="CollaborativeArrangementMaximumMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CommonStockNumberOfVotes" abstract="false" name="CommonStockNumberOfVotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_PharmakonCreditFacilityTrancheOneMember" abstract="true" name="PharmakonCreditFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_A2023ShelfRegistrationStatementMember" abstract="true" name="A2023ShelfRegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_LesseeOperatingLeaseNumberOfLeaseContracts" abstract="false" name="LesseeOperatingLeaseNumberOfLeaseContracts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" abstract="false" name="DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_LineOfCreditFacilityPeriodicPaymentInterestRate" abstract="false" name="LineOfCreditFacilityPeriodicPaymentInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="tars_LineOfCreditFacilityDrawDownIncrements" abstract="false" name="LineOfCreditFacilityDrawDownIncrements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CustomerEMember" abstract="true" name="CustomerEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_LianBioMember" abstract="true" name="LianBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_EquitySecuritiesFVNINumberOfShares" abstract="false" name="EquitySecuritiesFVNINumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_CreditFacilityTrancheTwoMember" abstract="true" name="CreditFacilityTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_PharmakonCreditFacilityTrancheTwoMember" abstract="true" name="PharmakonCreditFacilityTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" abstract="false" name="RevenueRemainingPerformanceObligationAdditionalCashPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" abstract="false" name="DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" abstract="false" name="DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CustomerDMember" abstract="true" name="CustomerDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_FiveCustomersMember" abstract="true" name="FiveCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_GrandpharmaMember" abstract="true" name="GrandpharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ClassOfWarrantOrRightSalePrice" abstract="false" name="ClassOfWarrantOrRightSalePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="tars_LicenseAndCollaborationMember" abstract="true" name="LicenseAndCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_ClinicalMilestonesMember" abstract="true" name="ClinicalMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="tars_CollaborativeArrangementFutureCashPayments" abstract="false" name="CollaborativeArrangementFutureCashPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_IntangibleAssetsMilestonePaymentMember" abstract="true" name="IntangibleAssetsMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_JoseTrevejoMember" abstract="true" name="JoseTrevejoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_FollowOnPublicOfferingMember" abstract="true" name="FollowOnPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>tars-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a12c9650-c665-4945-913e-9e9f011ed114,g:485e89bc-d27f-4026-942d-5c7ac04342fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7b8a15e8-0492-479d-b761-a26d61297099" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0cb1f332-ac3f-4c09-a398-d1aa330f6cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b8a15e8-0492-479d-b761-a26d61297099" xlink:to="loc_us-gaap_AssetsCurrent_0cb1f332-ac3f-4c09-a398-d1aa330f6cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fa13c13e-9bb3-4548-ab8f-e0c7711cdd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b8a15e8-0492-479d-b761-a26d61297099" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fa13c13e-9bb3-4548-ab8f-e0c7711cdd4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_a52c7f02-819e-4bdb-aecf-12bf4010cf20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b8a15e8-0492-479d-b761-a26d61297099" xlink:to="loc_us-gaap_LongTermInvestments_a52c7f02-819e-4bdb-aecf-12bf4010cf20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4dc3b7db-03fd-48f7-a637-08199f1e3bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b8a15e8-0492-479d-b761-a26d61297099" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4dc3b7db-03fd-48f7-a637-08199f1e3bbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e37067ee-8edd-44f1-a9a9-75fb82c4ff91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b8a15e8-0492-479d-b761-a26d61297099" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e37067ee-8edd-44f1-a9a9-75fb82c4ff91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_59d4c384-909a-41be-a6e4-8df282abb1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b8a15e8-0492-479d-b761-a26d61297099" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_59d4c384-909a-41be-a6e4-8df282abb1a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_628fd7fc-f919-4027-9125-8d6d80c4a7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_79a2bc5e-27cc-4e46-9ae3-b68d553ad296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_628fd7fc-f919-4027-9125-8d6d80c4a7d8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_79a2bc5e-27cc-4e46-9ae3-b68d553ad296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4a6c8e9d-3d21-4b26-99d6-763b4a98b47f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_628fd7fc-f919-4027-9125-8d6d80c4a7d8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4a6c8e9d-3d21-4b26-99d6-763b4a98b47f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bf7e0669-6e19-402d-b3ea-1bedaae3577a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_628fd7fc-f919-4027-9125-8d6d80c4a7d8" xlink:to="loc_us-gaap_LiabilitiesCurrent_bf7e0669-6e19-402d-b3ea-1bedaae3577a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_93dbc4f1-97c4-47e0-add3-3ffab96f7cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_05fc23eb-236e-4d45-9e61-a4c4df9af83c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93dbc4f1-97c4-47e0-add3-3ffab96f7cb0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_05fc23eb-236e-4d45-9e61-a4c4df9af83c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_c11f33e2-5a86-4516-96c3-83db80121f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93dbc4f1-97c4-47e0-add3-3ffab96f7cb0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_c11f33e2-5a86-4516-96c3-83db80121f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_613f7ce9-d4c0-4ed5-9c0e-6f265e67154d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93dbc4f1-97c4-47e0-add3-3ffab96f7cb0" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_613f7ce9-d4c0-4ed5-9c0e-6f265e67154d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2f8cbdd5-0c19-4962-8609-308ee671d596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93dbc4f1-97c4-47e0-add3-3ffab96f7cb0" xlink:to="loc_us-gaap_InventoryNet_2f8cbdd5-0c19-4962-8609-308ee671d596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a13defca-78d4-4fec-b5b7-e55cb9debe36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93dbc4f1-97c4-47e0-add3-3ffab96f7cb0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a13defca-78d4-4fec-b5b7-e55cb9debe36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_34754aba-b37c-4c0b-b827-c75f2d4935f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_93dbc4f1-97c4-47e0-add3-3ffab96f7cb0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_34754aba-b37c-4c0b-b827-c75f2d4935f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd7881ab-b64b-41d2-a2a8-2daa4f3139a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9dc7f09-c4dc-48ed-9e3a-3eb01adf0b47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd7881ab-b64b-41d2-a2a8-2daa4f3139a6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9dc7f09-c4dc-48ed-9e3a-3eb01adf0b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_924689dd-dd99-4033-9824-19d3106793ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd7881ab-b64b-41d2-a2a8-2daa4f3139a6" xlink:to="loc_us-gaap_CommonStockValue_924689dd-dd99-4033-9824-19d3106793ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b0902068-a2c4-4f55-a5c5-bb63e7fe7d41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd7881ab-b64b-41d2-a2a8-2daa4f3139a6" xlink:to="loc_us-gaap_PreferredStockValue_b0902068-a2c4-4f55-a5c5-bb63e7fe7d41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5dfa02a7-62ac-4976-bfec-4ffbaf40fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd7881ab-b64b-41d2-a2a8-2daa4f3139a6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5dfa02a7-62ac-4976-bfec-4ffbaf40fe5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_335eb6c4-a5ae-4bd1-ba26-c9939812dda0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd7881ab-b64b-41d2-a2a8-2daa4f3139a6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_335eb6c4-a5ae-4bd1-ba26-c9939812dda0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0ead427d-5355-4f23-8a1d-90e41105a857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_23a2bf00-b649-44fd-a373-a1df6e9b6fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ead427d-5355-4f23-8a1d-90e41105a857" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_23a2bf00-b649-44fd-a373-a1df6e9b6fcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2ad1e9ab-7c01-414c-be50-5885b63f8a45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ead427d-5355-4f23-8a1d-90e41105a857" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2ad1e9ab-7c01-414c-be50-5885b63f8a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6d0168d-9db4-4638-8833-273518cf67c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b25f6816-bf1c-4797-9fe7-a231f8726c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6d0168d-9db4-4638-8833-273518cf67c9" xlink:to="loc_us-gaap_Liabilities_b25f6816-bf1c-4797-9fe7-a231f8726c78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d86c2056-337c-4468-be80-2136d9f91891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6d0168d-9db4-4638-8833-273518cf67c9" xlink:to="loc_us-gaap_StockholdersEquity_d86c2056-337c-4468-be80-2136d9f91891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_08e88b2c-3fd2-49c0-8200-d6ca73daa1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6d0168d-9db4-4638-8833-273518cf67c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_08e88b2c-3fd2-49c0-8200-d6ca73daa1c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5272b6bc-8308-42d0-a05f-4bcec49faccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e22e3365-62a9-4d62-900f-c31974272a13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5272b6bc-8308-42d0-a05f-4bcec49faccf" xlink:to="loc_us-gaap_CostsAndExpenses_e22e3365-62a9-4d62-900f-c31974272a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f52045af-5d72-4087-ac56-d206aade4ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5272b6bc-8308-42d0-a05f-4bcec49faccf" xlink:to="loc_us-gaap_Revenues_f52045af-5d72-4087-ac56-d206aade4ff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_17376751-dfa1-45d1-9b38-3d9f74faccbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b3a7411a-8b5d-496d-895a-a51fcd4901ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_17376751-dfa1-45d1-9b38-3d9f74faccbe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b3a7411a-8b5d-496d-895a-a51fcd4901ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_73661d8f-9759-4a09-8e1a-f4c7d891e3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_17376751-dfa1-45d1-9b38-3d9f74faccbe" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_73661d8f-9759-4a09-8e1a-f4c7d891e3b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_44542698-e3aa-4b15-b83b-b64fd7a94c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_17376751-dfa1-45d1-9b38-3d9f74faccbe" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_44542698-e3aa-4b15-b83b-b64fd7a94c26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ea4166c2-28f8-46a0-95e4-e3cff2264cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_46eff424-97ca-484e-8eba-c61093ac22d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ea4166c2-28f8-46a0-95e4-e3cff2264cea" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_46eff424-97ca-484e-8eba-c61093ac22d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0d7bd5d6-38e7-4c92-88de-b906507f8740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ea4166c2-28f8-46a0-95e4-e3cff2264cea" xlink:to="loc_us-gaap_OperatingIncomeLoss_0d7bd5d6-38e7-4c92-88de-b906507f8740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8fdd7a03-2ec5-4809-8276-7bfdb5395efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_da1e960e-d200-4641-8dc9-95cf2be55930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8fdd7a03-2ec5-4809-8276-7bfdb5395efc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_da1e960e-d200-4641-8dc9-95cf2be55930" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2255af62-96f8-47d3-ba33-e3c5a2eeffaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8fdd7a03-2ec5-4809-8276-7bfdb5395efc" xlink:to="loc_us-gaap_NetIncomeLoss_2255af62-96f8-47d3-ba33-e3c5a2eeffaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7c99b3d5-6b47-4fac-9376-f1f3404a0016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_8e5a0d25-e9cb-4ef7-a8aa-3638dc2fd693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7c99b3d5-6b47-4fac-9376-f1f3404a0016" xlink:to="loc_us-gaap_InterestIncomeOther_8e5a0d25-e9cb-4ef7-a8aa-3638dc2fd693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c354e723-de67-4a9a-a1a9-6add92023547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7c99b3d5-6b47-4fac-9376-f1f3404a0016" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c354e723-de67-4a9a-a1a9-6add92023547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_bdbee200-3a13-4959-9ec4-4307a128c2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7c99b3d5-6b47-4fac-9376-f1f3404a0016" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_bdbee200-3a13-4959-9ec4-4307a128c2fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cfd1bfb8-3466-4099-97f5-bdfa98e03918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7c99b3d5-6b47-4fac-9376-f1f3404a0016" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cfd1bfb8-3466-4099-97f5-bdfa98e03918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c29e24f2-0146-469e-b304-cf6b1b368430" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7c99b3d5-6b47-4fac-9376-f1f3404a0016" xlink:to="loc_us-gaap_InterestExpense_c29e24f2-0146-469e-b304-cf6b1b368430" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10ab72ba-77f6-41a1-ad20-c16f8ee667e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_ed4f0997-7eb4-451a-9eb5-43d1169d4aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10ab72ba-77f6-41a1-ad20-c16f8ee667e0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_ed4f0997-7eb4-451a-9eb5-43d1169d4aa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2862c5ec-1105-47d9-aea8-43e3f2904e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10ab72ba-77f6-41a1-ad20-c16f8ee667e0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2862c5ec-1105-47d9-aea8-43e3f2904e39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e5ec55a-a51c-41a7-97da-59fbd2552440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10ab72ba-77f6-41a1-ad20-c16f8ee667e0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e5ec55a-a51c-41a7-97da-59fbd2552440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1a8e63bc-8a5d-4ae9-bd8c-ffab748ed414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1a8e63bc-8a5d-4ae9-bd8c-ffab748ed414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_c7fd966e-fab5-4c81-a566-c52d5d188147" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_c7fd966e-fab5-4c81-a566-c52d5d188147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d00c7605-c670-438a-8a5a-1057e88ce3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d00c7605-c670-438a-8a5a-1057e88ce3ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6f9cc123-2270-4969-9b97-56b18ddbbe98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6f9cc123-2270-4969-9b97-56b18ddbbe98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_cf07e6ba-2dcc-475c-b99a-a5399c05d998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_cf07e6ba-2dcc-475c-b99a-a5399c05d998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2b1a3255-5908-454c-9fc4-d5f83eba22d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2b1a3255-5908-454c-9fc4-d5f83eba22d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_043a5c28-2237-4b29-a193-b1b2a76fafbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_043a5c28-2237-4b29-a193-b1b2a76fafbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ed60cdf8-8b65-4fd3-a3d7-0a2e1ab81495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_Depreciation_ed60cdf8-8b65-4fd3-a3d7-0a2e1ab81495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_b84f049d-a10c-41f6-9092-8e3c18d62120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_b84f049d-a10c-41f6-9092-8e3c18d62120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3027e2ab-eba9-49cd-a732-0b442caac150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3027e2ab-eba9-49cd-a732-0b442caac150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3392125e-4b7a-426c-ae21-312fb445d7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3392125e-4b7a-426c-ae21-312fb445d7ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7e0c5d44-be25-4464-946c-ad282ee027e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_ShareBasedCompensation_7e0c5d44-be25-4464-946c-ad282ee027e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0d7030d8-a65f-4c74-b3e4-ef33eff33528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0d7030d8-a65f-4c74-b3e4-ef33eff33528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_06e4fa50-6883-4d3c-8096-9cbaa5327df3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_NetIncomeLoss_06e4fa50-6883-4d3c-8096-9cbaa5327df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseNoncashExpense_5958575d-f275-4800-998f-2d50429a5f85" xlink:href="tars-20240331.xsd#tars_OperatingLeaseNoncashExpense"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_tars_OperatingLeaseNoncashExpense_5958575d-f275-4800-998f-2d50429a5f85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_7213ec40-495a-4b27-a421-dd8904e0b68e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_7213ec40-495a-4b27-a421-dd8904e0b68e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e543f57f-1d3d-4858-be13-41cd389c7fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e543f57f-1d3d-4858-be13-41cd389c7fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_7945f0e6-a232-4298-b6b2-fec885b6d134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63540c1d-d484-4f76-b26f-886cd913e79a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_7945f0e6-a232-4298-b6b2-fec885b6d134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3122f921-dab5-49d8-acc6-e77c7f1c8a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f2fb1b6d-1233-4075-8e0e-501fc0dbf3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3122f921-dab5-49d8-acc6-e77c7f1c8a35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f2fb1b6d-1233-4075-8e0e-501fc0dbf3f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_88ed35cc-3a39-4dcc-810e-292fae9388d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3122f921-dab5-49d8-acc6-e77c7f1c8a35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_88ed35cc-3a39-4dcc-810e-292fae9388d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_90958fec-1cf8-428d-bd9a-dc515a9e354a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3122f921-dab5-49d8-acc6-e77c7f1c8a35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_90958fec-1cf8-428d-bd9a-dc515a9e354a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_f94dcbb6-1493-41cf-a112-f095045cae47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3122f921-dab5-49d8-acc6-e77c7f1c8a35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_f94dcbb6-1493-41cf-a112-f095045cae47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3e32d1f0-8f79-43af-88d2-43c812c52a50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35983802-a594-476b-8ed2-a41c8b231044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3e32d1f0-8f79-43af-88d2-43c812c52a50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35983802-a594-476b-8ed2-a41c8b231044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7995380-d24d-4e14-915a-846fbab6bc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3e32d1f0-8f79-43af-88d2-43c812c52a50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7995380-d24d-4e14-915a-846fbab6bc3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_127682bd-5487-4652-9283-f04a1126b900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3e32d1f0-8f79-43af-88d2-43c812c52a50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_127682bd-5487-4652-9283-f04a1126b900" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fc367524-8256-4760-80cb-57ee78a3f4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a87836b4-0e8e-45c8-a7d6-7bbe7e5c6848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fc367524-8256-4760-80cb-57ee78a3f4c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a87836b4-0e8e-45c8-a7d6-7bbe7e5c6848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1854654c-c1cd-4393-ad1f-351eebe125ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fc367524-8256-4760-80cb-57ee78a3f4c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1854654c-c1cd-4393-ad1f-351eebe125ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3b1394a9-e4b4-4538-bb34-6c61da309844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fc367524-8256-4760-80cb-57ee78a3f4c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3b1394a9-e4b4-4538-bb34-6c61da309844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_debe9707-f01b-4b04-9438-bbb46dc35130" xlink:href="tars-20240331.xsd#tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fc367524-8256-4760-80cb-57ee78a3f4c6" xlink:to="loc_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_debe9707-f01b-4b04-9438-bbb46dc35130" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_69f6c324-9335-42c3-8801-e366553a7142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fc367524-8256-4760-80cb-57ee78a3f4c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_69f6c324-9335-42c3-8801-e366553a7142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_acbc5622-f4ab-40a1-9654-568f010e5144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fc367524-8256-4760-80cb-57ee78a3f4c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_acbc5622-f4ab-40a1-9654-568f010e5144" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4a1f4106-2be3-4b70-85d3-f599b74e5790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_3f925084-417a-4c70-b29e-d9bbd1ea4be0" xlink:href="tars-20240331.xsd#tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4a1f4106-2be3-4b70-85d3-f599b74e5790" xlink:to="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_3f925084-417a-4c70-b29e-d9bbd1ea4be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_612a994b-b673-43e6-bbf2-e33df617aa1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4a1f4106-2be3-4b70-85d3-f599b74e5790" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_612a994b-b673-43e6-bbf2-e33df617aa1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_df0b7487-8587-4677-833c-08eb4bf13594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4a1f4106-2be3-4b70-85d3-f599b74e5790" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_df0b7487-8587-4677-833c-08eb4bf13594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_9df2c5f8-9265-4ef1-b3c9-341c51ec75ed" xlink:href="tars-20240331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4a1f4106-2be3-4b70-85d3-f599b74e5790" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_9df2c5f8-9265-4ef1-b3c9-341c51ec75ed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_626f9119-fb82-4aa2-9f8a-4597762674f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_107551e2-9453-4667-aac7-79f01b81538d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_626f9119-fb82-4aa2-9f8a-4597762674f4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_107551e2-9453-4667-aac7-79f01b81538d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d9ac202a-13bb-49ea-9ce8-2bb312d26a76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_626f9119-fb82-4aa2-9f8a-4597762674f4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d9ac202a-13bb-49ea-9ce8-2bb312d26a76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_03e15c57-6d25-441f-94c4-0a417be6a4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_626f9119-fb82-4aa2-9f8a-4597762674f4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_03e15c57-6d25-441f-94c4-0a417be6a4fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#BalanceSheetAccountDetailInventoriesDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8908d8eb-a516-45c1-8061-e9196a14a486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f3b1ccb0-cbad-43f6-9735-5272d3d978e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8908d8eb-a516-45c1-8061-e9196a14a486" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f3b1ccb0-cbad-43f6-9735-5272d3d978e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_84bd1a63-23b1-4093-9573-5ed83fdffc82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8908d8eb-a516-45c1-8061-e9196a14a486" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_84bd1a63-23b1-4093-9573-5ed83fdffc82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_cb8292fb-e0e3-4e29-9018-9022d61bbf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8908d8eb-a516-45c1-8061-e9196a14a486" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_cb8292fb-e0e3-4e29-9018-9022d61bbf6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7d650468-dd85-4b62-a364-fd634586b49c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eb7ed531-8b7c-4a9c-89de-eb7181590d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7d650468-dd85-4b62-a364-fd634586b49c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eb7ed531-8b7c-4a9c-89de-eb7181590d1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c96bbfa0-50b1-4acd-90c7-23d63b8db6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7d650468-dd85-4b62-a364-fd634586b49c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c96bbfa0-50b1-4acd-90c7-23d63b8db6f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3d253250-3116-468e-85a8-a773c7c68bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_29a08330-e146-4c9e-8276-b40e6542deb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3d253250-3116-468e-85a8-a773c7c68bd4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_29a08330-e146-4c9e-8276-b40e6542deb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_ffd68235-642b-42d3-aa5d-c4ca47a7ee87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3d253250-3116-468e-85a8-a773c7c68bd4" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_ffd68235-642b-42d3-aa5d-c4ca47a7ee87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent_130cb806-1077-400e-83bf-af531b65ae4a" xlink:href="tars-20240331.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3d253250-3116-468e-85a8-a773c7c68bd4" xlink:to="loc_tars_AccruedClinicalStudiesCurrent_130cb806-1077-400e-83bf-af531b65ae4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_486cd748-7b07-4897-8cfc-cedf80b58c55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3d253250-3116-468e-85a8-a773c7c68bd4" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_486cd748-7b07-4897-8cfc-cedf80b58c55" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationSharesReservedforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0ec1ebfd-fde6-4a41-be5d-a4a66d02e370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_7a13cb35-c64f-4062-ae6f-f9ca2a771d0a" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0ec1ebfd-fde6-4a41-be5d-a4a66d02e370" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_7a13cb35-c64f-4062-ae6f-f9ca2a771d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_4082d0f5-5db8-46e5-8c5e-c2b7cea7e61f" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0ec1ebfd-fde6-4a41-be5d-a4a66d02e370" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_4082d0f5-5db8-46e5-8c5e-c2b7cea7e61f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_140f8064-763c-434e-93ce-9b1ecf6f5384" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0ec1ebfd-fde6-4a41-be5d-a4a66d02e370" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_140f8064-763c-434e-93ce-9b1ecf6f5384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_c0da2216-1ae6-47e8-b154-06a95db33837" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0ec1ebfd-fde6-4a41-be5d-a4a66d02e370" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_c0da2216-1ae6-47e8-b154-06a95db33837" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingenciesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_4b4fbe9b-d65a-4916-b48d-ef842a9460a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0eadab6d-33a0-4964-a7a9-f1f9ba73e022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4b4fbe9b-d65a-4916-b48d-ef842a9460a5" xlink:to="loc_us-gaap_VariableLeaseCost_0eadab6d-33a0-4964-a7a9-f1f9ba73e022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_76c8691f-96f0-4bf1-900f-930ff1e6a43a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4b4fbe9b-d65a-4916-b48d-ef842a9460a5" xlink:to="loc_us-gaap_OperatingLeaseCost_76c8691f-96f0-4bf1-900f-930ff1e6a43a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2838d3e-199f-446e-857c-db8db214e7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e14a9524-9272-4ffd-ba67-af8c7d479387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2838d3e-199f-446e-857c-db8db214e7e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e14a9524-9272-4ffd-ba67-af8c7d479387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5ce52ad3-6e48-4d74-baec-b971b9552730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2838d3e-199f-446e-857c-db8db214e7e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5ce52ad3-6e48-4d74-baec-b971b9552730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_aa864e01-5d01-4dd0-aba3-80c76ae681bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2838d3e-199f-446e-857c-db8db214e7e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_aa864e01-5d01-4dd0-aba3-80c76ae681bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5c7d0e1b-64f1-4ac3-a6f0-bd1a9376ae95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2838d3e-199f-446e-857c-db8db214e7e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5c7d0e1b-64f1-4ac3-a6f0-bd1a9376ae95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eb9e1dea-09c5-4d28-aa32-d14a11d1c1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2838d3e-199f-446e-857c-db8db214e7e5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eb9e1dea-09c5-4d28-aa32-d14a11d1c1b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_05b89e76-9324-41b2-811f-a697508ab14f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e3befdb-6505-48bd-a8fb-a774a72f06ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_05b89e76-9324-41b2-811f-a697508ab14f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e3befdb-6505-48bd-a8fb-a774a72f06ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_62fc7dfe-0553-4627-b921-af537537e42b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_05b89e76-9324-41b2-811f-a697508ab14f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_62fc7dfe-0553-4627-b921-af537537e42b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0de823ef-8a5b-49ea-a181-66960975f856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e2f1241f-eca1-44c3-ae0e-6413b8fa0e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0de823ef-8a5b-49ea-a181-66960975f856" xlink:to="loc_us-gaap_OperatingLeaseLiability_e2f1241f-eca1-44c3-ae0e-6413b8fa0e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_18f2eebb-eb95-475a-8775-0aab34e88e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0de823ef-8a5b-49ea-a181-66960975f856" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_18f2eebb-eb95-475a-8775-0aab34e88e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_07661a6a-6e3f-4cb3-b585-cf6a1c49be6c" xlink:href="tars-20240331.xsd#tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0de823ef-8a5b-49ea-a181-66960975f856" xlink:to="loc_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_07661a6a-6e3f-4cb3-b585-cf6a1c49be6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CreditFacilityAgreementSummaryofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_ae38e8d6-1487-48a1-86ea-97271d36baff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_77808984-9463-4f17-9135-6ccdc5f567ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_ae38e8d6-1487-48a1-86ea-97271d36baff" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_77808984-9463-4f17-9135-6ccdc5f567ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_1ebdf27b-3909-4d79-a37f-e4825b90941c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_ae38e8d6-1487-48a1-86ea-97271d36baff" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_1ebdf27b-3909-4d79-a37f-e4825b90941c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0d318f93-6976-4fae-8afd-d633fe7e0569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_ae38e8d6-1487-48a1-86ea-97271d36baff" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0d318f93-6976-4fae-8afd-d633fe7e0569" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3f7105cb-5762-4ce2-9389-191b2f8692b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_939b3645-cf9b-41b2-942f-1c7e2221d07e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3f7105cb-5762-4ce2-9389-191b2f8692b7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_939b3645-cf9b-41b2-942f-1c7e2221d07e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_87ecc6d4-aab9-4e13-8c32-6bdb4e70ee09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3f7105cb-5762-4ce2-9389-191b2f8692b7" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_87ecc6d4-aab9-4e13-8c32-6bdb4e70ee09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_6e2266c3-fa9d-465c-9ef5-c1154d696bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3f7105cb-5762-4ce2-9389-191b2f8692b7" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_6e2266c3-fa9d-465c-9ef5-c1154d696bb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3b8c41d8-339a-462b-9ee9-7f8490bf7c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3f7105cb-5762-4ce2-9389-191b2f8692b7" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3b8c41d8-339a-462b-9ee9-7f8490bf7c5c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>tars-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a12c9650-c665-4945-913e-9e9f011ed114,g:485e89bc-d27f-4026-942d-5c7ac04342fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bdf1efc1-d777-4973-bf55-abcaf8cfd8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_StatementTable_bdf1efc1-d777-4973-bf55-abcaf8cfd8c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_35bf6bfe-9605-4f75-98ed-fe386bbade00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bdf1efc1-d777-4973-bf55-abcaf8cfd8c3" xlink:to="loc_srt_ProductOrServiceAxis_35bf6bfe-9605-4f75-98ed-fe386bbade00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35bf6bfe-9605-4f75-98ed-fe386bbade00_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_35bf6bfe-9605-4f75-98ed-fe386bbade00" xlink:to="loc_srt_ProductsAndServicesDomain_35bf6bfe-9605-4f75-98ed-fe386bbade00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a119080e-8a30-43cf-843d-75053403fd59" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_35bf6bfe-9605-4f75-98ed-fe386bbade00" xlink:to="loc_srt_ProductsAndServicesDomain_a119080e-8a30-43cf-843d-75053403fd59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e4048cec-2c98-47bf-9e7d-a19aaf31de58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a119080e-8a30-43cf-843d-75053403fd59" xlink:to="loc_us-gaap_ProductMember_e4048cec-2c98-47bf-9e7d-a19aaf31de58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember_6d5ff05c-c041-4b35-982d-24f3b78bcee3" xlink:href="tars-20240331.xsd#tars_LicenseAndCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a119080e-8a30-43cf-843d-75053403fd59" xlink:to="loc_tars_LicenseAndCollaborationMember_6d5ff05c-c041-4b35-982d-24f3b78bcee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_efcab350-70c8-4ee8-8225-44ecce675371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_RevenuesAbstract_efcab350-70c8-4ee8-8225-44ecce675371" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_59bf7f1e-83c7-4900-877b-3f8bc24db5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_efcab350-70c8-4ee8-8225-44ecce675371" xlink:to="loc_us-gaap_Revenues_59bf7f1e-83c7-4900-877b-3f8bc24db5fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_54a8d63a-db34-4ff0-8202-d79e0a2729ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_54a8d63a-db34-4ff0-8202-d79e0a2729ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ea397d1d-db8e-480d-b705-b137d8b88431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ea397d1d-db8e-480d-b705-b137d8b88431" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_98cac7ad-22c9-4d03-ac71-dc8a552aea88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_98cac7ad-22c9-4d03-ac71-dc8a552aea88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c3b32644-5c1c-439d-b39d-f3102d186f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:to="loc_us-gaap_CostsAndExpenses_c3b32644-5c1c-439d-b39d-f3102d186f56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_73e924d8-c7bd-4447-be08-bebf022ab4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_OperatingIncomeLoss_73e924d8-c7bd-4447-be08-bebf022ab4e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_ffebb73c-2583-4c32-af8d-3c7f80fc7243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_InterestIncomeOther_ffebb73c-2583-4c32-af8d-3c7f80fc7243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_98585ebc-8fce-4c72-ad85-dee23903d7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_InterestExpense_98585ebc-8fce-4c72-ad85-dee23903d7d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c46d1826-920d-465a-b7ef-b5660e39945c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c46d1826-920d-465a-b7ef-b5660e39945c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_eb637956-5f2e-4873-b2cd-88f126fbfb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_eb637956-5f2e-4873-b2cd-88f126fbfb8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_323ee1ad-a383-47a5-9efc-b8e33e243f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_323ee1ad-a383-47a5-9efc-b8e33e243f24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7467d3fa-145f-4e5e-96a6-444aef3208c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7467d3fa-145f-4e5e-96a6-444aef3208c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed9a86e5-8ffd-4a48-bda9-1131e61ebeca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_NetIncomeLoss_ed9a86e5-8ffd-4a48-bda9-1131e61ebeca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ba244957-0842-4359-8ad6-6d4410421558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ba244957-0842-4359-8ad6-6d4410421558" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0ddf9e0d-ce79-4bb6-9e65-4e0381ebed8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ba244957-0842-4359-8ad6-6d4410421558" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0ddf9e0d-ce79-4bb6-9e65-4e0381ebed8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_06437683-f6f6-4334-8512-214201bbe413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ba244957-0842-4359-8ad6-6d4410421558" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_06437683-f6f6-4334-8512-214201bbe413" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d5483e6a-3bbb-4789-90f5-932edcc53b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_d5483e6a-3bbb-4789-90f5-932edcc53b8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_07742e81-5ebd-4725-b788-02717209e62e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d5483e6a-3bbb-4789-90f5-932edcc53b8b" xlink:to="loc_us-gaap_EarningsPerShareBasic_07742e81-5ebd-4725-b788-02717209e62e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_eaeb6dc7-5fff-4791-9085-6f60b6cb4aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d5483e6a-3bbb-4789-90f5-932edcc53b8b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_eaeb6dc7-5fff-4791-9085-6f60b6cb4aaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae644d1d-6092-4ce2-87c0-e1b57f9c8600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae644d1d-6092-4ce2-87c0-e1b57f9c8600" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_98f02993-20e5-4752-8526-d6d60ac888d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae644d1d-6092-4ce2-87c0-e1b57f9c8600" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_98f02993-20e5-4752-8526-d6d60ac888d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5a4b171-d140-472b-8f84-fa007431ef54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae644d1d-6092-4ce2-87c0-e1b57f9c8600" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5a4b171-d140-472b-8f84-fa007431ef54" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_710e89fe-953c-48d5-a5e3-3d6c784e2d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ddb0389c-dbb0-4bb2-b91f-c4fc7992c1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_710e89fe-953c-48d5-a5e3-3d6c784e2d40" xlink:to="loc_us-gaap_StatementTable_ddb0389c-dbb0-4bb2-b91f-c4fc7992c1de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ebee4c5f-801d-4fa6-b6d7-b1ab014c7ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ddb0389c-dbb0-4bb2-b91f-c4fc7992c1de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ebee4c5f-801d-4fa6-b6d7-b1ab014c7ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ebee4c5f-801d-4fa6-b6d7-b1ab014c7ba8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebee4c5f-801d-4fa6-b6d7-b1ab014c7ba8" xlink:to="loc_us-gaap_EquityComponentDomain_ebee4c5f-801d-4fa6-b6d7-b1ab014c7ba8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebee4c5f-801d-4fa6-b6d7-b1ab014c7ba8" xlink:to="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8bcd94b6-d2e4-4391-96ef-b6e5df75cdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:to="loc_us-gaap_CommonStockMember_8bcd94b6-d2e4-4391-96ef-b6e5df75cdc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e35efe1b-f805-4d62-9c13-d77a46e87ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e35efe1b-f805-4d62-9c13-d77a46e87ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ba20b46-302f-4a28-92fb-6ad0d7accbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ba20b46-302f-4a28-92fb-6ad0d7accbd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f02554b0-6cef-488f-8001-40de447034fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:to="loc_us-gaap_RetainedEarningsMember_f02554b0-6cef-488f-8001-40de447034fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_710e89fe-953c-48d5-a5e3-3d6c784e2d40" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1a52b644-9ec5-470a-a7fc-54288f7ef8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1a52b644-9ec5-470a-a7fc-54288f7ef8fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_857674f6-d024-424d-adcf-49246c35642f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockholdersEquity_857674f6-d024-424d-adcf-49246c35642f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33504102-f7e4-4fd6-8817-e627bfc34ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_NetIncomeLoss_33504102-f7e4-4fd6-8817-e627bfc34ec8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04c49a50-375d-4747-ab5f-fc8aa7871d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04c49a50-375d-4747-ab5f-fc8aa7871d3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_88bdd60d-e53f-408e-8339-6516ec82bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_88bdd60d-e53f-408e-8339-6516ec82bc12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7e36dc06-6feb-452c-b2f1-a01d4a183637" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7e36dc06-6feb-452c-b2f1-a01d4a183637" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3e3f3fa1-c7b4-455b-a6bf-dfe16579a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3e3f3fa1-c7b4-455b-a6bf-dfe16579a7cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02276acf-3960-4efc-9ef6-c7cc33abeca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02276acf-3960-4efc-9ef6-c7cc33abeca4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3c2a1ca2-1e97-4f49-a0bc-8a7e17081742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3c2a1ca2-1e97-4f49-a0bc-8a7e17081742" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c031a4e2-3512-483f-91eb-c75c15b91f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c031a4e2-3512-483f-91eb-c75c15b91f79" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7a9d8e7d-0211-4582-90cb-fb31db209d78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7a9d8e7d-0211-4582-90cb-fb31db209d78" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4313f84f-ef85-498b-9c5e-329e5248ec15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1aac1091-db35-431f-afb5-752d73f4edca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#DescriptionofBusinessandPresentationofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab02934-9b78-4f01-a545-f79b2f82bc87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab02934-9b78-4f01-a545-f79b2f82bc87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b98af327-2bfc-4e4a-8654-b5f398d32c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab02934-9b78-4f01-a545-f79b2f82bc87" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b98af327-2bfc-4e4a-8654-b5f398d32c5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b98af327-2bfc-4e4a-8654-b5f398d32c5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b98af327-2bfc-4e4a-8654-b5f398d32c5c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b98af327-2bfc-4e4a-8654-b5f398d32c5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b98af327-2bfc-4e4a-8654-b5f398d32c5c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FollowOnPublicOfferingMember_a6af0af1-cbe3-4a83-a616-b8612974e090" xlink:href="tars-20240331.xsd#tars_FollowOnPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:to="loc_tars_FollowOnPublicOfferingMember_a6af0af1-cbe3-4a83-a616-b8612974e090" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_daec0e02-33b2-4d66-83ee-2cb188d0af01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:to="loc_us-gaap_OverAllotmentOptionMember_daec0e02-33b2-4d66-83ee-2cb188d0af01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_A2023ShelfRegistrationStatementMember_b1a74bcb-f407-4e92-aef3-e057b014e67e" xlink:href="tars-20240331.xsd#tars_A2023ShelfRegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:to="loc_tars_A2023ShelfRegistrationStatementMember_b1a74bcb-f407-4e92-aef3-e057b014e67e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_A2023ATMProspectusMember_2c3ec226-8247-42b9-88f1-1029595c5c4d" xlink:href="tars-20240331.xsd#tars_A2023ATMProspectusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:to="loc_tars_A2023ATMProspectusMember_2c3ec226-8247-42b9-88f1-1029595c5c4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3253f87f-55b8-4bdc-82ca-ee4c833758b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3253f87f-55b8-4bdc-82ca-ee4c833758b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_26d59f18-a261-4673-88fd-88813d3043f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_26d59f18-a261-4673-88fd-88813d3043f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClassOfWarrantOrRightReservedForFutureIssuance_f2e7df87-1dc1-4399-a251-ac3db984241a" xlink:href="tars-20240331.xsd#tars_ClassOfWarrantOrRightReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_tars_ClassOfWarrantOrRightReservedForFutureIssuance_f2e7df87-1dc1-4399-a251-ac3db984241a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4f6794f7-55eb-4569-9bdc-5ed2012482dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4f6794f7-55eb-4569-9bdc-5ed2012482dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClassOfWarrantOrRightSalePrice_5269ac62-1aa3-4a84-98c1-1343047cbf31" xlink:href="tars-20240331.xsd#tars_ClassOfWarrantOrRightSalePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_tars_ClassOfWarrantOrRightSalePrice_5269ac62-1aa3-4a84-98c1-1343047cbf31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c4eab9a-b821-4261-8eac-408659a65bca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c4eab9a-b821-4261-8eac-408659a65bca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0d1d641d-f5f8-4319-a31d-0e5d176cac8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0d1d641d-f5f8-4319-a31d-0e5d176cac8c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds_3eafdde1-2e3c-4cb4-b663-138a6bfad229" xlink:href="tars-20240331.xsd#tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds_3eafdde1-2e3c-4cb4-b663-138a6bfad229" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockConsiderationAmountAuthorized_b9242131-0bd7-4d3d-8469-535eefeb1208" xlink:href="tars-20240331.xsd#tars_SaleOfStockConsiderationAmountAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_tars_SaleOfStockConsiderationAmountAuthorized_b9242131-0bd7-4d3d-8469-535eefeb1208" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_754a4242-120c-403b-bd4e-005393be5bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_754a4242-120c-403b-bd4e-005393be5bb3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_71749c40-166c-43bc-8df7-8183cb11f301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_NumberOfReportableSegments_71749c40-166c-43bc-8df7-8183cb11f301" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bbe7e1ca-d429-4226-876a-d927ca430820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bbe7e1ca-d429-4226-876a-d927ca430820" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0d0df111-c258-482d-b2f4-619c26a7d21f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02df76ca-73f4-408a-8683-08da5bd7d7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0d0df111-c258-482d-b2f4-619c26a7d21f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02df76ca-73f4-408a-8683-08da5bd7d7d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_b445b2c0-40fd-45a8-b608-96ca5922b082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02df76ca-73f4-408a-8683-08da5bd7d7d2" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_b445b2c0-40fd-45a8-b608-96ca5922b082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_b445b2c0-40fd-45a8-b608-96ca5922b082_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_b445b2c0-40fd-45a8-b608-96ca5922b082" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_b445b2c0-40fd-45a8-b608-96ca5922b082_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_d9c785fc-a52e-447a-9af9-a98fd9bfc07c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_b445b2c0-40fd-45a8-b608-96ca5922b082" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_d9c785fc-a52e-447a-9af9-a98fd9bfc07c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IntangibleAssetsMilestonePaymentMember_e5f3fb5d-a141-468e-981b-24f543af9666" xlink:href="tars-20240331.xsd#tars_IntangibleAssetsMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_d9c785fc-a52e-447a-9af9-a98fd9bfc07c" xlink:to="loc_tars_IntangibleAssetsMilestonePaymentMember_e5f3fb5d-a141-468e-981b-24f543af9666" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_490d22fc-3d92-413f-a90e-669041a0f47b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0d0df111-c258-482d-b2f4-619c26a7d21f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_490d22fc-3d92-413f-a90e-669041a0f47b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e6087b6d-b774-4564-86d1-401e55917aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0d0df111-c258-482d-b2f4-619c26a7d21f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e6087b6d-b774-4564-86d1-401e55917aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_09054900-39da-4b4e-951f-9dcb756d1758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0d0df111-c258-482d-b2f4-619c26a7d21f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_09054900-39da-4b4e-951f-9dcb756d1758" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ccc91039-f3e4-4a53-8d69-8370063beae9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_srt_RangeAxis_ccc91039-f3e4-4a53-8d69-8370063beae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccc91039-f3e4-4a53-8d69-8370063beae9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ccc91039-f3e4-4a53-8d69-8370063beae9" xlink:to="loc_srt_RangeMember_ccc91039-f3e4-4a53-8d69-8370063beae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5627c355-e518-48de-89f0-7e8fb83c3e53" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ccc91039-f3e4-4a53-8d69-8370063beae9" xlink:to="loc_srt_RangeMember_5627c355-e518-48de-89f0-7e8fb83c3e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a84fe3c9-84a3-4d37-94c9-4160ad777e99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5627c355-e518-48de-89f0-7e8fb83c3e53" xlink:to="loc_srt_MinimumMember_a84fe3c9-84a3-4d37-94c9-4160ad777e99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5c2c79c-0804-4c3e-8a7d-1cf264cecdde" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5627c355-e518-48de-89f0-7e8fb83c3e53" xlink:to="loc_srt_MaximumMember_d5c2c79c-0804-4c3e-8a7d-1cf264cecdde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b3aa0c5c-2bf1-44b9-8c3f-8666061c60f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_us-gaap_PlanNameAxis_b3aa0c5c-2bf1-44b9-8c3f-8666061c60f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b3aa0c5c-2bf1-44b9-8c3f-8666061c60f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b3aa0c5c-2bf1-44b9-8c3f-8666061c60f1" xlink:to="loc_us-gaap_PlanNameDomain_b3aa0c5c-2bf1-44b9-8c3f-8666061c60f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e922fce4-539f-4f3f-b6a9-28c3bd306f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b3aa0c5c-2bf1-44b9-8c3f-8666061c60f1" xlink:to="loc_us-gaap_PlanNameDomain_e922fce4-539f-4f3f-b6a9-28c3bd306f16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member_4a069717-2008-44a2-9bba-425f92550fd1" xlink:href="tars-20240331.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e922fce4-539f-4f3f-b6a9-28c3bd306f16" xlink:to="loc_tars_EquityIncentivePlan2016Member_4a069717-2008-44a2-9bba-425f92550fd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_88c036b9-b05d-41c3-87b1-8839b2b9b577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_88c036b9-b05d-41c3-87b1-8839b2b9b577" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_88c036b9-b05d-41c3-87b1-8839b2b9b577_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_88c036b9-b05d-41c3-87b1-8839b2b9b577" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_88c036b9-b05d-41c3-87b1-8839b2b9b577_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5081e99-8582-4e2b-aa3a-07a53e3438e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_88c036b9-b05d-41c3-87b1-8839b2b9b577" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5081e99-8582-4e2b-aa3a-07a53e3438e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0056e173-da7a-4add-b1f9-8334f5be2021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5081e99-8582-4e2b-aa3a-07a53e3438e4" xlink:to="loc_us-gaap_SalesRevenueNetMember_0056e173-da7a-4add-b1f9-8334f5be2021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_1c9d14ff-99b7-4267-b109-13f423b2826d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5081e99-8582-4e2b-aa3a-07a53e3438e4" xlink:to="loc_us-gaap_AccountsReceivableMember_1c9d14ff-99b7-4267-b109-13f423b2826d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1e586146-8b45-4d20-9191-6af4b1b4f5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1e586146-8b45-4d20-9191-6af4b1b4f5ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1e586146-8b45-4d20-9191-6af4b1b4f5ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1e586146-8b45-4d20-9191-6af4b1b4f5ed" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1e586146-8b45-4d20-9191-6af4b1b4f5ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_23162c4b-bc2b-4aac-b0e3-9bbb07567272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1e586146-8b45-4d20-9191-6af4b1b4f5ed" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_23162c4b-bc2b-4aac-b0e3-9bbb07567272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_211ac48a-65de-4e69-8556-d7edeae63c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_23162c4b-bc2b-4aac-b0e3-9bbb07567272" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_211ac48a-65de-4e69-8556-d7edeae63c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_08c3d3f7-8c42-4f20-83d9-46fdb520a61f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_srt_MajorCustomersAxis_08c3d3f7-8c42-4f20-83d9-46fdb520a61f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_08c3d3f7-8c42-4f20-83d9-46fdb520a61f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_08c3d3f7-8c42-4f20-83d9-46fdb520a61f" xlink:to="loc_srt_NameOfMajorCustomerDomain_08c3d3f7-8c42-4f20-83d9-46fdb520a61f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0614b64b-7dee-479b-96d5-e286a94ca074" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_08c3d3f7-8c42-4f20-83d9-46fdb520a61f" xlink:to="loc_srt_NameOfMajorCustomerDomain_0614b64b-7dee-479b-96d5-e286a94ca074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FiveCustomersMember_f0a86aa8-c1ab-4486-a2f3-264ac0b80a7b" xlink:href="tars-20240331.xsd#tars_FiveCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0614b64b-7dee-479b-96d5-e286a94ca074" xlink:to="loc_tars_FiveCustomersMember_f0a86aa8-c1ab-4486-a2f3-264ac0b80a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2747c5b1-e711-4e98-9ee1-ca5443bf3196" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_srt_ProductOrServiceAxis_2747c5b1-e711-4e98-9ee1-ca5443bf3196" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2747c5b1-e711-4e98-9ee1-ca5443bf3196_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2747c5b1-e711-4e98-9ee1-ca5443bf3196" xlink:to="loc_srt_ProductsAndServicesDomain_2747c5b1-e711-4e98-9ee1-ca5443bf3196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e53b83d9-fa72-4b63-aaea-ad5fb64d5087" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2747c5b1-e711-4e98-9ee1-ca5443bf3196" xlink:to="loc_srt_ProductsAndServicesDomain_e53b83d9-fa72-4b63-aaea-ad5fb64d5087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationOtherMember_86058c5f-3493-4f36-b19d-25a994cd7905" xlink:href="tars-20240331.xsd#tars_LicenseAndCollaborationOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e53b83d9-fa72-4b63-aaea-ad5fb64d5087" xlink:to="loc_tars_LicenseAndCollaborationOtherMember_86058c5f-3493-4f36-b19d-25a994cd7905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e3a69006-b419-4e89-b4b8-52f05bcef0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e3a69006-b419-4e89-b4b8-52f05bcef0fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_66995f9a-0567-4e37-bec9-282e06f18ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_66995f9a-0567-4e37-bec9-282e06f18ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6fcd455f-06ee-4f72-b476-2d63e438aee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6fcd455f-06ee-4f72-b476-2d63e438aee3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_2f06abbb-6a2d-453e-bb47-41e3ce391dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_2f06abbb-6a2d-453e-bb47-41e3ce391dc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d745b96-6977-41a3-b6fa-4c79d2413a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d745b96-6977-41a3-b6fa-4c79d2413a1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bc617d06-fc1a-49fa-991e-6524c2232c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_Revenues_bc617d06-fc1a-49fa-991e-6524c2232c24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e2d7707d-fa5b-4991-83e6-2b77212d2313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e2d7707d-fa5b-4991-83e6-2b77212d2313" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5ecdde2f-0531-450f-b156-dc80eef0b611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5ecdde2f-0531-450f-b156-dc80eef0b611" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0aeb7364-d954-417a-a47c-58c39cdb7ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0aeb7364-d954-417a-a47c-58c39cdb7ca1" xlink:to="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_00beea65-e63d-45a4-bff5-f960d47b3dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_00beea65-e63d-45a4-bff5-f960d47b3dd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_00beea65-e63d-45a4-bff5-f960d47b3dd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_00beea65-e63d-45a4-bff5-f960d47b3dd9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_00beea65-e63d-45a4-bff5-f960d47b3dd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333ce2d8-9a84-4020-a765-2c1074f955e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_00beea65-e63d-45a4-bff5-f960d47b3dd9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333ce2d8-9a84-4020-a765-2c1074f955e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c86041fb-87f8-4132-b0ce-21a4445fa8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333ce2d8-9a84-4020-a765-2c1074f955e7" xlink:to="loc_us-gaap_SalesRevenueNetMember_c86041fb-87f8-4132-b0ce-21a4445fa8f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_60c5bcb0-ac03-440e-9c91-8a53100c3b90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_60c5bcb0-ac03-440e-9c91-8a53100c3b90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_60c5bcb0-ac03-440e-9c91-8a53100c3b90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_60c5bcb0-ac03-440e-9c91-8a53100c3b90" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_60c5bcb0-ac03-440e-9c91-8a53100c3b90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4701f5dc-21e4-42df-bd25-0ec6943fa489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_60c5bcb0-ac03-440e-9c91-8a53100c3b90" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4701f5dc-21e4-42df-bd25-0ec6943fa489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_f648c296-6460-4df5-991b-68e60f65c148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4701f5dc-21e4-42df-bd25-0ec6943fa489" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_f648c296-6460-4df5-991b-68e60f65c148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_607592af-f48e-40bd-9f08-148e357c7ae0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:to="loc_srt_MajorCustomersAxis_607592af-f48e-40bd-9f08-148e357c7ae0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_607592af-f48e-40bd-9f08-148e357c7ae0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_607592af-f48e-40bd-9f08-148e357c7ae0" xlink:to="loc_srt_NameOfMajorCustomerDomain_607592af-f48e-40bd-9f08-148e357c7ae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_607592af-f48e-40bd-9f08-148e357c7ae0" xlink:to="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerAMember_a7d8d214-6bfe-4ace-92a6-a1ac5a4633b0" xlink:href="tars-20240331.xsd#tars_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:to="loc_tars_CustomerAMember_a7d8d214-6bfe-4ace-92a6-a1ac5a4633b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerBMember_06ddebba-6bdc-4113-bc4c-27f6e65810c5" xlink:href="tars-20240331.xsd#tars_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:to="loc_tars_CustomerBMember_06ddebba-6bdc-4113-bc4c-27f6e65810c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerCMember_16aa4728-92a7-4361-add7-0991d52c4875" xlink:href="tars-20240331.xsd#tars_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:to="loc_tars_CustomerCMember_16aa4728-92a7-4361-add7-0991d52c4875" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerDMember_d2b9d283-8e59-4a61-930f-9a7aa145158d" xlink:href="tars-20240331.xsd#tars_CustomerDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:to="loc_tars_CustomerDMember_d2b9d283-8e59-4a61-930f-9a7aa145158d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerEMember_5e97b9b5-fe62-4832-ba24-3b09a096f46b" xlink:href="tars-20240331.xsd#tars_CustomerEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:to="loc_tars_CustomerEMember_5e97b9b5-fe62-4832-ba24-3b09a096f46b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_97f58229-ac2d-4949-8c07-f964be050234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0aeb7364-d954-417a-a47c-58c39cdb7ca1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_97f58229-ac2d-4949-8c07-f964be050234" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7e294477-ca85-4f73-b685-0b484aa42c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee6cdbfc-83a7-4024-ad3e-26a43b5f720f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7e294477-ca85-4f73-b685-0b484aa42c7a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee6cdbfc-83a7-4024-ad3e-26a43b5f720f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9981d55f-7d02-474c-9d37-421a0d0c37bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee6cdbfc-83a7-4024-ad3e-26a43b5f720f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9981d55f-7d02-474c-9d37-421a0d0c37bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9981d55f-7d02-474c-9d37-421a0d0c37bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9981d55f-7d02-474c-9d37-421a0d0c37bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9981d55f-7d02-474c-9d37-421a0d0c37bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97fe4679-1eba-4551-9403-67b13ab92f40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9981d55f-7d02-474c-9d37-421a0d0c37bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97fe4679-1eba-4551-9403-67b13ab92f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_27ed4f2f-3b70-49a0-862f-5efef4036eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97fe4679-1eba-4551-9403-67b13ab92f40" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_27ed4f2f-3b70-49a0-862f-5efef4036eeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_07cc3953-36fd-452a-8386-73c927aeeeff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97fe4679-1eba-4551-9403-67b13ab92f40" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_07cc3953-36fd-452a-8386-73c927aeeeff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_14672208-b5da-4e5f-a462-3916097a5d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97fe4679-1eba-4551-9403-67b13ab92f40" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_14672208-b5da-4e5f-a462-3916097a5d26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4f381721-d000-479d-a440-2cb7229dce7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee6cdbfc-83a7-4024-ad3e-26a43b5f720f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4f381721-d000-479d-a440-2cb7229dce7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f381721-d000-479d-a440-2cb7229dce7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4f381721-d000-479d-a440-2cb7229dce7d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f381721-d000-479d-a440-2cb7229dce7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4f381721-d000-479d-a440-2cb7229dce7d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8605e55a-82d0-40c8-8a9b-24d023e966b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8605e55a-82d0-40c8-8a9b-24d023e966b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_628e3caa-ac1f-406d-970e-9b857d39348e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_628e3caa-ac1f-406d-970e-9b857d39348e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a8ac576b-051a-410e-8bf2-4700df7720e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:to="loc_us-gaap_CommercialPaperMember_a8ac576b-051a-410e-8bf2-4700df7720e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_91f0ef73-a367-456f-9b2c-74e772c9bcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_91f0ef73-a367-456f-9b2c-74e772c9bcc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_3857205a-a947-4fac-8a2a-6e083532c00b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_3857205a-a947-4fac-8a2a-6e083532c00b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7e294477-ca85-4f73-b685-0b484aa42c7a" xlink:to="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fd70c8cd-cab3-4be8-b434-763f92a6efb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fd70c8cd-cab3-4be8-b434-763f92a6efb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_3fa021da-822c-4555-bb3d-8468da4c6993" xlink:href="tars-20240331.xsd#tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:to="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_3fa021da-822c-4555-bb3d-8468da4c6993" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_246d5251-d6f7-4468-970f-f59c79ecc038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_246d5251-d6f7-4468-970f-f59c79ecc038" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_3cfc3cba-7d2e-4d88-af9c-c0a3ad2ed685" xlink:href="tars-20240331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_3cfc3cba-7d2e-4d88-af9c-c0a3ad2ed685" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_510ab7f0-d698-4b24-be86-43e326c43b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_510ab7f0-d698-4b24-be86-43e326c43b74" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b70e607d-3b36-4d0a-b122-17ddbfc1fa87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_srt_RangeAxis_b70e607d-3b36-4d0a-b122-17ddbfc1fa87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b70e607d-3b36-4d0a-b122-17ddbfc1fa87_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b70e607d-3b36-4d0a-b122-17ddbfc1fa87" xlink:to="loc_srt_RangeMember_b70e607d-3b36-4d0a-b122-17ddbfc1fa87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_787dcb26-b19f-41c6-9a6b-1a79c4979918" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b70e607d-3b36-4d0a-b122-17ddbfc1fa87" xlink:to="loc_srt_RangeMember_787dcb26-b19f-41c6-9a6b-1a79c4979918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b3a20da-24e9-4138-ba43-723cfb1e882f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_787dcb26-b19f-41c6-9a6b-1a79c4979918" xlink:to="loc_srt_MinimumMember_1b3a20da-24e9-4138-ba43-723cfb1e882f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0d6a85ee-8c8c-447e-98e3-e9781d6fdbea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_787dcb26-b19f-41c6-9a6b-1a79c4979918" xlink:to="loc_srt_MaximumMember_0d6a85ee-8c8c-447e-98e3-e9781d6fdbea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_321384c3-9725-47d9-924e-a6aff641a151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_321384c3-9725-47d9-924e-a6aff641a151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_321384c3-9725-47d9-924e-a6aff641a151_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_321384c3-9725-47d9-924e-a6aff641a151" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_321384c3-9725-47d9-924e-a6aff641a151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_484d6079-7a23-4e95-a7d8-9781c640119e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_321384c3-9725-47d9-924e-a6aff641a151" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_484d6079-7a23-4e95-a7d8-9781c640119e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_b096007a-d798-4639-8a41-b938e9baf1b0" xlink:href="tars-20240331.xsd#tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_484d6079-7a23-4e95-a7d8-9781c640119e" xlink:to="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_b096007a-d798-4639-8a41-b938e9baf1b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e32b5f98-33c2-4f79-8494-1ff1db0c379b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_dei_LegalEntityAxis_e32b5f98-33c2-4f79-8494-1ff1db0c379b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e32b5f98-33c2-4f79-8494-1ff1db0c379b_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e32b5f98-33c2-4f79-8494-1ff1db0c379b" xlink:to="loc_dei_EntityDomain_e32b5f98-33c2-4f79-8494-1ff1db0c379b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ce79fdce-61b6-4d29-8cb1-93707cb657ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e32b5f98-33c2-4f79-8494-1ff1db0c379b" xlink:to="loc_dei_EntityDomain_ce79fdce-61b6-4d29-8cb1-93707cb657ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_a585032a-9d48-4632-82b8-e2364ae88d0a" xlink:href="tars-20240331.xsd#tars_LianBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ce79fdce-61b6-4d29-8cb1-93707cb657ad" xlink:to="loc_tars_LianBioMember_a585032a-9d48-4632-82b8-e2364ae88d0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5949f539-bb4b-4e6d-8661-e491136d3e34" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_srt_CounterpartyNameAxis_5949f539-bb4b-4e6d-8661-e491136d3e34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5949f539-bb4b-4e6d-8661-e491136d3e34_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5949f539-bb4b-4e6d-8661-e491136d3e34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5949f539-bb4b-4e6d-8661-e491136d3e34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9840037-d29b-49ae-aa10-340ec0beddac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5949f539-bb4b-4e6d-8661-e491136d3e34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9840037-d29b-49ae-aa10-340ec0beddac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_51bc5e92-d02b-401a-b538-2fb25bdb213d" xlink:href="tars-20240331.xsd#tars_LianBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9840037-d29b-49ae-aa10-340ec0beddac" xlink:to="loc_tars_LianBioMember_51bc5e92-d02b-401a-b538-2fb25bdb213d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f84f89e3-7a3f-44de-b7da-f89f40c1bcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f84f89e3-7a3f-44de-b7da-f89f40c1bcb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f84f89e3-7a3f-44de-b7da-f89f40c1bcb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f84f89e3-7a3f-44de-b7da-f89f40c1bcb2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f84f89e3-7a3f-44de-b7da-f89f40c1bcb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a308575-b22b-41cc-8b13-ca29205bd453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f84f89e3-7a3f-44de-b7da-f89f40c1bcb2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a308575-b22b-41cc-8b13-ca29205bd453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_03678a36-6e35-47f1-bec5-2a953ebbd8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a308575-b22b-41cc-8b13-ca29205bd453" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_03678a36-6e35-47f1-bec5-2a953ebbd8ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_WarrantAgreementNumberOfTranches_96d48e26-9d41-45b4-945f-5d4b7543d63f" xlink:href="tars-20240331.xsd#tars_WarrantAgreementNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_tars_WarrantAgreementNumberOfTranches_96d48e26-9d41-45b4-945f-5d4b7543d63f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfVestedWarrants_14bf52d0-dab0-4dc3-a790-590ae32506b1" xlink:href="tars-20240331.xsd#tars_NumberOfVestedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_tars_NumberOfVestedWarrants_14bf52d0-dab0-4dc3-a790-590ae32506b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquitySecuritiesFVNINumberOfShares_26e11b07-d936-4aff-9c80-75f2fab54a6c" xlink:href="tars-20240331.xsd#tars_EquitySecuritiesFVNINumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_tars_EquitySecuritiesFVNINumberOfShares_26e11b07-d936-4aff-9c80-75f2fab54a6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_ec292c47-1c36-47d2-8299-c1e30e4b06c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_DividendsCommonStockCash_ec292c47-1c36-47d2-8299-c1e30e4b06c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_95cfa70c-5fff-493c-b3f3-5a448a0272ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_95cfa70c-5fff-493c-b3f3-5a448a0272ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromCancellationOfWarrants_fdef852b-1674-4c3a-a3a9-59cfacb4890c" xlink:href="tars-20240331.xsd#tars_ProceedsFromCancellationOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_tars_ProceedsFromCancellationOfWarrants_fdef852b-1674-4c3a-a3a9-59cfacb4890c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_e1a04c3f-af14-41b6-91dc-36f64cdc3275" xlink:href="tars-20240331.xsd#tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_e1a04c3f-af14-41b6-91dc-36f64cdc3275" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_b859c249-de0c-4894-a742-90abc4b0e176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_b859c249-de0c-4894-a742-90abc4b0e176" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_049f290e-653c-48f3-a011-72eedd6c5e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_049f290e-653c-48f3-a011-72eedd6c5e2e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00e75658-1625-4d4e-9aa8-f434d489e59c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00e75658-1625-4d4e-9aa8-f434d489e59c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_61832307-1500-40e2-8045-4ee6350d3fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_61832307-1500-40e2-8045-4ee6350d3fa5" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_add8f29b-c00b-44bc-8826-361124c1213d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6854199b-7133-4066-b0e9-2e3dd7aa86ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_add8f29b-c00b-44bc-8826-361124c1213d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6854199b-7133-4066-b0e9-2e3dd7aa86ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c4349842-bbc2-4d57-8ec7-d5c624b1d6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6854199b-7133-4066-b0e9-2e3dd7aa86ff" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c4349842-bbc2-4d57-8ec7-d5c624b1d6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c4349842-bbc2-4d57-8ec7-d5c624b1d6ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c4349842-bbc2-4d57-8ec7-d5c624b1d6ec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c4349842-bbc2-4d57-8ec7-d5c624b1d6ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c4349842-bbc2-4d57-8ec7-d5c624b1d6ec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_12a43b1e-4b6a-48a1-9c25-8401879a760a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_12a43b1e-4b6a-48a1-9c25-8401879a760a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c38d652c-9508-49ad-9bbd-bc65ebcd0046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c38d652c-9508-49ad-9bbd-bc65ebcd0046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4143408c-a7da-4ecf-b867-cfbeb32a9ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_us-gaap_CommercialPaperMember_4143408c-a7da-4ecf-b867-cfbeb32a9ee4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8e983d64-0a8c-4dd6-96fc-0d6fd98075e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8e983d64-0a8c-4dd6-96fc-0d6fd98075e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_f4b50e77-bfe8-432c-9ea6-1a314f6bf311" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_f4b50e77-bfe8-432c-9ea6-1a314f6bf311" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockInLianBioMember_56a85913-a061-4569-b6b0-50e800461219" xlink:href="tars-20240331.xsd#tars_CommonStockInLianBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_tars_CommonStockInLianBioMember_56a85913-a061-4569-b6b0-50e800461219" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2a195b3b-eadd-4c9d-8e6c-5330476e7cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6854199b-7133-4066-b0e9-2e3dd7aa86ff" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2a195b3b-eadd-4c9d-8e6c-5330476e7cb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2a195b3b-eadd-4c9d-8e6c-5330476e7cb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2a195b3b-eadd-4c9d-8e6c-5330476e7cb6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2a195b3b-eadd-4c9d-8e6c-5330476e7cb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_eabf2a72-2a2f-4ede-b9f1-ce1e3bb09e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2a195b3b-eadd-4c9d-8e6c-5330476e7cb6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_eabf2a72-2a2f-4ede-b9f1-ce1e3bb09e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_2840ad71-a19d-490d-9cde-ca9d456bbaed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eabf2a72-2a2f-4ede-b9f1-ce1e3bb09e03" xlink:to="loc_us-gaap_CashEquivalentsMember_2840ad71-a19d-490d-9cde-ca9d456bbaed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_5099ed15-c4ec-4a9d-80d8-4b5d789bafef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_add8f29b-c00b-44bc-8826-361124c1213d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_5099ed15-c4ec-4a9d-80d8-4b5d789bafef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f596201-feeb-4252-a215-875518159309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5099ed15-c4ec-4a9d-80d8-4b5d789bafef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f596201-feeb-4252-a215-875518159309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b9c8a2da-22d6-4aa0-8496-c99829367f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5099ed15-c4ec-4a9d-80d8-4b5d789bafef" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b9c8a2da-22d6-4aa0-8496-c99829367f7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_add8f29b-c00b-44bc-8826-361124c1213d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461784ea-06d6-4234-b4c9-df02d84b057c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461784ea-06d6-4234-b4c9-df02d84b057c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1f6a954-cce3-4e2c-ad22-987f27249fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1f6a954-cce3-4e2c-ad22-987f27249fa5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4fecda66-0a9e-4a4d-94f2-b40aab9f317c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4fecda66-0a9e-4a4d-94f2-b40aab9f317c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6def5b83-57a0-43da-ac1d-70226119b5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6def5b83-57a0-43da-ac1d-70226119b5fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFVNIAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_add8f29b-c00b-44bc-8826-361124c1213d" xlink:to="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_8cc4de75-21df-4a58-a6ea-dfc0b924b074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_8cc4de75-21df-4a58-a6ea-dfc0b924b074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_1c5ab593-3a63-4e5d-bd39-35394aec6b34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_1c5ab593-3a63-4e5d-bd39-35394aec6b34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_aa7d2a49-ec71-4a40-8130-ab4abca7b7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_aa7d2a49-ec71-4a40-8130-ab4abca7b7ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_952b9e61-3b39-4324-b36a-f4bf7a5e6ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_952b9e61-3b39-4324-b36a-f4bf7a5e6ab2" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6037db1f-a869-4c4d-a45b-6c4e4c5a478d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6037db1f-a869-4c4d-a45b-6c4e4c5a478d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f87f5a4-22bf-41b3-b1ed-979db1ab770a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6037db1f-a869-4c4d-a45b-6c4e4c5a478d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f87f5a4-22bf-41b3-b1ed-979db1ab770a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f87f5a4-22bf-41b3-b1ed-979db1ab770a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f87f5a4-22bf-41b3-b1ed-979db1ab770a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f87f5a4-22bf-41b3-b1ed-979db1ab770a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f87f5a4-22bf-41b3-b1ed-979db1ab770a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_555cd4e8-4124-4abf-babe-960e275b4022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_555cd4e8-4124-4abf-babe-960e275b4022" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_e1d67226-96d3-46ac-beff-ba3dd1452e63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:to="loc_us-gaap_OfficeEquipmentMember_e1d67226-96d3-46ac-beff-ba3dd1452e63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_66393c08-8419-4e14-af26-1376a22e2481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_66393c08-8419-4e14-af26-1376a22e2481" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_fcfd3a4a-87ea-400a-be45-210e26ba9bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_fcfd3a4a-87ea-400a-be45-210e26ba9bc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_464ed6f3-69dc-4d2f-bd21-9f65616fe400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_464ed6f3-69dc-4d2f-bd21-9f65616fe400" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f6b935e-83ce-4a43-b758-b0833f7aea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f6b935e-83ce-4a43-b758-b0833f7aea7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_865485db-d9e0-41c5-a950-a1535adc236c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_865485db-d9e0-41c5-a950-a1535adc236c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_47fbef7d-e5f9-4b1b-b7b3-92efe1b5878a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:to="loc_us-gaap_Depreciation_47fbef7d-e5f9-4b1b-b7b3-92efe1b5878a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_160a8f22-d625-40a4-8f58-621ff4d923ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_160a8f22-d625-40a4-8f58-621ff4d923ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ee87988-699f-4abc-ac5c-1dc7508d3760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_160a8f22-d625-40a4-8f58-621ff4d923ec" xlink:to="loc_us-gaap_AwardTypeAxis_2ee87988-699f-4abc-ac5c-1dc7508d3760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ee87988-699f-4abc-ac5c-1dc7508d3760_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2ee87988-699f-4abc-ac5c-1dc7508d3760" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ee87988-699f-4abc-ac5c-1dc7508d3760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81d0ded0-1e2d-4960-a8ac-d7daa0ce3ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2ee87988-699f-4abc-ac5c-1dc7508d3760" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81d0ded0-1e2d-4960-a8ac-d7daa0ce3ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_49c37a13-fb69-49bc-adaa-7eb7fde59772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81d0ded0-1e2d-4960-a8ac-d7daa0ce3ba9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_49c37a13-fb69-49bc-adaa-7eb7fde59772" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c2648932-5835-446b-898e-d59aacb3d63f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81d0ded0-1e2d-4960-a8ac-d7daa0ce3ba9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c2648932-5835-446b-898e-d59aacb3d63f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_cff73be5-85fc-46d0-9790-9d4f9b732954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81d0ded0-1e2d-4960-a8ac-d7daa0ce3ba9" xlink:to="loc_us-gaap_EmployeeStockMember_cff73be5-85fc-46d0-9790-9d4f9b732954" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_af929f97-c085-43a4-aad8-7970de8913ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_af929f97-c085-43a4-aad8-7970de8913ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClassOfWarrantOrRightReservedForFutureIssuance_d846f242-9815-40ef-bab1-c515411425e8" xlink:href="tars-20240331.xsd#tars_ClassOfWarrantOrRightReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_tars_ClassOfWarrantOrRightReservedForFutureIssuance_d846f242-9815-40ef-bab1-c515411425e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_66e8c738-faa1-4687-b674-f859309f36d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_CommonStockSharesIssued_66e8c738-faa1-4687-b674-f859309f36d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockNumberOfVotes_2361a0eb-679d-4a39-a58d-6b78e80a31ec" xlink:href="tars-20240331.xsd#tars_CommonStockNumberOfVotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_tars_CommonStockNumberOfVotes_2361a0eb-679d-4a39-a58d-6b78e80a31ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2187b5c7-a351-4358-aaaf-9846b08a1a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2187b5c7-a351-4358-aaaf-9846b08a1a7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6caef0b9-4659-4e07-8831-6ab2e69124d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6caef0b9-4659-4e07-8831-6ab2e69124d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ab871711-ac1e-47f1-914c-f7e415855888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ab871711-ac1e-47f1-914c-f7e415855888" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c8b9258d-641d-4952-820f-edf69bf355ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c8b9258d-641d-4952-820f-edf69bf355ff" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb8af68-d03e-4008-a846-5dd31df5a99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_701c3eca-92a9-456f-9bd1-386c936b9405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb8af68-d03e-4008-a846-5dd31df5a99a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_701c3eca-92a9-456f-9bd1-386c936b9405" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4eb561b5-3879-4eb7-ba1a-b331b59388cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_701c3eca-92a9-456f-9bd1-386c936b9405" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4eb561b5-3879-4eb7-ba1a-b331b59388cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4eb561b5-3879-4eb7-ba1a-b331b59388cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4eb561b5-3879-4eb7-ba1a-b331b59388cc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4eb561b5-3879-4eb7-ba1a-b331b59388cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_56bf58c7-47e7-4154-a498-6762257c8338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4eb561b5-3879-4eb7-ba1a-b331b59388cc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_56bf58c7-47e7-4154-a498-6762257c8338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c24db05d-4301-485b-a0f1-2a4f911c42bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56bf58c7-47e7-4154-a498-6762257c8338" xlink:to="loc_us-gaap_CostOfSalesMember_c24db05d-4301-485b-a0f1-2a4f911c42bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0951a89e-41e0-49f7-8a6b-0e7bb3d0b83d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56bf58c7-47e7-4154-a498-6762257c8338" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0951a89e-41e0-49f7-8a6b-0e7bb3d0b83d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7fe3e25d-a5c7-46a3-86bb-28a09890cb05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56bf58c7-47e7-4154-a498-6762257c8338" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7fe3e25d-a5c7-46a3-86bb-28a09890cb05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_72418f2f-a27b-40c4-a22e-32a40d2ae285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb8af68-d03e-4008-a846-5dd31df5a99a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_72418f2f-a27b-40c4-a22e-32a40d2ae285" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17f29ae-b3ef-421d-8550-33ef65a4f41b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bbbfe46-c915-480b-b19e-f6f1b1162d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17f29ae-b3ef-421d-8550-33ef65a4f41b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bbbfe46-c915-480b-b19e-f6f1b1162d45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_778aa2a1-39e8-499b-b885-03572d087b25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bbbfe46-c915-480b-b19e-f6f1b1162d45" xlink:to="loc_us-gaap_AwardTypeAxis_778aa2a1-39e8-499b-b885-03572d087b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_778aa2a1-39e8-499b-b885-03572d087b25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_778aa2a1-39e8-499b-b885-03572d087b25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_778aa2a1-39e8-499b-b885-03572d087b25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c027c488-18a8-45ff-80f9-04e77ea25b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_778aa2a1-39e8-499b-b885-03572d087b25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c027c488-18a8-45ff-80f9-04e77ea25b8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b1c4c869-cb9b-4416-93e6-413bcb9bdfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c027c488-18a8-45ff-80f9-04e77ea25b8d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b1c4c869-cb9b-4416-93e6-413bcb9bdfbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17f29ae-b3ef-421d-8550-33ef65a4f41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59549e31-d1bf-423f-9036-46ebc020d917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59549e31-d1bf-423f-9036-46ebc020d917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0b801bc-9dcc-49d2-8c25-91d10203be2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0b801bc-9dcc-49d2-8c25-91d10203be2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53234cb7-56b0-4644-89c9-54e968ad2dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53234cb7-56b0-4644-89c9-54e968ad2dc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07a137d4-beb7-41ae-b836-29d7e39bffee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07a137d4-beb7-41ae-b836-29d7e39bffee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_467f5413-7a0f-4919-b664-a718e0db7506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17f29ae-b3ef-421d-8550-33ef65a4f41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_376fc26e-3888-49b0-a7be-af90bb6e908b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_376fc26e-3888-49b0-a7be-af90bb6e908b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_77e9c731-adae-4bb2-8492-ad513a492530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_77e9c731-adae-4bb2-8492-ad513a492530" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4dc73054-ebcb-47fb-b5ab-0dd955c45c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4dc73054-ebcb-47fb-b5ab-0dd955c45c04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d287d7e0-7462-4f72-a328-eedb34dcb9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d287d7e0-7462-4f72-a328-eedb34dcb9bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_275a2826-716f-4b92-ab44-5e810a574c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#NetLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48640ada-e106-4ad8-b207-1e24f4694628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a93082f5-dc29-4ecd-875d-65c2f9539d06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48640ada-e106-4ad8-b207-1e24f4694628" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a93082f5-dc29-4ecd-875d-65c2f9539d06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ba1a6a-cc30-4ba3-8b99-d91146484458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a93082f5-dc29-4ecd-875d-65c2f9539d06" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ba1a6a-cc30-4ba3-8b99-d91146484458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b2ba1a6a-cc30-4ba3-8b99-d91146484458_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ba1a6a-cc30-4ba3-8b99-d91146484458" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b2ba1a6a-cc30-4ba3-8b99-d91146484458_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c8c514a8-028f-4be6-9e36-8ac80b377dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ba1a6a-cc30-4ba3-8b99-d91146484458" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c8c514a8-028f-4be6-9e36-8ac80b377dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_357a6c7a-846e-4067-b5fb-2c888d550f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c8c514a8-028f-4be6-9e36-8ac80b377dc5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_357a6c7a-846e-4067-b5fb-2c888d550f2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_8ace0588-3020-477a-94e6-db465e0a6b0f" xlink:href="tars-20240331.xsd#tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c8c514a8-028f-4be6-9e36-8ac80b377dc5" xlink:to="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_8ace0588-3020-477a-94e6-db465e0a6b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7740a183-dc82-4532-8d57-94b743fdcbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48640ada-e106-4ad8-b207-1e24f4694628" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7740a183-dc82-4532-8d57-94b743fdcbbd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingenciesInLicenseAgreementforLotilanerDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_474bd3df-e77d-4ab4-903b-aff89c524c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:to="loc_us-gaap_TypeOfArrangementAxis_474bd3df-e77d-4ab4-903b-aff89c524c47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_474bd3df-e77d-4ab4-903b-aff89c524c47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_474bd3df-e77d-4ab4-903b-aff89c524c47" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_474bd3df-e77d-4ab4-903b-aff89c524c47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7af5cda2-1345-4c4e-9c05-c409234f2501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_474bd3df-e77d-4ab4-903b-aff89c524c47" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7af5cda2-1345-4c4e-9c05-c409234f2501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_972213cf-ca1c-49aa-8b3a-a88180a7effb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7af5cda2-1345-4c4e-9c05-c409234f2501" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_972213cf-ca1c-49aa-8b3a-a88180a7effb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9f10576e-8486-4c17-8733-c3e93e3e823c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:to="loc_srt_ProductOrServiceAxis_9f10576e-8486-4c17-8733-c3e93e3e823c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9f10576e-8486-4c17-8733-c3e93e3e823c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9f10576e-8486-4c17-8733-c3e93e3e823c" xlink:to="loc_srt_ProductsAndServicesDomain_9f10576e-8486-4c17-8733-c3e93e3e823c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_387ba7e7-198b-4db0-bb73-6bc978cfe3a7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9f10576e-8486-4c17-8733-c3e93e3e823c" xlink:to="loc_srt_ProductsAndServicesDomain_387ba7e7-198b-4db0-bb73-6bc978cfe3a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember_1bcc9381-f9d6-41a8-96b6-5384cddb112b" xlink:href="tars-20240331.xsd#tars_ClinicalMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_387ba7e7-198b-4db0-bb73-6bc978cfe3a7" xlink:to="loc_tars_ClinicalMilestonesMember_1bcc9381-f9d6-41a8-96b6-5384cddb112b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember_be572b64-1dfa-4174-a7ae-0d7a14e9a939" xlink:href="tars-20240331.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_387ba7e7-198b-4db0-bb73-6bc978cfe3a7" xlink:to="loc_tars_CommercialAndSalesMilestonesMember_be572b64-1dfa-4174-a7ae-0d7a14e9a939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_26a113c9-0fd9-43ad-9745-cd5f3427e61c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:to="loc_srt_CounterpartyNameAxis_26a113c9-0fd9-43ad-9745-cd5f3427e61c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26a113c9-0fd9-43ad-9745-cd5f3427e61c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_26a113c9-0fd9-43ad-9745-cd5f3427e61c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26a113c9-0fd9-43ad-9745-cd5f3427e61c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b6ded23-b22a-45bc-b802-97faab8c1f89" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_26a113c9-0fd9-43ad-9745-cd5f3427e61c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b6ded23-b22a-45bc-b802-97faab8c1f89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_31820307-570a-4eaa-951a-f3b163fa5cf8" xlink:href="tars-20240331.xsd#tars_ElancoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b6ded23-b22a-45bc-b802-97faab8c1f89" xlink:to="loc_tars_ElancoMember_31820307-570a-4eaa-951a-f3b163fa5cf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_c82f1ab8-c952-4082-8b64-060f6cd513f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_c82f1ab8-c952-4082-8b64-060f6cd513f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_c82f1ab8-c952-4082-8b64-060f6cd513f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_c82f1ab8-c952-4082-8b64-060f6cd513f4" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_c82f1ab8-c952-4082-8b64-060f6cd513f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_96f03869-8afe-49f7-9c61-4fc37be8cec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_c82f1ab8-c952-4082-8b64-060f6cd513f4" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_96f03869-8afe-49f7-9c61-4fc37be8cec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IntangibleAssetsMilestonePaymentMember_fdeaf0ea-ea58-4fce-8e99-b768d76b82d6" xlink:href="tars-20240331.xsd#tars_IntangibleAssetsMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_96f03869-8afe-49f7-9c61-4fc37be8cec1" xlink:to="loc_tars_IntangibleAssetsMilestonePaymentMember_fdeaf0ea-ea58-4fce-8e99-b768d76b82d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_5d2c38b5-8080-4f5e-a2fa-ca249fcf458b" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_5d2c38b5-8080-4f5e-a2fa-ca249fcf458b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_3a52a699-33eb-4ba7-9c70-ff1e6cf5e0dd" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_3a52a699-33eb-4ba7-9c70-ff1e6cf5e0dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cf30ade8-e000-4a7c-a962-2f71c92213ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cf30ade8-e000-4a7c-a962-2f71c92213ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementFutureCashPayments_93c27623-b1b8-4a8b-a65f-88583e798b8b" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementFutureCashPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_tars_CollaborativeArrangementFutureCashPayments_93c27623-b1b8-4a8b-a65f-88583e798b8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_826122d0-9ce4-4e3b-8081-a27541e1cfbd" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_826122d0-9ce4-4e3b-8081-a27541e1cfbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_2e5b48bf-fe20-4695-8704-b2fbf7d9c2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_RoyaltyExpense_2e5b48bf-fe20-4695-8704-b2fbf7d9c2ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e1597376-30f5-48e9-bead-d19704571934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e1597376-30f5-48e9-bead-d19704571934" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_26cb311a-66f5-4062-9efc-ae10b1737296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_26cb311a-66f5-4062-9efc-ae10b1737296" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_493dcea4-87ab-468a-990f-8d783bc9266e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_SharePrice_493dcea4-87ab-468a-990f-8d783bc9266e" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreementsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#OutLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b4b466c9-20d4-481f-af75-8691b26a588b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_srt_CounterpartyNameAxis_b4b466c9-20d4-481f-af75-8691b26a588b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b4b466c9-20d4-481f-af75-8691b26a588b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b4b466c9-20d4-481f-af75-8691b26a588b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b4b466c9-20d4-481f-af75-8691b26a588b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bba0197-8d38-48e7-af33-8bbb3a4658a7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b4b466c9-20d4-481f-af75-8691b26a588b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bba0197-8d38-48e7-af33-8bbb3a4658a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_5ccf2f5c-a5c8-40e5-ad17-6097a48ec2c0" xlink:href="tars-20240331.xsd#tars_LianBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bba0197-8d38-48e7-af33-8bbb3a4658a7" xlink:to="loc_tars_LianBioMember_5ccf2f5c-a5c8-40e5-ad17-6097a48ec2c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_ed649fda-4c67-42dd-a6ec-a50ec233dcb0" xlink:href="tars-20240331.xsd#tars_ElancoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bba0197-8d38-48e7-af33-8bbb3a4658a7" xlink:to="loc_tars_ElancoMember_ed649fda-4c67-42dd-a6ec-a50ec233dcb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_GrandpharmaMember_de5f366d-d8b3-4341-ba03-a84039b95e96" xlink:href="tars-20240331.xsd#tars_GrandpharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bba0197-8d38-48e7-af33-8bbb3a4658a7" xlink:to="loc_tars_GrandpharmaMember_de5f366d-d8b3-4341-ba03-a84039b95e96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_947a95bb-f465-4eab-8bc3-bcdfd2885885" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_947a95bb-f465-4eab-8bc3-bcdfd2885885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_947a95bb-f465-4eab-8bc3-bcdfd2885885_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_947a95bb-f465-4eab-8bc3-bcdfd2885885" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_947a95bb-f465-4eab-8bc3-bcdfd2885885_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14ba3b5e-08b5-424d-847c-1e102c4ca0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_947a95bb-f465-4eab-8bc3-bcdfd2885885" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14ba3b5e-08b5-424d-847c-1e102c4ca0f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d0d2b3e1-40ff-45f2-97a1-ce03879fed23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14ba3b5e-08b5-424d-847c-1e102c4ca0f4" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d0d2b3e1-40ff-45f2-97a1-ce03879fed23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_149afcd6-23c6-47b5-8563-3e534ef74330" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_srt_ProductOrServiceAxis_149afcd6-23c6-47b5-8563-3e534ef74330" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_149afcd6-23c6-47b5-8563-3e534ef74330_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_149afcd6-23c6-47b5-8563-3e534ef74330" xlink:to="loc_srt_ProductsAndServicesDomain_149afcd6-23c6-47b5-8563-3e534ef74330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cffb0464-5b1f-4cb0-a62c-ce6daeeff906" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_149afcd6-23c6-47b5-8563-3e534ef74330" xlink:to="loc_srt_ProductsAndServicesDomain_cffb0464-5b1f-4cb0-a62c-ce6daeeff906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_MilestoneDeterminedByTheCompanyMember_540990d2-fea1-4053-99f8-32ee10fd0906" xlink:href="tars-20240331.xsd#tars_MilestoneDeterminedByTheCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cffb0464-5b1f-4cb0-a62c-ce6daeeff906" xlink:to="loc_tars_MilestoneDeterminedByTheCompanyMember_540990d2-fea1-4053-99f8-32ee10fd0906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember_a4325d16-4d40-4ec2-86ae-23042975e0c1" xlink:href="tars-20240331.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cffb0464-5b1f-4cb0-a62c-ce6daeeff906" xlink:to="loc_tars_DevelopmentAndRegulatoryMilestoneMember_a4325d16-4d40-4ec2-86ae-23042975e0c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fbc6c635-2c93-4361-89f4-0555e0fa3889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fbc6c635-2c93-4361-89f4-0555e0fa3889" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fbc6c635-2c93-4361-89f4-0555e0fa3889_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fbc6c635-2c93-4361-89f4-0555e0fa3889" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fbc6c635-2c93-4361-89f4-0555e0fa3889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fd842751-5131-4906-bdae-097125176aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fbc6c635-2c93-4361-89f4-0555e0fa3889" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fd842751-5131-4906-bdae-097125176aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_07d43e73-61fc-465a-9383-43a1e4aee415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fd842751-5131-4906-bdae-097125176aaa" xlink:to="loc_us-gaap_SubsequentEventMember_07d43e73-61fc-465a-9383-43a1e4aee415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_93a1c5c6-d109-4576-bedd-069844fb6846" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_dei_LegalEntityAxis_93a1c5c6-d109-4576-bedd-069844fb6846" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_93a1c5c6-d109-4576-bedd-069844fb6846_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_93a1c5c6-d109-4576-bedd-069844fb6846" xlink:to="loc_dei_EntityDomain_93a1c5c6-d109-4576-bedd-069844fb6846_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4fe49de3-235d-48d8-9069-debc038f89b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_93a1c5c6-d109-4576-bedd-069844fb6846" xlink:to="loc_dei_EntityDomain_4fe49de3-235d-48d8-9069-debc038f89b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_33db2909-5e36-470b-911d-addbd855cdf3" xlink:href="tars-20240331.xsd#tars_LianBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4fe49de3-235d-48d8-9069-debc038f89b7" xlink:to="loc_tars_LianBioMember_33db2909-5e36-470b-911d-addbd855cdf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f4d1ffad-12f2-4ffb-b856-e03eb91314ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f4d1ffad-12f2-4ffb-b856-e03eb91314ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_f09f324c-ae8f-4529-9032-ecb086e55742" xlink:href="tars-20240331.xsd#tars_RevenueRemainingPerformanceObligationAdditionalCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_f09f324c-ae8f-4529-9032-ecb086e55742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_784edf32-176d-4209-8fa9-71649420da18" xlink:href="tars-20240331.xsd#tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_784edf32-176d-4209-8fa9-71649420da18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_37599b50-78a8-486c-8628-3befad993dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_37599b50-78a8-486c-8628-3befad993dc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d77dcc33-4e91-4807-b5e7-bddda6866b00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d77dcc33-4e91-4807-b5e7-bddda6866b00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_TerminationPaymentPeriodDue_1e527884-03bb-4c41-8830-a815624ecd1d" xlink:href="tars-20240331.xsd#tars_TerminationPaymentPeriodDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_TerminationPaymentPeriodDue_1e527884-03bb-4c41-8830-a815624ecd1d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7113b2f7-86e8-4b9b-9b5a-5da62b6ffe18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7113b2f7-86e8-4b9b-9b5a-5da62b6ffe18" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f289e0f6-3217-4476-9848-c8dd692fdeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f289e0f6-3217-4476-9848-c8dd692fdeeb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromCancellationOfWarrants_f504a64e-7647-4f54-bc06-8768e464d625" xlink:href="tars-20240331.xsd#tars_ProceedsFromCancellationOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_ProceedsFromCancellationOfWarrants_f504a64e-7647-4f54-bc06-8768e464d625" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2a12b545-7531-43bd-b18c-715d8e775615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2a12b545-7531-43bd-b18c-715d8e775615" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1db08970-eb83-4cb7-8c05-958a4868591d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1db08970-eb83-4cb7-8c05-958a4868591d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_1b0cf267-67ab-4560-a689-223f9a2ca224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_DividendsCommonStockCash_1b0cf267-67ab-4560-a689-223f9a2ca224" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_ef135890-9f47-4fc2-babb-f59a3c9ae97c" xlink:href="tars-20240331.xsd#tars_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_UpfrontPayment_ef135890-9f47-4fc2-babb-f59a3c9ae97c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_218a5f2f-773b-402a-b66b-aa93d525eb93" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_218a5f2f-773b-402a-b66b-aa93d525eb93" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CreditFacilityAgreementDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6ee1accb-77e6-4abf-a18a-174cd799705b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6ee1accb-77e6-4abf-a18a-174cd799705b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6ee1accb-77e6-4abf-a18a-174cd799705b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6ee1accb-77e6-4abf-a18a-174cd799705b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6ee1accb-77e6-4abf-a18a-174cd799705b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ce5ac0e8-ffee-46b3-ac20-8a6418d26860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6ee1accb-77e6-4abf-a18a-174cd799705b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ce5ac0e8-ffee-46b3-ac20-8a6418d26860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b48082db-5feb-4cad-9400-b1466ade805f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ce5ac0e8-ffee-46b3-ac20-8a6418d26860" xlink:to="loc_us-gaap_LineOfCreditMember_b48082db-5feb-4cad-9400-b1466ade805f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditSVBMember_61671e6f-0585-44ec-b1ec-a205497b14df" xlink:href="tars-20240331.xsd#tars_LineOfCreditSVBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ce5ac0e8-ffee-46b3-ac20-8a6418d26860" xlink:to="loc_tars_LineOfCreditSVBMember_61671e6f-0585-44ec-b1ec-a205497b14df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5edcbc91-537d-4b30-b19f-f9a599a2cef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:to="loc_us-gaap_DebtInstrumentAxis_5edcbc91-537d-4b30-b19f-f9a599a2cef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5edcbc91-537d-4b30-b19f-f9a599a2cef9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5edcbc91-537d-4b30-b19f-f9a599a2cef9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5edcbc91-537d-4b30-b19f-f9a599a2cef9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5edcbc91-537d-4b30-b19f-f9a599a2cef9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheOneMember_d7d427cc-540b-43d6-938a-fbea1b8cca5e" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:to="loc_tars_CreditFacilityTrancheOneMember_d7d427cc-540b-43d6-938a-fbea1b8cca5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheTwoMember_851fc337-68c8-4071-8ad0-7bfb374d0df5" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:to="loc_tars_CreditFacilityTrancheTwoMember_851fc337-68c8-4071-8ad0-7bfb374d0df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheThreeMember_211a4fa2-c824-4a74-a21c-2bb717101348" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:to="loc_tars_CreditFacilityTrancheThreeMember_211a4fa2-c824-4a74-a21c-2bb717101348" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFourMember_780f4995-307f-48d2-9944-4865dc536e90" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:to="loc_tars_CreditFacilityTrancheFourMember_780f4995-307f-48d2-9944-4865dc536e90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember_b0a3d504-75f6-4c35-be21-c91bb2a44822" xlink:href="tars-20240331.xsd#tars_CreditFacilityFirstAmendmentTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:to="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember_b0a3d504-75f6-4c35-be21-c91bb2a44822" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6d1eabe4-ef42-4edd-8102-5e5341b69bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:to="loc_us-gaap_VariableRateAxis_6d1eabe4-ef42-4edd-8102-5e5341b69bbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6d1eabe4-ef42-4edd-8102-5e5341b69bbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_6d1eabe4-ef42-4edd-8102-5e5341b69bbe" xlink:to="loc_us-gaap_VariableRateDomain_6d1eabe4-ef42-4edd-8102-5e5341b69bbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0f13a6cf-eda4-4a5c-8011-16c115ba83d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_6d1eabe4-ef42-4edd-8102-5e5341b69bbe" xlink:to="loc_us-gaap_VariableRateDomain_0f13a6cf-eda4-4a5c-8011-16c115ba83d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_dd713d54-3802-4921-8f53-e48e066bef04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0f13a6cf-eda4-4a5c-8011-16c115ba83d2" xlink:to="loc_us-gaap_PrimeRateMember_dd713d54-3802-4921-8f53-e48e066bef04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a4f2c0d-5e98-4949-bb8f-53c54644c28d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:to="loc_srt_RangeAxis_0a4f2c0d-5e98-4949-bb8f-53c54644c28d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0a4f2c0d-5e98-4949-bb8f-53c54644c28d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0a4f2c0d-5e98-4949-bb8f-53c54644c28d" xlink:to="loc_srt_RangeMember_0a4f2c0d-5e98-4949-bb8f-53c54644c28d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab088684-f6cc-40f9-8bad-5db14fda1712" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0a4f2c0d-5e98-4949-bb8f-53c54644c28d" xlink:to="loc_srt_RangeMember_ab088684-f6cc-40f9-8bad-5db14fda1712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f80db418-bb48-4af6-ad20-0c4e71176cc1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab088684-f6cc-40f9-8bad-5db14fda1712" xlink:to="loc_srt_MaximumMember_f80db418-bb48-4af6-ad20-0c4e71176cc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_7401b8d0-bfa5-435e-9475-0dcbef530235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_7401b8d0-bfa5-435e-9475-0dcbef530235" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0d5a0c7b-4014-4728-9d71-c34057c431e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0d5a0c7b-4014-4728-9d71-c34057c431e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements_c3514d38-a40b-4ee4-974d-5678b5926bcc" xlink:href="tars-20240331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_tars_LineOfCreditFacilityDrawDownIncrements_c3514d38-a40b-4ee4-974d-5678b5926bcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a7ee938f-0d72-4d6e-912e-32894d2c54c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a7ee938f-0d72-4d6e-912e-32894d2c54c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_179a7b81-4a95-40c5-b6dc-7d711954a1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_179a7b81-4a95-40c5-b6dc-7d711954a1cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_2638f136-e062-4ba1-8d16-bcb1a8c421a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_2638f136-e062-4ba1-8d16-bcb1a8c421a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_e22f25d0-b3d8-4d79-96bd-baa41e6b21d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_e22f25d0-b3d8-4d79-96bd-baa41e6b21d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_ea19f36f-aae3-473e-9e2a-eed4e4148115" xlink:href="tars-20240331.xsd#tars_LineOfCreditFacilityPeriodicPaymentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_ea19f36f-aae3-473e-9e2a-eed4e4148115" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0460e500-13c5-43d6-bdd9-30c17c3de49d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0460e500-13c5-43d6-bdd9-30c17c3de49d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2c835e7a-dfd5-489c-86c3-195a58f54253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2c835e7a-dfd5-489c-86c3-195a58f54253" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d460d98c-4acf-44e1-adf5-98bc5c824bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d460d98c-4acf-44e1-adf5-98bc5c824bb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f45310c0-d454-4877-9aec-af788c9aac6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d460d98c-4acf-44e1-adf5-98bc5c824bb2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f45310c0-d454-4877-9aec-af788c9aac6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f45310c0-d454-4877-9aec-af788c9aac6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f45310c0-d454-4877-9aec-af788c9aac6b" xlink:to="loc_us-gaap_RelatedPartyDomain_f45310c0-d454-4877-9aec-af788c9aac6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a10914e0-2e60-447a-8ab0-99a0e9cdd1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f45310c0-d454-4877-9aec-af788c9aac6b" xlink:to="loc_us-gaap_RelatedPartyDomain_a10914e0-2e60-447a-8ab0-99a0e9cdd1c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_50112458-7dd0-4e24-ba6b-76af7c395716" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a10914e0-2e60-447a-8ab0-99a0e9cdd1c0" xlink:to="loc_srt_DirectorMember_50112458-7dd0-4e24-ba6b-76af7c395716" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_189b1570-7e1b-4f4b-b3a3-2c577ca44c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a10914e0-2e60-447a-8ab0-99a0e9cdd1c0" xlink:to="loc_us-gaap_RelatedPartyMember_189b1570-7e1b-4f4b-b3a3-2c577ca44c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f9210f6-ab15-4ddb-a8c8-29cc3453a7af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d460d98c-4acf-44e1-adf5-98bc5c824bb2" xlink:to="loc_srt_RangeAxis_2f9210f6-ab15-4ddb-a8c8-29cc3453a7af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f9210f6-ab15-4ddb-a8c8-29cc3453a7af_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f9210f6-ab15-4ddb-a8c8-29cc3453a7af" xlink:to="loc_srt_RangeMember_2f9210f6-ab15-4ddb-a8c8-29cc3453a7af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1fffa57c-c2b0-4929-88d3-2d00995d8b84" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f9210f6-ab15-4ddb-a8c8-29cc3453a7af" xlink:to="loc_srt_RangeMember_1fffa57c-c2b0-4929-88d3-2d00995d8b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_acfe5593-4bfe-4875-8c0f-2682ef4a597e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1fffa57c-c2b0-4929-88d3-2d00995d8b84" xlink:to="loc_srt_MinimumMember_acfe5593-4bfe-4875-8c0f-2682ef4a597e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_45b2e140-3c33-4165-a8c1-56b696287b25" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1fffa57c-c2b0-4929-88d3-2d00995d8b84" xlink:to="loc_srt_MaximumMember_45b2e140-3c33-4165-a8c1-56b696287b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RelatedPartyTransactionAnnualCashCompensation_d910e2fd-dca7-4f7b-8c5a-4e31add989c5" xlink:href="tars-20240331.xsd#tars_RelatedPartyTransactionAnnualCashCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_tars_RelatedPartyTransactionAnnualCashCompensation_d910e2fd-dca7-4f7b-8c5a-4e31add989c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9ab0ba24-e0f1-432f-9a61-a48e789253d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9ab0ba24-e0f1-432f-9a61-a48e789253d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1e89516d-7451-4552-bbdd-4beab07a1a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1e89516d-7451-4552-bbdd-4beab07a1a9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RelatedPartTransactionTerminationNoticePeriod_8f569c34-4a43-444c-bb9d-05ebe847a9e8" xlink:href="tars-20240331.xsd#tars_RelatedPartTransactionTerminationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_tars_RelatedPartTransactionTerminationNoticePeriod_8f569c34-4a43-444c-bb9d-05ebe847a9e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e45cafa1-fda1-49ab-af0f-2756cbe80a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e45cafa1-fda1-49ab-af0f-2756cbe80a20" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5ca565ed-9e37-4f05-9ca6-36d0f4b30742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5ca565ed-9e37-4f05-9ca6-36d0f4b30742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5ca565ed-9e37-4f05-9ca6-36d0f4b30742_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5ca565ed-9e37-4f05-9ca6-36d0f4b30742" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5ca565ed-9e37-4f05-9ca6-36d0f4b30742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_54134e9b-d2a1-4d87-8936-de5b30a0c070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5ca565ed-9e37-4f05-9ca6-36d0f4b30742" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_54134e9b-d2a1-4d87-8936-de5b30a0c070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_aee5eeba-bd52-4787-8a70-3a822376ad2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_54134e9b-d2a1-4d87-8936-de5b30a0c070" xlink:to="loc_us-gaap_SubsequentEventMember_aee5eeba-bd52-4787-8a70-3a822376ad2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b380e7c1-4f59-40ad-beaa-25c7edf51155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:to="loc_us-gaap_DebtInstrumentAxis_b380e7c1-4f59-40ad-beaa-25c7edf51155" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b380e7c1-4f59-40ad-beaa-25c7edf51155_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b380e7c1-4f59-40ad-beaa-25c7edf51155" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b380e7c1-4f59-40ad-beaa-25c7edf51155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_285fea64-c19c-4094-84c1-955e983feba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b380e7c1-4f59-40ad-beaa-25c7edf51155" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_285fea64-c19c-4094-84c1-955e983feba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_285fea64-c19c-4094-84c1-955e983feba5" xlink:to="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheOneMember_6aada130-5e33-4464-9117-f32e0d49c114" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:to="loc_tars_PharmakonCreditFacilityTrancheOneMember_6aada130-5e33-4464-9117-f32e0d49c114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheTwoMember_8705f744-2f75-45a8-a1c7-a11b360b0ab4" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:to="loc_tars_PharmakonCreditFacilityTrancheTwoMember_8705f744-2f75-45a8-a1c7-a11b360b0ab4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheThreeMember_04c39a69-836f-4be8-950c-a14f324a57e1" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:to="loc_tars_PharmakonCreditFacilityTrancheThreeMember_04c39a69-836f-4be8-950c-a14f324a57e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheFourMember_722c533e-c9e7-4723-a2f7-de3b43ced3c6" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:to="loc_tars_PharmakonCreditFacilityTrancheFourMember_722c533e-c9e7-4723-a2f7-de3b43ced3c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_49743f69-a4ee-43af-bb3d-cfeda18ad84f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_49743f69-a4ee-43af-bb3d-cfeda18ad84f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_49743f69-a4ee-43af-bb3d-cfeda18ad84f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_49743f69-a4ee-43af-bb3d-cfeda18ad84f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_49743f69-a4ee-43af-bb3d-cfeda18ad84f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8a51d35e-7bd5-411f-ba41-1bb2b4e954dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_49743f69-a4ee-43af-bb3d-cfeda18ad84f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8a51d35e-7bd5-411f-ba41-1bb2b4e954dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6d7a7f59-ec8a-4056-a1dd-b0ec3f40b8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8a51d35e-7bd5-411f-ba41-1bb2b4e954dc" xlink:to="loc_us-gaap_LineOfCreditMember_6d7a7f59-ec8a-4056-a1dd-b0ec3f40b8c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bd9962d5-e0b3-4cbe-8e51-06da2fbe3ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:to="loc_us-gaap_VariableRateAxis_bd9962d5-e0b3-4cbe-8e51-06da2fbe3ea6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bd9962d5-e0b3-4cbe-8e51-06da2fbe3ea6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_bd9962d5-e0b3-4cbe-8e51-06da2fbe3ea6" xlink:to="loc_us-gaap_VariableRateDomain_bd9962d5-e0b3-4cbe-8e51-06da2fbe3ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ec4d5b17-331b-4565-a0e6-8c54f473939b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_bd9962d5-e0b3-4cbe-8e51-06da2fbe3ea6" xlink:to="loc_us-gaap_VariableRateDomain_ec4d5b17-331b-4565-a0e6-8c54f473939b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80f19217-42ba-498f-825f-737df6531b41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ec4d5b17-331b-4565-a0e6-8c54f473939b" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80f19217-42ba-498f-825f-737df6531b41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_ec9a737f-e99a-4230-b821-df3cb88e3c00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_ec9a737f-e99a-4230-b821-df3cb88e3c00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_cbbfd739-9143-428a-94d7-e221309f5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_cbbfd739-9143-428a-94d7-e221309f5bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtInstrumentNumberOfPotentialAdditionalTranches_9ddb7f3b-3841-4941-b259-efaa7c943197" xlink:href="tars-20240331.xsd#tars_DebtInstrumentNumberOfPotentialAdditionalTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_tars_DebtInstrumentNumberOfPotentialAdditionalTranches_9ddb7f3b-3841-4941-b259-efaa7c943197" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e170842a-fede-4cda-bcb3-98fa8596480d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e170842a-fede-4cda-bcb3-98fa8596480d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements_b75bdbcb-3c6b-4e01-a2aa-410f9ab7a4b9" xlink:href="tars-20240331.xsd#tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements_b75bdbcb-3c6b-4e01-a2aa-410f9ab7a4b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2722ab0b-b47e-47e2-9247-29f8442873fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2722ab0b-b47e-47e2-9247-29f8442873fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtInstrumentFloorInterestRate_f61ebb37-e277-4e54-af26-eda7df02f1aa" xlink:href="tars-20240331.xsd#tars_DebtInstrumentFloorInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_tars_DebtInstrumentFloorInterestRate_f61ebb37-e277-4e54-af26-eda7df02f1aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_d4d57396-0452-4ae1-bd4c-a71685969dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_d4d57396-0452-4ae1-bd4c-a71685969dbc" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_BobakAzamianMember_bb5096da-9df8-437c-949c-0e12b46b0cb2" xlink:href="tars-20240331.xsd#tars_BobakAzamianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_tars_BobakAzamianMember_bb5096da-9df8-437c-949c-0e12b46b0cb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_JoseTrevejoMember_bfb3b605-365e-4bf6-872f-687eb0bfda09" xlink:href="tars-20240331.xsd#tars_JoseTrevejoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_tars_JoseTrevejoMember_bfb3b605-365e-4bf6-872f-687eb0bfda09" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>tars-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a12c9650-c665-4945-913e-9e9f011ed114,g:485e89bc-d27f-4026-942d-5c7ac04342fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds_57c0719b-b178-4413-95fd-2cb0135ca6e5_terseLabel_en-US" xlink:label="lab_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agent fee percentage</link:label>
    <link:label id="lab_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Sales Agent Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Sales Agent Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds" xlink:href="tars-20240331.xsd#tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds" xlink:to="lab_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_13a7291f-db33-4dda-89a0-53d8613870ba_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_79e287cc-d04c-41bb-a1d1-33d862a9729b_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriters' option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7df110e7-76ce-4fb7-b7c0-88314c49285b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_433ef3c0-ceb3-401d-bbf3-047b51f293e8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility, aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8ffab807-ade6-4fd4-9452-28564a1b25a7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_01b921f6-946e-4562-b87a-8fdee499aa76_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_dcc65abb-fd64-463d-a6ec-427a1bc8faed_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_c2f06d22-b526-4476-afbb-4e251589bca6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70d991b1-6048-4933-8479-b419c9d54a29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6a582e8-9d9e-4e7f-a25c-cc25426e1702_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c10c07fe-a5a3-49b0-a27e-db36b32464e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ab3d29a3-e432-4d75-b2f2-330a60d68e4e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairments of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d187f2d4-da7b-46c1-8a0a-28b85d2bc775_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility Agreement</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_471d410f-262c-4524-b959-ee7125a36477_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheThreeMember_9ecc8b27-a4c2-4ee4-9911-ffc85696131b_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche Three</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheThreeMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche Three [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheThreeMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheThreeMember" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheThreeMember" xlink:to="lab_tars_CreditFacilityTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3190cc95-30cd-4083-9ba1-2aac1f126307_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_5902daf1-0486-4829-b2e7-649a67aeb6ba_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum milestone payments</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:to="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ProceedsFromCancellationOfWarrants_f4d94afa-74fd-43b2-96b5-a4497fcb5677_terseLabel_en-US" xlink:label="lab_tars_ProceedsFromCancellationOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant cancellation payment</link:label>
    <link:label id="lab_tars_ProceedsFromCancellationOfWarrants_label_en-US" xlink:label="lab_tars_ProceedsFromCancellationOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Cancellation Of Warrants</link:label>
    <link:label id="lab_tars_ProceedsFromCancellationOfWarrants_documentation_en-US" xlink:label="lab_tars_ProceedsFromCancellationOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Cancellation Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromCancellationOfWarrants" xlink:href="tars-20240331.xsd#tars_ProceedsFromCancellationOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ProceedsFromCancellationOfWarrants" xlink:to="lab_tars_ProceedsFromCancellationOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c2548ea7-1865-44f0-8d59-200ea2ec092f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_e9e5c7d7-3fc4-419e-abda-00a3a4dd0087_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_b8c63a48-93e2-4448-83ac-f04bcb1d9099_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_24ef862e-cccc-44f0-9f67-4ef5f0b2f6e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_a51419c3-2369-4142-b43b-e1f8a1eb7c04_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_6a8db84b-c067-44dd-928a-8f453d735285_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a439dcbb-b9c0-4b5b-8340-1908c861fd64_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e2ba7096-60b6-4930-a329-367d9925becc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c3478bb4-058a-4ebc-bf43-84f32a4d5bd4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of paid issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9519c360-20ab-4c33-90a9-0d1dd8617cbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_14918789-0b63-4fb1-87f6-409efeaddcca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service condition period for full vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8f96ccc5-83db-441c-96e9-57e660845b95_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_cb0632ea-e7fa-4485-b205-d9a10eb49069_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business and Presentation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b98df939-74f8-4e63-91b2-39be113ef65a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_e1b128d6-fc79-4011-bc26-5f617a7d4a10_terseLabel_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_label_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2016 [Member]</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_documentation_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2016</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member" xlink:href="tars-20240331.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityIncentivePlan2016Member" xlink:to="lab_tars_EquityIncentivePlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_28f3eb0e-793e-4a66-97c5-5ba2968ff4cd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_1e7784a1-52c9-4dfd-8465-0dc42bab86bf_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_63169031-e8d7-43be-824f-8c1ef454bbd2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_66577b5a-1a30-4aca-93ca-b5c5f0e82fc3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a2297deb-d22f-4bb9-897b-aae276db55b5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_975babda-10d0-442d-9a62-9f7894102cbb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CustomerEMember_5d3cd5c8-000c-46ca-8140-8610132b2454_terseLabel_en-US" xlink:label="lab_tars_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer E</link:label>
    <link:label id="lab_tars_CustomerEMember_label_en-US" xlink:label="lab_tars_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer E [Member]</link:label>
    <link:label id="lab_tars_CustomerEMember_documentation_en-US" xlink:label="lab_tars_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerEMember" xlink:href="tars-20240331.xsd#tars_CustomerEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CustomerEMember" xlink:to="lab_tars_CustomerEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_cb6b0790-a74b-45aa-b149-a73e8207f379_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9c7555a8-f923-46b9-b8df-a415f7b453f1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_cf5c3d0a-9f2b-4cdc-9602-3ddea0af2c86_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_768481b1-067e-4e4c-a528-94bb22a88479_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3115d8e4-67d6-456c-be05-6db49362631e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_372ce5be-6fe4-4e7e-95a1-952273221d4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_4d52dee6-74f2-43b8-8a21-da029f711444_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8c1de61e-c4b1-4e7a-a2cc-d052c70435f7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b2936019-594f-4347-a919-6afe78e0248a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_cedfa633-7e26-40bc-ac86-a8fd93e1f9df_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45abe7f1-06ef-4944-9bbd-80876da3e5f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a1dda72-d978-4b50-b3c6-70774ff61cc9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2718f1e5-3c69-4274-be13-4351cac1a700_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of vested stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0403a7aa-0994-4295-b9f1-d671cb2222d5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9dba62ad-82fb-426e-99aa-05f021b1cb31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5548234b-7894-46c7-9f8c-06667c758ae5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant-date fair value per stock option (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9622a55a-96c1-4a92-b0c4-1e24de3f37d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7206b5d8-e06c-4416-bc11-4a15b0d42a86_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5b791845-aae7-471d-9767-c86086ab65df_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a4a60b79-5dda-4bed-85a0-d236d441885c_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0300d81e-bced-49ae-874a-ee728d36c719_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_3286cd15-7d2c-44ad-ba71-0fdd255fcd00_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNIAbstract_b9740742-29d1-4683-8513-cf36aea73136_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNIAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments:</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNIAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNIAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNIAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFVNIAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFVNIAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_OperatingLeaseNoncashExpense_bec8dad2-37b4-4079-afa1-9804b143f3ee_terseLabel_en-US" xlink:label="lab_tars_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_tars_OperatingLeaseNoncashExpense_label_en-US" xlink:label="lab_tars_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:label id="lab_tars_OperatingLeaseNoncashExpense_documentation_en-US" xlink:label="lab_tars_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseNoncashExpense" xlink:href="tars-20240331.xsd#tars_OperatingLeaseNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_OperatingLeaseNoncashExpense" xlink:to="lab_tars_OperatingLeaseNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ecf46a7a-d89d-4411-b0a7-2aa334cc7884_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_997ad1d1-f018-4e35-9ad2-70cc80006ba8_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_97ee1833-5795-4432-8829-58afb3a4d571_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of end of term charge</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_b283698a-0fc3-4e50-af31-67297f534cac_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7e4f98fc-6df8-4fef-9a0c-78d8f0f01acb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_27ac4d55-a532-4fd9-8c97-85b81c844f5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_e8e02900-42e3-48c2-af83-e042ad178d34_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_cb8411fe-781a-43a3-bd34-543a82a72b20_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1a3d7a87-c9d9-4b46-b93e-93f6a0d7f965_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of vested stock options (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_abceb447-f572-42a9-bdae-fbd9724932e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d17854c1-e68a-4cfb-a35d-b171eabb6bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share, basis and diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_50570e06-f9ed-416d-b0ce-b38c60cdd1a6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0082d37d-b689-4360-a08a-fe2e55fe2980_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_aab86c0a-0065-475f-adee-7655620bc5a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of equity warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_081077ae-1ae8-4f5a-88e6-ae3115b05ff0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9292a7ea-1ace-457a-8a2f-26156e0c35a4_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies and Use of Estimates</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f634acc5-e296-429a-9bc8-9c52aba48108_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_69c0b7c8-a5bf-482d-9d4e-7d765bc8d43b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_33ec8f3c-0f07-4fd3-9ed1-677977519b69_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7a9d99d8-b258-40e5-a969-969c4488244b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of pre-funded warrants, net of issuance costs of $0.6 million</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8d613784-446c-4ce9-8a5e-beeffb5e515b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f80f4683-0c11-4b07-9a76-41125f92105b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d9e46d7-498a-415a-9e97-4e3e84c70744_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_57f9eae2-fca4-4ea8-b4b7-f4a7b1c3dcbd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price per warrant (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_04ad70f0-4457-49c4-854e-557b920a4d62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d5e0cc76-ca06-469b-8282-d888c32aad60_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_755bd3e3-048f-4512-8a86-cd498ed760ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_77839538-ffc6-47ab-8a5c-3d255187ff07_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_727fae6a-f1d1-45fd-a281-b24fc16b1a62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_45329191-8ce9-4178-945c-da9b9c1b83e1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e70995c9-5a94-42dd-907b-30b359eb087b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1287f5a3-c7fe-48b2-828d-636b689691fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain from transactions denominated in a foreign currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheOneMember_636f1d1b-b0d7-4989-ac17-c0fbf57d1e7e_terseLabel_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche One</link:label>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheOneMember_label_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche One [Member]</link:label>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheOneMember" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PharmakonCreditFacilityTrancheOneMember" xlink:to="lab_tars_PharmakonCreditFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8de894b5-ee7d-4996-b021-864b60e3fd8e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CustomerBMember_5b473032-b122-4596-a823-20f038236ac6_terseLabel_en-US" xlink:label="lab_tars_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_tars_CustomerBMember_label_en-US" xlink:label="lab_tars_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_tars_CustomerBMember_documentation_en-US" xlink:label="lab_tars_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerBMember" xlink:href="tars-20240331.xsd#tars_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CustomerBMember" xlink:to="lab_tars_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_978ae0c0-3571-419e-beb7-bfd83badb86d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_f8326de0-a0d1-4c78-bf6a-8af1d15ee46c_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options reserved for future grant (shares)</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_MilestoneDeterminedByTheCompanyMember_e0566862-a0df-4ac9-93fb-b07fe18f0f54_terseLabel_en-US" xlink:label="lab_tars_MilestoneDeterminedByTheCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Determined by the Company</link:label>
    <link:label id="lab_tars_MilestoneDeterminedByTheCompanyMember_label_en-US" xlink:label="lab_tars_MilestoneDeterminedByTheCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Determined by the Company [Member]</link:label>
    <link:label id="lab_tars_MilestoneDeterminedByTheCompanyMember_documentation_en-US" xlink:label="lab_tars_MilestoneDeterminedByTheCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Determined by the Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_MilestoneDeterminedByTheCompanyMember" xlink:href="tars-20240331.xsd#tars_MilestoneDeterminedByTheCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_MilestoneDeterminedByTheCompanyMember" xlink:to="lab_tars_MilestoneDeterminedByTheCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts_42a023c8-c555-4b22-a958-da9b3cf3b0e0_terseLabel_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts_label_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Lease Contracts</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts_documentation_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Lease Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:href="tars-20240331.xsd#tars_LesseeOperatingLeaseNumberOfLeaseContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:to="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_400a17af-b558-4680-9bca-19c42f2209ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ce5a9999-08d2-46a9-b6b7-4e39d566a6d4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3c0c8f54-934b-470d-9432-842388059460_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock unit activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_8d28c95b-90e8-459f-9a1c-fa5a5750e440_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_498b5774-34ac-4e8b-9e8d-4c18e4c15b95_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_1d80766f-8b3d-4fc0-9138-3bc0ec5a8114_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockInLianBioMember_81edebeb-7029-4cf9-a21f-784f719a9326_terseLabel_en-US" xlink:label="lab_tars_CommonStockInLianBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock in LianBio</link:label>
    <link:label id="lab_tars_CommonStockInLianBioMember_label_en-US" xlink:label="lab_tars_CommonStockInLianBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock In LianBio [Member]</link:label>
    <link:label id="lab_tars_CommonStockInLianBioMember_documentation_en-US" xlink:label="lab_tars_CommonStockInLianBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock In LianBio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockInLianBioMember" xlink:href="tars-20240331.xsd#tars_CommonStockInLianBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockInLianBioMember" xlink:to="lab_tars_CommonStockInLianBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ef69c4f1-1cc0-4a89-a240-33e393c37554_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b654af8d-b609-4a33-8723-ac2abc22600f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_963f06e2-6922-46b3-b58e-1e9f5d42d8ab_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_a55c5ebc-0d2e-417d-9a29-f3322f8602c2_terseLabel_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional cash payment</link:label>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_label_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Additional Cash Payment</link:label>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_documentation_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Additional Cash Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:href="tars-20240331.xsd#tars_RevenueRemainingPerformanceObligationAdditionalCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:to="lab_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6d0a205e-347f-4622-93ed-217910a13150_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contractual lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_abb39a17-40ff-4ef5-ae55-d0e8dbf64ed3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_5bfc3d05-c708-49e3-bed8-79dd1c735cf3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_8ee8878e-bad2-47d2-b279-f9662d617427_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_NumberOfVestedWarrants_8b19de8e-f009-47d1-81f2-724f883c5506_terseLabel_en-US" xlink:label="lab_tars_NumberOfVestedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of vested warrants</link:label>
    <link:label id="lab_tars_NumberOfVestedWarrants_label_en-US" xlink:label="lab_tars_NumberOfVestedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Vested Warrants</link:label>
    <link:label id="lab_tars_NumberOfVestedWarrants_documentation_en-US" xlink:label="lab_tars_NumberOfVestedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Vested Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfVestedWarrants" xlink:href="tars-20240331.xsd#tars_NumberOfVestedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_NumberOfVestedWarrants" xlink:to="lab_tars_NumberOfVestedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_277bdc7f-c803-43b3-a6ae-c975849e771a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments measured at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_323ea5f1-9381-48ae-98c4-40cdb4c7944b_terseLabel_en-US" xlink:label="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">End of term charge, interest rate</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_label_en-US" xlink:label="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest Rate</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_documentation_en-US" xlink:label="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:href="tars-20240331.xsd#tars_LineOfCreditFacilityPeriodicPaymentInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:to="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_55804699-30a4-4dc9-82cb-2046789b00dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding potentially dilutive securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_86ee5b6e-4131-4ce0-ab69-1922352d658a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_052d5524-7a12-4a74-af28-6e299bd586a4_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_3bb5e211-ae66-4482-8ce0-d62c36e03dfd_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense related to term loan</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_A2023ATMProspectusMember_9eb5ff6a-f498-46a8-9ef2-fddeb27004be_terseLabel_en-US" xlink:label="lab_tars_A2023ATMProspectusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 ATM Prospectus</link:label>
    <link:label id="lab_tars_A2023ATMProspectusMember_label_en-US" xlink:label="lab_tars_A2023ATMProspectusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 ATM Prospectus [Member]</link:label>
    <link:label id="lab_tars_A2023ATMProspectusMember_documentation_en-US" xlink:label="lab_tars_A2023ATMProspectusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 ATM Prospectus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_A2023ATMProspectusMember" xlink:href="tars-20240331.xsd#tars_A2023ATMProspectusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_A2023ATMProspectusMember" xlink:to="lab_tars_A2023ATMProspectusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_8cd1be15-dad6-4741-9766-f1a0c0f8098f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_a49b2c3b-7a61-4f41-b81e-19549b094fbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_74e5f569-26cb-4cd6-8ee5-21a6e17d1c23_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4a468b60-92dc-4b02-952f-36ff7b4050fa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bd895e8d-5698-472d-80a6-6aa478ebc986_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a026c799-ab4f-4d1d-bad0-a3a64c39dc41_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3b31e4a5-c55c-4b0a-bd56-0a6f718a3b28_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bd0be126-a608-4cad-b0c6-87063e6ead79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8b49b7e8-6c05-436b-b661-991db2dec5e1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_FollowOnPublicOfferingMember_249594a1-a3dc-4bbe-807b-31d9c1468697_terseLabel_en-US" xlink:label="lab_tars_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Follow-On Public Offering</link:label>
    <link:label id="lab_tars_FollowOnPublicOfferingMember_label_en-US" xlink:label="lab_tars_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Follow-On Public Offering [Member]</link:label>
    <link:label id="lab_tars_FollowOnPublicOfferingMember_documentation_en-US" xlink:label="lab_tars_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Follow-On Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FollowOnPublicOfferingMember" xlink:href="tars-20240331.xsd#tars_FollowOnPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_FollowOnPublicOfferingMember" xlink:to="lab_tars_FollowOnPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_3ba3717d-dfa8-464c-9592-25fc74792b66_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ea79c973-bbb4-4fa5-b767-7711946df0c0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosures Noncash Investing and Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_20809879-7865-4dac-ac08-ea8bd836bd55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5bb16451-e7dd-4dd9-b8af-a0ad8037b48c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LicenseAndCollaborationOtherMember_d5aa693e-7cca-43ca-8aaf-4f30dcdded32_terseLabel_en-US" xlink:label="lab_tars_LicenseAndCollaborationOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration, Other</link:label>
    <link:label id="lab_tars_LicenseAndCollaborationOtherMember_label_en-US" xlink:label="lab_tars_LicenseAndCollaborationOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration, Other [Member]</link:label>
    <link:label id="lab_tars_LicenseAndCollaborationOtherMember_documentation_en-US" xlink:label="lab_tars_LicenseAndCollaborationOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationOtherMember" xlink:href="tars-20240331.xsd#tars_LicenseAndCollaborationOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LicenseAndCollaborationOtherMember" xlink:to="lab_tars_LicenseAndCollaborationOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d4ad44be-1f2d-4bb5-bcc9-647ae3eb6c83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_9e3d2fe9-863a-4432-9707-141b6207ac94_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8d242407-868b-4ace-aa07-6e5b3d94432b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bb4ecc85-60d9-492f-98ad-d93a3d8d9f56_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset obtained in exchange for operating lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_bcc3142a-8d28-4845-9614-87ece7043ec8_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:href="tars-20240331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c8268c0e-e606-416e-84cd-6ed53da9e11f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ccb55965-c446-4abd-bcc3-9b97a95bdebd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_917767bd-1826-4ff1-952f-56694e542a96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Less): Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_13fbeb66-5d9d-4e69-b1b9-3d8a2c51c1a2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_00c38dfa-90b4-448a-901a-d27cadb73a51_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_f4239446-7de4-4fa5-b204-c39755ea353c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_567217ff-ea07-4cab-babc-75e14466d28c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d279d22d-52b2-423f-aa6c-8c1f973f93e1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_cf55507a-2147-4bd9-a4a2-2e6984a5cd7d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">End of term charge</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b81108ed-c63d-4500-b40b-1db858f2c7d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_e9f7e4fc-09db-4c10-b40d-8d4fa2bf141f_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_13a66207-7c25-4f52-b3dd-3e351f164249_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ClassOfWarrantOrRightReservedForFutureIssuance_2b345263-9226-4fca-b3f6-b954422a955d_terseLabel_en-US" xlink:label="lab_tars_ClassOfWarrantOrRightReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded warrants reserved for future issuance (shares)</link:label>
    <link:label id="lab_tars_ClassOfWarrantOrRightReservedForFutureIssuance_label_en-US" xlink:label="lab_tars_ClassOfWarrantOrRightReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right, Reserved for Future Issuance</link:label>
    <link:label id="lab_tars_ClassOfWarrantOrRightReservedForFutureIssuance_documentation_en-US" xlink:label="lab_tars_ClassOfWarrantOrRightReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right, Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClassOfWarrantOrRightReservedForFutureIssuance" xlink:href="tars-20240331.xsd#tars_ClassOfWarrantOrRightReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ClassOfWarrantOrRightReservedForFutureIssuance" xlink:to="lab_tars_ClassOfWarrantOrRightReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_2827124f-2038-47e7-85a2-01b6e910e869_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_aeecf707-faa9-4ca0-9b1f-6489393838c9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_PharmakonCreditFacilityMember_77c1495f-f020-44ba-93e2-d42983f1a76e_terseLabel_en-US" xlink:label="lab_tars_PharmakonCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility</link:label>
    <link:label id="lab_tars_PharmakonCreditFacilityMember_label_en-US" xlink:label="lab_tars_PharmakonCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility [Member]</link:label>
    <link:label id="lab_tars_PharmakonCreditFacilityMember_documentation_en-US" xlink:label="lab_tars_PharmakonCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityMember" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PharmakonCreditFacilityMember" xlink:to="lab_tars_PharmakonCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CustomerCMember_14dde99c-7c62-45e5-880e-f58a87ec0383_terseLabel_en-US" xlink:label="lab_tars_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_tars_CustomerCMember_label_en-US" xlink:label="lab_tars_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_tars_CustomerCMember_documentation_en-US" xlink:label="lab_tars_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerCMember" xlink:href="tars-20240331.xsd#tars_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CustomerCMember" xlink:to="lab_tars_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_c39ac6bb-c10e-40d7-a6d1-7802b2238e42_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f09a3ecc-bb32-4236-8959-05447ca3ad3a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12dd5d65-fea8-4041-b22a-0c94da70a6b0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_5ca5f938-d7d3-453e-a73d-5036cd838493_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_69c44ba2-9415-4ef6-b45e-59998d561d72_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_68a25735-8221-485e-8329-093391179383_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e18eb80d-2dc9-4f9c-bf57-98fc5d2ee558_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued or Effective Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1b6eb8d0-7b17-4437-b8b9-2f27e0cc3521_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b7b57034-e331-497d-8187-f86e107d9b48_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_55c9733e-6b99-40e8-bd72-c34b83667527_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa3f3692-f335-4e36-8af6-a75fc9f4730d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0e708b43-e56f-48b0-a855-dc178829ed74_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ed0d5a89-e6bc-4f54-8e1f-876db4f2803d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementFutureCashPayments_5e70ca5f-2964-4014-bf5c-e0bdc1d916d2_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementFutureCashPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future cash payments</link:label>
    <link:label id="lab_tars_CollaborativeArrangementFutureCashPayments_label_en-US" xlink:label="lab_tars_CollaborativeArrangementFutureCashPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Future Cash Payments</link:label>
    <link:label id="lab_tars_CollaborativeArrangementFutureCashPayments_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementFutureCashPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Future Cash Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementFutureCashPayments" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementFutureCashPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementFutureCashPayments" xlink:to="lab_tars_CollaborativeArrangementFutureCashPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_5d36f463-eda0-4cca-9a18-eb9cd3b88bb0_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets Held-for-Sale by Asset Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets Held-for-Sale by Asset Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_abaa43ba-3ea3-45dc-9fc9-d6c89b6cd546_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original issue price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_f2ced847-37bf-47a4-9a5a-0599eecb877a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ce19d2bc-3ae8-4ebc-b81f-de18854a1c7b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_88f3aac2-7428-4372-858b-7069831aaffb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_bd54e316-33c0-4358-b0ba-fc23aa83b736_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_0c1771cb-1090-4fa5-89cc-266cce15f8a9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of estimated value of cash, cash equivalents, marketable securities, and equity securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b39f5860-8da4-4e11-a263-e81ac0afb2d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation assumptions of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2f699e20-6a88-4f7f-be4d-2438820c2dda_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3fe463c7-ecc3-44c5-bb81-c7e056d6c8cd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_12101499-0c37-40b0-ba72-98ef5ff57e54_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Term loan, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9c550dc7-7dcc-46f2-9541-c11754279ebc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4339b27a-d840-48cd-976f-f7b79b00c08c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3337c39d-67d6-4c9a-846c-d14de9797083_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued, net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2cc81d72-d779-4e0f-921e-845f043055ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_f8686240-5ada-4844-964e-616d02d52ca6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_32f28687-2fcd-486d-9c18-958da6e904e0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cc09b0d4-6ef9-4cf4-948e-3fe7f9c2bb72_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options, unexercised&#8212;vested and unvested</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc45e27e-7d5c-4138-98b3-e4b3b52bfc92_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense, weighted average period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_cc2bc2b3-4bf4-49f2-b4b1-9d48d5935c02_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bec58b2e-d685-438a-ae79-f3cd214181f8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_95684559-1c0c-4a7e-9b33-55e0fd9c76de_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_639fd8ec-f44c-460d-a619-256e7c395cf9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_9c4ef8b9-00dc-4d88-9c0c-a1241ca1b0a1_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:href="tars-20240331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_f3b17de2-ebc9-45bf-8524-f75278ceacef_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9eda4676-b3fb-4267-b79d-91f0ca858301_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_b518ed57-2557-4ef0-b3a9-6c234a92a826_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_cb73d7ff-29d6-44df-8466-375ad4d31163_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquitySecuritiesFVNINumberOfShares_de44690d-f68c-4bcd-8019-21fddd9824d6_terseLabel_en-US" xlink:label="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities (in shares)</link:label>
    <link:label id="lab_tars_EquitySecuritiesFVNINumberOfShares_label_en-US" xlink:label="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Number Of Shares</link:label>
    <link:label id="lab_tars_EquitySecuritiesFVNINumberOfShares_documentation_en-US" xlink:label="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquitySecuritiesFVNINumberOfShares" xlink:href="tars-20240331.xsd#tars_EquitySecuritiesFVNINumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquitySecuritiesFVNINumberOfShares" xlink:to="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_26642a43-dbb7-4f2e-b87e-3fbf34161c50_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_50718fe6-3334-4aed-a94a-abf8fd75d94f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements_260df42d-389b-40ce-8a1d-cefdc010bcac_terseLabel_en-US" xlink:label="lab_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranches with minimum net sales milestones</link:label>
    <link:label id="lab_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements_label_en-US" xlink:label="lab_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Tranches With Milestone Requirements</link:label>
    <link:label id="lab_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements_documentation_en-US" xlink:label="lab_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Tranches With Milestone Requirements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements" xlink:href="tars-20240331.xsd#tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements" xlink:to="lab_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fc12c64c-01be-4238-8b7e-64f7e2a4207f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_29d1ce1e-b7ea-460c-bf3e-20fdf66f7bba_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4f2f75d7-3a39-43d8-ae65-10f7bcb36757_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_d71cef04-cb3d-48b3-b392-2c2d3e4f2336_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5e52c130-3aaa-4335-a7a4-9f5952ac4689_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_dc66c8b3-1a7c-41d3-8e3c-ab2e8abac84f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2df89de7-2ab4-46d7-8584-3e9adc1b2342_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_13a392e2-afc1-4e44-b818-9b6505583c4a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_80d605d8-af49-4dd1-bd61-ca8d50911146_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ef5a4a18-eb78-4194-a701-c2f066ccdec2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cc88127c-d271-478d-820b-2be6a3db0ed3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ecd26b0a-317c-4150-83b1-74efce77d28c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_f1884232-08b2-4637-8ed2-b15481301729_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets Held-for-Sale, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets Held-for-Sale, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_FiveCustomersMember_b607ed65-cbbd-49fa-8f19-94da0eb50f5a_terseLabel_en-US" xlink:label="lab_tars_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Five Customers</link:label>
    <link:label id="lab_tars_FiveCustomersMember_label_en-US" xlink:label="lab_tars_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five Customers [Member]</link:label>
    <link:label id="lab_tars_FiveCustomersMember_documentation_en-US" xlink:label="lab_tars_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Five Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FiveCustomersMember" xlink:href="tars-20240331.xsd#tars_FiveCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_FiveCustomersMember" xlink:to="lab_tars_FiveCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1f3fd81a-c7c9-4965-b212-496435a7d3e0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_6dc63e8a-d816-469f-97b2-4c6386117346_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LianBioMember_d42e0796-9af5-4dce-a88d-47a78ab5038d_terseLabel_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LianBio</link:label>
    <link:label id="lab_tars_LianBioMember_label_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LianBio [Member]</link:label>
    <link:label id="lab_tars_LianBioMember_documentation_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LianBio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember" xlink:href="tars-20240331.xsd#tars_LianBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LianBioMember" xlink:to="lab_tars_LianBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d89744b-58c7-4d8b-af4d-a6f1a54dd1e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9685c572-efb8-42ea-a5b3-053c5264e84e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities_6a33d41b-0987-487e-8165-083bc44b2571_terseLabel_en-US" xlink:label="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs included within accounts payable and accrued liabilities</link:label>
    <link:label id="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities</link:label>
    <link:label id="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities_documentation_en-US" xlink:label="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:href="tars-20240331.xsd#tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="lab_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_941b9cf3-2d76-4101-a074-bf4373a5e585_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b41d6a7f-9e7b-427c-9acd-bd055d5438a5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_RelatedPartTransactionTerminationNoticePeriod_cf5b7a76-55cf-4c94-8bbd-32f23be35120_terseLabel_en-US" xlink:label="lab_tars_RelatedPartTransactionTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction, termination notice, period</link:label>
    <link:label id="lab_tars_RelatedPartTransactionTerminationNoticePeriod_label_en-US" xlink:label="lab_tars_RelatedPartTransactionTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Part Transaction, Termination Notice, Period</link:label>
    <link:label id="lab_tars_RelatedPartTransactionTerminationNoticePeriod_documentation_en-US" xlink:label="lab_tars_RelatedPartTransactionTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Part Transaction, Termination Notice, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RelatedPartTransactionTerminationNoticePeriod" xlink:href="tars-20240331.xsd#tars_RelatedPartTransactionTerminationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_RelatedPartTransactionTerminationNoticePeriod" xlink:to="lab_tars_RelatedPartTransactionTerminationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_147f6a4a-8f5a-441c-b2ad-bfcabe9d6819_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_14ef0662-38e0-4421-b09f-07b3bc287d5a_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_54f9a79b-9849-4bbe-a1c7-539d80c76764_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_34b0e842-e7dd-4878-a33d-b0617cd88a7c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_WarrantAgreementNumberOfTranches_8d337395-39a1-46e1-b281-1d9a1f5129cf_terseLabel_en-US" xlink:label="lab_tars_WarrantAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_tars_WarrantAgreementNumberOfTranches_label_en-US" xlink:label="lab_tars_WarrantAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Agreement, Number of Tranches</link:label>
    <link:label id="lab_tars_WarrantAgreementNumberOfTranches_documentation_en-US" xlink:label="lab_tars_WarrantAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Agreement, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_WarrantAgreementNumberOfTranches" xlink:href="tars-20240331.xsd#tars_WarrantAgreementNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_WarrantAgreementNumberOfTranches" xlink:to="lab_tars_WarrantAgreementNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_35fe8d41-db0f-4b9b-a9eb-ba71f2948c59_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense for term loan</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_564b21e1-a268-4da1-a526-639017d2354c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_24eb6f59-ca5b-4ea4-a7fd-42a1bb2933cd_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_41bf3658-2e86-43ec-9476-d79572c0e3f4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_39e5137d-50f8-4c91-952d-44a87f21c06a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_25a79041-8702-42e3-a5d9-ed48ac71f94d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_172e8f32-7bf6-4392-9a80-3e62f4c003be_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_2ab519d6-53bd-495a-9974-be5c51c79b86_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_label_en-US" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Amortization, Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:to="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_2830344e-4334-498c-a3d3-36d7f60c741d_terseLabel_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities with contractual maturity between one and five years</link:label>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_label_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities</link:label>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_documentation_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:href="tars-20240331.xsd#tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:to="lab_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_9382cdf3-68d3-43ef-8615-12f18e53c893_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_369bad9c-a3f3-4d30-82ee-589e79fd4a6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2387180a-a4d4-43a4-bb68-2a3e448037cc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3ff116c2-2461-45d2-b2a1-f306c0ea1759_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_a436813a-eb1d-4f32-87ba-35d34e17816f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon the vesting of restricted stock units (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DebtInstrumentFloorInterestRate_558b38ea-4ae7-4ea2-9737-c08f65a2f16c_terseLabel_en-US" xlink:label="lab_tars_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate floor</link:label>
    <link:label id="lab_tars_DebtInstrumentFloorInterestRate_label_en-US" xlink:label="lab_tars_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:label id="lab_tars_DebtInstrumentFloorInterestRate_documentation_en-US" xlink:label="lab_tars_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtInstrumentFloorInterestRate" xlink:href="tars-20240331.xsd#tars_DebtInstrumentFloorInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DebtInstrumentFloorInterestRate" xlink:to="lab_tars_DebtInstrumentFloorInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_92ae3b2d-f2a5-4a68-9771-0a80af2154e1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6b0dd064-d893-4123-aff3-4f4ecf35eefd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_69a31f6c-31e1-49f1-8bb9-67936df9ada8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_34faf02f-2023-427a-ab1a-d49051dddc89_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_4743e584-896a-42b7-9e1e-c5a63ca5dedb_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock in LianBio</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b93143cb-2277-4c7b-875b-ccc00f99f14c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_020848ba-f274-4d3d-b06c-2e1f9888b5e9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_fd54cd77-22a3-4d6c-84c7-4e0ea90e5860_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24d2e705-2304-4c3c-8d2e-04ed519a4160_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f6aaf5d6-842c-4298-bd3d-52b8736a7ce8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_57575b75-a163-49f1-9202-3631274d5eb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3c89920f-826d-4125-ba93-5ed520d4870e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_94f8e456-655b-4feb-b372-708f32e24285_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on marketable securities and cash equivalents</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e30ae302-bf9d-4918-bcda-51246c97611e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_108f50bc-ebe4-406b-8e90-a11e747d0d86_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_38140bf7-8ff0-4982-a756-bd566a6eb8dc_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0a21c343-872a-4d86-a214-ca6eb38a8b2e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_6f45e2ae-7d22-4cdf-8465-4333e59d2a93_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_GrandpharmaMember_07f79797-8e1f-4cde-b7d6-22509bcaf1e4_terseLabel_en-US" xlink:label="lab_tars_GrandpharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grandpharma</link:label>
    <link:label id="lab_tars_GrandpharmaMember_label_en-US" xlink:label="lab_tars_GrandpharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grandpharma [Member]</link:label>
    <link:label id="lab_tars_GrandpharmaMember_documentation_en-US" xlink:label="lab_tars_GrandpharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grandpharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_GrandpharmaMember" xlink:href="tars-20240331.xsd#tars_GrandpharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_GrandpharmaMember" xlink:to="lab_tars_GrandpharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_0b7359b6-74b1-418d-905d-5b84cbf8f606_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_BobakAzamianMember_label_en-US" xlink:label="lab_tars_BobakAzamianMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bobak Azamian [Member]</link:label>
    <link:label id="lab_tars_BobakAzamianMember_documentation_en-US" xlink:label="lab_tars_BobakAzamianMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bobak Azamian</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_BobakAzamianMember" xlink:href="tars-20240331.xsd#tars_BobakAzamianMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_BobakAzamianMember" xlink:to="lab_tars_BobakAzamianMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_26730b19-e56f-4aa5-885f-634bcac0372d_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ecf71c95-d9d6-4c11-a68e-2ca731644020_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_03b10461-6041-4123-83e4-d9089997a28d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e581041-c988-4d28-9cdf-31c1a82b7903_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_59eab7a9-5eb2-4baa-a24e-bac37273ed2b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_dd389aa1-feaf-4745-8766-6b75293303dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad44c6bd-b696-41fa-a7ad-1b9832fc12c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_8fef6362-9d26-465b-958c-96e69dfada20_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8c3bcf14-d637-4b68-b6aa-a464c8d143a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c01876c5-a416-4f9b-9084-5e2a6da1a9bd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_c20ab6ac-a7b2-4a93-86a3-c2caa04970f7_terseLabel_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_label_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:href="tars-20240331.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:to="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_571a2fca-d1d8-40a8-b109-1d441b4cdf97_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fc0135ba-719c-476b-8c63-030515191531_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LineOfCreditSVBMember_0fdb1c7c-4bc1-4616-b4f1-953c766c604b_terseLabel_en-US" xlink:label="lab_tars_LineOfCreditSVBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit, SVB</link:label>
    <link:label id="lab_tars_LineOfCreditSVBMember_label_en-US" xlink:label="lab_tars_LineOfCreditSVBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit, SVB [Member]</link:label>
    <link:label id="lab_tars_LineOfCreditSVBMember_documentation_en-US" xlink:label="lab_tars_LineOfCreditSVBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit, SVB</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditSVBMember" xlink:href="tars-20240331.xsd#tars_LineOfCreditSVBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LineOfCreditSVBMember" xlink:to="lab_tars_LineOfCreditSVBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a4cfa3c5-942f-42c0-91a6-eb75f429014e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_05a38023-43b7-48bf-8075-b69787d252e2_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shares of common stock reserved (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_8c9e0087-8612-454d-addf-4ed6f698b813_terseLabel_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial and sales milestones</link:label>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_label_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial And Sales Milestones [Member]</link:label>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_documentation_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial And Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember" xlink:href="tars-20240331.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommercialAndSalesMilestonesMember" xlink:to="lab_tars_CommercialAndSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_a8380d2a-6869-4e94-bc5a-33d1152219ac_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_251789c6-0910-4151-9fec-4a97e6c8bbc8_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of equity warrants issued by licensee</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5d38507a-b824-4362-b65b-778362485426_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of equity warrants issued by licensee</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b0b19e5-c107-46a5-be34-1ff3fe7a6833_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_cf0c0305-b420-418d-8ddf-ce3b4a13103b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_50a69b21-5620-4c92-93d4-fe59394adacf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_1c17870e-94f1-48a8-a6fd-d7ca4a91f6d3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheFourMember_7ed8133b-2da9-4425-b111-a561f2ba0e7c_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche Four</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheFourMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche Four [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheFourMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFourMember" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheFourMember" xlink:to="lab_tars_CreditFacilityTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_0ee818ba-b828-48c4-8915-a36905d97b93_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Long-Term Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_b4f43118-42b4-4972-814a-fa25cdb19854_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 200,000,000 shares authorized; 37,749,468 shares issued and outstanding at March&#160;31, 2024 (unaudited); 34,211,190 shares issued and outstanding at December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_88776203-7df8-4cc4-8b98-e921d5c7c9e2_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government-related debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_172477a3-015c-4952-81c7-70d12109121b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts_9f3e3f5e-67d8-4451-b926-9e2d05a97c59_terseLabel_en-US" xlink:label="lab_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs, warrants</link:label>
    <link:label id="lab_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts_label_en-US" xlink:label="lab_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Payments of Issuance Costs</link:label>
    <link:label id="lab_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts_documentation_en-US" xlink:label="lab_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Payments of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts" xlink:href="tars-20240331.xsd#tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts" xlink:to="lab_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_IntangibleAssetsMilestonePaymentMember_2b85a160-7846-43fe-b333-3d403802da62_terseLabel_en-US" xlink:label="lab_tars_IntangibleAssetsMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Milestone Payment</link:label>
    <link:label id="lab_tars_IntangibleAssetsMilestonePaymentMember_label_en-US" xlink:label="lab_tars_IntangibleAssetsMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Milestone Payment [Member]</link:label>
    <link:label id="lab_tars_IntangibleAssetsMilestonePaymentMember_documentation_en-US" xlink:label="lab_tars_IntangibleAssetsMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IntangibleAssetsMilestonePaymentMember" xlink:href="tars-20240331.xsd#tars_IntangibleAssetsMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_IntangibleAssetsMilestonePaymentMember" xlink:to="lab_tars_IntangibleAssetsMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_b1cfa8e1-630d-4251-885c-9d2a725c7e77_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:href="tars-20240331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_98367cbb-15d0-4bdf-9015-02e3a924d761_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="tars-20240331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_859611f4-81c7-4d73-adbd-a9baf87c57d8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segment</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_640b1e33-7639-4f84-a3e6-4e90818ca22c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockNumberOfVotes_a20e8cb4-275e-4c9a-aa67-3b02b2b7f3c9_terseLabel_en-US" xlink:label="lab_tars_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock votes</link:label>
    <link:label id="lab_tars_CommonStockNumberOfVotes_label_en-US" xlink:label="lab_tars_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number Of Votes</link:label>
    <link:label id="lab_tars_CommonStockNumberOfVotes_documentation_en-US" xlink:label="lab_tars_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Number Of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockNumberOfVotes" xlink:href="tars-20240331.xsd#tars_CommonStockNumberOfVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockNumberOfVotes" xlink:to="lab_tars_CommonStockNumberOfVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ea270b84-0e90-4c42-8e02-6a460b3ccebe_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Sales from Each of our Largest Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_871c6c39-d164-4011-a7f9-a312942ed5c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b4e59731-99ca-46dc-aeeb-12d38ef55cf9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_2d9c36cd-3801-47a1-81a8-df442037888c_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options issued and outstanding (shares)</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6a937b7a-afe5-4f86-9919-83f4e4a6c579_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3bf5f01d-7696-4250-9017-785288628ff8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_RelatedPartyTransactionAnnualCashCompensation_646db40a-34be-4e0f-b92b-f873f4c6f0a7_terseLabel_en-US" xlink:label="lab_tars_RelatedPartyTransactionAnnualCashCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction, annual cash compensation</link:label>
    <link:label id="lab_tars_RelatedPartyTransactionAnnualCashCompensation_label_en-US" xlink:label="lab_tars_RelatedPartyTransactionAnnualCashCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Annual Cash Compensation</link:label>
    <link:label id="lab_tars_RelatedPartyTransactionAnnualCashCompensation_documentation_en-US" xlink:label="lab_tars_RelatedPartyTransactionAnnualCashCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Annual Cash Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RelatedPartyTransactionAnnualCashCompensation" xlink:href="tars-20240331.xsd#tars_RelatedPartyTransactionAnnualCashCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_RelatedPartyTransactionAnnualCashCompensation" xlink:to="lab_tars_RelatedPartyTransactionAnnualCashCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_d50badce-5a51-405e-8831-41677ad6b5eb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_7e687192-f669-437d-9c33-2ae06accc366_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable and other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_ef48b83b-234c-4d6d-9881-84c8fa12fa65_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_c065f1ed-138c-495e-87f9-f30270215d28_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_57e42013-279a-49f9-8e65-977d81b52b4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d6a2e81b-c265-4941-a565-2e98e2f311bb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cb2dd311-263f-4ff2-b6e6-e3518deb0a68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e5a41309-5ffd-47ec-b0bd-84670e2dc73d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c186f9b3-39c1-443e-a070-c923aae28f38_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_fb4c2545-1250-4603-aa4b-49d112ac4639_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb1d2109-66d6-4f62-bbda-4dd79d77a94d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d9de365d-f457-4c96-affa-70e84c71164c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fe1f0a42-ce8e-4b48-9258-8d15378304a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Expected Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ClassOfWarrantOrRightSalePrice_63d37c33-6deb-466f-9fdf-c47e87829dd5_terseLabel_en-US" xlink:label="lab_tars_ClassOfWarrantOrRightSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per warrant (usd per share)</link:label>
    <link:label id="lab_tars_ClassOfWarrantOrRightSalePrice_label_en-US" xlink:label="lab_tars_ClassOfWarrantOrRightSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Sale Price</link:label>
    <link:label id="lab_tars_ClassOfWarrantOrRightSalePrice_documentation_en-US" xlink:label="lab_tars_ClassOfWarrantOrRightSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Sale Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClassOfWarrantOrRightSalePrice" xlink:href="tars-20240331.xsd#tars_ClassOfWarrantOrRightSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ClassOfWarrantOrRightSalePrice" xlink:to="lab_tars_ClassOfWarrantOrRightSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_d2002f4f-abd1-4c4e-a3bf-50845dce7dc9_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_15874445-3b86-490d-8125-d1eec6ddd77a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8dca9822-d8a9-4141-a665-7c4687986233_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_d521b858-9d8a-45c1-921b-73a2360b2bdd_terseLabel_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical studies</link:label>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_label_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Studies, Current</link:label>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_documentation_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Studies, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent" xlink:href="tars-20240331.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AccruedClinicalStudiesCurrent" xlink:to="lab_tars_AccruedClinicalStudiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e7f08d47-23ff-4a6c-ab79-abada38ad610_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e1e0db4f-ee91-43ff-9554-46a6b75e89cc_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_026c1444-9a00-4d95-a879-b4319d0df5c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_fc1dc3cf-6185-494f-a2fd-10dadbfc4598_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_a90d62de-ca8d-41c1-9b4f-7c8b7a3264c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Termination of equity warrants</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CustomerAMember_a8616550-1665-419b-a50d-47b1c19337ad_terseLabel_en-US" xlink:label="lab_tars_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_tars_CustomerAMember_label_en-US" xlink:label="lab_tars_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_tars_CustomerAMember_documentation_en-US" xlink:label="lab_tars_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerAMember" xlink:href="tars-20240331.xsd#tars_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CustomerAMember" xlink:to="lab_tars_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8963d299-a812-4767-8862-f1d87c812da6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1d89f2a6-fb67-43da-b3b7-e3c72e77c170_terseLabel_en-US" xlink:label="lab_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:label id="lab_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="tars-20240331.xsd#tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_f64247cb-9ae9-43d1-9695-9bc795c23231_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1648431a-89ab-4c41-852d-c50bc92e4f4d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_84333db3-f862-45b0-a066-079cd781c4ea_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued product sales deductions</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9386cd83-10d3-4fd5-8146-006d44d95152_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1bbe0183-b580-4690-babc-94e77ee9a874_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_79ca38d3-7a3d-4482-a654-569104598d46_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_714b69e3-1f50-4aed-994a-abbd295fa18c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_16180685-66fa-4a60-a454-3f7a25d7a5a7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_ee7f0a19-2d94-4cda-925b-6cf734902141_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_08323ba2-f9e6-498a-acf3-ea14d6ea97b8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock purchased</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_89db5128-73e0-437d-af64-6ef68a19a16f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9e159f33-4187-46ba-b977-a615bd5f134c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8327ad6f-d467-43bc-accb-016e7f83d40a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_50cbceeb-cbbe-464e-9ccf-2a1ba99c644f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_161e8813-4247-4fa8-98f7-09b858d249a0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_becdf32a-9e6d-48bf-9ff4-78c3aa9c37fa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fac7fe55-2d32-417f-962d-0d921011720b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9a1f49ec-805d-4945-90cf-587ea8309ade_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20c2eefb-2c22-440b-b81c-23330b130cda_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76efdc99-0a13-4e6b-8b04-193f2b1f6c63_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c50368a3-1852-4bcf-84b9-cd4a5a7c5222_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d7dfdbaa-b204-4696-a2ef-f00cf4781b08_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheTwoMember_c40bad13-d415-4e38-8581-268d59f005ba_terseLabel_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche Two</link:label>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheTwoMember_label_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheTwoMember_documentation_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheTwoMember" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PharmakonCreditFacilityTrancheTwoMember" xlink:to="lab_tars_PharmakonCreditFacilityTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember_cf54c0c7-1ca4-4a67-aae1-6733265e6df9_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility, First Amendment, Tranche Two</link:label>
    <link:label id="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember_label_en-US" xlink:label="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility, First Amendment, Tranche Two [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility, First Amendment, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:href="tars-20240331.xsd#tars_CreditFacilityFirstAmendmentTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:to="lab_tars_CreditFacilityFirstAmendmentTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4d49d0c3-6141-40bc-b41c-3093cf5d5bfe_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9fc3acb2-e995-404f-9e87-3d8363d615b8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_90e6c14c-f693-4269-85cf-08f990099edf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b759ebc3-7e8c-487e-a25b-aa05a367f2f0_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6081c192-99e8-4bb2-975e-7d975696c1eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_9433465d-5d3e-471a-9302-75078e9d7a7a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accretion of end of term charge</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_114c35c9-ec95-40d6-bd68-0185d297ff01_negatedTerseLabel_en-US" xlink:label="lab_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Less): Tenant improvement allowance</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_label_en-US" xlink:label="lab_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_documentation_en-US" xlink:label="lab_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:href="tars-20240331.xsd#tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:to="lab_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d7a422a6-c7e6-496e-b1c3-cd851a19b0f6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_88e2dfd3-067e-4d58-b22f-793210d23522_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_58baa5fb-abc5-41c7-8671-07fea3f735ca_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3f3a59ad-779c-409f-8113-630c51d2287f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c1f74e46-e2d2-4af3-8821-e4531d72361b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0529fbaf-865a-4bd4-b3e3-80f7ec485986_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_e3a0acdf-a087-49b0-b7b8-9a20299f5e55_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_3383290e-4669-417c-a8b3-c4c0c8919685_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special cash dividend (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_47795d19-bab1-491f-8a82-979c41d0ba38_terseLabel_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units&#8212;unvested</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_label_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested [Member]</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_documentation_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:href="tars-20240331.xsd#tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:to="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9b25a546-c9b1-496b-a485-b8c9f61d0c8a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_2f7e5324-7573-40f9-99f3-54ab9e020718_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a00ed8ea-61b4-419b-b0fa-a76ba096e71e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_3494220f-d6a2-4897-b13c-a39cde3632b0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_496bd84e-f046-4654-9f58-468b48c55312_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LicenseAndCollaborationMember_fd39cc6d-007c-4f76-ad97-e052146fbedd_terseLabel_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fees and Collaboration</link:label>
    <link:label id="lab_tars_LicenseAndCollaborationMember_label_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration [Member]</link:label>
    <link:label id="lab_tars_LicenseAndCollaborationMember_documentation_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember" xlink:href="tars-20240331.xsd#tars_LicenseAndCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LicenseAndCollaborationMember" xlink:to="lab_tars_LicenseAndCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_b64c8a28-4d8a-4614-aa22-201aa3f36cbf_terseLabel_en-US" xlink:label="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months</link:label>
    <link:label id="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_label_en-US" xlink:label="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months [Member]</link:label>
    <link:label id="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_documentation_en-US" xlink:label="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:href="tars-20240331.xsd#tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:to="lab_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_125d0fd3-babf-4e7a-b194-6449cffb408d_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1fdc6cb1-0dee-45c9-87a4-716746ab87b9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_10978697-37ce-4a31-a86b-673772e3fc1f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment &amp; Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dba69ffe-27b6-43fb-a27c-4624440d9d87_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_c17e1fa1-90b1-4874-9679-fdec36110088_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of available-for-sale debt securities in gross unrealized loss position for less than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ed860939-cd30-4cfd-9de7-914da29e21f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f8c826dc-649b-4edc-bb67-029d6e16b777_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net amortization/accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f198a9f8-a78a-42b6-90b2-27496615d9dc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheTwoMember_ad91c20a-8624-482c-a8b5-c37bce2efbef_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche Two</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheTwoMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheTwoMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheTwoMember" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheTwoMember" xlink:to="lab_tars_CreditFacilityTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ClinicalMilestonesMember_c3d0b197-87cf-4909-afed-47261816eece_terseLabel_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical milestones</link:label>
    <link:label id="lab_tars_ClinicalMilestonesMember_label_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Milestones [Member]</link:label>
    <link:label id="lab_tars_ClinicalMilestonesMember_documentation_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember" xlink:href="tars-20240331.xsd#tars_ClinicalMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ClinicalMilestonesMember" xlink:to="lab_tars_ClinicalMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5c8cb77c-abe0-4d6c-919f-86e69e630501_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7b85d513-1fd8-4ef7-9aaf-11ec06fb88a5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_e5f36a6b-f02b-484d-b3b2-c8e2776d06d5_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8b8f680c-a5da-4d08-890c-eedba5e09d1b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_23168a99-63d8-40b7-b95d-99a6e13cee5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_27547c16-b2ad-467d-84dd-955ec2da093b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1790bb4d-0b04-4fea-a35c-5443b946b013_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ecff8e26-1cfe-4d5e-b85f-7463d4b10f5b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cd8e38de-7eeb-435a-a39f-6bfa268548de_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_6e3cba27-1d96-4921-add0-e5a3a5c83d49_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d9cdf4c6-9cc3-4384-b408-e863769f32a3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c67be0cb-28ca-482b-abea-31ed2e52ea6c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in warrant conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9ab0ab86-5127-4d4b-9657-e5cacbee5a00_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_d1168443-631b-4c4e-9cfe-32229b576c8e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CustomerDMember_afe1fd76-bfa2-49f4-b7b4-1321cd9511d3_terseLabel_en-US" xlink:label="lab_tars_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer D</link:label>
    <link:label id="lab_tars_CustomerDMember_label_en-US" xlink:label="lab_tars_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_tars_CustomerDMember_documentation_en-US" xlink:label="lab_tars_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerDMember" xlink:href="tars-20240331.xsd#tars_CustomerDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CustomerDMember" xlink:to="lab_tars_CustomerDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_TerminationPaymentPeriodDue_ed0986aa-e8c7-49bc-8e4b-81b21bec32d5_terseLabel_en-US" xlink:label="lab_tars_TerminationPaymentPeriodDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Days due within</link:label>
    <link:label id="lab_tars_TerminationPaymentPeriodDue_label_en-US" xlink:label="lab_tars_TerminationPaymentPeriodDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Termination Payment, Period Due</link:label>
    <link:label id="lab_tars_TerminationPaymentPeriodDue_documentation_en-US" xlink:label="lab_tars_TerminationPaymentPeriodDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Termination Payment, Period Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_TerminationPaymentPeriodDue" xlink:href="tars-20240331.xsd#tars_TerminationPaymentPeriodDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_TerminationPaymentPeriodDue" xlink:to="lab_tars_TerminationPaymentPeriodDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a076cee6-60d8-4894-acca-96fd466502e3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Account Detail</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_bb9db440-c729-48cb-aab8-d73d6ad6e9a0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for license agreement, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_16e29c13-e3fe-442f-80c0-c7b686012185_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e0ec0bad-e010-47af-a0ca-5c117451c3e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4b514f1-18c5-45fa-8939-b7aed3fd7041_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_4a5965f6-a423-470b-a9d0-481f0f831681_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1ab75521-e71e-46fc-900a-317e0b2f8def_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_618b8e25-8ae2-4d97-8afa-d5ec71148f9d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2cc58ef7-d446-406c-bcc0-056810942cc9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term loan, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6a0cb7c7-df74-430c-8b5f-c0788232ba2b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_038b0667-632b-4b0d-87d0-95641e5c38ee_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ElancoMember_608d4fe5-92e7-4e02-a4c6-f5c52d9d6fac_terseLabel_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elanco</link:label>
    <link:label id="lab_tars_ElancoMember_label_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elanco [Member]</link:label>
    <link:label id="lab_tars_ElancoMember_documentation_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Elanco</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember" xlink:href="tars-20240331.xsd#tars_ElancoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ElancoMember" xlink:to="lab_tars_ElancoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_32777805-3b3d-4d60-aeb3-e180f51e5db5_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_452eaa4a-0bb1-4058-b914-17d7183b4e42_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DebtInstrumentNumberOfPotentialAdditionalTranches_a03edd05-6503-40e6-9aef-49bde0aef18a_terseLabel_en-US" xlink:label="lab_tars_DebtInstrumentNumberOfPotentialAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential additional tranches</link:label>
    <link:label id="lab_tars_DebtInstrumentNumberOfPotentialAdditionalTranches_label_en-US" xlink:label="lab_tars_DebtInstrumentNumberOfPotentialAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Potential Additional Tranches</link:label>
    <link:label id="lab_tars_DebtInstrumentNumberOfPotentialAdditionalTranches_documentation_en-US" xlink:label="lab_tars_DebtInstrumentNumberOfPotentialAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Potential Additional Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtInstrumentNumberOfPotentialAdditionalTranches" xlink:href="tars-20240331.xsd#tars_DebtInstrumentNumberOfPotentialAdditionalTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DebtInstrumentNumberOfPotentialAdditionalTranches" xlink:to="lab_tars_DebtInstrumentNumberOfPotentialAdditionalTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d6385e45-1845-4af5-a378-96f54ac4f1c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_5b8189be-33b4-4cf8-a78c-bcef9e5da7ac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_SaleOfStockConsiderationAmountAuthorized_15ee2ad9-5884-418e-9420-2d14edbf6cda_terseLabel_en-US" xlink:label="lab_tars_SaleOfStockConsiderationAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized consideration</link:label>
    <link:label id="lab_tars_SaleOfStockConsiderationAmountAuthorized_label_en-US" xlink:label="lab_tars_SaleOfStockConsiderationAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Amount Authorized</link:label>
    <link:label id="lab_tars_SaleOfStockConsiderationAmountAuthorized_documentation_en-US" xlink:label="lab_tars_SaleOfStockConsiderationAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Amount Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockConsiderationAmountAuthorized" xlink:href="tars-20240331.xsd#tars_SaleOfStockConsiderationAmountAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_SaleOfStockConsiderationAmountAuthorized" xlink:to="lab_tars_SaleOfStockConsiderationAmountAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheOneMember_ca8a5265-1caa-4bcb-a8ce-c1baa581e948_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche One</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheOneMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche One [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheOneMember" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheOneMember" xlink:to="lab_tars_CreditFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_7343c65f-76d3-4294-9dad-a9dc6377b37d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1b164205-46d7-44d6-8941-2e487c8f607c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f0e7c89e-c308-4546-8f8a-372e1aa6ee6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5f16edb8-65b0-4a67-a9f9-e0d585cde73a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d4096067-9ced-44df-aa86-b3c094110edb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2854491a-bc73-4b5c-9f25-856424da2ff3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_UpfrontPayment_0708c835-abda-4302-bdf8-0cddf63ab8f3_terseLabel_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_tars_UpfrontPayment_label_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_tars_UpfrontPayment_documentation_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment" xlink:href="tars-20240331.xsd#tars_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_UpfrontPayment" xlink:to="lab_tars_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_7bded80f-f0a4-46aa-97f2-5fbbb79f1a04_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for license agreement, share price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4c4fd84e-cccb-493a-9cec-df055b9d25db_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17ae7ace-9ac2-4d31-88c5-b8e31a2ce260_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d0a8ba83-d543-40f6-b599-debb69718515_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cad16f91-9955-4840-bfe1-c1db5a2581b9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f2771918-a2ac-4c98-bef8-23b95882baa5_terseLabel_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments to be achieved</link:label>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration, Amount</link:label>
    <link:label id="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="tars-20240331.xsd#tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_075ff1fc-5b34-4255-bfa1-689de1aba8ca_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9cac639e-9f32-4fc6-8edd-e06314a03d43_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_592c0036-82c1-4af8-b437-033ffae1b650_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e4801c6a-8ead-4c0c-9246-bc51273250f7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_69c8694d-ac47-48f3-b483-1dcc5030946e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Draw on credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e448e878-7156-4469-978b-07055335d0e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Less): Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c6aaab49-7516-4f8d-b7f2-934bd007bfd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_712f35ab-bafd-4c20-ad47-530608b484c6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_66454475-4cb9-4440-87bb-21324ec8f405_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of term loan-related costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_4aa3ca12-6f4d-4bb0-8ed2-6f89c35cbaba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement of equity warrants prior to termination</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7aec41f1-88fa-4c14-8564-eb511352ba58_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_A2023ShelfRegistrationStatementMember_70b33274-9e7d-47d7-bf5b-e46af88b1479_terseLabel_en-US" xlink:label="lab_tars_A2023ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Shelf Registration Statement</link:label>
    <link:label id="lab_tars_A2023ShelfRegistrationStatementMember_label_en-US" xlink:label="lab_tars_A2023ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Shelf Registration Statement [Member]</link:label>
    <link:label id="lab_tars_A2023ShelfRegistrationStatementMember_documentation_en-US" xlink:label="lab_tars_A2023ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Shelf Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_A2023ShelfRegistrationStatementMember" xlink:href="tars-20240331.xsd#tars_A2023ShelfRegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_A2023ShelfRegistrationStatementMember" xlink:to="lab_tars_A2023ShelfRegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_39f8339c-d383-4e1b-ab30-38d7ba401b76_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_65855671-f0bf-4c18-bfc9-4dc025455337_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ec06b11c-8903-4235-ac47-24d3aea952bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_be74c05f-d1c0-423b-b931-a32ee84e25f6_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_306bea9e-faed-40d4-9431-0bcb5733cb8d_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_a03bdce1-ac19-436b-b532-71fc3f0219ac_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ff3d259d-606f-4b4d-b4f9-3fd6ecc938cd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs of $6.7 million</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ff3e08-9c32-41a2-99d0-01c01538d251_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8fe252a1-e2d5-444a-a962-d86dc1e8c5d9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheThreeMember_f359df6e-e6ca-46d6-9b0b-141ca1af56f9_terseLabel_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche Three</link:label>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheThreeMember_label_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche Three [Member]</link:label>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheThreeMember_documentation_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheThreeMember" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PharmakonCreditFacilityTrancheThreeMember" xlink:to="lab_tars_PharmakonCreditFacilityTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_67c0421d-7133-4dce-9d5c-2dd6d76c2d41_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_ec2370c9-0938-4f49-8bd1-e18e1a62bdf2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_7afd4cc7-9379-43d5-af7f-af2c08268374_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_70a8d7ea-1fda-4f05-8e52-3aaddcd09c01_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_321cd74a-defb-41b4-a575-edb5406973f8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_15a4cd56-c272-4df7-921d-7cc2e4289ee9_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_553e40bb-4cc1-419b-994e-bb126603e278_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3996963a-1ca2-46c7-b029-3bd842cdd60c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7da68c39-ce95-4707-90a9-06d90f667ae6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_280e6de3-f6a0-47fb-af65-b6fffe02973c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense paid in cash</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3197d2c7-5b69-46b4-8cb7-d23371d1e7dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_74508eb8-c5a9-4aa8-b7d9-718a63783266_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for license agreement (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c12b1cf1-7e07-400c-a4ff-d921f890f2c5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_cf2d682f-2700-4e7a-aa2f-9dc1e1e46dcd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_22140d9c-2085-4932-a1de-35cf0ce8bc0d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_0bf0f0b5-8454-4613-b5e4-eb5a7c211d8e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8f594d0d-d2fa-4386-9ea1-daa729753399_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding, diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_977c0ff4-ee2e-4900-92b9-db24f78f8227_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_3f187114-0092-4195-88e3-cb74d467af1d_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual milestone payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:to="lab_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_16a60950-8a71-4e5c-a2e9-d758522c0d4a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_2eb169d0-1376-4d21-b5fd-7fd15c08e917_terseLabel_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available for sale and cash and cash equivalents</link:label>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_label_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale And Cash And Cash Equivalents</link:label>
    <link:label id="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_documentation_en-US" xlink:label="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale And Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:href="tars-20240331.xsd#tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:to="lab_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5120cf3b-35ed-4216-8d12-41ddd561c191_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_10fdb648-ef9a-441e-ab20-1e07a6ef001d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_34e5c54a-7f97-4349-b1dd-4900edc29c3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_99ffbf0b-c795-4841-ab19-ff70466770d9_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5389dc9d-845d-484f-a473-4060f9a02aab_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0ddab7c5-cb45-40bd-abf2-21b43328894e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of pre-funded warrants, net of paid issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7c2adba8-d813-4468-bbac-6cc764ce3933_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f0213af9-028f-4c83-88bf-49cc90d5f820_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_8f61c83f-9e8a-4844-8a45-0f9436881588_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_63e0b1b7-31a6-4af8-a860-5e66ffff2c4f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_31fffb05-fa8a-424b-89ef-0f382516b1f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_d343ae77-5846-41c5-b7ab-789e8c4b44eb_terseLabel_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employment arrangements with executive officers</link:label>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_label_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Employment Arrangements With Executive Officers</link:label>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_documentation_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Employment Arrangements With Executive Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:href="tars-20240331.xsd#tars_NumberOfEmploymentArrangementsWithExecutiveOfficers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:to="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8f7c1952-5cf6-4d56-832b-88c28193d48d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future lease payments, undiscounted</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LineOfCreditFacilityDrawDownIncrements_59c678f4-2c45-470e-a360-c3700e8da237_terseLabel_en-US" xlink:label="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increments to draw on credit facility at company's election</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityDrawDownIncrements_label_en-US" xlink:label="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Draw Down Increments</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityDrawDownIncrements_documentation_en-US" xlink:label="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Draw Down Increments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements" xlink:href="tars-20240331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LineOfCreditFacilityDrawDownIncrements" xlink:to="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_ae74c314-ddff-4ee5-88ad-7ff050a53045_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5f3342bf-042e-4387-8cfd-a46b0c6cdf30_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c626eeec-bd7e-4efb-be8a-1f4cab64ec32_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_64243305-a3d1-4f0d-bc6c-f57a87811fe4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_48b95ca2-28c8-4c73-a542-2df612b83a96_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6e6c0588-d2e1-43d1-b3b1-47e3f1daea2e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair market value of common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_a9a1301e-1aa7-4318-a722-351c78c6522c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_00dfa182-2aa1-458e-9745-94fb3ae7b487_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_022f1642-cdb3-4815-b7bc-241948e8f938_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding, basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_168d79c3-436a-48c8-a919-ac430beb0c52_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_db3d07ff-9947-4c16-9b59-21f589394799_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ce20ab03-5d51-4cfc-a473-427394d4c3fa_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations before other income (expense)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_JoseTrevejoMember_label_en-US" xlink:label="lab_tars_JoseTrevejoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jose Trevejo [Member]</link:label>
    <link:label id="lab_tars_JoseTrevejoMember_documentation_en-US" xlink:label="lab_tars_JoseTrevejoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jose Trevejo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_JoseTrevejoMember" xlink:href="tars-20240331.xsd#tars_JoseTrevejoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_JoseTrevejoMember" xlink:to="lab_tars_JoseTrevejoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_de931523-0bdf-4c5a-905a-7ced9dd30645_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_98d2a5cb-083c-4910-a803-aa17935021f9_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_05c528aa-c13d-4fa2-807a-8c24870f7878_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheFourMember_d08ea2e9-a94d-4c59-aa5c-8fd865dd5d1c_terseLabel_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche Four</link:label>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheFourMember_label_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche Four [Member]</link:label>
    <link:label id="lab_tars_PharmakonCreditFacilityTrancheFourMember_documentation_en-US" xlink:label="lab_tars_PharmakonCreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon Credit Facility, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheFourMember" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PharmakonCreditFacilityTrancheFourMember" xlink:to="lab_tars_PharmakonCreditFacilityTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_237556d9-e841-4455-a395-09220a2a6168_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of equity awards</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c2a1613-fd50-4084-abbf-cb20b2108bfa_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_17c2e4a1-3de9-4e1f-9e4f-b6168d574f8b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_a458b52b-1345-4609-97b2-646fb3663bbe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4e0eb255-c44d-4e39-82a7-e212541328ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b423137e-5f95-449a-8da1-788ea6f8644d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_ef0bbf91-f0eb-47d6-8c57-a0f98eb29c87_terseLabel_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity warrants (for LianBio shares)</link:label>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_label_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Warrants, Fair Value Disclosure</link:label>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_documentation_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Warrants, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure" xlink:href="tars-20240331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityWarrantsFairValueDisclosure" xlink:to="lab_tars_EquityWarrantsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_58b69f5b-0365-4565-afbc-1e5d5da998a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balances of Debt, Debt Issuance Costs, and Accumulated Accretion</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>tars-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a12c9650-c665-4945-913e-9e9f011ed114,g:485e89bc-d27f-4026-942d-5c7ac04342fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tarsusrx.com/role/Cover" xlink:type="simple" xlink:href="tars-20240331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0e3d979d-dfce-47e9-a598-e85657e96e58" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_DocumentType_0e3d979d-dfce-47e9-a598-e85657e96e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_361a0bb7-5030-4d18-898d-1b086d85ccf6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_DocumentQuarterlyReport_361a0bb7-5030-4d18-898d-1b086d85ccf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ac06e099-f68b-463d-9d94-d8dd0543de3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_DocumentPeriodEndDate_ac06e099-f68b-463d-9d94-d8dd0543de3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c0ba2d8a-835d-48bf-98e5-23e11b279997" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_DocumentTransitionReport_c0ba2d8a-835d-48bf-98e5-23e11b279997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1874c67f-c569-4c89-be5c-68e814976a43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityFileNumber_1874c67f-c569-4c89-be5c-68e814976a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f0122687-320f-4a45-a544-f5ee049feb76" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityRegistrantName_f0122687-320f-4a45-a544-f5ee049feb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_931cc187-5c61-47c7-afaf-535420fe9331" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_931cc187-5c61-47c7-afaf-535420fe9331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_90eb8997-5b19-4f78-85cf-716a13b7d9f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityTaxIdentificationNumber_90eb8997-5b19-4f78-85cf-716a13b7d9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4c8dcd07-c0a5-4230-b722-e710273b846c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityAddressAddressLine1_4c8dcd07-c0a5-4230-b722-e710273b846c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_65c3d6b3-7fd8-49e0-88dd-0519cd46f6f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityAddressCityOrTown_65c3d6b3-7fd8-49e0-88dd-0519cd46f6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_41077705-9454-43ca-ada9-0daff1d5f079" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityAddressStateOrProvince_41077705-9454-43ca-ada9-0daff1d5f079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3b93bb50-1808-48d2-a118-2e903f39d1d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityAddressPostalZipCode_3b93bb50-1808-48d2-a118-2e903f39d1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ba703323-ede9-4e03-8d6f-927b89e9063b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_CityAreaCode_ba703323-ede9-4e03-8d6f-927b89e9063b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cedcca7d-c306-4c2e-9cf0-a73fb1b58fef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_LocalPhoneNumber_cedcca7d-c306-4c2e-9cf0-a73fb1b58fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a91a6234-2aa3-4aab-8962-19c08a9a3538" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_Security12bTitle_a91a6234-2aa3-4aab-8962-19c08a9a3538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_80abf761-9538-454f-8bca-89e5a0c32fde" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_TradingSymbol_80abf761-9538-454f-8bca-89e5a0c32fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a6d7e329-98a6-4529-b558-c183ed53b6ae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_SecurityExchangeName_a6d7e329-98a6-4529-b558-c183ed53b6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3ffd8b46-189d-4bf9-9b5a-cc2b01e681bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityCurrentReportingStatus_3ffd8b46-189d-4bf9-9b5a-cc2b01e681bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ea5ec0b9-82ef-47d7-9bfe-ac00455191da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityInteractiveDataCurrent_ea5ec0b9-82ef-47d7-9bfe-ac00455191da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f6a1b0c9-54ed-4669-8656-e1ab0100f25e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityFilerCategory_f6a1b0c9-54ed-4669-8656-e1ab0100f25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3faec5b3-f22a-4b6f-93f9-a1c65bb0d744" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntitySmallBusiness_3faec5b3-f22a-4b6f-93f9-a1c65bb0d744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ee4c6cca-a59e-4232-9742-693e07a1d387" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityEmergingGrowthCompany_ee4c6cca-a59e-4232-9742-693e07a1d387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_cda4a2e3-f758-4f0a-a6c4-b9c5f3653e14" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityExTransitionPeriod_cda4a2e3-f758-4f0a-a6c4-b9c5f3653e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8f5db222-ccdc-4763-90eb-b8c87e03c0fa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityShellCompany_8f5db222-ccdc-4763-90eb-b8c87e03c0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_08f71264-6754-42c3-9d70-9154c53420ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_08f71264-6754-42c3-9d70-9154c53420ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_04d2b25c-55a3-4841-9b6e-7b39176ae091" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_AmendmentFlag_04d2b25c-55a3-4841-9b6e-7b39176ae091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e1196eb5-1601-45b9-89d2-023c440232eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_EntityCentralIndexKey_e1196eb5-1601-45b9-89d2-023c440232eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cf6b1101-7def-4d42-ba6a-c64f68c2d157" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_CurrentFiscalYearEndDate_cf6b1101-7def-4d42-ba6a-c64f68c2d157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_fb0711db-e417-4b6b-8274-8460553c6bc0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_DocumentFiscalYearFocus_fb0711db-e417-4b6b-8274-8460553c6bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d02d529b-5eb9-4ce8-bd47-804413afca87" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cce5551c-0c03-493a-8d39-a60932e3313b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d02d529b-5eb9-4ce8-bd47-804413afca87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7f4d60be-44b6-4462-9e8f-529aa533aff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4aa9a9a4-3efa-4776-a07a-e74c0ee44db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7f4d60be-44b6-4462-9e8f-529aa533aff1" xlink:to="loc_us-gaap_AssetsAbstract_4aa9a9a4-3efa-4776-a07a-e74c0ee44db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5dbd806a-cc66-449f-bae3-0afe782f6ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4aa9a9a4-3efa-4776-a07a-e74c0ee44db2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5dbd806a-cc66-449f-bae3-0afe782f6ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0ae281eb-5ff4-4eb7-9915-44097562adbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5dbd806a-cc66-449f-bae3-0afe782f6ca3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0ae281eb-5ff4-4eb7-9915-44097562adbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_7531053c-64fd-4fac-bda7-3b7a36407c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5dbd806a-cc66-449f-bae3-0afe782f6ca3" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_7531053c-64fd-4fac-bda7-3b7a36407c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_826bd906-24b5-4409-b6ff-d945f7690dca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5dbd806a-cc66-449f-bae3-0afe782f6ca3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_826bd906-24b5-4409-b6ff-d945f7690dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0fa44ee9-91a5-4ebe-9e2c-974a3bba6dca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5dbd806a-cc66-449f-bae3-0afe782f6ca3" xlink:to="loc_us-gaap_InventoryNet_0fa44ee9-91a5-4ebe-9e2c-974a3bba6dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_872b1437-992b-4ff3-b85d-750bc380432c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5dbd806a-cc66-449f-bae3-0afe782f6ca3" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_872b1437-992b-4ff3-b85d-750bc380432c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_ba781d95-5a6d-4bae-9c21-d8f68dc50995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5dbd806a-cc66-449f-bae3-0afe782f6ca3" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_ba781d95-5a6d-4bae-9c21-d8f68dc50995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dc35e73a-509e-4385-8858-816cb3ebf5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5dbd806a-cc66-449f-bae3-0afe782f6ca3" xlink:to="loc_us-gaap_AssetsCurrent_dc35e73a-509e-4385-8858-816cb3ebf5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2c3e30ef-15d5-4a6b-a913-257dd6757908" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4aa9a9a4-3efa-4776-a07a-e74c0ee44db2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2c3e30ef-15d5-4a6b-a913-257dd6757908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_30f9912a-d133-41f6-a386-8de92f1b355e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4aa9a9a4-3efa-4776-a07a-e74c0ee44db2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_30f9912a-d133-41f6-a386-8de92f1b355e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_461b40a3-9524-429c-bccf-155b79058432" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4aa9a9a4-3efa-4776-a07a-e74c0ee44db2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_461b40a3-9524-429c-bccf-155b79058432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_3492102d-141a-4042-880e-efd9b5ac9eba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4aa9a9a4-3efa-4776-a07a-e74c0ee44db2" xlink:to="loc_us-gaap_LongTermInvestments_3492102d-141a-4042-880e-efd9b5ac9eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9a6e912b-a18a-4581-aa6a-aba75d85ede6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4aa9a9a4-3efa-4776-a07a-e74c0ee44db2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9a6e912b-a18a-4581-aa6a-aba75d85ede6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_64325c09-1c2f-4f93-9114-13a192dc1592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4aa9a9a4-3efa-4776-a07a-e74c0ee44db2" xlink:to="loc_us-gaap_Assets_64325c09-1c2f-4f93-9114-13a192dc1592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef6f7616-e81e-4d95-9e41-f1cfb9f288aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7f4d60be-44b6-4462-9e8f-529aa533aff1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef6f7616-e81e-4d95-9e41-f1cfb9f288aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5f421dd3-e3e9-4529-ac4e-ab89dff97f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef6f7616-e81e-4d95-9e41-f1cfb9f288aa" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5f421dd3-e3e9-4529-ac4e-ab89dff97f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_f161a950-bbe0-4af9-9ba5-ff358fc1f891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5f421dd3-e3e9-4529-ac4e-ab89dff97f6e" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_f161a950-bbe0-4af9-9ba5-ff358fc1f891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d77f143a-fca3-46cf-be0a-fb6a1042356f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5f421dd3-e3e9-4529-ac4e-ab89dff97f6e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d77f143a-fca3-46cf-be0a-fb6a1042356f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_73859432-da37-4ee0-8ea5-8842cb579320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5f421dd3-e3e9-4529-ac4e-ab89dff97f6e" xlink:to="loc_us-gaap_LiabilitiesCurrent_73859432-da37-4ee0-8ea5-8842cb579320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4ad5c134-e46b-45f5-b089-faea44cdcc28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef6f7616-e81e-4d95-9e41-f1cfb9f288aa" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4ad5c134-e46b-45f5-b089-faea44cdcc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8a5ed29a-cf46-41f6-944a-084d96c9620c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef6f7616-e81e-4d95-9e41-f1cfb9f288aa" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8a5ed29a-cf46-41f6-944a-084d96c9620c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6878de4f-a4f1-4a1c-be1a-02b5cd333b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef6f7616-e81e-4d95-9e41-f1cfb9f288aa" xlink:to="loc_us-gaap_Liabilities_6878de4f-a4f1-4a1c-be1a-02b5cd333b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8b78f421-bac7-4128-bd1e-a93a8eef366e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef6f7616-e81e-4d95-9e41-f1cfb9f288aa" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8b78f421-bac7-4128-bd1e-a93a8eef366e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_12178779-f500-49af-b578-f5782fd3e253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef6f7616-e81e-4d95-9e41-f1cfb9f288aa" xlink:to="loc_us-gaap_StockholdersEquityAbstract_12178779-f500-49af-b578-f5782fd3e253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_83c58c95-4467-46ad-99a5-2c0825b6af7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_12178779-f500-49af-b578-f5782fd3e253" xlink:to="loc_us-gaap_PreferredStockValue_83c58c95-4467-46ad-99a5-2c0825b6af7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5ba71695-9832-49df-9df9-7854fd822e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_12178779-f500-49af-b578-f5782fd3e253" xlink:to="loc_us-gaap_CommonStockValue_5ba71695-9832-49df-9df9-7854fd822e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f1089826-c1c0-4654-aca3-65ce992b2c57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_12178779-f500-49af-b578-f5782fd3e253" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f1089826-c1c0-4654-aca3-65ce992b2c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7978cf6b-be73-46f4-8dd1-ad30e23d6628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_12178779-f500-49af-b578-f5782fd3e253" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7978cf6b-be73-46f4-8dd1-ad30e23d6628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13831d57-dd96-45fe-9e4c-934cfa233c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_12178779-f500-49af-b578-f5782fd3e253" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13831d57-dd96-45fe-9e4c-934cfa233c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6ca5038b-d321-40e9-8246-7c77be73bba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_12178779-f500-49af-b578-f5782fd3e253" xlink:to="loc_us-gaap_StockholdersEquity_6ca5038b-d321-40e9-8246-7c77be73bba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_61a2e36a-6246-400a-b9b3-36a146cc350e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef6f7616-e81e-4d95-9e41-f1cfb9f288aa" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_61a2e36a-6246-400a-b9b3-36a146cc350e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9ce5ed25-3d29-4188-a2ee-da61495d3d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fe8d75c8-cc1e-4df5-8c85-47ed8fea2f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ce5ed25-3d29-4188-a2ee-da61495d3d53" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fe8d75c8-cc1e-4df5-8c85-47ed8fea2f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_64642e9b-b48e-4824-9373-359f9497aa93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ce5ed25-3d29-4188-a2ee-da61495d3d53" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_64642e9b-b48e-4824-9373-359f9497aa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_65724a87-dfe4-4923-8590-d48e37da14ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ce5ed25-3d29-4188-a2ee-da61495d3d53" xlink:to="loc_us-gaap_PreferredStockSharesIssued_65724a87-dfe4-4923-8590-d48e37da14ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_11d8bf84-deb4-4b57-990c-d6a83a23bdef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ce5ed25-3d29-4188-a2ee-da61495d3d53" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_11d8bf84-deb4-4b57-990c-d6a83a23bdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0a5a8922-3fae-4d22-957c-db6793580078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ce5ed25-3d29-4188-a2ee-da61495d3d53" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0a5a8922-3fae-4d22-957c-db6793580078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_11379606-f52e-4dfb-91b4-85d311969ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ce5ed25-3d29-4188-a2ee-da61495d3d53" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_11379606-f52e-4dfb-91b4-85d311969ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4ed703b9-3633-4025-a732-19be516909f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ce5ed25-3d29-4188-a2ee-da61495d3d53" xlink:to="loc_us-gaap_CommonStockSharesIssued_4ed703b9-3633-4025-a732-19be516909f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c32a54d7-5171-4c9c-a79a-4cbc78e84966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ce5ed25-3d29-4188-a2ee-da61495d3d53" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c32a54d7-5171-4c9c-a79a-4cbc78e84966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_68e0af44-d0f9-4ba6-ac59-a93ab9c5968a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bdf1efc1-d777-4973-bf55-abcaf8cfd8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_68e0af44-d0f9-4ba6-ac59-a93ab9c5968a" xlink:to="loc_us-gaap_StatementTable_bdf1efc1-d777-4973-bf55-abcaf8cfd8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_35bf6bfe-9605-4f75-98ed-fe386bbade00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bdf1efc1-d777-4973-bf55-abcaf8cfd8c3" xlink:to="loc_srt_ProductOrServiceAxis_35bf6bfe-9605-4f75-98ed-fe386bbade00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a119080e-8a30-43cf-843d-75053403fd59" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_35bf6bfe-9605-4f75-98ed-fe386bbade00" xlink:to="loc_srt_ProductsAndServicesDomain_a119080e-8a30-43cf-843d-75053403fd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e4048cec-2c98-47bf-9e7d-a19aaf31de58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a119080e-8a30-43cf-843d-75053403fd59" xlink:to="loc_us-gaap_ProductMember_e4048cec-2c98-47bf-9e7d-a19aaf31de58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember_6d5ff05c-c041-4b35-982d-24f3b78bcee3" xlink:href="tars-20240331.xsd#tars_LicenseAndCollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a119080e-8a30-43cf-843d-75053403fd59" xlink:to="loc_tars_LicenseAndCollaborationMember_6d5ff05c-c041-4b35-982d-24f3b78bcee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bdf1efc1-d777-4973-bf55-abcaf8cfd8c3" xlink:to="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_efcab350-70c8-4ee8-8225-44ecce675371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_RevenuesAbstract_efcab350-70c8-4ee8-8225-44ecce675371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_59bf7f1e-83c7-4900-877b-3f8bc24db5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_efcab350-70c8-4ee8-8225-44ecce675371" xlink:to="loc_us-gaap_Revenues_59bf7f1e-83c7-4900-877b-3f8bc24db5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_54a8d63a-db34-4ff0-8202-d79e0a2729ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_54a8d63a-db34-4ff0-8202-d79e0a2729ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ea397d1d-db8e-480d-b705-b137d8b88431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ea397d1d-db8e-480d-b705-b137d8b88431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_98cac7ad-22c9-4d03-ac71-dc8a552aea88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_98cac7ad-22c9-4d03-ac71-dc8a552aea88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c3b32644-5c1c-439d-b39d-f3102d186f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5b7599c4-f62c-46c3-ab17-bb55459c8442" xlink:to="loc_us-gaap_CostsAndExpenses_c3b32644-5c1c-439d-b39d-f3102d186f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_73e924d8-c7bd-4447-be08-bebf022ab4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_OperatingIncomeLoss_73e924d8-c7bd-4447-be08-bebf022ab4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_ffebb73c-2583-4c32-af8d-3c7f80fc7243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_InterestIncomeOther_ffebb73c-2583-4c32-af8d-3c7f80fc7243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_98585ebc-8fce-4c72-ad85-dee23903d7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_InterestExpense_98585ebc-8fce-4c72-ad85-dee23903d7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c46d1826-920d-465a-b7ef-b5660e39945c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c46d1826-920d-465a-b7ef-b5660e39945c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_eb637956-5f2e-4873-b2cd-88f126fbfb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_eb637956-5f2e-4873-b2cd-88f126fbfb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_323ee1ad-a383-47a5-9efc-b8e33e243f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_323ee1ad-a383-47a5-9efc-b8e33e243f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7467d3fa-145f-4e5e-96a6-444aef3208c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e81589a9-1672-474c-8041-1027f4a57e92" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7467d3fa-145f-4e5e-96a6-444aef3208c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed9a86e5-8ffd-4a48-bda9-1131e61ebeca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_NetIncomeLoss_ed9a86e5-8ffd-4a48-bda9-1131e61ebeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ba244957-0842-4359-8ad6-6d4410421558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ba244957-0842-4359-8ad6-6d4410421558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0ddf9e0d-ce79-4bb6-9e65-4e0381ebed8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ba244957-0842-4359-8ad6-6d4410421558" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0ddf9e0d-ce79-4bb6-9e65-4e0381ebed8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_06437683-f6f6-4334-8512-214201bbe413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ba244957-0842-4359-8ad6-6d4410421558" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_06437683-f6f6-4334-8512-214201bbe413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d5483e6a-3bbb-4789-90f5-932edcc53b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_d5483e6a-3bbb-4789-90f5-932edcc53b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_07742e81-5ebd-4725-b788-02717209e62e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d5483e6a-3bbb-4789-90f5-932edcc53b8b" xlink:to="loc_us-gaap_EarningsPerShareBasic_07742e81-5ebd-4725-b788-02717209e62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_eaeb6dc7-5fff-4791-9085-6f60b6cb4aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d5483e6a-3bbb-4789-90f5-932edcc53b8b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_eaeb6dc7-5fff-4791-9085-6f60b6cb4aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae644d1d-6092-4ce2-87c0-e1b57f9c8600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eca3410d-c7b2-4579-b9a9-3ba31fe9922d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae644d1d-6092-4ce2-87c0-e1b57f9c8600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_98f02993-20e5-4752-8526-d6d60ac888d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae644d1d-6092-4ce2-87c0-e1b57f9c8600" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_98f02993-20e5-4752-8526-d6d60ac888d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5a4b171-d140-472b-8f84-fa007431ef54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ae644d1d-6092-4ce2-87c0-e1b57f9c8600" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e5a4b171-d140-472b-8f84-fa007431ef54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_74c20b82-f33d-4e68-b387-2839954a70d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ddb0389c-dbb0-4bb2-b91f-c4fc7992c1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_74c20b82-f33d-4e68-b387-2839954a70d0" xlink:to="loc_us-gaap_StatementTable_ddb0389c-dbb0-4bb2-b91f-c4fc7992c1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ebee4c5f-801d-4fa6-b6d7-b1ab014c7ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ddb0389c-dbb0-4bb2-b91f-c4fc7992c1de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ebee4c5f-801d-4fa6-b6d7-b1ab014c7ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebee4c5f-801d-4fa6-b6d7-b1ab014c7ba8" xlink:to="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8bcd94b6-d2e4-4391-96ef-b6e5df75cdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:to="loc_us-gaap_CommonStockMember_8bcd94b6-d2e4-4391-96ef-b6e5df75cdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e35efe1b-f805-4d62-9c13-d77a46e87ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e35efe1b-f805-4d62-9c13-d77a46e87ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ba20b46-302f-4a28-92fb-6ad0d7accbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ba20b46-302f-4a28-92fb-6ad0d7accbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f02554b0-6cef-488f-8001-40de447034fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_652eb08a-3488-4e8f-a2bf-4523f8008194" xlink:to="loc_us-gaap_RetainedEarningsMember_f02554b0-6cef-488f-8001-40de447034fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_710e89fe-953c-48d5-a5e3-3d6c784e2d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ddb0389c-dbb0-4bb2-b91f-c4fc7992c1de" xlink:to="loc_us-gaap_StatementLineItems_710e89fe-953c-48d5-a5e3-3d6c784e2d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_710e89fe-953c-48d5-a5e3-3d6c784e2d40" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1a52b644-9ec5-470a-a7fc-54288f7ef8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1a52b644-9ec5-470a-a7fc-54288f7ef8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_857674f6-d024-424d-adcf-49246c35642f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockholdersEquity_857674f6-d024-424d-adcf-49246c35642f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33504102-f7e4-4fd6-8817-e627bfc34ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_NetIncomeLoss_33504102-f7e4-4fd6-8817-e627bfc34ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04c49a50-375d-4747-ab5f-fc8aa7871d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04c49a50-375d-4747-ab5f-fc8aa7871d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_88bdd60d-e53f-408e-8339-6516ec82bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_88bdd60d-e53f-408e-8339-6516ec82bc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7e36dc06-6feb-452c-b2f1-a01d4a183637" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7e36dc06-6feb-452c-b2f1-a01d4a183637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3e3f3fa1-c7b4-455b-a6bf-dfe16579a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3e3f3fa1-c7b4-455b-a6bf-dfe16579a7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02276acf-3960-4efc-9ef6-c7cc33abeca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02276acf-3960-4efc-9ef6-c7cc33abeca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3c2a1ca2-1e97-4f49-a0bc-8a7e17081742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3c2a1ca2-1e97-4f49-a0bc-8a7e17081742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c031a4e2-3512-483f-91eb-c75c15b91f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c031a4e2-3512-483f-91eb-c75c15b91f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7a9d8e7d-0211-4582-90cb-fb31db209d78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7a9d8e7d-0211-4582-90cb-fb31db209d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4313f84f-ef85-498b-9c5e-329e5248ec15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4313f84f-ef85-498b-9c5e-329e5248ec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1aac1091-db35-431f-afb5-752d73f4edca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96b1ab5e-1980-4d85-9f60-a10b183db578" xlink:to="loc_us-gaap_StockholdersEquity_1aac1091-db35-431f-afb5-752d73f4edca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_00a4a679-2168-462d-a467-f93aa888cb53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_37bba075-3cd8-44f4-87f7-0776d7ee31ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00a4a679-2168-462d-a467-f93aa888cb53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_37bba075-3cd8-44f4-87f7-0776d7ee31ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5b6224c0-eb4b-42eb-9774-1ea8d07c4429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_37bba075-3cd8-44f4-87f7-0776d7ee31ab" xlink:to="loc_us-gaap_NetIncomeLoss_5b6224c0-eb4b-42eb-9774-1ea8d07c4429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_37bba075-3cd8-44f4-87f7-0776d7ee31ab" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c90aad8e-edc6-492f-b248-b2f43d3b574b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:to="loc_us-gaap_Depreciation_c90aad8e-edc6-492f-b248-b2f43d3b574b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_11f2947e-9994-4ad6-b25f-d90ce6dae299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_11f2947e-9994-4ad6-b25f-d90ce6dae299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_856780a2-f9d8-4b50-b818-1b9e8c85486d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_856780a2-f9d8-4b50-b818-1b9e8c85486d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f941a222-fb84-43fd-93ee-2befd6365dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:to="loc_us-gaap_ShareBasedCompensation_f941a222-fb84-43fd-93ee-2befd6365dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseNoncashExpense_2becc0c3-a388-4155-80ec-96b1d2f9854d" xlink:href="tars-20240331.xsd#tars_OperatingLeaseNoncashExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:to="loc_tars_OperatingLeaseNoncashExpense_2becc0c3-a388-4155-80ec-96b1d2f9854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9c25a5cf-81a5-45bd-9577-09128da50b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9c25a5cf-81a5-45bd-9577-09128da50b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_086498ff-c4b4-4de6-b8a3-f667516ed2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_086498ff-c4b4-4de6-b8a3-f667516ed2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_9e4ed0a6-bf09-4280-ab5f-60a6de814940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_9e4ed0a6-bf09-4280-ab5f-60a6de814940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_bbf5e4c8-16f6-4bff-98ec-01e66f13545c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_bbf5e4c8-16f6-4bff-98ec-01e66f13545c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17e9db08-d08e-45bb-8103-653f9cff92c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_673fb2dc-fcae-486f-9766-57bb9ef0a4db" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17e9db08-d08e-45bb-8103-653f9cff92c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6430a346-3454-4e17-956f-084ad5856067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17e9db08-d08e-45bb-8103-653f9cff92c8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6430a346-3454-4e17-956f-084ad5856067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b48c77a1-439e-4f7c-847f-6e76b135b247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17e9db08-d08e-45bb-8103-653f9cff92c8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b48c77a1-439e-4f7c-847f-6e76b135b247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_a1c9ee0f-3707-4c92-86e9-1681b40e221e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17e9db08-d08e-45bb-8103-653f9cff92c8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_a1c9ee0f-3707-4c92-86e9-1681b40e221e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1b80e275-014f-4565-a24b-f79827366e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17e9db08-d08e-45bb-8103-653f9cff92c8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1b80e275-014f-4565-a24b-f79827366e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9886fe3a-ee35-4e64-9c5f-4e020536fe6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17e9db08-d08e-45bb-8103-653f9cff92c8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9886fe3a-ee35-4e64-9c5f-4e020536fe6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_fd97932a-2b26-4d92-9e4a-5aaa269eec6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17e9db08-d08e-45bb-8103-653f9cff92c8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_fd97932a-2b26-4d92-9e4a-5aaa269eec6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fb72d318-1ee6-4b01-bff0-953af55bdd16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17e9db08-d08e-45bb-8103-653f9cff92c8" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fb72d318-1ee6-4b01-bff0-953af55bdd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_052c09d0-6924-4f69-bd7d-6720cbebb56e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17e9db08-d08e-45bb-8103-653f9cff92c8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_052c09d0-6924-4f69-bd7d-6720cbebb56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f316bb2-b8b7-44e2-bbc0-03f91866058f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_37bba075-3cd8-44f4-87f7-0776d7ee31ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f316bb2-b8b7-44e2-bbc0-03f91866058f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d2ab2c69-4d76-4417-86b2-4a1f24fe3b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00a4a679-2168-462d-a467-f93aa888cb53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d2ab2c69-4d76-4417-86b2-4a1f24fe3b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2b871c59-7b9e-4ac7-9d92-8f50445367b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d2ab2c69-4d76-4417-86b2-4a1f24fe3b99" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2b871c59-7b9e-4ac7-9d92-8f50445367b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_055475eb-7a9d-428d-87a3-08ba463bc20f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d2ab2c69-4d76-4417-86b2-4a1f24fe3b99" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_055475eb-7a9d-428d-87a3-08ba463bc20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b9dc5948-5aa9-418e-92ae-0c1ac7b45e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d2ab2c69-4d76-4417-86b2-4a1f24fe3b99" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b9dc5948-5aa9-418e-92ae-0c1ac7b45e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f2db77a2-1520-40c9-9119-9a982606f026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d2ab2c69-4d76-4417-86b2-4a1f24fe3b99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f2db77a2-1520-40c9-9119-9a982606f026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aab09912-4333-4d14-9106-b211ac57d133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00a4a679-2168-462d-a467-f93aa888cb53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aab09912-4333-4d14-9106-b211ac57d133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_043be54d-56a4-4707-891b-e79b55090f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aab09912-4333-4d14-9106-b211ac57d133" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_043be54d-56a4-4707-891b-e79b55090f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_9389f225-d369-4f29-a5e2-b85bf9c68251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aab09912-4333-4d14-9106-b211ac57d133" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_9389f225-d369-4f29-a5e2-b85bf9c68251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_71ca04b6-d59f-4af0-b889-a3bd16e72ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aab09912-4333-4d14-9106-b211ac57d133" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_71ca04b6-d59f-4af0-b889-a3bd16e72ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ed5691ed-b55a-42ed-931b-95f3666fec97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aab09912-4333-4d14-9106-b211ac57d133" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ed5691ed-b55a-42ed-931b-95f3666fec97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ccd8f682-0596-44ff-827c-1aee5215c4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_aab09912-4333-4d14-9106-b211ac57d133" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ccd8f682-0596-44ff-827c-1aee5215c4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4221432d-51f1-4c73-a58e-c5a6db71fa10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00a4a679-2168-462d-a467-f93aa888cb53" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4221432d-51f1-4c73-a58e-c5a6db71fa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbec524d-cdc5-4642-9781-831b348c9d12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00a4a679-2168-462d-a467-f93aa888cb53" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbec524d-cdc5-4642-9781-831b348c9d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb39b6bb-971d-416a-9f8d-8d0a188aa804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00a4a679-2168-462d-a467-f93aa888cb53" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb39b6bb-971d-416a-9f8d-8d0a188aa804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_950fc312-b1fd-425f-8c0c-069d56703187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00a4a679-2168-462d-a467-f93aa888cb53" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_950fc312-b1fd-425f-8c0c-069d56703187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f2693b2-a28b-4b30-8274-1409bd004d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_950fc312-b1fd-425f-8c0c-069d56703187" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f2693b2-a28b-4b30-8274-1409bd004d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3fa5fee7-b5fe-434d-9eaa-43b5116dc1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_950fc312-b1fd-425f-8c0c-069d56703187" xlink:to="loc_us-gaap_InterestPaidNet_3fa5fee7-b5fe-434d-9eaa-43b5116dc1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities_402246bb-3667-4c64-b084-db36ddf600c5" xlink:href="tars-20240331.xsd#tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_950fc312-b1fd-425f-8c0c-069d56703187" xlink:to="loc_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities_402246bb-3667-4c64-b084-db36ddf600c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="tars-20240331.xsd#CondensedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ed9efdb1-99e1-4a43-89f9-7ccf7004241c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c45ae804-0bbe-4d02-8ede-816cfe1b03e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ed9efdb1-99e1-4a43-89f9-7ccf7004241c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c45ae804-0bbe-4d02-8ede-816cfe1b03e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts_c85619f0-89f4-4c47-ae9e-efa9f472a8eb" xlink:href="tars-20240331.xsd#tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ed9efdb1-99e1-4a43-89f9-7ccf7004241c" xlink:to="loc_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts_c85619f0-89f4-4c47-ae9e-efa9f472a8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements" xlink:type="simple" xlink:href="tars-20240331.xsd#DescriptionofBusinessandPresentationofFinancialStatements"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f961b90c-6a97-49d6-9d5d-21ca1d65ed80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_adceff0f-f618-4877-8a4a-afcd00cdc9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f961b90c-6a97-49d6-9d5d-21ca1d65ed80" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_adceff0f-f618-4877-8a4a-afcd00cdc9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimates"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1635f81b-0496-4473-a4e5-a1929b91ae59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4ce87e40-19d1-4006-927a-f4bba33936c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1635f81b-0496-4473-a4e5-a1929b91ae59" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4ce87e40-19d1-4006-927a-f4bba33936c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_47be68e5-04d0-4ef2-bd2a-eab650c8a766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5b7c5dc8-c49c-40f3-acf4-9a891f3dc084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_47be68e5-04d0-4ef2-bd2a-eab650c8a766" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5b7c5dc8-c49c-40f3-acf4-9a891f3dc084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetail" xlink:type="simple" xlink:href="tars-20240331.xsd#BalanceSheetAccountDetail"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e833d1f-f768-4d9d-bc46-872a1457175f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_7fb5b71f-c765-4e8f-969b-da37679deab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e833d1f-f768-4d9d-bc46-872a1457175f" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_7fb5b71f-c765-4e8f-969b-da37679deab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b42013a1-3f7c-4cb4-82b6-841a8a2605ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1ca4cacc-ade8-4b6d-b471-eea8f9bf3ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b42013a1-3f7c-4cb4-82b6-841a8a2605ed" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1ca4cacc-ade8-4b6d-b471-eea8f9bf3ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossPerShare" xlink:type="simple" xlink:href="tars-20240331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_451580c2-5eca-4439-85c7-9e254402f4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_bbb41fbb-03ba-4bdc-be26-158daaefba16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_451580c2-5eca-4439-85c7-9e254402f4c3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_bbb41fbb-03ba-4bdc-be26-158daaefba16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingencies" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingencies"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba65f71b-3268-4a8c-9410-57f97755537e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f7d09919-a8ce-44c2-a437-bd14986a778a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba65f71b-3268-4a8c-9410-57f97755537e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f7d09919-a8ce-44c2-a437-bd14986a778a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreements" xlink:type="simple" xlink:href="tars-20240331.xsd#OutLicenseAgreements"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_40cc156a-e312-4c28-b38e-e090aeb5b598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_a76e5c30-d2cb-47b9-b59c-886f28482c62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_40cc156a-e312-4c28-b38e-e090aeb5b598" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_a76e5c30-d2cb-47b9-b59c-886f28482c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreement" xlink:type="simple" xlink:href="tars-20240331.xsd#CreditFacilityAgreement"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a4d6b13b-899c-4440-877f-e97eaf699768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a11d2368-7f5a-4150-9d49-c5b93420b0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a4d6b13b-899c-4440-877f-e97eaf699768" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a11d2368-7f5a-4150-9d49-c5b93420b0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="tars-20240331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_496a8a69-8e9e-4c22-8f99-d2e8d0074b44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a942a46f-3f4a-48d0-bab7-f124c282dc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_496a8a69-8e9e-4c22-8f99-d2e8d0074b44" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a942a46f-3f4a-48d0-bab7-f124c282dc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SubsequentEvent" xlink:type="simple" xlink:href="tars-20240331.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_13e54bb6-1215-4160-b615-0f0eb16d5cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3daaeac2-1ab7-4ee7-bdf8-3644e5eb6c67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_13e54bb6-1215-4160-b615-0f0eb16d5cc1" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3daaeac2-1ab7-4ee7-bdf8-3644e5eb6c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_08f4fbfc-29e2-4844-847f-19b8fc13898e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_08f4fbfc-29e2-4844-847f-19b8fc13898e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5b5f88df-809b-48b5-a4ca-9ae086ea16e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5b5f88df-809b-48b5-a4ca-9ae086ea16e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_dc1f6695-8c84-4e26-9021-1c92495984f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_UseOfEstimates_dc1f6695-8c84-4e26-9021-1c92495984f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_ff55f5ba-c72b-4a51-b176-1ef9324288f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_ff55f5ba-c72b-4a51-b176-1ef9324288f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_3351aa7a-6655-4b2c-b8df-f3faf4aab480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_3351aa7a-6655-4b2c-b8df-f3faf4aab480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_c231898a-4a8b-4343-a26d-453d0ce62c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_c231898a-4a8b-4343-a26d-453d0ce62c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_330dc09c-ec47-495d-badf-47b16a3e240d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_330dc09c-ec47-495d-badf-47b16a3e240d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_fc8b64b5-6c97-4d4a-9245-9d75cb76aab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_fc8b64b5-6c97-4d4a-9245-9d75cb76aab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_98a063da-5512-4725-aa32-f60cc8a0b4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_98a063da-5512-4725-aa32-f60cc8a0b4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_50ed252e-16f8-4237-bc0e-13b858624954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_50ed252e-16f8-4237-bc0e-13b858624954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_4c0b30f9-43ba-4b5c-b3e2-4e98923d5895" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_4c0b30f9-43ba-4b5c-b3e2-4e98923d5895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_96cfa66d-1765-4872-b236-c36da2813768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_96cfa66d-1765-4872-b236-c36da2813768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_91a96e98-963a-4f1d-b647-e0ea04bf87d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_91a96e98-963a-4f1d-b647-e0ea04bf87d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_8d3dc85f-d693-4f17-82a7-51db2fbb42f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_8d3dc85f-d693-4f17-82a7-51db2fbb42f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_98294eee-4d63-42c7-b7cb-b0b1acfcc678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_98294eee-4d63-42c7-b7cb-b0b1acfcc678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_6566b100-a9ee-42cd-bc63-4e210f8b0dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_6566b100-a9ee-42cd-bc63-4e210f8b0dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_05d5a959-585c-4694-baa6-1f4668fc0731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_05d5a959-585c-4694-baa6-1f4668fc0731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_8b486e3d-73f1-4726-87aa-2d57fb310fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_8b486e3d-73f1-4726-87aa-2d57fb310fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_812b3073-4e64-4cdd-944b-1e29227ae39d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_812b3073-4e64-4cdd-944b-1e29227ae39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_50fa7603-097c-4366-900d-02c0f2085cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_50fa7603-097c-4366-900d-02c0f2085cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_353ecf58-52a2-4b54-91e7-2b796bfb1588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a8c7542-090d-4e41-a957-d03801395f29" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_353ecf58-52a2-4b54-91e7-2b796bfb1588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ac9b3e9b-598b-421c-bfa6-9a724d3e00ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7c968e9a-87cc-43ca-9abb-c7f3b79b3270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9b3e9b-598b-421c-bfa6-9a724d3e00ca" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7c968e9a-87cc-43ca-9abb-c7f3b79b3270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_2c59c361-ea92-4673-87ad-2e0d50ab5d98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac9b3e9b-598b-421c-bfa6-9a724d3e00ca" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_2c59c361-ea92-4673-87ad-2e0d50ab5d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_69347fd7-68d2-42e7-ad67-a47428d8905b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_c070b1c1-e531-4e49-bcf4-54bceff91eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_69347fd7-68d2-42e7-ad67-a47428d8905b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_c070b1c1-e531-4e49-bcf4-54bceff91eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2a72905f-35b7-4112-aa1e-2d76f42341ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_69347fd7-68d2-42e7-ad67-a47428d8905b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2a72905f-35b7-4112-aa1e-2d76f42341ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_d65c32e1-3366-42de-ad1e-b49996cd7817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_69347fd7-68d2-42e7-ad67-a47428d8905b" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_d65c32e1-3366-42de-ad1e-b49996cd7817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailTables" xlink:type="simple" xlink:href="tars-20240331.xsd#BalanceSheetAccountDetailTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7d323d63-f6d0-455f-96c6-5513354061b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a4672bae-ffc0-46b8-be9c-ec5e552a87f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7d323d63-f6d0-455f-96c6-5513354061b3" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a4672bae-ffc0-46b8-be9c-ec5e552a87f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3efc4044-5b94-4c01-b933-6ccaffe5e3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7d323d63-f6d0-455f-96c6-5513354061b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3efc4044-5b94-4c01-b933-6ccaffe5e3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_5080b63a-7394-498f-a388-bf5808230d19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7d323d63-f6d0-455f-96c6-5513354061b3" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_5080b63a-7394-498f-a388-bf5808230d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12606b5a-b4e5-44ee-9a6b-1ec34ae83819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_ccc5538a-37e4-47e1-859e-68e70f87d636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12606b5a-b4e5-44ee-9a6b-1ec34ae83819" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_ccc5538a-37e4-47e1-859e-68e70f87d636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_be3b66ef-ad6d-4407-9d99-458a7724996f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12606b5a-b4e5-44ee-9a6b-1ec34ae83819" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_be3b66ef-ad6d-4407-9d99-458a7724996f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d604bbb9-75d5-4ed7-ab03-9f95acdfd1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12606b5a-b4e5-44ee-9a6b-1ec34ae83819" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d604bbb9-75d5-4ed7-ab03-9f95acdfd1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_967cc222-4e14-41f7-bccc-963ff61d0ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12606b5a-b4e5-44ee-9a6b-1ec34ae83819" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_967cc222-4e14-41f7-bccc-963ff61d0ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_21a87c17-66f7-4182-bab1-4c394aac940b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12606b5a-b4e5-44ee-9a6b-1ec34ae83819" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_21a87c17-66f7-4182-bab1-4c394aac940b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="tars-20240331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9eb7a115-4126-4bbb-a43e-04a8d94193b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8c23c800-f2c5-4d02-9981-9a4721981ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9eb7a115-4126-4bbb-a43e-04a8d94193b1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8c23c800-f2c5-4d02-9981-9a4721981ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0229eee8-5f73-4ab4-866e-adccc49686eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9eb7a115-4126-4bbb-a43e-04a8d94193b1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0229eee8-5f73-4ab4-866e-adccc49686eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesTables" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingenciesTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0396db26-814a-4949-b021-56dae0ad791e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c90a8f6a-22b6-420d-86d2-806b19474b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0396db26-814a-4949-b021-56dae0ad791e" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c90a8f6a-22b6-420d-86d2-806b19474b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_656a8496-1343-4f0f-a041-f6e00627b72d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0396db26-814a-4949-b021-56dae0ad791e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_656a8496-1343-4f0f-a041-f6e00627b72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementTables" xlink:type="simple" xlink:href="tars-20240331.xsd#CreditFacilityAgreementTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_511ce4a0-d6ee-4998-a339-ba1d2d2648ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_f68e58ea-07ca-406a-a2cf-9fae65736044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_511ce4a0-d6ee-4998-a339-ba1d2d2648ee" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_f68e58ea-07ca-406a-a2cf-9fae65736044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_ef440f9f-1d23-4885-8340-ab6bb84c1643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_511ce4a0-d6ee-4998-a339-ba1d2d2648ee" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_ef440f9f-1d23-4885-8340-ab6bb84c1643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#DescriptionofBusinessandPresentationofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_954407d5-68de-4667-a5a4-49d197e13281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab02934-9b78-4f01-a545-f79b2f82bc87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_954407d5-68de-4667-a5a4-49d197e13281" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab02934-9b78-4f01-a545-f79b2f82bc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b98af327-2bfc-4e4a-8654-b5f398d32c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab02934-9b78-4f01-a545-f79b2f82bc87" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b98af327-2bfc-4e4a-8654-b5f398d32c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b98af327-2bfc-4e4a-8654-b5f398d32c5c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FollowOnPublicOfferingMember_a6af0af1-cbe3-4a83-a616-b8612974e090" xlink:href="tars-20240331.xsd#tars_FollowOnPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:to="loc_tars_FollowOnPublicOfferingMember_a6af0af1-cbe3-4a83-a616-b8612974e090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_daec0e02-33b2-4d66-83ee-2cb188d0af01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:to="loc_us-gaap_OverAllotmentOptionMember_daec0e02-33b2-4d66-83ee-2cb188d0af01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_A2023ShelfRegistrationStatementMember_b1a74bcb-f407-4e92-aef3-e057b014e67e" xlink:href="tars-20240331.xsd#tars_A2023ShelfRegistrationStatementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:to="loc_tars_A2023ShelfRegistrationStatementMember_b1a74bcb-f407-4e92-aef3-e057b014e67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_A2023ATMProspectusMember_2c3ec226-8247-42b9-88f1-1029595c5c4d" xlink:href="tars-20240331.xsd#tars_A2023ATMProspectusMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ae0b63e-3ff6-4799-a6df-e45b026e4162" xlink:to="loc_tars_A2023ATMProspectusMember_2c3ec226-8247-42b9-88f1-1029595c5c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab02934-9b78-4f01-a545-f79b2f82bc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3253f87f-55b8-4bdc-82ca-ee4c833758b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3253f87f-55b8-4bdc-82ca-ee4c833758b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_26d59f18-a261-4673-88fd-88813d3043f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_26d59f18-a261-4673-88fd-88813d3043f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClassOfWarrantOrRightReservedForFutureIssuance_f2e7df87-1dc1-4399-a251-ac3db984241a" xlink:href="tars-20240331.xsd#tars_ClassOfWarrantOrRightReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_tars_ClassOfWarrantOrRightReservedForFutureIssuance_f2e7df87-1dc1-4399-a251-ac3db984241a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4f6794f7-55eb-4569-9bdc-5ed2012482dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4f6794f7-55eb-4569-9bdc-5ed2012482dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClassOfWarrantOrRightSalePrice_5269ac62-1aa3-4a84-98c1-1343047cbf31" xlink:href="tars-20240331.xsd#tars_ClassOfWarrantOrRightSalePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_tars_ClassOfWarrantOrRightSalePrice_5269ac62-1aa3-4a84-98c1-1343047cbf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c4eab9a-b821-4261-8eac-408659a65bca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c4eab9a-b821-4261-8eac-408659a65bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0d1d641d-f5f8-4319-a31d-0e5d176cac8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0d1d641d-f5f8-4319-a31d-0e5d176cac8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds_3eafdde1-2e3c-4cb4-b663-138a6bfad229" xlink:href="tars-20240331.xsd#tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds_3eafdde1-2e3c-4cb4-b663-138a6bfad229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockConsiderationAmountAuthorized_b9242131-0bd7-4d3d-8469-535eefeb1208" xlink:href="tars-20240331.xsd#tars_SaleOfStockConsiderationAmountAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_tars_SaleOfStockConsiderationAmountAuthorized_b9242131-0bd7-4d3d-8469-535eefeb1208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_754a4242-120c-403b-bd4e-005393be5bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_754a4242-120c-403b-bd4e-005393be5bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_71749c40-166c-43bc-8df7-8183cb11f301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_NumberOfReportableSegments_71749c40-166c-43bc-8df7-8183cb11f301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bbe7e1ca-d429-4226-876a-d927ca430820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33fe9ef-f470-45ab-82e3-8924c72adb43" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bbe7e1ca-d429-4226-876a-d927ca430820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eefc1749-0c5c-47f3-ad5b-beacc76bbd67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02df76ca-73f4-408a-8683-08da5bd7d7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eefc1749-0c5c-47f3-ad5b-beacc76bbd67" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02df76ca-73f4-408a-8683-08da5bd7d7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_b445b2c0-40fd-45a8-b608-96ca5922b082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02df76ca-73f4-408a-8683-08da5bd7d7d2" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_b445b2c0-40fd-45a8-b608-96ca5922b082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_d9c785fc-a52e-447a-9af9-a98fd9bfc07c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_b445b2c0-40fd-45a8-b608-96ca5922b082" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_d9c785fc-a52e-447a-9af9-a98fd9bfc07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IntangibleAssetsMilestonePaymentMember_e5f3fb5d-a141-468e-981b-24f543af9666" xlink:href="tars-20240331.xsd#tars_IntangibleAssetsMilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_d9c785fc-a52e-447a-9af9-a98fd9bfc07c" xlink:to="loc_tars_IntangibleAssetsMilestonePaymentMember_e5f3fb5d-a141-468e-981b-24f543af9666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0d0df111-c258-482d-b2f4-619c26a7d21f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02df76ca-73f4-408a-8683-08da5bd7d7d2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0d0df111-c258-482d-b2f4-619c26a7d21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_490d22fc-3d92-413f-a90e-669041a0f47b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0d0df111-c258-482d-b2f4-619c26a7d21f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_490d22fc-3d92-413f-a90e-669041a0f47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e6087b6d-b774-4564-86d1-401e55917aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0d0df111-c258-482d-b2f4-619c26a7d21f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e6087b6d-b774-4564-86d1-401e55917aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_09054900-39da-4b4e-951f-9dcb756d1758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0d0df111-c258-482d-b2f4-619c26a7d21f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_09054900-39da-4b4e-951f-9dcb756d1758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12b4b8fd-3797-49d3-a820-93d4c9c3533b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_64ce19fb-e82d-4bcf-bb29-9be1485a2d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b4b8fd-3797-49d3-a820-93d4c9c3533b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_64ce19fb-e82d-4bcf-bb29-9be1485a2d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_327261c0-3e06-45d2-9802-ed94be2ad921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b4b8fd-3797-49d3-a820-93d4c9c3533b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_327261c0-3e06-45d2-9802-ed94be2ad921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cef0845c-55da-401f-a2e3-ab605a22eb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b4b8fd-3797-49d3-a820-93d4c9c3533b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cef0845c-55da-401f-a2e3-ab605a22eb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d42a91e0-48a9-4d5e-bc59-747b4c821d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b4b8fd-3797-49d3-a820-93d4c9c3533b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d42a91e0-48a9-4d5e-bc59-747b4c821d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_16be2d27-38ad-471f-9383-0b6536e1795b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b4b8fd-3797-49d3-a820-93d4c9c3533b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_16be2d27-38ad-471f-9383-0b6536e1795b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_b1908908-83bf-4b28-8668-ebb827337af6" xlink:href="tars-20240331.xsd#tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b4b8fd-3797-49d3-a820-93d4c9c3533b" xlink:to="loc_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_b1908908-83bf-4b28-8668-ebb827337af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_257148c2-4479-4173-94fc-ed5316d2d14b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b4b8fd-3797-49d3-a820-93d4c9c3533b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_257148c2-4479-4173-94fc-ed5316d2d14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bfdf84e5-8b66-44f4-84d6-6688e2d3db1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bfdf84e5-8b66-44f4-84d6-6688e2d3db1b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ccc91039-f3e4-4a53-8d69-8370063beae9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_srt_RangeAxis_ccc91039-f3e4-4a53-8d69-8370063beae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5627c355-e518-48de-89f0-7e8fb83c3e53" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ccc91039-f3e4-4a53-8d69-8370063beae9" xlink:to="loc_srt_RangeMember_5627c355-e518-48de-89f0-7e8fb83c3e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a84fe3c9-84a3-4d37-94c9-4160ad777e99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5627c355-e518-48de-89f0-7e8fb83c3e53" xlink:to="loc_srt_MinimumMember_a84fe3c9-84a3-4d37-94c9-4160ad777e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5c2c79c-0804-4c3e-8a7d-1cf264cecdde" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5627c355-e518-48de-89f0-7e8fb83c3e53" xlink:to="loc_srt_MaximumMember_d5c2c79c-0804-4c3e-8a7d-1cf264cecdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b3aa0c5c-2bf1-44b9-8c3f-8666061c60f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_us-gaap_PlanNameAxis_b3aa0c5c-2bf1-44b9-8c3f-8666061c60f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e922fce4-539f-4f3f-b6a9-28c3bd306f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b3aa0c5c-2bf1-44b9-8c3f-8666061c60f1" xlink:to="loc_us-gaap_PlanNameDomain_e922fce4-539f-4f3f-b6a9-28c3bd306f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member_4a069717-2008-44a2-9bba-425f92550fd1" xlink:href="tars-20240331.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e922fce4-539f-4f3f-b6a9-28c3bd306f16" xlink:to="loc_tars_EquityIncentivePlan2016Member_4a069717-2008-44a2-9bba-425f92550fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_88c036b9-b05d-41c3-87b1-8839b2b9b577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_88c036b9-b05d-41c3-87b1-8839b2b9b577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5081e99-8582-4e2b-aa3a-07a53e3438e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_88c036b9-b05d-41c3-87b1-8839b2b9b577" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5081e99-8582-4e2b-aa3a-07a53e3438e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0056e173-da7a-4add-b1f9-8334f5be2021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5081e99-8582-4e2b-aa3a-07a53e3438e4" xlink:to="loc_us-gaap_SalesRevenueNetMember_0056e173-da7a-4add-b1f9-8334f5be2021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_1c9d14ff-99b7-4267-b109-13f423b2826d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5081e99-8582-4e2b-aa3a-07a53e3438e4" xlink:to="loc_us-gaap_AccountsReceivableMember_1c9d14ff-99b7-4267-b109-13f423b2826d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1e586146-8b45-4d20-9191-6af4b1b4f5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1e586146-8b45-4d20-9191-6af4b1b4f5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_23162c4b-bc2b-4aac-b0e3-9bbb07567272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1e586146-8b45-4d20-9191-6af4b1b4f5ed" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_23162c4b-bc2b-4aac-b0e3-9bbb07567272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_211ac48a-65de-4e69-8556-d7edeae63c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_23162c4b-bc2b-4aac-b0e3-9bbb07567272" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_211ac48a-65de-4e69-8556-d7edeae63c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_08c3d3f7-8c42-4f20-83d9-46fdb520a61f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_srt_MajorCustomersAxis_08c3d3f7-8c42-4f20-83d9-46fdb520a61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0614b64b-7dee-479b-96d5-e286a94ca074" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_08c3d3f7-8c42-4f20-83d9-46fdb520a61f" xlink:to="loc_srt_NameOfMajorCustomerDomain_0614b64b-7dee-479b-96d5-e286a94ca074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_FiveCustomersMember_f0a86aa8-c1ab-4486-a2f3-264ac0b80a7b" xlink:href="tars-20240331.xsd#tars_FiveCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0614b64b-7dee-479b-96d5-e286a94ca074" xlink:to="loc_tars_FiveCustomersMember_f0a86aa8-c1ab-4486-a2f3-264ac0b80a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2747c5b1-e711-4e98-9ee1-ca5443bf3196" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_srt_ProductOrServiceAxis_2747c5b1-e711-4e98-9ee1-ca5443bf3196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e53b83d9-fa72-4b63-aaea-ad5fb64d5087" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2747c5b1-e711-4e98-9ee1-ca5443bf3196" xlink:to="loc_srt_ProductsAndServicesDomain_e53b83d9-fa72-4b63-aaea-ad5fb64d5087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationOtherMember_86058c5f-3493-4f36-b19d-25a994cd7905" xlink:href="tars-20240331.xsd#tars_LicenseAndCollaborationOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e53b83d9-fa72-4b63-aaea-ad5fb64d5087" xlink:to="loc_tars_LicenseAndCollaborationOtherMember_86058c5f-3493-4f36-b19d-25a994cd7905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2996b4c-eaea-4f32-a5b9-978a6f2157c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e3a69006-b419-4e89-b4b8-52f05bcef0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e3a69006-b419-4e89-b4b8-52f05bcef0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_66995f9a-0567-4e37-bec9-282e06f18ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_66995f9a-0567-4e37-bec9-282e06f18ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6fcd455f-06ee-4f72-b476-2d63e438aee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6fcd455f-06ee-4f72-b476-2d63e438aee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_2f06abbb-6a2d-453e-bb47-41e3ce391dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_2f06abbb-6a2d-453e-bb47-41e3ce391dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d745b96-6977-41a3-b6fa-4c79d2413a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d745b96-6977-41a3-b6fa-4c79d2413a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bc617d06-fc1a-49fa-991e-6524c2232c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_Revenues_bc617d06-fc1a-49fa-991e-6524c2232c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e2d7707d-fa5b-4991-83e6-2b77212d2313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e2d7707d-fa5b-4991-83e6-2b77212d2313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5ecdde2f-0531-450f-b156-dc80eef0b611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9562b999-c44d-4bfd-b900-a7e078e45795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5ecdde2f-0531-450f-b156-dc80eef0b611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b82da6f9-41bc-4106-8fb1-53e40dec9abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b82da6f9-41bc-4106-8fb1-53e40dec9abb" xlink:to="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_00beea65-e63d-45a4-bff5-f960d47b3dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_00beea65-e63d-45a4-bff5-f960d47b3dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333ce2d8-9a84-4020-a765-2c1074f955e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_00beea65-e63d-45a4-bff5-f960d47b3dd9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333ce2d8-9a84-4020-a765-2c1074f955e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c86041fb-87f8-4132-b0ce-21a4445fa8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333ce2d8-9a84-4020-a765-2c1074f955e7" xlink:to="loc_us-gaap_SalesRevenueNetMember_c86041fb-87f8-4132-b0ce-21a4445fa8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_60c5bcb0-ac03-440e-9c91-8a53100c3b90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_60c5bcb0-ac03-440e-9c91-8a53100c3b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4701f5dc-21e4-42df-bd25-0ec6943fa489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_60c5bcb0-ac03-440e-9c91-8a53100c3b90" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4701f5dc-21e4-42df-bd25-0ec6943fa489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_f648c296-6460-4df5-991b-68e60f65c148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4701f5dc-21e4-42df-bd25-0ec6943fa489" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_f648c296-6460-4df5-991b-68e60f65c148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_607592af-f48e-40bd-9f08-148e357c7ae0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:to="loc_srt_MajorCustomersAxis_607592af-f48e-40bd-9f08-148e357c7ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_607592af-f48e-40bd-9f08-148e357c7ae0" xlink:to="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerAMember_a7d8d214-6bfe-4ace-92a6-a1ac5a4633b0" xlink:href="tars-20240331.xsd#tars_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:to="loc_tars_CustomerAMember_a7d8d214-6bfe-4ace-92a6-a1ac5a4633b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerBMember_06ddebba-6bdc-4113-bc4c-27f6e65810c5" xlink:href="tars-20240331.xsd#tars_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:to="loc_tars_CustomerBMember_06ddebba-6bdc-4113-bc4c-27f6e65810c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerCMember_16aa4728-92a7-4361-add7-0991d52c4875" xlink:href="tars-20240331.xsd#tars_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:to="loc_tars_CustomerCMember_16aa4728-92a7-4361-add7-0991d52c4875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerDMember_d2b9d283-8e59-4a61-930f-9a7aa145158d" xlink:href="tars-20240331.xsd#tars_CustomerDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:to="loc_tars_CustomerDMember_d2b9d283-8e59-4a61-930f-9a7aa145158d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CustomerEMember_5e97b9b5-fe62-4832-ba24-3b09a096f46b" xlink:href="tars-20240331.xsd#tars_CustomerEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8434d64-4ee5-42b5-93f1-fd51dff92eeb" xlink:to="loc_tars_CustomerEMember_5e97b9b5-fe62-4832-ba24-3b09a096f46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0aeb7364-d954-417a-a47c-58c39cdb7ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_41fe9736-e6b4-43a1-a7f4-ead9e6cf7deb" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_0aeb7364-d954-417a-a47c-58c39cdb7ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_97f58229-ac2d-4949-8c07-f964be050234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0aeb7364-d954-417a-a47c-58c39cdb7ca1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_97f58229-ac2d-4949-8c07-f964be050234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_19d74927-51d9-4f53-8318-1ff1e2bb3a05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee6cdbfc-83a7-4024-ad3e-26a43b5f720f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_19d74927-51d9-4f53-8318-1ff1e2bb3a05" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee6cdbfc-83a7-4024-ad3e-26a43b5f720f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9981d55f-7d02-474c-9d37-421a0d0c37bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee6cdbfc-83a7-4024-ad3e-26a43b5f720f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9981d55f-7d02-474c-9d37-421a0d0c37bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97fe4679-1eba-4551-9403-67b13ab92f40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9981d55f-7d02-474c-9d37-421a0d0c37bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97fe4679-1eba-4551-9403-67b13ab92f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_27ed4f2f-3b70-49a0-862f-5efef4036eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97fe4679-1eba-4551-9403-67b13ab92f40" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_27ed4f2f-3b70-49a0-862f-5efef4036eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_07cc3953-36fd-452a-8386-73c927aeeeff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97fe4679-1eba-4551-9403-67b13ab92f40" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_07cc3953-36fd-452a-8386-73c927aeeeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_14672208-b5da-4e5f-a462-3916097a5d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97fe4679-1eba-4551-9403-67b13ab92f40" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_14672208-b5da-4e5f-a462-3916097a5d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4f381721-d000-479d-a440-2cb7229dce7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee6cdbfc-83a7-4024-ad3e-26a43b5f720f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4f381721-d000-479d-a440-2cb7229dce7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4f381721-d000-479d-a440-2cb7229dce7d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8605e55a-82d0-40c8-8a9b-24d023e966b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8605e55a-82d0-40c8-8a9b-24d023e966b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_628e3caa-ac1f-406d-970e-9b857d39348e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_628e3caa-ac1f-406d-970e-9b857d39348e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a8ac576b-051a-410e-8bf2-4700df7720e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:to="loc_us-gaap_CommercialPaperMember_a8ac576b-051a-410e-8bf2-4700df7720e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_91f0ef73-a367-456f-9b2c-74e772c9bcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_91f0ef73-a367-456f-9b2c-74e772c9bcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_3857205a-a947-4fac-8a2a-6e083532c00b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b223ed8d-f1d5-40a9-bef4-227142767a08" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_3857205a-a947-4fac-8a2a-6e083532c00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7e294477-ca85-4f73-b685-0b484aa42c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee6cdbfc-83a7-4024-ad3e-26a43b5f720f" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7e294477-ca85-4f73-b685-0b484aa42c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7e294477-ca85-4f73-b685-0b484aa42c7a" xlink:to="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fd70c8cd-cab3-4be8-b434-763f92a6efb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fd70c8cd-cab3-4be8-b434-763f92a6efb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_3fa021da-822c-4555-bb3d-8468da4c6993" xlink:href="tars-20240331.xsd#tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:to="loc_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents_3fa021da-822c-4555-bb3d-8468da4c6993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_246d5251-d6f7-4468-970f-f59c79ecc038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_246d5251-d6f7-4468-970f-f59c79ecc038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_3cfc3cba-7d2e-4d88-af9c-c0a3ad2ed685" xlink:href="tars-20240331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_3cfc3cba-7d2e-4d88-af9c-c0a3ad2ed685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_510ab7f0-d698-4b24-be86-43e326c43b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cb174fb4-24bf-4803-93b5-8ef97743c684" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_510ab7f0-d698-4b24-be86-43e326c43b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_baab4ad7-fd76-4849-af78-184351d1c1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_303d784e-0bab-4938-ac22-da44bb60f0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baab4ad7-fd76-4849-af78-184351d1c1bd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_303d784e-0bab-4938-ac22-da44bb60f0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baab4ad7-fd76-4849-af78-184351d1c1bd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b70e607d-3b36-4d0a-b122-17ddbfc1fa87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_srt_RangeAxis_b70e607d-3b36-4d0a-b122-17ddbfc1fa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_787dcb26-b19f-41c6-9a6b-1a79c4979918" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b70e607d-3b36-4d0a-b122-17ddbfc1fa87" xlink:to="loc_srt_RangeMember_787dcb26-b19f-41c6-9a6b-1a79c4979918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b3a20da-24e9-4138-ba43-723cfb1e882f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_787dcb26-b19f-41c6-9a6b-1a79c4979918" xlink:to="loc_srt_MinimumMember_1b3a20da-24e9-4138-ba43-723cfb1e882f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0d6a85ee-8c8c-447e-98e3-e9781d6fdbea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_787dcb26-b19f-41c6-9a6b-1a79c4979918" xlink:to="loc_srt_MaximumMember_0d6a85ee-8c8c-447e-98e3-e9781d6fdbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_321384c3-9725-47d9-924e-a6aff641a151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_321384c3-9725-47d9-924e-a6aff641a151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_484d6079-7a23-4e95-a7d8-9781c640119e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_321384c3-9725-47d9-924e-a6aff641a151" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_484d6079-7a23-4e95-a7d8-9781c640119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_b096007a-d798-4639-8a41-b938e9baf1b0" xlink:href="tars-20240331.xsd#tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_484d6079-7a23-4e95-a7d8-9781c640119e" xlink:to="loc_tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember_b096007a-d798-4639-8a41-b938e9baf1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e32b5f98-33c2-4f79-8494-1ff1db0c379b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_dei_LegalEntityAxis_e32b5f98-33c2-4f79-8494-1ff1db0c379b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ce79fdce-61b6-4d29-8cb1-93707cb657ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e32b5f98-33c2-4f79-8494-1ff1db0c379b" xlink:to="loc_dei_EntityDomain_ce79fdce-61b6-4d29-8cb1-93707cb657ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_a585032a-9d48-4632-82b8-e2364ae88d0a" xlink:href="tars-20240331.xsd#tars_LianBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ce79fdce-61b6-4d29-8cb1-93707cb657ad" xlink:to="loc_tars_LianBioMember_a585032a-9d48-4632-82b8-e2364ae88d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5949f539-bb4b-4e6d-8661-e491136d3e34" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_srt_CounterpartyNameAxis_5949f539-bb4b-4e6d-8661-e491136d3e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9840037-d29b-49ae-aa10-340ec0beddac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5949f539-bb4b-4e6d-8661-e491136d3e34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9840037-d29b-49ae-aa10-340ec0beddac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_51bc5e92-d02b-401a-b538-2fb25bdb213d" xlink:href="tars-20240331.xsd#tars_LianBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9840037-d29b-49ae-aa10-340ec0beddac" xlink:to="loc_tars_LianBioMember_51bc5e92-d02b-401a-b538-2fb25bdb213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f84f89e3-7a3f-44de-b7da-f89f40c1bcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f84f89e3-7a3f-44de-b7da-f89f40c1bcb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a308575-b22b-41cc-8b13-ca29205bd453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f84f89e3-7a3f-44de-b7da-f89f40c1bcb2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a308575-b22b-41cc-8b13-ca29205bd453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_03678a36-6e35-47f1-bec5-2a953ebbd8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5a308575-b22b-41cc-8b13-ca29205bd453" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_03678a36-6e35-47f1-bec5-2a953ebbd8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dfa3cf45-9307-4fbd-831d-e6fdeeb13acd" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_WarrantAgreementNumberOfTranches_96d48e26-9d41-45b4-945f-5d4b7543d63f" xlink:href="tars-20240331.xsd#tars_WarrantAgreementNumberOfTranches"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_tars_WarrantAgreementNumberOfTranches_96d48e26-9d41-45b4-945f-5d4b7543d63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfVestedWarrants_14bf52d0-dab0-4dc3-a790-590ae32506b1" xlink:href="tars-20240331.xsd#tars_NumberOfVestedWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_tars_NumberOfVestedWarrants_14bf52d0-dab0-4dc3-a790-590ae32506b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquitySecuritiesFVNINumberOfShares_26e11b07-d936-4aff-9c80-75f2fab54a6c" xlink:href="tars-20240331.xsd#tars_EquitySecuritiesFVNINumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_tars_EquitySecuritiesFVNINumberOfShares_26e11b07-d936-4aff-9c80-75f2fab54a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_ec292c47-1c36-47d2-8299-c1e30e4b06c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_DividendsCommonStockCash_ec292c47-1c36-47d2-8299-c1e30e4b06c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_95cfa70c-5fff-493c-b3f3-5a448a0272ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_95cfa70c-5fff-493c-b3f3-5a448a0272ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromCancellationOfWarrants_fdef852b-1674-4c3a-a3a9-59cfacb4890c" xlink:href="tars-20240331.xsd#tars_ProceedsFromCancellationOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_tars_ProceedsFromCancellationOfWarrants_fdef852b-1674-4c3a-a3a9-59cfacb4890c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_e1a04c3f-af14-41b6-91dc-36f64cdc3275" xlink:href="tars-20240331.xsd#tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities_e1a04c3f-af14-41b6-91dc-36f64cdc3275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_b859c249-de0c-4894-a742-90abc4b0e176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_b859c249-de0c-4894-a742-90abc4b0e176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_049f290e-653c-48f3-a011-72eedd6c5e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_049f290e-653c-48f3-a011-72eedd6c5e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00e75658-1625-4d4e-9aa8-f434d489e59c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00e75658-1625-4d4e-9aa8-f434d489e59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_61832307-1500-40e2-8045-4ee6350d3fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6dc8b8ac-defe-4580-9080-9389014fc5dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_61832307-1500-40e2-8045-4ee6350d3fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8533302c-a920-40d2-ae17-ff8d7db866e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aa8297f8-f324-4a2b-a2ba-15609c43bd77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8533302c-a920-40d2-ae17-ff8d7db866e8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aa8297f8-f324-4a2b-a2ba-15609c43bd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f25ee4de-774a-4998-8df5-32faed84af02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aa8297f8-f324-4a2b-a2ba-15609c43bd77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f25ee4de-774a-4998-8df5-32faed84af02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_f5e07b6b-441e-4144-90a8-6a0b95d500ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aa8297f8-f324-4a2b-a2ba-15609c43bd77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_f5e07b6b-441e-4144-90a8-6a0b95d500ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_0d34d76d-8478-4af6-b784-08bddf1d4f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aa8297f8-f324-4a2b-a2ba-15609c43bd77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_0d34d76d-8478-4af6-b784-08bddf1d4f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_eaad257b-38a8-4faa-ae95-b21dde149f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aa8297f8-f324-4a2b-a2ba-15609c43bd77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_eaad257b-38a8-4faa-ae95-b21dde149f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_35fb6e9b-1929-4293-9d7c-8b7e0ef0f286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6854199b-7133-4066-b0e9-2e3dd7aa86ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_35fb6e9b-1929-4293-9d7c-8b7e0ef0f286" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6854199b-7133-4066-b0e9-2e3dd7aa86ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c4349842-bbc2-4d57-8ec7-d5c624b1d6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6854199b-7133-4066-b0e9-2e3dd7aa86ff" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c4349842-bbc2-4d57-8ec7-d5c624b1d6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c4349842-bbc2-4d57-8ec7-d5c624b1d6ec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_12a43b1e-4b6a-48a1-9c25-8401879a760a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_12a43b1e-4b6a-48a1-9c25-8401879a760a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c38d652c-9508-49ad-9bbd-bc65ebcd0046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c38d652c-9508-49ad-9bbd-bc65ebcd0046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4143408c-a7da-4ecf-b867-cfbeb32a9ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_us-gaap_CommercialPaperMember_4143408c-a7da-4ecf-b867-cfbeb32a9ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8e983d64-0a8c-4dd6-96fc-0d6fd98075e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8e983d64-0a8c-4dd6-96fc-0d6fd98075e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_f4b50e77-bfe8-432c-9ea6-1a314f6bf311" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_f4b50e77-bfe8-432c-9ea6-1a314f6bf311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockInLianBioMember_56a85913-a061-4569-b6b0-50e800461219" xlink:href="tars-20240331.xsd#tars_CommonStockInLianBioMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dd7fab47-8a74-4b1f-8d4d-17ceca3486a9" xlink:to="loc_tars_CommonStockInLianBioMember_56a85913-a061-4569-b6b0-50e800461219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2a195b3b-eadd-4c9d-8e6c-5330476e7cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6854199b-7133-4066-b0e9-2e3dd7aa86ff" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2a195b3b-eadd-4c9d-8e6c-5330476e7cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_eabf2a72-2a2f-4ede-b9f1-ce1e3bb09e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2a195b3b-eadd-4c9d-8e6c-5330476e7cb6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_eabf2a72-2a2f-4ede-b9f1-ce1e3bb09e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_2840ad71-a19d-490d-9cde-ca9d456bbaed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eabf2a72-2a2f-4ede-b9f1-ce1e3bb09e03" xlink:to="loc_us-gaap_CashEquivalentsMember_2840ad71-a19d-490d-9cde-ca9d456bbaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_add8f29b-c00b-44bc-8826-361124c1213d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6854199b-7133-4066-b0e9-2e3dd7aa86ff" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_add8f29b-c00b-44bc-8826-361124c1213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_5099ed15-c4ec-4a9d-80d8-4b5d789bafef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_add8f29b-c00b-44bc-8826-361124c1213d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_5099ed15-c4ec-4a9d-80d8-4b5d789bafef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f596201-feeb-4252-a215-875518159309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5099ed15-c4ec-4a9d-80d8-4b5d789bafef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f596201-feeb-4252-a215-875518159309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b9c8a2da-22d6-4aa0-8496-c99829367f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5099ed15-c4ec-4a9d-80d8-4b5d789bafef" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b9c8a2da-22d6-4aa0-8496-c99829367f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_add8f29b-c00b-44bc-8826-361124c1213d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461784ea-06d6-4234-b4c9-df02d84b057c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461784ea-06d6-4234-b4c9-df02d84b057c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1f6a954-cce3-4e2c-ad22-987f27249fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1f6a954-cce3-4e2c-ad22-987f27249fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4fecda66-0a9e-4a4d-94f2-b40aab9f317c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4fecda66-0a9e-4a4d-94f2-b40aab9f317c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6def5b83-57a0-43da-ac1d-70226119b5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_01cb99e2-4046-4494-b9fc-abdc7184d834" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6def5b83-57a0-43da-ac1d-70226119b5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFVNIAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_add8f29b-c00b-44bc-8826-361124c1213d" xlink:to="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_8cc4de75-21df-4a58-a6ea-dfc0b924b074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_8cc4de75-21df-4a58-a6ea-dfc0b924b074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_1c5ab593-3a63-4e5d-bd39-35394aec6b34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_1c5ab593-3a63-4e5d-bd39-35394aec6b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_aa7d2a49-ec71-4a40-8130-ab4abca7b7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_aa7d2a49-ec71-4a40-8130-ab4abca7b7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_952b9e61-3b39-4324-b36a-f4bf7a5e6ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFVNIAbstract_d3b595a0-070f-4de3-90ec-7948753d4190" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_952b9e61-3b39-4324-b36a-f4bf7a5e6ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#BalanceSheetAccountDetailInventoriesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cf5ddba-10c9-41c5-a758-d9bc3d78ab48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_7bbdf4ff-ba65-49e6-8f36-bac498d53443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cf5ddba-10c9-41c5-a758-d9bc3d78ab48" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_7bbdf4ff-ba65-49e6-8f36-bac498d53443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_374342f1-3687-4a2c-8f78-7cabb90b86f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cf5ddba-10c9-41c5-a758-d9bc3d78ab48" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_374342f1-3687-4a2c-8f78-7cabb90b86f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7d3286b4-94e4-4c8a-a033-7b3940c1b031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cf5ddba-10c9-41c5-a758-d9bc3d78ab48" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7d3286b4-94e4-4c8a-a033-7b3940c1b031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e26d8f8e-56a1-4d3c-83d5-6c36eeef54e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cf5ddba-10c9-41c5-a758-d9bc3d78ab48" xlink:to="loc_us-gaap_InventoryNet_e26d8f8e-56a1-4d3c-83d5-6c36eeef54e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbfcc55e-3672-4438-b64f-1e2910bec004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6037db1f-a869-4c4d-a45b-6c4e4c5a478d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbfcc55e-3672-4438-b64f-1e2910bec004" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6037db1f-a869-4c4d-a45b-6c4e4c5a478d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f87f5a4-22bf-41b3-b1ed-979db1ab770a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6037db1f-a869-4c4d-a45b-6c4e4c5a478d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f87f5a4-22bf-41b3-b1ed-979db1ab770a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f87f5a4-22bf-41b3-b1ed-979db1ab770a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_555cd4e8-4124-4abf-babe-960e275b4022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_555cd4e8-4124-4abf-babe-960e275b4022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_e1d67226-96d3-46ac-beff-ba3dd1452e63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:to="loc_us-gaap_OfficeEquipmentMember_e1d67226-96d3-46ac-beff-ba3dd1452e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_66393c08-8419-4e14-af26-1376a22e2481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_66393c08-8419-4e14-af26-1376a22e2481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_fcfd3a4a-87ea-400a-be45-210e26ba9bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_63483405-2be4-4fc3-a59c-201f050bb8cd" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_fcfd3a4a-87ea-400a-be45-210e26ba9bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6037db1f-a869-4c4d-a45b-6c4e4c5a478d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_464ed6f3-69dc-4d2f-bd21-9f65616fe400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_464ed6f3-69dc-4d2f-bd21-9f65616fe400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f6b935e-83ce-4a43-b758-b0833f7aea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f6b935e-83ce-4a43-b758-b0833f7aea7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_865485db-d9e0-41c5-a950-a1535adc236c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_865485db-d9e0-41c5-a950-a1535adc236c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_47fbef7d-e5f9-4b1b-b7b3-92efe1b5878a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac9ed1eb-4472-46e1-a47d-20d96b600e0a" xlink:to="loc_us-gaap_Depreciation_47fbef7d-e5f9-4b1b-b7b3-92efe1b5878a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22df2468-98b3-4ae3-86d9-aeb818336de8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_30927877-1f3b-4bf5-bc5e-5743b7911887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22df2468-98b3-4ae3-86d9-aeb818336de8" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_30927877-1f3b-4bf5-bc5e-5743b7911887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_7aa0e3e7-9cf7-4c1c-9735-2509d2fff6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22df2468-98b3-4ae3-86d9-aeb818336de8" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_7aa0e3e7-9cf7-4c1c-9735-2509d2fff6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent_6fda5fa9-9bec-464e-b336-5bc20f9727f7" xlink:href="tars-20240331.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22df2468-98b3-4ae3-86d9-aeb818336de8" xlink:to="loc_tars_AccruedClinicalStudiesCurrent_6fda5fa9-9bec-464e-b336-5bc20f9727f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b4978181-e559-4bc7-9789-484a150596c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22df2468-98b3-4ae3-86d9-aeb818336de8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b4978181-e559-4bc7-9789-484a150596c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_44b13837-3150-4ffb-92ec-1305c403285b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22df2468-98b3-4ae3-86d9-aeb818336de8" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_44b13837-3150-4ffb-92ec-1305c403285b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6442d28-0101-4778-995f-570bfab77ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_160a8f22-d625-40a4-8f58-621ff4d923ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6442d28-0101-4778-995f-570bfab77ed7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_160a8f22-d625-40a4-8f58-621ff4d923ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ee87988-699f-4abc-ac5c-1dc7508d3760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_160a8f22-d625-40a4-8f58-621ff4d923ec" xlink:to="loc_us-gaap_AwardTypeAxis_2ee87988-699f-4abc-ac5c-1dc7508d3760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81d0ded0-1e2d-4960-a8ac-d7daa0ce3ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2ee87988-699f-4abc-ac5c-1dc7508d3760" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81d0ded0-1e2d-4960-a8ac-d7daa0ce3ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_49c37a13-fb69-49bc-adaa-7eb7fde59772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81d0ded0-1e2d-4960-a8ac-d7daa0ce3ba9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_49c37a13-fb69-49bc-adaa-7eb7fde59772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c2648932-5835-446b-898e-d59aacb3d63f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81d0ded0-1e2d-4960-a8ac-d7daa0ce3ba9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c2648932-5835-446b-898e-d59aacb3d63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_cff73be5-85fc-46d0-9790-9d4f9b732954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81d0ded0-1e2d-4960-a8ac-d7daa0ce3ba9" xlink:to="loc_us-gaap_EmployeeStockMember_cff73be5-85fc-46d0-9790-9d4f9b732954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_160a8f22-d625-40a4-8f58-621ff4d923ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_af929f97-c085-43a4-aad8-7970de8913ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_af929f97-c085-43a4-aad8-7970de8913ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClassOfWarrantOrRightReservedForFutureIssuance_d846f242-9815-40ef-bab1-c515411425e8" xlink:href="tars-20240331.xsd#tars_ClassOfWarrantOrRightReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_tars_ClassOfWarrantOrRightReservedForFutureIssuance_d846f242-9815-40ef-bab1-c515411425e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_66e8c738-faa1-4687-b674-f859309f36d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_CommonStockSharesIssued_66e8c738-faa1-4687-b674-f859309f36d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockNumberOfVotes_2361a0eb-679d-4a39-a58d-6b78e80a31ec" xlink:href="tars-20240331.xsd#tars_CommonStockNumberOfVotes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_tars_CommonStockNumberOfVotes_2361a0eb-679d-4a39-a58d-6b78e80a31ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2187b5c7-a351-4358-aaaf-9846b08a1a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2187b5c7-a351-4358-aaaf-9846b08a1a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6caef0b9-4659-4e07-8831-6ab2e69124d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6caef0b9-4659-4e07-8831-6ab2e69124d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ab871711-ac1e-47f1-914c-f7e415855888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ab871711-ac1e-47f1-914c-f7e415855888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c8b9258d-641d-4952-820f-edf69bf355ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20135668-d76a-4210-859f-e760f993a345" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c8b9258d-641d-4952-820f-edf69bf355ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationSharesReservedforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4534c570-b98a-4eb2-9c7e-7405787e1152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_31bece5f-31c9-4321-97d8-f52e62a5bb8d" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4534c570-b98a-4eb2-9c7e-7405787e1152" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_31bece5f-31c9-4321-97d8-f52e62a5bb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_ac7e0b43-8f79-489f-af8f-f99b68d53bbc" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4534c570-b98a-4eb2-9c7e-7405787e1152" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_ac7e0b43-8f79-489f-af8f-f99b68d53bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_d4d2efcc-1096-4c07-b39d-5b05245e6cae" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4534c570-b98a-4eb2-9c7e-7405787e1152" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_d4d2efcc-1096-4c07-b39d-5b05245e6cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_035bf9e3-8316-4549-998f-43b7a8ab9049" xlink:href="tars-20240331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4534c570-b98a-4eb2-9c7e-7405787e1152" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_035bf9e3-8316-4549-998f-43b7a8ab9049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8e3dc337-c314-428b-9bfc-0d3d44d60bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4534c570-b98a-4eb2-9c7e-7405787e1152" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8e3dc337-c314-428b-9bfc-0d3d44d60bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7f1c0ed-8a9f-4828-b83e-8a678b45b1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_701c3eca-92a9-456f-9bd1-386c936b9405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7f1c0ed-8a9f-4828-b83e-8a678b45b1b8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_701c3eca-92a9-456f-9bd1-386c936b9405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4eb561b5-3879-4eb7-ba1a-b331b59388cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_701c3eca-92a9-456f-9bd1-386c936b9405" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4eb561b5-3879-4eb7-ba1a-b331b59388cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_56bf58c7-47e7-4154-a498-6762257c8338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4eb561b5-3879-4eb7-ba1a-b331b59388cc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_56bf58c7-47e7-4154-a498-6762257c8338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c24db05d-4301-485b-a0f1-2a4f911c42bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56bf58c7-47e7-4154-a498-6762257c8338" xlink:to="loc_us-gaap_CostOfSalesMember_c24db05d-4301-485b-a0f1-2a4f911c42bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0951a89e-41e0-49f7-8a6b-0e7bb3d0b83d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56bf58c7-47e7-4154-a498-6762257c8338" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0951a89e-41e0-49f7-8a6b-0e7bb3d0b83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7fe3e25d-a5c7-46a3-86bb-28a09890cb05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56bf58c7-47e7-4154-a498-6762257c8338" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7fe3e25d-a5c7-46a3-86bb-28a09890cb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb8af68-d03e-4008-a846-5dd31df5a99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_701c3eca-92a9-456f-9bd1-386c936b9405" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb8af68-d03e-4008-a846-5dd31df5a99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_72418f2f-a27b-40c4-a22e-32a40d2ae285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb8af68-d03e-4008-a846-5dd31df5a99a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_72418f2f-a27b-40c4-a22e-32a40d2ae285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationValuationAssumptionsofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a1d0d2d-5867-49be-8660-98a7e5e9c68e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a430087c-2ea3-479e-9eb9-affa1c681fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a1d0d2d-5867-49be-8660-98a7e5e9c68e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a430087c-2ea3-479e-9eb9-affa1c681fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ab20b257-b566-4ad9-bedf-f60a6c939e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a1d0d2d-5867-49be-8660-98a7e5e9c68e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ab20b257-b566-4ad9-bedf-f60a6c939e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_699daf80-2968-437a-91d7-26da4c3af113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a1d0d2d-5867-49be-8660-98a7e5e9c68e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_699daf80-2968-437a-91d7-26da4c3af113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ba4770eb-cc8a-4159-ad0e-d347a41fdbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a1d0d2d-5867-49be-8660-98a7e5e9c68e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ba4770eb-cc8a-4159-ad0e-d347a41fdbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc94b10c-55e7-4ec3-9806-d841620f03d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a1d0d2d-5867-49be-8660-98a7e5e9c68e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc94b10c-55e7-4ec3-9806-d841620f03d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6c3b420-776d-49b9-b19b-81d602d1531c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7ad75d-7cb0-44bf-9968-4d12af06bb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6c3b420-776d-49b9-b19b-81d602d1531c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7ad75d-7cb0-44bf-9968-4d12af06bb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3aa4c3b-5b3f-49e7-92cb-ca58f9077a10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7ad75d-7cb0-44bf-9968-4d12af06bb1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3aa4c3b-5b3f-49e7-92cb-ca58f9077a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a93814b1-606a-4e54-81ed-92505965ad94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7ad75d-7cb0-44bf-9968-4d12af06bb1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a93814b1-606a-4e54-81ed-92505965ad94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_90d9db6e-0394-48d9-b615-c49034389d69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7ad75d-7cb0-44bf-9968-4d12af06bb1e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_90d9db6e-0394-48d9-b615-c49034389d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5660bad2-6ef4-4ad9-8e27-826408520847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7ad75d-7cb0-44bf-9968-4d12af06bb1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5660bad2-6ef4-4ad9-8e27-826408520847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1fb2c76f-a8af-47ea-ad2f-6762b56047f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7ad75d-7cb0-44bf-9968-4d12af06bb1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1fb2c76f-a8af-47ea-ad2f-6762b56047f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_96cef690-d032-4db8-b684-2ac35087ebb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7b7ad75d-7cb0-44bf-9968-4d12af06bb1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_96cef690-d032-4db8-b684-2ac35087ebb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a859bb1f-cf68-4b71-be8d-92580b5681af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6c3b420-776d-49b9-b19b-81d602d1531c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a859bb1f-cf68-4b71-be8d-92580b5681af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_f4cd4225-52ff-4a0b-950e-f6fd7e1a39f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6c3b420-776d-49b9-b19b-81d602d1531c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_f4cd4225-52ff-4a0b-950e-f6fd7e1a39f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e33b01-3eed-4095-a2df-7c43db0c0be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6c3b420-776d-49b9-b19b-81d602d1531c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e33b01-3eed-4095-a2df-7c43db0c0be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4dc28384-6eb4-44f8-9efc-5835ebe411bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e33b01-3eed-4095-a2df-7c43db0c0be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4dc28384-6eb4-44f8-9efc-5835ebe411bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0e5b273c-3b6f-4e55-8677-6a9477b3e606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e33b01-3eed-4095-a2df-7c43db0c0be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0e5b273c-3b6f-4e55-8677-6a9477b3e606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637b4152-6f35-4bb6-951f-d549380d95f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e33b01-3eed-4095-a2df-7c43db0c0be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637b4152-6f35-4bb6-951f-d549380d95f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_690f08da-a666-4ec8-a492-a8a9fe91946d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e33b01-3eed-4095-a2df-7c43db0c0be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_690f08da-a666-4ec8-a492-a8a9fe91946d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4813ad81-15cc-4a0b-9119-447ca060c26f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e33b01-3eed-4095-a2df-7c43db0c0be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4813ad81-15cc-4a0b-9119-447ca060c26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7bc7e71-5177-48ce-b317-7b525ac5d454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e33b01-3eed-4095-a2df-7c43db0c0be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7bc7e71-5177-48ce-b317-7b525ac5d454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_75268eb4-0363-40ca-a035-a030ba18f52f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6c3b420-776d-49b9-b19b-81d602d1531c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_75268eb4-0363-40ca-a035-a030ba18f52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_26dee54b-56c6-4a7d-9ebf-a5ece9e1ddfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6c3b420-776d-49b9-b19b-81d602d1531c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_26dee54b-56c6-4a7d-9ebf-a5ece9e1ddfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_ec876186-76f5-4829-be9d-9242a98b5fcf" xlink:href="tars-20240331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6c3b420-776d-49b9-b19b-81d602d1531c" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_ec876186-76f5-4829-be9d-9242a98b5fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1bd92d95-0635-412d-b9c2-44f73377ba83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_ec876186-76f5-4829-be9d-9242a98b5fcf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1bd92d95-0635-412d-b9c2-44f73377ba83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6b6a0568-d915-4f7e-afdc-bf9bfa55c254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_ec876186-76f5-4829-be9d-9242a98b5fcf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6b6a0568-d915-4f7e-afdc-bf9bfa55c254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_e734c537-79ba-4c34-8fa7-4cac6b14d777" xlink:href="tars-20240331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_ec876186-76f5-4829-be9d-9242a98b5fcf" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_e734c537-79ba-4c34-8fa7-4cac6b14d777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_965d6f7e-5336-4245-9bc4-21a3af2602df" xlink:href="tars-20240331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6c3b420-776d-49b9-b19b-81d602d1531c" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_965d6f7e-5336-4245-9bc4-21a3af2602df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_39a80770-115b-4cd5-ae07-b6580902640e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_965d6f7e-5336-4245-9bc4-21a3af2602df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_39a80770-115b-4cd5-ae07-b6580902640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_14af1081-166b-4a02-8070-fb2baf9dd694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_965d6f7e-5336-4245-9bc4-21a3af2602df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_14af1081-166b-4a02-8070-fb2baf9dd694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_a8a25fba-89cf-40fc-bf38-8acc5600cb63" xlink:href="tars-20240331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_965d6f7e-5336-4245-9bc4-21a3af2602df" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_a8a25fba-89cf-40fc-bf38-8acc5600cb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec8b3946-934a-4b13-896a-0eea6aa013d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bbbfe46-c915-480b-b19e-f6f1b1162d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec8b3946-934a-4b13-896a-0eea6aa013d8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bbbfe46-c915-480b-b19e-f6f1b1162d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_778aa2a1-39e8-499b-b885-03572d087b25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bbbfe46-c915-480b-b19e-f6f1b1162d45" xlink:to="loc_us-gaap_AwardTypeAxis_778aa2a1-39e8-499b-b885-03572d087b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c027c488-18a8-45ff-80f9-04e77ea25b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_778aa2a1-39e8-499b-b885-03572d087b25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c027c488-18a8-45ff-80f9-04e77ea25b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b1c4c869-cb9b-4416-93e6-413bcb9bdfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c027c488-18a8-45ff-80f9-04e77ea25b8d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b1c4c869-cb9b-4416-93e6-413bcb9bdfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17f29ae-b3ef-421d-8550-33ef65a4f41b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bbbfe46-c915-480b-b19e-f6f1b1162d45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17f29ae-b3ef-421d-8550-33ef65a4f41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17f29ae-b3ef-421d-8550-33ef65a4f41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59549e31-d1bf-423f-9036-46ebc020d917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59549e31-d1bf-423f-9036-46ebc020d917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0b801bc-9dcc-49d2-8c25-91d10203be2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0b801bc-9dcc-49d2-8c25-91d10203be2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53234cb7-56b0-4644-89c9-54e968ad2dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53234cb7-56b0-4644-89c9-54e968ad2dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07a137d4-beb7-41ae-b836-29d7e39bffee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07a137d4-beb7-41ae-b836-29d7e39bffee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_467f5413-7a0f-4919-b664-a718e0db7506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_79d4a62a-3580-49f1-90b7-3c898bde77f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_467f5413-7a0f-4919-b664-a718e0db7506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17f29ae-b3ef-421d-8550-33ef65a4f41b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_376fc26e-3888-49b0-a7be-af90bb6e908b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_376fc26e-3888-49b0-a7be-af90bb6e908b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_77e9c731-adae-4bb2-8492-ad513a492530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_77e9c731-adae-4bb2-8492-ad513a492530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4dc73054-ebcb-47fb-b5ab-0dd955c45c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4dc73054-ebcb-47fb-b5ab-0dd955c45c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d287d7e0-7462-4f72-a328-eedb34dcb9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d287d7e0-7462-4f72-a328-eedb34dcb9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_275a2826-716f-4b92-ab44-5e810a574c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_abb43442-9e36-4d4f-8ea4-aab1614d17ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_275a2826-716f-4b92-ab44-5e810a574c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a304ac67-462b-4482-802a-4e3d8a01455a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_32edd7a6-2a15-4f68-87d9-d44b15977577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a304ac67-462b-4482-802a-4e3d8a01455a" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_32edd7a6-2a15-4f68-87d9-d44b15977577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15ce07f7-a736-40f7-9ea2-e1bf992051e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_32edd7a6-2a15-4f68-87d9-d44b15977577" xlink:to="loc_us-gaap_NetIncomeLoss_15ce07f7-a736-40f7-9ea2-e1bf992051e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_94b36758-9913-4fe9-8ebb-341d9d93533b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_32edd7a6-2a15-4f68-87d9-d44b15977577" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_94b36758-9913-4fe9-8ebb-341d9d93533b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9212fdd-1568-401b-a3fe-79c130a70940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_32edd7a6-2a15-4f68-87d9-d44b15977577" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9212fdd-1568-401b-a3fe-79c130a70940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5463c284-f7a9-460b-a11a-88b1a708cd45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_32edd7a6-2a15-4f68-87d9-d44b15977577" xlink:to="loc_us-gaap_EarningsPerShareBasic_5463c284-f7a9-460b-a11a-88b1a708cd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_30390b77-046e-4f7b-aa39-fcaac36e4092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_32edd7a6-2a15-4f68-87d9-d44b15977577" xlink:to="loc_us-gaap_EarningsPerShareDiluted_30390b77-046e-4f7b-aa39-fcaac36e4092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#NetLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8d3da73e-fea4-43ed-99bc-fca41fabbb39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a93082f5-dc29-4ecd-875d-65c2f9539d06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8d3da73e-fea4-43ed-99bc-fca41fabbb39" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a93082f5-dc29-4ecd-875d-65c2f9539d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ba1a6a-cc30-4ba3-8b99-d91146484458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a93082f5-dc29-4ecd-875d-65c2f9539d06" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ba1a6a-cc30-4ba3-8b99-d91146484458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c8c514a8-028f-4be6-9e36-8ac80b377dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ba1a6a-cc30-4ba3-8b99-d91146484458" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c8c514a8-028f-4be6-9e36-8ac80b377dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_357a6c7a-846e-4067-b5fb-2c888d550f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c8c514a8-028f-4be6-9e36-8ac80b377dc5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_357a6c7a-846e-4067-b5fb-2c888d550f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_8ace0588-3020-477a-94e6-db465e0a6b0f" xlink:href="tars-20240331.xsd#tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c8c514a8-028f-4be6-9e36-8ac80b377dc5" xlink:to="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_8ace0588-3020-477a-94e6-db465e0a6b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48640ada-e106-4ad8-b207-1e24f4694628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a93082f5-dc29-4ecd-875d-65c2f9539d06" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48640ada-e106-4ad8-b207-1e24f4694628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7740a183-dc82-4532-8d57-94b743fdcbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48640ada-e106-4ad8-b207-1e24f4694628" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7740a183-dc82-4532-8d57-94b743fdcbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingenciesLeaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78d64e80-0a2f-4aab-9ead-1503b8859a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2c0f0312-e7ac-4ca9-9720-45c790fa2a83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78d64e80-0a2f-4aab-9ead-1503b8859a8b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2c0f0312-e7ac-4ca9-9720-45c790fa2a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts_4a83f4fd-dc68-43de-83fc-bb123d29b3cd" xlink:href="tars-20240331.xsd#tars_LesseeOperatingLeaseNumberOfLeaseContracts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78d64e80-0a2f-4aab-9ead-1503b8859a8b" xlink:to="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts_4a83f4fd-dc68-43de-83fc-bb123d29b3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c9283fac-1041-4e11-9d23-5eb573c65f40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78d64e80-0a2f-4aab-9ead-1503b8859a8b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c9283fac-1041-4e11-9d23-5eb573c65f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4d814e17-6ff0-43d2-afc8-3b729c44aeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78d64e80-0a2f-4aab-9ead-1503b8859a8b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4d814e17-6ff0-43d2-afc8-3b729c44aeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingenciesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa9aeca9-5ae4-4810-adf1-a6bdb63ace8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_043d53f7-9563-45c5-88bf-88316a0dadde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa9aeca9-5ae4-4810-adf1-a6bdb63ace8d" xlink:to="loc_us-gaap_OperatingLeaseCost_043d53f7-9563-45c5-88bf-88316a0dadde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_bd79c624-e810-4169-b156-3c0415a0636c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa9aeca9-5ae4-4810-adf1-a6bdb63ace8d" xlink:to="loc_us-gaap_VariableLeaseCost_bd79c624-e810-4169-b156-3c0415a0636c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0080fcf1-db1d-4748-8434-e79212dc17fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa9aeca9-5ae4-4810-adf1-a6bdb63ace8d" xlink:to="loc_us-gaap_LeaseCost_0080fcf1-db1d-4748-8434-e79212dc17fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1e2ad47b-1574-4b76-94bd-82dacc2e6ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1e2ad47b-1574-4b76-94bd-82dacc2e6ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8fd31984-f0f2-4b34-bdde-bb7d35752a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8fd31984-f0f2-4b34-bdde-bb7d35752a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_46361c49-9bf1-4c4f-af0a-59da0e21bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_46361c49-9bf1-4c4f-af0a-59da0e21bd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7d988bba-46f9-4303-aa48-0c48c466ec74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7d988bba-46f9-4303-aa48-0c48c466ec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_40f422f0-2f52-4017-a0fd-e278b58900e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_40f422f0-2f52-4017-a0fd-e278b58900e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db929594-c2d6-4728-901d-3bc80fbcb15d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_db929594-c2d6-4728-901d-3bc80fbcb15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_433f5329-891e-46bc-b550-852bca835a92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_433f5329-891e-46bc-b550-852bca835a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_a7841ae3-bbc3-48f1-badc-c92ca5c79195" xlink:href="tars-20240331.xsd#tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_a7841ae3-bbc3-48f1-badc-c92ca5c79195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b666960e-1b9e-43ff-b24c-1f7c7caaf360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_OperatingLeaseLiability_b666960e-1b9e-43ff-b24c-1f7c7caaf360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ab3ed82-6705-4d75-bea8-966640a36407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ab3ed82-6705-4d75-bea8-966640a36407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fbb3cd3b-629d-4c41-bb77-4121fae752d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fbb3cd3b-629d-4c41-bb77-4121fae752d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7d275955-4e9f-4f86-a676-5f99f228d647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bff84b3-64ee-4c1f-83f7-16da7910b88c" xlink:to="loc_us-gaap_OperatingLeaseLiability_7d275955-4e9f-4f86-a676-5f99f228d647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingenciesInLicenseAgreementforLotilanerDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba5758aa-a98c-43f0-ac0b-b5e4760582f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba5758aa-a98c-43f0-ac0b-b5e4760582f8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_474bd3df-e77d-4ab4-903b-aff89c524c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:to="loc_us-gaap_TypeOfArrangementAxis_474bd3df-e77d-4ab4-903b-aff89c524c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7af5cda2-1345-4c4e-9c05-c409234f2501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_474bd3df-e77d-4ab4-903b-aff89c524c47" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7af5cda2-1345-4c4e-9c05-c409234f2501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_972213cf-ca1c-49aa-8b3a-a88180a7effb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7af5cda2-1345-4c4e-9c05-c409234f2501" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_972213cf-ca1c-49aa-8b3a-a88180a7effb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9f10576e-8486-4c17-8733-c3e93e3e823c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:to="loc_srt_ProductOrServiceAxis_9f10576e-8486-4c17-8733-c3e93e3e823c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_387ba7e7-198b-4db0-bb73-6bc978cfe3a7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9f10576e-8486-4c17-8733-c3e93e3e823c" xlink:to="loc_srt_ProductsAndServicesDomain_387ba7e7-198b-4db0-bb73-6bc978cfe3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember_1bcc9381-f9d6-41a8-96b6-5384cddb112b" xlink:href="tars-20240331.xsd#tars_ClinicalMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_387ba7e7-198b-4db0-bb73-6bc978cfe3a7" xlink:to="loc_tars_ClinicalMilestonesMember_1bcc9381-f9d6-41a8-96b6-5384cddb112b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember_be572b64-1dfa-4174-a7ae-0d7a14e9a939" xlink:href="tars-20240331.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_387ba7e7-198b-4db0-bb73-6bc978cfe3a7" xlink:to="loc_tars_CommercialAndSalesMilestonesMember_be572b64-1dfa-4174-a7ae-0d7a14e9a939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_26a113c9-0fd9-43ad-9745-cd5f3427e61c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:to="loc_srt_CounterpartyNameAxis_26a113c9-0fd9-43ad-9745-cd5f3427e61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b6ded23-b22a-45bc-b802-97faab8c1f89" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_26a113c9-0fd9-43ad-9745-cd5f3427e61c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b6ded23-b22a-45bc-b802-97faab8c1f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_31820307-570a-4eaa-951a-f3b163fa5cf8" xlink:href="tars-20240331.xsd#tars_ElancoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b6ded23-b22a-45bc-b802-97faab8c1f89" xlink:to="loc_tars_ElancoMember_31820307-570a-4eaa-951a-f3b163fa5cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_c82f1ab8-c952-4082-8b64-060f6cd513f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_c82f1ab8-c952-4082-8b64-060f6cd513f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_96f03869-8afe-49f7-9c61-4fc37be8cec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_c82f1ab8-c952-4082-8b64-060f6cd513f4" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_96f03869-8afe-49f7-9c61-4fc37be8cec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IntangibleAssetsMilestonePaymentMember_fdeaf0ea-ea58-4fce-8e99-b768d76b82d6" xlink:href="tars-20240331.xsd#tars_IntangibleAssetsMilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_96f03869-8afe-49f7-9c61-4fc37be8cec1" xlink:to="loc_tars_IntangibleAssetsMilestonePaymentMember_fdeaf0ea-ea58-4fce-8e99-b768d76b82d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86f2f26c-27ca-4de3-acae-7931caa98a23" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_5d2c38b5-8080-4f5e-a2fa-ca249fcf458b" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment_5d2c38b5-8080-4f5e-a2fa-ca249fcf458b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_3a52a699-33eb-4ba7-9c70-ff1e6cf5e0dd" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment_3a52a699-33eb-4ba7-9c70-ff1e6cf5e0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cf30ade8-e000-4a7c-a962-2f71c92213ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cf30ade8-e000-4a7c-a962-2f71c92213ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementFutureCashPayments_93c27623-b1b8-4a8b-a65f-88583e798b8b" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementFutureCashPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_tars_CollaborativeArrangementFutureCashPayments_93c27623-b1b8-4a8b-a65f-88583e798b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_826122d0-9ce4-4e3b-8081-a27541e1cfbd" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_826122d0-9ce4-4e3b-8081-a27541e1cfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_2e5b48bf-fe20-4695-8704-b2fbf7d9c2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_RoyaltyExpense_2e5b48bf-fe20-4695-8704-b2fbf7d9c2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e1597376-30f5-48e9-bead-d19704571934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e1597376-30f5-48e9-bead-d19704571934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_26cb311a-66f5-4062-9efc-ae10b1737296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_26cb311a-66f5-4062-9efc-ae10b1737296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_493dcea4-87ab-468a-990f-8d783bc9266e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2fc2c757-d366-48e5-b1f7-4af20f4804aa" xlink:to="loc_us-gaap_SharePrice_493dcea4-87ab-468a-990f-8d783bc9266e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CommitmentContingenciesEmploymentArrangementsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ae0b9130-83e5-4843-9176-ea7ab13bd7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_701f312a-3189-4631-bf43-3b6b57b5b660" xlink:href="tars-20240331.xsd#tars_NumberOfEmploymentArrangementsWithExecutiveOfficers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ae0b9130-83e5-4843-9176-ea7ab13bd7ac" xlink:to="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_701f312a-3189-4631-bf43-3b6b57b5b660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreementsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#OutLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_250764a3-a6b8-49c2-b0eb-e9fdbd6180e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_250764a3-a6b8-49c2-b0eb-e9fdbd6180e9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b4b466c9-20d4-481f-af75-8691b26a588b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_srt_CounterpartyNameAxis_b4b466c9-20d4-481f-af75-8691b26a588b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bba0197-8d38-48e7-af33-8bbb3a4658a7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b4b466c9-20d4-481f-af75-8691b26a588b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bba0197-8d38-48e7-af33-8bbb3a4658a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_5ccf2f5c-a5c8-40e5-ad17-6097a48ec2c0" xlink:href="tars-20240331.xsd#tars_LianBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bba0197-8d38-48e7-af33-8bbb3a4658a7" xlink:to="loc_tars_LianBioMember_5ccf2f5c-a5c8-40e5-ad17-6097a48ec2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_ed649fda-4c67-42dd-a6ec-a50ec233dcb0" xlink:href="tars-20240331.xsd#tars_ElancoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bba0197-8d38-48e7-af33-8bbb3a4658a7" xlink:to="loc_tars_ElancoMember_ed649fda-4c67-42dd-a6ec-a50ec233dcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_GrandpharmaMember_de5f366d-d8b3-4341-ba03-a84039b95e96" xlink:href="tars-20240331.xsd#tars_GrandpharmaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1bba0197-8d38-48e7-af33-8bbb3a4658a7" xlink:to="loc_tars_GrandpharmaMember_de5f366d-d8b3-4341-ba03-a84039b95e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_947a95bb-f465-4eab-8bc3-bcdfd2885885" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_947a95bb-f465-4eab-8bc3-bcdfd2885885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14ba3b5e-08b5-424d-847c-1e102c4ca0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_947a95bb-f465-4eab-8bc3-bcdfd2885885" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14ba3b5e-08b5-424d-847c-1e102c4ca0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d0d2b3e1-40ff-45f2-97a1-ce03879fed23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14ba3b5e-08b5-424d-847c-1e102c4ca0f4" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d0d2b3e1-40ff-45f2-97a1-ce03879fed23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_149afcd6-23c6-47b5-8563-3e534ef74330" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_srt_ProductOrServiceAxis_149afcd6-23c6-47b5-8563-3e534ef74330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cffb0464-5b1f-4cb0-a62c-ce6daeeff906" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_149afcd6-23c6-47b5-8563-3e534ef74330" xlink:to="loc_srt_ProductsAndServicesDomain_cffb0464-5b1f-4cb0-a62c-ce6daeeff906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_MilestoneDeterminedByTheCompanyMember_540990d2-fea1-4053-99f8-32ee10fd0906" xlink:href="tars-20240331.xsd#tars_MilestoneDeterminedByTheCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cffb0464-5b1f-4cb0-a62c-ce6daeeff906" xlink:to="loc_tars_MilestoneDeterminedByTheCompanyMember_540990d2-fea1-4053-99f8-32ee10fd0906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember_a4325d16-4d40-4ec2-86ae-23042975e0c1" xlink:href="tars-20240331.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cffb0464-5b1f-4cb0-a62c-ce6daeeff906" xlink:to="loc_tars_DevelopmentAndRegulatoryMilestoneMember_a4325d16-4d40-4ec2-86ae-23042975e0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fbc6c635-2c93-4361-89f4-0555e0fa3889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fbc6c635-2c93-4361-89f4-0555e0fa3889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fd842751-5131-4906-bdae-097125176aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fbc6c635-2c93-4361-89f4-0555e0fa3889" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fd842751-5131-4906-bdae-097125176aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_07d43e73-61fc-465a-9383-43a1e4aee415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fd842751-5131-4906-bdae-097125176aaa" xlink:to="loc_us-gaap_SubsequentEventMember_07d43e73-61fc-465a-9383-43a1e4aee415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_93a1c5c6-d109-4576-bedd-069844fb6846" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_dei_LegalEntityAxis_93a1c5c6-d109-4576-bedd-069844fb6846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4fe49de3-235d-48d8-9069-debc038f89b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_93a1c5c6-d109-4576-bedd-069844fb6846" xlink:to="loc_dei_EntityDomain_4fe49de3-235d-48d8-9069-debc038f89b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_33db2909-5e36-470b-911d-addbd855cdf3" xlink:href="tars-20240331.xsd#tars_LianBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4fe49de3-235d-48d8-9069-debc038f89b7" xlink:to="loc_tars_LianBioMember_33db2909-5e36-470b-911d-addbd855cdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b1c779c7-4f1c-4463-8582-d911d653adbc" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f4d1ffad-12f2-4ffb-b856-e03eb91314ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f4d1ffad-12f2-4ffb-b856-e03eb91314ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_f09f324c-ae8f-4529-9032-ecb086e55742" xlink:href="tars-20240331.xsd#tars_RevenueRemainingPerformanceObligationAdditionalCashPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment_f09f324c-ae8f-4529-9032-ecb086e55742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_784edf32-176d-4209-8fa9-71649420da18" xlink:href="tars-20240331.xsd#tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount_784edf32-176d-4209-8fa9-71649420da18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_37599b50-78a8-486c-8628-3befad993dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_37599b50-78a8-486c-8628-3befad993dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d77dcc33-4e91-4807-b5e7-bddda6866b00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d77dcc33-4e91-4807-b5e7-bddda6866b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_TerminationPaymentPeriodDue_1e527884-03bb-4c41-8830-a815624ecd1d" xlink:href="tars-20240331.xsd#tars_TerminationPaymentPeriodDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_TerminationPaymentPeriodDue_1e527884-03bb-4c41-8830-a815624ecd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7113b2f7-86e8-4b9b-9b5a-5da62b6ffe18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7113b2f7-86e8-4b9b-9b5a-5da62b6ffe18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f289e0f6-3217-4476-9848-c8dd692fdeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f289e0f6-3217-4476-9848-c8dd692fdeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromCancellationOfWarrants_f504a64e-7647-4f54-bc06-8768e464d625" xlink:href="tars-20240331.xsd#tars_ProceedsFromCancellationOfWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_ProceedsFromCancellationOfWarrants_f504a64e-7647-4f54-bc06-8768e464d625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2a12b545-7531-43bd-b18c-715d8e775615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2a12b545-7531-43bd-b18c-715d8e775615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1db08970-eb83-4cb7-8c05-958a4868591d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1db08970-eb83-4cb7-8c05-958a4868591d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_1b0cf267-67ab-4560-a689-223f9a2ca224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_us-gaap_DividendsCommonStockCash_1b0cf267-67ab-4560-a689-223f9a2ca224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_ef135890-9f47-4fc2-babb-f59a3c9ae97c" xlink:href="tars-20240331.xsd#tars_UpfrontPayment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_UpfrontPayment_ef135890-9f47-4fc2-babb-f59a3c9ae97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_218a5f2f-773b-402a-b66b-aa93d525eb93" xlink:href="tars-20240331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91e27622-f901-4448-9c7d-d6c76ff392f3" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_218a5f2f-773b-402a-b66b-aa93d525eb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CreditFacilityAgreementDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_16cafeb0-6a02-4d11-9f2f-6600c4c526c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_16cafeb0-6a02-4d11-9f2f-6600c4c526c8" xlink:to="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6ee1accb-77e6-4abf-a18a-174cd799705b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6ee1accb-77e6-4abf-a18a-174cd799705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ce5ac0e8-ffee-46b3-ac20-8a6418d26860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6ee1accb-77e6-4abf-a18a-174cd799705b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ce5ac0e8-ffee-46b3-ac20-8a6418d26860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b48082db-5feb-4cad-9400-b1466ade805f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ce5ac0e8-ffee-46b3-ac20-8a6418d26860" xlink:to="loc_us-gaap_LineOfCreditMember_b48082db-5feb-4cad-9400-b1466ade805f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditSVBMember_61671e6f-0585-44ec-b1ec-a205497b14df" xlink:href="tars-20240331.xsd#tars_LineOfCreditSVBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ce5ac0e8-ffee-46b3-ac20-8a6418d26860" xlink:to="loc_tars_LineOfCreditSVBMember_61671e6f-0585-44ec-b1ec-a205497b14df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5edcbc91-537d-4b30-b19f-f9a599a2cef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:to="loc_us-gaap_DebtInstrumentAxis_5edcbc91-537d-4b30-b19f-f9a599a2cef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5edcbc91-537d-4b30-b19f-f9a599a2cef9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheOneMember_d7d427cc-540b-43d6-938a-fbea1b8cca5e" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:to="loc_tars_CreditFacilityTrancheOneMember_d7d427cc-540b-43d6-938a-fbea1b8cca5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheTwoMember_851fc337-68c8-4071-8ad0-7bfb374d0df5" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:to="loc_tars_CreditFacilityTrancheTwoMember_851fc337-68c8-4071-8ad0-7bfb374d0df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheThreeMember_211a4fa2-c824-4a74-a21c-2bb717101348" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:to="loc_tars_CreditFacilityTrancheThreeMember_211a4fa2-c824-4a74-a21c-2bb717101348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFourMember_780f4995-307f-48d2-9944-4865dc536e90" xlink:href="tars-20240331.xsd#tars_CreditFacilityTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:to="loc_tars_CreditFacilityTrancheFourMember_780f4995-307f-48d2-9944-4865dc536e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember_b0a3d504-75f6-4c35-be21-c91bb2a44822" xlink:href="tars-20240331.xsd#tars_CreditFacilityFirstAmendmentTrancheTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9af779d0-14df-40c7-a3c0-56bc549b9d0a" xlink:to="loc_tars_CreditFacilityFirstAmendmentTrancheTwoMember_b0a3d504-75f6-4c35-be21-c91bb2a44822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6d1eabe4-ef42-4edd-8102-5e5341b69bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:to="loc_us-gaap_VariableRateAxis_6d1eabe4-ef42-4edd-8102-5e5341b69bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0f13a6cf-eda4-4a5c-8011-16c115ba83d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_6d1eabe4-ef42-4edd-8102-5e5341b69bbe" xlink:to="loc_us-gaap_VariableRateDomain_0f13a6cf-eda4-4a5c-8011-16c115ba83d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_dd713d54-3802-4921-8f53-e48e066bef04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0f13a6cf-eda4-4a5c-8011-16c115ba83d2" xlink:to="loc_us-gaap_PrimeRateMember_dd713d54-3802-4921-8f53-e48e066bef04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a4f2c0d-5e98-4949-bb8f-53c54644c28d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:to="loc_srt_RangeAxis_0a4f2c0d-5e98-4949-bb8f-53c54644c28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab088684-f6cc-40f9-8bad-5db14fda1712" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0a4f2c0d-5e98-4949-bb8f-53c54644c28d" xlink:to="loc_srt_RangeMember_ab088684-f6cc-40f9-8bad-5db14fda1712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f80db418-bb48-4af6-ad20-0c4e71176cc1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab088684-f6cc-40f9-8bad-5db14fda1712" xlink:to="loc_srt_MaximumMember_f80db418-bb48-4af6-ad20-0c4e71176cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_97f8c01c-c529-426a-9288-3de65d180062" xlink:to="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_7401b8d0-bfa5-435e-9475-0dcbef530235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_7401b8d0-bfa5-435e-9475-0dcbef530235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0d5a0c7b-4014-4728-9d71-c34057c431e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0d5a0c7b-4014-4728-9d71-c34057c431e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements_c3514d38-a40b-4ee4-974d-5678b5926bcc" xlink:href="tars-20240331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_tars_LineOfCreditFacilityDrawDownIncrements_c3514d38-a40b-4ee4-974d-5678b5926bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a7ee938f-0d72-4d6e-912e-32894d2c54c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a7ee938f-0d72-4d6e-912e-32894d2c54c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_179a7b81-4a95-40c5-b6dc-7d711954a1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_179a7b81-4a95-40c5-b6dc-7d711954a1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_2638f136-e062-4ba1-8d16-bcb1a8c421a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_2638f136-e062-4ba1-8d16-bcb1a8c421a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_e22f25d0-b3d8-4d79-96bd-baa41e6b21d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_e22f25d0-b3d8-4d79-96bd-baa41e6b21d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_ea19f36f-aae3-473e-9e2a-eed4e4148115" xlink:href="tars-20240331.xsd#tars_LineOfCreditFacilityPeriodicPaymentInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_ea19f36f-aae3-473e-9e2a-eed4e4148115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0460e500-13c5-43d6-bdd9-30c17c3de49d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0460e500-13c5-43d6-bdd9-30c17c3de49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2c835e7a-dfd5-489c-86c3-195a58f54253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63c89ab8-6c94-4d5d-a19a-3676f62acc83" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2c835e7a-dfd5-489c-86c3-195a58f54253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CreditFacilityAgreementSummaryofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2cbb3fcb-824f-47c2-9d72-780a7cc96103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_0e5ef907-15f8-435d-b0a7-11b0caf7192f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2cbb3fcb-824f-47c2-9d72-780a7cc96103" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_0e5ef907-15f8-435d-b0a7-11b0caf7192f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_70bfdda7-0a09-4f0e-a9dc-433eae645be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2cbb3fcb-824f-47c2-9d72-780a7cc96103" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_70bfdda7-0a09-4f0e-a9dc-433eae645be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_07806748-7e3b-4b44-80ea-3c0543f907fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2cbb3fcb-824f-47c2-9d72-780a7cc96103" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_07806748-7e3b-4b44-80ea-3c0543f907fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_370a4c2b-3026-477f-93bd-b2d91f185ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2cbb3fcb-824f-47c2-9d72-780a7cc96103" xlink:to="loc_us-gaap_InterestExpenseDebt_370a4c2b-3026-477f-93bd-b2d91f185ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_982a0c95-b338-4129-b411-c5614865dde2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3b214216-3462-4ae0-9a1c-01493920681b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_982a0c95-b338-4129-b411-c5614865dde2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3b214216-3462-4ae0-9a1c-01493920681b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_3337939c-cd2d-4b3b-bd1d-2c54186b59f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_982a0c95-b338-4129-b411-c5614865dde2" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_3337939c-cd2d-4b3b-bd1d-2c54186b59f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_7ba794d8-c246-442a-aa7a-234afb5e25f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_982a0c95-b338-4129-b411-c5614865dde2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_7ba794d8-c246-442a-aa7a-234afb5e25f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_5a869d7f-8d05-4ad6-bc8e-1a1337891e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_982a0c95-b338-4129-b411-c5614865dde2" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_5a869d7f-8d05-4ad6-bc8e-1a1337891e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0a1aa0ea-8a75-45cd-be70-241d24cc00c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_982a0c95-b338-4129-b411-c5614865dde2" xlink:to="loc_us-gaap_LongTermDebt_0a1aa0ea-8a75-45cd-be70-241d24cc00c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8165c58d-c7a0-459f-946a-ae1471505530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d460d98c-4acf-44e1-adf5-98bc5c824bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8165c58d-c7a0-459f-946a-ae1471505530" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d460d98c-4acf-44e1-adf5-98bc5c824bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f45310c0-d454-4877-9aec-af788c9aac6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d460d98c-4acf-44e1-adf5-98bc5c824bb2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f45310c0-d454-4877-9aec-af788c9aac6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a10914e0-2e60-447a-8ab0-99a0e9cdd1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f45310c0-d454-4877-9aec-af788c9aac6b" xlink:to="loc_us-gaap_RelatedPartyDomain_a10914e0-2e60-447a-8ab0-99a0e9cdd1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_50112458-7dd0-4e24-ba6b-76af7c395716" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a10914e0-2e60-447a-8ab0-99a0e9cdd1c0" xlink:to="loc_srt_DirectorMember_50112458-7dd0-4e24-ba6b-76af7c395716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_189b1570-7e1b-4f4b-b3a3-2c577ca44c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a10914e0-2e60-447a-8ab0-99a0e9cdd1c0" xlink:to="loc_us-gaap_RelatedPartyMember_189b1570-7e1b-4f4b-b3a3-2c577ca44c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f9210f6-ab15-4ddb-a8c8-29cc3453a7af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d460d98c-4acf-44e1-adf5-98bc5c824bb2" xlink:to="loc_srt_RangeAxis_2f9210f6-ab15-4ddb-a8c8-29cc3453a7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1fffa57c-c2b0-4929-88d3-2d00995d8b84" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f9210f6-ab15-4ddb-a8c8-29cc3453a7af" xlink:to="loc_srt_RangeMember_1fffa57c-c2b0-4929-88d3-2d00995d8b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_acfe5593-4bfe-4875-8c0f-2682ef4a597e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1fffa57c-c2b0-4929-88d3-2d00995d8b84" xlink:to="loc_srt_MinimumMember_acfe5593-4bfe-4875-8c0f-2682ef4a597e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_45b2e140-3c33-4165-a8c1-56b696287b25" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1fffa57c-c2b0-4929-88d3-2d00995d8b84" xlink:to="loc_srt_MaximumMember_45b2e140-3c33-4165-a8c1-56b696287b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d460d98c-4acf-44e1-adf5-98bc5c824bb2" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RelatedPartyTransactionAnnualCashCompensation_d910e2fd-dca7-4f7b-8c5a-4e31add989c5" xlink:href="tars-20240331.xsd#tars_RelatedPartyTransactionAnnualCashCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_tars_RelatedPartyTransactionAnnualCashCompensation_d910e2fd-dca7-4f7b-8c5a-4e31add989c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9ab0ba24-e0f1-432f-9a61-a48e789253d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9ab0ba24-e0f1-432f-9a61-a48e789253d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1e89516d-7451-4552-bbdd-4beab07a1a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1e89516d-7451-4552-bbdd-4beab07a1a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_RelatedPartTransactionTerminationNoticePeriod_8f569c34-4a43-444c-bb9d-05ebe847a9e8" xlink:href="tars-20240331.xsd#tars_RelatedPartTransactionTerminationNoticePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_tars_RelatedPartTransactionTerminationNoticePeriod_8f569c34-4a43-444c-bb9d-05ebe847a9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e45cafa1-fda1-49ab-af0f-2756cbe80a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4fa28f8-99b7-4477-a80c-7be7f29bcb52" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e45cafa1-fda1-49ab-af0f-2756cbe80a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="tars-20240331.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_584b0ce2-6919-49c4-b9fb-3ee35974a90a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_584b0ce2-6919-49c4-b9fb-3ee35974a90a" xlink:to="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5ca565ed-9e37-4f05-9ca6-36d0f4b30742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5ca565ed-9e37-4f05-9ca6-36d0f4b30742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_54134e9b-d2a1-4d87-8936-de5b30a0c070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5ca565ed-9e37-4f05-9ca6-36d0f4b30742" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_54134e9b-d2a1-4d87-8936-de5b30a0c070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_aee5eeba-bd52-4787-8a70-3a822376ad2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_54134e9b-d2a1-4d87-8936-de5b30a0c070" xlink:to="loc_us-gaap_SubsequentEventMember_aee5eeba-bd52-4787-8a70-3a822376ad2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b380e7c1-4f59-40ad-beaa-25c7edf51155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:to="loc_us-gaap_DebtInstrumentAxis_b380e7c1-4f59-40ad-beaa-25c7edf51155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_285fea64-c19c-4094-84c1-955e983feba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b380e7c1-4f59-40ad-beaa-25c7edf51155" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_285fea64-c19c-4094-84c1-955e983feba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_285fea64-c19c-4094-84c1-955e983feba5" xlink:to="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheOneMember_6aada130-5e33-4464-9117-f32e0d49c114" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:to="loc_tars_PharmakonCreditFacilityTrancheOneMember_6aada130-5e33-4464-9117-f32e0d49c114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheTwoMember_8705f744-2f75-45a8-a1c7-a11b360b0ab4" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:to="loc_tars_PharmakonCreditFacilityTrancheTwoMember_8705f744-2f75-45a8-a1c7-a11b360b0ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheThreeMember_04c39a69-836f-4be8-950c-a14f324a57e1" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:to="loc_tars_PharmakonCreditFacilityTrancheThreeMember_04c39a69-836f-4be8-950c-a14f324a57e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PharmakonCreditFacilityTrancheFourMember_722c533e-c9e7-4723-a2f7-de3b43ced3c6" xlink:href="tars-20240331.xsd#tars_PharmakonCreditFacilityTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_PharmakonCreditFacilityMember_47053513-c9f9-4bb2-879f-3df7234645e0" xlink:to="loc_tars_PharmakonCreditFacilityTrancheFourMember_722c533e-c9e7-4723-a2f7-de3b43ced3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_49743f69-a4ee-43af-bb3d-cfeda18ad84f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_49743f69-a4ee-43af-bb3d-cfeda18ad84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8a51d35e-7bd5-411f-ba41-1bb2b4e954dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_49743f69-a4ee-43af-bb3d-cfeda18ad84f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8a51d35e-7bd5-411f-ba41-1bb2b4e954dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6d7a7f59-ec8a-4056-a1dd-b0ec3f40b8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8a51d35e-7bd5-411f-ba41-1bb2b4e954dc" xlink:to="loc_us-gaap_LineOfCreditMember_6d7a7f59-ec8a-4056-a1dd-b0ec3f40b8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bd9962d5-e0b3-4cbe-8e51-06da2fbe3ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:to="loc_us-gaap_VariableRateAxis_bd9962d5-e0b3-4cbe-8e51-06da2fbe3ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ec4d5b17-331b-4565-a0e6-8c54f473939b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_bd9962d5-e0b3-4cbe-8e51-06da2fbe3ea6" xlink:to="loc_us-gaap_VariableRateDomain_ec4d5b17-331b-4565-a0e6-8c54f473939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80f19217-42ba-498f-825f-737df6531b41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ec4d5b17-331b-4565-a0e6-8c54f473939b" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80f19217-42ba-498f-825f-737df6531b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_14ef90e7-b712-4054-96d0-1aac51bde9aa" xlink:to="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_ec9a737f-e99a-4230-b821-df3cb88e3c00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_ec9a737f-e99a-4230-b821-df3cb88e3c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_cbbfd739-9143-428a-94d7-e221309f5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_cbbfd739-9143-428a-94d7-e221309f5bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtInstrumentNumberOfPotentialAdditionalTranches_9ddb7f3b-3841-4941-b259-efaa7c943197" xlink:href="tars-20240331.xsd#tars_DebtInstrumentNumberOfPotentialAdditionalTranches"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_tars_DebtInstrumentNumberOfPotentialAdditionalTranches_9ddb7f3b-3841-4941-b259-efaa7c943197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e170842a-fede-4cda-bcb3-98fa8596480d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e170842a-fede-4cda-bcb3-98fa8596480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements_b75bdbcb-3c6b-4e01-a2aa-410f9ab7a4b9" xlink:href="tars-20240331.xsd#tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements_b75bdbcb-3c6b-4e01-a2aa-410f9ab7a4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2722ab0b-b47e-47e2-9247-29f8442873fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2722ab0b-b47e-47e2-9247-29f8442873fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DebtInstrumentFloorInterestRate_f61ebb37-e277-4e54-af26-eda7df02f1aa" xlink:href="tars-20240331.xsd#tars_DebtInstrumentFloorInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_tars_DebtInstrumentFloorInterestRate_f61ebb37-e277-4e54-af26-eda7df02f1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_d4d57396-0452-4ae1-bd4c-a71685969dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a45e30a-fd32-4ad2-b82b-72baffdafed7" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_d4d57396-0452-4ae1-bd4c-a71685969dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_BobakAzamianMember" xlink:href="tars-20240331.xsd#tars_BobakAzamianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_tars_BobakAzamianMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_JoseTrevejoMember" xlink:href="tars-20240331.xsd#tars_JoseTrevejoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_tars_JoseTrevejoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>josetrevejo-tarsussepara001.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*Y_P"/6;_</\J\A\!&
MT_X031M_Q(GT]OLPS:+/9@1=?EP\9;\S7L9 (P>16;_PCNB?] ?3_P#P&3_"
M@#@?'CS76H63^%9I;C6#8.UY-:.I,E@1SR.#(6_U>.^[MFGPV7A_4_&?@Q=/
MMX)]'31KE[6,KE,!H0,@]QD]><^XKT>"SM;4DV]M#"2JJ?+0+D+P!QV':DBL
MK2!E:*UAC9 P4I& 5W'+8^IY/K0!Y$(8[:26V@C6*"+Q]"(XT&%0%$) '89)
M/XUK6J>&V^)/CG^WA8E@EKC[9MP(O(7?MW?AG'^S[5Z/]BM22?LT.3()B?+'
MW_[W^][]:BN=)TV]+&ZT^TG+,')EA5LL!@'D=0.* /+? *SMJ7@I;L.2?#MV
M )1R8_.BV9S_ +&VNE^%2V,?ABXBMEMTN$U"[6=8PH=<7$FT,!STZ9[5VOD0
M^<LWE1^:BE%?:,A3U /IP/RID%E:6TTTUO:PQ2SMNE>.,*9#ZL1U//>@#BOB
M=JFGP:196LU_:QW U2QD,3S*'""=26P3G& >?:DMM7TVT^)]]>S:A:BSU+2H
M?LER9E\MS%)()$5LX)&Y2178W.DZ;>R^;=:?:3R8QOEA5CCTR122:/IDUFEG
M)IMF]JAW+"T"E%/J%Q@&@#DO &H6@CU*5KB-5UG6;RYTY6;!N(EV@L@[CY2W
MT.:K-X@T?_A;IFCU73V3^PO*5C=(%,GGYV9SU]NM=]]EM]\+^1%NA!$1V#,8
M(P0OIQZ53&@:,'WC2+#=G.?LR9S^5 'E"Z#]K*;/"&A_\3'6RL>+C[JV^=R#
M]SPA^SMSWW].:]BM(5M[."%(8X%CC51%']U !]T<#@=.@IRV\*;-L,:["2F%
M VYZX],U)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "L;1_"NCZ#?W]]IMM)#<W[^9=.9Y'\ULDY(9B,\G\ZV:* "BBB@
MHHHH **** "BBB@ ILD:2Q/'(BO&X*LK#((/4&G44 8L'A/1[>WBMD@F-K"5
M,=M)=2O"NTY4"-F*X! P,8&!BMJBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)94W#!VL 1G\#0!/1110 454?4$35HM/,%P7DA:82B(F(!2!@OT#<\#V-6Z
M"BBB@ HHHH **** "BBB@ HHHH ***0LH8*6 8]!GDT +115!=8LW8!)"X:?
M[.C*I(>09W*OKMVG)Z#!YX. "_14,%W#<O,L+%O)?8[ '&[N >^.^.AXZU!J
M>JV6CVR3WTZPI)*D"9ZO([!54#N230!=HHHH **** "BBB@ HHHH ***Q+KQ
M9H]GJMUILT\@NK:T:]D40NP,2_>VD##$>@YH VZ*RM+\1Z9J\5I+:3,4O(S)
M;ET*^8 <,!G^('J.HK3=@B,Y!(49.T$G\ .30 ZBL[0];L_$.DQZG8&0VTCN
MBF1"C91RAR#R.5-:- !12;E+E-PW 9(SR!_D&EH **** "BBB@ HILCB.-G(
M8A1G"J2?P ZUFZ%XAT[Q)9->:7+)+;J[1EWA>/Y@<$#<!G!&* -2BBB@ HJE
MINJV^K1W$EJ)3'#.]N7="H9D.UMN>HR",].#4&O^(=-\,Z8VI:M,\%FA >58
M7D"Y( SM!QR0* -2BF12I-$DL3J\;J&5E.00>A%9FA>)=*\2PSSZ1<M<PPRM
M"\HB95WKU ) #?49% &M117,MX]T%6LU+WX-ZQ6U_P");<?OB!GY/D^;CGCM
M0!TU%4M,U6UU:"26U\[$4AB=9H'B=6 !P5< ]"#T[U=H **** "BJE]J"6#6
MH>"YE^TSK OD1%]A()W-C[J\<D\#BK= !1156?4;:WN5MY)!YI0RL/[B#JS'
ML/K_ $- %JBJD>I6TK6RHS[[E#)$I0@E1C+$=AR.OJ*MT %%%% !169JGB#3
MM&N]/M;Z5XY-0F\BW(C9E+\  D#"Y) &>YJM9>+M'OS<>3/(%M[LV<S21,@C
MES@ Y X)X!Z$\9S0!N4444 %%%% !16;HVNV6O1WCV7F[;2Z>TE\V,H1(N-P
MP>>]0:IXITO1YKB*[-WFW@%Q,T5G+*D<?S<LR*0/NMW[4 ;-%8NF>*M+U>:V
MBM&N\W,/GP-+9S1)(G!RK.H!X8'KWK:H **** "BBB@ HK&U/Q3I>CZI:Z;=
MM<_:[L,;>**TEE,@49;&Q3T!YJK-XYT"+19-62ZDFMHK@6THCA??%*6"[74@
M%#DC[V.M '1T444 %%%% !1110 4444 %%%4[W4HK**WD,4\ZSSI OV>(R;2
MQQN;'11W/:@"Y1110 45F'7;(>)%T'][]N:V:Z ,9">6&53\QX)RPX%:= !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !2%%+!BH++G!QR*6D8$J0&*DCJ.HH X;X;(LD/BY74
M,I\2WN01D'E:YAKS5='\/^,=<T_4Y+<V/B*9_LZQ(R3 O$&#E@3@@\;2N/?M
MZ3H/ANU\/?;OLD]RXO;E[N83,&S*^-S# &,X''3VK/E\"Z;/H^J:7)<WK6NJ
M7)NKH>8H+2$@D@[> 2J\#T^M &?J&HZ[K6K>(M.T6Y:UN-,\N* JT8!D:(2!
MI RL2I+;<#'"GOTZ_3GNI-,M7O1"+MH4,P@;<F_ W;3W&<XK!U+P-IVHZRNK
M?;-2M+XQ+#<2V5T8#<H.@DVXS]1@_I720PQV\$<$*!(HU"(BCA0!@ 4 >=PR
MRZ1X]\<ZH]Y=3)8Z=:W+0XCQ( D[!#\F<#'&,'GDFI)M>UG3] \+>(SJ#72Z
MG/:QWEH8T$>VX YCP-P*EAC).1UR>:ZNW\-VEOKNH:MYUQ)-J$:17$<A4QNB
M A5V[> -Q^N><U6T_P &Z=IT=I;QRW4ME92^=:6<T@:.!N<%>-QQDX#$@=N@
MP <I-]WXL?\ 7/\ ]L5J[HNK7-U>^'?#,-S):1?\(]'?RRQ!=\GW(U4%@0 .
M2>,_=]\[[>$;%O[<S<W?_$[&+SYUY&S9\OR_+\HV_P#U^:&\(6&W2FBN+N"[
MTN+R;6[C9?,$> "C94JRX Z@],]>: .0N/$OB*'P]J]R;Z0R^&]7\J[DCACS
M>68*,Q(*D*X1\G;C[OO5K_A*KV'Q3KMC_:$T]M<6JOHK%(PC2Y$;HK!?FQ(Z
M#G..>N,UVEKH=C::;<6"Q&2*Z,C7)D.6F9_OLQ[D_D!@#  %5(/".C6\>AHE
MM_R! 19DG)7*%#GUSU^H!H RS=ZK;?$#3=%?599K671YI7W11@F5'C42<+U^
M8\=/:N9T[7O$?_"->'-=N-<DF>XUH6$]N8(ECEB:Y>+)PN=P &""!QTZD^@7
M'A^WN/$,.N&XN4O(;=[:/:R[0C$$\$'N ?PK-3P)IL>BV>DI=7PM;.\%["/,
M7<)0YD!SMY&XDX]_2@# \0>(M:BD\5107LEGJ-@8CI-HD:M]J5E!! ()?<VY
M3C[N!T.2>_L4G2Q@6ZD:2<(/,=@H);O]T ?E7G5QIMY+XCU:2XA\7V-Q<71,
M9TJX4V\R*JHCY)VJQ51D';CIVKT#28KR#2;6*_F,UVD8$LAQEC[X !/J0!GT
M% '"^(/$6KZ?-=7=MJ33B#6;>V\N")/L\4+O&ABD+#)D^9B=I.#CITJ?Q#X@
MU2#4O%%JM\]A-8V44VDQI&K?:G*L3PP)<EP$VC^9S6I=?#S1[L7Z-/J"0WMV
M+UX8[HJB3A@Q=1V)*@\Y'IBL"_TRY?Q1J3SP>+;-I&CCMY=)N=T,\2( K,6)
MP^=V=V.W7DD L7,_B>77O#NCMKL]G)J&EW$UT1;Q,T<J^61CY<<%R/3 ]>:4
MW_BC6X-731;[;>:9>?8XFD,:QR-&J%C*NTGY\L?E(P",="3N:;X9D-SI6JZG
M?7DNIV,4D4;.Z?ZMVSM?:N&;:$!([KD4E[X$TJ[UZ;5UGU"UEN@HO(;2Z:**
MZP,#S%'7CCC&10!D3ZIXB\07&NVVC7 M;O3FCA@"21F,R&))-S[E)9"7*\8X
M&1S3DN=?U'QK)HTNM/9Q/H<-XPM(XV\N9I&5MC,IROR]P?PK6U'P+I>H:X=7
MCN-0L;J2-8KC[!=- MRB\*) O7 XR,''>KJ>&K2'76U>">XAN3:+9*J%=B1*
M25 4KV))_P#K<4 <+IOB'Q#)X;\(:_<:P\CWVHQ6%S:B"-8I$9VC+GC<'RH;
M((';%:+:IXGUZVU*^T*X2&:RU*6VCBFD00%(I-K+(-I;Y@"<@C&1CWVX_ NF
MPZ+INDQW-ZMKIUT+NV'F+N616+ D[>0"2<'U^E))X"TE]<N-4CGU"#[6XDN[
M2"Z9+>Y8?Q2(.N>_0'OG)H YW4M0\0RWOCI(-?GMH]&ACN+01P1$@F R;6)4
MY7/X].?62VN+S5?B#X7O'O[F(7.@/=-#'M\L,6A) !4\'/)Z\#!%=/)X1LI)
MM<E-S=AM:C$=V ZX*A=@"_+\OR\?_7YI$\'Z='<:1.LUX)M*@-M"ZS;2\1V_
M(^ -P^5?RYS0 _QKJ4^C^"-;U&U)%Q;V4KQ,/X6VG!_ \_A5.S\+:9JG@_P_
M9W22E+&*">%XI6C8.J8SE2"<Y.?7-=#?V,&IZ=<V%TF^WN8FAE7U5@01^1JC
MX<MKK3]%MM,O 6ELHU@$PZ3(HPK^Q( R.QSVP2 1V^DZ3X;GU;5T:2 7C">Z
M+RLR C/*J3@$DD\#DFO)O'U[=:MXR\#/=V][;&76H_*MIXRBQQATYYX9SG)/
M;@#H2?8M1TB+4[BSEFN+A%M)A,D4; ([CH6!!SCMZ'!Z@&L[7O!FG>(M7TS4
M[Z:[%QIDGFV@BD"K&^0<XQSRHZYZ4 <OXK\5:W8>+=4LQ</8:;9:2;JV\F)7
MDO;AOE51N!Z'C:!GCGBLZ?Q/XRMK;P197%SY>N:S.\ES;-;HH6)5!V,,$KVR
M1R 6]*JZGX;\37D^H^(;"]UK2/%<TN#8VRE[.8(=L>6/R$; "23@9/RCH?2(
M_#5M<:YIWB'4,R:Q:6GV<%&_=*6^^0OJ23SZ4 <<WBKQ#I>L67A*\NCJ&K+#
M+?:A>65IN98=Y$<<: 8#GY02PPH/.>M10^+O$VEG0?#.K,9/$%[')>7TT-N)
M7MK8,VU0J##2'&W.-H/)S77:CX'TV_\ %"^(EN;^SU'R/L\CVEQY8ECSG:W'
MTZ8/ ]*9J/@/2K_7++68Y[ZQO[.#[,DMI/L+QY)VMD'/)//7GK0!PVL>(O'&
MDZ-X<L;B\>/7M9U9U2(10LZ6G]UL+MW@%>1P,G/2L:_^(OC%=(\5WEMJ$)6+
M58].TV1+5<&3<0R1@]<CG+9Z#CYN/7'\(:4^O:=K)6?[7IT+PVV92P7?G<QS
MDECDY).366OPQ\-IHNG:2([H6UA>_;HB+A@[2Y)RS#D]?KQ0!FZOXSU)?$P\
M,6$<TMW96 N=0FM8/,=I"!LBC!!5=Q()9A@#TZUDW.O^-;#5O!'AR:_236[M
M)+C50D4>PQJ<J"0ORC *DKZ''.*[*?P'I4GB:37X+B_LKN:%8)UM+@QI,B@
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MWX/*ZY?^-9KY?,WZK)IQ1O\ GA%&JA?H=[GZL:[2&&.WACAA18XHU"(BC 4
M8  ]*Q-.TE]&\2:G<0(6LM5=;APO_+&<*%8D>C!5.>Q!SU% $-MX'T:T&D&$
M78?2?,^RNUT[-\YR0Q)^89YP?2N/T3Q'XIUB+6-/35XAJ6G^)/LD;FV3][;*
M1N4C&!\H=MW7C'<5Z!K^J7>CZ:+JRTBYU23S40V]LP#A2<%N>N/\XZUC^$?"
M$6B7^L:S.&^W:O=R7+1L0?(1CD(,$C/3<1U([@ T </J_P 2-8O/!NN>*M+N
M!:6L%_'8Z1 (E<W3!UWL^X$G<"<!<8P>IYK7OO&VH6?Q$NH;B\\C1='T87NI
M0"-#^_8?+&&QN_B4@9Y(KH],^'N@Z6MI%%%-+:V5P]U:6LSAHX)6.=P& 21D
MXW$XSQ4-]\-/#^HZAK=[<"[,^L1B.X(G("X7;E!T!QD9.>I P"10 SP!<:EX
MG\$:;JWB)Q+<W$INDC50BJH;]WD#KC 89[D'L*V]8TFUFT#6H&7/VV"7SF8Y
M)RF!], #'IBK6C:3:Z%I%MIED'^SVT8C3S'+,0!@9)]A46OPW=WH]S860Q<7
M<;0"4_=A##!<^N <@=SCMD@ H^ ]3N-9\!Z'J%VQ:XFLXS(QZLP&"WXXS^-<
MSXN\1:OI<>MWUCJ3RFPN;98X;>)##"C&,,DQ89+MN;A22 5/&>>]TS3K?2-*
MM--M%VV]K"D,8/7:H '\JY[4/A]H^HG51+-?I#JDBS7$$5R5C\T;?W@'][Y1
MUR..E &=>7&N7OC/Q!I,&O3V=K;Z=!<P>5!$6C=C(, LIR/D&<@GT(J#0/%>
MH>(W\+Z=)<FVFO=&.IWD\2J&D(*H%7((7)8L>.P Q731^%K6'4[O4([N]%Q=
M6R6LC-(&^1<[>H)R-S<]>>:I#P!I4=GI$-O<7UM-I"E+.ZAE E2,\%"<893Z
M$&@"G\-HI(8/$T4L[3NNOW0,K@ OPG)  &?H!6QXS11X&\1L% 9M,N,D#D_N
MFJ?0O#EEX>%[]CDN7-[<-<S&>8OEVQDC/3H*M:MIL6L:5<Z=/)*D%S&T4OE$
M!BC @C)!QD'ZT <G:7,MI\,/"TD-[%9R-;6,?FM'YDA5E0,D2X.9&&0.#UK#
MU/Q/K]KX5\;O%?7$%SH]S&+62>.)I%1TC;:V 5/WC@]>F37:7'@W3KKP[8:+
M)/>"'3GBDM)DE"RPM&,(0P'.!QR#UJI<?#W1[FWU>"2XU$QZML^U@W);>5 &
M><X)VKD^V!@<4 4M=N=?\-""YN+S4M4TV2:22[>RMXO.M5VKL"H!EHP=Q/5A
MQDGG++'7[J?7O!\=IK9U#3]4L[MY91$@$QC";7^Z"I^8Y' R,8XKJ;K1OM,]
MG<#4;V&XM8WC66-DRZMMSN!4J?N#MQ6=+X(TIK?2HK:2[LWTMI#;S6TVU_WG
M^L!)!R&/)]^F* .<A\0^(CH.H7""[U'[%X@N+2<6L<?VC[(A8#8N &8';GC)
M&<<\CJO".JP:SH*WEOJ;ZA&TT@$LL8CD3YCA'4 891@'CMGO4%IX)T_3XV6Q
MN]0MV-^^H;UN-Q$K!E/# @KASP0<\$Y-:VE:3;:1!-';[BT\SW$TCD;I)&.6
M8X &?H .* ./\7M.OQ0\"FVCCDEVZAM620HI_=+U(4X_*L+Q/X8O-&\'>+-6
MOIX#?:QJ-E,T4&3%"%N(U4 G!8\Y)P,^E>A:AX:M=2U_3M9EN;I+K3A(+8(R
MA4WC:_!7G('?\,5-K^A6WB/2FTV]DF2W=T=A"P4DHP9>2#_$H/X4 <N^J:OI
M/BG7=+FUI)HET4:C!/?1HD=M)O=#G8!^[^53SD\=:CT?6-6F\6#27O[Q[:?0
M_MBS7$,:MYHD52Z+M!"G=]UQV'%;VH>#=-U6^N[N^EN9WN[#^SYE+J%:').,
M #!R2<CG/MQ45KX(L+2_M[];_5'O(+1K19Y+HL6C)!P01@X(';'<@F@#B?[7
M\5#X2+XO/B64W<ME$WDBUAV*QE +?=SDJ<?7ICI712-K@^(#:#_PD5R+2[TQ
MKPN((=\#K*J8B.W 4AA]X,>.N3FM4^"-,/@U?"OG7G]F* H'F#>%#;@N['3(
M^OOBKI\/0-X@CULW=T;V.U-H&RFWRR0QXVXSN .?;TXH Y+1O$&K:AX;T-KK
M5<7,E]=6T_DQ+]HO!$TBKY8QM4_*I8\ #/(J+2/%VJW-AI&GW-RT=U>ZU=Z>
MUVZ)O6.$R$< ;-YV*N<8Y)K?C^'VE0PV"0W6H1O8W$UQ;S).%=3*29%R!RK$
MG(_+%-D^'6A2:3<:<3>B.6]-]')]J;S+>8DMOC;JIR3SR3GG- %;5-0UKP['
M#9S:FEVVHZM':VDI5%E@B=&;#'&TMF-E4D=QG-9NOWWB[P_X=UV\EU$+'#-;
M/I[DQR3!7D5)$D&P*5Y.TXSSUXKI+CP1I-[X?ETB^:\O$E=97NI[AFG\Q?NN
M'[$8XQ@>W)H'@G37\/WND7=SJ%\EXH2:XN[EI)B%.5PW;:>1@8SD]S0!0U/4
M-1/C?4-(34)HK-M!:[145 T4OF%=RMMST'?-<]I=_JFE_#?P+<6VJ3DWEYI\
M,ZR)&VZ.1E#)G;G'OG/)YKL[/P=86FKKJLEU?W5[]D-F\ES<%O,C)S\P&!_3
MVSDU!'X#TR+1M/TI+K4!;6%Q'<VX:?<4:,YC&2#\J]A^>: *4=[K/B:3Q$NE
M:K_9UQIM]]CMD,:LA*JC%I 020Q8CC& !CFLSQEXBU?3;/Q!>V&JF233[>&:
M&&TB1HX>,L9BXYW9X53D+@X'6NBO/ NE7>NS:L)[^VEN55;R*VN6CBNPHP/,
M4=>..,<4S4O &C:G-JSRR7L<>JQJEU!#<%(W*J%5]H[@ #TX&10!3N68_%W3
MW4+N.@7!&X\9\Z+K4'A#Q'=WVM1Z;K%S?6FL1VC&ZTZ[A0)*^Y/WL#J,,@PP
MQD\$<<$UOCPK9C5K?4OM-XUQ!:-9+OE# Q,06!R,DD@'.>WIQ3(_"EK"D3R7
M5_=2VMK):VKR2KYD*. &VL #N(51N8D\=>M '045E>'-,GT?0;:PN+J:YDBW
M#S)Y#(^TL2JEC]X@$+GOBM6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\ &VN7?AGPC?ZU:1PR
MR6:"0Q3 X<9 QD'CK[UT%<5\7)HXOA;KPDD5"\ 50QQN.Y>!ZT =1!?)'9P-
M?W-M'/)%YC8.P8 R2 3G '>IDO+62S%VES"UL5W><L@*8]=W3%>?:J-'OOB'
MX*:3['.);"[R6*L' 6+9GUYW8]P<5SEIJ=OI>G17!93H%CXONOMBP_,D,1+^
M4Q Z('*MZ9 - 'LMM=6][ )K6XBGB)P'B<,I_$5'J6HVND:9<ZC>RB*VMHVE
ME<]E R:Y[3M8\)Z=;ZGK=C<Q1V-U=(UQ>J[-#+,V$^7J/[H)48R?4'%7XLI(
MWPWU,H"51X))0/\ GFLR%_PP#^% &O+XFMM,MM.?6I8;.YU&4)!;%@&3(SAB
M3SM'4],\>F:FF>*'?Q+XAL-3GL8+33Y+9;>7=LW^:A?#%FP3T QBJ'Q"DM;>
M[\(WEVT4=M%K2>9-+@(JF&4#)/ &2*YS45TB^U/XGR7 M)BEA#Y9E"DI_HIZ
M9Z'./?(% 'JEW?6EA$);RZ@MXR<!YI @)],FF7]Z++2KJ_6-IQ! \PCBY:3:
MI.%]2<<5Y9;ZY9VFI:))KVJM9Z9?>';>.VNV$;0M*,^<C,ZL Q!3/3.WGM7H
M7A&QLM-\*V%GIKW3V,2,+=[HY=DW$J>@XQTXZ8H S['QQI][=Z#!'-N35XI)
M()A;2A9&3JJY'RXP3EL< >O%>;QM-J?B^?PQX:MHKFYLUW7][.3Y%K_LX'+O
M[9'?G@X[.O%OA#>6/A6Y\4Z;XDO;>PUHZ@99?M<@C,T>/E92V-PR6/'J/6@#
MT[3+C7O[:O+/5(K-K2*".2*[MT9/-9BP*E6)P5V\\G[PZ=*U(;RUN(WDAN89
M$0X9D<,%/N1TKSKXC:E<:I/X4T:%YK;2=9OBM[,V8]\*8;82>@<9ZXR!7):S
M=W%MH_Q#\5+ 8].U98=+TN'9@7  \KS57TQDJ?K0![E'?6DIB$=U YEW>6%D
M!WXZX]<=Z/MUH+=IS=0>2I(,GF#:".HSTKY^AT--&\611.2Z>$/#K3WS)GYY
MG1CY2D= 0W_H1ZG-10V5L?A/X+\+EE$OB#51-<.PV@1AMS%<^@*#CN"* /HB
M*ZM[AW2&>*1TQO5'!*YZ9QTS35O;1I3$MU"9 Q0H)!G=UQCU]J\(UB6X\/?\
M)WXS\.6PM-.>*'3;&2%=JR-N19)EQU ((#=R<^M7/#TVBK\3K0Q'&G>&=!WQ
MRE#NGD=2[S$'G!5F.X]21_>% 'M37]DHD+7< $1 D)D'R$],\\9J4S1+)Y9D
M0/M+[2PSM]<>E?,;Z2MWX$TF2^39<>+?$!N JJ<00[CN( ZL>,>Q('4Y]%\2
MK!I_QOT=HK)9#J.C36SP!<>><MA6]N@)/0#T% ':76L:W_;5W!80Z7-8'36N
M+6X:=OEE&,"7 P$;)P1SA6_#5T*\O+_0K.ZU&W2WNY(PTL<9)4'U&><'J,\\
MTWP]HL'AWP_8Z1;?ZJUB" ^IZD_F33?$UQ#:>%=7N+BWFN(([.5I(86*NZ[#
MD*1R"1W[4 7+;4;&\:1;6\MYS']\12JVSZX/%)'J5A+-'#'>VSRRJ7C195+.
MHX) SR.*\NT/4M*G\=:0S7NGRV4_AMX%2'F%0LD9$6XD[RJYSGIR2%K*T-=+
MM? WPWO(OLL5V=7B5Y@5$A!64,"W7'W1CZ>U 'I/CGQ,WAKPQJ%[9W%C_:-O
M 9H[>Y;.\#T4$$]_RKI8V+Q(QZE037B>L:I8R?#KQWINL2P)KWVRX>2"<@2.
M-P,+(#R5"!<$= *]7L/$6D7>H1Z3;ZA#)?BU6Y\E3DF(\!@>A% #[GQ%I=IK
MMMHLUW$M]<1M*L9< A00.?J6 'K@^E7#?V:W@LS=P"Z(R(#(-Y'^[G-<=K<M
MI9_%K0);MHHUFTVZBC:0#YY/,B(4>K8Z#K7)[S??".^TVX8#Q=#?OF/.+C[;
MYY9'7OR"N".-OL* /7;B^M+1T2YNH(7D^XLD@4MVXSUZT7-]9V<'GW5U!!#G
M'F2R!5S]3Q7EWB2_L;/Q'XKTS4M5TQ9=6TN" ?;Y_)6!MCKQD?,G._CH3CW#
MY;O2O#6M:!!=:LEMH#Z-]GM-0A2(V\DX;,F259077:<]\'F@#T"^\2:3IU_I
MUE<WL*3Z@6\@&0<J$+%NOW>,9]2*S= \3R7=]KEMJT]E ;+4_L5N5.SS!Y:,
M!\Q.6^8]/RKD/LVB:%J/@$V\TG]CQSWJ0W%[CY@T;% #@<$D[!CD8QVK+UE-
M*N?#7Q0N)!:R7"7KF*1BI92(8L;3V.X=NX]J /8[N_L[ (;R[@MPYVJ9I FX
M^@R>:+B_L[3/VF[@APF\^9(%PN0,\GID@9]Q7F>H:OI:^*M2M?$NK-96&IZ9
M +*=A&8IXMK"5 [(P#;FS@$9R/:DMM'\/M\0M#TR:!+BW_X1V2)8]056DD D
MC""0$<G9G (R!]* /3Y[RUM51KBYAB#\*9'"[OIGK31?V;2R1+=P&2($R()!
ME .I(SQ6)XTT)M:\(W5I9HJWEN%N+$A?N31$-'CTY&/H37$PZAJ<^NV7B2RM
M)((/%MJ+$($PT$BKNCE?UX\\_P"ZJT >C/>2R:G9-;7NGG3Y(I&D5FS+(1C:
M4(.,#YL\'M7.:YX[B'A.ZUGP]<6=U]FO([=Q)\X8&98B1M([DD'H<56U"WTW
M3_BGX2M8$MX=NFW<(08!V@1!%]^ V/QKD+J[T^/X3:]8M- EU%KK+-%N"N@-
M^" >X^7)'L">U 'M$%Y:W3RI;W,,KPMLE6-PQ1O0XZ'ZTGVRU^U?9?M,/VC_
M )Y>8-_3/3KTKB=,&G6?QAN[;3Q;0QRZ%"S10;5#,)GP<#J=I'X5-XVC?0=5
MTWQI:6KS/9G['?11+EY;:0@#'J5?:1[$T =?]OLQ#+-]K@\J(XD?S!M0^A.>
M*:-2L3:I="]MC;N<)+YJ[&/L<X-<%JL,V@:EX,EU+8NGF\N)=3E_Y9K=RH2C
M,?[H=F )Z?+[5A^*;1WTOXD3V $FD2I:RJ(OFC,ZX,S+CC@!2Q'<>H- 'KRW
M,#7#6ZSQF=1N:,.-P'J1U[BI&944LQ 4#))/ %>>QZ_H]S\6X+VWU"VEMCX>
ME'GQN&1L3HQ 8<' !.!TP:[;2M5T_7M+AU'3;F.ZLIP=DB]& )!Z^X(P: .7
MUGQU&?# UCP]<6=RB7\=K)YGS95IQ"6&TCOD@G@BNO@O+6Z:5;>YAF,3;)!&
MX;8WH<=#[5XLUWIR?".>Q>:!+F+70EQ%N"LG_$P+ -Z?+S].:U=>3[-XF\7V
M?AQ8H[F7PW$Z06F%+N'E!VA?XMA '?D4 >I6U_9WDDL=K=P3O$<2+%(&*'T(
M!XK%U#Q7!8>(9])>*5IXM/:^CC6%V-P!NR%8#:"-HX)R2P].<#PO<^%]>U[3
M]7T?5;F\OH;-H3"BQH((CCY)55%QA@  >_3@$UZ#0!Q^J>-XK;X:3^+K*6"=
M(X3(F^)T21MVS;AL,,MQD_7%8=K\2=5MM4\(VNL:9:A/$D0>,6SMOMB<8W Y
MR/F'/'?TYH_&R_BOXM \()=1QR:KJ,8N/G \N($<MZ<L"/\ =K>\0:!I?A32
M-3\6VMM->ZQI^GN+2:ZE:7R5"G 13PH&><#IGUH [5KVT28PM=0K*I *&0 @
MGIQ[]J#>VJR-&US"'4JK*9!D%N%!'J>WK7@?AZ2PU?Q1\/=-,C3&*!]9O+F1
M27N;J0^_+;77&>@"GLM;O@O0M*\2_P#"2>+]6MR]G_;,EY:(C%01!]UR!PW<
M<^K>M 'I3>*-/N+G5+#3;JWN+_3X-\BM(!&KG.U&;L<CGT[]14VA:A?3^&K2
M_P!=CM+.[>/?.L,P:).>"&R1C&#U/7J:^>T2R_X4VTJ16D6H^*=:$3RB, 6R
M-)G;NQ@ >7G';=78:EJ(N?B/-X>EU&WTG3M*TN*/3$O00"[HH\U8SCS)%4E5
M4G@]LY% 'L+ZC91PQ3/>6ZQ2_P"K<RJ%?Z'/-<_=ZQKXU/58;*#27M([(7%E
M<R3N%#\<38& #EB-O9>>M>;^(M-B\*1Z/>^%9S=R>'%33[S2;H9>XBN-K<*>
M=S&3GC_T'!]JLK2&PL;>SMH_+@@B6*-/[JJ, ?D* ,.T\0W<0T7^V+9+4ZK&
MJ*%S^ZN-FXQMGU ;!XZ8(R170R2)#&TDKJD:C+,QP /4FN,^)222:;H,<&?M
M+:[9^3CJ&#Y)_!0Q^F:7XB7QTR'0;^Y5VTBWU2-]1*J6"Q[6"NP'\*N4)]P*
M .M@O;2ZMC<V]U#- ,YECD#+QUY'%);W]G=P-/;7<$T2$AI(I RC'7)!KS;Q
M+<:0^DR:QX?7[1IDVLV=QK5Q S/%-$IPY S@@80MM&.N>AQ)KT=I=^*]7OK*
M2WETM_#DJZBZLK0O)NS#N/0OC=COC'J* /1(M1LKB988;RWDE:,2A$E4L4/1
ML ]/>N5D\4:CK&IZK9^'+K2!)ILT<12\+,+@%%=V#*WR@!L=#RI_#E-'72[1
MOA3/;_98IY8&661"H9\VAR&/4_, .>^*U=$?2IM1^(:.UF\8NN02I&W[,@/X
M9!_$4 =Q87VS2;.34[ZP:YDBR\D#[8I&"Y8IDYQ@$_05*VK::D)F?4+58@@D
M+F90NP]&SGH?6O(]-72;K3?A.MW]DDS$\;B0J<C[,PVGVW8&#WXK?M-+\.V_
MQ5U2Q^QZ;':Q:);CR-B!%Q)(#\O0$+C\#0!Z"+^S-Q';B[@,\J>9'%Y@W.O]
MX#.2/>D_M"R^V?8_MEO]J_YX^:-_3/W<YZ5XSH_]F6_@#X<WJFU2[_M>!'GR
MHDQ^\4@MUQC:,>F!Z5T-M=3:=XIMQ;7%IK.D7.N3J(6&V[T^Y+2"0C'WHQ\_
M7!"D=J /1YKRUMY$CGN88G?[BO(%+?0'K3A<VYG>$3QF6,;G3>-RCU([5SGC
MO1Y]1T-+[3XU;5M)E6^LLCEG3DI]'7*_B/2N7U^>ZU'X?W?B>&UF\O4;BVGG
MAVYD&GHZ_+@=05W.1Z2,* /1H=3T^X@DFAOK:2*(XD=)5*H?<@\4\7MH6B47
M4),PS$!(/G'^SZ_A7#WB0ZG\0M/O="EAGMY-(N$U!X&#(Z';Y ;'&<E\=\ ]
MJY32=8TQ_#7PRMQ>0&>TOHX[A-W,#>3*I5_[ISV.,X]J /8AJ%DTZP"[MS,S
M,@C$@W%@,D8SG(!!(]Z+J_L[(H+N[@M]_P!WS9 F[Z9/-<'\/-.T2?4_$MS%
M:V,ES;:_<&&144M$I1!\O]T'+=/>D\<O-:ZS>WFGW]A)<1Z2/MVD:AQ'=VVZ
M3E&SE7SO'<'*Y[4 =Y<ZA960C-W>6\ D.$,LJKN/H,GFEN+^SM QN;N"$*F]
MO,D"X7.,G/;) S[UY?=ZOIC>(]5L_%-Y/H]IJNFVWV1)T3:\)C(DBW.APZNQ
MR 0>13[72_#\'Q&TVTO88WMO^$:41C4U4O)ME 4N&'+!/49 SZ4 >FRW]G!:
M+=2W<$=LP!$SR (<].>E+]MM?(BG^TP^5*0(Y/,&UR>@![YKR+1)K/0(-"M[
M@QVUK)J^HOHUY=R,(+>WY"<9 8NK'9DC@DCT.=!+I4WA'0K:YE@<V_C!HV$H
M"E$,\A((XV@@@D<<$9% 'M#ZQID=O'</J5FL,I(CD:=0KD'!P<X/-5[WQ%I=
MAJ]EI=Q>1)=W@9HXRX!VJ,[C[9P!ZD_6N%\2/H>F:YJ&CVEO9Z9*VAR;24XG
M1W<F*&(84L6R6.">1P>HI:1?V'VGX87EQ/"8CI$T!E?D-+Y4("9[MD$8ZY!'
M6@#TVPFNGNM06YN;*2*.8"%8,[XTV@XDR3\V<GC'&*GM;^SO5=K2[@G$9PYB
MD#;3[X/%>0W[E-'^(*:4BR1QZS!)<P6V"S6^V'SL =B ^?\ @5=->_8-2^(&
MBW^ES6L]@=,N1JCQLK1-;D+Y(?M]XL0#V#>] ';1ZE8S31PQWML\LJEXT652
MSJ.I SR*S_%?B*#PMX;O-5E".T*?NXF<+YCDX _,C/M7E6AKI=KX(^&MY%]E
MBNSJL223 J)""LH8%NN/NC'T]J[GXMR01_#753.T:G$83>1U\Q.E &QI^IW4
M,]V^K:GH\EB5$EI/ QC8J,B3>&8C ./F![\XK5EU&QMY(HYKRWC>;_5*\J@O
M_N@GG\*X+6K30;_XJZ!!/#I\\4^EW2M&P1ED^:/:".C?Q8S[U4MFT^.#Q[H^
MOB"*9IG:&*0 ;[3RE6 1CN 00 O1O<T >E3WMK;$B>YAB(0R$22!<*.K<]AD
M<^],&IV!:W47UL3<C, $J_O1_L\_-^%>8Z):(/&GA6'Q EN^I_\ ",L+H3[2
MYD#Q8WYZL #U]":Q0FD0?"Z:ZA%FD]OXBQ!*I7=&HON IZ@!"3@<8)- 'N+,
MJ*68A5 R23@ 56BU.PGM9+J&^MI+>/(>5)5*+CKD@X%<U\1KF:W\)I=Q>:]I
M#>6\MYY"AV^SB0%R 00P P2,$$ YXKCO$J^&-0\(>+]9TS5'U-[G3@L\S;/)
M\Q1^[X55'F\GW QG&10!ZM_:=AOF3[;;;H%WS#S5S&OJW/ ^M/2]M)((ITNH
M6AE($<@D!5R>@!Z'->=3VFA_\+%\)JD5B4GTNY,@ 7$N#$R;O[W.XC/?)KF6
M&DOX>M$D^RFSMO'#QCD;8H6E<X']U2/PQ0!ZUJNLJGAO4M2TFXM+F2T@DD4[
MO,3<BD[3M/MZTND:REQX5TS5]1FM[<W-I#-*S,$0,Z D#)X&3ZUP5W866G:Y
MXUNM(6"WT=M "W(APL/VK$F,8XW;-N<?WAZTNB7ZVVK>!)[Z5!I$GA\06\K,
M/+2\VQY!/0,45@,_[0'>@#TI]1L8HHI9+RW2.49C=I5 ?Z'/-.>\M8I#')<P
MI($WE6< A?7'I[UYK9>%Y-;T#Q7:V3*EM_:S7>AR<;8ID"MN3L$\T,../O>M
M2W-TOB3X=>(_$NIV2VS7&E26\4-PHS'Y:-NZ]"9BP'J$0T >A+J=@\C1I?6S
M2)&)642J2J'D,1GI[]*?%>VL]I]KAN89+;!;SDD!3 ZG<.*\MCM=$.L_#4"*
MR/VBSF$O"_O?]'4C=_>^<9YSR/6LYKZ'3M,UJ2VD*:59^,#)>"T57\FV,:_/
MLP1M$FUNAZ&@#V"/4["6S-Y'?6SVJG!F652@/^]G%(VJ:>B73M?6P6T&;@^:
MO[GO\_/R_C7DWBR+PU<>"?%.K:9J3:@+Q[1I;ARGD^:LB@;-JJ ^W[V.>F:W
M98=-@^*%S::>EJBS^&FS% % D82_+P.IP3CVH [?1=9LM?TJ#4=/F66WF4,I
M!&0#R,CL<=JG34+*2\:S2\MVNEY:%95+CZKG-<Q\+[FTN/ASH:VLD;M#9QQS
M>7SMD"@%6_VAW'6N%M=;TN:;P?=6L\-I!'KDX-GN+S6Y=9LB9R2=[MSMXZX&
M[&: /8'U.PCD5'OK97:3R54RJ"7X.WK][D<=>:9J>H0V%JQ>[M;>9P1#]H<!
M6;L,9!/T%>,ZE!HR> /B%<1)9">'6I?(=0NZ/#1%=A[<YZ>]=;'K&G1>/O%-
MMKUQ;HEU9VXTUKAALGMMAWK&3P?G)R!R<CKB@#JO!NLW'B'P=I6KW:1I<7=N
MLKK$"%!/IDD_K6Y7'_"N:.;X8Z!Y;J^RU5&VG.&'4'WKL* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *0J&Z@'ZTM4]3U2UTFU6>Z8X>188D49:21CA54=R3_ (G !- %K8G]U?RH
M\M"I4HNTC!&.#6/;>);:ZNKZQ%K=1ZE9HLDEE(%$A1ONLIW;64X/(;@C!P:\
MSDUO5)?AW9^+E?68M2EQ'(Z3KY$BS3!/N%CC:&PI !!QVH ]C\J,1B/RUV#&
M%QP,=.*2XMX;NVEMKB-9894*21N,AE(P01Z8KF;6XM]!GO6@CUJ[EGC6ZDTY
MY1,UJ@RNX;FXW$$[=QR0<#@TDGQ#T,)I[6JWU[_:%J]U:K:VK.953&X =V&>
MG;OB@#?T^Q-C8QV;3&>.'"Q-(,L$'W0Q_B(]>_UY-K8G/RKS[5B1>*K6=AY-
MI>O&)XK:601@"&60*0KJ3N!&]<\8&?8U;U[6K?P[HUQJMW%/);6Z[I?(3>RK
MW;&>@[T 7WABD0(\:,H.0&4$9I]9K:U EQ80F*4M>1-,C#:51% )+'/ ^9>1
MD<BJ$?C'37?3V9+F*TU)Q'97DB 13L1E0#G(W ';N SVS0!T-1O!#)(LDD4;
M.GW6902OT-<_-XVTR#1M6U22&[$&DW#6UXNP%D90I) SR,,O0UT32(L1E=@J
M!=Q9C@ >IH 22*.9=LB*ZYSAAD4X@$8(!%8-MXNT^YU#3[3RKJ(:E&\EC/)&
M!'<*HW'&#D?+R-P&1TIH\9::+O3XI([F.#46*65VT8\JX8#("X)89 )&0-W;
M- '0;1SP.>O'6N1O?!UQJ'Q#L?$MS>V\EI96SV\-B;<G&[.YMV[&><=.@J.7
MXD6#:;>WECI6K7:VB7!=EMBB*T.=RL[$!3QGGGVSQ5VP\6K+INC?:+&Z.I:E
M;^=':QA-SA45G8$MM"_,,9.>1Q0!TC1HT?ELBE,8VD<8^E C0,S!%#,,,<<G
MZURE[XFT34]*\/:A]HU%;>_U");4VX>,F7<5"2XXVY!!4]<=Z??>/M*L9M6B
M-IJ4SZ3M-YY-J3Y:E=V_G'R@<^_;.#0!TTL9>%E1A&^"$?:#L..N*P?#_AJX
MT^2*^UK41J^L1PFW6]:W6+;'NW8"CH3QD]\"MR*6&^LDEBD+03QAD="1E6&0
M01R.#7G'@KQS;:=X4TB'66U.0SW,T#:E-$[Q!S/($5Y3W(P,\@="10!Z;16!
MJWB_3M'CN;BXCN7LK258KN[B0-';L<?>YW'&Y<E0<9Y[U6O/'>F6EUJELMKJ
M-S+ID:2W"P6I;",&.X$X! "DY[]LT =,(HU  10 ,  =!1Y:?W%_*LEO$=H\
M%K)913W[W5L+N**V5=S1$ A_F*@#D8!.3V!P:YGQ!XS6]T3P]=Z(MU-9ZKJ4
M-N\L6$;9N;?'RP*N2A7\^10!W;0Q.^]HD+8V[BHSCTJN=/A;5%U!\M,D9B3(
M&$4D$^Y)P.O3MC)SRFD'3]&\2ZC:P3^(+J^6Q^U_8KJ<O''$S\)'N."=V1G)
MQR-V!5GP]XU&K>'=*U"XL)X[G4R?L]NA3,G#/\I+ 8"KR3CI[B@#K"H)!(!(
MZ>U-\J/S?-\M?,QC?CG'IFH-.ODU*R6Y2*6(%G0QS+M92K%2"/J#7.Z5XUCN
MI/$4NH6DMA9:1<M"T\NTC"HA.<$G<2Q( '3'?B@!\WAW6DU>]N;35[)[6\D$
MC0W^GF=HB%"X1ED7Y>.A!P2?4UMZ?I-KI^F)8HBO$K,YW(,%F8NQP!@98DX
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M'<[<G"KDDX^N!QQUA\3V,UM;3:<DVI&YM_M44=H%+&+LWS%0.N "<DYP.#@
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M*"U9FDC^7@=L_,/ISDBI;'QMH^I:-!J-L\S>?<FT2V:/;/YXSF(J>C#!)R<
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MKR[AC#1P-QG=SN.,C)4''?H<-N_&>G6VK2:7%;7]Y>+:B[6.UMR_F1DX!4\
M]^<X[9S@4 ="JA5"J  !@ =J6J.C:O9Z]H]KJE@Y>UNHQ)&6&#CT([$'BKU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<MXWT?4-2MM)O-,0376E:C%>BV+A?/50RL@)X#88X)XR
M*ZFB@#DK?3KNY\:S^*7L9X$CTL6,-NY3S929#(QP&P /E R>I;M@GFAX?U]?
M@O8^'O[&G.J0O 'A$T. $G60G=OQC:OK7J54(]:TN74O[-CU"V:]PQ\@2C>=
MIPV!WQW]* ..US3=3M?&9UR'PRFN6-]9QV\UNS1":VDC9RK#>=I4AR#@]LU9
M_LG4T\8^&+Q-&2&SM+6ZCG%JT8B@:4H54#()QM.2%Y/..:[>B@#SW5/#VHR^
M)FU;1[*\TS5?ML0DN(IE^RWML"NXRIN/(3<!P&R!CCIWT\$5U;RV\\:R0RH4
M=&&0RD8(/X5)5#6-&L=>TY]/U&)I;9V5BJR-&<J<CYE((Y'K0!QWA/PU=R>'
MM6L+V]\V)(Y]'T^<<LMLK.H8_P"UD[3_ -<EJ&'0=9U3PCX>\-:AISVTVF7%
MM]HNQ(AB:.W((:,@[B7"@8(&,G/3GT"UM8+*UBM;:)8H(E"1QH,!0.@J:@#R
MS6M!\0G1O'.B6FBRW!U>Z:ZM;H3QK&RND:[3EMP8%#VQ[BO0;^QDU?PU=:?(
M&MI+NT> Y()C+(5['!QGM6E10!Q7AEO$LVC6V@ZOHGV'[+;_ &:>^$Z.DP";
M08@IW9/!.X#'/>L[P?I6K:=;V&CZCX/L8Y]-VI_:ZF)DF1.%=!]_>P '.,')
M)['O+?4K&[N[FTMKR":XM=HGBCD#-$6S@,!T)P>OI5J@#@]%T+5O^$$\3:3<
MV+VMW?37[6ZRR(0PF+E#E6./O#.:B@A\2B#PS;SZ'<_V?#9F"\MH[J)9!*JH
M%9V#\Q\/PI.>,@]*]!JJFI6,FHOIR7D#7L:>8]NL@+HN<9*]0.: /-;'P[X@
MMO!/A?3)-%D%QINMK<S(D\1 B69W+ EAQAA@=>O K4N='UB2Z^(++I4Y75K9
M([(^;%^]86_EG^/Y?F]<<5Z!10!F>'()[7PQI5M=0-!<0VD44D;%2595 /*D
M@].QKA;7PQJ]U\/E\&76FR0.;LF:\9T,0B^TF;<F&+$E< # P>N!7IM% 'F\
M6BZKI7B#6+23PE9ZS::A>/=VNH2-%B'S,%DE#?-A3DC:#D5=&DZK%KWC.<:7
M*T%_86\%HZ/$!*R1R*0!ORHRXQG'>N[HH \J@\/ZYI \.:B_AE-62'18=,O;
M!WA,D+Q\B1"QVD$E@>>F*VM;TG5)]/\ #*VF@I$;75XKV>WM'B5((QOR.64,
MWS#..IS760:UI=SJ+Z?!J%M)>(I8P+*"^ <$X]CP?0U?H Y(:=J#_$V?4S8R
MII\FC):"X9TQY@E9R-H;=T8<XZUSVF>&KR7P'H6@:[X<NB+',;S6UU&)H'4'
M;-$ROTYQZ\\C Y]$AU*QN+^>QAO()+N!0TT*2 O&#TW =,X/6K5 &'X1M=7L
MO#L-OK5Q)<7222!9)BIE,6\^7YA7@OMVYQW]>M<?J/A+6]0TWQKH\=MY/]HW
MZZA97C2KY<A41%4(!W [HB#D 8/>O1+&_M-2M5NK&YBN;=BRB2)PRDJ2",CT
M((_"K% ''M87_B'Q-X<U:ZTV;3ETE9Y)5F="6DDCV;%VL<@98D\=!UR<:OB[
M16\0>%K_ $^)MERR>9;2?W)D(:-OP8"MNB@#SR+PEK#^(=,U:8QJ^I0;=>0-
MD95A)&J^H&#%[J:UA9:C'\2[[5O[-F:Q;2([5)5>/YY%D=R "V>C#D@<UUM%
M 'EVE^'M>M?"_@.QETB83Z3?":\431'RT"2+D'?S]\=/>M31(/$WAW4=5T>/
M1OM=I=W\UW::D)T$<2RMN(D4G=E23T!S[=:[:\O;73[62ZO;F&VMXQEY9G"*
MH]R>!4D,L<\,<T3AXY%#(RG(8$9!% '!7.CZQ)>?$%ETJ8IJUJD5D?,B_>L(
M#&?X_E^8]\<5UGAN">U\,:5;74+07$%I%%)&Q!*LJ@'E20>1V-6KS4K'3C +
MV\@MVN)%BA$L@4R.3@*H/4Y(X%6'19(V1AE6!!'M0!Q%OH,T/Q)O4@E3^QY1
M'JL]OW6[^:,>V&V[_P#>C!IEII>L:)/XKL5TV2_MM6N);RTG21 H:5 K1R;F
M!4 J.0#D>_%=3H?A_2_#EC]CTJU\B$MN.79V8].68DGCCD\5IT >=V'AS5/"
MFM>&Y;:QEU2"TT5M+F:&1%*2;XV#G>P^0[3TR1Z5M?#W3M1TGPHMCJ=F;:X2
MZN'V^8KAE>9W!!!]&'7!]JZ"\U*QT]H%O+R"W:XD$4*RR!3(Y. J@]3DC@5+
M<7,%G;R7%S-'#!&-SR2,%51ZDG@4 <EK/A>ZO?&<=U $_LK4;/[-JZ$XWB-@
MT?'?<&=#_LDU3T;P9J7_  A&L:%J5R!-+;2Z79S9SMM5WB(M[X;GV ':NP&L
M::8K&47UOY=^0+1O,&)R5W#9ZY SQ5Z@#@%T?5]<TOPKIVH:;)93:1>07-U,
MTB,C&!2!Y>UB3O..H&!G//!R-4T'Q%_PC?BK0K;0Y9WO-7:^M[@3Q+')&\R/
M@9;(88.00!QUZ ^K44 <)JN@ZIK'B_59?L<UM9WWATZ<MT7C(CE9G/0-NX#C
MG'45F+9^)KK2/!UA<>')X[C1-0@-U()X3&Z1Q21[T._)!R#@@$9QS7HUI?VE
M_P"?]DN8I_L\K02^6X;RY%ZJ<=",CBK% ',?$/3;[6/ NIZ=IMJUS=W"*D<:
MNJ_Q Y)8@=!65KF@:EKGBV=_L<]O8W?AZXTYKDO'^ZED92/E#9. #R!UKO**
M //8]$UC6/#_ (8T74-->TFTF[MIKFX,B&-A .#&0<G>0.H& 3GI@Z_A+3]2
MTK5?$<%W8LEO=:G+>P7/F(5D5U0   [@1M.<@=L9KJZ* .0N].U+3/B(?$%O
M:2WUA>:>MG.D++YD#HY96PQ&5(8@XY!YK"E\)ZM9:;9WD%BUQ<MXH;6I[..5
M T<;[QM!8A2P!4GG&<X)KTRB@#@CI>L-K/C:Y;29@FIV,$5J5EB(D=8G5A]X
M$<N.2!61%H&MZ0WAW47\,)JZ1Z)!IE[8N\/FP21<B1"QVD$LP.#Z&O18=:TN
MXU%M/AU"VDO%4L8%E!? ."<=\'@^AJ_0!PLNDZF/$OA&[BT-+>VLC=M<QVK1
M*EN)4PHQD;C_ 'BHQG.*N>)/#E]?>*--U'3RJ13PR:?J9)P3;'YP1[Y4J#V\
MS/:NNJK;:E8WEU<VMM>037%J0)XXY S1$YP& Z'@\&@#F?!GAR]\/O?PW6'M
M+262#2E!R5MF;S,?FP3G_GD*Q+'PU=2>#TTK6O#MQ,CZO<7#B.>,2P([R.DT
M;*_W@648!SR>#7I=5[._M-021[.YBG6*5H7,;A@KJ<,IQW![4 >:S^'/$]O9
M:-J$]H=??2[NY065\\?GS6DF A9C\IE7:#[@^M=UX=AD2QDEDT:#2/.?<+6,
M)N P!ERGRECST)P,<UL44 <7%:ZMI/B_Q/>1Z1+>0ZHENUJ\<D83<D6PJ^Y@
M5Y[X/'OQ7/0^#M3\(W&BRP:)#XDM8M+33[J',8>.179Q(GF8!4F1AC(.,5Z7
M8ZE8ZG'))87D%TD4AB=X9 X5QC*DCN,BG?;[3^T3IWVF+[:(O/\ L^\;_+SM
MW8ZXSQF@"#1H'M]*A22RM[)CEC;6X&R+))V\<$\\D<$YKA/#VAZKI$KZ%=^$
MK*[2.Z=[?6G,10Q,Y<,ZGY]ZYQ@#D@<@<UZ503@9/2@#S*_T#7+CPSX^LDTB
M;S]7NWDLU,L7[Q6CC0$G?QRAZ]L5MPV.JV_Q M]6&ERO9SZ-':2-YL8,$BR,
MY##=SD-QMSSZ#FNOBECGB26*19(W4,CH<A@>00>XI] 'EX\.:\/!$EO_ &3+
M]LA\0_VDML9HMTL7VKS?E.[:#M[$CFMF]T?4]4\<O=R6$UO8W&@26#S^9&?+
ME=PV,!LG [@8S^==O10!YWX4TK58K2TTC4O"-E97-E&(GU=#$RR!5VAXP/GW
MMQU QDGVK*BT;Q/#X&TKPQ)X?FDN=)U"V;[3'/$(9X8I@VY<N&!*CH0/KVKU
MFB@#'T[6;J[U[4M,N=*EM%M5CDAG:57$Z-GG Y7!4C!ZXK"UNVUS2?'<7B'3
M-+?5K.YL!8W-O#*B2Q,KLZ.-Y (.X@C/O79)#%$SM'&BM(=SE1@L?4^M/H X
MF[T_7(/%VC^)S9?:/]#ELKVTMY%+0J[AT9=Q ;!4*V/J :R-3\*ZO)::C>0:
M=(]SJ6O6M^;59(P8886CY8E@-Q"$X!/4"O3:* /-?$WA76/$.J>*XX;5[>'4
MM)@MK:XDD3:98W=RI 8L =P&<>M6S_PD&K^*/">IW/ANZLQ8+<K>[YX2$9XP
MN5PYW+D>QQVKOZ* /+Y_#>NS>"O$=HNE2+=SZ\=1MX6FCS-%]H23@AB =JG@
MD<UNWFFZGJ/CO3]0?39X+(Z3<6LLOFQDQ/(R$# ;)("G. 1GH3UKLZ* /,H?
M#.LW?P\L_!%[8/%);30Q/?JZ&$PQ2JXD7YMVXJN,8SD\\<U9O-%UF:+XBHFE
M3$ZS%LL?WL7[T_9A%_?^7YAGG''Y5Z)10!YDVC:QI6L6>IMX636K:ZTRWM+F
MV=X?.M9HMP!&\[2IW'.#VS5[^R]9T3QAI^NVVBI<6<VFFQN+*P:-3:-YID4J
M&*JP^;:<8Y&<=J[^B@#E/ 5AJ.G:;J<>I6+6DDVJW5S&&D5]R22%@?E)]>]9
M&J:7K<&N^,1:Z1+=PZY8QK;SI+&J(Z0M&5?)W \C& <Y[<FO0J* /+]/^VZ5
MXO\ !MO<Z=.;F#PY+!/#&R,R%3""?O8(R.Q[T[_A#]8LKJV\16UKOO$UZ?4Y
M-.$BAO)E3RB <[3(% ;KC)(SZ]W+H.GS:]#K;I*;^&(PQR"=PH0D$KM!VX)
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M,[R:6;T26P94CD5U1HBV6#X+#YE]#Q4NH^#)M1U77;MM4\J+5=.&GE(H"'B
MWX8/OY/SGC IFF^#]3LM<T[5I]<AEFM-.;3VCCL1&CIN5E(&\E>4&>3GMMH
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M8(&00<\].E:WAN]U>[\;^*K>[O()+6SF@BBC6$J55H@XP=Q_O'/!S[=!6C\
MWD?A>QT4:S"?LFI#4!-]B/S$3&;;CS.FXXSGI6K;^&KVSU_7-3M-66,:HB,8
MC;!C%,D?EAPQ;E> =N.HZXXH Z2BJ]A%<P:?;0WMR+JZ2-5FG$802.!RVT<#
M)YQ5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'R\'CT .UHKA]8\0+?\ C&R\/QS:A#9SZ=+<M-:0RAV<M&L95E7[H#,2>F<
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M $Y;:WW7$RV[K+ K!L.ORG.-I.0"!CFA_%FC:<]E837=U+<SV@GA46TDDDZ
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MU&?0'N=1U.74?.NI3;3RQHC&$-M0X0 <A=W_  *@#I:*K7Z7<EC+'8RI#<L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^M^'?"^IZ-'I5[.VF7+C2S+'M^U6QD!5=S8PP!(YQQ@]CCT:B@#SB^T"WO\
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M&[\-WVK:=>Z5;6KK;QAIK6:+=\K(Q'RG>>?45W^CV45MH<%HNG0V$6P@6<0
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M!IJ5SHHU;6C&VHW2)$60Y!CBRJD'T8[Y/^VGM6QK>A6VO6\,%S/>0I%*)?\
M1;EX2W!&UBI!*D'I6A##';P1PPHL<4:A$11@* ,  4 9OB1[U?#UXFFH[7LR
M>3"4&=C.0@<^R[MQ]@:K:EJ$'@[0K%(--N[FSA,=MMM5#&",+C>V2/E ';U%
M;U136\5P$$R!PCAU!Z;AT..^#S]0#VH @U6^DTW3)[N*RN+V6-<I;VXR\A[
M?X]JY;0K^?4[J>WO/#>LV]Q?H1>7EY%''&J!2%1,.QP,X QW9CR3GM:* /,8
M_#>I77@72/!,]K*LEI=Q)=7&PB(V\4F\.K="6"J HY!)R!C-:NJ^(+J77&CN
M/"FOW5C92AH/L]O&4GD'20[G!P#]T8Z_-U QW-% '&>(M<OG,&G2>&]9GM)H
M0]Z;*-'SD<PABR^X9AVX'7(O2>*)+'2=.O)O#VI017-RMOY(1"]LA.U7D .%
M'3@$]1WXKI:BEMXIS&94#^6P=0>@8=#CU';TH EHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^AF-=,^S0+ B<>6!*@V$=B.A'K77?8X=+U.RU&XUB[E#(;6.":0,'>1DP5
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MIOB!-4CU?6H;#7;+5Y3E8U%Y&5E)A$1)R59-J@ 8()'4T:E-8:OX>^)/]M+
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M]FL6Q&)!YO3!^9@H'S8'&.!5JS\!Z=JWPMT^ZT^TB76Y=,L[B*Y<EB\T<89
MV3C!R5/L<=A0!ZE17(>#[V+Q3*?%1M#!OMTM(%D3#)MYE]_ODI_VS]ZZ^@#"
MT?Q"^J>(-<TJ2Q:V.EO"N]I QE\Q-P.!TXQW-%MXA>?QG>>'WL6B%O9I=+.9
M ?,#.R\*.G*GJ?PK+\-D'XC>-QGD/8_^B*+8C_A<FHC//]A6_P#Z/EH [&J]
M]<M9V4LZ023N@^2&/&YVZ!1G@9..3P.]);:C97EQ<V]K>033VK!)XXY S1,1
MD!@.A^M275U!96LMU=3)#!$I>221L*JCJ2: .8TOQ7J;>*$T'7M$33KBXMVN
M+26&Z\^.55(#*3M4AAN';%,B\<I)8V^LFT4:#<7OV..[\WY^7,:R%-N A<8Z
MYP0<=A'8ZAH^O:X=1&JV37LUN]II]LDZM)'&?F=RH.0S;03Z!0#@YKC3:S3_
M  $TWP\B%=3DNX=.\G^)9DN@7!'L$9OIS0!VOB/Q=J^@QW6HQ^'#<Z+9'_2;
MC[4$EVC[[I&5Y5>>K#.#CCD[NJ:Y;:9H;ZH5:9#&&AC0?-*2,JH]S^G)/ -8
M?B76-%U*2?PY=:M8V\!P-1,MRB$1]?*&3U8<'T4GN15+7YM=GDGU#3M(L=0T
ME; _8Y6O_*V!D.]PGEG)(( .>F<?>- '4^'=5.N^&M,U9H1";VUCN#$&W;-R
M@XSQG&:LZAJ5IID$<UW,L:231P)G^)W8*H'N217.?#*6[E^'.A?:[:.#;90K
M%LE\SS(Q&NUSP-I/]WG'J:J?$^WM)M(T:2[AA=(];LLM*H(53,H;D] 1P: -
MJUU^XF\:ZAH,MK%'%:V<5TDRR%BX=F7D8&,;/?ZUO$@#).*\VFTC1]8^(FL6
MMQ;6]Q8#0+;RXA@Q8WRX( XX['MVK+T"^L=1T7P5:ZC)'->'1I)<Z@X-L$&Q
M"S*?]9(.@&1@%R30!ZG=ZE:6,]I#<3*DMW+Y,"=W;:6('X*35JO$=(.G7WAO
MX:3:@;6Y$=[-;RR3[7VJ(YMJ,6S@<+P?05[:A4HI3&W'&.F* %H) &37G>O*
MW@_QJ=6LK)98O$,'V(J$R%O1DQ$^BN"0WNH)I8["VT_Q[HWAF\ACDTA-%<VB
M3(#'/="0>8Q7H7V<^VYO6@#T.BO&G1[.PMA(P_LZP\:QQ6$SGB*WW %0Q_@#
MEE_#':NL\+7-F_Q,\9I;30L&2R;$;#!;9)N/'4YZ^] '<T53U73+;6=*NM.O
M$#P7,;1N/3(ZCW'4'U%>/PWLUE9Z#K=Q9('\)3_V9J[B')=2WE;EQUV@))_V
MTX[T >V4 Y&17F^I0G3=0\(V]];I#I^JZA/-J:%0$-P\;-#&_8@,<#/4HM87
MBVR:TT[XAV=G$!I$$%K<11J/DM[@\R;!_#\NUB!TW9[T >QN7$;&-59\':&.
M 3[G!Q^58O@_7I?$OABVU:>W2VDF>96B1RP79*Z=2!G[OI7/I>V$OQEM&M[F
MW<RZ#*&,;@[V\Z(KG'4[>GM7*Z/J"V_A+P1;7KJNBW>KWD=ZS'Y&(EG,2/VV
ME\<'@XH ](TC7[C4?%&O:1-;11)IGD&.1)"YE$BLV3P,=!QS]:M>)-4FT3PU
MJ6JV]O'</96TEQY3R% P12Q&0#V'I^5<MX/CT^T^)'C6VL!;QH19/Y4)  /E
MMNP!TYZ^YK>\=?\ )/O$O_8*NO\ T4U &KIEV;[2[2[90K3P)*5!Z%E!Q^M6
MLC.,\UY7#HEKIVJ^!]2T"/9J=W'B\*2$_:+?R"6:3GD!M@!/0L!Z57\*?V7K
MMCX>U*YUN&#Q!;70^TQ11*MW)/DK+%)D[BAY)&,  '@"@#URC(SC/-%>8V_G
M:5XMM)[JUM-4TZ\UB=+34X/EN;:=C(IBE!^^B_.H(/ 49' H ].R,XSSZ49'
MK7D/AW^S?$%CI=[?ZU#:^(K34<W$<4:K>&<.0T3$G<4(.,8QM Z!>*,^@:5=
M^#/'-\X8:AIVKWK6,RRMYD$JE3&$YX);:..3D#L* /;,@8R>M&0.IKQ?QC=6
M]SI'BMIWB76++3K7[3)=N"T<WE[U6V7@KR<EL_>Z XK<FTC2/$OQ.$-]&EY:
MW'AU)73S#M=A/C=P>HQ^GM0!Z9D9QGGTJDFI075Q?6EG)'+=68 D0M@*[+E5
M)'3C!^A%>3:C?::UUI^I64\,)'BQ(WFN9 ;IOWA209XV1 ?*%.?EQG%;.F6>
MD?\ "0_$)/(LTF9T,>U55]K6JL2N.<$Y)QUY- 'HE@]V^GV[W\<,5XT8,R0N
M617QR%) R*LYSTKR"RL[:\TKX3K.I820F-QO(W+]D<D'!Y&>OY4DL2Z=X2\=
M6%A<0V-I::V@BA+^7&$80,T(/10Y++Z?-S@9H ]@!!Z'-%<-X9TZSN?&VI:Y
M9K:P6CVL,4=M%-&Y$@W;Y"(V*KD%5ZY.WV%=O)&DT;QR(KQN"K*PR&!Z@CTH
M YNR\0ZEJUV9M-L;>;3(K^6QN&>4I*OEDJTHXP1N!&WJ1@Y[#ILCUKQ&ZTW3
MH_@[XMGAM;>*1-4NE$L2!6"BZP!D=@.@Z5U>JZ;I^B^-?#FG):)%HVI37,UP
MK$M'/=^6HCW[B020&(!ZL,]10!Z'D8SVI,CGGIUKQCQ-:&UT+Q[90@KHUK?6
M+62JQ"PRN8S,B8Z#+#@<#<:Z)O#FC_\ "V)=/-A";.[T0SW-N>4GD6<*'D7H
M[88\MG\Z /1JJW^HVNFQPO=S+&)YX[>,'J\CL%4#UY/Y GM7,?"YRWP^L%+E
MEBEN8DR<X1)Y%4?0* /PJO\ $RVLYK?PW)>00.B:[:*S3(" C,=PR>QXSZT
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M)<S2$VR"2X,4#RB!#G!<J#M& 3SVYZ4 6H=(TVWM9+:'3[2.WD^_$D*A&^H
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M^Q=*^P26']F6?V.0Y>W\A?+;ZKC!J]10!4L]+T_3R396-M;%E"GR853(' '
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MWF36"@R),\N\0-+D%(P#U! )4<X%=Y9Z!;V7B"_UJ.XN6N+Y(TF1RNS:F=@
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M_=^7;P !3O"ES=:?XBTRPUFUWW-S;RFSU>TF+PZBN Y:13RLFT \Y')P<<4
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M4 %8OBGQ!_PB^BRZM)8S7=M!@S"%E#JI(&0#C/7US6U6+XL_Y%Z3/_/>W_\
M1R4 +<>)+4>$Y/$=@!?62VS70\IP"\:J6.,]^.AQS27_ (BCL;NRT[[,\^K7
MBL\=G$X)55^\[,<!5' SW)P 37GGBVUN/AY8ZV+.)Y/"NLV\T;0H,_V?=.A
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MO[625+AX_M,4<<H1F (Y(4?-U[@\T >OU4U&XO+:U$EC8_;9O,13%YJQX4L
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M /U[?^S&NQH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMZ;ITC1W=TD3*H9\@D("< L0,+D@@9QG'% %]E#*5.<$8.#BJ.FZ)INCF?\
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MUJ<$^8 ,Y'J,<_2L+P7XAFO? ]OJFMWB-.UQ<1-+L";ML\B* H[X4  <GW-
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M1H(TF,+%7(:0LH..3@KP/:N]HH X+P/KEOI'A#PCH]_#>17=U:B%0ULX6-T
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MNRX.2%&%/3DXQ7H-% 'F'A!M+U"+0K*]T36(]=T=55TN3<"*U94V,X8GRRI
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M_>_'/0UT-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'!BC-Q_JWB3Y(T;@\>6!G@\LU &K'K=[)9WLR:49VAMEGMQ:W"R)=;@V%1R
M,_*.O]X=:UK:1YK6&62%H9'0,T3$$H2.5..,CIQ7&Z%X8OO#DVM76BVD-G!<
M6ZFUTJ2X+0K<C<6<8'R*V5&!Z9XX%=E;&9K6(W*HDY0&18SE0V.0">HS0!+1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2-7DN8].U&VNGMB!,(I VS/0GV.#STXID/B319Y)HX]4M=T,7G/ND"XC_O\
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M:5$6..-2S.=ZG  Y/ )KL** ,^^UFTL(+2:3S9([N=+>(PQ-)\S]"<#@>I/
MK0HHH **** "BBB@ KSOQ/9>&/$[W::Y#/INIV$S)::A%&\<I Y5HG _>=<;
M1GD'@<5Z)6*?#<18G^T]7&3VOI/\: //TNM9TN'PCK/BZ#4I(183VM[-:B02
M6\C.C(\BQ_-RJ 'T/6GZC!HFG7/@^>SL)K73)M<FN!]J$C,Y:%R9"LF60%N>
M<8 W<5WO_"-1?]!36/\ P/D_QK)U7P$NI:AIUT-<U2,V,IF16N&<EBI4\D\<
M$CC!H Y?4X?L=_XJUVUTP76EWMYIZJWD-(@>,_O+D(O+A<J<C[Q4]JI:F9)+
M/XE1JFHW#7UE UM)-:,IG/D[> $ SG@#&>/QKTO_ (1J+_H*:Q_X'R?XTG_"
M-1?]!36/_ ^3_&@#GM9N[:Q'A.2&QV0R,0=0AM&E>T(AV@!0#AFSL!(('/%<
MK L\7A,E[2_Q9>,1=3&2U?<(?M);?@+SP03M'>O3/^$:B_Z"FL?^!\G^-'_"
M-1?]!36/_ ^3_&@#EM26XU'XA:A_9_FPSW/A=H+>9T9 LQD9E4DCA@"&QU K
M.CC?6O!O@[2+6WEM]9TR\L_/A:,J]IY(Q*S<<*0& /1MPQG-=U_PC47_ $%-
M8_\  ^3_ !H_X1J+_H*:Q_X'R?XT >;ZI")?!/Q*CCMW:XNM2D:!1$=TPV1[
M2O&6&X-@CT->O6\BS6\<B-N5E!!]:R?^$:B_Z"FL?^!\G^-'_"-1?]!36/\
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MR6KB2+789)H6@.Y%$[EF9<9 VD9)[$>M>F?\(U%_T%-8_P# ^3_&C_A&HO\
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M(K%QCY1N9<D^M;_AN\@TE/&L>IVET4CU2YNY$-J[B2%E3!'&&R,\#/0UTO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&_D^X'7&16]I>D36MR][?W,-S?/&(C)#;B%%7.<!<L>OJQZ<8K555484 #T
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M906&?NE@67H<8Y%03>#_ !!_PA?B71H["R22_P!4^U6JPW'R!#(CD'*C  3
M]3V H ]0KC;_ .(*6<VL10^']6NCH[@7GE+'\B% ^\9?YAM(.!SZ@5V",6C5
MF0H2,E3C(]N.*\\TY]0;Q=\0+:RL!<-/- B.TJJB.;5!\^>=O(^Z">O% &_<
M>-;3[,MQ86ES?0G3O[3,D8"+Y)Z8+$9<X/R^W..*?'XQM)=2T.UCM+HQ:W;F
M>TNCM$9 3>5/S9#;3G&/7T-<T_@W6K*"WT6"*VU'2(M&6S@,\_EK#< $-*4P
M=Q.1@]L8XR33]2T>[A^%VE6%RUO:Z_I,5LUD$EW_ .D1[40=!D.?E/;YSUH
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M79\E0>0-P'7J/3FM+PRWBM_(@U[3=/M/LR[9+FWG\PW;8P"J[1L'<Y.>V.:
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M<2TC D9)8\#/ 'J< '1V'BN.\\0KH\VFWEG++:F[MI)]FV>,$!L ,2I!9>&
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MN+FUEAC4L%&YE*C)/0<T 8D/BVST^+P[IUGI&H2C4K#SK)$*-\B1J=A9GSN
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MD 99W+M@#@#+' '05IUC^%=>'B?PW9ZP+8VPN0Q\EGW%<.5ZX'I6Q0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5#6=1_LK2;B[5/,E4!88\X\R5B%1/Q8J/QJ_5._P!+L=46);ZV
M2=89!)&''W7'1A[CL: /--1M=1\&:SX;\1W=M;16\7_$MU6XBN3(95F;=YK
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MWEQ=WFC6<T]P@29WC'[P#IN]3[GF@"+Q'>P6'@2^NKB]N+*%+(YN;89DCRN
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M^5KI8[R1/-(CAP3@\'+$Y&">^1Q71?$J)K'X7ZBMK<W,+6T,8CE2=P_#*O+
MY;CKG.>]=!#X9T2VGLYH-+MHI+)=ELT:!?)4]0N.@/?U[U:U+3+'6+)K/4;6
M.YMG(+12C*MCID=Z .*\2Z3%H-WX;:QNK\&Z\10F<27DKB3=&^X$%L8)0''0
M'IBJ.MV^K:I<^,+& W,VI^9"NDW%M*5%MF-3MW _NR#EFSC<&'7@5WUUHFFW
MR6J75G',+1P]OOR?*8=&7T(]>M<1>^")K_7;^XU3PKH.K-<W#217\ERT+K'P
M%5U$9.5  R#SUXH DGT:"Y^)]CIMU)</"OAR028N9-TG[^/.7W;R,^]<Y9QC
M4_#GP]DOWEN)$UR:U\V25BQC7[0H!.<YPB\]>*]+TWPOIUBEK(\*S7T%L+87
M1+;]G]T$DG;[9/XGFGGPIH!TU-..D6C623>>D#1@HLG)W =CR?S/K0!QNH75
MSI7B,W6H6[7NC7&I0K;ZG9SGS+)MR((9$[QEAC(X^;)&36G\3[6&YT/2S,N[
M9K-ECYB,9F4'I[$UTJ^'])2[-RMC$)6E$S8SM:0='*]"PP,'&1BK&HZ;9:M9
M266H6L5U;28W12J&4X.1Q[$ T <=9+#K?CCQ%H=^9/LNGVMJMC")67".K%Y5
M(.=V[Y=W4;1TR<WOA[JMW>^"],;5KH27LC311R2, ]PD<C*KX[DJ 2>_7O6U
M<^'=(NW@>73X-UO'Y,3*NTK'_<R,?+_L]/:H=0\-6&H7VDW#6T"'3'WV[+'A
MHQQA4(^ZO S[#% %'Q=-";K0[%Y9FFNKP^5:(X1+G;&S%96[(/O'KD@#!K@7
MN;M_!EU']ON(WM?%HM8C!<OA(C<H-@.?F4;B &!'3BO5]4T73-;ABBU.Q@NT
MBD$D:S(&VL.X]*IGPCX>,<L?]C682687$BK$ &D'1CCN.WI0!R]GH\;^,O%/
MAV.ZO8[&XTZVG'^E2,\4K&52Z,6)!^53UY(I/!]W<:T=-TF]$B7GAPNFHD,P
MWS+E(^?XE==TGU"UU5]I7V,7>J:+I]I)K;Q!%>=V02 'A689. ,X]ZDT/3Y[
M.&XN;X0?VA>R^?<^1DH#M"JH) )"JJC)QD@G SB@#G?'5LEYXD\&6TCRHDFH
M3*QBD*-C[/)D!AR/3(YKE[V\N_"<_B33;6_N$T*&_P!.3SYY7E^QK,?WR[RV
M[;C9_$" _!!.:]3U'2K#5H4BO[2*X6-Q)'O'*,.C*>JGW'-(ND:<NG2Z?]B@
M-I*&\V%D#+)GKNS]XGN3UH \Z\3Z5+I'AGQ7=6WB E)M,^T16=GYD2P.O216
M$C8#=". V,\X-6I1/H7C.Q?3Y;J:2\T*YFFBEG>032Q^64.TG /S$<8X.*ZV
MU\'^';+29]+MM&M(K&X.Z:!8\+(?]KU_&K2Z%I:7MO>+91_:;9/+AEYW1I_=
M![#VH X?PS;?VM:>&?$D/B2(/*@6Y2.-RUXS)\\<F9"-RG)X7Y=IP !4&B:=
M;PZ/\0Y8#/%+%?W:1R1W#JR@01L,$'.<]^M=Q8^%- TS59]4L='L[>^GSYD\
M405CGKSVSWQUJ2+PWH\$5Y%%I\*1WI)NE&<3$]2_]XGN30!Y[;VL%YJ?PNN+
MO<\DFE2^9(TC G%O&W)SZDFKUM=7>E^+K0:O;-<6UWJ<PL=8M)B0S-Y@6WG3
MJ HRHQD90=.:[1_#>BR6UE;R:7:O#8MNM4>,$0G&/ESTX[4ZWT#2K6Z^TPV4
M:2"5IAC.U9&SN<+T#')RP&3D^M '.>/XWDOO"B)=74"SZPD$H@G>,/&8I"00
M#ZJ.>H[$5E&PBF\3ZAX/_M#[/;VNG1-8QW3RRNP<R%Y4;S%)93M&3D@ 8QSG
MO-0T?3M4>W>^M(YVMW\R$N,^6_\ >7T/OUJOK/AC0_$+0MK&E6EZT!S&9XPQ
M7VSZ>W2@#D=(F-[XIL_#>JZJ=3M[;1DGBE;,8O7,C(TA&?FP%7')'S%NX-8>
MFW,RZ!X:F2]N'/\ PELMMYK7#,7A\R8!&8GYE^5>N>@KTK5/#6B:NML=0TFU
MNS:<VXDB!V>P]N!QTK#\->$POA>ZT?Q#IUO+%)?SW2QE@ZX>5I%QZ$9H P[Z
M:0R?%&**\N%2UM8Y(?*N'7R7^S,QVD'Y?F&2!U[TDUG_ &KK?@>RN+R^%O>Z
M+/\ :8XKN1!)MCBP>#P?F/(P3WR.*[=/"N@1I=*FD6:"ZC6*?;$!YB 8"GU7
M Z=*D3P[H\=Q9W":?")K)/+M7QS"O]U?0>PH X(6K:_+XETM]>73;G2;A8K>
M27>TUI"L:%)5;S%X;YB21SSDD8 N6DZ^(M:\66.JSO*VG6T"6R@M%M1H=YF5
M0>&9B>>H  ]<];J'A70-5U2#4[_2+.YO8,>7/+$"PQR.>^.V>E/U#PUHNJWT
M=[?:9;7%U&AC65T!;;_=)[CV- &3\.XTG^%_A^)QE'TZ-6 .."N#R*X3P]<#
M2_ /@ZVA9X+74M6-M>R)(1\GF3;4SGY0S*%.,9&1WKUS3]-LM)LH[+3[6&UM
MHQA(H4"J/P%5%\,:$EC=62:19K:W;F2>(0C;(V<Y(]<\^QH P=)$^F?$S4M(
MM&<Z1)ID5X8BQ9;><R,F%S]T,JDXZ9!-4=2T:UUSXLWEI>M<>0= A)6&=XMQ
M\^7&2A!./3.*[>QTVSTU'6T@6/S""[<EG(& 68\GCCDU!?:%I>I7275W9127
M"(8UFQA]AZJ6')7V/% 'F.B:MJ$D?AS1=3U(-8SS:A##=7@9Q>>5(%A#D,N[
M*ER,GYL#@FN_\):=)I6G7=A)K!U-8KN38VUE^SJ<,(02S$A<\$G/..U7M2\/
MZ/J^F)INH:;:W%DF-D#QC:F!@;1VP..*LV-A::5816=A:Q6]M"N(X85"JH]A
M0!Y#<Z<\W@GQ=K"ZMJ::CI&K7IL9?MLA\KRY/E3!.&R,+\V3R*Z"RTPZW\0M
M4@U.XOT5-/L+K[/'>2(J3%I"< -P,KTZ>V:U/"GA+[&^K2ZOI\7FW.K3W\6)
M-ZE7?<FY>A=?4@XXP:Z6+1].AU675([2-;Z5=DDX'SLHZ GN/:@#S!KZ[O\
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MHH)VL.,@=5&:YZXT'4;#2AJ@L+J2)O%HU@VL41:6.W)VY\L<Y/WRHY&>F<T
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M[IYD2Z9'AMQ=,DL$D;>2>C@,H++QC(S5>Q\;>'M2NK*WM-1$CWR%K8^2X27
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MH0^T?*0^2=N0 >#0!V%(2 "2< =2:Y"'QK=2?VM"-#FN+JQ$30BS=I(KD2'
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M:JT@!VJS8!/8$X./R->7:'>P_P!DW^M>(-/M)IH/$$XM)1.3(+CSO*1<[1A
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M<]M10!S&NZ-K.HZMH>H6TEEMLC(;BSN"[1,S !9%('+)@XR!]X\BN/O](O=
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M""3/RK@8R1G./K7744 (V0IV@%L< G S7 IX&U27PIJ&ES7EO;7KZH^J6=U
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M$VBRN8DV;<JL/8J>H;!/7TQ6.EYJNC>'?%&N6&IO +/Q-.3:B)"DZM.BL'+
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M;*U:1?,P-[!>"V,#KUQBN>N=0\1Z#YVM3SB[T:'3II[B*>2/>9$0NIBV*."
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MZ\BCBF?U"9Q^/(!]=J^E '$ZCXBU>SU*UFAU)KF.3Q#'82+#$GV9(7?9Y9+
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M#5X;>]U*V75)FGE\BZ*&)V(+-'C[I)'/7OTS71*-J@9)P,<T +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK3C&K&-=S"(JP^8-\H)W9!R< 5T=]KVDZ;,8KW4+>W<!6822 ; QPI;^Z">
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBJ&K:M!I$,#2J\DMQ,MO;PQXW2R-G &>.@))/0 T 7
MZ*YL^+?*AO1<:1?QW5K=16ODK'N65I2 C(_0K\W)XQ@Y]XSXWLH;75GO('MY
MM+NHK6>,NI4O+L\LA\XVG>N2<8YSTH ZBBO/?B#?2W7@J[DGM+BTEL]1LU!6
M3<) 98B67;]Y2'(Y'4'BNETKQ*-1UV]T>XTZYL;RVB2X59V1O-B<L P*,<<J
M00: -VBL?4-?2SU9-*@MVN;YK=KKR1(J$QJ<?+NZL3VZ>I'&:.H^-+2Q78L.
M^Z6T2[DMY)TB9$;.%^8C+G:W ].2,C(!TU%<M8>.K#4[W0X;6VN&M]:@>:UN
M6VA/D&60C.0X],=CSQ5FX\66MK%NFB,;27CV=N))443.F=S!B<*HVMDGN, $
MD9 .@HKB/^%F::-.GN?L-U));:A'I]Q%"R2>6[D!6!#?,ISP1D^PK1'BNZ+K
M WAZ_AO/*FG:&9D"K'&P7.\$KELC SZYP.: .FHKDAX]LY8_#SVFFW]RNNQ-
M):[ @P50N5;+<'C']WWXJ:R\;6ESI<US-9W-O=PZ@=,:R8JTAN.,(I!VD$$'
M.<8R>U '3T5SC>+X+6/4?[3L;FRDL98HB'QLG:7&SRW.%;).#G&TYS@<TNA^
M+[/6M9OM("".]M$25@LJRI)&W1E93V(P0<$4 =%17,ZGXO:Q\03:':Z'J%]?
MI:"[183&JR(6V\,S#'(/7'MG-,T[QQ:ZSIVF7&FV-U+-J#RQB&1=GD/&#O$I
MY"X(QWR2,4 =317(CQ_:-HNEZJNGW9MKZ\^PLQ* 6\OF&/YSN^[N!&1GMZU;
MUWQ=%H4.K32:==7$.F6R7$SPE,?-GY>6'( R?8CKF@#HZ*Y5O&C+K,6EMH.H
M">ZMFN++F/%P%(##[WR8W _-CCWXI;;QUI\^C17LL,EM<27DEA]EG=%99T+;
MU+9VX 4G.>GN0* .IHKB3\3--73[RX-E<R2V5[%97,4#))L:0@(X8-\RG=QC
M)]JLS>-9(TUZ$Z+<PZAI=H+Q;>>2/$T1#88,K$#E#D=?K0!UM%9'A;4;K5O"
M^FW]["8IY[:*1^5PY9 2PP> 23Q6-=?$72+6XMRV'LIKS[$+A)D)63<5W&/.
M[9N&-WXXQS0!V%%<MJWC:'3=,U/5(=.N;S3],=X[F:)D'S+PP0,1NVG@GCD'
M&<5>B\2)+X@N=&6SF^TPV27JG<NV1&8J #G@Y4]: -NBN8L/&<6JZ;HUUI^G
M74KZM')+#&^%$:I][>W('4 =<Y^M8'B'6K;Q)X>\(:U9B>*.;7[10CM@@B8J
MRL <'E3Z]* /1J*Q/&&LW/A[PCJFK6EN)Y[6W>149@ ,#J?8=<=ZAA\1R?\
M$OL3922:K=6QN/L^]1MC7 +LP. "6 &,G)Z<' !T-%9.@:_;>(+2>6".6&:V
MG>VN;>8 /#*O53@D'J""#@@BL*'Q?J/]M^*89-'FEM]&$>U(9$+N#'YA/)&2
M01@>WK0!V=%<Q!XUM;B[\/0I:3>7KL!FM9MZ;1A Y5N<[MIZ#/?TJ6?Q=:V\
M2F:$Q2374MK;K+*B"4QY#/N)P%!4\GGV.1D Z*J>HVES>11);:A-9%90SO$B
M,77!ROS @9R.>O%>>^*?$UGXG\$7%Q:^;#<:?K%K;31^:#M?SXP<%3AU*MP?
M>NTA\1)+XKN?#[V<T5Q#;"Z65V79+&6VY7!SP>#D#''K0!K001VT"PPKM1>@
MSGZDGN3U)[U)7-/XRM5MK(F )<WL+7$,,\\<?[H$#>6)P,Y&!R3GIP<7O#7B
M*R\4Z)%JEB'6-F:-XY,;HW4X93@D=1U!P: ->BN8\)ZBWB)]0UIR3"+R6ULE
M[+%&=A;ZLP8D^F!VJKX3:5?&7C.W>YN)HH;NW$8FE9]@:!6(&3P,D\"@#L:*
M\\\1>&Y=,OM&U/3-1U!M?GU*%)':Y<I<1DYE4Q$E50(&. !C:.];>H:BVA>-
M=(MPQ^QZUYL3H3Q'.B[U8>FX!P1W(4^N0#J**Q?$/B.+PZNGM-9W-P+V\CLT
M, 4['<X&02#Z] ?PK)/CF;S=6M5\.:B;_3%62:WWQ?ZIE+*X??MY"D;02<C\
M: .PHKGX?%MI?II:Z9#)=7&I6?VZ&$D)LAPOS.3]WEE&.3D^@)%"3XA6$>F1
M78L+YG.I+I=Q %7?;3E@N&&[D<@@KG.1ZT =?6(V@.WC-/$7VP K9FR^S^5Q
ML+AR=V?O9 ]L=N]8]]XZF@TKQ,Z:-<0ZEHEM]H:VN)$PZ,C,K[E8C'RMD#GC
M%9&H:A=R>)_ 6HRV=R]U-!=;H(Y%/FGR 0<;M@Y).3C% 'I5%<K;>.;2?2TN
M)+66VNCJ+:6;:=U&RX&?E+@E<8&<C.>,<G%;^G7DM[;N\UI+:R)(T;1R$$\'
M&01P0>H]O2@!NKV5QJ.F36MIJ$VGSOC;<P*K.F"#P&!'.,?C2Z9IT>EV"6L<
MDDI!9WEE(+R.Q)9FP ,DDG@ =@ *Q;[QG;VEKJ5]%8W%UIVF2M%>7$17Y"N-
MY52<L$S\WT.,XK(\1ZF^H^,/#.FI9?;M(O;>YN&3>ACN0$CVG!/(4.3SW((Z
M4 =[17-:E?6GP_\ "4<D=I>76GV>$;$N]XD+?>)<Y*C/KP/85>O?$-MI]VT=
MPA6"*R>]N+D,"D,:_P![OSSC YVGTH UZ*YM/%T:7FF0WNGW%HFJ@_8I9&4A
MGV[A&^#\C$<@<C@C.>*KMX\M$\.RZTUA="&"_-A-'E-RN)1%GK@C<1WZ4 =4
MX<QL(V57Q\I89 /N,C-8_A;0#X9T*+2A=&YCB>1TD:/:WSN7.<''5C^%47\8
MN?$=[HMMH6HW,]D\ F=#&%"2DXDY;H,=.O7C@UL:KJ\.EBU1D>6YNYA!;0)C
M=(^"QZ\ !58D^@]<"@#0K&M]!E37IM3N]5N[M-Q:UM9 @CMB5VDK@ DXR,DG
M )]36=/XV2SM99KS2+Z%H=0CL)5(&-TC*%=6) =#N'(Y]JL7GBZ"QU#6+.2P
MNGDTNR6^?RRA\R,[ONY8<C8W!Q0!T58VBZ#)ID\]S>:K=ZG=295);D(/*CR3
ML4* .O4]3@>@ PW^(@BTNVU.?P[JL=E=-:K!-^[(?S^!QOW<'VR<CCFKK^,U
MA"07.FR6>HNLD@M+NXBC(16VABVXK\QZ8SW[#- '445QEK\1]/U"+0Y+#3K^
MY&L><(0@C!1X@2Z-EN#D8S]WOFJVJ>/KD>%9]0L-+ECO+?4TTVY@F=,P.9$4
MG()#<.,8XYYZ4 =Y1566\%MIDM[<PR1B*)I9(U&]@ ,D +G)X[5BV/BX7>IQ
MZ=+IEU#=3:?_ &C!&60EX\@%3R-K@LO!XYZT =)17&:=\0[?48=$NO[(OX+#
M6)?L\%U+LPLIW%5*AMW.P\XQG\Z;=_$6*UM=7NCH>I-;:1=FWO9,Q#RP I+C
MY_F'SYP,G YQQ0!VM%8J>(HY/$5WHB6DQN8+-+Q6W+LD1F90 <\'*GK5*P\9
MQ:MINC7>GZ==2OJT4DL,;X41JGWM[<A>H ZYS]: .GHKSGQ%K5MXD\/>$=:L
MQ/%'-KUJH1VP01*596 .#RI]>E;L6JV,?BWQ L&DWC:I:64+S,'!^TI^\V*@
MW8!R&Z[>O- '4T5S"^,HE\0OH]QIUQ#)!:M=W4QDC:.VC&<&0AN"<' Z]^G-
M0VGQ TRYUG3M/=/*&I1O):R^=&X.U=Q5PI)0[>1GZ<'B@#K:*\T\5ZV=:@\)
MW]K9W*V$^O6GD77F@"1?,ZE ?NMC*DY]P,UW6MZQ;:%IIO;H_)YD<2\A06=P
MBY)X RPR3T% &C16%-XCDMK9FGTJZ%Q]M2RCB3#B1G52'##@)\W+'&-IXSQ7
M+^,]<BU[X9^+E6*:VN=,\RWF3S.DBJK AE/*D,.OXB@#T6BN<U'Q/_9*2Q)I
M]Q<FTT_[=.ZD(HC&1A6/#.=K<>W)&15:\\=10W&F066D:A?R:G8M>V@B\L"1
M556V_,PP<..N!Z9/% '645SNE^+$U#4M3L+C3[BPN-/@CGD6Z=!N1P2""I/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVFNW.IVT,TN8YX9MP:-B/NMM8\X(!_3OH=9T^XU>XTJ&Y5[ZVC62:( Y16)
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M;VMTT-JUE<V$\ODAXBP92C8(4@CN.AKI-,^WFR5]2$*73DLT4)W)'Z*&(!;
M[X&3G@#BKE% '(^ +)]$L-2T&;B2ROYGCS_'#*YDC<>QW$?56':I_#^F:C9>
M*O$NH75L$M]2FAE@(D#'"1+&0P[$D9'6NC:&)IEF,:^:H*J^.0#U&?3@?E56
MWUG3[K5KK2X+E7O;5%>:( _(K9QSC'.#0!RL;^-SJLUW)X>THRN3%#,^I$BW
MB)[((^3P"W/S$#D #%KQ!8OJ_CKPS#$,QZ8TM_<L/X,H8XQ]69F/T1JZZF1P
MQ1%S'&JF1MSD#ECZGU[?E0!SGC+2K_5H]%%A LIM-5@O9=T@7Y(SD@9ZDYX[
M>XJHNCZK'XG\4ZA]C4P:E9P06W[U=VZ-9 =P[ [QZ]*Z6_U:QTORA>7*1O,2
ML4?+/(1U"J,EOP%,L]:T[4+A[:VNT>Y1=[P'*R(/5D."OX@4 <3H?A76] G\
M-ZI';QS7%CI(TF_M1, 60$,LD;'@G<.AQP:+WP;JAMFN(88GO+SQ!#JUQ'YH
M"Q1QLN$!/5MJCMC)/. ,^BT4 <)J/AG5=2U/QFPACB@UK2DLK:1Y 2KJDBY8
M#H"9!TSTIT6C:[+JW@Z\N+""-=)BF2Y6.X#8WQ",;<@9Y&3TX/&:[FB@#SZW
M\,ZA_9^L6FI:):W]GJ.M2WDMM)*I)MW3 P>@D#*IZCV:N@\&Z+=Z#HTME<SS
M21?:9'M(II?->" XV1EN^.>YQG&3C-=#10!P,/AG6M.TSQ-H-M##/9ZO-<36
MMTTH'D>>/G61>IVDDC;G/0XJVWAR]LO$OA1[*W\S3=%L9K-W:4!V#)&JD#OC
MR^>1UKLZH:CK6FZ3-9Q:A>PVTEY,(+=9&QYCGHH]Z )=1CL[BPFM=0,7V:X0
MPR+(P <,""O/J,UP_A_PE+J7PXO]-OM0:=]1MVM8+LKR+9 4MS[_ "_/[ES7
M::KHVF:Y;);:K8V][ D@E6.= ZAAT.#]3^=754*H50  , #M0!Q::%K&LP>&
MK;6;:&W.C7,=U--'*'%Q)&C(FP=0"6W'=@C&.<Y&+>^$_$S>'M9T*VL[)HIM
M8_M""Y>Z(\Q&N5FVE=ORD8.3STX!S7I]% '+Z/I>I6WCG7M4N;:-+2_AMDC9
M90Q#1!PV1QP=W'TY H\9:+JE^=)U31# =2TFZ^T1PSL52=&0HZ%AG:2K<&NH
MHH XO7]*\1>(O"DGG6UI;ZBEU;W,%BL^] (I%?:TNT?,V#SC X]S52YT+Q'>
MZQX@U&6PM(UU+15LHXENMS)(#)@$[<$?."3QCMNKL;/6=/O]0OK"UN5ENK$H
M+F, _NRP)7)QCG!Z5>H X34/#^LW'@/P[I,5I&;W3YK)YE,P"8@*EL-WSMXX
M^N*M:]IOB"V\56GB30;:VO2UG]BN["YG\DE Q=65\$ @E@?8UV-4;76=/O=3
MO=-MKE9+NQ"&YC /[O?G;DXQSM/3TH YV\TG7+OQ'X6U.X@@;[ ]Q)=B*083
MS8RBJF0"VW/).,]<<X&/<^$M<N-!\1VZ6T"W%WKB:I:J\PPZ*\3;&(!VMB,^
MHY'->D44 9NI1ZK=^'+N*SDBM-5EMG6%PVY(I2IVG..0#CG'X5QVC>'M>LO$
M^F:S)I-E$(]+DM+I4O#)*\A9&WEBHWEBAZGW)[5Z'10!YM9>%-=MO!_A#2WM
M(C<Z/J4=S<E9QM*+O^X>Y.\<''0T^]\+:W<^&_&^GK:1B;6[MYK4F88"LB)\
M_H?D)XSUKT:FNZQQM(YPJ@DD]@* ./?2M<MO&L.M6EE;RQ7.E1V,RRW&TV[I
M(S;N =P(<C ].U8NB^%_%.F:+X6T^XM+&ZM+&&6*\LC=E49R08Y&.PA@OS?+
M@@$Y&3C'8KXNT%]+L]374$-G>SBWMY=C?O)"^S &,_>&,]*VZ /,[3PCX@MO
M!^A:2]I:M-IVM+>L8Y_E:)9WDXR!AB&P![<D=*W#IVN6GB[Q!K5G8PR?:K"&
M"T66<*#)&7/SXZ*=_;)XKL** ."T?PQJ46@W>E7UL#<:NLW]KZDTRL\C/&RY
M51V!*A1P HJQH5EXMETM-"UVVL(;:&W-O)?VUP7>Z785!"%1L/0DD]L <\=K
M10!YC%X;\6KX:\/Z#+8V#G1-0MI%N_M959X86RIV[25.W /7GIGMW/B&UEOM
M&>V33[:_65D6:UN"-DD>1N&2.N,D>X'2M6H+R\M]/LYKNZE$5O"I>1ST4#O0
M!Y['X2U_2])DM='+C3?[3BGCTJYO#N6U"8>+S!NP"_S;<D8&">2*CF\':\?#
M?C32XK&PB_MF7S+189\(FZ-%((VC &P\]_05Z+8WMOJ5A;WUI)YEM<Q++$^"
M-R,,@X//0U8H X+6]!\0ZK?7"-:6EQ87&E?9X([BXP+.XPP9]H4AR<KANHQC
MC)I-(\/Z[;:IX/GNK.!8])TR2RN?+N WS,L:@KD#/^KR?KQG'/?44 </XKT>
M+5_%6BM97B)<R>;9ZA&A!,MEC>ZMZ?,$4>GF>]=C>6R7EC/:N2$FC:-B.P(Q
M_6J]GHFEZ=?7=]9Z?;P75XV^XFCC >4_[1[U?H Y?X>QRV?@NQTNZ&V\TP&R
MG3T9#@'Z%=K#U#"K?BJ/7I-.MAX>6!KI;N*203RF-6B4[F7(!/. O3O6O(MO
M;F6\=55EC^>0+R5'/..3CG\S3;"^MM3T^WOK.3S+:XC$D3[2NY2,@X."/QH
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M% !1110 4444 %%%% !1110 4QH8WECD9 7CSL)_ASP<4^D8$J0IP<<'&<4
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MA"3(K2(CQRJ<;6RQ[#CCWK<\3:UK.CK>K'?VX-KIC74(C@\R2:52Q.]!G9$
M%&[(Y/7C%6[WP+9ZE8ZU'=7+K=:NT+3W$"*FTQ$&,JIR.",G.<Y],8;=>!EN
M[Z]N6UO4%.H6(LKY0(_WX&[#?=^4_.WW<"@"C_PD6O:CKGAZSLY[*VAU;2'O
M6+V[.T3@1GCYAN'S\#CU.>E0:7XTU*[T_1]/F: :O?:G=:>UPL>$"VY<O(%S
MU*H !G&6ST&*V;#P8-/O]'O%U6YFDTNR:RB$J)AT;;DM@#GY%QC'3OR:J'X=
M6W]FQP)JEW'=V^H2:C:WB*@>&5V)<8QAE.XC:1TH Q[.?5-*\2_$&>*ZLY;R
M*.Q,<]WB*,+Y;<OCC@9Z8SCMFK3>+=6C7QA#!,DITC3X[ZTGNK1D9MR2$JR9
M7(S'P<#KWJ[=?#N._&LO=ZW?R3ZJ+<R2*L:A'@(*,H"]B.G3'7)YJ:7P)Y\^
MKSS:Y?22ZM8K9719(L, &&X *,'#D =.YR: *,7B#7[>VT07=Y927'B!X$M5
M2W*BU'E&24L=WSG &.G)Z8XJ3PM%<P_$WQBES<"X86VG[9-@4E<38W <9Z\C
M'TK2U#P9!J'A_2]->_N8KG2FCDL[Z(*)(W0;02,;3D<$8P:GT?PP^EZ]?ZS-
MJMU=W5]%%%,KI&J'R]VT@*N1]X]^_.: *OBO5]8T_6O#UCI<EFBZE<R6\AN(
M6<KB)W####@;>G?U%8]MXF\16S>(M'O[C36O]*EMF34'4PQ/;S'[Q3)^=0&P
M,\G ^MKQRLDOB7P>(97B>*_DD>5(]XC7R7 +=@I)"\XZ\$=:NW_@:WU&VNFE
MO[A-2N;N&\:]B504DAQY852"-JXZ'/4DG)H S(-?\1:A#XLL=+D22_THQ-8O
M=6I1I@\0?8Z<8.<@' ZCBM+2O$-QXB31Y-)NXQ%-8FZNFDAW;2?E12 1@[Q)
MD9_Y9L/>D&FP>#;K5O$EQ>ZK?F]\D7$4< E)90$#A8UST[#@#/%3^$M"CTS3
M]0NH+=[*75+J6[\N0?-"&)VC:>G]XKV+L* .7T[QEXC3P39^)[^XT^07P6UA
MM$MV4+.\_EJ[/NY4#)*X'0<]ZZ3^V=1TGQOI^A7TR7=KJEM+);S",(\<L6"Z
MG'!4A@1W&,<T6_@33T\#?\(G<W-Q<V2@^7*<+*AW;U8$#&0W(./KFK]KX?=-
M0AU*^OWO;^WMVM[>5XE01AL%FVCJS;5R?;@#)R >;VO_ "1_PY_V'XO_ $O:
MO89 YC81,JR$':S+N /N,C/YBN13P##'X7LM!75+GR+.\%Y'*43>7$IE /&,
M;CZ=*ZUW6&$O*X"J,LQX'UH \M@\8^+(_!VD^+[F;3I;%[A8;RRCMV5BC3&/
M>KEN""1\N.G<UL0:_P"(9-8\1/->V,>FZ%= RHEHQ>:'R!(5!W_*PSUYSZ#H
M:?P_T!]3\ :1:ZE<3&UM[AIWL9(=C;UF9T5R>=N=K8QD\<D<5UFF^&HK#4-:
MNI+E[E-7D$D\,B+M!"!,#';: ,'- '/2^*]7LO#OA_Q/.\$MEJ<MN+FS6/'D
M1SXV%&ZEE+*#G(;G&VKMKJ^O:_:7&I:++:(D&HO:I:SK\LD4<FR1F<9(8X9E
MQP. 0:L6'@F"SLK'3)+^>XTK3YUGM;655RA4Y16?JRJ>0.O R3BHX? J6FL7
MMQ9ZQ?V^FW\YN;O3$V&*20_>(8KN4-W (S].* *-YXA\2ZDNJS>'+$SOI]ZU
MK' PB$<Y0@2!V:0,IY;&!Q@=<TM_K&H>(+3Q7!93)9PZ7$UN5>,.99?)WN&.
M>%&X+QSD$YZ"KLO@8+KUYJ&GZYJ.GVVH.)+ZR@*>7,^,%@2I*$@#)4@GU%.N
M? \9U74KS3M5NM/BU2(1WMM$B,DA"[0Z[@=K8X..OUYH QO".KWUNG@C1TDC
M^QWOAX3,"GS(\:1 8/I\YX([5"WC#Q"=#L[B*6R-P_B1M)<O <-&)C&#PW!P
M.>O7C%;J>!5MH= %GK-[!<:- UK%<;(F:2%@H*L"N/X%P<<8[U"GP\ABL(K.
M/5[W9%JQU92RHQ$N\N%R1DKD\YR3ZB@!AU7Q"NIOX>^T"YU"WM!=2W=K;1J#
MOD=8QLDD   3YL$YR.1WIWGB_6M)L=(?Q/ =#^T6[BYNHHA<0Q7 8!%<J2%1
MAENO?&X8-;FN^$#JNL6NLV.KWFDZK!$;<W%LJ,)8B<[&1P00#DCTS4[^&Y!&
M(X-4F$36YMYTN(UF6;<22[ X^?+-[<],8  -;3I9)],M)998I9'A1GDA.4<E
M1DJ?0]JX#5/%?B#3M-\50>?;OJ^DW$;VD8M\BXMY "ORYR6XD!(X!3TS7>:3
MIEOHNCV>EV@86UI"L,>\Y.U1@9/K52?PY8S^*;?Q ZL;N&V:V S\K G()'J
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M*'.2#&"9  21N '5: /3;[4;73HX7NIEC$TT<$>>KN[!5 ]>3^0)[4BR7_\
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M#W4?=!]!6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !45S;07EO);W4$<\$@VO'*@96'H0>#4M5[
MV_MM.MO/NI1''N"#@DLQ. J@<DD\ #DT 0#0])72_P"RQI=D-/\ ^?7[.OE=
M<_<QCKSTI3HFDE9E.F6169524?9TQ(JC"AN.0!T!Z55A\4:-/;7LXO-BV,@B
MN4EC9'B<XVJ48!LG(QQSGC-+'XGTES>J;AXI+*,2W$4T+QR(AZ/M8 E>#R 1
MQB@">YT+2+VRBLKK2K&>UA.8X);=&1#[*1@5+)I6G2SP3R6%J\UN-L,C0J6C
M'HIQQ^%8T7CWPW,]FJZ@P6]B\VVD:WD5)AMW85BN"V/X0=W;&:>/&_A[^R;G
M4WOFBMK6?[//YMO(CQ2<85D90P)R.H[T :2Z)I*6UQ;KI=DL%SS/&+=0LO\
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M8VEZT+75K!.87$D1EC#>6PZ,N>A]Q6-_PEEJ?&,?AY(+EG:S^U&86[E>6"J
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M1A%+8YY/3).*BN/$YT_XBNEU>WATM]%%S':?96+B3SMI*QJGF$[1T(..>@H
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MIIXTFP%DAW+;_9T\M3ZA<8S6%\.]5N=8\/W=S=7DMV5U*ZBCFE4*QC60A,@
M8X XP*T)?&6A06FI74MW(L.F2>5>,;67]RV,\C;G&"#D<8(]: -.?2M.N6MF
MN+"UE:U.;<R0JWDGU3(^7H.E1#0=' B TFQ B<O'BW3Y&)R2.."3SFDEUJQB
MDBB>69'F@:X3]P_^K7&2?EX(W#@\\CBN/O\ 5YH_#W@ZZTC7KN\MKK5K>WDN
M9$4-=1,S9W?*".G;''7- ':QZ1IL7VCR].M$^T@B?;"H\T'KNX^;\:6RTK3M
M-LS9V-A:VMJV288(51#GK\H&.:P-&OKZ3XB>)K">\EFM+>WLY((G"@1%_,W
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MB@"W=Z#H]_=&ZO-*L;BX,9B,LUNCOL(P5R1G&"1CWJ[%%'!$L4,:1QH,*B#
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M!4C;U]!7JDLT4"AI9$C4L%!=@ 23@#ZDT+-&TKQ+(AD0 L@894'ID=LX/Y4
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ML=4NDL8KNROVGCU"W9EG>WW,5A<;0"-I"DECP#QS0!N:QKBZ9>:;I\,0FO\
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M5Q;7EE'JVG:K<7]L6+M%(D[,7C?@$<-C<,].E $&DZJOA_Q7X]U"_M(8&5[
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MP7/DRHFP/&0/F&.JG;TZBL[1O!7B#1XO#2C4-.G&E6;VLD4L;F-6)&)4&>7
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M$EY9PP12%51(DP0R]&+\D[LX!&,8S6U;7=\GC/PY8)?SK9W.ARR- -NT.OE
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ME;V[2'+M%$J%OK@<U9HH **** (I;6WGEBEF@BDDA.Z)G0$H?4$]/PJ6BB@
MHHHH **** "BBB@ HHHH *K/IMC)>K>/96[72_=G:)2X^C8S5FB@ HHHH CG
M@BN87AGB26)QADD4,K#T(/6G(B1HJ(JJBC"JHP /04ZB@ HHHH **** "H+N
MRM;^'R;RVAN(LYV31AUSZX-3T4 0FUMS:_93!%]GV[?*V#9CTQTQ26MG:V,
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M<-PJR!I&!9QM.!_#@DUZ%10!ROB'0%'A37Q86UQ=ZGJ-A);!I'W2/E&"+EB
MJ@L>.!R3U-3^&O#\%KIFDSW,-S]LM;18D2YE+FW)4!PO) Z8SR<< XXKHZ*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK@'@' .]H&K:0&CTRUNGFFD,S">1"!=2(^V9E/0D,<''X<"@#HJ*P=0UR?\
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MO$\I-F#Y;*JJ<889^X,>@Z[CS7>5BZ=X@_M#Q-K&BFS>%M-2!_-9P1*) Q&
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M-P;;\P#9 )(P<'K7?4 <=?\ @5KS3[B-=12.\N]2BU&ZN#;;@[QE2BJN\;5
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MG?U[5M4 5=.M9+*RCAFNI+J89:2=P 78G).!P!Z =!@5:HHH **** "BBB@
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MR""*R::21IHXS"")U82+N;>6R3G[H!XXKNG\.Z1))8R&PA#6 Q:;!M$ QCY
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MGZ5/IEKI-K'93ILFAV9$B^C9Y(YJ31O#FC^'H6BTG3X+1&X/ECD@=!D\X]J
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MWC^ULI!8!C\I))R5^[G/;GG-;=0VMK;V-K%:VD,<%O$H2.*-0JJHZ  =*FH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K \7^)1X8T>.XC@%Q>W5Q'9V<!;:))I#A03V'4GV%;]<9
M\1]%OM3TK3+_ $R W-YHVI0ZBMLIYG5"=R#WP<CZ4 :%[:^)[;29;BUU2"ZU
M!8]Q@>U"Q,>X3!W ^FYF]ZTK_7M*TR1DO;Z& JH9]QXC4G 9S_""0>3@<54M
M/%>GZC"IL5N);EA_QZM \<B'T<,/DQW)X^M<S9R?V5K/C.QURWF==1F^T6KB
M)G%U"T*IY2X!RR[<;>O.<8- '7WGB+1K"X%O=ZG:0S&(S"-I1NV#'S8].1]<
MU63QEX;D6R9-;LF6];;;D2CYSDKCVY!'/<8ZUQ'A_3+S2->\"6FIH[7%EHMQ
M%/(5++$[>7M0MT!P& Y[5G74)_X5GXJABM)O/F\02311K;MO=#=JZLHQDC:"
M01V% 'I-_P",?#>EO<)>ZW8PO;LJ3*TPS&S9P".QX)Q[5=N=9TZTM8KF6[B\
MF9=\3(=_F+C.5 SD8YR.U</:7NDQ?$?QD;]4>.>RL@ 8B_FH8WR@P.2>/EZG
MT.*P=)M+SP7%X9D\0VVIG3_[):U>2S,K-:2F4R!7$1W8*E5[\H* /3G\4Z!&
MEH[:S8A;R-I;<^>O[Q%!)8<\@ 'FGVWB'2+S3/[2MM0@FM-_E^8C9R^<;<==
MV>,=:X4:?I]EKW@5-.TNYM-.BNKR81S)(QB#Q/M=]V2FYSD X(SV.0*T-M;W
M-OXCAN9;^P\WQ,;BUO;:)@83Y2[9N1@H65E)Z<G)'6@#T3^W]*^R?:OML?E&
M;R!UR9?[@7J6_P!G&>#6?JOC71=,T6+5!=)/#-<K:Q^6<_O"X0@_W=ISG/3&
M.M<<NJ:M%::<=8LX[@IK+QC6[6Q9\H(<+<+& <,Q)CS@J,9P>*S3%<KX0UQ3
M9ZBQ@\5)>/YEJ^]H?/C;>!M^;@$G X]!0!Z7#J4%UXFCAM]<@<?8C(=-55+G
M++B8M]X#!QCH<Y[58CU_29;Y+-+^ SR,R1KNXD9?O*IZ,1@Y )(P:Y*^,U_\
M24ELQ-"TWAR>&*=X64)*TJL@)(X; W8//M6+#;SZK\.O#GAV*UGM]>T^ZM%D
MC:,AK9H7&^4G&-I4,0V<-N &2: .]N/&7AJU+B;7+!/+F\A\S#Y7XX/IC(SZ
M9&:W*\EU&'S-#^*"+:RM+=RL+<"%MT_[A%&SCYOF!Z=Z].TIQ)I%FX).8$ZC
M!S@=<T <_9ZY?>)?$6K6.F7"V>G:5*+::Y$8>2:?&65-V555X!)!))XQCG3L
MY=3L;W4/[7NK9M-AACD@NMGE$??\SS#G&1A3D8&#T%<IX>)\#>)O$=EJL<T>
MGZIJ#ZE9WPC9HB9 -\;L =C CC.,BKOCE[W6_!]PVCVD]PD$]O<% A5KI$D5
MW1%(R>!^/09H Z:WU_2;DW COX0UN@DF5VV%$/1B&P0I]>E58O&/AN::WBCU
MNQ9[A#)%^^&'4#)(/3H"?IS6!<-%K/CO1]=TYG^QV6GW*WLYC90P?9Y<1R,E
M@0S;>HQSC(SR^GV_E_#OX>V\EG*);;5H'N(F@;=$!YFYG&/E W#)/J* /28_
M%OA^73;G44UBS^QVK[)YC* L;>ASW]/7M2?\)=X>\^X@_MFS\VWC\R5#*,JN
M<9]^2!QW..M>?^)$>1_B>D<$SF[L;9+<+"Q\YQ$RD)Q\Q!(!QTK;F$+>/O!T
MZ0GR8=,N4:01';&6$6P$XPI.&P#[T ;VH:_IUWH%O?6'B.TLH;B=%AN\+()"
M' :,!NI."OJ,^U*?&.DKXBOM&>?;-90+-*Q!Q\V[Y1QR0%SQZXZUYY<HY\!Z
MY"MM<&1_%)GBC$#[FC^UH^\#&=NT$YZ5UUJS6_Q5U9G@N#'?Z9:BWE6%FC;8
MTN[+@;1C<.I'4>M &OHOB[2M:\/Q:S'.L5M*?E#_ 'N20HQ_>(QP/7%78-=T
MJZT][^&_@>U1S&\@;[K@XV$=0V2!MZY(KRK39+NP\#>"[J;3M5:UT:5XM3@A
MBECFB+(Z;P!AF"D\[<\,?>M'58+./3K;Q#H.D:M)IRZNEY?X:=9[E?*>-I51
MB'^4LI[9VD]!D@'I.G:K8:M%))8W4<XB<QR!3S&XZJP/*GV-4]=UDZ=+I]C;
MA6O]2G\BW5N0H"EG<CN%52<=S@<9S6?X231KBXU'5M'L[V-+TQ^;=7?G!KAD
M! PLO.%&!G !]\53\2PR1_$GP5>L#]F!O+8MV61X@5_,(PH U/\ A)K(^)'\
M,QW)_M".U$K2NO\ $3A>  ">"3C '\LKP-XTM]4\/Z1'J^JVK:W>"3]UE49R
MKN  HZ?*O3J<4LDAL/BY/<3PW M[C18HXYEA9DW)-(S L!@8# \D=:Y#38FA
M^'O@B(VLR3P:]'+/'Y#!XU$LA9F&,@;6&2>Q% 'J-UK^DV5XEK<W\,4S.L0#
M-@!V^ZI/0,>, \G-:+$A20NX@<#UKR>..Q>XUOPSXETG6+JZN=1FN+:.(W'D
M7D;R>9&0R'8NW@$G&-M>LCI0!QECXNU&XL]"EGT/5XC>W+070-EAK=P0!D9^
M6/)/SG/"^IXKWWC2]U3QR_A#PRD/GVJ>9J.H3J72V7CY54$;GY'4X'O@X[NO
M'_!B'P+\0_&*:_!<Q+JMT+FRO! \D<R;I&V[E!PWSCCV^E 'H5K#KMEKN+S4
M8KK1_LK.9)(52190R\$C V[=QZ#IR:NVNOZ1>M,MMJ5K*88Q-)ME'RQGH_\
MNG!^;I7#?$Z34=:\,:7:VMO=V^F7^J0PW\A1E=;4GEG'5%)ZYQP!G&<5D:C;
M:K!JGB_QK:V-Q';PZ5_9&CP1Q'?,,@>8$ SM#\CCD<]* /2(/%OAVY^R^1K=
MA)]KE,-MLG4^<XZA>?FZCIZU*GB70Y+*[O$UBQ-K:2&*XF\]=D3CLS9P#R*\
M6TKP1/:ZYX2TR6PNGM]&TN34[Z582/,F?GR%;'4'' YY8]2:BM--U=/@G+80
M:7>1ZMXEU;$Z_9F7RP[\G&,A-J 9.!\U 'M<7BG09Y8XH]8L6DDM_M2KYZY,
M/7S.OW<<Y]*S/$7BBU_X0Y]1T37]'MYKD;+&[NY@8'<-@@8ZGAA@ \]J\JU#
MPW<VFK>+M1M=,NY;?1-(CTO3U^SDFYD8 &0#'S!6R>.  .PQ5Z71YX=-^&/A
M?^S;[['%*;Z\!MVYD0;@K?W=S,WWL8!&<<X /1'\?Z)8:S::!J&JV1U00,]Z
MR2A(H"BY;))X)/1>N,D]*N:!XUT3Q'I]_J%E>1?8;.<PM/(X52  =YS]U<D@
M9QG&:\QDNM11_BCXC&G7IOWSI]F!;ME8UQ&&7CG.X-QG[I)]X;JTNM(@^'6D
M20W5OH5O"UQ<RFRDE1KH E=\:_-C><@'USCB@#V6TUS2K^VN;BUU"VEAM7:.
M=UD&(F7DAO3'O6/J&MW&IO:'PMJ=E<&WOHX[Z$(928VZC(/R?+EMQZXX]#YW
MXHTHZ,?#-K;PZ@-&O]4EO]7N[FU>5YY@5*&:-,$*3SLP.!TR*]*\(Z-9Z;:W
MEY;B[DN-1N#<7-S>)LDG8]#LP"BCH%(&!^9 *PN?$UI'KMS/)!<Q6DQFLXU@
M,?FQ $M$<]2!@!QP6/<#%=#INHVVK:7:ZC9OOMKJ)9HF]589%/O)H[:QN)YB
M!%'&SN3T"@9-<S\+[.XL/AGH%O=*RR_90Y5NH#$LH_(B@#=U#7-,TMBM[>Q0
ME4\Q@Q^XG3<V/NK_ +1P*QO%GBJ'1DTB&&ZC1M3O(X1,,-Y<3!F,B]0>%P.H
MY!YK-LYSHWCKQ2-:BD^RZDL$MG-Y3.DL:Q[&B& ?F!S\O4[L@5@P:;>Z+X2^
M'FG7\<QN;754FF0(7,$16;&\C. H=%R>.* /1]%BOK>P?^T-234,R,\-QY0C
M)B/*A@."P]0 #Z5Q_B'QZ+KP3KVI^';L0W.FS^4&>+<6 =58[6'')(&<]/>O
M000P!!R#R#7CNJ+,/AYXXTIK*\-X^L7$B1_9G/F*\ZLI4XPV5R>,\#F@#U*Q
MU[2=3O+FSL=0M[BXML>='&X)3/?Z<'FBUU_2;V^^Q6U_#)<E#(L8;ET!P67^
M\,]QD5Q'B"VGU#QM?0Z6&1[GPI/:V\RH503,X*+NQ@''./2G>$Y]&UJ[T60Z
M/K$6M:7&R2+>?:%2R)3:X!<[&#8  &>.<#% '9>(]=M?#/AV^UF]R8+2(N57
MJQZ!1[DD#\:H6$7B6\TF.^GU"WMK^:,2+9BW#01$C(1CG>Q'0D,.>W:F?$+P
M[/XK\":KHULP6YGC#0[C@%T8. 3VR5Q^-&C^,+.\T^%;N"[M=35 L]A);/YJ
MR <@#'S#/1AQCG- %^'64L=(L'UN:."_EMEDFB4$D,%'F$*,G:">3T'%22^(
MM%@BM)9=6LECO.;9C,N)1C.5.>1CG-<S]HN-)^)<VHZM%)%87^EQ1038+I!(
MCL6B9AP"=V0>AQ@=*YJ'2I].LO#B3VTRP/XKFOH8&A;-M:MYVS<,?(/F4\XQ
MN]: ._/C?PPMDUXVN60@64Q,YE'RL,9!'48R/S%6+_Q3H.F2/'>ZQ90.D/GL
MCS+D1Y #8]"6 'KGBN)GC0ZC\3F^SO\ Z5:QK"?)/[XBVV$+Q\WS<<9YJOH]
MU:6GC#PA+?\ [O9X6*%I4(\J0-$#NR/E/WASCDX[T >AIXATB33+?48M0@EM
M+EML$D;;_-;GY5 Y8\'@<\'TIA\3:&MG;W;:K:+!<R^1"[2@;Y-VW8/]K/!'
M4=Z\YL+>70%M9&TV:"POO$%Y=6URMHTKV$3(50K& =ID.<9! #<BJ2QR'PU)
M:36=\67QBL[+/:OEHOM <N?EP1MY)' S[T >GQ>+/#\UE=WD>L6C6UFP6XE$
M@VQ$]-Q[ ]CT-7?[6L-MFWVJ/;>G;;'/^M.,_+Z\ GZ FN3L+:"]^(_BJ&>
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M_&T-E9W=]:V$UU96EBFH2W&[RU:)P2!&2,.V%)QQVYR: .H0%8U5G+L  6(
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M"SMI;FZFCA@B4O))(P554=22>@H XZ?PE+KGBX:W=V46FJ+":RE\J0-+=>8
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MI7<ZOK5AH5H+F_E9$9MB+'&TCNV"<*B@LQP">!T!J#2_%&BZSH\NK65_&]E
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MKEEBND(8+\VPG )#;2,'%1?\(;XB31;NQ6WT[+^(5U6+9<,J^6)5D*XV<'C
M_I7IM% ''Z[I&O0>+;/Q-H,-K=2&S-C=V-S,8@R;]ZLKA6P0Q.>.AI;W1M<N
M_$7A?4IEM9/[.DN)+O9(5 \V,H%08^8+D<G&<>^*Z2;48H-2M;!HYS)<J[HZ
M1,R*$QG<PX4G/&>M8\OCC1(="U+67DN19Z;</;7#?9I-RNN,C;C..0,D 4 -
M\):1J&DW&OO?1Q(M_J<EY#Y<F[",J+AN!@_+[]:B\2Q>)[K4(8M-TW3;K3$
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MFV7)(:.%"F02@^9LYQT'K7H-8MUXJTFTFNHY)9V6T.+F6*VDDCA.,X9U4@$
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M\PK*0K@@H,8.&PQR><8]:[=ONGZ5B#PS&\TWVO5-1O+62?S_ +'<2(T2MNW
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MQ<3S&R:Q>.39Y<D+$%@R[>Y&?_K<4 <Y<:WK.EV7A35Y-0-Y#JUQ;VUW;F)
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M+E=5MTMKJ&0KL9%SMQA001N)SGO]*ALO ]I:W^E7LNJZM=S:6LB6IN)U.%<
M%3M4;N%')Y]2>, %#QY'/+KG@Z.VG$$S:HX64IOV?Z/+SCN?K^O2LB\U[Q+H
M^G>-M.FU87-UHUFE[9Z@UN@<JZ.=CJ!MR"AYQR#7<ZUH-MK?V-Y9IX+BRG^T
M6T\# -&^"N<,"IR&(P0>M5;GPE87>DZI8337+-J@VWMSN7S91MVXSMP %X
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M#IMC':0&1D3.7E<N[DG)9F/)))))]ZLT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U'4K32K=)[
MR98T>6.%,]6=V"JH]2215NN'^*-O:RZ!IDEW#"Z1ZQ99:500JF90W)Z C@T
M=N6 ZD#ZFC<N[;D;L9QGFO-ET#0=7^*5_:RVEO/9?V+:S1Q(<1[A-)A@ <<
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M 92Q4,-PZC/(KS*R,VD^*K":YMK/5=-O-5N!9:G!\MU;S.)=T4H_C4#>N0>
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MJ-:O,J!UMC$A1X'8\8;<?E[GWJ[8SV-_XM\1Z;XC=)3;Z?;"R%^ K- 8LR2
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M0X]1E3S7!:)X?T35_B#XO:[LX;I;>[LYX%<[E1C #N SCDD_6L?P[X8L-?\
MA$+;3X+)=:MIYKB%@B[EFCN)#&']B!MP>Q- 'L%5)=2M(M4M]-:9?M<\;RI$
M.I1< M],L!7.>#[N+Q1(WBLV9@,L"6L"R)AT"\R]>?\ 6$I_VSSWJAK=OIJ_
M%[0IKV&T!?3+G:\R+\SK)%MP3U89..] '>;EW;<C=C.,\UD^*=6GT'POJ6K6
MUO'<26=N\_ER2% P4$GD ^G_ .JO,B6U#X27VJ2+L\76U])NF4?Z1'>"XPB
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M>JZ[K^B^+]4M+"X-K;^0UTJ#$1A&]X78X!$N\Y'<#TH ]8=UC1G=@J*,LQ.
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MI9[.*5C)&L6Y-CH"3DL"2O( YP#0!U1TO3S?_;S86OVS_GX\E?,Z8^]C-6B
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M6,AEV[N 21\P.?H-B;Q-'+XPE\,)%=Q2BS$YN4@8@%FVKM.TC PWS'C.!ZT
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M'1-),:1G2[+8C%U7[.F%8\D@8X)INDZY8:TMQ]CE8R6LIAGBDC:.2)\9PRL
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MX)Z&@"_%%'!$D4,:1QH-JHBX"CT '2GU4T[4K;5;3[3:,[0[V3+Q,F2I(/#
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MR7QU6R%I'(8FG\]=@<=5W9QGVIGB#0K;Q)I,FF7DLZ6TC*SB%@I;:P8<D'N
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M#Z9->?:6FJRR_#T'0-3B71XG@O&EB"[&^S>7D9/*Y[]^V><>DC4+,Z@=/%W
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M#[IHUC5R$POWL,>O'0<]:6/4(]8^(7AG5+,!%O?#]Q/$77. S0LNX#KC-5-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M:44MN*@GUQ2LBM]Y0?J*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@! JABP R>IQ2T44 %%%% !3515^ZH'T%.HH *,#.<<^M%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4  # &!110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9/B;5Y=
M \-:CJT-JMTUG \YB:38&"@D\X/8>E:U<YX^RWP^\01J"TDNGSQQHHR78H0
M!W)- &]:S&XM(9B,&2-7QZ9&:EJGI3K)I%FR'*F%.?P%7* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>josetrevejo-tarsussepara002.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N>U#QCIVFK<320W4MG:W"VUS=PH&CAD8@8/.XX+*"5!QGGH<=#7
M!:/;>*/#NJ:OI<&D)=V5[?S7EKJ/VA%2$2MN99$)W$J2<8!S[=: .]HJE;75
M[+JE];SZ>T-K#Y?V>Z,JL+C(RWRCE=IXYZ]JNT %%%% !1110 C,$4LQ 4#)
M)[5QGA>\NO'%O+KUS<7$&D22NFG6MO*T)>-6*^;(RD,2Q!PN< =B>:["XA2Y
MMI8),[)4*-CK@C%<9X-@UKPIH$'AR\T6XNQ9%HX+VUDB\N:/<2I(9PRM@X(P
M>G!- !K5]>>#XY(K2YEOK_6;Z.UTJWNIFD6'*#<6).=JG>QY)Q@9]&^,K:?P
M[X%U#6(]8OSJEC%YZW+W#;)) 1P8@?+VMTV[>_KS5GQ)HFIW>L>&-?BMTN;C
M2)Y6FM(G W1RIL.PL0"R\'G&>>G2EUW1[[QG+:6%Y:O9:%%,L]TDS*9+PJ<K
M'A20J9 )).3@ #O0!F>*-<675/"-O<:A-I:72O>WY2Z>(+"D>2C8(ZNZC/7@
MU:\+ZK<M:>(]2N;BYD\,QMYNF3W#'S6A$>96#'YBFX':3SCOTHCBUN'QQK&N
M2>'KN=3:166GA9X%&P$LY;,F5RY'8\*/I6/)X1U_3OAA=>'X+;[5>ZI=O)<K
M;2HL5K%)(&D1"Y7(V9 QW)H S] U+4Y=)\*'3-9O-0UZYNXYM2A-TUQ'#:.6
M9A*"2L95"H!X8D=^:]+\0:N=(TR22%%ENV1S#&W3Y1DLWHJCDGZ <D5BG2[_
M $GQVFK:=ISRZ=?:>MM>11/&K121',389AGY69>,]!576M&U+6_#.JWLVFWR
M:W<6\UM:VL=\(Q$I!" E9 C G#-DGDXZ "@#:\#W5W?>!]&O;^9I;NZM4N)7
M;N7&[\!STK*^)>H/::+IUI;ZA+876H:C!;)<1SF(Q*6W2,2". BMU]170>&[
M66Q\,:59S0-!+;6D4+1L5)4JH7JI([>M8M]I^I:C\2M*O9M.E&DZ9:S^5/YD
M>&N),+G;NW8" \XZF@#/M-5:V\:.ND7UU?>'K?3WDU"1IGN8XY0PV!)&))?&
M[*@X ["MNV\<:'=+&ZS3I$]FMX)9(&5 C%0HSC!<[UP@R>>E3^,++4-1\)W^
MG:4O^DW:"V#;@NQ'(5VY]%+'UXK&\5>'[Q+#P[#HUG+<6>EWJ2S6<,JQR2($
M8!E9R 65B&Y(R><YH U+KQEI5C#J4EXMU!_9T,<]PK0DL(WW;6P,]=K<'!&.
M0*9)XYT6*>\@9KKS;6W6Y91;L2Z'=]SCYON-TXX)Z FLS6?#=QJNC0:=;:8U
MI!?:C#)J)DN \QA0[R7?<26)14 #-@'KC@9VK^%M9FM/&5[;V>;[4A%I]C"D
MB#99J%1F4D@ D-(V"1T% '27NOVU]'H$=G?W5J^K/'/;/';AO-C"^8RMN&%!
M0'/<5*/&6C'3-6U S2K;:5*8KEVA8?-M5L*,9;.]<?6J"Z5J)\=:3<'3U32]
M/TMHH7652L<KL P ^\2$10#C'S'GM7,Q^&_$EQH-C:W.E%6FUXWVI1&XC_>C
MS6D#$@D>6-L2XY;'.W@9 .UU'QAI6EWUQ97)N?M%O:_:W1(&8E"3C&!R?E;Z
M!23@"G6/B_2=2U&QLK:29I;ZU-U QA8*4 4D;B,;@'7([9KF-8\+:SJ,?BZZ
MC@"7^KO%IUL3(O[JS 57?.>,[I6QUZ5<72-4TOQ5<WNGZ0)K2QTJ*ST\&9!O
M)<M)U.<DB/).,[3S0!T&G>)+'5)X8[59W2X$C0S>7^[D6-@K$'MR0.<$YXR.
M:NV&H1:@+DQ13Q_9YW@;SHFCW,O4KG[R\\,.#7-:!H][H-]XAN+*RE73I\7%
MGI\DB BX(8RA""0BL=G4XSDX Z]7:R2S6D,L\!@F>-6DA+!O+8CE<C@X/&10
M!SWBK3'>QU35!J-_$T&GOY$5O=/$B.H=MY"D;B<J.?[M86BZ=<7?P[T[6FUC
M5?M4ND>=<;KZ5A(S0YW#+?*0V""N.XKL/$<-Q<^&]3MK6W:>XGM9(HXU95)9
ME('+$ <GUK'T/3]1L_AA:Z5/82)J$&F"U,'F1DLXCV\,&VXSZF@"AX*\6P/H
MGA32[R._^U7VG1F*[FC_ '<\BQ!G&XG);&3DC!P<$UL7'C/3;::U\V.Y%G=7
M7V.*^VJ83-DJ%^]N + @-MVY[]*YRRT+6H;7X>1/I<H;1DVWO[V+]W_HYBX^
M?YN3GCM^5,\,:'K&C%="NO"UA<1V\[&'6V:(AHBY8%D^_P"8 <=,9 Y[T >@
MWMW%86%S>39\JWB:5\==J@D_RKD?!L=SXJ\.6_B'6+N\$VH;IHK>WNI(8[>(
MD[% 0C<< $LV3DGMQ77W=M%>V<]I.NZ&>-HW'JK#!_0UQWA*#7/".CQ>';O2
M+C4(+,LEI?6DD6)8LDJ'5W4JP!QW''6@#7MKE_#EK!87]W<:E>7-U*+0?*9I
M5RSX.<*-J\$G X'J!5>Y\>Z19Z/J.H7$=Y&=-F$-Y;>5F6%CC;D XP<@A@<'
M/6JNN:7K,FO^'O$<%LMQ)I[SQW%C%( QAF4#*LQ +*5!/(SR!VK%\1>%-6U+
M3/&%[;:?(;S6S:106AEC#*D./F<[MH)^;@$\!?<  Z=O&MHNK3Z7_9FJF^2'
M[1##]F -Q'G:63)P #UW[>H]:B_X6#HITS2K\)?-'J<S00HMLQ=95W;D8#HV
M488&<D<4V2RU)OB3:ZP--F^PII$EJTGF1Y$C2(X&-^>BD9Z9_.N--EJ>AZ9X
M/M[W395ND\33RB$21DNL@N'&"&QG:W0D<B@#M+;X@:/-8:G<317MI-IDB17-
MI<P[9E:0@1_+D@AB1@YQ]*FF\:Z=:VNM375M>P2:,BR7<!C#.J,NY6&TE2"
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M .-T*^G\9^(-?EFNKF'2M*O6T^WM[>9H3)(@'F2.R$,>2 !G&.Q-,\6:C?>
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M;.XN#;82!PX3+Y.<;CC@$CN!D5HV?BNSO-6N],:TO[>Z@MQ<JD\&TS1$E=Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%8_B.^N]/L8)+22VB#W,<<TUP?]7&3R57^)^@"]R>_0@&Q17FMSXWUN+PA
MK^H0?9FNM*U9;)6GMW3S8V:( E<@JV)?3''3FM"Y\6ZCX=UO6[?6Y+:ZMK32
M/[5B-M"8F4!V4Q<LV[[HPW'7I0!UMUJ^GV6H6=A<74<=W>LRV\)^](0"QQ^
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MI%-:VMI.[3P&02%('.T ,-H..N3CTH [W3M!T_2KV]O+2.5)[YQ)<,T[OO8
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M1K'+=VR2R(GW0Q'./;-;- !1110 4444 %%%% !1110 4444 %%%% !1110
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ML;768V%Y:K$CJ9"FPNI(^4D=?7VKH=&TT:/HMEIJW$EPMK"D*R2A0S!1@9P
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M=/,4%A%M$G(Y8ACU!)%;=YX&BNM/, OY$N)=234[BY\H%I9D*E1CH%&U1CT
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M%@S[S;[?D#9SN ['/.1WYI[>'M)?3Y["2RCDMK@YG1R6\[C'SDG+< #DGH*
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M+$[1C!D QRY[GY0!Z 'UK-\=Z+=Z_I-E96MJEP$U"WN)ED<*ICC<,PYZD@8
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M[A])TBTLVN/]:8HP-P]/I[=*@M_!'ABUDBDAT.R4PRF:+]T"(W.>5!X7KVH
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M^%= T_6)M7M-(M(-0FR7N$C 8D]3[$]R.M6[+1]-TZZNKJSL8()[M_,N)(T
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M#2I;N778=2A:[D2.>) !]X[8E"9W%>F1DG%75US3'L?MJWD9M_,,6[GEP<%
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MZ8ZUT"SQ/;BX$B^24W[SP-N,Y_*O(C%,OARYF%I=&.V\:?;75;=RPM_M.[S
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MI!!!'7- &W16+XF\0#PUIT=_)://;F>.&5U<+Y(=@H=L_P ()&?2H%\51_\
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M4--N+2&\GLI)5VK<6^-\9]1D$4S2=,CTFQ%NDTT[EB\L\Y!DE<]68@ 9^@
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M#M**\KT3Q%+X4M_%EPFB7M[I]MKMP]S- Z?N(]L>2%9MS8') Z#O6TMQ:O\
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MLWE@N&WJ"0'!]&QD>Q%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN[;E6&5P<=17IE% '%ZSI'B36[#2)+B&Q2ZM]6@OI($G.R*.,YV!]N78\G.
M.<=LF_I&D:C:>-_$&K3QPBSU".V2';*2X,08'<,8&=WJ>E=+10 R::*WA>:>
M5(HD&6=V"JH]R:XSP9H<5IK.MW5O<B?2UNI(].1?NPB3:\X4CJOF<>VTBNOO
M;*UU&SEL[VWBN+:9=LD4JAE8>A!I;.WMK6SA@LHHHK9$ B2%0J*O; '&* .
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M:PWV@[-GVKS\9VYSCY>E>D54N=0BM;^SM'BG9[MG5&CB9D7:NX[V'"^V>IH
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MBRN(V90C1#=@#"@@_,W.>]4AX2DLSH$-AJFJK'IC\E[K*21X4;)%Q\_"A5X
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MBUU>266Z65U^_(,,5*J,=OIBFV'@NQL-5M-3^W:G<7=M:FT#SW.[S(R0<,
M."!TQGOF@#BM&U+5],^$_A;4+?59VENKNT2;S4C?*23!74';GG)Y.3[UU$.I
M:GXCU?Q+9V&HOIYTJ1+:W"1HV^0QAR[[E.5RP&!C@'N>)H_ &F1:!;:+'>:B
M+.UN$N(5,P8H4;<BC*GY0?Q/<FKT_A6U?5KK4[:\O+*YO(EBNS;.H%P%&%+
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M* ,F^U/5]#U/PTTFI27UKJ\WV.X5HHQY<C1EUDCVJ, %3D'=QCOURAXGUP>
MXM3.HL;N/7?L3/Y,?[R+[7Y6"-N/N]Q@YKKM.\*6FGM8%[N\O$TY2MDETZL(
M 5V\$*"QV_*"Q) )]36=/\.M*GBN;=KW4UM)[P7PMDN (XI=XD)3C(RPS@DX
MR<8H K6<_B#4_'>O:>FNM;V6FS6<J1+:QL71U+/&21G!QC/7IZ<ZVO:O/#XC
MT+0K><VQU(SN\Z@%@L2 [5W C)+#D@\ ]^1;T_P];Z;KFH:M%<W3SWXC$Z2,
MI3Y!A,?+D8!/?GOFF>(_"]CXF@MENI+FWN+27SK:ZM9/+FA?&"5;W'!!!!H
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M^3TW^4F_]<4 =H64,%+ $] 3UK M=?N)?&NHZ%/;PQP6MG#<QS"0DOO9EY!
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M%C.9U'(VG')Q@G'>@#T.BH+.]M=1LXKNRN(KBVE&Z.6)PRL/4$=:GH ****
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M"QN85R@'0 XXJY10!A:7INKG59+_ %RZLYFB\R.SCM(F0)&S DON)R^%4<8
MP>N:W:** *)T72BB(=,LMJ,71?(7"L>21QP34L>G6,,LLL5E;I),,2LL2@N/
M]HXY_&K-% %:RTZQTV$PV%G;VL1;<4@B5%)]< =:DN+:"\@>"Y@CGA<8:.5
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MK-+8.?+"J$1.)1D #]34-[X8OXI-%U>;Q# M]I;7#W%U<VW[J19AAL+O&S:
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MP1Z8KHV.%)QG Z5AZ!I>NV9\S7=<CU&5$\N/R;;R%QQEF&X[F.!Z <X'-;M
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MS>2RV]E<306YN)HXV:.%6"F1@,A03P,GC-4=$L=3M87?6-22^O), M##Y42
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M<$CMG';-:5(JJBA54*JC  & !2T %%%% !1110 4444 %%%% !1110 4444
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M!H=NT'& #G=D YYH ZO5/%$6GW%W;VVGWNI364<<MU'9HK/&KDA<*2"Q^4G
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M<% ;UQS3J** "C SG'-%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;ZT\JPJ5VX;S(M['' X(&!V&*Z[2%OXK<6]W865G#"BI MK=-,-H&,'=&F,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7(Z
MQ\0])T87,TJF2SM+@6]S,DJ;HVR%)"$[F"DX) ]< XKKJX2PTKQ5H6KZI8V5
MII]WI5_>2WD-[+/M>T,K;G5H]IWX8DC!&>Y'8 [L$$ @Y!HJC:RZBVIWT5S:
MPQV,8C^RSK+N>7(^?<N/EP>!R<U>H **** "BBB@ KR^VO-*OO%_BV]U"[O#
M:V\R6=K:V\\P9I$3,K(B')8LP'']VO2KJ2:*UD>W@\^8+\D>X+N/;)/05@>
M]&O-!\*06>I(HU RRS73JP822.Y<L#^..?2@"IX4U/4].\+Z-8Z^MQ<Z_/&[
M?9P5:;RPQP7)( VJ4!)/4XY)HO?%]CJ'A.:]BCU6"&XNCIL<MN(UF$I?RMR9
M;'WSC//0G&*;=Z7XBA\6:YJ-A#:R+>6$4-G<RS8-N4#DKLQSEF!SG'KTQ5"S
M\*ZU;Z1X+TXP6QBTR;[1>AIB?WHC;:V<?-^\=G('< 9[T =/=Z]::<9[3;<7
MLME;B:Z,84F),'!<D@9(!.!R>N,5G_#NV>+P=;WDJ&.74I)-09/[@E8LJ@=@
M$*#'M7/W_A?Q3+H?BS3(([<-JE_),MT+C#S0.57R^GR[8P5R<], <Y'HEK&8
M+.&(HB%$"[(_NK@=!GM0!#J5]]AMU\N/S;F5O+MX<XWN??L  23V )KE/ ^N
MLO@#^WM=O=[375P[R[3S^^9$55&3R H51D]!S6B^EW&J&]OM6TJ.6YC)CL+<
MS!E6/ YSV9CRWL !G'/-V'A/7M/\(>#[%;2":?1KP375LUP%2;A\.K8/1G#8
M([>PH OZA>'5OB%I$3Z?<0?V59RZC,LA0%PW[N)<AB.OF'!(Y05=LOB+I-\=
M*,=KJ"QZI%)+!(T2X^4 [2 Q))!7& >6 Z\5F2^&_$TJ^,IBUJ+W5XTM[67S
M3A(P@7CCY0I>4^I..G>\GA*>SU^*]LXH1:Z3H_V/2HF;_ELQ.YF].%C&>^2:
M )+SQ?97_@V344BU6VCN;AM/!@$8N(Y3*805^8J3OZ$$^M6[KQ99Z5?W.DR6
M]_<7-E9K<LRA&,JG('.X?,=C$YVC@GCBL&T\*:U;Z)X,TTPVQ339_M-\#,3^
M\"-M;./F_>.7(&.0!GO4FJ>$]7N;#QE=0B(ZKK+"UM_WN!':A53&<<$@R,?<
MCTH U+OQ#:ZK:^&UA;5+;^VFCGMGM]BL%5?-*R9)PI48. >N,\U>MO$]K>:@
MUK;6MU*J7CV+SJ$V+*J%F!^;<  #SCK]1G+GT75T\5:?>V]M:?9-/TF2"V7S
M3A)V(R ,<_*B*"<<$GVIVF:%?V_BNZUV.W6S:ZL!'>6_F I<72D;9!CH  RY
M."01QQ0!%#X[866NZK=:3=IING77V2/RS$SR,IVN1\_]\[0!Z=<D@:H\66/^
ME%[:]C2&2.*)WAP+MY!E5AY^?Z].^<<US=EX/U6;P?X>T+4(X%CCO4NM3 EW
M&3:6E8>^Z;!]A6WXATS59_$WA[4;"V@N;:Q\\2PRS>7M=T"I(.#G WCU^;B@
M"1O&-JAUM&L+U)=&MUGNT;RP &4L &WX)VKD\X ([\5G)X@GU/2_#L6H0:EI
MU[K$PEB%HT>5"@R[6)).W8,'C)]!G%9<OA7Q'/X7\36EPEO+>ZQJ6^1UEVF2
MVWHI _NCR5P!D]3^/02:3JL_CG2]1DAMOL%EISQ*5<_),[+OVKCGY44 \=3]
M" 3#QA:-INL7@LK[=I-P8+FW"*9<@*V5 ;!&UP>O0&GZMXNL-*@OYC%<7,6G
MX%V]N%(B8XPGS,-S8(.U<GD>HS6L?#=S'XMUS4+B2/\ L^\G@GCA7[SO'$JY
M;T *Y [D ]N<SPSX9U+3)[BVU#3K:Y*ZA-=QW\MRSJP=RX81'[L@!QGCIUH
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MND^5;07-P%%E.=P9MJ@A\Y7:P[#C .: -F\\=00W&F06>DZA?R:G9->V@A"
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M-)\Y '<XX['-O_&VMVOA;Q;=6[P-<Z+=)'#)<VK(9(W5&&Y,C##>><8X'RT
M>F45Q&M:GXG\-FSU'4;^PFTM]06*[\JT*FW@?"JVXN?NN<$XZ'/&*Z+2KNZO
MM1U.1I$-A%/Y%N F"64#S#G/(#Y7IU4T 6=1U73](MQ<:C>06L18*&F<+N8]
M ,]3["F:MK6F:#9B[U:_@LK<N(Q).X4%CD@<]^#^5<Y\4U!^'M^2 2)K;'_@
M1'75SV=M<R123P1RM%GRRZYVD]2,]_>@"CHWB;1/$)F&CZI:WWD8\WR) VS.
M<9QZX/Y5JUS7A"*.=-3UI$51J-VQAVC \B/]W'CV.TO_ ,#KI: ,6#Q=X>N=
M;;18=8LWU)25-NLHW9'4#U([@<C%6[W6]-TZ<07=Y%%(5#D,?N*3@,W]U2>,
MG S7/>(=#M-2O/#VCV4"1G3;V*^9T'_'O%'D@9]7("X[C<?X:R=$ U!_B1)?
M#<6NY+5@W_/%+=0H^F&)_$T =CK7B;1/#B1/K&IV]F)21'YKX+8ZX'7 R,GM
MFM"WN(+NVCN;::.:"50\<D;!E93T((ZBN.\&W4 ^&VD:SJD7FW,NF0PR$KO>
M90"$0 ]2Q;IW+5G075I\/_!FB^'=1U.#3;FZ$I:5Y,+;H6+R!#W*^8$7WP<8
M!H [VRU&SU$3FSN8YQ;S-!*4.0DBXW*?<9JR3@$GM7G?PHU/1IXO$-CI5U Z
M)J\\L4<39Q"=H1OH<=:]%H PQXR\.%IU.L6JFW8I-N?'E,.H;/W2/>M>VN8+
MRW2XM9XYX)!E)(G#*P]01P:XOX>@'5/&P[?V_+_Z+CKD?[5O/!^H?$A-",26
M6FR6MW!"Z;HHY95'F* ", DYP.F* /9ZK:AJ%KI6G7%_>R^5:VZ&263:3M4=
M3@9)_"L&ZUC4D\>_V)#+;BWETB2\0R1%BDJR(@SAAE<,>.#[US%OXG\72?#*
M;Q@]YI8SIAN$MA:,=L@)R=V\9!';'''7N >F1NLL:R(<JP# ^H-.KC+K6=?G
M\8V.BV=U90076D/>>:]LSO&ZO&N?O -]XX'&,\YQBJ-EXTU.?POH-Q<+ EU?
M:J^FW-TJ?NX]KR)O )X+&, 9X!;OT(!Z#03CK7+^%M5U;4=6UVVO9;>6UTZ[
M^S02QP%6E^56R6W;21NVD!1R/PJGKTNI?\+,\-6L&H>5:RVUW*83$&&Y/+&3
MSR<.1[?C0!TVF:QI^LQ3RZ=<K<)!,UO(R@@+(N,KSUQD4\:G9G5SI0F_TT0"
MX,6T_P"K+;=V<8ZC&,YKRZWU;6/#^B^+-:L)[46UGXDG,MO)"6:=6DC5ANW#
M;PW'!YKLI]<U6+QW?:/&D$]O'H_VZWB5"KM+YA7:6)((^7T'6@#JJ*X[P;XH
M/B&Y9#J"-/% /MEA-;F"XM9LC(*GDIU Z_4YXG\5:QK&G:UX>L=+DLU74KF2
M"0W$3,5Q$SAAAAP-O3OTR.M '545YQ%XUUO2KG5]$U5;:[U.UO;2WM;F"+RT
MF6Y)VDH6X9=K<;@#@#(ZU-K.O>,-$T3Q)>26L2P65J+FRNKF-"S$??C9(Y.W
M!#<#U!H [:_U.STM('O)O*6>=+>,[2=TCG"KP.Y[]*CU#1M/U2:VFO;?S9+5
M_,@;>P\M_P"\,'@\GFN5U35O$^C6^EW-Q>:=,FH:M:6YC2U8&.&4@,H;?R0<
M_-CGT':S_;FK:U)XC.C300?V/.;:))8M_GRK&KMOY!"Y8*,8/!.3TH Z]F"J
M68@ #))[53TO5[#6K0W>G7"W$ D:(NH(&Y3AAR.Q%<GHGC2;Q==:;:Z<18^?
MI2ZE<NRAV3<VQ8USQU5B21T ]<B3X7B5?"]V)V1IAJMZ)&1<*6\]\D#)P,T
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M@#_\!8],5UM% '%7_P .X[ZUUFQ&M7L.GZI=?;'MXTC_ '<I968AB,D$KT/
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M7VJ_BM#9I*(A&3&6#$OC[S94>@'. ,FL+QR'D\3>#Q#.T+Q7\DC2A-XC7R7
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M7_4#IA/[O''';B@#RNYEBU[X4:?XBNY&?59=5MVN',A!1_M:J8B,\*HQA>G
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MG:B]_!XB^T/''9R,/*-Z) X8## J<@#)]N#74&*:Y^(/B1HK:XV7&B0PQ2-
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M^U]!:R#E3&+J4R!PHSC.%4KGI\^,\' !WUEKVEZC>/9VMXCW*1B7RB"K&,G
M=00-R_[0R/>I[[4;33D5KJ79O)"*JEV; R<*H).!SP*Y#PQ<Z1KNKVNIV^BZ
MQ#J-M T<TNH^>OV8-UC!D.')/ID8&<C@%GC"632O&&E:Q=VFHW&C_9)K25[
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M-V;.R-FQM5V^ZI.1@$C.1ZU@>+/-M_&?A#4?LMS-;02W22M!"TFPO#A,A0<
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M?FQS\-OC)*#! '?/7M61%XCU#S_ =OH^GV=MI^J6C3?9C,5V!8-PC!"$!5W
MYQR0.G< [Y98W=T216>,@.H.2I(R,^G%/KBD\5:=I5UXOO+C24M)--FA6XDA
M8,]XS1KY?8<_,JC)[]:T6\2W=GX@LM&U/3HH9]0AD>RDAN#(CO&,M&Q*KM.#
MD'D'GTH Z2L;5/#ZZGKND:J;R6*32WD>*-%4JY="C;LC/W2>F*YS3_B%>7EA
MH6IS:$L&G:I>_8=_VL-)'(795.W;@KE<$Y!YZ$<GO* "HKBY@M8O-N)HX8\X
MWR.%&?J:Y*Y\=F'0)?$D6G";089VC>=9OWIC60QM*L>W!4,#QNR0,^U4]0DN
M]3^*5MI\MI9W6FMHLKB.6<E61Y8U9]NPC=C@#N">1G% '3:UH(UV2U,FI7T%
MK&&$UM;2!8[I& RK\$XX[$=36P    , = *J06B:9I4=GIMN@CMH1';PLY"@
M*,*N[!('OS7/:9XQGU/PY;:A'ID:7\U\;%K![DYBD#E7#-LZJJLY&.@H ZRB
MN2O/&<L>FZMJUCIJW>FZ5-)%<.)]LC^7_K6C7:00O/5AG:?;-JR\5?VCXA?2
M[6UCD1M,BU*VN//(65)&*J"-N5^[GOUH Z.BN%@^(5S>:=X9NK70_,?7C*D<
M9NP/*=%=L$[>1\G)QP.QZ'L=.FN[C3K>6^M5M+IT!E@642"-NXW #/UH LT5
MR2^+-3G\3:EI%MH2/'ILT"W-P]X% BD7<7 V\D#G;]>>F8;7QY]KNM(>'3O.
MT_5) D<L,C/+$&&4>1-F%4]SN.,C- '9T5R^B^+9=?Q+86EO-;^9+'(%NOWL
M#IG"RIM^4G;Z\9'6L2W^)=X^D:3KMSX<:#1+Z=;>2Y%V&>!F<HK%-O*9P"<@
M\].F0#T.BN3N_&,RV.L:CI^FK>6&D3/%<MY^R1S& 9?+7:0=N2.2,E2/0EA\
M9W5YKD6F:-I4=X+G2UU*VN);KRD=&8 !OE)7KV![<=2 #KZ8\L:.B/(JO(<(
MI."QQGCUXKCK7X@V]WI6@77D0VLNL"4(MY<>7'&\9PR;PIRQ;@<#(!^AGOM7
M']M^%(=2T"'[5>RS!)'E#&SD6)V;;\OS9 QGCK0!U22QR%A&ZML;:VTYVGT/
MO1YL?G>3YB^;MW;,_-CIG'I7E6BZ[?>%--\57=EX?%WI=GKMW)<M'<+&T<8*
MY,:8.[:.2"5]L]NNM]6L-0\=I:#2H'>?1OM,>HD@M) T@'EXQD+DYZ_A0!TO
MVJW$7FF>+R]VS?O&-V<8SZYXQZTEO:0VQE:-3NE??(Q))9L <D^P ]@*\NT*
M]M-(^%-F]QI$%_:?VQ)#Y,A"K&3>LJ, 0?ND@X]JZJTUK6I_B'K.E&"U:QM+
M."2-1.P;+F3G[F"25 QD  =30!U44L<\8DBD61#G#(<@XX/-/KAM"\7:?%X2
MT>6STNWTYM0GGBM[(2;8XRCR;V+!>GRD\+U8#WIZ_$)(K$R7]DME,-1&G^9-
M,5MB2I99!*5'R$+C[OWB <=: .VHJGI=U<WEGYMW;);R[W7:DOF*RAB%8-@9
M!&#T[U2UG6+K3[J""WL4D22*262ZN)3%!"%V@!GVG#,6X'H">U &S7.R^%IE
MU>[O]/\ $&IV O)!)<01B*1&<*%W#S$8J<*!P<<=*SK7X@VMYI?AZ[6&&V?6
MDD,0O+CRXT9, IO"G+$GC@9 /T/5:?/<7-A!-=6WV:X=<R0[]VQNXS@9^N*
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MO66F^&OMDFC&-I=UZ(_,1DW_ "_*?FQT'UY'&0#K-0M3?:?<6@E:+SXVC+J
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M/P+<Z;*-,N;F6:"4N8I?-<LK]/OH6. >.2<BG6_@;6K?1;2V-[82W%AKCZK
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT4QO:WD=T60O&NW"J$R%8<'/3T.*[K1%N(M+AAGT^*P\I%18(YO,"@#UP/\
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M6:M\R*<99BI<DX );T%=5KNNV/AW2WU'46E6V1E4M'$SD%B .@XY(&3@5I4
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M$X4YX')!->AT4 </9Z1XLT+6=4MM,&G7&D:C=R7D=Q/*RRV;2',@V!2)!G)
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M5N1TH S_  EI-YHGANVT^^NGN98F?:SR&0I&7)1"QY;:I"Y]JVZ** "BBB@
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MXU:43WMU)*//ED#;@VX# P>@ QUXYK;T30H]%MTC^W7U\Z((UEO)0[!!T P
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M.0-H^7 (R0:Z;P6WB&30/-\2G%[+/(\<;*@>.$GY%?8 N['7'K4&I> ]-O\
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M=SY0NU7IY@ ZCIE=I]ZO?\(W:+XAM=9CEGCFM;4V<4*%1&(B02N-N>JKW[4
M<;9>*-;F\$^$]4>_)NKS68[.Z/E1XEC:=T((V\':HY7%,\0ZG>^)? _CNZCO
MY+6VL/MEC';QQH0XBCPY<LI.6);&",#'?-;R_#G2E@AMA?:H+6WOA?6UN+@!
M() Y?"X7.-Q)Y)([$9.9+WX?Z9=RZN8[W4;2WU=&6^MK>91%*S+M+X*DAB.I
M! ..0: ,R#5=5U&5]$TJ6>W>QTJUD$D'D[C)(K8+"0'*C8.@[G)Z5U.FRZP?
M#$4FH1VO]LK 1(L3YB,H!'7L"1^%95[X TVZN+&Z@OM4L;RSMQ:BZM+K9)+$
M.0CD@[AGGI6__9EL-(;3$#K;M"83AB6P1@G<<DGDG)Y)YH \]M_'T]EI.JW5
M[/>C5M,TQIKG1[^W2-A*" )$95&Z,G(R">"*UKW5=8T.]\,3R:BU_;:O.MG<
M1O$@"2/&762/:H( *G()/'OR=I?"=A)*9=0EN-2?[&]D#=E#B%\;U^55SG:N
M2<GCW.4T[PE:6'V!6O+V[CTX$64=RZL+?*[<@A06(4E06+$ F@#B)_$'B>+P
MAJ6NC7"9M-UI[00FUB\N>(7(BP_&>AZJ5/UK5U#Q'JWA;7M<AN[YM3MK?0GU
M6-)(DC,<BNRE%* ?(>/O9(]36P_@/3Y-!O-&:]OS:WEV;R7YTW&0N)#@[.!N
M ./Z5=F\+65SKDFJW4UQ/++8FPEBDV>7)"3D@@+W//7].* ,W2W\3MK>FW#W
M'GZ3<0-]J%P805?;N1H?+&2#R"&)XP?6J?C"&YN/'_@^*TN_LDS1WX$XC#E!
MY:9(!XS]<CV-:WA[P58^')$^SW^J7,,(*VUO=W1DCM@>,(,>G )R0,@'DU>U
M;P_;ZM>V%\;BYM;VP9S;SV[+E0X <$,&4@@#J/IB@#B(/%FNZ=/=^'K^Y%Y?
MQ:S#I\5^D:1L\<L)F!*_<W@#;TQDC@]Y/$&I>,=!\,Z_=R7RHL$MN^GS2K$\
MVQW5)$D"@+@$_*0,^M=/>^"='U'1+C3+I)G%Q.+J2Y$FV<SC&)0PZ,, # P
M,8QQ4$O@6RN= N-(N]2U6Z6Y9#-<SW >9PC;E7<5P #S@ =_4T 9%_XBU;PQ
MX@UR*\OFU*V@T)]5CC>%(_+D1V4HI4 [#Q]XDCUJ_IS>*)M5TZ<W3/I5U;,+
MDS& %'*Y1X-B\\YX8GC!YYK5E\+6=SKCZK<SW$\LEB;"2*39Y<D).2" HZGG
MK^G%5= \$V/AUE%MJ&J3PQ K:P75UYD=J",?NU(]#@9S@9'<T <;I4VIZ/\
M#KQEJEEJLXN;6_U*2,R11,-R2L=V-HY..>WH!6PQO;OXE^'6;4[I$DT26=HD
M";"V^'/!4_>SR>O'!%;4?@BQC\/ZIHOVV^:TU*262XW.FXF4Y?!V<9R?SXQ5
MF3PI9R7^E7QN;Q;G386MTD24*98SMRKX'(RJGC'2@"IXZO-5TG1HM8TVZEC@
ML9DEOH8XT<RVV1YF-RDAE'S<=@?:LW7_ !9=:=INL:Y8W0FL8C;V=HK*IB,S
MLH:7(&2H\Q1C.,JP^G0^(=3EL8(K>'1+S5&O-T6R!%,:'''FEB-JGIGGO4%E
MX/TN#P/#X5N($FL%MA!*G(#'J6'<'=EL]C0!G7=_JNC^--'T>34I[NSUB&=!
M))'&)+:6)0^X%4 *D9&"#@X^E8VG^*=;N/!_@?5)+XFXU/48K:\Q$FV5&\S/
M&W@_(.F*[*P\.PV=W;W<]Y=W]S;0F"WENV0F)&QNQM5<D[5RQR>.O7./#\.-
M*AM[*V6^U0VUC>"\M(/M "P,"QVK@9VY8]23V!QD$ N>.;G5=/\ "USJ6CW$
MD4]EBXD1(T;S8E(,B_,#@[=Q!'<"L$^,9;?QA>1-?S7&D7.G&?3ML<8#3J%9
MHT.W+$K)&1GN2.<5Z Z+)&T;J&1@592,@CTKG[?P3H=MIVB6,=L?)T:83VF6
MR0^&&2>_+9^H'I0!G6VH:I<^)T\+S:K+'-::6EU<W<4<8>:5W*\ H5"C:>B]
MQSP<XUIXNUR5=)BFN0MQ%XEDT6\9(E"7**KG> 1E2<+T(YS7::CX<MK_ %BW
MU>.XN;/48(F@%Q;%=SQ$Y*,&5E9<\\C@],55N_!>F76CV^GI)=6YM[O[='=0
MR 3"XR29"2""26;.1CGITH YK6]3OKK2?B;IUS<F:WL+(K;AD4% ]J7(RH&>
M3WJ_INK7-YJ^D^&[:Z>S2+0XKZ:6)5+ON(15&X$ ##$\9^[TYSH?\()IOEZX
MAO-18ZU$L5XS3ABP";#C(P"1W]^,# #[CP5933Z9=PWU_:W^G0?9HKR!T$CP
M_P!QP5*LO /W>O- &?\ #!)(_#VHI-*995UF^#R%0-Y\YLG X&:PM3UOQ-'I
M?C:^AUTQG0KIC;(MK$0ZB)'V/D'*_,1QAO?M7=^'_#MIX;M;BWLY;F1+BXDN
M7-Q+O.]V+-CVR?\ '-4)O!%A/9ZY:O>7QBUIR]V-R9)*A3M^3CY0!^% %6WU
MF]\0>*-2TBWO9=.CL+*WE+PHC/)),&;/SJPVJ%'&.23FN5CUG5?$<W@N2ZOI
M[2Z75KNSN?LH01R/%'*OF ,IZXZ'(&3QT-=V_A.V&HV^HV][>VM_%;"U>XA,
M>Z:(<@.&0J<'D$ 'WIMQX,TJ6QTNUB-S:C3)S/;R6\NUPY#!R6.<[M[9/4YZ
MT 9WQ4!_X5KJH!YS!R?^NR5#_:FLZ9XPU32I]7BN(3HQU&&2[B2..VD#E2"5
M /E]"<DD8ZUT>OZ#;>(]%DTF[EGCMI2I?R6 8[2& R0>X'Y52O\ P=8:IJ-S
M>WMQ=S/<Z>VFS(64*T+<D<*"#GG(/Z<4 86B:UJUSXKM-)EU*ZFMKS16NOM$
MD$:?OE=%+Q#:#M.\\.O8'ZN\/:WJ^HZ>FCW>HR#7[74Y+:]E6*,?NHSOWA=N
M K(4 ..KCGBMC3_!-CI^IV&HB_U.XNK*W:U1Y[G.^,E2%8  <;1TQGOFM.WT
M'3[;Q!>:Y%%B^O(8X97SP0F<?B<@'_=7TH Y :SXGURSN=2T-]C6VHRPK;S-
M"+=HHI2C!R09 Q52V01@D=NM_P"*F?\ A76H[2 WFVV"1D9^T1U9_P"$"TM=
M<N=2@N]2MX[N7SKJQAN2MM/)W9TQU/< @'N#6SK>C6GB#1Y]+O@YMY]N[RW*
ML"K!E(/J" ?PH XK5?$&N^#->G74-0_M>QGTNZOHD:!(F@D@ 8J"HY0A@.<D
M>OK;BU'Q-9O::Q)*;G2#9237D<S0CYA'O1H-@S@D$$,3Q@]<UT4'ART$TL]]
M--J5Q+;FU:6[V$^4?O( BJH!/7C)P,]!BAH/@;3O#[!8;W4KJUC#+;VEY<F6
M&W4@@A%QZ$CG. 2.YH S-(O/%6HG0]5BG!T^]A#WB3&'RU#H"C0[1NR&(&&)
MR/>L2S\0^)1X:TC79]:,I?6_L$UM]FC5)8C=-#R<9# 8P5(''(/6NLT3P'IV
M@3@V5]JAM8RS6UE+=%X+8G/**1VR<;B<9I%\!Z>FAP:0+Z_^RP7GVY/G3<)?
M,\S.=G3>2<?TH N>+M:ET32(9;<?O[F\@M$8X^0R.%+<\9 )QGC.,\5S.NWW
MC#1-"\2WIO=EO!9&YL9;A87G211\ZD(H4KT()&1^5=GK>B6/B'1I]*U*,S6T
MZ@-@[6!!R&!'0@@'-8Z^!;)M"O=*NM4U:]6\B\B6XNKD22B+^XI*X ]<#)[G
M@4 4+:^UN#QEI^F7.L23VVJZ7-/@01I]FE0Q\QG;G&'/#;N1^%<WI.IZQI7P
M9L-7MM7G:YDNXPYF2-^'N]C\[<\[B<G)STQ7H*^&;<:SIVJM>7;W%A;M;1 E
M-I1L;MP"\D[5].E9X^'^F+X=;0DO-16P,ZSJGG ^7MD\Q57*G"AN?4]"2* *
M=A'=/\7M8#:E=&&/3;9U@.PH SR@K]W('&>#G/4GI6%X5UFYL/"'AW3;3<LV
MIZG?1^8FS<JI+,YV[_EW' '.>,]\5W;>&[4^(O[<6YNX[QK9;:39( DJJ25+
M+CD@L?;GD&LQ_AYH\GAJ+0WGOC#!<FZMKA90LUO*6+%D=0,'+-USUH RKC6O
M$NBI#IVI3)YNI:O%9V%T_EM+'"X+,750$+#8P7C!R,@X.9]#MY[;XM:ZD]Y+
M=9TJU*/*JAE'F2\?* #SGMWK3N/ VF7FAG3;RYU"YD\Y+A;Z:X)N4E3[CJ^,
M*5[ #')XY.;.F>%+?3=<EUEK_4+N^EMTMI)+B52&522#M55&?F/;'MG)H Q;
MU;EOC%9@:E=I NBS3>0FPIQ-$",%3][ R>O P165+XMU@_#>+QY!>$KY@F?3
MC&GE- 9=FP';O#A>=V[[P/&.!VU[X=M+WQ!9ZT9KF*[M8FA'DR;5DC9@Q5QW
M&5!XQ^548/!&F6T3VD<UT-+>Y^U?V:64P!]V_CY=P7>-VW=MSVQQ0!9\8WMY
MIW@K6=0T^?R+JULI;B-R@;!1"PX/':N5\0)=7^L_#Z=M1N8GGF8MY:QX#_99
M"7&4/)SCG(QT /-=QK.EPZWH]WI=Q)+';W<30RF(@,488(!(.,@D5G7'A.VN
M)-%=KZ]5M'YMBK)UVE,M\G/RDC_Z] &9\5 1\+M<&2Q$"\GO\ZTP:EK.F^.+
MS2[C5H[FWET:34(S<Q)'';R)(%ZJ ?+PP)W$D8ZUT/B#0K;Q)HEQI-Y+.EM<
M "0PL S '.,D''(%4[WPA8ZEJ4E]>W-W,\NGOITJ%D"O"_+ X4')(!R"* .9
MT[Q3J5GKEC'>7L]]8S:+->RR/ B*\D6PEH<*K;#N.-PY&"/6J&J7&H:QX>\#
MZ[=:@[?;M9L;AK143RHPY+*JG;NRO R2<\^V.LLO >G6=YIUTU]J5S+80/;1
MFXN-P>)MOR,  "!M'IGOFJT7PWTN&UM;*/4=6%A9W:W=I:?:!L@=22 IV[MN
M3T)..V* -/QG_;4?AB[N= N7BU"V7SE18T?SE7ED^8'DC.".^*Q;SQD3I5YX
MDTVX>XTNPTG[28MJXFF==R*QQE2J@%@"/OCTKI]:U5]&LXYX],O]1+RK%Y5D
MBNZYS\QW,/E&.3GO5#P[X9L],\+OI<UE"D=X99;JW7E,RDED]P =H]E% &->
M:MK&BR^%KN34GOK;5[B.SN8C%& CR(662(JH( *GABW'OS6;+XGUR/P%J&IC
M46-Y9ZZUDLAAC^>(72Q88;<?=/48.:ZW3O"5GI_]GH;J\NX=.S]BAN75EM_E
M*C!"@L0I*@L6(!K/NOAUI5W#J%N][J:6E[=B\:VCN L<<V\.67Y<\LO()(Y.
M,'F@"]XZU"^TGP/K&HZ;<?9[NUMGFCDV!\%1GH>*PSKFKZ)XGMDO]1>_LKK1
MY[YX/(1/*>+8?D*C."&(PQ//>NKUG1;?7-"N-'NI9UMKB/RI3&PWLO<9(/7U
MJK_PB]JVKV&IR7=U)-96S6L:N4VM&V-P8;><[5_*@#E9?$FM6GA'P_XM-\9X
M[Z6V-W8^6GEB.<@8C(7<&4L,98YP<^U_P3'='Q-XP>?4KJX6/5/+6.785QY,
M1'101C.  0,=L\UIV'@K3M/AMK2.>[DTZTG^T6UC*ZF*%P25Q\NXA2<@%B <
M>@Q=L/#MIIVMZAJEO-<B2_<230F3]UO"A=P7U(4=^U '->+O$E]HFKRQW=U>
M:9I<MN@M=2A@26".<ELB?*L5'W,'@8SSZ:"ZOJ0^(U[IB3B>Q&C)>00!5'[P
MR,OWNIR%'?O6CJ?AFWU5[X37MZEO?Q"&YMD9/+D7!!ZJ2I()!*D'\AB&[\/K
M9ZC=Z_IXGGU%=.-I#:>8J1.JY9$!QE?F/7/?TH Y72O$6O:JWA9K?5&:YOGE
M&K6@@C/V3:I)XQN3:P"?,3G([U4O_$'B>#PWXKUA=<(;1-6>*&$6L6V6-?+^
M1R1G&&/(P<GJ> )?#NE7\,5A!IU[XQMKBW\M7M]05/LJ*,;@2RG<N,@;6)Z<
M]ZZB;P)I\^D:QIDE[?FVU>Y-S=?.F2YQG!V< [5_+ZT 4=1U77-7UC7],T26
M6WGTQ(DB:/R2K2O&) 9/,!)7D#"XZ-SG&'Z;J^K:YX@GT6:[&G3Z?I]O+=FT
M"/ON)0V=I=6&Q=OIDEN>G-S4? UCJ&L1ZLFHZI97_E+#/-97/DFY0=!( ,'Z
MC!]^E37/@S3Y-7MM4L[B\TV[@MQ:EK.0*)81T1PP8$#L>"/6@#.^%2N/AMIB
MN^7WW + 8R?/DYQ7%7Z71^%?C>2XU&ZNB-6GB GV'[MPJ@Y"@YP ,9QZ 5ZG
MX=\/VGAC1X]+L9+A[>-F93/)O;+,6//U)K*N? &EW-AJU@;O4$M-4N#<SQ),
M-JNS!FVY4XRP![^V 30!#:7FL6WQ!N-#N=5:ZM[C2C>QEH$7[/()0A"8'*X8
M'#%CQUK$L/%6OOX T#6K@7EVDLLW]I36$"-,B!G566,@@J"%S@9P/K79'PY$
M?$*ZX;Z\^VK9FS!S'M\LD,>-G7< <_TXJKIW@VVTC3]/L[#4M1A2Q,GDN'C+
M%9#EE;*$,,\\C^E %SPQJ$>J^'K6]AU)=2BEW%+I4"[UW'&5 && P",#D&M>
MJ.D:3:Z)IZV5HK",.\C,QR7=V+,Q[9+$GC ],"KU !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9
MNO:D=*TB6>/8;ERL-LCG >9R%C7Z;B,^V30!0TCQ=9ZOXIUC0HD9)M."$.W2
M93E6*^RNI4^XKH"P498@#W->5Z]97W@J[\-^)IS:BUTUAI]_+$S;I()B 7?(
MYQ)A_JQK5\2W=E!X_M6U&2TO+&72)$6RFGB38QD'[P"1@I##Y<@Y^7TS0!Z
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MVMU!++;%5FCC<$Q$C*A@.F1R*LT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%-DD2*-I)'5$0%F9C@ #J2: '457L+^UU2P@OK*99K
M6= \4B]&4]"*L4 %%%% !1110 445COXIT6.^GL6OE^UP8\V$1L73/0D8X![
M>M &Q156PU&TU.W-Q93K-$&*%E[,#@@Y[BK5 !11533]3M-5MWGLY3)&DKPL
M2C+AT8JPY Z$'F@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ;3%I+9_+_?KM(PVTM\N3G@YXH UJ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME$BOPAC*DAB6^7'!R16:EU<S?&'3A/9W-H6T:=BDDP=&_>18P 2 PY!^O4T
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MKA+"^M](\?>-[R[N'2TM[.RGD+NS!!ME+8!SCIT%:VG^-+*]\11:))"T%U/
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MA**Q+, 6_P!:Q[_,#BI-4TZ*YTN\D.IZ3<:AJ^I6T^HH+U%1;:)AB)6/4 *
M3CG<QQVKN+3PWH<-Y-J5M80&:Z ,DH^82#MWQ@9X],\5?_LZQ_Y\[?\ []+_
M (4 <:\RW/CF74I=6TI+5=*%I!,MVN4=F+2$+GCD1]^BUE6NG6]QX-T7PG=:
MCIEM8VAB.H2K>1M]J\M@V(P#D!W )+8(&1@YR.YN9] L]3M--N/L,5[>!C;P
M,BAI-HR<#%7O[.L?^?.W_P"_2_X4 >;ZG8)=:3XNFCU/3&U77+A84_TY $LQ
MMCVYSP3&'8^Y'I5O71#K"6T2W>EVMUI]W!+IE]!>Q@0( GFAAG<0<2+MP0PV
MYQV[W^SK'_GSM_\ OTO^%']G6/\ SYV__?I?\* ,>UG\13^,)G_XE[^%FM%:
MWEC;,K2Y'X8^][=/>MV=G2!VCB,K@?*@(&X_4\5ES>)= L)+^UEU*TA?38EE
MNHMP!@0C()'IR/S'K5VSU.RO]OV2YCF#1+,I0YW1L,JP]5/J.* .+\/^#+[_
M (5"W@[50MM<FVE@,L;AURS,RL.Y R,@XJTNB:OK<?AJ#6+2.V.C7*74\J2A
MUGDCC9%\O'(4EMQW $8Q@YR.UHH \ON_"OB8^'M5T*WL;1XWUG^T(+E[K D0
MW*S;=NW*D#(/TXSFO2+FUCU#3YK2\C5HKB)HIH\Y!##!&?Q-6** /,X_A]K'
M]D:,\E^AUFQF^RO<CO8%3"4!]=F)/]\FMKQ#H^M6?B6PU_P_9VE\L=H;&YT^
M>7R=T>X,K(V" 0<]1T-=E10!QE]I6NWFM^%M1EL[?-A<33W4<,HVQK)$T81"
M0"Y&X$D@9YQZ".ZTSQ)H_C+4M2TC3K'5+#5A$TL=Q<>2UM*B"/=G:VY2JKD
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M)+18[=I0!%' 5(+MTW'YNF>H&>IK4U#2]8E\9W.LVUA$T3:&]E&L\BX,Q?>
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ME;:)&<94#/J*2'Q%H]Q<75O%J,#RVDZV]PJMGRI&Z*WID\#/?CKQ0!IT444
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MIW]H7L,J-N@79N'SYX7(()*D@#OTK$TKXJ^*=2TOP[,MEI_GZOK)M4/EN T
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MHL5PZ^5+LF.X8/RGA<XZ\9I+".32]>\#W-M/=R2ZEID_VM9+AW$^R!'7Y2<
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M/MXV$:$''FJ2[8W XP,9QGL:ROBRDD>D:#J#!C8:?KEK=7V!D"%6(+'V!(H
MWKOQ%J.GZ5+JEUX?G6V1/,,<<Z/.@]73H .^UF(]*Z*H);FV6R:XDDC-L4W%
M\Y5E/\\_K7#6NWQ+JOC.VU.>:&>PF6&UVRLAM8O*#)*F",,6W-N[X Z#% 'H
M%%>3Z+/?Z_J?@>36)[Q9-0T6YDNXDN'C64KY6UBH( )#9.,9SCIQ6?/!):_#
M_6M1COK_ .U:+KDEO8.UW(?)C6Z50N,X8;6(^;)QQT H ]HHKS@Z)!X@\>^+
M].OK_45M8[>S>-([V1!$[+)\RX;C!&<?=SVZ5F^';^XUW1_#UOJEQ->:D='F
MFDAGE\N$Q>8$6Y<]6?:!MQ_>)R.I /6:*\ATB>YU>S^&#76HWS/=QW$=R4NG
M4RA;=R-V#UX^]UYZU<L]%N]5\,^+M(T^\NDGTW5Y?[,)N'RFU(Y!&6SDH2S
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MJ%G"C)R <KP.AYZ9 S6!X8EBN?B7XM\77,B6VBZ5;C2;>5SA L9!DP?0,O\
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M7\/75_#:B.PA>SCE5\D-OWRIM=?F! &><8&,9.0#OV)"DA2Q X [UC^%]?\
M^$DT<WYM#:E;B: Q%PY!CD9"<@#KMKDM(G:^\7V?AS5=3.IVUKHBSPRL"BWL
MAD*-*1GYB JXY/WBPZ@UC:*;BS\#:3';2N]JOB6>.ZA$F9+B'SY?E&3E^0&(
MZD*W7D$ ]?HKRW4AJ7AO1?$FL">[M=/GU"WCM1+-(1;6K/&LSB/=A!DN1C#
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M!<)]L"1.9)W8[9+=P9,8R>/E^7 ( % 'J-<]JGBN&Q&B2VT'VRVU6^2S2=)
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MM;NJ2Z_8*6G-N/WP(\P8R">@QD<]*<?%NFCQ7+X?+D7$5L)Y'92%&3@#.,=
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M/M8K:VC&$BB7:HJU7.^ ]4O-;\"Z/J>H2B6[N;<22N%"Y))[#@5T5 !1110
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M^6P1 I4,V,XSC'.!GG&;J,$WV/2[W3;^]TO6;;1H@ADM6DM[M><P2(1]X,O
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MR&654QD@\\XYVD\\&O0M5\/C5-;TC4S>20OIDCR11J@*N74HV[//W2>F*VJ
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MIU ')_#*.6#X<:';SPRPSPVXCDBEC*,C G@@@&NLHHH **** "BBB@ HHHH
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M4MK<%XI OWHV<HNU^X&#D4:;XVO+R]\/QW.BK;6^NVIFM9?M6]E<1"0JZA>
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M+J-Y#OM_,APA'#DC:#DC /I7GR6NM2ZGX]NM'UMM.EM;X2HH@21966VC.'+
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MDED8*JJ.I)/2LD>*]*'D-,US;P7#*D,]Q:R11NQ^Z-S  9[9QGMFN:^++/\
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M7$:1&Y7"L)-PVL!TSOV\?A0 ^W\3:=<7]M8D7<%S=;C EQ:21>8 I8D%E X
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M]WJ5S-<S27=E]@FC9E"-#R<8 !!RS'(.>:W%8,,J01Z@TCNL:EG8*HZEC@4
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MJ4ZCJUQ_9+,;)9KG(B5EV[> "1CCDDXXSBM^PU2SU-KH6<RRBUG-O*RG(#@
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M8,LD)))#*H /7T_7FND!!Z$49&,Y&* .9T/P/8: -MIJ&JR1HI2VBN+HRI:
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MJ<"@">6*.:)XI462-P59&&0P/4$=Z\2TZ/3C\*O"\,(MTF;7;5;D1$*^?M3
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MI%F,*#Z+DC';)KN1H^F!8U&G6F(SE!Y"_*?4<<4V]TFTO+:ZB^SVZM= "9S
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M>NPV%G;W#W$-I!'-)]^1(P&;ZD#)ID6EZ? 4,-A:Q[',B[(5&USP6&!P3ZT
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M[FD8A]H!8GC.>,]\"UKEKJEYXF\(W\&D7+06,LTET?,B!B#PL@&"_)R>V>*
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M'5NA4GW[=0:M:MIVHV7Q L/$EK:R7EHU@^GW4,17?$"XD6102-PR,$#GIUK
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M9#N@D*J6)PW!Y("\CO73^.-7FT/PT]_%9VUVJSP(\=QG;AY50$#')!8'MTH
MZ.F0PQ6\8CAC6- 20JC YY-<E>^(?$#^*]4T/3;33@;6QCNXIKAW(.YG&&
M_N=NG7)Z5L>&M=77O">G:X\8@%U;+.Z9R$..1GTZT /_ .$<TK_A(3KIMBVH
ME @D:1B% !&0I.T'!(R!G!/J:U:Y72]>US5[;1]6L["VETK46R\>[;+;PD$I
M(6+8;.!E0N1NZG&:SKCQS>CPE)XPMK:WET6*9@T&&\]H%D,9E#9QG@MMQT[Y
MH [NBN&NO%>OS:MXBLM,M--V:7:PW44L[N?,5U=L$ #D[/P]Z@'B+5M7\1^"
MY;2:&WL=5TZ6]>W>,L0P2,X)##.!(0..O)SQ@ [BWOK2[EN(K:YBFDMI/+F5
M'!,;X!VMCH<$58KSR^\::CIN@^,M2ATNP%QHUYY>T.P$H\N,[F(&6;# =NG6
MM:/Q!K4?BR71+R"QC\[3GOK62(N^S8ZJ4?.-WW@<C'>@#K:*X>S\;7UUH?@[
M4S;6ZC7;A()HQN_=[D=LJ<_[&,$=Z=<^,M0?P]JOB/3K:VFTW39Y4:!PWFSQ
MQ-B1U?.%/#$ J<@#D9X .VHKE;'Q/<ZEXAO=/MQ;FW73(-0M9RC9(D+ !AGG
M[O;'6LF#XB&31?#5[>O::6NL6SRFZN$9X(Y!MVQ9R-I8%CDG^$]<\ 'H%%4;
M>ZNO[#BN[B!6N_LPEDA@;<"^W)53W&>!7)Z;X_CN=!N]=>YLKFRM+)Y[F"W5
MDGMIEQ^Y=68G/WAG Y% '=45R,/B#7QJR6S:8MQ;36KRBX6VF@2WE49$;EQ\
MP/9@!R.@S61!XO\ %]UX$/BN'3=*-O\ 85NUM@TC2L0?G'IC;R.2>,=^ #T7
MI5>ROK34K..\L;F*YMI1E)8G#*PSC@CKS69!J]QJ%Y;C37M;BV>Q%TSL&7<7
M_P!5@@G ;#D\$C:/7C \/^,)=2T'PQ';V=I:WVLI,Z1JI\F!(\ECM!!;JHQD
M<MG(Q0!W5%<E+XEU:PCMK/5+&*'4KN^EMK=XE:5)(D4OY_EH2P!48V9SGJ0.
M:T/#6K:GJ0OXM4T]K=[:?9%.(7B2YC(R'57^9>X(.>G7F@#=HKA]0\6ZO8OX
MIMC!9&\TF&.YM(RKXNHG!QWSN+ IQW ]:U=+U^YUE=-ET]K6:&XTX7DI*LN"
M^!& <G&2'SP<;#ZT ;=E?6FI6<=W8W,5S;29V2PN&5L'!P1[@BDM]1LKNYN+
M:VNX)I[8@3QQR!FB)S@,!T/!ZUYR/$NKZCX8\%7M@++3EU/4Q#/!'$2H ,A
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M?-.C\3Z]/XBUNS6TTR*QT:XB^U2R2N6:!HA(2H ^^ >^!VYZT =HS!5+,0%
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M7SI"43GHJA0!UP 3R2:WO%-\\OBSPOX>SBWOIIKFY']]($W!#[%V0GU"X[T
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MXY8$,&V5UC.Z)';=@A3CHHR%'3G+9_ ]W/I?BJR.KP :_([L_P!C/[C=&L9
M'F?-PH].:[.B@#EY/#=RNMZ%J\^JVZIH]K+ Z?9BHD#A0S;C)\N-@['O7*^
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M3V?B>;RXHY-L3!KI%8.O\8(8]>G&,<Y]2O\ P_IFIWUE>W=NSW-EN$$@E=2
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M0-<O+:\O[)Y+JW3RTG2XDC<I_=9E8%A['/?UK=BAC@A2&*-8XHU"(BC 4 8
M ]* /&="BU+1OAKX3\0:?J]^9EGMX&L"X,$T<DVPH$Q][YL[NO7VQT$=SKGB
M6RU2_L-2BL+NPU2:(2R7L@CA2&3&R2 +M8,@R23GYLY& *Z[3_">C:88/LMJ
MZQV[F2"%YY'BA8YR41F*J>3T'&3C&:AF\#^'9]?;6WTX?;G96D9975)&7H70
M':Q'J0: .2U?6+G0-?\ B+JUI&'N;72[*2,$9 ;;+@D>@ZGZ5HW\UWH^I^$I
M[+4+N[@U686EW'+.SB4-$SB5<GY"-I/RX&#TZ8ZE/#VEIJ5]J'V8M<W\8BNB
M\KLLJ $!2A)7 !/;N:9IOAC2M)>W:U@D_P!&4I;K+.\BP*>H0,2%&...W'3B
M@#S?4M4UC3])U?28[W4+C6=%U$W8Q<N&N+# E^8YY&S,?'\0'J:]!\/W<>LS
MW6M6US+)83A(K4>83&RJ/F<+G )8E?\ @ ]36D-+L1J<VI?9HS>30+;R2D9+
M1J6(7Z98_P"0*BCL1H^AQ:?HMK&BP1B&WC)PD8 P"W<@=^I- '.?"V:1_!IM
MV),=I?75M 3_ ,\TE8*/H!Q^%=I6!I_A#2['2M'LF1YO[+D\^&4N5)F.[<[
M$ DEF.#QS6_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@W\VJ3^
M(ET^QOHK6);3SV+6_F%COV^HQ4G]GZ__ -!^'_P '_Q= _Y'<_\ 8-'_ *,K
M:H Q?[/U_P#Z#\/_ ( #_P"+H_L_7_\ H/P_^  _^+K1U"[-AI]Q=B%YO)C,
MAC0@,P R<9(&:YJW\>+/X;A\0G0-5&ERQ";SD$4C)'_>**Y;'?@$^U &I_9^
MO_\ 0?A_\ !_\71_9^O_ /0?A_\   ?_ !=:5A?VNJ6$%]8SI/:SH)(I4/#*
M>AI]Q<P6JHT\JQAY%C7<>K,< #W)- &5_9^O_P#0?A_\ !_\71_9^O\ _0?A
M_P#  ?\ Q=;5% &+_9^O_P#0?A_\ !_\71_9^O\ _0?A_P#  ?\ Q=;5<]>>
M)IDO[RUTW2Y=1-A+%'>"*0*Z&0!OD4\-A2">1P>,\T 3_P!GZ_\ ]!^'_P
M!_\ %T?V?K__ $'X?_  ?_%UM44 <MHX\0ZGI<5V^MV\;.SC:+$$#:Q7^_[5
M?_L_7_\ H/P_^  _^+H\)_\ (MVW^_+_ .C&K:H Q?[/U_\ Z#\/_@ /_BZ/
M[/U__H/P_P#@ /\ XNK.N:H=$T>YU+['-=1VT;2R1PE0VQ1DD;B >!TS4.E>
M(K+7?#D6MZ5NNH)(]ZH"%<$=4.3@,#D$&@!G]GZ__P!!^'_P '_Q=']GZ_\
M]!^'_P  !_\ %U>TG4!JNDVNH""2!+F)94CD(+!6 (S@D9P?6KE &+_9^O\
M_0?A_P#  ?\ Q=']GZ__ -!^'_P '_Q=;58VH>(!I_B71]&:SD<ZGYVVX# *
MAC0N01U)X^G/6@!/[/U__H/P_P#@ /\ XNC^S]?_ .@_#_X #_XNMJB@#%_L
M_7_^@_#_ .  _P#BZ/[/U_\ Z#\/_@ /_BZVJ* .6U,>(;#['MUNW?S[I(#F
MQ P&SS]_VJ__ &?K_P#T'X?_   '_P 71XCZ:5_V$H?ZUM4 8O\ 9^O_ /0?
MA_\   ?_ !=']GZ__P!!^'_P '_Q=;5-D9EC9D0NP'"@XS0!C_V?K_\ T'X?
M_  ?_%T?V?K_ /T'X?\ P '_ ,76?H_C.77=&.JZ?X>U&6WW2(%,D(8LC%6
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MHT/_ )"OB3_L)+_Z2V];5 &+_9^O_P#0?A_\ !_\71_9^O\ _0?A_P#  ?\
MQ=;5% &+_9^O_P#0?A_\ !_\71_9^O\ _0?A_P#  ?\ Q=;5<_H?BJ/6M<U;
M2/[/NK2YTMD6?SRF&WC*E=K$D$#.>* )O[/U_P#Z#\/_ ( #_P"+H_L_7_\
MH/P_^  _^+J>SU=KS6[_ $X6,Z+9[ ]RS(8V9AN"C!SG!!.0.H]:TZ ,7^S]
M?_Z#\/\ X #_ .+H_L_7_P#H/P_^  _^+K5FN8+=X4FE5&G?RX@3]]L$X'X
MG\*EH Q?[/U__H/P_P#@ /\ XNC^S]?_ .@_#_X #_XNKVJW_P#9>D7=_P"0
M\XMH6E,49 9@HR<9(%)HVHKK&AZ?J:QF);RVCN!&3DJ'4-C/?&: *7]GZ_\
M]!^'_P  !_\ %T?V?K__ $'X?_  ?_%UM44 8O\ 9^O_ /0?A_\   ?_ !=4
M-7'B'3;*.=-;MW+7-O!@V('$DR1D_?[!L_A74UB^*?\ D$0?]A&Q_P#2J*@
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M 8O]GZ__ -!^'_P '_Q=']GZ_P#]!^'_ , !_P#%UM44 8O]GZ__ -!^'_P
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MRS P-(KD ,0#E>.0 ?QJW0!B_P!GZ_\ ]!^'_P  !_\ %T?V?K__ $'X?_
M?_%UM44 8O\ 9^O_ /0?A_\   ?_ !=']GZ__P!!^'_P '_Q=;5% &1X>NKR
MZM+D7TR3307<L'F)'L#!6P.,FM>L7PW_ *K4_P#L)7'_ *%6U0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME !1110!B^&_]5J?_82N/_0JVJQ?#?\ JM3_ .PE<?\ H5;5 !1110 4444
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MQ;S3M\O.[;MZ=3GUK3K@-,\4ZN_B#0+*XN;>X_M2*Y%QY,),,,L:[@(I./,
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M($<.JN.#@@D8/7J>M:- !1110!BZ'_R%?$G_ &$E_P#26WK:K%T/_D*^)/\
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M=* .XHHHH **** ,7Q3_ ,@B#_L)6'_I7%6U6+XI_P"01!_V$K#_ -*XJVJ
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MGVS4K.^U>\:^>R?S+:'RQ'%')C'F;1DLX!(!)P,\ &M*\U.PT\H+V^MK;?\
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MBBB@ HHHH **** "BBB@ HHHH **** ,4?\ ([G_ +!H_P#1E;58H_Y'<_\
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M'3!SBM#3;VTA\<>$[B65%BN?#C00N1_K)=\)VCU; /'M7I152<E03C'([4M
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M#-#ROIP&Z=@:]LB>"3<86C;:Q5BA!PW<''>I* /.)%TV/XF:E:64\-I'/X9
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M8 ("#N_V1Z5H:O/---\2UTPFXN%GLG:& AG>)8X_- '.?E#KC'M7K@50Q8*
M3U..M+0!P_A:Y\.:[XC.NZ/JEWJ5V;'[/-*55$C3<&5'"HHWYS@'D 'M1X]N
MK6#7?!JSS0HW]L!B'8#Y?)E&>>V2!]37;JJJ,* ,G/ H=UC1G=@JJ,EB< "@
M#SFVN[&'6O'&G^)7B0W;+)!YY $]H8@JK'G[V"&X'1F]36+HVG1?V_X#L/$D
M5M-?G1+B.XBN0K,2?+V(X/4[<C!]#7KRF*9$E4I(I 9'&""#W!I] #8XXX8D
MBB14C10JHHP% Z #L*=110!B^*?^01!_V$K#_P!*XJVJQ?%/_((@_P"PE8?^
ME<5;5 !5/5KU=-T:^OWB,JVUO),8QU<*I./QQ5R@C(P: /(KC3],T+6M,U?X
M?ZJJ27][$EUHL$F^&>-C\[>5UC*C))XQCMW9JXTJY7XKR3?9)91$HB9RI8$6
MB@;??>,<=QZBO7@J"0L N\CD@<XIU 'D.JZQ87,5[:^9'#>3^%T'VAR9'O5*
MN?+B7[O!SN.">>V,T:8=%U;Q#X!6Y%G<B70)8Y%E56\QMD( 8'[W1\9]#7KV
M!G..:.E 'D4\VB_VCXF\+^)[V[LC<W8>VM(H5Q=6^U!$(3L))7;MPIX(X[U:
MUBXGTG6KZYT^[@U&(W=FNHZ'>$?:/-"Q!)(6!R6QL."""5;%>GRR0Q;7F>-/
MF"JSD#D\ #/<T\JI8,5&X=#CD4 8OC&:*#P5KCS2)&IL)U!8XR3&V!]:Y[P+
MH&D:CX3\*ZI,7O+BRL83")+AG2"3RU#83. PZ<C([8KO** /'FD6Y^&7B/1-
M0(_X2=;VX80$XGEN&E+0.@ZD8V;6'&%]!5S6[B]TG4[^ZMKZTU*0/:)JNB7(
MQ))*$CVR6[#G/*X!&,J>]>I2&.,--(44(I)=L#:._/I0OERA)5VN",JXYR#W
M!H X/2YI(OB!XVL[2:W@U.X-K+:BXC+*0( "Y4$$J"""01SQG)KK-&CUN."0
M:Y<V$\Q;]V;*!XE"X[AG;)S6GWS10 4444 8OAO_ %6I_P#82N/_ $*MJL7P
MW_JM3_["5Q_Z%6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 8H_P"1W/\ V#1_Z,K:K%'_ ".Y_P"P:/\
MT96U0 4444 %%%% !1110 4444 %%%% &+X3_P"1;MO]^7_T8U;58OA/_D6[
M;_?E_P#1C5M4 %%%% !1110 4444 %%%% !1110!B^(^FE?]A*'^M;58OB/I
MI7_82A_K6U0 4444 %%%% !1110 4444 %%%% !1110!BZ'_ ,A7Q)_V$E_]
M);>MJL70_P#D*^)/^PDO_I+;UM4 %%%% ''^(?&L_A_[9<3Z8JV5K<0PAII_
M+DN0^W<T*[2&"[QWYPW3%6;CQ8W_  D5[HME;VTMW9^47@EN?+EE1P"7C7:=
MRJ#Z]01QQG$UWP1KNJ)XDMX[_3VBU26*:&:=',L00H1#QP$!0D8S]X\9.:M^
M(O!]_P")2Z7JZ<9%EBDL]1BW)<69 7?L&#G+!B!N'WN<XH Z;7M:MO#VAW6J
MW88PVZ@E4^\[$@*H]R2!^-9A\2W=GXAL-&U2PA@EU**1K.6&X,B-(@W-&V4!
M4XY!Y!P:M^*O#\7BGPS?:--,T(N4&V51DQNK!E;'?#*#BJ,>AZGJ.KZ/J6MF
MS$VDI(8EMG9A-*Z["YW*-HQN^7YN6Z\<@&)X.M'UZYUR;6K"TF-MK\TD4OG,
M[Q2Q;%0+\@^50, Y_#FM6ZU;5F^)D&B)#:OIK:6]PZM*0S9E12Q&T@D#("]\
MG)[5:\)Z)J&B?VN+UK9A?:C-?(878[!(1\IRHSC'7]*+[0M0;QO9^(+*>V$:
M6+V4\4P;.TR*X*D=_EQSTSGGI0!QGA+7[GPUX8M]NE1-I+ZY/9R2B?8\?F73
MHI6,*05!(!R0?05TNL>.6LO[1?3].%^FG3"&:-)&$TC *7\M0A!V[NY&2"..
M"<\>"=8'A!=&\VP\Y=6_M'S/,?;C[1YVW&WKGY<_C[5<C\.>)M*U_49M$U+3
MDTO5)OM,\5U$[R6TI #M%@@,#@'#8Y_'(!V44BS0I*H8*ZA@&&#@^H[4^FHN
MR-4W,VT 98Y)^M.H *Q?%/\ R"(/^PC8_P#I5%6U6+XI_P"01!_V$;'_ -*H
MJ -JBBB@ HHHH X_Q/XUG\-QZC=3:8OV*P,7[R:?RVN=V"WDC:0VT'U&2"..
MM6;[Q8T7B"[T6RM[::]MH4F\B:Y\J2=6SDQC:=V /SXXZUB^(O!&N:PWB>&*
M_L#;ZQ$BPRW".TL 50/*&. A(W9'<G@]:M>)/"&H>)[::VU!-,=SL:TODWI/
M8R #<T> 2>1D#</?V .GUS6+7P_H=YJUZ6%M:1&1]HR3CH![DX ^M93>)KNQ
MUS3--U;3HK?^U%<6TL5P9 LJKN,;Y48)&<$9S@CZW_$F@0>)O#-]HES(Z1W<
M/EF0<E3U#>^" :S(M U34;W1+G77LV?2"TBFV9C]HF*% Y!4;  6.T;N2.>.
M0#&\*6DGB#4_$AUS3[.=;?7"R/YS.T4D4<6P)\@^4=<Y'4\<FM74=7U9/B/I
MNC0Q6K:?-833N'E968AXU)/RD<!C@=\G)%6O"VBZAHUUK;WAM634=0>]3R78
ME-RJNTY49^[G/OTHU30K^;QCI>NV,]LJV]M+:SQSJQ)1V1LKCOE,<^M '&>'
M->N?"NAZG/%I,3Z3'XCN;>:03[&B5[GRU*(%(8 L,Y*^U=/K/C9[%M3&G6"W
MQTQPD\0D99)&VJ[+& C D*PZD9/'O6;-X)UB7PAJFC>=8B6]U8Z@)/,?:@,Z
MS;<;>3\NW/OGVJZ?#WB;3/$>H7NA:AIJ6.JNLUU!>1NYMY@H5GB*D;LA1PV.
M10!U]M.MU:0W"*ZK*BN%==K $9P1V/M4M,BC,4*1EVD*J%+OU;'<^]/H ***
M* ,71/\ D+^)/^PBG_I+;UM5BZ)_R%_$G_813_TEMZVJ #I7EMMKLEI\1-.U
MV2_632_$0;3TA#@B#82;9L=?G&\^WF5WWB*TU#4-$N++3GACFN%\MGE=EVH>
M&P0"<XR!Z9SVQ6/XL\&Q:[X5ETW3[6RLKTF-H)U7;Y#HP8,I"Y.,>V: -.^U
MJ5-;31=/MXY[XVQNG\Z4QI''NVC) ))+9P,?PDYZ TK7Q3=WG]F68TA[76+R
M"2XDM+J7:+=(V"L68 YRS+MP.0<\8JA?^'O$IUK3O$>G7>FQZO'9_8KZ"<.;
M>>/=N#*0 RD-DCCOC/J[5?#&OMJ.E:[IFIVC:U:1R07 N8V$%Q%(P8KA264*
M0-O7H,YH L_\)?/':Z?%>:6;'5+QIE%M<2G8BQ'#/N"DE3E<?+SN'3K7->)-
M8_X2/PO875UIC6EU9^([2W(<%@2)T&^-BH)1@1@X'<=JW=8\,^(+MM)U>RU2
MT7Q!I[R$^;$WV:5)  \6 2P7Y5P>3D9[\.UGP]KVM:%:P7-U8M?+J$%[)MWI
M"@B=6$:<$G.WJ>Y)QT  %UGQL]B^IC3K!;XZ8P2>+S6621MJN5C 1@2%8=2,
MGCWIDGC'5+C7Y-*TOP^+AQ907RM/=>23'(Q4@@J=K#!X_E2-X>\3:;XEU"^T
M'4-.2QU5UFNK>]C=S!*%"%X]I&[(49!QTJ]9:#J%MXXGUEY89+633HK+YG)E
M)1F;>?EQSN/'X^U %27QK/:ZIIUO>:8MO'?Z@]C$DD^+@8WA93'M^XQ0]^A!
MYSBJ5EXAU:YA\:OJ.GV=U::;/+$MN)SAD6%&*8*8((9B2>YQC'-5U\#^(A!9
M1-J.FR/9ZU_:0N9(G,MP,O\ ZPYZ@/@ <8 &1BM1?"VJP-XLBAN;-[;6F>6(
M.&#I(\2QG<1D;1MSP,GVH ETWQ+'+:^']-TK3X([J]TM;Y+8R;(K6 *@ R%.
M>750 .QZ8JE/\0Y(=,>;^QRU[;:K'I=Y:BX \MW90K(Q'SJ0P(SM]\4ZT\(:
MGIL_AS4[.:T;4=+TX:9<Q.["*YAPO1MI*D,H;[IZX]ZCO_ ]]<64[PRVOV^\
MUB'5+EG9@BB)E*QK@9/" 9..23CL #:T3Q#=W^OZIHNHZ?%:75DD4RF&X,J2
M1R;L')5<$%2",?B:Z&N=L=%O[?QOJ6N2FV^SWEI#;B-'8NIC+G/W0.=Y_*NB
MH Q?%/\ R"(/^PE8?^E<5;58OBG_ )!$'_82L/\ TKBK:H *0D $D@ =2:6L
MKQ'97^HZ+-8Z>T"O<8CD:5V7$9^^ 0"<E<@'MG/;% '!:?KLMI\1;#69;Y9-
M,\3(UI'#O!%NT9)MSCMO4L<>KFNXOM;F76_[&TZVBN+Y;7[5)YTIC1$+%5Y"
MDDL0W;HI/H#F>+_!R:[X9:QTVWLK+4!)%+!<!=OD.C!@P(7)Z8[=:@O_  ]X
MD_M^R\1Z7=:;'JGV,65_;S[V@F0,6#*0 P8$GMT.,^H!>M?%%W>MIUDFDM;:
MO=VKW4MI=R[1;(K!3N8 YRQ&,#D9/&,5$/&$ZVVG176F&QU6\$S&UN93MC6)
M@K-N522"67''.[M5?5/#&OC5=,U[2M2M&UBV@DMKI;N-A!<1.V\@;267:P^7
MKQC)/==8\,^(+B;2=9T_5+0:]8F4/Y\3"VFCDQNCP"64#:N#R>,GK0!A^(-8
M_P"$CT#0[RZTQK.[M?$UI;E9%)&1,H+1L0"R,""#@9_"M[6?&[V)U(Z?IXOA
MIL@BGB$C"61MJLPC4(02 PZD9.1[TNL>'M=UC2-.CN+JR>]AU*"_EQO2)1&P
M81H,$X..I[DG'.!%_P ([XFTOQ'J-UH6HZ<FG:I*)[B&\B=WMYMH5GCVD!LA
M0<-CD4 2-XPU2Y\0W&DZ9H"W#16]O=>9-=^5F*5B#D%>&&T_+['D=P^-9X-6
MTNUO-,6V34;V2TBC>?%PFW?MD:/;]QMAZ'H5ZYJWI^@W]IXVO=8>6"2TN+*&
MT +L9<QECN/RX.=Y_*N>A\#^(HX=+CDU'39)-/U=K\W+Q.9+D$2#,AS]X!\8
MZ<#D8H FL_$>JW.E>-[C5-.L[RTTZYN(?LPG.&C2&,F/!3!!!8DGJ21C%:]C
MXD65-%TO2["!;JZTQ;X0-)LBMH % &0ISRP4 #H#TQS4_P"$4U6&V\76<-S9
M-;:V\TL)<,'C>6)8SN(R,#;GCKGM26_A/4].O]!U>SEM&U"QTT:9=PR.PBN(
M1@@JP4E2&&?NGJ1[T 1R_$-TTU)ET=FO(]732+RU^T &&5F #*Q&'4@@@G;U
MYQS6QH7B&[U'6]7T?4-/BM+O3Q#)^YN#,DD<H8J<E5((VD$8_&L6\\#WLEH&
M@EM3>SZW%J]TSLP3Y&4K&N 3C:H&3CN<<X&SINB7UKXTUC6IC;_9[^"")41V
M+H8M_)RH'.\_3'>@#HJ*** ,7PW_ *K4_P#L)7'_ *%6U6+X;_U6I_\ 82N/
M_0JVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#%'_([G_L&C_T96U6*/\ D=S_ -@T?^C*VJ "BBB@ HHH
MH **** "BBB@ HHHH Q?"?\ R+=M_OR_^C&K:K%\)_\ (MVW^_+_ .C&K:H
M**** "BBB@ HHHH **** "BBB@#%\1]-*_["4/\ 6MJL7Q'TTK_L)0_UK:H
M**** "BBB@ HHHH **** "BBB@ HHHH Q=#_ .0KXD_["2_^DMO6U6+H?_(5
M\2?]A)?_ $EMZVJ "N?/B2:YOM0M]+TR2^33I!#<N)E0F3:&*(#]X@,N<E1S
MC/6N@KSW5O#%U=:SJ'B+P3K)T_65D\J]M91OMKIT P)%_A;!'S#L>V<T =MI
M6H+JND6>H)%)"MU"DPCD&&0, <'W&:N5Y=:>*9O$\GA**Z%OIEMJEC<2>1*K
M-%+<(Z*$&&7(QO9020<C@D B.[TNXT^Z\+:4_B2]O8VUF>W>2&62+$1A=A"3
MO;=MZ!L[AT!!% 'JM%>2L?[ O?%.A'4M2725NM/%FJ3EY5EF;YH%D<Y"M@9R
M> Q/?F+4Y[NWTGXEV@G>U%E!#-;PVMT^V!V@W$(WRG!(!(P!UXH ]?J&ZN[>
MRB62YE6-&D2)2W=W8*H^I8@?C7"W.FV.G3Z%;)=7]Q=ZI,9C:37;&*Z9(#N,
MA;.U!D-A1R0/EXXY9Q_:'A+2X[V5I_LGC);:(^<S;(_M14*&SD@#@$\@4 >O
M?:+S^US;?8?]"\CS/M?FC_6;L>7LZ].=W3M5NO/K^YN=+^(&I'3WGF$/A=IX
M+9IG=#*LA"X4DX)V@<=:S3/-'X0\&>(],NYY=4N[FS2Y?S2WVL2\2HXS@X)8
MC^[MXP!0!ZG17C.JP2+X3^(&HB_U'[5I>K2O9/\ ;)/W)6.%ACYN>N,'(QTQ
MS7LB'=&K'J0#0 ZL7Q3_ ,@B#_L(V/\ Z515M5B^*?\ D$0?]A&Q_P#2J*@#
M:HHHH *P7\12SZK?V.EZ:UZVGE5NF\Y8\.RA@B9^\VT@\[1R.>N-ZN UGPO-
MJ&OZAKW@_6FTS7X'6"\B<;[>Z945E$J=CM9<,.<=N] '9:1J*ZOI-M?K!+ )
MTW>5,,.GLP'0U=KRRV\67/B*/PC'>K;Z9%J:WBSQNK-#)<1,$"<,N0W[Q@"3
MDXZD4W4M+N=+CT#3CXDO+I7\2>06@DDB\J%XG?R/OMNVG&&)R,@#&* /5:*\
MFN@/#>H^+-'75-3CT8QV4D.R=I)89I9"IB1W.1OP,Y/ ;.11=RW5O'\2;/S6
MLUM-,AN8(+6[?$$AAE)*L-I!.Q20  ?>@#UFH;J[M[&W,]S*L4095W-ZL0H'
MU)('XUY\=/LK"P\.J+O49KW5Y(7:V>Z8QW;) Q(<L2$0?>(4<[0-IZ5SMV#>
M^";N&\D,HLO%R00J)F811_:(QM4GG #$#T'I0!Z\;B\&KI;"QS9& NUWYH^6
M3< $V=>1DYZ<8JW7!7<DVG?$O98O/*B>&YY([4S.Z-(DJ 84D@'MD<UB"[N6
M^'?AGQ5I]W-+K<US:^<XD)^U-+($EB89P5!9L#'R[1C&* /6**\?U>T:32OB
M/=&^U'S=,N#+9$7LH\EA;HX(^;GGL<@=L9->L6,K3Z?;2N<N\2LQ]R : +%%
M%% &+HG_ "%_$G_813_TEMZVJQ=$_P"0OXD_["*?^DMO6U0 4444 %%%% !1
M110 4444 %%%% !1110 4444 8OBG_D$0?\ 82L/_2N*MJL7Q3_R"(/^PE8?
M^E<5;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8OAO\ U6I_
M]A*X_P#0JVJQ?#?^JU/_ +"5Q_Z%6U0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 8H_Y'<_]@T?^C*VJQ1_
MR.Y_[!H_]&5M4 %%%% !1110 4444 %%%% !1110!B^$_P#D6[;_ 'Y?_1C5
MM5B^$_\ D6[;_?E_]&-6U0 4444 %%%% !1110 4444 %%%% &+XCZ:5_P!A
M*'^M;58OB/II7_82A_K6U0 4444 %%%% !1110 4444 %%%% !1110!BZ'_R
M%?$G_827_P!);>MJL70_^0KXD_["2_\ I+;UM4 %9%QX8T2ZGFFDTZ'S9SF=
MTRAF_P!_:1O'L<UKT4 9>I^'-%UG3(]-U'2[6XLHL>7"\8VQX&!M_N\<<5@>
M(?"GVFY\,6VFZ9 -,TJ[,TD2,(PJ^6R@(!_$"P;/'3KFNSI& 92IS@C'!P:
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M9ZO);6Q2]D'E1A%( &<'!8]0:=H?C.?2;GQ+I'B6Z-Q-H4L(2[2,![F*;'E
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^&_\ 5:G_ -A*X_\
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MKWBC191IFR_0[+^)V^5N ,Y/2MC_ (2[0?\ H(I_WPW^% &U16+_ ,)=H/\
MT$4_[X;_  H_X2[0?^@BG_?#?X4 ;5%8O_"7:#_T$4_[X;_"C_A+M!_Z"*?]
M\-_A0!M45B_\)=H/_013_OAO\*/^$NT'_H(I_P!\-_A0!M45B_\ "7:#_P!!
M%/\ OAO\*/\ A+M!_P"@BG_?#?X4 ;5%8O\ PEV@_P#013_OAO\ "C_A+M!_
MZ"*?]\-_A0!M45B_\)=H/_013_OAO\*/^$NT'_H(I_WPW^% !H?_ "%?$G_8
M27_TEMZVJXW1O%&BQZGK[/?H!)J"LAVMR/LT ST]0:V/^$NT'_H(I_WPW^%
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MEQ+)8V]B[$L;:W VQ9.0.."<=2.,YK0K%_X2[0?^@BG_ 'PW^%'_  EV@_\
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M:5_V$H?ZUM4 %%%% !17!_$/Q'<Z+<V5J]W-I^GW=O./ML2C_CX 7RXRQ!V
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M* ,7PW_JM3_["5Q_Z%6U6+X;_P!5J?\ V$KC_P!"K:H **** "BBB@ HHHH
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MT;4-,MK<A$6^0))(3RS8R2>3DL3DDFMVBB@#%\)_\BW;?[\O_HQJVJQ?"?\
MR+=M_OR_^C&K:H *Y#P9#/#J_BII[6YA2ZU0W$#2PL@DC\J-<@D>JGCK77T4
M <AH44\?Q%\4W,EK<QV]U':+!,\+*DAC5P^"1C@L/KVS7//X=NX/!?BGPE)I
M\T]Q>W5Q)92B(F*43-N1V?&%*$\Y(/R<9R*]0HH Y2YE;4#-X+D.IVLYT]2-
M3$2[)0-JOM8Y!;YAD$?Q5B1^%=?MOB1I%X^O:A=6<%A*KSM:P*H'F1GR?E0
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M%UC:Q7]R;>YDL=/E,5W=H%V1,,;N"VXA<C) /?K@UJ7VHQ6'V8.-QN)A$G.
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MSQC3,Z]JK[K^)?F:+CKR/W?6M?\ L"X_Z&+6/^^H?_C=+XCZ:5_V$H?ZUM4
M8G]@7'_0Q:Q_WU#_ /&Z/[ N/^ABUC_OJ'_XW6W10!B?V!<?]#%K'_?4/_QN
MC^P+C_H8M8_[ZA_^-TNO>)+?1"(1!+=WCP27"6\14'RTQN8EB  "RCUYX!JU
M9ZO'=V=Q.;6ZA>W<QRP21YD5@ < *2#D$$$$@YH J?V!<?\ 0Q:Q_P!]0_\
MQNC^P+C_ *&+6/\ OJ'_ .-U9T#7+7Q)H=MJ]DLJVUR&*"5=K8#%>1DXZ51T
MKQ9%K&J&SM](U=(,,R7TMMLMI%'1E?/(/;CF@"7^P+C_ *&+6/\ OJ'_ .-T
M?V!<?]#%K'_?4/\ \;JYJVKVNC6:W%SO/F2I#%%&,O+(QPJ*/4G\!R3@"JL/
MB;3S!J;W9>R?2QNO([C&Z)2NX-\I(*D9P03T(Z@B@!O]@7'_ $,6L?\ ?4/_
M ,;H_L"X_P"ABUC_ +ZA_P#C=.T_Q';WU]#926US9W%Q;_:;=+E5!FC! )&U
MC@C<N5."-PXK9H Q/[ N/^ABUC_OJ'_XW1_8%Q_T,6L?]]0__&ZVZ* .-T;0
MYWU/Q HU[55V:@JDJT66_P!&@.3^[Z\X^@%:_P#8%Q_T,6L?]]0__&Z70_\
MD*^)/^PDO_I+;UM4 8G]@7'_ $,6L?\ ?4/_ ,;H_L"X_P"ABUC_ +ZA_P#C
M=;=% &)_8%Q_T,6L?]]0_P#QNC^P+C_H8M8_[ZA_^-UMT4 8G]@7'_0Q:Q_W
MU#_\;H_L"X_Z&+6/^^H?_C=;=4=6U:UT73VO+MF"!EC54&6D=B%5%'<DD 4
M4O[ N/\ H8M8_P"^H?\ XW1_8%Q_T,6L?]]0_P#QNK.G:U!J%Y=6+0S6U]:A
M&EMYMNX*P.U@5)!!P1D'J"*TJ ,3^P+C_H8M8_[ZA_\ C=']@7'_ $,6L?\
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M3W\2V"^*XO#@,CWTEL]R=J_(BJ5&&.?O'<#CTY.,C-?4?%D5AK TV+2-7OY
M5626RMM\43-R%=B0 <$$^@(- $O]@7'_ $,6L?\ ?4/_ ,;H_L"X_P"ABUC_
M +ZA_P#C=%_XFM[*XO8(K2[O7L(EEN_LRJ?)4@D [F!)P"=JY.,>HSJ65[;Z
MC8P7MG,LUM<1K)%(O1E(R#0!E_V!<?\ 0Q:Q_P!]0_\ QNC^P+C_ *&+6/\
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M0Q'K@$X^AP?:J.E>)=/UK5]5TZR,CR:8Z1SR%<(68$X4YYQ@@^] #/[ N/\
MH8M8_P"^H?\ XW1_8%Q_T,6L?]]0_P#QNMNB@#$_L"X_Z&+6/^^H?_C=']@7
M'_0Q:Q_WU#_\;K;HH XWQ)H<\>EPL=>U63.H62X=HL<W,0SQ'U&<CW K7_L"
MX_Z&+6/^^H?_ (W2^*?^01!_V$K#_P!*XJVJ ,3^P+C_ *&+6/\ OJ'_ .-T
M?V!<?]#%K'_?4/\ \;K;HH Q/[ N/^ABUC_OJ'_XW1_8%Q_T,6L?]]0__&ZV
MZ* ,3^P+C_H8M8_[ZA_^-T?V!<?]#%K'_?4/_P ;K;J*ZN$M+:2>0.509(12
MS'V '))Z 4 9/]@7'_0Q:Q_WU#_\;H_L"X_Z&+6/^^H?_C=1Z+XKM]7U>[TF
M33[_ $[4+:-9C!>QJI>-B0'4JS C(QUZU/?^)=/T_P 1:7H4ID:^U(OY2HN0
M@5&?<YSP#L('J0?0X &?V!<?]#%K'_?4/_QNC^P+C_H8M8_[ZA_^-UI:AJ%K
MI6G7%_>S+#:V\9DED;HJ@9-4++Q';75]]BN+>XL+EK?[5''=!07BS@L-K$<$
MC(.",CB@!G]@7'_0Q:Q_WU#_ /&Z/[ N/^ABUC_OJ'_XW4-OXPL)WTYFM[J&
MTU-_+LKR15$4[$$J!ABPW $KN S]<4NL^+(M(U!;*/2-7U*;8'?^S[;S5BR3
M@,<@ G!/TH E_L"X_P"ABUC_ +ZA_P#C=']@7'_0Q:Q_WU#_ /&ZVQR.F/:B
M@#$_L"X_Z&+6/^^H?_C=']@7'_0Q:Q_WU#_\;K;HH P/"<+065_$TTDQ34)P
M9)<;F^;J< #]*WZQ?#?^JU/_ +"5Q_Z%6U0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8H_Y'<_]@T?^C*V
MJQ1_R.Y_[!H_]&5M4 <WXYT_4]2\)WUOIEU;0N8F:1+B$NLR 9,9.X;0P!!/
M/!J*QOW\0VWADO;B 36R:G<0#HF$78G_ 'VX8?\ 7,UHW'AC2KK4;B^FBG:6
MY4+.GVJ412@# #1AMC<<<CFM%+2".[DND3$TD:1LV3]U2Q48[8W-^= 'DNN6
M]Q%<>(?$.E1M<>'8;XKK.CN^/M1B \V9/[N"!E>CA#G@XKT:%TU7Q$9E&ZVL
MK4*,C@R2X8Y'J$5?PD-32^'-*FFN9'MCBZ8/<1K*ZQS-@#+H#M;( !R.0.<U
M<6PMTCND1&473%Y2KL&8D!<Y!R.  ,=,#% &)?VL7B#6["1BO]GZ/<FY:4GB
M2X"LBJ#Z+N8D_P![ [-CC]/(MO 'Q+6\XE6_U-I0W<-&"GX%2N*ZNS^'/A2P
MN8+BWTLK);R+)%NN9F"LIR#M+D<'GI6K=>'=*O;N2YN+7?)+L,JB1@DNS[N]
M =KX[;@>@]* ,G29KO3_  -HE@D8;6IM.AC6-^SB-0SO_LKQD_0#D@5I:3HJ
MZ)X6MM%TFY2,VD @CFD3S,,!RS*",DG)QD=:KZMX)\/ZYJ+7^HV4DURR!-XN
MI4^4=  K  =?S-/'@_1$M;"VAMY[>.P+FW^SW<T17><MEE8%LGKDF@#-^';7
MT6C:AINHQP?:=.U&:W>X@7:MT3B0RX[,QD.??-=?4%I9V]C;K;VT2QQ*2<#N
M2<DD]22222>234] &+X3_P"1;MO]^7_T8U;58OA/_D6[;_?E_P#1C5M4 %<)
MXOU2Z6]O(9M U:ZLK6U9H)+:)&B:5D.78EP?E!P!CJ6/88[NF30QW$$D,J[H
MY%*,OJ",$4 <#X5TBS\8?"GP_9ZA;ZC:);VUOY;+*8'+)& )$*-RO.1G\JU_
M!9U2T_M?1]2OI-033;L0V][+_K)(VC1PKGNR[L$]^*T+CPIHUS8Z=9-;2QPZ
M: MIY%S+$T("[0 R,&Z<<FDUCPU8:GX9N-#-I$UK-C,;R.H+;@VYBIW$Y&X\
MY8]3SF@#E?'.J76-:BN- U:>TM;&5;6:")&A+O$=TK$N#\H8J../F/.1BWHV
MBV?C/X<Z!#?PZG8_9K>%H628P2*ZQA1(I1CD$$XSZ]*ZY=.A.CC3+@M<0&W^
MSR>8QS(NW:<GU(JE=^%M(O(=.BD@F0:<NRT:"YEA:)<!<!D8$C  Y/:@#CTT
M37]<\,WNCRZFMQJ.A:S')87UR.+@1!)4$N.I^<H2.Z]SFK&E-J.L_%F6^GMH
M((M*TO[).8)C*OG2.'\O<57)"@$C'&1ZUVZZ=;1V(LX4:& =H79#R<D[@0<D
MY).<G-.LK&UTZV6VLX$AB!)VJ.I)R2?4D\DGDF@"Q1110!B^(^FE?]A*'^M;
M58OB/II7_82A_K6U0 4444 <5\0O#T6L:>]_:7[V6LZ=;2/#(AR'C8?-'(O=
M&V_@1D5I>#]=N]:L;V/4[..UU2PNVM+Q86W1O(JJ=Z'KM*LIYY'2KNL>';#6
MP6N!-'/Y+0B:"9XV"-U!VD C@'!R*LVFE65C9/:6L311.S.Y61M[,W)8OG<6
M/J3F@#EOAI;QW?PJTRVEW>7+#+&VQBIP9'!P1R#[BHM'T:Z\'>,+'2M.U"[N
MM"O[:9OLEW*93:-'MPR,>0AW8P>A(]:Z2W\+Z/:^'Y-!AM"-,D5D-N9G8;6Y
M(!+9'))X-3Z9HMCI"$6D<I8J$\R>=YGVCHN]R6P/3.* .9\=(_\ PD/@F5L_
M94UC$GH',3A,_CD?C7%?$F&YN-5\;O:JQ@BT:Q6YV^UP7.?^V8;\*]5A\,Z/
M!I,FEQV8%G),TYC+L2)"^_<&)R#NY!!X/3%6+72+"S@N(8K<,MR2UP96,C3$
MC;\[,26X '/88Z4 <KXDW3_$KP+]F.[9]NE<KT$7DJ,GV)9?QQ7<5G:=H6G:
M7+YMI PD$0A5Y)7D*1CHBEB=J^PP.E:- !1110!BZ'_R%?$G_827_P!);>MJ
ML70_^0KXD_["2_\ I+;UM4 %%%% !1110 5Q/Q%1S)X2DY^SQ^(;5ICV&=P4
MGVW%?Q(KMJKWUC;:E9RVEY"LUO*,,C=^<CZ$$ @CD$4 <C&LDGQOGDCR88O#
MR),1T#M<,4!]\!J[:J=AI=GIIF:VC823L&EEDD:1Y"!@;F8DG X'/%7* "BB
MB@ HHHH *Q?%/_((@_["-C_Z515M5B^*?^01!_V$;'_TJBH VJ*** "BBB@"
MIJ=U/9:7=75M:27<\43/';Q_>D8#A1]37ER:K+%\0O"9ET'6TN72]-Q)/!&K
M3/((@7 #GY5  QGA0H&<5ZY52?3+.YU*TU&6 -=VBR)!)DY0/C<,=.=HZ^E
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MUNP'D3+.FW36'S+TS^^Z59^Q^)?^@UIW_@L?_P"/5MT4 8GV/Q+_ -!K3O\
MP6/_ /'J/L?B7_H-:=_X+'_^/5MT4 8GV/Q+_P!!K3O_  6/_P#'J/L?B7_H
M-:=_X+'_ /CU;=% &)]C\2_]!K3O_!8__P >H^Q^)?\ H-:=_P""Q_\ X]6W
M10!B?8_$O_0:T[_P6/\ _'J/L?B7_H-:=_X+'_\ CU;=% &)]C\2_P#0:T[_
M ,%C_P#QZC['XE_Z#6G?^"Q__CU;=% &)]C\2_\ 0:T[_P %C_\ QZC['XE_
MZ#6G?^"Q_P#X]6W10!S=KHNOVEQ>S1ZW8%KR83R;M-; 81I'Q^^Z80?CFK/V
M/Q+_ -!K3O\ P6/_ /'JVZ* ,3['XE_Z#6G?^"Q__CU'V/Q+_P!!K3O_  6/
M_P#'JVZ* ,3['XE_Z#6G?^"Q_P#X]1]C\2_]!K3O_!8__P >K;HH Q/L?B7_
M *#6G?\ @L?_ ./4?8_$O_0:T[_P6/\ _'JVZ* ,3['XE_Z#6G?^"Q__ (]1
M]C\2_P#0:T[_ ,%C_P#QZMNB@#$^Q^)?^@UIW_@L?_X]1]C\2_\ 0:T[_P %
MC_\ QZMNB@#$^Q^)?^@UIW_@L?\ ^/4?8_$O_0:T[_P6/_\ 'JVZ* ,3['XE
M_P"@UIW_ (+'_P#CU5K_ $77]1MU@FUNP"+-%,-FFL#NCD61?^6W3*C/M724
M4 8GV/Q+_P!!K3O_  6/_P#'J/L?B7_H-:=_X+'_ /CU;=% &)]C\2_]!K3O
M_!8__P >H^Q^)?\ H-:=_P""Q_\ X]6W10!B?8_$O_0:T[_P6/\ _'J/L?B7
M_H-:=_X+'_\ CU;=% &)]C\2_P#0:T[_ ,%C_P#QZC['XE_Z#6G?^"Q__CU;
M=% &)]C\2_\ 0:T[_P %C_\ QZC['XE_Z#6G?^"Q_P#X]6W10!B?8_$O_0:T
M[_P6/_\ 'J/L?B7_ *#6G?\ @L?_ ./5MT4 8GV/Q+_T&M._\%C_ /QZC['X
ME_Z#6G?^"Q__ (]6W10!B?8_$O\ T&M._P#!8_\ \>H^Q^)?^@UIW_@L?_X]
M6W10!S=KHNOVEQ>SQZW8%[R832;M-; 81I'Q^^Z80?CFK/V/Q+_T&M._\%C_
M /QZMNB@#$^Q^)?^@UIW_@L?_P"/4?8_$O\ T&M._P#!8_\ \>K;HH Q/L?B
M7_H-:=_X+'_^/4?8_$O_ $&M._\ !8__ ,>K;HH Q/L?B7_H-:=_X+'_ /CU
M'V/Q+_T&M._\%C__ !ZMNB@#$^Q^)?\ H-:=_P""Q_\ X]1]C\2_]!K3O_!8
M_P#\>K;HH Q/L?B7_H-:=_X+'_\ CU'V/Q+_ -!K3O\ P6/_ /'JVZ* ,3['
MXE_Z#6G?^"Q__CU'V/Q+_P!!K3O_  6/_P#'JVZ* ,3['XE_Z#6G?^"Q_P#X
M]1]C\2_]!K3O_!8__P >K;HH YN_T77]1MT@FUNP"+-%.-FFL#NCD61?^6W3
M*C/MFK/V/Q+_ -!K3O\ P6/_ /'JVZ* ,3['XE_Z#6G?^"Q__CU'V/Q+_P!!
MK3O_  6/_P#'JVZ* ,3['XE_Z#6G?^"Q_P#X]1]C\2_]!K3O_!8__P >K;HH
M Q/L?B7_ *#6G?\ @L?_ ./4?8_$O_0:T[_P6/\ _'JVZ* ,3['XE_Z#6G?^
M"Q__ (]1]C\2_P#0:T[_ ,%C_P#QZMNB@#$^Q^)?^@UIW_@L?_X]1]C\2_\
M0:T[_P %C_\ QZMNB@#$^Q^)?^@UIW_@L?\ ^/4?8_$O_0:T[_P6/_\ 'JVZ
M* ,3['XE_P"@UIW_ (+'_P#CU'V/Q+_T&M._\%C_ /QZMNB@#$^Q^)?^@UIW
M_@L?_P"/4?8_$O\ T&M._P#!8_\ \>K;HH SM%TV;3+2:.XN4N)IIWG>1(O+
M7+'. N3C\ZT:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ JO?7D.G6%Q>W#;8;>-I'(&3@#)JQ7+^([E-
M1U?3_#D%Y##/(WVR;>-WR1$%5QD9+.5..ZJU $O@GQ++XGT-[B\MA::C;7,M
MK>6N?]3(C=/^^2I_&LB3Q-K26?CIA)9F;0R3:GR&VE1 )<,-V2><9S^':J$$
MS^$/BNR7E[%);>([;=(RQ^6(KF+ 4L,G:&4XSW(JM-<P&V^*H$J9D5M@W?>_
MT14X]?F&WZ\4 >B:)=2WV@Z=>3D&6>UBE<@8&YE!/ZFD.N:0+26[.J6(MH9/
M*DF-PFQ'_NDYP#R.#5?PK(DGA'1F1@P^Q0C(.>0@!'YUY?K][!9^&_B9H\Q8
M:A<7LEQ%;A"6>)XH@'&!]W*D9]: /5[O7=(L&E6\U6RMS$@DD$UPB;%)P"<G
M@$GK3FUG2UDM8VU*S#W:AK=3.N9@>A09^8?2N*MY-+N/BR]Q*+<Q_P#"/1_/
M*H&&\UR<YZ':1GO@^E8FE6<TWP6T+5+!=^IZ"QO(4_B/ENV^(]QNC+#'TH ]
M5.HV(>X0WEN&MANG4RKF(=<MS\OXU%!K.EW5K-=6^I6<MO"2LLJ3JRQD=0Q!
MP/QKB?$QO8_!]OKHM[HB74X-1OHH4S*ML"-HV\\HHC)'JI-5)U\+ZQIFK:OI
M^K:BJWCVBS:N 0J2I*OE'#* =AQNXX'4^@!V.J^,M"TG2FU"74K62$3+;CRY
ME;,C$87@\'D$^@YJ]<:[I%I;Q7%SJEE#!*-T<DEPBJX]02<$<BO,=6O=2N/!
M6MC4EM+IK+5;&1]3L$/EW:"2$F3 SAE4 -C@8]JO:KK.G6WC/5%U^[O+;2=8
MLH4L;A(B8YD </$?E)!RQ('<-]* /1;W4K*QMUDN;ZUMED!\MYY JDXSW(SZ
M_2L;P+K=WXA\+QZA?/!).US<1[H%VH529T4@9/&%'<URNG75GX5\;V,>H">R
MT>318[;2I;PG$9#DM&S'[KE=AP?[H':MCX5/%_PA?E1(R+'?78"F,I@&=R,
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M63 _A#?>/8<U#X[-OXUT^P\/:+<17KSWL,MS-;N'2VA1MS,S#@$X  ZDGV-
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M<].:DCU;39;S[''J%J]UEAY*S*7R.ORYSQW]*\OTG[%;6WPI:/R(I$B*S%<
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MO:1):W-U'JEG)!:C=/(DZL(AC/S8/'%,T#7[#Q)I$.I:=,DD,JAL!@63/(#
M=#C'!KD[D1ZWX^M=5T*>.YMET>XBO9X&W(^XJ84)'!;.\XZ@?6M'X8W44_P[
MT2*,MYEM:1PS*4(V.HPRG(Z@]: .AOM7TS3&1;_4;2U9_NB>94+<XXR?7BL>
M36;^/XCP:*SP?V=+I4EV (R'#K(B\MG!&&/8?C7):M>Z;:^+O$ND>*KB^MK7
M5A%]D,<19+J'RE1HU*J3N#!N!S\V1UK1M1;6?Q+T2U^:*.+PV\&R=]S+^\B(
M1CW;:I^N": .KTN_7^RY[N\U>PNHDFD_TF A(T0,<*3N(RHP"<]:D;6=.N+:
MX^R:M8^9&C9?S581D=V /0'&>E>612VT7PVFN!<B%;/Q,UR@V,T9Q=ED$@4$
MA""#G![$ \ ZVFWWA_59O&6KPZKIMS<WMFN^UA8MY21QE=Q+*I)8D9XQPHYH
M V[CQ+>Z;K'A2&YU33IM.O[2>6[NT38CF.(,)%?<5"'.?ZU8\7^)WLO =UK_
M (>O;*X$939*,31L"X4X*MC//OTZ5Q]D;)+/X6W6H"$6-O8213RS@>5%)]G0
M*')X4[@0,]Q5;7K&.S\&^/+JSC6'2=0O[=["-1A9&'E"1T'<,P8@CJ%STH ]
M9O\ 5M-TM5;4-0M;0-]TW$RQY_,^XJVK!E#*001D$=Z\RUG5=/L?&VK0^(;R
MZM]+U>R@2RN(4WQ3H%8/%D*W.6) [[OI7>Z!:06'A^PM+:*>&WAA5(H[@DR*
M@'RAL\YQCCMTH YH^*+K7?$&J:7H&JZ9#/ITD*QI,1(+K*[Y.AR  <?+T(.?
M0=3;:QIEY<O;6NHVD\Z+N:.*968#.,D YQGBO.IFN;^Z^)]MHTX.H7"QBV"-
M\SD6RJ=I]<@C(Z&II)[37U\"OHC(MW8W"-<QKPUI;B%EECD'\&2%7!ZG% '>
M0:[I%U=1VMOJME+<2;MD4=PC,VW[V #DX[^E6+N^M+"(2WEU#;QEMH::0("?
M09[UQ7PUM=.DMM9N(H+9KB/6[UDD" LJ-(=I!Z@%>F."*N>,M2MM/U[PW]HC
M6%I)IA'J+JS+:GR\8"C@NX8A=V1P>#TH Z==3L'T\:@M];-9$;A<"53&1G&=
MV<=:2'5=.N+%[V&_M9+1"0\Z3*44CKELX&*\>TO4FTG2-(O[A+J32],\1WK:
M@# P,0=I1'(RA1PI8,0!QD<#BM[Q!>Z;'86?B+1;*671UUN&]U.:*)\3J$*F
M4*>65&\LY QE<]LT >A6^JZ==VLMU;W]K-;Q$B26.965".H)!P,>]9&O^(TC
M\&ZUJV@W]C<SZ?;2R[@1,@9$+;6"L,'CU_.N5\1WFG7FB7'B'PY:W$]J=1M+
MK4;FUC;=<QQG#%%8?-L 0Y QQZ@XBU";P_J/A+QEK>BW5U>/>Z1)#-=RAE25
MQ&PC0 JN7&<<#(R!WH [V#6K2WT*QOM4O;:U\Z!'9YI%C4DJ"<9-33ZYI-JD
M;W&J6422QF6-I+A5#H!DL,GD <YZ5YS/K-OH^N:)?:K>7-KHMUH45O!>0KOC
M2<,2Z,=K;=PV?79CM2+IFA67B+P#96UN5T]!?^7'>#+;'7*%@W(#')4'V&,\
M4 >BMK^C(T(?5K%3.J-$#<(/,#_=*\\@]O7M5;_A*M(_X29] ^VP"^CA$KH9
M ,9. ONV,G'8?6O,O'-U9C3?&VEVEM_9\L*6_P#H\,#,]TJHFV3H52-0-HV@
M8*Y)YQ760WUJOQ9FFE9A!?:'"(&:-@)-LLA;J.P()SV.>E '2Z5?J-'>[O=7
ML+N-99,W<!"1*H<@*3N(RO //45836M+ELI;U-2LVM(B1).)U*(1U#-G _&O
M)M,F>V\)Z!>("^EV/B2XEOTC&?+C,LOER,!_ I96_(]JO>*(H;RX\;ZK8212
MZ5<>'A"\D9#1SW?[S;M(X9@FT<?W@* /2[76=+O;R2SM-2M)[J- [PQ3JSJI
MZ$J#D#D<^]6;BY@L[=Y[F:.&%!EI)&"JOU)X%>=6S6,/C'P$;4P(#I=RCF/
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M3YQ^8!V"KP!W&?<T >A45YUKOB"U\0Z5X2U?3)KJ*.37[>&2)F:-E.Y@\<B
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MCMQ0!M45R/POGEN?AIH<T\LDLKP$L\C%F8[FY)/6NNH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MFO'.DWVKZ!%'IT2S7-O>VUT(F<)Y@CE5BH)X!P#UKI:* /-_%&A^*->'B&UF
MTV"YM[S3PFG;KL".UDV$."I'+ECP^.G&1S6C;Z;K5CXJL-;?2C/&=&6PEAM[
MA"\4@DWY.\J",<<$\]B.:[>B@#SJ?PCJEKI6E)#;+<71\1?VS>K%(H2,%V9E
M4L1G 8 >N">*E@TCQ%HOB'5H;70[#4]/U*Z:[AO)IE1K5G W*ZD$LH(R-O\
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MI\$$&R9#F1%D##D@XS(,$@=#TKMJ* /.K[0[NV^$VDVLH6UUW18K=[3+!O\
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M:..-TWH!\W.02" 03T/417OA[Q5?26TUWID%U?66O)>+=/>*!);+(2JQK@[
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M^3*2X!/<=NM>H44 >?:_IGB#7_!&HVR^'[>PN[EH!%9QW$;$;) [,[C Y P
M,]/?C7U[3]1O_$_A74+>Q=H+">66YS(@*!X60#&[D@MDX[#O7544 >=77A[6
MI]&\>VJZ<PDUJ1VL\S1X(:%8_F^;CE2?I3==\+7^KP1R1:3/::U:V<::?JEK
M=)&\,@7E)<-\T8;G&&R"< 'KZ/10 R$2+!&LKAY H#L!@$XY.*\R;P]XKNI-
M'N;[2X+C4K#63<S7;W@_>P_O OEC!V( R_+P>,X))->H44 >:7WAK7+GPKXY
MTY-.83ZS>R36F9H\%62-1N.[C[A/XBM2UT_7M&\:ZAJMMIGVRRUFWMQ*AN$1
M[26)2G.3@H0<Y7)![&NWHH YGX>Z5J&A^!M+TS5($AN[:,HR)(''WB>HX[^]
M=-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !6+XAUJ32CIEK;K&;O4KQ;2%I 2B?*SLQ (SA4.!
MD9)'-;58?BGPU%XGTV&W:ZFL[FVG2ZM+N'!>&5<X8 \$<D$'J#0!EZCX@US0
M+>2/48K.66ZU*"QTR=,JLGFD#=(F21M^;H?FQVIEYXDU?2=?NM%N3:322:;)
M?V-R(65=T9P\;KN.>H(((X./K9N_!C:KH<EGK&KW-W?-)'-'?+&D1ADC.8RB
M 8&#D\Y)R>>F+#^&9KJXN+Z^OHYM1DLFL8IDM]B11L<L0FXY8G&3G'RC '.0
M#!TCQ9K\TO@ZYO\ ^SVM/$$.'BAB</"_D&4,&+$$'!&,<9ZGK63XMUF_\3?#
M"[UJ"2VCTR:]B6* Q$R-$ETJ!BV[ 8LN<8P <=>:ZF#P6]O!X8A74P5\/\0D
MV_,H\LQ_-\W]TGIWY]JSYOAM)_8E]H-KKT]OHMQ<"XBMOLZLUN?,$A57/\.X
M$@8R,]3R" :,^M:H?&6K:+&UK''%I*7EO-Y)9U9G=<-\V& VY[=:Y[2?$.MV
M'PY\):C)/:W4FH7=I#,TL+;MLK@$YW\MDDYQCVKKH_#;+XJGUN6^,AFL5L7B
M,0&45BV[<#][+'MCVK*B\ R1>&-*T,:U(\.FW4-Q [VZYQ$VY$(!'XGJ?:@"
M<Z]JNKW/B"/1&M(_[(D^SJMQ$S_:)@@=@2&&U?F"YY.<GVK+LO&NK:_?>'%T
ME;*WMM9TZ:ZS<1L[0/&4!'# ,,L1CCIG/:MP^%9;;6-3U#2]2-G_ &HJ_;(C
M#Y@WA=OF1\C8V.N=P. <4VW\&PV&JZ+=6%P(+?2+-[."W,6X%'VY+-D'/R#]
M?6@##C\>7\'A>WU#4DCB\K4Y]/U"]@MWDCA6-G42[ 20"54<D@;J['0+V34=
M&@NY+JTN_-+E)[/_ %4B;R$(Y./EQD9.#FL?3/"=[I$!2TUD9:^GO'#VV4D\
MTDLC+N&1DY'((P.M:GAW0+?PYIC65L05>>2X?:NQ0SL6(51]U1G '8#OUH P
M-+\7SZAXI?2);FUM+N&[F2;3KB%DE:!0_ERQ.6P^<(QP#P3TQDPV/BKQ!JT6
MD:KIFFBXTV]N )83#M,5NQ($HD+X)'!*[><D#IDZK^$WN[^PGU&_6Z33[Q[R
MV/V?;*I.["&3<<H-W0 9VKD\<U=%\#SZ'=&"U\07G]A+,9XM+,28C);=M$F-
MVS=SM_ DC.0!O@.YU6[G\1OJ-]'<K%K$\"@0E"-@0#'S$!<#ICWR:K^)EU%O
MB7X22WN[>-&CO617@9\$1IDG#C/!XZ8YZUO:'X=.AZAJL\5_++;W]T]W]G9%
M CD?&[YNI^[QZ9/6DU+P_+?^)M)UI;X1'35F6.'R=P?S  VX[A_=&,?K0!@-
MXFU%_#>MZWHD-BEEI-Q<(MFT1!G6$GS3N!&TL0Y'RGMG.>#_ (2;Q!K'B--/
MT-]-BMKC2(-4@DNX79@'?&U@K#/ ZC&,]ZT#X)$2:S96FHO!I6L2/+=6OE;F
M5I!B3RWS\H;N"&P2<8JY;>&19^*UUJ"Y5(EL$T]+18?E6)6++AL]<GZ8[=Z
M."U&YU6[\ _$IM0OHKA(;JZ@51"5(VQ18P=Q 4#MC.><UUNF:SK%MXNL=%U!
MK*2UO=-:Z@\B-E>%HV12K,6.\$/UPO3I27?@,W%CXCL8]7ECL]<D>62(PJWE
M,ZJKD'J>%&,\#)ZUHCPW,?$>FZS)?JSV-H]IY:P8#JY4DYW<'*#]: &>+=9O
M=&.B-:+;M'>:K;V<PE0DA)&P2I!&#QWSUK"U'Q+XF6\\80V3Z7&FA11SQ-+
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MZ<D2,&D;[Y1S\R!N^.>3@CC !G:CXF\3K<^,([-]+C308TGC,L#L95,/FE"
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M<A*[=K#ACC<>!P5&3S@@&O=ZYK&B^(-%L-1>TG@U?? LL,+(;>=4W#@L=R$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>josetrevejo-tarsussepara003.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ#W:K/$=J")TS][G)8' SQ[\4 >B:CJ%KI5A-?7DGEP1#+-@D\G   Y))(
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M=Q.W>0A8\XYQFM*_T/4]6\:7-S-92V]C=^'WT][@2QMY<KONZ;LG /7'7\Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@B4)'&@P%4= *X6/QEJRZ?XFVVTEY+I%Y#&CI:LLK02+&S.8C@EE5F..,X'
MKH?"FM1Z]I\]Y;ZI:ZC:^=M@EA38RKM7*R*>CAMW8<8XH WJ@N[RWL8/.N9
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M>,H])GNBD>B0WR++,\WEREY%:0;R>=H!/;Y:[IO"/A]HIXCI%KY<\_VB50F
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MYYY=2TOPO%]HB><Q16;[&Q(I'+2Y7 ] G49Y]'M_#FC6ES%<PZ9;">(8BE9
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M9KAY%D=#$5;:3A2-S#@#@XKK6\/:2^GSV$EE');7!S.CDMYW&/G).6X ')/
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M%);?4H)8WN/LJLAR#+C.S_>QVJ"P\6:;J/B#4]'AD_?:?L$C," 6(+$#(Z
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MXRT4JCY0N<9(&<8JYKFG:CJUW\2;33(IEN;RTM%MR4*B;8A$B*QX)Q\IP>]
M'HEKX@TF]G:""_A:01><%)V[H_[ZY^\O^T,CWJM#XQ\.7$]K##K5E))=N8X
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M6/V4MT"J6)4\ Y;V%4?"2:?<6.C:'K.C:P=?T>=&9)6N/(1XSC[0'SY>TC)
M[YQCF@#OK;Q;X>O+Z.RMM9LIKF4R!(XY02VS[^/IS^1]#4MOXBT>[FDAAU&
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MNO"UG-JEI':WK;_,2)"BM\[8<*>1N&&P>FZMR@ HHHH **** "BBB@ HHHH
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MT&\NI-'BCFE(EC571E9MRDMZ+P.I]!6_;:HM_H$&K6$+SI<6RW,,1(5G#*&
MYX!P: +]%<?;^/H+BR\.7BV+K;Z[-Y$;M*!Y,GS'8X]?E(XSR,>])XIUVR&@
M:B^J:-+>:=;WT-N=DH =MZ8;J" KE0<9.01C H [&BN476K^\^(%]X>ELD.G
M16$<I;S1EM[,"Q&/]G&!]>_'-?#[Q.VE>#?"=G<Z;<_9+Z1K1+TNN/.+2%1M
MSNP=I&[U_.@#U"BL[5]4;2XK8QVDUU-<W"6\:1C@,V?F<X.U0 <G'\ZYZ?X@
MV]MX?U#5'TVX<Z?J TZYCA=6"R%D4,#D;E/F+T&>>E '945@:7XE:^\17FB7
M>F3V-W! EU&)'1Q+$S%0WRDX(*D$4FM>*K?2KR2QB6&:\BMQ</'+<K"-A)"@
M%NK$JV!TXY(XR =!17&GXB6 L]"U)K66/2=7.U;V9@BV[X/R2#L25(!Y&1UK
M2E\4I::38W=]:_8Y[^3R[>WGE5#G:6R['A1M4DYY'3&3B@#H**X=_B79QZ;>
M7+:=<22V=]%93QV\B2*#(0$=6S\RG=V&<\$"M6#Q-=S7,>GMHLL&JR"65;6:
M=,+"C!?,9UW !BP  R<Y[ F@#HZ*XN[\0V.H1>%[G4- OHY+O4?+MUN (VM9
MP'&6&<GA7QP01SZ5J6OB<7]_-#96GGP6]Z;*=UF&^)QU9DQPN> <Y/!QCF@#
MH**XZY^(FFV\UNX1);&:\^Q^='.ID5]Q3>8NOE[AC/7OC'-:WB7Q)'X:@LII
M;*YNEN[R*T'D;25:1L D$@G\ ?PH VZ*XO\ X6"+?^VX-1T.^M+_ $JT-\UJ
M9(W,UOS\ZL&VG&"",\>]5]6\40WOA^.ZUCPO>_V;+<V9MV>:/#F1U*/@-N 5
MMO!&>1QUP =Y17/:EXH:UDU-+#39]1.EHK7:PMA@2N[8@P=[[<'' Y'.3BJ^
MJ^-[33Q.L,*RS6ULMS-#-.L#A6!(15;DO@9V\=N>: +^L>'SJ^K:1?\ VQX6
MTR9IXD5 0[%2AW9[;6/3%;58SZ^D_@]O$&FPFX1K,W4,4A\LL-N[#=<>]<+=
MZG>:C:_#?6KRT9[V>='*PL"9M]H[9 X R3WZ>M 'J=%<K:^-//T[4))-(NTO
MK&]2QELT(D/F/LVG<O&S#J2>PS6?KGCJYM?#7BF:TL575-# 21#,&C!9 RN&
MQ\P /0@'(Q[T =U156TGN)-.2>>V*S[,F)7#$GV/ Y_"N2\/^*-)M_"^A_V9
MIXLH]2N9H;2UN)MH5E>0MN?YN25. ,\L![T =O1533[F2^L5EGM9+60LZ-"Y
M!*[6*]1U!QD'T(KAO"&K6V@:#JI=7<R>)+JTM84/S2.TQ55!/3@=3T - 'HE
M%<Q+XO:VNM3T^?3)1JEC:?;5MHY PN8<D%HVP,D$$$$#G'KFFP>-8+B\\.0K
M:'RM>@::VF\T;5VH'*GONP?T- '4T5SDWBZ"WCC\Z*.*6>ZEMK82W"HLGEDA
MG+'[JY!'0GI@'-98^)5H=/CN%TRZEE_M1=+ECA='"2L0 P;/SJ0<@C\<4 =O
M163#J=^_A^:_FTB2UO(UD(LYID).TG'SKD8(&?QKSZ]U>\UCP]\/]=O;1C=S
MZI X6%@3(&AD; ' &2!U].30!ZO17*P>--]GK!GTB\CO]+N([>6SC(E9C(%,
M94KQ@AP2>V#Z4R?QS'9VOB-KC3I6N=!19;F*WE5PR,A<%6.WL#D$ C'0T =;
M17-:?XN-WKUGIESI5S9B^M&NK2:1T82A=NX$ Y4C>#SV]#Q3/$.OZEIOBOPY
MI=G9I+#J$DYE8R!2=D3-M&1QS@Y]L=Z .HHKRW3?$!\)S^-KQ=+N;JRMM7\R
MX>.11Y4?DQ9(W'+'DG _PKK-:\9VFERW4,"Q7,UK;K<31M<I$2K D*F[[SD
MG' Z<C(H Z:BLJ#Q%IT_A=?$1E,>G&U^U%Y%P43;N.1ZCTJG'XDO#>102Z'=
M1BXM6NH)-VY!MQE)"!B-\$8'(//- '0T5RMMXWM[G3O#5^ME,(->E6*++#=$
MS*S#</3"GI45KXXN+VXODMO#6HR16%W+:W,@EA&PI&'S@OSG..#QQZXH Z^L
M7P_X?_L&34W%X]Q_:%X]Y(&0+L=@ 0,?PX4<'GWK'L/B EUI%OJUQI%S9V%W
M%"UK---&!-)(<!,;LKCKDX& 3Z9@NOB7:6>GZY/)I\DT^CK')*EK.DB2(_W7
M1\C(SP1C(]#0!W-%<U%XKF?7;K1Y-'G@NULFO;42RIB= P4Y(SL.2.#G@_A3
MO NMWWB+PC8:K?P+%+=1^:-K @@DG@=L=/PH Z/-%>9.5USQ)XO77]*DN+33
M/(:+R9,RVX6'S?W6W#;F)S\I!Y -=5IWBHW>M'2+C3I(+QM/&H1QK(K$QE@N
MULXVN"1P>.>M '1T5P.E>,-,TOPAH5UIN@WD=GJ-^]G#;HZEHI#+(#NRW<JQ
MXR!GJ!741ZO=+X<DU2\TFXMIXHW=[+S(WD&TGHP;:<@9Z]Z )/$&D#7M!O=)
M>=H([R%H9)$4%@K#!QGC.*L6EK)::9#:"?>\40C65DZX& 2,URMO\0#,NA2M
MH-ZMOK<0:TD$D9+2&/S A&> 0#\QP..PYJU;>-/-L=2>72+N._T^\2SELT(D
M)=]NQ@R\;2'!)[ &@#2\,: OAG0XM*CNGN8HF=D>10&^9BYSCCJQK8KD+KQ[
M%8Z;XBGGTV9[C02OVF&"57#!D#AE8XXP>>,C!X-8OB?4Y;^]\+WMYID^G1Q:
M["(I;B5,2Q&&1BV ?E' R&Y&* /2:*Y]_%,5OI,^JW=J\%BLHCMW9P#<;F"H
M5!QM#$C!8CUZ<UA:G\1#!IWB!+6SA?4M+L3>H$N1)#)'@_,' ZJ1RI /3L<T
M =[15'1KBYN]'M)[N+RYGB5F&X-G('/'K5Z@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\::->Z
MWH4<&G^2;J"\M[I$F<HK^7(KE2P!QD \X-=%10!Q]MHVM:3XNU+6[:"VN8]7
M@A^U6_GE##/$I52K%?F0J<'@'C..<5I>&?#\GAWPK'I<<ZFY_>R/,%^42R,S
MD@'L"W'L*WJ9-*L$+RN'*HI8A$+''L!DGZ"@#SG2_"GB:#4/#%]=VVF&ZTQI
MQ>SBZ=Y+HO'M\TDIU[[3ZXR!2OX0U]_!5YH_DV?VJ;63?J?M!V",W(FP3MSG
M QTKN=&U>TU_1[;5;!V>TN5WQ,RE21G&<'ITJ_0!B>*O#D'BWPS<Z1=.T!F"
MLDJ<F*12&5AZX('U&:I7D?BC4=!DTI[>SM[N>$P37ZS%HU!&&=$P&+8R0IP
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M6*#<Q*'@],]>U-@\(:_%X*TC2##9FZL]96_D(N#L,8N6FP#MSG#8Z=J](HH
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MSQD]O5:_O[72[&6]O9EAMXAEW;MV' Y))(  Y).* .$O? VK!7UK3YK5-?\
M[8_M18I&)A*^7Y7DE@,\I_%CJ3VYJ[XCT?Q+XF\(7%G<VVGPW=Q/ PM1<%HX
MDCE5SE]F69MI'W0!Q[D]#:^)-/N]1CT\?:8;R5&D2&XM9(BR#&2-R@$#(^F1
M6J&5L[2#@X.#T- '*^%=%U;PY>7>FJL+^'BWF6(,Q,MKD9:+&,% V=O.0..>
MRW.BZE8>.9/$6FQQ7,%Y9K:W=L\FQE9&)1U."",$@@X]1GI755%<3I:VTD\N
M_P N-2S;$+G ]  2?PH \QU/1+GP[<>%@JQ3W]WXDGOIT5RJ;Y8Y6*J2.@&
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MY>>*+764M+>PU&"_WR:A:S$?:;0,<1R( -S%=J\YQC.>U=PCB2-77HP!%.H
MX;P]H_BWP^[Z'%_9TNB+</);WS2MY\43.6,9CVX9AD@-D#H<'I4GQ*,JZ9H1
M@57F&OV)17;:"WFC )P<#WQ7:*RL,J01DC@]QUK%\3'1(M)EO]<MUN+73_\
M2#^Z,IB*\[PH!((ZY[>U &%K7AC4M:FU[4O)AAN[S1GTFTA>7[H?<6=V /<C
M &>%]\"36_#^KZCX#TS2(8;87MN]HTH:<A!Y+HQPVW)SLXX'6NNM9X[JS@N(
M<^5+&KIGK@C(J:@#B?[(\3Z-XLU2_P!&BT^ZL-8,<LJ74[1M:S*@0L,*=ZD
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MPL,%$)&%!'4XR<#G@8T/^$>C73],M(M0OHCIQ'DS(R;R A3#94JPVGN/0]:
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M8 QN]L@&[H*WXT6V;4YGDO)%\R3>J@H6YV?* /ESC/?%:-%% !1110 4444
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M*06\L,!LK#QM]GB6104@A^T\H,]%P>G3% 'L]S<0V=M+<W,J101(7DD<X55
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M0G=%$\"LL9]5!&!^%9&B:YI4/A;3;J/5KK4;>Y8QVUQ.A:>Y;+<;0H)/![#
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MF373WGBC2;/RPT[S-):F\"V\32GR!C,F%!^7D?7MF@#6$48E:4(HD90I?')
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M:;8:CY?VZRMKKRSE//B5]I]LCBL+Q#X<GUCQ#H%XL5E)9::\K2PSD_O \93
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M'U>\N;J_O)[F-&\EI7DV32#)"*< *!SP!Q7975U!96DMU=3)#;PH7DD<X55
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MDQX+,,'Y5R=IX)(-==;^,-$N(M3D-U) NF*'NQ<P20M&A!(;:Z@E2 <$=<4
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M5>500,$8SW]LCCK765B>*M!?Q%HRV<-TMK/%<PW,4K1^8H>-PXRN1D'&.HH
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M[+."K=?[G4#O1J?A34M:\,7-CJ6LH^I2R12I<1V^V*)HG#H!'N/&1SELG/;
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MN0Q$DLBEEC&TC:-N,MS][IQ6+:^/[[5SX8.EZ;;JNM+<JXN9F#02P@[E.!R
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M\(8/;_NG==JG."5&"<]R/>J\?PSL4\/V&EF\F8V=\+A9S]XQ<IY/^[Y)\O\
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M;Q(XY)U\Q412N$/*Y!)(.,$CL3CM6C0!@8'2B@ HHHH **** "BBB@ HHHH
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MX3@M=2N[&QU#6[N.)8MHS;%964C(]5)';D'!H ]MFFCMX))IG6.*-2[NQP%
M&22:KSWLD.I6EHME<2I.KEKA /+AV@8#Y.?FSQ@'I7D/BD:C:Z!X\T"ZU.^O
MK.PCM+FTGGF/FJ)3\T;L,;AQP#V-=QJ,EUIWQ \*V$%]=FRN(+SS8'E+ARBH
M5))Y)^8]2>U '8T5Y2^OZI=?"M_'-O?7":K%*\_V?S#Y.U9RGD&/[N-HQG&[
M/.:MWAU/4-<\<0-K>IV\5E96UQ;1PRA/*=HI&X('3*CCOWS0!Z7163X6OI]3
M\(Z-?W3!KBYL8)I6 QEF0$G\S7)>-;^[0^)7L-2NWGT[2A.D5O(84LG"N^]V
M!_>%MHPA! "\X#9H ]#HKS;Q'K.JVUO!J-VE_)H\NE1M+<Z7,5EL)B&+3/$"
M-Z$%3W V'CFO1+:>*YM(9X9!)%*BNCCHRD9!H EHKS#Q5J]_;0ZSJ6G:G=SR
M66J6T0D1S'!; O$K0%,D2L=Y))'&[KE<5:O4U"_\6^,+(ZYJ4%M:Z?;3P)!*
M$\MV64\$#(&5'U[YH ]%JI)>R)JL%D+*X>.2)Y#=*!Y:$$ *><Y.>..QK/\
M!VH7&J^"M#U"[??<W-C#+*^,;F* D_B:S+^YO4^*&EV27UPMI<:7<NT (V!U
M:,!@,<GYCUS0!UU%>0V-]K$?A+1-=?7=1ENO[?\ LCH\H\N2%KMHBK*!S\O0
MGI@8Q716TUYXJ3Q(Z:W/I=YINIO;0/&QV6Z1[3N>/(#A_F)W9X/&,4 =Y17G
ML]QK/BF_\2V>FWPL[K3KA(+607CQ>3F)'$C1JI$@9F;[QQ@8 ')+434]7\9W
M^FW&OWJ6YT2VN?\ 0I0BB5F<%D(&0OR@^I[G'% 'H+S1QO&CNJM*VQ 3RQP3
M@?@"?P-5[:]DN+Z\MFLKB%+=D"3R ;)]RY)3!SQT.0.:\NTZ>?Q#/\,+_4+J
MY:YNK>Y\YXYWCW,L!^;"D $]S[XZ5T%HFIZMK?CK25U>\C:%H%LI1)@V[- &
MXQCC<>G<=: .\HK@O#>O3ZYI.GW!:X%SI5I(VHP"9MS7*YC\MN>?F21N?1>Q
MJ'P\^N:Q8^&_$D6J0QPW"H]\&O'DCN XP46(J%C96.!M/;!SUH ]#HJ"]:1;
M&X:&6.*41,4DD^ZIQP3["O-+?4KBXL=5T?65U?3M:BT>9Y8);IWBN=H&9X9
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MG:T!#-;R.0"QV[L,1NZ<T >CT5P.M^)7B\.:MXKTV[<V>RWM[5S(?+PSJ'F
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MO4]IK.EW\@CL]2L[F0KO"PSJY*^N >E6+:[MKR,R6MQ%.@8J6B<, 1U&1WH
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M-7;75-/ODE>TO[6X6+_6&*97"=^<'BF0ZSI=Q=1VL&I6<MQ(GF)$DZL[)_>
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MGBY8">16>4'<'9@VYCD Y)/0>E2:!XDTOQ+:27.EW<4\<<KQG8X)^5F7=@=
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M'[N:RH)/!UUIWB#4UNY=4L]66*"YDD*K'<RX*(B<*-_3)'3@D\''HU(  ,
M#T% 'E>B2W^GZ-XF\(S3A_%D-BWV6Y$NYKJ/RB(=IX.4Z$8'/S?Q$U/X9O?"
MWB"YT6[6]NYK_3+9XI+66-8ULD,>V19@$4;<@  D\X([FO3J0  D@ $]: /%
M=+M+>/X(6&I:?817%Q!*AOO(C#326RW(:6,D<X*J,KZ#TKK+_4?"FO:)XBUC
M2_*NC-I3Q7-X PC(56,:'=QN!)Z#(XSU%=_2  #   ]J /*(YF'A_P *WFDZ
M[966JV^@QJ+>_P &VNXMJ;XR<@JP9!R.?UPQ-?MK'6--N=?-SH.EZCH5O%:
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M!^[E1DCT//2O;BJE@Q4$CH<=*PO$_A^?7TTQ8;V.U^PW\5[\\!DWF,Y"_>7
M- '!ZWI4#7WCFZT"&,Z=-X::*<6JCRY+K$A&-O!8)C./[P]:MWFH:9=7OPWN
MH+BW?$Y7S00./LS@\^FX@?7CK7IRC:H& /H,"EH \C:6&7P1XUT/5\?V\]W=
MO' W^MG=N;9XQU8<(%(Z;<=JOZ9;V2_$J2+6?L4MU'X;MA=-+M(,P=_,)SWP
M>?8^E>F8&0<#([TM '&_"F42_##0L.'*6^QN<E2&(P?3 Q7'ZE>6T'@_XGZ?
M+*L=XU[<R")N&*/%&$/_  (]/7!QTKV*B@#S*>?3+#QSHDMG'"RMX?N@\=J0
M&F&8V51CJ3AL?C67X?U73Y_$G@&:UN(EMC8W5NEM K,ML2D>V$N<EG&/FR>V
M<#//L-&!Z4 <3\+[B$^&9[$,/M5K?W8GBP<QDW$A ;T)!!^E4]1EL(OBS>^:
MRKN\-.)O*($C8ES@?[6WD5Z%10!YUX*N;NVU^UTIKRRUNP336-EJENNV:&(,
M@$4P'&3Q@\$[&XZXL^,8]/D^(/@E;M;=F,USN$H!X\EMN<]MV,>]=V !G  S
MUI: /%GG$-AK;V>V33;3QE'<WT4/S 6H6,LVT=5#C<?]T^AKH=3B&J>+]9U#
M19$N;*7PY+#=26[!TEF)/E#(X+A=WN 1ZBO2*0 *,  #T% '-_#^\MKWP#H1
MMI5D$5A!$Y7H'6-0R_4'@^XQ72T44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5GZOJRZ3#;M]GFN
M)+FX2WBCB7.7;H6/15&"23Z>O%:%<[XOL]9O;.Q72%258[Q'O+9IO*^T0 '*
M;\<<E21W ([X(!3N/']I::#J6IRZ=>'^S;X6%U%'L8I(2@!!W?,I\Q>1SSTK
M1TSQ,M_X@NM%N-.NK&[A@6ZC$Y0B6%F*[AM8XY!!!YZ5Q=QX-\0'P[XGTN'3
M[",:EJD-[;+#<81%4PDKC:,8\HCIR3T KJHM,U _$=M;:V"6+Z4MGDR+O$@D
M+]!VP<9SU]N: )=>O=/@\2>'+:\L;F6XGN9!9SH^(XI!$Q.X!@3E<]B.:S+G
MXC06UGJEXVB:E]ETJ\-K>R_NOW6 N7^_\P^?HN3@9..*O^)-*O[_ ,1>&KRT
M@62#3KMYYR9 IVM$R *.YRV?PKG;[PKKEUX4\:Z8EI&)]:OI)[4F9=H1E1?G
M/8C8>F>HH ZO4O$R6<U_#:6%QJ$NGP">Z2 KE%()"C)^9R 2%'MR,C-:^\;6
M-K$IAA>:;[&EZT$DB0.L; E00Y'SG#?+[<XXSF'3?$^C^+K[5M)L+2]M-8BA
M^T07%UY+6LT:[-V0K;E*XR!SQ^9>:5XGTGQ2=:TNVLM72^M(K>^@FF^SE98]
MVV1#AAM^8@KUZ=: +4/Q!LKZ;2XM-TV_O3JEF]W:E!&H8*0&4EF&T@MSG XX
M)XJG?>/IY=$T6^TS3)MU[JR:?/%*R!X&$A5TZX).U@#G'.<U=?2-8;QIHNK3
M0Q216MC<0W#1.%^>1D8! >JC9C)P>E8:>$]>3P_!&MK ;NU\1G5EB:< 21&5
MGV[@#A@&].U '0IJ=G_PFM]$FD7G]LQ:7'*Q,J[98B[;44;]N=V[D@?7%3Z9
MXNM]6T'3-5M;*X9=0F\F.%B@D4@MNW<X&W8Q(SD8-06NEZF/B+-K4]O&MI)I
M45GN24$B19'<G'7;\V >O'2FZ#X6N-(\3ZM<F5#I<DS7-E .L4LH'G$_BN1_
MOMZT 1WOQ$TFQEC=P7LFO/L37"2H2DF[9N*9W;-P(W8]\8YK?UK6+;0M.^V7
M7W#+'"HR!EW<(N2> ,L,D]!7*:#I7BK0)IM#CM-/GTDW,DMMJ33XDAB=RY5H
M]IW."Q .0.F?2NE\1VDE_H[VJ:?;ZA'*ZK-:W! 62//S=>,XY'N!TZT 8GB3
MQ;J.E:,;B#2)4N!J4%DV^1"N'9/G4Y^8$/@=.<YQBM67Q&WVR:QM--GNKZV@
M2>Y@1T'E!L[5R3@N=K8 XXY(R,\B_@C5H/"]]I^G;_LZ:G;7FFZ?>7.XPQQL
MC-'YGS8!*M@9(''/)K9MM*UG2/&&HZY#9QW4&KV\(N8(YP&@FB!5<%L!D*GD
M]<CI0!?M/&6G:I9Z9+I:27<NI(\D$'",JH<2%\_=VL0IZ\D8S7.:_K":K+X/
MU+R+RP9==-O-#<YC*[8Y=V1G:1E00WI44'@O7/#!T35-%6UOKZU%RE]:/*8D
MF6>3S&\MR#C:P&,CD#M5_P 4^'-6\566BP:E8V\L:7_VF]MXYOE2$QO'Y:L0
M"S?/G.!SG&.* .KTK5#JL<DZ6<T-N'(AED*XG4'AU .=I[$XR.>E5KOQ (]2
MN=.L+*:_N[6%9[B.)E78&SM7+$99MIP/;DC(S5\(VVNZ;92:7K&+B*U<I9WI
MD!>:$'Y/,'9P.,]\>M55TC4]&\<:IK5E;B]L]6@A6:(2A'AEB!52-W!0J>><
M@CH: &_\+"TZ:/1'L+"_O1K"R_9O)1 0\:DM&P9AM8$8YX'.3@5FZG\1I?\
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M<\\9X]ZZ>QM;^'PE!9H4M]0CLA"K,0RI*$V@^XR,_2@#/L/&45[?:?:OIMU
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M7$DMM#"9\0IO9U S\H[DUR5MIGBK0]>U1-.L;"]TS5+DW:37%QL>SD<#>&4
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M]6TS48R9K9U.M0V!MHHS(BP2,JAGD'W9?FW;<],<=ZFL/^2C^-/^P=8_RFH
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M!CS%E"DYPT.6!SUP*@USQ!K;:=\0[9+N&!]'ME>UFAAPP#0&0YRQ^;MG\<4
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M$3S1 '*(3@$G&.QK@-%UV31-*U-+=4-WJ/BZYL;<R E$9Y22Q (R JL<9&2
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M(=,\.V":G-Y>A2K+;L8US(54H _MACTQ6#\0/#QL?"OBZ^CNIKBXUDVY,"Q
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M&>TO)KIW@G:Y2W=(HE#ABXDZ!@%( !SD@>N.QC1(HUCC4*B@*J@8  Z"G44
M<3/\.HY8KF!-<U"*VDU,:I%$JQGR9O,$AY*DL,YP#P,]ZUH?##0:WJVJ)J$A
MEU*WCMW5HU(01A@I'O\ ,V<]:Z"B@#+\.:*GASP_9Z/'<//%:1B*.1U 8J.F
M<<9KG?\ A7,:V\5LFNZ@EM;ZG_:5M&%B/DR%RY&2N6&6;KGKWKMJ* /-_#^F
MS:MJOC:T&H2V]I>Z@5=1$-TD1A12T;GIG#*6^8<<8/-3"S:'XL)!IDXLX(-
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M%DY,,:IM#,0VT#KEO7\^@ZBB@#D;3P*EE:^'+>/4YBF@,3;[HUS)E"F'_P"
ML>F*S?$>A2:-HVM2Q7.I2KK-_%+=26=N'>U7Y0S! "63:@!7!SD]LUZ!10!P
MO@\7Z:@@M-:N-1TLJQF$^D+9JAQ\I5@B;FSP1@\9SCC._K'AR/4]4T_5H+E[
M34K#>(9U4,&1QAD=3]Y3@'J"",@UMT4 <Q=>";.\TRYMWNYUN[F]CU"2\4+O
M,Z%2AP01M&Q0%]!USDU;3P[NGN[VYO#-J5S;?9/M'EA1%%R<(O;).3DG)QV
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MC@]*PET75I-4\$.^F3)%IUE-!>/YL7[IGB1!T?GE3TSVJMX.T76-)ALM#O\
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M(21DQPQY&WGMGIFLWP8WBBSTW3]!U314MUTZ-8'U 7"/'/&@VJ8U!W9( SN
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M&.:2Y2S6]3;M*2Q,Q4%6SCD@]<5R<&A:UINC^*O#RZ<UW%JD]S+9W8D01@7
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MKPV+JWLET[7[=Y(4C+&6!EB\T;F/# C(P ,'N:CL_&.KZDNDZCIVG&ZTZ^N
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M\O[*"Y^S16BVOEF*5,(R D D%^YZ'@5J2>*;.SBVWBSBYAM$NKJ.*!F,*-D
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MTKU&[M8=0L)[.ZCW07$312H>ZL,$?D: ,Y/$5J_B&+1##<+=RVINT8A=AC!
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MZ)K=CXATJ+4=/D9X)"RX=2K(RDAE8'H0017FUEX=UW1K'PM?2^&EU3['I?\
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MB%R<8^4A=QSQ]*Z"VM=4E^):ZO+I4\%D^CBU,C21G9)YI?:0&)Z'J 1GN>M
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M1OL3SQ;;NSD$8./GPC@IN!.,XP<]@#TR]OEL-+FOYH92D,1ED10"X4#)[X)
MSW^E9L?BO3I)=#15N-NM1&6S?R^& C\P@\Y!VC/2KNHP2:GH-Y;*AAEN;9XP
MLF,J64CG!([]JX'2]/\ $)?P%YWAZY@70T>"[+SPYS]F,6Y0'.5R<]C[4 =
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MZ=!?6,EG<06\<+0R.K,"J@$Y4D=0<<],=.E;% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(S!5+,
M0 !DD]J6N/\ BG)=1?#77'M94C_T9A(64DE#P0,$8//7GZ4 ='8ZQINJ231V
M%_;7+P$"58I Q3(R,@=,CIZU=KDEOIHO$\&C6\>G#6IM/-S<WOV8X$"OMC7;
MNW-\S-_%@8)[XK*F\?ZFFGH(]-M3J,&N1Z/>1M*P3+, 'C..C!@>>GOB@#T(
MD $DX JM8ZC9:G"\UC=P742.8V>&0.H8=1D=Q7%_;_%8\>Z'IVH76FQ++:74
MTD5M'(R-M= "2S YVMZ8!SUXQAZ5KNJ>&]&U[4[:WLY-.A\37"7"2,WFLKW
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MRVY( D'JZ''U'':M":^;0H8-4N+:,ZWK]Y#:QHYXA#9V(2.H1 S''5BV,9&
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M3T)'4?C5JO/+C^V(_BG?C3A8M??\(_;EI)U98LB:7^$'//3KQZGH;]CXOO\
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MR1D9 [\CZBM&\\'+JZZW+J5TKW6J6']GB2&/:L$/S$!02<G<Y8DGG@<8KJ"
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M\P>6,#DO\X(ZC SDTK>#=4FU6\U*?7(&GO-+&G2HECM08+D,HWY ^<\9)SW
MXKLZR/$6OP^&].2^N+:>>)IXX#Y.WY"[A%)R1QEATS0!C6_@R[@'A(?VI"P\
M/(4'^BG]^/*,7/S_ "_*<]^?RKH],M[^VAF74+Y;R1IW>-UA$>R,GY4P"<X'
M&>]7::[%(V949R 2%7&6]AGB@##\8^'I?%7A>\T2.\2T6[4*\K0^80 P/ W#
MGBF:[X9;7M%LK::\$-_8SQW5M=Q1<),G1MA)R""01GH3S5SPYKT'B70H-6MH
M9H8IFD41S8WC8[(<X)'53WK5H YJ3PI_:-SJ%YJURDMW>:<VF@V\1C6*%LEL
M EB22<Y)_A QU)S[#P7JT%]X;N;S78)CH<<D*)'9;!+&R!.<N2&P.3TZ<#G/
M:T4 87BG0)]?L[)+6^%G<6=[%>1L\7FQNR9PKID9'.>HY /:L&Y^'4M[#KB7
M6MN7U&ZBOH98K<(UM<1J@#CDY&4&!QP2"2>:[NB@#D+WPKK6K^%]1TO5O$$4
M]U>P&V\Z.SV1QH>I$8?ECW)..!@#G,FF>$[W1M<GU#3]4@BANX5%W:&T)CDG
M48\Y?WGRL1@$<YQSSS741313JS12*ZJS(2ISA@<$?4$$4^@#AK;P#>6WAKP_
MHZZQ"W]CWRWBRFS/[W:S$*1YG'WCSGTJR/!4]O#KFGV6II#I6LR22S0M!NDA
M:08E\MMP #<D9!VD]^E:6J^)TL+F[MK73KS4KBSBCGN8;0*71'+!< D;F.UC
MM'.![C.ZK;E#8(R,X(P: .=UGP=8ZK;Z-;JS6\6ERJ8Q'_%#L*-$?]EE.#["
MIM(\,6VCZ_K&JPR,3J4JR^4?NQ-M <K_ +Y4$_0>E;M8NI>)K73I]'C\F6XC
MU6Y%M#/"5**Q5F&><XPIZ ]* ,&3X?2SZ/JMG-JY2XN]4.JVMU;V^QK6?((P
M"Q# 8]L@FI[WP;J&N^';G3]?UYKF\D*-!<VUN(5MW1@RN$R<MN SD\C@8KL:
MAEN4C9XU!EG6,R"%"-[#IQD@=>.2* .2.AZQ8ZQ'XHU/58[R:QTV:W>"RL"K
M3*2'^4%V^<E!QT.<8%<GX4GGMS82:5XA\/:K=\>9:+IQ6Z^<@R;F5\H<Y)8H
M!D<BO2_#FN0>)?#]GK%K%+%!=*71)0-P&2.<$CM6I@#MUH XVQ\&ZII6IW<>
MG^(7AT*[N'N7L3; R1LYW.L<N?E5B3VR,G&#S6WXHT,^)/#5]I NGM3=(%$R
MKNVX(/([@XP1W!(K7HH XQ_!FJ3:G?ZA/KD!FOM+&GRJECM1<%\,HWY ^<\$
MDY[XXJ2#P;=PGPG_ ,32%AX?C,8'V4_OP8O*_O\ R_+SWY_*NOHH \];X<ZC
M'X<F\-6FOQ1Z,+I+BU22S+RP 2B79OW@,N0<< \]>*[#6]*.M^';[2GNG@:[
MMV@,\0P5+#&0,_IFKUQ*8+>258GE**6\N/&YO89(&?J:H>'M:@\1Z!9:Q;1R
M1P7<8D1),;@#ZXR,T <W'X;U+1=0B\1W6JB[>PTF2TDMK/3PIE12''EKN.&R
MHXYSVQ7+^%)Y[<V$FE>(?#VJW7RB6T33BMT Y!DW,KY0]26*@$CD5Z_1@#H.
MM '+Z;X0-O9>(K+4+N.[M=;N)IY4C@,902($9<[FSP!SQ46B>$]6L[0:=K'B
M$ZIID,300P_9A$[(5*XE<,=^%)'0<\G)KK:ANKJ&RLY[NYD$<$$;22.>BJHR
M3^0H YCPUX5UG0A!97/B1[W2+/BUMS;!)=HX59) ?F"CT S@9XXK3\4Z"_B/
M1ULXKL6L\=Q#<Q3&/S KQN'&5R,CC'44NE:^^J78A.E7UO#);+=0W,BJ8Y$;
MME2</SG:>U;- '-0^&]0B\57&NMJD$DDVGI9&,VA &UF8-D/ZN>/3'/>LG2O
M &H:,GA_[+KT9DTBVEM"9+/<LD;D'(7?\KC&-W(]NQ[NB@#A;3X?W=EH6BV$
M.N*9](U!KRWF>TRI5M^490XR<2'G(Z#BNY4%5 +%B!@D]335FB:=X%D4RHJL
MR \@'."?K@_E3Z ,'0_"]MH>KZQ?P2NPU&X\Y8C]V'(&\+_O/EC^'I67H7@W
M5- F^Q6WB%SX>28RPV)MAYL8+;O+$N?N9[8SCC-;>KZ_#H^H:39S6T\AU*Y^
MS1RIMV(^UF^;)ST4] :UZ .4/A&:ZU?2]0U*\MYYM,N'FAN([8I.RD,!&S[C
ME0&YXYVCISFC-X NY/"&K^&UUJ-;6^N))8F-IEH5>4R,#\_S')P#QQV-=S10
M!SH\/7H\8?\ "0'4+<M_9WV'R/LIQ]_?OSO]>WIW[UQ6L:4/"^@^'?#EYKUK
M;10W$UR+^[L,VQ()*HX+X#;I,J=P^X3U SZ!J>OPZ7K.D:;+;3NVIRO%%*FW
M8C*C.0W.>BGH*UR 1@C(H Y/P3/>-#<P-=:7?:>@5X+O3;4P1NS%BXQN8,>A
MW ]6YYJU=^&YT\5GQ#I5[';W,UL+6ZBFA,D<RJ<HW#*0RY(SSD''O7144 <;
M>>!6D\.VVE6>HI"ZZBNI7%Q);[S-,)?-)P&& 6^N!@>]=;),+:T>:Y<!8D+R
M.JG& ,DXY-2T4 <5X;M=*USQ??>+]*DDDLY[:*)'*LL<TPSND"L!R$V)N_WA
MV-3_ /"&W%L==MM/U-(--UJ1YIX7@WO#)(,2-&VX ;NN"#@\\]*Z[I4:3122
MR1I(K/&0'4'E21D9_"@#F9/"$UIKNGZCHE_'8QVVGC3'ADM_-S K!EV'<-K#
M&,G<.>E9VG^ +VPT[PY9KK4+C1;N2Z5FLSF7?O!4X?C_ %C<_2N[K(U#7X=.
M\0:1I$EM.TFJ-*L4R[?+4I&SD-SG.%].] &JX8HP0@/CY2PR ?I7&6'P^C3P
MOJF@ZI>I>07UU+=K+% 8GAD=MVY3N;E6Y!KM:R-3\00Z7K.D:;+;3NVIRO%%
M*FW8C*C.0W.>BGH* *$>A>(%@TQI/$$,M[8AE:<V1"W*D 8D7S.O&<@CD#Z5
M/I_AV2/Q'<Z_J,\,]]-:K9JL$)C1(@Q;'))8DGJ>P QZ[]% '):-X8UCPYI8
MT?2=7M1IL;-]F^T6C/+ C$G;D. V,G!(^N:T)-!G@L;"RL+J(6MO$T4T-W#Y
MRW*L!][!'S9!.<'J>.:W:* ,?PQH$/AG0HM+@??'&\CC"[54NY<JJY.%&[ &
M3P*V*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Y?Q\M_%X7FU+39[A+C3G6[,<,K)Y\2$&2,X/
M.4#>^<5U%(RJZ,CJ&5A@@C@B@#S$>)Y(O%=\\%S<W&FZU9[=&9[AS&URNU75
M!GY03(O/;8V,"MMS>:;\0_#NF+J5Y-:OIER94EDW"1T,8#GU;YCU]>,5T,/A
M[2;>WTN"*QC6+2CFR7G]T=A3CU^5CU^O6G3Z'I]SK-OJ\L4AOK>-HXI!,X"J
MV-PV@XYP.W84 >7:C_R2CQY_V'+O_P!*%KTGQ;JMQH?A#5]5M8Q)<6EI)+&I
M&1N"D@GV'6H6\%Z"^E7NF/:2M9WTYN+F(W4I\R0G)8G=GD\G'6MHV\36QMW7
MS(BFQED)?<N,$'.<_C0!R$PFTG3$\1V6N7-U&-+ED^RS2&5+R01^8KKDX0_*
MW"@ @]L55T9=5F_L+Q"-;B2PFMBUX)+QYENMR;@RH5"QLI!/RX&,CH*Z'0_!
MN@^''D?2['R2ZE<-*\@12<E4#$A%)ZA<#@>E1:3X%\-Z'=2W&GZ8L32;AL,C
MO&F[[VQ&)5,]]H'''2@#E-%U+4$\1^#RFH7MU::I!=>=<7$A"WFU ZR+"21$
M/3&#@X(HT[Q!J&F:@MOK<=^FJBWN9[:5+AIK+5 J%P4YPC #.W P,^U=39^
M_#5A)8O;Z<RM8.SVI:XE?RLC!498_+_L_=]JNV'AG2M-DMGMX)?]%5EMUEN)
M)1"&&#M#,0....W'2@#EO#ZZSJ47ASQ#'J\2VUQ$K7BM>22I=;UZ+&5"QL&_
MNXQ@@YK<\3W!&HZ+9K>W*/<32'[%;$H]T%C/_+0,I15)#$YYP!SG!DTGP1X=
MT/4GO]-TX03LS, )7*(6ZE$)VH3R/E X.*N:MX>TS7);26_MV>6S<R6\L<SQ
M/&2,'#(0<$<$=#0!P>FZEXCN?!\,D EU&:SUBZAN+5;PQSW%O&\BA4EX+,IV
M'L6"X/7GL?!NIVNJ^'4GM9[V11-,CK? B>%A(V8GR2<KG;U/ %%OX+T"T7;:
M6;VV+EKM3!<2(5D8$$C#<#YF^4?+R>*U;#3[73+8V]I%Y<9=I&RQ8LS'+,Q.
M2222230!YK)K6I7_ ,,M1\8PZA<V^K6L\\J1"5O*C6*4J(6BSM(** 21G)SG
MI6H;2.[^+^GW$OVJ*2309)VC%S(NUA-%\N V,>J]#W%=-_PB>B_:KBX%HP^T
M3"XFA69Q#)(,'>T>=A.0#G') )Z5.^@:=)KJ:VT4O]H)%Y*RB>0 )D$KM#;<
M9 .,=J ,GQ[%J,>@?VII<]TL^FR+=/;P2L@N85(,D9P><J#COD>YK"U[Q3,G
MAC6_%VD7<C6GEP6UF^XM&-SJ))PIXR/,QR.L1]378:Y>:Q:I;II&DQW[S,4D
M:2Y$2P#'#,""6&>H'-+I_A^PL?#,&@M!%+9);B!XV0;9!C#9'3DY/XT <]??
M:M&\<>'[&TN[R?3]7BN(;J*:Y>0J8X]ZRHQ.5/8X('(XS6!I^LZG)X$\#W\F
MHW375SK,5O/(93F6,RR JWKPHZ^E>@Z;X>TW2I(Y+:*4O%%Y,33SR3&./CY5
M+L=HX'3K@>@K.7P!X:7:!I[[4NOM<:?:9=L4N2<HN["<DG"X!/T% &/X>M;W
M4_%_B$W.N:H8=,U1/(@68!"I@1BC#'*Y;IQTK3\8>'8O$,VGK:ZK-I>NVGF7
M&GW40R5QM5PRGAE.Y01_]>MG3]"T[2KV]O+.*1)[UQ)<,T[N'8# .&) . !Q
MV%&I:'8:M<6UQ=Q2&>UW>1+%,\3Q[L;L,I!YP* //9?&GB#2-(\26FN6EK%K
MVF6T#B^M>8IX7<HLF"#@KEC@C'7BM/4;/6].@U34(=:,%E)I,S1P+>O<OYR+
MN66-I%^48X(''(/6NLM_#NE6\%[%]F\X7PVW37+M,TRXQM9G)) !( Z#)K$E
M\%:7H7AG5[;P_IDAN+FSE@C0W#.?F4@*ID;"KDC@$#B@#G+=]8TQ/ FMIKFH
M7C:L]O:WMK<2[HG62$OO5<?*5VYSU/<GG+K;5KX:IX7O+74[R\MK_5)X);N2
M0K%=(5E8!(<D*J[0 WRD[<X(.:ZGPEX;AT[0]%:\M)X]0LK1(MD]P91"^P*^
MP;F49P1D=CC@<4Z+X?\ AB 0+'IF%M[@W,*_:)2L3G.=@W853N.5'RGN* .9
MT@7<L7BG5+[Q1J5NFD:G>1Q.[AHHT$2X+ICYPN[<%XY''4YET.>]?QE::7-<
M:@;"]T!YW%Q=.9))%DC7S0 Q,1(<\*W<="*ZZW\+Z/:VNI6T=HS0:FSO>1R3
M/(LK.,,2&8X)''%06'@O0--O+.\M;)Q<V<1AAEDN))&5#CY268[@,# .<8XQ
M0!YYI3W.F_!7P]>V5_>0327=J)"L['>&N0K#DG ()X&,]ZZRVGG\3>)_%6FS
M7MW9C3&A@M5MIVB,>^/?YIVD;B2> V1A>G)SJKX'\.II?]F)8NMF)A.(EN90
M%<-N&/FR &Y"C@'D"K5WX9TJ\OS?20RI=-#Y$DL-Q)$TD?97*L-P^N: //\
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M: ..T.>];QE::7-<:B;"]T%IG%Q=.9))%D1?-&&)B)#GA6[C@$5B^%;^;3O
MG@>S@FD4:Q,\<\DMW(@.%D945N2A9@/N@9P1WS7H%AX+T#3;RSO+6R87-G$8
M899+B21E0X^4EF.X# P#G&.,5&W@3PT^ARZ*VEJVGR2>;Y+2N=C9)!0ELI@D
MX"D 9..IH ?X9LM4TV74;;4=12ZC,PEM8C,TTEO&P^XSL 6&0<$\]JZ"L)/!
MVAQZ,-)6S;[()DG(,\A=I%(*LSEMS'*CJ>@ Z5NT <3\7!_Q:KQ!_P!<%_\
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M:/JTWV,B? 4*L1"L ,,O)&T\>V<FNZM_ 'AJU^RB+3W M)_M%LK7,K"%N?N
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M>>"PT\+%/&8G2:5YAY9ZH-Y.%_V1Q45GX"\.V$ME)!9S9L'9[0/>3.L&1@A
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MF7<9EQM<'=E6& ,KC@8IDG@3PW*E^CZ>2NH*J7?^D2CS@H &X[NO R>I[YH
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MZ[549(&/Q!H ](%_9FQ-\+J V@0N9Q(-FT=3NZ8]ZSM&\4Z/KFC'5;2^@^R
MMN=I%&P!B 6Y^7.,\^M:=M<PWMK'<V[B2&091P.&'J/;W[UXYHE\;?P/X&F?
M>;#2M0*ZLNPXMV_>*C2<<!&()]/E)[4 >PV=]9ZA"9K*Z@N8@Q4O#('7(ZC(
M[TV^U.PTR(2ZA?6UI&>CW$JQ@_B2*Y70HA<?$G7-4TV1)-)GL;=)9(FS'+<@
MMD@C@D)M!(]0*S?$FK6VB?$&1]>O;FQTJ^TV."UN5C#1;U=S)&Q*M@L&4]LX
M'H* .ZNM6TVQACFN]0M+>*0;D>6945AC.02>>*?/J%E;6JW5Q>6\5NV-LTDJ
MJASTP2<<UYK&^CZ+J.D:/:0W%C&=(F2TN[M7DEEB:7B"-#QO.%;E2P7 QUQD
M^&=?@T6P\":IJCR+HL>E2V37#(QCMKHE,%N.,JK(#]1ZT =_KOB2:SU'PRVG
MW5G+INIWAAFDQORGEN^Y7#8Q\GH?K70V.HV6IVWVG3[RWNX"2OFV\JR+D=1D
M$C-><:PFA+-X-BL+:.#39-;DG5)00) T<I,FUN0I=N,\<C'!%;/@F2W'BKQI
M#;M&(_[2CD5(R,<P1AB /]H$$^HH ZN\U;3=.D5+[4+2V=QE5GF5"1G'&3Z\
M4KZKIT=U):O?VJW$:>8\33*'5>NXC.0/>O-/'6H6CW?C/3@GV2\;15RVQI);
M\!)"H0'*JB$D,0,\]5QFKU_--9P^$O%VEV[W;_9UTVXC4$&6.51Y><]A,J<^
MC$T =VFLZ7);1W*:E9M;R/Y:2K.I5G_N@YP3[4JZOIK7_P!@74+0WF2/LXF7
MS,@9/RYSP*X7P;I=_INKS>%KM&DL=&N#?07&T*LBS E% ]%<SGVVI7.2:Q8S
MCP_-!FS2V\4L9K!8W=[<L9@S2L<G<Y.0!@8; !QF@#UL:UI1NEM1J=F;AI#$
ML0G7>7 R5 SG(!!QUP:Y_P 0^*_L6MZ#8Z;?Z?*;O4EM+N#(>5%*N21AOEP5
MP<@]>U<YHMG;71^(#Z7!:/JR7TSV#A%+(_V=0C(>WS[AD=\UFIK>BW>A_#N&
MVD07=CJ5O%<P;#YMNXAD5PZXRI+#OUQGF@#V&21(HVDD=41069F.  .Y-5(-
M8TRYMYKBWU&TEA@_UTD<ZLL?&?F(.!QZUSGQ(%VOANVG@BDFMK;4;6>^BC4L
M7MDD#.,#J. 2/0&JT4EOJ'Q-M]:TFZAET]-)=+^YBD!B8[P8E+#C</G/J!]1
M0!/X:\1W_BJ2#4M.O]--B+B>.YLB-TJ1*[I&X8'AB5!P1C#<=,E][KFN?\+#
M3PW9RZ='!)IK7XEFMG=@1($V\2*.^<_I4/PJN(9O L"1RHS)<W190>5S<2$9
M';(((K&\06UOJ_Q@6P_M*:SDD\/2P)/:W!C>.4S# !4C)QD[3UQTH W-#\;R
MWWASQ#?7MB%N]!GN(+B.W8LDS1+NRA//(['I4FEZSKNHZ7I.K6USI-]97KQ>
M<MM$X,"L1G:V\[BI.#D+W/&,5E>%-=M] \+ZEHU]8P6NL:+%*\]K$NT7H52P
MFC_O;P,GN#G-8UQI^E:/K^F:KX U,17-]>Q)>:-!)NBFB8_O&:+K$5&23@8Q
MC /4 [+1M>U2^\=Z_HEP;/[)I:6[HT<3"23S5)Y)<@8V^G/M6C%?7Y\57=C)
M):BQ@M(K@8B829=I%P6W8P/+ST[US-O=V_AWXJ^()]6FCL[;5K2U>TN)V"1N
MT0973<>-PR#CKBK=[/I^KQ>*-0:6231GTE;5[FVYWA1.TAC/1L+(O(R,Y'8T
M =39ZII^H,ZV5];7+( 7$,RN5!Z9P>,X-%[JFGZ8%-_?VMJ&!*F>98\XZXR?
M>N/\%WFH_P!OW>GWEW8ZS%'91-#K-H K.FY@L4H!*[QEB,=B?6J_BW4;2/Q;
M=6#I]ENYM$=4N2C2/<J6;]S$O*Y!&2<$X(X[T =S<ZG864<<EW?6T"2#*-+*
MJAA[$GFK$<B31)+$ZO&X#*RG(8'H0>XKR#3[HMX6\+WNE:[;6.K6NA)&8-13
M_1KR/"[XR3@A@R#E?UYQZ)IDMW>^!K66ULSIUY+IRF&V?_E@YC^53GT..M &
MBFK:=+?&QCU"U>[&<P+,ID&.ORYSQ7+WOBFXU+Q)J.@:%J>F6][901O&;DB0
M3S,7S'@," H3G&2-WMSRL+QZK\._"VEV)\OQ)8WEJK0'B>WF1P)G=>H&W>23
MP0W?(KI]$N[=OBSXIC$\9=K.R55W#)*^;N ]QD9],T =9+J5G:26]O>WMK!=
M3 ;(GE"ESWV@\GFG_;[/SIH?M<'FP+OE3S!NC7U8=A[FN?\ '>DW%]H2W^GH
M#JNDRB^LO]ID^\GT==R_B/2N:U_[=?\ @,^(H[28K?7]K?W=L%S)]A1UPF!U
M^0!B/]IZ ._AUG2[B":>#4K.6&#_ %LB3JRQ_P"\0<#\:>NJ:>S6RK?6I:Z&
MZW F7,HQG*\_,,>E<3>+'KGCR'4M!GBN;8Z+<0WLT#!D?<5\E"1P6SO..H'U
MKFM(UBPFT?X96\<V^:RN%ANE5"3"XMI%*/QPV>QY[T >L1ZUI4UTEK'J=F]P
M[,B1+.I=F498 9R2 02.U9'B3Q')I6M:)H\,UK:RZHTH6ZNE+1KL .T ,N78
ML .1T/7I6)\.K32IKKQ'<1V]H]Q%KUTT4@12R*0 "IZ@$%NG!R?>M;QC_P (
MY?M:Z'XFMX6LKR.619ICM6)T* ?/_ 2'.#D=,=Z -32I]7%W?0:N+79#L:">
MW1D612#DD,3M((QC)]>]6(-;TFZBGEM]3LIH[?\ US1W",(_]X@\?C7E AUJ
MU\,>+=)TG4;K7=&LQ;/8SEA+(R[PT\"OTDP@QWZX]JOWT_AKQ'HGB'7-+O+O
M4KH:!<032RIM2)0I948;5&_.2.I&#[4 >DVVLZ7>7C6EKJ5G/<J@D,,4ZLX0
M\AMH.<'(Y]Z6+5]-GO6LH=0M)+I<Y@292XQU^4'/'>O-;.RTR]D^'UQH*6YU
M"U"RW;VP&Y(/(/F"3'.2Y48;G)/O69IFL6%Q>^![F#_1;:'4+F-K!(W;[(7B
ME^21SEC(6/3(SG@<9H ]:36])EN5MH]4LGG<NJQ+<(6)498 9SP.3Z4D>O:/
M-#<31:K8R16Z>9,Z7",(U]6P>!QWKS?18]%3PMXZOFTJ#47@U+4&$4( D:-A
MC",/F564L,KV)Q4F@:C;77Q#L98+Q+F.Y\.-%";>%EBRLJG8AY)VC.<DD<YQ
MTH Z^'Q1::[H5GJ.C:Q86Z37,:[KDAMRE_N8W##L.@///2MF\U73M.=$O=0M
M;9G^ZL\RH6YQQD\\UY%!>63_  A\'QLZ>?9ZC8QR!UP8F68;QST( .?0=:Z6
MTO;.T\3>,[+Q+)$B7WER6S3D!;FU\H+L3/WMIW94<Y;WH [FYU33[)]EW?6T
M#;#)MEF53L'5N3T'K4MI=VU_:QW5G<17%O(,I+"X=&'J".#7DV@6+6>M?#RU
MUU8C?PZ3="99P"R']V8E;/\ $ "!GN#74_#.2 Z1K$4#IY<>M7NQ$(PJ&4E<
M#T(.10!+_;>O7/C^_P##MM/IL4%O91W:RR6DCL=[%=IQ*HXQU_2K&D>*;I_%
M5SX8UNUAM]2C@%U;S0,3%=0YP64'E6!X*G/U(K#AU?3;/XT:Q+=7]K!'_9$$
M6^6957>)&)7)/4 CBJNH*^O>,[WQ1%I]S/HND:-/;IA61K^1@2RQ]RNWC<.Y
MXS0!Z!#KFDW'G>1JEE+Y">9+LN$;RU_O-@\#@\FJFB^*M'UW2'U2SOH#:HS!
MG:11M 8J&;GY0=N1G'!K@/#>IV<_C;PI/;W*/!+HDUO%';Q-Y46#"1$&.2Q4
M#G).,9(6L[3M3-A\//#$S-=+:Z1JDG]K""+<]N"9@K,"I^ZS*Q&"1P?0T >Q
M6=_9ZC;^?8W<%U#DKYD$@=<CJ,CC-6*XC0]4\+Z5;:OXCM;^YEL;V>$SWLBL
M8Y93\@V*JCU4$@8SU.0<=O0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#@''_A0!M45B_\(?X9_P"A=TG_ , X_P#"C_A#_#/_ $+ND_\ @''_ (4
M;5%8O_"'^&?^A=TG_P  X_\ "C_A#_#/_0NZ3_X!Q_X4 ;5%8O\ PA_AG_H7
M=)_\ X_\*/\ A#_#/_0NZ3_X!Q_X4 ;5%8O_  A_AG_H7=)_\ X_\*/^$/\
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M&?\ H7=)_P# ./\ PH_X0_PS_P!"[I/_ (!Q_P"% &U16+_PA_AG_H7=)_\
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MS_T+ND_^ <?^%'_"'^&?^A=TG_P#C_PH VJ*Q?\ A#_#/_0NZ3_X!Q_X4?\
M"'^&?^A=TG_P#C_PH VJ*Q?^$/\ #/\ T+ND_P#@''_A1_PA_AG_ *%W2?\
MP#C_ ,* -JBL7_A#_#/_ $+ND_\ @''_ (4?\(?X9_Z%W2?_  #C_P * -JB
ML7_A#_#/_0NZ3_X!Q_X4?\(?X9_Z%W2?_ ./_"@#:HK%_P"$/\,_]"[I/_@'
M'_A1_P (?X9_Z%W2?_ ./_"@#:HK%_X0_P ,_P#0NZ3_ . <?^%'_"'^&?\
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MCN*6@ HHHH *Q?&'_(DZ[_V#Y_\ T6U;58OC#_D2==_[!\__ *+:@#:HHHH
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M!8E?NC)'/%-\+Q?\(5XBO=!NH'>QOY#=V&I^66,F3\T4TF,EES\K,>5/7C%
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M<SK/&C64D>?/#-@JK9&UO3K]*ZBL#Q3<10P::'8@G4+<X )P X))QT [GH*
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M&#C %7O"7A^X\-Z9<6=Q?)=F6[FN0RP^7M\QRY'WCGD^U;]% !1110 4444
M%%%% !6+X7_Y!=S_ -A*^_\ 2F6MJL7PO_R"[G_L)7W_ *4RT ;5%%% !113
M)94@A>:0X1%+,?0#DT 8/B_PG:^+M.MK6XE>%K>ZCN$ECX8 '#KG_:0LOX@]
MJB\2^%[K5+O3-3T?4AIFJ:;O6&1H?,C>-P T;ID9!VCOQBJ]IXLU.^T6QURW
MT:"73;UXO+V7F9DCD<*'9=FWC.2 Q(]ZZ[- '.MHFKO;0K<:G;7KMYGVV*XM
M<PW 8* JIN^0#;Q][J<]2:R[;P ^G6OAY--U)()='N+B52]N70K-N#(J[AM
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M'<9S1D>M ''7G@[4]?\ #=YIOB/71<7$RJ(9K2W\E8&1@ROMW'<VY03R!@8
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M@ K%UW_D)>'?^PD?_2>>MJL77?\ D)>'?^PD?_2>>@#:HHHH **** "BBB@
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M^H?_ (W6U10!B_V!<_\ 0QZQ_P!]0_\ QNC^P+G_ *&/6/\ OJ'_ .-UM44
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MJNR;E/!&5(-06NC6%G;6-M!"PAL#FV5I&;R_D*#J3G"L1S0!%=S1Z/80VEA
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MW-BUE.!*Y\]"1PPSA<8(&.3N/- '/VF@W'@CQ3H\&C7][/HNH/)!/IUS,9A
M5B:19(RW*C*;2,X^8>U<UXCUN[DET2]OO#6MQ7TFN6LC;X$VA%W[(8SOY/)/
M.,DL>. /4-)\/:;HJJ+**7*)Y:-/<23LB?W5:1F*KP.!QP*LWVF6>I_9OMD
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M^X>8G'S5TU8K_P#([P_]@V3_ -&)0 G]E:S_ -#'-_X"1?X4?V5K/_0QS?\
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M!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+J-AJ9UN'4
M=.>S^6V:!TN W=@V1M^E;5% &)_Q5'_4'_\ (M'_ !5'_4'_ /(M;=% &)_Q
M5'_4'_\ (M'_ !5'_4'_ /(M;=% &)_Q5'_4'_\ (M'_ !5'_4'_ /(M;=%
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MM;=% &)_Q5'_ %!__(M'_%4?]0?_ ,BUMT4 8G_%4?\ 4'_\BT?\51_U!_\
MR+6W10!B?\51_P!0?_R+1_Q5'_4'_P#(M;=% &)_Q5'_ %!__(M'_%4?]0?_
M ,BUMT4 8G_%4?\ 4'_\BT?\51_U!_\ R+6W10!B?\51_P!0?_R+1_Q5'_4'
M_P#(M;=% &)_Q5'_ %!__(M5--L/$NFVTD*2:2X>XFG)(D&#)(TA'X%L?A73
M44 8G_%4?]0?_P BT?\ %4?]0?\ \BUMT4 8G_%4?]0?_P BT?\ %4?]0?\
M\BUMT4 8G_%4?]0?_P BT?\ %4?]0?\ \BUMT4 8G_%4?]0?_P BT?\ %4?]
M0?\ \BUMT4 8G_%4?]0?_P BT?\ %4?]0?\ \BUMT4 8G_%4?]0?_P BT?\
M%4?]0?\ \BUMT4 8G_%4?]0?_P BT?\ %4?]0?\ \BUMT4 8G_%4?]0?_P B
MT?\ %4?]0?\ \BUMT4 8G_%4?]0?_P BT?\ %4?]0?\ \BUMT4 8G_%4?]0?
M_P BT?\ %4?]0?\ \BUMT4 8G_%4?]0?_P BT?\ %4?]0?\ \BUMT4 8G_%4
M?]0?_P BU4CL/$L>L7&HB322\UO% 4Q)@!&D8'\?,/Y5TU% &)_Q5'_4'_\
M(M'_ !5'_4'_ /(M;=% &)_Q5'_4'_\ (M'_ !5'_4'_ /(M;=% &)_Q5'_4
M'_\ (M'_ !5'_4'_ /(M;=% &)_Q5'_4'_\ (M'_ !5'_4'_ /(M;=% &)_Q
M5'_4'_\ (M'_ !5'_4'_ /(M;=% &)_Q5'_4'_\ (M'_ !5'_4'_ /(M;=%
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M35B@ HHI&940N[!549))P * %HJI::II^H#-E?6MR,D9AF5^?P-6Z "BBB@
MHHHH **9++'!"\TTBQQ1J6=W. H'))/84D$\-U;QW%O*DL,JAXY(V#*ZD9!!
M'4$4 24444 %%07-]:6>W[5=00;ON^;(%S],T6][:W@)MKF&<#J8I V/RH G
MHHHH **** "BH&O+5+R.S>YB6ZE1GCA+@.RC&2!U(&1^=3T %%%% !1110 4
M444 %%5[N^M-/A$MY=0V\98*'FD" D]!D]ZL4 %%%% !1110 4444 %%06UY
M:WHE-K<Q3B*1HI#$X;8Z\,IQT([BD6^M&OFL5NH3=JGF- )!O"]-Q7KCD<T
M6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIP:6NA^$O&VBKIMY93PC3=2B3=;7$D; J5?^!VQ@@]<G.,XK?TA$'QH\2.%
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MXNG@W12K( 'C,>>$PJXYR,9R3S70Z3:WMK9D:C>B[NY&WR2)'Y: X PBY.%
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MUH'L9F+2Q>8W[TDY)<YRQ)ZY)S6K10!%;V\=K;I!%N\M!A0SEB!]22:EHHH
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M0YZ5Z!::M:7VH7UC [F>Q9$G#1LH!9=PP2,-QZ9J[10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5]M*W&T^7*)=GR8 P"#T]JF\<7M[8+H$EE>2VXEUJUMYD0+B6-WP5.1G\B*
M.KHKS/4IM8N-1\>QKX@OX(]*MXI[18MB[&,#28)V\KD=._<FN[T"\EU'PYI=
M]/CSKFTBF? P-S("?U- $\=_#-?S6<6Z22 #SF7[L9(R%)_O$'.!T&"<9&9Y
MI#%"\@C>0J,[$QN/TR17G7A#4I?^%/W>N2ZA'87ET][<RWDR;Q%(9G4$KWP
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M-=7$4$0."\KA5_,T?:[;[+]J^T1?9]N[SMXV;?7/3% %&?P_8W.OV^MR>?\
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M&3R <#%:XU"R,T,(O+<RSKOB3S!F1?51GD>XI)M2L;<L)[VVBVN$;?*JX8]
M<GJ?2@"/1](M-#TV+3[+S?(B 5/-F:1@ , 98DX   '8"L6WMKO7?$L%_J>B
M?88](>9;2261)'F9_EWKM)VKM!X/)+#TKHDO+5[M[1+F%KF-0SPAP74'N1U
MIHO[,WGV,7<'VK&?(\P;\>NWK0!1OO#MA?:I'JA\Z"_2(P?:+>4QLT9.=C8Z
MC/(ST/3%0WGA'1[S3;&Q\F6WBL)!+:O;3-%)$V""0X.>0QSD\Y.:TYM2L;8L
M)[VWB*,JMYDJK@GH#D]3VJS0!E:/X<TW0I[V;3XI4>\D\V?=,[AFP!G#$C.
M,GJ>Y-1:EX6TS5-7@U:47$-_#&8A<6MP\+O&3G8Q4C*YYYZ=JSK?Q#J.L:UK
M5CI+Z?&VDS"!X+H,9)F*!MV5(\M/FP#ALX/%6H?%=I;V^A1ZP\5EJ6J1AOLQ
MD'[MA&7?.?X1C;GU(]: &P^!M!M])M=-A@FCBM)S<VSBX?S(9222R,3E<DG(
M'!R<BM;3]+M=-$Q@5C+</YD\TC%GE; &6)]@ !T &!4LM_9P7,=M-=P1SR?Z
MN)Y &?Z \FBZOK2Q56N[J"W5CM4S2! 3Z#- %.70+&;7EUMO.%^EN;99%F8
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M>E>A>5'_ '%_*EV)Q\J\# XZ4 >;>"KBXLM;TC33/9:SISZ;)_9NJ6XVSPP
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M_:83!=VL-L+=8B"@C+$'=G!SO/&/2@#B[/6M)O\ Q-\.FMKZVF5=/N8G9'!
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M_ VLSWMK+=6JVK"6&)RC.IX(W#D#GD]AFO/+O4YG\1Z^VB:C;75_<>%5-H;
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M41236>CWK->+&I8I%(NTR8')"XR<=C74Q>(M(NDB-E?V]XTV/+2VE61G![@
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M\$[20&_,<^EW7M+\0^(? VJVG_"/VNG7EVL<<-I'<(Y!#AF9W  QQ@ 9_7@
M['2M3?4TN'?3KVR$4IC472!3*, AUP3\ISWP>#D"J-AXBM]:$ M[2[-E>>8D
M5VK*$.W(/*MN4G!QP#QV-;<3L\2.\;1L1DHQ!*^QP2*X+1_#-_8^);36+/3I
MM)+B5M7M8KA&MKQBIVE$W</NP<D+QD'/< I^ O%:Z?X2\/6M_:ZC(E[=2VJZ
M@^&3SFEDVJQ+;SG&-V",\9KI[CQK96UR5>SO#:KJ*Z8UUM4()VP!P6W%<L!N
MQU]N:Y>T\,:[!X*\,:6^G'[5INL)>7 $T>/+69W.T[N3AAQZ@TW6/#OBG4S=
M&XTV"[N8-:BO+6Y>[ 'V9)598T7'R$*,-TR><M0!U/\ PFD+^(+O1X-(U2:>
MSGAAN)$B39&)!E9"=WW<<GO[<4Q/'FEM>Z9$8YEMM4E\FSN\H4D?!*C ;<NX
M#@D<^U1Z/I&H)XL\4W5[9F&TU1;<12+*K?<BV-T.1STXZ=<=*SO"&E^)-(M[
M+0K_ $73A!I^V-=72529HD^[B/&X.0 "2<#D\]* .CTSQ+#JKVS6MG<M:7+2
M+%=Y0QDIG.<-N&<'&1VYQTK;KS_1_#%_9^)[/5[/3Y-(:3S6U>WCN%-K=L5(
M5D0$X;=@YPO&>O?J/#6JWVL:3]HU'3EL+M)7BDA282J"IQD.!@^GU!':@#*F
M^(%C;Z)J6JRZ;J*Q:;>&SNHR(M\;Y4;B/,QM^9><]#GIS6EJ?B:UTG[8UU:W
M7E6=F+N:2-5< $D*H ;)8E3VQQUK%U+P2VI>*M2>9D.@ZK:J;V#N]P@9%/TV
ML#]8UJ*TT'Q1I_PXNK2&[C?Q,\:H)]V 0FU% 8YP3&N<]F8F@#7/B^WBFU2W
MN=/O8;K3;5;R6 A&9XFW<J0Q!QM8$$CIWK./Q'LTTJ#5)=$UF.QN!;>3.T";
M7\\X7&&R<$X/'IC(()RT\.ZTFLZS>PZ'%;V^H:(+01B[5Y!,#)]\G[S'>,MD
M\#J3Q5F_T'69OAMX?T>/3RU_8M8^='YR #R&0L0V<'.PX^O.* -I/%Y>5+;^
MPM52]:.:7[-(D:L(XV"EMQ?;R6& #S].:B_X3W3I(]!DMK._N5UR-GM#%$O5
M4+E6RPP>,>GJ0,FFZ[9:W>>)+-DLH[W16M'1[:2X$:QW!8$/(.=Z[> .<'G'
M0US^@>&?$%A;^ XKK3E7^Q#.MT8[A&X:)HU(Y&3ELX';WXH T]5^(#Q^$[S4
M[#2KI;JVOUTZXMYS&&MY"Z+DX8AOOJ1@D'(Z#-;5SXIC@FNH%TV\FN+2W6YN
M8(S$7B5MV!C?\Q^4GY<_GQ7)WOA;7+K0/%5O'8JMQ>ZS'J-JCS(!(B-"=I()
MVM^Z/7CD<U:\4>'-0U^:2[329+/6HH%_L[4[.[5&@?GY)3D%D!Y(PV06P.Y
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M]WC(7)!W>K 8JIKVEZO;>-M,\3:5:K?I':26-U:>:L;[&8.'0MA205Y!(XH
MRO!6NQV&F:_/>_:PS^(9[>"WN)=\N[:F(]S,1P >=V, G.*TI_B1I5K8:M<3
MVEZ)=*FBBNX$".R>9CRW!#8*G/8YZ\5@/X2\3/87UU'96:7\/B)]8M;:6<.E
MPC)L:-CC"DJ6P?7'2M'7M+\0:_X)U"V&@6UA=W+P"*SCN$8J$E5V9Y!@<@8
M&>GN< &A>^(+*ZO]&74M&UBTE;5#!:&3$:F01L0[;7Y0J6P"#R.16A:^+;6Y
MEUR)K.[@DT7!N5F\L%@5W@KASD%>03C^=5?%.G:CJE]X9GM+)W6RU%;NX#2(
M"B"-UQUY.7'3C@\TS6/"]U=^-;+5;21$L[B#[/JD9ZRI&PDBP.YW;E/^RQ%
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M=GI-OJ$]EI2:9?:=/,B$@!2'C<Y7(93UZ@_EI:SX?FURRL(-6\/1RQXEE/\
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M7R\'=AB03N"X&1S0!6LA)XL\7>([+4K34(4L;FW6UFCG1&M<1+)P5<G+%CG
M.00#TP-R_P#$=W!X[L/#\>G326]Q9RW#S(Z \,B\98$ ;CGOR, TWPYIVHV?
MBKQ->W=DT5MJ-Q%+;OYB-PD2QG(!R#E<_C1JNF:F/'VDZU9VL=Q;1V4]I.#*
M$,>]T8-SU'R$8% '-^%O%*:!INH+>VNI7%H/$%S:M>DAT@W3[(PQ=MS#)49
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M$V.%)XW 8(S@>XK \1^$]4UFR\67T-F4O=8M(;*VMGE0%%3)+.0=N26/ )X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK"\3:Z^C+IEO;JAN]2O4LX3("50D%BQ (SA5/&1DXY% &[6
M9%XATF;5$TR.]C-VX<QQX($FPX?:<88J>H!..]8UOK>JKXLOO#%U);&X^PK?
MV=XL!VF/?L973=]X''((R#[<U/A5#-)\/-#N+MX)B(-T+"'#QY)W98DY)]0!
M0!UD>I6<VISZ;'<(UY;QI)+".JJV=I/UVFK=<7>:]J_]M^*],BEM8?L&FQ75
MK,L)+ L),[LMAL;..@YZ&LJR\4WN@^!_"5SJ=VJVEY:1F?4OLKR+;_ND*"3#
M'[Q)R_ XZ#.0 >DT50TBXGO-%MKB6>UGFDCW>=;<POGHR\GY3P>OXUY[-XU\
M6P^%+OQ.8])DL]-O9H;JU2*0/-%',4+(Q;"D 9P0<\G/:@#U&BN!\4^,=4T.
M/4KR(V?DVCV[06WEM*\T3E0S2%3^ZY9@N1U7OFK=SJ_B6Y\;W^A:=+I<4-M:
MV]VLD\#LQ5W960X;KA3@]O0YR #LZ*X6W\4^(=4@LM5TC3A<V,UX8WMS$%(M
MPY0R"0O]X8W8VX[=LG.O_&'B>WT?Q3J<;:7Y>@7[1&,V[YN(U6-B,[_D.'//
MS9/88Y /2R 1@C(IJ(L:*B*%11A548 %<;%=ZI-\6I;7[=']@31XKA(&A/R[
MY65@#N^\=@YY],=Z[2@ HKBK;Q=<7/BR;1)+JVL;R*[9%L;J!E:>W'22)RP#
MD]<#H,C'&:I7'C368/!FMZN%L3=:9J[V('DOLDC698\XWY#8;/7'M0!VMMJV
MGWNH7=A;7<4MU9[/M$2')BW9VY]SM/'M5VO.?+UV3XC^+QH,]A!<"TL&+7D3
M2*Q"S87"D8SW;)QZ'/#8OB3)-H^A:A>^7H]MJ$$HDNYH&EACN4?9Y;$$;5)#
M')/('44 =[-J5G!J5MITMPBWERCO#$>KJF-Q'TR*;J6K:?H\,<VH7<5NDDBQ
M(9#C<['  '<Y-8#:]J4'BGPYITYLGM]0L)IYGB4DB2-4)VMNQM)?T[=:Y7Q-
MK&H>)?A]9ZXDEO'IUUJ=J8[?RB7$0NE5&+[OO$@$C& #CJ,D ]+CU*SEU.?3
M8[A&O((UEEA'548D*?QP:MUR8U[51XK\1:8D-I,++3HKJT7F,N[>9A7<DC&4
M'.!C-4]'\4ZI>^)!H[3V<_FZ3]N2XCMW6-90ZJRJ=V)$^88(/;J: .V6-%9V
M5%#.<L0.6.,<_A3J\VL?$7CG4O *^*;4:,[/8_:$LOLTC,S*QW 'S!U4' ]<
M#GK74Z=KLFLZC8'3IX)=.DL%NYW,9W'><1!3NP,XD)!!QM'K0!T%%<_J^N30
M^)-+\/V1C2YO8I9WFD4L(XX\#A<C+$L,<\8/6N8U/QSK>GZ7K\/E63:KHM];
M02,8V$<\4[($8#=E&P_/+#(]Z /1Z*H:4FJQV\HU>>TFF\UC&UK$R*(_X00Q
M//7G/I7)-XNU:VUK28+G[&PO=3DL9K:%&<0+ARA\X':7P@)4\_-T&* .IU3Q
M!I6B\ZC>QVX 4LS D1AC@,Y PH)XRV!FJFH>-/#FE2^7?:M! 22%9\[6((#*
MK8PQ!." 21WKG=(M]2NOB)XRADN[)X_*LT9);-G4J8Y"HQYG09.?7VK"T;4]
M4T3X+PZW&UA<S6\SO$L]JQ*[[ET<[M_4[R0<#T.<T >H#5M/.L?V0+N(ZAY)
MG-N#EA&"!N([#)%.T_4K/5;=Y[&X2>))7A9EZ!T)5A^!!KF+D'_A<=GM(#?V
M!/@D9_Y;QU7TWQ1K%YX7%\_]G0S#5I;.>8@I''$DK)N52V6<[0 N>2W?I0!W
M C02-($4.P + <D#IS^-.KRS6?%.LZCX#UV6*YCMY[#64T]I1;,AFB+Q#E6.
M4)$N#]#TSQT=_KVLOJ5_I&FB.2]L+6.6246I97EDWE5VF0;5PG)R2<]L<@'7
MLP52S$!0,DD\ 54TW5;'6+3[5IUU'<V^]H_,C.5+*<$9]B*YNP\1ZOJNJ6>C
M-;1:7J0TY;V_64>=Y3,Q147# ')5CG/0 =3D1?"X2CPI<"<H9O[4O?,,8(7=
MY[YP#VS0!VM%<->^*/$%XFI7'A[3UNOL%ZUJMLT0_P!(V,%D_>%QL/WL<'H,
MYSQ%>^(O$TFI^*[6RDTR!='MX;F%IK=W9PT;N48!P,_+C<#QCH<\ '?54L]2
ML]0ENX[2X25[28P3A?\ EG( #M/X$5Q$>M:MJ_B[P?/#=16]IJ&D27K6S1%@
M&Q$3SN&3AR >W/!S5#Q'XDUNX\"^-W6XM[:XTV^:S26"$@M%MCSU8X8[SS^0
M[T >C3ZE9VVHVFGS7")=W8=H(CUD" %L?0$5;KE[O5]4L/&/A[2)GLYH+^*Y
M:61(&1@T84C;ES@'</7IUYK-LO%/B'5H=+U72]-%SIUW<A98#$%*6Y8CS!(7
MY88!*[>Y';) .ZHKBM'\73ZEXG;29KFVM+R&ZF2?3;B!DE,"[_+DB8MA\X0G
M /!/3'/:T 5(=2L[C4KK3XKA'N[54>>(=4#YVD_7!JW7%7'B75X=4\9VR"R_
MXD]C#=6C&)OFW)*Q#_-S]P#C%0Z5XFUY]4\)C4#8/:Z_9M)Y<$3*\$BPB3.X
ML0P//&T8XY/4@'=T5B>(-:DTR?2K&V$?VO4[K[/$\H)6,!&=F(!&>%( R.2*
MRM0U_7-!@\G48[.2>\U2&PTV= 0KB3G=(F>"N'X!^; Z9S0!V%%<3?\ B;5]
M(UK4M&G-I-.NE2:E8W/DLJG8</'(H;KG!!!'!]N:^E>*/$$MYX1>^;3VMO$%
MHS&.&%PT$@@\T-N+?,#@\8&..3U(!WU%>:?\)EXFCT*;6Y3IAM[/63I\\"0/
MNFC^T"'<K%_D(SG&&S^E:NH^)==NY-97P[9K/)IEP+=(GAW"XD"*[ OO79]_
M X/(SR#B@#MJ*Y#^W=;UB?6+71H[6UN],BB!ANU+^9</&)/+)# *H!5<C/)/
MIS6BN]<F^*,-K-=00Q#0UN&M?*+JCM* X#!ADY4?-CIV[T =;8:E9ZI%++97
M"3I%,\#E?X9$.&7\#5NN L_&]^='3[1':?VC<Z_+H\!2-A$-KL-Y7=D_*C'&
M>3@9%3:EXJUC1]2UO2)OLDUU;:0^K65QY+!'1"59)%#=0<8((X/3CD [FBN&
MTOQ+KIUCPLFH-8/:Z]9O((X(F5X)%B63.XL0P.3QM&..O4ZWC/6=0\/:5!JE
MI]G^R0W42W_G1,Y6!G"LZX88*YSSGC/I0!T=5&U*S358],:X07LD+3I#W**0
M"WYD5R7_  F%[%XE\2:3,]HYL[5)].\N!@9BW!4DOAB'*+QC[PZ5=_M?6(O&
MUGH4\EBRS:3+<F5(&!$RNB]"Y^3YB<=?>@#>U'5M/TE(7O[N*W$\JPQ;SR[L
M<!0.YR:NUXXUUJE[\*--O+ZZCNYY==A*$H4.X7Q!W')X)QC &!QS7=Z%K&JO
MXMUC0M5DM)S:P07,$UM"T7RR%P58%FY!3KGG- '445S.N:WJ.C>*=$BD-J-%
MU"1K620Q-YD<Y4F,;MV,-@CIUQZU3F\57Z264*&U+ZMJ<EKI[&)@$A0,6D?Y
MOF)V';C&=RGUH [*BO/M9\9:SH?_  DUA*+.2^TO3AJ=I.86V31<@JZAN&#*
M1D'D'.!6O)K^I#Q7HNEI]E$&HZ=-<DM$Q9)$\O'.[!7Y^F,\=: .JHKCO VL
M>(O$6FVNKZB^FI93),AA@B<2>8DI4,&+$;<*>,9Z'/. SQ1XNGT;7#IKW-MI
MHFM0]C=7L#-!<3DL#&SA@$P O7KN]L$ [2BN-U3Q%K-Q?:U9Z!;J]QI:HH5X
M?,$TS1B0*3O7:N&49YY)/;!K2Z]XLO?$L>C6<6FV$TNCQZ@5NXFD,,AD"M&Q
M5\-T(R,?C0!U>IZ)I^LFV-_"TOV:43PXE=-D@Z,-I'([&I3J5DNJII1N%^W-
M ;A8>=QC!"EOID@5RL'B?5X;WQ+IE^;,ZA8^4VGB.%E6=)1B,D%SD^9E#C&"
M/>K$WB*^TWQF=-OVM9+*/1)-0DDBA97WHZJV,L?EP20/UH ZVBN5TG5/$.H6
M^BZOLL6TR_@\^YB *O;(R;XRK9.\] >!UR,50TWQ/XBU9-$U6QTT3Z;J$BF:
M$Q!#! X)602%_F*\9&WG)QC% '<T5SOC75M2T'PY+JVG+ XM'22Y26)G)@W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)"%S_=6JFJ:)?ZYX<FN],\*6NEW<-S;W,=E<+$KWAB;<R2%,J%(.%R>N<XH
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M;70[.W?RS)-=7*6L*[6;YVR<D*"2  QP.N,>] #/^$0\-?\ 0OZ7_P" D?\
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MY!JFM:1<06$5W!I?]HVDL1>1 NYE*N#@D@KU&,Y[4 ;7_"(>&O\ H7]+_P#
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MD#&<#T%:M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW%UXIN=8GOHO*N-+_LUX$@((&YFWABQ[L>,5TU% '$6W@6]MM.\.[=7A;5-
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MGEF.<#EC[5AC1+OPSK7B7Q+%>B2RO8?/DT^WLRT@>-,!D._!8XY&WGBNRHH
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MW-NRV' /3@=><UU$8=8U$C!G  9@,9/KCM3J* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDDD,H,G#?.<$[EXZ >G2@#J[#QOI&I7EA;0?:PVH6YN+1Y+9D2<!0Q56(P6
M.2*EM?%VEWFB7>KPBY-M:2M#*&A(<.IPR[#SD'C'Y5S%IIFIQO\ #G?IER/[
M*MVCO3A?W)-MY7///S>F>.:MG0KB+XD30VSI_8]ZL>J7D/=;B,[5P.P<A&]S
M": .QN[^VT_3Y+Z\D\BWC3>[/_"/3 ZGM@=36'>^(K:^MM7TR%[NRU.WL6N0
MCILD"$':ZGD8R,>H[@4[QWI%_K7A&ZM=+V&_22*X@1SA9&CD60*3[[<5!'J>
MJ:WHM_)+X=N].8V;Q>5<%#++*1P$VL?E'/+8SD<#!H A\->)$A\'^%DO'N;S
M4[_3(YEC7YY9=L:EW))_VAR3R3WJ:]\2:+J.G^'[Y-1OXK>_OHA:/:JZ"63)
M CDXX4G.5.,[?:L'3;77[+3/!]A/H]Z]E;Z9]GO$MG1)4G54 #-N!$?#?=/)
M SQQ5#3]$UNW\$>$M.ET6Y2XTW6TGG0,C;8EDD8N,-R,,,#J>>* .QO?'>C6
M4NJ1LM]*^EE?MBQ6<C&(%=VX\?=V\YZ8Z9JQ:>,-(O=6M-/A>XW7L;26DS0.
ML5P% 8['(P2 <_2N=ET[4CJ'Q!D&FW)34[>-+,X'[XBW\L@<\?-ZXXYID&FZ
MFMS\.V;3;D#2X&2].%_<DVWE#///S>F>.: .TU/6+72FM8YR[3W<ODV\,8R\
MKX+$#MP%)R2!Q5*+Q;I$ND'4A,ZQ"Y^QF-HR)/M&_9Y6WKNW<>G?IS53Q:=6
M%SHWV&RN+JQ^TM]N%HRK.J["%V%B-HW'YB"#COUKB6TK4+'PK?6EQHMXEW_P
MDIO-/2*:-I&S+Y@:,%L.50-D-C(SZ$T =X?&NC1/JD=U)<6LFE1^;>K-;OB%
M<9&7 *G(Y !)/;I4]OXEL;JXO+-TN[>ZM8%N)(7A/F>4V=KJ%SN^Z1@<@CD5
MQ?VO4);?Q)+I^AZG#XGU*V615U&WB2*5(L)MC =ERH<G#'DMW' N:19ZC;^.
M+K53HNIQV5SH\<7F74R22^8KNQ##>3D[A@#CZ=* -/3?%NA:=H&@XOM2NX=1
M799SW$4DLLV 3\S <L0#@=3V%:%IXPTJ\L+BZ0W$;6]T+.2WFA*2B9BH5-I[
MG<N#TYZ]:XS2-%UBUT#X?6LVE7*S:5<EKU?E/E+Y<B9Z\\N.F:M2:+-<W/BR
M/4M N[JPU'4H)4",%<QK&BF1"&!#*R9['CC- &[KGC6/2M-2XBT^\>8ZC#8/
M$\6#&SLF2>>1M<8QG)Q[FMK5=732_#]UJ[VUQ(EO TYA5?WA &<8/0_RK@+G
M0O$?_"+36Y-[JL-GK-K=6/VDJ+N6WC>-F#9QD@A@-V"0/I7=ZU;W&J^%-1MH
MX#'<W5E+&D3L,JS(0 2#CJ?7'O0!QUYXFN9[_P !ZH\E[:PWID-S:QJVV4FU
M9QA!DO\ ,1CKVKJK'Q9I5_ID]]&T\:P7)M)8986659L@"/9UW'<N,>HKE+:R
MU>1_A^\FBWD(TK<MV'*$QC[,8@>&/!8]N<<\51O/#VN3V^O7%OI)EF3Q$FJV
M]K<%0MY"L:HRY)(!.&QN]!0!Z#I7B"RU:\O;*(2Q7MBRBXMITVNFX94^A!'0
M@D5@-JUWXA\?ZAX>MKF6UT_2((GO'A.V2:6491 W55"C)(P2>X[Z'AA5G>>^
M7PNNA>8JH1+%&L\I&<YV$_*.V3D\\#OE3:7J'AKX@:AXBLK&6_TW6((DO8[<
MKYL$L0VJX4D;E*G! YSSB@#<2RN-)U0WCZK,=&CM)#+%=2!A$X*D/O/S$;0^
M=Q./QI;?Q5IL][:6K"X@>]C:6S,\)47"@9.WWQSM.&QVJEXAM+[Q=X5U;2[>
M"2Q2ZM'BCDN1M9G(X^4$D+V.>>>!69)8ZEXC'A1;K3+BPFTFZ2[O6DVX5DC9
M=B$$[PS,#D<8'.#@4 :#?$30%MOM1>\%HMT;26X:TD$<,@;9B0D?+\W'/XXJ
MW%XRTF2XOX'%Y!+90?:I$FM)%9X<D>8BXRRY!' KBKG1=9D^'>OZ<ND77VRZ
MUN2ZAA^7+1-=+*&SG ^4'@G.:V-:M;Q_&6HZG]BG6P;PW+;>>P  DW%]I&<]
M.^,9XH U+#X@Z#J%]IMK%)=)_:48>SFFMG2*8E=VQ7(P6 [>O'7BK4/C'29K
MNVA1YO*NKF2S@N?+_=23)NW(#Z_*W) !P<$UQ^BV%QXD\&?#^UCLYX5T\V5]
M-/*H"JL47&TY^8N2.G0$YP>*@DL/$MZ^B7-[H-Z]_8ZZ9[C9-&L B_>A3$N_
M&,,I)(!)SDF@#J[CXAZ#;QWDKF],5C<_9KN06<FV!OEY?CA?F')]\<"M:+Q!
M93>(Y="43"^B@%P0T9"F,G 8-T(SQQ7!ZAHNKW'A+Q_91Z5<FXU6^DDLTPO[
MU6CC4'.>.4/7%;/C"POV30M:T9A;ZQ#*MFJS#[\4P"NK#OL.)/\ @!H ZS3=
M2AU6T-S;K((Q(\?[Q=I)5BIQZC(//>LV7QAI,&R21Y19/<?91>^6?(\W=MVE
MNWS?+NQMSQG-:UE9PZ?I]O96X*PP1K$@)R< 8'XUYI#X:UA_AE/X!N;&;[4)
M# E[P87A,V\3;L\$+_#][<.F.: .QE\:Z3'K4^D*E]+>6\T4,RQ6<C",R9VL
M3C[O^UTYI?$_B;_A'I](A%G/<-J-ZML&C3(3@L?J2%.!5/0;.\MO'_B>ZFLY
MX[2[2T6WG?&V0QHRMWSU(ZCFG>-[&^N3X>NK&REO/L&KQ7,T4)4/Y?ER(2-Q
M ."X[T 8\'BD:)XO\8-J,VI7-G;):2QPI$\WV=#&S.=H&%4=3].^*ZZX\064
M44+0+->--!]ICCM8][&+CY^W'/'<]LUR<FGZF^I^/9CI=R%U*RABM,;3YKK"
MR,!SQ\S#DX]:S(=*U71[C0=3N/#$FKVIT2WTZ[M56-IK6:+)# .0"IW,#@]@
M: /1M+U2QU[2(-1TZX$]G<INCD7*Y'0^X(.1Z@BO+?[=OX/#/C"_?Q/=PZAI
MNK75MIT;.C^8(\>7%L*G?N)V^O->GZ+;BRT6%!IL&G@!G%G;*H6($D[<+QNY
MYQQG.*\ZT[P7?:A8^()6M)=+UL:[<:II-Y(JY ;&P$@GY6Y#*>QZ4 =[9ZS+
M'X?TJYU:W:'4;R&/=:1J2YF*;F0#VPW7H <FN9\7^)DU#P1>7NCWMW:W5EJ$
M%M.@S%)&YFC5D8=?NMV.#GK4.MC7M7L] UR3PP\MWILK?;M(E:-O,5TVLT9)
M*L5(!&<'%)K^F76I>!KQ-,\*G3YKN[MI%LXXXDF8)*CL\FT[0<*<#)/ ]<
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M&]E>,PR1*3R-N=AP"#U(/0=:LCQ3K=M?:IINHVFGP7UKI::A!ME8QS=1(-Q
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MR*PO$FJWOB#0_"NLBWMDT^ZUVRD@0Y\Y(S,-C$],L,94 8SU.* /4:*X2_\
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MSWH ZZVO;2]\W[+=0S^3(8I/*D#;' !*G'0X(X]ZGKC/ *+'?>,510JC7Y<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO&$(D#%F^\<8&  028[G4)K+X@3:DXBN)X?"33D0DE)&$N[Y?8D<5T&H>!-
MU+5EU.XMIOM?EK%*\=S(GVA!T64*PWC_ 'LYZ'BM'_A']._M[^VO*D^W?9_L
MN[S7V>5G.W9G;C//2@#E=%.NW0T#Q -6MEL+B /?"6\:1+@.F040H%C8-V4C
MC(.>M4-'U?4AXA\([=1NKRVU1;H7%S*=L5WMC+J\<1)\M01Q]W(['K74:1X#
M\/:'=O/86;H&+%8&G=X8MV=VR,DJN<D<#H2.E,L_ 'AVQ;3V@MKC.G2,]IOO
M)6\D,""JY;A,'[O3VH YS3O$=[8:JMKKBZA!J@CN9HB)#)9ZFJJS#RB#A"%
M.W XZY-6=#D\0:C:^'O$<6I6XMKB)9+Y&NWD2X#KPJ1E (V#$  'V.>M=19>
M&-,L);1XUG<6886J33M(L.X8.W<3V)'L"0,"JND>!?#^A:BU[I]I)$Q=G2'S
MW,,3-]YDC)VJ3D\@=R!0!SF@7/B'Q!IGA_Q+;:C;P)/*LEZLEX[1R1,2K1"+
M9M5U) !!SD<DYJ31M:O(O%5IINO&_M;Z:>=K>=9#)9:A'ABH3!PC*N#C /R]
MR:W[#P+X?TS6)-3L[22*5Y#-Y(G?R!(>KB+.P-[XX[5:M/#&FV<MLZ+.XM7:
M2VCEG=UA9@02H)X.&8>P) Q0!LUYWY8L?BAXDOQ)=2M;:/!<B(3-ASNF.W'I
MQP.U=5X7T%/#FDM8QL_EF9Y4C>9I?*!_A#-R?7ZDU-%X>T^'7I];1)A?SQK%
M(YG<JR#)"[2=N!D]N] '"R:UJD'@;P[XO@U">>\NIK4W=OOS%,LSA6C5.BE2
MPP1S\O.<FM/P[#J>J>*M?-SK^HF#2]5"PP*4".AA1BC_ "\KEN@QT]:WK+PA
MHVGM$+>"1;>&8W$-J9F,,4A).Y4)P.22!T!.0!5K3=!L-)O;Z\M$E6:^D\VX
M+SNX=\ 9PQ('  XQTH R_$&J2+XL\/Z#Y[V]OJ*W,DCQL4>3RE4B,,.1G<6.
M,'Y?<U@>*K.ZL/#5E:W6JMJ+)XCLS&[KAXHS.C)&QR=Q (^8\D$5V&O^&M+\
M2VL4&IP,_D2"6&6.1HY(G'\2NI!!J";PAHUQI5OILD$QMK>=;A/])D#F53D.
MS[MS-GG))H X_P ::SJ%E;>)-0T[4[F6;3I;?R_)/EPV?W-T;C.)6;<2>#@,
M.16^]U?-\4WTT:A<+9R:&TZPC;B.3S@NY>.3CUS5F^\!>'M2EU%[FUF8:B%^
MU1K=2JDC*  Y4-C=@#YL9XJZOAG3$U9=41+@7BVOV,2?:I/]5G.,;L9SSGKG
MG- 'G.GZAKK^#O!VMMX@OS>7NI1V<^XJ8VCDD=#E<8+# ()Z$>G%;*3Z];:C
MXRT;3=1FNYK:*TFLOMLPW!I=V] ^.,[<+GH371IX(T*+2K#3$@N%L["X%S;1
MB[E_=R Y!SNR<$DX)QS4T_A'2+B[O[N2.X\^_$0N'6ZE4MY9W)C#?*5/0C%
M&?X+UF'5)M3B']IVUU;M&)].U$EI+4D'D,2=R-@D')Z'V%5=;U67PKXUM=0U
M"^G_ +!O[>2+:[DI;W*#>./1T# #U7WKJ+#2+73Y[BXB$CW-QM$T\KEG<*"%
M&3V&3P/4GJ36-JUM>Z_K":3=Z*%TBVN(;K[=+*C"8IAPJH/F!W@ D\8#>HH
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M1W$LOGR1K.XA>7_GH8L[2V><XZ\]>:?)X+T.:RU2TD@N&@U60RWJ&ZE_>L0
M3][C@ <8Z"@##MK?SOC'+*UQ<C.APS>6)FV F9P1CIC@<>O-=?I5A)IUF8);
M^YO6,COYMR06PS$A> .!G ^E5?\ A&M+_M:UU3RIOMEM +=)/M$GS1@Y"N,X
M?!Y&[//-,\,: GAW3Y[6-I/*EN'F2)YFE\H,!\H9N3D@M]6- &U1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)+$ZR1NH9'4Y# \@@]Q3JX7PWX@U&TE\+Z/>V-NEIJ.F;K66.8M(K11H2'&
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M&A:9XEGL8AH=]+&APY\Z".1ML<K=B"2N5'3=U.* .VILDB11M)(ZHBC+,QP
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MBDN&?=F)>P9< 'KR>@'- ':T45S\^NW5UK]]HND1V[7%A;QS7$EPQ"AI-VQ
M!SDA22>W'!SP =!17 Q_$*\O[?0'T[2(C+JES-9RQ7%R5-O/&KEE.%.5RGWN
MN.V:[33GO9-.MWU&&&&\* S1PN716[X) )'X4 6J*P;K7)Y?$<N@Z8D!NH+4
M74\LY.Q S%47 Y).UCGL .N:R]-\=_VO%86L%FL.KW-U<6DMO*^4MW@_UI)
M^8#*XQC.X=.< '945RP\2ZG +:ROM+2#5;N_DL[9?-S%*B*7,^1R%V@_*><\
M>]5]1\4:WH]BTU_I$*E-4AL@XE^6>.1U42IU(QNY4^G6@#L:*Y#5/%]YINH^
M([5;"";^R=-744)F*>:IWY4_*<$>6?KGM5:U\::O'J>@#5=(MH--UQ0EM/#<
M%WBE*;PLBE0 & .,$X[T =Q4=Q<0VEO)<7$T<,$:EGDD8*J@=22> *X^W\9W
MHU[1]/O;*W@?4Y9HOLPES-:E%9T,F,@[E7..,9[UE6_B36/^$1\9:EJEG8:C
M%87=W$;9W8(R1  I@J1MP.G<D],T >D(ZR(KHP96&0P.01ZTM<TGB&6YU.UT
M73(;=;LZ<E]*TN?+B1CM10!R22&], =\XK'/Q"NY+"PD@TB,W<FLG1KR![DC
MR9QG.T[?F4@9SQP1P>E '>TV26.&)I975(U&69C@ >I-<C;>*]79?$-I+H\,
MVJZ3)$JPVLY,<RRJ&4[F (P"=W'\)Q5<^(QKMGXNT>=;2X&GV2N+BW.Z.99(
MW(X.<$%".I[4 =I#-%<P1SP2I+#(H=)$8,K*1D$$=014E<_X$_Y)[X;_ .P7
M;?\ HI:Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBJFIWQTVP>Z%I=790J/)M4WR-E@,@9'3.
M3[ T 6Z*R3X@M1XG;0/)N/M8LS>[MGR% P7 .<DY/3%.T#7;7Q'I0U"TCFCB
M,LD6V90K!D<HW )[J: -2BBB@ HHHH **** "BBB@ HHIOF)YHBWKYA7<%SS
MCUQ^- #J**J:??&_CF<VEU;>5.\.VX3:7VG&]>3E3U![B@"W7('PKJ4,_B&*
MUO[=;/7)3+([1'S;<M&L;!><-PO!.,$]#TKKZ* ,FPTRZTRZM+6TF@30[6Q6
MWCM3&3('4@*V_/W=HQC'6M:LK4]?M=*U/2[">*=I-2F,,+H@**P4M\QSQPI]
M:->U^U\/6D%S=Q3O'-<1VX\E VUG8*I.2,#)% &K1110 4444 %<SKGAV^U/
MQ9H&LP7-O''I#3-Y3HQ,OF)L/(^[@>QKIJ* .<O_  [=+XNB\2:7/"ER;7['
M<V\X.R:/=N4@CE64Y['(...M9EUX%G&DVXL;V%=4BUDZR\TL1\J68[@RE0<A
M=K;1SG@5VU94VOVL'B6UT%XI_M5S!)<1OL'E[4(##.>OS#M0!0T#P]J&E^(=
M;U6]O[>X_M,PL8XX"FQDC"<$L>.#QR>G-:?B#3Y=7\/:CIL$B127EM);B1P2
M$WJ5S@=<9K1HH Y!?">H?;O"TYO+=1HEM);OM1LR[XUCW#^[@*#W]/>L[3/
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MC#B-1(RL^!N*K@$^PR<?G69K>OVN@K8FZBG<7EW%9QF) 0KR,%4MDC R:U:
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M"K9QC@-TZBNRHH X^S\,Z]>:/<:1XGUN"^LWMGM5-K;F*24,I7?(2Q!8 G
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M&F6VL"VNK>Y67R9+&S:\+3J ZB9!(Z#[RY"DYPQ%:?@O6;?5X=1\J74%EAN
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ML)V^9%!"@#H,!CTQUJA=?#[0+K3=,LC%=1#3%VV4\-TZ30KC&T2 [L8&,$T
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M!HEIJUF)!;748DC$@PV#ZBH]5UZTT>\TVVN4G+ZC<"VA:-,J'()^8]N%/Y4
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M1+%#&D<:#"HB@!1Z "GT <I/HM_J&JVVN:PEI#+IUE/%#%:RM("\H4.Y9E7
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M$N[=N"]OF^;;G;GG&:Z"@#SQ=7U33=0\0>&KK4IYM3FDCDT>=PNXPR_*"
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M&,Y1LY^\#W[=!BI[CPAI%]::C;ZC$]]_:*)'=23M\SJF=@RN,;221C')SUH
MY?6]3\2^#M.UB_N+RUDM)5A2QCEG,TEO*\BQLQ)1<H-X;!SR,=#5B2P>R^+>
MA!KZYN5;2KO_ %[!B&#Q9(( QGCCH,< 5M6O@?18-&N]+N%NK^WNXQ%,;ZY>
M9R@Z*&8Y4#J,8P>>M%AX*TRQU&QU#[1J-Q=6430P27%Y(^U&QD$9P1\HZ_CF
M@"QXOUJ7PYX0U76(8A+-:6S21H>A;MGVSU]JP+Z]U/0]2\+2Q:G/>V^K3"SN
MDDVG+-&SK*F!\N"IR!\N#T[UVMS;0WEK+;7,22P3(8Y(W&0RD8((],5D:=X5
MT_33:>6]S*MDA2S6>4R"V4C'R9]N 3D@< X)H X%=7\01>%CKKZ_=RS6FOFT
M\DI&(Y8OM?E$. O)VGMC&!@=SZU7-'P-I!T>32BUW]CDNOMC)YYR9=^_=GK]
M[G'3-=(HVJ 23@8R>IH \].KZII6J>(?#MWJ,\VH7'ERZ+-)MSY<I$8   SY
M;Y+9YVX-:%I=7>M>*=>T+^TKNVCT>"V2.2(J))))$+&5CCG&  ,;>#D'C%JR
MM[C7O$UOJ^HZ&^G_ -E">*U:X=&>1G(!==I.%VKWZ[O;)T;SPW97>K_VJCW%
MK?&'R))K:3898\Y"L.AQS@]1G@B@#BO#_BK6=5O/!,EU<%&O7O[>^C10(YV@
M5@K@8R,E<\8J#4->UV+PQXAF@U>=)['Q(EE Y1&_<L\*[#\O(^=N1@^]=M>>
M$-(N[/3;9(YK1=,;=:/:3-&\65*D!AR002#GK55O &A-8WED%NU@O+L7DZBZ
M?YI000W7CE5/J<<YH VM*L+C3K:2&XU*YU!FE:02W(0,H/\ #\H P/I6 ^HW
M&L>.]2T#[7/:6UA8Q3#R&"O*\A;YLXZ*% QTR3G/%=8B[452Q8@8R>IK*O\
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MU1$8,ABD;/()R"HQV]0:YV>77%B\<6:^)-0 T-1<6DNV+S"6MQ+M<[/F4-V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>josetrevejo-tarsussepara004.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K*U_Q#9>'+2&ZODN&CFGCMU\F(OAG8*,^@
MR16K7+^/-.O]4T2UM].LWN94U"VG95=%PD<JNQ^8CL* #_A.;0WE]8KI.KM?
MVB+*;46P\R2-LX=?FQM^4]2#GC&>*CN/$>B:FOA:\66_,>HW >Q:#<B,Y1CM
MEY QC=\ISR*2&RU*/XBZCJYTR<V4NE0VT;B2++2([L1C?GHX&3WS7.Z7X<UZ
MT\->!+*7291/I%]YMX!-$0B!)%R#OY^^.GH: -*RO1:>(?B +VXOI+&V%NP1
M)7=XE:#<_E\Y7DD\8Q5B/Q7]DD\'Z=IFG7UU9ZK:^;'-+(AD,:P[@"6?)?E2
M2??&2>(O[)U8:KX[G_LR4QZI#&MF?-B_>E8/+/\ %\O/KCC\JK6^B:Y:1> +
MA=+:271[5[6\A\^,%"T"Q[L[L%0R\XR<'H>E '0-XTTU;M(O*NC ^H'3!=!%
M\O[1G&S[V[J"N=N,]ZC/CBR?5KK3;73-7NKFUN%MYQ#:Y$99=RL22,*1CD^O
MIS7*:CHWBK4)(9;O17N;RRU^.[2?[7&(VM5DRHB4M\I"XW9 )QG+5T_AJPU*
MU\5^*;R\L'@M[^XAEMY#(C!@L*QG@,2.5)Y X_*@"W9^+['4/#D&MVUO=M;S
MSBW2(HHE+F3R\%2W'S<')R.M:6I:K!I:VPE5WENIA!!$F-TCE2V!N('W58\D
M=/6N5TK09;;XA:HL4R-HR,NI+ !S'>2JR-^&T%\>K@UK^+]+BUC3;:RN-(?4
M[5[D&98I!')  K$2H2R_,&VC@YP3UH LCQ%;FVA<VEVMS--)!':,JB5G0G=_
M%MP I.XMC&.>1G+;XAZ+'9)<21WJL=0&F2P>1N>&<D#:^"1W!R"<]LUS4WAG
MQ/;6.D7SV_\ ;LFEWERJ6.H2QF:6SD "[G/RF1=H.2>G?M6AJVE:M?Z5I,EK
MX:CLWCUFVO9+."2$-'%&P+%SN"ESS@ GMS0!O67C&VN]5L=-ETS5+*YO4E>%
M;R!8\B,X;^+Z'W!!Z57UW7M,>RA-['J<,(U6*UC>W.W?,) HRRM]S=P<]<$8
MXJ3QIHU_J>G65[HZH-9TVZ2ZM/,. W\+HQ_NLC,#^%5/%6@WK^&=)T[3+62\
MDMK^UGE8.B%A'('=SN(R3@GZF@#4U;Q;8Z2M\[P75S%IZJU[);HK"W!&?FR0
M2=IW$*"0,''(RNI>*[+3H;B9+>ZO([6 7%RULJGR8R"03N89X!.%R<=N1G!M
MH/$OAWQ5K1LM%&I:=J\ZW<4PN4C^S2[%1ED!Y*_(""H/T-5[S1]9TOQC?WP\
M-VOB&SU1(69]\4;VTR($.1)_ P /&2.>#0!WEE>6^HV-O>VDHEMKB-98I%Z,
MK#(/Y&L[4_$5MIM^+$6US=W9MGNS#;JN5B4@%B691U( &<GTJ"VU*^LM<L=#
MFTA$MI+/S!>6\BB-9%^]&(_O!1Q\W3D#O6?XBM=<N_$L44>GM>Z))8NFQ+A8
MU2Y+?>E!(+)MQ@ -SGY3Q@ LOXZTD?V+Y,=Y<?VS"TUGY-N6W@)NP?0X[=N^
M!S4EIXSTNZT:742ES"8KLV+VLL>)A<;@HBV@D%B2,8.,'.<9KE- T#7[1? "
MW6CR1C1H9XKLB>)MFZ+8I^]SSSQGCWXJ&X\,>(C;WMY;Z:1=6WBC^V;>VDGC
M NH=@0J"&(5L9(S[4 ;>B7]Q<_%36H)$O[>)-,MW^S74NY5<N^60!F4 @+T/
M;UJ.^U2;2OBK.JIJ-Y$VAK*ME;EI,OYQ!95)"J< <\?F>;6D6^KS_$.\UJYT
M>>RLKC3(;=3--$75TDD8@A&;^\.A/]!.UCJ*?$Z35QI\KV']CBU$RR1_-()2
M^ "V>AQG'7\Z +4'C+3+RRTBXL8[FZ;5D=[6"-55V"#+YW$*NWH<GKTS40\<
MZ6VF:3J"07CVVIW(M(F$:CRYMQ38^6&T[E89Y''7D9Y;0]'\4Z7H/AC39](F
MDL[?[2NH6T5U$C;F?,3%M_S1\G*@Y]0>E7-&\'W]S\+[SPSJ5HMC="6X:V=)
M58*YF:6*12O0 E?0\'@4 =?=:_:64]Y'<),B6J1L\NT%6:0X1%P<ER>,8[CU
M&8M-\26NH:S=:.\%Q::C;Q+.UO<!<M&QP'4JS C(QUR#UKGM3\-ZUJWP],4@
MM_\ A(998=0ECDYB:=&1A$W8KA GIQFM3PNMY-(UU=>%K;02(]A0/$\DC9!.
M#'P$&._)ST&.0!U_XSLK+5KW2UL-2NKRS@6X>.WM\[D8D94D@'[I_ID\58B\
M5Z==6>ESV0FNWU2(S6D$0 =T !9CN("@9 .2.2!U-9@T_4HOB!K&J?V=,]G-
MI<5M%(LD?SR(TC$8+9'WQR<=ZY[P[X:U[0$\):DVG222Z?I\FFW]FLL9=58A
MA(AW;3\RC(R#B@#=U?Q]%;^'FU#3;*>>=+^/3YX'VH]M*TBJ0X+=?F&,9!R.
M<<U:\>S3_P#"M];NHVN;.XCL9)4*2[)(V"DCYD/\B17/:KX1U:XTO7]0M[,F
M^U'5K2^2Q\U PC@:/@MG;O(1CUQR!FNL\4:?>Z_X&U73X85BO;RRDB2*1QA6
M92 "1Q^7% %/1O&=A<:A8Z+/!?VMU/;;[:6[@*1W6U06V,>20.>0#CFK"^,M
M--[IT+Q7,<&IN4LKQU7R9VQD 8;<,@$C< #VK*ET2^\1W>@->6$^G0Z7'(TA
ME>,N\C1&(*NQFX&XL2<=%Z\XI>#M)UG38+'1M1\*6$3Z?MC_ +85HF69$X5E
M4?.'( '.,<G/8@'12^,]-AN+(2QW*VE]<_9+>]VJ89)<D!>&W#)! )7!QP>1
M5*3XC:1'!<W!M-3^RVEZ;*ZG^S82!\JN6R<[<L.@)]0!C.-X2T/6=%2WT&\\
M+6$BV4N(M;+1%9(0V0VW[_F8X],\YJO?>'->N/!'B_34TB7[7J6K27-JAFB^
M:-G0@D[\#A#P?:@#T35-3M](L'O+IB(E9$ '5F9@JJ,\9+,!S@<\UEWOBZVT
MVSGN;ZPO[=(+F*VD#(A(:0J%/#$%2749&>_I4_B.V.H^&Y[=](&HI/Y:RV,C
M*I9"Z[\$L!N"Y(YZ@<UQ-SX2UX>$-;TRT-W<6JW5K<:7:7]PK3*L;H[IOR1M
M)7"[CQWH Z;Q'KD$MKK^BH;NWO[;2WO%DC;9\I#!65U.0=RGTZ5G>%/&MG_9
MWAK2KZ'48KB\L85AO+F B*YE$0+*')R6ZGD#/8FH9M*UW5_%&KWSZ0UG;7^@
M?88S-/&627=(<.%)Q]X=,C&.<Y =9Z%J>IZ5X0TV]TZ6Q70Y()[B662-M[PQ
M%%6/8QR"QSDXX'J<  U='UW1X[;6[N"2_P!L>J-;S)=%BQN"$ 2-2<A264 <
M#)/;FIT\::6LNIPWBSV-QIJ))/!<*"Q1^$9=A8-D\  DYXQFN+&AW^LZ1XL7
M38X9+RV\4F\@@N/]7.8UB)1L]B,CZUHZCH>L>(O"UXMKX<M/#]^IAEMXG>-F
MEECD60!FCX"?+@<YR<D#'(!MZEXWBL+76,Z7?"_TRR-\UK+L4R18/S!@Q7 *
MG/.>.AJS8^)6ETG39)["Y;4+RW$RVD?E[V4*I9QE]H7+#JP/(%4;D^(?$_A3
M6+.[T4:3+<:=-;QPS7"2L\KH0#E"0$'J>3GH,<X5UH^OQ'P[K(\-17[VE@=/
MO-+GFB,@7Y")$8DID,AXSR"/? !U5IXTTJ_TZTNK3SYI;N=[>*T" 3>:F=ZD
M$@#;@DDG'OR,Y?@2]GN]<\7+*;U4BU)$CANY"[1#R4)4<D 9)(P<<\54O](U
MN#5/#WB.QT.%39/<+<:3;21JZQ3*HW!B0C."@)Y .< G&3J>$K+5+?7_ !->
M7^FO:0ZA=QSV^^5&) A1""%)P<J?_K]: )++Q>TWB+Q#97EC):66CK&9+F1T
MV@%"Y=L-D KC& >G..@N6_BNREU"PLY[>[LVU%"]D]PBA9\#<0,$E6V\[6"G
MVX-<SJGA35=3U+QO8_9_+L]=MX?L][YJ[49(=FUESN^\!VQ@GG/!MMI>K>(3
MX774M-DL'TFY6[NI&D1E=TC9 L>UB2&9LY(' ]>* .FU/6[?3+JRLVBFN+N]
M9U@@A"[GV+N8Y8A0 /4]ZR6\>Z.NE:9J.R],.H71LXE6W+,DH9E*L!T(*L.,
MYQQFE\41:U)JVC_8K.6\TK=*+^&"=8G)('EDEB,H#NW 'GC@CBN2L?#7B&U\
M/Z%I[Z(5:P\1M?.(KB(KY'F2MN7+#C$BX'7@Y [@'5MX\T^/3-7O)K'4HFTA
M@+VW:%?-C4KN#X#8*D'.0?7CBM<:S"USIT"PS.U_&TL97:0BJ 26.[I\RC(S
MR16+I&DW@\9>*[F^T]ET_4EMUB=W1EE"1E'!4,2,Y[CI5;X?Z/<Z?;W0NKD7
M,%E+)IVG/U(MHY&QG_:S\A]HEH UM7OM/A\4^'[.Y:^6\G>8VHA9EA8B)BPD
MP<-P#@'/.*SY_B-I$%G>WC6>IFUL+LVEW,+;"P,-H+-D@[?F'0$]\8Q4WB'3
MM0NO&/A6]M;)YK6PFG>YD5T&P/$R#@L">3V'2N9OO#FO7/@GQMIJ:3*+K5=1
MFGM$,T6&1]F"3OP/NG(/M0!U\'B^REU>?3'M-0@GCMC=Q^;;D?:(@0I9 "2<
M$C@@'D<5G6?Q*T6\?2F%OJ,5IJC".UO)K;; TAZ1EL_>./IGC.0:6[L=2F\?
M:=JPTZ9;*+2I[>61I(_D=V1@,!LG[AR1GM7+>%M-O/$OPO\ "&F"QEAAAEM[
MF6Z=TV^7$^_Y<,6W-@#H,9.>V0#LK7QSIUYJ,]I#9ZD1;73VMS.;8B*!E0.6
M=B?E4@]3WZXR,S1>,=/>;31+!=V]OJ9VV-U,@$<Y(W*!@EE+#D!@,_7BL?3/
M#NH76G^-M.O;:6RCUFZG>WF+HWR20K&#A6)!!4G!]JKQZ'K.L:%X8T?4M.:T
METB[MYKFY\U&C<0#@QX8L=Y"]0, G/09 +UQ\3=%MH+FY>TU4VEI=-:W=PMF
M=ENRD ESG(&3V!/J.1G6U3Q79:9%=2B"YO(K.(3W3VH5A"A&03EAGY06PN3C
MG'(SQ&FV]]JWAWQUH=II[R/?:Q?6Z7#.@B3?A2S9;=\N<X .>,>UL^'M4\/>
M)KMK?PU;^(-,OHK<)(\D226TD<2Q$-OZJ0BGC..>* -^Z\?Z5#=K:VMKJ6H2
MR627\0LK4R>;"Q #+TSUS_\ 7P*L>+?$<_AZWTQ[>PENFO=0@M/E*@('< _>
M8<D9 [9ZD50LM*U.W^(<%^^GJMBFBK9--"R+&LHDWD*F[<%QP.*M>.-,O]1T
MW37TZU-U-9:I:WC0*ZHSI&^6"EB!G'J10 3^-[.'5YM*&F:M->P+"\L4-KO*
M+(2 V0<$ CDC(],U+/XSTVVGM/-CN5L[JZ^QPWVU3"TV2H7[VX L" VW;[]*
MJ:58ZHGQ"U75+G39(;2[L+:%)?-C8!T+EA@-NQ\XP<=C6'X8T/6-&*:%=>%K
M">.WG8PZVS1$-#O+ LGW_, ..F,@<T =-_PFFF_:XHO*NO(EU Z:EWL7RS<#
M(*?>W=01G;C(ZU2M_'#"[\3->Z7=PV6B-M:1 CD@1AR2%8GD-D<8P.2#Q7.W
MVC>*M0DM9KS17N;VRU]+OS_M<8C>V60E1$N[Y<*1G(!)&?F/31N=%UQ'\>6\
M>EM-'K,1>UF2>,*S&V6+9@D$$,.I &.^>* -=/'NG/=6-N;#5%.H6YGLF-MQ
M<84,47!SN .>0!CG..:M6/C#3K_3);Q8KF*2*[-B]I+&!,)P1^[P"1GD'.<8
MY) !K#32-7&I> YCI<P32K>2.\/FQ?NRT C'\?S<CMGC\JR+OPKX@GL]7N(=
M*C:YC\1_VO:VMU)&4NXO+$90D$A21NZ^WX '3W7Q!TBQL]5FO(+V"72GC2[M
MC$&D3S/N-\K%2ISUW?7%6D\86LM]?V*:?J"WEK:_:TAEB6,W$62-R;F'<8^;
M:1GI7-ZYI.KZWX%U:WM/"D.F75V(4CM$DA$C;9 S,[ A<8' R3U]:UKC3-2N
MOB$=2%A*EB^B/9><\D?RRM('P0&)Q@=0.M &IX0UR?Q'X7L-5N+1[9[F)9=I
M*D$$9RN">.<<X/M5_4M4M]*@CDN"Q:65888T&7ED;HJCUZ]>  22 ":X_P /
MWFN>%/!?AVPN_#LC/"\-A<D7<>8UX02@ G<"2,*#GGM6GXXTO5;RWTK4=%B2
MXOM*OENUM7<()UVLC(&/ .'.": +4?C'33#?M<)<VL]C<);36\J#S#(^/+5=
MI(;=N&,$]><4O_"76,=S?6EU;W=K>6=M]K>VDC#.\/3>FPL&&1@X/!ZXK%\0
M6'B+Q/H5O=KIJV%[87]O?6MA-.K-*8F)97=25&X' &3C )//#M0T?4-9UV;7
M?[-GMS!I$UE#;2/'YDLDI!/1BH4;0.3R2?3D T--\=:9J=WI,$=K?PIJT)EL
MYYX-L<A";RF<YW!<GI@X.":P?B#XC%QX0NI=,&HA(;V& 7]L^R/>)E5U)#!F
M7[RDX*YXS19:%K4-I\/8WTJ4-HR[;W][%^[_ -':+CY_FY.>.WY5E/X?\46O
MPZN_!JZ))=2V]TKVU\EQ$(YXOM(ER<L&5\9!!&..M '?GQ1:"ZUJU^SW)GTB
M-);A J_,CAF!4[L'A3UP:2+Q3975KITME#<W<NH6@O8+>)5$GDD*=S;F"K]Y
M1R>IXS@USM]INN6_B7Q)<6VCO<PZUIT,<<JSQJL$B)(I5\G/\8P5!_K6?IND
M>*/#DGAO5;?13>M!HD6DW]BES&LD9CP5D5B=I&<@C/0B@#:D\?+<WGAD:5IU
MU=6NLM-\Y"(RB-'+)M9AA@RC.>, X)S7:5Q>L6.O7.L>%=9&FI-+93W#7-M%
M.H\I98F1?F; ;;D;B/? -;FDZQ=W^JZK8W>EO9?8I%$4AF61;B-LX<8^Z?E/
MRGD CUH BU#Q59V+7^VVN[M-. -Z]LBL(,KNY!8%B%PQ"@D CU%5;[QWI5I<
MVUO!!?W\EW9M>VPLK<R>=&,?=Z9.&!K.L],UC0=4\3PQ::^H6>KSM>6TJ2(-
MDC1A&CD#,"!E000#Q[\55T/PKJ.@:]X5B2VDN+/3-(ELI[M70+YCLC9"EMV,
MJ>W<4 =?J.N6NEZ=;WERDP^TR10PPA/WCR2$!4P< ')[D =S52'Q=ILEGJ$\
MPGMGT^X%K<02H#()6V[% 4D,6WKC!.<TSQ@FM/I=L-%ADG87D1NXH95BE>WR
M=XC9B K=.<@XS@@UQ4WA'Q#)%XA:RTR*SE.J6NJZ>LEPK)*T2Q_NVQR"2K9)
MXSCDCF@#I]9\=QZ;I.O2QZ7>?VAI-L+B2UFV#*L#M?<&*E>#G!)X/%2RZQ:3
MZOX8COX=2MK^Z,K6\:MB(D1$MYFUBI& 2!R0<<"JNK1>(?%G@G6[.;1O[+GN
M;&2&"VFN$D=Y"#U9255>@'.3DYQCEES8ZS?:SX,OFT::)-/>5KM3/$3$&A,8
MS\W)R<_+GCWXH U;SQGIME#<7<D5RVG6T_V>XOD13%$X.UL\[B QP2%(!SSP
M<,O?&UA::G>Z='8ZE=W5G EPZ6UONW1MGE22 ?NG^F37-P^&];M?!NN^#OL#
M3)=RW"VE_P"8GE^5,Q;<X+;@REFR IS@8]M*QT74=-\7ZG<)I\\EB='M[*"7
MS(\R/&7SP6R,[AR<=Z -J'Q987D&GR:?'/>M?VIO(8H0H;RAMRQWLO=U&.N>
MW!K2AU&WETB/4V8P6SP"X)F^4HA7=\WI@=:\XM/"-W+X1\/:7JNAWT=YIUD4
MCOK"ZC2XM)AQ\K!P"K#ZCCD>G4W.AZOK'PSET/4[M/[7N=.,$TX^[YI3&3CM
MGKCWH QM6UV2^\8^"I+6'4[>VNYYF!=MD5S'Y#L,H&Z]"-X!Y]CC=;QOIB:'
M-J[078MH+TV,PV+NCE$@CY&[D;B!D9KGTM_$NHWO@Z6Z\.RVTFD3M]L8W,)0
MY@:/<F&)*Y.>0#[&LZ_\/^)/^$:U_0;?1'F:?6C?P7'VF)4EB:Y27 !;(8 '
M(( XX)X! .XUCQ99:-'>RR6]U<06 !O9;=586X(#?,"P)PI#$*"0"#CD4[Q'
MXB&C>#KW7[2 WR0VIN(UC8 ,NW(;)(^7')QSCH#7+2:3K&F>*]5F7PK:ZW8Z
MM(ES'+)+$KVLGEJC(^_DI\@.5SCG@YKI?$VD76I^ =3T>V6(W<^GO!&J#8A<
MI@ ?W1G\J 'P^(U\C3XI;*Y;4KN$RI9IY?F%5 W/G?M"Y8=6[@=:MZ+KEEKU
MG)<69<&*5H)XI5VO#*IPR,.Q']01Q7*Q:=K=MXDT7Q*-*E8#3&TV\L1-&98A
MN5UD'S;3\RX(#=,'GH-GPIHL^FSZWJ%TGDS:K?M=>1N!,2[510<9&XA<G!(Y
MQDXH #XTTT7<<7E77D2:@=-6[V+Y?V@9&S[V[J",[<9'6KOB#Q%9>&K&.\OU
MG,,DR0@PQ%\,[!1GT&2*X._T;Q5J$EM->:*]S>V6OQW8G^UQB-[99"5$2[OE
MPN,Y )(S\QZ=3X\T[4=5\/V]MI]DUS.M];3LB2(N%CE5VY8CLIQ0!:A\513H
MJQZ7J8NV,A6SDA6.4HA +_.P7:21@YYSQT.&V?C+2M2TZPN[#S[E[YG6"V1
M)2R<2 AB NTC!)('3GD9Q_%.E:HGBJP\0V6A0ZU;FT-G=6$CQK)'\V]9$+_*
M2#D$9J"[TS7=.UO1/$5AH,$@BAGMKK2[66-&A21E964DJC,"@W<CKQD<T :_
M_">::MA=WDMI?1)9WZZ?<*\:[HYFV 9PW(S(HR,_ES6C)XFT^WU>^TZY,EO)
M96@O9I) !'Y)+#<"#ZJW7'2O/8]-U+7/#OC:&TM%-^/$4=PMMYH^8QBW<IN.
M!G"D>F?SK1U7P]K?B?6]<DETU].M=3T!;&*26:-FCE#R, ZJ3_>&<9&#USD
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MZO%;S!X2^X;7<<AAQE.1WXY'((!T&C:'IOA_3UL-+M5M[93G:&+$GIDDDDG
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M)"'W 1XR0,AL[??C"FNM7L?&WCJ[TA;(2P6=G,QNU9E;;'(=H"D=<=<\>AH
M]*) !). .IJK8:E8ZI"\VGW<-U$DAC:2%PZAAU&1QD5%H>I#6= T[5!'Y8O+
M6*XV9SMWJ&Q^M<)X>UL:'I.K;(]T]YXJO+2$;&<!FD9B2J\G"JQP.N ,C.0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%U)Y=O;Q %Y6 ).,D   $DD@#UKEWT[5?$=QX7:_TR73Y-*N!=7;NZ$%UC9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDLERLT/VB,6L33%HN/G 4'CD<]^U<S''=Z7XK\7R3:5=W,>IB!K/RHMZ3[8
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ML8KBZB\H+*9'.U@3D=<=/TP: .WM/$^EWFIQZ<DLL=S+"9X4G@>+SHQU9"P
M;&1GOSGI7->(O%(GU7PH-)OKM8+S55B<K"5AN8MCDX<KR,A<8."#D9'-4[.T
MF\2:7+;MX1GT?64L9X&O;M%"PR/&4_<N"2P)(.0 , ]\545M7N]$\$6+>&]3
MBN]'U&W%XOE*$58X9(RRL3AE.001QV/.,@'H.L^(=+\/K;-J=S]G6YF$,3&-
MF!<] 2 0._7TJA:>.?#UY9ZE=+?-"FF8^V)<02121 ]"490W/;CFLSXD2^1!
MX9E\MY GB"U)5%RQ^_T'<UEZ]I^JSZGXB\2:1I;3,^G6]E#!/!AKAA*6DD$;
MXR54X7<.2OIU .O7Q)IETFI0^?<03640>Y1H'66)&!*N%*Y/0] >E1:9K>FV
MWAS1Y5U"YOTNXD%K+(A>>Z^7.XJ #G R3@8[XKE]-MKZ'Q5K][_96K_9;W2(
M5CFN1O=G7S<@C<2"=P^4#C/0"J&E6.L:'!X%U232KV>#3]-?3[ZVCB)EMW8)
M\X3JPRF#CMZT =+X!U:YU67Q,9[RYN8[?6'AA^T)L:-!'&=FW Q@D]JL6_C&
MTOM0\06+QWMK%I>(WG%M)GE-Q8?*<8!& >3C."*@\#PWL6H^*);K3KJTCN]5
M:Y@:=0N]#%&O R3U4U4MK:_LO$/C<2:;=M#?[)K>=$W(X%NJ8&#G=N&,8]^E
M &I9>*M$T_2M"ADU2ZNO[0MPUG/-"[27(";LG"_>('3 ))''--;XA^'%L9;Q
MKFY6*"4PW(-E-NMF!&?-&W,8Y'+8%<UI>GZA!;_#5)=.O%;3(G2]S W[@_9S
M&,\?WCV^O2DO-.U"7P]\1K=-.O#+J<\C6:^0W[X- B CC^\IZ_6@#N]2\0Z?
MI2N9WE?RXO/D%O"\ICCY^=@H.!P<>N#C.#5RWO[2ZT^/4(+B-[.2(3),&^4H
M1G=GTQ7G,MO=Z7XC:]O?#5_J^F:G86T8^S1[I+:6-2K(Z,1A3G.>F:ZG4]!E
MO_AW>Z%96\.FRW%C)#%!$<)"64X3(XQS@D>] %RU\4Z3=WMK:I-(DEXADM#+
M"\:W"@9)1F #<<XZXYZ<URC:[-KNL^((EO=7L!I4\(M3;6DIX$:N^]-N&W%B
M,-V ([DO:SOO$EKX0MWTZZL;K2KR*ZO3-$46+RHV4HK='W,0!M)&.3BK6AK<
MVVN>-+B:QO$BN[A);9C;M^^40(AV\?WE- "^!;F\\0Z;I?B.74K]9)K<FZM'
MC802,W*E-PXV],KU[YK;3Q;HTE[#;+<N?.N6LXI?*?RGG7.Z,/C&?E;OU!'4
M53^'EO<6/@'1K&\MIK>ZMK98I8I4*E6'\_J*XVXM]=O#I$]SH&I"\LO$/GSQ
M0*J6Z0[I,&-=P#Y#*2Y!.2V2!Q0!V5Q\0/#EJ+LRW<^VSG\BZ86DI$#<<N=O
MRK\P^8\>_!K3U+6K*TD-FTTYN6A,NVUA,KI'TWX .!GID<X. <&N!U#3=1G\
M-?$6V33;PS:G<NUFGD-^^!AC0$<?WE/6M+3CJ6A^.+Z_FTJ_NK#5[&U6&6"+
M<UO)$K QNIP5!W$Y/'O0!K?#?4;K5OA]I-]>W+W-Q,CL\S]7_>, ?R KH+_4
M;738DDNI"OF.(XU52S2.>BJHY)X)X[ GH*X?P7J-YX9\&^&M,U+0]2BDGF>W
MD?RU*VY:0["_S9 8N /QK3\;0:G!?:!KVG6,NH+I5T[W%G#CS'CDC:,L@/5E
MSG'?- &K!XKT:XL;B[6Z*K;W'V2:-XV$B39 $>S&XL21@ '.>*0^+='2WU&6
M6XEA.FH'O(I('$D2D9#%,9*D G(!'!]#7-^((-4UBRTO6[#1)X!8:M%?/8R*
MJ7%Q&%*.Q4'&X!N%)SA?4@5!KVE76KZEXAURTL[L12^')-,AB>!DDN)G+-]P
M@, ,@9('WCV&: .IT_QAHNJ:C;V-M<2F:Y@-Q 7MY$29!@G8[ *Q&1D G'YU
M/:^)-.O98T@:=A-$\\,GV=]DL:XRRMC!^\,=SG(R*Y.*TO/[8^'\OV"[V6-E
M-'=,8& A9H40!N/[RD?KTYJ/PKIM]I.M6+:8FIV^B2P227NF7T3,MC)@$"!R
M,D%LC:I(QD^E '0Z%KNEKX>LI[?4[S4XKJ>6.WEFC)FF8.Y9=H4'"[6'('"B
MH]0\<65I<Z+'#;WDRZG<RP[A:R9C\L/NRNW=NW)C&,]3TKE-*T(S>!-(TW5=
M/UBTN(;ZZE6YLT=9[)VDD9'&T$D%7P< CYN1P<6?LGB1;?PE?:E:7&H3:?JE
MP97AA5)7A9)4CE=,@*3N4GTSSWH ['4?%>D:47-Y/(D44BQ33B%VBA=L8#N!
MA?O+UZ9&<9JM?>.M T^XU&":XN#-IP5KI(K25S$I!.XA5/RX&2W0<<\UR45A
M<66JZWH^K>$+C5H[^]DNK2Z55>W9)#NV3$GY-IXZ'@< \9O-97B:SX];[!=>
M7>V,$-JRP-MF9870A>/5@/\ ZW- &]<^,;2+Q+I6D0PSS+J%L]TMQ'"[H4&W
M;@@<YW D] .O6M/4=<L-*O+&UO))$EOY?)M\0NRN^,[=P! . 3R1T-<1I=CJ
M5EJ/@2[;2[QTMM&>PN0J &"4K#]_)&!\C<]./<5TWCC2;C5_"UP+$9U*T9+R
MR(Z^=$=Z@?7!7_@5 %F+Q5I$T>JR)--C2B1>;K:0&(A=QX*Y;CGC/%5O[8T_
M_A)YPM_J+7,6FB9M.\A]@CW9$@4KDN3\N >V,<5SL'AO64\6P7DB?Z+K<"S:
MRN_(AEB</&H]0581>ZH36J;6Y;XKS7GV6?[(VBBU%P8SL\T2L^W/^Z0<].W6
M@#$U#QI+JGA[PMKMI/=:?!=:O!'/&T917A8MP21\W"C.TXZUVVC^(-.UUKM+
M)Y?-M)!'/%/ \,D9(R,JX!P0<@XYKSFQT_58O W@O39M&OX[G2]5MVN5,6[:
MD9?<XQG*\CZYXS@UUN@6]S'\0/%=U):W$=M="T\B5XBJR;(RKX)]"1]>V: )
M_P#A)TO?%&J>'(H[R"6UMHW^TK V-S[^A*E0 %X)X)) SBLCP%XUM;SPUX<M
MM3O9Y=4OX.)I(7V2R %BOF8V;L _+G/%6EAO=/\ B-K5X^G74MG>Z=;K'<0I
MN4-&9=RGG.?F7  .<USFFZ7J4'@_X>V<FFWBW&FW\<EXGD-F%5CD4D\=,NO3
M/6@#O+OQ7I%E<)%<7#HCW M?/\ES")2<!#)C:#GCKUXZ\54\;^))O#6BP/9Q
M)+J-_=Q6-DDF=GFR' +8[  G\,5R>DZ;/:27?AS5_"$^H2_;I9K;4&17M9$>
M4R*\C%OE9=W(P3QQ72_$#P[>:_HMI)IFPZEI=]%J-K'(VU97C)^0GMD$_CB@
M"S>Z)K,>CS&P\07CZIY9*R3+'Y<CXZ;-N%![8Y'OWN:CXETS3'N$N))6-J@D
MN3# \@@4\@OM!QP,^N.>G-0VGB*2_@5(M'U*"](P8;JV:-8S[R?<('^R23V!
MK"L8;[0/$/BF.\T^ZO+;591=VDL$1D$A,81HFQ]PC:,%L+@]: -^Z\7:+:7=
MK:M=/)-=P&XMU@A>7SHQ@Y0J"&ZC@9/-4T^(/AQ[6"Z%W/Y$LWD-(;67;!)N
MV;93M_=G=QAL?E7-:!X=U#0-6\$6EQ!/,NFZ9<P74\<;,D<DGEE5SCD?*P_
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M*=L<$"[L2,"PW;BH  (^\#[5GZ=XZFOM,MU-M%_:-QJTNE1XW",M'N)EP?F
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MR/;EP$W%D9<=R0W&.O&C9:XVIW^F+8203VEQ9?;)I@I!"M@1XYXW'?US]PT
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MAH"J*I8L0,%CC)]^*6N2C\575MJ_B+3]42W@;3;9;NV:-6/GPD'Y\$\D,-I
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MZ?)'\VUU%P(=P.>#SG'/I4M]XI\0?VOXFL+"QT[_ (D]O#<))/*Y\Q75VP0
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MV1XW-],D#]: .5U'PIK.K:1"MYKL3:G%>0W8=;4BW_=$D1F+?DJ222=V<X]
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M4[@%D+=3@CVXJ&Q\!7UGHGAG33K,,@T*[%PKFT(\T!64+C?QPYYYY_*NZHH
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MUO*\#1<;2%*$$ C@CI0!YG<3WFK>%-'74;NZ>6V\7I9AA<-N,:W)4!F&-Q
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ML,,OF*O)QAL#/&#T[U=HHH **HZMK&GZ'9&\U*Y6WM]RIO8$_,3@# YZFKU
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M <.^C1W7Q+%Y8W:-8S6T=SJ,"?,'FB8K Q/J?F/_ &Q%=3K?_(!U'_KUE_\
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M\T!8HH2F%+=V(3G'&6ZX&3Z-10 BDLH)4J2,X/44M%% !1110 4444 %%%%
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ML<+*1$I=08D+,9&<JI&!T;H<9JGXLM5@UG3K*34-6L+6VM&*7@L!?17$KO\
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M\*)/"^A2ZXNMOI%FVIKC%T8AOR. <^OOUK6HH RV\.:,YO2VG6Y^WC%WE?\
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MM(=8MA!>0)$C;BJ%%8,>1P<$#KCJ*T5\.0GP:?#4UU/+;FR-D9CM6384V9X
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MC>7DVJ0P&2,DDD=\UUECX,MH-"UC1[VX:\M-4GGFF!0(5,I)8 @],G([CWH
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M&JMO20 ,IW X^Z,'M61<> A<Z%K^DR:HXBUJ[:ZF=81NC9MN0O.,?(O7/?\
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M?_(G:Y_V#Y__ $6U &.WCV&W\.V7B"_TF\MM(NDBD^U!HW$*28VM(H;('(Z
MXS77 @@$'(/0UXQK-A>K\"-)OIM5\[3[?3[2>?3IHU1+E $(BWKAAVQSS@#O
M7127LOBGQ-<Z1/<+IZMI-O<VEK-O##S ^]UVNOS*0HSSC'&,G(!Z-17F4-A/
M-XN\-Z9>:[>ZC%)H]RMQ-%/)"MR4>-0V W!YY(/S>I!K/TS6;N#2-!TJXU I
M92ZW?6+7%T[-E8VD\F)VW!B"0!UYV@'(R" >GZSJUKH6C7FJWI86UI$TLFT9
M) '0#U/2LZUUC79-<2QN/#;16A&YK]+Q'C52I(X(#%MPVD <9!R17$>+]$?3
M?AKXMMKC5S?I&?/AA7>HM-V/W>2[$CN%)XSTZ5OZO#_9_CCP5;VL]TD$KW:R
M1?:9&1P(&89!)!().#UH [&"Z@N7G2&57:"3RI0O\+X#8^N&'YU-7E.B:9*O
MA_Q8FCW"6]^?$$T<(GG<)(!+&?+)!R-X^7<.?FZUT_@S5X)8]5@N;.XTF]M[
MM!=65U.'2%F10HB?."C8R,8Y)XYH Z^BFNBR1LC?=8$'!QQ7FNF_:+6_O? 4
M]Q=R7'VY;J"Y>=S(UBQ\PMOSG*E3#G/5EH ],HKSF!V\00>-C>W5Q;7FF7<L
M%H8YF0VL21*T;K@\;CEB>_0\#%1^&-1U#4O%F@3:E)*DE_X6,]S#O*H\OF1#
M?LS@-@GMD9H ]*HKD?AG<RW?@:VEEN)+AOM-THDDD+DJ+B0+\Q))P !]*HW=
M@NI?%6]TZYNKXV,FB1RM;I=R(F\S.I(VL,< =, XH [RBO'-+>Z7P=X(UQM1
MOY=1DU>"S>62Z<AX3*\90KG:<J!R1G(SFKFIW4T'A?XF 7MPALKEC;'[0X:$
M^1&R[#G*C<3@#UH ]7J$74#7CV8E4W"1K*T?<*Q(!/U*M^1KSCQ1<ZA9B74Y
M[>;4M%73HEN6M+DI=:<0&9IE7(# A@3SGY>>!5_0[:SE^+'B&\CW_-86,R-Y
MC ,6\T9(SSQC@]* .^HKCOB<TT?@UIK>ZN+:9+RU59()60X:=%(..",$\'(K
M-O;6/3O&%AX92]>.QO+:XNT6^GEF$\^] 4#%P3M7)"YQR3C." #O9[J"V>!)
MI51IY/*B!ZNV"V!^"D_A4U>476B"WU;P397VK2:L\.IW4'VG<Z%4\F1@F=Q)
M*\#=G/&#TI^H7,L.A_$]5O;A!9L7M3]H8&$FV1EV'.1\QS@>M 'JE%>:/I_]
MN>.;#3[J_P!16UN/#8FDCAO9(P7$L8##!X/TQG'.:R-4M9/["^(=U_:.I^=I
M5VTEDWVZ7]RRP1N"/FYY['(';&30![%4,%U!<O.D,JNT$GE2[?X7P#CZX846
MDC364$CGYGC5CCCDBO((KC_A'/"7BB[L7E@)\2RVLLRRL3# TZ*[#)X(!QNZ
MC(.: /9:ANKJ"RMGN;F58H4^\[=!S@?KQ7(2)-HOQ*T>STUY38:C97#7=N9&
M=$,6S9* 2<$E]I/?ODTGQ6MHKCP46E!/EWUF5PQ&,W$:GH?0F@#<3Q!N\9R>
M'39NI2Q%Z+@N,,"^S  YZYZUM5Y[=:/:7_Q5^P2/<"U'AX K'<.A;_2",%P=
MWZUB:#K=[>Z/X(TV_P!0 BOX+M6ENBS"XEB<+&C$,I)V[C@GD@=30!Z[6/J?
MB&"PU2VTF""2\U2Y1I8[:(@;8P<&1V/"KGC/4G@ U!X2T^?2M/N[&?5SJ?E7
M<GEL58&!#AA#EF8MMSP2<X(':N<L";+XZ:L+T[3J&E0FP9NC*A_>(I]<_,1Z
M<T =5;ZU<'68=+O-,FMY98))EF5UDA;:5!4-P=WSYP0.AZUL5C>*-2DTOP]J
M-U:*LFH064\]M'MW$LB$YQZ9Q^8'>N-EDFL]*\#ZUI-W<37.H7=K!=EIF<74
M4J$R%P3C*X+ _P ."!@<4 >ET5XQJ4<\?@;QIJBZCJ7VS2]:G^Q2&]D/E;6C
MP/O?,,''S9XKIYK3^S?B,]C;WE]Y%]H<\TZM=R,6E21 K@Y^5L,1\N* /0**
M\:T^WO+?P;X'\36NJ:E+JT]S:03B6[=TN(I&VNA0G;P,G.,\$DD\U>O+]S=Z
M5JFGWEQ+'-XH%LUY+.5:1"[(T*QCCREQ@9QRN<<YH ]7HKR+5K9YK'XD7!U'
M4M^F2>=9%;Z4"%Q;)(",-R-W8Y [ <UM:Q?MX<U?0O%UW<7!TRZMA::@GF,8
MXG=0T<P3. <@H3C^(4 >AT5D^'+.:ST>,W7F"ZN&:XF1W+>6SDML&3T7(48_
MNUP7CR\8V_C"XL+NY>ZTRUA8NTYB6Q?;O41!>69L@G.!T&3T !W$WB'R?&$'
MA\V4A,UE)=K<;Q@[&52H'7^+J<4[PUKX\16%S<_9'M3!>36C1NX8YC8J3D<=
M16%)(9?BMH3D@EM#N22/7S(:E^''_((UC_L.7_\ Z/:@#L:S];U>VT'1[C4[
MO<880/E7JS$A54>Y) _&N=O;HZA\3DT&]+BP72#=11!RJS2F7:Q..NU0,#MN
M)]*XW6/M-W\,?$-OJ$T]PFF:Z+2SGDE8L\(N8@-QS\Q&67)S]WUH ]2TR^U"
MYNKR#4-+-F8&7RY4F$L<ZD9RIP"".A! ]LU(E].DVH->V@M+.UPT=R\RD2IM
MW,V!RH!R.?3-6;>WCM8$@B#!$Z;G+'\R237E7B!&GTGXJVTT]Q-#;QH\*23N
MPC_T8/@9/ W$G'2@#U>*1)HDEC.4=0RGU!Z4^O.=7AO["VTR?3;,ZMI]O89N
M]-2[9+A-^")HR3\S *P R"/X>M=IX>N[:_\ #>F75G+++;2VL;Q23??92HP6
M]_7WH TJ*\>GTU[SPQXYU%M9U6*[TC4KM[&07\F(3'&C*,;OF!Z8;.!TQ6I:
M6,WB#QQ]FU6[U&)9- L[R6WAO)(@DYD?<0 ?E^Z!@<>HS0!Z;17D[WUUJ?PU
MU[Q*UY<6^OV-U=.K)*P-N\4A"0[<XVE0H*D<[B3R<U=MM+;Q+XUUZQU2\U*&
M(Z;93&WAOI(Q%*XDW%<-Q@CI]W/4'B@#TNBO(?#6M:GK$/AC2=9OTQ<Z?<ND
MER&Q>NDVQ22K*6;RP&ZG.[/7!%NYTNZM+SPAI,_B*]OT;4;JVEFAGDBWQB&1
MA&V'.XK]W=G<,=010!Z;]J@^V"S\U?M!C\WR^^S.,_3/]?2IJ\WTSP[IUG\4
M;VR#7+11Z%;@-)=R%V_>R+RV[)X '\J9H37/GOX$N[BZDO+"_,\ERTS^9+99
M\R-R^<DDE8B,]-U 'I=%9^NW45CX?U&ZGNGM(H;:1VN$7<T0"GY@.Y'4"N$T
M$S)XXT^Q+W$-G>>'FE=&O&:25A)&%E?!PLA#-RI/7J: /2ZQ_%.N_P#",^&K
M[6?LCW2VD9D:)'"D@>Y_^O7F>A?:(?"OP_UO^T+^2_NM3CMIY);IV$D3^;N4
MJ3M/0'.,Y&<T[7)E\2?#/QOJ5]+*;^VNKJ ()67[.L;82, ' !7!/][<<]L
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M4=*TJWT:R^R6SW#Q;V<&XG>5@6.2-S$G'/K5Z@ HHHH **** "BBB@ HHHH
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M4[80>ID&2N5)/(SP<UZI10!D:=XAM;_5[K2?+GAO[2-'F22(A3N /R-C#8R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;>]NY9(PD 2,.7(#$D<]LXX]<5.OC*-'T>2\T^:VLM8=8[.X9P?G9=R+(O\
M 6 XZ^AP:IZ;X5O9=/\ %^G:HL45OKEU/+&\,N]E22-8^1@8(VY[CFH8/#6L
MZAI/AW2=8CMD31KF&>2YBE+?:/)!$>U< KD[2V>F"!G.0 +-\1EALM0OVT*_
M%EIU^;*\E9X_W6&52P 8[N6' SQW[5HR:II<'C^YBGL9(;Z#2//>_=QL-N)/
MN@ GHV220#Q7/7GA#7KGP?XKTI8;07&K:F]W 3<':J,R'YCMR"-G8'KUK6O_
M  U?:MXOO+RYBBBTZ\T-M,D*RYD5F8L2!C&,''7KVH T;+Q/)=WFF*=(O$L]
M3B:6VN0-P4!=P\T#_5[AR.3Z'!XJ"P\9I=ZEI%I/IT]JNKQRR69D8!\1C)$B
M<%"5Y'7WQ57PS9>,;/3;;2-2_LZ*&QA\E+Z"5G>Y"KM3]V5 3L2<G., <Y&1
MI7A3Q-#J7AB^O+;33=::\POKC[4[R76^,IYI)3.>X4^N,@4 8NH6\:_##XCH
M-VV+5KLI\QXP(\<UZ(OB(0^*+/P_-9R(;FT:X@N6<;) F R ==PW X].:YFY
M\(ZY<>#_ !AI(BM%N-9OIKBW)G.U4DVCYCMX(V]L]:O^-+4ZAIFEQVM[%9^(
M[6Z@>SVL'9&8['&.I0H7)]ESVH Z?2=2.J6TLX@,4:SR1(2P/F!&*EA[$@X]
MJR]*\4OK=M!=Z?I_GVES%(\$RSKU7&$D&/D8YZ<XP<\\5N65G#I]A;V=NNV&
M"-8D!.?E P*XO0_"5Y:>)[/6A9P:5.87&K):39AOG(&U@F  0V6W$ ]N<YH
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MQ6A>']7\+Z=J2:-!%Y$UU&]EIMW=,R6T?RB3#<XS\Q"C(''KBNUH \WU9(_
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M(NG)9XX"2D?HH) +8]2!DYX'07* "BBB@ HHHH **** "BBB@ HHHH ****
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MF"G@-C'48![$<5T'@C4M0OK75[;4KHW<VG:I-9+<,BHTB*%92P4 9PV. .E
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M8]2O[FZCC\ZT@5'9PF0H1<#D!CWY]ZU[G4[2TO;*SFF5;B]=D@CSRQ52[?@
MIY]QZU:W+NVY&[KC/- '/^%]*2WFU366T\V-SJ]P)Y(7QO554*H;!(W'!8@=
M"Y%:>L:3:Z[HUWI5ZK-;7<312!3@X/H?6KI91U('XTDC%(V(VYQQN; )[<T
M8,?A.WCU33M1;4=0EN=/A>&)I9$;<KXW;LKR3M7IC&.,52F^'FD3Z/+ILMQ?
M$/?-J$=PLH2:"X8EB\;*HP<D^HYJ30/$.K>(/#=MJ4%E9QW#7TD$\3S-M2))
MFC8JVWEL+D @ GTKJ"RCJ0/J: ,[1M&BT:U:);J[O)7.9+F\E\R5^PR>  .P
M  Z^IJ#4_#L>IW%S(]_>PI=6PM9X8F39(@W=F4D'YV&01^E;#,%&6( ]32T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFW@R"XGL8]*GM$>\\)B:V5VB $L_2)U^L>&/O(#5'PD-&UJU\-:H=<1-<MW
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M _#6K10HM_'XD6*.YSEU0WKJ4![*5)RO0YS78^%;?3;?XD^,U$-I'=?:K<Q
M(H?#6R%MO?!.2<=3FNN_L/2?)$/]EV7E*V\)]G3:&]<8ZU86SM4NFNDMH5N&
M0(90@#E1T&>N/:@#BO$.G:=<?%CPOY]G:R/+9WK/OB4ERHBVDY'..<>E<I>Z
MAIC76E:G93P09\5[7DN)0;MOG9)-QXV1]@IS\NW)'2O79=-L)[I;J:RMI+A?
MNRO$I<?0D9IAT?3"\KG3K,O+()9&\A<NXZ,>.2.QH X>T6&/Q1\2!%M"FTMG
M.#QDP.2?QZUF:2UO;'X3W<K11*=.DB:9B%!_T5<*3]<X%>F'2M.,D[G3[4O.
M,3-Y*YD'^UQS^--DT;2YK-+.73;-[5&#I"T"E%;U"XP#[T >/7G]GW'@[Q,(
M)(MD?BV,Q&)\;%:6 97'0$$X(KH]8M=&\/\ C'3M(F%GIFB7=M/+$+B(-;O=
M%UW9#':&V=,^I ZUW\FCZ7*CI)IMFZ.YD96@4AG/\1XY/O3[O3+"_M1:WEC;
M7-LN,0S1*Z#'3@C% &3X+L;33?#<5GI^HRZA9Q2.(9W((V[C\J$=4!R!]*Z"
MFQQI%&L<:*B( JJHP !T %.H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD?B!J-SI.GZ1=P7\EI'
M_:]I'<%2 KQ-( P8D9QCT(KKJY7Q[8W=YI&GO9VLMRUIJEI=RQQ %_+CD#,0
M.YP.@YH F@\>>'I[;4IENIT_LU0]W'):3++&AZ/Y97<5QSD#%:2Z]I[P:9,L
MLK1ZF0+0B!SORI<9&/E&T$Y;' K$L],;5?'EQX@-K)%8_P!E#3P+B(QM.6DW
ML2C $*!@<@9+'MR:7@?1[VPU"]L;IUDL-#E>STQ]V28Y-LGS>Z*4C!]FH ZG
M6]=T_P .Z:VHZI,\-HC!6D6%Y-N3@9"@D#/&>E22ZM9PWUM9R/(L]Q$\T8,3
MXV)C<6.,+C<O4CJ*?J6G6VK:7=:=>1^9;74312+ZJPP:X30M#UG5_!6LVNHW
M*'4&M)M&M;D-D-''O02GT+-U_P!T4 =7;^*](N;JTMTN)%-XI:T=X75+@ 9/
MEL1AN.1CJ.1D5&_C+0H])N=4>[D6SM;DVD[FVES'*&"E2NW(Y(&<8YZURXL;
M_7]%\(:;)IMU97NE7MM/>&6(JD0@4@[7^Z^XX VD\-SC%9&K:?K">%_&.A1:
M'J$]U=:NUY \<8,<D3RQN"&SR>"".H[X'- 'K<L@BB>1@Q"*6(52Q./0#DGV
M%<UH/C:PUCPXNLS)-:1-,T2)) X+'S61%7CYV.!PN<$XKI8V+QJY1D+ $JV,
MCV..*\GL='UVW\'Z @TJ[^T:!K+7-Q;, #<1F27)BY^8A9 PZ9Z#F@#TG3M<
ML-4N;JUMY'%U:E1/!+&T<D>X94E6 .#V(X-1:QXDTO09K2'49WBDNV*0*L+O
MO8 G:-H/. <#J>V:R-.T^6^^(=QXD2&>"S&EI8KY\31-,_F%R=C , HP,D#.
M3CI2>+X+B;7_  G+#:7$\=KJ)FG:*(L(T,3IDX]V'O0!?;QCHRZ:M^)+EX#!
M]I?9:2LT47(W.H7*CY6ZCG:<=#5<^-;%_%%EI%O'//%=6!O5N88'D1E+($VE
M0<@AB2>@XYYK"U>WN=*\<:E<WOAR]UG2]5AA$3V2B0PNBE61U+#"D8.>G)]\
M68--N]+\=:'=0Z*\5C_8\EEY=H%,=JYE1PK'(P H//?''I0!O#QAH;:7!J8N
MY/L<US]D23[/)_K=_E[2-N5^;C)P*CG\;Z#;ZI-IKW,YO(9HX)8TM)6*,_W<
MX7H?[W3D<\UP4MCK$/A*70ET+49+JV\0"Z+K&/+DB-WYH9&)^;Y3^&#G%==H
M$5Q#X]\67DUE=16]TMJ897A.)/+C*N >^"?Q[9H MVWC[PY=M9^1>2M'>3FV
MBE-K*(_-W%=C,5PK$@X!()X]170W%Q#:6TMS<2+'#$ADD=C@*H&23[ 5Y5#I
MFI)\/-+LCI=\+N'Q MT\7V=MRQ"[,N[ITV$'].M>E:RJRZ!J"M9M>J]K(#:C
M@S J?D_'I^- %.7Q9I5O;75Q<-=0Q6MN+F8R6DHVQ'/SXVY(^4YQTQSBK \0
M:8VHV%@)V^T7\+3VJF)P)$4 DAL8X!'!.>:X.'0-8&D^(=%TZ?4+O1KG1I8[
M--3C*S6\[ J(5=@"R8]<@<<]:? FIZIK?@V5-%U.UAM+"YMKB6:((87:.-<D
M$YQE3SW[9H [$>*]'>]MK073JUW(\-M,8F$<LBYRJN1M)X/?G!QFN9\+>,[>
MSM[VWUS4;F:;^V[FRCG>!F5 )=D:NZKL3/ &<4O@FXU6ST?3/#>I>&KF.\TK
M$37DD:FVV)D"2-\Y+%>  ,Y//&:QKG3-2D^'VOV2:7?&ZN/$#74,7V=MSQ&Z
M60,..FT$_IUH ]5FF2W@>:0D(BEFPI8X'L.37-V?Q#\,7]U806^H,W]H';:R
M-;R+'(W9 Y7;N_V<YKI2P>$L,X*YY&#^1KR/PY92>)/A5X0TFVM+A9HKBWN'
MG>$JD*1R;RX<C!) P "3EN<8. #OX/&V@W.IG3X;F9[E;EK5U^S2@)(%W$,2
MN%XZ$X!P<=#4T'BO1[BYM($N7'VW/V25X76.XP,_(Y&UN.1SR.1D5S>DZ3>W
MMIX\L##<6<FJ7<[6L\L3(&5X$C# X[,I]ZJ)IVH:YX:\)Z-+IMU9W^E7EK+=
MM)$5CB$ Y*/]UMV,#:3][G&#0!O3_$?PM;>89=0D5(K@VTTGV679#("!B0[<
M(,G&6P#SZ&M75/$FF:0LK74LI6",33F&!Y1%&<_,^T' X)^@)Z UY]:*^H^&
MO'^B06%Q<75[J][##B$F,LX50Q?&U=IY.2#QQGBI_P"R[GPYXAO;;4?#M]KV
MFW]M;I#/:('VO'"L3I(I8 *=H.3QR?? !UM]X[\/:=/Y,U[(\AMENU$-O)+O
MA) #KM4[ASVST/I52U^(.F2#79[N*\MK32;@Q22M9S'Y0B$L<*<<MTZX&<8J
MIIVGSV?Q&LI5TM[:SBT 68,,1\F*3S0WEJV.@4=>G'KQ4_ANPN(=;\6V&H:;
M-]EOK]KA)G4>3+$\,:8SGD_*P(Q0!T7]M6.=/ >4G4.;;$#G=\N[GCY>.?FQ
M6A7GOA2VU+1+'4I+R&;48M 66PTU+?YY9X@0_'8MCRX_K&WK7;:5J,>K:3:Z
MA%%+$EQ$L@CE&'7(Z$>HH Q8-<L()?$=U#?WUZ]G(OGVK0N1;L(QA4 3.#PQ
M/(YSFJ?@B6[UO3=+\0RZG?[[FR4W=I+$RPO(P#!H]PX R1\O!&.IY-:Q@NH=
M5\>3O8W8CO'1K8^0W[X"W6,[>.?F&/UZ5M>!(9[7P+HEG=0307-M910312H5
M*NJ $<]?J* 'MJ=@GB^X@.I7GVJ#3Q))8")C$(]_^M'R_,Q/R\$].E5H?B#X
M:G2QE2^D$%]D6]PUM*L3L,G;O*[0Q /RDY]JK/%<1?%:746M+HV0T06_GK"S
M*9!,7VC Y.T_TZUR^GZ7J5O\/_ MC)IEZ+K3]4@ENHO(8F)$+[F/'3YATZYX
MZ&@#MQXWT+^SM2OGN)XHM-(%XLUI*DD.1D$H5W8(Y!QBD_X3C0?MOV3[1<>>
MT/GQ)]DE_P!(3@'ROE_>=1PN:Y'7]/U"XG^(RPZ=>2?VEI\$%F5@;$SK&ZL
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M%WJOP^T:^O[A[BZFA+22OU8[CS6]J6HVVDZ=<:A>,Z6UNADE9(V<JHZG"@G
M^E<1X/U&Y\*^ O#-AJ&CZCYSR"TGVP\6S,Y"L^3]TEE&1GK7?R1I-$\4BAXW
M4JRD9!!ZB@#(C\4Z1+>Z;:)/*9M3A,]H/LT@$J  D[MN!@$'!(/(JGJVO:5*
MEDK:I?66=4CM4:&!U$TP?'E$E"-I/!/ X//!KBQX7\266B6\L$+2WOAB]\O2
M(RY'VJVWD-N^L3JGMY9]:Z'Q3I-S!HGANTMH)[N2UU>TN;AXHBQ(5]\LAQZD
MD^^>* +%I=7\WQ!\2:<VHW'V:/3[:6!?E_<,YE!*_+C^$=<U:^'E_=ZI\/\
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M-I5#!B1D#&>A%86@6^I'QMH>IR:3JRQ-I$MM/+<JJ".4O&V-@.$4;2  !G'
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MEXE72K^YL]5TVR:X93$8Y4&TE3AUZ''4?H:U=#\4Z;J,]OI:W$K7_P!D6?\
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M)B(238CAL'';</KVS6%X1T^:WM=-\/ZOX0G?4-+E0#4)%#6I"'Y9D<MG?MZ
M#.3V&< ':S>*M(M[R&WEN'03W'V6.8POY+39(\OS,;=V01UZ@CKQ5.X^('AR
MVBNY9+N?R[.X^SW3K:3$0-Q]\A?E7YA\QXZ^AKE/#VFSVB+X;U?PC<7=W;7;
M/#J+J&M9$\PLLI8MPP!^[C.1[\)>:=J$OA7XB6J:;>&?4KN9[-/(;,RM%&@(
MX]5/6@#NK+Q1I-_K#:5!/)]J$1F0/ Z++&" 6C=@%< D<J3UIB>+-'>^MK07
M$@>[#&U=H'$=QM&3Y;XPW'(P>1R,US>IV%WJ/BGP^\-M=QPKI-W;2W!@8"%Y
M%C"YXX^Z?IBJGA"WD^SZ5IFJ>#;B#4])"K)>S(&MUV#;YD39RS,!P .,^@H
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M=I$LTT,-I+(X0YPP"J<C@Y(X'>K;>(M,^QV%U%<&=-04/:+"C.TR[=V0H&<
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M')4 D\< =LF32?%U]<^(['2+R*S:6\L)+EE@8_Z+*A4-"[9(8C?@D8P1TY%
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MVJP&4NK1U/RHX8\YY&[ &?7M%IOB_49]?TS2KN&R6?4+.:8QPDL;.:/:3$[
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MZE8SW$4[MF6,JJ$J.. =ZY.3G'2@#K*@2]M7O9+)+F%KJ)%DDA#@NJG."1U
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M:VP(FV*F.6;/"CG ZFNCHH YS4?##W/B#0=1LKBVM(-):9A;"VR)/,0J<$,
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MY>S:VS+$SG<ZQR;OE4DD]"1GCGFEN?!5Y<6_BV$ZK H\0C!/V0_N!Y0B_O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBL#7_#-KKEPES?:EJ-O!!&0L=I>/;J.<LS%""> .O3
M'O0!OT5S'@"S>U\)6\K374HNW>ZC^U3-*Z1.V8U)8D\)LS[YKIZ "BBB@ HH
MHH ***\JN'TU/B!XQM]5U:[L[:&TM9+98[^6(QNR.6,:JPRV0O !Y[<T >JT
M5YSX9\9:QIWACPS:>(=*U&ZUO4XIM@1$5G\O<RA@S##% IY '.21S71+XL,R
M3K;:/>S7-I;QSWEL"@> NNX1\MAI,<X!QTYY% '245R3_$"PD?2%TZPOM1_M
M>VDN+,VZH ^S&Y3N8;2-PSNP!SS5=?B38'1A?OIFHI)'J*Z;<VI1?,MYF8 !
MANY'S @KG- ':T5Q[ZY:WGB/P['J>@ZE9ZA-+=+:&:1 L91&W%@CD-E1QP1S
M3KOXAZ39S0LZLUE+>?8OM*2H=LFXIDINW;-P(W8]\8YH ZZBN+L/&UP6\47&
MH:7<)::1=&%!#MD8@1QG;@')9B^?09Z\5?;QC%!)K,%UIUTEUI5JMW+"C(Y>
M)@QRIW 9&QL@XZ<9H Z6BN*?XB+%I4.K3>'M5CTV86Q2Z;R@F)N QR^0H) )
M([@]#73+J8;7'TM;>4LENL[S KL4,Q"J><Y.UNW:@"_17#?$W>EEH#Q33PM)
MKEI [0S-&6C=R&4[2,@UI7GBT66M7>AVFB:A=W=I:)<A8C&%>,DJ"&9Q_=/7
M!] : .GHKS[Q+XJ?4O#OAB]TJVN)++6-0M5<912T;$L8B"W4[<'MC()YK3T^
M[L]!;4M/T72KRX>WQ>7=K'*I%NTBY\I S8SA<[%XYZC(H ZZBN1E^(-@PT8Z
M=87VHC6()9K,VX0!_+7+(=S#:PZ<X'7GBD'CIWFU"VB\.:JUY86L-S-;DQ*0
MLBLW7?C(VD8SDGH.IH Z^BN4L_'=I>W&BE=.OH['60!:7L@0(SE"^TKNW#@'
MG&"1QQS4O_":6ZW=HDEA=QVMWJ#Z;#<. ,S+N'*YW!248 _H <T =-17$VWB
MJXU!?%T>HZ1<&QTR1X2L,B;FC$2LPSN!W$,3P>!QG-:&F^(+"+2= M-,M)GD
MOK!)[2T+@M' J+R[,>@W*N<DDGOR: .FHKD9OB%I\&E->M8WQ>'4%TZYMPJF
M2WF9@HW#=R#N!!7.015W3_%(OK[5;"32KVVOM/B6?[/(8V::-PVTJ58C)*D8
M)X- '0T56T^Z>^TZVNI+6:U>:-7:"8 /&2,[6QW%1:OID6L:7/8RRSPB5"HE
MMY3')&<<,K Y!% %ZBO,/#^IWK:'=> [UI?^$DMG-JT^]B9(6Y%V&SG[OO\
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MO')Y?EX#$EB>F..<9X. #L:*YS2O&%GJ?B&70VB:&]6W%T@$J2+)'NVDAD)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-W*+R-<O.,G8I.2 Q/7'&.IK32XBB\6^)M2^U6#6^H64$%N1>Q9+1B0'(W<
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M0W,]PDH99VA4A/+'4;C@G<!@9'-=NB+&BHBA44 *JC  ]!3J /,-2\*>)9-
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MEW>6NGVLEU>7$5O;QC+RS.$51[D\"LVV\5Z%>7=O:PZE$;BYSY$;95I@!DE
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M9)++4(E7S$$A)=64C:RG/3'8?CU6DZ<^FV?E37DU[<.V^:YF"AI&P!G"@ #
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M** "BBB@ HHHH **** "BBN:\97$$=MI=M+/<*]UJ$444$+!1<MAF\MV/1"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)YK5@LZ12!C$3T#8Z'CI5J@ HH) &2< 52L]7TS497BL=1M+F1.72"=7*_4
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MGZ4 6J*** "BJMWJ=C836\-W>002W,@C@220*TK'LHZD_2K5 !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P?C6ZU+1O$^E
M:UI%N-3NH[6>&72@2))(,HS2QG!P5*J#G[V0!SBN\K&O=$DE\0V^MV5TD-W'
M;-:NLL1D22-F#= P((8=<]R,=, %+P"]E-X1MKFPO!=17,LUP[A2@6221G=
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MK9;67S'C60QM(LN=F05+;<=.,YK'M=,2UT/PSIBW>IE="N5G20^'KK,VU64
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M\."Q/?!'4T =[HE]<ZE!<W,WE?9S<2);&-2"T:L5W').<D$C';![UQGB 2>
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MP%C*HS\CJ>%_^O7,^&-+6_\ %GB.:YO]2D_L[6 ;:,WLFQ08$)!&?F'S'@Y
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MM+6*\NHS"WR2?;$/6),GJV1R.10 [3?!_AW1KNYN]-TBUM+BY!622%-K8/4
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M82!@UMC,9#?>&T\8.3GUS6!X.\717OA'0+G6]0@74M2C.Q6PAF;<1A5'7C'
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M*<GC!%>QT4 >:6M[;V&J^)_#WB+1[N];4M0:ZM%%HTT=Y$RH$7< 5!78 =Q
M& <\5*0@\8^.)9H"!)I-M%&WEDJY"2AT4X^;!900/:O1J* .=\!;U\ >'XY%
M=)8M/ACD1U*LK*@!!!Y!!%8&E:3>6/C&[\-K%_Q(DG76H6!X3<6_<8[#S@9!
M[+BN^F0RP21K(T992H=,97(ZC/&:S-"T3^QK=Q-?W6H7<N/-N[HKO<#A1\H
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M1*J[-'A22, E0W!]ZQ[&/3W_ +1\+>(](U>XU$ZE-/!&C7 @NU:8R1R!T.Q
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M\^Q&9)T+J^XIN,>=VS<,9Z]\8YJIIWA;59]!\,Z)J<$$$&B2P2R31S>9]H:
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MTFZ[LWNHY0PV[5*JRGN#\XKF5\(:O=>$O&&CW*V\$NL75U<6SK*751(!M#\
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MKRU7:7A=V4*W7YE.X$%<DYZ=<69/&)MV2VO-.-AJ$AE:.WO+J) 8D(&\N"0
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M%;L-GXHL?$-WK&AVEG<Z=KB0W$MO?3-!):3"-4SPK;AM5<CKD=J .L&J+<:
MNJV$?VE);87$"EMF\%=RY)Z<&O-KW6KS6O#7@+7;VT<74^KV[A86!\P-'(V
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M(HYIB)(U5T96;();T7@=3Z"L'7?"7B;5$UF-H=.NI)=1BNK*[FN&#+ DD;"
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M\I&8*I8YP!G@9/Y4M<'IGB:\;Q='I&KW=UI]\;J?R[6:!/L]Y  _E^3(%R6
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MJU[=:1$S6FHV6GV\DQLC"R_:) V?]:#E 5&,#/)R>E5=7\2Z]HUM8OK[S:?
M]CMGU#3H5N(8+O<03*"K$)@*1@=203TP =S<:/IMWJ-MJ-S86TU[:@B">2,,
M\>>NTGD5<.T?.1R ><9.*BM)!-902B5)@\:L)$.5?(ZCV-<]?:M<W?CF'PU;
M7+VBIIQU"::-5+OF3RU5=P( R&).,_=Z<T 6X/%FF7>ERZC;"[F@BNS9L$M7
M+B0.$/R8W  GDD=JW*\BT[4-4T/P-J-S:7V+E/%,L,TIB4^:'NPC<8P,[B>!
M73-<>(=1\?ZOI%MKGV.SM+>TN4"VJ.?F9]R9/8A<9ZCC&.<@';T5Y_IFL^)]
M?L-+UW2V(MYKHF>WF,(@^S;V4@$#S!( !R3C(/&.!:TO4=;\2Z9_;6G:I%:A
M-1DC-I+&IB^SQRLC!CMW;RJEL@@ D#I0!VH8%BH(R.HSTI:\L;6[SPR?B'K;
MWMS>&PND6&";9LRT4>W.%! !;H"./?FN@O\ 4=7T'Q)X?M9-1>_M-7:2VD\R
M) 891&75TVJ/E.""#GMSZ@'9T5YKHNH>,=0\(7&NQ:I]LN8VNH$L4MHD\TI.
MRA@W]\*I '0\9'7/1>#M?AUW[>T.HW4YA9$DM+V!8;BT?!RKJ%'7J#SWYXH
MZBBLSQ#=3V7AW4+FUNK2UN(X&:.>[)$4;8X9L=A7&_VUJTFI^(-).H7X@31%
MOK:XFACCG1R9%)4!1@':.&4,#GIQ0!Z'YB%5;>NUL8.>#FG5Y+;PWW]@?#%5
MUJ_5;EX=P'E8'^B,P_@YQCC=GJ<Y.".@36-7URT\476G:BUG)H]U+:6T7E(R
MR-$BL3)E<D,Q(^4K@8QS0!W5%>:VOB'Q!XHU?1H;#5/[*@U30&ORHMDE,,H>
M,9&[J/F/7M[X(AU#6/%$=EXWFCU_RVT!A);[;2/]X! LI5L@_*<D<<^_:@#U
M"BN'EUW5M<U.[TW3'GM9;?3[>X#6_DDF28,1N\T'*C:.@[G)Z4R35O$6D:AX
M8NM<NXTM+W-EJ$,"H8XKHC]VP;;NVL001G@D4 =W17"7^N:W:Z+;ZS']ON]/
MN;UY)!9PQO/!9X;RV1=OS G8QX) ;VKH_"VI1:MX>M[V'4UU.*5G*700(67>
MV R@## 8!&!R#0!L45SOC#4M2TFPM;JQMKN>W6X'VW[%&LDZ0[6^9%8$'#;,
M\$XSCU&!!XGN)V\)3Z?KO]H6>I:A/;S.844O&%E=0PV@JZ[5!QCH>.: .OUS
M7+'P]IK:AJ+2);JZH6CB9\%B%&<#CD@9.!S6E7D_BW4[^]\*>.;.YN?.2PU*
MTAMBZ*"JEH'P=H&>6/O6W<:AXHT/Q:NEMJ$>K)J>GW,]FLL"1>1/$%(7*]8S
MO YR1Z^H!W4L@AA>5@Q5%+$*I8D#T Y)J*PO(]1T^WO8DE2.>-9%66,HX!&>
M5/(/M7#Z)XGN=3MM4B&IWMOJMI8%YM/U&U1);>49^=<* Z'IG)'3UHT;Q/J.
MKQ>#],>[:*[U/2O[0O+I$3<VU4^5005!+/D\< <=<@ Z2/Q;IDVGZG>PB[EC
MTVX-M<(EK(9/, 4D!,;C]\=JW*\A%_JOA_P=\0+ZRU$_;K77'87#PH2P*0CD
M8VYP>H'7M72>,M9U6P;6GL=2*&RTLW4%O:Q([JXWDO.74@(=H  ()P^ 2* .
MZJI!J,5QJ5W8I'.);4(79XF5&W@D;6(PW3G'2N)N-4\0ZMXDTC3K+6%TZ+4=
M#>\8I:I(8Y08\$;NOWSP>,9[X(;=^+-4T.[\;-=7*7<6D6MI):JT2H%:17R6
MQR1N )YZ#M0!Z'17&,WC&UN[F2V875J]A(84OFA5A= $IM\L#*-W!Z=<T[P;
MXC_MJ^NX);Z]%W!#']HTW4;=(I[=\G+#:H#(>,$9''O0!L#PCX<74CJ(T/3Q
M>%_,,PMUW%O[W3K[]:V:KWTKP:?<S1R0QR)$S*\YQ&I )!8]E]?:N(T+7=6F
M\5:;IL^H3W-M?:1)<-.\"(IF5D!>'Y0VP[SC>.< C/.0#H[OQ;I-C=B":24)
M]H^RO<+$6BCEQG8S#@'!'/0="0:@B\:Z5-JEKIZ17_G781X&^QR;'C8'$F[&
M O'.<8R,UPUI9W(^'?Q!D_M:\^2\U4%=L6'V[LD_)GGO@CVQ6XU[JFBZ3X&2
MWU*22*^N[>VG66*,DQM S;00HP 4'OSUH ZNW\0Z?=7NJV<)G:?2PIN4\AP1
MN4L H(RV0.V<\8J[8W<>H6%O>1)*D<\:R*LJ%' (S@J>0?:N'MY9X/%GQ$FM
M91%/';VCQN5#;2(&(X/7I4MCK6JZAH?A*1]3*3:AI@N+B.VB0W,\IC0@J"I1
M4!9BQ. "5&><4 =T6"XW$#)P,GO2UY/'JNJ^(=*^'E_<ZE<07%W?R1S^0J*K
MLL<P#D%2,_)TZ<GCIC:FU;Q-K::P_A^5DN-/OVM(4?R?)<Q[=WFY&_YLM]W&
M 5QWR =]17 :CXHO;'Q.++5;JYTJ">YMQ87"PI):3H0ADB>3:2LA/F 9*C&T
MCOGOZ &NBR1LC9VL,'!Q573=*L='M!:Z=:QVUN"6$48PH).3@=LGFN/UWQ->
M:7XHDLM1N[K2[.6:!=/O! CVLH.W?'*VTE')W 9(&,'US'=Z_K$-K\00FH/O
MT5!)9.8H\I_HPEP?EPPW'N,X[T >@45Q5CK6HZ_JG]D0Z@UC)!I%O=O-'&A>
M267=SAE(VKMR0!R6]N7VVI:Q=:_9^&;S48X+V+2OMEW<V2+^]D\SR\('!  (
M)/'4CISD Z631]-EU>/5I+"V?48H_*CNFC!D5.> W4#D_F:NUP_]JZ]%?Z5X
M<N[H2ZD]E-<W5U8+&I?8ZHH42#:.&RW'4<8%5;O6O%.B:/82ZY'<20QSS)?7
M6F1I+,D8P8I&3! &"=^T<8!'!Q0!Z%17GE_XLN;+2]'U%M1N[G0I[5VGUC3K
M=)"DFX;7D0J=J8W9PO!&#5ZPURZUO7XM$M]6VQPZ1#>27MJB$W+R$@,NY2 G
MRD].K#IC! .UHKRX>+/$5U8Z5"+V*WO$\1OHEY*MNI6<*'/F 'ID*.!WSVJU
MKNMZSX8D%IK&L7L=HUJ%AUN*SC,0N"S_ /'PH4[!@Q@$  _-SGH >CU4FU&*
M#4[6P:.<RW*.Z,L3%%"8SN8#"GGC/6K2LKH'5@RL,@@Y!%<OJNIZC;?$'0=-
MBN@MC>VMT\D7E@_/&$VG/7^,\>U '4T5Y4GB+Q-'X:_MV76O,-KKILGMQ:QA
M)HOM7DX8XR#@\%2.G.:Z"XUZ^T/QIJ5CJ=Y+-8W%A]KTQ!'&IWH<21 A<LV6
M0KG/![T =K17$R:CK3:S%X;^V7+7D.F)=W%S;K '>1W9> XV[5*'H,\C)]:-
M]XA\1Z)IFE3>)!/!!Y$JZA>Z3$DXAE# ([J5;"%02<#AN.E 'H98!@I(R>@S
MUI:\[MI;J]^(WA^0:Y-<0OX?><M (_*E/F0[F4%>C]?7I@BJ\OB[6'^&X\>6
MUX=JR&=M.,:>4T E*%,XWA]O.[/WNV.* /3*0@,"& (/4&N(L[GQ!JOCK7-/
MCUS[-8Z<]E,D8M$8LCJS/&2>0"!C/4<8Q@YC\*^)KR^UV+3-8N[JRU=(I&N-
M-N8$6.4Y&)+=POS(.?XB<'GIF@#O**** "BBB@ HHHH **** "BBB@ HHHH
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M646HV8\%1Z)?2V=Q%&7O6 ,$:!\L3(6W&0;<C@DL03W-=@6 (!(R>@JKOO\
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M(7,ACWI$3D@80#).#D@]*I/X"TW[!HUO!>7]O<:,NRRO(9$$T:8"E#E2K*0
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MIKI>GIJ+:@EA:K?.NUKD0J)&'H6QG%#Z5ITM\M])86KWBXVW#0J9!CIAL9H
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M%HX#G]XZ[<J.#U&>#Z&N/70?$=[J.DZU/ 8KC6[<V>M0;N+>':&7'H0%=?\
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ME(@;CER%^5?F'S' ]^#7*:#ITUJ&\-ZQX1N;RZAO'D@U!E#6DB&0NLK,6X8
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M[>VS- ZEMK!/3EBV0%'S<@8S5ZW\4Z/.=0#71@?3E$EVES&T+1(1D,0P'RD
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M*VY$"D@9Z9!QZUT5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\MV&YMF1A5( .>M ':45Q^F^,+^YU?0K:^TJ&WMM:M&GMI([G>ZLJ*Y5UV@
M$-P03TYQGC>UK4;G3K>!K6R-R\LZQ,2VU(5.29'/.% 'YD#CK0!I45P<GQ$E
M3POJ6K1:;#<OI^IC3Y5BNLI)ED42(VWD'S%.#COS6C%XFU@ZUJFC2Z-;#4+>
MR6^M(TO"5G1F9=K,4&ULKZ$<]: .KHKE]*\6R:QHV@7MK9Q&;5'(D@,Y_P!'
M"AC)D[>2I7:1@<D"K?BW7[CPSHAU6*R2ZABD07&Z8Q^7&S!2_"G.W.2.. :
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M?*> 3CCKTK2U'Q9K6DZ;/<7^BVMK);637,IDO/W4CAGQ#&^WEBJ9Y'&X#!H
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M=<?[3!%J^JW4%V7VEHHS 4\M.Q*X3D\'+$X[5UFIWCZ?IT]W'9W%X\2Y%O;
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MTNFZFE\TNYPL@68RA0,<$[L9]L]\#T"LO6]=M=#T;4-3E26XCL$,D\=OM+J
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M'NW"+=G;M[;L$XSTXQVM% '&KX0N;GQ'IFLWJV,5]8S.S7UKN66YB*LJQ.,
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MI6Y110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBV]5$NX#)SCR\^N>37=+X4TOS=1GD6=[C4XEAO9/M$B^<JC X#87@G[N.IH
MF\,7T^I^$]&O[E@UQ=6,$TI QEFC4G]37F\MHL7A7XJR^?<NRS7<8$D[.,?9
MHST)Z]L]AQTKU/3=.MM)TVWT^S1DMK>,1Q(SL^U0, 98D\"LNY\&Z'=R:H\M
MK+_Q-!B\5;F15DX"D[0V 2  2,$@<T <YIK7VF>+_#EHNJ7DUOJ>DS--%*P*
M(\8B*LBXPO#$>_?)YJGIVH^(I_!AGMGN-4N(-;N8IX?M BGN+=))!LC88PPP
MIP,9"D=Z[4>&-+%]87OES_:+"%H+9S<R'8C  C&[!S@=<]!4,'@_1[6TCMK>
M.YB2.[:]0I=R[EF8,&8'=GG>V1T.>E #/!FJ6NK:$T]K<7LH6XE1X[Y2)X&#
M9,3YYRN0.IXQ65XIM1XFU&XTB73+J^T^VMGCE,#1#9<2I@'YW7YDC)(QG_6#
MTKJ]/TVUTN!XK6,J))&ED9F+,[L<EF)Y)-1Z;H]GI)N3:"8&YE,TIDG>3<YX
M)^8G'0=/04 <AX3US5[SX9WL2HO_  DFCQ36,D<I'_'Q$I"$\X.1M.>G)YJ+
M1WU;4M9\/2V-_JPL)-.:75#,#CSL)L_UBD!B2^57 P >F*UM6\(V]OIWB"YT
M2S\S5-5A*3I/=R>7/D;3D$E0=I(!QZ=JR=!\,/'?6LEGIGB#1?)8>;]LU@S1
M,@ZHJ"5]V>F2%QU'(Q0!D6>IZM8> ;_Q5/KNH3W-K<75JL<KKY(4W)C#L-O)
M0<@],<8QQ6OK-QX@\*VFJZY%>PO8KICO'9R7;W3&=>1*I900N#RHXZ=*ZRQ\
M,:1IVDW.E06I:QN2YF@FE>56+DE_OD]223]:K:-X*T'0;>:"RLV,4T9A9+B9
MY@(SUC7>3M7V'![T 94%CK:7\-[%K*QZ;=6;HZ?;6N6EDV[DEBWH IP#D#Y<
M=N*YG3[S66\-> M7.OZB;K5;B*TN@SJR,CQ2$G:1C<"H(8Y_+BNXT?P-H&@I
M,NGVTT2R(T8!NI6\I#U6/+'8#_LX[>E2)X+T..PTRQ2WG6VTR436:"ZE_=.
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M6:LMM;H(XP[ER /4DDFK= !1110 4444 %%%% !1110 4444 %%%% !1110
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M*I96VJ3@X(/.*\[U74])7Q9XDTKQ-J<UI9:K##]B8(K1W5N8@K(C%&.X/O.
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MT9]3L([Y;%[ZV6\?E;<RJ)&[\+G-8GC;Q(/#OAK4;JUO+%-1M[9YX8+ELF3
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MU*TN?&7P_D2ZC??I5UR6Y)*0@=?4JV/7!J/0=*LO%GAOQKI/GQDS:Y=M%(C
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MR3I%-!+<PQ#+26ZRJ95 [Y4'(],T :FH:W$V@:G>Z/>V5S-:0/("'$J!E4L
MP5@><>M1Z/K\,OA+1]6U:[M;5[RSAF=I'$:;VC#$#)]S7/W&J^%]8TO7]<T:
M2.>232GBN+U"PC"A6V(<X&[YCQC([XR*QM*UC388? UO))#;3OH 6._E)=?N
MQ*\$:9VM*2 >02-N,'- 'H>H74N-.>RO[&*.:X3>9_F\Z,@_+&01\QXP>?I4
MMQK.EVF_[3J5G#L<1MYDZKM8]%.3P3Z5X_I-W8GP#\-R\L0FM]:CC9GP&0#S
M01ST RN?PK0O(M'=_BMN2R8B$;,A>#]D7./?>.W\0]: /5$U"REOI+&.\MWN
MXUW/ LJF15]2N<@4D6IV%Q=-:PWUM)<)G=$DJEQC@Y .>*\VM'TV#Q!\-)+=
M[5))K.<2.A4,^Z!?O$=<N._?WJ3P==S6NM:+86]Y:ZWH\UM,UC= ;;NQ3 )2
M8 X(^ZN>#N S0!Z0;ZT%R]L;J$3HGF-$9!N5?[Q'4#WIBZG8/#%,M];&*9]D
M;B5=KMTP#GD^PKC];OK32/BOH][J$\=M;S:3<V\<LIVJTGFQ,$!_O8!P.]<1
M;2:7<>%?"Z7'V<E?%LH=)@ 0AEG)!!Z#!7(]QF@#VFTU"ROX6FL[N"YB5BK/
M#('4$=02#UKG$\4M<^/[31[*[L+K3YK":X9H3O=)$9  6#$8P^<8K@]?D\B;
MXB0:2BO&LVGR3V]KC+0A5$^%'^R"&_&M74-7T[5O']A<^'+VUGGF\/WD-O-;
ML"/,W1F-<CH1R<'D4 >D1:GI\]Y)9PWUM)=1#,D*2J70=.5!R*2#5-/N9U@M
M[^UEE96=8XYE9BH.TD 'H#P??BO-?"=UX;UV/P\)+Z\?6-)B*26$D:QFT.S;
M*)<(/DX/WCSQWK5^$]EI+>%(KRWM[1KR.ZNT,R(ID13.Y"YZ@%0IQTQB@#MK
MK4K"RDCCN[VVMY)3B-9950N>G )YHO-2L=/"&]O;:VW\+YTJIN^F3S7G;ZIH
ML/B+Q=H'B\$-J,R-;)(K?Z7;>6JJD6WDE6#<+SECCG-7+"[MK#QWXCMO$/E6
MMM=V5K]A%XPV-;K&1)&&)P2')R,\[LT =W->VENR+/<PQ-("4#R!2P R2,]<
M $GVJN-=T@P03C5;$PW#[(9/M";96Z84YY/L*\HT6Q2UN/AI:ZRL9N ;X*ET
M!O$)1S"K9YZ;  >_'6H=0BT<^"OB:46R,BZA-Y.-N1F.,KM]/GW8QWS0![#<
MZII]D9!=7UM 8T\Q_-F5=JYQN.3P,\9H&JZ<UQ!;K?VIFN$\R&,3+NE7^\HS
MDCW%<%:MH]W\6&EE:QF#^'8G9F*L&;S6R3[[>_I[5R^F'2[?X;^"KE&M8YU\
M00!I05#A1<,#D]<!,#Z8[4 >S3ZG86MS';7%];0SR8\N*2559\], G)HN=3L
M+(N+J^MH"B>8XEE5=J9 W')X&2!GWKS07%JVB>/](UYD&HSW=S)%%)]^XB9
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M%G!9"C,&P>",Y''%0^'/%]GXH6*6PL=16UE@\^.ZGM]D3#=M*AL_>]O_ *]
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MN;$)I;_:42*-]AWAT)R7+?=8@@<<KR:['5/$FD:*V-0O%@ V;V*,RQACA2[
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MG020S(8Y$/1E(P1^5<S;> -*M['P[;;YG.AR^;%*S?-*=I!W'T+;6Q_L =*
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MBL@C.XC'10,8_'-2IX2$MYIDVHWIO1ICO):EX0LGS*5VN^?F4!CQ@9P,DXH
M@T74_$.M66AZW;FR-AJ \VXM6!#0PLI*%6_B<< YX.3C%<?IFK:QH'A[5-6M
M);3[%#XFGBFMGA+/*LEWL)#[AM(W9'!Z?A77Z#X(;P^RVT&N7TNCP2&2UTZ5
M4*0G.0"^-[*"<A2?3KBHG\ B3P[>Z,VJR^3=Z@=0>00KO#F42D#G&-P';.*
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MHC20$;2A^\3C=GMTZ]G:MX?-_K6G:Q;7K6M]8I+$F8Q)&Z2;=P9>#_",$$4
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MB[H&CW[)5CF#'.1D J<#Z&NRD\+M#KU]J^EZA)8S:C&B7B>6)%<J,+(N?NN
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M<H2+AU5&?>P/RCYL#'IDYS@2)K.J:UK&N:=I4]O:OI(CCS+$9!+.Z;\'D80
MJ..2<\C%)-X)9?$-[J>FZY?:=#J)5K^T@"%9F QN4L"8R1P2O/T/-6F\*BVU
MV[U72+Y["2]A2*ZC$0='V#".H/W7 XSR,8R#0!S]GXYU&^L?"6N;(;?2=5G-
MI>QM&6>"?YE7:V<;3(I7)'<>M:=[XDO[;R1$$F.I:FUG8!8QE(T1B[G+ ,28
MWV\@8*GGO?NO!^F7'@IO"T8DALA"(HW4Y=&!W*^?[P8!L^M+KOA*RUO0K73%
MFGLC9/'+97%NV)+=T&%89Z\9!!Z@F@#F]7\1>,=$\/ZO=W%G;Q_9;NW2SN+A
M%_TF*5U1@520[&4MUZ'CBM"/7-?L_$VL:/<O87DL>E#4;-EC,"JVYT\MR6;Y
M<J#NX[U->>"Y]3\/3:;J.O75U<7$D3S7;Q1JV(W#HJHH"J,CG@DY//3#]6\%
M1ZUJ6H7=Y?R 7VEG3)8XD"@1Y+;E.20VYCUR,<8[T 9^D>)]4N_$ATC[5;7
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M.RY#G.64L"-W'/L*2,Z7K>M> +N.*\2-I=0B9+N5A+$41]R,<_PL",YY &:
M/6:*\PL+.0W7C34UN-0N+K1[^66PB:[D90PMD8*5W?,"3T.1Z8YS9\/VIO(_
M#WB2V\41*LT#+,D<3L;TM'DB3,A&Y""V=O&".!Q0!Z-17ENCW5]I]Q_9FL!K
M'4Y-)N/LNM03F6VO% 0F=@>5D7 ;GL3SC K0\,S2#5+W0M>T^73-2&FDR207
M3-;7,0.UID;.4?+<Y^;D')Q0!Z%1573+:"STJTMK65Y;>*%4CD>0R%E P"6/
M7CO5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ19PS0Q&&.1(AN5#U&::GA+P_'9P6<>D6B6T$WGQ1)'M5).S@#^(=CV[5E^
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M;A^^9NJ@ XP>.<TVU\8>';VYM+:VUBTEEN\_9U23/F8ST/KP?KVH L:1I?\
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MRS7$\&R**&-G9VW#@  FH/$6KSZEX.FT?1+"\N]1O[4VJ!K:2..'>NUGD=U
M4 $G'4]A7<44 >=0:/\ V#XK\!Z9&LLT>G:;<VTMPL3% Q2(+DXP-Q5L FL_
M2;75(;BWT_0[NXGTJ\MKG;;7T!6?1Y#&VW$F =I8[0#VY&0,UZK10!Y[X,U2
MTN]*T+2[S0+J+6-&A6&7[19LJVA1-C.LA&T[@. I).?3)$'AF$1?"O6HWM)H
M[@MJ'[M[=ED;S))"N 1D[@5QCVKTFD)"J68@ <DGM0!YCIZ-]N^&&^VG_P!$
MT^5)RT#_ +AC;H@#\?*=P(YQR*SM0MWD\!?$:".RN#/=ZI.]N@MGW3*5CVE1
MC+#(;D>AKU]'61%=&#*PR&!R"/6EH X=9@?BM:WOES?9O^$?>,S&%]@<S(P4
MG&-VT$XZURNFP20?#SP/ ;*Y2>WUR.6>/[,X>)1)(69AC(&&')]:]BHH \>U
MFXGNA*/[,O[9[3Q1#/):6U@Y0QK.I-PS!3YC,.?E/?IQFNET^5K3QGXT%Q:W
M:+>);S0N;=RC(+<*?F QD,,8SG/:N\HH \DT".^TNP^'FIW-K<BPL;.:TO4,
M+;K65T4*[+C('RE2<<9]#4?B73+B72?&]_;VT\EEJM]8&T@2!F,IC:/S9 @&
M<'!YQSLSTP:]?HH XR [OB\\\<4OV=]"2(2B)@A<3,VW=C&=ISCTI_Q/22;P
M)=0PPRS3/<6Q6.*-G8[9XV/ !/ 4G\*["FK+&TCQJZETQN4'E<],CM0!P\;1
M_P#"T=7O'AD-NVB0QK,8&*L0\C,H;&"<%>!5[X9QRP_#C0X)XI8IX;81R1RH
M49&'8@\BNLHH \VU*+3YOC)+<ZGIS7-@FA+ )9+%YHQ,)V;:#M(SM-1^*A92
M_#Z^TK1=+NA9PWMOY:"T==[&Y660(FT':H.<@8ZCM7IM% '$AHQ\7GO?)D\@
M:"L8G\EMF[SBVW=C&=ISBN,T=H['2_APM_;RQ>1J=Z'CF@8-'E9BI*D9  *G
M..!SVKVFL75_#_\ :NLZ1J)O)(6TR5I8HU0$.S*4.[/;:3TQ0!Y]K^E32:/\
M1]1LK69K75HH8K2..)B9Y%CP[JH&2"2!G'.TGIS6_#<2:7\0SJ=ZDW]EW^DP
MPVUSY;%8I$9BT;<?*6W9&<9QCJ*[RB@#S*T\)7TGP^U!8E-K>QZI<:MHZ2C:
M;?$A>)2#]T,,Y!Z!SFD\1I=ZK\(-9U*6RF_M#6HDG6UC0R.JG:(T  SP@!/N
M6KMM;T$ZY);!]3OK:VCWK/;V[JJ7*L "KY!...Q!Y-:X 50J@ #@ =J .(G,
M3?%;2;M('^S)HT\?G"!MB,9(RJ[L8!VAN/K7(V8N].T?2M2DT_4Y-/L=;OVN
MX+9)8YDCE9_+E51ABH#=NS&O9J* /*M:M=,FT2UN]'TF_6WO-?L[J9IXYG><
M*Z[Y2CY95"C&2!G'3&";&L6T]YK7Q#CMK6=VO-"CB@*PMB:18Y@54XPQ&Y1@
M>M>FT4 9'A:Y6Z\,::ZQS1A;:-")HFC;(4 _*P!ZY'3M6O110 4444 %%%%
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MNL3W<D$5EJ6D+IQ\N1FDC8,S!\%0#R_3/;WJ_P"'[7Q?"B)K]YIDRVZ%8VM
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MQ!X8>TOI]-6^DN;>79"SB&)8I%? )!9F8K@G '3CCD F'BK6FU^]T)?#\/\
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M^W^1]JQ^\$&=@/H">3]>/H*Y[7M!U+4?&/AS6+4V@@TEIV=)9&#2>;'LXPI
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M(P6 Y('0?J?SK B\;:'<37D4,E_*]E(8KGR]-N6$3CD@D1XZ<_2NAKAO /\
MR'_&_P#V&V_]%)0!TT.OZ;=Z'+K%C<"^LXXVDW6H\QFVC)4*.2W&,=<U?MYE
MN+:*=5=5D0.%=2K $9P0>0?:O)8[F[TGQ#\5)]#G^SV]K;1W:,J!D2Z$!9\
MC&21\U;FL^)M2TRRTF\O9;^#29]-1YM1LH$E\BX(!W2J5)"8[@8SG/; !Z%6
M;_;ME_PD8T',OVXVQNL&)@GEA@N0Q&"<L.!FN/\ $.NZG#87]QI^M"4VVBK>
M0K8QHYW[7;S92Z[1&=HV@$$C=@''%>0W^N>/-#EM[]M/N+KPR\KS0Q*[+NDB
M)"AL@<GN#Q^8 ._U#4(]-BBDEBN)!),D($$32$%C@$@=%'<]J@@UVQN=>N]%
MC,OVRUA2:56B95VL2 02/FZ'IFN 3Q1XC3P_"MQ?J;VQ\31:1<7"0*!=Q&5
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MYP/0 $G\*\LU#7_$UOX:\6:PNNOOT/59(H(1;1;98U\OY'^7.,,?NX.3G)X
MZC^TKW7?$WB'2K:_EL8M(BA0&)$9I)9$+[FW _*!M  QGYL]L '0Z-JUIKNC
MVNJ6+,UK<IYD3,NTE?IVJ]7(_"[_ ))CX>_Z\U_K774 %%%% !1110 4444
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M2"!4*[!O #Y!4DY '?CMBI=3T:WU@"*^DFEL\@O:9 CDQR-V!EA_LDX/<&M
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M:?=SR7,-Q82,\,EO+L/S+M92?0C\?0BLZ;P/I\^GZU8R7=\8-9E,MV-Z99B
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M<L6/H,[E%-9U1=SL%7U)P* .6;P!I?\ 9<NFI=:@EF]V+Q8A,"(W$GF +D'
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M>]TF#R(Y[23864JJNIR#E3M'N,<$4ECX*L=,A"6%]J-N5O);P.)PQWR9W##
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M8L]SI]F\#%5)DW><&9#WR.I':N;T"Y^S^$O ,$^/[#FU2[CN]W*%M\WDJ_\
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M[\!W)).,#YMW7K7K\4,4$2Q0QI'&HPJ(H  ]@*JII5C;QK]DL;2%XRS0E8%
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M[T\\'_IF]=0=*TYGE<V%J6E<22,85R[#HQXY([&GQV%G#<O<Q6D"7$GWY5C
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MXK#7M5\"&R3[!/=KJD)\H;?LK'<Z>G$J[,==K^U:6EQ06_Q-\8")40'3K-F
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M?:'J$<MA]H78M];PS!XQD]#M&,''04 =EJ7CK2]/TW6+@1W3W.EV_P!HFM#
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MK:&WO6LK5+GYO*VM@AQY;A&"X(8< ]^0#O&\2Z=]EAGB-S/YT;31QQ6TC2%
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M8VUU'87QLS;2-MDN"C 2E7+!4QEL9!SM[9H ZRBN,U3Q=J6[5CHEC]K?3)A
M;<VTKFY<*K,JR*-J$!L#.<D=A@DF\9RMXA?1XS:V5X$@D@M+]61[I7 +;&W
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MS+H'FA<V9'FJZ%,??XP#UYY]N*;<_#R>ZM-25M86.[GU==8M+B*VQ]FG554
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M2QGM#'.\0$P7,@4X#C!/RGJ,\T 6@ J@   < #M2T44 %%%% !1110 4444
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M'[;,+B=5N954R@@^8%# *^5&64 G\:M2>%]*-U=WB6KFYN;3[)(?M,BAH@"
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M(K\E,G'W<9QCO7=^%[/5-.6_M=3U!+M1/YELGFM+)!$PX1G8 M@@X)YQ4;^
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M;A%V%L[0<G@G!QZXKS"2XTF[NO$7ACQ1>:A%>W&IR3P6<: -=QE@T+1,$))
M55^]QM["K;1Z4?$GQ(\Y;0G[# /GVGGR'#?CG /OB@#TA-4T^2_-@E]:M>A/
M,-NLRF0+_>VYSCWH.JZ<-0&GF_M1>GI;^<OF'C/W<YZ<UY?ISZ?;P_"F6)K:
M.8QXF=2H;+6A#;C[O@'/?WJ/P]<:5J=M9:#KMYJ/_"1Z?J1G.GA K&<2,PF5
M@F2A#;BV[&": /4'US2(Y%CDU6Q1VF\A5:X0$R\'8.?O<CCKR*JCQ3H[>)7T
M 7T'V^.(2O&9 ",GA?=L G'I]:\IU*/2O^$"^([QI:>=_;$ODE0N[I$5V]_O
M!L8[@UV<5[:1_%JY,\J>7>Z% (">5F EE+8/0@ @GT!STH Z;3-25=.CDU'5
MM.G>6X>*.:!@D;DN0J#+'+#A2,]15RSU*PU&.22QO;:Z2)BDC02JX1AU!(/!
M]J\:A.F2?#[P]'*;5D3Q8/E;;\L9NW)^B[2#Z8K9U!+!M8^)5G%<BUAETBW)
M-JNY@1'*&(4=2!M!'TZ4 >DV^KZ9=R>7;:C:32<?+'.K'GIP#5VO+_#.I:'X
MA\8:/?-JVC&_LM,-HEI;3;WD<E6) 95("A3@#)Y/3'/IS[=C;\;,?-NZ8]Z
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MM$^'FP\S%%QSN*D>_(K.\-ZI93^.?"T]O=Q202Z%+;Q);QMY<6&B(B#')8J
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MP>UL8$1]%NED\@J"PQ$0,CN2&(]\T =ZVOZ.BSL=5LL6Z-)-BX4^6H."6YX
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M56*[Q@GY3C(]L5?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K&\36]_>Z2;&Q@$HN76.Y)E"%8"1
MYF/]HKN ^N<\5LT4 <-XO\%"?3K*X\,:;9V^LV-W%<VTG$2C:?F5B!G:5R,#
MVJKKC:M=^,X;C1]-AEU"TTWR[M(]0$$L8E?(4DHRLOR$C@$=>,BO0ZR=3\+Z
M'K-TEUJ.E6MQ<(NU9GC&\+Z;NN/;I0!Q\.FWM_:>&H-/T)-/CT#4\SVQNED
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MIZ1K5YKGA6_DCAF.G3S3791]H'F1L@5 >6V[NIQD#U-==2.ZQHSNP55&2Q.
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MY:X+'W/4_C0!Q=KX5U=M<U:X_L[3["TU+1A9[([@NT<@,G7Y!N)W@D_SI?\
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M,J%-X&2N1C.*YV7P3#-X 7P@VH3_ &185M_/"+YGEKC Z8SP.<4 &I:W>?\
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M*HRSL3@*H[DD@ >IJQ6!KNG:[=ZE97.EW6G)%;*Q\J\@>0>8> XVNO(&0/\
M>/X $WA37)/$?AJTU:6V%L\^_,(;=MVNRXSWZ5LUQOPNM]3MO UI%J0B5@\O
MEHD3(RKYC?>W$Y.<D=."/K794 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>josetrevejo-tarsussepara005.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7<6L<=PZ%Y)9L==C,-JA?7DGVJCI_A_5+_PYX1T2]TZ2R_L6:VFN9Y)(V5S
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MEZ?<7][,L-M;H9)9&Z*HZUFP^)[9]5@TRYM+NSN[F%IK5+A5'VA5Y8*0Q&X
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M,B2'!!Z-T/I6E'J^O1^,7T.ZN;(I=Z7)>V\D5N0;=U=4VG+'>/G!SQR.@Z4
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MM;E8-IBFB 9E9=V"I!!'0C&.>M '745P%EXRU:Y\.^"=4<6H?6KN.WND$1P
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M!MVX/!4KP1Z5M1/YL*28QN4-CTS5?3;B[NK,2WUB;*?>Z^3YHD^4,0K9''(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZEJVI:U9WL%LJZ9=FU$T)8>:=JN#M.<<,,C)P: -J/4K&;4);"*\@>\B0/)
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M* 1G.W!'&XG@<BL/1/%VJ:=\/X-;U>YAE6?4IH9;G[,Y6V7[1*"[@-DH-JJ
M,8R,DXH ]+HK,T*^FU+3?M4D]G<([MY,]FV8Y8_X6')Q[C/!K G\5:E=:?KV
MIZ1!:R6VC3RP-#,&WW)B ,FU@<)W R&R1VS0!U=Y>VMA 9[NXC@BSC=(V!GT
M^M):W]G>V*7UK=0S6CKO6>-PR%?7<.,5P6I:G=ZUXN\"7VFW,"6=];W-S DT
M+,1F%3EL,,G#$#&,9/6NB\4^&VU/P5?:)HWV>QDE :(",+%NWAR& [,00?\
M>/6@#5L];TK47V66IV5RV<;89U<YQGL?0&KU>>:'XFM]4\5:=IWB719-%\4V
MJ2?9PP#17*%2'$4@ZK_%M[8[X-6[7QEJFHKI>HZ=IS7>FWMR(WB2TE$D4))
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !2$ C!&12T4 %%%% !1110 4444 %4GT?3Y-535'M(C?HF
MQ;@CYU7^Z#Z>U7:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *IZMJ"Z5I5S>LAD,292,=9'/"H/=F( ]S5RN
M<UR"35]<T_3)(+Q-/C)NI;B+*J95QY:;AR.27SZHO/- %7P!K>H:GIM[I^ML
MAUO2KM[:[V<!^=R.!_=*D8^AKK:X!M)N_#GQ-M]1TVUU"[T_4K0P:FY9I?+=
M#^ZD)8Y/!*X&<"N_H XKPWJ-UXWEU#4S>3VVD0W3VMG!;-L,H0X:5W'S<G.%
M!  '.35AY9X-.U]8O$7VSR[<S6C+)&9;?:AR#M'(# ')'.<'..:'A33[WP)-
MJ.CW%G<7.C2W3W5C=VT9E,:OR8I$7+ @]" 0<]NE5].TN^BF\>ZFVFW$<6KE
M?L:%/WDN(-G*]5RV?O8]: &^&=4&K>$M$N)O%\PUB]AB/EB6(EI2,E2@7..#
MGT&:-?\ $6K^$?&TMU++->>%UMH&OD8!GLS*\JB5<#)0>7\P)/WN*F\-F?2_
M FC6-QX:OYM4L;:)5C,( $RC ._. ,]3Z9Z]*WX8C<>*]42ZLY'M9]/M[<N\
M)\J5E:<NO/;$B]>#GO0 OF/=>*X!#J$S6,^GM,L<;C8QW* X(&>A]<=ZY#PO
MKJWFC:I-K7BZX@N+;4+FW11-"CA$<JF%*\G\.36EX6\+ZCX4\47<'FO/X>BM
M&.G9RSP!G#-#ZD#&5]CCM53PA;R:=H&JV6L>'=0<W.HW4XC%N&WQNY*\YX./
M<8H M^(;C5++Q3X+TS^VKF*.^$\5\\>P>:8X=P;E3M^8=O6I_!>MZE?^)/$F
MFRWIU/2K"6);34"B@LS+EXRR *VP\9 SZU2\0V=[K?B;P9>7NB2R6UN;F2_B
M,7F+ )(MJ*W]X@D [<\@U<\-VNH^#K^YT!K.ZNO#XS-IMU$OF&!223 X^]P?
MNG!X.">* &^._%.H:!=6,]BH:QL)8[C6#C)6WD8QJ ._)9_;RQZUI^/KZYL?
M .KZEIUV]O<VULT\,T1!Y R.H((JE9^'(?$&D:E<ZS%J5O-J;2?:;8S.FV/&
MQ%VJ<'$87IG)S7/QP:_<_!;4/#U]I5\VK16SV, ,?_'P@XC?.<#Y<9R1R/<4
M >AZ'YAT.Q>:>2>5X$=Y)""68J"3QQ^5:%<M8ZU?1:3I]G#H.I"Z\N*%C+$J
MQQ' #,QW<A>3QR<5U- 'G*W]W)XS\96=WXGNM.L-,AM)+=RT6V$R1NS$[U.X
M94<&G6?B#7=1^"5QK]ZTEEJ\=A/.DD:;"Q0-L?:1C#  XQCFJLOA!/$?C+QB
M-3T^YAM=0BLQI]^8L-')$C9=#U4ABO7&<5?N[CQ!J7PWUK1]6TJY.M_8YK-7
MACW1W;%2JR(1P V02#C'- $VB7T6H:=H++XMEDU*Z6"1X!-$_F$*))%*A<@%
M0P[8XJ72[R_F^*>N:=+J%P]A:V=O-#;DKM5GW;N<9/W>A/>C3)Y;7P]HL \.
MWKZG:00Q(7A"K%)L\MF9L_= +9QGCI56V-]I_P 3]=U1]'U&6QN;.WABFBA!
M#,F[=P2#CYNN* +WQ0U&^T;P!J.J:;>26EW;&(I(F#]Z5%.000>":M6<MI-K
M5I#8^*9;N50\TEMYT4JR1@;3G:N1AG0@Y'2L/QZ=6\3?#W6+.UT2]6>>6*.U
MMW0>8ZK(C,[8.%'!P"<_+[X'0M?A]0M)+70+P7)/E&>6 (L41(9\G//"# &>
M<4 9OQ"\0:KHNF(^B1B6YML7]TO_ $ZQ,OF#ZMG ]@WI6GK^L78\"WFL^'D^
MUW#6?VBT"KNWY7(('<X.<=^E4[#21KMWJFHZE%J-K)/)]G2$RO$/LZ9" A3@
MY)=O4;\'I6-X1_M_P]X5U#1H])O)FTVZ9=+,H"_:K4R JN2?E8 D?-C P>QP
M 7O#.HV_B!M,U+P_XFN;ZT1S_:%K<,A?F-@-RX#(P?;P,*>PJAI^K,_C;Q7I
MVJ>)YK2UL);<6J//%'A7B#-RRY/)I;WP_#J/C?1=<T/2;O3-1BN"VIW#Q>2D
MD&T[D?M(Q.T KGN2>!4NBQW%CXW\77]WHM\]IJ$MN;:06^X.$BV-QU'/J* .
MOT+<VBVTAOGOEE!ECN)  SQL2R9P .%*CIVK!^)^HWVC_#[4]3TV\EM;RV"-
M')'@]9%4Y!!!X)K=T*1WTQ0=/>P@C/E6]O)C>L2X5=P!.,X) ST([U@?%&QO
M-5^'NJ:;IUI-=7ERJ+%%$N<XD4G)Z#@'K0!'XJ&N^&O#\^NZ5K%Q=FPC\^>S
MO5C9)XEY?#*H96QD@@XXZ5#!XKE\5^*;'1])N)+2P.EQZI=3H!YK+)CRXE)S
MMX.2>O88ZU8\5/K'B7P]<:%I.EW-NU_&8)[R\"QQV\;<.<9W,V,@ #'/)%58
M?"TOA'Q98:QIEO+=:;_9<>EW44>#+&(\>7*!_%P,$#GN : +.I:K=>$_%FAV
M<EU-=:3K,C6NV=MSV\X&4*MU*MR"#G'!![5EZ/K'F^(_%-IJ_BF:TAL+U8[9
M'N(H]L9C#'[RY/)/-:NI:9<>+/%6AW9MI[?2='E:[+SH8WN)L8150_, O))(
M&> ,\FJ'AZ.>P\1>+;B_T.^>VU"]66W;[,&$B",*>.HY'0T +XDU^?P_I/AZ
M6\U*\.BW,["^U2.,>8D; F'=A?E!RH9@ >.,9KH_#R3-/<W4.LMJFD3Q1-9N
M71]AR^\!E'S#[O)R>W:J@O[]+:PC?P[<'2I4FAFMMJN\$:[5C+J3\V0&^49.
M&'!P:S?!?AQ=&\5:U=Z39W&G>'[J*+R[292@:X!.]TC/*+C:.0,G/& * .WG
MB\^!XA))&6&-\9PR^XKS[P1XLU(7J^'O%$I:ZN0\NF7Y 47<0)!0X  D7N .
M1S[GT-W$<;.0Q"C)"J2?P Y-<4/"\?B;P';Z=>Q7%A?6[F6WG*[9;68,2CJ?
MQ'0\@XH IZCXEU#0_#\2P7+W6J:IKDFEV;W.&6+]^Z*Q QD*J_B<9K2\3QZG
MX9\-76N:?JEW=7.GQ_:)XKI@T=RB\N"  $.,D%,8('4<5B/X2\0:EX$TMKQ8
M1XETK5GU-5SMCG=9W;&>P=6R/J.E;?B:>_\ $WABZT33M-O(+O4(C;S/=Q&.
M.U1N'9FZ.0,X"%LG';F@"CXGO;]_ NI^+M-UN]@1]/6[L88Q'L13&&&X%222
M2<\^E=!H%C?HMG?S:Q=W44UF#)!/L($AVD,NU01QN&,]Q6;XMT5X/A9>>']*
MMYKF0:>+*VC1<LV%"C/8<#J:Z+1-XT*P62*2*1+=$=)%VLK!0"#^- %FZ0R6
MLJ"1XR5.'0X9?<5YIX0UIM;\!:9=WOC&:+6KU?+ 66'(E9RJ?N]N?3CTKTN[
MD\FTEDV.^%.%C4LQ]@!7GG@N*?1/ASI>FZGX9U&;4+)=YA6!23(LA=,-G'7'
M.: -+QVVMZ+]E\1Z=?WDFG6<H?4].C"G?!_$Z'&05ZD9Y'IWOZ;)=^(;B;6[
M'4;B+2Y(=EC%P$F;G]\01N"DX '<#/<4^]DOM7O[?1;BRN(K)HM]]<JA\N4C
M'[E3UP><D\8&!RW&/X1M=2\*^(M1\.I87<OAMI/.TZZV96V+<O">^T$D@XP*
M (=2CU;3_''A;1%\2:G);W\%VURS>5N9HD0J1A..2:3Q5<:GX>;PQ!)XBNEC
MNM5-O<W#F-2T+!W 8[< @ #( Z5?U^UO)OB;X6OH;*YDL[&*[2YG2,E4,B*$
M]SRO;.*3QY:WEWJOA9[73[F[CLM36ZN?*CR$C",N>>IR>@YH TM/6&^O[F.Q
M\37-Y$D&V94EC?RW8Y1@RKP<*W!SU'%<]X$\6ZE++%X?\42$W]S";G3KWA1>
M0GDC@ "1.X ''/N>FMKX'5V>WT2ZMT>'=<W,D.W<$SL15!R6RY/3H#[5C?\
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M.Q%4');+D].@/M7-> Y=6\.^!(=.F\.ZC)J,<L["#"(IWRNZY<MM PPS_(T
M96J>-M8O?A-K>IK.=/U_1;S[#<M;8*&5945B P/RE6[]#76>*+/4K'0M8U2W
MUV^A^R:;(]O$A0CS$1VWME222<<9Q@5R>K^#-6L?A-KFG"!K_7]:O/MUPEJN
M4$K2HS*"<84*O?K7=^*?-OO ^KPVMM/+/=6,T,4(C(<NR,H!!Z<GJ>* .:&L
M7OA[X?6OC.]U:\O572DGGM)M@22614VD%5!7YSCKT8^E;5KI&M7?A^*ZFURY
MCUJ6$2[TVB".0C.SR\8* \<_,1WS5/\ X1I_$7PA@\-7BR6EPVF0VSB5,&*5
M$7&?4!E'3K5RQUK5;7P_#;7&B7CZW%"(C"B9ADD QN$OW A//)W =L\4 <G>
M>-+_ %WP5X5UJSNIM-N+W6(-/O4A*D#+LD@&X''3(/4#%;FC:SJ(^)=[H,.H
MOJND1V"SR3.J%K2??CRBZ  Y7YL')_"L&_\ !=WHO@CPKH45K+J<]MK,%]?M
M%'N0KO9I3SP0-V .I':M[3-.O?!WB::/3K&:X\,ZH3<>7"G.GSG&[Y>#Y;]<
M <$'@4 =S7&:9JMUXM\4ZY:QW4UKI.CS+:;8&VO<3XRY9NH5>  N,\DGM79U
MQ.EZ9=>$?%FNW'V:>YTC6)EO%DMT,CV\V,.K(/F(;@@@''(- #[/5[O3_'DO
MA&^NI;B"ZL?MMC<M@2IAMKQL0!NQU!QG'!S7%Q>*-=MOA?!XAC\0W$^N&\>*
M&RD2)UN\7!C$80*&SM&<J0>,UVMKI5SJ'CN3Q=>VTUM:VEC]CLH'7,LF6W/*
M5&2O90IYZD@5R.@>#M4MO!ECJ-EIS6/BS2+FXGC29 OVJ-Y&8PNPX(9" .?E
M('2@#UV)G>%&D38Y4%ESG:>XI]4]+OGU&PBN);.XLY6 WP7"X9#CD<<'ZCBK
ME !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !117'^*-5U6R\7>&=,L+U8
M(-5DGCFW0JY7RX]X*Y]<8.<T =A17(>&?$.I7_BCQ'X=OVAF;2C$8[ZW38&$
MB[MK*20'7VX/H*I^&M5UG6;37KB\UI+:/3=3N;-6%LF/+B(PS9[XZ]* .[HK
MB=?U77=+U#PC9?;HEEU*X%M?%85()$98LF?NY(/7/6NSD1GA*+*R,1@2  D>
M_(Q^E #Z*X#PGJOB#Q%X$MM;GUN&VN[@R(H^RKY8<2M&GOR0._>NOU;47TO1
M9KORQ)<*@6.('_62L0J)^+$#\: -"BN=\#^()?$GA6VO;I!'J$9:WO8@,>7/
M&=KC';D9QZ$5S^F^)-7\2Z?K,^E:M;P:U933Q#2)8%81[&*H''#DL #N!VY.
M,'!H ]"HKD->U;4[/QWX7TFVNQ'::J+G[0IB4LOE1AAM)'&2><YJ@GC&_P!$
M\=W&C:XRR://,EO9:AY83RYRBOY4F..0W#8'(_( [ZBN;NM9?2=7UN?4+UO[
M,T_3XKPIY:Y&XS;AG&3Q$,#U)ZU'H4FN:_HUOK%Q?G3C=QB:WLX84=8XV&4$
MA8$LV,$[2O7'O0!U%%4='.I'3(_[6\G[<&<2&%=J$!R%*@DD K@X))YKF=0U
M/6G^),7A^SU)+>TETM[W+VZR,KB0)CM\N#GU]Z .THKBO"_C6XU'POK%_JEO
M']ITB\GLI#; A+EX\8,8))^8D #)YJ_X&\0W/B'P^SZC&D.JV=Q)9WT*=$E0
MXX]B-I_&@#IJ*\]AUKQ#<:GXP@CU>VA31&3R&GME*L#%YG[P@CCMD8K3\/:K
MK?B_P[HVLPS)I45S:M)/%Y(D9GW #;N/"X#'OD,* .OHK@O!.I>)?$WA72M<
MFU2$?:'D$\"VJC"AW3*MG@C ;G/<5+X<\2W]MK>O:-XJO8EN[$?:K>18Q''+
M9XXD'4Y!R&YP.* .XHK'\._VK)IYN=6G+/.[/#"8@ABB).P-CJ^W&[MG@#CG
M%U;5-87XC:=H5IJ"P6=W8RW+Y@5V5D91@'T.>^: .RHKCE\2:GHGC.QT#73;
M3VVJ)(UA?0QF,[T&6CD4DC..0P(STQ2^'-8U#QM83:Q:7S:?I;3/'8B*)&>5
M48J9'+@\$@X4 8 ZG/ !V%%<"WC#4'\/>+H7:*#7O#<;O(T:9CF'EF2-]IR0
M& Y&<C!YK3TJ;6KS1-$U!M9B\Z]2WE:![=0KAE#NJD<@[0^/I0!U=%<3!XAN
M=7\8:UH<>L1Z7>6#(MK:/"K&X4H&\UMW++DD80J0!R>:ZG1WOGT:S;4U1;\P
MJ;@1C"B3'S8'IG- %VBN!U#QC?\ AGQV;#5V67P].D2I?>6%-I-(7"K(1P5;
M8?FP,<9]:WKO4Y;#Q!=M<WI73+;3OMDB>6O&"P)SC.,+G'KW[4 =!17):!=Z
MWXIT"'7!?_V8MVIEL[5(4D58S]PREAEB1@G:5QG'O46@Z]JOBVPQ;S0Z;>:?
M>36>IJ(_- DCXPF2.#D-DYXX]Z .RHK@O"^H^)M>AU*<ZK;YL-9ELC$;50)8
MHI &YSD,5SSZUTGBR\NM-\):MJ-E*(KFSM);B,E0P)1"P!!['% &S17%:=K&
MKZYH^CPZ;?I_:,L$-SJ%R85:*!70,4V_WSGY5SD#DGID\;:WKOA?^R[[3E;4
M;<RE;RS,:^8\:QLS.A&/F 4G'.?:@#M:*YNYUL:G8:'J.B:B/L>H7*)O5%;=
M&RL3U'# KCVYR*K6&N7GB?Q!K%EIUR;+3M)F%K)<1HK2S3XRP7<"JJN0#P22
M>V.0#K:*Y&RUV_\ ^$GU#PC?7""_6T%[8WJ1@>;$3M.Y.FY6X..".0!7-2>,
M?$/_  J:^UY;N"/7-+N9(+V%X5\O>DFTH!U!VD$<]3[\ 'J=%<]<:E/>KX?&
ME7YVWY$SR&-6+VXCW%NG!R4&1P"_0U;\3^(+;PMX;OM;NU9H;2/?L7J[$@*H
M^I('XT :U%<PL7BE]"&HB_B75##YHL/(7[/G&?+S]_/;=NZ\[>U8%_XYNM4\
M.>$M;T.X%M'K6I0V4T<L:R>7NWA\=/F#(1GH?2@#T:BN/TGQ#J:_$.^\*WSP
M7D45@E['=Q1[&CRVWRY!DC)Z@C'':MGQ5J\^@^%=3U:VMOM$UI;M*D7."0.^
M.<#J?84 :]%<GH][J.HG2-0TW7[?5]*N787;"!04'EL04*XV_.%!5@3SU]6^
M%=6U/4?$WB>RO;L2V^F7206X$2J2&0/EB.IYQQB@#KJ*Y+4M:U+23XHNU9KQ
M--LUN+:U$8!9BC,02!DC*C\,]:9HFHZCJUKI.J:9K]MJMA<2 7H$"CRP4)^3
M;@KAMH*ON.#UH ["BN 75_$=UXG\7:=:ZK;11Z-%;R6WGVH8.9(V<B0@C@%<
M9&.#5)?'&K:OH/@K5;-EL3KEX+6XB:,.$X?+)GGJG&<\$4 >F45@FYNM(GNK
MG4-7CN+"ULWGN%:%5>+!R&XZ@A9/RJEX=N]:\3Z+!KDEZ=.CO%\ZTM(H4<+$
M?N&4L"6)&"=I7&<>] '5T5R\:>*I+(S7=_:VCPQR^8(;8,)7$C[2-Q^5=@0X
MY/S=>*I>"-0\1:]H&A:[=:C \5VA>ZMQ;!<#:P&ULY^\%Z]LT =K169J-OJM
MQ>6XL;^.TME1S,3")&=LKM R>!C=G\*Y/PAK>OZSX2LO$E[JMNL(EF-U!]F"
MKY4<CH2&SD'"[N_0B@#OZ*Y#P[J&K^+]#378[XZ9;W19K*W2%'(C!(5I2P.2
M<9PI7 (&3UJYX0\2OXAM+Z&[A2'4M,NWLKR.,G877HZ9YVL,$9Z<CG&: .CH
MKC_$>JZK:>-_#6D65Z(;;51<B;="KE#%&&&W/J3SG-:]M!JC3WT+:PDJJJ)&
MZP*'AEY)##H059#CZ^M &S17G>D>+-8C_MC0-:F5O%,$VRSCAB")<(PS'(@.
M?EX)<G.T U>\6ZEKOASP[I4T>II+?37]O:SR&W4(PD8*Q5>HQVY/OF@#MJ*X
MS4?$4B>.8?#$NK?V8&LEG@F>-"]Y(692JEAMX"@D 9.[C&*T;>'Q//:Q17%_
M:V\Z7,HFGCMLB2($B/:I8X)!!/)Z$4 =%17!>&-1\3Z[%JLO]JV^[3M9ELO+
M-HH$L43J#DYX8J3SZUU/B2YN++PUJ=[:2^5<6UK)/&Q4,-RJ6 (/;B@#4HKS
MJ\\0>*(? /A[Q!I[I?7]XD$L]B85"S!TWLJ$<J<9 ZUM2>)DUOPG8ZWH-Z8T
MN+JVA.Z-6*>9,D;JP/1EW'\1W% '5T4THQBV>8P;;C?QG/KTQG\*Y+P+JVIZ
M_I.ISZA>9EAU"XLXS%$JA5C;:#C!R3^7M0!U]%>96OBS7I?A'J?BA[V,ZC;-
M.8P(%$>(I&0 KUY R>?_ *^IJ_BF?2Y/#%C>ZFMC'JL;M-J4D:X5PJD1KD;%
M+%C@L#PN.2<@ [FBLG1UU>.YO8M2N(KF!2AM)DBV%D(YW8."V>XP,8X%9_B3
MQ'/8:SH^@::L9U/57?;)*"R01(NYW(!&3C@#(R3[4 =-17'Z_K5_X,-C?WMZ
MU_I,]REM=&:-%DMR_"R*4 !4' (()YR#Q@PG4M<NOB%JF@V^J1P6MO817<3/
M;*Y#.S#!Y&5&WV/O0!VU%<OX \2W7BOPP-0O8(HYTN);=G@SY4NQL;TSSM/U
M/0U%XVU?4M'N/#PT^Z$2ZAJL-C,&C5L(X8EEST;Y?<>U '6T5R/BS5M3TO7/
M#-I97FR'4KW[+<;HE8[0A;*G'!XQW'M4(U+6;GXCZAH$>I>59P:?%=H?(1GW
M,[*5SZ<>F: .THKAO%NLZUX>\ :SK-OJ4%Q<V<F;>3R%VLNY4*NOJ&WC((Z#
MZ5)<:_J^B>-] T2YN(-1MM7CFSMA\N:W:-0V[@X*'..@QZGI0!VM%-=2\;*K
MLA(P&7&1[\\5P/AG5?$.O^%[C4)-;@MKI;N:UBW6JF,LLA1,C.>3COWH ] H
MKD?'/BF^\+Z)!<V=J+FZ4K/<1KSMMHRIF<?0$#_@0/:H/&^OZCI&CZ;X@TN]
M3^R#<0_;CY0<BVD('FH?49'7(P?;D [6BL37KJ]#:9:Z7=K%<W=R%+&,./*
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M0"V7' YP/;E/!>NKI7AK3]"UNVN;+5-.@6U>(V[LLH0;5>-E!#@@ \<UW%%
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M4"7.E.^Z 7!9)45%;<K[>^[T]JNVNI:]/:V%V=/L##<F(NL=RY=$?&2 4P<
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M5 ,B@$[?488=<5:N_%,%AI^G27%G<#4-0?RK?3EVF9I,99>NT!<$EB< =^E
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M<E"W& "!GC)'I2^(/&EQX=TZ_P!2N="N'L;*1(VF69!YA8JN5!Y(#-C)QT-
M'3Q6EM!;?9H;>*.WP1Y2( N#VP.*2WLK2TW?9[6&'=][RXPN?KBN?U'Q5>Z3
MIVIWM]H4T4=A;?:FQ.C"5!G<%(_B&!P<=:?J?BPZ7X(/B>;3W:!8%N'@64;P
MC $=L$\C(_4T ;UO:V]JI6WMXH58Y(C0*"?PIJZ?9)<?:%M+=9LY\P1@-GUS
MC-+93O=64,\D0B:1 ^S=NVYYQFF:C=O8Z?-<QVTES(@^2",@-(Q. HSQR3WH
M /[,L [/]AMM[9W-Y2Y.>N>*9_8VE_\ 0-L_^_"_X5@#QA?'Q&^@CP],;]+,
M7I7[5'M\LN4'/KD'BI$\82-KNCZ2^DRQ3ZI:M<H7E4>2% +JX_O G'&0?6@#
M??3K&20226=NT@P S1*2,=.<4Z:SMYY%EDMX7F481WC#%:QIO$KQ>-(?#0L"
MTTMHUXL_F@((PP4Y&,[LD<?K5?3/%EWJ]YJEM::*[/IMT;68M<J 7 !RO'(P
M1UQ0!MZ5I=MI%B+6U153>TAVJ%!9CDX X YZ#M5VJNG74E[8QW$MM);2-D/#
M(060@D$9'!Z=15J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC_ (F:
M?/=>$)-0LESJ&CS)J5K_ +T1RP_%=PQ[UV%(RJZ,CJ&5A@@]"* /(+[5+C3]
M:TCXC6\,\L&L&2Q-O@Y,3*/LH [;GCW9_P"FM:GC[3)-)\-^$IG8RVFDZS:7
M.H28X*@G?*W_  )LGZUZ$=.LS9P6AMHC;VYC,,>WA"A!3'I@@8^E6)(TEC:.
M1%='!5E89!!Z@B@#F/B-/!'\.-=$F'\^S>"%1R7D<;4"CN2Q&*YFTL[C2/&?
MP[M]0.)DT6>T=B>LJQQDKGUX/Y5W=MX;T>TFAE@T^)6@.80<E8>WR*>$_P"
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M?D:Z&JEYIEEJ$D$EW;I*\#[XBW\#=-P]#@GGWH \[\(27MQL\"7XD=] NO\
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M?\5"WOY+0K966XQHC;N'_O UZ'6?!H>EVVJ2ZG!911WTPQ+<*/G<=@Q[CZT
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M,>@I!=O;/_9-R?,158XWIQA@17H%9\NAZ7-JL>J2V437\8VI<$?.H] >P]J
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M;6T-G;1V]O&(X8QM1!T4>@]J .+\+_\ )5?'OTT[_P!$M1'_ ,EVG_[%J/\
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MQR#<&4C!!SUXIM[I]IJ5D]G>6Z3VSC:\3C*L/0CN/:@#/\(?\B5H/_8.M_\
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MK\K<]\$$?4&K=06=E:Z=:1VEG!';V\8PD4:[54=>!4] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !6-JWBC3=%U&RL+S[5]IO2PMDAMI)?,*C+ ;0>@Y
MK9KAO%W_ "4?P#_U\WG_ *3F@#HK'Q-I.H:FVFQ7#QWZIYGV6YA>&0K_ 'E5
MP"P]QD5!'XOTN;4[W3HDOI;NQ*"YCCLI6\O<-RY(7'(YKF?B:N-9\$26?_(5
M&N1+$5^]Y!!\[_@.-N:31%U(_%'QY_9\EHIS8;OM",V3]GXQ@B@#IKSQEH]A
MI,.IW+7<=K-.;92;23<)-Y3:5V[@=P(Y%6(/$VES:I%IC2S6][,I>&&YMWA,
MH'786 #8[@$D5QWQ"%X/AWI2W1A_M);^P^T;?N^=O4MT[9.?H:B\62:A:>.?
M!]WX@6W.EK?>1;&QSO%U(NU/,W?P8S]W\: .HN?'>B6AB\[^T%6:Y^R0O_9\
MQ667)&U3MPV2IQCKBKB^*M)^PW=Y---:Q6L@BE%U;R1,'(!4!6 +$[AC .2<
M"N>^(RJC^#510JCQ):8 & .'JOX[!'CSP")5 L'U"8RDC@S"/]SGWSNQ0!U2
M>);'[7;VMRES9R73;;<W4#1K*V,[03P&Q_"<$^G%17?BW2[/7&T:07K7X@^T
M^5#9RR$Q9V[@54Y&>*P?C$/^+9:DZ9%RDD#6Q3[XE\Y-NWWK,U:ZUBS^*WVG
M3[&&]U&/PHS&WDE,8=A< D @')ST''U% '?Z/K6G:]8"]TRZ6X@W%"P!4JPZ
MJRD J1Z$ T[4]6LM(ACDO9MGFN(HD52[RN>BJH!+'V KE_AA:6:>&)M4MKPW
M4VKWDM]=L8_+\N=SAX]F3MVD8P2>E5-5+GXY^'TN<_91I-PUIGIY^[#X]]F/
MPH ZNV\064^HIIT@GM;V1"\4-S$8S*HZE#T;'< Y'<52D\:Z/%J%_8M]N:XT
M]5>Z6.QF?RE894G:IX(!/'I6%\5!(+?PO):9_M!=?MA;E?O<[MP^FW.?:L6_
MU76-%\<?$"_T>PBO)(;6P>168[D7RWRRH!\^!D[=RYQUH ]/T[4K/5]/@O\
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M#).!R:XS7RG_  M;P-Y>W8(-0 V]/]6E=5KKJ-"U%"PWFTF(7/) 4Y/ZC\Z
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M9500/?& 1U'0V>MZ]JESJ>G6C::E_I,44=PS1.\<URT>\JOS J@R!DY//MR
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MDC/'7."<$4X-&NDL]$L9M3UJ6UT6[2XM,Z(XD*(C(J.W1L!L9 '3D'J/4Z*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYQQ5""#2]-\::5YC^(+>]U 2F"RFNF>W4HAWLPW$$E<'&3S@X!S6A\0]-O\
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M"/:@PJ!@3EG  SP >O< ZBPU.QU2.62PO(+I(I##(T+APKC!*Y'<9%6J\O\
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M]Y.&&T'S&]<<>E.E\'7,K>*C_:D0_P"$@C"-_HI_<8B\KCY_F^7Z<_E76T4
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M+_H>T2AHO*QP_P OR\]^>>G%=?10!Q%QX<UW1],UN31]:5+_ %'4/MT96P#
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MY.23] !6K4<$\5U;QW$$BR0RJ'1U.0RGD$4 <]J7A>ZD\5Q>(M(U-+&\-O\
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M]0&I0@ZO:QVY0VIQ%L5@#G?S]\^G:M3P[I+Z%X=T_27N!<?8H$@641[-RJ
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MCKUK:=BJ,P4L0,A1C)]N:YG2_&0UJWN9]/T#5IDMKB2VDYMU(D0X8 &49YH
M+KP@NIIK,NIW:R7NJ:>=.::&+RUAAPW"J68YW.223SQTQ44/A&_6_P##EY/K
M,4TFC1R)C['M$H= AZ/\O 'KSGMP.ELKI;ZPM[M$=$GB655D&&4,,X(['FIZ
M .&F^'DD^G7\+:RT5W-JQU>TNX+?:UK.1CH6(=<9&#C()JSJ7@_5=9\,76F:
MEXA$]W=-$7N19A418W#@+&'X)(Y))SGV&.PJMJ%X-/TZXO##),((VD,<6-S
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MM8\*V.I^(K74DEM1I<CQ6+W4MT'E7E9E9^@ /('!&.]=E8^'=*TW3[C3[:T
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M:\8/.QE=M[ 8!P21G  X[#%4%\$^'5TTZ<FG;+,S"?REFD #AMP(PW #<@=
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M8K:9H&DDE+!Y 5(.%PN!G W'VQV5WX7T>]OI[R:T/G7*".X,<SQK.HX D52
MXQQ\P/''2H]9\(Z%X@DM9-2T])9+48@D1VB9!_=#(0=OMTH YC[3?2^(-/\
M"TFJM>A-*:4W)N7M7NI%D,;'='R2H7H#_$2<X&(;>YUBWU/1/"NHZO'>R/:W
M3M<BXD@-P\<BA4WI\Q959LXQDC)Z5UFK>#O#^N6EG;7^F1/%9?\ 'MY;-$T(
MQC"LA! P!P#C@4FH^#?#VK:5:Z9>:7$]I:$-;JC,C1'U5E(8'UYY[T <I%<:
MKIVL>'/"FI:R]REU<7;2W$4K+(4C17C@:3AB?G!)X)"CU-9-VD^DZ-\46L;Z
M\AFMIEEBG$[&52+9"!O//'3KG KT.Y\(:#=Z3:Z7+IR?9;5Q);A'9'B?KN5U
M(8-DG)SDYYJ,>"?#PM]0@_L_,>HX^V9GD)FP /F.[)X SSSWS0!S]PEU?_$'
M3-/?5-1BL[C09)I88+EHPSB2(9R.0?F/((/OR:S--U;67\$^'W>[N[B)=:DM
M+V5'9KB2!)947!'S,?E3=M^8@$^M=ZOAS2TU""_6&47<$'V:.7[1)E8O[OWN
MG /X"N9\1>#HDL=.LM,T)+_2H;J2YN+/[:\<OF,#AXW9N.68D;ESGKUR :'A
M&TU./4=<N+N>_:P:[VZ='>.Q81;5+'#?,!OW 9YQ[8K>U>\DT_1;^]AC\V6W
MMY)4C_O,JD@?CBL+PEX>.D33W$5G<Z=;RH%^Q37[W1W _?.YF"G'&%)SW[5U
M1&1@T <1H:R7.C^'_$T6NWDLDMH9+BW,I>.]D>/.T(3M0JP)&T#&".E8#:QJ
M3?##2_&MKJ%U)JK30R2PB9C%-YDPC:'R\[0!NP,#(*]<YSW.D>#/#VA7\E[I
MFF1V\[EC\KL53=UV*253/^R!4MOX5T6UN3-!9[/WYN1$)7\H2]=XBSL#9YR!
MUYZT <%JRW\W_"QI/[;U6/\ LE%GLEBNV01.+82=L97=_#TYZ5L:9JT_B/Q7
M'I5[<3Q0PZ+;W@C@F:$S22D[GRA!PN  ,XRQ]L=(_A71I/[3WVKG^U!B]_TB
M3]\,;<'YO3CCMQTJ.X\'Z%=-8/)9N);"/RK:6.XD21$_N;U8,5]B2* ///#4
MUSI_ASP4L%Y<J)?$%W;38E($R;[DX<#@\J#TJ[J?B.^TBY\7*+^=;:+6+"U$
MLDA?[)%,D7F,N[./O-CT)'I79_\ "$>'/['32ETU4LTG^THD<KHR2Y)WJX8,
MIR3T/<U)'X.\/11ZA&NEPE-155NU?+"4!0HSD^@'/KSUYH YCQOHRV7A+Q81
MJ][+;SZ4\L=E+<._E,BG+ARQ;:<KE>AQWR:7SYO[:T7PU#-(MO+I!NE$E_-&
MTTF5! D!+G:,G:#CYL]ACI].\(:#I6EW6FVFG(MI=1F*=)':0R)@C:68DXP3
M@9P,G%07G@7PWJ&F6FG76F+);V;;K<^:XDC/M(&W]AW[#TH YJTN=4M=<\.^
M$M4UE[H2+=RS74,C(\_EXV1%P025#98C!.T9[YT/A];BTU#QA LDLBIK;8:5
MR[8\F+@L>3CID\\5N7?A'0KW3K.PFT]1!9-OMO*=HWA;U5U(8$]SGGO5C2?#
MVE:')=2:=:"&2Z?S)WWLQD; &26)YX_&@!?$/_(M:K_UYS?^@&O-]-MK_1="
M^'^JV.K:C(U]]CLKFRDG+0O$\.3M3HI0+D$<X!R37K$D:31/%*BO&ZE65AD,
M#U!%9>G>&=)TIX6M+9U^SJ5@62>218 >"(PS$(,<?+CCCI0!QD5U>Z=JFL^#
M9[^]DO;Z=)=,N9+AVD%M)]\JQ.08MDGU^7/6O1XU5(U122%&T%F+'CU)Y)^M
M<[I%KJ>I:PNM:YI5OI]Q;0O;6T23B=MK,"[E@!C(1,#M\V>M6O#_ (=MM ?4
MFMD$2WUTURT2R,ZJQ R<L>I/)Z#D#MD@$OB:)9_"VK1L7 -I*<H[(>%)ZJ0:
M\ZALE_X1OX611SW$?G/"S.)F9E)LFSM+$[1[# ';%>L21I-$\<BAT<%65AD$
M'J#6'!X+T"UBL8H+%HTL)/,M@MQ)^[;&,CYO3CGH..E '#OKM]H-KKVGC4+A
M[:#Q!;627%W<,[P0RK&S R'+ 98@,<D;O85V.@Z;J6F:[?\ VG4Q+9W,:20V
M37$D[0L.&8._.ULCCH"..]7&\*:(\6I12V*RQZF=UXDLCN)C@ $AB<$8&".F
M!Z5)H7AK2/#5L\&DV8MT<C<3(TC''0%F).!S@9P,T :M>7^";+6+OP_XE33-
M4CM&?6K]4!@W$-YA_BW<?7'%>GNH=&4YP1@X)!_,=*P;;P;HEE%-%:17EO'-
M(TLB1:A<('=OO,0'Y)[F@#.FU-=9^(!T$W<J64&F?:PMO.T332&5HS\RD'";
M,8!QEN>@KE;+4M131]#D.IWSO_PELEBSO<.QD@$DJA&Y^885>OI7>7O@WP_>
MQ:>)],5CIJ;+0QR/&\:@8V[E8$CCH3@]ZQ/#/A%)?"]WI&OZ28HCJ<]W#&)0
M"H:4O&RM&V5(!'0C% &??:I-;:EX\@EUN[L[> V2P2*3,T+2KRL:D\%B<#!&
M"0>,5+I]U?+K7C/39VN$M8M-@GAMY[IIS$724-\S$XSM&0"1D<'FNC;P-X:>
M&^B?2HW6_1$NMSN3($QM).<Y!&<CG/.<\U)#X-T"WGGGBL-LT]N+:67SGWN@
MSU;=DGDC=UP<9H A^'__ "3KPW_V#+?_ -%K71U5TW3K72=/AL+&,Q6L"A(H
MR[-L4= "23@5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KFO'NNW_AGP9J&M:<+=I[15?9<1LRL
M"P&.&!'6NEKB/BZR_P#"K]:ASF66)5C0<LYWKP!WH W$.O1W%FTE]IDT4CCS
M8EM'C<ICDJ3*1D'!Z=,U._B708V17UK3E:28P(#=(-T@QE!SRW(XZ\BL&UN/
M"MMJ.GW=A=1W&H,/LT<4%P921(5W9&3@#;DGL ?I7#:DED_PY^(HC2$S2ZO.
M8@JC<_,90KW(R&(QZ'% 'KD&MZ3<W%U;P:G9RS6G_'Q&DZEH?]\ _+^-,@\1
M:)=7D5G;ZQ8374R>9%#'<HSNO]X ')'O7(7AT_\ X6=IXM_L_D/H%Q%B,#:<
MR1LB\<= Q ^M<KHEEI^J_#OP-;Z4L#:U#>6TV8@/-B"MF5WQR%V ]>#E1W%
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MK[+6UB:60CDX SQZGTK'TFY\2:OI$&J&2QLC<QB:&R>!I-BL,J'?>,MC&<
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MF=0FYC]U1SM'H,\^I_ 8L56U"_MM*TZYU"\E$5M;1-+*Y_A51DFL0>+/)O\
M2[?4-.EM$U4'['(9 P+[=PCDQ]QR,XZC@C- '245Y'XBUN_\0_"_Q!=ZC9K
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M.W))W]P.E=;HVI:G=ZMJ]K?VMM'!:RJ+::WE+[T.>'R.'& 2!_>%;5(  ,
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MZU<>'WTV&V<:;J<5_+Y\QCW! PVC"GGYJW8M:L)M;FT:.<F_AA$\D6QAA"<
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M].ABMQ/<%0'C+G+_ "\*=_KVKLJ0@$8(!'O0!3T>[N+[1K*[N[<6]Q-"CR1
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MXD-E%9:QJ$\R@W PT<B ;3D##84GC-6?A]IEQI_A:WDO;E[JYN%5A,ZX8PJ
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M&DZ7?",7-G:QP.8GW*2J@9!('7'I6U110 4444 %%%% !1110 4444 %%%%
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MCMK+PW#8>(K_ %F&\N/,O88H7@(3RT6/.S: N1C<>_>LMO %J_A^XT8ZK?\
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M.JGS)-V"N6XP@P2!S\PY'=VK> ;35KG7';4]0@@UJ)4N[>)DV,RIL5P2I8'
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M)M4U9+)[.75[HW+0R##HN,*".Q)W.1V,A%=)0!RW]K7VM>*M:T2PO/L(TJ&
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MMW]N@OQ*"RW, PDB[C@@=N,9'8YK3K.T/1;7P_I,6G68;R49WRV,EG8NQX
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MO48HUAB2),[44*,DDX'N>M #ZP[G7Y;;QG8:";-3'>6LUPMQYO(,94%=N/\
M;'.:Y?QG)9WFKZO;;O-N;71&E=;F0"&V5B^)(QC)E)&,@C  YSP<RT@A\1:O
MX 34I9+@7'AV5I\3,ID8I;D[BI!.2<D=^] 'IFI37L%GOT^TCNKC>@\IY?+&
MTL QS@]!DX[XK.CU^5O&\OAU[-51+ 7JW ER6!?9MVXXY![GM7FUW#/8^"-;
MM8[JZ:PT_P 1P0:<[3N2(O.A#)G/S*K,Z\YZ'TKLBHD^,<R,3AO#J@[6(/\
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M-LOS=0%VA@.GSX[UN>&;J/Q9I!UF6V:V,%A]A*)F,QS 9F (QP#M4'MAO4T
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M""#R* *UWX7T"_L+>PN]%L)K2V_U$#VZE(O]T8P/PK4CCCAB2*)%2-%"JBC
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M^TZ[/8V<LT#Y;]YMC1L* G'J!WKJ5\1Z2;G5+=KORY-+17O/-C9!$K E3E@
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M\-ZG%=Z-J-L+M?*4(JQQ.A97)PRG@Y''KSC,NK:;J-Q9?$F.+3;QGU,(MD!
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MD8$.0>0<XQQ7IE<[=^&],O\ 7;F]M]1O;34"B+=+97A3> #LWIR.F<' ..]
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MDDW$_-CL !DD\\8Q].\&>((/^$46YU+3BGA\E$$<#_OH_*,0)R>&P>W ]^@
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MRZ'+J6G10V6M2+#"\<Q9H)77=&CC: =V",CH>.1S6_J^F6^M:->Z7=;OL]W
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M=,CB\.7#Q01E93YMO$QV12,N,;?NY .0".O2M(>'KV3QK>:S<&U:SNM.2P:
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MV9%#([!R-RL&) Q_"!^)/M5/3-*\1>%=$TC3+.>PF(U%VN5\MV,L,DI=MO\
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MRQO=,T"RL=0F@EGMX4BW0(57"J%'4DYXS^-:E !1110 4444 %%%% !1110
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MC9>'/[02W=5&9%=P>54$Y"#KZFJLVLZOI^A^$O$*ZC)=G4[BUBO;=E7RW6X
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MF-N.-SG<,8^537=4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !67K>IWFF00/9:/<ZF\LOEF.W=%V @
M_,Q8@8S@?C6I10!AZ+X9L=-\)1Z#+:P-;O$RW$*K^[<N27 'H2QQ[8IVF^&+
M'39+1Q+<W'V*,Q6@N9=_V=2,$+ZG QELG'&<$UM44 <H_P /-"D22)C??9VO
M!>I;B[<1Q2[]Y* 'Y<MSQZG&,FM;3_#]IINKZAJ<$EP;B_V&X\R3<K;!M7CM
M@<<=>^:U:* ,O6=!M-=-D;MYU^QW"W4/E/MQ*N=K'UQD\=.:2[T&UNM<LM9=
MYC>64;QP8?"@/C<",<YP/RXK5HH \IT[0=3>)XQ:^+=+U9Y))7$.I+]A25V+
M%ER[ IN.<;23Z$UV_P#PB=DTVK3R3W)FU>)8KUA)@.JKM&!CY?E)''KZ\UOT
M4 8">#]+1](=3=!])A,%LRSLI,1"C8^,;E^5>OI]:O:WHMGX@TM]/OED,+,C
M@QN4965@RLK#D$$ UHT4 8<OA6Q;4(M0@FN[6]2#[,UQ#,=\L><[7+9W<Y.3
MR,G!K3L+"UTNPAL;*(0V\*[40'.!]3R3W)/)-6:* ,?3?#6GZ9#J4,?FS0ZC
M,\]U'.V]7=QASC' ([=/:J>A>!]'\/DBU-[+"%9(;>ZNGFB@4]5C1B0H(X]<
M<9Y-=)10!SFA>"-(\.SB2Q:\,2%C!;373R0V^[.?+0G"]2,]<$CN:9I'@/1=
M#U W5C]L2+S&ECLC=.;:)SU9(L[0>3],\8KIJ* ,S1]"M-#-Z;1YF^VW+74W
MFONS*WWF'IG XZ<4:=X?TO2]*FTNUM(ULIGE>2$C*MYC$L#[<XQZ8%:=% '.
M^'_!6E>&Y0UC)?.B K!#<7;RQVRGJ(U8X7TSUQQFK>K^&[#6KZPOKAKF*ZL2
M_DRVT[1,%< ,I*GD' _*M>B@#EXO .BV]M;6T#7D<-M?'4(5%PQ"39)R,YX!
M9N.G)SFM2QT&UT_6=0U6%YS<ZAL^T;WRK;!A<#'&!QQ^.:U** ,#4?!VDZIJ
MESJ$XNEENK;[+<I#</&D\8S@.H/.-Q_.I&\)Z3)X;MM GA>>PMS$46:0NW[M
M@RY8\_P@8]..E;=% %"/1[&+7+C64@ OIX$MY)?5%+$#\V_0>E8;_#S0F#I_
MIRQ&]%_'$EY(J0S;MQ9 #\N3D_B<8KJZ* ,G3O#MEIFH:C>PM,\FHLK7*RON
M5RJA1QV^4 ?SK(B^'.A0PV]LDFHK9VMTMW;6HO'$<#@DC8 <@9.<9X[8YKK:
M* *NHV$6J:;<6$[2+!<1F*3RVPQ4C!&>V167)X0TR32]-L2UP/[,*FQG63$M
MOM7:-K8Y&."#G(ZYK>HH Y^]\':7J&DWNG71N'2^D66[E\S$D[+C&6'0#:N
M, 8K>C0QQJA=G*C&YNI^M.HH YRX\$Z5=6NL6TSW31:PX>]7S<>80 ../EX
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MK:QB>5X[>-8U:9R[D 8R6/)-6:* "BBB@ HHHH **** "BBB@ HHHH ****
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M3*Z;\_<^4@=N?K6GXNT.\UNTTY]/F@CO-/OXKV(7&?+<ID%6(Y&0QY%<_?\
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M-"M_#>B0Z7:@+#&SLJKG:NYBVU<DG S@<UJT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445SOB
MO6)M-DT6S@E\A]4U!+0SX!,:[6<XSD;CLVC(/WL]J .BHKAM<U'6/"\!A?5E
MN5U'5;6SLY)(U,MI'*<,6XPV,/M)'7&<]*;J&I:MI'BJXT5-1GFMKO29KRWF
MD1&DMI8B >=N"IW#J#@^U '=T5Y=9:IXB;3_  )?MK\[/K:)!=1M!$4&Z!GW
MJ-N0X*]22,GICBH]5U[7]*T#QC!#K,\MQH]_;I;74L49=HY1$2K84 XWM@@
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M-7"2H5=<C.&!Z'U%2UPFFZ_?:MJOA_0WNY8#/H*ZG<SQA0\SDH@4$C &2S'
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M  1B,N<?5G)_ >E85[X@UV'X?^-[Y-6E^VZ7J5Q%;3^5'E8T"84C;CN><9H
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M1\G&[;MW]-W?'IS5ICM4M@G S@#)KB;>ZUNP\<'17U9[Z./0/M"_:(T0-.)
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MP!MPBXZCIZUVUR]^NI6*P?9/L;;Q<^:S"7.WY/+ X/.<Y[58,\*L%,J!BVT
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M65KB>6X+S38((RYYQP.!CI[FFWW@?2M1O+ZZN);[??VHM;Q8[@HMPH4J"P7
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M2,A4A2BM-%\RXY4$9Y%=7XAT)-)U!#X9@T@/!:32SZ+=QA(KF)V!=D(^XV5
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M7G CP!CC:,>M>T#3+ ;,6-M\GW?W2_+]..*)--L)9WGDLK9YG #2-$I9@""
M3CG! _*@#S+4KG0M5\1>*=)\3ZS'8K.(FLWD,0$EJ8EVF%W4\A]Y^4]3FK%M
MH&C:E\3'LK^U6\3_ (1VU=EO%!DD<2N-\@_YZ8 R<9&:](GLK2YEBEGM899(
M3F-Y(PQ0^H)Z?A0+.U%S]I%M")_^>OEC=Z=>M ',_$^%)OAGX@#1K(4LW=<K
MG! ZCZ5AWD&BZEXV\%V\,=G<6#6%\?*CVF)SB+L.&Y!_$>U>D,JNI5E#*PP0
M1D$57_LVQW(WV*WS& J'RE^4#H!QQ0!X_;7T.DZ';1RS?9O#UKXKO;>X:-%:
M."/=)Y08$$! Y4\C X/I7?\ @VRT>UEU:;1-4>_M[JX6:1HVC-NDI7YA'L &
M3P6Z\D5T*Z?9)#)"EG;K%*,2((E"N/<8YJ6"WAM8%@MX8X8D&%CC4*H^@% '
MG^]/#OQFOKW4W$-EK=A%%:7,AQ&)8S@Q%CP&(^8>OUKI_$6I3'0M5@T63SM6
M6QF>!8OF*/L.PGT).,#O^!QL7%M!=PM#<PQS1-]Y)%#*?J#26MG:V,(AM+:&
MWB!R$B0(OY"@#S$+:7.A_#[4- \L:@;NW1VC_P!8T)0_:5D[GH2V?X@.]8>J
M:9I:_#SX@W:6MN+BSUJX-M*%&Z!@T1&P_P !SZ8KVB&PL[>XEN(;2".:7_62
M)& S_4CDTS^R]/",GV"UVL02ODK@D?A[F@#A;G3-+L_B?#;6MK;1Q7N@7)N$
M51B<B6/#/_>/+<G)Y-<KI&BZ>W@'P#JVE11#7S>6R+<1',LBY(E1CU*! V1T
M ':O8;C3;?R7:VL[47 0K&S(%V\8'(&0*R_!OAE?#7AZQL9HK1[RVA$#74*8
M,JCH22,_ASTH \XU'5=*>:PO;6XMK81^+E,HGDW7(/FE)'=B1Y:8X"X/R[>>
MU2ZKI.D7-I\5)GM+61K<>; 2H/E/]D5MR_W6W<Y'.:]<-A9EI&-I 6D8.Y\L
M99AT)]2/6FG3+ [\V-L=_P!_]TOS=^>.: . UK;H3^'?'L=N;AEM8[/4C$FZ
M22&55VN/4K)M^H8UVGA[2_[,TB-)8HUNYF:YN2@&#,Y+/^ )('L!56XT74;G
M5XT:[M(] B,<BV45OB1I$;<,OG&W< < <XQZYWZ /,=1:?3?$<U^J66LZ1/K
M,"S(1MO+"YW(B[3_ !KPIQP=K>F:ZCXA3W=KX$U2>S$ID1$9Q",OY6]?-Q[^
M7OK=&GV0N_M8L[?[2/\ EMY0W_\ ?6,U9H \[TF'P9>:E=:Q:ZU#?6TNF&.]
MA00BV$ .0TRJHVL.0-W.-PQQQ2\#VMMHGB(:%JL&&:V=] :Y"EOL;,2T73B0
M9&X<DKM]#7H\>F6$,$D$5E;)#(VYXUB4*Q]2,<FEDLK9BDGV2W>6)0(BR#Y<
M= #C@?2@#Q,:%ID_PKO;RQMXAK]MJ\T>GS1?ZZ*879V1H>H!!^Z..2<=ZV[]
M]%U76/%>C>*]8_LZZ-RK0AQ&KM;[$\MH6=2<A@W"\[B>,FNS\(>%CH%BR7D5
ME-=_:)IDN8D^8"21GVY(R,;B.O-=!+96D]Q%<36L,DT7^KD>,%D^A/(H \U3
M1M)O?'7B:&^M(KE1HEH[K=(I8OB4%W'3?C'/49XZU2TM=0O/"7A2\TVZT^\O
MX-#Q+IFI<QW4)VABK?PL-@&3D<C->JMI]D\CR-9V[._#,8E);ZG'-,?2--D1
M4?3K1D4Y56A4@'VXH \OAUG2+O5M-BUF;^R-(O?#\!TY+T1F,<L)4+2*1NVF
M/TR *]"\)6=KI_A73[2QN[J[M(HRD$]T07D3)VG( !&,8./NXK3N;*TO8UCN
MK6&=%.Y5EC# 'U -3XXQ0!Y)I>C6K:1X\O\ 2[&%]9L=3O\ ^SWC4%X',*@;
M,="23P.IQZ5H^%D\*:UJ6AZGIFL&>[2TDB:RA$0/ELGS+<*JAL!@,;OXB.N:
M]#@L[6U+&WMH82WWC'&%S]<4D5A9P-,T5I!&T_,I2, R?[W'/XT >-VEO92?
M#CPDK)%M3Q5Y:$'!53>29 (Z<8Z5N1Z!H3>,_&MB^G67V--/M9A;>6OEHY24
M,X3H&P%^;&?SKT7^RM.V!/L%KM!R!Y*X!]>E*=-L2[L;*W+.,,?*7+?7CF@#
MRC2(;/5G^&,>K+%=02Z+<JR7!#)(P2'"L#PW3H<]/:JT]A!I>D3R0JD>@VGB
M^UDL78_)#%OC$I0GI&'W#CC@U[!)IEA+;"VDL;9[<'=Y31*5SZXQBI9+:WEM
MC;201O 5VF)D!4CTQTQ0!Y-K-QI5YJGQ+$<MI,DFA0R+M*D.RQSY8>I!V\CH
M:TCX>M(O#?ARYT&73[#6+GR)T:YCWQ7\BP,-DN.2=K.0W)!&:]#_ +.LMA3[
M';[&55*^4N"%Z#IT':A].L9;9;:2SMW@4Y$31*5'X8Q0!Y3_ &[!&OAHZG;+
MH6E"\O[>Z V26\=X'^4[F4KL),V#C@GVS2ZEI&@VNF: NFWK7UG)XKB:.9F3
MRUW@ETA* #R\]AQG([5ZN]E:26GV22UA:VP%\EHP4P.VWI37T^RDBCB>SMVC
MB&(U:)2$'H!CB@#S/^P=#;Q'\0;)M.L_LL%E;S1V_EKY<3M#)N=4Z*WRK\P&
M:IZ=JUJ#X0C\0ZBMMIUUX;B\BXN1&T3W''F*QD!4,5V\GW'?GU<Z;8EG8V5L
M6D^^3$N6[\\<T2:982VHMI+&V>W!W")HE* ^N,8S0!Y>FAZ'#K?P_L+>5]0L
M-U_'%-=%6,T7EL0N0!NCR>!C!&.H-9M];V,/@OQ- (K=;.Q\6QB--HV01F6
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M'#+;30!<Q.D6PQR!B-O0$'IR>] %SP=XA/\ P@7AZ:^EN;W4;NR$NU%,DLN
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MW]G5-R'/3)0CG&>.U=1X7$=Y=/J">$?[#<0^4\EQ#$DTAR#M4H2=@P>N,DC
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MQN&^0A6SN!QV(%;"VFH'Q'XRNWTRZ2*_TZWBM_D!\QU20,HP>Q<#/0\X..:
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MM&?^/GS,YSMQM&>OMUKJ/LU]%\4/[333YY+&[TB.W$Z[0(G65V(<$@CAAV-
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MB6:^8FX9,1QQK>,[2!NF<*0 .<]L<T =58:C-#XR\:Q7M_=O8VMO:21JN7,
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MN(!.T]QGI7"IXHU#1=2\<ZEJMU%<6.D/&(X(X2K$&%655.X@9+X)(.2<\#@
M'HE%<I/XAU31]<T2TU9+22VU=FA62V1E-O.%W!3ECO4@$9&WD=.>-;Q)K:>'
MM"N-2:+S60I'''NV[W=PB GL-S#)["@#1N+B&TMWN+F:.&&,;GDD8*JCU)/
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MG.,$!B>../6H?%OB+_A&M.MKQ\1V\ERL,]T\32);(58[V52#C(5>HQN![8H
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MDJ%7: &X/RYQ@YKU&N;C\ ^%X_*":2@6*X^U1+YKE8Y#G.T;L*#DY4?*>XH
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MS7$C-.H&W#,6R>.O//.<U8D\,:/,^G/)9[WTU2EJS2N2BG *DY^8<#ALC@4
M<;#=WNG:GK/@V>_O9+Z\N$ETRY>X<R?9I/O%6)R#%LD^ORYZUZ.B".-4!8A0
M "S$G\2>37.Z/:ZEJ6L+K6MZ3!IUQ;0O;6T*7 G;:S NY< #G8F!V^;UKI*
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MW%]INI?%+0+M9(I;?^R;DH[C #%X]I&>F0&(]1DCB@#M5U33VTY-16^MC9.
MRW E7RV!X!#9P:?97UIJ-LMS8W4-S Q($D,@=21U&17CFGWW]E^']$OW:X31
MK#6[\7;6B[C;*[R"*3;@_*-W7'1N*]$\'1:/Y.HW^BM<RVU]<>?)<S9"SR8
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M,=:Z:34["*Q2^DO;=+20 I.95",#R,-G!S7%+=:;>_%TW3O"\/\ PCXVO*,
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M=X(]2LVE169T$ZDJJG#$C/0'@GM4<'B'1;J\BL[?5["6ZF3S(X8[A&=U_O
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MUU8-:.VE7+<3"0,-T> <=&'.>W(P30!Z!17-^.M=OO#OA>6_L+=99O.AARS
M;!)(J;L=SEAQ4\GB"8Z@^F6FG_:-1AMUN;B'S@JQ*Q(52V#EFVM@8QQR1QD
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MDW9VGTSWH ?17)S^.K6WTM=<-G(V@FX\AKY7&5^?R_,*?\\]W&<Y[XQS3_\
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MN >BMT*X^;)QP#QVK.\2^,]4TSPUK<\.CRP7^GR10EI6S"PD*@21N1\^-W3
MP>M '<T5';O+) CS1>5(1\R;@V/Q%8/CJ]L-/\&:E<ZIITNH6"Q_O[>)@I9<
MCN2.,XZ<^U '0NN]&7)&1C*G!'TKE;#PEJ-KIZZ3<>(9;K25C\GR7M4$S1XQ
MM:0=<C@G:"?7/-37OBJ2U\1G0+31;NZN_L/VR,K)&B.NX+C);CD]_P  :;I_
MC2UU72]'N;*VE:ZU42>1:R,%*>7D2%VYP%(QD9Y(P.: .F "@   #I2UYSXO
MU(ZSX;TZYFL+JQN+;Q!:P-%."OS+<*"5/1T(Z-WKI3XJ47OB&S^Q2&;188YW
M^<8E1U9AM/8X0\'O^= '0T<5SEOXLAU&'24L+5IKO5+$7Z0/($$4)"G<[#..
M6"C .3[ D</HU_8V7@;59-5TBXN+4^)I8S;^8,P,;E0FX[NBMM'&>GI0!ZW1
M7*WWC&:WUK5-)M-"O+NZL+=+EL21HKHV[D$MQ]T\'DGMCFIH?&-I>PZ";"%Y
M9];@:XMHY&V!450S%SSC&X#@'D^F30!TE%8GAKQ(GB6VNIDL+FT^RW#VL@G*
M',B$JX&UB< CJ0,Y%)/XA,'BI-!-D_FS6CW5O,T@"2[" R#ON!8?@<T ;E%<
MQI/C!-:T2PU&VL7!O;MK06[2KOC92P8MCCC8QQZ#\*Y3P_XC'A6Q\13/IES/
MIT7B.XCGN$=<0*SH@P&.YL$C..@H ]2HKE=>\<V6BOJ"K&EPVG('ND^T)&_*
M[MJ*W+MM(..!R "3Q3#XX^TZH-/TO1KR^EDTZ/48&#QQK+$YPIRS<=#UYSV[
MT =;16;X?UNW\1Z!9:Q:HZ0W<8D5)!AE[$'W!!%:5 !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[
MXOT_5]1L[%=*\F18KQ)+NUFE,2W,(!RA8 ]RIQC!Q@\<'HJ,XZT >5ZCH5_I
M'AWQ'8WL&D*NMZK$UC%Y[*I=Q$-@.T;"HC8JP[C.!C!T[)-92^OK?4- @CU+
M4[-HDO!J8G+!%.U6'EJ40;CR >3SR:ZFYNM#UN_NO#EW'#>31Q+-/:SP%EV$
MX4_,-IY!Z>E6-+T+2=$C=-+TZULU?&_R(@I;'3)'6@#DY/">MGX?>']/MI;6
M#7-#-O+ 6<O#(\2E"&. =K*6[9&:GU71_%'B7PZYNC8Z7JD$\-S8Q1RF:-98
MFW9D;:"0W3 ' ]:[6B@#AM7T3Q/XO\)WMCJBV&EW9$;6R6\K3+YJ.KAW8J,
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ML;.ZU&X5S:+/;;V*J,MAL8 'IF@!/!CF/1Y-/;2$TQK&8PF&.Y^T(20'+"3
M))+<Y&<YK#\4^&/$&M7OB&)$L;JSO]/\BQ>XF8&S?8RL FT@EB0=V0<>N *[
MFUM;>RMDMK2"*"",82*) JJ/8#@47=W#8V<]W.Q6&"-I)"%+$*HR>!R>.PH
M@T>&ZM]%LX;Q(DN8X5218G+*"!C@D#/Y5PEYX0UZY\'^*=)6&T%SJVJ/=P$W
M!VJC.C88[<@C9V!Z]:]#MKB*\M(;F!BT4R+(A*E25(R.#R.#T-2T <A;:/K&
MC>*]7U:RMX+JVUA(I)(7GV-;SHFSK@Y0C&2.01T-9^F>";_1+SP>EMY$UMHZ
M71NI"Y5G><9)1<'@,2>2.,5W]&: /-9?!?B#[)=W5LUG#J</B!]9LE>4M'(K
M+M,;D#*DJ3R,]JU=:T+Q#XGT*.6[^Q6&J6EY!>V5NDIEB22)LX=]H)W9(.!Q
MQUYSVM% ''WF@ZCJ^KR:U<6L5O<1:9+96UMY^[+R$%F9@, #: .O4GCI5&T\
M+ZU;V7@6!H;4MH( NB)SAL0&+Y/EYZYYQ7?44 <!;^#+J7Q':ZLUG#IERPE3
M59+.<^7?HR,JY0 #=DAB2!@@\MP19\*:=XPT:TM="O1ITFG6 $<6H1RMYLT*
M_<0QE<*V  3NZ=.>:[:D=@B,[?=49- 'G$GA#7G\%7^D"&S%U<:R;]3]H.P1
MFY$V"=N<X&.E7-;\)WNL:TFHI9066J0743VVJV\^UQ "I=)5 &_@.H!R#D<C
MFNNTC5['7=.2_P!-G\ZU=W17V%<E6*MP0#U!%7J /.=8\*>(9K?QGIMC#8O:
MZZ3-#<2SE6C8Q*A0IM]4ZYZ'OTI^L>&/$NIOJ,$T6FW%O=:2+6V\VX;;93;&
M5RJ[/FW%A\W! &/8^AT=1D4 <1;>'];&K^#KN>"T5-(LY;>Z"3DG+HBC;E1G
M&S)SCK73:[;W%UH\\%K:VMT[E UO='$<L>X;U/!ZKN X/.*?J^L6&A:9/J6I
M3^3:0#,DFQFVCZ*":NHP=%=3E6&10!YK_P *^U*WTN^CT69=/$5]!?Z38W$I
MEBMY(P=ZD\X1\GY03CKWP.F@F\7SZ7/-<6>G6M\P$<-O'<&14Y^:1G*C)]$
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M1Q%*RA93^(C3'^\WK6'=^#]>N/!WB;25ALQ<ZIJKWL!-P=JHTB/ACMR#A,<
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M.5P?3'&.4O\ PS_PCNH>"=)T^\U&2"SOKB7[0T0D,"-$^ Q"X"ECMYY.3SW
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MM]9C9;ZUA$;1R.5VEQN4E21UP>:Z'2M/72=)M-.CFEFCM8EA22;;O*J,#.T
M=!Z4 ><:'X@U+2/#$L\U\UW>7_B*338'GC&U':X9-YVXR H)V\#@#BNIM]7U
M#3_'B>';V;[9;7=DUW;7#(JR(R,%=&V@ C# @X'<'/6F-\/]-DTS4=.EO+Y[
M6[NVO8EWJ#:3%_,W1D+G.[D;L^G0G.M8Z$MOJG]J7=W)>WX@^S+-(BJ$CSN(
M"J ,D@$GV'0<4 5M:U>:+Q#H^@VT@@EU!9Y7GVAF1(@N0H/&XEUZ@@ 'BLR?
M6==TRYTC0[^>U:_U._FAANXEZ6R(9 S*0 )2 !C[N3GGI6KXE\+6_B/[%/\
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M-W;:/907\_GWD<"+/+_?<* QZ#J?85<H **** "BBB@ HHHH **** "BBB@
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M3"S/<^=AED!&$V8Y!&3G/:I8KNVGGF@BN(GFAQYL:N"T>1D;AU&1ZUR5TO\
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MQ-YB[03N)('7KQ@4 >H5DZ]KD>B16:^3Y]U?7*VMM%O"!Y&!/+'H %))P>G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,RD@$;L9/'/?-;ES*MCI<TUQ<N$@A9Y)R%W  9+=,9[],5X?%\1_&-O\/\
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M 9'()ZB@"S8:=9:5:)::?:06ELF2L4$811GKP.*LT44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MQGQ%@D,/AN^ /D6.NVLUP>RH24W'V!=:[.JVH"S:PF34##]DD7RY1.0$(;C!
MSQSG'XT 6:PM3N//\2:38>1=&.-GNI)1;N8MRKM12^-N27+=?X/I6Q;0?9K=
M(1))($& TC;FQVR>_P!3SZY-2T >:7W@B\A^,MIK=AN32M0@WZDJCY3+"5:/
M/H2PC/\ P%O6LV1[B^^.DFO:AI>KII.E6!ALI1IL[B60_>("H?[[\^PKUF6>
M&#9YTL<>]@B;V W,>@&>I/I4E 'F7COQ!K&K_#75DTWP_JZW-\YM+: V<AF,
M60'D=0/D!&\ 'G&#WP,'2?#$_@OX@^$]0L=+O)],GT@6=[)%:.WDR@<NP"Y7
M+;>H'\5>UU7^WV9B647<'EM)Y2OY@P7SC:#GKGC'K0!S<BS>)YY+MYM3TVRT
MZ;]Q&+3;).X'^L*2QME1GY0!U&>N,<W\$]/O]/T?71J5C?6L\^J23J+NW:)G
M1E7#<@ \@]*]0HH *XSP';R?VCXMO\$6]WK,@A]&$:K&S#_@2L/^ UU\T9FA
M>,2/'N&-R'##Z5%%%::5IZQH([:TMTP,G:J*/4G^9H YGQK;WT>J>&M8MX)K
MFTTV^9[N"%"[A'C:,2!1RVW=G R<$US7B?2[O4%\;ZM8VEVUO?Z1'90Q+;OO
MN9AO^8)C=@!E7./7TKT\75N9DA$\1ED0R(F\;F48R0.XY'/O4M %/2BITBS*
MQO&/)0;'C*,N !@J0"/I7,^-!+:^(/"FK_9KF>TLKV7[0;:!IFC#PNBMM0%B
M-Q X'>NRHH \>U.WOKKPQXUA&CZGYEYKD%Q!&;-V,D8-ODC .<!&SZ8YYK6\
M4:=J.K^*]<CTRWND:[\+M:P7!@=(S*9';9O( !P?7C->ET4 >8#49-4O? ;Q
M:-JL#Z?.R7D;V$JBV/V=DP25P1N(Y&1C'2H?#MJH@@\-:[X>UBYU2RO"Z2NT
MQLY,2%EG#[M@P#G'7.0!DUZC#<0W"LT$T<H5BC%&#88'!!QW![5)0!QW@6*2
M+4/%9FL[F SZS)/$TUN\8DC,<:AE+ 9&5;_)K<\2PP7'AK48;JTGN[>2!DE@
M@!,CJ1@A<<[L=,5JT4 >8I!K4.@^*].:>]UG3VTEDL;J>S9;IG99%$#?*#)C
M(.<<;N:L6L-Q_P )!\/I&L+T)::7/'<.UI(!"[1Q* QV_*258<^E>C44 >0W
M]E>2?#OQQ:Q:7J!N+O69IK>(64N^56D0JRC;DC"DY]JZM#(WQ9:^%I>?9#H0
MB\\VL@3?YQ?;G;C=M.<=>W6NSHH \FT9[_3?"'AN&;1KY FJ71N)_P"SGDGL
MU9YF1T0J2-P8#=@X#'O5-[.]'A?5;)M'U8N?%:W01[221GA\]'+9 .X;023S
M7LM% "*0RA@#@C/(Q^E>?^-K.X;6;B^TF?4;+6(=/4(R6K3VM^NZ0B"1=I&0
M<]P0),UZ#10!P .IVWCV2^GT>>22[\.PQ*D49:'SU>1GB9_NK]X=3R.F3Q6-
MHAO)_$'@B];2M4B6&WN8+F+[ T,-F[(@$:K@;4!!&XYS@?,>@]8HH \ACM-7
M@\%QPQ:1J4EQI&ORWES;1H\3SPF:4_NFXWG:X8;3V]:[;PH-.N[J]U:PTC4+
M0W*QI+<:@)%EG*YP-LA+84'&??CI7444 <C\3H+BZ^'NJVUK;7%S<2B-4BMX
MFD=CYBGHH)Z U@>+Y+R_N?$]E'I-^HN=&"VDMI9-F]8I)E9),?+L)&$)!.3U
MR!7IM% 'GE_::HND^$?$&D6$S:E9(EI+;S(49HI4"'>.H"N(WYZ $U+X4\/:
MCHWB&[TB822:-8S?;[.XDZO),I#+Z?*WG,1_MK7=3W$-M$9;B:.*,$#?(P49
M)P!D^I(%24 %>1?V?JZ^%9K>#3+YKC2O$S:E/;F!E^TP"Y:0",GB3((88S]W
MUQGUVB@#CK>V;5_B/;:_9QSQV5OI;VTLLL+Q&5GD#*F& )V@,3QP2!US6CXY
MT^^U7P5JMGIJ[KR2',2;MN\@AMN>VX C\:Z"B@#SFVGL-:L[S4H/#FN0:A%I
MTT,DFH).9(RR_P"J0,27)/\ =&./<56T^VNHK?X8*=.OE:QC*W8^QR#R#]E,
M9W_+\OSD#GZUZ?10!XY]HL(H[[2+]=7@TJ/79+WS!I4TOW)MY F0%=I=2<]0
MO!YYJ;QFU[JVG^+[6#2+_?)Y$EJ+&S8I>H%0^:TH'SL,%0N> !P>W;6'@N/3
MHOLD&N:Q_9@R!8-,A0*?X0^SS,<_WZZ9$6-%1%"JHP !@ 4 >9Z]J(L?&5]=
M0V^IHNH:1%%.1IDMTJY:38=J<H0"V5;KD=,&JI-OI7_"+ZEIUOK&I>'K33Y-
M+E-JLR7-NX9,.\:[7Y,>",<<<=*[:Y\*[]9N=3LM:U33I;HJ;B.W>-HY"JA0
M=LB-M. !\N.E;-E9Q6-L((=Q&2S,[%F=B<DDGJ2: ,WPO:VEKI+-8Z9-I]O/
M,\RQ3[O,8MU=PQ)4DY.#STS@Y R?&,<TGB'PB\5K<S)!J1EF>&!W6-/)D7+%
M00!EAUKL** /)M2L[N;PI\28$TR_:>^O)&M4%G)F<&*-05^7D;E:O4K)_,L;
M=]KKF->'4JPX[@\C\:GJ-YX4FCA>6-99,[$+ ,V.N!WH X.UO;2S^*'B\74$
MTJR6-D,1VS2[AB7*_*#R?3OCVK(\/Z%?:'>_#RSN[*Z9K*WOO/9('D2V,N"B
M,X! (Y7KV]*[^R\/16/B34=;2\N7FU!(XY8GV>6!'NVXPH/&X]^];% '!6)F
MT/Q+XLAU6RN[BWU.1+FTEBMWE69/*"&+Y0<$;<8.,@Y]:RM%T74_#5WX COK
M6ZN#::==6L[P1&412/Y95&(X &"NX\?+UKU*B@#RK0K55C/AG7?#VL76HV]\
M\D4K-,;.4&4NDV_=L7&<D=<C@$G%7=#N)].?5?#&L>';N^N)-3FN;:5K7S+:
MX223S$=I"-JE2><\C:,9/%>B33PVX4S2QQAV"*78#<Q. !GN3VH2XADFDA2:
M-I8L>8BL"R9Z9';- 'FNK:7JEW?_ !$TVUL[H7&J1026<IB812A;=5*^9]W)
M92N,YY],F@Q)XMTB];3M!UBRUP:;<6XGU,S+]G=T(\M&D8[LMCD< #)P< ^E
M2W$,+QI+-'&TK;(PS %VQG ]3@$_A4E 'EBW\NHIX#1-%U6";3;M4O(GL)5%
MOBW=#SMP5SCD$C&,XKOM&UZWUM[Z.*VO+>2RN&@D2ZA,9;'1ESU4]C6K4,%K
M#;>88DPTK[Y&))+-@#))]@![  4 <KX\6_MI- UFSLI[Z#2[_P ZZM;==\C1
MM&\9=5_B*[\XK*\1+/J^F6FMZ-H=S%%;:O;7]S$UMY5Q>I'D,WED!B0"I&[D
M[.!TSZ+10!YUK-G+JOB#5M>LK>[-HOAV6Q/^C2*]Q*[%E54(W-M&><=6QZX@
ML[>Y27X9#[!?)]BM72Z/V.0>03:[,/\ +\OS\<UZ)=WUG8(KWEU!;J[;5,T@
M0$^@SWJQ0!YOX+N)[?2-/\+:OX=NY-4TRX_U\UJ6M^')%PLI&W.TDC'S9)'O
M5+1K5567PSKWA[6+N_AOY)892TQLY@96D2;<&V+C=DCKD< DXKU6B@#C/!\,
MJ:_XP:2SN8?M&I"6&2:W>,2IY*+E68 $9#5Q^GPZI8>!_!\[Z/J\BZ',\>HV
MD,<D4^&1TWQ@$,^W<#\O!#'GKCV.HYIX;:/S)Y8XDR!N=@HR> ,F@#S'5K3-
ME8^(-#T#4EM8=8@O;V*5)#<W2*K*9/+<ECMW*0#R=N<8 )VM"N&O?B;JVH16
M5\EG<Z9;)%/-:21*S*\A(^91@_,.#7<44 <]XXEN8?"%\]IIBZE*/+_T9H?.
MR-ZY8)_$5&6 [E:X#4M+U75KGQG#I]KJDCZEI5H;:>]@:,3F-I"ZG(4*3D+M
MPO7ICFO8** .-M=43Q59W,\'AV\M+W[!+!)-?6AA>,L/]2K,,L"W)Q\O'J17
M.*+J7P'X!MQI>IK-I]_8"YC:REW1B),.Q&W(4'OT/;->JT4 </XAT?48O&=M
M>:7$YMM:MSIVI,G'E!<LLWU">:H/J5J;6()%^)'A1X;.X-M;6UY'))';N8XM
MZQA 6 P,[3W[5V5% ' >&=&74O#7B3PWJMC=0K/J%[O:2%E4I)*S(Z,>&X(8
M$9QCG'%7_ 2ZK=V3ZAK@4WT(.G*RMD.L+,K2#W=P2?95K?UK23K-DELNHW]@
M5E63S;&41N<?PDD'@YY%6K.TAL+.&TMDV0PH$1<DX ]SR?K0 ZYMXKRUFMIT
M$D,R-'(AZ,I&"/RKR=-&\3V6C:;?K;2SW_A:[^QV4.<&]MBQC=OHT9CQGH8V
M/>O7::SHA7<P7<<#)QD^E '#>*M-FL]*\*6L4%S=R6^LVT]Q)!;O)T+&21MH
M.,LQ)^M5ITNK77_'\;Z??.-0M8GMI(K9W20"VV$!@,9W<;>O/3&2/0(;B&Y0
MO!-'*@8J61@P# X(X[@\4YW6,9=@HR!DG'). /SH \TL+>YCD^& .GWR_8;9
MTN_]$D'D$VOEX?Y?E^?CGZUZ/=Q236<\44GER/&RH_\ =)& ?PJ:B@#R>+3K
M[4OAEI/A-K"ZMM;L[FVB=F@8)#Y4JLTPDQM(**2"#R6QUJ]>17=O<?$BU;3K
M]WU"'S+5HK5W24&U6/"L!@G<,8'/MC)KTJB@#S>&WN3JGP[V65[&+6PFBG?[
M)(! S0(H#_+\OS*>OI5/PC;QFRTC0=9\.:PVL:1,G[R8S-:J8S@3HY;9]W)
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M8X(H_N@<98YW$G ^][<ZDFB:E)XUL]?)M1'!I\EFT.]LDNRL6!V] 4 _'\*
M,A/B#>2:-HMY'HBO<7^HOILL(NL>5,A<'!*_,I\L\\8ST-20^/YK236++7=+
M2TU/3V@"103F6.Y$[;(RC;0?O'!^7CK[5@:IHNH>';+PO9/-:27#^*3<QD%@
MI\P3/M/&1][&>?7':NBU7P-)KRZS=7EVMKJ5\L"V\EOEQ:>0V^,@D#<=Y)/
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M'M;W#0R%V^XF48E1G'8]\G@=[.L^!;C7[[Q&;RXABM=8LH+9?*)+PM$697Y
M!^9LXXZ5-#X>\2W7B#P_JNJWVF%]+2>.7R(G)G\Q57=R1M)V].WOG@ W=7UK
M[!?:=IT$2RWVH.ZPJ[;5547<[L<$X P, <DCIR1F-XJO;6&&WO\ 2?L^IW.H
MM86L1FS'. "WG!L9";03TSD8]ZD\6>';[5KC2]3T>]BM=6TN5I(&G0M%(KKM
M=' YP1CD=,55U/PMJVK6>GWESJ-N-<L+Q;R!XXV%NN!M,6TDMM*DY.<Y.>G%
M $.H>.+G2E\06UUIL3:CI%E_:"QK.1'<V^#\RMMR""I!!'7'/-3V?BZ\_MW3
M[+5--@M+;4;&2[MYDN=[+Y84L)!M '#@\$]*BU;PA>ZS%KMW/):Q:EJ>F_V9
M&%9FCMXOF).< L27)Z#H!ZDOG\*WUWJV@W-P]K]GT^QFLYXU=LRB544E3CC&
MS]: .?\ $^JW'B#3/"6KKI]NMA<:[9O;2,Y,RH9/E8C;@;AV!XR.O.-:_P#$
M,]I/XY>PTFQM]1TJTBF-R6R;D>4[*7PH/RA< 9/U JG%X&\1Q:#I.A?VIISV
M>D7\%Q:W#PN97CB?<JNH(&0,#(//M6N_A.]N=0\723W%NL&O6B6R%,EH=L;1
MY(/!SNSC/&,<]: *BZU<1V?@K^U=*M+N6_EC1+EI=[0N82WF %/O$!@<$8SW
MJW=^,KD:9K&KZ?IT=UIVDS213YF*RRB+_6L@P1\O. 3\VT].,Q-X6UJ6S\*Q
MSW-@TFBW"3.4#J) L1C"CKV8G/X8I$\'ZC96OB#2;&[MO[+UF66;=*&\VT,P
MQ(% &''4C)7!/.: )#XPU"^UX:7HNF6URLVEQZE;7,UT8T='; # (2.G;/4=
M*AM_B'!=:5X=NFCM[%]9CD*F\FVQ1R1D Q[P.6))QTR >_!N67A>YTOQ7'J5
ME]F^PP:1'ID,#.P8!&+*Q.,>V/Q]JH:9X-U&Q\*Z=H%Y%I6IV4$<T=S;W&X)
M,6<,C@[3M*_,.AZYR* .OLKF:32X;F^A6UF,0>:/?N$9QR-V!D#UQ7+2>.Y(
M="L?$DFGH-!NYD3S1*?-BC=MJ2LNW&"2,@'(![]*V_#V@C1/"MIHDT[72P0F
M)G?/S YXY.< ' ]@*YZU\#WJ^%X/"5W=6\VBP3HRS?-Y[PI()%B9<;0<@*6!
MZ#H#S0!$T=UJWQ1U?3;^SL[C3_[)AC:*25B/*>23) V_>.T9'^R.371:MK,.
MA2:=I5K"IGN$<0(0VR..,#).T$\;E&,=^HJ&VT2_A\=WVNL]L;6YM(K41!FW
MJ$9F#=,'.\\?K3/%7A[4=3O-+U;1+Z&TU;36D\K[0A>&6.0 .C@<X.U3D=,4
M 99\>ZBEA8RR^'Y(YYM7&E2))(T8)/W98RR#>A'KC'X4\^+]?\_7K%=#L3?Z
M0B3R?Z<WE21.A9=K>7NW_*1@J!QG-6-3\.Z[JMGI)NKVRDO+74XM0FVJZ1 (
M,".,<D Y^\2><G'. _\ X1S4EUOQ-?K):%-7MHH(T+MF,HK*">.<[R>.F,>]
M %;_ (3B^O+G0H-*T:*8ZSIK7T#377EB/ 0[7PIP/G'(R?;O7/\ B/Q!_P )
M/X$G>]TY;/4],UNUM+B L)!'(+B+E&P,@JPYXZFIH-.U#0O%W@;2D:TFN;'1
MKFW;<[*LJKY*Y!P2I.,]#T(]ZUM0\#WESH%[:Q7-L+_4-4CU*YE8-L!1T8(H
MZD 1JN3[GOB@#7F\0WESJFJZ?HMG!<S:6B>?YTQC#R.NX1KA3SMP23P-PX/.
M,VT\?"_;PS=6]BHTK7&:(7,LQ5H)P&_=LNT@DE64'/4'VS;C\/ZGIGB;4]8T
MJ2T*:M'&;FWN&8"*9%VB1"!\P(P"I SC.16)K>DZ)I'@6'P2FHI_:WE"33TW
M 3O<>9N655ZC]YDG'0;NP- &IJ_C&]TRVFNX]*BN+5=4BTZ-UN2&DW.J,P!7
M'#DKC/53S2+XH\02:WJ>AIHEC_:%K!'=1,;YO)>)RPP3Y>X-E2,;<>X[S:WX
M5N+SPSIND6$\0-I<V]P\L^<R&)PY)P.K$')]SUJ:/1-2B\9W^N@VA2YL([1(
M2[94HS,&)V]"7(_"@"E9^/(]3TO19K.V"W6IV;7?EREF6%%*J<E%)/S, .!G
M!/'0UT\>:D\&BD^'7BN-0OI+%XIYFCV.JLP9=R#<A"YW<<'H3Q5.R\!Z[HVE
M^'Y-)U.RCU?1X)+1C-&S074#L&*L!AE((!&/2MF^\.ZU?W&@75Q>VDMQI]Z;
MR?"LB,3&R;(QSM #=2221[T 8NO>-=:3P;XE>.TMK/5M)N4M92D[2)M<(0Z'
M:#G$@X(&",^U=J;C5UO=/C-A;M!*)/MDJ7!_<$#Y-H*@OD\'IBN5U#P/J&I6
M7BZW>[MHCK<T4\+ ,WE-&J !A@9!\L<CUK;N9O$4.JZ)&DMA+#(7&H1K$X;&
M,AD.?E4=.>IQZ\ %O7M<318K-1$)KJ^NDM+:(MM#.V3DG!P  Q)P>E8E[XTN
MM,N-;L+O3HCJ.G:>=3B5)R([F 9!(8KE6!!&"#U'//&EXK\.OX@M+)[:Y6VO
M]/NX[VTE==R;UR-K <E2"0<>N:SM1\*WNK/J^H7+6L>HWNE-I<*([-'#&VXL
MQ8@%B2P.,#[H'J: -3PUJNJZQ:"\O],AL[::"&:V*7'F,X=<L&&T;2..YSFL
M[P[?OKOB7Q'>L T>FW7]FVB,<!2J*TC?5F<#/HHK=T.SGT[0;"QN6C::VMTA
M9HR=K;5 R,^N,XK#\/V#Z!XG\06K#$.J7/\ :-HQ. [L@65,^H* _1N^#@ S
MK/Q3=6W@:]UO2?#-MFUO+D7%C!/MR$E97=2$^9C@L1@9^M=%H^IKXGL;B<VL
M+Z/.-MM*7)^TH1\S%"HVKG(')SC/0BLG2/#&KZ;H,FE/<6ICN-0EN+AXV<,8
M9)"[(O'!YVY].F#R+'A_19_"4VJH;BV3P\TIN+6#)#6F>74<8V%LD =,XYH
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M,(S[>8B'Z;O6JNM>'=;7Q0GB'PY?V<-Q);+:W=M?1L\4J*Q96&T@AAN;Z@T
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MH,:\# ' K>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRW3[@C  HQSDJ=J\>U;T<T4I<1RHY1MKA6!VGT/H:B6^LVAEF6Z@,4()D<2
MJF.N3VH AUG2+/7M(N=+OXR]K<+M<*Q4]<@@CH00"/I63#X)TV*_:_-QJ$MZ
MUF;-KB6[9F:,DDY[$\^G';!YK7TG5;36M,@U"QE$EO.H=&]0>GTJRL\+,RK+
M&2OW@&''UH P8O!FF0VVC6\<MV(M&;=9+YO^K.TJ,\?-\I(YSUJ.X\"Z1=6V
MI03-=LNH7*WDS"8JRS+MVNA'W2-J]..*Z![NVB@\^2XB2+./,9P%_.GF:(%
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M"@;H@+Y<!#_"-I/ XY-6O'.IZ;+9^,OL\MO;7<%Y:^:+A]UQ*Z>40\8R/+C
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M;2VG8--;Q2,!@%T!./QH \KU:XTZQNOBE97$EO"]Q:1O! V 9/\ 0\95>_S
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MF.,*6^N.M '.>/=$DU/0TO[&!)-6TF5;ZRRN2S(<F/Z,N5^I![5R^OW<VH^
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M.*"6,LK894"GE201D5B>)+'7;[Q"84L/MNBRZ>T:(+A8TCN2Q^:4$Y==NW&
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M][J4,, AW1NDXEV!9<$84,"",D''>M=_$EN+V:WAM;JX6"ZCLYYH@A6*1]N
M06#8&]<D @9]C7$P>&]>C\'Z/8-I,OVFU\0C4)4\Z+B$7+2Y!WX)VL!CUJ_J
MWAO4;KQ(VKZ787.F:LMY$#>PW""WN[8%=PF3=DD+N ^7.0O..@!>MO';+_PD
M]SJ&E7D-EHL[1LZ!'.U8T<Y ;.3N)],8R0>*N0^-[.;R0--U16N94BM%DMPG
MVDLADRA+ 8"J<DD=/<5@WN@ZZ++Q]I\.EF9-9,DEI.L\8#%X%CVD$@@@J<YP
M,=,UIZG;^(1I'AN.TL)Y((F5=3LXKA(YBHC(&'W 8#8) ;)''J* &ZKX]6'0
M8M0T[3KF:1M433)HI-BM!)YH1@V6P3Z8)&2.0.:OC5+)O&HMS;:FNK+I33>0
M7 B,7F+QC=L,FX@9'N,UR*^%?$$7AG4K1-'B25/$2ZI;P17"8EB$ROM4\!<
M8&['T%=-'8:I)\2K?69=.>.S_L=K5Y/-1MLIE5\8SDC QG'7VYH NV'BZRU/
MP_!K-K:W;0SW'V=(BJ"7?YGE\J6XPV<\Y !/2F:GXUTW24DN+B*Y-A#<"VGO
M453%#(6"X;YMV Q )"D \=CBGI'AF\T[QGJ<^Y/[$DE_M"VCSRMU(I23\, M
MZ9E]JQ]/T/6](U74M-/AFPU&TNKV:ZM=5D>/]RLKERLB'YV*ECC'7@<=: /1
MZQO%V\>#=:>.66*1+&9TDAD9&5E0D$,I!'(I=/U>\N?$&IZ9<Z6UM%:K&\%S
MYRN+A&SSM'*<J1@]<4_Q-;7%[X6U:TM(3-<7%I+#%&&"Y9D*CDD =: ,S1M<
M6U\,:#"8KB^OYM,BG\F(KO90BY8EV4=2!R<DGV.);/QMI&H6.F7%D9IWU*22
M.WMU4+(6C!,@8,0%V[3G)],9R*Y:70-=TZ3P[JL7A^'53;Z2FFWVG32Q!XRN
M")$9B4/.0>>A'X3Z]!J"7'AMK/1(QJT$L]T+2PN(HY+>(KL8 N-C ED#$]^G
MJ "]J_C+1-0\(ZS<W<&KQ6EE+]FNQ ICECD#8*AE;J#C)!Q@CG!K=U#Q);6%
MS=VZ6MU=R64"SW(MPA,:-NQD,P)/RL>,]*XB]TZ]U3P%XC\/V/A^_MM9NG%S
M-'=SP$S/*Y)DWJVS'[LC QC XK1\6^'K[6KV:^L-+O++6H8%&G:I:W,<9#=3
M',-_S(&Z\-P3CW +GVLV7Q5U,S74XLH]!CN7C>5F1#YKAF"Y('"CH.U:5AXP
MM-0NK>VCL;Y)KJQ-_:+(J#[1$,?=._@_,O#;>OUQE7>F>(1XSU+4[.V4.^@B
MSM[IV3RS<JSN"5SNVY8=O6L_1-&U]/%>@:O=:))"8]/FMK^:>\CDD\UC&=Q(
M)RIVMM Z9QA10!,GC"VUGX?1:QK=CJ5I;3W2JIM) &_X^-J#<C9 !"JV<9R<
M9%=5#XAMY?$\^@?9[E+R&W%SN<*$>,G:"IW9//'3CO7"CPWXB7X5#PT=()O(
M+R,H5N(\2HMUYI<988&T<9YSV'6ND\6>']1U._T?5-(?[/?0.UM<,Q /V65<
M2=#RRD*P]UH T4\3V\MO;/#9W<L]TCR0VR^6'>-2 7R7"A>5P2W.X59T'7;+
MQ'I2:A8,_E%VC9)%VO&ZG#*P[$$5S/B?0]0M=?TK6=(T6VU>VMK5[&?3G=$(
MC)5E>,O\N05Q@]C6@-2U+18-*4^'88XKZ[$=Q';3HOV(,0JDC'[PY.3MZ8/4
M#) .IKG;WQGIUC!=7;PW4FG6<_D7-[$BF*%P0&R-VXA2<$JI Y]#CHJ\XA\.
M:W9^%/$7A(6)GBOI;G['?^:GEK'.229 6W!D+-T4YP,>P!T-[XWL;369M*BL
M-3O+J*&.<K:6V\&-VVAAR,@$')_+-=-7&Z-H=]IGCN2<6DITQ-'M[".Y:1/F
M:)G/*[MW(8<XZYKLJ .,C\5:-I%GXDU58M4>*SO]E\)#N*.43E%9N$P5X&.I
MXK>?Q!:1^(FT2598[@6;7OF, (S$K!2<YR""PZ@5P<VBWFO:)\2=.L44W-QJ
M>(0YVAF6&%L9[9QC\:NWVC:[XC\237<^DOIMI>>'[C36:2XC=X9)'4@D*3GH
M>A/;IT  >(?$!U'4_!ES8QZE!:W>K($G+[(;F(QN>5#9.<*PW*.!Q6U8Z_HM
MK<>);OS+Z+['<HMY]I+%0Y1=HB4DX!!7  &2:YQ=/\4W.E>$+"X\/-'/HFH0
M-<S"ZB,4L<<3Q[T^;=@Y!P0",XP></U+PIKFI1>,5@MQ:SWM_;7VGR32(4D:
M$1X#!22,F/OZB@#IYO%%G(=4L+RRU&UGM;/[3)$4&]H6R-R-&Q&<@CJ"*BTW
MQ'IUOH^@6^GP:A=F_L1/:0DJTQA5%)9V=@,_,H.6R2:2.[\1:QH=^+[0#ITC
M6CQ);&YCE>65AC(8':%'N<G/08YQ+#2_$MGIWA/3YM*>?3[731;7MJEU&F)U
M5%5G.[YX\!N!GKDJ< 4 2^(=<AUG3O!NLZ7<W4=O=ZU;I@.T>]#OW(Z@X/*]
M\]*[^O+=/\->(;;P;X3TR72"+C2]86YG6.XC($2O(=PRP'.\8'7CG%>I4 <A
M?_$73+"35$_L[5[C^RY EX8+3(B7:&WG)'RX.?7J<8%2W?C[2[>ZAMK:TU'4
M)9['^T(!96_F>=%E1\N2,GY@?_KX!PM/EO6\2?$*TM-,DNWGN(D1@Z*@8VJ#
M#[F! Y!R >,]^#:T+POJ&@^*=!5;9Y["PT(Z=)=AT ,F]&SM+;L?(>W<4 ;=
MYXRL+."]NOLM[-9V#;+VXAC4K;G 9@P+!CM!!;:#C\#B>\\46=OO%K#<:B\=
MJ+R1;,*VV$YVMEF .[!P 23@\5S4&AZUI5EXKT6/3S>0:M<7%S9W0E0(GGCY
MEE!(8;6).0&R/?BHK#0=?\$ZW$^DZ=_;6G7&FVME,!<)#)#) I57^<X*D'G'
M(/;U .H_X2NRFM+:>P@NK]KBU%XD,"JKB(]&(=E R<@#.3@\<&H[7QCINI:=
M8WFEI/?_ &V%IX880JOL4[6)WLH&&.W!/7IG!KG]8TG7K7Q3;Z\FA6FNI<V*
M6MY:"1$:!U=F5XS)@%?G*GH3@&F:KH>M6FL:7KEKX=L-23[(]K=Z5&\:>2#)
MYBM&S@*2,D'IGKWX .BL_&FE:CI^GW5B)[F2_=T@M40"7<F?,#!B NW'))QT
MQG(SQECK5K!X8\<7.M'6A8PZP\;(DSFXA7RXOE5@W !]&Q@]<&M:[TC7+/7=
M!\1V>C0O]GCGM[K2[62-&CCE*D%&8JC,"HW<C/;UK,O_  YXBO?"?C>R&CLE
MQK%]Y]HAN(LE2L8^8[L#&PYY^F>M '8W_BZTL-<DT1+#4;N_2U^U+';PAMZ;
MMO#,0,Y]2!QUS@%8/&.E76B:7JD!FD35)!%:0A )'<YRN"0 1M;.3@;3S5(6
M6I'XD?VT=,F%E_8WV7=YD6?-\W?MQO\ 3C/3/MS7*)I.JZ9X+\+:7)I,C:Y:
MZC)<10Q742RJH,CET))0C#JI#<?-ZXH [_1O$EKK=Y?6D%O=PSV$ODW"SQ@;
M'X.,@D'@@\'H:O:EJ5KI-A)>WCE(4P.!DLQ("J .I)( 'J:YSP=(T5]J4%WH
MNH:?J-TXO)Y+N6*7S\X0$-$2  % Q@?CR:M^.-&O];\-M#I;QKJ%O<0W=L)3
MA'>)PX4^QQB@!X\8:=#+J<6H17.G2:= MQ.+E%/[MLX92A8-R", YSVJ2+Q1
M;?VK%IEW9WEE=SPM/;QSHO[]5^\$VLWS#(RIP>>E86MZ?XB\;^#=2T^ZTU=$
MGDB0P12W"S%IE=7!)3("94#N3DG QS8EL-2U[7_#^K7NES6']D+--)&\L;&2
M5X]@1"K'Y>6.3CHO')P /LOB)I5]%IDZ66I)::C<FTBN9( L:S;F4(WS9Y*G
M! (Y )!XJ[J/C'3]-6YF>"[FM+2=;>ZNH$5DAD8J,$9W'!9<[0<9]CCD+7PW
MKT/@;PWIKZ3+]KL-:2\G0318$2W#29!WX)VL./6M32+7Q3X>U75]-M])CN[&
M_OI;VVU W**MOYIW,LB'YCM.<;<Y]1U !MZQXPL-&CO)Y8+J:VL65;R>!59;
M<D _,"P8X#*3M#8!J"?QUI\>K3Z;;V&J7MQ"D,C?9;;>#'*2 XYY48Y/ITSS
M6'_8VM:1XGU=8_#-EK5AJ=S]J@NY98T:V=E5620,-Q7*Y&T'KT]-?2=,U&T\
M?ZK?RV+"RGL+:WCG5HPK/&7)PH;(!WC'':@!H^(VE>2UP;'4Q:QWQL)[AK<!
M()-X3Y\MG&XXX!QW XJRVKZ9!XOU--NHF^M=.265/F,1BW-@HF<%L[AD#MUK
ME;GPYKTO@77M,729?M=YK;7L*&:+!B-RLN2=^ =JD8]:W9=.U0^.M4U5=,F-
MI/HT=I&WFQ9:57=B,;^/O@9Z9!H LZ;X^TS4YM'6.SU&*#5U)M+F:$+&[!2V
MS.[(; /;!QP:DOO'.EV%O=730W<ME:W?V*:YBC5D2;(7;C=N.&(7(&,FN<L?
M#VN6^@^ ;1]+D\W1IT:\ FBP@$3QY'S\\L#QVK/%M>3OJX3PUJ%_H%SJKWF+
M*]M_)F*."6PY#\NFX@'!(XX/(!ZM%)YL*2;67>H;:XPPSV([&N?U?QIIVCR:
MB)H+N6/3%C>]EA12L ?H3E@6XY.T' K=M+J.]LH+N+=Y<\:R)N&#AAD9'8\U
MYWXST/Q-KJ^*-/\ [,^V6]Q;(NE2&Z1(H_D^<%"<^86SAB,8P-RT ;-Q))_P
MMRQA6YN/L\VB3NT7G-Y>X2Q ,%S@'!ZCFJO@K5Q8^&KM[V>YN9#K5W:P*\AD
MDD(F8*@+'G '<X !)( JTEAJTGC[2]7ETQTM8M(DMI6$T;;)&=& ^]D\(02!
MC)[CFN=/A3Q!_P (TKQZ7$VH66OSZI%974L92ZBD:3Y,@D*VV0]>A% '7+XY
MTD6VJR7(N+6;2Y8XKJVE53(K28\L#:2&WY&,'ZXJ5/%]@-6O--NH+NSN+.W^
MU3F=%V)%@G>65B,?*PZ]17-:[;7-YX*ODN/#5KIMQ>2V\-K8)/&LSRB0$-O3
MY=PZJ.0-I)X) A.GW>M'6+#5=&U/3]3UK3WLHK^ZFMY4"JK$)B$_*,L6/'//
M/04 =7!XOL'UBWTRY@NK*:Z@>XMFN0@69$ +8(8D$ @D, <5S?B/Q =1OO!U
MS81ZE#:76KQA+C?LAN8BCGE0V2#A6&Y1P.*?IFE:UJ^CSZ7J?AFQT:<V<MM+
M?Q/&_FLT93=$$Y4'.X[L8Z<YR*2:=XIN-&\(Z;<>'V2?0[^W:XF%U%Y4L<<;
MIO3YMW((." 1GOV /3JYZ[\8Z?:,7,%W+9K=BRDO(D5HDF+;<'G<0&.TD*0#
MQG@XZ&N#\.VGBGP[/>:"FE1W%@][-/:ZI]I4+''*Y<AX_O%U+'H,'CD#F@#6
MC\;64^LW.EV^FZK--:W*VUPT=KE8BR[@S'.0N.^/PJAIOB[0],\-6M["FJO:
M7>I/:)YRM+(LK3%3G))"[LX'7';/%6_#EAJ-EXH\57EU8216]]<Q36SF2,[P
ML*H1@,2#E3U[5S,7AO7D\'Z?8'29?M,/B$:@Z>=%Q#]I,N<[\9VG&/7\Z .F
M_P"$[M?/U&U&C:PU]8*LDEH(%WM&P)$BG?MQP>"0<C&,TEQXAT74KGPI<J]^
MPU&0RV#PEDC),3'$O(!^7/!SR*BBT_4XO'.O:H=-F-I=:=!!"PDBR[H9"1C=
MD??&,^AK$TOP[KEII'@"VETN02:-*3>8FB(0>4Z9'S<\L#QVH V[CXC:5;0:
MC<-8ZHUOIMT;6\E%L-L)PIWG)!*_..F3WQCFK^K^,;#2)=01[>[N!IUNES>/
M BD01MNP3N8$\*QPN3@?2N4O_#FNW'A3QUIZ:5)]HU>^DFLP9HL,C)&H)._C
M[A//J*?XGTCQ-K<>OV+Z2UQ:76F"/30UU&D<$OEL'$BYY?<1M;! XY7DT :]
M]<.WQ0\.&"YG-M=:==NT8E;RVP8MK;,XSACSC/-=E7$0:9K#^*O"U_-I;QPV
M6FS6]R1-&WEN_EX'WLG[AS@'KQFNUD021LA) 8$$B@# 3QCI[W%@%@NS:7\Y
MMK6]"*89)!GC@[@#M;#%<''7!!IMUXUTRTMY+V2*Z.EQ7!MI=055,*.&V'/S
M;MH;Y2P4C/>LCP7;^*M#TZS\-7FDQ"WL#Y2ZJ+A#'- #\N(Q\P<C"X. .N>Q
MSH/"VMP^ ]2\#O9&2.666.VU'S$,?DR2%]S@MO#KN;@*<D#GN #I+[QQ8V>H
M:I8IIVIW5SIL233);P Y1@QW*2P!P%/U[9JX/%%A/!IK62S7DFIV_P!IMH8
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MZK8+F.3<%W#)4+@G(]^ #LJ*XC4?%NL2_P!J2:!8K=MIUU]F%LUM(QN67;O
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M:,[B=QX&&&WZ"@#MJ*Y"SUSQ)-K%G =/CFLKNW=FG%M)"+24 %0Q8GS%;D9
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M0D.."3C'>I;RZ\61>-O#5A>ZAIB+<F\D,=M;2%&"*NTMEP2=KGCH#SSQ@ ]
MIC11O(DC1J73.UB.5SUP>U5=8U.#1=%OM4N=Q@LX'G<+U(4$X'OQ7,R^*-5T
MW_A'+S48K1['6IHK9D@1@]M+*N8_F+$.N?E)POK[4 ='J&NZ5I4J1W]_!;LY
M4#S'QC<<+D]LD$#/4BM"N!\.6UW>^.?&<&HRV=U:BXM4DA:U.&'V=64#+D
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MY3(QP<+S\H'>J_\ PKVY6PEM%UYF5M9&KJTMHI(<2>9M.UAG+=3QQT KNJ*
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M!Y]4O]>EBUJ2WMM;LUM;B'[.KLNU&4%&)X&&.5QSS@C.:YOQ%$MMK6GZ;?\
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MY?H6(89)&.."?K6C+:P:'<W?BO7KU)9H;,6[2P6S*D4(;<<("[$EB"3D_='
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M=,-S8$N<[U&<*2>N,9[YJ'X@Z3>:UX&U#2=-M//N+A41(PRHH =2<EB!C -
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ME=FB##! )8D# X'0=L9J[9>'-)T_3;G3K>T L[HN9H7D9U??G?G<3UR<^N:
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MWMTL;^6TI4*681KU<@ D*,C+'@5SWPW1XM OHY(9H6_M2\=4EB:,[&F9E(!
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M3-=G0!R/AK5M3O\ Q?XHTV[O/,MM+FACMP(E4D/'O)8@<D9P,8IOA/6M0O\
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MMD 8QP<D<9 -6YB::VDB23RV=2H<#.W/?%9_AO0T\-^'[/1XKB2>&T3RXWD
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M%'4L)FFV,Y^;NQZ+FM:#QG$EQKD&JZ?-ISZ3;+>2!G63? 0QW#:>OR,"/U-
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M5#%5&3U('05RFK>)H[S1(+G6/"UT=/EN[/[,SS1X=I&4HY ;<NUB.",]..N
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MVS2X=&RP8-QU78Q(]%/6@#IJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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MIUQ?WTICMK=#)*X1GVJ.IPH)H KZ,=8DMWGUI+6"=\;;:U<R)&!ZN0"Q/?@
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M:T-IJ-G;W=N6#&*>,.I(.0<'B@#C/"'A6)O"6J64UW)<65ZLUC9R=TL076,
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MUH+]F N&RNV$1?/\G'3/&:AG\(:I-X(\-62O:Q:QH#VTT7[QFAE>)-A4MMR
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M=]X.MK_3M/M)-2U!?L5VE[YP=&DFF0Y#.60YY[  = ,  4 =!"C1PJKR&1P
M&<@ L?4XXKG?'^K:AH7@C4]4TR6**ZMHPZM)'O&,@'C(YY]_I5F'3=0C\72:
MA_:%X]@UH(GMI77RO,!7#HH&0<;MQ/J,>T_B/08/$V@W6CW5Q/!;W*A9&@*A
M\9S@%@1V]* ,*^U#7KGQ^V@V>I06EH^D_:U?[,'='\T)W.#^6/8]:T? VLW>
MO^#=/U*^V&ZD#I*8UPK,CLA(';.W/XU*OAI!XD77?[1O3=BR^Q;2(]FS=NSC
M9G=NYZX]JF\-Z!!X9T2+2K:YN+B")G9&N"I8;F+$?*H'4GM0!SOC'7=5TO\
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M39GP"42)-S;0>-QR ,Y &3@US'BZ+6X=%TV'4[FUN)U\2VGV29%(+1>:-AE
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M5_,D50'?&-QQR<5S9\#V(34K2*[NHM+U*9IKJP4KY;,WWP"5W*K=P#W.,9H
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M^8"BN&Z#'WNE<!HFFSZ[8>'$$JO?V^H2R:CJ,5T +N$&3."K;V#'9@$<;>P
MS!K>G6]QIOQ-OI/,^TV5SYULZR,OE2+;1D,N#][(ZT >MF^MAJ2:>95^U/"T
MXC[[ 0I)].6'Z^E6*\[M;>RF^+EM=W,-N9Y/#T4WF,HR9/. #9]>@_*M'Q_9
MM:P6/BJWA,MQHDPGFC7GS;;I(,=RH)<9Z%>.M '9T5YEKMZT.@P:]'NBL];U
MJU%U,N5V6!8*I)ZA7"J3_P!=2*=KED;#Q5J^GZ;"$TRY\.S7%S:QC$<<RMB.
M15'"L?F'&,[<]10!Z717EUA=Q/=_"IQ<J9Y;)A*=_P SC[(?O>HW9Z]\UM_$
M"!9+_P (YDF3S-;CA?RY63<ABE)'!]5'/6@#MJ*\EFT'3C+\1=/\MQ9V$4=Q
M:0"9PD$K6V\NHSP=P!SV[=34EQ=VVKV%G'=2_:;]?"T=S-]MD'D1*X_UJKC+
M2EAC.1@#KSR >K45Y29&M_!G@SQP7:YFTVUM_P"TB6W&2!XU5W;U9"P?/7[W
MK7=>&+<-93ZJT>R;5)3=$8P0A&(QCL=@4D?WBQ[T )X=U^76[G6H)K1;9M-O
MC:?++O#X1&W9P,??Z5NUXQK5A!+X?^).I'S!=V6I/-;2+(R^3(L,)#+@\'W_
M  K1\:W-K>P>+'CDWWMCHT;O)<R +:N4=T^SJ!G>QQELCD+UZ4 >K45YOK%S
M'HUSX7\;.QEMS$MGJ3K\W$B@)+@?Q*X"D]</BDUESHTWAJTOWM;.UU2YN);X
MW,>^'[0R[DC?#*"!E@,G&46@#TFJ]K?6U[+=1V\JR-:S>1-M_A?:K8_)A6%X
M.TZ'2[74+:VU5;^#[6SJD:XCMMP!,2?,?E&<XSQFO/9)(] \*^.[O3(H[:Y3
M79(GD@ 62.V+0>85QR %8G(Z9S0![/17#36R:5\1O#@T)4BL]0M;G[=#!_JW
MC15,<I XSN8#=U(;&:9XPTZWU+X@^%+2Z:8V]U#?)-$LSJLBB-< @$>IZ4 =
MY17E$EK8ZGJ/B3P]?:K:::VG&**R:Y#&:VMA"FR2*1I!@[MQ+<G/4G@5<@ET
M[6O$'B#1/$E]GRK"U^Q2W!$+B)H<O/&&^Z_F$Y;J,*.U 'I=5)Y;Y-1LXH+6
M.2S</]HF:7:T1 &S"X^;)R#R,>]>=W$MKJGB:XT#4=2MQ:_V1;-I[:G&7:92
M'#RJ=Z8DR%R<9X&,<U/';_9O%7@"$:G/J2FUO8C<R,<7"K&NUBN<'@GYNX.<
M\T >D45YG:6@T[Q#K7@DQ$P:G.E_:N03BV;_ %RY[;2A5?3S%J&]6UU[6_%6
MCZGJMCILUG(@M&FCQ+;6_E(5DA;>H7YMQ) Z]>,"@#U*BN6\47=O9?#FYFU"
M^O1#]EC22YM\13N6VJ",\*6)&<],FLCPL_V3XDZ[8#[);Q-86LOV2T?,:29D
M!QTRVT#) &1CCO0!Z!17GNIZ/9:S\6IM/U S2VDN@B5[?[0ZHS>>5S@'TQP.
M,X/6L/P_*K6>AZ-?337Q34-1CTY+N4>1<6T1*AY202^T'Y0/T R #UZBO(-,
ML9]7^%D5Y9R+=ZGHE_/<6J!B1+''</\ NNI)1D4J <]%]*O>(9[?Q!\._%'B
MRW\R..ZL"MDX)C;RXU)W''<N6^H5: /4:*\UGT2Q3Q]X=@59?*U+2[G[:GG/
MBYV>45W\\XW'\..G%8MKJ;:5H]KI\MTD&BIXHO+&1[D-)%'$/,\J-_F'R;]O
M4XX&>.* /9*;(Z11M)(RHB@LS,<  =237DWB+2;?3?#.I+9ZS]HB?5K&18;,
MF.&T+S(K(F&/!'S;<\9S@9JSJ6F6EEX@\9Z5!%_H4_AY;N2!V+JTV9AO^8GY
MCM7)[X% 'I=G=PW]C;WEL^^"XC66-L8W*PR#^1J>N<\!Q6D/@71!:)$@:Q@>
M01@<N8E))QW/%='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !4%Y96NH6KVM[;0W-N_#Q3('5OJ#Q
M4]5;_4;73+;[1=R^7&76-< LSLQPJJ!R22< "@"--%TI+"6Q73;3[)+_ *R
MPJ4?M\PQ@]!UIQTG36TS^S#I]K]@V[/LODKY6WTVXQBL\^+M'2#4I9IIH6TU
M!)>120/YD2$9#;0,E< \C(X/H:FT7Q)IWB R_P!GM.ZQ)'(7D@>-65P2I4L
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MRU@7(M7?S+68P7$4B%'C< '!!]B#D<'-<_)K%YKWCJ]\.V-T]I9Z5!'+?S1
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MNM(L9[J6(PR326ZL[H1@J21DC'&/2I(M#TF"\CO(=+LH[J-/+29+= ZI_=#
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M9P7$[2+-+!(S6LBI&\:[F#L5 7C/7&<&K%MXJTJYN[2V665'O4,EHTL+HMP
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MI[N*:5T:T1'E)B;:-YPH!QAF)X"C)Z<<BL^7QMHEM%J3W4T]NVFQB6ZBEMI
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MDBI<,XCQT&649;/3C'>@#H(?%NKSZYJUH-)LX[+2+I8[RX>\.1$8A)O4;.2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*AGM+:ZV_:+>*;:<KYB!L'VS4U%  !@8%%%% !39(XYHVCE171AAE89!'N*=
M10 @ 4    < #M2T44 %%%% !1110 4444 %-DC26-HY$5T8896&01[BG44
M16]K;VB%+:"*%"<E8T"C/X5+110 4444 -=$EC:.1%=&&&5AD$>],M[6WM$*
M6T$4*$Y*QH%!/X5+10 4444 %%%% !1110 4444 %%%% !1110 4444 (RAE
M*L 5(P0>AJ*WL[6T#"VMH80W+"- N?KBIJ* (([&TAG:>*U@29L[I%C 8YZY
M-3T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !6+XG\0Q>'=-2<M:_:)Y5@MTNKD01NYR<%R#M& 3T/3'4UM5B^(+K0HUM
M[+78(YHKHLL:S6IEC) &03M(!.>,XSVH MZ1/J-SIR2ZI:V]K<L3^[MYS,FW
ML=Q5<Y^E7ZYWP5I;Z/H!L_WJVJW,S6<4V=\4!<E%.>1@= >0" >E=%0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>josetrevejo-tarsussepara006.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>0KC$94_*O<EB.PP>35.RT'6X-/^'T+Z5*'T; O?WT7R8@:+CY_FY.>.WY4
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M9O(X+;-N2.^>3UH LZ_JC:)H%_JBVLEU]D@>8Q1LJE@HR>20,<?X ]*S=/\
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M44 %(S*B%W8*JC)). !2UP/Q6N)/[+T'32Q6SU36[6SO2#C,+$EE)]#@#Z4
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MDRISE3@\<$<5>B\2ZOIWB*PAU>:SDL+_ $R:] @A96MS$$)&XL=X(?T'([4
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MM0NS=R>:B*%<JJG&T#LHIDOA@_\ "1WVLVNHS0/?6R03P[%9&*;@C<C/&\\
MC/'TKH** .0M_ WV;3/#E@FIN8]!F$L#&$9D(5E ?GIACTQ59?AT$MK>U37[
MY;:TU/\ M&UC$<9,3%F8@DKEN7;D^O>NXK-U_53H7A^_U7[,UR+.!YVB5@I8
M*"3R?84 5M,\.#2M>U34H;Z=HM1D6:2U95VK($5"P.-W(4<9QU_"KJGA$:AK
M\^JQ:K=6OVJQ^PW,,:HPDC!8C!8$J?F/3]#S6YI]W]OTVUO FSSX4EVYSMW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5U9:7:PW$47DI*J#>J9)P">>I.?6M&YMH;RUFM;F-98)D,<D;#(92,$'V(H
M\PT^\G.OZMH9>Y$'B'9=Z5)Y[L4M\E9=K9^3"KYB@=/, KHK+?!\6[VT2><V
MW]B0R+"\S,BMYSJ2 20.%'3TKJOL-K]I@N/L\?G6\;11/MY16QD#T!VK^50'
M1M..IR:E]E47LD7DO."0Y3^[G/3OCUYH \LL?^22^#?^P_;?^EC5ZCKZEO#N
MI 221D6TA#Q2%&4A200RD$5 /"NA+I\&GKID LX)?.A@ (2-\YW*.QSSGU)K
M2N+6&ZM9+6=/,AD78Z$GYE[@T >7Z&DMFWPTU!+V]>XU*V\J[,MR[K*OV0N
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ML0?XL\YZ\"@#@?%NE3:/\/O&=N^L+>0R)%-':+&P6SW$ JI9V.&(SMXQ^-=
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M+5Y?ASKD$4<DLTUJT<<<2%V=CT  Y- $FF:A):,;V^\0+>6-TBBWA:W E64
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M#_D2M!_[!UO_ .BUIVM>(+;1Y[6U9H3=W0=HDFF$2;4QN9F/0?,HX!.2..I
M!L45P5QXQT?7-'TNZN=(N)U.N16)3>N+:Z$@"N6#?,H)!!&01Z5)<:U?ZKJW
MC'1KFR1;&PM$5&67GYHW?<>,\_*,=L>] '<T5Y[X(\3M:Z%X,TBYTVXCBO\
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MR<C%1:MXUATO[3&;>)[NSMUN+FW:Z1&7()V)G[[X&<<#ISS0!U5%<HOCBVO
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M0T[24M[Q%U!K>5=YR!NV-N7Y,C@$$Y[BO2ZRM3\-:'K5Q'/J>D6-Y-&,+)/
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MV '% %2YO=3TSQ+X-TY-2EFM+[[0MRLL4>Z39 SKRJC&#CICIS63+XGUF\\
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M:=X?F!LK[5#;1EC;6<UT7AM2<\QJ1VR<;LXS0!2\ 7&O:SIEOK&IZV9XR]U
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M-,T.TLKNZEN9H4VM+*^]R,G +<;B!@9P,XS6C0 4444 %%%% !1110 4444
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MBT]Y/LK#<8\D3LN.X7=DCH?>@#U+7-1ETS0-1U&UBBN);2"241O)M#;5)()
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MT\CWXU:!(X[8Z>8G,KLY$HDR-H5<8(QG//I5L,I) 8$CJ,]*XK4$BC^,6CR
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI;I;VT,<,,8VI'&H55'H .!4E%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45'/,E
MO \TI(1!N8A2<#Z#FJ6DZ]IFNV;WFEW:7=LI*F6($J2.H!QR?84 :-%4M,U>
MPUF!I]/N!/$K%"ZJ0-P.",D=0>#Z5=H **** "BBB@ HJAJVLZ?H=JMSJ-P(
M(6D6)6*ELLQP!@ ]20*OT %%%% !1110 4450O-9T_3]0LK&ZN!'<WSE+>/:
M3O8 L1P,#@'K0!?HHJAJFM:?HL4,NH7(A2:98(R5+;G8X4< ]210!?HHHH *
M*** "BBB@ HHHH ***I:KJUCHFFS:CJ-P(+2 ;I)"I;:/H 30!=HIL<BRQ)(
MARC@,I]0:=0 44UW$:,[;B%&3M4D_D.36)%XR\/SV[7$.HI)"A(:1(W*@CKD
M@8X[T ;M%4KC5K*UM8+F2;,<^!"(T9VE)4L JJ"6. 3P.@)[5E'QWX;&FKJ'
M]I!K0J&>189&$0+%,R +F,;E8?-CD'T- '144@(8 @@@\@BEH **J:GJ=IH^
MG3:A?2F*VA ,CA&? R!T4$GD^E6Z "BBB@ HK-U77]+T0P#4KM;;SV"1%U.'
M;^Z#CD\=.M%EX@TG4;MK2UU"WDNE7<;??B0+Z[#SCWQ0!I4444 %%%% !115
M#3-9T_6#=_8+@3?9)S;SX4C9( "5Y'/##IQS0!?HJH=3M%U=-*,I^V/ ;A8]
MC8,88*3NQCJ1QG-6Z "BBH(;VVN;BY@AG1Y;9PDR*>8V*A@#^!!_&@">BBB@
M HHHH **** "BBB@ HHHH ***AO+N"PLI[RY<I!!&TLC!2V%49)P.3P.U $U
M%9G_  D.E"\TVT-T!<:FADM$*-F10N\GIQ\HSSBI-.UG3]7DO$L;@3-9S&"?
M"D;'P#CD<\$=* +]%4-4UG3]&2!]0N!"MQ,D$65+;I&("C@'J2*OT %%%% !
M17/77CGPY9W<-M/J!22=MD)^SR%9CO"$(P7:V&(!P3CJ>*Z&@ HHJA?:SI^F
M75E:WEP(IKV7R;=-I.]\$XX'' /7TH OT444 %%%,EE2"%Y9&VH@+,<=!0 ^
MBJ>EZI9:UID&HZ?.)[2<;HI I 89QG! /:KE !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5QT.K:]K]OJ-[H<]I&UEJ3V<=
MK<+\DJQ.%D+L 6!/S%<=.,YS78UR8\"Q0ZU?7EGJ^H6MCJ$OGWNG1%/*FD/W
MCDJ67=_%M(S0!UE%4K:QFM]4OKM[^XFBN?+\NV?;Y<&T8.S S\W4Y)J[0 44
M44 %%%% !7F<\%_X0\<G1='94T_Q29)8!G_CQN4 ,SJ.X*98#^\ .!7IE8.K
M>&5U7Q%I&LM?SPRZ49#!&BJ4)D7:V[(R>/0B@"BEXT?B5/"&DR"Q@LM-6Y>4
M('<[F*HHW<?PL6)R3D=.36+;>-=7FBTM9?(2Z3Q$VAWX6/Y)=JNWF)DY7(5>
M,GJ:ZK4/#:76OV^NVEW)9ZE% ;9I%4,LT1.[8ZGK@\@@@@U3N_!%G/H\%G;W
MES;7,%__ &DEZH5I#<DL6=@1M.=S#&,8X'2@"70M7O;SQ5XFTRYD1X-.E@$!
M";6Q)$'(/K@FD\;:O>Z%H<5_8R(L@O+>%E=-P99)50_0X;BIM%\,)HVL:IJ?
M]HWEU-J/E&83;-NY$"AAA1@\'@<<].*L^(]"@\2:)-ID\TL =D=)HL;HW1@Z
ML,@CAE% &#J?B#5K3Q'X@T^WFM_+L]&74+<RP[MKEI 0<$9'R#\ZI:3XCU\W
MW@V6_NK6:VU^T+20QV^PQ.(!*&#9YS@@C '/%:A\$>9?WU_/KE_-=7NGBPG=
MEB *Y8[@H7 /S'&,#UR<U+#X,CA;PV1J-R1H"&.W!1/W@,?E_/QS\O'&/6@#
MCO$FK7WB?X:1>(%N4CLKK4;<QV@C!Q"+I54ENN\D GMR1CO707^O>(M2EUM?
M#ELSS:9<_9H8RL1CGD"(["0LX8 [\#;C&,Y.<!'^&L']DW&C6^MZA;Z/)<K<
MQ6:+&1 PD$F$8J3MW#(!Z9[U=N? X;7Y]5L-=U/3FO @OX;=DVW)48#<J=C$
M<%EP?3% %(:IXIU'QC>:/;W5C8)#96MYM>V,K(7=@\9(?!^Z1N'Y=Z31O%5U
MJ7B Z3=7W]GZJDLPFTVZM]N8QN\N2%O^6@X4GDYY^Z*WK/PU%8^)I]:BNI09
MK6.T-MM7RUC0DKCC.1N/>H8?"B?;-,GO;^:\&ER/+:>8BAU+*5PS <@!B ..
M@SG% '+>%=2UF'X?VU])JL+O<:G+'+-<J R(;F0.4 'SR'@*N.IX!Z4EWXTU
MV#PCXEO()(3<Z1J:6L4EQ;%6DB8Q8W*"-K?O.N.WW:V1\/+>/38+*#6=0B6T
MU$ZA9,/+/V=RSL5 *_,#YC_>SV]*2Y^'=O<V.LV;ZSJ)BU:XCN9R?+)#KLY'
MR]S&OL.@ H ANO%.I^'-?UFWUB>"\M+;1CJL?DP>4R;7*F,<G(.!@FJ&J'4[
MC7/A_?7UY')]IO&E>%(@%C=K:0@(>NT D<Y)X/'2NGN_"%MJ.N3ZE?7,LXN-
M.;39K<JHC>)CD]!D')ZYK/M? +0#1DE\0ZE/#HTWF6:NL65784"LVS+?*<9/
M;\Z .PD#-&RHVQR"%;&<'UQ7CGFZC<?".RNKN]-W/+KL94R*%PPOR"21ZG\N
MU>RUQO\ PKVW70_['35[\6:WPO8D(C/E$2F4*#MY&\YYR>@S0!"FNZ_9ZMXF
MTN>ZT^ZGL]/COK.:5/L\:%_,!63YC\H* YSG&<GO4$'B/5)M6U728[]G1=%6
M_M[Q[4(RN696V@@!D^4%21^8K3U;P):ZU=:O->7]UC5+)+*9(PJA50EE9>,Y
M!8GG(/I4MMX-$>M_VM=ZS?WER]A]AF$@C594R2,A5&,%CTQ[YH /AX;E_A_H
M<UU=-<22V4,FYEP1E!P3W^M/U75[VR\<>'],BD0V>HQ71E5D^93&JE2I_P"!
M<YSTJ]X;T(>'-$M]+2]N+N*W01Q-/MRJ 85?E ' []34.N^'!K-_IFH0ZA<6
M-[ISN89H51LJZ[74AP0<@#MQB@#D9_&'B"/2+B:&6S>:'Q,-)!EA/SQ&14'0
M\-SR<'V I=1\:ZUX.U'7+377MM22#2_[3LYH(3!G]X(S$PW-QN9><],]:@\5
M>&%T+0H[>TOM0G>^\16]^Y*"1H295+N,+T  )+9''X5U\OA.QU,ZA-JSF_DU
M"T%G(Q4(JPY)VH!TR3N)R3G'H  "A>ZQK&A:[H-M=W,-Y;:NS6SL(=I@GV%U
M*X/*'!&#R.#NK MO%GB;_A'[#7;B[L6B_MG^SY[9+4CS$-R8=P8L=I'! YZ<
MDYXZZR\+>1)ISWFI7%^VF(RV1F104)7;O; &YPN1GCJ>,\U0'@" >'DT;^U;
MOR$O_MXDV)O\SS?-Q]W&-_/2@#L*\BO7U"?P/\37O=0:Y6.ZNH55HP,;88L8
MQT '&/QZUZX 0H!.3W-<G=> [>YMO$%JNJ7L5KKCM)/"H0A&955V4E<Y(4=2
M0.>* *,.OZKHFOVEIJ5Q!<:?<:/+>JD4&QH##LR V3N!5N^.1VZ5+I&K^*M0
MGT/4$LC)IM_&)+Q'\E5@5DW(T;!RS8) .1SUXZ5JMX4CEUG3]2GO996LK1[,
M1,B;)$?;NW<=3M'3%5?#_@A?#\L<46MZE<:7;L6M=/G93'">PW;=S =@3@<=
MP#0!U=>7^ +G7(/!=\=-T^TG4:E=[6>Y97_US9(3802.<#=S[5Z<X9HV"-M8
MCAL9Q7+Z-X-GT#39;'3_ !#?)%)-),2T,+,'<EF(RGJ: ,SQ1:W"^/?!4%I=
MBVA#72Q(L0(CVVY_/CCVJE:W$VC>,?'VI7%QYUM8V=O<2P"%1YJB*5]OMW^N
M:Z>;PDDE_H5VNHW*OHZN(LA6\UG38[2$C))&3QCDDT^'PI FLZU?SW4MPFL1
MI%=6TBKY>Q5*@# ST8YR3F@#(@UOQ-;SV>I7-FTVC26<D]\S"%/((3>IBVN6
M93R,')Z'/:KFD77B/5+71-7CN;,V6H6_G74#)CR%=-T?ED<L02 VXX/48Z4:
M#X(7152VEUK4=0TZ!2EK9790I"I!7!(4,^%) W' !Z=*7P]X)7P\T<,>LZC<
MZ9;,6M+"=D,<&<X^8+N8#/ 8D#Z@$ '(V.N:_I'PEU;78]2CN+R&\N2#<0!N
MERZ'H1R>W88QBNOU#6K[2?'FG6=Y<1KHNH6\HA)0 I<( VUF_NE-Q'?*FH)?
MA];2>&]3T :K?+87T[R[,1YA#2&1E0[>['JV3CBM?7O#=GXDTNWL=2+N(9XI
MPZ_*2R'GZ!AN4^S&@#$;Q!JHETC3QYKW6J1W%V&CCC$D4"%=B@.0N_$B9)ST
M;CIC:\,3Z[-ILR^(+5(+J*X>.-U*_OH@?DD(5F"D@\C/45%XE\*P^(FL;A+Z
MZT_4;!V>UO+4C?'N&&4@@@J0!D'TK1TG33IEGY3W<]Y.[;YKF<C?(V ,D* !
MP    ,"@#E/B1_K_  9_V,MK_P"@2U4^,""U\/:=K%J NKV.I0?8I%^^69L,
M@]0PSD=\5TWB3PPOB2336DU"XM?[/NTO(?)5#F500"=P.1ACQ2-X4@N]6M-2
MU6]NM2ELVWVL4^Q8H7_OA$49;T+9QVQ0!SWB3Q5JVC27]REQ XM;^VA2UAC\
MQ/(D:-297Q\DA+D@9' '!SFF'5KW2O&WC74+F]>:RTO3;>X%L$ &P),^T'MR
M,Y[_ $Q6A?\ P[M[V+5[<:SJ,-IJ5VM\T">61'.&1MP)4DC*+\I./:M%O"%J
M^MWFH27EU)'?6B6EY:OL,=PJAE!8[<@X=LX(!H I:7?^*IM7TN62T,NE7<#-
M=NXA06[[0R&/:Y9E)XP<GH<]JZ^N5T#P:V@*D7]O:I>V=JI6RMK@H1;C! P0
MN7(!(&XD =JTO#%EJ.GZ)';:G>W%Y.KN5EN=IE*%CMW%>,X_PYQ0!A^*'U$_
M$#PC;6VH-!;S&Z9HA&&!9(N"<]>&(]JYA]3UC0]/\>ZUIES;1I8:T\[PRPES
M/B*'*YR-HQW&3G]?0=:\.QZQJ6EZ@+VYM+G3GD:-X-OS*Z[74[@>H[CD5EW'
M@."YTGQ!ITFIW7DZY.T]R0J;D)"J0G' PJ]<T 3/K>I+\0DTA#"]C)H\E['&
M$VOYBR(H!;)&,,>PZ]ZH^#O%4NNWXMKF^,=_%;$W^EW-OY,UO-E>4_O1_>&>
M>J\\UK/X6$FOQZP^H3F=-/;3]@50I1B&)Z9W9 /7'M3K+PRL&JV6I7E[+>W=
MC;/;02R(JL5;;N+E1\S?*/0<GC)S0!J:E?Q:7IES?SAC';QM(P499L#H!W)Z
M >IKS'0[D^&_B#8SS?:UC\2P&.^:>UEB1;]277:9% P0S( /[HKT76=);5X[
M:/[;+;QPSI.RQJI$I1@RAL@\9 /&.@JKXJ\,Q>*M-ALIKR>T\FX2YCFMPN])
M$.5(+ XH H:MKMXOBJ?1H[F/3XHM+-]'<R(")7#%2/FXVJ "P'/S#D=\.#Q/
MXKN['P;(TEA:SZZT@F0V;CRAY+.I ,ASC&>V>.E,\2QRR>+2+S4=;T_R+6**
MWN(-+%W#<G)9F \IPC D C@G [8K:LO#VH:M_9&H:KJMTUQIES)-;.ULD3S*
MRE<RIC@X9A@8.,9 /  *DFL>)[B34])L7%QJ>DP1*\T,$2QSW#)O&Y7D!5""
MH^7GKSVJ1O$'B'4KF?3+:S>SU*TL()[A(O)E"W$H;Y"7< H-G49)SU&.=#5/
M!@O/$+:WIVM:AI-W-&L-W]DV%;A%^[D.I 8 X#=A3-1\#13ZI:ZGI6KW^D7L
M-N+5Y;8J_GQ Y <.&!().&///>@#.36_%<VOZ%I5T++39[_39IKF/RO-,,L9
M0$@A\,#NX';OGI66WBSQ/!X3N=;EO+)CI6J-87$2VI'VM5N!$6SN^0X8$  \
MCWP.P'A2*/7-.U2*^N ]A;R6Z(V&#B0@NSDC)8E0<YK/D\ 02^'-0T1M4N_(
MOKXWTL@1-X<R"4@?+C&X#M0!!J.O>(-1N-<A\.V[-/I<P@B0K$4FE\M7(D+N
MK!3O"C;C&"<GH&-JWBB_\5W>C17-GIVW28;T;K?S6AD=G4H3NPV"O7ICMWJ]
M=^"/,U^;6+#7-1TV:[1%OX[4ILN=HP&PRG8V.,KSC\ZNQ>%H[?Q!/J]O>S1O
M)9)8K#M4I'&A)7&1G(+'J: .-@UW5_$5S\.;X7HM/[12XDGBCC!0R+ _S<\X
MY.!VSWKU @E2 <''7TKD;;P!;6>FZ!:6^J7T;Z([FVG41[RCJ596RI!R"><9
M%=?0!YAJ7C+7=,\/ZR\UQ&VJZ1J?E2Q); ^=:D"3>JYX/D[GSG&485T.JZYJ
M"Z3XAU72KR![:PL/,MS)#O5Y1&96.01E=I0#W+>F*U7\,:;)XCN=;DC+W%Q9
MBSD0_<9 2<D=SAL9].*KV_A"SL_ [>%;6>:*T:V>V,O#2;7!#'D8SR?I0!@7
MEU+?>)/AM=SD&:=+B5R!@;FM<G]35_P5_P A_P :?]AG_P!H15=_X1%/M/AZ
M?^T;C=H:,D V)B0%/+._C^[Z8YYJWHOA]-&O]5NDNYICJ5S]IE615 1]H7Y<
M#IA1US0!B_$W?_PCEAY6WS/[7L=F[IGSUQGVK-O_ !?K?A'5-6L];EM=2CCT
MMM2M)H83!@JX0Q,-S<99<-GIGK78>(-"@\1:8+*>:: I-'/'+#C<DD;!E/((
M/('!%5)/"=G?"^?5Y&OY[ZU^QRNRA L/)VH!]W).2>3G'/   *^FW'BA?$<<
M5W:M+I,MN3)-*(4:&8= H1V)0C/!R1QR:Z"_69K"<03>3+L.V3;NV_A6)X=\
M*RZ&8Q<:[J.J1P+Y=JEV4Q"O3JJ@LV.-S9XSC&36]<Q-/:RPI*8F=2H< $KG
MN >* /+-#U+5="^#_AG4+6Y@=G>TBVRP9*QR2*C!2".?FZG-;U[J_B2X\3>)
M-+LK^RMHK"R@N8'-J78%Q)\IRV#]P<^G0=ZN_P#"!P?\(?8>&AJ=T+2RDB>*
M7:GF'RW#J#QCJ!VJY_PBP&LZKJ8U&<3:E;);2KL3:BH&VE>,Y^=NN>M &/;^
M)=3U72/#]XMQ#9KJ.F?:76"/S9VGVH0J1D']V-S$L>G R.M94^M3^(M ^'&K
MW21I<76JQ/(L8PN[R9@<9[<5O6/@"'3I=*DM-9OXGT^Q_L[*B/,T&00K94X(
M('S+@T6GP_@L])T+3H]6O6BT:Z%S;EUC)) 8!3\OW0&/OSUH ["O/W\5:M:Z
MQI"2W$$PO-6DL)X((]T,28D*;9<#,@"#<,GDD8&*] KB8?AQ!!:V-JFN:F+?
M3[\WMI'^Z_=$ER5SLRP^=N3DCM0!C:AXJ\4V^A^+-52\L -!U%XUB%H?W\:I
M&VTDO\O#GGDY] ,5TZZQ>ZUXFU;2-.N5LUTN"%GD,8<R2RJ64$'^ *!G')+<
M$8YAG\!P7.D:_ILFIW7DZY<-<7)"IN1F"J0G' PB]<U8?P?LU_\ MJRU>[LK
MN:!+>]\I(RMRJ?=8AE(##ID=J *GPI_Y)?H&>OV<_P#H35V-8_A?P_%X7\/6
MNC074]S#;*51Y]N[!.<?*!QDGW]ZV* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P?%&O7&@1:9)#
M:QSI=ZC;V<A>0J8Q(X7<  =W7ID5O5Q7Q,1)-%T=)6*QMKEB&8.5('G#)R.1
M]: .RE,@AD,*JTH4[%8X!;L">PJ*P>[DT^W>_CBBNVC4S)"Y9%?'(4D#(S7G
M1T*TTCQAXAL=)B\G2)=",U[;QL?+2Y+'8W7Y6*!B<=< ]ZSM/LK:]MOA.EPI
M=9;)T==Y =1:$X.#R/7UR10!Z]UKGX=?NI?&M[H!M(0D%@EY%,)22^YV7!&/
MEY4^M><-=KH>C:G81'[/H<?C%;2Y53M2"T98V9?]E"YP>V&([UOP6FCP_%'6
M[6T2UBBGT")GB@(4$^9)G@?[.T\?6@#OM.>]DTZW?48H8;QD'G1PN716[@$@
M9%6J\;TJT@O/#_PJ$X9O,9D?YR-R_9Y"0<'UZU+/"--\+>/M/TZXAL+6TU:/
MR8B_EQJK+"S1 _PAR67TRW;F@#U_.>E%<)X>L;&7QGJ.OVPM+6P%E$BVZ3QM
MMD&[?*1&Q51M*KG/.WV%=K:W5O?6L5U:3QSV\JAHY8F#*X/<$<$4 1:E/>6V
MG3S6%HEW<HI9('E\H2$=MV#@_A^58&B>,UUGP/)XC^RQ021K)YEHTQ)C=#@Q
ML=F0V>,;3U&,YKJJ\W33+>U^-<UC"[I97NGC5Y[4$;'NDD\M7Q]#N]V4'J*
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MGN,>M%[H.E)H'Q*@6TC$.F2236,8SMM7^S))NC'1#NYR,4 >M2R7XU6W2.&
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MZRL7+&[*&+K]TJ6)7IU)[UKZO)96NE_%6UE:"(K^\AB8@88VJE2H]2V2".]
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M70=:U:";3FT6+[!<:K$&6Y^9Q(V6(&\KY?/7'/KD ]7HR/6O*XM&L/\ A)?
MUBUY+JMJ;&_B\^X;/VF-=FW..&7!..Q'KFL.]TJPMOAUXKNHH56;1];F33I-
MQS9JLZ$"+^X.3TQF@#W#.*,XKR[6&T[6?%?BC1?$.IV5CMCB-FUVB[D@,0S)
M"[, &$F\DCG(&>@J2UT33M2^(L5G?A]1@?PS TGVO.9SYI7>Z=,D 'D=?<4
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MZ=HD4\>G6P@6XF,\N&)WR$ %CDGDX%7Z "BBB@ HHHH **** "BBB@ HHHH
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M3J[Q0PQ-*[*N-Q"J"<#(Y]P.]0Q^)=*N+*RN[:Y:XBOD,EMY$3R-(HZG:!D
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M@]"Y4$*._/;GI0!;?2=-DOQ?OI]HUX,8N&A4R#'3YL9XJTY<1L8U5GQ\H9L
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M4POY3S#(\L28V[L@C&>H(ZC% %J30M(FGGGETJQ>:X"B:1K="TNT@KN.,G!
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MM)!+96]O$PD+;-H\PD[<+EB !UVGC%7K_7+#39C!.\KSB+SFB@@>9U3.-Q"
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M]I&FZH8CJ&GVEV86W1_:(5DV'U&0<&B_TG3M5C2/4=/M;Q(VW(MQ"L@4^H#
MX-8ME\0/#.H7MC:6VI;I+Y<VK&"14E.,[0Y4+NQ_#G/M5F3QAH<6E7NIR7;K
M9V5P;:Y<V\N8I!C(*[<_Q#G&.: -.33+"6YBN9+&V>>(8CE:)2R#T!QD5#_8
M.C^1)!_9-CY4C;WC^SIM9O4C')]ZST\56\GC.?PX+>Y$D%LD[2F!]I+,0,'&
M /E/S'C/ /!J>#Q3H]QJ-M8I<L)KM6:U9X75+@*,GRW(VMQSP>1R.* +=SHN
ME7CV[W6F64[6V/(,MNK&+_=R/E_"GOI>GR7373V%JUPZ[&E:%2Y7I@G&<>U5
MK+Q!IVHW,,%M)*S3Q--"Y@=4E12 65R-I'S+T/.<CBM2@"B-%TI;5+4:99BW
MCD$J1"!=BN.C 8P#[U8BM+:">>>&WBCFG(::1$ :0@8!8CK@<<U2U/6;*RD-
MI)/.+EHC+MMH&ED1.F_ 5L#/3(Y([UQWA;Q +[P7X2N=6UV[CO;VZ.QT3/VM
MMT@$;D*0%(Y[?=H ]$JFNDZ:MXUXNGV@NFSNF$*[SGKEL9KC]3UN;5_%VJ:!
M%>:G81V=C')%-:6DA83,SY8_(=R@(,#[K9.,\8K^&]:GUJT&N7>LW]K]COIH
MI8S:LL,\2R&)$VE<;R0I^7+;B1CH  =U::;86!<V=E;6Q<Y<PQ*FX^^!S2W.
MGV5Y+!+=6=O/);MOA>6)6,;>JDC@_2LB;QMH%M::C<7%Y) NG;3=I+;R+)$&
M&5)0KNP>Q Q4MOXMT:Z25H+B60QS"#:MO)N=RN[Y!MRXV\Y7(QSG% &;KOA(
MW^JZ ]E8Z8NGZ=<RW$UO(-HD+HRG"A",Y;=D]2/QJ7Q?X9DU?PA-H>D065L)
M98GP^8XU"RK(>%4]=N/QS4Y\<>'5LH;M]0"137?V(;XG4I/G!C<$90C_ &L5
M8L?%6C7\&H3179C73SB[%S$\#0C&X%E< @$<@XP: +=MI.GP6CP)IMG"DP'G
M111+L?CH>!N'U%2Q:=906;6<-G;QVK @P)$H0@]?E QS5&W\3Z1<75S:_:6@
MGMH!<RQW,3PE83G]YAP/EX//;O38O%6CR74UJ]R\$T-N;IEN87AS".L@W@94
M=R.G>@"]:Z5IUE;/;6EA:P6\@P\44*HK#&.0!@\<4VVT?3+)H6M=.M(&@4I$
M8H%4QJ>2%P. >^*98ZS9ZA<O;P>>LJ1K*5FMWC^1B0"-P&>AZ?C6A0!2M]&T
MNTEN);;3;.&2Y_U[QP*IE_WB!\WXTS^P='$"0_V38^4C;T3[,FU6]0,<'WJO
MJ/B?2-*>Z6[N67[(BR73)$[B!6Z%RH.WIGGMSTYJI=^._#MB8Q/?2!I+=KF-
M%MI69XU(!( 7)QGIUQSTYH UI=(TR?4(M0ETZTDO8AB.Y>!3(@]FQD4EWHFD
MW]TMU>:997-PBE%EFMU=PIZ@$C..3Q69IVLZ9<:UK$D6LSR"W@@DGMYEV16J
ME6(8$J/O $GD].U3+XLT=KF6V,UPD\=N;GRI+657>(<%T4KEP/\ 9SB@#8AA
MBMX4A@B2*)!A410JJ/0 =*JG2-,;4/[0.G6AO>/](,"^9QT^;&:K6_B32KO2
M[+4K>>22TOG5+>18)#O)Z<;<@<'DC%1IXLT62]AM5NV+37#VL4GDOY3S+G<@
M?&TL-K=^H(ZB@!DVG:Q?>(-U[<6/]B02)/;PQ1MYSN%X\QB=N WS# SD+Z<[
MM<S<>/\ PU;"Z,M^X6TG^SW+"VE(@?C[Y"_*OS#YC@>_!K2U/Q#IND&07<TF
M8H3/*L,+RF./GYV" [1P>3UP<=#0!-+HFDSRW$LVF64DER )W>W0F4 @C<2/
MFP0,9]*4Z-I;232-IMF7G&V9C N9!Z,<<_C5:X\2Z5;VL5R)WGBE@^TH;6%Y
MB8NN_" G;[]Z:?%&D&V@N8;IKB*>#[2C6T3R_NO[Y"@D#Z^_H: *E_HFH7%S
M%IMH=-M?#;1@7$"0,)F(;)1<$($88!XS@GUR-ZYMH+RW>WNH(YX)!AXY4#*P
M]"#P:6">.YMXIXFW1RH'0XQD$9%,N[RWL+26ZNYEA@B7<[L> * (5TC3$L6L
M5TZT6T8Y, @41D_[N,4+I&F)-#,FG6BRP#;$X@4-&/13CC\*Q=4\1VMYHVNP
M:;>SVVIV-DTY5X#'+'\I*L%D7D''7!_ TFB^);:#POX?;4;B::_O--BN"D<3
M2R28C4N^U03C+#GU(% &Y!I&FVU_+?P:=:17DW$MQ'"JR/\ [S 9/XU/<6T%
MY T%S!'/"WWHY4#*?J#6!>Z]I-[%X?N8=;F@AOKI&M&MT)6[RIQ&V5. >IS@
M_+[47?CSP[9&^$UY+_H#A+O9:ROY.1G+;5.%P0=W3WH V&TC37L#8-IUHUF>
MMN85,?\ WSC%(VD:8]DMD^G6C6BG*P&!3&#Z[<8JG:>*M&O=732[>[9KF6-I
M8<PNL<RKC<8W(VOC(SM)J6R\0Z=J%S#!;22NT\;2PN8'5)44@%E<C:1\PZ'G
M.1Q0!I1QI#&L<2*D:C"JHP /0"G444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R7CRVU(V^CZII
MEG)?/I6HI=36D6-\L>QT;8#U8!\@>U=;10!Y]XBBU'Q#HD6JZ7H=S;/::E:7
MYMKB-8KB\$398%<^F-N[G*].F9[W2[CQ'XJ?5[2WN(((]%GLMUQ"T+2R2D%5
MVL <+@DG&,L,9YQV\TT5O$99I4CC'5G8 #\33Z /*M*74Y$^'D9T'5(_['S#
M>F6#:$86S1Y&3RN2/FZ'/&>E17>G:C+\/O$]FFEWQNKK7GN8(OLS[GC-RD@8
M<=-JD_\ UZ]:HH \WUNPO_\ A(KO5?#J:G::FUS;B2WD@9K/48\)\[9&U&5<
MC=D$;.G(JNEC-9ZMKFBZOX4OM6CO[Z6YL[B,;K:1)#N"RDMA-IXY'0< \9]0
MHH X_3;:XB^)^JW+6DZ6LFF6T$<WDL(V=&D+ '&. PJ7Q]IVH7VCV%QIL+7$
MVG:E;W[6RD!ITC;+(,\9[CW%=710!P.IV4VK^);C7[:TO([:#0Y[/$EL\<D\
MDC A A 8A<9SC&6&.^-[P-#+:^!="M;B"6WN+>QAAEBE0HRNJ ,,'W!YKH**
M .2\12WZ^+-+0:;=RZ<]O*KW-C&#,)"5Q&7R#&A R2",D#) %<AHVA3/X,\-
MV.H6>NZ3J-BMR(;^TB9I+=]XX*J&W(X/<8.S\:]<HH \QN-.U:_TW2KG4O[3
MTSQ);V3F/4M-MF=6)<_NY8E!!# (Q4C )/([Z$$.KR^*_!=WJ.GR1SP:9.E\
MT$),4,LBQ87(X'*MTX&*[ZB@#SGPMINH:;KVG?V4NI0:-.DKWNF:A"VVP?;D
M>3(P'!8XV@D8)-9^C+K6E>"?#6G2:#?J;*]:*]D2V62:%?WF'A!SP<J"X'"L
M<<]/5J* /'Y-,U1?#&NV/]BZHLDOB6.\B5T,K/#YL3EMP+$X5&R<GTR36GXH
MT/4M>U_Q/#8V]P@OM BMH)Y(F2-Y5DD8H6(P,A@.?6O2O.B\_P CS$\W;N\O
M<-V.F<>E/H X5[F_\:>'+^R_X1Z[TG4)=.FMI+B^B">7(Z;=D;9RREN<CC ]
M>D?A,C4+K33>^$+VPU/3T*S7-XO[N)MFUO)<L=VXXZ#&,Y/3/=13Q3H7AE21
M0Q4E&!&0<$<=P>*DH PO&D,MSX'UVVMX9)I[C3YX8HXD+,SM&RJ ![D5SEK;
MW0\5>#;AK&\$-II$T,[FW?$4C"+"GC@_(W^37H%% ')?#^WN+73-4CN;6>W:
M35KN=%FB9"T;REE89'<&FZW!>0?$70-3CL+FYM5L[FVD>!-WENS1E=W/ (4\
M^U=?10!Y+=Z=J,OP_P#%%FFF7QNKK7WNH(OLS[I(S<I(&''3:I/_ ->K]S!+
M8>*M=AU/PQJ6L:=K,B3VTUJA9>8DC:*52P"#Y!RW&#S7I=1R3Q1-&LDJ(TC;
M4#, 6.,X'J< _E0!'8P"UT^VMQ#'"(HE011?<3  VK[#H*\OM VH^&OB!HD%
MA<7%W>ZM>PP@0L8RSJJJ2^-J[3R<D=/I7K!Z=<5DZ'X?@T$WQM[FYF^VW3W<
MOG%3^\;&XC"C&<#B@#G-"TVYT[XA2B2"Y>WCT.ULENVA8(\D;.6&[&.A!K&T
M'3Y;8-X;UGPG>WEW!>/)#?,-UI(AD+K*6+85@#RN,Y''7CU*B@#SFWTW4+/Q
M9'>:&NI6T=QJDG]I:;=0LUJ4W-NN(W(PC' ;"GDMC'6J?AK3Y;:&#PWK/A.]
MN;ZRNBT=_(-UHZARRS;BV P!SMQG/IDX]/\ .B$X@,J><5+B/<-Q4'!./3D?
MG3Z /)M2TW49_ WC^SBTR^:YU#4Y9;2/[,^9D81@,..GR-^7TKH)UU&#X@WV
MHVVE7%S%>:''%;LT>V/S4>1MDA.-OWEZ^M=S32ZJ<%@#[F@#RW1H=4E\1>#-
M0FT758S!:W$%YOA$45N[)& J1@@)&-I ('( Y8U!/INJCX1:UH)T>_\ MZWD
MP1!#D2[KHR ICJ-ISGIVZUZW10!Q, N]&^(6JZK/:7D^F:O9V_DS0V[R&%X@
MP,;(H++G?N!(QG(ZU@Z9X>U'1Y/!R2V5P1#JEY>SI'&76UCE678I*Y'!=0<=
M\]N:]1CFBFW^5(C[&*-M8':P['T-/H Y'P=!<0:WXK>:UN(8[G4_/@:6)D$B
M>5&N1D>JFF^)+6^M?&OA_7XK>>ZL+:.XM;J.!#(\7F!2L@0<L,J < D ]*["
MB@#RCQ#H5_/IGB[4+>PNW&L:A8O;6JP,7*0F/?(5QE<[6.#@X4>M>JHXD17
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MMM:\(:RNAW$=K:O=I-;6<(D> 2IA-RI]/FQD GKWK"FTS6)?"WB#.BWRR_\
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M2-E8J0PR>XK3J.""*VA6&% D:]%'OR3]2><U)0 4444 %%%% !1110 4444
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MP>VU76-.D>"!H[:>VA</*^TJKR[CCCJ54<GG/&" 7?#?B*3Q#%%=0I9R6,T
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M[(SY(Z9W#.:QY]0UN#PIK6M_V_J#W.EZ^]O"A90CQBY2/:X"_,-K'T [ <Y
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M<"P^7R)D:\9&0KC))W9!SG/2@#VFBO/;8ZG<^+?%;2ZYJ1MM&N8)H+:)D42
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MF; YXZXR" =W17 +_;.GQ6&EZKKAN)WU*41VUFY:XN(!&76)I?DVE,AF?C(
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MTN)(Y9X7N',<KH%"DJ3C^!<^N.<U6N_ OA^]UU]9ELW%W+M\\1SND<^WIYB
MA7Q[@^^:V8=2L+BZ>U@O;:6XCSOB256=<'!R <CFA]2L([K[,][;+<?\\C*H
M?IGIG/2@"O#H5A!KT^M1QRB_GB6&20S.59%R0-I.T8R>W<TW4/#]AJ6H6^H2
MK+%?6Z-''<02M&X0]5)!Y7O@YYYZU:DU.PBF\F2^MDEW*FQI5#;FSM&,]3@X
M'?%*NI6+7QL5O;<WBC)MQ*OF >NW.: ,V?PEHUQ;Z? UM(L>GS_:+81W$B;9
M>?G)##<QW-DMG.3GK6AJFF6>LZ7<:;J$ GM+A#'+&21N!]QR/J*<=2L1?"Q-
M[;B\(R+<RKYA'7.W.:EN+B&UMY+BXE2*&-2SR2,%50.I)/04 <^O@30!*\S6
M]S),]FUC))+>2NSPMG(8ELGJ<'J.V*LOX4TN5)EG6YG>6)8#+)<N9%C5MP57
MSD?, <@Y) R3@5-I/B/2]9T5-6M;R'[&R[C(S@;1VW<_+Z\^M7[:[MKV 3VE
MQ%/"W22)PRG\10!E3>%-*NK2_M[J.><7\2PW3O.^^2-<X0L""%&YN!ZGU-+)
MX5TV3'-V@^RK9N$NI 'A7=A6YY^\W/WN>M:LUS!;[/.FCCWG:N]@-QZX&>M1
M0:E8W-FUY;WMM+:KG=-'*K(,=<L#CB@"A+X5T:74;>^-GMFM[;[(@21E0P@Y
M",@.U@#R 0<52M/ 'AZQ;3V@MKD-I[,;0M>3-Y088*C+?=Q_#T]JV4U?3'M6
MNDU&T:W5MAE$ZE WIG.,^U2_;K0>1_I4'[__ %/[P?O/]WU_"@#%_P"$'T$Z
M2VE_9[C[&US]K,?VR;F7=OW9W9^]SC.,T7O@?0+_ %DZM/:R_:G14G,=Q(BW
M"K]T2J"!)C_:!]#FM/6M9L?#^D7.J:C.L-K;H79F.,^@'J3T [FL*Z\5O'XK
MT2UBN+)M(O[2YGDFSRAB"?Q[MN/GYX[=: +>K>"-!UK5TU2[MI5O%01M)!<2
M0F5!_"^PC</8UI1Z-91:P-4CC=+D6HM %D8((PVX )G:#GOC/:IUO[-[(7JW
M<#6A7<)Q(#'CUW=,4ZUN[:^MUN+2XAN(6Z20N'4_B.* ))$$L;(2P##!*L5/
MX$<BL"#P1H5MX<G\/Q6\ZZ7<;O,@^URG.XDL-Q;(!).0#S2^(/$;:7J&F:18
MP+<:MJ;LL$;MM2-$&7D<CG:!V')/'N)))_$%E=V*RBQO;::;R[B2&)X6@4J<
M,%+/N&[:.HQGOV -%(/[,TLQ6<,DWD1$11-*2SX'"[F/X9)K(\/V5S=:E<^(
M=3TI-.O[F".V6 R+(\<:%F^9EX)+,>G95[Y%;)U&Q%\+(WMN+LC(@\U?,Z9^
M[G--N-5TZT\S[3?VL/E%1)YLRKL+9VYR>,X./7% &=/X1T>XN[RX:"11?$&\
MACF=8K@@8RZ X/'!]1P<BI+_ ,,:7J6JV^I3Q2K=01& -#.\8>,G.QPI 9<\
MX.16@M_9->_8UNX#=;-_D"0;]OKMSG'O49U;35FCA.H6HEE<QQH9EW.PZJ!G
MDCTH BT/0[#P[I46F:9$\5I%G8C2,^,G)Y8GOVZ53M/"&CV+(((9?(CG-Q';
M/.[0QR$EMRH3@<DD=@>1@UISZE86MS';7%[;0SR8V122JK-G@8!.31<ZG86?
MF?:KVV@\M0[^;*J[5)P"<G@9XS0!6L= T_3M4O\ 4K:.5;J_*M<LT[N'*C"G
M:20, 8X XK/TKP+X?T74GOK"S>)B[2+#Y[F&-F^\R1D[5)R>0._%;3:C8K+%
M$U[;B28!HD,JY<'H5&><^U4]9U&>/2[_ /LBXT]M1MT!"74A\M#_ +>WYAQF
M@#,M_A[X;M5LUAM)PME.9[93=RD0D@@J@W?*IW'*C@]P:DD\">'I;*>TDM9V
MBFO?M[_Z7+N%QG/F!MV5/T(K0MM9A33;&75I;?3[RX@21[>68*48@%E&<9P3
MBM2@"G?Z59ZGI$^EWL1GLYXC%*CN264C'7.<^^<U0A\)Z3!?65ZJ71N;*)H8
M)7NY6(5L;LY;YLX')ST'I6E_:-B+X6)O+?[61D0>:OF8QG[N<T2:C8Q7B6<E
M[;I=/]R%I5#M]%SDT 8Q\#Z"=-?3S;W'V5[O[:R?;)N9MV[?G=G[W..F:LS^
M%],N9[F299W2ZD26XA:X<QRL@4*2N<=$7..N.<U?N-2L;2=(;F]MX97&5225
M59OH">:IVGB72;W6[W2+>]A>[L@GG*''!;<=ON0%R?3(H R/B+IEYK'AN*QL
MK*:Z=KVVD=8G"$(DJLQR6&. <8.:U1X<TZ6&[\Y+B5[V 03R2SMYACY^0,#E
M1R>!CJ3UJ_::C8W^_P"QWEO<;,;O)E5]N>F<'BI+FZM[.$S74\4$0P"\KA5'
MXF@#,?PMI$OAV+09+9GT^%46)'F<M'LQL*N3N!7 P0<B@^&-,>TO;>9)YOMT
M0@N99)W,DD8! 3?G('S-P,=2>I-7UU"R:UCN5O+<V\K!8Y1*NQR3@ '."2>*
M=;7UI>^9]DNH)_*<I)Y4@;8WH<=#[4 9:^$](6729!%/OTE2ED?M4O[H%=I'
MWOF^7CG/%03>"-!N+#4K*6WN&M]3F\^\0W<O[U^.<[LC[J],=!5:[\4L/'&B
M:18W5A<VEZMQ]H$;;Y(VC0$#(; SGH1VKJZ ,:Z\+Z;>/<&?[2RW42PW,?VE
M]LR 8 89P>"03U/0DU6U/P-H&KZLFIW-I(EVL8B9[>=X?-0=$<(0&'L?ITK5
MBUC3)XII8M2LY(X"!*Z3J1&?]HYX_&GQZE8S-$L5[;NTP)B"RJ2X'7;SST/2
M@#-@\/10>+GUR+=%NLQ:M&LK%7 *E?D^ZNW! QUW'IWL:AX?L-2O[?4)5EBO
M;=62.X@E:-PC=5)!Y4]<'///6K']K:;Y\4']H6OFRL5CC\Y=SD'! &>2#UI]
MQJ5C9SQ07-[;P33'$<<LJJSGV!//X4 9L_A+1KBWL(&MI%CL)_M-N([B1-LO
M)WDA@68EFR6SG)SUK7GMX;JVEM[B-)894*21N,JRD8(([@BH+G5-/L_,^U7U
MM!Y0#2>;,J[ > 3D\9[4ZXU"RM(DEN;RWACD^XTDJJ&^A)YH H:;X8TS2GMF
MMTF?[(ACM1/.\H@4\$)N)QQQZXXZ<54E\">'YK.\M'M9_LUW<?:I8ENY57S-
MV_*@-\HW?-@8&<>E;-SJ=A9VR7-U?6T$$F-DLLJJK9Y&"3@TMQJ-C:)&]S>6
M\*2?<:255#?3)YH I'PUI;:M+JDD$DMU+:_8Y&EF=U>'D["A.TC))Z=S5+1_
M N@Z")1I\%Q&KHT:JUU*XA4]1'EODS_LX-="CK(BNC!D895E.01ZBJVJ23Q:
M5=26L]O!<+$QCEN?]4C8X+X(XSUYH CT;1K'0-*ATS38WBM(1B.-Y6DVCT!8
MDXJM%X6T6'3K*PCL(EM;&Y%U;QCI'*&+;A[Y8_G5P:A;6]O$;R^M$D,/FLWF
M!5( &YAD_=YZ^]2"^M#9"]%U ;0KO$_F#9M]=W3% %6]T*PU#5;#4[F.5KNP
M+&V=9G4(6&&^4$ Y''(-0VOAC3+2:WD19W%M(TUO'+.\B1.P(+*&)P<,P]LG
M&*S_ !=XEFTOPB^M:+/9W(2:%-Q_>(RO*L9P58<C=GOTKH#J%D&F4W=N&@&9
M1Y@S&/\ :YX_&@#$T[P+X?TK5WU*RLWBE>0R^4)W,*R'JZQ9V!O<#CM6EJVB
M6.M+;_;$DWVTHF@EBE:-XGP1D,I!Z$CT(-69+^SBLQ=R7<"6QP1,T@"'/3YL
MXKDM(\2ZGK&B^(ITO=)AFL=3>UMKIU/V<QJL;!F^?DD,W(..E &S=^$=&OM(
MN],NK>26VO'$ET3.X>9AC!9P=QZ 8S@  =!3M;\*Z1XAL+>SU*"25;9P\$HF
M=98F'\2R [L_CS6A<ZE8V>_[5>VT'EIYC^;*J[5SC<<G@9XS3Y+RUBMEN9+F
M%+=@")6<!2#TYZ<T 8TG@K0Y;6P@-O.IL96E@F2ZE68.PPQ,@;<=PX.3S43^
M ?#4FEWFFMIY-K=W!NI$\Y\K+G.Y#G*'))^7'4UOV]U;W<8DMIXID(R&C<,"
M/J*2XO;6TV_:;F&'<&*^9(%R ,G&?0 D^PH QF\%:))HITF6&XEM6E6:0O=R
MF21U(*LS[MS8*C&3Q@>E78M T^'77UI$F^WO +=I&G=@8P20NTG;U)/3O4TN
MKZ9!'!)+J-I&EP 86>=0)<]-ISSU'2GW6I6%BZ)=WMM;M)]Q9I50MVXR>: ,
M+7;:^U^__L*XT53H^^&>6^EF0JX1@^P1_>SE0,GC!)],ZVK:)8:W' M[$Q>W
ME$T$L;E)(G'\2L""/Z]ZL7>HV-@4%Y>6]N7SM\Z54W8],FB[U&QL%1KR\M[<
M.<(9I53=],GF@"A+X7TFXTF^TVXMC-!?\W1DD9GF. ,ELYR !CGC QC%5H/!
M6BV]Y]L"7CW9M3:-<27LS2-&3DAF+9/X],#&,5MRW=M;LBS7$,9D!*!W W #
M)QGK@ GZ5&FI6,MC]NCO;9[/&?M"RJ8\9Q][..M $>D:19Z%I<&FZ?&\=I N
MV)'E:3:/0%B3BJ5SX3TFZOKN[:*5'O4"7BQ3NB7( P-Z@X/'&>I'!R*I>+O$
MLNE^$)M:T6>RN?*EB0L?WB,&D5#@JPY&[/?I6]'?6]Z+B*QO+:6>$E'"N)/+
M;T8 Y'TXH IWGAO3KR_@OMDUO=P0FW26VF:(^43G8=I *Y ..W;%,N?"FC7=
MA8V,EJZVUC.MQ;I%,\>V13D.2I!8Y).3G)))JIX/\1R:QX'L==U9[:V>97:5
ME.R-<.RC[QX' ZFM^VN;>\MTN+6>*>%QE9(G#*WT(X- &#JWAQ$CUG4]*MA+
MK5[9F#_2+B3RY, [5(S@ 9/0#K7-Z!X8E@N;(V6F>(]':V>,N;S5Q- 44C<@
M02N&R 1]U0,YXQBN^O-1LM/56O;RWME8X4S2J@/TR:I7_B72=-U2PTZYO84N
M;[<8D,@'RA2=QR>G  ]2: ,V+X>^&X5MTCLYQ';7)NK=/M<NV%SG(0;L*IW'
M*C@YY%6W\'Z+(=6S;S!=6#"\1;F15DW *Q #84D  D8)Q4^D^)-*UNZO[>PO
M(9GLIC#(%<')"J21Z@%L9]015VUU&QOO,^R7MO<>6</Y,JOM^N#Q0!FR^%-)
MDBTY5CFCDTU=EI/'.XEB7&"N_.2" !@Y' HN/"6C7-E;6DEO)Y5M="\CVW$B
ML9PV[S&8-EFSSDDU=_MG2\,?[2L\+&96/GKP@.-QYZ9XSZU-#?6ES<36\%U!
M+-#@2QI(&://3<!R/QH RYO".CW%W?W4D5QY]^L:W#K=R@L(SE,8;Y2IZ$8J
M]8:1:Z?/<7$0D>YN HEFE<N[A<A1D]AD\>Y/4FGKJNG///"E_:M+;J6FC$RE
MHP.I89X'UH&IZ>;4W0OK8VX.TS"9=F?3.<9H R]1\&:+JE_>7ES#-YE[!Y%R
ML=Q(B3* 0"Z [6(!."1Q^ I]MX1T>TO+*Z@AN$FL;8VMNWVJ4[(CC*X+8/0=
M?0>E:1U*P6[%HU[;"Y.,0F5=YST^7.:S]-OM7F\1ZM9WL%G]@@\MK6:W9BWS
M Y63/&[@'CL1ZT 57\">'WTG^S3:S" 7)O(V^TR>9%,229$?=N4Y)/![FI(O
M!.A1_P!I;[66X_M.-8KS[3<22^<JC SN8\CUZBCQ5XF@\.6MGF6!;B\NX;6+
MSF "[W +D9!*J,GMV&1G-2:?JDUG W]OZII/[Z8_8IH9/+$\1 VDAB?FR2/E
M)!X/>@"O9>!-!L-)N],B@N6MKJ+R)?-NY7;RNGEJQ;*K@] 16Y864&FV$%E;
M!Q! @CC#NSD*. ,L23^)I+S4;'3E1KV\M[97.%,TJH&/H,GFBZU&QL=GVN]M
M[??]SS953=],GGK0!CW/@C0;N/5(Y;68Q:HY>[C6ZE59&.,D -A2=HSC&<#-
M6QX;TS^UK?5#',UY;P&VC=[B1@(SC*E2V#G Z@]*U000"#D'H13)[B&UA::X
MFCAB7[SR,%4?4F@#!T7P-H'A^^:[TVTDB;+-'$9W:*$M]XHA)5"<GH.A(Z5I
MG1[,ZV-7(F^V+$80?/?8$)!(V9V]0#T[5(VJZ<EO+<-?VJP0N8Y9#,H5''56
M.< ^QK$\3>(;G3;?0[K3)+2>WOM3M[21B"X,<C8+(0V,_G0!?OO#.EZCKEGK
M-Q%,;^S5EMY4N9$V ]1M5@"#WR.:X2W\,7DMW=FZT'7;74I[F69KK3]:\JT9
MF<D, )0P&,9_=D^QKTB74K""[2TFO;:.YDQLA>50[9Z84G)JG#XDTJ?Q#<:'
M'>0M?V\:/)&'&1NW87_>PI)'8$>M #=.\.6ECJ)U5VFEU66WC@N+@S/B4*./
MDSM'))X'&352W\"^'[37)-7M[-X[B67SWC6=Q"TO_/0Q9V;N^<=>>O-;4.I6
M-S=2VL%[;RW$7^LBCE5G3MR <BN=\4^*6TF[TBVT^ZL))KC5+>TN8';=(L<C
M $@!A@CW!ZT 6/\ A!?#_P#;\FM+9NEU+()942=UBED'1VC!VLW?)'7GK4[^
M$-&D35U:&<KJ_%\/M4O[WY=O][CY>.,<5LRRQP1/+-(L<:*6=W. H'4D]A69
MH_B32M<TDZG97D+6@+9D+@!0&(W'T!QD9[4 ,7PMI2W6E7(BG\[2D,=FQN9#
MY:D8(QNPV0 .<]*JZ?X%\/Z7JTFHV5I)%*\AE\H3OY*R'JZQYVAO<#CMBMVU
MO+6^A\ZTN8;B+)&^%PZY'49%4=:\0Z9H"VIU&ZCA-U.EO"K, 69B!GGL <D]
M@* *+>!]!?2KK3&M[@V=U<_:YH_MDWSR[MY;.[/W@#@'&15BX\+Z7+J%QJ7D
M2F\GMOLTC+<R()% (&X X+ ,V&QD9K.LO%3?\)7KUCJ-W80Z=90VDMM/NV;O
M.$A^9F;!^Z,8Q71W5_9V%O\ :+R[@MX3QYDT@1?S/% %+PYHXT#0;;3%D9U@
MW;=SL^U2Q8+N;DA00H)[#M6K38Y$EC62-U=& 964Y!![@TZ@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "L+Q?H'_"1^&[FQC81W:XGLYB/]5.AW1M^8&?8FMVLO6['5;Z"!-*U<:8
MZRAI9/LRS%TP05 8X4]#GGITH X2]N-:\3?#G7?$%K9S6VJW-A]E@MP,2(J?
MZX+WR7,H'J%2KD\]CK7B/P3?>&Y(6,(D\[R"/W5H8N4<#H-X0 'HWT-=Y8V<
M.GV,%G;@B&",1IDY. ,<GN?>I51$+%552QR<#&30!XDFJ:?;^ =/TN6YB6^L
MO$ZFXM\_/ /MS-EA_"-I&">#FO:Y90EL\P5I J%@$Y+<9X]Z=Y:;BVQ<DY)Q
MU-.H \8T+6-,GUKX?3VEQ!#:K]KA6TB)<VI:(XBD<Y+2$XR#CGH.YC%UH5[!
M+X;U#7=)C^S^(WO&FO9@DS!9BQ4QL/O$Y3)."O/M7M6U<< #OP.]<A9^$=6@
MLCI=UKEM=Z80RDRZ<#<LK$DYDW[23DY;9D]>M &1HNGZ'=_%#Q?%]FT^6:)+
M&2%&1&V.JL2P'8@A<D<CBLGPG<Z-K%EH.G:IJ-__ ,))I5X'DT\*B2I< D2.
MQ"!BA!9F);!!YR:];CC2&)(XUVH@"J/0"@(H<N%&XC!;')H \BT*XTC5;:WT
M37=1OD\16.J-.=/1$60SB5F613LW%"#DMNQC.3BO6KI/,M)DV[LH1CUXI^Q=
M^_:-^,;L<XIU 'C&A:E%#X5^'-RTJ-I-E-Y6ID?=@F\IEB,G8;7/.>A*D]J[
M/PW"3\0?$U[8.K:3/';;FC.8WN@&WE<<9V[-Q'?&>179E5*E2 0>HQUH5510
MJ@*HX  P!0!P?Q&ATXZMX/EU%(/)_M;RY'F QM,,GRDG^$G&0>#WKF]2CTS1
MKKQA>P64;^'IY]/0K$Q2W6Y#_/(2G15_=E\=3P>^/0O$/A^XUO4-%N8KR&!-
M-N_M11X#)YIV,FW.X8&&/8UNA$"; JA,8V@<8H \ST"+3O$/BOQQI5W=Q7T&
MHVUH2T2;4E4Q,I=.O XPV3T')K2\$'4M0FCM]8A83>'%>P,K#B>;H)1_VRV'
M/_35JZ[5[6_NM,FATN_73[QMNRY: 3!,$$_(2,Y&1U[TNE:=_9EB(&F:>9F:
M2:=P 99&.6; Z<]!V  [4 87Q*B:7X:^(E5"[?89" !D\"N?O;W1=5\>>"2L
M]G<VS6-X5!92C'$6T^AY!Q[@^E>E48 & * /$[34X=-T:*Z2X:/0[#Q7>?:F
MM%5Q;Q,9!$^W##8&8'IZ$<XKT+P;%HK2ZKJ.B7L][#?3K+-<$KY3RXP2@50,
MX W$#!/?(-=20""" 0>HH5510J@*HX  P!0!Y_XN1M$^(OA_Q9<JQTF*WFL;
MN8 D6V_E)&QT4G@GH.]=?#KNFWDD<5A>07LC\@6TBR;5_O,0>![GKT'-:5,C
MBCB7;&BH,YPHQ0!XV'>_^$+Z2[A?&$%]_J2<7"WOVC<) .O(.[=TVY["M-HM
M%D\5_$87*V#%;&W+;PO#>3('//0YQG\*]2V)OW[5WXQNQSBG4 >/::VEP6?P
MJGC>T2XD4+-("H9]UHP8,>IRV <]\"L]M+T2\\ >++6&WM6UE=9NX[%8PHG6
M43GREC[@9].,;O>O<"#M.W /;(K!\+>'9?#\%['<74-T]S>SW8=(#&4\URQ7
MEFR 3[4 >:>-]2M6TOQM8F2.UU&*.V-RC9>:[940B10>$C7U Z@DD=^A0Z!J
M'Q8U&67[!-"^@0R$R;2K'S),MSWV$<^A'8UZ054DDJ#D8/':EH \@TBW>;X/
M^&/$>G!9]3\/I]HC"G+/&N5FASVS'GCU"UZ+X9C:73Y-5EC9)]3D^U,K##*A
M $:GT(C"9'KFDUK1K_5[F&--6^S:4R,EY9K;JS7 ../,)R@QD' Z$]#S6WC
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MR,XK=NKK_BN?%D=A*J:C?Z% ^FCHTKA9\,GT)7)[5Z5M4DG:.>#QUI<#.>]
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MXW+P>,'\:NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVPR':%4@C.#R3QZ&M.\\>^6NC%I;33$U73DN[>>^1FA>5@"(=X*A2 <Y/7/
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MHFW?N;+,?XL#!/>LNX\?:K%ILBI869U*SUN+2KM&=A&X=E"R)W 96!YSCWH
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MAN[29)K>9!)'(ARKJ1D$&N0LO%M[=W'B6R465V^F6L5S!.D;Q1S*ZN<$$MD
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M@#N**QO#&I:EJFCB;5M/:QO$E>-DVD+( >'4'D*PP<'D=*V: "BBB@ HHHH
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M@^?E;(Y.#U['FJ&F^ +^P/AW=XA$@T(R+ !9*N^-T*$-\Q^;!^]T]L\UW5%
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MK][)E=PQ<JB-NXX'W^G/2@#G9/A[>M"UNGB$K FL#5H UF&=7\S>5=MWSC/
M/&.^>E:G_"(/)J?B2YGU$/#KEJEK)&L&UH@B,@(;=@G#DG@=NE=110!Q]MX-
MOXG\,O-K44S:%N"_Z'M$H,7E8X?CY>>_/MQ4,WP^^TVNJQSZIB:[U1=6MIXK
M?:UK.H4*1EB&&%'''4_AN:%X@_MJ^UBU-F]LVF7?V9M[AM_R*^[CIPP]:VJ
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M> S>5F/<5 !P<L2&P#@<<D4 9:>!&ATS4M#AU(+H.H3/*]L8,RQ*YS)&DF[
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M:V9=A;- 6+.RE=V[<,$*6 X_B/MBAKOABXU7Q)HNMV>HQV5QIGF#!MC)YRN
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M\@??QD]>OXU3U/P?X>UIK5]3TBUNWM1MA:9-Q5?3)ZCV/%;2J$4*H 4#  '
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MO[:*XMWP3'(N1D'(/L0>0>U0IH>FI8W%F+53!<C$X9BQFXQ\[$Y;CCD]..E
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M1@8R#C% &DZ"2-D)8!@0=K$'\".17CVGM-IGPL;Q3_:.HO?I)+:O-+=22+'
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MBDHMI3)=EQ;CR&S-_HRH-G'S?."..] 'H=MX@TB\U672[;4;:6^B4N\"."P
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MC+#"D@CT-:=_/96OBOQ#9^(K'5KC3]9$<EE+9K.\<\9A6-H2(CP<J>O9LY%
M';W_ (M\/:7-)%?:U9021JK.KS#*ACA2?3-,\6^)(_"^AM?&$W%Q)*EO:VX;
M!FF<X5<]O4GT!KF]+LH(/B;#%]@>&WB\-PVJ*ZM(L;+*Q,7F'()"X[\]:O\
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M=LD@:4[0<8+89>/>M_P3>1_\(#I#21SP_9;&&*430O&P9(U##! )P01QZ<4
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M=8D+ML2=&8@#DX )X]*IPW$,WQ9?4##,MN= 5%EE@90&\YF*Y(X.T@XZX[4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.EQVD-M \<;.9@@+.R #+#+  C@X/:@#NZ*9%*LT*2IG:ZAAN!!P?4'D4^@
MHHHH *Y.SUV^\2>(=5L-+F2TT_2I1;3W7EAY)I\99$!X4+P"2#DGC&,UUE>=
M>'7'@;Q)XCL-762&QU/47U*SOBA,3>8!OC9APK*1T.,B@#K;*;5+2]U :O<6
MK:?##')!=!/*X^??OR2,C"\C P>U3P:]I-R+@Q:C;'[.H>8-(%,:GHQST4]C
MT-<SXZEO-:\'W#Z/:SW,5O<6\[JB$&ZC216=$!Y;@9]#T&:BNG@UCQUI.NZ;
M+FRM--N5OK@*0K*^SRXCG^($,VWJ,<XR* .EM?%.@7UY;V=KK%E-<W*&2&*.
M92TBXSD#OQS].:YRZ\3SZOX@UG2=*URUTV734A:*25$D29R&:0.#SM"J!\I!
M')R>E<OI$:V_@GX:Q^28YK;48VN%\LAHAY<H8N,?*,LN2?45U>@7,,?Q$\92
MR/LB<6A21@0K[(F#[2>#COCI0!NZ3JD$7AJVO;W7+74$;*_;XU6-)B6(&T D
M=?E !.2*RO#7B:34M=\4I<ZA;RZ?ITT0AD51&L:F+<X8GN#D'/3':N'T.6XT
MKPW\/]1N;>X_LO3Y[I;]%A8M;NX=8W9,9 &X\XX# ]ZFU%KJ]N_&UUI5C>W$
M?V_3;T1QP21FZBB6-I%1B!EOE)P.3VZT >ECQ/H9M[JX.K6B16F/M#22A/*S
MR-V<8SV]>U.MO$NB7EW/:VVJVDMQ!%YTL:2@LB=V(]!W]*\_U:30-9\+>)M7
MT:TU*6ZGT:6T>XNA."S$'9"%D^\V2>5!QTSS6A$85\9^!F@4+''I5Q$Y1,*A
M*Q;5;T)*M@'N#0!K+XQTW7?"KZCI^NVVE;I_*2XN%5L;92H^1B.7"' ZC=[5
MNWVO:3IDIBOM0M[=U4,PD<#8I. S?W03P"<"O*V9E^"%QI3VURM];7VV2%K=
MPV[[=OP./F^7YN,X%7?&]V;P^,[&"SN(9)=+0PO;6K2'41Y;')?:0$3.W P<
MYYY H [&]U>_M_B)I>EB>/\ LZYL+B=X_+&=Z-& =WI\Q]*AE\7:?HFA7.IW
MFMV^IQ-?M! ]NJ@*6<!8LJ2#MSRU9<5RD_CWPG<!95B&CW",TD;)M9C%M#9'
M!.UL ]<5S\\<DG@#Q(8H)GV>*&NRB1,6,/VM'WA0,E=H)R.P- 'J-MKNDWM\
M;&VU&VFNQ&)3"D@+A#T;'7'O2?V_I&(3_:5MB>Y-I%^\'SS#.8Q_M#!X]JY;
MQ>;JRN](\8Z);-/<H18S0,I0SPS,%3(/(VRE#]"U;JC3_#]CHVGW:/<2O.L4
M4H@,A,Y#,TA(!VDG<2W'4T ;M<GXVUK4]%?0?[.FA3^T-5AL)1+%OVK)NRPY
M'(Q765P'Q1$,R>%X98S-&FNVTT\:QE]L(#AF8 'Y>>M '30MJ5IJ3&\U.UGL
MX[=GF40>6\9)&UL[C\N%D[=JFMO$6C7L=K):ZI:3)=NR6[1RAA*R_>"D=2.^
M*Q].NO#>FZQ*^DV^V2ZA!N6AA98XXX@Y#'C&<OC'4Y]C7-Z$5\.>,(KXVK+H
MWB 22VB*K$Z=(2"P8=$67Y6/3:PP>F: ._GUW2K6]6SGU"WCN&=8@C.!\[#*
MJ?1CV'4]J+O7=*L+I;:[U"WAF9E0*[@89ON@GL3V!Z]JX+0KZVA34?"VOZ1<
MW6J#59KF&-[5WCN@TIDCE$F"H R,DGC;^%57_LXZAXB\-^*=.U:XFO=0DGM8
MH?/,5[$Q#1@,AV@K@*22 -HYXX .]O?&'AO36E6\UW3X&AD6.0/<*"CG.%//
M!X)Q3+OQ;I-IK^GZ.]RAN+V)ID8-\H08P<]"26&!^-<C:S:1;^.?'<&J1QL)
M;>T3RV0NTJ^0047C+$\?*.3QQ530-/OO#E_\/X]4@N"\.E7-K(4B:3RY&,16
M-BH." ".>/E- 'J%U=V]C;27-W/'!!&,O)(P55'N35:#7-+N;>YGBOH#':G;
M<$MM\DXSAP>5X(//K61X]NOLGA9Y3IXO4%S!O5HFD$(\U3YI1>6"8W8'7%<6
MBVMUJGC:._?6'M+U=/=+Q;5HY,#"^8N$ ^5L'&,D+T- 'J%EJ5EJ)E%I<)*T
M)"RJ/O(2,@,#R#CGFJFH^)]"TB:2'4-7LK:6*/S7CEF565,@;B,Y RP'XUB>
M"9]6>ZU:VU*YM]2B@:(6^K0Q"/[4I4DJP'REDX!(X^;U!J"]CMYOC#9&>%9(
M_P"Q)H=SQ[E#M*A"DXQDKNX]* .EG\0:1:W,=O/J5M'+(RHH:08+-RHST!/8
M=^U.O]=TK2W*7VH6]NP4.WF.!L4\!F_NC/<X%>;*-->YU[PQXGTW5I[JZU&6
M>UAB,_E7D;/OB*LAVKM^4$D@#;UX-27.J?V5#X_TC5K>Z%]>_:+BUD%N[I/
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MMOL\;V[$W2"':R(,?,<\;1SGM0!UEU?QG7M)@BUNUA\U9'-CA6>[7;E64YR
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M(H3:[2.I!8G)X3_ZU<FJZ==^'OB/I<END^H7>J74<$ CS),YC3R]OKASG/\
M#U.*V='@%C\0]FH,KM;^&K:VEN'&5:17<N QZG!!(ZX- 'H-O<0W=M%<VTJ3
M02J'CDC8,KJ1D$$=14E<A\+@Z?#70X95=)HH/+D1U*LA!/!!Y':NOH ****
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M:GY7F1>7@)Y:[5VG/IUSW]*VZXJ'XC0RVEO?'1-0CL)+\Z?+<.8\0R>9Y0R
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M_.2.1&YZ_,1D$]0:WEL[?PQHVKZQIVE&&>2(W$EB)@L>Y%/0 E5R.25'/N:
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M^UK 7@MWAC9W5-Y!WJK$!QC^$XR/8BK] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[XOL=8OK.Q
M721'*L=XDEW;23&(7$(!RFX XY*DCH0"#P<'HJ* /,W\$ZZ^A>);!+?38/MN
MJ0ZA:I'.VS"&$F/[GR_ZH@'')/0"M;6/"5QXONKFYU-/L"-I<VGP1AQ(ZM+@
MM(Q'&!M4 9YYSCI7;44 <3'H&L:O:>&[/6;>"#^QKF*YFGBEWBX>)&5-@QD
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M]YQP,\+[X%I]$UAO$'AB_6VB6/3+">WGS*"=\BQ@%1W *>W6NMENH89HH9)
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M&P],]15U]-\4Z/XGN=5T>RLKVUU2&$75K<W1A:WFC78&5@K;E*XR,9XKN:*
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MP:XN"/L3[&#@(%(+,Q^\#T[\8K1AT76#XH\-ZE/:P+%8:?+;7 2?=AWV8VY
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M18XT'15 P!^52T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^$[34(;VWNI&EM;BR%E' Z@K;QXYV=\GY22<_=7TJA=^!/M-EI&W7=0CU32
M5M=3 0R[" "K@KM<$ =1V^N0".76O$%@^E:-?)#)JE[)<?OK(*<PQ8(8+(54
M.0R9&2!SP:SKW7_&>FV.G)=V]G!<7&N)8(\R!O/@<$K(0CD(W!!'?MBMK4_
M\&I6%DIU6_BU2SF-Q#JB,OG>81AB1C:5(P"N , #M6'XPTJ:QT_P[;G4+V[O
M#KMO<3WKQAG 4,"Y55VJB\#& /Q)- %'Q!K_ (FL+#QAH=]J$+75II)U&SO[
M6W\HF,[E9"I) (*X!!SCGK7HFAQS1Z)9+/-YS^2AW[ O&!@8K-N/"-KJ%OK
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MLRQ.R!2X4E0QP"?<]JY!/"M]I7@?2=%T:_N;.[M&C8RPE2';DL'+=4R<D=2
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MB/S8L9&3MXDY ZX]":W/%6O:SHD&JO%?6^ZPTW[7 D<'F/,ZARYE4?ZN/Y0
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MS]O@@A*SNL/DR%]T7\+-D##'N.<>M6^M>4:992W/A[7+*PO+:WN!XJN!;I>
MO#,R-N$+]]I"_H*ZWP)=K<Z?J,3Z2-*N[:^>*ZMHW#Q"78A)C( ^4@J?8DT
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M@XE5(EDSNV\'#=,?CWKK+&X-WI]M<LH4S1+(0.V0#7F5T1_PBWQ8Y'^ON/\
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M-VT=U))?R>7:3_9[EUMI6$#\??(7Y5^8?,<#WXJW;^*]&NM3ET^*Z<W$<)G
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MNXTRZU)K>X55P' CD)5@5WA@R@;>.>U=5HVNZ?KT$TNGRNX@E,,R2Q/$\;@
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M (YW$8QSF@#9_L32=DZ?V79;;@YF'V=,2'_:XY_&K26MO%:BUC@B2W"[!$J
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MW5F* DG\:W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *S/$.BP>(O#][I-P2J7,14..L;=5<>X8
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MTN!<_:XY#,T#+'"J7!=I ^-I^4$  YRV/7%C7(=9OENUDT+41-:^(8;A(K6
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M6\L;.0&0$':PDZ]B*]!HH \[DMKJRU+3=/M_#=Q9:4VG2B,:?&N])&DR(9)
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MO_BJ/^$4T?\ YX3_ /@7-_\ %4 <W>?:K[6_ MVNF:A'%:R3-<>9;MF(- R
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M59=/C4*EC-=EH54=%Z;BH'&TDC''2NDH \HT>'59M<\%:A/H>J1/;)<17J&
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MK:L7%NN[?NW$*68N%/0<*!ZFK_AZT\51%/\ A(M0T^984V)]BB=3,>F^3<<
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M3S$CW #H?F.[Z#'?/%V[\*:I<3^,W62S"Z_;);Q9D;,.V(Q9;Y>>#GCTQ[T
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MAJ>B@".""&VA6&")(HE&%2-0JCZ 5)110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(Z<T :E%4%UK36NK.V%Y'YU[&9;9<_ZY ,DKZX&#^-79)$BC:21U1$!9F8X
M ZDF@!U%9UAKVEZG<&WL[Q))O*$P3!4M&> Z@@;E/]X9'O4#>*M!CECCEU6U
MB\UF6)I7V)*5.&",<!R#P0"<4 ;%%8L7B[P]/?I8PZQ9R74DS6ZQI("3(J[F
M7CN :L6OB#2;V^%E;WT3W+(9$3D>8@X+(3PX]UR* -*BLR'Q#I-QJ*6$5]$U
MS(&,2<CS=OWMA/#8[X)Q5N_OK?3+">^NG*00(9)&"EB /8<F@"Q16'I/BK3=
M3\.V6LF7R8KI$*QL"6WLH8(!C+-@]LUHZ?J=EJMNT]C<I/&KF-]IY1QU5AU4
MCT/- %NBJ.I:UIFC^1_:-_;VOGOY<0E<+O;T%5%\6:%)ID6HQZE%):2J[))&
M"^50X9L 9 !X)Z"@#9HK,N/$6D6T$$SWT31SQ&>(Q9DWQC!+@+GY1D9;H,BG
MR:WIL=O;S_:TDBN8_-A:(&3>F 2XV@_* 1EN@R/6@#0HK/EUS38K6VN3=JT=
MU'YL'E@NTJ8!W*J@DC!!SCC-12>)]"BM+.ZDU:S6WO6VVTAF&)3_ +/K[^G>
M@#5HK)M?$^B7MA=7UOJEL]K:,5N)=^!$0,_-GIU'UK+\1^)%_P"$/\07>B7Z
MQW^FVCS,'B^>)@A==R.,C('&1S0!U5%<]H/BO2=7\G3XM6M9]56V62:%6&[.
M!N..AP>N.GM67X;\6"+2K^?Q%J<8,>LW-A#*Z! P20JBX4=3CZF@#M:*K'4+
M47\=B90+J2,RK'@Y* X)^F2/S%27%Q#:6\EQ<RI##&-SR2,%51ZDF@"6BLZV
MU[2[M;LQ7L8^Q@&Y63,;0@C(+AL%01SD\8I;+6]-U&Y>VM;I7N$02-$P*OL/
M1@" 2I_O#B@#0HK,B\0Z3->QV<=]$9I698AR%E9?O!&Z,1@Y )(P:I7'CGPM
M:MMGU^P0B<VY/G @2#&03T&-PR>@S0!T%%9^HZYIFDKNOKM(@$\QN"VU/[S8
M!PO^T>*J7_B_P[IC%;S6K*(B#[3@R@GRB0 W'8[ACUS0!MT5E-XET9;I+<ZA
M#O>5801DIYC %4W?=#$$$+G)R/6J]CXKTZ_\2ZEHD3-Y]@L?F,RD LP8D#CL
M%'/O[4 ;M%9MGK^E:A>FSM;V.2X\OS5CY!>/.-ZY^\ON,BK&HZE9:18R7NH7
M"6]K']^5^%7ZGM0!:HK/37--?4HM.6[4WDL7GI#@AFC_ +V,=/?UXJA>:W8W
M$^F+;:_%:%[XQ>445FNBNX-$ W(PW4CH5Q0!OT5Q6J^-8KK2O%<6CW#0WVC6
M\C+*\6076+><!AC'0>_...:U/#GBC3M5M[*R.I03:JUG'/-$"-Q.T;C@<<$\
M@=/:@#H:*K:A?V^EZ=<7]VY2WMT,DC!2Q 'H!R:XJ\\:O<KX/U2SO%M=.U*?
M;>1RH/E4P-+@LPXQ@<C\Z .^HK,LO$.D:CILNH6FH026D+LDLN[ 1AU#9Z'D
M<'U%2Z?K&GZJ]Q'9W*R2V[!9HB"KQDC(W*0",CID<T 7J*Y[QAXE/AK2[=X(
M%N+^^NH[*RA8X5YG.!N/91R3]/>DO;/Q):Z7)/9ZNEU?JN6AEMD$3>H0##*>
MN-S,/6@#HJ*S;_7]*TR1TO;V.$Q@-(3DB('@%R.$![%L"FWGB31=/NOLMUJ=
MM%<>49_*,@W;,@;L#GJ0!ZYXH U**PH_&?AN461CUFT87S!;<A_ODDJ![$D$
M8..01UHO_&GAK2Y+B.]UNRA>W=4F4R@E&;. 0.AX_#O0!NT5FW>OZ591Q237
ML>V6(SQ^7F0M&,9?"@_*,CYNG(YJ.X\3Z%:FU$VK6:?:XC-;YE'[R,#=N'J,
M=Z -:BL4>+M .FP:B-5MS:3R^1'+DX,F<;/9L]CS6B;^U%^EB90+IXS*L>#D
MH#@GZ9(_,4 6:*IZEJNGZ-:?:M2O(;6#<%WRL%!)X 'J?:JD/BC1+FVDN+;4
M89XXYVMSY.7)D49*@ $D@<\9XYH UZ*X[Q'XDD^Q>';_ $+4HGM+W5[>UE:-
M5<21NQ#+D_=/!![CGI6]<^(M(M+PVMQ?1)*LB1-G.U'?[JLV,*QR, D$Y'K0
M!IT5@Q>+M,E\3W^A^84FLH4DED<$+EMY(R1C@)DGISCL:BTSQ'I=IH=A-?\
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MC47%I=HMXD$\+_9W*.@MPI^8#&=PQC.<]JZ/_A%['_G[U?\ \&US_P#'*/\
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MN9[6&([_ "$!4X3&25)#;<9^7VJCK&F3Z]K^OZII4<CVLWAJ6PW;"HN)V+%
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M6VALK2&UMT$<$*".-!_"H& * .4^*,3W'P^U"WCMY;B25X L4432,V)D8_*
M3T!/X52\72_V;XET37)+._GT7[-/;SM8"0/ SF-ED*QX8J0FT^G'M7?44 >8
MZK9V4&BZ$^D:3?6]K+XDM[UEDCE>1EW9>9U;+(">><=CQFL[Q=-<7MAXIM4T
MR^MYH]2MI4M[6Q=EN8U>$_:&D"G>2%("@C&T<$\UZ_36D1/O.J\$\G' ZF@#
MB].G:U^)NM7$]K>)#?:=:/!(;9]A">;O#-C"D;AP<'FN3TZ"5? G@>WEL;H2
M6VOB6:)K5]T2"28[F&W@893D^HKU])8Y5!CD5P5# J<Y!Z'Z&GT >4ZY:)=O
M\38[B"]6WN;>W:-X8&S(4AP=F1AL, "!6GX=UG3=7\;PZC<WLB:JVG_88K=K
M">W63#>8[9D4 GY>%'0 ]>W9:YH\.NZ6UC-/<0 NDB2V[[71T8,K D$<$ X(
M(JOI^AW%O-'-J&LWFIR0DM%YZ1(J$@C=B-%R<$CG/7C% #/&=M/>^!]>M;:)
MI9YM/G2.-!DNQC8  >I-<C;74\&O>$]=EMKS^R%TI["1GMW4VTQ\L[V4C<%.
MS;NQCCT(->E44 <EX,T^:WU/Q-J&QXK'4=1\^UC=2I($:J\F#R-S GW ![U%
MXP0OXJ\',()9$@U"225DB9UC4PNH+$# ^8CK7944 >5WD+-IWQ25+.X+WJL+
M8"V?,Y-JJ#9Q\WSY''>H]2N)[BWO+ :;>PR3>&XXX9K>R=I+Q]C@Q.^T[ A/
MW3@DMU['UBB@#S+2GF@UGP'>R6-^(1HLMFQ^RR924B'"L,97.UN6P.,YQS5"
M6WU-/#GB"VM]-OY;FS\2OJ,END;QFX@$ZR 1OP&)7YAM.>/IGURB@#RK6AI.
ML>#_ !-J6BZ3JS75UIC6K3W4=QYDK?PQ*CY+8.<D# ]3SC;UVSM;O3- :&[O
M=(NHT+VNH6\!*P.$"[94(QM()&&Q]T"NWCECE!,;JX#%25.<$<$?6E\Q/-\K
M>OF8W;,\X]<>E &'X.GU*Y\,6TNK6T<%Z7E#^5&8UD_>-B0*>5WC#8/]ZMZB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "L/Q5X@E\-:;%J LUN+;[1'%<.TWE^0CL%\P_*<@$C-
M;E4M7TRWUK1KW3+H9@NX7A?V##&1[CK0!BCQ?L\0Z[I-S:P0G2[-;Q9/M);S
MHR"<[=GRXQSUZCKFH6U8MXPT:UO-!@CU.XTZ>:.X,X8PXV;HL[<X)9<GVZ&J
M4/@"?/AVYN=0\R_LB1J<X'_'XA"DJ?4!XX@,_P (-;%]HE]<^.M*UN-K<6MG
M:S0.K.P=C(4.0-N.-GKSF@#@=7U34=?^%LNI:M:VS31:U&(6A<LP*WP3: RC
M;@#:#GD=<5W%MXFO)]6U?1K[1XXKJUM$NXD2Y$BSQ.67!)4;3E2".1[FL.3P
M1K@\(W7A]+C3VC.I_;()&+J=GVGS\-P>?X>/KGM6VVA:H?&-_K:BS\JXTQ+)
M(S,V0RLS9)V=/GQ^% &7IGC!;;0O""Z7X>2.WUE"D%O%.J+;XC9POW>1\O)X
M[]>AZ#PSX@FUP:E#=V*V=[IUVUK/$DWFH3M5@RMM7((8=0*Y[3O!FKV.G^#+
M9I+%CH#L96$C_O08VC&WY>.&SSZ8K<\.:+?:5JVOW5T;<QZE>"YC$3L2@\M4
MP<J/[F?QH D\2^(9O#K:=*;%)K.ZNX[6:X:?9]G+G"L1M.5SQG(Y(J+5/%B:
M2^IO-:[[:R,,*NDN7FN)2-L04C /S(<YZ,/?#O&4^A-X?N],UR\@ACOH)$2-
MI ))"!_RS4\LP)4@#G.*RY/!5QJ7PZAT:\OF75V\N[DO"-Q%T&#[B.X##;_N
MB@#0;Q/=6NOIHE_I\,-W<VSW%D\=R7BFV8WH6* JPR#T((_*JEKXY-UI'A;4
MAINV+7IE@"F?YH&968'[OS#"'TJW'H5]J6OZ?K&M+:12Z?;2Q0Q6LC2!GEVA
MW)95QPN ,'J>:YVQ\$>([;2?#6F27>E^3H-\LT<BB0M-&JNH)&!M;#CCD=\]
MJ -S1O%>J:SJ]W:PZ $MK+49+&ZN&O%^3;&K!@NWYLE@".V0>><,^*,,4WPR
M\0"6-7"V;NNX9PP'!'O5SPOHM_HUUKLEX;9DU'47O8_)=F*;D1=IRH_N Y]Z
MF\8:/=>(/"6I:1:/"DUY"80\S$*H/?@'/TH 9I>LW%^"-/LXKBPAA"B[^T;1
M)*,AD4;2" 1@MG&<CD@XP],^(5W?67A[49M"%OIVLW'V59/M8:2.0[MOR!>5
M.S&<@Y[=S;T+PYJWAS5[E]/^Q#2;N,2RV+3./*N?XGC.SA6X)&.O(QT.=:>"
M=9M?"GA?2#)8-+HVH)=R2>:X615+G ^3@G?^GO0!J7GC26/3=5U:RTP7>F:5
M-)%<.)]LC>7_ *UHTVD,%YZL,[3[9FB\6R7&O?V;;V4+QSZ:-1L;AKDJMRF0
M"N-GRD9!/7@CWQG1^$-5L;#Q!HME/:'2]8EFE265F$MKYPQ( H4AQDDK\R]<
M'-7=9\%17]MH$%E.;5=*(ASU+VIC\N2+_@2[>>V,T +H/C!O$.BZ)J%K8Q9U
M.1U>+[228%3=O).SG!7;CCEASSFL+PMJMGX;TOQ&_EHJOXFN+>"($(I=BH S
MC@#DGCH#@'I71Z#X5&B>(-9OTF#6UY,9;:W XMRX4S8_WW4'\*PW\"ZM-H^J
MPB]MK6_DUIM9L)XRSK')D$*X(&1@$''KTXY +J^/XX(]6^WZ>R/8F(0M;R&2
M*[,IVHJ.57YMQ"D$<9SG%4$>XC^,D%Q?V-M;/_8$[-)!*9-X$T74E5.1]._X
M5<U3PSXB\3^&;BUUJ_L+;40\4MH;%':**2-@X9M_+9( QV'K2-I^NVWB&+Q9
MK<FEP06.E307,=J9)<C<LA=<A?[G3M[T .A\>3SP^'[J+2%:TUV0I:M]JPZ?
M*67>-N!E5)X)P>/>EO?B D&;BUL1>6*7AM)/*E)G&'\MG6,(<J&!_B!P,UR_
MAK^T=-M=&O%C\,ZA"K PK;W\OFJ93\YBB.Z-6^8\+@ 9&0*Z;2_#?B?0[^[L
M+#4M//A^XN9+A&E1_M-L)&+.B8^4C).">F>AZ4 =MTKC)O'HAT&+Q(=/#>'G
MG$9N1/\ O5C+^6)3'MQMW8/WLX(..U=DRAE*D9!&"*X&W\"ZA'X0?P9-/:R:
M'YV$N=[>?]G\SS/+*;<;OX=V[ISCC% &G'XKU2Z\4:CHUGH F&GS6ZSSM>*H
M$4H)W@;>2!SM[\\],]!JUZ^FZ1>7R0>>UO"TOE;]N[:,XSVZ5D:/HE_8>+]?
MU68VQM=2\CRU1V+IY2%>05 YSGKQ[UJZS:S7VB7UI;^7YT\#Q(9&(4%@1DD
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MBYQM(R.0%Z'))(Z#-A\8Q:3X;U+5+3PXD7E:V]E<00S*-\IE6-I<[>26;/\
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MEY-@<HGRMDA2.I R0/4BC'X\.H7>AQ:1IOVJ+6;.6ZMY9+@1!2FW*N,$C!8
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M<=NF#2?#?B?0[VZT^QU+3SX?GN9+B-I$?[5;B1B[QICY2,DX8],]#TH [8D
M9/05PWA[5CJO@74?%=S:B\:]6XE6W<@#[.C,J19/ &U<GU+'UKN2 00>AKA_
M"^D7.G^!K_PB-@O+,7%O$9255XI&8QR< \;6QQW5AVH @U?58[#X9Z5XMTVS
M2S-E;6UREM&?E%NVS?#T&5V,<<=54]J[U'61%=3E6 (/J*X/6M"O#\,;#P86
MC:_N((+ M$25$:%1)+R 0 BD_4@=2*[Q$6.-8T&%4  >PH X33/&=];6GBG4
M=;@@^RZ=J36L*6\Q9BP6)4C4%0#N9OO$CEN@'-;B>))[;Q-9Z'JUC';2W\+R
M6DL,YE21D +H<JI# $'H01GZ5A7?@*]O['Q1IDM[;QV>JWOV^VF16,L,W[LC
M<.F T8Z=0>U;,6B:CJ.O:1J^M"SCETN*41):2,XDDD4*SDLJ[0%!PO/WNO'(
M!J:_JCZ)X?U#5$MOM/V.W><Q;]FX*I8\X/85SJ>--3.H:/;-H"@:S:M-9,+T
M$[U17*R#;\JX.<@L>.F>*W_$>GW&K>&=4TVU,:S7EK);JTI(5=ZE<G )XSFL
M-?#6JC4O"-R39[=%@DBG E;,A:,1Y7Y.V,\^N/>@ M?':/I4TM[9):W\6IMI
M1M_/W1F8#=D2;1\NSYL[<\'@FFP^/HU344OK'R9[6XA@B:.4M!<F7[A20J.G
M.[CY<'K6?-X%UF6TU)X;VTM=1.N'6;"52TB(^P)Y<@(&05R"1_>]N;^I>'/$
M7B'P^Z:GJ-E::O%-%<6362,T,$D3;@3OY;=R#TP,<'G(!G:[X\U.'P]XF-II
M\,5[IMJ)XKE96D@D1@?F5M@RZG^$CTYQ7=Z>]S)80O=QQQS%066.0N/S*K_*
MN7OM!\2>(O"6K:;KEYIL-U>6K6\2V*N8D)'WV+<G)QQC@9ZYKIM,2\CTZ!-0
M,'VH* _V?.P'V)Y/UXH Q+CQ1=0:_JND'38A+:6 OK9GNMHN4R0?X/DP1@]>
MH]:-&\6/KFEZ%>VEE$W]J1O*\?V@Y@11\W.SYB&*J1QR:=XC\+?V[JVD7R7'
MD&T>2.Y&/]?;.OSQ'V+*GX9H\.>%O^$?U+6;A9Q)#=W+2VD/:W1OG=1Z9D+'
MCL%H YBX\47-MX0DO-#TBTTZ1M?^Q7$?F]6-P$=P0O)8YR>P.>>E32OJ%G\5
MK^73])MI[^70('DB^T>7&6\Z3.7V9/0 ';Z9P*E/@C5V\*7VG>?9+>2:R=5@
M;<YC_P!>)MC?*".F,C-;%OHNL1^-9]?E^PNLFF)9^6LCJ=ZNSY^Z>,MC\,^U
M &IX;UR+Q)X;T_688FB2\A$GEL<E#W&>^#GFM2L#P3HEUX;\(:?HUX\,DUHA
MC,D))5ADD'D#'6M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9]9NIQIMK'-;W.R-)=LD19D)50,9!Y !P>M 'JH(8 @@@\@CO0S*I4,P!8X
M)ZGK_0UQ=U/J-LVG6$.LW#[M/>4101Q&Z=_EVN<H$6-02,G&3@9-<_;ZCJ?B
M*7X:7\^I7%O-?1SO,+<(%+BW?Y]K*1DY(YX )P!0!WNFV^D1:O?QV6D1VMU
M5$MPMF(A+N&[Y7P-_OCH:V*XB"[U[4M9\:Z5;:LT4UGY T^3R8_W3/#OP05.
MX;CWYQ2^'_$ESKFDZ1=K=3J]M://JD>Q-QD7*&-AMX)=9"-N/N>] ';45P6B
M:AXIU>#P]KL$Z?8KP))>P3/'Y0CD7($>%W!E) &3SSGFCP[XDO+CQ)!I6LW5
MY8ZMF9GLIX4\BZ09P\$@7Y@!CC.<9SG&: .]JI<ZA':WMG:O#<.UVS*CQQ%D
M3:I;YV'"CC SU-6ZY?7]2U"R\:>%+2WNBEG?37$=S#L4[]L#NIR1D<@=#VH
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MN\. N<YZY[<4#5O$^NV=WJ6AS+$]KJ,L"PS/&(#'%*499,J7!*J6R",$CMU
M/064,I5@"",$'O52RTC3=-=WL=/M+5Y/OM!"J%OK@<UQT_B2]M/%YTW5KJ\T
MT37R+I\ODHUI=Q<?NM^TE9#\W!(YQCCBN\8[5)R!@9R>E "T@96)"L"5.#@]
M#7G6E^(-8;Q!X8@DU-[R#54NEN)DB1;=V1-ZM!E0^!C&3D,#GGK6A\-([G^R
M]5EN-0NKH_VM>1XFV'[LS#.0H.2 .^/0"@#MJ*Y3QOJ.IZ=_8!TV]^S&ZU:"
MTF!B5PZ/G/7D=.Q%8GG^(GU+Q=I*^);H+I4$-U;7'V: RYDC=MC?)M* I_=!
MYZ\<@'HU(S*@RS!1D#)..3P*X+1_$FJZCK'@_P RZ*P:OHLEW<PK&FT2A8B&
M4XR/OMQG'2L*_P!1U75O#]@;G5KD21>+Q9;XUC4O&ESM3< N"1M!Z8)Z@T >
MMT5Q4.I:H/$WBC2VU.9X;+3K>>W=HXM\;L)-QX0 YV#J#5/3-<U;5=$\+R2:
MHXN+[2C<30V<2?:9I2$PXW+L2,9;).T9*COB@#K]4UVRTBZT^WNS*)-0N!;0
M;8F92Y!."W0< ]3VHL==LM1U?4M,MS+]ITXQBX#Q,@!<$K@GKP.HXKSYM7N]
M>\)?#C5+YE:ZN-9@:5E7:&81S#.!P,XK5M;>]NO&OCZ'3;PV=ZT-CY$X16V/
MY3XR&!!&>O'2@#OJ*XCPUX@O?$5MH4:7<T5W"DC:PA2/(>,^68V&WY<R9(QC
MY4/K72>(]6.A>&M3U81>:;*UDG$?]XJI('Z4 :=%<B)]7TZSM]>EUA;W3QIT
MD]U;/&@,CA-ZF$J 0.&&"3QCOS61+XAUFR\,>&?%!OS<KJ,UJ+RS\M/+V7&!
MB/ W H6&,DYP<T >BT5Y5J6M^)8M#\::E%KTB-H5^XMHQ;18D18XWV/E>5^8
M],'GJ> .CU'6[S1?&NG27^H.N@ZE:2!$9$"PW"#?RVW=@H&P,]5- '945P\F
MK:RE]HVC23W!NM0M[B]D;]TDD:JR;81E=N0).3C/R>]4+R_\8:;;Z#;7NIPQ
MW-QK9LGD2-)#+;LCNA<  !\*,[<#\Z .YU86<5B]]>67VI;,&=%6#S9 5'5%
MQG=Z8YJW#*)H(Y55E#J& =2K#(SR#T/M7G5QK>NZ?HWCZV_M>6>YT-/.M+R6
M&/S,-;B7:P"A3@Y&<=*T&UO5-3U6WT6UFFBE&D0WTDL#1*[M(67/SJ1@;,\#
MJP^A .XI&947<S!1ZDXKSS[=XM75O"6EZCJL-M=7T-VE\;6)'4M$!M=2R\-@
MY(Z ]CBL?4]0U:_\)F"ZU>Y::Q\5Q:?]H141IXUN$VEP%QD9'0 $@9!H ]<J
M.29(TD8Y8QKO*H,MCGL.>QI84:.%$>5Y650#(X&YO<X &?H!7 :0M^OB;Q[(
MFKW>ZWDC$0=8V5<VZN."O0$G ''KD\T =9I]GI&H"WUN+288KF=!()9K01SK
MD?Q9&X&M:O-;/7M>O;'X>N-5:-]9A87K"",[V^SL^X<<'([<=.".#6NM4\2P
M>'_&,J^(YS+X=N)#;R&VAW3J(DE"R_+@CYB/E"GWH ]3HKA9M;UC7=4O]-TN
M62UEM;&WF5H6C!\V568%O,4Y48 P/?/;%+6?$6OZ-;6;Z])/96[6 6?4=+B6
M>*WN]S!FE4J2(\!<<8SN![8 /1Z:44N'*C> 0&QR >O\A^5,M95FM(95E657
MC5A(AR'!'4>QKSWQ-XBU?3/[2O;34FF^R:G;0B*WB0P11.T2M'*S#)D.]C\A
M)&5Z4 >B[%#E]HWD8+8YQZ?J:<3@$^E>?7UYK]WXD\76%OKTUI!I]E!<VWE6
M\19&99#C+*<KE1G(STP1SE^B^*+_ ,1WOA[3#<&TDNM!35KN6%5W.S%5"+N!
M &2Q/&?NCUH ZS1M<LM>M[B>Q,I2"XDMG\R,H0Z'##!YZ^M:5<5\-(Y(M+UV
M.:8S2+KMZK2LH!<^9U(' S[5-XJOM7A\5^&=.T[4OL<.HO<1S_N4<_)"S C(
MZCMVSC((X(!NZ]KMEX;T:XU743*+6 9<Q1,Y'X#^9XK2ZBO'_$6HZN? _P 0
M= UB\^WR:4L7DWAC5&DCE <!@H W+TR ,UT_B_5M3LY-6^PZFZ-9Z4;F*WM(
MD9XY!O/F3%P5"?* !D$X? .. #N:*XFPUZ^\0ZO:Z4MXU@QT2'49'@52[O*2
M,#<" J[2>G)8<\<L_M37?[3T[PW<7BRZ@-.>YNKFRV1F5A((QMW@@8Y)&.N.
M@R" =S17GEWK/BG0])TR37DGEBC,Z:C=:2B22I@KY4C(5/R[2Q;:.#@].#V/
MA^\2_P##VGW27Z:@)8%;[6BA1,<<M@ 8R>V!CI0!I45Q6LZM?Z1XQDMKO59X
M=+O]-EDM"L49,%Q%RX'RY;*$$ YZ-^$'A#7-6UW3])M;J]FCU6UEG76%\N+[
MT1V;" N!N9D88Q\H//>@#L++4H;V.YD$<\*V\SPN;B(QY*]67/5?1NAJ%-=L
MG\1OH(,OVY+;[4P,3!?+W;<ACP>?3/2O-M;U+5M1\ ZZUSJMQYMIXC%FDD:H
MA:(7$:!3A>F"3[GKD<5M7=A>3_%86L&K7%O)_P ([AKM8XVE/^D'IE=@/_ ?
MRZT >@T5SG@+5[S7?!.F:CJ#K)=R(RRNJA0[*[)NP.!G;GCUKHZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *IZKI5CK>F3Z=J-NEQ:3KMDC?H1_0@\@CD&KE(2%&20![T 8EGX;%
MM$EO-J^IWMHF MO=2(RX'0%@@=A[,QSWS3;CPI9RZI>ZA;W-W9RW\:QWBVSJ
M%N !@%LJ<, <;EP<=ZVS+&J%S(H0<%B>*5G1 "S*H)P"3B@#%'A6P35=-O[=
MYK=M-MVM;6&(J(TC8 %<$'^ZO?M5*3P)ITNAW^D/=WQM;^[-Y/\ .FXR%PY(
M.W@%@#CV]*Z<NH&2P QG)/:EW+LW[AMQG.>,4 <'I^D7=Q\0_$TSSZK:07%M
M:0QW"1;%GV*X?YF0C()'(QU.*VF\$:0M[8W-J;JR-G:?8E2UG,:O!G(1NY&>
M<@@^]=$KJR!U8%2,@@\53U'5K'2M,DU"[N$2V3'SY'S$G  ]23@ 4 8=AX#T
MS34T5;:ZOPNCL[6@>8-C>I5@<KTVG&./SYIS6J>#DO+RRL=6U:34[WS9X;<1
MNRR,N"_.T!<*H//''N:Z8L I8D #DFJFFZG::OIZ7UE,LMM(6V2#HP5BN1[<
M<>U %'PKH<7A_08K..".!W=[B:.+E5DD8LR@]P,[1[**L:_HEMXCT6XTF\DF
M2VN%VR^4P#,O7&2#BM%75U#(P93T(.0:1Y$C +NJY.!DXR: ,/7/"5AXAL;.
M"]GNUN+)Q);7L$OESQ-C!(8#'(Z\8-<YXK\/M;6?ANRL?[4N6BUJ&[N;L!YY
M@ C@R,V",C*C&,8 &,"O0"P7J0,^M('5E#!@5/((/!H P+OP?87]AJEM=3W4
MKZHBQW=P642/& 0$&%PJ@$\ #J3U)-.UCPAI^NZ19V%Y-=[[-EDMKR*7RYXG
M48#*RCKCCI6_D9QWJG</?KJ5DMNEL;)M_P!I:1R) <?)L &#SG.2.* ,V+PK
M!!:VT<6HZD+B"<S_ &MIP\LKE2AWE@0PVG&,8&!C&*J7W@'1K_3H[9VNX9X[
MM[U+ZWF\NX6=R2[A@,#.>1C'3C@5NZ?JEGJ@N&LYEE6WG:!V4Y&]<;@/H3CZ
M@U:61'0NKJRCN#D4 <]+X,L9K*QMWO-09K.[6]$[S!Y)9EX5W9@<X'&.!C Q
MP*=/X.TZZFUR2XEN91K<*P7B,X"E54JNW !! )[_ %S6_P"8A)&]<J,GGH*#
M(@C\PNNS&=V>,?6@#FQX'T\7MG>?;=3^TV]L;1I1=$-/%G.UR/?D;<4RW\ :
M3:Z=I%E#/J"#29&>UE%R?,4,I5ES_=*G&!C\^:Z@$,,@@CU%&X>HH R]/T"V
MTW6M2U6*>X>?42AG61E*Y1=JX  Q@<=?K3]+T+3]'GU&6RAV/J%R;F?OER #
MCVXSCU)]:T)"WEMY>TR;3M#' )[9]JRX=7^RPZ3;ZQ);1:G?GRQ%;N61I A=
MMI."5 4\_3UH S=&\!:5H5]YUE<:B+59#+%I[W3&UA<G.5C^I) )(!Y'-6K7
MPI:6KV+O=7MU_9ZN+-9W4^3N4J2"%!)VD@9)QFFZ#X@N-3U?7K*[@@@_LV[2
MWC*2%MX:-7!)('/S=,?G6I(]^-6@2-+;[ 8G,K,Y$H?(VA1C!&-V>?2@"EX7
MTFXT714LKB\NKHK([(UW-YLJH3D*S]S_ "Z#@"I-2T"WU/5M,U*6>X2?379X
M!&RA<LI5L@@YRI(K3\Q-P7>N3G SUQUJ&_OK;3+">^O)EAMK=#))(YP%4#)-
M &+_ ,(;8(^I-!=7]O\ ;[E;MQ%/@1S!D;>H((!)C7.<]QT)K1TW1K?3;F\N
MUDEFN[QE:XGEV[GVKM484   >@K-NO$D\/BK0=,CMXC9ZK!/-YS.=Z^6JMC;
MC'\0YR>]=$'5DWA@5(SD'C% &/XB\,6'B:V@BO&N(9;:436US:R>7- X[JW;
MC\*@F\&Z9<Z/'I\\EW*\=PMTEX\Y:X6=>DF\_P 0  Z8QQC'%;Z.LBAD8,IZ
M$'(-(9$5@K.H8\@$\F@#'_X1BPEM]2CO6FO9-2@^SW4\Y =XL$!1M "@;FZ
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MW.JY.!DXR: ,[P_H5MX;T>+2[.29[:(L4\Y@S#<Q8C( [DG\:TZ** "BBB@
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M]<8ZU<,:-&8RBE"-I4C@CTQ0!YI<VFCW_BCP%:PQ6DUB]I?;HHMOEN?+B)!
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M"W!')08.0*Z_Q$8K_P $:H[Q'RY=/D<)(,$?NR1D=B*OOI&F2R1R2:=:.\0
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MB/\ B56_BZUCTXAB/+4R1^8L9'10Q<#'0@^E>O2:7I\UF+.2PM7M5.1 T*E
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M#ND107MO8R7T4LSBZA3+$22,^,E01C=C\*Z&&PL[>X>>&T@BFD^_(D85F^I
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M9UZS77X=&<2K<S6S74;%1L:-2H;G/!!8<&N$NM(N]<@^*&FV2!KBZFCCA#'
M9_LL9 R>G;\ZM7&GZWK_ (DLKM]&NM/M9-%NK"2266(O#)(4P2%8\?*<8)/J
M!0 [Q/XD^VS^%)]-;4(K6YUJ"-;E&*0W,?S9& <E3@$;@ 0,C(K=L]<T>#4_
M$MPU[>I]A:(WHNB_E0_N^/+4] 1@\#DGC-<E'8^)9/#?A/2)O#EPMSH>HVIG
ME2:'RI(H59=Z$N"<C!P0/2K&K>%];U>7QU'#:-:MJ+VDVGS2NA25H%3@A6)
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M9A\I'.1GO7+Z7X;U_1M%\)WTWAI=1>PLI;&^TV1XBX5F5EDCR2I(*X(R#@T
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MSQWQ7&:KX6U[4;CQ1/;6+0ROJEGJ-@)I4"7/D)&"APQ*Y*'&0.U;\FEW>O\
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M&KA]C1DY8-@D?,ON,4 =I17E6I^*_%NH?#)O$4:Z986]U;0,AC+O,"\H1AV
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MV526PX;"'A< /UXYKV_C/4[\:;J&G::]WIUY=")XDM91)%"6*B;S3\A P"5
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M,'+'[Q&,^OUK3\H^*=/U>SO8K233FN&MX-\'F!PA 9F5B02'# <=4![XH Z
M$, 000>01WI:XJX\2?V3K?\ PC%G)9VDUM;PBR@O@P-ZN,$1ON R,8QR2?2N
MKU*XFM-+NKFWC22:*)G5)&*J2!GD@&@"U17!6'C/6GT#2]8U"SL(X=72V2SC
M@,DD@ED!9BR@'*A06 '/&/>F:IXUU_1]&UR[FTA)1I[0FWN7BEMX[E)&"G"/
ME@RD\C.#UR* /0**XO\ X2?7[#Q4NBZKI^GC[=:2W&G26\SXW1X+1R$CK@@[
M@/P]*>F>-]:F\-Z=KM_96$=MJ:01VL4+2/*)Y&Q\P .5"Y; YXQWX /0**X>
MX\8:OIEIK,U]I<DEO9"%X;Z.TEC1T=@KDQMELQ@EB >0.U6!XQ*:.EZMQ8ZA
M'>7L=I83V2LR2;E!)9068%</E1R=HZ9X .PHKS_5O&GB#1]#\07DFDQR?V:(
MI+>ZDAEMXKE'."-C98,IX(S@YSD5I+K^N)XHN]"N8;"*1]-:^M)8][B/:X0K
M("1NY8'(V]Z .NHKS_PSKVN-X#\/ZA<RVDC7P#7%[/\ *MNI5FW,"XWDMA0%
M(^\/2J6H>+]9U/PO97-I)!:7"^(HM,N&$3XD"W 7*@D%0>,@Y."1GO0!Z+]N
MM/[0_L_[3%]L\KSO(WC?Y><;MO7&>,U8KEAJU_\ \)VVB-;6(E_L?[4EX%8L
M6\P+M(SPN<G&3VYJOHGBG4=7T*W=HK6'6#J+V%Q;;6*1,C'?WSPBEP>^0.^:
M .QK,;0;!_$*:Z5F_M!(#;JXF;:(R02NW.W&0#T[5S5SXSU.6*6^T?37OK>"
M]:U:U2UE,DJ)(8W=91\@((8A3G('4$X'<4 %%<]K'B"6VUJ/1K+"W36S73RM
M:R7"HN[:HV1X/)SSD8QWS6+=^,=>L/#%AK]]HZVENDXCU6&1',D$>[:9D'!9
M<8.",@'OB@#KM6TFSUS2YM.OXWDM9L;U21HR<$$892".0.AJ6RLK;3K**SM(
MEBMXEVHB]O\ $]R3R:Y^;Q)>V>BV-U<PVYNM4O$MK&)<A0)"2A<Y/(0%B!W&
M!ZTR\\0ZOH<-\=6LH'47-O;Z?<09"W+2D+S&"S+L8\]<CIZ4 =717 ZIXRU_
M2--U^YDTI)X]/M1=6]V\$MM%*/XD*OD[AP>#@@]JLKXGU^U\4:;I>IV5A%;Z
MS#*;&:!W<Q2HF_;*#C.1S\N.F/>@#M:*Y+X;W^IZKX,M;_5+F.>6=Y6W)&5(
M_>OG.2>/0#&!Q4/B[Q;J7AV/5+E(+1(+&V6>%)B7DO>ID"A6R@4 #<5(R?2@
M#LZ*XS5_&<EKK?\ 94,MG:7,MFEQ9+?JP6]=MV8T?<%4C"CN3NZ<<];=R2Q6
M<TD"(\JH2BNQ52<=R ?Y4 345YU:>./$$VE>%M6?3].-MKDBVPB61PZ2.CLK
M;L$;?D((P3W]JT;;Q1KFSQ)92V%G<:II$L*IY,ACBD250P8[SQM!)//.WB@#
MM**XFU\5ZO?OXDLM.CL;V]TJ*&:VD1'2.Z$BLVW&XX.4(# D'(J_I/B676[?
MP]-8M;N-0@:YN<HW[M% # <\,'8+@Y[GMB@#>O-1LM/\G[;=P6_G2"*+S9 N
M]R<!5SU))Z"K-<7\3=PT'3&C17D76;$HK' )\Y<#/;ZU7F\<:EH&I:K8^)+*
MUWV]@=1M9+%V*S('"&,[AD-N*C/0YS@4 =Y17,:;K>LR^(TL+JP,MC+;F07D
M5I+ L,@/^K;S/O9'1ACITIWBO7]1T2XT6*PM+:?^T;Y;,F:1EV$H[ \#I\AS
M_(T =+17%2>)M<5KG3/)L_[8LK9)KCR+:>XA=W+[$7;@KD*"6;INX!P:LV'B
M;4=8NK73K>R73M1-@M[>)>(7^S[F*JFT%2Q)5N<C  XYX .LJ*YN8;.UEN;F
M5(8(4,DDDC85% R23V %<-9^.-3FT[1KJ:UM%:\UM])FC3<0NUI!O4D_],^A
M'?VJS?\ BJ^CC\:PM9V=Q_8<"R(K[E69&A,A##GMQ[^U '90S1W$$<T,BR12
M*'1T.0RD9!![BGUP]QXHUS[9X>T[2[#3?,U73)+E&F=U2-T1#@@#A?G XR?I
M27?B_63;7[Z;I\=U=:;*L$UK';32"YE"J9 D@&U,;B!N!SCD#- ':SSPVT#S
MSRI%$@W/)(P55'J2>E-M;JWO;2*ZM9HYK>50\<L;!E=3T((ZBN5NM>O=:.N6
M6EQ01+IULHG^UHQ+RO'O\L $;<*1EN>3TXYL_#C_ ))MX<_[!\/_ *"* -ZR
MU&RU)))+&[@N4BD,3M#('"N,94D=QD<53_X1S2CXA.NFV+:B4""1I&(4 $9"
MD[0<$C(&<$^M>>:?JVOZ#I_C'4]*L;"YLK+7+N>YCFD999$ 0L$P, @#.3G/
MIZ]9:>*YY/%5K97"V\6F:AIWVZPG((:3&"Z-DX!56#>X/;% '645FZ#>7>H:
M-;WMXL:/< R(J*5Q&3E,@DD$K@D=B<=JTJ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P?%&@7.NQ
M:<UG?K9W%A>I=QF2'S8W*@C:Z;ER/FSU&" :WJR/$FOP^&=&?4[BVGGA1T1A
M#MRN]@@)R1QEATS]* .9NOA[?W.EZ]8G7X]NK7T=\S-99,;J8R1PXR"8EQZ
MGJ>:U;O3O[(\2W/C'4=4A2S@TS[--$+5OE56+E]P<GJ3QM/%=110!Q_A#3+"
M76=9\2Z>9#9ZE*&MMP(4_*OF2(" 0'91GUV ]"*U?%V@2>)_#%YHT=XMI]I"
MJTS0^9M 8'A=R^GK6W5>_O$T_3[F]D21TMXFE9(EW,P49PH[GC@4 <_>^$9-
M3\2-J=]>PR6TNE2:9/:K;%=Z.P9F#;SCITP>*ALO!MREAH^F:EJ:7EAI$R2V
MP$&R23RP1$)&W$';QT R5'3D&8^-4&M)HYT'5QJ#VQNUAVP9\H,%+9\W'4@8
MSFI].\76VI:];Z2MC>P336+WH:=%4!5D6-E(#$A@S<C':@#'N? -Y<^&_$6C
MMK, &M7SW;2BR/[K<5)4#S.?N#G([UUZV%NSI//;VTET,%IA" 2P[C.2/SJU
M10!XY9W_ -HU6]O[/Q%H::A+>R3KIFHZ66O$8$JBX5PQ8*  0N0#U/4]S;>'
M-1M=8O-:T^[ALIM5AB-]:S0F94F5<!T(9><<$=#@'BM!O$EO+J=S8Z?9W6HS
MVA"7)M@@2%B,[2SLH+8YP"2.^*LZ3K$&K_:Q%#<0R6D_V>:.XCV,K[%?\1AQ
MR.#VR.: ,BZ\$64G@-/"UK-)!'#&OV>YQEXY5;>LO;G>-QZ=33]?\(IJNAZ?
M96%]+IUWIDD<UC=JH<QNBE?F!^\""01WS72T4 <=J?A'6-;\-3:?J/B")[R>
M6&1YULL1H(G#JJQAQC)'))).?88TM3\/W6H^(]"U<7\,?]E^:6B^S%O.,B;#
M@[QMXZ<&M^B@#A9_ %[/IFJ67]M6Z_;]7752_P!A/R%61MF/-Y&8UY^M;*^'
MKU/&-QX@&HP9EL%LA ;4_+M9G#;O,YY8\8Z=^]=#10!Y_;_#F_T[1M#CT[Q
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M-\?/0X)'ZU;H Y35O"NIR>)CKV@:VNFW,\*V]Y%-;>?%.JDE6QN4AADC.?\
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ME+J"QW NY;<6SR_:Y23&,X7[W;).>N2:H7'@'PU=:+9Z1)IQ^R63;[4">0/
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M$\F^!P<AD?=N4\GH>YI]SX3T:\TJZTVYM7EMKMQ)<;IY-\S#&"S[MQQ@=3T
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MMVC$7V)FB(V2 (H^^% !)YY'&35.+6](U/0/A_9V3?Z99:M:1W,#1D/!((Y
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MSZK;B]T6Y \])<QJLT# Y( 5&P01A6Y&#@ ])N+JWLXQ)<SQ0H6"AI'"@D\
M9/<U%::KIVH&<6=_:W)MVVS"&97\L^C8/!^M<E\5TMSX)\RX12D=]:$LPSM'
MVA,X_#-8.N6VF0>)-7U;1]/CO-,B\.31:C#8':DY+#RX\I_%M#\CD+CU% 'I
M-KK&F7HE-IJ-I.(@&D\J=6V ]"<'@4R/7='E$ACU6Q<1Q"9RMPAVQGHQYX7W
MZ5YMI.IZ=/X[MIY+ZWN+.?PTT:LD16 ;95.Q2<Y"C.=Q..<XZ56TAM%TWX->
M']0ETVUEDWVL,UP5(^SL)@V^4KABJ, Q4G!X'&: /6;74;*^@>>TO+>XA0E7
MDBE#*I'4$@\$5'!K.EW+%;?4K.5AR1'.K$<9['TYKRBYEMKVU^)UN^I3E9[>
M"<7,=N?G7R%RP4  J2,>XYR>M;.AZIX>\0^-DUB?5M$:YBTK[(+2&;?GYM[O
M\ZK@*,@#'0MG% '=QZ[I$N_R]5L7V1&9MMPAVQ@XWGG[N>,]*?'K&F2VDMW'
MJ-H]M"2)9EG4HA]&.<#\:\GT3^Q=/^"6G:A+I=M<2!XX9Y=I!B_TD'=(R_-L
M4A6*YY"@=*@UBYMKJU^)P:Y%X9M-M[B*7R=JOB)AO3C& < ')[<F@#UZ+5;&
M]GN+.QU&SEO(5R\:2+(T>>A90<X_*L'P5XL36O#^FR:I>V,>K79FQ;HX0N$E
M=<HA)8C"^]8*6>E3^,/!^H:#]E7[);3MJ$UO@!8#%@"4CN7((#<\,>QKF]-;
M3X?A[X.G4VZ7 \2(\C\!P/M$F23UQL(_ CM0![->7]GI\:R7MW!;1LVU6FD"
M GT!)ZTQ-4T^2[>U2^MFN8UW/")E+J/4C.0*H^*]$'B/PMJ&EA@LDT68)/[D
MJ_,C?@P!KSV+4->GU#1O%\%E)#-K%O\ V/- 8QF)]NY)F'H)1(/]S'K0!Z*^
MHK<ZEI9L=6TXVLWF[XMP=[C"\>60W\)!)X/ [5RL_BS7(O"_C6_#V1N]$NYH
MK<^0VQD2)'&1OSGYCSG\*=K-O8:9\0/ =K%Y4?D1W4*Y(W!/)"J"?<]/4U@7
M5U;MX,^*:+/&6>]N=@##+9@C48]<D$?44 >JVEQYFFP7,S*NZ%7=CP!D9-00
MZWI-S<Q6T&IV4MQ,GF11).K,Z?WE .2.#R*BM);67PQ!+*\+VIM%+,Q!0C;S
MGMBO*=%_L^U\%?#.5/L\5RNIQ^:XP' ,<H;<>O7:#GV]J /7Y=5TZ"\2SFO[
M6.Z<@)"\RAV)Z84G)JD/%&DMXF?P^+V'[>D0E>/S ",G 7W;J<>GUKSII(Y?
M 7C#0=5Q_P ) ]W=,D#?ZVXD9MUN\8ZL/N $=-O;%;NE22:?\4$@U27_ $RX
M\/VL8;!/G2K))YF/7&<GT!S0!U^IW$T-SIR0W]G:^9< 2)<#+3IM/R1\CYLX
M/?ITI9M>T>V8K/JMC$PE$)#W"*?,/.SD_>Y''6N8\?/;1ZUX->1HEE76D.YB
M 0GE2 _ADK^)%<AJ<6E/HGQ3(2T,AE;RN%R3Y"8V_P# P>G<>M 'ITGBC2(O
M$R>'VO81J#0F8QF0 K\RA5_WCG('7 ^E7$U;3I+\V"7]JUXH)-N)E,@QU^7.
M:X6&]1?B+ITPG4/>^&A%:RD%A)+YH. 1U(SD^@YK)\)7.BZO9>']-U.ZU$^(
M='E4R:>Z!&AE4%9'9@@RA!8DEB&SW)H ]+/B#15;:VKV ;#'!N4S\OWN_;OZ
M5S?AKQ1>>(;:UUV/4M+327$AN[9SB2W7)$1WYQDX&0P YXJC\.8=&73]:OO+
MLA);ZQ?,)RJYB1I#@AOX5*_@17-:9J!LOA9X+U 23?8+"\W:D;9 [PH1*H=E
M(/"LRMT/0$=* /6DUK2I++[8FI6;6N_R_/$ZE-V<;=V<9SVI#KFDBT>[.J67
MV9)#$TWVA=BN.JDYP"/2O+/$\?ARX\%ZWJFFW4MY'?WUE))=38"2R+*@8QC:
MHR$'S%1^.0:V_$EU8>&/%NCW\CG3- GM9X_M=E"GEQW#LA#/\I W*N V.W7&
M: /0X)X;J!)[>6.:&0;DDC8,K#U!'!J2N?\ !MEIMCH 31_M!T^2:26)I\C?
MN.2RC PI)) P!W'!%=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !116/XC\01^'+.WNY[2::"2XC
MMW>,J!"78*K-DCY<D9(]: -BBN?3Q7 =;UC2Y;62&72[9;IWD=0LL; D%><X
M^4@Y Q5,ZM9S^+M'2YT:\BU6;3IIK=WD4!$^3?&0'QNR5ZC [&@#K**\EUO7
M[WQ#\,I=4OK22VDAUB-(_*DR-JWHCVX7EL*,<CG/%=[I/B4:CKM]H]QIUS87
MEK$DX69D;S(G+ ,"C$#E2"#0!ND C!&139 YC81LJOCY2RY /N,C/YUD>)_$
M*>&-).ISV<]Q;)(J2F$J/*#$#>V2/E!(SCI2W_B*VTRZGCND9+>VLC>W%SN!
M2) 2 ".N3AL8'.TT 1^$?#\GACP]!I,EVEWY+.5E6'RR0SL^"-S=V-;E<XOB
MQ8]0TVTOM/N+/^U%)LGD92'<+N\M\'Y'(Y Y!P><\56_X3NT_P"$>763870@
M^W_8)$RFY'\[RL]<$;O0]* .LHKESXQ=_$=[HMKH6HW$UE+ D\BF,(J2YQ)R
MW*@#..O7CBMC7-6CT+0[W598)IXK.%IY$AV[MJC)(W$#H#WH Q+'PKJ]G;-I
M[>(_/TPE_EELE-QAB209<X)Y/)3-=1##';P1P1*$CC4(BCL , 5REIX[CGUC
M3["YT>_LUU2(R:?<3[-D[!=Q7@DH<=-P&:?'X[M)?#^GZR+&Z$%Y?BPV$INC
MD,QAR><$;AV)XH ZH@X., ]LBL+PSX?F\/IJ2S7L=U]MOI;W*P&/89#DK]YL
MC\JJ+XS:7Q!>Z1;Z%J,KV%Q%%=3 QA(ED7<)/O<KC!P,GV'>;3_%G]IV,5_;
M:=+)93V;WD$R2H0RJ5^1N?E<ALX]CSD4 ='17,V_C2TN+;PW<K9W(AUX@0,=
MN8R8RX#C/HIZ9K!U/Q3#H_A_QKJNC:1-%J%C<%;G[1*"&E\M,28W,-H4KP.N
M.@R: /1**@M)99[6.2:!H)&',;,"1^(XJ+5M2BT?2;K49HYI8[:,R-' F]VQ
MV4=S0!<K%O-$O+[7([F?5Y#I4>QQIH@0 RHVX,9/O$9VG;ZJ/<56C\86L-[J
M=IJD#6$NG6:WTS,X=/);=R".<C:01CTQFGQ^*0EZL.H:9=V,$EH]XMS( T:H
MN-PD(^XP!!QS]: .@HKGK7Q3Y]YI\<NEWD%KJ$#SV]TP!1550W[S'^K)4Y&?
MIP>*H0_$/3)M0TR!8F,.J$K:2I-&Q9L;E#IG*;ATS]#M- '88 Z#K6#XC\/S
M:[+I+PWL=K_9]\E[AH#)YC*& 7[RX'S'U[5A?\+/METV'5I=#U2+2#<M:W%Z
MXCVV[B0Q_, Q)&1R1D#.,D\5<MO%MW_PDOB>VN]/D6PT>*)]T15V(,;2%MHY
M)88  ST]Z .NP/09I2 >HKF[3Q:)]3?3IM,N8KS^SQJ,<09&+Q$[=O4!7!(R
M#QSU-4M,^(,&HC0ISI%];V.LMY=M=2E-HDVLP4J&W<A3SC&1Z<T =B0#U'2B
MN;E\7QC%Q;:;=W>G_;?L37,"AL/NV%@@Y**V5+>H. 1S536?B'I6C"YFD7S;
M2SN!;W,B3)O1LA21&3N8*3@X]#@'% '7T$ ]1TI 0P!!R#R#6?J^L0:/';>:
MKR3W4ZV]O"F-TDAR<<\   DGL : -&BN5N?'%O8PZVMYI]TE[H]O]JGM49&,
MD."?,C8D!EX(/0@CITSIZ%K4VM1R3/I5W90;8W@DN"F)U9<Y !)&/0@'I^ !
MK@ =!B@ #H.M<YJWBPZ;K\6B0:/?7M[-:O<PB$QA7"LJD;F8;?O=6P/3)(%5
M;'X@Z7?:/#>>7);W,EV]BUG<LL;Q3H"75R3@  9SGH1W(% '6X&<XY]:P=)\
M/3Z;XDUO5I;V*9=4:)_)6W*&(QH$'S;CG@>@YK'_ .%EZ<-.FN?L%U));ZA'
MI]Q%"R2;'<@*P(;YE.>",GM@53\2Z]JES)X=MI-"N[6*\U4PSVTTL1,R*DA"
M'#$$$JK>AQCZ@'H1 /49HKCK+4K'P[9ZI::+I=W<VVF.9;N..8'R69?,:.(,
M>2JD':, 9 '/%/N?'UM]HT^'3-+O=3;4;%[VT:W*!957;D?,PP?F'7'IR>*
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M[V\<J_)_K2W+-@?0=>PZF@#TBBN:?QKISV6FS6I6234;07D$<TR0XBP.6+'
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MW2LDBAA\GR@!AA/P&!4MYX3UVY\'>*]*6UA%SJVJ27=OF<;0C.C?,<<$!#P
M>HKTFB@#A_[,\3Z-XNU/4M(LK*\LM9$4DL5S<F)K29$"$\*V]2 .!SD47.E>
M*-&\53:MI,%EJT.H6T,5Y#<3?9V26,$"12%8;2#RN,\5W%5+O4[.QN;.WN9=
MDMY*8H%V$[V"EL9 XX!ZXH EM$G2TB6Z='N-O[QD7"[N^!Z>G?%<=;Z#K.BW
M/B6ULH(;NSUF>2[@D>7:8)9$"N) 1DKD @KD]L=Z[>B@#A1X3O=+O/!4-A$M
MQ9Z!'(DTCR!6?="8P5'KDY.2*[2\MEO;*XM7)5)HVC8KU (QQ^=344 >81>&
MO%J^&= T"2RL)/[$U"VE2[^UE5GAA?*_+M)4[0 >O/3/:SJ_ACQ%(GC2QLK6
MTDM]>3S(KA[C:8V,*QE"NWGE>#G&#[8KT:B@#C;?1-:M?%VDZN(+1XUTC^S[
MI1<']TP=7W+\OS @$=N:R#X/\0?V)=M;BV@U2#Q!+K-DLDFZ.0,S?NW(&1E6
M8'WQS7I-% ')S0:_J^B3+JVAZ:5F:-'TLSB56CS\Y+E0-W3:,8&T<\\2^#/#
M]QX=MK^VWS1Z<]QOL;.:;S6M8]J@KNR>-P8@9. 1SUKIZ* .9\1:3?W_ (E\
M-7MK"CP:=<R33EI IPT31@*.Y^;/;I7.WOA/7+GPEXRTM;6$7&LZA)<VQ,XV
MJC",?.<<$;#TSU%>D44 ,A+F%"Z;'VC*YS@^F:XS3O"U]/H_C#2]11;>+6[N
MXEBDCD#E4EC5!D?WAMSCI[UVU% ''Z$OC06*V>JV>F0O:0,@NH9S)]K<*0IV
M%1L&<$Y)Z8Q@\8A\*S:1%K6I6ED-'LYM(N%O;"*??!+<%<AXU'"@ ,,X!.1Q
MUKO-2UG3](-J+^Y6$W<Z6T ()WR,0%7@=R?I4FIQVDNEW2Z@NZS\IC..<% ,
MMG')&.W>@#A]"TF]\0^%O R7-LMO:Z9':WS2^8&,K)#B,(!R,[@3G&,8&<YJ
MQX8TGQ7X?5/#YM]/ETF"9C!J?G'S1 6+!#%MY?!VYR!WYQ@]9HJZ>NBV1TI0
MNGM"K6P 8 1D K@-R!C'':K] '"^'](\5>'9[K1((;&71WNY9[?4&G(D@CD<
MNR&+:=S LV#D#G)]*T]#TC4],\6^(;F2*W;3]1GCN8YA*=X(B5"I3'JN<Y_^
MMT]% '->,-"O-7CTJ]TUH_M^E7R7D4<K%4F !5D)P<95C@XZU'#H][-XGO?$
MT]J(IVTY;"WM?,4L1O+LSL.!DD 8)X&>^!U-% '.^!=*O="\&:9I.H1HES9P
MB)S&^Y6QW!_Q%5]2T;4+;QU;>)]/B6Z1K$V%W;%PC;0^]'0G@D$D$$C@UU5%
M 'GEUX+U--,-S;);R:E+XA36Y;=I2J85@/+#XZ[0.<=<UH1Z-K"^)O$.I26D
M)CU#3H;:(),#^\0/G.0,+E^#UXZ5V=% 'FECX9\4>'[;PY?Z;:V=W>6.F+IE
M]8S7&Q94!!5XY,'!!!ZCH:V;_2=>O=:\+ZC-;VS-87$T]TD4N%C#QL@1"0"V
M-V23C//3H.DT[6=/U:2[CL;E9FLYO(GPI&Q\ XY'/!'2KU !7":%I/BO0)Y]
M$AM]/GT=KF2:VU%IB)8(W<N4,>T[V!8@'('3/I7=$@#). *I:7K%AK4$L^G7
M GCBF:!V"D8=>&'([4 <=<>&M9FT_P =VZVL6[7=_P!D)F&!N@6+Y_3D9XSQ
M5S^Q-5?Q!X0O3:QK#I5I-#=?O1G<Z(HVCN 4SVX-=G5:_N;:SL)I[R0QVR(3
M(XS\JXY)(Y 'KVH \P\+Z3>^)OA59:$ULL=G->.TMT9 1Y27;.0%Z[R5V^@S
MG/:MK5/!E]KFH>,X;@)!9ZW:6\-O,K[F1H@W++Z$L._0'I6UX<U3PG%%!IN@
MWMDB2AI8+>.3&\'DLBGJ.<G'KFNDH X\:/JVN77AV76;:*U.CRFXF:.4.)YA
M&4&S'(3YBQW8/ &.]5[;1XKCXE7%]8WB2:<\$5Y=P1D,IN@&CC;(XY3)(]40
M^E=NRAE*L 5(P0>]8\<.@^#=)"V]M!IUB9E7;!"<&1V"C(49R20,T 8;:%JP
MU?QG<BUC,>KV\45I^^&<I$T9W>@RV>_'OQ4%OX<UB*+P&C6L6="0)=GSAS_H
MYA^3UY.><<5WE% '">%])\5^'T3P\UOI\NDV\I,&I^<?-$&XL$,6WE\';G(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"L+Q-K<VD+IMO:Q%[G4;L6L> #M^1G8X8@$X0@9/4CKT.[6-XF\-VOB?2TL[
MB:>WDAF6XM[FW;;)!*OW74^O)'T)H Y36?$'C'0_#FMWD]O#&+2XMQ97%PB%
MIXI'56#+&Y"LI;[W0C'%7C?^)O\ A-KCP[_:=B$FT\7T5P+,Y@Q)L*!=_P W
M4')/KQ5J[\$OJ7AVYTO4==OKJ:Z:(S7CI&'*QL'554*%49'IDY//IH'PZQ\4
MCQ!]OD^TBQ-EY?EKLV[MV[USN]\8XH Y&T\8^(K_ $CPE+"^GQW&J7D]E<EX
M&*[HQ*-ZX;I^[SM[],BJFN:SK$WA3X@>']<D@N+G3;#S(KN"+RQ-%*C$97)P
MP*D=:EU7P\?#TW@W2K2_N76WU6:X-PT(8Q!TE)+X&-I=\<XX/7O757G@V"_T
MO6[:XO)3<ZTH2[ND50VP+M"H.0H SCKU)YS0!7M]8NK[7H?#EE.+7[/I<5W-
M/Y8=B7.U%4'C'RDGZ@#%8C^--<_X1PZK)]GB&D:NVGZT$A+!HU<*TT>3D8#*
MV#GC/I732>% -4LM6M+^2WU.VM?L;S>6K+<0YR%=?4'D$$8.>W%5;]-.\,:-
M_8_]FW^IMJK3[UC@,GGRODOYK*-J;BV,G  ] * *GBGQ%J]AH?B;5]*N+;R-
M-A40"6'>&D W2$$,,C#*![ALYI9=3\2Q^,+31OM]CY6I6$MQ&_V4YM6C9 <?
M-\^0_?'//^S5U?!5NWP[C\(M<R10M;""::/!=B>7(W9Y+9/XU<?PV9/$&GZR
MVH2F>RMGMD3RUVNK[=Q/?/RCH: .;TWQGJEQIUA93(DVJW&J7>G--!&H#+!O
M)=49@-Q"C@G R3SC!;J?B#QCI&BRRW5M;1.NJV]M;S3HI-Q!*ZKR$<A&!)!/
M(/8"M"3X<VLNDO9_VI>QW"ZB^IVUY%M66WG<DMMP,%3N(P1T-6KOP6VH:/'9
MWVMWMS<?:8KF2[=(P[M$P9%"A0JJ".@'<\\F@#'U'6_$%LWC#2IM1@,]EI2W
M]K=P6WEF/<),KM+'.#'P??O4>K?:[7X)PZA]IWWMC8V]];S;-I1D5& ]^ 0?
M4,1WKHYO"4-UJ^J7]Q>3/_:=B+">(*JJ(QNP5.,@_.WKUJAJ?AF>3P9%X/CN
M[FZ6=8X);J95'E6ZE0WW0!G:NT#J2<G@$T =79W O+&WN0I431K( >V1FN-\
M4_\ )4_ 'UU#_P!$"NJ@TZ2#5I+M;Z<VIMTA2RPOE1E2?F'&<D$#KVJAJOAD
M:IXDTC6S?S0RZ5YI@B1%*MYB[6W9&3QZ$4 <EJ7B?Q3%8^,;R"\T]%\/W!,:
M?9&/G((DDV'Y_EX8\\Y/ICGKO$/B(:'X/N==\D.8X5=(V; +,0%!/IEAD^E4
M9_ \=Q9>([5]2N/+UYRUR0BY3*!"$XX^50.<UKWF@VNI^&I-"U#-Q:RV_D2'
M[I88QGCH>A^M &/JFIZWX7M]1U;4)K:^TFVTYISM3RY1<*?N*!D;"/4D@]S5
M:ZU[6-&G\-W%Y/!=6NLSI:3(D6WR)I$+(4(.2F000V3T.>U7M.\&B'3IK'5]
M7O=:MWMVM42[V )$PP1\@&YB,#<<GTQDY?8>$5MDTN&[U&>^@TD[K))D4%6"
ME%9R!\Y520#QUR<G!H Y1_%OB>'P]?:Y)=6!BT[6FL9+=+4CSXQ<+#G<7.PX
M;(Z].IZ#2OM:\2S:[XKL+.^L;>+2K6"YMW:U+L=RR-M/S\YV#)].@[U=D\ Q
M2^'M0T9M5N?(OK\W\D@1-X<RB4@<8QN4=NE7?^$4_P")EK5]_:4WFZO;QV\P
M\M=J!%905]\,W7/6@#(M?%NHZVNDVME#)%<W>CQ:G,T"1N4,G"JHD8#&0V>I
MZ=,YJ33=?\07EYI.@ZI;Q:9J\UI-=7CIMD 2-U1?+&2,MN#<YP 1WR'2?#V-
M+;1CI^M7UAJ&DVPLX;V%4+20#'R2*058< ].O-6=2\#17@TVYMM6O[/5M/+F
M/44*/))O^^) 1M8$\XP .,8'% &+K<GB=+KPA;ZAJ%O!<RZI)%-]ECW1R@1R
M,CD'G.%!V],GV&+5]XSO=$U#QDU^(9[31;*VN+=(HRC,9!)PQR<Y*J,\?2M>
M]\'QWEKIJG5+U+RPN_M:WOR-))(596W KMP58C   P,<#%#>#;.?4M;N;R>6
MYAUBVCM;FW<#;L0,%P1SGYVYSU]* *-WK>L:'J?AX7MQ!=VNL2?99-L.WR)R
MA9"F#RAVD$')Z'/:L)/%OB=/#XUR:ZL&BMM:-A-;I:D>=']I\G(8L=I&00.>
MG).<#K+'PH+<Z8+S49[Y-*!^Q"9%!4[2@9R!\[!20#QU)P3S5)O ,3>'9M%.
MJW/D2W_V]I-B;_,\WS<=,8WCTZ4 :/C2^U72_"M[J6CE#<V:^>T;Q[]\:\N!
MR.=N2/<5B?\ "9F'QBUK+>H^C3Z6;RVF2'GS%4.R;NY\ME<#'0UW!0/$8Y0'
M#+M8$<-Z\5RL'P]T:#2-'TU1*T>E78NH79LLS#(VL>ZX(7'HH':@")]7UZQ\
M0>$M-O)K9O[2CN#>*(<,LB1;P%.[& 3CIVZ\UQ>JR:C/\+_'\M]?FZ*:E<0C
M=&%/R2(H.1VP ,5Z9J7A]=1\0Z1JYNY8GTPR&.)54J_F+M;=GGITQBL>\^'U
MO=:7KNF_VK>QV>L7#W$D0"'RF=@S[3MSR0.N<#.* )K'5=8@\?OH>H7%M<6\
M^G&^B\J$QF%ED"%,Y.X88')QTI?$^K:E8WK0VUU#;Q"QDFC$<?G3R3*> 4P<
M1 =6XY(&1WOCP\3XJ@\027TC7$5F;/RMBA&0L&)]<Y4=Z@U/PDFH>(&U>/4[
MRU>6R^PW$4.PK+%N+#EE)4Y8\CUH P(?%6O:G+X*%K)8VZZ]823S[H&?RW6)
M7ROS#(RW3CIU-0OXG\2KX.U344EMYKK0]3EMKPI;_P#'Q;QL-[JN?E<(<]QP
M:VM.\"IILGAUDU:[E_L.%X8!(B8=74*0V .BJ ,?CFD6&U\$6MX9EU'4UU?4
M))FC@M/-(DD&2,*.$.,<_G0!J:?J<FJ:W,UI<I)I<-M$=RJ#OE<;QAO0(4/_
M  ,5GW&JZKJVM:[I6CW$-K-I4,6TRQ[Q+/(A=0WH@&T'')R>1CF[X.T"/PUX
M7L]-2/RV5=\B[MVUFY*Y[A>%'LHJIJ?@W[5XC;7--UF^TF[GB6&[^S!&6X1?
MNY#J0&&2 PYQ0!%!K.J:IXADT 30V-U9Z=#<WDD2>8/.DR J;OX!M))(R<CI
M65I7CN^U:32='>.&VU:YO;RSNI44LB?9A\[1@]VRN,YQD]<<]!+X3ABUBVU;
M3+N6RO(K46;G D6:('(#@\E@>0V<\G.:AE\#:?\ 9-/%K//;WVGW,EW#>C:9
M#+(292XQA@^XY'';&,"@#G-;\::[H]CXILPUK)?Z*UM)%</"=L\,S #*@X5P
M=PST.!Q5S4/%.N>$_$3PZ[):7VGW.G7-] ;: Q-"T"AWC.6.X%3PQP<]JA^(
M&AK9^!/$,RO-=:IJ;0>9(D>7?8Z!515!P%4$XY[DDUTR>';?4+H7^IW']HL;
M1[2(,@1%BDQOX'\3 *"?0< <Y ,S3M1\6W.HZ9*+17TZ\MV:YDD6(+;.5W(R
M!9"SJ3P0>>AR.E9>B:_XMU#P6/$DNH:.BO#(HBEA,:1N)]OF%RW0(&^7') Y
MK<T#P9+H(CA7Q!J-Y9VJD6-M<["MOP0.0H9\ X )P/3IB-/ 5LO@A?"_]I79
MACE$T-R @DC<2^:#TVG#>HZ4 8>H>)M6FTKQU9PWLJ-I6GI<VEV]MY<V'CD8
M@J0.\?!P.#^-:$>JZMI,7@BT%S!+;ZBZP3[H,/M$#.,'=@?=].:OCP-#)<ZU
M-=ZM?7)UBR6SNPPC4, K*&&U1@@.< <>N33_ /A#BR:")=7NY7T:3S8G=$S(
M=A3#  #&TD<8]<T 94WBG5[WPUKOB/3)(%BTN>X6*TDCR)XX#A]S=0S;6QC
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MTOY?E[@Q&X< 9&>2/3(J[9^%!9^(+35QJ5S+);6']GA)$3#Q[@V3@#YL@<C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+:"+..S&D68M8I?.CA$0V))G.X#H#GG-+#XFTBXL9;R.Z)CAG%O(AB<2)*2
M$,9&X,21QC/(I5\1::T+2>9,"MQ]E\MK>02&7;NVA"NXG:<\#&,GH* -4
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M)Y4BQ;5MY-SLR[@$&W+_ "@G*Y& 3VJ2W\4:-=:=+?17G[F*?[-(K1LLBRY
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MR*)0JK] .E6:IZ5JMEK>F0ZCIT_G6DP)CDVE<X)!X(!'(-7* "BBB@ HHHH
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M^ O%OA^VL9YKN]UF^BB)@;R@3.<.9,;0%QGDY^7@<C/KK E2 2"1U':LK0=
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MH-H)]\8&3Q75PVT-NTC1)AI7WNV<ECZDGV 'L !4M 'D@T_4/^%>+9_V9?\
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MPS*ZNB+N7H<_NP<'UZ\4 <UHVO7'A+3?%%[;Z3#+I=MXBG%PPG$;(C-&O[M
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M!..3M_#W[3>&/#OB?0(X-&DU6QFT&T;_ $>01.+LQ Y6-N=@ X&>20,8&<@
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M?B#1[;5_LLNFBXO]6:^4R%W58G*[T. #N"J<'ID]J .OHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JR:?91WCWD=G;K=/P
MTRQ*';ZMC)JS10 4444 %%%% !1110 4444 %1SP0W4+PW$4<L3C#)(H96'N
M#4E% $5M:V]G L%K!%!$O2.) JC\!4M%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(K-KN20+;JGF%R#@+C.?RJG'X@TJ72X=3CO8WL9G5(IUR5=F.T 'OD\#WXH
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MW-U-/821R7$C9+%58 L>.PP!@#@<=?10 R*030I*H8*ZA@&4@C/J#T-/HHH
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M1&9.1N"@]STKG8()(OA=IUNME<K<)XA$[1"V<.J"]+[]N,XV8.?2O21X9LB
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MUG+9K</'(OE"-X66(\'()Y'\1Z5Z=10!2TFWBL-%L[:*V-K#! B+ 7+F)0H
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MLKR.1WLI4$3-Y6%8E<#H1Z"NI_X1BS_Y_-7_ /!I<?\ Q='_  C%G_S^:O\
M^#2X_P#BZ ,?XJ))/\-=:M8(99[B>$)%%#&SLYW#@  FLB*S_P"$2\46OB&S
MLI[O2-6A2WN]L#RS64@'RN!@N(SR&7L>?:NO_P"$8L_^?S5__!I<?_%T?\(Q
M9_\ /YJ__@TN/_BZ .>VI=_$K69&BN?LEQH,4/FI$P#$/(656(QN"L#CWKF_
M"NJZ5.W@Z'4+Z>VDT>,Q6JR:?/%YK/'Y:!W9=@PIQP2&;!!['O[OP=IU[9SV
MLUWJYBFC:-Q_:EP<@C!ZOBLNR^'@AD/V[Q1XBU&W!!6WGOBJC!!!.P D@@=Q
M0!R-_!+)\/O'$4=E<FXN==DEA06S[Y5,L95E&,L,*3D>E=%<.L/CSQ#)<6%Y
M<6FH:+#Y7E0.5F">=O7>!A3AAP2#R,5TW_",6?\ S^:O_P"#2X_^+H_X1BS_
M .?S5_\ P:7'_P 70!S?@Q-1LM>73X[Z75M#2Q+6]U=0%+BS.Y0('; W9'/(
MW#;SVS-X\E@@\0^"Y;E<Q)JCD_(6Q^XDP<#T.#GMC/:NEL]#MK*Y6>.YU%V7
M.%FOYI5Y&.59B#^50:SX?_M?5-)OC>20MIDYGB14!#L5*'=GMACTQ0!P>IP2
M6E_XIU^TTHW6G7UYIZ*3;-( 8S^\N5C'+[<C&.I4GD51U)9Y+/XD1I;:K<-?
MV4!M9)K-PUP?)V\ *!G/&, \=.*]DHH X76KM+0>%'AT^1;=V(:^ALFEDL_W
M.T!4"DJ6SLR5( R,=,<I&K6O@R=I[?4X+BQ\5-=PF2SD?.9V92R@9=2I.=N>
M2*]C61'9E5U9D.& .2IZ\UD:]HL>LO9;=2N;"]M93/;2VSKN!VE3E6!5AAB.
M1W[4 <!<7VEZIH?CRXL[F>?5M6L&)LA9S1D!(O*0(KH&<DD9('<# [[&I72V
M6C^#VCTV00ET22\CLFEDLL0E01&%)#$_)D@@9/'2NKTK3?(D-S<:I/J=TH:'
MSI1&/+&1N4+&J@<J,YYX'/%:M 'B=Q_H_AB\BO+2]"#QG',1<VS;I8VG4@@8
M^8D=AGK[UO\ B"R^W:WXFUO3X9'M7\-26+/'&Q^TW#%BH4 ?.5&!D?W@.QQV
MGB/P^/$5M:0/=R6RVUW%=J8U!+/&P90<]LCFM@9"C)R<<F@#S>U0KK/PV*6T
MZK;V$T<Q$# 0EH$4*_'RY92,''(KHO'=R]IH5O*NG_:U%];[V\@S&V7>"9@@
MY8KC(]_4<5T]% 'C6J6=[?:7\1[6VLM4N9+P6LUNTUHRM.HBC!(^4#.0?E S
MQTKHM;T]_%'B'3[WP]NA-IIEY"UYY;1 -+&%BCY )(;+8_AQSC(KT.FQR1S)
MOC=77)&Y3D9!P?UH \NC@FUKP9X0T:"SN+;5],N[/SXWA93:^1Q(Y.,8(!P<
M_-N&,UKW^CWUMX\N+>TMV;2/$4"O?./NPR0D!\_]=(R$^HS7>44 >:ZO+!IG
MCC68]?L-6FTS5H(1:S60G=#M0H\+K$>I))&1_$:ZC2M4T[2[G3/#$=E=64AL
ME>WB9&>.-!D",R'(+@*>,GIUKHJK2P6RW<=W,0)%'EQEVX7<>PZ9/ ]>U %'
MQ/H:>(_#EYIC/Y<DJ9AE'6*53N1Q]& -<1<6>O\ BSX8:U?M;^3K>HVBP) K
M#E(N&4'I\[>:1[.OI7=:WI$NL0P11:K?:<(Y=[M9NJM(N""I)!XY[<U?MK>&
MTM8K:WC$<,*".-!T50, ?E0!Q%PX\4>(_"%_IL$\+6#RS79DA:,VZ-$5,39
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MK-K8+ITUL#;7B3S6UT6$5R@!RC%03U(8<$949% &/+\1?*\,ZIJZ:8L[:;J
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M=(U.TMXY(KJ"=V"298%'4["0P^;MWZT 7K[Q=J5GJ&CZ=_PC[/>ZFDY6/[4
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MXRS%.<],YRU5[;P%J]OX;TVQ%[9"\T74#>:?* ^V0%W)67TW*Y7Y<XQG)Z4
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M;I?DN)/LP81N Q"LH;G! !Y]:UJ "BBB@ HHHH **** "BBB@ HHHH ****
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M!X)XDEBD4J\;J&5@>H(/45Q4>J:]IGB7Q%I8NWU=X=)34+..6)$82DR+Y8V
M94E!C.3[FJNC:WJ^IZMX7%GK$EW;7EDUQJB^3&?(=0A .%!3<S,NT\_+QT-
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M* 5)/& #R035SQ7K>H^'+J-;R]U./2#:D?VK!;Q2F"<LW,ZA.$ VX(4#KGU
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M#'<0203(LD4BE'1AD,I&""/2G$@ DD #J30'4J&# J>ASP: .?T[P?8:<EC
M+B[GM-/??96T[JR6YP0,':&.T$@;BV,\=!5O1- M]":^-O<7,OVVY>[E$S*?
MWC8W$8 QG XZ<5J&1 K,77"G!.>E*2!U(% &9K^@VWB+3EL;N:>.$2I-^Y8
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M^TV]@[J88G!W#'R[L!CD*6(!QQP*)/!MC)%KL37=[LUO/VP;DYR@0[?EX^4
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MW,\S7]["+BU%I/'$R;)(P6/(93@_.W(P>:URZJP4L 6Z GK065?O,!QGD]J
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M+<7LB7>_[C2^4?(5_4%\X!XR!71SZ1;7.LVNIRQQF>U4B)A&-P)!!RW4C#'
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M;AUN9)6>2XD9,"5W)+';S@<X YP !VIW]BZ5Y21?V99^6C%E3R%PI/4@8X/
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MKRA[AD:)B//?(RS. =N.&'4U5FTS3H/ &LZI%;Q+>V/B=A:W'\4 ^W(N$/\
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M*+EW8 A<D]6(SSZ5S"6FH?\ "1ZU>II&L&WOM 6".6ZP[M*&DX(W':3N7Y0
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MS)5!XM@%Y&3]X],< G-/O;C49]=TU(]!OHM(-I-$AM46.4.' 5';(,<950P
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M3PW.,&@#I7\<:#'I=UJ3W,ZVEI=?9)W-I-F.7(&TC;D<D#.,<BM==2MGU+[
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MJ]B$B;S'^I?(^D:GO72C5I+[6/&6ESV5K$+&UA*RQ\O,)(Y#\Y('3' [9/-
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M,,:QQH,*JC  I]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-H0 59F#9W^KGCTQSWKIJ* .(TGP'>:6OA1/[7@D7P^LJC_1"#.'0IS^\^7
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M/N&#?9#^_ C:/'W_ )>&/KS7922)%&TDC!$0%F9C@ #J32JRN@93E6&01W%
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M9YKBV^RSO+/)(98^1AMS'<<,1N/.#C.*2/P;H<=MIUNMM-Y>G2"6U!NY28W
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MDZ;=2W:06,$4MO$]VTCQ;X=Q4OG)!(R5)(Y(Y%=%+<7#>(K#PQ;R2" Z3]L
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MBCW+&&'*[B<\8.%([UQ_B75M:TK3?'6FVVIWBQ:9%;7-E<^9NEC$N=T1<Y)
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MU.<P3>9JB".\;[5+^]4# 'WN, D<8X-:&GV%MI>GV]A9HR6UN@CB1G9]J@8
MRQ)X% 'G.LSZK:ZCXF\.0:E??VC>I%=Z&XN&W#=E60'/W492Q_V6]A6A8:S)
MXF\-S:S8W=W:I;:25(29CMN2I9PP;.63 &3_ 'SW QVDNF6<^IVVI2VZ->6T
M;QPRGJBOMW ?7:/\DU#'H6FPZ9<Z=%;>5:W3RO,D;LFYI&+.<@Y&23T/MTH
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MGK<V/BKP/97\Z#4X?#\\4OF-DB4B' /J<J?K@T >B?VKIQO_ +#]OM?MG/\
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M634+**2..2\MT>52\:M*H+J!DD#/(QWK@K/PY!XCU#QU;A@=#U0P""2/E/M
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M6(J#CKDAL9[YH [;P_XDTOQ-8M>:7=13QK(Z':X) 5V4$CJ VTD9ZBM:O//
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MB@#H**Y:V\<V=UI?AW44L[H6^N3+! 3MS&S!B-XSTPAZ9KIY&9(G9$+L%)"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]JEL<L0ASCC+8Z#)]%HH 1260$J5)&2I[>U<K-I6I#X@7FM):J]F^D+9)^]
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M=YYND2X#;?,CV *2!N(ZGI[9KL:"<#)H \Z@\(:Q;^#=3\%B.)[&YEE6VO\
MS!^[@E<NP=>I==S8QP>.16E!H&HV?B37[N&T5K.[TV"SM?WHW;HPX^;T!WCG
MGI72Z7K&GZS%/+IURL\<$S6\C*"-LBXW+R.V:O4 8?@W3;O1_!VDZ7?(J7-G
M:I!)L;<I*C&0?2MRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N9\;ZQJ6AZ59W.F-;B26_M[9U
MG0ME9)%4X(/!YZX-=-6/XCT!?$5E;VKW4ENL-S%<AHU!):-@RCGMD#- ',7'
MB_5?#]WXGM]4DMK[^SK2"[MGBA\D$REDV,"QX#*.<]":FO?$/B3P\=0U'4M/
M>XT:WT^2Y:1Q%&Z3IR$ 1VRK#U&1W)K3N_!=IJ6I:M=7]Q)/%JMFEE<6^T*H
M1=Q!4]0V6)SFH]-\%>1I\UAJ^M7^M6CP-;1Q7>P".-A@\J 6;'&XDGTQDY %
M>^U[2X1JU[/:76E)I\ES=JB;'CD5=P$77<I&1\QSP#GM573-5\67-]I%U_9_
MG:9>PE[K<8D%N2FY#&1(68$\'(SWXZ5;T3P9_9=J+.]UJ^U6QBB:"VMKL(%B
MC(VD$JH+G:2N6/ )Q4>@^"6T-4MO[?U*[TVW!6SLYRFV $$#Y@H9\ X )P/3
M(! !F>'O&%]JPN$693K%M82R76BW$'DS1W(V[0F?O1_>&[GJISSBG:1XON=5
MTO4[BQU&UEO;2R+R6.H1?99+6X&<B0'&(_?V/S'MJ_\ "&B=X)KW4YY[JVL9
M;*WNA&J2JL@ +LP^\PP,< =>,U#J7@.VUM;UM5O99KFZL/[/-Q#&L3"/<'R<
M9!;<H/IQ@ 9.0"C:>*-4;6=5TV.YCN%ATA=0M[F:T9!OW,I&W*[D.T$'CZFJ
M2:SXUD^'\7BJ*\L)2]A!>&S2S.[;C=+AMW)*\@8ZC'O6ZO@J0ZI)J<VO7TUW
M-IYL)6>.(*ZY)!P%&"-QZ?CFIXWM? OA;3K"87]_;PA+.(P6IFD(VX7<J#I@
M8SCTH L:=JSZOK"/87*2Z6EE',[A,^8\G*8/;"#)'^TOO61XJDU+_A.O"%M:
MZ@;>">6Y+1^4&!98&P3SSP2,?CS6IX,T"+PYX<BLXX/(:1WGDB+;O++G(3/?
M8NU![**FUOPZFLZAI=\M[<6ESITKO%)"%.0ZE&4A@1R#U[4 <]-XGU>^\/Z_
MK^ER0)'I-Q/'%:R1Y$ZP??W-G(+8;;C&.,YKIXM<MY?"J>(-CBV:R%[L_B"%
M-^/KBLIO!,*G5[>UOY[?3M8=I+RT55.6<8D*,>4WCKU[D8-=%]CMQ8_8O)3[
M+Y?E>5CY=F,;<>F.* .1TS5O%M]<Z/>1V(?3K^$O=%Q$%MMR;D9")-SC/!!&
M3U&.E8UCXN\3/H&B:Y<W%@T-QJ_]GSVT=L1O5KAHMP8L=I&!@8/3DG/'1:!X
M)?0#'!'K^HW.FVV?L=C<;"D'IE@ SA>P)P..X!$4?@&./P]9Z,NJW'DVE^+]
M)#&F\R"4R@'C&-Q/;I0!G[[BV^*NN7-Q>!K6#1H)9$\D',7F3';U]CSWHD\6
MZM9^$M&\6N8'L+R2#[18K'CR89F"H4;.2R[ESG@\X"UTD?AL)XHN]<DO'E:Z
MM4M)+=HU\ORU+$8[YRS=2>M4;'P/;V=A:Z2U]//HUI<+<6]G(H.TJV]$+]61
M6P0.O !)'% &;!K_ (ADU7Q')->6*:=H-UF5$M6+S0B 2%0=_P K#/7G/H,8
M.EIE_P"(+JWT?6GFLWTV[MC<7L&T@P*R;T\HC[V.AW=>HQTJ]IOAF*POM:N)
M;E[E-7D\R>&1%"@[ F!CG&T <YJEX>\%?V!Y5M_;>H7FF6V?L=C<;"D(.0 6
M"[G !P QP/3(! !GZ5KWBG5ET+5K33C+INH%7N8G\I5@A<95T;S-Q*\9!'/.
M O2NC\27MW8:8DUI+;0DW$22RW!X2-F 8J/XGQPJ]R1UZ')T/P,-!N%AM];U
M%]&BD,MOI<A0QQ-G(&_&\J#R%SCIG-:GB3P^GB&TM(_MD]G/:74=W!/"%)61
M,XR&!!&">#0!QE]XUUNV\*^++JW>%KG1KQ(H9+FU93)&ZQD;DR,,-YYQV'RU
MMQ:EKZ>-+K0)[VS?S]+-];2I;$?9W$@3:1N.]?F!SP>#TIEW\.XKNSUVVDUJ
M_*:S)')<%EC)#*%&5^4<G8/8#H!6E=Z2MCKK>*Y[JXEDM=.>V:WA@#;X\ASA
M1\Q8E1C'TQ0!DZ%XFU36-(TRW>6*+7#?26VHQB+*P^5GS<#/3&S!_P"FBUT?
MB.]N]/T66XLI+6*4/&IENFPD:%P&;W(!.!W.!63X8T^UNM<U3Q5#93VIU%8X
MXUN(S&[*JC<Y0\J6.T<]1&I[UI^)- C\1Z9':/=36LD-Q'<PSPX+))&P93@@
M@C(Z&@#EO^$UU.TT[QFX@:^DT-8Y+7S(#$\BO$'^=>.AR> ,CM5ZUUC6IO&,
M&DVNH6=U8RZ6+YKEK4L58MM505=0%;.X9R<*1GN*FN>&IM&TWQ%J4%]K%]<:
MM%##<+;HAD3 $9E554$E5).T=<8QSD1>%X]0&H0KI6OWE[9,6^T)=:(MJJ#:
M<,&$<>6W;>.>,Y ZT 5])\7>)&\'V/B2^GL95OBEK%:16Y4K.]P(U<L7P5 )
M.WCH/F[UHWGB+Q)X?BU:ZU'3S+IT<,1L[B8Q(_G/((_+94<Y7+*V>.,@GO5^
M#P'8+X%/A*YN;BXL@#LFX25#OWA@0,9#<@X[=Z6/P2MUHMYINOZQ?:RMS#Y'
MF7 1#&F0?EV ?-D*=QR<J* *=QJ?B^P;59'M4-C%ISW,%U=1Q@QW"Y)C*1R$
MLA'(/!'<FJ-MXB\3M+X/=KO3V3Q!;8:,VS?N'$'F[P0WS=#\O Y'UK:L_!]U
M%I=U97WB/4-1:6W:UBEN%CS#&PP<!5&YB/XFR?URZ/P:L?\ PC>-1F_XD"[;
M?,:_O!Y9C^?_ (">V.>: ,:W\8ZK:6FH65YY-WJ,&MII4$T<002!U5PQ4L!D
M*6&-P!('3-1Z]X@\8Z#X<\27TEM$D5E$DUA=7,<9:0'AT9(Y,9!Z-T]JU;GX
M?6=]:ZS!=7UTW]IW:WWF1X1[:=0H5XR.F-HZY_6G77@B74O#5]I.JZ_?7TE[
M&(9+J1(U98P<[455"C/<D$GN>!@ 8FJ:[#XTET*ZO+5H[O2Y+R"2*WP;9U=4
MV\L=XPX.3CD=.U.^&,U[=_#_ $F\OKLW,MQ#YI9EP<DDG)[DGG-:?_".E_%%
MMKTM](T\%FUGY8C4(Z,P8D]\Y4?X4[POX=3POHL6EPWMQ=6\/RP^>%S&F20O
MR@9QGJ>: ..2/Q _C+QT^@7EE;312VLF+F R^:PMEPG##:#W/)Y[8YMZ9XUU
M'Q1!91Z9;R6\\NE17\QC2-RCR,RA0)'4;08VSU)R.E;LWA0_VOJM]::I<VHU
M946[C5%8Y5-@,;$94[>.<_A574/ =L]UIUYHFHW6AW=A;"SCDM0K!H!TC97!
M# 'D$]SWH Q&O?%%WXF\$QZJZ:9=W$-X]U9QA9$$D:@!LACG*L<#/&>YINJ>
M+?$&FZ3XHC,UN^KZ1=(8(UMLBXMG4,I"YR6VB3)' *'M73W/A"&:YT:ZCU&]
MAN=+,NV8%6:82C]YORI&21G( QVQ5N;PW83^*8O$#JQNX[4VVW/RL"20Q'J
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M),;FP,9. !GZ"N3A^'L5OHFGZ3'K%X;73[U+RV#I&2A1RZI]T9&2<YY/'(H
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M&5SG/<5+;>(]=CLO$=I/=:>]YI5_% +R5?)C\F18V+%<GYE#G SR0/QUI_"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *R];UN#1+:%GC>>YN9EM[6VCQNFD/0#/ & 22>  36I7%^,--CG
M\6>%]2OH%FTJU:YBN Z[DC:1 $=Q_=^4KD\#<,T =;:FZ, -XL*RGDI$2RK[
M9.,_7 ^E3URO@:PFT^VU>-=ZZ8VI2/IL;9PD!"\*#T3?OVCICD<$5U5 !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>josetrevejo-tarsussepara007.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ JEJFJVVDVR37);,DJPQ1H,M+(QPJJ/4_D.
M2< $U=KE_&NC:AJ4&DWNF()KK2M1CO1;,X7SU 960$\!MK'!/&10!-)XSTZW
M351=P7=O<Z7!]HN+5XPTGE8)#KM)#+P>0>,<XJUH7B*#Q CR6UE?P0B.*6.:
MY@V),KKD%#GYL=_P[$&N9UK0-2UF^UW6H].FBEGT%]*M;61XQ)(SEF+,0VT
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M[S)DX=AQC.2,U2\<VCB^\,ZR!F'3-35KCT2*13&7/L"RD^@R>U3ZQIVH7'Q
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MM5#P\M_I][H+Z]X=UE&L818VMU+/;2Q0&3:F2(VW'.%7)!P.O<T >EDA022
M!R2:YY/&>FM]@E>*YCL=0E$-I?.B^3*YSM P=PW8."R@'UY&=K4+07^FW5FS
ME!<0O$77JNX$9'YUY_!X<UJ_\$Z-X2U#3V@>PGMUEO5D0Q-% X(9,-NW,J@8
M*C!)STY .DM?&MC>ZS-IEM8:I++!=_9)Y%M3LA;9N#,<\*0>M;=_>Q:;I]Q>
MS+(T4$9D<1H6; &3@#K7/>%=/U"RU[Q//>6,D$-]?BXMY&D1@ZB)$Z*Q(.5)
MY[5MZW%-/H5_#;PM--);R(D:D LQ4@<D@=^YH Q]/\<:?J5I'=166I1P31PO
M;/+;[5N3+G:D9S@L,'/0#KG'-5]3\;(- \226-I<IJNC6[M-:RA-T1,9='/S
M%60XSP2>#Q63>>&]:F^''ABWATZ)]5T0VTKV%RZ%+@QQF-TW E>0Q()]JNW%
MEJ6H^"]?BA\+1:7<WUC);0VD;P^8SLC+N=E(4+EA@9)X)[XH C\.WEO97^A2
MW7]LQ7NM68B"3SB2"61(_,:0C>VUB >>,CC%6=<\>I9>'M4O[#3[F:>POET^
M5'V+Y<C%!N/S<K^\7IW/89(JWNF:Q%#X*U&'29IYM')2ZLTEB$F&@,9*DL%.
M"?[U9=UX:\17?AKQ?;G2@ES?:O'J%K']H0B5%:$E<YX/[INN* .LDU2Q;QA8
M6\\6IP:D;&:5(23Y6P,N[<%8JSCY<8SUJM;?$32;J*QG2TU);6\NS9+<O;[8
MXYMY0*QSD988R <9&<4D]IJMSX^T;6#I,R6L&GW$,Q\Z(E'=D*KC=R<(<XR,
MGJ1S7.Q>'=?3P'I^F'1YOMD&N"]>/SH>(A=&;.=^,[3C'K0!V&I^,=.TO^TV
M>*YGBTL(;Z6! P@W#=R"03A2&.T' -;5E=I?6<5U$LBQRKN42*5;'N#7FFJ6
MM[>:[XGCL] U&]TK4&C@NSI]Y;J)66-0X82$%6P=AVG&!USG'HFCW<-]I%K<
M6\$EO$R +#(H#1XXVD D<8QP2* ,W5_&%AH\NH))!=SC3H$N+UX$4B"-LX)R
MP)X5CA03@?2DN_&-A;:P-)BM;^[O'L_MD:6\&X21[@."2!GGO@>^<"N;\8:1
MXCUF;Q+8#3&O+*YT[R],<7*)%')L;?O4G)<L1M)! XY7DU=TS3M8C\::=JEQ
MI,L=O%H)LY")HFVR^8K;?O<\+UZ9/7'- &C%XZTN>RT6\BAO&M]8F^SV[^6
M$ER1L?)^4Y5A^!QFMJ#4H[C5+NP2&7?:JADD(&PEAD '.<XY(QZ>HKA['PS<
M?\*DNM(UF,Z;<P-<7,<S2*WDN)GFCD!4GIE2?H175>%+6\AT&&XU-5&IWO\
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M:KBW*W(A "Q*T;%4Y?N/XCSVH [VLN^UR&TO_P"SX;:XO;T0_:&M[<+N6/.
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M2%.>ORY).<\#C%6M.U?Q7>7NDSK8(^G7T):Y9D11:DIN1E(DS(N>", ]^.E
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M90;^.UNIHD,C#/[Q%8(Q('.0?>NAN+JSTFTC\PK#$,111QH22<<*B*,DX!X
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MDXR/OMD+@&JOA_P;<Z ([<>(KZ\TZU!%E9W")MAXPNY@ SA0> 3@?@,=,+N
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M&NRRRS[4"-&TB!&V'GC &,YJK;^$)]*N[#6'U>^O[G2[&2V6%8HE\^/Y2$
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M'C')_"JOBB+3_%FI0^&7L[QYK2ZAN9IC Z11Q@9;$F-K;E)CP#GYSZ'':44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<YXRBU.;3;1=)-O)<B[5S9W$IC6\4*Q:+<.AP-W
M/'R<\9KHZJ7^F6>J1Q)>0"40R"6(Y(*. 0&4CD'!/(]: /+;R2QUJQ\+/]DO
MK66'Q/\ 9I[6ZF8O;N4D9HPP/*_=VD=L 8Z4_P 7WNW3_$>HZ7>7$DFGWMK$
M+F2X*?96!BS%"H^\"&RQ. =Q^]CCT:?PYHUUIZV%QIUO-:K+YXCD7=^\SG>2
M>2V2>3R<FH+GP=X;O)KF:XT2QDDNE"3,T(^<#@9^@ Y]J .1N$6Q^(?B_4K2
M,O>0:+!<0KYC$/+^^ &,\] ,5)X=L6U)/#GB"#Q,ACN(2D\<2R;KXO'DJY\T
MX=2"<@ K@C@5VJZ%I*ZC!J"Z=;+>6\/D13",!DC[*/0#)_,^M5=/\(^'M)O[
MB_T_1[2UN[@$22PQ[6(/7!'3/MB@#S&TBG'P_P##VKC4M2_M :X+83F\D)\M
MKQXV4@G!RIZD$]/2M+6+VZ\*:AXUBTJXNA##I5M=HLDSSF)V>17D7>2<[1D^
MZUWP\*:$+".P&F0"TBE\Z. 9V+)G.X#. <\Y]>:L+H>F)?S7PLXS=3Q^5+*V
M29$_NMGJ/8T <:^DF$SZG:>)%-I>:5+MMK,R@3$#<LX?S6(8< L.N0">E96B
M1RVH^&E^M[>O<:E;>5>&2Y=EE0VA< J3@89000,]^237=Z=X.\.:1#=PZ=H]
MI:QW8VSB)-OF+_=/M[=*G7PUHR+8JMA$%L/^/0#.(.WR<_+QQQVH \]T+39E
M\+^((M&FB@OCXAN4BCN)W5)E2X!,1(/&X#;GKSSUKK/ ^HQWD&J0-I]UIM[;
MW>+JQN)?,$#F-,"-NA0@!AC'4\"M1_"VA.]TYTJU#W<HFG94P7D!R&)'?(SG
MUYZU>L["UT]'6VB">8^^1B2S.V ,LQR6. !DGH!0!RCJ[_%JYM#<W7V>70/,
M,0N'"JWG[=R@'Y3@#D8Z5R&@^?!X8^'FM_;[Z2_N]0CMKB26Z=A)$ZRY4J3M
M/W0<XSD9S7J<FB:;+J3ZB]JIO7B\AIP2',?]S.?NYYQZ\U77PKH:6MI:IIL*
MV]G)YMM$,A87_O(,_*>O(]3ZT 8OQ6@CG^&&OB0$A+8N.2.01CZUGZKI=K/\
M0?"U@'F%M_9M]N$<[AF&83@N#NQSV/MTXKO+NTM[ZTFM+N%)[>9"DD4BY5U/
M!!%4(?#.BVTUK-!IT,4EI&8[=D!4Q*>H7'3/?U[T >;Z?K%U:Z3I.E3Z@8K!
M_$%[I[7%T[N-D9E\J)VW!B"0!][G: <C(KNO"VES:/-JEK)K OHVG$L< C8"
MT##F,%G8X.,@9XSZ$5;;PKH+Z7<:8^E6SV5RYEF@=,J[DY+8/\6><]:MZ5I&
MG:'8)8Z79PVEJA)$<2X&3U/N?>@#CV:'Q)XK\6:+J-[-;/9PPK9^7,8VAC>+
M<9TY^\')&[MM ^J:=,FN>,[[1M0N9[FSM=)M9+/<Y0W ?=YDYVXRV0HSVYQC
M)KI]5\*Z#KEY!>:II-I=W$'$<DT88@=<>X]CQ4]]HFFZE/#/=6B//""L<H)5
MU4]5#*0<'N.AH \OL+C4]1A\'17VHW[?\3B\L3.ERZ&Z@C68*S8/)^7&[KQD
M'/-5]>MU7P7XWTUI)Y+73M9M_LJRSNYB#&!B 2<D99L ],UZO+H.E3-9%[&'
M_0?^/4*-H@XQ\@'W>...U1MX9T5X;^)].@>/4#F[5QN$Y]6SU/ YZT <G?*-
M3\:7OAAKV.V@BTV*2SBE,C%RS2"212)%)92%&3DCMCFJ6NVFJZ;X>T+4=+UB
MXUG7-/#@A0P348E!#EH]^"5&"&SRV!G+"NSU'P=X<U:VM;:_T6SGAM.(%>(?
MNQZ#V/<=ZOQZ58Q72W,5M'',D/V=60;=L?\ <&.@]J ///$%MI-]X7\$SV-Q
M->6DFLV9CN))V+N')W%CGALC'MR!BNV\27EQI'@[5+W34\RXM;&22W'WLLJ$
MK]>GXT#PGH"Z6VF#2;7["THF-OL^3>#G<!V.>]:Z1I'$L4:*L:J%55&  .P'
MI0!YQ,\EC9>!M8TBZGEGU"ZM[>Z+3,XNXI8RSLX)P67;N![8(Z<5>\(Z=;0^
M/_&CHLFZ*[M@F97/6V0G()YZ]ZZBP\.Z1IDRRV5A#"R[O+"CY8]WWMB]$SWV
M@9J2ST73K"]N+RUM4BN;DAIY%)S*1P"W/)'O0!S_ (S75A>Z?<:;:1:I%#',
MUSI33F)YE.P"2,]"R=,'^_QSBN>L-7@\0:GHFD0WKQZ=/H@FMDU .7GD#E'#
M8=29%"CN>I(]:]"O=(L=1GAN+F#=/"K+%*KLCH&QN 92#@X&1WQ534O"?A_6
M+"VL=0TBTGM;;'D1M& (NV%QT'TH XF!KNVU70?"U]XACOX'M+K9=7,3A;N9
M)541G$@+,BEARQSC)&0,4]<@U30K/PO;VE\-?O[35[@6WF93)%O*5B+%F+;<
M[<D]L'&*]$U'POH6K:7#IE]I-I/908\F%HP%BP,#;C[O''%/_P"$;T;R[&,:
M= J6'-HJ+M$!]5 Z'WH X;6+FSNO@SK.KZ7?WQN)+>2:29IWCECF!^9" ?DP
M<C8.,>O6KMU9#4?B;9V-Q=7OV.;0'DE@CNY$1F$L8S@$8X/.,9[YKJ&\*Z$\
M5[$VF0&*^<R7:8.V=B<DN.C'ZU,N@:6M['>K:*+J.'R$F#-O6/\ N YR![4
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MTKU^TL[>PM([6TA2&"(;4C08"BD%G;"\DNQ!']HEC6)Y-OS,BDD*3Z LWYT
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M[1E6)@H8I%L1CC"DE6 !K&T2YDGUSP)=BQOX8X8[F&:V33Y(X;)VB $0RN<
M@@L21QG(Z4 =MX+U34-4AUL:C<"=[35[BTC81A,1I@*,"M?4==TO221?WL4&
MU/,;=_ F<;FQ]U<]S@5SOP^W!?$@>.6/S-<NID\R-EWHQ&UAD<@X."*S9M0C
MT3QMXEM->TV\N;#6DA-H\5F]PDRB+RW@(4'!SDX/'S$\4 =K>:UINGJC7-W&
MN]#(H7+$H.KX&3M&1EN@S4<_B/1;9;1IM5LT6\4O;DS+B50"Q9>>1@$YZ5RF
MGO)X?\>WL^I6C6NG7^F6L=FR(7CMS%N#0948!R^1V..*P-/TBYTN'P9#<VLR
MQIK=U=I"86/V6!Q+Y8;CY/O+P<8)QVH [X^-_#"V7VQM<LA!YIA+F3&UQC((
MZC&1G/J/6I]0\5:!I4LL5_J]G!+%$)G1Y1N5"0 2.O)(QZUPEW%NM?BD%M92
MUXA%OB!LSG[*$^3CYOGR.,\U)IMY9VOQ!T2:]_=_\4JJAY8S\C>:H(.1\IZC
MG'IWH []-<TN73(=2BOH9;.?'DRQMO$A/9<<D\'@<\&LO4?'.AV%A8WB7:7$
M5[>):1&+)PY8*V[CY=HR2#SQCJ:\^@TV[\-0:7JT^GZC_80U74)FMK02++:P
M3$>2^Q"&  4Y'4!^F>*U-5M+"/1-/U31M*U"*Q;Q';7]P\D<SRRC(#S&-\N!
MT'3)QG'() .S_MFS77+I_P"WH7@AL5EDT](P6BY)\TD?-R"!MQVK/A\7:?KG
MA_3=1M-:BTH7=S$(_.16:4%Q^Z ;NPP,CD9JK&6N/BM=3I!.L4OA^.)7>)E'
MF>:[;"2,;@&!QUKE[<RGX3^$[)K*]6YLM0L5GB>UD#(8Y07.",X4#D]/>@#T
M^_UW2]+=DO;V*$HH=]Q_U:DX#.1]U>#R<#@TR\\2:+I\ZP7>J6D,KQ&94:49
M*#'S8].1CUSQ7*6,W]D^)?%UOK<$TD&I.EQ:2"%G6YB\H(8EP#EEQC;U.[('
M-9'AW2KW1]7^']IJ<<C7%CI5TD[E"RPL_E[$+8P" "HY[4 >F:;J5EJ]A%?:
M?<QW-K+G9+&V0<'!_(@BK5<!X,U*+1])U'[3;7@%QXAN8X52V<G;+,2C8QPA
M'.[I7?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &+K/A_^V-3TF^^V/ =,G,\:*@(=BI0[
ML]L,>F*VJ** "LC7-#?6S;(=4OK.",L)H;5U47"L,%7)!('N"#R?8C7HH 1$
M6-%1%"JHP% P *6BB@ HHHH **** "BBB@#FU\*W-MJ-W<6'B/4[2WNYFGEM
M@L,BASU*LZ,R@XZ9(';%;UK:Q65K';P*1&@XR22>Y))Y))R2>Y-344 %%%%
M!1110 4444 %%%% !1110 5BGP^3XQ'B+[8_F"S-EY&P;?+W;\YZ[LCKTQVK
M:HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0&O:.8+><:M8F&X?9!)]I3;*W3"G/)]A4EWJVFV'F?;-0M+?RU#/YTRIM!.
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M&X;BU\-:9:W=NT%Q!:Q121LRMAE0 \J2",BM2@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JU]J-C
MID'GW]Y;VD.<>9/*L:Y^I.*LUQ/Q=_Y)5K__ %Q7_P!&+0!TD'B+1+JXCM[?
M6=/FGD.$CCND9F.,\ ')XK2KGX;J]O=0L+:ZT1X;8(TPN))$?9(NW: %.02"
MWY8[UF6GBC52?$EA>+9#5M.N(XK1$B8),LH'DL<N3\S$@X/&#UH ZK^T;/\
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M&X@  XXSSFMJY\8ZOHMOJTNJ::)8(?)%A<K"UNMQ)(P01LK%BI#$9;IC/'%
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MGBN6TWQ#K]WJ6D.=.6;3;^(M.R6SQFS)7<AWL<2*?NY 'K[5?\>C/P\\2?\
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MX7*@@@,5 W$X!- 'HE%4-%NIKW28+F>6UF>3<1+:',4B[CM9>3P5P>IZU?H
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M+DMYC(9 P^8YPQ_+\ZFN?!5WK/AV[TSQ%KTVH3SJHCN(H%M_(*L&5E49^;<
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M*P99 ?4,!CZ 5=T#1]6T_,FL:^^K3*GEQM]F6!57@DE5)W,<#DGMP!DYW:*
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M]F-O;D'O0!+X;T"W\-:)'IELV8UDDDX7:H+N7(5?X5!; '88ZUK444 %%%%
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M]C&\-U_Q\))ES+QCYR<EN..2>*?+HFF3Z2NERV,$E@H 6!ERJ@=,#MCMZ=J
M/-?$>J:CX5O?%=MILTZ:5%:V5P2K%OL1EF\N7R_[OR O@=#R,5L^)/L_AS1]
M9UK0=1F$TFE[TMHI/,B"JPS< <_/ANN><=\5V<&DZ?;VDUK':1>3/GSE9=WF
MY&#O)R6XXYSQQ5?2?#6B:#;S6^E:7:VD4YS*L48 ?Z^HY/% '$W\4^CV-[XC
MT37H)B^CSO#9VT3LEPRKN68[I&^9>,MCG."<D4Z&-K2VM/%.DZ]#< Z=.RV<
M,;M_:#"(NI<F1OG4K][&>2#UKL]'\+Z%H#3MI.DVEDT_^M,,07=[?3VZ4FE>
M%M!T*ZGNM*TBSLYY_P#620Q!2PSG'L,]AQ0!YY+%:7>@?#G6EG:XO+O5+5Y[
M@R$F5VC<ONYQPP( _AZ# XIVLO/'I_Q35+V\7[*L<D#"ZDW1G[,KX4YR!N)X
MZ>U=TG@GPQ'+YBZ#8!A-]H \D$"3GY@.@//;ZU9D\,Z)*+T2:;;L+['VL%<^
M?CIO_O?C0!R=C;G2_B#X?6WN;HC4=)G:Z$L[R"1D,15L$X!&YN@'!QTK+TC3
M]4UO3?#Q\V[_ +2BU&5M5OH;EXTN( TF<2(PWJQV;0/NXZ 5Z!+H%@&CN;:T
M@COK:%HK2=T+&$$< <_=Z9'?%<+IOP\)2&*\\,:+9WD8&_5K.[?S"XZR(@1<
M,3S@G /J." =%\3FDC^&^NS1330RQ6K.CPRM&P(]U(X]NE9MW8IJ7Q0MK*YN
M+PVDWA]Y)($NI$1F$T8S@$8X/.,9[YKMM0TZSU6R>SO[:.YMI/OQ2#*M]1WJ
MNN@Z4MZEXME$+I(?(289WK'_ ' >N/:@##^&D\]SX"L3<3R3O'+<0AY6+,52
M9T4$GKA5 _"N/UBTOH7\2^$+*2X;4IIDU/2)#.^1$1N9=V<[%:-DQT_>*.]>
MI:=I=CI%K]FTZUBMH-Q;RXEPN3R3CW-2FUMS>"\,*?:1&8A+CY@A()7/ID T
M >=WFH0>)OAYXC\20(\=O+H<D$,9)P"(6:0XZ9#-L_[9GUI=,MAI?BSP;]FG
MNL:GI,ZW8>X=EDV1Q,IP3A2,G&T# .*[Q]'TZ32WTQ[.$V+A@UOM^1@2201Z
M$D_G4*^'M)6>TG6PA$MFACMGQS"IX(4]ACC H \UM=8FT[0(8KB]N%L9_%T]
ME=7$D[%E@$DFU2Y.0"512<]"?6M'QWIMGIG@GQ1%97\SK-):2FT+AH[7,J#Y
M./E#;2V/7G S7;KX:T1=-NM.&EVILKIB\\!C!21B<EB.YSSGK4<?A/P_%HW]
MCQZ1:+IV_>;81C8S>I'<\#D^@]* ,'3;<:5\5[JPMIK@VUSHRW4L<L[R!I1,
M5W_,3@X../05+XD:WO?%5OII=YYUTZ:=K267R[=$+*OG,1R7!!"@=,DY7J>D
MCT;3H]274DM(Q>K%Y(N.K^7_ '<^G?'KS3;[0M)U.]M[R^TZVN+FVSY,LL89
MDSZ$T >8Z1/<ZQ8?#%[K4;UGNXYX[DI=.IE MW(W8/7C[W7GK5RST2ZU;PSX
MOT?3[NY2?3M8E&F$W#YC(CCD$9;.2A+,"">C5W5OX4T"T%H+?2;2'[&S-;>7
M&%\HMU*XZ$]S4%YIMUI$#R^%M,T[[9<W >Z^T2-$K@@Y<E026Z=>U &=X3U2
M+Q;<Q^((8Y(8(;5;98B2-LQ^:4$=#M^5 >QWTW4+DW_Q/@T&_!.G?V0UU#$2
M0DTWFA6S_>*KC [;B?2NDT?35TG2X;0,KN"SRR*NT22.Q9VQVRS,<>]+J&D:
M?JAA-[:QS/ Q:%SP\9(P2K#D9'H: /*-:6XN/ACXIM;Z26X@TS63;6,TLC%C
M")HL MG+;2S+DYZ>U>M&PMETY[(1G[.492A8G(.<C.<]ZKW.@:1>:8NF7&G6
MTE@IR+9D'EYSG[O3KS]>:OQ1I#&L:#"J, 9S0!XQIEI /A;X"6-FC>?6+,R,
MCG</G<9'I^%:&HW]QX7/CR#3[FXCM+1M/D7?*\I@68[9G4D[ON@MP>O/%>@K
MX2\/)"D*:/9I$D_VE$2(*%E_OC'1O0]NU64T/2X[J[N5L(/.O$V7+E<F9<8P
M^?O#''- &#H.E"R\3&]M]=MY;6\LLBPMHV\MRK#$X)D;!PP4XZY!ZBL_QDLS
M_$KP&MO*D4I:_P!K.F\#]P.V1G\ZZK1O#>B^'4F31],M;(3-ND\B,+N/;/TR
M>.U27>AZ7?7\%_=644UW;Y\F9QEHL]=I[9]J ..U30;+PUI][=W.I7LNHZ[J
M=LLTL6V-KA]X"0#LD>,@\YP3R>E<YJ\]U!X;^)5HMP]L+$Q26\5I=/M@+0H6
M"$8.W)Y& ,D\5ZSJ6EV&LV3V6I6D-U;.03%*NX9!R#]15!O"/AUEN%.BV.VY
M18Y@(0!(J_=5O4#CCV% '&>)O#.FV>J^$Y ;F5[O6E,KSW4CY)MY,XR?ER5!
MXQ3=5U&]TC6?']SIT\[O;:-;3VZM(TBQL1-EE!) Z9P..*[^[T+2K^PAL;S3
M[>XM8&5XHI4#*C+T(SZ<BG1:-IL%_/?Q64*74Z!)90OS.HZ ^H'84 <7;Z>B
MO#K6G>*[>"WNM.F7$,;LLWR;EG8M(WS)U+8R<X)Y%2^#KFYM?$3Z/K&F-8ZM
M'8A_,@G,MK>1JP!E7/(?)&<C)R,D\5T>G^$/#NE"[%AHME;"\4I<".$#S%/5
M3[>W2KECH^GZ:Q:SM4B;8(PPR2$'11GHH]!Q0!QWC"2&[UC4K6.62:XMM%>9
MX9)?+AM@2V)E(Y,IVX&.@7J,\TK:[EOKCX575Q,9;B6%WED8Y+,;(DD^YSFN
MZO?#VCZE?QW][IEK<7<:&-)98@S!>N,GMGFHXO#&AP+8K#I=K&+#/V0(F/)S
MU*XZ$]_6@#SR]U6?1[;QW=PS&!1KMK'/. <Q0LL"R-P0>%)Y!!'7(K6NM,N]
M+MM>O=*\2VD;76D/)!;QJ4AB=1Q<!F=@N0<'H#C/.#791:#I,/VW9I]N!?9^
MU H")\C!W@_>XXYK'O/!UG8^%=3TOPQI^G6$MXN&5XOW<@S\ROCG!7<,\XSD
M"@#%TO3[V?6M,U6QM[^VL[?22;J"2>2,377RE RAOWC#Y\L<@Y')/2GX7C?7
M-,\->)5\20Q71=/M8CB<O<NPQ)!(#(1PV<?+\NW( %:6@^"8;;5;:_7PSI>A
M2V[[S)8W;R/)P1MP$4!3GG.?IW'36GA70+'69=7M-(LX=1ESON$B <YZG/8G
MN>] &?XNF@-UH=@\DS375X?*M$<)'<[8V)65CT0?>(YR0!@U3^'%Q-+I>L03
M3>8+76+N")1(7$<8?A5)YVC) ]JZ75-&TS6H8HM3L8+N.*021K,@;:P[CTI=
M/T?3=*:X;3["WM6N'\R8PQA=[>IQ0!YU+H5GK&O_ !!DN[N[MOL\T,D4L%T\
M/DL+1#YGRD D8_BS^IJOIEM=^)=;\-0:Y<WZM?>&7ENXH[J2+>X>(!L*1M/.
M3C'/7TKT>X\.Z/=WSWL^G6[W$@ E<K_K0.@<='QVSG%2R:/ITNJ1ZH]G$U]&
MNQ+@CYU7T![#VH \Y6*7Q'%XA1_$$>EWNE:B\:3,KM-:11D>6P_> %649.1A
MMQSFH/&%\38>)-3L+N:2XL+ZUC-U+*8S;2 Q9BA0<[2&);.,[B/FQ7HEUX5T
M"^UF+6+K2+.;48L;+EX@7!'0Y[D=O2FW?A+P]?7-U<W6C64TUVH6=WA!,@'3
M/Y#GVH YDO;>)?%'BW1]4OI+=[..%;,I-Y;01-$&,T?;=O+9;MM J Z;::Q\
M2XK:XN+FYMG\,QDN)6C:8><<,Q7!YZXXY[5UM_X2\/:I<6L]]HMC/+:*$@9X
M5.Q1T4>P].E6GT737U)M1:SC^VO%Y+3@8<I_=SZ>U &'\-+NXO?AWH\]U/)/
M-Y;(9)&W,P5V49/<X KJZJ:=IECI%FMGIUK%:VRDE8HEVJN>3@=N:MT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=W--]G>-H9)5%V9=HR ?FC  QZ@4 >CV>O:7?S7$-O>(9K=0\L;@HR(>C$,
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M<=:Y;PC)INJOHD5QH.L0ZWI2;9!=^>([1@FQBK,=C!L8 &<@] !QC6B:C9^
MM%_XE>J2-HFLRS:A:Q121R-$SSC,9&"^!(K?*?QH ]5T[5K#5HY7L;E9O)D,
M<JX(:-Q_"RG!4^Q%0:SK%GIT$L4EZMO<&%I 0A<QJ/XV !PH/<\5F>$UTFXN
M-1U;2M/O8%O?*\VYO/.5[AD! ^64[L*"!G'/X5CI>2Z+\0?$HU2UNWM]4AMV
ML)XK9YD94C*M%E0=I#$G!_O$T :GA+Q*;GP%HFJZS=!KN\MP[%8\M(W).U$'
M/'H.E,\2^-+.P\/6-_IMW%,NH74-O#/&-ZJKR*CMZ94$\'N.G45PNAO<Z)H_
M@W4M2TW6#ID6ER6-R+:*9);64NC!V1<,48+C(R.GM6WKEI9VOA/2ETG2+ZVM
MY=>MKP0M%+)*4$RL\K*<LF<$X/MT)Q0!U%MJT6AP7$NL^(!=V\C>?!));A'A
M@('^LV #:#GYBJ^]7;KQ5H%G,89]7M%E\C[1L$@8F,D , .H.1CUSQ7&ZK<0
MZ=XVU4ZW8:M<:5J]M"+6>Q6=T.U2K0NL1SDYR,C^(U/IUG#IWQ$T<1:;/:65
MMX?>!%9'D6 ^:A6,OR-VT'C)[]: .Q37]+ET^UOH;Q)[:[_X]VA!D,O!)VA0
M2< '/'&#FE.NZ8+&&]%VKP3Y\HQJ7,F,YVJ 2<8/0=J\RT:P\SPAHL#W.IZ)
MJ5M>7\EM>I;-M@+3,0LJ,N"CJP/.!P.<U,;W5K*?P]KWB'2[W[(;:ZM+HZ8D
MJF%VF#+,8T(<+($!([$CCI0!Z?8:A9ZI8Q7MA<QW-M*,I+&V5/8_KQ63H_B_
M2]9N-6CAE\M--G:&224%%(5$9FR0  "V/PSTI_A6TL+32&.FZ?/8VL\SSI'<
M%_,<L<EV5SN4DY.#^(!.*X'4M.U6YT+Q]I%G8W1OYM5^W1(865+B$" E5<C:
M2P1UP#F@#TJRUS3=1NGM;:Z5KA4$IB8%&*'HX# $K_M#BIK[4K33EB-U,$,K
M[(D +/(V"<*HR6. 3@#H#7(S8\2>-_"^KZ;'.D-A#<O=R20M&561 JQ-N ^;
M=SM[;>V1FWXPO'M-7\/'[%,86GE#ZA!:-<26A\L@!5"M@ODKD@C&>.<@ UF\
M4Z$EE:WC:M:+;W<ODP.T@'F29V[1WR#P1V[XJ-/%_A^6PN[Y-6MS:V;A+B7=
MQ$3TW>@/8]#7FD$,Z^&[2TET[4-T/C'[0ZRVCD^5]H9BYXY&T@DCCFNNTVTB
MOO'_ (R@NK61K*^M+2(EXF$<P"2*X#$8. P!QZT =8=5L0;(&<#[:<6WRG]Y
MQNXX],GZ FL3QMJ>H:3::3-87(A\[5K6VF'EJV^.20*PYZ<'J.:S/ EGJ:S2
M6NJY== WZ;:S$Y\\$AA(?<1^4OUWU9^(JR/I>D".&:4IK-G*PBB9RJ)*&9B%
M!P !G- &[=^(M(L+IK>ZOHXY$9$DSG;&S_<#MC"$\8W$9I7\0Z3'<7MN]Z@F
ML8Q)=)@YA0]&;C@=\^@)[5YGXUEN;^Q\86<>EWT,WG02116MD["\0>6?.>0*
M0Q ! 4$8V]">G2^(K/4/^$GTK6-'MY"-5MGTN[W1X,2$&2.5E/\ <P_!_O 4
M =5%KFFSP6,\5TKQ7YVVK@'$IP3\O'H"?H">E1Q^(])E<JEV&(B:8$(V'C4@
M,ZG&&4%AR,CFN7\$:1?Z;)=:7?0N;'0I);;3I'.?.CDPZGZHA5,^["L[PK;W
M]G?V5AIL]S>Z%-82[(+^W*7&E'"[8BY )4G@*>?ER,@4 =VGB#29$T]TOX63
M4?\ CT8'Y9^,X4]"< FL6[\5V&BZ=XBU>?65U*VLI/\ CW@C4FW8(/W65ZDG
MG)Z9YX%<3I-Q*?#WP]L?[.U(3Z7?I'>J;*7]RRPRJ<_+R,GJ,@#J1D9MZG9W
M=[HWQ0@MK.Y>6Z??;KY##S@($4[,CYN5(XH ].M;M-0L$N+=\+(ORMM/!^A]
MZXWP9XZLKK1["VUS6[4ZS<W%Q$J-M0OMGD1!@< X4 #J?>NOTJ[2^TNWN(DF
M1'0;1-$T;=.ZL 1^(KRR'2I-0^&$WA064Z:V^HR$(]NRF$FZ9Q,6(P%"<[@>
M>@R3B@#T63Q=X>BU 6#ZQ:"[,ZVWE"0%O-;[J<=_\1ZU./$.DM>QV@OHO.DD
M:*/.0KR#JBM]UF&#E0<C!KF-%@>7QUXW*121/<?91;W$D#!6*P[258C!VMZ5
MST5E=ZC\+M+\*_9+FW\0V=S;QLK1,/):.8,T^_&-I0,P8'G=CJ<4 >CMXCTA
M+>^G>^C6*P;;=L01Y!QGY^...>>U2W.M:=:+$TMRO[V,RQJBEV9  2^%!.T9
M&3T&1ZUYOKC36G_"RM.:QOI+G4H#+:"*V=UE7[*$)# ;>&4@@G/89) J>\U1
M-"\1:%JOE7R2/H7V:9)+">15 =2N0BED8,&SD8(Q]: -K7_%T2S^'+S1];LY
M-,N=3%K=O$\<B%/*=SE^=N-H].M:&I>.]#LO"U]KT%TMW;VC&-EA!)\WLA&,
MJ>1R>QS7&0PZ;'H7@2QTB:YU&VT[6 9Y3:2*8R(Y"Q="N8P&D7 /0$?6F:_9
MW=YI_P 38K6RNI&N)+>2!5@?]\%BC#%./FP5(X]* /58YTO;/S;:4A9 =C[>
MAZ9P:XSP/X[LM0T+2;?6=:M6UR[\P>62J,Y$C!1@< X P.I]Z[.RNX[ZSCN8
MEE6.0942QM&V/=6 (_$5Y/8Z5)J/POT_PNEE/%K<5^K%9+=D-J5N2YE+$8 V
M9P0><X&<T >G6NNZ9?->+:W:2M9$K<JH),3#G!XZ^W6K5K=V][9Q7=O*)+>5
M Z2#HRGH1[5P_B+2[ZT\9(=,7_1?$L7V*_VM@Q-&,^</?RO,7ZA*[2^!M](N
M1!:"<QP-Y=L.!)A3A/QZ4 5;3Q)H]].(;>_B9VB,Z9RHDC!P70GAE'J,BH(/
M&7ANZFM(8-9M)'O',=OLDR)&!(P#TSE2!ZXXS7!:)<22>(_!5\;+44ABL;F"
M:,:?)%#9N5CQ$HVY"KM(W$G..IZ56M8)8_AOHD/V&[6XB\2+<21_99 ZH+QG
MWD;<XV$'/I0!ZE:ZYIM]->0VMTLTED=MRB DQ'T(QU]JG@U&SN=.34(KB,V;
MIYBS$X4IUW9/;'.:XGQ)IM_:>+X)])!\CQ)#_9]]M;:8F0%EG'N(A(OU"5WD
M<20PI%$@2-%"JJC  '0"@#$MO&OAF\OK6RM];LI;B[&8$60'S/IVSZ#O5J3Q
M%I$5\+-[Z,3&86_?;YI&1'NQM#X_ASGVKRO0K2+7OA)X8TFP@8ZDE]#,K"(C
MR-DY9Y2<8 V!AGN2 .:L:U/<72W _LK4+9[3Q-#.]I;6#E&B6=?](+!3YC,.
M>#W^[QF@#T2X\8^'+6\:TFUFT6X698#&),L)",A>._\ ];UJGI?C[0M1TB+4
MGNOLT,UR]O%YR,NYA(R*.1U;;D#KSBJ/AE0_Q"\83O:S(L[VC122P,H<)" <
M,1@X;C@]:S?#&A_VW\,;SPS>P75I=137*EY863RI3<221NA(&['R-E<B@#OS
M?VHU!; R_P"E-&91'@Y* X)^F>*LUP_AS6+N/P[)XIU^SG^V3"*U,-K&96"H
MVPD*O9I&D?(_A*^E=Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %4-:TF#7-(N--N9)HXI@,O ^QU((8$'Z@>WK5^B@#$L-!N()8WU'7+[
M5!$VZ)+A(D56'1B(T7<1[Y'?&>:VZ** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *0YP<'!]:6B@#&\/>'U\/I?HEW+<"]O)+Q_,51M>0Y8#
MZ9Z5LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+5["35-,FLX;
M^ZL)),8N;4@2)@@\9!'.,'CH35VB@"IINGQ:781VD+2.%)9I)6W/(S$EF8]R
M22?QJW110 4444 %%%% !1110 4444 %%%% !6!?^&9;C6I-6L-;U#3;B:)(
MIUA$<B2*A.WY9$;!&X\C'6M^B@"K86"6$+(LDLTDC;Y9I2"\C8 W'  Z #
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9!(N&"L 1D=CS0!;HK(\1>((O#EE!=36L\\<MS%;9BV_(9'"@MDCC)'3-:]
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M=-<Z1'&Y3*9N"ZLRA/FQSMQSCD]JV+:5Y[2&:2%X'D16:)R-R$C)4XXR.G%
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M9WR$.5C*YQ&P4@@8_@Z\U#H7@SR)K(V_AZ^T2XMGC9KC^V6DC(4C<JHKD,&
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MK'LO$6EV>E:6NH>(;.XGN;??'<L5B^T@+N:0*#@# )XX%:>KLJ:->ELX\A^
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M<$HV7&,J"$VY/'YUUW@K3YK?4/$M^$>*PU#4C/:QLI7(V*'D /0,P)]\9[T
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M?!/B'4O#MVL5UI<IB5WBW%MK*K':W3EB!G/3/>O000P!!R#R#7CVJK.OP_\
M'VE&SO#>2ZK<RQQBV<^8KRJR%3C#9&3QG@&@#T^U\1:->W5W;6VIVLLUHNZX
M19!^['J?;@\U5TC5[9/#]I<W&N1:H)G=([R*, 3D,W"JF<X (XS]TFL4R1+\
M6;6YC4K:#0)(O-6,B,'SD95SC .T$X]*YK0[)9/ 'AR"2]OM$U&VN;I[>\6
MXMW,C\2HPQL96_BP.G/- 'JMG>VVH6J75I,DT#YVR(<@X)!_4$5/6!X,N-1N
MO#4,FJVT4-WYLH8PH428"1L2A3R _P![G^]6_0 4444 %%%% !1110 4444
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M+GY_O<@ =!SUXXI;7QHD^HZ3;RZ;<6\>K-,MFTA D)C!8[T."N0I(Y/;.,T
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M,>QL@*0RG (QC'3WKI?">GWFD>$M)TR_6$7-G:16[^2Y=244+D$@=<>E;%%
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MY3MR2=_<#IUJG+:ZAJ>H>(+FPT;3]4T6ZOOWZ+JAMTD:$*K>8AC/.Y#DY 8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@9YKT73]1LM5LTO-/NX+NV?(6:"0.IP<'!'O0!8+!1DD >]!8*,L0!ZFO/\
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M]S&TD,?D.5=5^\0^W;QQGGN*:_B+2XUN"\[C[/<"U<&%\M*<$(@Q\YY'W<T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML!.?PZ\5J>)-&O\ 7O%6LQVD%Q'%?>&6L8KEXF5/.+LP4DCCAA^9'7BO1J*
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M:WA4/:R))(9 926^4J3R,$\<9XJW<Z9?P>*3J&@IJ5I<S:D@O[&:)GL[J(,
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MP<8[G%>I+/"\[P+*C2Q@%XPP+*#G!([9P?RJ2@!%8.BL,X(R,@@_D>E+110
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MX-@>[LY3H!8R$*R^:#$T>!UZ!LY[^@H BNOB#JEMI>MZG_85N;71=0:UNO\
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M#9+&^,+M484@]#GIUH ]"HKBM,B\3SWVE7PU2(Z9=VS?:M\ZNS,R;HY(1Y8
M.<Y!)&.Q(KG='UOQ ?#O@S7;G7+BXEU#4EL[FW:*-8G1VD&<!<[AM!R#CCI0
M!ZJ'1F9592R\, >1]:=7#^!H)AXA\822W]U.$U8QA)64C_4Q$'IGCH #C':M
M/QC?:IIUK97%A:7=W;).3?16)'V@Q;3R@/7#%20.<?C0!HZAKUGINKZ9IDZS
M?:-2=HX"L9*952QRW0<*?>M2O+KJ^37)_ =Q8ZQ+<B;4KL+>-$!*H\J;@J0
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M5HET9[M+.!Q )=DC/M&3T7YNO/8UFBXU*/XC1:(VJW,EE)H;S8*QAA*)43S
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M6YN(O/D7>D>\;F7U ZD5-0!B3^%M/GU>\U0/=17-Y L$_E3%5< $ E>A(#,
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MH T;ZRMM2L9[*\A2:VG0QRQN.&4C!%9NG>&;/3I;63SKJZ:SC,5H;F3?Y"$
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MG3P7: W'WBI8G(X&%))(XZ$5F_$HW2>%X9H8WEM8+^VFOXT4L7MED!D&!U&
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M\^>1WS5.*2#5O!'@JTTM@FO6-Y:J\(XFMW3BX,B_> QOW9ZY'7(KUNDVJ&+
M ,>IQUH \9:P\.W&@?$6SN;:S:^.I7*VL01?-WF-/*$8ZY+],=ZUM)TRPN/B
M3%8ZU#97=X/#5LMPDRK)OG61MY(/5NASUQ79>'/#T^AW&K2SWD-S_:%\]Z-L
M!C,1954KDL<C"CTK?H \=O9"EG\01I2^8(M6M9Y8+0*7>!5A,NU>AR%<'C!Y
M%7[M] \0:+XGUG0M1N]5NY]!GMY90H" !241E5%S)R<=2!G.,BO4Z1551A0
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M?8MC8"1U.>X-=1Y^D:=\6;62VDM(+<^'Y2YA*@,!,C#IU^7<1[9KT
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MA 692<,I)X&1GK7GL_@36)-$U?3=+DNK;3P;:YTRRU&<2^5/&^]D#!FQ&0$
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MII<I_MF$1V1\V+]X?LPBY^?Y?FYY[>_%=AHUM-'X;L+6ZB>"9+5(I$+ E2%
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M2U#3%6+R!F520J\*.,C/;)K2F\4:#K$?AB^CEOWBO[S_ $-X-R+YH5P5EY'
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M9PW0D<C\:UM?\':IK\VOZO!!':WDZV8LK:Y*L)#;R>9^\VDC#$[0,\ 9/7%
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M;K+&/)AB9."2P!8A,\$\G&>,UT6EZ?J$7Q#US4YK&2.RN[2VBBF+H<M&9-W
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M)(M695MU4)N&5+Y;YN %4D]2,>M4(+#4#\39]7>PDCL)-(CM!,TD?$BRNY&
MQ.,,!G'45F>&=%NM(U?71;A;O3]-EE_LJU5MNUY5662/)X&&PJGL'84 =[16
M9X?U.?6-$M[ZYLFLIY-RR6YD$FQE8J0&'##(R".H(K3H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#4O+_Z4&@#L:*Y[QOKMYX:\)7NKV,,$TUOL.R;.T@L%[?7U%99\1^(]/\
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M)@KC\: /1**X6X\9:G)X8U/Q/IT-I)IVGSS#[-(C>;/%"Q61@X;"GY6(!4\
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MXADTR2]1%OX1:K,DQ0;0ZAC\C8XSR.!D&DN_!=W%KRZOH6O2Z;/);1VMVLD
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MT>TN+:T&+>.2/(B'HOH.!QTX%6FT'2FN[2Z-A )[--ELX7!A7&,)C[HQQ@4
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MC222L5**SY "X5GX&<DCTYM6WA^TM_$UYKJ0Q1W5S$L+M&N#(!CESW(V@#T
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MY.]A$TMZGEW+G.9D_NL>X]C3#X9T;R[=%L(T%O$8(?+)0I&>J @_=Z?+TXH
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MR1_#G0H9H)H)8K1(WCFB:-@0/1@#^-=50 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117,^-]=O\
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M*V*.)<GYQ(=Q&.^ ,=L>] '4T4A 92K $$8(/>O-"\7PW\;W$EPDLFAZX/\
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M(@0&WDE2""1D -UZU5M?B#87.I:5 L2&VU4[;::*=7=3C*^;&.4##IR?0X-
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M)C*@^8N/4$,/PJK%XRD.J:18RZ/<!]6MS<VK131MA% +!]Q7# ,IP-W7@\4
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M0E57^\N>H/N#D5I4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA-GD7"1QH^PDME>">1SD]0*] TO3ETRR$ GGN7)+23W#!I)6/5F( 'H,
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MR[1LSD%CU)K.A\ 64&@Z/H\>J:B+?2;M;NW8F+>74D@,?+P1ECV% %-_$/B
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M#>L(HQ:<3(L<;[&RQP/F/(YSW'2NHL/!-G8VMG8&]NY],L9Q/:V<I4K&RDE
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M(9(%#!AMPN,Y5<E@2<"M'3="AL-4O-4>9Y[Z\2..65E5<I'G:,*!_>//7\
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M<5O^(=!M_$FA3:5=33Q1RE&$L+ .C(P96!((R"H/2@#D6\4:Q$?&-O#<L_\
M9>G1WUG->VH5SN20D,HV\9CXR 1GG-20ZYX@M;+0WN[Y+N;7S"L,=O;(C6V(
M&DDP68*Y.T 9P 23@_=K3D\!P33ZI/-K.J23:I8BRNG+1#>H##<!LP#AV& ,
M<YQGFI]0\%6.I>&;'19[R]!T\QM:7L;JD\+H,*P(4#...G- $WAN37S)J,.M
MP_N8Y@;*=S&)98R.0ZQDJ&!R,C&1CBLC4M;U[4K_ %ZST!)5N-+9(H0JPF.6
M4QK)^\WL&"G<%^7!&"<GH.CT71SI-NXFU"[U"YDQYES=,I=@.@PH  &3P!W)
MZFLK4?!,-WXADUJRU?4]+N;E%CO%LI%"W*J,+N#*<,!QN&#B@#'\2^(]?\.R
MZ1?W<D,=EJ$0MIK<E/\ 0[MU^1B^.8@V03SCKR.*U=2U74+/4])\/QS3W%Y<
MVTUQ/=0)$KD1E!\BN0@R7]\!>ASD7KGPI8WD=Y#<2S26UQ9?84@8(4@CQ@[,
MKG)X)))SM7T%9UWX!M[K2]*M_P"V=52]TG/V/4A(GVA%( *DA=K*0 #D<XH
MIVFN^(X[G2-"U=([34+^YN56Z4(6:WB4,&"@LJR-N4$<@88XZ4[5-2\2:%#I
M:WE[;3-/KT5FK1QC,MK(>"XP-L@P1\O']+VH>!;/4=-M(I-1U%-0M)_M,.J+
M(OV@2D8))QM((P"N,8 &.*EO/!L%]HB6,VI7[7274=XNH,RF83H1M?&W9@8
MV[<8[4 <YXFUO5C:?$.RCOWA32]/BGM9(T4.F^.1F7..GR@ ]0.^>:T?[2U7
M2KOP38I>I+:Z@S17&^$;R! SK@C@ %1VS[U=7P+9L^N/=:CJ%R=:M5M;SS&0
M;@JE0PPHVMAFZ<>U2_\ "'1,^AR2ZMJ,LNCN7A=C%^\)0I\XV=-I(XQZ]>:
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M2T32-0LEN8W60B6%FP51@>&RK9R,8((QT-= 98PH8NH5N <\&O(CI6EGP?\
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M9KA#)8_\)'XLL_.TSRKCPZDGD61 BWKYO3GYF50/FP. .!0!ZV'1C@,I)&<
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MGN[)WM\2,1'YX0,%8C/ W*#CISZ5Q$^D:'XB^*T\=W!;WMM/H$4Q7=E9&$[
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ME?&Q=A&3NR"".".<X!IEUXRT6Q@2:]GFME:[%G^]MY%Q*0#M/''!!R>".A-
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M,]*JG5],G\4VB1:I=M,VG/<1VL2,8)HB4/FY"X9AD 8/<\4 ;36-H]V+MK6
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MRW4^^&:2"9FM956)T3>V]BN%&,\G&<''2@#:33-/BAFBCL;9(IAB5%B4!_\
M>&.?QJ2TL[6PMUM[.VAMX%^['"@11] .*J6&M6NH7)MXEN$E$2S 30,FY"<
M@D8/3IU'<"M&@"M>:=9:BBI?6=O=(IW*L\2N ?49%/FM+:XM6M9[>*6W9=IB
M= R$>F#QBLK4_%ND:1+=QW4\G^AHDEVT<+.MNKYVER!QG!/TYZ5/J&M6=K(+
M3S)WN9(3*$M8C*ZQ]-^ #@9Z9ZGH#0!8.DZ:;6*U.GVIMXO]7%Y*[$^@Q@5)
M'I]E#<-<16D"3L,&18P&(^N,UP_@OQG;1>"= EUO4+B:\U*2=(I7B=S,5DDP
M,JN,[5X'7L!6NWQ#\/)9W5RTMX%M)#'=)]AF\RWP 2TB[<HN"#D\'\#0!O6^
ME:=:1S1VUA:PI,<RK%"JB0_[0 Y_&FC1],$!@&G6@A)#&/R%VDCOC'6LVYU3
M3F\4Z9#_ &G=K</:RRQ6L2DPW"?*2Y.W!*\8P<_-TYJO#\0/#MP;8QW4YCN+
MDVBS&TE$:R[BH1V*X0EA@ X[>M '0"RM1+#*+:'S(5*Q/Y8S&#U"GL/I4LD:
M2QM'(BNC AE89!'H17/QZQI<'B'6VDU:Z#V-K')=V\RE8;=!O.]<J,D@')!/
MW12:MXRLM+T?5+XVMZ[Z?;"Y> VSJS*V[:02,8^0Y/;'.* -FWTRPM+5K6VL
MK:&W?[T4<2JA^H Q3[:RM;)"EK;0P*>2(HPH/Y5S[^.M(M+>P^W-=17-Y TT
M<(LIMS[5!;:-N3C/3KR*ED\<:%%$TSW$PAC$)GE^SOM@\T QB3CY20R\'ID9
MQ0!N2VEM/+'+-;Q221@A'= 2H/!P3TS5?^QM+\H1?V;9^6&W;/(7&?7&.M9D
M?BJ*7QK<>'1:W*M!;),TQA;:2S$#G& HVGD\$\#I4T7BW1YKBSB6X=4O7,=I
M.\3+%.PSPCD8).#C^]VS0!HRZ983W4-U+96TEQ ,12O$I>/_ '3C(_"K#HLB
M,CJ&1A@JPR"*YU/'6@27TMFMS/YL,[6\Q-K*%B=4WG>Q7"C'0G .#CH:TK#7
M+/4;@00K<*[0B=?-@9 T9. P)&#UZ=1W H M6MA9V.[[):06^[[WE1A,_7%-
METVPGFDFFLK:262/RG=XE+,G]TDCD>U6JQ-4\6:1I$MU'=329LXEFNC%"T@M
MXV)VL^ < X/O@$]* -)-.L8[D7*65NLX&!*L2A@,8QG&>G%#Z=8RM,TEG;N9
M\>:6B4^9CINXYQ[UEWOB_1['4_[-DEN)+W[-]J6&"UDE:2/(&4VJ=W7MGH<X
MQ4L/BG2+G1[+5+>Y,MO?-LM0D;%Y6Y^4)C.1M;/'&#G&#0!<FTG3;FS2SGT^
MUEM4.5A>%613ZA2,"EN=+T^\6-;JPM9Q&,()85;:/;(XKF/!>K7.I^(?%D<M
MU=306U[%' ERFQH@8E++MP,?,3VY]3UKI]0U*UTR%);J0J))!%&JJ6:1ST55
M')/T]">@H M*H50J@  8 ':JO]EZ=OD?[!:[I)!*Y\E<LXZ,>.2/6L/4_'&F
MV&@:SJ,27$TVE(3<6GE,LJ-MRNX$<*1SNZ8SR:R-2\2RP^+O"EP;F]CL;VTN
MVFLQ XWNBIMQ'MWL<L<#GVH [(Z1IA$@.G6F)3F0>0OSGWXYHETG3IU@6;3[
M61;<YA#PJ1$?5<CC\*I6?BG2;_2$U.WGD:%YC $,+B7S02#'Y9&[<"#QCL3T
MYJK+XZ\/V]A<W=Q=20I:W"VMPDD#AX9&("AQCY0<C#'@YZT ;\%O!:PK#;PQ
MPQ+T2-0JC\!4E4-*U>UUFVDGM!.$CE:%A- \3;EZ\. <>]7Z "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *Y7X@6-Y>^'8#96LMU);:A:W+0Q %V2.96;:#U. >*ZJHKBY@M(3-<S1
MPQ#@O(X51^)H Y"W6Z/Q)O=5ETZ\BM)-%B@#-"3^\621RGRYYPPZ<9XS7(Z3
MI&KZ)HOA"_NO#UWJ$5E8S6%_8H@,T)9U99$4D!ON@'!Z&O8J* /.]7TV1]+T
M!M/\.R6,8UZ&_DM881OCC7.Z20+D;CUP"3R.I!K6\.6]S%XZ\6W,MI<16]Y)
M;-;S/&0L@2$(V#[,._7MFNNJ*>Y@M45[B:.)68(ID<*"Q. !GN3VH H^(TDE
M\,ZI%%$\LLEI+&B1J69F92  /J:XJ_TK53\//",EMI4EU=:*;:2ZTV0;'E58
M6BD5<\%AN)'8XXKTBB@#SZ?3M/U?1KB5_!]]86UY/")"D8BO04W$380DC8=N
M.<_>XQC.+JB:QI^AZ4NJ2W5_%#XIM/L4TT02YG@&,;UXRP.X D D 'N*];K*
MUO0+;7A9BYGN(Q9W*747DL!^]0Y4G(.<>G3UH XCQ-X8U'Q+J.OZKIENT+/I
M<%I;+<(8C<R1S^<<JV"!@*F3C.3V&:+K2I/%_AO58;/PE+HFHRZ?);^?>HBL
M7.#Y2,"24)!RQP.G!YQZ8. !G/O10!RFCZKJ7B"U"W7ANZTRYCMFCGDO%0#>
M1C9$0264GG=P, =SQRL-AJO_  KKPAITFC7\=UINH6)N(S&"0L+@NXP3\N!Q
MW/85ZK10!Q?B;0M1F\4Z=J6DJ0E]"^F:F0=I6 Y=9!_M+AP/=Q53Q'9W.E>-
M8-7_ .$?N-7TB?3TLGBLT5I+9T=F5@A(RI#D<=,5W]% &;H%I'9:+!#%ID6F
M1_,RV<04"(,Q.#MXW<Y.,C)/)ZUQWB_2;R?5[W4=$CU.RUV*%$MYH$+VU^,9
M$4RGY< DC+8P#G)Q@>AU$+F!KE[99HS.BAVB##<JG."1U .#S[4 <#>V^JV/
MBCQ0YTB[NAK&F0)!+;*#&)$2165B3\OW@1ZCID\5G:1!KOAF7PQJTN@W]U;K
MH,6E7EM;A6GMY$((?;NY4\@\Y&!GTKU2B@#S_4QK.E^(=$\30Z!/-:+;3VES
MI]H%::W61U=7"@X8Y0;L'C/?K4?B*WU-KG0O$*>&Y+BTMGN%N=+B"&=8Y=N)
M-H.TN&3) /\ %CU->B44 >>WNBV&HZ9;;O#NH:/'/>/<Q3V"[+NUDV "9Q'G
MEN5(^;C;D=<57T?4M0TC2(]?.J1ZE;M=-;:SI\16:(;U$9DC0'_6)RRX/W><
M&O3** /.-+M?$>F^(-"\0:U:R7'F:0VGWPM8MS02>;YBR&-<GY@ &"@X/M5*
M\\/:C!:/=I87+F^\50ZI]GCCW-% C+EF Z$A=V.O(&,@UZI10!PGC/2Y+[5/
MME@-6L=6@L@;/4+&-G65BS'R)4P05R%/S #YCR*VM-UR[34K#1-2TR>*\DT]
M9Y+F-1]G,H #QJ<YX)],8Q[5T-1"WB%R;C8/.*[-YY(7T'H* ,?QDVI+X2OS
MI%FMY>[5V0LBON&X;B%;@L%R0#P2!7&IIUR^O^(9[CPYJUWIVHZ3!&4NG!>;
M:TF]3\^58AA@#&/1:]/HH \S@T6\BTW6=,NHM5UKPW)';"W2[1ENXR9?G56.
M'81C:X)[C )P:K:II'B"3P!XJT@/J&K02B./2I+J$BZD! +*^0"0IZ,P!//M
M7JM% 'GGB"]N+'QS!J>FZ;J<TS:2()WMK59\*9"R!HRZ,A!#D'G.2,<53M;2
M 6O@JUT;3M4%KHVH,MREU;LLL \EQF08ZDR*>.S9'%=E?^$[&]U9]4CN=0LK
MN5529[.Z:,3!?N[EZ'&3SC/O6K9V4%A;B"W5@N227<NS$]2S$DD^Y- 'GDFD
MFZN?%D6I:-J$UE?ZI!+$T*,D@18T7SHR.<JZ9]<#H:O:9JFL>$]"OIM4BU/6
M;**]"6UPT(6Y^S[ 6DE!P2%(89(W' XY%=[44UO%<*JS('56#A6Z9'0X[X//
MU /:@"6O)]0TK5)_ GCBRCTR\-UJ&KR3VD7DD&6-FC(8>GW&ZXZ>XKUBB@#S
M>]M[BP\8ZO/>^%;O6],UI8I()((U8Q,(EC:*17*[5.T')XY/OC02PN+/Q]HD
MZZ8T-E::++;/]FB)AA<M&51<#IA#C ]*[BB@#SK0M+=?A3)I6K:)>3$W,HFL
MPI60H]RSAE(/4*P88/45+I5YK'A/2]:N+E-6UO2[9XOL+31 7A0C]X&W;2RI
MP0S 'KVKT"HI[>*ZB,4Z"2,]4;H?J.X]J '12+-"DJYVNH89&#@UYK9S-)=_
M$73DL+BZFNKLQQ(D19)&:VC7:6Z+U&2V!@]^:]-K)TG0+?1[[4;N">XDDU";
MSYQ*RD%\!<C &. !^% ' 6^AWOA#4[1+W0;GQ!ITVE6EFTEFBR/!-"K*058C
MY&W9SGBMFVTV>T\<>'98=&:SLK?3;B%TMXOW5NTCHRID<=%.2.,UWE% 'G5U
MI5_#XI.HZ%'J-E=RZD@OK21"UE=PA@&FR?E1]@SD$'*XP<YJM%I.JVO@WQ/X
M1GTZXGN[R:Z^Q7 0M%,DY+*[/T0J6.0V#\O&>*].HH X32].NM+\;W,DEO=R
MVD6@VUDMSY+$2R1LY8#'?# UC>'+;7--T;PCIUUHM^+:&QEANC;(%G2;<NU"
MY(*1D9.5(R0,G (KU2B@#R6PTK5X/A]X4T^;1[V.YL-<BFGCV;BL23L[/P3Q
M@CW/8&O6<\9Y_*EHH \YL-"U#4O"'C?2?(FL[C4KZ]DMFG0H'20?(V?0XP>X
M]*GT1CJ*)/=>"Y=*U"SMY!/=7,:;48H05A8$E@3WP!@>N*[^HKJ#[5:RP&1X
MQ(I4NF-P!],@B@#RO0+*7Q)\.? ^G6]I<(]K/:7<L\D15(DB^8LK'ABW  4D
M_-SC!K7TS1;Z_P! \=Z88)[.75;V[>UDFC*ADDB5%;/ID'CK[5V6AZ/;Z!H]
MMI=H\K6UL@CB\T@LJCH,@#-:% 'G>A![Z" WG@22TU.PMY%FFN8TV%C&5*PL
M"2V\X'0#&<GIG-3PKJTNG:GHNBS:C'HMYI$T:6NJ*<V,YVA(HW;DH1N! + ;
M1SR*]6HH X+0)/MQAN;KP3/IFH64#B:XGA0[6*X*P%26;<>^ ,#Z5D:=I>I0
M>$OA[:2:;>"XTR^C>\3R3F%5CD4D^O+KTS7JE% 'F;P>(-+TOQA;VFB3SW$^
MKF\A<QHZR0N8LF,,<,X <@$8!49[ PG1]4N;KQRD&DZDL>KZ+'%:RW<@)>01
MS+AB6)!)<<=O:O4J* //)X=0NXO <G]DWT7V&Y5KE7BYB40-'DX)Q\S#CKWQ
M5[4_#U__ ,)V+BRC!TK6+=4U7G[K0D%#COO4F,CT^E=K10!YWJUK<Z7XXU*Z
MO/#-UKFEZK#"(WM$61H)$4JR.K,,*PP<].OX0:_H$X*S:197VC:S:Z<B6;Z=
M'OMIN7(MI%QL*J<<L /FSGC%>ET4 8=CKEP^NIHE[IUQ%<BR%P;H*/(D8;0Z
MH<YX+CJ*K>/-+O\ 5O"DT6F1)/>0SP74=N[;5G\J17V$^^W'UQ70+;Q+</<!
M!YS@*7/)P.WL/:I: .*TF\C$=UK=MX*O+"XCMO**S0*MQ,V01&NTD[ >23@<
M@CO5'PYHM_X8U;4-"2WD?2M4B-S'=P0%5M)V!#Q>NS^)?[O0^M>AT4 >:>#[
M&>.VTO1=4\&/%J6E[$.HR(C6^(Q@2QOG)8@< #()YXJSX);6=+TJQ\*ZCX>N
M6N=.EV#4'53:O&&)$JMG.XJ>@&<GG SCT*B@#R/5M-UI?"_C#0H=#OY[FZU=
MKR"2-5\N2)Y8W!#$\G@@CMCG YK>OM*U*[\7^(%6RN88-9T2.VBNQMVP2#S0
M=Y!X(WKTSFN^HH \VCTS4M:\*>%M!GTVYL[_ $J[M'NG=,1QK;]61_NMNV@#
M:2?FYQ@U?T&UN8;+QLMSI-Q*MW?W%Q!!+&5%U&T2* "?[Q4C!YYKNJ* //?#
M]OJ?AJYOFL4U?4- AL/,@LKR,_:(9@>(8F?!9=H]2!@8)KMM)U%-6TFUU".*
M6%;B,2".489,]C[BK,L:S1-&X)1A@@$C(_"ECC2*-8XT5$4!551@ #H * /,
M_&UGK>JGQ;IRZ/>RQS6*C3WM-J1S'8=QE;(+,&R IR,8P.<U=T\ZMHWC6?4[
MC1K^>QU;3[:)#$BN]K)%N&QP#\H.[.<XSUQS7H-% 'DVAZ7JUOHG@:"XT>]A
MDT_5)Y[D&//EQMYP#':3_P ]%XZ]>,5HW5A?R1?$E5T^[)U.+;9?N6_?G[*(
MN/\ @8QSCUZ5Z110!Y_;6MZOB7P7<M87:PV6E307+F%L12,L0"G\4;I_6L?^
MR]3_ .%>M8_V7>_:_P"W_M8B\DY\K[7YN[T^YS^E>L44 <#<V<\GBOQ;<S:-
M<WEC=Z3#"D9C*BY*B3?&"<8)#@<XZUF'P_K7_"/^*-'T^;4+W2;C2&2Q34D*
MSQ3D,/)5F 9D QR>!D 'K7J-% ' !+Z[\3>"+TZ3?PPV=M<QW!DBYA+QHJ[L
M$XR5/T[XK)\:66NZM:^++ :+?2.S1-8FUVK#-& A+.0P+R9!&#G "X'4UZK1
M0!P5WIVI7?C75)!87<-OJVA):QW(VXMY TN0^&X(#J>,YJA%I.IZMX*\.>&K
MC3KBTU#3;FU%Q*R$1QI;D9D23HVX+@ $GYN0,&O3** .'T&VNH#XV,^E3R+=
MWLMQ;Q2QE1<QF%%P"?4J1@^M5/#UKJ7AN\NVT^/5[SP_#I[2Q6%[&?/MYP1B
M&)FP64J#QD@$#!.:]#ILD:RQM&^=K#!P2./J* *FCZDFL:1;:@D,L G3=Y4P
MPZ'N#CN#7 ^,[76M3F\5:<NCWLL,^FA-/DM-J),VQMWFMD%B&. AR,=CFO28
MXTAB2*)%2- %55& H'0 4Z@#@M+BO5\=:9J,^F7L%M'X>-M(SQ9VR^8C;3MS
MSM4G].O%<_H^EZYH]AX1U-M(O95TJZU!+RS2/]ZJ7$C%)%7^+ (R!SAC[UZ[
M10!QWA&*]_X2OQ7>7&F7=K;7MS!+;R3JJ[P($4\9)ZCT^O/%2>,[#4'U#P[K
M-C!)=+I5\9;BVC^\\;HT;,H[LN[.._.*ZVB@#S;7_#M_KK>,=4LK69!?:*MA
M:PR(8WN)%WL6*M@C[RJ-V.A[8)N%;V\\6>#;\Z5?0P6MI=)<&2+F(ND87=C/
M4JWT[XKO:* /(VT;68["74(M%N+HV?B:ZU!K"1=C7-M*'7<F>"P#Y Z\5?UZ
MP;4O!][+I7A2YL);N[LW\EK=5N)A%,K,SA20 %! R<\'U%>FT4 (C!T5P" P
MR,@@_D>E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7%_%6*.3X>WK.BLR3VS*2,E3]HC&1Z5V
ME8'C+0[GQ)X9GTFUFBA>:2)C)*"0H217Z#KG;C\: *>M>+;BUN]2M-+L1=W&
MG1*\J,LA\QV7<(UV(V#MQR?[PXZX=%XKN-0U*TTVQL#!>SZ6-2>.^W1F,%@H
MC(QG=NR">V.AS5>\\.>(;;Q1<:WH&IV-O_:,4:7]M>0M*F]!M61"I4YQQ@X!
MQ^6%XED<^+H+.'6](AN[#3@CMJY>)IO,;YF1T="P^0;ARHR/P -O2O&=_K'A
M[2M6CTJ&UAOVD+S2W.Z*UC4'YI#M7DL-H X[Y[5AZ_K<?BGP)H^JO:QQ3)KU
MM"0&WA62Z"$JV!P=N?H:OV6EZSK,>A7UM+H]NFD32QI%!&[V=Q&R*%DC&004
M^8#M][!P:%\":M'X972/[1LY"FL?VBDAB9?E$YFVD9/))Q[>] '8:[J$NDZ#
M?ZC# EP]I \_E/)L#!5)(S@XX'I7-V_C+4QI]A=7VE00#51"-/6.=I68M&TC
M[U5,J%52>,YR!Q71ZY8SZIX>O]/A:-)KJV> ,Y)5=RE2>.N,_C[5SU_X0U"[
M\*:'9V^HQ6FL:*8GM;I4+1LR(4(93SM9201VSWH J7?C[4[#3;Z>?P_(9+2^
M@M=Q+Q1W"2LJJ\9=!D@G!4XP1UJ8^--6L=6U+2M4T6VBO(=/?4;/R;PM'/&A
MPREB@*N..Q%9OCF#68? C2ZQ?V;W\FH6(46\3)!%BX3& S$D]23D=AQBM^]\
M-7NJ7UYJ=T]JEX^FR:?;1HS,D:N<N[,0"2<+Q@8"]>> "E9^-=3;2-.U&^TF
M""+54MQ8+'<-(SO(A=@X"9 55)XSD8Z'HDOCVXL++4Y-4TQ[5;*Y@A6\=)$M
MI$E('F9900%Y##G!QSSD27/@R^N/!.B:5%J,=KJNB^2]I>1H63?$FP%E/9E)
M!'OWJ_'IWB:73RU_?:;->O(N^".!UMC$ 0R88EB6W<MVP...0!DOBN2ULK=Y
M8;>::]N_L]D]M(TL4Z^7YADRH)P K\ 'D8SSFLJ\\>ZI8:1J-U/H#^98WD%O
MN8O%'<)*RJKQET&2"V"IQ@CK43?#B6#3I&TB\ATN^CU/^T[*.)2]O;-LV-'@
MXRK#<3@#[W XYOZOX;\0Z]X9DLM1U&P-]-/!*3#$ZP1+%(' 522Q)(Y)/<<<
M<@!<>*]8@NM?TV?3[*"_LM.&H6K+.TD;H2XP_P JD$%#P.#ZCK2:/X@UA?"?
MAR>Y@MV>]LTEGOYIB(H5\I6#2$@?,S'&!QUY];5SX8O+WQ/J.IS3P1V][I(T
MTQIDLG+MOR0 >7(Q[?A6=:^#]?M8?"^-4T^1]%A:W,;V[F)UV*BR ;L^8 IY
MX^\0,=P"I<^-=5U30?"^HZ;!;V_]HZN+*X1I6/*-("%8+]TF(\XS@XQ6U%JU
MPWC'6+"'1K$:C;Z=#,EQYO-P&9P$9MF5 *MCKUS67!X#U6V\/:=8)JEH]QIV
ML-J5N[6[;6!>1BK@-G/[T],=!]:WK+0KZW\:WFN33V[Q7-E%:[%!# QLS;O3
MDN>.WJ: (-%\63ZWH>BWT%G"MS?RM'-;M*?]'V;O,R=N25*XZ#DCUJG_ ,)U
M<S&SN['29KS3KB\^S$PQ2M*J;BOG<)M*Y&<9Z'.<\#3T3PK'HOB'6-2CG+0W
MTOFPV^.(&<+YI'^^RJQ^E9FA^%O$.@SOIMKK-J?#OGM-$C0-]JB5F+&)7W;=
MN2?F() /&." "WI7BU]8UJ:SM4M#]FO);6ZMVF(N(%3<!(4QRK%5Q[,.3R!U
M5<=-X0N;_7].U.^-DMU87CSQWUN"L\D)W;86XQC# $Y.=O09S72:9'J4<,XU
M.>WFD,[F(P1E L6?D!R3E@.IH NT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !4-Q9VUWM^TV\,VPY7S$#8/MFIJ*  # P**
M** "BBB@"&XM+:[55N;>*95.0)$#8_.I5544*H"J!@ #  I:* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y;XB:CJ.D>"K[4-+N_LU
MQ 8R'\L.2#(JD<\#@GM0!U-%<]XQ\3IX7TB*95B>\N[A+2T25]J&5^A8]E !
M8GT%3^'+RVO;21XM;759D;9<.I4"-QU4(/N_0Y.,9)ZT ;5%%% !1110 445
MY_%XB;4/&FL:#?Z[<:-J,,H73;<+&$FB* B0%U/F$MNRN> .!G)H ] HK'M]
M1?2]'TV+6)'FU-[=1*D$1D>215'F,%0'C)Z]!D>HJ"+QIH$T>FR17KNNI2F&
MV*V\A#2#.4/R_*PP>&P>#0!OT5GRZWI\$MW'+,Z&TV>:3$^ 7^Z <89CD !<
MGD<<UG3>-M!MK749[FZE@&FA3=QRVTBR1!AE6*;<E3V(&* .AHK B\::'._E
MPW$SRF?R(XQ;2;I7V;_D&WYAMYW#C'>L+Q1XIB?3O#NKZ5JLD5C+K45M<X79
MN3+!T<,NX$%<8X_&@#O**YI/&&A:MI&KO;ZC<6XL8V6[/V>2.>V!4X?8R[NG
M(.TCBLR\U*XCU?P$+'5KJ:POBZR&0*#<H+9G5W^4'<2 <<#/:@#N**XV\\6:
M?HNG>*-7BO;_ %$V$G[VU:(XMW$8PB_*,*>&).1SUK7M_%6F37]CISO<1WU[
M$988I+25-P7[QRR@<>Y[CU% &W16/<^)]*M(KF6::94MKI+24BWD.)6(  ^7
MG[PY&1S6Q0 445PGQ EUS0_"^OZ]9Z]<P/ JO:6Z10F-!A%.[=&6)+;CU[B@
M#NZ*X#QBFNZ-X)U?5;;Q)?,8[ R+OCA#)("#E2L8X()![],5TNF>)]*U+4'T
MR"XD-Y' )RLD+H)(\XWHS !USQE210!M45C6_BG2+G4;:Q2X<37:,]J7A=$N
M%49)C<C#<<\'IR..:V&8*I8] ,F@!:*Y4?$?PJ7@']I,$FG-N)3;RB-9 Q7:
M[E<(<@_>(]>E6IO&NA0:M+I;W4IO8IHH9(EMI6V-)]S)"XP?[W3D<\T =!16
M*WBO1EGAC:Z8)-.;:.<Q/Y+R@D;!)C;G((Z]1CKQ4UIX@TV^U#4;"WEE:ZT[
M;]JC,$BE-PRO51G(&1C.: -2BN<&MZ9?Z]HGDZK>1R75O+-;VGDLD=RF =S;
MD_A&".0?F]ZO6_B/3;J>**&29O.#F*3R'V2!/O%6Q@_GSVS0!JT5SFBZYI4?
MA[[>NL7-]:O=R1I-<(?,:0R$>6JA03@_* !GBIV\7:+'::C<RW+Q+IH!O(Y(
M'$D((R"4QNP1R"!@X/I0!N45B:?XNT74]2CT^UN9#<2P?:(M\#HLL8QDHS *
MV,C."<9J>P\0:?J5S#!:O,QG@:XA=H'5)8P5!96(P1\Z]^00>E &I116+'XK
MT:2XM8A=,%NY##;3-$XBF<9^59"-I/!QSSCC- &U17"76JW'B'QCJ_A^"^U+
M3A9VT!MY[>W<;9F,A9W)7!7"* &^4\XSV[?<8;?=(S.43+%5R6P.< =_84 2
M45YIJ_C:75O!%OKFGS7>FA=6BAD#Q% T7VKRB"S+C[HR=IX)P:ZZ'Q3I&H1:
MI'#=7$3V" W(:VDCDC5@=KA67)!P2" 1Q0!NT5S^EZYIT.A:3Y=_=ZB+FU$L
M$K0L\T\:A<R,JKG^)<\#E@.IK9LKR#4+&WO;9B\%Q&LL;%2I*L,@X/(X/>@"
M>BLCQ+?75CHDHT\*=2N"+>S5NGFOP"?9>6/LIJKX(U]O$GA*QU"==EX%,-W&
M1@I.AVN".W()^A% '0T5@2^--"@$+/=R>5/,T$,RV\C)+(I(*JP4@G@].N#C
M.#2+XUT%]5;3$NI6NUN!:N@MI?DD*[@&.W !'0G@^M '045C0^*M(GU&UL4N
M'$MX&:U9X76.X"C)\MR-K<<\'D<C(I/^$KT<7UM:-<NK73M';RM"XBF=<Y59
M,;2>#C!YP<9H VJ*YAOB#X:2(S-?2B%;DVLDQM9=D4@;;B1MN$^8XRV*OV'B
MC2=2U"YL(+AUN+>(3.LT+Q9C)QYBEP R9!^89% &Q16+%XLT>:]CM!/*LTT+
M3P"2WD43HOWC&2OSXR#@9."#TJK9>//#NHRZ>EK>R.NH,4MI3;2+&[C/R;RN
MT-\I.TG/M0!TE%<_H/BF#7M4U>RBMKF+^S[DV^Z2!U#X1&)R1@<MP"<X&<5M
M7=W;V%G->7<R0V\"&261S@(H&23^% $U%8L'BO2)WN(Q--');VZW3QRV\B-Y
M+9PX4KEAP>G3O4%AXX\/ZG$TMI>2/$(8Y@YMY KJYVJ%)7YF)XVC)SQC- '0
MT5FZ9KVGZO<7=M:RN+FS95N()8FCDCW#*DJP!P1R#T-6[V]M]/LY+JZD$<,8
MRS8)[X  ')))  '))H GHK+3Q!I[174CO+"+5E659H'1@6^Z ",L3D ;<Y)Q
MUJG+XUT*WMM1FN+F:$:=M-VDEK*)(5;E6*;<[3_> Q[T =!15'^U[/S;.+?)
MOO$,D(\E^5 !))Q\O4?>QUJG'XLT>6^M[07$@DND:2V9H'5+A5&6\MB,/QSP
M3D<C(H VJ*YB#XA>&+B%YH]1;R$BDE:5K>14"QML8%BN-V<?+U.1QR*B\0>(
MX;GPOXD73+RXM-3TVP>=@T)CDC_=LR'#KR#M/(]#T- '645R?AOQII.HIIFE
M-?R'5)K-)!YL+J)R$!<H[#:Y'.=I/?T-0^$=:E33=>FU>_EG6UUNYM8Y) "Q
M4,%1 JCD\@  <DT =E16;I>NZ?J\]W;VLK_:;-@EQ!+$T<D9(RN58 X(Y!Z&
MM*@ HK)U3Q)IFD3O!=32>;';FZD2*%Y#'"#@NP4' R#]<''0U#=>,-#M+BT@
MDO&:6\@-Q;+%!)(9HP <IM4[C@C@<\]* -RBL:V\5:/=Z)'J\-V3:22>2N8G
M$ADW;?+V8W;]W&W&:Q?#&LW&I>/?%5JUU=26MK'9F*"XB\LP,PD+ #:#S@<G
M.>.30!V=%07L\=M8SS32/%$D9+.BEF48Z@ 'G\#7$ZKXH33/!_AY].OKZ^34
MKFUMUOWMW>1XG<!G.%^^5S@8SD\#B@#O:*R]#LI;.VF+ZA=WD,TIE@%VI$D*
M$#Y"2 QP<GYN1G!Z5'JGB?2M'FFBNYY-]O!]IG$4+R>5%DC>VT' X/Y'T- &
MQ16'=^+]$LKV&SDNG>YGMS<PQPP22&6/CE-JG<>1P,FHT\:Z ]EIMXMY(8-2
MF^SVK"VD.Z7)&PX7Y6R",-CH?2@#H**JIJ-M)JDNFJSFZAB69U\MMH5B0IW8
MV\E6XSG@TFJ:G9Z-IL^H7\IBM8$+RR;&;:HZG !- %NBN?T_QKH&J:NFEVMZ
MQNY(C+$KPNBS*.I1F #X[X)[^AJ6S\7:+?W5K;V]T[-=K(UJYA<).$^_L8C#
M8Z\=1R,B@#;HKDYOB/X=2WN)8)KJY,"SEDALY2=T7WU)VX4CW(]>E;7A_5AK
MF@V6HB*2(SPI(R/&R8)4$XW 9'/!Z&@#2HJI?ZE:Z:D37,A4S/Y<2*I=Y'P3
MA5 ))P"?8 GH*R;SQ=8)X=U;4[-I)I-/202P&!P\<BJ6"NF-RCIR1C!SG% '
M0T5RG@X76H6=EKCZI?R+<V,8N+6XB*H9B%8R)N (')&%^4_A5WQ+XGA\.-IB
M26\\SW]XEJACA9PN>23M!YP#@#DGZ&@#>HK@(/%J:1XQ\5#5K^\DL+>&SF@B
M%LTA@5D=G.U%R%&!DL..,FNLN-?T^W@@E$DDXGB\^);:)IF>/ .\*H)QR.?<
M>M &G1533-3LM9TV#4=/N$N+2==T<J=&']#GC!Z5;H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **0$$D C(ZCTI: "BBB@ HHHH *Y/XE6US?> ]0LK*UGN;F;RQ'%#&6)Q
M(K'ITX!ZUUE% ')>+M.N+ZY\.ZW9P2SC2[X3RVX0AVB9"C$*>2RY#8ZG!QS@
M57MK>;3_ !-XE\60Z?>26TUI!&EK%$1-=/&&RP1L'HRJ,X)P>V,]K10 R)S+
M"DA1D+*&V.,,N>Q]Z?39)$AB>65U2-%+,[' 4#J2>PH1UD171@R, 593D$>H
MH =114#7UHEXMFUU MTXW+"9 '8>H7K0!/7"^(;73?$EG?:=XG\.WTODS2+9
MSP6C2,Z_PM&Z E#V^; .,\BNZK%/A/168DVCY)R?W\G_ ,50!P4>F>(M"@\*
MZEK.FWFM^1ITEE?Q6S>9/"S.K(X /SD!0K8/;/-;VI^'3J7@.X72M)&DWJ3_
M -HV$)4"19T(96< D!F((/)X;GG-;W_"):)_SZ/_ .!$G_Q5!\)Z( 2;5@!W
M^T2?_%4 <[KVD:Q>>"8;V&Q\[5OML.J7%COP9-K F'=ZJ@50>Y05G:W;#6_!
M7B&?3/"=_8W=W8FV7[3;XN9W/1< D[1ZG YXKL(?#'A^XB66&#S(V&5=+F0@
M_0AJ?_PB6B?\^C_^!$G_ ,50!D:]<7XD\--;Z9=RV+,XNI+>#_28/W>% SR@
M8DAF&"!W&<URMII&KP>'+1'T;4$.G^*FOY$8!W: RR-N7YB7P&7IG.>,\UZ#
M_P (EHG_ #Z/_P"!$G_Q5,?PSX?CECB>$+)*2(U:ZD!<@9.!NYXYH YW4M+N
M=0U+Q-K\%G<)#<:)_9UO$8666YD^=BVPC<!\RJ,@=#VP3#'9WJK\-\V%Y_Q+
MTQ>?N&_<'[,8_FX_O''Z].:ZO_A$M$_Y]'_\")/_ (JC_A$M$_Y]'_\  B3_
M .*H XO4='U*_P!-^)5O!87/F:B0UF'B*B<"!$.TG_:4BM;Q3%<W?A"P\06=
MK-;ZKH[I=VT-P CN -KQ'KC>I*XZYVUM'PSX>%PMN80)F4N(S=2;BHX)QNSC
MD<^]59_A]H%QJ45Y)'=D1J +?[9)Y+$'(8KNY8'H?8>@H MP-/X<\/6YDLKF
M_NGE4W"VB!F,LKYD?!(^4,Q/L![5O53T_2K/2U=;.(QAR"V79LX^I-7* "N0
M^)]I=:C\.]7T^QM9[J[N8@D44,98L=P/;IP#UKJWGACECB>5%DDSL0L 6P,G
M [\413PS&012I(8VV.$8':W7!]#R./>@#D_'$-QJGPPU.ULK2YEN;FT\J* 0
MMO+''!7&1^-9^L:=>:MXOMC;V]U%#-X?NK(W+0.JQ2R%"H)QQ]TG\*[SSX?M
M M_-3SBI<1[ANVYQG'7&2.:DH \[\(1O<#2K/4?!UU::IIBA9;RY4&!"J[2\
M+[CN+>@'&3D\<^B44C LI 8J2,9'44 >06-I)X@^&6M^'+:SG>ZO-5NHT<PM
MY2YNB?,+XV@+@G&<Y7@<BNNT.TN8_'OBN1[>ZB@NH;1(+EHF"N8T96PV.Q(^
MO;-;N@Z#;^';*6TM9[B6*29YSYS*2'=BS8P!U))K5H \HBT/5+OX6Q^!KBPN
M8M5AFC@-QY3>3L6</YZR_=^Z,XSNSQBNB\1Z#J+>+[.^TM";?5+=M-U4@XV1
M#+K)_O >8@/JZUVM% '(:S:SM\1?"UQ#:3M:VL%VDLJ1$I&75 @) QSM/T[X
MK'\.:=?Z9K]A)I2:G;Z1.)9-0TN^A8QV3[208'([N<;5)!#$\5Z/4%M?6EXT
MBVMU!.8FVR"*0-L/H<=#0!Y;9Z/K,/A[2+R/3KLR:7XAN+Z>S:,J\D$DDGS(
M#]Y@L@8#ZCK5_P 1:3=ZM=>*=:L[.[$5SX>.F6\+0,LEQ,2[9V$!@!N5<D#J
M>PS7I5% 'G[6]VWB/P1.NGW9BL].N8KDM;L!&SQQ!5;CN48?_KJ/PAIE_I6M
MV2:8-2BT*6UD:XT_4HF_XE\GRE4AD89()R-H) VYSTKT2B@"MJ%L]YIMU:QR
MF)YH7C60?P$@@'\,UYQ%I.I:IX T+PI/IUS:ZGI]Q:I-*T1$4:0."95D^ZVY
M5X .<MR!SCTR6>&$H)94C,C!$W,!N8]AZFG22)%&TDCJB*,LS'  ]2: .2TB
M.XC^)GB*YDM+I+:YM;2*&=H6".T?F;P#CMN'/?M77TU'26-9(V5T8!E93D$'
MH0:=0!Y(NG:K%\.(-%?1[\7=IK2RL!#N#H+PREEQG(V8.?? R:Z&6&Y_X3GQ
M%>BRO#;3Z-%!%(+=\/(ID)4<=<.M=U4?GP^?Y'FIYVW?Y>X;MO3..N* /,;;
M0WF\(^$K6ZAUK2]3L-/*1ZA90N7M90$!C= #N5L9P1@[.HKO/#!U1O#.G'6H
MXX]2\D>>L:A0&^@X!QC(' -:U% ',7=O)K?BP12#4+6VTZ'=!,B,BRS/D,0Q
M&/E48]_,;TK(\.65WX9^(&M6$=M?S:+J02\6Z>-BD=T>)%+8_B #9Z9XS7?4
MR:*.>&2&50T<BE64]P1@B@#Q_1Y[:VTS2;34=-UZ'1]+U![^V==/,D: ,Y0M
M.C$-& Y;(49&.<=>KTC3[NXUKQU$T%Q:KJ,J_9KB2)E5A]G6,L"1V8'^=:.D
M^$],M[>-+74]1NM-C^2*UDOC+ H4XV^I QC:21QC%=/0!YMX4MI;BUTS2]1\
M(75IJNFH(WOIU!@C*KM\R)]WS%NP XSSP.8O"%E+#::7H.K^$+DZCI+H/M\J
M!K7$?"S(^?O%>@ SD]AFO3J* /)KS3=1E^'7BJQ32[XW5WK<MQ;P_9VW21M<
M*X8<=-H)_P BM;Q%I5[K?C"_2U@N8X;SPS/81W3PNJ+,[@JI....?TZ\5Z'1
M0!Y_X7D%W)I[W_@V\L=2TV-A/=7,6Y(SLVMY# DONX^Z.F<]LXVGZ;J,'@+P
M19R:7?+<V.L137,7V=BT2*TA+'CIAEZ>OL:]9HH Y'PK;WEAXF\4P7-A<)'=
M:A]KAN"H\IT,4:C!SR<J>,<8K6\5&^'A35#IEE%>WOV9Q%;3*&60XZ$'@_3O
MTK8J.:>&VA::>5(HE&6>1@JCZDT >;6<-\/%\NI?V5K36MQX?-N9KJ/+>:)"
MQ!0'Y.H 4 >PQS3?[(U?_A4WAJ.WTR:2_P!(>VFN-/D!C>81@AT&>^"2#WQ7
MI]% ',^%A:W<]SJ=OX<N=),J(CO>Q".>8C/!&2=J]L]<G' YO>*K:"\\-W=M
M=6$U];R[$D@@SYA4NN67'.5'S#']VM'[=:>09_M4'DAMAD\P;=V<8STSGCZU
M/0!Y3=:+XG;1;^&W>[UFTT^]M+NP%^AAN;E$):2%F(!;'&UB.23UKJ-"M=/U
MM;ZX/A>YTV*ZM_LT[7\02:=3G*8R3M )Y/7/%==10!P?AGP_K/\ PC5]IVJN
M4N+:VETFQG8Y+0C(6;V+#RP?^N8/>JGA)&DBTNSU/P;=VVIZ4@66\GC#0H57
M:7A;)+%L<!1QD^G/H]% 'FFE0:QI_P ([VVM]&EDU-+B=A:7%ODLKW+/N"MP
MQ"-N ]0![57?2M3O-3\6BWTK52FJZ L-O->D O*%F&&RWRDEU^7C&>@%>GS3
MPVZ!YY4B0L%W.P49)P!SW).*DH X"'3[C7!X-C6QNK8Z,ZSW<MQ T10K"4\M
M<CYMS$<KD87KTSBOI&LOH.J3VVE7,LUMXHDU1;.13$UW;ECPI..2"2!UR.G2
MO6:* .)LM3M]/T[4?$5IX.U.W;9&KQ- HO+C!Q]TM]U0<Y)]<<#GL;6XCO+2
M&YBW>7-&LB[A@X(R,C\:+BWBNH&AG0/$_#(>C#T/J/4=#2B:'S_LXEC\[;O\
MO<-VWIG'I0!PWBM-4NM>U"R72KR2TGTDI;SV2A3+*2^4EDR"JC((7(!RW7@5
M0T.UOTU/P!)/I5_ NGZ/+;71> _NG*0J <9QDHW]<9KTB&>&YB$L$J2QDD!X
MV# D'!Y'N"*%GA>:2%)4:6, N@8%ESTR.V<&@#R:+3=:M(8-4BTJ]F2P\47=
M_+9B(K)+;REPLB*<;B ^<=:ZGPW]KF^('B/47TR^M[*]MK,037$7EAB@DW#!
M.0?F';\J[2B@"KJ1(TNZPCN?*8!44LQ..@ ZUYNMAJ$7PZ\#6)TV]-U8WUC)
M=1"W8M$L39<GCM^O;->I5&L\+S20I*C2Q@%T# LH/3([9P?RH >K!U##.",C
M(P?R->>>+XM6OM2U^P72+V2WN-(,=G+9(%$\A63*RR9!PI(PF<'+<$D"O1**
M /.M&@O5\3>%+J?3+Z"*UT%[:=G@/[N0F+"G&>3L;],X/%-TCPW/JGPZU72K
MJ*:PNS?W5U:RS1E#$_G-+#(,_P# 3^8KT>L+4=,TKQ8(#_:,TL-K(PDCLKTJ
MDF1@I*$/S#'8_P!30!%X+^V76@QZQJ<2QZAJ86YF13D(-H"*/;: <>K-2?$#
M_DG7B3_L&7'_ *+:NB "@   #@ 52UG2H=<T>ZTNYDE2WNHVBE,1 8HPP1D@
MXR* .,%G/K]QX-N;.RGC.DQ-<2R3Q-$!F#8(P2/FW,1DKD87KTSD:7#K$NK>
M#-1NM!U2*6SEN4O8Q$L<-N7B90L<8. @)^]CD8Y)KU"QM5L;&"T622184$:M
M)C<0!@9P /TJQ0!Y]H.FWTG@CQ;8&RN(;F\N]1>!)HS'YBRES&1GUR/IWKI?
M![3'PCI45Q9W%I+!:Q0O'<+M;<J 'C/3(/7TK8>>&*2..25$>4[8U9@"YQG
M'?@9I9IHK>%YII$CB099W8 */4DT <IXLL[^/Q+X9UZVMY;JUTV:=+N"%=SA
M)8]HD51RVTCD#)P3@5EW6E74K^.M9BM;D1ZK8):VL'DL))F2)UW%,9&2X49
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M9>6OVC&QG90KHVWYE(8$9V^]:D'B#5Y=031Y=,M(=7,4ERZ?:B\20A]B-N"
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M,<$:-)*B,5\R0NK=2#A0!@=S0!V%%8ME>WFG6=R_B&YM]RW1C@DBC*B5"%V
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M2K%YX@TNP!:XNU"B(3,R*SJB'.&8J"%!P<$XS@XH TJ*IC5+%M7;21<QF_6
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%->1(HVDD=411EF8X 'J30
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MX \601Z;J/FW'B,W$,?V*4-)&;B)]P&WD85B?3'->D?\(M8?\_6L?^#>Z_\
MCE'_  BUA_S]:Q_X-[K_ ..4 8U_(S?%;1;A8+EK==,N(VF%NYC5G>,J"V,
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MERP">._U1X67<)%UFY*D>N?,Z5%;Z+HEV5%MJNHS%E+#R];N&R <$\2=,\4
M8$&J)J'Q%TC58;+418#1IXC.]E*H#F2-L$%<CA3R1@]LU@:7;7$'P^\ V[:=
M>I/::S%+<1?8Y T*@R[F8;<@?,.3ZUZ-_P (M8?\_6L?^#>Z_P#CE-D\-Z9"
MF^6^U5%R!EM8N0,G@#_64 </?6.JR:?X]TVTL+MKZ74TOX%\MT2>)5@)59,8
M);8RX!S5MYM*UO2=8U6PT/6DOO[(GM7FOH[CS%W#B!5<G>=W/RY QUYKK_\
MA%K#_GZUC_P;W7_QRC_A%K#_ )^M8_\ !O=?_'* .(UP16_PU\%>=:R((;[2
MTFA:W8.-I4,I0C).<\8I_B.VFGUOQ%XBTS1_[2MAHB6;020,4NY?-W9V\%]B
M=<=?N@Y!QT.M?#ZPUB.U0ZGK, M[A+A<:C-)ED.5^^QQSW&#Z$5ICPM8@#-W
MK!/K_:]U_P#'* .&$DK^*-;NU@U>Y@O/#BQQW$UC(GF.&ERH4(-OWE 7 )SG
MGK4M[9S_ /"E]!2*PN?/LQIS7$"VS^:OER1F3Y,;CC#'IZUVG_"+6'_/UK'_
M (-[K_XY1_PBUA_S]:Q_X-[K_P".4 <=XG%VVHW^K^'Y+^WU,P1J^G75F[V^
MJ1X^5<$?*_S%3@@C^("NUM]<M)O$L^C&VN(K^.V6=I&A(CD7(R%DZ-M+C([;
MOK49\+V !)N]7 '?^U[K_P".5#'X4TF9TNX[K5)"4PDJZO<GY3@X!\SH< _@
M* (_B$KR?#_78(89III[*6**.&-I&=V4@ !036+HZZ!8:9HEQ;:!,NL0Q11I
MY6ER1-YC)L8._E@!?F)))P,9[5TG_"+6'_/UK'_@WNO_ (Y1_P (M8?\_6L?
M^#>Z_P#CE '#ZQI^IZA??$6'3[2X,]PEFUMNC>-;CRT&]%<@ YP5X/>EO;:U
M\9:%JLVB:-K%OK+:7-:^=J1FC:/<,^0#(<,2?3@=R,C/;_\ "+6'_/UK'_@W
MNO\ XY3)?#FF01^9-?:K&F0-SZS<@9)P.3)ZF@#,T+6+7Q(MM+'X?NK;4+>U
M:*:2[LVA-J2 #&KL/FR0.%XP,G' /(6:S'P)X LI=,U$3:=JEM]JC>QES%L5
MPS$;>@)7YNG/7@X]%_X1:P_Y^M8_\&]U_P#'*/\ A%K#_GZUC_P;W7_QR@#$
ME:;1?B=<:A>0S'3+_38X8+B.)G6&1'9F1MH.W=OW G@D8ZUS,.CW>GV_AT2V
M5UY+^*9]0CA%N[?9;9A+LW #Y.64X.,;O8UZ#_PBUA_S]:Q_X-[K_P".4?\
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M/5?I4_B"/3M8\$^)M0T71=7-U>6(MVEN8IS-.P/RHJ/ECMYRV,<\$\X]6HH
MX<Y?XFZ)<0VUP+8:+-"9?L[A%9GC*J3C .%;@^E3_"\2P> ].L+FUNK:YLU:
M&9)X6CPV]N!N W#IR,CGK78T4 <;K"L?BGX=G^SSM##8W:/,L#,B,YCV@L!@
M$[6[UR%W;3M\-/%=O'IU[]HGUZ2:*(6<F^1#<HX<+MR1M!.?:O8:9)+'"%,D
MB(&8*NXXR3P!]30!Y)XXDN]3L?&=E#I5_%+)'"]NMK8N1?*$4^8\FWDK@J%R
M"-O0GITGB]+^VO='\5Z%;EKT_P#$OEAF4QF6*8@1[@>1LDV-@C(!;-=U6/\
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MF5\%0#RW3/;WJ[%H&J:C>:'/KSVA;2&:53;,S?:)2A0.05&P %CM!;DCGCD
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M:6?>)8-[[V0@###.<-G//2NKL[G7!XJDM+DV,NF"T#!X$<21S KPV21A@6(
MY 7GKR ;I(52Q(  R2:XRW\?&ZN-)EM]-\_3]3E$4<L+LTL08$H\B;,!#QD[
MOER/P[)T61&1AE6&"/45QGACP[XHT".#1GU2PFT*T;_1I!&XNC&#E8F_A '
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M_NC-=RH8( Q!;') P": //+][ZQ^+>H2:+I4%W=RZ%"S(\P@5CY\@RS8))P
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MGO+>W6[E28O(2<)$"T:RX8K@#J2,\DT =E#XPU*?7-4LDT2-;72KI(KRY>\
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MQHICD9W0K\BKE,J#Z]>: /1Z*XOR_%5O>O/_ &B/[-ELI-QF>)Y$G W*\85
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M/-<Y8>)M<G\%>#-3DU%S=7^K1VMVWE1XFC:1U((V\<*.5Q0!Z8'4L5# LO4
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M'3MCW?V,J2A*[0"X8C=M&2!QWKIO"FIPZOX=M[VWU,ZE'(TFVX9 C$;VPK*
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M<&ZN85@D0LNPHI)4 8XP2><]ZU!(AC\P.I3&=P/&/7-(LL;QB175D/1@<@T
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M)/"\4B[HW4JP]0>#5/4-9L-,LUN[JYC6%Y4A0A@=[NP55'J22*<TMZ-75?\
M1!IOV=F9BY\[S PZ#&-FW.3G.<4 8L7@328=(L-/CEO1_9T@DLK@SEI;<@8
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MWTI7DCCSO=5P"QR<<#O0!5TK2[71M-AT^RC*019V@G)))+,3[DDD_6KE(""
M000>A%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !67X@U0Z3I$DT;1_:I66"U5S@/,Y"H/IN(S[
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MQ25]1M/L5_$LUYAFN(EV;-V  R8)V\8(Q7IUW8V=_&L=Y:P7**VY5FC#@'U
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MGA;4+;5=4TG68KXS:)+'+;VRQ+"(P-RM*JJ-K@\#.#U]#CTU;>!)WG6&-97
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MME+>7MQ';VT*[I)96"JH]237#6_C_4M2B\.&RTZUCEU*[GLKJ.>5LP31*Y8
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M1^%/_)+M _Z]O_9C0!V-%<[XPUZ^\/Z?97-E;V\YGOX+5Q,Q&!(X7(QWY_\
MUUEIKWBF37]7T)(=(%W:VT5W#<$2>7L?>-C+G);*8R"!CG':@#MJRKO0+:\U
M^QUF2:X%U9*Z0A6 0*^-X(QSG:/RXQ6!9>+M0U70= U."&TLH=1MFEFGN#Y@
MCD &V)(PRLY8EL8[+TYJI#XZU*;PSX;\0M;6L-A?W"V^H%@Q-N6<H'!R/E+
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M>AK3S8KA%)*ML+ JPR<')]/KT]G;FTM(X#-),R#YI9#\SGN3CCD\\<>E3T4
M87B'0)M<NM'FBO8[<:;>K>;6@,GF,%9=N=PP,.?7M5&3PC=/=>*9O[3A']O1
M+$1]E/[C;'Y8/W_FX^G/Y5U=% '$0^!+ZWGM7BUU55-(329P;/)9%SAX\O\
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M:M#(\+1+C&U60@@8'3.*FN?#&BW::>DM@FW3B3:A&9/+R,$?*1D$<$'(/<4
M</9S:E%;^,=;?5]4N9-"U"[:UM3/^[D"VZL$=0/F7)SCC!&1U.;$][?Z?I/@
MS7++4;NZFU*YM8+Q))F>.X2=<LP0G:A4_,-H& ".E=KIV@Z;I,EY)9P.C7LI
MFN-\SN)'(P6(8D9P /P%0:?X5T;2WA:TM&18&9X(FF=XX"V<F-&8JG!(^4#
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M,RB5U,BCHK@,!(/9LT ;-@\DFG6KRRQS2M$A>2(81S@9*^QZBK%(    , =
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M2,RN3&PZ%'W;EQSC!&,U-)X-\/RZ"-%DTY6L5D$H4R/O$@Z/YF=^[_:SGWH
MP_"MHME\3/&422SR(8-/8>=*TC+E9N-S$DCZGO7<UD:9X8TG2+^>_L[>07<Z
M+'+/+<22O(%^[N+L<D9//6M>@"CK,=C+H=_'J>/L#V\BW.>GEE3N_3->>JOB
M'X=76FV5W<KKWA2>[AM87G&+JR9F CR>CJ#CW^E>DWEI!J%C/9W48DM[B-HI
M4/1E88(_(UFP^%=(@FMI!#/(+5@]O'-=2R1Q,!@%49BH('3CCMB@#AK=8=,N
M?B->_P!JW.G-#<JJW;223^46@CY$9;#')P/3@# XJ9I;W^V_$>D3O?PV3^'T
MNT@FO7DD1]TBEM^XE"0HRJL1Q[FNPN_!^@7]QJ,UUIR2OJ2".[#.VV4   [<
MX#  #< #QUHM/!V@V5ZM[#89N1;_ &8RR3/(S1\\,68[NI&3DXXSB@#B=%NY
M;/0O .B6\KK%JFF^=(9+V6,NZ0Q8C5QEE'S%MJX'R^F0;T]OXITK2TA6Z.M&
MVU"222R@O6CN3:E,K&)3AG9"ZMR06&W\>AF\!^&9]"BT673 UC"XDB0S2;HV
M' *ONW+@<#!X''2K4?A31X;2TMH+:2%+1F>%HKB1'#,,,2X;<Q/?).: (O!V
MHVNJ^&H+FTGO)HS)*I^V@B:-A(V8WR2<K]WKVK>JM86%KIEJ+:SB$<09FQDD
MEF)9F)/)))))/))JS0!POQ:#'P?;A&"L=3L\$C(!\Y>U=#!#JEMJR3ZAJ=O-
M:-$8DBCA\K$I9<'EFW9&1[<^M3:UH&F^(;9+;5('FA1Q(J"9XQN'(/RD9(/2
MFP^'=.AO8+S%W+/;DF(W%[-,$)!4D*[D9P2,X[T >>7MAJ_@?2;G7?#-U%JW
MA&1&NKC1[KK%$WS.87[#!)VGWZFMK5;A+SXI^![F,,$FL+V10PP<%(R,UOKX
M+T)+46BVLPL\Y-K]KE\ECG/S1[MIR>2",$]<U:NO#FEWFLVNKSP2-?6JE8)1
M<2+Y8(P0%#8P>_'- ')?"R1D;Q99WG&JQ:Y/)<JWWBKA?+;_ '2!Q]*OZ9K6
MI7WC'Q;I-R;/[-ID-N(GB@*R.)(V?#,6(^7GMWK?O/#NF7VHKJ,D#QWRIY?V
MFWF>&0K_ '69""P]CD4VV\-Z5:)>B&"027V/M4QN)&EEP,#,A;=P.!SP* //
MHK2X\"6>F^+M+A>31[JS@_MNRC&=OR#_ $E!_>'\0[CGW'=>#)4G\&Z3-$P:
M.2W5E8=P>0:U+/3[:QT^.P@C(MHT$:QN[/A0,8RQ)(QQ2V-C;:98PV5G"L-M
M H2.->BJ.@% %BN>\6S2RV4&D6\$EQ+J#[)(HV4-]G7!E.6( RN$SGJXKH:H
MMI%F^L)JQ27[:D1A5_/?:$)!(VYV\D ].PH XGPA-+H/CW6O#T]G)96NIYU7
M3XI&4X8X6905)'WL,!V!-2Z)-<>*-%?6VURYL+RVU242JDA,<4<4I7R&CR%.
M4 R2,Y;/H*ZJ_P##>E:GJUGJEW!(][99^S2K/(ACS][ 5@.>A]:JKX*\/+KS
MZVNFJM_(XE=A(X1G'1S'G86[[L9SS0!B^"K**+Q?XSE5[@LFI*H#W,C#!@C)
MR"Q!Y/![#@8'%=S6=;Z#IEKK-UJT%L$O;H+YT@=L.0, [<[0< #(&<5HT 8O
MB[5;C0O!^KZK:1B2XM+226-2,C<!P2/0=3]*YF[N+S1Y_!NH6&H7=VFJ7,=I
M=QS3M(DZR1,_FA22$*E=WRX&#CIBN^DC26-HY$5T<%65AD$'J"*RM-\,:1I+
MP-9VSJ+<,+='GDD6 'J(U9B$XXX XXZ4 <WX*T^&#Q?XQ='N28]1C5=]U(X(
M-O&>06(8^YR17=UFZ?H&G:5>WEY9Q2)/>/YEPS3R/YC8QDAF(S@ ?05I4 (0
M&4A@"#U!KG'M8M<\36&K,5%EI7F+;2$_ZZ>0;"1_LJ,J/4L?09WKNUBO;2:U
MG#&&9"CA7*$@]>5((_ US^G?#_PQI-[;W=GIK)-;G,1:YE<(<8X5F(Z'TH X
M"-6B^ /B."Y!-XMQ>Q3*?O&8W# #ZDE?TKI/!:36GC3QF-2;]^$L'9F/5!;X
MS]-P?\0:ZV3P[I4MZUV]KF1Y5G=?,81O(N-KM'G:6&!R1G@>@IVH:!INJ3F:
M[MV:0Q&%V25XR\9.=C;2-R]>#D<GU- 'D_PT@NK?5O!3WJLL4N@78MMWJ;@.
M,?\ ;,K^%=IX#60ZWXTF&1;/K3"/T++&@<C\1C\*ZB[T>PO8K:.:# MFW0&)
MFB:(XV_*RD%>"1P>AQ4UC8VNFVB6MG"L4*DD*,G))R22>22222>23DT 6*XO
MXF32+HFDVH)\B\UJRM[C_KF902#[' 'XUVE9GB#18?$&BSZ=,YCW[7CE49,4
MBL&1Q]& - &3K^N72^)M.\/6*3F2>"2\N6@"^8(D(4*I8@ LS#)/0 XY((T?
M#EMJ-M97']I3[WEN7DBB,AD-O&<;8RYY8C!)/J<#( IESX?L];:RO=6M&CU*
MT#*DUK<R1,N?O!71E8J<=#^(JQ-HMHLEO=6MO&EY9Q2I:$LP1"X&<J#@Y(&2
M<F@#B=3U#Q'=P>)8K:2^37(KX6^E6]NI$4<7RE)&.-C!@69B^0,8 !Z^A64$
MMM9Q0SW4MU*HPT\H4,Y]3M55_("N!C\*ZF85NK-=7TO7YF62ZNDOD-K+-QO=
MHMQ!4X. $!Q@<=:[.31+$MJDJV^Z74HQ'<YF<"0!2H'7Y>#C*@>M &EUHK+\
M.Z-%X?T&VTN$GRH-VP;F8("Q8*"Q)(7.!GG %:E !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KO4
M;+3_ "OMMY;VWFMLC\Z54WMZ#)Y-6:Y_QMHTNN>%+RWM>+^';<V;=UGC(=,?
MB,?0F@#435M.DGN($U"U::V!:>-9E+1 =2PSE?QJ.+7M'F9EBU:QD98_-(6X
M0D)_>Z_=]^E><Q3:Q=:W9:];6LT$'BZU%G)$%PUKM7='*3W.SSV&?]D5N^*K
M:?0==T+7M(LO-(5M)EMXQ@-'(/W.?15D51GL'- '5KK6E/:QW2ZG9M;ROY<<
MHG4H[?W0<X)]JC_X2'1?LPN?[8T_R&?RQ+]I3:7_ +N<XS[5QO@K2[[3=3F\
M,72O)8Z%<-<VUP5"B59ES& /]DM,".V$K.U7P[J-S?\ B3PC8QM%;7CKK5G=
M;1MAD.24!['ST5O]UFH ].6]M7NC:K<PM<A!(81("X4_Q8ZX]ZRO%&O0Z)HM
M[*E_8V]_';/+ ETP^<@' V[@3DC'!ZFLGP_X@B_L2#Q/KB/8S:JT%LD31L60
M_=5, '@R&1@3V89KG+G5;:QG^(6EZZXBO[P2268F7_CYMO("HL?][:0V0.A)
M]Z .ZTG7H&\*:1JFK7EM;/=V<,KO(XC4NR!CC)^M:9O[-;(7INX!:%0PG,@\
ML@]#NZ8KS+PUJ T[6_#%[J<GD:7-X9AM;:XF^2..X4J9$)/"LP"]>NS':L^$
MW'AL6.L7,4W_  B\7B2\N%5$++#!(A6*7:.D8D+L..C CJ* /5DUS29(89DU
M2R:*:3RHG%PA#OG&U3GDYXP.:F74;%Y;B);VW,EL-TZ"5<Q#U89^7H>OI7G7
MB>71I?#!UK1[<KIYUVSO[J[5&"RXE3?* ?X0 ,D<<'T-07=]I.J^)_&)ENIU
MTZ[TBT3[5;H?N[I 74XP0-P/<'WH [^ZUBSN=)OI-.UG3DEAB/\ I#RJ\<#$
M':S@$<9]QG%6/[1M;2PMIK[4+1?,0?OBX1)#MR2N3TZGJ>*\TO+V]F\)^-K+
M5I]/U7RM(Q!K%JH47.4EV1N 2OF@\X7^^/458O\ 6K'0]4\':Q-?0)'_ &1+
M"5N"ZPX(BR5=5;#Y &,<C/(P,@'H8UK2FCB<:G9%)7$<;"=<.QZ*.>2?2GV&
MJ:?JL3RZ=?6UY&CE'>WE60*PZ@D$X/M7D;VWA^'P9X5@M;_3M1C_ .$CB>:2
M'!1=SN[KSR%4.!SVQG&:Z;2M4TS1O''CN[FFCALX(;.:0QC(PL;!R O)(X!P
M/2@#M[W4K#3(Q)?WMM:H<X:>54!QUY)HN-3L+2V2YN+VVAMY,;)9)556R,C!
M)P>.:X74?$%CH_Q">\UQF31]3TF**QNGC8QA@S%XSQPS!D//7:!VJ.WDM= \
M;:%/);MIWAQM'DM;$SY5()O-#88M]PO&%QNP>,=<B@#O3JNG+;V]P;^U$-RR
MK!(9EVRLQPH4YPQ)Z8JJ?$^@"TFNSKFFBVAD\J6;[7'L1_[K'. ?8UY9>V45
MMI&^98QIMSXRBN+%) -OD&1?,90>D9(<^F#GH:Z&)=)'Q&\6M(MGL.E6PRP7
M!($H;]-H/MB@#KM7UL:.+._D>-]+FDCAED7_ )9&0[4DST*EBH/U!SP:V:\B
MO";G]FNW@0F2X>QMK=$!^;S3(BJOUS@8KTZTU6SGU*YTI)R]]9QQO<)L8;0X
M.TY(P<X/0T 7ZP_%VMS^'_#=W?6=M]JO@I6UM^OFR8) QW  +'V4UN5R<L[Z
M_P"+Y(]/U&WC&CQ[2&C\W=-(/F.-P^ZH"Y_Z:,.U &WI&M6FL:!::S!(JVMS
M LX9FP%!&2"?;H?I2P:]H]U=16MOJMC+<31^;'%'<(SNG]X ')'O7 ^#KJV\
M/WGB7P7?W5N\%H[75FQ 6,Q2#>\8!) V,3QG.#6-HWV&V\(_#%T\B*X2_3SF
M& RYAD5MW<<E0<^U 'K4.LZ7<VT]Q!J5G+!!_KI4G5EC_P!X@X'XU:BECGB2
M6&19(W 970Y# ]"".HKSV^TV[T[QE>:':P,=)\3C[3*R_=@=-HN ?^NB;1G^
M\:]%    & .@H H_VSI9N6M_[2L_/3=NC\]=PV_>R,YX[^E*NL:8T5M*NI69
MCNFV6[B=<3-G&$.?F.>,"O/O#=S/9^(M)L[&^@UC1;F6=XHY%Q=Z6Q5V8.1]
MY,DKE@#EEZ\9Y^RU*TA\#^%M+=V^W:?XDB%W (V+08N9#\PQQP<CU'3H: /8
MKC5M-M+J.UN=0M8;B0@)%),JNQ/3 )R<USEGXL^S>*O$=CKFH:?:V-@]JMM)
M(1"#YJ,Q!+-RW';'3I7.66IZ2+GQ+X9\46LLU_=:K)<P6K1.6O8B5:$H1Z!5
M7K\NWG S27O]GS:]\3&G^S.YTZ%$+X)_U#A@,_[6T''?% 'J8((!!R#T(JG<
M:MIMG<QVUSJ%K!<2$!(I9E5F)X& 3DYJAX-E$W@C0G#[S_9\ 8YS\PC (/OG
M.:XFUU+24O/%'ACQ3:RS7MYJ;W$%L8G)O83M,.PCKMVJO7Y=O..: /1;S5M-
MTZ18[W4+2V=_NK-,J$\XXR?7BI#J%DMW]D:[MQ<[/,\DR#?M_O;<YQ[UP5K=
MVMEKWC6P\3-'&;YEDM_.Z7-L8@H2//WBI# J.<MTYK*T<W'AG4/ 4OB25H'7
M1[BU>6;/RRDQ,D9/][:,8[D&@#TQ=9TIH8IEU*S,4TGE1.)UVN^<;5.>3GC
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MXYM..D"&[F@8-')+YN8QD<%@N[W (]12_$6YEL8M OI4=M)M=5BEU#8I;9&
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M^_CB<$A%*@,RJ 3QTP#GF@#TF/7='EM)[N/5;%[:W.)IEN$*1GT8YP/QI/\
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M[M[<H?)!7=T9@6(4AL*#P1ZUL?VA'+I2ZC:(]W"\(FB6'&Z52,C;D@<CU(H
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MR >A /:MJB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M406"*1N!/ Y'''':6,MQ/86\MY;"VN7C5I8!('$;D<KN'!P>,]ZL44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF :(O<*-X)P"N3R,^E>9:Y'HH\):AK&CW-Q=VEQJ]C=W5Y(,1,RS)O=0% P
M!N8#'OD&D\9ZOIUX?&5K;E;:>7148.49Y-07RY&7RU/ 1<G) SSG(QF@#T2;
MQ/I,'B6'0)+R%;^2 S^69 ,#<J@'_:;=P.^#4NF7<C07TUWJ-C<1QW,FU[?Y
M5AC'(1SD_,!U/'T%<3I^HV@^('AV[EE'DWGAQH(9&4XED\V([1QR< GZ<]*P
M%E\OPWJDUDJRZ?:>,VN+^* ;O]$$H).T=5R%;TPIH ]=M]5TZ[MY;BVO[6:&
M(XDDCF5E3OR0<"FV^KZ9=7*VUOJ-I-<-$)EBCG5F,9Y#  YVG(YZ<UY_K@M-
M0\4:OJMA/;S:6?#DL5],C!H9)-V802."X&[W (]15#23IUJ_PIDA-M%*;=UE
M9-H.3:$$-]7P.>_O0!ZY52/5=.EO391W]J]V,Y@692XQU^7.>*MUXM9ZSI]Q
M/X-N;=A:00ZU.K6"HSO:EUFRLK'+&1F.<<=< '&: /6FUS24D2-]4LE=Y3 B
MFX0%I!CY ,\MR..O(I-7U2WTVT<R7UG:SLC&'[2X 9A[9!/;H>]>/ZBFE+\/
MOB!+$MH)QKDAA90NX /&5V]\9#$8]ZZA-9L;3QUXJ@UR>%$O[6#^S'F(*7%N
M(R&2,]&.]F)4<G=T- '6>#=7N=?\&Z3JUX(Q<7=LLL@C&%!/H/2HO$/B-],U
M'2]&L(4GU;4W80)(2$C1!EY'QS@#L.I...M4OA=*DOPR\/[#G9:(C<=".HK-
M\7PR:-\0?#WBV:-WTN"":RO)$4M]F#\I(0/X<\$]J .DDD\0V=U8AS8WMM+,
M([EHH'B>%2#A@"[;ANVCMC.>>VB=4T];X6)O[47AZ6YF7S#QG[N<].:KVWB#
M3-0>./3;VWOW?_GUD60(/[S$' 'UZ]J\L#/??".?0I6"^+X;T_N"<7'VO[1N
M64=\$'=O'&W/. : /6+G6])LC+]JU.R@\HJLGFSJNPMG:#D\$X./7!J2ZU.P
ML0AO+VVMPX)0S2JF[Z9//45YI/#I3^(_B1]H6S9QIT RP7[WDR!\>^=N??%5
M?M4B>']$U#3-:LH]2A\.0"XL-1 :"]AVG<F<Y5PP8''J : /1CXJT8>(DT/[
M? ;UH//V^8O ) 4=>K9R!Z#/I4[>(M$7&[6-/&5+C-RG*AMI/7H&!'UXKBK*
M^MD^(NF7%_;_ &!+[PS&B6\X)VMYNYH^>I4'GT )/%8.EZ787?P*UF6RL[:6
M_6'4$WQQ@R@&9R%R.<%0IQW % 'KPO;1KH6HNH3<%-XA$@WE?7'7'O42ZMIK
M7<EHNH6AN8P6>$3+O4#J2,Y&*\YGUJUU?QEH,NB7L<TCZ%>1031\KYI\K:-W
M3((Y';O5GP3JOAW6-+\-V+VSMX@TB/RWMV1UEM9=FR5W[8/)RW4D=Z .B7Q7
M8ZYX=OKS0]9TZ!X7:-;BZ8-&FURNY@&'RG:<'(SP:W;S4K'345[Z]MK56Z-/
M*J _3)KQV\GLS\%/$EA*8_MEM?W(>)U^:-S=,5'/0D'([XKL(]2@L?B9JDFL
M3PI87VF0#3;B9P(F12_FH&/&265B.X /:@#M);^S@\GSKN"/SLF+?(!OP,G;
MSSP,\=J+*_L]2MA<V-W!=0$D"6"0.I(ZC(XKQZPT^&TC\#6^I1Q"'^V+QK6.
MX W):%9?*!!YV\K@'U KLO DELOB#QG!;/$(QJPD6.,C',,8) '^T#^(- ':
MNZ11M)(RHB@EF8X 'J356#5M-N;>:X@U"TE@A_ULD<RLJ=_F(.!^-<W\23=)
MX<M;B&-Y;2WU&UGOXT4L6MED!?@=1P"1Z U6B>WOOB=#K&E74$FGKI#IJ%Q$
MX:)CO!B!8<;@-Y]0/J* +'AKQ'J'BE[?4M/O--.G^?/'<V9R9DC5W2-PP)^9
MB@." ,-QTR>NEE2&)Y97"1HI9F8X  Y)-<9\*9X)O 5LL4B,R7%SO"D97-Q(
M1GTR""*T/%MW%<FS\.1W<$-UJC[6$OS?N5&Y\KD$AL!,9&=YQTH 3P5XL/BJ
MTOVFM6M+JSNFB>W<881GYHF([90K^(-;ESJFGV<RPW5];02MC"2RJI.3@<$^
MM>?W\\O@_P"*&GZEJ%_:-;:] ;.Z\J(PA)(^8I&!=O4IG@#BLGQ+?:5'JOC7
M0KW6=/MQJX@'F7[LC0DQ*/E&TAU PPY'S9'O0!ZG/K6E6H)N-3LX0(_-)DG5
M?DR!NY/3) SZD4Z75M-@NHK6;4+6.XFQY43S*'?/3 )R:\_%GX>NOB?I-L%T
M^\M'\/2(F51TE)DCV\="2NXCVS689])N;CQ!X6\2WE_!>2ZG)-;V,42@W4>\
M- T3!"V0 J\-QM["@#U2YU73K*XBM[J_M8)I2!''+,JLY/ P"<FF76LZ78^=
M]KU*SM_)"F7S9U39N^[NR>,X.,]<5YG=W6E/K'B?PWXLOKZW>^NQ)! D087D
M!1 @C;86+ KC /!''>K]G#I*_$#Q.ETEMA='M0_GE6.0)0^X]S@KD^] 'H"Z
MKISWJ62W]JUW(GF) )E+LG7<%SDCWH?5-/BODL9+^U2\?[MNTRB1N_"YR:\C
MTIM/M_!_PQF1K>.Y6_B$K@@.!Y,BMN/7KM!S["K&G7&E:@ESX;\17NHIKD&K
M27"V"1JKS/YS/%+&X3=MP5YW8 !SA: /4)M<TFW8K/JEE$PE$)#W"*1(>0G)
M^][=:K2>)])C\2IX?:\A&H- 9C&7 *C<H5?]XYR!UP/I7F.IPZ2^C?%0^79F
M3S&\KA<Y^SIC;_P,'IW'K71V-];I\3=)GFF4K>>'4C@?J)9!,"0".I .3Z#F
M@#O;>[MKM9&MKB*81N8W,;AMKCJIQT([BJFI_P!L--;1Z6UG$C;C-+<QM(%
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MGT'/%;M<?\+)4E^&.@;#G9:JC<=".U=A0 4444 %%%% !1110 4444 %%%%
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M6MQ%!.T5OE(O,&5=CGA,=_TZT 6O["O?^AGUC_OFV_\ C-']@WO_ $,VL?\
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ME>1TS]:-3\6VNEP74KV5Y,+*$37BPB,FV4C=ALN,D+R0NXX^HR 2_P!A7O\
MT,^L?]\VW_QFL!_ _B*+4)I+'QW?0V<\IEEAFL()9"QP#ARHQP  -N  !6I>
M>.=+MH)Y[>&ZOH+>Q34)Y;95VQP."5;YF7.0K' R<#Z50U2[+_$;PE-:W$[6
MUW97LAB65MD@58BAV$XS\YYQWH U+3PO-8VR6UMXBU:.%,[5"VV!DY/_ "Q]
M34W]@7F<_P#"3:OD=]MM_P#&:X7Q#XHOM=^&VMZBUK>Z:]IJ(AC>.<+PMRL9
M4['R3C.01CGC/6NZTWQ-;:EK=UI!M+VTNX(5N%6ZC"^;$Q*AUP3QD8P<$>E
M!_8%X2"?$VKY'3Y;;_XS1_85[_T,^L?]\VW_ ,9J76-?M]$N=-AN;>X<7]RM
MK'+&%*+(WW0Q+ C.#V/3UQ56/Q=:.^N(;2\CDT4 W*.$R05WC;\W.5Y'3\Z
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MU&]@\7G+.IRI3&<T_3M0M=6TZWU"QF$UK<()(I " RGH<'F@#BM$\+ZAX?\
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M9.J!")HF<R'JIVG<2<KCT&* *NA>,+[Q%;^&[5#%:7FIZ:^H7,JKN"*I5=J
M]RSYYS@ ]<Y%+Q$-=W>#4U,V0U-=<9%DB#&-E\J8*Y7@YVX)7/7N.U^/X;0V
MNE:-!8ZW?VU_HX9+2_58RPC;@QLNW:RX ZCKSFM.Y\("Y.DN^J73S:==?;#-
M(JLT\NTKE^  ,,1A0,#&.E '-WWB[7]+T#Q4TMQ:SWVAWT,23"WVI-'((R R
M[N"!(1D'L*WK[7=5MO&EWI-M%%<Q+HKW\$.W#M,'VA=V>A^G>DNO EM?0>(X
M;F^G9-=9))=JJIB=%55*?38O7/2@>"I9-4DU.ZU^_FO9--?3WD5(T&UCG< %
MX(.",=QR30!CVGQ 7^PM4U07JW,EC:J9]/G@^SW%O<$@;74]$R0 ><8/)J_/
M>^+XIKU&B9+!M/DD6\DCB5[>=1D *LC;E(Z9S@CDFKT_@FSU.>[GUF7[;-<V
M!TYW$8B)B+;B3CJV0#G@#' '-+HWA*;3K=K?4->U#5H5B:"!;G8/*0C!Y4 L
MV.-S9.,XQDY .-MI]:/ACX;XU<@7LT D!A!W9MV<;CGYL%<]LDY[5T#>++A/
M%SZ)=WBZ==?:HUM8;FWQ%>P87<T<G0ORW&>, 8)YJS'X#2/0M&TU=:OM^CSI
M+:7.V/<BJA0)C;M(VL1DC.>?:K=WX2%_M@O=0EN+);U+U(I(U+QNK!@%?J%R
M.>,\D9 .* *4]V^G?%FSM8_]1JVF2&5!T\V%AM?Z[7*_@/2NKNEG>TE6UE6*
MX*GRW==RJW8D=Q6%!I;W_C9O$$J,D%K9FRM%88+EFW228[#A5'KACT()Z.@#
MS.+QYJ:Z;X8N[J:"-KB\>RUB(0<P.K^66!S\JB0HO.>'!K5\0^(=9TWPS?ZU
M:3VQB748H+=9("3Y1F2%CD,.=Q8@XQC''.:OW/@32;F#Q'$WF :Z<S8/^J;:
M!N0=CN&_Z_2K6M^%K?6/#,6@K<2VMK&8<-& S8B964<^ZC- &3:2ZE)\6=4M
MWO\ =:0Z9;R) 8AA0SR @'/7*@D]_P *Y?P9JVL:+X.\#RK/:OIM]="P>V\D
M[QO\PA_,W=05Z8Q@_C7?2>&B?$S:[#J,\-Q):+:S1*BF.3:696.1D8+'@$9X
M_'-M_ 45MH6A:2FJ7!AT:[6[@<QKN=EW8#=L?.W3':@"G-XIU>]\-Z[XCTN2
MW6'2IYUCM)(\B>. X?<V<AFVMMQTXR#5S2?$MYJ_BE[&&1$L;C18-2MRT7[R
M-I688/." %%3-X)@4:O:VU_/!IFKR/+>6BJ#\SC$FQNJ!QU'/4XQ5BY\)H_B
M&WU:QU"XL&2S6QEA@1"LD*L651D':02>1S@T <;;:]KGB"+X=WS7T=L^HR3O
M/'%#E"ZPR8."<XQVSU.>>,>J5QMI\/H+'1] L8-7ODDT65I+>XVQEL,K*RD%
M<8PQQP2/6NR P * .#@U_P 0RZQXB>6\L$T[0KL>:BVK%YH?)$A4'?\ *PSU
MYSZ#&#8TG5_%5]=Z+>BP\S3+^+?=AA$HMPR[D:-A(689X.1D]>.E:^F^&8[#
M4-:N9+E[E-7D$D\,B *"$"8&.<;0!SFL_0O!C^' D<>MZE>Z9:9:STZ4IMB]
M!NP&8#^$$X''H" #$7QAKUWI>DZA9R6L5S?ZR^FRV,UN9/LZAW7) 96+*J!F
MR<8)X'%6?$/BO5]&ENYQ-;,+;4;>W6UBB,BF"1HU+2O_ ,LY"7) ST X.<U@
M:,NI8,^FZUJ\&LR%Y'T^\T,-LD9BQC><QJ2@)QOWCCIV%=3>_#N*\AU6W&M7
M\-KJ%ZM^846,B.<,K%@2I)&4'!.!0 +JGB2^\;:UI5M?:?;V>F_9)@SVK,S1
MOO+H?GZX7[WL..<USOB+5;_Q+\/;#7Q<1QV5WJ=JR6GE9Q%]J4(=V<[^ 3VY
M(QWKN].\.?V?XBU'6/M\T[W\444L<B+C$8(4@@=?F.?7/:L$_#6--(?1;?7;
M^#1Q=)<V]JJ1DP$2"3:K%2=NX< ]/>@#NJ\Y.NWNB^)_'>IWMX;BSTJVMY$M
MA&!E?*=PBG/'S$\\YS7HJ@JH!8L0,%CU/OQ7/3>#[.XUK5KZ:YG>WU:W6"\L
MB%\N3:A0'.-P^5CP#UYH S;CQ!J^C3^&KF^E@NK369X[29(XMI@ED0LA0YY7
M((.[)Z'/:NTKF[#PBMLFE0WFHSWUMI+;K))44%6"E%9R/OE5) /'7)R<&NDH
M X[1]7U[Q%INFZ]IDEG]CN;LB2TE4C;:AV4L''/F< XZ<X[9JE-XKU>[\*ZQ
MXHTUX!;Z;/.([.2/(FBA8ARS9R&.UB,<#C(-:.E>!4T>^D%IK-^NCO<&Y72O
MD\I9"VX@-MW[-W.W./7(R"\^![=8M5LH+^>'2=5E:6ZL@H/S/_K C=55^XYZ
MG&* ,Y?$&O:SXEGT[3+RSM;231X-1MY9;4NZ>8S#:PW@$_+UXQZ'K6-JNKZC
MXD\'>!-7,T5M+>:K9F6-8]R^9EN1D],C./UKM4\,K#XCN-9@O&C>6R2Q6$1K
MLCC0DKCOD%C[5G1> HX?#^AZ/'JMP(-'NDN8'\M"SLA)4-QC')Z8H @BB>/X
MOR@-'Y[>'%W2>7@,_GD;B ?;IG\:K:)XRU+4M%\.Q3M;KJ>L7EU 9EC(CC2%
MI"2JD]=J  $]3DYQ@])_PCS#Q6WB$7S_ &@V(LO*\L;-H8OGUSN/KTX]ZQ_^
M%<VH\-V6E)JEY'/I]T]Y97T842PR,S,>V&!+L"".10!G^+I?$]IX?1+J_MXR
M=;M889H$^::W:5 /,'0').<=<=LFNF?Q9HUCJT6B7FI ZH2D900.-S,!CD @
M9R.]5KSP<-1T!K"]U>\GO&GBN3?LJ!Q)&P9,*%VA01]W'<]R371P1M# D;RO
M*RC!D?&YCZG  _( 4 <%-XOU:?P7?^,;!H#:6DTQ2Q>/_6P12%&)?.0Y"LPQ
MP. 0>M.DDN[[XLZ1<07@2WET.6:-&AR50RPY'7J>.>U:8\"VR6NHZ;%>S)HN
MH3M//8[00"QRZHW548]1SU.",UH2>' _BRWU]+QT>"U:S6W$:[/+9E8^^<J/
M\* *]IXKT#68[S3M*O%EFAMG8Q+"Z!5'!ZJ!U(KG/"M_>6G@#P7#!<Q6]O/9
M 32!?,G)" JL4>#N).2>#@#\1Z#=0M<6DT"R&,R(5W@9VY&,XKE+7P"EC%H(
MM-9O()=&@>VBE5(R9(7VY5@RD9^4<@4 95MXSUF3P=H'B*8VT=O)J!M-4 A/
MRQ^<T(D7GY?F5<CG[Q]*LV_BS46U7Q/I3W$+75JT8TMO(VK*)&\L$\_-ME!1
MB,=*U;'P19VG@Z^\,R7=Q<V-UYP!FV[HQ(S,<8 Y#,3DY.:L1^#],BU71M04
M2>?I5N]O$2V2X8#ES_$>"?JQ- &+J?BNZT[Q,='O;Y-.D8PBQFN+?]Q?9 \P
M;^BOG< N1C@_-FNZKG-8\*#6UO[:\OY)-.OI8Y)+9HU)0H%&(VZKG8">O4XP
M>:Z.@#SZYUCQA?:CXJM=,O-+B.C2(8!):,WG@PB38?G^7KC=S]!4-KXL\0^(
M[_1H-)GL;&/5-$:_!FMVD,,@9 1]X;AEB!TZYYZ4_2+&XU+QGXWBAOY;6WNY
M8%R(02Z"!59HV/<'(S\P''%=%;^$;:RU[3M2L[AX(M/L380VJH"GE$J>2><Y
M5><]J ,6X\2Z[;S>-H3-8M)HEE#<6K?9V"DM$[L&&_)Y7'4?2BP\2:Y!K'AK
M^TKBTFL]:L))FCB@*- \<:R9#;CNR"0>!VQ6K<^#EN+KQ'.=1F7^W;=;>=1&
MN(U5"@V>^UCUSS3D\(JMYX>N#J$K'1(7@B4QKB560(=_OM Z8Y_*@"MHFJ>(
M-=T_1-=M)+/[#?-YEQ:2+@Q0,"5*L,DR#Y<YX.3C%8M_XQ\06GA?Q5?H]BUU
MI.KBSBS P1HCY0Z;LAOWA.>?I6YH7@9= F$%OK5^^C12F:WTQ]GEQ,3N W8W
ME0>0N<9]:Y_QOX=.D> _$RPW5Q<S:M>Q71C6(%ED,D6[8%&<!4!YST- &U:Z
MQX@TWQ[:Z)K,UG=VFIVTL]K);P&(PO&5W(<L=PPPPW!SVK \&:W<6'@;PGI=
MG$[7.HFZPR!2R)&[LQ4,P!/*]3ZG!QBNVMM%\W4H]9N+[[7=I;-!:R",*D2,
M068*#RS;5R<]A@#G.+_PKFV3PUIFE0ZK>PW.E3--8ZA&%$L3,26!XVL#N((Q
MR* *USXD\2Z-HS7&N:?-#!'J)BDO;>%976TV$K,8T9@"&VJW4 9.*ZCPWJ']
MJZ'#>B_MK])6<I<VPPCIO.WCL=N 1Z@U6A\.WD$%LPUV[EOXYO.ENIHT/G_*
M5V,@  0 Y 7'(SG))+;#PJNEV]O%8:A/; 7[WUR(D4+<,^2R$8^5,D<#T'.>
M: .AHHHH \IUW/ASQS=>-8\B"#48]/U3'_/M);P;7/\ N/@_C1XW/]J>(_#6
MJYS;VWB6UL;4]CC>9F'U=53_ +9'UKN9/#,5U!K=M?7#7-MJ^?.B*!=F8UC^
M4_[J#KGGFJ=_X(M;K3=!T^WNY;6VT2XAN;=416+/&"%+$]0<G/3)/6@"-=9U
M37-3\06FCW$-L=(=8(_-BWB:8H'.[D83D+Q@]3GM6':^,]=\1/X7_LE[.Q36
M["YE;SX&D,$L6T''S#<,DX''KSTKIW\+&+6K[5-.U&6RFU&-$O52-661E&U9
M%!^ZX'&>1TR#3(?!EI9ZEH5S97$EO#HUN]O;VZJ"K(X4-N)Y)^4<^OK0!CS:
M_P"*;Z#5%T6W2XO-+F6UVB.,17,JHC2;BT@9 2Q QTP#DYP+]OK>K:_JNLV&
MGR1:?+I:0H5EC$NZ=X]Y#<_<&0..2<\TZY\$D^(;K5=-UW4=,6_*F^MK?84G
M(&-PW*2C$  LO/T/-6CX42VUNYU32;Z33Y;N!(+J-8U=) @PC@'HZCC/(QC(
M- '/6GCC4KW3_"6NE8K;2]3N#9W\1CW-#-ED4JV>%,B[>1W%:=]XDO[40^5B
M;^T]3-G8A8URB*C%V.6 8DQOMY P5//.=&Y\(:9/X+;PLBO%8^1Y2,IRZ$'(
M?/\ >#?-GUHUWPE8ZWH-MI?FSVGV-XY+.XMVQ);N@PK*3[9'/4$T <UK/B'Q
MCHGAW6;N>U@3[+=6ZV5Q<(N;B*1U1@RHY"LI;[W0C'%=KI4.J0P3+JMY;W4I
MF9HV@@,06,XPI!9LD<\Y]*P;SP3+J?AZXTS4=>O;J>Y>)IKQHXU?$;AT55"A
M5 (ST).3SZ:,]CJK>*=/NXM1G%E' R75L440R<'##^+?NV^P"GUY -J0.T3K
M&X1RI"L1G!]<=Z\<6;4KKX4:-=W=X+JXFUZ%E,B;?F^W-G)'J?0<5[+7&+\/
M8H]#BT>/6+S[)!?+>P*R1DQE93*%!QR-QYSDXP.* &0:YKMOJGB?2KFZLYY]
M/LHKVUG%L44;P^49-_(!3@YSS5*3QO=VOASPOJ>IR/9V6HV"S7>HQ6QD2&<J
MA56'.U#N?GV R.M=#)X5\S6-6U+^T)!+J5FEI(HC7:BKNP5]_G;KFFV7A:;3
M=-TZQM-5D\FRL_L6R:!72:/  +KQ\P QD<<G(- &QI,\ESH]E/-/!/+) C/+
M;G,;L5&67_9)Z>U<YXV-IJ@@\-WGVDVEVC2WGV>&21A$O"K\@)&YRIYZA&%=
M!HFD6V@:)9Z39[_L]K&(T+G)('<U'8Z2]IJ^H:A)>/.UYL&QD $2IG:JD<XY
M8\YY8F@#G/AOKD]YX,:TNQ)+J6C,]C<(5*O(8Q\C8;GYDVGGOFJ%AXLUW4(_
M"5S;SVA_MQI!<V[6Y?[*%4L=N&4_*1L8L3R0<#I6W)X=DT?7-<\465Q=7%Q>
M6P\S3XE0+,T:$)M.,A^V<]^E<EX8@OK<V8TG7]4FNAY8N+2]T,1Y&1O$LQC4
M^O)8DG^\>H!J6WB?Q$MOXBU>\NK Z?H-[=1RP16S![B..(,H#%SM.2/7.3TJ
MZFN>)K*YAO[RQ,VC&REGO)-L2&W94WKY>)&+*W(P1D<'-:NF^$[>RMM;M;BX
M>\MM8GEGN(I$"@&10K 8_AP![^]5="\%'28EM+K7-0U/3X4:*UM+H)MB0J5P
M650S_*2HR< 'I0!5TS5O%E]<Z/>1V(?3K^$O=;UC"VVY-R,A$FYQG@@C)ZC'
M2L6+Q=XI/A33O$#W&G-OU4V,UL+=E$BFY:$$-N)7''&#TY)SQT>@>"I- ,<"
M:_J-UIMMG['8W&PI!Z98 ,X7L"<#CN 1$O@&-?#,&AC5+CR(;[[<LGEIO+^;
MYN#QC&\^G3B@"C=>+M4\.7_B2WU62VOUL-/BO[=HH3#R[.GEMEFXW*.<]">M
M7?M_B^WOI]UJC6!LGE^TW$4:^1.O(&U)260C/N/4U<O/!EKJ6K:G>W]P\\>H
MV"V$]OM"KY8+$$'J&RQ.<U'I?@^ZL+*2UNO$>HZ@BPM!:_:53]PI&,\ ;VQQ
MN;/ZF@#$TCQ3XAE7P7?7UQ926VO1^7+!';E3&YA,@<-NYY7D8 P?;)T?A_+J
M-Q_PD,E_?_:MFLW, S&%/R%5!X/3  Q5F#P0EO:>'+9-2G*:"P:W)C7,F$*
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M#CJN220>#FMBB@!%540(BA548  P *QT\)>'HX(H(]&LDBBF^T1HD(4)+_?
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MO*8P6B7T4]0*FT[3;+2;)+/3[6*VMD+%8HEVJ"22>/<DFK5% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %9.MWFLVH@31=*@OI7),AN+GR$C4>X5B22>F
M.QK6JCK-\VF:->7L<1EDAB9HXE&2[X^51]3@?C0!2\,:O?ZS87,VHV,%G+#=
M26X6"X,R/L.UB&*K_$&'3^&MNL_0]-_LC1+.P+^8\,0623^^_5F^I8D_C6A0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>josetrevejo-tarsussepara008.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y'XF7-Y8^ ]0
MO+"^N+.>$QD/ 0"09%4C.,C@GI@UUU<O\0M-O]8\%7^FZ;:-<W4_EA$#HH&)
M%8DEB!T!H 9XOU66SU3PWIOG/;VFIWY@N)T<HV!&S*@8<J68*,CG&<5'X=U"
MX@\;>(?#CW$MQ:VL<%U;--(9'B$@.Z,L<DC*Y&23AL= *V]8M[?4-)\F]T8Z
M@CX;[)(L;88<C.YMH(]<UA:'X>N/"NFZSJL&GP7>M7S><UI;.(H\*,1PHQ &
M /XB.22>^* .QHID3.\*-)'Y;LH+)G.T]QD=:?0 4444 %>8RWUG%\0/%5IJ
M_B*\L;*VM;62V']HO'Y;.K;B@W?,<@<8/TYKTZO.W\+2:UXP\5C5],D72-6M
M;:&*?S8\JT0;Y@ Q92"00<=10!I^#-<U-?A[9ZGXJ$D=V25R\6R24%]L64'1
MFRHQW)'K5J;QQ86QU2.YLK^*ZTR 74]J41I#"<_O%VL591@YP<C'2N?O-+\5
M:MX*DT:_@AEU73;B*:UO)9$,&H"*0,N]<[E+ 8((QGG-;_AM9[H2S7OA>TT-
M6B\IXM\4CRD]>8^-@QWY.>@QR :<>O6\T>F/%!/(NH1F6(H%.U-H;<V#TP1T
MSR0.XK*T'7M)30FNK-M0DCFU":".*Y8M,\^]MR+N/ !#8R0  2<8-0^"M O=
M AN;>^D66&R9[73,,"PM=V]<G/7E5^D2US/_  C&O+X9ADCTN&2_L-=N-22P
MNIHREU#(TF5R"5#;9.,]"* .KF^(&EVUI?33VU]')I]S';7D!1-\!DQL9L-M
MVMD88$BM2/Q%;2>(;K1/L]REW;VZW+%PH5HR2 5.[GD$>V.<5DVFE+KOA[5+
M/4="MM%@U"'R#;H8VDZ$;V*?+W&!DXQGO@<ZGA#7[B/0M2N[B(:RZM8ZNRR<
M&S9 I .>H**P_P!J1C0!Z+IM\FIZ;;WT<4L4=P@D190 VT\@D GJ.:QF\:Z8
MD=M=/'<KIMS<?9HM0*KY#/N*CON"E@0&*[3QS@@G>D6*2W:$.$5E*?*<8&,<
M5YK!X9U>X^'47@6\L]IAECA.HK*GE- DP<.!NW!MJXVX^]WQS0!I:E<W&N_$
M"[\.7$&I16,>F(Z/;7"Q,CO(R^=E7SP$&."1SQS5SQU>7^A^&;&6V^WW%G!<
MQ+J4EL?])-L =S C!SD+DK@X)QCJ)+>TOU^)U[JC6+C3Y=,BM$N/-CP761V/
MR[MV,..W:M?6KO4;;[!)IEJ+Q1<XNHED1&,/EORI8@9#;.,C- &/X:O-+NWD
MUO1_$$E[HAMB'CFNFE$#@Y+'>2R_+U#'C'&,U<3QE8?VE:64UM>V[WT+S632
M1 BY5!N8*%)8-M(.U@#BN7;P6-2\1:W>V5BVAVFI:1+8W",R#[1,_238C$#:
M,\G!)/XF_P"$8-50V=OJGA33].GLTV3:A')$XG(4J#$%^8;N"=V,#(YH LVO
MQ,T2Z&F2BWU**RU*00P7LML5@$A) 0MG@DCTQZD$'%^7QIIL-T8S%=& :@NF
MM=!%\M;@X 0_-NZD#.W&>]<+X7T^Z\2_"?P]HHLWBB^T1RRW;NFQ8XYRY*X;
M=N.W:!CC)[=;6LZ3XGU-IS<Z0UU<VVN0W=M-]KB$;6J2JRK&I;Y6VCYMP!//
M)X% '7_\)K8MKMQH\-AJD]S;7$4$YBM24B\P95V/9,=3_/!PNG^-=.U*YTZ*
M&"[5-3262QF=%"7 C&6Q\V5XY&X#(JEHEGJEOXN\57TMD((K\6[6LKRHR,T<
M6PY"MN W>H''I7/:9I7B236?">J:AH[_ &VQ>==1GEO8F+%XRH= &.(\]%&"
M/[O>@#1?QE#JG@K7]0UK3]3LK"VGGMW:U<>:%1]APR-D-D')X'/4UU5SKD%K
M=)86]O<WMY]G^T&"#:76/. S%V Y/ YR<'T-<+<Z!KI\ ^+= 33-\]Y=W4EK
M(+B+;,LLA=2,MQ@'G=@^F:VH[+4]+\;MKT5C+=6>H:?%;W$*2Q^;;RQDE3RP
M4J0Q'!.#[4 7V\?:(++2KN(W<T6IS&WA\JW8E9 &RC#J&&UACKQ6AH7B*UU[
M[:D4%S;7%E-Y%Q;W2!71MH8="000000:XJ/PMJ=BNB/'9F:3_A(IM8NTCFC
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M4-)M;X1-$;B!)O)8C<NY0=I[9&<4 >;Z!J^E(/%C^(=?O$-AK%U% C:K,C+
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M/&PX(%NQ!^]D$MW 7_:!K23QGI@6QE:.Z33[Z86]K?NH\F5SD*,[MP#$'#,
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MY(I;L1J)GA4JC/CD@$D@9KE/$,^ICXC^%K2VOUBM9H;N1H3%N!9%09/(SPY
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M_P 5=-EG@^S7,GAN1GA8A_*<S1DJ2#@X/'!YH Z[3M3L]6MFN+&<31+*\18
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M/%::=::1)?RW&C65PL]O:R(-PVMN1&?^)%;! P#P 21Q7645BZ[X@_L.[T>
MV;S+J5ZMF) X41LP8@D=3PIH 8OAZ6/Q5>:]'?8FN;1+3RFARJ*I9E/7).6-
M94'@(6WA_0='CU1_*T6Z2Z@<P@L[+G:&YQCYCG&.WX]E10!R$7@9K36+R>QU
MV^M=+OIVN+K3$5"CR-][:Y&Y W<*>YY%=?110!RVJ^"UU+5M3O8]6N[6/5+(
M6=W!&J,'50P4@L"5X=LXZT6_@O[-<Z#<IJ]WY^DVK6A?9'^_B;;\I&/E^XO(
MYQ[\UU-% !7)W/@J7_A(KO5=+U^_TM+\J;ZV@5&28@;=RE@=C$  D5UE% '/
MP>&6M?$-YJ]O>[&N+..S$)BRL:(6*D<Y)^8]:SH/ 8M]"\/Z3'JC^5HERES
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M1CDQ@L65#_NJ0OX5S.GWD5E>>(_#6OZ)=7L][JDMW:(;1I8;R-R&CR^"J[<
M'<0!M'I0!W=_KVE:7(R7M]%"44-)N/$:DX#.>B@D'DX'%,O?$FBZ=<"WN]4M
M(9C$9O+:4;MG W8],D >N>*Y&SD.DZQXSL=<MII%U&;[1:N(6D6ZB:%4\I<
MY9=N-O7G.,5G>'M+O-'\0>"+74XY'GL=$GBGE*%EBD8Q[4+XP" &'7M0!Z#%
MK^E7&FV^HP7T4UK<G;!)%E_,/.0H')(VMD 9&#Z53O=:LK@:3):>(+>U6XO
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MEM)!Y>P.&)!7[H)&6Z<]:T]15FNOB@%@G(NK&-8,0L1,WV9D(3CYCNP.,\T
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MV4+F.68/PC@@;3Z')''4Y'K7G=K)Y_A[X:0M9W8:PN(%N5EM)%\HI;,A)RO
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M,M([,%55'J6('XUF#Q28-9;1[_3I(;YK5KJV2.176X1>&56.W#C(R#CKD$T
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MP_'87MKJ,,4=W:W<S0F.2/(616"MQ@X(QVKKH((;6!(+>*.&&,;4CC4*JCT
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MCL,Y''P>"M6B\$W/@=_(;37E9(K[S3O6V:3>04Q_K "5'..ASVKT6B@#B_\
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M8VL<2%!&(B02N-N>2H[YXJHG@G3(UNK=);I=-NKC[3+IP9?(9]P8_P .X L
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MHGVAH?*BW%%QM+[>V.><#-=IX/UB#7-*FN[;5)+^+[0R S1".6' &8Y%"C#
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MK<1V\P1)T!)7<,9R-QY!'7!R* )/!NHW6K^"M%U&]D$EU=644LKA0NYF4$G
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MEX+V+YTW"4.9 2=G(WDG']*O1^%[2'5]2U.&YO8IM115G5)MJ[@FP. !PVW
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M3I#->(JM+(V%S& QRFT$Y..2N.AK3O/#5M<ZV-9M[JZL=0,/V>26V*_O8\Y
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M<)\J2H^Y@\#&><U;@U/4?$FM>([*PU)]/&EM'!;F.-&WR-&'WON4Y7)  &.
M>>1C5U+PQ;ZHU\L][>+;7\8BNK9&7RY% QW4E21P2I!_(8;+X4L_[5GU&RN;
MO3Y[F%8+G[(RA9E487<&4X(!P&&#CO0 >"M>F\3^#M,UBXA$,]S%F1%Z!E)4
MX]B02/8UO57L+&VTRPM[&RA6&VMXQ'%&O15 P!5B@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@D
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M5ZCC)R/>@#VVD#*6*A@6'49Y%1FXB^RFX5P\6S>&3YLC&>,=:\>T2]TO^W_
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M>;$/Q[T =YN7(&X9.<#-9'BG6)M!\,ZCJEO#%/+:6\DXBED*!@BECR >P_\
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M!IQ:?90W$EQ%9V\<\O\ K)%B 9_J<9-16VBZ59.KVNF64#JS,K16ZJ06QDC
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M#4QIUK<3R7/VA[5A]EE 21%W,K$KA>.F<9P<=* -?3K"#2].M[&V7;!;QB-
M?0"JL>CQV^L75[!M$=\H%Y"PR'95VAQ[XPI]0!TQS8U#4K72X%FNY"H=UBC5
M5+,[GHJJ.2?8>_I7(^'O$32^+/&)O+^Y^P6/V4I'=)L^S[D8L N >3C'7/')
MXH ZO^Q-*\@0?V99>2&WB/[.NT-ZXQC-1KI*2:VFIW&UGMXFAM8U'RPJV-Q_
MWFVJ/8# ZDF"#Q3I,US>6SW#6T]G"+B:.ZB:$K%S^\^8#*\'GMT.*2'Q3I5S
M>2V0EGCN5MOM0BDMI$=X<XWJ"N6&>,#GIQ0!:UE-6?3R-$ELXKW>I#7D;/'M
MS\P(4@YQ3])T\Z;IZP/+YTQ9I)I=NWS)&)9FQV&2<#L,#M61HFN:9'X=TI[?
M4KS4TNHV-M-+&7GN%7.6("CIZD#MW(HN=;TN[U#P^5U.]MVNY7-M"D3*MSA&
MRLF5XP 3@D'(% &S!I>GVUW)=P6-M%<RY\R:.%5=\]<L!DTV72-,GN);B;3K
M22:90DLCP*6=1@@,2,D# X/I5*\\6:/8-,;BY=88)1#/<"%VBA<XPKN!M'49
MYP,\XJ._\9:+IVH7&GS2W#WEO")W@AM)9'V$D!@%4[AP>1D#'.* -T *
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M" 1^- #$TK3HYHYDL+598AMC<0J&0>@..*:^D:9) T#Z=:-"TGFM&T"E2_\
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MW4[*TN+<]B(MT;C\"RG_ ($*[$D*"20 .23VJA&VFZVD-Y;7$-R()&\JXMY
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M""!YDT@1<GH,GO5F@#SF?3+^+Q1_:.@QZE9W,^I*+^RFB9K.ZAW -."1A'V
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MA8, % '7@ <UZ?10!Q/@W3]2TO6+JUBNM0N?#XMD-O\ VG&5G@EW',09@&9
MN#SD#@ GFK/B6WN9?&OA&YBM9Y8+2>X>XDCC++&'A9%R1ZL176TA(4$D@ <D
MF@#RFXT3698M7N[73[DR6WBJ/6(K=T*&[@5$4A<X&>&(!_NCU%;E]I-SX@\3
M7>LVEO/#"-"FL$^T1&%II9&W!=K8.%QU(QEN,X-=I9WEKJ%I%=V5Q%<6THW1
MRQ.&5AZ@C@U/0!SW@<7,?@K1[6[LKBSGM;.&WDCG4!MR(JD@ GC(.*Z&BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N<\<ZO+H?A6?4([*VO%CEA5XK@_+AI%7.,')!8'MTKHZP
MO%^@3>)_#D^DPW:6AF>-C*\1DP$=7QC<.I4#K0!G7OB#7G\7W^@:;9Z>&AL(
M[R*>XE<@[G9<, /5.@^N>U0Z3XWEUZS\.QV4$4-_J]H]W()<NEO&F QP""V6
M8 #([GM@Z*>'KY/%]UKXO[?=/IZ60A^S-A=K,P;._GESQCICFL.Q^'E]I%GX
M>?3]9A74]%BDMEFDM28KB!SDHZ;\@@@$$-UH R-%UO4/#FG>)[TPVKRGQ4+>
M9%#!2)! FY>>/O9P<^GO73ZIXT.AZSKL%_"C6>F:8FH*\>0[;F==F"<9RG7W
MJG)X O9M&URSFUF(SZEJ*:E%*EH0(9E,9 QO.Y?W8XX/)Y-33^!;G5=2U2ZU
MK4X;B/4],73[B&"V,87#.0R$L2,;N^[GOV !H3:SK6D--=ZO96S:5%827<UQ
M;-@V[H,F,ACE\C.& '3H,U2M_%FJ)J%D]YIS-I=S;233W$=K-&+$JN\!V<8<
M$9&X <CIS4VF>%M6;2Y=,\1:XNJ6?V9[5%BMO)9T9=I:0[CN;:2.,#DGDXPS
M1/">L6=F-,UCQ!_:6E0Q-!#$+;RI'0J5 E<,=V%.. ,G!- '/^(-2U#6]/\
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M,^#R<G+'G@=./6"3PU>)XHU/6+/4HHH]1M(X)H)+8N0T8<*P8,./G.1CMU%
M')^"->U32?#'@6VFM;0Z9J42VBLKMYR/Y;.K'C;@[",=1P<]JU;;QIK31:UJ
M5W8:?#I6BW=U#>%9G:5EBCW QC&"2< YQU]N9K7P+>6ND>%; :M PT"=90YM
M#^^PC(!C?\O#'UYJYIW@XPZ9XBT[4KN.ZM=:N9YY!%"8C&)5"LH)9LX X/%
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MD'!V;F#. 0>5!![9K2TK4[?6-,AU"U\SR)@2GF(4;@D<@\CIT/-97@22UE\
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M\1Z)I"0R:^ZL^N6BP"&8RR102R*ICD=U!<=<9ZC@YH ].ICS1QO&CNJM*VQ
M3RQP3@?@"?PKA;^TFL=172(==U:_D%C/<"V:X*2(6<;97F4J=B\JJX/?@XXP
M[*6?7[OX87]_=7+7-U:7#3-'.\>YA;YW84@ G)R1ZXZ4 >G6U[)<7UY;M97$
M*6[*J32 ;)\KG*8.<#H<@<U;KR_6/$^JZ#%\0;E+V:8V$]HEJ9<,+<2HFY@,
M8PI<MT[<UM7[WNB>-/#UE97UY-9:NEQ!<I-,92C)'O65"V=IX(('R\CB@#MJ
M*\BTJ_UA/"WA'7)=<U">ZN-:6SF224&.2)YY$(9<8)P 03R,<8'%>NT <Q-X
MVM8=6U+31I>J2SZ;&DMSY42.%1@2K##Y;(!X )XZ5MZ3JUCKFEV^IZ;<+<6=
MPN^.5>A'3OR"#D$'IBN%M(]2E^*WC%-,FMH9FL;(;YXRX4[7P< C./3O3+#3
M&\*7.@>!+&=I+<V5Q<M(]RUJUQ*)%) 9 2,;W;:.V.>.0#TFJC7LBZM'9"RN
M#&\+2FZ 'E*00-AYSN.<].@KSV\C\16#^&-,O/$<KRRZM):S/;."QA,3NJNQ
M4$N!@9^AQFM 2WV@>.;73QJ>HZA:PZ!<3^5<R!FDD21,,2 ,M@D9/K0!WM9V
MO:O#H.A7NJW%O-/!:1-+(D(4MM R<9('3WKS]]9U./X>:%XSMM0N)M0GFMGN
M8/,)BG6:0(T0C^ZN-V 0,_+R3SEFMW<OB;P-X_O9[NYB:PDO+.&"*8HB)"F,
M,HX8OR3NSPPQC% 'IMG+'<6<-Q$FQ)D60#'(!&:GJCHW_(#T_P#Z]H__ $$4
M[5[U]-T:^OHXC*]M;R3+&/XRJDX_'% %RBO,Y-4U*U\)>$_%%MJ-S<W=]/:+
M>0M(6BG6? 953HA4MQM QMYSS6AX5MK_ %/Q!KLUWKNIO'IFLR1PP"11&R>2
MAVN-O*Y;( Q@C/<T =K>7/V.SFN3%)*(D+E(\;F YP,D#/XU6T/5X=>T*QU:
MW22.&\A69%DQN 89&<<9J?4/^0;=?]<7_D:\GT6/4]$\%^!=:L=8OG,\EG9S
M6#L# \4N%(5 .&7KNZ\'- 'L-%><G4+_ $C5]>\+SW]U+>W[)-HT\DS%A%)\
MC <_\LF#,>Y7&:]#AB$,*1!G8(H7<[%F..Y)ZF@!]%<!<VNHZU\0=<T<Z_J=
MI9II]M-&MK(J&-V:0<'' ^4'U/<XXK!TG5->UR+P1#>:S>0/>O?VMV]L53SQ
M"KJL@XX)VYSZ\CGF@#UVBN#TD7.LZSXAT*;5M13^QDM[6VE$Y24EHMWGN5P'
M8D]P5^7IR:R+3Q%JTOAGP?XQU"YF2#S_ +-JT2.5B=&9HDG*C@ .%;C@AO84
M >D:E>R:?8M<165Q>.K*ODVX!<Y8#(R0.,Y//0&I[B4P6\DHB>4HI;8F-S8[
M#) S^-<!XIN[^W\"7^NV>HWEN]Q?020!)20L#31Q@#/0,I+\8Y?'0 5?2[E\
M0^,/$VE2W=S;0Z3#!'"EO,8R6DC+F4X^]V !R/E/!S0!KZ7XGCUC2-'U.RTZ
M\DMM3/! 7,"X)W2?-P.,<9Y(K=KR3PS=WEIX2^&*V]Y-%#<S>3/"A 61?*D;
MGC)Y4=\4FJ7.L+H'CS4%U_4EFT:_=K,+* J[8HGVD ?,O)&WIR>,\T >N45P
M^K7][)XG>UNY;V'3I-'\ZV-COW?:-Q#$[.<@;-H/!YZFMOP=%J\?A/3CKTLL
MFJ/"KW/F[<JY'*_* /\ )H W:YZW\5I>6NM26NEW\TVDW!MI+953S)7"JWR?
M-@C##J1577]3E;QIH'AT326]O>Q7%Q,\;E'E\L+B,,.1]XL<8/RCL37$737>
MC>$/B5+8:C=PW%KJ9>.<29D_U4. 6.3T.,]>.M 'J&I:S%ITMG;^3)->7C,M
MO;H5#.54LW)(   ZY[CUK&C\<QS6LDL&A:Q+-;!&O+40*)[?<Q !0MEC\I;Y
M<_+@]Q6=XEL([GXD^#B\URIDBO<^7<.F,1ITP>/?'7O64)&T#7?B3J]JUQ+<
M:?!#/$CSNRLWV4M\PS\P!]>@Z4 >HT5Q&G66LRW^F:C%K*IIUW:LLR_;6N#<
M,R;DDB#(%1A@DA>,=N*YK2M3U6R^'6C>);G7+Z>ZU$V]G-]HF @B5YP#)]T[
M6VY&[G&<XX H ]<HKS7Q)!XAT+P_XHNUUEK>#^SVN+2!+MYYH9$^\5DD7=L.
M1QV/0C-7;?[;:>.=*L9-6O[BVU729Y+B.68X5T,>&CQC8<.1Q_/F@#NHIHYT
M+Q.KJ&9<J<C*D@C\""/PHEFC@3?*ZHNY5RQP,D@ ?B2!^-<9\)X!%\.]-E\R
M9VE$A;S)6?D2OTR3C\.M'Q+MUGT[0MTDR?\ $\LE/E2LF091UP1GV]#R* .V
MHKS^YDU77M:\1:'I]XUM+I:0PVLGV^2-XRT0<2L I\W+''S$@[/<DP>3J^K^
M-(=)N?$E[%%)X?BN97TZ144S>;M+QG:< XSW].F10!Z/17DFHW&K_P#"->.[
M\:_J:SZ-J$K6964*%"Q1N%( P5Y(V].3QGFM[S]0TWQSI<2ZM<RQ:GI=S-,E
MU)F))(_+*LJ\!!\Y! [>_- '>T5P'A#5KO\ MZ'2M<34K/6DLG,D<TQFMKW#
M)F:)LX&.?E & _3BNPUN,3:%?QEY$S;O\T;E&'RGHP((_"@"Y#-'<0K+"ZR1
MN,JRG((]J?7E?AR]EM-"^'6B1SW$5OK%J9+B43-N/EP!A&K9R@)(/RX^Z<=:
MZ;PS>7T/B_Q'H,T\MS960MY[669B[QB56)C+'EL%<@G)P>3TH ZZBL;Q5IU_
MJGAN]M]*O9K/4?++6TT3[2)!R ?8]#]:Y>T\5OJ^C/XAL!/Y>E:3)-/:>8V&
MNL']T_/)3RVSGGYU- 'H-%>;S:CJ-CH'@_Q!:ZC<W4^I7%I%>QO*6CG6<?,5
M3HA4G(VXX&#FJ.H:OJ<'P_\ &MU'J5VMQIVL2Q6LOG'=&@:,!<]QACUSUH ]
M6K+U36X].N8+..WEN[ZX222&VA*AF5,;CEB !\RCKU(]\:E<)JMA'-\8-%9I
M;E2VEW+D)<.H!5X1@ '@>HZ'O0!V.FWPU+3;>]%M<VWG('\FYC\N1/9E[&K5
M>6R:WJ6H?#75/&,.H7%OJEI/<2I")#Y4:Q2LHA:/[IRB\DC=ELY'%:%JFI:[
MX\U2UFUK5+.VBLK&\2W@D5?+=F<E?N_=^7!'?\* /0J**\[T75[V+Q/9Z9KI
MU"UOKB2=K:ZCF,MEJ"$,R[.<(RK@A<#[O?- '<Z?>R7T$DDEE<6A25XPDX +
M!6(##!/!QD5;KS"UUC6U\"7%PMY<W+Q>('MKB;.Z86HNMC!,?Q;< !1GGCG%
M3WG]M0VWC:^M]3U2'2[:P,FFM(>1*(F:0J9%+$!@N#G'+ =. #TBJEA>R7J3
MM)97%J8IWB G !D"G =<$_*>H[UPNFSZC9^(_!I;5[ZX76-.F-W'/)N3<D2.
MK*N,*02>>I[YK+N=5UE?!&KSIK-Z+FV\3M:)-N&XQ?:DC"GCIM/08H ]9I"
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MDJ213(&&QPVTD9P2.XS5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 \C%20Z=H>G^+/ -E;(?LL=K?"(7N#(4.PQ;L\\\E01D>F17JA /4 _6EH
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M@( IP3R<]!CGG?!GA#Q!X-72GM;>-EEA\G6+7SQL9E^Y-$?[V/E(. 0/4 T
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M&2]@F!TIX(Y6B;[S7BJT9E/U1N?5N: (KKQ#:Z;<^-;VPTBY.J:9;Q377G3
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M@C\*TJYOP%I-]H/@RPTO48T2ZM@ZOL<,IRY8$'Z&NDH **** "BBB@ HHHH
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MSK_BN'1]%_M.V@^W1+>):2;) H1C*(CS@YPQQQZ5T5 ',0^#A#+X;<:C*?[
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M<?NUS&!&(_D_X".^>>:ZJJFG7%Y<V[O?60LY1*ZK&)A)N0,0K9']X8..V<4
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MG6S10!S\WACR_$-WK6F7\EC<WT217:B-7278,(X!Z. <9Y&.H-01>"[2TO-
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M&T>>$S264J*KF6-@K%E&. >O&: .CU[Q18^'[S3+6ZWF74)_)CVH2% 4L6)
M]!TZG\ZLWOB+2=.=EN[Z.+8%,C$';$&^Z7.,(#VW8K!\<++%J7A2^%O<306F
MJ[YS!"TK(K0R*"54$XR0.G>LBT,NG+XVTO5[*ZDDU*YFNK3$#.+J*2)56-2
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MT?6++Q5K^JZBEDL.IBW9%@E9F0QQ[2#E1D<]>.G09JIXR\*W'B5YXVL+20K
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M]O!J=G+/<Q>=!&DZLTL?]Y0#RON*X":?4)M*\=W]K977]I7]W_9UKF%AA%Q
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M?LQ@BN6R/+5%(&XKR2P&,<9H Z'3]1O;SQWK-JMT6TRPMH$,11>+A\N<,!G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>josetrevejo-tarsussepara009.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY*D@\^AKS[3M'\42:MX4U34=#E:^L)9QJ$\EY$Q<O$R!D 8@1Y/W1@C^[WH
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MXR0F2X4NN\[E(4!5R5RV21VP,WO!>CZCHIU*VEFO#I/F(=/AOI1+-"NWYUW
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M%% !1110 4444 %%%% !116/XCOKO3[&"2TDMH@]S''--<'_ %<9/)5?XGZ
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M00W$2\F/=G;GMSM/Y5YY=:Q<^(?!G@#5KQ8UN;K6K2201+A0?GZ#)XK?T/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7=MJ/B*[U*>:W:VCGGB1?*C88.%4#<QX^9L]![YRM8M+2R\)6_@)XKN_GN+
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MI+F&0P@M(4SM#<XQ\QSC&>.G?7L= -EXHU/6_MA=M0CBCDA,8 41[MN#G/\
M$<Y_2MJB@#%U;0#JFMZ/J?VLPMI<KRQQB,,'+H4.XYZ;2<8[UCW'@(7.@Z]I
M+ZHXBUJ[:[G<0C=&S;<A><8^1>N>_P"'944 5+RSEO-(GLC=/%+- T7VB(89
M"5QN4'.".M8DGA'[1=:A?7-XC:A>6']GM/';A (\DDE<G<_/7.!@8'7/344
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M(PC @F0D,PZKZXQZC10!YY:Z#?\ B7PY?Z)<:W)/I,RQ>3=?V8MJZD,6957
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MWGV+=<W;W)9#*SEW0(6[%C@X^Z ,\8I@='1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1[B+3;J0QS1JI4-Y<G0K\PX;\.AK2-I1Y;ZF;O&7,>G45Y]_9]W_ -$ZA_\
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M^$3T'_H%P?D:/^$3T'_H%P?D: -FBL;_ (1/0?\ H%P?D:/^$3T'_H%P?D:
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MH=P&"CS2DT;&3RXL\$$.Q&<#Y<_Q8K=LKCQ/_;C6]]9Z:-,4$K=13,)).!M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH JWVF6&J1"+4+&VNXU.0EQ$L@!]<$&C^S-/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]:HH YR'7+A=,N=73PWJ""22-5MA$@NI<D*79=W  (ZG.%/;%='110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '.MXNA_X2&[T.'2M2GO;6-9I!&L
M>W8V=K EQG.#QU]JN:-XDTW79+J"TDD6ZM&"7-K/&8Y82>FY3S@]B,@]C7.:
M7_R6CQ#_ -@JU_\ 0GK(UB=8OC'>7EG=I:+9>&Y/[1NRNY("6+1EQW(^]CJ0
M* /4*9%-'.F^)U==S+E3D9!((_ @C\*\\T.ZOF\86&FR76H&QOM">9S<7#;Y
M9%>,><!N)B)#G@$8R. 16/X6OY]-\">#+2":0?VQ=20S237;H.!*P17^8H68
M ?*,GGN<@ ]>HKD;#0M8DL]7TJ^UV>))94FM'M;DR7-K&3DH9'7+ E3@D$X)
M&:ZZ@#F_$_ABY\07FE7-OK$E@^G2O,BB!)4=R,*Q5N,J-V/3=FF:II.MW'AM
M=&:_:]EO)A#=WNQ(3';GE\*O?:"@QSE@>U=/10!2O-/\[19].M)FLM]NT$4L
M(YARNT%1[=OI6-X7\,:CX;AMK-M?:[TZWA\J.V-G''CT.Y>2>OUSS7344 <?
M-X0UB7Q&NMKXG9+I+=[:,?88R%C9PQ'7DY4<UI:=IMW)XGU'6=0C"E5%G8IN
M!VPC#._'0N_;T1:WJ* .8\0>%;S6-?L-7M-<EL);&)TBC%NDJAG^\^&Z-CC/
MIGU-3:AX:GU/2]/2XU60ZKI\PN+?41 H(?D<H."I5BI'&1[UT-% ')/X*DET
M/7+:76)_[3UK NM0CB"$* %"HF?E4*".I/S$YJ]H.@ZAI4/V6]UD:A9+"(8K
M8V<<2HHX_AZC'&*WZ* .?E\'Z4_B+3=8BM;>![&.55BC@4!R^S#$XZKLX^IK
MH*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$
MFMG0],62&#[1>W$JV]I!G'F2MT!] .23Z"MBN7UY0_CCPFC#*AKMP#_>$0P?
MU-732<M2)MJ.A#'X)?48UF\1ZM?7UTW+1PSM#!&?1$4C@>IY-/\ ^%<^'?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KG_&OB*?PIX5O-;AM([L6H5GA>4Q[@6"\':?7TKH*X
MCXP,%^%.NDD#]W&.?^NJ4 6]8\4ZIX:L%U/6-&A;3%*_:9[&Z:5X 3C<4:-<
MJ,\D'/M73I=6\D,4R31F*8 QON&'!&1CUS7'_$#6;-? ]_IL#I=ZAJ=J]I9V
MD)#R2O(NT$*.PSDGH,5R&J6UCI^E7F@W<EM_:6G>%8H)I+U]R'Y' $"<?,6'
M+YXPG![ 'K$VJ6<&JVVF/,OVRX1Y(X@>=BXRQ]LD#\:M>8GF>7O7?C.W/./7
M%>56,FE77BCP'?7K6<QFT*0&>7:V^91!CYCU8'/N#FJVA'2-=M;,ZKK9M?$E
MEJK/+;QK&MV;@2,-HR-S(RD#TV\<!> #U\,I) ()!P0#TI:RM+BT6/4]6?3#
M;F]>93J'E/EA)M&W<,\';BM6@ KA]?LO$MQXR@O8M%M=3TJRB#6D$E\(0)SU
ME8%&R0.%].3U/'<44 <IK_VC7)M*\.R0>6+L"ZU-5;<J0)@F/=@9WOM7W4/5
MOQE#KMSX<EMO#H07DSJC,9O**Q$_.5;!PV. <<9SVKH** .+'A^[UOP+J/AF
M\T6VT.W>W\BV6"Z^T '!(8_*O1@">I/-%KIVNZOXAT;4]=LK>PBT6*5ODN!+
M]HG=-A88 VH%W'GGYAQQ7:44 <SX3CDU"2]\2W*,LFI,!;*XP8[1,B(8[;LM
M(?\ ?QVK)O[3Q3_PF]QJIT&TU.TMU6/3 ^H"$09'[Q]I1OG8\9[ 8'4Y[RB@
M#D]3TW5M/\7#Q'I5C'??:+$6=S:F<1,"K%D<,1@CYF!'T(STK%N?#'B2P\$6
MVDV"07-U>7KW.K[+DP;UD=GDCC?!(!)"YQG&>F>/1J* .8CT5O$'AC^R=:TE
M=)@CD016]C>;@%0JR$,JKC!'3':JOASPA/HOC'6=3>]O9K:YC@2#S[MI"^U6
M#;P>N#C'IDUV-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %0W-G:WB!+JVAG4'($J!@#^-35C>*+K4K/1C-I*2O>"6,)
M'';>>7RPR"-R@ ]VR,=: -&VT^RLR3:VEO 6ZF*,+G\A2RV5I-<+/+:PR3*I
M19'C!8*>H!ZX/I7 ^"=6UJY\,7[S37;I#9![*7[,;@N<.2RR;LS-N&-A"D8
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M8<CCG)P*VE^(N@G13JC_ &R.-+L64T+VS"6"8D#;(O\ #U'Y\9H T_-\3?\
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M=7 4JV!@,-_R_P"R?2@#JK-]::X OK?3T@P<M!.[-GMP4 _6M*O+D\1ZE;^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% #4C2) D:*B#HJC %"QHA8HBJ7.YB!C)QC)_(4ZB@!OEIYGF;%W
MD;=V.<>F:H:_'/-X?U"&VMWN)Y;:2..-"H+,5('+$#OZUHT4 <)H/_"3:3X
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M,VQD8E03G/3'/0NK&YU#PCJ&D:;X?U6+5&U*WU"ZCO'A5Y"TXD:0,'V8Q&P
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M@   !@#M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVJV!GNYT4[=XC)S&V?NEL8!!//O6WX@\702^!;S6?#FLZ6'#".*ZNF/D(^X
MA\?=.,XSW(]: .OHKB[SXB:7I.K:!H]]=027NH0^;<2PY\J)1$6W ^C,  /0
MY/;/:=: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"BFBZ9'K$NKI86RZE*@C>Z$8\QE'0;NN.!^0J]
M110 55U'3+'5[-[/4;."[MGY:*>,.I/8X/>K5% &?I>A:5HB.FF:?;VH?&\Q
M( 6QTR>IK0HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "L?5=::TU;3M(MHT>]OQ*Z&1B$1(P
M"S'')Y90![]>*V*YSQ1IUA-/I^J37=U::A8,YM7M 'E<, 'C"%6W@@#C'& >
M* +?A[71KEM=[X?(N[*ZDL[J(-N"R)CE3@94@JPX'!K8KF/ ^B7FCZ5>3ZD6
M_M#4[V2^N%8@F,M@*A*X!(55!QQG..*Z>@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>josetrevejo-tarsussepara010.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4\G)'KW]* .CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>josetrevejo-tarsussepara011.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>@3W3SZEYEO(VD/<@IL X8(>,UW7A36/#E[/<6NA:5+8D*)) =,>U5N<#DJ
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MX6&5(/MZ4 8VH:WJJ?#/X@WB:E=K<VFLW45M,)FWPH)$ 53G*@ G@>M=':>
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MQV3$[K8*.@W*"..N<U2M;/5;[X2^$/!<-M=V\VK.8[V7RF!M[='9G+9'RDC
M /7FNB\0_#"^U#PS+8P^+-8G:WC#V<$H@""1!F/[L8(Y '!% '5ZYX537+U+
MEM;URQ*QB/R["^:%#@DY*COSU]A7!?#?0+KQ+X9&J:AXJ\3&=;N:/":FX4JC
MD#(^@KT/PCK$^O>%-.U&[MI;:[EB N(98RC+(.&X/(&02/8BN<^$%K<6?@8Q
M75O+!)]NN6V2H5.#(<'!H I:AJVHQ_M!Z3I:7URNGR:0TKVHE(C9\R_,5Z$\
M#GVJ4'4O'GC#6K(:O>Z;H.C2K:[+"7RI;J?;ERSCD*N<8'6JNHV5VW[1>D7J
MVLQM5T9D:<1G8&S+P6Z9Y''O4Z3W'P_\9:Y<7EA>7&@:S,MVEW:0-,;:;;AU
MD506 . 00/;Z ":I%J/PZU72+VVUG4=0T.]O([&\M=1G,[0F3A9(W/S  ]1D
MYS^69J7B/6M"^*&OZHUY<3^'M.:S@O;,L66".:+_ %R+VVLH)QU#&M'6+Z3X
MD:GH^FZ38WJZ-:7T=]>ZA=6[P(PCY6*,. 6)/4XXK4T73C/\0?':WEHS6=W'
M91_O$.R5?)8, 3P>N#0!+K>HW"_$CP;;VUW(+.[@OGDCCD/ES;8T*D@<'&21
M]:[*O'M'TO6-&^*/A[0;FWN9]-TA+PV-^5+*;>5!LC9NFY"A7Z8KM?B-?ZC:
M>$9K31X)9=2U)UL;<QJ3Y9DX+DC[H"Y.>QQ0!PLGBC6?[9;Q\NH7'_"+1ZJ-
M.^R!SY)M<>6;C'3_ %ASGKQBNI^*LFIG1=%M='U2?3KJ]UB"V6X@<J0'5\9Q
MU7."1[563X4,OAG_ (1__A+=9_L[R?)-N%@V8[\>7GKSUS[UBP2:Q?>$_"-A
MJ-G<G4=&\36UI=-Y389(MX$H..5*[?FZ9S0!T+>*[K5OA7X@NW+V6N:=97$-
MY'&VUH+A(SRI'0'AE([&LK69+_5-4^&NF'6-3M(=2M)VNWL[IHGE*VZ."6'4
MYSU]3ZT[XHZ-J&FP:EK^B6LMR-2L)-.U2TA4LT@9"L4P ZLC$ _[)]J@UF9]
M'U;X8:G<VEZUM8V=P+DP6SRM&6MXU *J"1R<?G0!>\26FL?#S3?^$CT[7]4U
M*PM70WVGZG,)]\18*3&Y&Y6&<]<?R/I,;K+&LB'*L P/J#7F?BC5KGXB:9_P
MC&@Z7J4=M>2(+W4;NT>WB@A#!F"[P"SG&, =Z],CC6*)(T&%0!0/0"@#S?X9
M:MJ.H^+?'T%[?7-S#::J8[=)92RQ)OD&U0>@X' ]*R_A7XFU>WCT^T\0WT]Y
M;:XLLVG7=PY9EE1V5X"Q]E#+^(J_\+;*[M?&'Q"DN+6:&.?5R\321E1(N^7E
M2>HY'3UI?"WA1]<^"VFZ5<K+97\1DFM974K);3K,[(^#R.WU!/K0!++'K&O:
MI\1=)L]5O+>>$VOV!HYV7R'\@/A<'Y0S#G'7)KI?!?B=/$7@JSUBY813+$5O
M W'ERIQ)GTY!/T(KF?A?/JU[KWBR_P!9TZ:QNYIK5)5="JM)'%L<H>ZEE)&.
MQ%8GBC2M;TOQ!K7AC1K6X_L[Q=)'*MQ&A*6C,=MR6/;<@S^- $5_K6NW7PI\
M7>,QJ5];F_G5M,C69E^SVZ2JBE0#\I;G..O'K6\FE>%S&I;XF:OD@9_XJ,?X
MU?\ B=I/D_!W4])TNUD=8;>&&"")"S;5D0  #D\"L^/7OAZ(U#>%9,@#/_%.
M2?\ QN@"+QZ_B"SUKPA8^&=4NFGCMKF81R3%A?>2L1"RG^,L-PR>[9J_XJ\5
M_P!J?#&UU[1;J:V-Q=6H)C<H\9,Z*\;8[CE2*GO7_M/Q_P"!M2L[:X%E]EOC
MN:!D\L%(]H8$?+TZ'%<K\0]#U+1+R:+2K*>YT?7;ZWGEBA0M]ENDE1F? Z*Z
M@D_[2T =5XX\,NFCZ[KMOXB\0VUQ#9RW$<-OJ+)"K)&2,(.@R.E1> O#<ESH
M&@:_<^(_$-Q<S6L5Q)#-J+O"[,@)!0]1STKI?&<4D_@;7XHD:21].N%1$&2Q
M,;8 '<U%X"AEM_A]X>AFC>.5-.@5T=2&4A!D$'H: .6\':MJ-W\7_&UA<7US
M+9VHA\B"24LD61SM4\#\*9X>M=0^)$5SX@O];U.RTI[B2+3K'3K@VX\I&*[Y
M&7YF8D'C.!C\F^"[&[@^,OCFYFM9H[>80^5*\9"O@<X)X/X4>&=4;X:V]SX;
MUVQOETZ&YEDT[4+>U>>*2)V+!6V E7!)X(_^N 7;*;4_!OCW3/#]QJMWJ>CZ
MS%+]D>]?S)K::,;BI?JRE>F><_KA^$/$VKZ7XJOWUF^GNM#U/6;JPMY)G+?8
M[A)&V)D]$=> .Q7M6W:&Z\;^/])UR.PN[30]$CF,$MW$8GNYI5VY5&YV*O<X
MYIOAGPU%K?A#Q/H^JV\L<5WK5ZREE*LN9,I(N?0X(/M0!?34=1'Q-U^TAFEE
MCAT:&:"U9SY?FEGY Z G !-<MX:BM_%&B0W%MX[U.#Q>5#S0S7I40SC[T9M3
M@; <C&.G>I?!4GB8>,O$$FIZ=(^J66DQ6BRR I%>21LY5E?&,,"I/H2>*C\2
MZOX=\5>'YX;KPMJ \6/ 5B@73)%GAN,?*1,% VAL'=NQ@?A0!ZY'O$:B0J7P
M-Q48!/?%>;^.[G6_$/B1/"_AK4KBQGL;*34+J>WD*$R$%8(B1V+<D>E=S9R7
M&F^&[>34W:6YMK-6N60;B[JGSD =22#7G?@[P=K.JVUWXIO-=U;1M1UN8W$M
MM;K$-D8)$2G>A/"_SH ZK2/&D%]\-QXKD3_4V;S7,(X*R1@[T]OF4@?A6'X?
M\+ZEXJT.UUWQ#XCUJ.[OXEN$MM/O&MH;9&&5557J0",DYJCI'ABZTC6?$W@F
MYFO+G2M=LWN[>^DC!V3."DJL5 4,3A@,#@4[3O$-II_A&+PEXZTG48)K:%;1
MFBM9I8;M$P%9)(@>H R.#F@#I(-/UWP_X6U^&^UN348XH)7L+F08N$7RR<.P
MQN(/0]?Y#G?"7AD:SX*TK5K[QAXECN;FT2:5EU=E56(R3@Y _&JGAK0O)_X3
M#4=*T2_TW1;K3/(LX;O>)97"ON8(Q+ '(QG&:-$^%'A_6_A;813Z/#9ZQ/8(
M3=-$5ECFQD%@??J.XS0!!)XFUJ;X+^*KO^U9IIM.O);6RU2(['N(DD0+)N7'
M/)&1UQ6I;Z7X9DMHGD^)>KAV0%A_PD8&#CGO576+B]U?X%:QI[Z-)9ZI9QBT
MFLH+<JI='7+1*!@H1R,<=?2K-MKOP^2UA63PK)O5 &SX<D/..?\ EG0 >.'%
MIKO@;26\2ZC8Z7<+=)<7B:@8GE"1*49Y,X))[GKD^M:.DZ1X?_M:U:T\?ZK>
MSK('2V;71*)2.=I3/S#CD>E9'C:ZTZ[U_P !ZO-I5S<Z)']L,L1TYY-BF-50
M-%M)'., CM[5J:=XC\#1ZC;FQ\.S6]T7"QRKH$D94GC.[RQCKUH YS5_$VKZ
M)\8]2O9-0N6T"RELK:[M6E)BB2XC(\W;T&'5<G_:/K7:_$75[RST2WTK2IGB
MU;6+A;.VDC.&B4\R2#'(VH"<]B16-%X=&M^//B%8W]O*MCJ-E9PK*R':3Y3#
M*GH2IP?8BJ?@&QUW5]8;4O$EK+%+H%F=)MO,4XEER?-F7/7*A!GH<F@#&.N:
MI+\!_#5_-K5]#<W.HQQ7%Z+EEE\LSNIR^<_='?TKI5T;PP[A5^)6L,S'  \1
M@DG\ZY/^S[J+X >%[>YTZY=H-2CDN+;[.S.(Q<2%LIC.,>W>NK7Q%\/4<.GA
M:564Y!'AR0$'_OW0!4\;:GXBTWXBVDFC75S+!INCF_N-.$A*W:+-L<8Z%]K$
M@^JBMOQ5X@^UZ?X,U'1[Z1;74-;M%+Q.5\V)E<E6QVX&0>XJ2-)+GXOVNH)!
M-]DD\.$"1HRH!,ZL%.1PV.W6N/UW0]2\/^,-#T:RLIY_#]QKT&IVS1(66R8%
MA+&<?=4EPPZ <T :_P 2?#\^C^$]<\0V/B;Q'%=1@S1Q+J3B)"SC@*.BC/ K
MHO"_A7[$MCJCZ_K]W(T"LT-WJ#2Q$LO.5/UXJ/XJ6\]W\,==@MH9)IG@4+'&
MI9F^=>@'6NDTA631;!64JRV\8((P0=HH NT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC,J*69@JJ,DDX %+7+?$=;YOA[KAL;B& K93M,98B^Z/RVW*N&&UCV;G'H:
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MNW=G[O'3'6LZXU?QI9>,=(T(:EHU]+<MY]U'%821F"U4_,Y8RG!)^5>.3]*
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MNP90> R[L9*XXY(.>,$ ]%HKR^#Q+XXO-&\031S:/#/X>FGBFD:V=A>M&N_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6FO86EHTZ2R,7;<SL5RHZ* ,GO7;T4 >.-X \1'X&Z9X8%I'_:L%V)9(O.7
M7SF?.[..A%==?:?K>A>-K[7M(TH:K:ZG:Q17$"7"121R1;@K N0"I5L'G/%=
MK37=(QEV51ZDXH \X;P7K#^!M6+I"/$-YJG]LQ1))E(9E=62,.<9^5 I/N:I
MZGX+\1Q^ -(&F11-XE@EN)KC,H W7*R"7YNAP9 ?^ "O4DECD.$D5C['-/H
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M:[2&V\CEER0<=B<BRTJ_\3^&_!UK/8FUM;!K2^FF>1&$GE1Y14 )/)()+!<
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M;4KK0;G3KHV>J_:3:!QRS02H?.7CNJ@N/0K[UV<$,=M;QP0H$BB4(B+T50,
M"@#E[;P19Z=HNL6E@BVC7L[74 A8XMY=H"NI/\65#'MSC&*N^"?$#>*?!FEZ
MRZA9;F']ZHZ"125?'MN4UJ:I?Q:7I5W?S']W;Q-(?4X&<#W/2L+X=:'<>'/
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M?Y6!JE?>'-?7Q!XE%IIMC-%K@01ZI-,-UJ@B$94IC+8()4 XYYIEWX8\0R^
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MXV@J#D=LU2\,>+[F;QA9:._BG3O$,=Y:RR2FTB1/LLJ;3@%2=R$,P&>?EZT
M=<OB[06T6\UA=2B.GV<IAN)\-B-P0"#QGJ1^=:\$T=S!'/"P>*10Z,.X(R#7
M@=M_R0'QQ_V%I_\ T9%7M^@?\BWI?_7I%_Z * )M-U.SUBQ2]T^=9[9RRK(H
M(!*L5/7T((_"K=>*^&KCQ7I?PKEU[3M2M8K737NIDL'M0XN(TF=GWOG*D_,!
MM]!ZUN:KX\-]KT]E;^*M-\.6]M9P3JUXB.]Q)*F\##$815VYQSENM 'IU%8?
M@[7F\3>$=-UAT1)+B+]XL9RN]25;;[94X]JW* "BBB@ HHHH **** "BBB@
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M<X!9BS=?4DG\:IZ[XFT?PU!#+J]\ELL[^7$"K,TC>BJH)/X"@#B4\,>+-/\
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M%.Z!Q#OR6?:>"0JG /?%=17-^-- O-=TRR?3)88]1TZ^BOK7S\^6[IGY6(Y
M(8CB@#D;AM2\/?$RVN-6U$ZG#:Z!>7"3M$L4A"LA92% 4_=&" .OMFJ.B_$2
M9[SP_<2^+K#4IM5N8X+K2(HD7[+YH^78P^8E&*@[B<\]*Z)/#'B#6_%JZQKZ
M6%O:/I<^GM:6LS2,@D*_-N*C)/S9X&,#KS5OP_I_C+3DTO2;HZ4NG:>HCDO8
MW9Y;J-5VH/+*@(?NY.X].* .)N/BBZ6ESKP\66,;PW;!/#YB3+VZR;,%OO\
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MMY8R"D:+U$>!@GJ<DU:M-&U_5_%NFZYX@@L+*/2HI5MK:TG:8O)( K.S%5P
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M8//;-79]"NI/B)9Z^KQ?9(=,EM&4L=^]I%8$#&,84]Z .*MM2\:7NA^)I/\
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M Y[6/B-,MQK]Y%XML-/FTNYEAM=&DB1OM0BX;>Q^8%R& VD8XZUW_B.[2_\
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M_GX5MXP1D<?=Z\\:^F> KG2-0\$>1/#);:#;7,5RS$AI'E0#*C'3=D\G@>M
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M5?.TYQ@YVGI5ZO,8-+U:\^)VOV=MKL]GLTVQ^T7D<,9FE8"0#@J54$[B<+Z
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MN%VD;&*A@,D<\$=*O5Y=I6EZUJGC3QNFGZ[+I,,=]$5>"&.1I)# GWMX/RC
MX&"<]>*H#XC7.H:1X9@U#6ET-[R"XDO[V&$.Q:&3RML8*L!N;+$XX XH ]@H
MKQ\_$:Y7P\ML==C#-K)T\:V;8<V_E^;YNS&-^/DZ8SSBFW'CR_MO#?BQ-+U]
MM4;3K>"YLM1>!%<;WVM&XVA21CKMZ-[4 >LVFGVEB]R]K;I$UU*9YRHQYCD
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M*[Z_TZRU6T>TU"T@N[9_O13QAU/X'BF:;I.G:-:_9=,L;:RM\[O+MXA&N?7
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MME]ETZSMK*U4EO+@C$:@]S@?SK.\/>,-'\4M/_9$EQ/#%Q]H-M(D3X.#L=@
MW([4 9E[H?B'3_$,FM:#+I]U-=VD5M>Q7[-$'>/=LE4HK<_.P*X].:S_ !T^
MI1?#R/P_<74=[K^LE;!&CCV*[.<NP4=$5-W/H!GK7H%5WL+22_BOGMHFNXD:
M..9D!=%/4 ]@<#- #K.V2RLH+6/_ %<,:QKGT P/Y5Q7ASP%/I/BG6[Z\G@F
MTVY26*QMTSF*.:0R2ALC RV,8SP*[NB@#@?!W@74= \.ZS::A>6]S?WL2VT4
ML9;:L,<(BB4Y&<CDGZU37X?ZU:_#KPSHUM<V#:KH=_%? R,XAE*.YVY"[@,/
MUQVKTJB@#F=%T+4;7Q7J>N7[6H-_9VL1B@9FV21A]_4#Y<MP>OJ!4W@_0;GP
M]I-S:74D4CRWUQ<@Q$D!9)"P'('.#S7044 <,_A77(?%?B:ZM9-/?3->MT60
MRNZS0ND)C& %(()().>F:ENO!]]/X!T#0%GMQ<Z<]DTKDML;R2I;;QGG:<9
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MQ5H&H:AJ&D:SHTMLFJ:5)(8TNMPBFCD7:Z,5!(Z @X/(Z5TJJ%4*H 4#  '
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MXZ@CG&:I1>%?$6D:AI%_I+Z7-/!HL6E7 NVD"H4.?,3:N6!.<J=N<#D5WU%
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M>6-H=46U$<:YW)Y2,ISVYSQBL$> KT?":'PA]KM_M2.C&;#;.+@2^F>@Q]:
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ME5T*LH96&"",@BEHH JV&FV.E6WV;3K*WM(,EO*MXEC7/K@ "K5%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117%>
M(?%.N:9XJTBQM],ACTJYU"*RENKAB6E9T9_W2@\!0N"S=^ .": .UHHHH **
M** "BBB@ HHKD/A[XHOO%6G:M<7\<"/::I/9QB%2 43;@G)//)H Z^BN%?QQ
M!I'C;Q%8ZS?>796T5H;2)("[Y=7,A 12S#A<GH/;-;\WC#0(-!MM;?4HCIUT
M0L$J*SF5CG"JH!8MP> ,\'TH VZ*P;?QGX>NK.TNHM20PW=V+*(E'4^>>D;
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M,JW$NQ@JLQ("@X^8D@C"Y.>.M6-/\5Z'J>G7=_;:@GV>SS]I,RM$T.!GYU<
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MQ' MKI/V?[.R*0[>8A9MQS@\CC % '7T5C:YXJT;PZ\*:G>&*68%HXDB>5V
MZG:@)P,]<8HN_%FA6.AV^M3ZE"-/N2H@F7+^:6Z!54$L>O &>#Z4 ;-%<_;^
M-O#EW#=2PZFC+:6QN[@>6X,40+ E@1D$%6XZ\=*+?QQX;NK;4+F'58C;Z>JM
M<S%6"(&SCYB,$\8P,G/'6@#H**QM)\5Z)K4%U-97RE;0;K@3(T+1#&0S*X!
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M:%H=S-<:5H]E933#$DD$"H6'7&0.GM0!Q7QO_P"1(L_^PI;?S-=MXETA-?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0RQ:Q=S723, 3$X!1L'JI3 'TKG/"]E+'J7PEBOXSYT>G7TBJXY4;%*?DI%
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M^2-^/O\ KXU3_P!%T =)8^(YIO!O@J_U/Q')87>HRVZNRV@D^VNP_P!4<+A
MW]X8Q70:UXWT#0+TV=_=R"=(Q+*L-O)-Y*'HTA12$'UQ7EU__P B%\(_^PK8
M_P JZ_0]1T[2O%7CR/6KB""0W,=PWGL!OMO(4*1GJHPP^O% &C>?$73+;QEI
MNA)YDT=W;&8W$5O+(O.SR]I52&4AB2PX&!DBNDNM8L+/5;#3+B?9>7_F?9HR
MC'S-@W-R!@$ YY(SVKS^WO=*_P"%F^%;FR6.STZ?0)OLJ.@A 4NA50IQCCM6
MW\1T^R:9I?B!>&T74H;EV'7R6/ERCZ;7)_"@#?MO$6E7FOWNA6]VKZE9(LEQ
M!L8%%8 @Y(P>".A.,UAZAXJTR[O-'-GXD>S234VLO+6S+B\D0X:+<5^49_C'
M'O7 KJG_  CEG8_$20;5U6?43+GNDBEK8?\ DO&!_O5+JFCOH5A\*=/E!\]-
M3C>?/4ROAW_\>8T =@GQ#M;WQ!XBT*W2>.?3X/W$IM9?FDV.S[B5VJ!M&"<!
MNV:C\)_$;2KO0] AU349'U.]@A1YC;.(GN&4'9Y@7RPQ/\.>O%4+.>&/Q]\3
M(7E199;6T,:,P#.!;/G [UG7421? ?PL$0+A]-<8'\1EC)/UR3^= '>^-?%,
M/@_PM=ZQ)$TKQJ1#&$8AI"#M#%0=HXZG _,5SU_X^AB\1^'9UO)H='O+.Z>:
M)[1P\DB&-5 1D\PG+$  <Y[U=^+0)^%?B# S_HX_]#6J5U);7OQ+\%SQ/%.B
MZ=>,CHP8 XB&01[$_G0!KS^+M(U7PCJVI6&LR6$=FK)/<M:,9+1@ 26B=<DC
M/3'-2/XOTC2-'TB2]U&>\DO+5987ALY'EN%"J3+Y:*2H.03P ,XKA/$HQ;_%
MT#@>3;'_ ,EUK1L[5)=+\(W&F>(H=(\00Z#$$2XB$D5Q;E8RRL#CHRCE3D4
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M<4 ;T%G:VTLTL%M#%).0TKH@4R$# +$=<  <]J6UM+:QMDMK.WBM[>,82*)
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MW[K&)'5=J?+MZ\XP3UKK]:\6:7H5W!9S_:KB]G0R1VME;/<2E!P7VH#A?<T
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M%O%9SI;W<<]L\<EN[D!=Z$94'(YZ4 ;]MI]E9S7$UK:002W+[YWBC"M*WJQ
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M<!^@KTF:SM;F6&6>VAED@;=$[H&,9]5)Z'Z4K6=J]VEVUM"URBE$F* NJGJ
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M)RN,<DDTR^TG3=3@2#4-/M;N%#E8[B%9%4^P(.* /%M26*_\.:O=Q!9-,O\
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M<M\@D\U1NQZX)K4L/'^CZA?VUO%%?I;W<IAM+Z6V*V]PXS\J/WS@XR #CC-
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MLCBG7%A9W;*US:03,GW3)&&*_3(KD[OQT\'Q&M/#<6FW<UM+9^>T\5N6R6=
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M+Q3I6N>,KW3-^I72S:7'' 7G29R5,:LAD?>K#H3SZ8KK-%MDM_C)J,8+.8=
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MXS&JC=CDKR1D5ZJ88B7)C0F08<[1\P]#ZU''96D21I';0HD1S&JQ@!#ZCTH
M\+T?_DVCQ!_UVG_]&K7M/AW_ )%G2?\ KSA_] %71;0"$PB",1'J@0;3^%2
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M;WD 0A%&=Q(8C!Y P3R"#BM+7_$5GX>@MVN(KBXGNI?)MK6UCWRS/@G"C('
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M^2%3_P !&[_@59XUG3O"7Q-\23Z]=QV-OJ=K:S6D\YVHXB5E= >FX$@[>O-
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M,LBB27I>+.1E2TF7)7 X&.?6@#9UGX@/9^)_#ECI^FW=]9:I!)<>;!"&,J;
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MQ)!$&V[I"SA1D\#GFJOPYU>76CXGN7FN7C76I4BCN2VZ%1''\FT_=P2>/7-
M':E5)!*@D=..E))&DJ%)$5T/56&0:YG5/&UOI_B&70;?2M1U#4X[=+D0VJ)A
MD8D9W,P P1SG'WAC--C\?:;-X;CUB&TOI'>Z^PBP$0^T"XS@Q%2< C!)).,=
MZ .I "@   #@ =J H&< #/7WKD_^$_L8=#UG4;W3K^TFT;:;RRE5#*H8 J1A
MBK @\'/8UB^(_B3=VN@1ZAI>@ZF(Y[V"""YFB0),C.N64%\X9<A21W!X% 'H
MK1QM&8V12A&"I''Y4*BH@15"J!@*!@"L/2O%5OJ>N7&C26-Y8W\-K'=F*Z5
M6C?(R-K'.TC!]_6K&E>(;76-5U:PM8ILZ7,L$TS >6\A7<54YR2N1G(')[T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ_Q(^K62>.]$O-6N;ZQM_#ZRVOGD%P&+YW$ 9;((SZ 9YYK7:'5O#EWX.O\
M^WK^Z.I74=G=VLK+]GVO$S#8F/EVE1CG/J3S0!Z1%=6\\DT<,\<DD#[)51@3
M&V <,.QP0<'L14M>-Z!I^LV=I\0;O1M1U.ZU.WU":""-Y%?>0D?S[2/FD"Y
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M,@N5E+ZC="UAV*" Y5F^;G@84^M &%;>!POPSM_"-Q>G?# J+=1)C;(K;T<
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M^\OVC*XM[- \KY(' ) XSD\]!5^N$^,5_>:9\,-5N["[GM+E&AV302%'7,J
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MP?86#2,&"NS<'!S@=J .VU;Q39:/XCT31)X;A[G6&E6!XU!1/+4,=Q)!'7C
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MO/,Y9Y& Y8D\DDY- %VBO*;Z>2S\67A\0ZGK^E7#Z@ITV_C=VT\PY79&5!V
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M' QWKVN@ K#D\4V4?C:+PJ8;C[;)8_;A(%'E[-Y3&<YW9'ICWKS;QEJQMO\
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M5)O#VGR1ZE_:2- A6]( ,XQ]X@=SWK2H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGO&_A<>,_"5
MYH1O#:"X*'SA'OV[7#?=R,_=QUKH:BN+B&TMI;FXD6*"%#))(QP%4#))]L4
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MLL9GB@VQ8SEW"@\]LF@#'3P(%^&]SX/_ +1)$ZS+]J\G[OF2,_W=W;=CKVK
M^)JV6N6^F^$M.O"WB/[5%Y0@^_;1E<22/C[J>6S?7(KT^FA%#EPH#'@MCDT
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M#"ECY4;.2J9C<G:.@SWQ7G%S:_VUX2\$SW]U>RRR>*7M6<7<BDQF:?T;J-H
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MRM)Y7F1;F +$G&1G%.UF^/A_XEV%_<3NNG:AID\,B%CL26']Z&QTR4WC_@-
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MF$@0[W.TC8<9ZYH [NBN%\31G7OB%H_ANZFG32_L,]]/#%*T?VAE9456*D'
MW$XSSWKD?$4MQH.B?$30K*[NA96-K:W5GNG9FMS)G<BN3NQE<@9XR: /:*SW
MOKM==CL%TR9K1H#*U\'78KY(V%<[LXYSC'-4_"^A0:-IWF)+<3W5X%FNIYYF
M<R28Y(!.%'LN!7,7MU<#X_Z=:B>46YT%W,0<["WFMSCIGWH ]#HKPU-)\[X.
MW_B>6_U!M7LWN9;.X%W(/L_ESN JJ#@@X.<@GGV&/;;60S6D,K8W.BL<>I%
M$N,]:*\,L-(9O@F/%K:EJ!UVUADN+>Z^UR8B$<K80+G:00,'(.<FMOQ-+9ZY
MJ-_)]BU_5+RWT^)MEE.((=-=D+ALF1,N<AOXC@#Z4 >L54&I69U8Z4)Q]M6
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M= Q ;"1XR.^*Y?X?:4+CP=>>(KR[O+B_3[=#;L]R^V&,._ 7."<Y.2">@[4
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M^1FD5F "X&2<$FL^_&NR:!X3TV]FU33WD\0M:(\TN+EK4K)LW,"?FV$#.3R
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MHH QM \.Q:!-J\D4[RG4K^2^<, -C.%&T>WRT>)_#L7B?2DL)IW@5;B*XW(
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M2?/B5B5#D;E5L D>YQC-=E>>!S<ZSJ-S!K-U:V&J!!?V44:8FVH$X<C<@*@
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M$AAC+&,E,=7^\.O%6(OAQ)81/9:/XKUK3=)<D_886C81@G)$;LI9!]#6C<>
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M>2Z>QD5"B3.06<-C=VZ9QS0!2\?O936^EZ==PZC>/=77[K3K%PAN]J$E78D
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MJSS^3?Z#)+>QQR-'Y^ AP2I! +8/';CH:[&\^'RS2:E#9:]J-AIFIRM+>V,
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MSDL2<8YH V]+TNST738=.T^'R;6$$1IO9L9))Y8DGDGO5RBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "J>K:K9:'I5SJ>HSK!:6Z;Y)&[#^I)X [DU<K@_BL470]%:XQ]@77+,W
MN[[OD[^=WMG;0 Y_B4;>U&I7OA/7[71SAC?20H=B_P!]HPQ=5[YQ7;07$-S;
M1W,$JR0RH'213D,I&00?3%)<M MK,UT8Q;A&,IDQMV8YSGC&*\^O+/3?%OQ*
MCTR^6*\T2TT6.[M;8-F"1Y)"OF8'# *H Z@9H ]&K%N_$ M?%NF:%]FW_;K>
M><3[\;/+V\8QSG=Z]J\LO6DM(=2\'P3S+H[>*+.P4"1LQV\R"1X5;.0N1C'H
MV*U]2TBP\)?$?3)-$MUMXUT:^F6UC)\L.H0[@O8MP#CKMH ]6SSBBO%/#.E:
MM+:>&-9T[PK>1:E)+;W-[K+WT)-W#)@S%QOW%2&) (R,#@5[70!S.J^+S::S
M+I&EZ+?ZQ?01K+<+:F-$@5L[0S.RC<<$@#/%7O#GB.U\26,UQ!#<6TUO,UO<
MVUR@62&1<95@"1T(.02"#6'JOA[5QXDO=<\)ZW:6][,D<5]97D7FPRL@^0DJ
M=R-M...HQ7,^(O%6K:GX=DT:]TLPZK'K5MIVH6UC< +<1R#S!Y<AQM#KA>2"
M,\T >M YZ49KQF^36_">D^)]1TKPY/X=TQM).V+[3%(JW0<*)$5'.T[&.3QR
M@KL;#X=>'K"6SGLP\!>W>"[19"1J".F")<GYC_%GKF@#;_M]K_P[-JGA^T_M
M219'CB@,H@\UDD*-\S# P0QSWQ[UKQ.[0(\J>4Y4%TW9VG'(SWKP.#3+*P_9
MKUB^M;=8KJY9EFE7.7"7A"Y^@XKLGLK?Q+XVT30]7C^TZ7;>'DOEM7)\N69G
M";F'\6T#C/3=0!Z;1FO$-=B;3-%\;>';&:6&PL-4TUK,!R?L_G/$S*A/0 \@
M=!FNIDT'3O"_Q0\,#1H#:C4;>]CO-KL?M&Q492^2=S DG)YYH ]&KC=1^(45
MI=ZBECH6J:G:Z6Q2^N[54V0L!EE&Y@7*CJ .*[*N,\3:G-=7%QX2\-PQG5+N
M,M>7&W]U8QN,&1\=7(SM7J>IXH N7_C:SA72DTNSN=6NM4@^TVL%KM4F( $N
MS.0%7Y@.3G)Q26GC-;[2KVXMM%U*2_L9Q;W6F!8_/C<X/=MI7!!!#<BN;U'2
MIK#QAX9T/PM)';:EIFDOON;L;XC:95-K(,%F+@'@KC!ZYQ6C\/Q-;ZWXJLM3
M*RZ['>137MQ&?W4JO&/*V+C*@*N-IR<@\G- %RQ\=R7/B*PT6[\,ZQI\]Z)&
MC>Y$6T!%RQ.UR0.@SCJ14$OQ*LXVENQI&I/H4-P;>76%5/(5@VTMC=O*!N"P
M&.#2>%"VNZIK_BD_,9)7T[3CV6"$D$C_ 'Y-Q/T7TK!TPP#]FF7=C;_8EP#G
M_GIA_P!=_P"M 'JH.1D=*Q_$WB&'PUI!O)(7N)Y)%@M;6,X:XF<X1!Z9/?L
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M/.10![)16%X-FT^?PE8/I4MU)9!62/[6294VL04;/.5(*_\  >_6HO'/B/\
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M(2%9 K_)@KVP .IR3VM7+7.K>/? ]V]]=0F\TJ>=HX6 16V1$X!!Z[CD]>E
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M="OKIBT\EHHD=NK%?EW'W.,_C4OBJZGM_P"RTBU$6D4UV$FCC4M/<+M8^7$
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M106.T9/4^E ',ZGX)CNM:GU?3=9U+1[VY55N39NA2?:,*61U8;@.,C'%)'X
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M^;'7L*UFEC1 [R(JDX!+ "G$@=2!0!F:'H5MH$5[';22N+N\FO'\T@X>1MQ
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M'2-UDC7[I8;1\P[$8[Y!KH6DC3[SJO(')QR>E4--UNQU66_CM9=QL;DVLQ/
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M%B!P"Q)%7(_"&G1:-K>E+)<?9]9FN)KDEQN#3##[3C@>F<_C0!PDVC66E/\
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M-9:AJ$]Y;:CJ>F/<Q+#=)83+&MPJC"[@5."!QE<''>@#3\,1ZG#X7TN+6?\
MD)1VR)<G>&RX&"<C@YQFN1\5VUAK7C,60\.-X@O+2Q!DAN;A([6V61CAOF!_
M>-M/(' %=[:6D-A906=LFR""-8HUR3M51@#GV%86J^#;35=:.J"_U&SFE@6W
MN4LYQ&MS&I)"OP3QN;E2#@GF@#RNXN);GP+\+7F=G=?$4$8+/N(59751GO@
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MV\"VUM% A)2) BYZX Q4E !1110 4444 %%%% !1110 4444 %%%% !1110
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M#M* #ABPX)/7/>LW3-!TK6OA!K'B/4K2&36YTO;N2_=1YT,L;R;-K]5"[%P
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M?$L7BJ:+PK;7VH2:G<PV^K27R1S6K1-MB" KN4)M4X!&>?6O9[+[1]@M_M8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K)\3>'+'Q7H-QHVI>;]DG*E_*;:WRL&&#@]P*UJSM=UR
MQ\.:+<ZMJ,A2UMURVT99B3@*!W)) 'UH :F@V<?B%=;'F?:ULOL(^;Y?+W[^
MGKGO5"X\%:3<Z1KFF2&X^SZU<-<76)/FWL%!VG' ^05BS^.O$5C8G5=0\"W<
M&DHOF22)>QO<11_WFAQV')&[(KL/[6T]=.AU"2\@BM)D5XYI7"*0PR.3CM0!
MG:EX2TW4]*L+&1KF$Z=L-I<P2[)H2J[05;W'!!&#Z57MO ^EP:9J]I+->W4N
MKQ&&]O+F;?/(FTJ!NQ@  G  P,UO_:[<P)/]HB\F3 23>-K9Z8/?-1+JNG.L
M[)?VK+;\3$3*1%_O<\?C0!0O?"^GW^A6.CS>=]ELF@:+:^&S$04R<<_=&:L2
MZ':2^([?76\S[9!;/;)AOEV,P8Y'KE15M+ZTEMDN8[J!X)" DJR JQ)P,'H>
M:2WO[.\>5+:[@G>([9%BD#%#Z''2@# NO FDW5M?1>9=Q/=Z@-3\^*7;)#<
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M 'WVNYL18MM? \L%F&..#ECS6N2 ,G@57M+^SOU=K.[@N AVL89 ^T^AQTH
MI>&M.GTCPQIFGW4GF7%M;1QRON+98*,\GD\]ZL:QI5OKFC7FEW>_[-=Q-#)L
M.&VL,'!J2WU"RO)98K:\MYY(CB1(I58H?< \4TZIIXEAB-_:B2?_ %2F9<R<
MX^49YYXXH -*TZ#1](L],M=_V>TA2"/><MM4 #)]<"DU?2[76](N]+O5+6UW
M$T,@4X.",<'L:N5!/?6EJ'-Q=00A$WMYD@7:N<9.>@SQF@#G;OP!HEYX+A\*
MR"Y&GPD,C++B4,&+;MV.I).>.YJYJ_A+2]9M](@N%E2+2KF*ZM5B;: T8PH/
M'(]JTFU73D2!WO[55N.(6,R@2_[O//X4^[O[.P17O+N"V1CM5II @)]!F@#/
MB\-6$/BV?Q,OF_VA/:BT?+_)L#!N!CKD>M'AKPU8>%=-DL-.\WR9)WG/FON.
MYNO8<55U[Q'+I.N>'+"&&.6/5KEX7<DY0",L",=>E;WGP_:/L_FQ^=MW^7N&
M[;TSCKB@"OJVEVFMZ3=:9?1^9:W49BD4'!P?0]C6!;> =/M]0L=2?4=6N=0L
MGS'=W%UOD9,8\L\8V'N  3US71VM_9WID%I=P7!C.U_*D#[3Z''2K% '*0_#
MW1;;19],A>\C22_;45G2?;+#.?XD8#CT[]34D7@32/[,U*RO7O-1.I;!=7%Y
M.7E?9]S##&W:>1@#!YK>34+*2\>S2\MVND&6A652ZCW7.139]4T^V ,]_:Q9
M<QCS)E7Y_P"[R>OM0!D:3X-LM+U5=3EOM2U*]CB,,,VH7'FF%#C(0  #.!D]
M3CK7145EZS=ZA:O8"Q%@1+=)'/\ :YC&?+/7R\#YG]!0!DWO@#2KW5;R]^U:
MC;I?D&]M+>Y*07) QEUQW'!P1GOFGKX#T9;;P] #<[- ??9_O!G/^UQST]JW
M;C4K"S5VN;VV@",%8RRJNTD9 .3P2*DFO+:VMC<SW$,5N "97<*N#T.3Q0!S
M-Q\/M*N;R>1KS4ULKBX^TSZ<ER1;22;MQ)7&<%AD@$ GM3M7\ :5J^H7=V;O
M4K/[<JK?0V=T8H[H 8^<8].,C!(JSIOB0ZCXPU/1XUA:VM;2WN(YXVW>9YA?
M/MCY1^=;-M?V=Z9/LMW!/Y1VR>5(&V'T.#Q0!E?\(CI2^(--UJ..2*XTVU-I
M;1HV(UC(QC;CL*S;KX<:/=370^U:E%87DQGN=-ANBMM,Y.6)7&0">2 0#72+
MJFGM/% M];&:9=T<8F7<X]0,\BGW%_9V<D4=S=P0/*<1K+(%+GT /6@#!U3P
M18:E?2W<5]J>G//$L-PEA<^4DZ*,*&&#T!QD8..]%[X&TRX:S>RN+_2I;2V%
MG'+I\_EL8!TC;(.0.W<>M;\]Y:VV[[1<PQ;$WMYCA<+G&3GMGO2QW=M-:BZB
MN(GMRI;SE<%,#J<],4 0Z3I=IHNEV^G6,92V@7:@9BQZY))/)))))]357Q!X
M?M/$5E#;W,MQ \$ZW$$]M)LDBD7(#*<'L2.0>#5&7Q5&WBS1=*LFMKJUU""Y
ME:XCDW;3%LP!CC^+FMQ+^SENWM([N![F,9>%9 74>Z]10!RTGPVT61;X/<ZB
MS:A:_9;UFN=S7(R2'<D<N,D ] .,8 K=O] LM1ETJ2?S-VF3BXM]K8^8*5Y]
M1AC5F;5-/MRHGO[6(LYC7?,JY<=5&3U]JI7_ (GTO3==L-'N;A4N[U9&C!90
M%" $[LGC.1CUH Y.33#XQ^)6EZO)HUY9V.A1R?O[R$Q-=3$C8JJ>2BX+;O4C
M%=-JWA.RU;7K'6C=7UI?6:&-9+2;9YD9(8H_!RN1[5O56FU"RM[J.UFO+>.X
ME_U<3RJ'?Z G)H S(?"FFP>']3T5/.^R:BUPT^7^;,V=^#CC[QQ3!X/TL:SH
MNJ_O_M.CVS6UM\_R["NT[ACDXK7N+^SM)(X[F[@A>4XC620*7/L">:+B_L[.
M2..YNX('E.(UED"ES[ GF@#-@\+:=;:/JVEQ^=]GU26XEN,O\VZ;._:<<=3B
MN6\4Z-:Z;<Z"8]+UUH;*U-JFHZ-*3<1* H$;HHRR,!G/8CMFN[NK^SL51KR[
M@MU<[5,T@0,?09ZFENKVTL81-=W4-O$3@/+($!/IDT <?\-M%FTRSUF[DL)[
M"+4-0:>WMKDYF6((JAI,DG>Q4L<DGGFNWJO<7]G:6ZW%S=P0P-C;))(%4YZ8
M)XIS7=LBHSW$2JZED)<#< ,DCU&.: ,SPQX9T_PEHRZ5IGG?9ED:0>:^YLL<
MGG JYK&EV^MZ/>:7=[_L]W$T,FPX;:PP<&@ZQI8LQ>'4K/[*6VB;SUV%O3=G
M&:GGN[:VMC<SW$44  )ED<*H!]SQ0!S=EX TJSU"QN?M6HSPZ>=UE9W%R7@M
MVQ@,JXSD G&20,\8I+_X?Z3?WUW,UUJ,-M>R"6\L8+DI;W+\9+KC/.!G!&<<
MUTJW=LT,<RW$1BE($;AQM<GI@]\U'%J=A.LS0WUM((/]<4E4^7_O8/'XT 4/
M^$9T_P#X2Y?$P\T7ZV?V( -\GE[MW3'7-4K7P'H=KH.IZ,(YI+/4;I[N8/)\
MPD8@Y4C!7!4$>A%:'A[Q'IWB?3!?Z;+OB+NI5B-PVNRY(!. =I(]16M0!A:)
MX5M=%O9KXWNH:A>RQB'[1?S^8ZQ@YV+@  9YZ9/>F:3X-TC1?$>IZ[9QRB\U
M#_6[GRJY.YMH[;FY/O705SGBGQ8GAF[T.![-K@ZKJ$=B")-OEEOXNAS].* (
M-0\ :5J-]=SM=:E!;WSA[VRM[DI!<M@ EUQGD  X(SCFNI50JA5   P .U+7
M.?\ "4)%XQU'1[LV]O:6EE#<_:9)-O+LZX)/ 'RC\Z +>K^&K#6]4TG4;OS?
M/TJ8S6^Q\#<0 =PQR.*RYOA]I4]Y+(UYJ:V4UQ]JETU;DBV>3=N)*8S@M\Q
M.">U=-]KMA:_:OM$7V?;O\[>-FWUSTQ34O[.2S^V1W<#VO\ SV60%/3[V<4
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MG72W=OL<KB1>A/J/:@#6KSPZ-IVK_&;53J-I#=I#I%L4BG0.@8O(-VT\9QD
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M6%E<Z:VIR7M_%%;V1F\J.609<"0X/R (21@YQTK7\.>'M/\ "VAP:1IB.EI
M6*!W+'YF+'GZDTNO>'[+Q%916UXT\9AF6>&:WE,<D4BYPRL.AP2/QH \QM=#
MO=2OO'6@+;Z5I$T]O82"VM92]MYA+G#?*N-X15; Z'O5O^RHM5M]=\/'P_:^
M&=?N;*(D12AK.ZB63@_)CJ<H<KNPV.:ZD_#?P^S3LZWKM<PK%<.UVY:8J^]9
M&.<F16.0W;H.!4L?@#1OLU[%>27^H27<:127%Y=O)*JHVY0C9^7#?,,8YYH
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MDIG<%.#C//6N4TFXO=-^$47C)]8U.;4EB> M-=,T:J]UL+E3D%E!)#')^H
M /9Z*X[3]%U.Q\46FHQ:C%#I\T#0RV9O);@7#X+(ZE^C#!R1U%<G:+K>K>'M
M#59]47Q&=6*:H\4LJ)Y(D<2_,#L\L*!MQW  YS0!Z[5+4;B_M_LGV&P%YYEP
MD<^9A'Y,1SNDY'S8X^4<G-<?HY_X2O7/%5G?75Y&--N4LK9(;EXVB3RP?-RI
M&69B3N.> !ZYYZ#7-8U+P9X'U"\O;A;QO$$5E/)%(46ZC61URRC@YV \]\T
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MN[AIK68_+BX1R2#@CGC.&YSB@#TVJ6DW%_=Z='-J5@+"Z+,&MQ,)0H#$ [@
M#D8/MG%</X2U RZ\-&UBTU32=;2P=9()+IY8+L;ES-%)N(W#'/1OFZG%9VA3
M^(+SX4:-<V3RZG=I?S-<6\UV4EO8EEF!02$YSPIZ\A<=.* /3[N[M[&V:XNI
M5BB4@%F]20 /Q) _&IZ\;UZ[TW7O @FMSJD;P^(+9);2]ED6:TD,D8:,_-R
M.5.>-W&,5[!;P);0)#&9"B# ,DC.WXLQ)/XF@#-U[Q#9^'[>![A9)I[J406M
MK" 9)Y#T502![DD@ =35.]\0:II5JEUJ&A?N'DCC)M+H2M%N8+ND!5< 9Y*[
MORYKFO%A:#XR^!KBZ.+$QW4,3-]U9V3@?4C %>ASF%8',Y00[3OWXVX]\T 2
M45P>D,WC#5O%D-]=7<#6-Z;*U2"X>(P($!$@VD?,S%CDYX '2N:T_5]8UW3/
MA[=7NH7D-Q=WEQ:W1@E,:W"HLH#%1QD[ <X[Y&.* /8:*\QT[1OM7B/QIH,F
MJ:O_ &;9"WFMHAJ$NZ-Y(F+'S-V\C*Y"EB,GH:SK._U36-*^&<LVKZA%)J D
MBNWAG*F4"%SEO5N.O7//6@#U^BO)GDN?#&J>,-#/B.^MM)33HKRWO+AVN9;)
MY&*%5).YBQ' SG.,<UJZ.UW'\2IM)(O;.PN="%Q]FEO&D<.)MF\\G8Y!(.UC
MT!SF@#T2BO$[![Z+X9>&O$K:QJDNIKJ<<9>2\<J\;73(RLF=K @]2"??  KK
M=8OO^$.^($6J7]]=G0]5MGB*RW,C16UR@+C"D[0'0$  =5]Z ._HK'\,V=S:
M:)$UX\[7=PS7$RS3-(8F<EO+!8G 4$* /[M;% !4#W=O'>0VCRJ+B96>./NR
MKC<?PW#\Z\R\;74_V+QC>Z?J-[<7%A&C))',T$>G,J!MBX/SN2=Q^7&& )XQ
M5V6SBO?B[H=S,T_FRZ%)*YCN)$RPDCQPK#CD\=#W!H ]'K"OO$J1ZZ-"TVU:
M^U,1":5 X2.W0\ R/@XSV !)ZXQS6[7G'@(M#\2/']O=G%Z]W!,N[JT&T["/
M4 8'MF@#K+;6[O\ MV'2+_2GMY98))UN(Y1) VPH"H; ;=\^<%1T[UMUFZ]J
M"Z7HU[?K&DMS;6TT\,9ZNR(6P._;M7G6IW=[8_"K2?&ECJ%W-K"I:W,Q,[,E
MT9617B9,[=N7(  ^7 QB@#U>BO/+?36UGXB^+M,N]2U/[$EM9ND,5[)&$9Q)
MDJ5((&1G .#W!P*YJTN=0;X:^$_%,FK:E)JOVVVA9VNGV/&9O+960':V5ZD@
ML3WH ]HHKS>/2)/$'Q \8:7=:SJ\=E##9O%%!>O'Y;.DA)4@Y R,XZ'N#@8S
M_#NJ7VIZ!X<M=5U.[NKQ+R\M_LT)VMJ2Q%D#N^X;53@DDG) X)H ]8HKQB\O
M]4'PJ\1.=1O(;G3=?>T@>.Z=F2/[3&FPN<%U 8CYNV*ZJ"VDTOXJQZ=%?W\M
MIJ&CRS7$<]T[@RK*JAUR?D.&(^7 ] * .]K$O]>GL?$^FZ4VE7$EK?!E%^C+
MLCD"LVPKU^ZA.?I^'$V=U>:8^N^![C4+Z34Y[E?[-NI;J1I6MIL_.K$YS$%D
MSC'W!ZUZ3%96\1A8(7DAC\N.21B[A>,_,<GG R>^.: +%%>8W.IW6D^*/*\0
MQ7T=M<ZJ#8:S:7#/ 5\P;;>9 ?DZ;.1@GGKDUZ=0 45YY.;_ ,6:]XJTN.X\
MF2P>.WM]MY+"]N&B5EE"H.26+<GLN/7-7Q0FMZ)H>AZ_;:M/J.KZ>=ES:032
M"'4E52'/EJ<;E +YQV/7B@#TVBO,O%,@MO@R^HZ/KE_,S^1.E\+J3=(7E0-U
M8D+AB-F<#IVJ74+:]\)_$/09;'4M2O+?5DN8[VUN;AI59HXS(KJ#PAR,84 8
MP !0!Z117E^BPZSXD\-Z#XGMM7BM;DNEU<W!NY721<GS(6B^X!G@#L1QSS52
M:RGO;7XBM+J^K?\ $LF>2SV7TB^2RVZN""""0#_"<CVH ];HKS2_U/6CI7A_
M6Y;&ZUC36TF.2_MK&X,=Q%(ZJWG*JD;^C #.1R1WI;/65UK5-!T6PO6O-.DT
M3[5')<7,D+W3!@A+%?F+* 25]6).<# !Z517/^$-/U'2M*GL-2U-=0DAN7\I
M][.T41 98W9N6(!ZGJ"*Z"@"!KNW6^CLC*HN9(VE6/N44J&/X%U_.IZ\_ETZ
MWD^.B2$SACH/G'9<2*"PN% & WW?]GH>XK(M;R[U_P"$VH>+_P"T+NVUJ,75
MW&Z3LJVYB=]L6S.W;M0 @@YR2>: /5ZR]=UN'0[6WDD3S);JYBM+>/.-\LC8
M4$]AU).#P#P>E2Z'>S:EH&FWUQ%Y4]S:Q321_P!UF4$C\":Y#XFV,-Q)X5=V
MG!;7[2(^7<.@VG=V4@ _[74=C0!U6CWVIW;7D>J:4+&2";9&R3B6.=, AU.
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MD&3@%VV]#G/:J^O6&MZ'X9M[6;Q#</*/$%ND#07#EX8))%Q"[-S)@'C=V(H
M]7HK.T?1XM%M9;>&ZO+A))FEW7=PTS*6[!FYQ[?6M&@ HHHH **** "BBB@
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MCZE>S6=CJME<W4&?-AAN%=TYP<@'(YH DTK3+?1M+MM.M/,^S6T8BB5W+%4
MP!D\\"H==T.R\1Z3-I>HB5K2; E2.0IO .<$CG&16E6<_B#1H]672GU:Q746
MZ6AN$$I_X!G- %35/"FGZO:V,-U)=B2PD\RVN8KADFC.,'#CGD'!]:J?\(!H
M/D:M"(KH1ZL +P"ZD_>@*%YYZD#D]3DY/-:USK^C66HQ:?=:M8P7LN/+MY;A
M%D?/3"DY.:+K7]&LM0BT^[U:Q@O9<>7;RW"+(^>F%)R<T 5[[POINI>'XM%N
MQ/):PE#$WG,)$*$%"'!SD8'--B\*Z=#K4>KQM="]CM?LBR&X9OW6=Q!!)R2W
M))R2>]/COKMO%TM@;S2C9K:"46RN?M@?<!N*YQY>.,XZXI[^)M!CNKBUDUO3
MDN+92T\372!H@.I89R/QH SF\ ^'Y- NM$FMI)K&YG:Y=)9F9EE)R75LY4YY
MX/\ ,TZW\$:1;Z'>:3NO9H;U/+N99[IY)94P1L+DY"X)X&!R?4UI7WB'1=,$
MIO\ 5[&U\HJ)/.N$386!*YR>,@''K@U,VK::EO;W#:A:""X_U$AF7;+P6^4Y
MP> 3QV% #]/L8M,T^"QMS(88$$<?F.6(4# &3R>*KZYH=AXBTB;3-2B,EM+M
M)"N58$$$$$<@@@&H%\6^'&T^34%U_2S9QOY;W NX]BMV4MG&?:KDFKZ;#I@U
M.74+5+ J'%TTRB(J>AW9QB@#%_X0+0C=373I>2W$]DUE-)+>2LTL9SG<2W)^
M8X)Z=L8%6CX3TZ19!=/<W;/:/9*]Q,6:.%\;E4]<G RQRW YJ]%K6E3Z:NI0
MZG9R6+$*+E9U,9)(4#=G&<D#ZFHK;Q%HEY<7,%MK%A--:@M<1QW*,T0'4L >
M />@".U\.6EM<I=--=3W,4#6\$T\N]H8VQD*?4[5RQR3@<U4M?!6E6&E6FG6
M;WD$%G<-<VY2Y;='(=V3D]0=[9!R#GI2:%XYT'7[2_N;?4+5(K*:2.4O<)PB
M,5\P\\(V,@FM?3=6T[6+8W&F7]K>P!MIDMIED4'TRI/- &9<^#M'O-(N].N8
MI9$O)Q<SS>:5E>4%2'W#!!&U<8P  !BMJUMH[2VCMXMY1!@%W+L?<L223[FI
M:J:CJFGZ/:_:M3OK:SM\[?-N)5C7/IDGK0!%K.B:=X@T]K'5+5;B L' )(*,
M.C*PP58>H.:KV7AVWM&C,M[J%Z(B#&MW<M(%(Z''\1'4%LD'FKBZOIKV=O=I
MJ%HUM<,$@F$RE)6/0*V<$G!X%1Z;KND:RTRZ9JEE>M"<2BVG60H??:3B@"I<
M^%=.GU:XU.-KFTNKJ,173VLQC\]1P-X'<#@,,,!WI+CPGI-P^DD120KI)S9)
M!(46(XV]!P>..<UE^)_'=CINESOH^HZ;>:A!=00RVXF$C1AYEC;*JV01N_.N
MPH Q8O"]A!J6IZA$]TMSJ:JETXG/S!1A<#HN 2!C'6N0USPO#IVH^"],TNVU
M+^S=.NI9&DA$CFW4QL%^< _Q$<<\=1BNH?QIHL?C >&7O;=;TP"7F9 -Q8*(
M\9SO.<XZXJ])XCT.'5!I<FLZ>FH$@"U:Y02DGH-N<YH J7'A#1[W3-2L;V%[
MI=2V_:Y97/F2E<;>1C&W P!@#TY-16W@C2+74X=31KYK^*W-L+B2\D=V0G/S
M$D[L'D9X'X"NCJE>ZSI>F%A?ZC:6I2/S6$\RIA,@;CD],D#/J: ,5? 6B+X>
MM]"5;H:=;3">*(7+Y5PV\'=G/#<XSUJOJ:3>)=630;G0KI;"RNH;B2_N@GES
M!,.HCP<DE@ >,8W>H%=';ZMIUWIO]HV]_:RV(4L;F.96C '4[@<<5'9Z]H^H
M6$U]9:K8W%I""99X;A62/ R=S X&!SS0!0UWP\-7UG1;Y7GBFT^8RK*DY50N
M1N4H/O%@-O/ !;V!WZY?Q#X[T/1-"U*^BU/3[FXM(/,6V6Z3<[%2R+US\P&1
MZC)%5?"/C ZCX5_MO7M7T".-E1V-I-M2VW*#LE+,</S[4 6[[P!H&H7.J33P
MW.-47%W"EU(L4C8V[R@.-V,<X[9ZU8;P=H[7&F7'EW(FTV-HH7%U(&9#@E7.
M[+@D D-FM6WU.PN]/&H6U[;3614M]HCE5H\#J=P.,"J</BC0+G3[F_M]:T^:
MTMO]?-%<HR1_[Q!P* -:L75O"VF:Q?P:A*LUOJ,"E(KRUE:*4*>JDC[R^QR*
M/"_B?3O%FB0:GI\J%9%!>(2*SPD_PN >#[5M4 4++2;>R+.9)[F9EV--<R&1
MBOH,\ >P !K-LO!>CV"QP0)/]AAG^T0V+3$P129W JOH#R!T!Y !K2U/6]*T
M2))=5U*SL8W.$:YG6,,?0;B,UD>)/$YTRST.[TZ2UN+?4=3M[1I2VY/*D)RR
MD'&>.#R* +T7AJQ@UF_U:*2Y2\OT6.=Q,<%5R% '08R<8]:HCP'HB^'K7056
MZ&G6LHFAB%R^58-N'S9R<-SC-:5KXET&]M[FXM=:TZ>"UYN)([I&6(?[1!PO
MXU1T#QMH?B#P\=:AOK:&V0$S>;.@, W$#?S\N<9&?6@# TW1Y[CXE>)[J3^U
M;6"XM[2*"Y17C6;8C"09(QP2N#P>NT]:Z"Z\$Z'=1Z4BP36O]E;A:/:7#PO&
MK##+N4@D-CGG)JVVMVE_H%WJ.BZIILZQQ.4N6F#VZ.%S\[*>%'!//2DLM9@C
MT>QGU34]+$\\!D,L$P$,FU<LT98Y*@<Y["@#,?X=^'FTZ_T\0W*VE]<_:IXE
MNI #)N#9'/R_, >.I ST%:,GAZR_MR'72;J74+>W,$9\X\H<$KMZ') //>KF
MFZOINLVYN-+U"UO85;:9+:99%!]"03S5V@#D]$CE\0Z]%XDOM#N-+>UMFM;>
M.\"^<2[ NQ"DX4;5"YYY?C!&>LJO=:A96)07=W!;F3=L\V0)NV@LV,GG !)]
M *SAXM\-G3CJ(U_2_L0D\HW'VN/RP_\ =W9QGVH C_X1/3C(P=[J2W:[-Z;6
M28M%YV_?NP>0-WS;<[<\XK=JE<:QIEGIJZE<ZC:0V+ ,MS),JQD'H0Q.#FJ.
MIZTDGA>?5-%U32,;08;R[FS:CY@#N93TZC@]<4 5=9\":'KFLIJTZ74%\$$;
MS6=T\#2I_=<H1D?K6G#H=E;:A%>0JZ/#;?98HU<^7''QPJ]!]T<^P]*'UK3[
M*UC?4=3L('^SB=V:=57;P"XR?N9(&?<5G:UXWT+1O"TOB'[?;75DO$1MYT;S
MG_N(<X+=>/8T <SXS\(6^E_#35=%T&SOI_M<T<BVL9>7!\Y7<K_<& 3V'XUV
M=AHMG'=Q:D7NKFY6$Q0R7;$M%&<$J 0,$X&21N.!DTLWB;0;;3H=1GUK3HK*
M8E8KA[I!&Y!P0K9P<$'IZ5!KFJS0Z5:7>EZCH\2SSQ@3W\I\J1&SPA4\L>W:
M@"E8_#SP]INL/J-I!<1;IO/^RK<O]G$N<[_*SMSGD<<'IC JTO@[2UCUA ;K
M;K&3>_OV_>97:<?W?EXXQQ5Z^U_1],$OV_5;&U\G;YGGW")LW9VYR>,X./7!
MJY;7-O>6T=S:SQSP2+N26)PRL/4$<$4 8T/A.QM!:_9+F^MVMK5;.-H[@_ZD
M=%(.0<=B>1V-5]3\ >'M3TW3K)[22W731BSEM9FBE@]=K@YY[YSGKUKIJS]2
MUW2-&,0U35+*R,QQ&+F=8]Y]MQ&: ,/5O!5G<Z/I^FV7VF$VMTMQ'.+IPRN.
MLCMG,C<GKG)QG KK*IW>K:;8 &\U"UMP8S*#-,J908RW)Z#(Y]Q69J7C'1;+
MPM=Z_!J5C<VL,;F-H[E-LLBJ6$8;.-QQC'6@"S>^&]-O]=M=9F247UM&8E>.
M9T#H6#;7 (#+D X/%5#X*T;S+P*DZ6M]+YUU9I,1!,YZL4]\#(& W<&LKP+X
MQGU[PY)K6LZCH4<7EI*8[24@VJMGB8LQP>GIWKIM/UW2-6M9+G3M4LKN"+_6
M2P3JZIWY(/'XT :     P!63K?AVQU]K,WQG/V.X6Y@$4S)ME7[K<=2,GKQ4
MUMKND7DSQ6VJ64\B0B=ECG5BL9Z.<'A3Z]*-,UW2-:\W^R]4LK[RCB3[-.LF
MP^^TG% %/4?">FZIJMKJ<[7:7EO$8/-@N7B,L9.2C[2-RYYQ5%?A[X?328],
MCCNH[2.[^V+&ETX FW;@PYXP><# ]JVK+7M'U&]FL['5;*YNH/\ 6PPW"NZ=
MN0#D<UH4 9&K>&].UN2PEO1.9K!R\$T4[Q.I*[6&Y2#@C@BH8_".F17&K3HU
MTLFK*%O")V^<!=HQ_=PO'&.*VY)$BC:21U2- 69F. H'4DU0T_7]&U6&>;3M
M6L;N*#_7/!<(XC_WB#QT/6@#'O?A]X?OM$T_2IH;@1:;C[%,EPRS6_&,*X.<
M8 _(>@J:?P1HUQI%OIDBW1MX)UN0WVE_,>4$$.[YW,P('4]AZ"K\?B70IKZ&
MQBUK3WNYD#Q0+<H7=2,@JN<D$<CVJ2[U[2+&_AL+O5;*WO)\>5;RSJLCYX&%
M)R: +ZKM15R3@8R>II:Y_P #Z[<^)O!>F:S>1Q1W%U&7=800H.XCC))[>M=!
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7"?$\7<MGX=MK:*VE$^M0H\5VQ6&3"NRJ^ 3@N%['D"
MN[JEJVD6&N:=)I^I6ZSVTF"R$D$$'(((P001D$<B@#SJZ\$ZOK+>)X-071;6
M34=.B"VVG3.Q%Q&S-%,P95QSQGOMJ/3=8/Q"UKP;"X)CT^U.K:BA' N%)B13
MZ$2"1L>@KO\ 1/#6E^'OM#6$4OG7!!FGGG>:63' R[DG [#.!1H_AC1M O-0
MN]+LEMY]1E\ZZ8.QWMDGH20!EFX&!S0!XW>RS0Z#\7VA9E8Z@B,5Z[&;#_\
MCI-=IXMTS2+'Q-X -E;6\,BZCY</E*!F(1-Z=0#M_/WKKH/"NB6QU?R[!2-8
M8O?*[LXF)!!R"2!P3P,50L/AYX:TZXM+B&RF>:SD$EL\UW+*8< @!=S'"X8_
M+TZ9' H \XL-&\0Z[X)U+RX/#L)GU&XEDU"[N)$N(IUN&PQPA *E0!STQZUU
M^@Z79WOQ2\:SWMK#/*D=E&OF(&"AH?F !]<#/T%;EQX#\.W6JOJ,MDYDDF%Q
M+$+B00R2C&':(-L9N!R16O;:38V>IWVI00[+N_\ +^TR;V._8NU>"<# ],4
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M6X$5S)$EP%Z"158!\=.0>..E '+^&K'[3\0+JVU[[/?7=GH-C'"[#S$<-O\
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MV.]4SM&,X&-QZ"@#R;PQ*)/"/@S2K;2[6^U%KJ_DLS>RLL%NL4KJ6(7.X@.
MHQQG/&*H:OYR?"[XE0S?9%>/55#)9Y\E6Q!N"@\CG.??->I3> _#TNF6>GBS
MEAALI9);9H;J6.2)I"2^'#;L,6.1G'Y"FM\/_##6>H6?]FE;74(XX[F%+B14
MD"8VG ;AOE7+#DXY)H YF&PM;_XC>$Q=0I,L7AQY45QD;@T8!Q^)KF/%-K;P
M>#/B?;Q0QI##JL$D:!0 C,(-Q [$Y->Q1Z%IL.I6NH);XNK6U-G"^]OEB)!*
MXS@\J.3SQ5:Y\)Z)=VNKVUQ8B2'5V#WJF1OWK !0>ORX"CICIF@#G=;03>-+
M+3-'T33)=0M=.:<W%\["&"%Y-NU(U!!9F4Y/& .O.*\\U)RWP;T,;HBJ>)RJ
M>3_JPOVB7 3_ &?3VKU:3X>^')8K1'M[HFUC:)'^W3;WC9MQ1VWY=<_PL2*D
MD\ ^&I+22T;3C]F>]%_Y(N) BS#)W* V%&2>!@>U &-8:;9WOQC\1S75M',\
M.G68C\Q0P7=YF>#WXZ_7UJ?X7>7;^%;JW7;'##JUY%$G0*HG;"C_  KJH=)L
M;?5[K58H=M[=1QQ32;V.Y4SM&,X&-QZ#O6-J'@S3Y=-MK&Q@2".+58]3):1S
MB02^8Y')Y;YA@\#=["@#IJ\ON+;6=0^)OBA;/3]$O1':VD(75)'!6%D8D(%1
MOE+;\^X%>H5A:WX/T7Q!=I=WT$PN5C,)EM[F2!GC)SL8HPW+GL: //\ 2]!\
MGQ'\/M-U62TOS::??%6A<RPL%9/+P2/F"KMZCJOM4MU9VT0^+5K';Q+;QVRS
M)$$&U7-F26 [$GG->B0^'-)M[K3KF"R2*338&M[38Q"Q1MC*A0<'[HZCM2/X
M<TJ1M89[7)UA!'??O&_>J$\L#K\OR\?+C\Z /+[6TMG\&?#"VF@B%C=W5O\
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MM-)@A^'1M(X$9=7M4M2@ /D["3CVX0_E7I22QR.Z)(C,APX!R5/OZ4 /KEO
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M_!.BZYX@U"RL6OK6*5FD<1J79 Q"@GWZ<UR6BP6%QX(^(,VI)$TC:EJ/VII
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MUU_PC2&4:>C(F?WN-P8DEMI'/H10!ZG:^*- O=5.EVNLV$U^!DV\=PK/TR>
M?2HKSQAX:T^01WFO:; _FM#MDN4!#KPRGG@C(SZ5PVMVEA;>#OA]+IL42RKJ
M>GBV>,#<P8?/SWRNXGU[U)X4L=)N++XBO=Q0.SZO>)<F0 D1!00#GMRQ^N:
M/0-4US2M$M%NM4U&ULX'.$DGE"ACZ#/7\*IZCKEO<>%+C5='UC2TC"9COIY
M]NAR =Q!'TZ]:\Y\ ^9=>(_!XU0;_*\*>99B49Q)YH#%<_Q>7L_"JGBA$AT3
MXLP6BJMBLEJRJ@P@F9$,N/?.W/O0!ZN^OZ9I]C!)JFKZ?$[6PG:0S*B.O +K
MD_=RP_,5G:QX^T#2_",_B./4+6\LTRL7DSJ?.D R(U/][CI7+VEI;W?CCP)]
MHB63RO#\DB!AD!@(@#^IK \60Q0^'/BO#'&JQ+=6TBH!@!FCB+$#U)H ]CTW
M4K+5[".^T^ZANK:3.V6%PZG!P<$<<$$5;J*U1$M8E155=HP%&!4M !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %4M6TBPUW39=.U.U2YM)<;XWSS@Y!!'((/<<U=K'\3^(K;PMH%QJ
MMS')*(]J1PQ_?FD8X5%]R2* (M*\&Z!HEXEY86 CND1D$[RO(Y5MN068DG[J
M]>F.*CL/ WAO3-474;/3$CN$9FC_ 'CE(F;[Q1"=J$Y/W0.M8D^L?$6QL3JM
MQH.C3VZ+YDFG6MQ(;I4ZD!B-C,!V Y[5TE_XIT;2=.M+W5;U-/2Z4-''=?)(
M20#MV=<C/([4 6+/1-.T_4]0U*UM5CO-0*&ZE#$F4H"%R"<# )Z8K.L/ WAO
M2]474;/3$CN$9FB_>.4B+?>*(3M0G)^Z!UJ]'XCT:72H=4CU.U>PF=8X[A9
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M1&225Y6" YV N3M7V&!6Y6-K'BSP_H%S%;:MJ]I9S2C<J2R ';G&3Z#/<\4
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MU5[[QCX<TV\@M+W6K.">=5>-))0"5;[I/H#VSB@!^K>%M%UNVM8+ZQ5EM/\
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M484.K;@WN<C.35Q],LY-4BU-[=3>Q1-#'-W5&()'XD#\J /%]>2U7PSXSBN
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M]LK74K&:RO8$GMIT*212#*LIZ@UC6W@;PS9BV\C1X%-M(TD3$LS!F 4Y8G+
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MBAM42.^E>:Y49_>.X 8GZ@"J%]X,\.ZE8Z?97>EPR6^G@+:+E@81@# (.<8
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MOB]X::-%0MIEXC;1C*@QD#Z#-:]MX'\-6?G_ &?2((Q/.ES(JEMID1MRL!G
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MX(!/X5VU5?[-L_[6_M3[.OV[R/L_G=_+W;MOTSS5J@#R'0E+6WQ; &2;FY
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MXX-6U.&VED7>J$%FVYQN( .%]SQ4NJ>)=%T;3X+^_P!1@AMKC'DOG=YN1D;
M,EN.>,UR6K7UY=>*O$4>GRZ3I<6G64(OKV[M3/+.K*SA0 Z@(!GKG))KG_ T
M@&L?#\WC#RCX<F2T+GCSPZ;@/?8/RH ['7/B5X?TC2--U*&\ANX-0ND@B:-S
M@+O"R,>#C8#D@\]JZNUNH;ZTAN[:0203()(W'\2D9!KS'QC-H36FGMHIB&SQ
MA:?;FC5@OVC(WDD\$XVY(XKU2@#R[QA\1'M?'%GX<T_6[33(%A>2]O);5IV1
MQTC"Y _'WKL=2\;^&M'OS8ZAK%O#<H%,BG)\O/3>0"$S_M$5S6J?\E^T+_L"
MS?\ H9IOA%[*/P]XW&IF,.NJWQO_ #,?</W<Y_AV8Q[4 =AJOBG0]$5&U+4[
M>V$D33(7;AD! )&.O++]<BM&TNH;ZS@N[:0203QK+&X!&Y6&0>?8UX[X9M7F
MUCX6#4(]\D>CW,BB09QA4V'\ 1C\*]HH PM5\9^'-$U 6&I:M;V]R0I*-D[
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M]@FD&YF.'A0+F4D@!1EB,>V:ZVO$KOS6^&/Q-6'<6'B*Z,@3KY?F1;_PV;J
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M)]D3;"I=GWQA23@!MW&>] 'K6D:QI^O:='J&EW*W-I(6"2J" 2#@]1ZBKU
M P!@44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV\K*P$GE@ENW& IZ]>U8Z?$_0I_%.GZ/;R/)%>6QE$Y@E4ABR!%VE,\[B<G
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M\-ZE:VEM>:-:316<?E6X*<QITV@CG'M6O:6EM86D5I9P1V]O$NV.*)0JJ/0
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M^NPJ')^<@'@X&01P*Y;3--L;?X2>"]4BMHEOUU:UQ=!1Y@'VDKC=UQC(QTH
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MB@#O5O+5[3[4MS"UMC=YP<%,>N>E4=4N;B2T/]EZA8PS17$:RO<?.JKN&Y2
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M ^M3_#R"6SNO%%G%D:3!J\BV*_PH"H,BIZ*')&!P#F@#8\4^)D\.P6445O\
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M\2Q#0K?[';Z)<A1?7+2,9R@;+1HFW'( &XGC)XKJ888[>&.&) D<:A$51PH
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MW\]N4:9P7."JKQPC <<X'<UK:'XMTOQ!=W-G:?:HKNV57DM[NV>"0(WW6"N
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M@4MCIGUQVJ2\L[74+22TO;:*YMI1B2*9 Z,/<'@T^XGCM;:6XE.(XD+N<9P
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MT)HVEQZDVI)IMFM^W#70@42GZMC/ZT <1X8C3[#\0VVC<VKW88XZ@0IQ^IK
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MX[5C?%.'3KCQ-X)BU:80V#7EQYTAG,(4>5Q\X(*\X[BO1TM+:.ZDNDMXEN)
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M-KNL:!X@M)HUO"VH:#?1 ^;-\JL(R<.K, ,<,I/(XKTEM&TMM2&I-IMF;\#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKEO'OBU_!WA\7T5I+<S231Q(%A9T&YU!W%>G!./4X%=37"?%YA'X!DE<[8X[
MVT=V/15$R9)]J *]UXU-I\0+=95U/[%<:)YT6G+:N9GF\\C/EXW [0>O  J[
MK/C#1]1^'^H:S'JFHZ9:P2B">:&';<VT@D4%"C X.2 >.AJ*VN+6_P#C-%=V
MLT-Q"WAP^7-$X=3_ *3@X(X[5POBW_DF/Q-'_4Q?^S6U 'J&K>-M'T":ULKM
M[N:ZGMO/@BA@:228 A<*%'+9.<>F3T%)>>.])L[];(P:C-.L"7%PMO9O)]E1
MAD&7 ^4XSQUXZ5@NBO\ %WPPS*"4T*9E)['<@_D32:1K.F>'O'_C9-9OK>RD
MFDMKJ)KB0)YL/DA<KG[V"",#O0!L_#;5+G6O ]I?W=TUU+)/<#S6.=RB=POX
M;0!727UY#IVGW-[<$B"WB::0@9(502>/H*X[X0%6^&NGE8S&IFNB$(P5'VB3
MC';%=!XN_P"1+UW_ +!UQ_Z+:@#+M/B/H%Y=6,<?VY+>_=8K:]DM'6WED(X0
M2$8W=1Z9!&:EU+Q_HFEZC<6LXO7CM'6.[NXK5W@MF;! DD P.HSZ9YK@[S5]
M+U3X4>$M&TZZ@?4Y9=.ACM4<&6.1&0N2O4 !6))]<]ZJ^,-9EU+P]XS%QXA-
MG)#<7-I#HMK##OF5!C>^5,C;E&XD$ */:@#TG6?'.CZ'JITJ=;R?4/*29+:U
MMFE>16+ ;0O7&UB?0"L>V^)<!U[Q):W>FZA'9:0JMYRV4F0!&7<OV'3Y>F1S
MS5;1)+>[^,;W4+QS(?#,'ERH0P(,QS@_A3O#5Q8_\+-\>:9=S0":[EM=EM(X
M#3)]G^;"GEAC.<4 =;J'B;2],\,_\)#<7!_LWRDE61%+%E? 7 '))W#\ZUD;
M>BM@C(S@CD5XQHEO<W>LZ;\.+D.\/A_49+R=V'^LM(\/; GH<M(HQ_TSKVB@
M#%\0>*M*\,?9/[4EDC^U,R1;(R^YE4MC YR0, =S@5DOXALKSQ1X9!OM6L)[
MZ*=X=-D@\M9@JG/F@C*E<9'(JGX[C23QAX#5U# :H[8/J(F(_453\5?\EO\
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MT$*&4HX'7'KBN^\ VUG!H-Q-8ZM+JL5U?3W#7<D0C$CEL.5  !7<"01P<\4
M=/)(D,3RR.$C12S,QP !U)KF]'\=Z/K6H6]G;I?0F[1I+.6YM'BCNE49)C9A
M\W'/;CFM3Q#>RZ9X:U2_@@$\MM:2S)$PR'*H2 1[XKRN#4XG\3>!+FX\6C5"
MTS/+&B0);VI>W<*HV*"I)R K,2=IH [.;XG^'HK>2Y U"6UAE:*YN8K)WCMF
M5RI\Q@,+R,^N"#W%;]OK^GW.OW&B1R-]MAMTN2I7 >)C@,I[C/!KSBQ11\"O
M%9"C+-J9/'4^9)_@*O\ B60>'+?PGXV ;RK"*.TU$J,DVTJ@9/KM?:<>] '=
M66NV.H:SJ6EVSN]SIWEBY^0[5+KN4 ]SCKZ5I5R7PYT^:V\+C4KU-NH:S,^I
M7(/53(<JO_ 4VC'L:Z34(I9]-NHH#ME>%U0YZ,00/UH YVW^(>@W6HPVT9O!
M!<3_ &:"^:U<6LTN2-BRXP3D$#L2.#2ZA\0=%TZ\O(&CU"XCL6V7MS:V;RPV
MQQDAW QD Y.,X[US?@_Q3X=M/ /AO2;ORKC4%:*R.FJJO.EPK8),9.5VD%BQ
MZ#FH- US2= \)>+-.UF\M[>^@OKYIX)G"R3"0ED95/+!E(QCK0!V>I>-=&TV
M[MK1I)[BXN[;[5;1VD+3-.F0/D"]3SGZ GH*Q=?^(ENO@#5M:T>*]-U;>;;^
M6]FV^UG52?WJD?*!P<GCD5B>#;&XL?%?@^VOHRMS!X48,KCE#YD7'L0#BH-3
MX\-_%H?]-W_])XZ )=)UT)X&TF_UCQ%XE@GN[RUW3S6H3S)'0GRX_D&83SSS
MT'-=QJOC/3-)U?\ LMHKZZNTB$TR65J\_D1DX#/M'&<'CKQTKSOQG_R27X??
M]?FF?^BC70Z;J^F^'_B9XS_MF^M[$W*6=Q;O<R!!)$L14[2>N&!X'K0!)X3\
M:0Q>!EUC5KR:[,^HW%O;>4AEDG_?.(T15&6.T<>PK;'CO1%T.]U:=[BVBL94
MANX;B!HY8&9E"[D/(!WJ<],5Y5I>\^&/"6HQZA)HUE'KE^KW9B1OLQD,H3<K
M@J!GY<D<;JT/$EI9/X/\87D?B237[B:73X+J4P1I&"DR$ &-0K'#X.,D<9H
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M\5&W\&W&J>'-9M'E@E@#-"4F^6254]P."><=J .WJM-I]E<W,5S/9V\L\/\
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M[V Q.0/XMIYP>U:- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[)I%MJVEV<MC]M*PA%C#!XLD[0REERH-<K<W,,6C6^NR(W]F7?CM;Z!MA^>
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MO#\L5Q<6[AXP[R HFX<9PK'%<=X6867PM^'FKW/&G6&K2O=N1\L2L\R+(WH
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MYMI!E)87#HP]01P:>UO"T;QM#&4D)+J5&&SUR.].CCCAC6.)%1%& JC 'X4
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M<#CTJY!XET2YT[^T+?5;26T,IA$L<H96D_NC'5O85X_:W%@WP7\#I/-;F/\
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M8<Y;8H&X^IKEIOB+HL>D:3J21WLT6J3M;0)%#F195#91E)R&RI7'/..W-7-
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MHX/'D+ZE)876AZO97!M9+NU2>) ;I$^\$PYPW(^5L'GG% '5"&)8EB6-!&O
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ML]9N&=K<!Q;0!4P!O8>C$*N>_ SSU5YXVL8[?2WTZUN]6GU2$W%K;V:KN:(
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MK,6 #%&)7&&!]LC!QUESXKL;71]&U-XK@P:M-;0P*JKN5I\;-W. !GG!/XT
M;/D1<?NDXZ?*.*<8HR6)126QNXZX]:Y/5/B#9Z;>7\<6E:I?6VFG&H7EK$K1
M6QP&(.6!8J""=H.!4^H^-K6VNX[73=-O]9F-LMW(+!$81PMG:Q+,HRV#A1DG
M'2@#HS!$5"F)"H.X#:, ^M*8HR"#&GS'<?E')]:YB[\>:<EII$FG6MWJD^KH
M9+2VM%7>R* 69MY4*!D Y/7BJ'@G6YM:\8^,&=KR."&6T6.UNB0;=O)^==N2
M!\P.<<'KD]: .X50H 4  =A2T44 %%%% !1110 4444 %%%% !1110 4444
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M%==;ZSIW@_XA^*GU^Z2QAU/[-<V=Q-D),J1;&4'IN4C[O7D5Z( !T %!4-U
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MNM7/3KR]0Z/J%KX7\3:3JNM3+:Z=?^&K6WANY>(UECY,9;HI(8$9ZX->KTA
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MEWJZJ[*#A6&?Q455\[3K/P->66A6FHZC<>([R6&W7506-P[*$:=L\B(*N[)
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M%IJMY;FS#1LK2I&8D\P*1G#$''TH ]&F\33Z=;Z586>CWVKW\]DMPR0,BA$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<?\1+NYM-)TXI<WEKI\FH1IJ-Q9;O-CM]K9(*C<H+!
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M.YN$$+%XXUNG)8KC/0CM77^/M133K;1/B)IB//'8,8YU"%#+;3#;R" >'V$
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M&6<E&QB7+*, _,0 3D=J .@M_B9/-I6F:X_ANYBT*]>*)KQKA-T3.0N?+ZE
MQQNXSU QC.K=>,;LZ_J&FZ3H,^I1:8$^W3I.D>QF7=L13]]MO.,CKBN5N=/O
M3\!-%LQ9W!ND6PW0"([UQ/&3E<9& "35^PU4^$/%WBFVOK#4)6U&[2\L&M[5
MY5N<QJI0,H(4AEQ\Q YSTH T_A/,;CX9:/,SLY<3'<QR2/.>CXM2/%\+=>>-
MV1Q N&4X(^=:?\*[:YL_AMI%O>0/;W""7?$ZE2I\UST-'Q5MI[SX8Z[;VT$D
M\SPJ%CB0LS?.O0#DT 9L^I:;;:C\.[:^L)KF]NX&%K<+<,@@81(6+*#A\@CK
MTJ_?^.[J*ZU-M,\.W6I:=I4IAO;J*9%8.H!=8XSRY4'GISP,U@:O87C^)OA7
M(EI.R6T<HG81DB+]S&/F./EY!ZU+INN2^!Y/$FF7.DZC=7\^IW%[IT=O;.Z7
MBRD,H$BJ54@Y#9Z8SS0!T-]XSNCJ,UGH6A3ZLUK;QW%TPF6'RPXW(@##+.5&
M=O&,CGFH9OB#%+<Z/;Z1I<^HR:O8M>6H618^A7*N3PN 22?;&"2*Y;4]/LK'
MQEK.H>)K;78!J45O/;'2YKED+K$$>$^3@%@5&"P&0:UM&T@6'C/PJ+32[JRL
MH=$N!Y4Q+F!FDC;8S\_-U[]J -"+XA?\2F^DN=&GAU:TOX].;3A,K;YI-OEX
MDX&TA@<G&,'BK3^,[G3](O[K6M N[*YM9(HX[='65;IY#MC6)Q@,2QP1QCO7
M-W-M;QW_ (X.LZ'>7^EW.I6N\11,6">2@,J[?F.U@/N\C\*QKG3KW5M!U6+3
M9-=U/0+&\LKNT%T)4N7V.3/'$S!9" NTJ>N> : /1M$\2W5[K,VC:MI#Z7J*
MVXNHX_/69)8MVTD, .0< @CN.N:Z"5G2%VCC\QPI*IG&X]AGM7!^#;/P]-XD
MEOM&M-<E,-J8S?ZC+<%!N8$Q*LQR3\H)(&!ZUW] 'FOAKX@Z@OAO7M;\16#I
M:6=[/'$T<B.Q(DV+ J@#)!(&X]:WK'Q??+KEAI>NZ!)I3ZBK_8Y!=).KLJ[B
MC;0-K8Y[@X/-<!#9WMSX+\2:##87AU>RUN34EMFMW59XUN%<;7(VL64' !R:
MZ>[U-/&OBSPP-*M;X6^FW+WMY/<6DD AQ&RK'\X&6);H,\"@#T2N0U3QK=6N
MH:E#I>@3ZG;Z4 ;^=)TCV$KO*HI^^P4@D<=0.M=?7D&HZ7I>E>)O$@UVV\0N
M][<_:K$:;)=".Z5HU!CQ$=H<,I!W8X([4 =VOC*S_MG3+22(QV6JVGVFQORX
M\N4XW&,_W6VG<,]1GTK,G^(\$/A:7Q)_9=PVF?;EM;9PWSW"%PGFJN/NYS@=
M3CM6/XA\/'Q/8:1X#L;&XT_3;:VCN+NYD7>;4*N(X4<Y#29ZD'A0?6L_Q#J5
M^WPR@L;[3&AU32=4L[62!(]D<Y25=C1$X&U@!CTY':@#M-.\7WDGB2WT36="
MFTJ>\A>:R=KA)EF"8W*=OW6 (..1[UQWP]\21>'_ (?:WJ=Z)[DKKD\,,*'<
M\KLR*B+GU)K:;4%\6_$;PY<Z;:WJVNCQ74MW-<VDD 1Y$"+'\X&6ZDX]*Y'1
M-$U9?AW=3IIMT]QI_BK^TQ:^41)-&CJ3M!Z\9(]<<4 >CZ;XLO6\06VBZYH;
MZ5=7D3RVC"Y6=)=F"ZY && (.,8QWKB9_%XTSX6^)=7\*Z7+9R6^I302-+<^
M:8Y/E!F&_.1DJ-GO6\;]/&/C_P .7FE6]Y]ATA;F:YN;BUD@7=)'L6-=X!+<
MDG'0"N-M=%U23X*>.+)=/NOM4VJW$L4)B8.ZAXSE1C)& >GI0![/I=Q>76G1
M37]E]BN6SO@\T2;>>/F'!R,'\:JZ_J]QH]G"]GIEQJ5U/,L$4$/RC)R=SN>$
M4 ')/L.]3Z/JMMK6EPWUH)A#(, 30O$W'!RK &N9^(4LT8T59Y-0CT1[MAJ;
MZ?YGF!/+;8"8_G"%\ XH 2?XAC3_  ]K6H:GI,MK>:--%%=V8F#\2%-K*X&&
M!#YZ9X(JU9^,;QO$MCI.J:!/IR:DDCV,SW"2%RB[BKJOW&V\XR:\UOK)AHOC
MBRL-(U2&.]:PN;&*XBFD>6)9(U9MSY.<@G:3D ]!@X]&\36L\WC_ ,%2QPR/
M%%+>>;(JDK'FW(&3VR>.: .7\8^-[S6/AYK]Y9:'<+HKQ2V\&I+<+N8AMF_R
M^H0L,9SGOC%>H6!SIUJ3U\I/Y"O%WOKFP^#6H>"3I.I2:];0S6[0I9R%&3S&
M;S1)C:5*G(YR3P!7M%@"NGVP(((B4$'MP* ,G7_$<NE7MCINGZ<^HZI>AWBM
MQ*(E6-,;G=SG:!N4=#DFLR3QZL/AV75YM)N$%C>?9-4@WAGL\$;GX^^H#*V1
M_"<^M9?CW2[?_A+='UG4TU,Z2MK-:SRZ<\RO Y9&1F\KYBIVL#VSC-16TT&D
M>#KUO#>@ZF]UK%X8+:/4O,D,[,H3SY/,RRQ[1GYL9"CU% '4Q^++:Y\2S:59
MQ>?!:VHN;R^60>5 &&47_:8CYO8<UF:?X]FNY=,N+G0;BTT?591#8WSS*Q=F
M!,9>,<H'QP<GJ,XS6'X8\.77A"/4/ SJ\]GJ5H\MGJ2PX'F&,))'(0.", KG
M^'C/%9GA;2M#9/#^F76E^))-;M)(?M-O+/<B"UDB&?-)9O**;E!4+G(( % '
M9:5XYGUC7;^PM-#F^RZ=>S6M]>O<*J0A.C 'ELXZ#H,$GFHM/\?7-\]A>'PW
M>1Z%J$XAMM0$JLQW$A7>(?,J$CKGC()Q5;P=I=S+8>.;2:*2W-[K=[Y32(5W
M*Z* PSU'N*K>$_%-UIV@:!X870M0?6K8165W#) \<<")\K3&7:4*X&1@G.0*
M )=/\5:+I5QXWOH-+N8I-.NT6Z(G,AN9#PNT,<)DD#L.:V%\875A9:E<^(M!
MN=+2QM_M.])5GCE7)&U77 WYP-I]1VKD=&M'M;WXE2:CH5U?V5Q?H3;+$<W$
M1R&* _>P#GCGCCG%4)]+N-9T;Q#H_A>;6;S0VT])(HM065=ERDH810M* ^"B
MD$<@''/- 'H&D^*[VXUFWTO6="ETF>\A>:T+7"S"0)C<IV_=<!@<<CKSQ745
MYMX6M?#EYXGL;G3+#Q'+<VL4DC3ZC+<^7:,R[2A$QP6()'RYZ9KTF@#C-2\<
MWFF3W5Q+X<NQHEI<BVGOWE5&!+!2ZQ$99 6'S9YY(S69!+)_PT/<Q>8WE_\
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M,1 #@[1\Y  YK(L#-I?AKP!<W=A?HFBZC/#J"K:2LT+%7 .T+EEY'S $<^M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)$BF2/>TA"$9;D $] * /0Z*\7CNM2U#3O#^D2ZK>_Z-XHN=+:Z68B6:!%D
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M>W9Y$!="ARCE&RI (Y4]: +U%%% !1110 4444 %%%-=Q'&SD$A020!D_E0
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MM&2,['QD?7!(H Y@>$+RZTO6;;5_$-W?S:G9M9ES&L4<*%6&5C7C=\Q))Y/
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M0_,[?BQ)_&JFN>&+C4M:M=8T[6)M+OH8'M7DCA2421,P8KAA@$%00?YUT=%
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MLBE@PRJJ,8(SQC/<XR#43X>11^$-/\-KJUQ]EL;E;F.4QIYA99/, /;&X^E
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MQDM&&8 G&<@<9R!T .HN-3UO5M2UW2M.N+U)M*6*".:W%N-\S1!]\@D[98#
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MR'S'9<$88L?O=1MKD;>UDO/"'A.QDO9W$WBN>"6X60AY$+3!CN'0D9Y'3/%
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MBDW+O8Q,&7<<8Y(YP!5JU\*V5IXOU'Q(DL[7=_ D$L;$>6%3&,#&<\>M;E%
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>josetrevejo-tarsussepara012.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHYZ]ADXS0!U%CXPOX?$$^D>(M)ATYQ8O?Q3077GHT:, X;Y5PPR#W%<=XO\
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M;1L(F&T_*""W'/7B@#HW\=R:B-(@\-::NH7NI6?V\)<3^0D$((&78!CG<=N
M#R#Z4V7QU=QZ;81_\(_<)KU[>2646G32;%WH"7?S,<QA1G< <YZ5CPV<G@_Q
M!HVMQ>'KV/2Y-&^P36EFK74EE)YGF@$#+,/F89&>14FHW&N7UWX<\83Z!=QQ
M:;>W*M8QH6N?LLJ;%D,?7<" 2@R<&@#9MO&=Y#+K-AK&DQVFJZ;8F_6*&Y\V
M*XAPW*N5!'S*5.5X]ZH6WQ&O7\(R>)[KP^T&GR00FR07(:6YF<A=FW:-HW'
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MY;<MM$JB-B5SVR.,^];EKXT73/#W@V#2/#VX:U 5M;1+G @VQAE4L5Y7U/8
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MO]/1S%=8 V-(X_=[>S!^0!7H$6M9\2_V%):S"860N_M&/W3?/L*@^H.#]"*
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M > 3CUH [6BO/KCX@:O_ &=K&N6.@0W&@Z;)-%YINRL\ICR&D5-N-@8'^+.
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M+1\!>[9 X'.,GM76>']-T?PWI+FUOO-CNIVFFO;FX#M<2MP69^A/&,#TK>H
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MX$\/:I:>++E=0LI8;#0X)K+39)%P)EEG9]Z_2-8UKT^B@#R@Z%JO_#.ZZ/\
MV?<?VEY"K]E\L^9GS]V-O7IS7J],EECAC:25UC11DLQP!^-$4L<T:R12+)&P
MRK(<@_0T >:-;:C:>*?'UFVD:A(NLVZO9W,4!:%MML5*EAT;<, =R:L:AI&H
MR?#7P;9)93M=6L^EM/"$.Z,1E-^X=MN#FO1J* /'KOPS8:=J_B"/4_!FHZU=
MWM]+=64UMO\ )F67!V.X;;'M8L"6'3GFO6K*WCM+"WMHH5ACAB6-8E;(0  !
M0>^.E3T4 <#J.E7\GQPT;5$LYFL(M)DBDN AV*Y9L*3Z\BLI=#U3_A3WBC3?
M[/N/MMQ<7S0P;#OD#2DJ0.^1R*]3J-;B!YW@6:-IHP"\88%E!Z9':@#C];TV
M]G\0>!9HK65X[.>1KAE7(B!MV4%O3DXKS_4] N[S0K])_"FI7GBB.^:XN-0F
MC)4Q+/N'D,3ALQA5"*/7\?=** /.[&ZU+P]XMU^Y7P_JE[;:V8+NS>"(?*_E
M!&CER1Y9! Y/')]*X_1M!.H>"O".JW^DRZK:V-UJ*7EM9[B^)9F^= ""P#(.
M!S@]*]/U;P9;ZGJTNI0:MJVF7,\2Q7!L+@()E7.W<&4\C) (P:V-(TFST+2;
M;3-/B\JTMDV1IG/'J3W).23[T <#!IVEV_AJ_>'X>W1TN[NTCGM926N)857B
M;RFR00QP%R&Q\WM6K\/K2XM'U=8;?5+70C+'_9UOJ9;S8_E_>8#DLJ9Q@'WK
MMJ* .*^(5K/<G1#+8WU_HJ7;'4;6R5F>1?+;R\JIRRA\$CZ5PUSH%^NC>,K#
M3_"]Y8Q:A)8W5C;QPY'EI)&&!(R _!8KU&3Z5[6TT22I$\B+))G8I8 MCK@=
MZ?0!R7B/3[NZ\=^#[J&WD>VMGO//E5<K&&@*KD]LGBN"ECUVS^$=]X&C\-ZI
M+JEO%+;B98/]'DCWE@ZOGDE>BCG/;O7M5% $-FI2R@5@0PC4$'L<5Y)XBT*X
MU2^\5VM_X:OM4U>Z9UTJZD4FUA@,0"[6)VJ5;<2,9)QZU[#10!Y79:=J5WXZ
M\ :F-+O8;:TTJ:&Y::$IY+^65PV>F2./7BM?P!I5_I_B?QM/>6DT$5WJGFV[
MR(0)4P?F7U%=[10!QWQ2TZ\U7X=ZE9V%M+<W,C0%(HEW,V)D)P/8 G\*I_%C
M2K_5O#^DPZ?:374D>KV\KK$A8J@W98^PS7>T4 <#YFH>&/B!X@O/[$U#4+36
M4MI+>2RC#A9(T\LH^2-N< @GCWKF/"-CJ-Y8^%+G[*SFW\0W\MTT0+)%GS@3
MGTW'&:]"UCP?;ZKJQU.#5=4TR\>$02R6$X3S4!) 8,K#(R<$8//6M31=&LO#
M^D6^EZ?&8[6W4A0S%B22222>I)))/J: .1U;1M0N_&7B:2&UD,5WX<6UAE(P
MCR[I?ESTS\P_.L:SDANOA]H&E:]X)U:[M;.!+:Z!MF$T$L<:A7C0?,5/S#>I
M&/QX]6HH Y7X?V^H6V@3QWJWR0?:Y#8QZ@VZ=+;C8'R2<YW8!Y Q4'B73KRZ
M^(7@J\@MI9+:TDO#<2JN5BW0X7<>V3Q78T4 >9>*/#]C%X[NM7U?P[?ZQI]]
M9Q)&]BCR/!+&6!4JA!PP9<'ID=JJZSX=NFL?  TWPY-816VM1W5Q9QL9?LR%
MB2SM^.3Z$D5ZO3/.B\_R/,3S2N_R]PW;<XSCTS0!X_XBT&XU2Z\66M]X:OM4
MUFY>0:7=R(3;0P&(!-KD[5*G=QC);'KD:5LU_9^+O"FM/H>JM:MHIT^4):DO
M!+O7_6+U4<'DUZC2.ZQHSNP55&2Q. !ZT >//X>U@Z+\4XAIMUYFHW+M9KY9
MS.,'E/6NO\2Z=>7-UX+:"VED%IJ223E5SY2B%QEO09('XUUAOK00QS&Z@$4K
M!8W\P;7)Z 'N:GH \?FEU;PW\/?%'AB30KYY46^:*]V#[,UO)O?S"^>"%8_+
MC.0!]/2/"8QX.T,'K_9\'_HM:PKSP'HNHZAJ%NNM:E';WDAGO=*@O (I&.-Q
M*X+*&XR 0#79QQI%&D<:A$0!551@ #H!0!PMPMYIOQC&H-IE]/8WVE1V:7-O
M"72.03$GS"/NC!!R:QTT/51^S_>Z0=/N/[1>*Y"VVP^82T[L./<$&O5*9)-%
M"%,LB)N8(NY@,L>@'O0!Y7K'AVQL_&.IZCK7AC4=7M]0@MWMI+%'D,<B)L:-
M@K#&<*03QR>:T8="N;?Q1\/Y;70WT^SL[:^-Q!&YE2T:2-2%9_4MG\<UZ-10
M!Y9K_AZPM?'.L:EK/AG4=8MM1CADM9;%'D*.B;&C8*PVYPI!/')YI^H:?<Z'
MJ?@+4[;PU=Q66GQ7:7-C8 W+VK31C ]6&[.3TKU"B@#SC3KO4O!=QXCL'T#5
M+\WFH37]A+9P>9'*)<'8S?P$-D'=CCFM'PLL_@O0O"'AB\M9)9[I)(I)HR"D
M,@1IBI/?.& QZ5VU0R6L$UQ!<21*TL!8Q.1RA(P2/PXH ?,)#!((2!*5.PGH
M#CBO#H-%G73M O/^$1U9]<T[4+>YUB^N(6>60J_S^4229,D[OEX"BO<99HH(
MFEFD2.-1EG=@ /J33E97171@RL,@@Y!% '#^'=-OH--\;K-:31M>:I=2VZNA
M!E1HD"E?4$@C\*Y_1K/5/"MQX2UJXT;4+F$>'ETN[AM8#)-;R!E<%D'.."..
ME>LT4 <1X$AU)M?\6:CJ&FW%BM]>12VZ3+@M&(E Z<9P!D=CD5>^)%C=:E\.
MM<L[*WDN+F:WVQQ1KEF.1P!74T4 97AF"6U\*:/;SQM'-%8PHZ,,%6" $'WS
M60]A=GXMQ:A]GD^QC0G@,^WY/,\]6VY]<#.*ZRB@#R+5?"E_?6NORS:3/=10
M^*$U$6HRK74 B1&V'(R<%L<\E<5=@T73Y]!\4OH7A"^TYI=)FMHIKH.DUR[(
MV8UB8DX!"\\9)P.E>H44 ><:UX;N]0^%/ARU?3I+F?34L;B>PSM>41J!)&.1
MAL%OQ%9LNA:?=>'?%#>'_!NH6$DFDRVT4]TKI+.[@DQK$Q)QPOS=SP*]9HH
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M,#.,UZ# VI'20UQ':#4O+.4CD8P[^<#<1NQTYQFO*+SP[J\G@'6H-,TK4H[
M:C;7&FZ9=ONG2)&C,@4%B0"0Q52<_G7K.G7IU#3X;LVMS:&09\FY0+(G./F
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M;J#3K5[JY2:"80QXW.$E5F SWP#46GQWNH_$BVUXZ9>6EE)H3P'[4@5DD^T
M[6 )P<#/TH KP>/K[^P;DW&EP_V[#JW]CK;1S'R99S@A@Y&0FT[CQG@ULZ%K
MNIS:Y=Z%KMI:P:A# EU'):2,\4T3$KD;@""&7!!]0:XG5/!]_?V6O23Z0UY'
M'XG74DLVP/M< B5&"Y.,X+8SCE:Z3P3I>F6^I7MWIG@U]"@\I8UGN%$<TQ))
M9?+R<*,+R3R>W% '/?&A=3N6\,6,<%C+IMSK-M&8YI'!EE);Y' 4CRR,9/)]
MJW(-8UN'4%\+:!H^BPW6GVJ37I\UTM8-Y;9'&%3)) )Z #WI_P 1](U#5I?"
M9L+62X%IK]K<S[!_JXESN8^PIMR+_P +>/M6UE=(OM2T[6+:W5FL4$DD,T.Y
M<%20=I5NOJ* *UW\2KBV\,V^H?V/NU!=9&CW=D)<[)<D'8V.<_*1G'WJT)O$
M/B>.XT[11IVEG7[N.6YD N'-O;P(0-Q.W<S$LHP!USVKF'\+ZW)HEC=2Z?(M
MW>^+XM8GME(9K:'=CYB#C(503CUK8\=>'+>[\4:7K=_X?DUW3H[66TGMH4#R
M1,65DD5<C=T93CIF@":7Q]>1Z(BKI<1\0/JO]C_9/./E"?&[?OQGR]F&Z9YQ
M3HO'&I:=XCN](\1:=;6XL])EU26YM96=)$1E'R!@#W;(/<>AK&GT">UT+2-6
MT7PD=..GZR+TZ9&Z^=-"5,98C.!(5(.W)Z8SGBH+^*]\8?$+4+.:QFTV.]\*
M7-M;I=8$HW2J-[JI.T9/ SG"Y[T ;2>-?$-G8:9KFKZ/8P:)J$L28AN6:XME
ME($;N"H4C)7(!XSWI\'B&WA\?>,H(='M8[K3K"*=[Q>)+G]WN"OQT'05E72Z
MYXE\+Z1X2E\.ZA97,<MJNH74RJ+>-(65F9'#'>6*#  [\XJRN@ZH/B#X]OC9
M2_9;_3(HK67'$KB+! ]\\4 20>//$']E:%K]WHUE%HNIRV\+*MPQN(S+@"3&
MW;MW'IG.,?0:4WBG7;SQ!JMIH6DVEU9Z.RI=//<,DD\A4.4B 4C(!'+8&3CW
MK,O=#U.3X5>%M-2RE-[:OIIGA ^:/RV0OGZ8.?I4UH=9\+^*/$D,&A7>H1:K
M<K>6=Q R>6KF-59926!0 KG.#QTYXH Z+P9XA?Q5X2L-;> 0-=!SY8.=H#LH
M_E7(Z'XIUVUUSQK?:V;0Z5I4F9$BF=FBVP@A8E*@8;J<D<FM;X1AA\+M%W$%
MMLN2.A_>OS6'+H.I76I^/M!ETV[2/7?WEI?A0;<?N0 &;.0=PQC% &M'XQ\1
M6,>D:EKFD6$&E:I/% HM[AWFM3+_ *LR J%(S@''3/>M;X@W^I:7X#UF]TLQ
MK<PVLC;W<J47:<LI /S#J/?O7,7C:WXKTO0O#\OA[4+"6WNK:74;BY51"BPD
M,WEL&.\L5 &!T/.*Z_QMIUSJW@?7-/LH_,NKBRECB3.-S%3@?C0!P=[>Z_\
MVM\.KB>UM;G59([L1(D[;&#6ZX>1RN1@$LV >G&:WH_'E]IMKXDCU_3H!?Z*
ML+!;*4M'<B;B(*6 ();Y3FJNG0ZEJFK^ [PZ/?V<>FQ7,-T+J,*8S]G50>">
M"V0#[56\2^$=3US4/',<=GN2^M=/:U,APD[PLSE,^Y '_ J .DTO7];A\0VV
MC>(["Q@EOK=Y[26RF9URFW?&VX#Y@&!R.#S57X@7M])+H7AS3[N6SDUJ\,,U
MS"<2) BEY-A[,0  :I>$=(TA/$$=UIO@*71?)@;S+RZ41NLAP-B*"=PQNRW
MX'7-:WCK0M2U*WTS5-$6-]6T>[%U!#(VU9UP5>//;<IZ^U %&X^%FC6T<<_A
MV:YT;58G5DOHYI)"V#R)%9L.",Y!JY?>(];N_$UYH7AVRL)9=.ACDO+B^E=$
M#2 E$4*"2<#)/09JE<>+/$^L0+8:+X4U+3M0D(62[U-$6WMAGYF&&)D[X '-
M-;^T?"?CC6]3;1[_ %.QUB*W=9+",.T4L2%"K*2" 1@@]* (Y?B/='0](NK?
M1PVH7>K-I-Q9M-CR9U#@C?CIE1SCH<X[4Z#Q5XOE\07OAHZ1I/\ :T,*727
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M%1<2/)$5#-R69%/5B?XN.E:,&@:JOP0U;1VL91J,JWHCM\?,V^:1E_,$'\:
M.IM/%#R^-YM GMUCBEL4OK&<,<S)G:X([$''3L:D\.^(I=?U3742W1+#3[O[
M'#.&),SJH\SCL QP/7FN7^(J76B^'=$\4V4:G4]$D11$QP94E B>/W))4_\
M :W-%LKOP9X*TFQAL)=1N]\:W8C8 ^9(V992>X#,3]* .LKSCX,2R2^&M9,C
MLY&MW0!8YP/EXKT>N#^%.CZCHN@:K!J5I);2RZO<3(L@Y9&VX;Z'!H OZSXC
MUD>*&T'0;/3I;F&S6\D-]<-'YBLS*%C"J<GY#DG@9%<_>W^LR?%'2YK'2XTU
M*Y\.-O@NYL);$SHS;V4'.,8XZDCH.1H>-[6TO]0$&K>#[[5(4A#65_IN#-')
MD[E)!5H_X2#D@]^E1>&-'U^W\7:)>:S'))+%X:-K<W)8,//\Y&VEN[8!R>^#
M0!>TWQ=K=]H6J;=$BFUW3[_^SWMX9CY+-\I$FXC(3:^3QGBJMQX@U*]T?Q;H
MFLVUG'?V>EM.)+*5GBECDCD QN ((*$$?2L75- U?[/XA+Z9=W%C<>)8KJXM
MH#A[NS$:!@HR-PW <9YVFF6.B7%OJGB5M.\)RZ7I^JZ(8K2..%$_>*)!B4*?
ME=MPP.>,9P<@ &!??\D:^&O_ &&;/^<M>Y7YO5L93IZ0/=X_=+<.5C)_VB 2
M/P%>27?A?6W^%O@/35TV<WEAJMM-=0X&Z)%,FYC[#(_.O8Z /!?A_J-]X:\
MZKXN?2=*GE^T2*UT7;[5*[3HI5CM^YR3UZ@<5Z[J^OR:;XF\/Z4L"NFJR3H\
MA;!C\N(N,#OG&*\\TKPEKA^!FJ:(UA)'J;W$DT5O(0"X$PD _$+Q]:W9;G5O
M$OC?PGJ,?A[4;'3["2Y-P]ZBHP9X&4?*"?E!XR>I(QWH ET?Q?XF\13ZFVFZ
M1IT=IIUW<VDDUU<.ID>,D+M"J>/NDD_WN.E<9'K&O7_PO\)ZIJB1WDK:Y:26
M_ES,TLY\U^'W !3D #!(Q7?^ =*OM.TG78;VW>![C6+R:(/_ !1NWRM]#7'Z
M)I6M-X"\+:'-H6H6]YHVM6CW!E10C()79G0@G<H&,GW[T ==:^+=5T_Q#<Z5
MXGLK&W5=.DU**>QF>1?+C8!U;<H.X9!R.#4>G^,-<\S1;S5])L[;2M:D6*V,
M,[/- SJ6C$H*@'<!C@\$BD\2>'KS6?&PVQ,MG/X?O+%[C'RH\C( #^&3^%8/
MA/PYI]M=Z+;M\.VMM4M"OVS4)@JQ1LB_ZR-P3YA+ $ #OSC% '1>&?%FN>)=
M:O8XM+M(=+T^_N+*YN'F;>[(2%\M<8/\).2!\W'2M[Q!?:M9VUNFC:?'=W4\
MPCW3R%(H%P27<@$XXQ@#DD5C_#[3+W2[/7EO;9X&GUR\N(@_\<;,"K#V-0?$
M"PFO+G0I)]+NM5T6&XD:_LK9=[2$H1&Q3(W*&ZCW% %9_'U_:Z5?1W=C9+K-
MIJ4.FD+<$6I:4*R2%R,A<-R,9R,=ZM7_ (JU_1-'F?5M)L4O3=P6MK-'=$6L
MIE( =F(W(%YSD>F.O',Z5IUWI'_"202> FDTK4+B"X&GQ)'L%OY85@JYVF4$
M!BGKD@GC-C2M.N+#3-:6W\)W]QX9GE@6+1KY@TJIAO.>.-V/&=A"$CH2,<4
M:_B'6M5LO GB"?Q+H&GSBTC5E2.8R6UVA(_O ,,'J"/3!-2-XGU)Y=$T?0+#
M3([FYTM+[;>3M'&B?*!&@522>?P KE;CPYJ,_@;QE9:-H^IVFEW4,*Z;IMXV
M9!(#^]**6)53\N 3V/2MO6+"!]%T/3]>\'7FJVL6GQ!)[)0T]O.% 9< JR#
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M691+N ^F1^=#MJ_BC3_"6C?V%?6IL[JTO+V[E"BWV0C=^[8'YMQQ@8R,\XH
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M0)<; &90-VX$ Y^8#-/TSQC9ZG8:S=?8KVU_L>5XKJ*Y\M7W(NXXPY&,="2
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MH.,[MFX$;L?IS7+Z?K \->,/'TT6F7]_'#-;3.EMM8HGD!F8EV [DX!)/84
M>GT56TZ_M]5TRUU"T8M;W4*31,1@E6 (_0UA:MXTM=*EU918WETFD0I/?/"$
M B5@6&-S#<0H+'';WXH Z:BL2;Q+;_:XK2RMIKZXDM!>B.$HI\DG"GYV&23G
M ]N<<98/%,,LEK!:V-U<74]DM^;=2BND1X&=S ;L\8'IR1QD WJ*Y*\UC1KO
MQ!X1:[TR\-[>K)-I\K#:L!,)9P^&Z[>,8/)J?4/&UE8QZO.EI=75MH[!;Z:
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MO:+%?RV$UA,SO');3$%HW1BI&1P>17*>)+?7;_7]8L9])NK[3)M/":;Y,B+
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MY%_4O^O67_T U?JGJL,ESH]]!$NZ22WD1%SC)*D 4 <C\&O^22Z#_P!<Y?\
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M';_:V>2") 01#N/EELDY)7!XXYKH*BMK:&SM8;6W01PPHL<:#HJ@8 _(5+0
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MQ"^%>KQ(42\M[N<(3G;NA4X_#I0!ZU17(:%XOE>R\2#7A##=Z#<2BX\E2JM
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M;A <%HI X!_"N#UNRB\7?%&/0=3!ET;3-.6]:T)(2>=W*J7'\2J!P/4UM1>
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M!*H.QF.TD,!U(!&>>E>KUEWEGI5CJ,OB6[*PSP6;027+N0J0!MYR.G49SUH
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MU'3K/5M/GL+^W2XM)UV21.,AA0!YQJ,NKZU\2?"2:OI8TR%K>_06QN%FDYA
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MV%Q8><P*3- H+*PYP"1MY'>O2*K0W]I<7US917$;W-J$,\2GYHPP)7([9 -
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M)(WQC)!^7=@CGIFB/P_JMUXAT*^C\(0:3IMO'-9SVL,T/FJLJ!3(2IVE5P
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MUIDUQ$7@9'9D=78;3D,01QVZU+<>&]9O)/"%Q)8:?;26&H/=7D-F0L<2,K
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M=( "^XO*<GK\S&MW4-+UJU^*5KX@LM/2\L)M-&GSG[0L;0'SMY?!^\,'H.:
M.+T'4?%.B_#6]US3KG3X['3;J[E^R36[.URHN'+Y<,-G4@  ],YYX]DMYA<6
MT4Z@A9$#@'W&:X&#PGJR?"+5O#K11_VC<B\\M/,&T^9*[+STZ,*[JQB>#3[:
M&08>.)58>X % 'E#V&MS_M SA=4L?-31_-C>2P+A8//XC \S[W/W\_\  :Z6
MT\6ZE-\./$.O.(/ME@U\(0$.S]RSA,C//W1FK,7A[4%^,$WB(QI_9KZ,+,/O
M&[S/-#8V]<8[USLOA[Q=;>&/$OA6TTJVD@OI;R2WU%KM0I28LVPIC=OY*YZ#
M.<\<@"7US)>_%[X>W4N/,FTNXD;:,#)B)./SJY\-?^1Q^(/_ &%Q_)JL-X5U
M4^.O!FJ^4GV72M.DM[IO,&5=H]H '?GTJ[X+\.ZCHOB/Q=>WL:)#J>H">V*N
M&+)@\D#IUH M^/=?U#PYX=COM,BBFNFO((!'+T<.X4C/8G/7M6:NNZ_X=\66
M.F^(KRQO;/4K>XEBEMK9H3!)"H=EP6;<NW.#UXI?BPLS>$;5;9D6<ZI9B-G'
MRAO.7!/MFFMI&N>*/%NGW^M:5'IEAIEM<1JHNEF:>290A(VCA0N>N#STH RV
M\5^+8O!J>.I)=/\ [-(6X.DBV;>+8MC/G;OO[3N^[BM!_'%]::-XRDN%A>]T
MB?%FJH0)$E13;Y&>22V#ZXK+/AWQ=-X'3P%)IUNMJ%6T;6!=+L-N&'(BQNW[
M1C'3/.:T/$/@O4;WQYIMW8I&-&F^S'4@7 )-L[/%Q_%DD#\* #_A--7;P=I3
M!;8>(+K5AI,J["4219661MN<XV(S=>XK+O/B1>I;:AKT.M:''965T\2:/(1]
MIGAC?8S[MX*N<,RKM(QCKFM:S\'ZG%\49=2D6,:#%++?V_S@L;J6*.)LKZ *
MYSZM56T\-:SHIN=)M/#&CWT4E[)-;ZI=,A6.*20N1(F-[,NY@,'!XY% %X:]
MXEU;X@ZMH6ESV-O86"6L[7$L)=BCJ24 R.6]>P'0YKN;B>.UMI;B4XCB0NQ]
M !DUS.C:'>V/Q!\3:M+&BV5_#:);L&&28T8-QVZBNENK=+NTFMI<^7,C1MCT
M(P: /-6\5^+8?!J>.I9=/.FL%N&TD6S;Q;,P&1-NY?:=WW<5FZW9:U>?'731
M;ZK8J[:3)+:O+8&18HRY&TKY@W-_M9'TJ^WAWQ=/X'C\!RZ=;K:JJVCZP+I=
MIMU8<B+&[?M&,=,\YK?N/#=^WQ8TW7HHD_LRVTE[1FWC(<N2!CKT[T =A,YC
MAD=4+LJDA!U8@=*X/P3XBUWQ$;+4&U;1KRUN$)O+"",QS:>V"0N2Q+$'Y2&
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MDX2*ZCF0K+&O&4(S@%AV%:FNZ3XN\7^$/$EI?6UM8&\A2/3[ RK(R%3N9GD
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M/5KS?&NX'?$850Y';H17,_"+2KD_;]4O+A;J.SSHVFSCH]K"[?,/4,2!_P
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M6..*>]W3QQ(N-D3$F,'GD[<'/O70TR**."%(8D"1QJ%55&  . !3Z "BBB@
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M@N&*^9&CQ @NO/*@JS 9Y&!GO7I.GQ74&GP17MTMU=(@$LZQB,2-W.T$X^E
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M\NT'WSUXJQI6I^)] \+>#-2EO[233KLV-BVGBVP4BD555_-SDN."1C')';D
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MCF@#O*1W5$9V.%49)]!7EUEXY\1WNE0V16SAUR]UZ?3$;RRT=M'$"7;&1O(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M51%V/QQN <=\9%7+O2/$&M^&_$5K-HVF:4;S3WMK2WBD$DAD96!9Y   IRH
MP>F:[NB@#D=:\.W]]IOA*"$1[]+U&UN+G+XPD<;*V/4Y(J/PWI&M:)XQ\0F6
MS@DTK4[K[9'=K<8=#L5=ACQSR.N:[*L_3]<TW5+V_L[*Z6:XL)!%=(%(\MSV
M.1ST[4 <_P")=)U8^+=)U[3=.M=46UMIK8VUQ.(O*9RA$JDJ1_"0>,X/%<_;
M>#?$@5+>[CLW*>)X=9,\4N%>,\R*%(R-IX&>HKU"B@#D-;\*W&L^,)+MRBZ?
M/H5QILC!OF#2.IX'I@&N:N/#WC;4?"FD^';BPT^&/2YK4O=+=[OM20NN-J[1
MMX&XY/48QSQZI6?=:YIMGK%CI%Q=*E_?!VMH2I)D"#+<XP,#UH L7UN;O3[F
MV#!3-$T88]L@BO-M.\*>*(O"7A^![&R@U;PU<(]L#=;H[Q K*X)"_N\JW'7D
M5Z3?7UKIEC->WUQ';VL*EY)9&PJCU)JMHNNZ;XBL/MVE70N;;>4\P(RC( /\
M0'8B@# TC2=9U#QF?$VMV<%@(+(V5K9QS^<WS.&>1F  [  #/>I/%VC:I<:M
MH6OZ+##<WNDRRYM9I?+$T4J;6 ;!PPP",\<5UE% 'FLG@O7/$5_XHGUQ+:SC
MUG3(K6&.&7S?L[(6P"<#=@D,2,=2.V:M2:3XK\1R:%8ZW865E::9=Q7=S<Q7
M7FFZ>+[H1=HV@M@G/3I7H%% '/\ C?1;KQ#X.U#2[(Q_:)E0HLIPC[75BC'T
M8*5/UK#M-+\2S>--(UZXTFQL[2&VFLGLHKD,T"L4;S-P4!LE<;1T '/)QWE%
M 'D*_#K7Q\$=0\*;;;^U)[KS4'F_)M\Y7^]CT!KUFWC,=K%&V,J@4_E4M4[_
M %2RTPVHO)Q%]JN%MH,@G?(V=J\>N#0!YXGAGQ98^#[KP-9VEB^GRB6WAU5[
MG!CMY&)(:+;DN%8C@XZ<UJR>'=6TCQ_I6K:59PW>G)I*:3*LEQY;PJL@;S.A
MW<=N/PKNJ"0!D\"@#@;?PCJD?PJUCPZRP_;[O[9Y0W_+^]D=ER?HPI)O#VL:
M/K;:II^CV&KK>6,$%Q!<3B)HI8@0'5BI!4@X(Z\"NAT_QIX<U6.^DL=7MYH;
M%2]S*,B.-1G)WD;2.#T)JUH?B+2?$EH]UI%XMU C["ZHRC.,\9 SUZB@#G9?
M#>L7&N^"M0N%L0VE&Z:^%L"D8:2(J-BGDC)_K[5VU%!.!D]* /)[#P#KMCX,
MELGM[2XNH_$/]JK:/-B.YB# [&;& 3UY!&0*W]*T77I/&ESJVJZ?9)8ZCIRV
MDEO%/N-L$9B%/RC?NW')&,9QSC)[D$$ @Y!HH \MT#X=:K#X3\2:9JTL+W-U
M:KI]@ZOG;#"I\DD]CN;)'M6IIWA/6%^&VOV%_P"0=>UE;N6?8_R>;(I5!N]
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MHQ!P5(3!(YVGUJWKGASQ!XA\%7UG+I^F6-W<7L$L-K;OQ'$DB,0\F &;Y6/
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M_!>K>$_^$=OM$C@U"YT[3FTZ\MY)?*\]&8/N1B" 0X)P>H-=W8Z79::]VUG
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M04@Q[QE<DC!R/2M"@#SPZ!XAT:^UBVTK1M)OH-1O)+NWO;N0 VK28+ATVDN
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M!"<;6!.,\_+U-6[[0/%'BK2-8AUJ>TTX7$<0L+*!_/6"2-_,$COM4L2P48'
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MDVKG)(X X ]Z /(]/TW5_P#AFZ2Y372MB;21OL8M$^[YK KOZ\GG-=*-?O\
MPWH'A32+KQ3;6*ZE:B;^T+BVC7[+#'$F(T4_*S$L!EL\ \5KVG@?58/@BW@]
MWMO[3-K)#N#GR]S2%ASC.,'TJ[>^&=6M[?PQ?Z=%9W.HZ-:FUFM9Y"D<\;(J
ML ^TX(9%()'K0!A6WQ!U"XT>;3['4K+4-2;68=*M=3CC!B=95#B4HIP650X(
M'&5_"KGBBU\7Z?X.\3Q7>MQ7=HNFO-#?"V2.;<%;?$4'RX(QAA@C/>K^I>'?
M$6N:!%-<G3;36+34H]1L8(MS0Q[.!&[X!;(+98 ?>X'%.N=)\6^)-+UZ#5WL
MM.AO=.>SM;&"7SE61@<RO)L![@8'&/>@#6\#V]W;^#-*6\O3=NUK$R,8A'L0
MHN$P.N/7J:XNY\::CINO6@G\5Z7=W$VJI:3:+:QJZQ1/)L&)/O;U!!.>,Y&*
M[GPE!JUKX:M+/6;6WMKJUC6 "WG,JNJJ &R5&"2#QSCUKA8O!WB^'PGI^@16
M^E)'I%W%=1RBX;.H&.8.-PV?N\C))^8EL=LT 78?$6LW_BZ_L4\26%A>VM_Y
M4.B7=N%%Q;@CYPY^<EERP*Y X&*W?B7KM_X:^'VJ:OIDBQWEN(_+=D# 9D53
MP>.A-9/B#0?%/B*-]+OM/T=X3=+-!JOG$36L8<-A4V<N -H8, >IQR*VOB+X
M>O?%7@34M%T]HENKD1[#,Q5?ED5CD@'LI[4 <1X]MM4O?&7@"9-7\DW,[&$?
M9D;R'\M27Y^]GT/2NV\8:]<^$_!1O#<PR7P,-LMS<*%C\QV5#(P'  R6(]L5
M4UWPIJ&I:WX,O(&@$6C2L]SN<@D%%7Y>.>1[5K^+]"E\0^'I+.VECBO(Y8KB
MVDD&4$L;AUW =B5P?8T <EH'BJYU#Q!/X>M/&%GK+7.GO<6]_!!&'MIE(!5E
M7Y2IW C//!&>].TSQ?K^NW]CX:AB%GKEE*?[=F\H,D,:8P8\C!,N05]!GTK=
MLCXO?[9<SZ9H]FR6Q2UM8YVD\R?/WWDV#:G^R 3[UC6O@'4=#.F:UIEU%/XC
M64OJLLS%4OTD(,BD@'&T@%..-OO0!DZW\0)QJ7B!X/%FF:2VDS/!:Z9<1HS7
M;1J"Q<D[@&;*C;C&,\UM0Z_K/C+65LM"U-='M8=,MKZ:;[,L\CO."R)AN H4
M9)ZG/:I9-$\3:-J6LIH5GI5U:ZI<F[CGNYBC6<K* ^5"'S%R-P (ZD5-?:+X
MATCQ1)KVA0V-^U[9Q6UY;7$QM_GCSLD4A6XPQ!7Z<T -MM:\1VWB7PKI.KFV
M2:\MKQKU8!E)&BV;&4GE<ALD>^.U87C;6=7O-+^(VGQWP@M]-MH/*"Q*24D@
M)D0GWSUZBM6[\/>+8IO#>M^?9:MK&FBY6[BD?[/'(LV.$8*<;-J@9'('/-5W
M\%:_J-EXW_M&:QCNO$$$2P")V9(F6,KM)(!P/E&['/)P.E %.]\27F@VGAO0
MKOQ5;:>;JS:ZFU.X@C4I&H0)$BGY2Q+=3GA338/'VIW^A16&GZE9W.IS:XND
M1ZI%$&C:,IYGGA,XW;.,=-PK4&A^)U_L36AINFG5-/MGL9[%KLF.>!@F&$FS
MY6#(#C!&">:FU7P[XDU;0[&[D_LR+7+#4UU"VMXRPA" %?)9\9)*L<MM'/;'
M- %+3K;5;/XS6MOJFH+J&-!F:*Y\E8G(,\>595^7((Z@#@].,E_B.'4[GXO:
M5!I5XEG+)HLXDN6B$AC3S4)*J>"20!SP,D\U?TK1?$=S\0(_$^L0V-K -,DL
MEM+>=I6C)D1P2Q50V<-G &,#KS4FO:)KY\=6/B/1TLYH[73Y+:2WN)FC,Q9U
M.T,%.WIG.#R,8YR # N?$_BK3M%\3VYNHKW4_#5U#-),+=5^UVC*)""HX5MA
M;E<?=KH=7\27-UK7A73M"G3&J,;R>78&Q9HH8]>FXLH!J3POH%[;2Z]JNOI:
MK>:S,KS6\+EXXHDC"(A8@;CM!R< <US7PBT9XSJ6J/<_:K2W=]*TF;^]:1R,
MV0>X+-C/^P* -_Q=JVM6_BKPSHVCW45L-4-TLTDD0DV!$5@P'J.<#IDC/%8^
MFS^--2UCQ%X>'B2&)]'>-DU#[#&9)_-C#JC)]T!><D#)R.F.>GUG0KN_\:>&
M=7A:(6VF?:O/#,0Q\R,*NT8YY'/2DT;0KNP\7^*-5F:(V^J-;& *Q+#RXMC;
MACCGIUH XU_B-<W7AGP@]QJUGHD^LPR2W5_*BE8A%@$(K?+N9B,9S@9ZUTW@
M+Q,^OQ:K:R:E;:HVG7(B2_ME"K<1L@96(' 89*G'&5K%TWP3K>B>'?"DEM'8
MW6K:)%-#-;22E8IXY3\P#[3@@JI!(]:Z2%?%J>'KZ98-'CUF64-:VV6:"&/*
MC:[@ NV-QR .2!TH Z*>"&ZA:&XBCEB;[R2*&4_4&O.#HVE_\+W%M_9MGY'_
M  C)D\KR%V[OM(&[&,9QQFO2ZY?_ (1^\_X6F/$FZ+[#_8IL,;CO\SSP_3&,
M8[YH P/$%E=K\3_#]EHDL&G$Z7=#S5A#"%-\9)5. 23QSQSGG&#4N/&^L:#H
MWB&SU'4+6>_L-3@L(-1FB$:!9@C!Y%7CY S$XP#@5V%WH=W/\0-,UQ#%]DMK
M">W<%COW.R$8&.GRGO6#J/@;4;VX\2W,4UM'/=:C::AIS.2RAX$3B08X!*D<
M9X.?:@!/"'BXWOBV;0O^$EM/$,+V1NX[J&-$>)E<*T;!."#N4@]>O6JWQ%_Y
M*%\.O^PA-_Z"E=3H(\137\UQJ]CINGVPB"16UK*9G9\\N7VK@8P N#]:H>+?
M#%_K?BOPEJ=JT(@TFZDFN!(Q#%6"@;1CD\'TH RY-0\5ZUXC\6V&GZU%IUMI
M+Q?9W%HDK.6A#[3NXVYR2>3SP1CG+A\4^+&\*>'_ !C/J5LMO>7%M%/IB6J[
M#'(XC+"0_,&S\WH,XYQD]CI/A^\LM?\ %E[*T1BU66)[<*Q) 6$(=W''(]ZQ
M?^$*U3_A5^A^'-]M]NL9K5Y3O.PB.4.V#C)X''% %/QOXJU'0[[595\7:5I[
MV<(ELM*$2RR7.$W$2Y^9=QR!MQQ@YK1N-;UOQ#XIM-'T?4$TJ!-+CU&YG\A9
MG9I&PD8#< #!)/7Z55O?"GB4_P#"5Z59)IRV>O2R3'4I)F\V-7C"&(Q[><8(
M!W8 .<9XJ&"RUS2/$^E7-H-'?6)=&6SN],FO63*Q/\LR.$)(Y.1M[]^M %,^
M/M<L?#^J_P!JWMC;7R>(1H\=VT8$,";%8RX)YX#L 3W ).*6+Q]?P6WB"ST[
M6[7Q'-:6"7MK>00J2@+[)%=(^&VC#C&,CBJ_AS0=1US1=>G@NK6?4[7Q4]_!
M*X(MYI$1%9>,D(<NH/.*[.&/QE<6>H7'D:1IET4C%E;*QG7*MES))M7AA\HP
M..O- ">#-0N]1,\Z^*;'Q#IK1J4FBC6.:*3)RK*G&,8(S@CWJGJ.H>(M1^(E
MYX=TW5(]/LX]-BNC/]F6617+NN%#<<X'7.-O3G(G\.Z'J@\77?B+4=,T_2C+
M:"U-O9S^:9VW[O,=MBC(Z#@GD\U?M]"NXOB)?:\S1?8Y]-BM4 8[]ZR.QR,=
M,,.] '"#Q)XUD\ ZAXE;6+6*71I987@2S4K>^5)M9G)Y3(XPN,8SWP-_Q7K]
MW;7\ _X2[3?#]K)9K+#&\:33S2$G.Y6'$8&!D<DYY%(/!>J#X:^(/#^^V^VZ
MA/=R0G>=@$LA9<G''!YXJ7^P/$>F^)KZ\TR'3Y8]2L[>W:ZGF*O9F-2IVKM.
M\'.X#*\]: *EEXUU22/P1K-R8TTO6X_LMY&J#$=RRYC8'K@L&7&?2MW3M9O]
M4^(6K6,$BC2-*MHHI1L!,ET_S\-Z*F,CU-<UJ&@R:1\#KO2->FMK633+<FWN
M8I2P+QG=$XR 0Q8 ;1G]:Z7X?:5=:;X4AGU(8U349'O[WC'[V4[L8[;1M7'^
MS0!S=O9ZW?\ Q1\9P:3JRZ7&$L6DG%NLSLWE':H#< ?>)[],8JFWQ&OGT31+
M2_U6RT>_N;NZM;W49$4I']F.&**W&YR4QG@9/%;[Z1XITCQKX@UW2K73[ZVU
M)+=%MIKEH6!C3;NW;&'4GCN".1C!HVO@76-(TS1+ZV:RO=;L;FYN;J&5BD-Q
M]H.9%5L$K@[<$C^'GK0!K> O$[:\=7L9-4MM6.G3HD>H6ZA5GC= RDA> P.Y
M3CCBI] UR_OY_%B7$BL-.U!X+;" ;4$2, ?7ECUK3\/IK(M[B;6HK*WEEEW1
M6UH2PACP %9R!O;.3G ZUS7]A>*-,UKQ#%I<6GR:?K4_V@7<T[*]JQC5'S&%
M._[N1R/<T 8B>-=6N=&\*2:AK\.A0ZEI[3S:F]JCK)."H$7S?(G!9N>N.,5H
M:]XMO]+7P_I.H>(M+TRXO899[K5D56C*(0%\L/\ +N?<#SD#!QGBK.G:)XIT
M'PKHNDQ6&DZM;P6(MKNRN)C&/,!X=7*,&7'!! [57LO!.LZ#8Z!>:?'876H:
M<MS'/9/(T<+Q3R>9LC<J2-A"@9'(!Z4 4(/'^IWNBKIVGZG9W>IRZVFDPZI%
M$&C:-D\SSM@."P7(QTR*O:?;:K9_&6SM]4U!=0QH4S17/DK$Y!FCRK*ORY!'
M4 <'IQDW=5\.^)=7T.SNY?[,AUNPU--0M;:,MY(105\EGQDDJ6RVT<GICFI=
M+T;Q)=?$"'Q-K$-C:P+ILEFMI;SM*T9,B,"6*J"3ALX Q@=>: ,#XM6=_-X@
M\&-#J9ABDUB".*/R%;RI>?WF3][M\IXXK86Z\2:QXHO?#UGKPLTT>V@-U>K9
MQO)<S2AF&%;*JH4=AG)K0\:>&K[Q!J'AB>S:$)IFJQWD_F,02B]=N <G\JBO
M=(U[1_%]_KV@VMG?Q:G!%'=6MQ<&!EDBR$=6"L"-K8(QV% '.7GCGQ&GAFS$
M+6IUJ'Q*-#N'\O$4_+ -CDJ""A..G.*]$TNVU*QT@1:AJ*ZE>KN)N&A6 -U(
M&U<@ =,\UQ/_  @.JC1M+1Y[634?^$D37-0925C^\2RQ\9.!M SC..U=UK%B
MVIZ)?V"2F)[JVDA60?P%E(S^&: /.='\9WZ>)]$LY_%FF:S)J$SP7EE9Q+LM
M6V,X,<@Y8 KM.[.<]J9_;?C*^\*^(=?@UNWM5T>YO!#;BS1Q<)"S'#D\C@;1
MMP>,DG/%N'PYXO>V\,*]CI-LF@3QXMHKIB+D"-HV?=L^3 .0N#G)R>E:MGX3
MU&#P%XET1V@^U:E+?O 0YV@3%BFXXX^\,\4 %MXHU!/&6APW;*-)U[3?-M5V
MC,5RH#LN[N"AR,]Q5WPQK-_KOB#Q%,9%_L>SNA96:!!EI$7]ZQ/4C<<#MP:P
M?']FVE?#/2W\Z./6=)DM&L-OS>9<KM78HZMN!88].>U=;X2T/_A'/"NGZ6S;
MYHHLSO\ WY6.YV_%B30!YW9:R/#WCSXK:P8Q(;.WM)E0G&YA"V!^)Q5WP_XX
MF_X231;*7Q=INNC5-\<]O;1HIM) A<%"O)3Y2OS9/0YK0_X0&[O->\>RWLL*
M6/B*WAAMVC8LZ%8RI+# '!((Y[5J:%#XL-[9Q:K9:1:VMK&5GFMY3*]V^, J
M"J^6.YR2>WO0!R,_B;QC/\.K_P =6>J6R1,DLMOIK6BE8H0Y16W]2X W<\'I
M@=1L^)]?OK2ZMED\8:;H,+V2RQ*T22S7$ISDLK#Y8Q@?=Y))Y&*Y#5X=5TOX
M0ZUHMK>Z1/H5J9H8;^*X9IG'F$B Q[<!]QVD[NG0=Z[1-!\1Z?XCO;W38+!X
M]4L[:!KFXF*R61C4J<(%.\<Y RO/6@#F=;UF7Q#)\*-7GC5)KN]6214^Z&*K
MG'MG-=Q\0=:U/0?#D-WI!C^V/?6\"K*N58/(%(/IG/7K7,6O@/7Q8^!K:<62
MGP[>,TS+,S>;$,;67Y1@GT_6MGXKI+)X2M8[>01S-JMF(W(R%8S+@X[X- #4
MU'Q#X?\ &FEZ5JNKQZI::O!<&-OLJPM!+$H<@;>JD$]<GCK5)O%^L#X(6_B?
MST_M1XH6:3RUVY:94/R].A-:=OHWB#6O&.G:QKUK8V5OI4$R016MRTQFEE 5
MG)*+M4*#@<GFN;?P9XRD^'__  A0CTM+6V91'??:6+7"+*'5=FSY#P,G)Z8
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MOFN&M[J6202Q)*2QC*!2#RQ&[/ .<$\5WVBV<FG:%I]C,4:6VMHX7*$E2RJ
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MX90(Q_$<$\C'2NFM;B.[M(;F+=Y<R+(FY2IP1D9!Y'TJ6@#RN?P/XO3P3?\
M@FSGTA=+82K;7LDDGG>6S%UC9 N!R=I8$\=LUT+^$;]OB+HOB'SK;[)8Z6UG
M*FYO,+G/*C;C'/<CZ5V$LL<$3RS2+'&@+,[G 4#J23TJE?:U9Z=?6%G<&7S;
M]RD&R)G4D $Y(&%'/4XH \\7P1XNC\*6?A^.31T@TJZCN;>422;KPI,) )!L
M_=Y&22-Q+8[9KU&,N8T,@59,#<%.0#WP>,TZB@#AO'G@B]\4ZEI=Q8W%O!&H
M-MJ(E+ RVK21NRK@')S'T.!\QYHU3P1>WWQ(LM<2XMUTA3#<75NQ;S'N(5E6
M)@,8P/,&>?X17<T4 <C8^%;VV^)FM>)));<V5]916T:*S>8&7&21C&./4USV
MD^!?$EMX3T?P]=OI?E:1JEO=0SQS2$S1)*SMN4I\K8( &2#SDBO3Z* .8U;P
MO+JOC&VU*5XCIXTNXL9H]Q$A,K+T&,8P#WKG#X.\57GABU\&7TVE_P!B0&**
M2^CD?SYK>-@53R]N%8A5!.XCK7I5% '$RZ'XFTWQAK.I:(=,DM-86$R-=2.K
MVSQILW!54AQ@ XRO/<5D)X!UZP\'>%K*SGL)]3T+4&NR)I'6*92TAQN"Y!PX
M[=<UZ;10!' 9C;Q&X5%G*#S!&25#8YP2 2,^U8<^A74OQ LM?62'[+!ITMHR
M$G>7:1&! QC&%/>N@HH X#4/ 5]?KXD87=O#<7NI0:CI\HW-Y4D2IMWC ZE"
M.,\'\*NVNB>(=7\5:7K/B%-.M8M*27[/;V4SR^9+(NTNS,JX 7.!@]>M=7+>
MV\,-S*9 PME+2A/F9<+NP0.<XYQ[U'I>I6VL:;!J%H9#;SKN3S(V1L9QRK $
M=.] 'G:>!?$8\#>(O"A?2_(NY)9+*Y\Z0,=\N_$B[/EP,]"?ZUK:SX,U'4;+
MP5##-:JVA7=M/<EV8!UC4!@F%Y/'&<5W-% 'F_Q<@:XL]&&EW:P^(C>_9[$+
MRY65"DO'90IW$]MHJ_XK\"3:EX2T'0M&>WACTN\MI?W[%08X@0<8!^8Y_GS7
M4KH>E)K+ZPNG6HU-U"-=^4/-*XQC=UZ#%:% '/:=H5U9^-]<UJ22$VU_;VT4
M2J3O!C#[MPQC'S#&":XZ_P##%SX?\/Z9++JFFVNJ6NORW=F]P[^1*9G?$3-M
MRI*MUQP17HFL:Q9:#I<NHZA*8K6)D5G"EL%F"+P.>K"IKZPL]3LY+._M8;JV
MD&'AF0.K?4'B@#S[0#J5S\9+RXU&>SDGCT)8Y8[)B\5MNFRJ;B 2Q 9LD#KT
MXKTFL_2=#TK0;=H-)TZUL8G.YEMX@@8^IQUK0H X)?!.I#X<^(/#WGVGVO49
M[N2%][>6HE<LNX[<C@\X!_&M74_#EY>ZIX4NHY( FD3-)<!F.6!A*?+QSR>^
M.*ZBB@#A=*T+Q;H42Z'ILVE+I"73217LC.9XX&D+F/R]NTMR5#;L8YQFN@LK
M[4I?%VK6,P@.G06]O);LBG<&?>'5B>"?D!P.@(]:N:5K%EK,,\UC*9$@N)+:
M0E2N)$;:PY]".M7J "N*M?"&H0> ?$6@M-;&ZU)[]H7#-L7SRY3<=N1C<,X!
M]LUVM% '"_\ ",:]HNJV.L:)]@N;@:7%I][:W,KQH_E\K(CA6.021@CD>]5A
MX"U233%>XNK-]5N=?@UB]92PB549?W<?&3A5 &0,GKBO0(IHIXEEAD22-AE7
M1@01[$4^@#GKS0+FY\>:=K@>'[);6$]M)&Q.]F=D(P,8QA3GFK.N:(E_X:U?
M3K&&W@GO;*:W1MNU=SH5&X@9QD^];%% 'F]S\/\ 5IO"?@C2EN+(3Z#?6US=
M,7?:ZQYW!#MR3SQD"NFTC0;JP\:>(]9EDA-OJ:VHA52=Z^4C*VX8P.3Q@G\*
MZ*J.F:Q9:PETUE*9!:W4EI+E2NV6,X8<]<'OTH XH> ]4'P?B\(^?9_V@KJQ
MDWMY7%R)>NW/W1CIU_.M:+PO?1_%>X\5&6W^PR:2+(1AF\W?Y@;.,8VX'KGV
MKK:* /+E\!>)#\.]=\'L^E^5/([65SYTF6WS>8?,79\N!Z9_K72VOAB]@\3:
M!J32VYAT[2GLI5#-N9V\O!7C!7Y#U(/3BNLK-U/7=/TG1Y=5N)6>TC(#/;HT
MQR6V\!02>>/:@#AO$_A1X+'Q;J=YJ=G8QW5]:7UG<R;F6%XEC5?,&. 67'&>
M#GVJ$RZQ?_%7PE)JD^FM-%;7DGV;3I6E2*,QJOF,S 'YF( &,#'4YKTR6*"\
MM6BFB26"5,/'(N592.A!ZCVJAI'AO1- :5M(TFRL6E_UC6\*H6]B0.GM0!J5
MPR:%XLT:XU.ST&72OL%_>27<=S<L_FVAD.9 (PI5^<E?F'7FNYHH X[5?!C^
M*/$,TWB,P7&CP6Q@L;1&).]UQ),_  ?'"XSCKUK/?POXK33M!>2XT[4=0T*\
MD: W$KJMU 49%:0[#ME 8= PR,YYKT&B@#R_4_ GBC5+/Q5#/<Z6TFO1VTF\
M22*()8F7Y -ARFP?>ZDCH,\=?J^@W5_XS\-ZQ%)"+?3!="97)#MYJ*J[1C!Y
M'.2/QKH:9%-%.F^*1)%R5W(P(R#@CZ@@B@#ROXA>'[JP\-_$#5)98O(U5K)H
M!&2701^6AW C Y'&":Z'^P?$NL>(]&N-=.FQV.CR-.AM9'9[J4H45BI4", $
MG&6YXS777UA::G926=];QW%M)C?%(N5;!!&1]0#5B@#SBU^'5^-)\7V=Q>6T
M<FKZJVHV4L6YO*(</'O! YW*,@9X[UO6L/C6\^U&^GTK3<6K16XL]UQF<])6
M+JN%&.%YSDY/ KJ:* .*T[0M?O?%UCKFN6ND6DEC;RP[K"1Y'NBX4?,65<(,
M9 YY-=K1574=0@TK3I[^Z+B"!"[[$+M@>B@$G\* .$_X17Q7IFDZIX;T>32C
MI%]+.8;N>1Q-:1S$EU\L*0Y!9MIW#WJ]?^!YSK/@>73Y8%L?#BR1R+*Q#NIC
M5%VX!!/R\Y(KL;2ZBO;*"[AW>5/&LB;E*G:PR,@\@\]#5'7_ !#IOAC3#J.J
MSM#:B18]ZH7^9C@< $T :E<1\0_!=_XL&G-IMU!;RQ&2WNFE+#?:R@"11@'+
M?*, X'O7;T4 <)KW@:[U3QUI6JVTUM%I,7DF^MR6#R- SM#M &" S\Y(X K:
MTG0KJP\9>(]8EDA-OJ2VHA52=Z^4C*VX8P.2,8)_"NAHH \QN?ASJ\W@S0M'
M6YL1<6&NG4I6+OL,?FR/A3MSNPXX( SGFMF]T/Q+I7B?5=6\-?V9/'JR1>?%
M?R/'Y,J+L#J54[@5QE>.G6NUK%F\5:3!!JTK2RLNDR"*["0NS(Q"D  #+<,.
MF: ,K2_"^JVGBG2]6OM1COC;:0]E<3.-LDLS2*^X*!@+\I'7/3ZU>\.Z%=:1
MK'B*[N)(6CU*^%S"(R2541HN&R!@Y4],UNV\Z7-M%<1Y\N5 Z[@0<$9&0>E2
M4 5M1MWO-+N[:,J'FA>-2W0$J0,_G7":-X"U33O#'@O3)KBS:;0[\W-RR.Q5
MU(EX3*Y)_>#J!WKT2B@#C]9\&R:WXGU2[N)8ET^_T(Z60I/F*YD9MV,8P P[
M]1TJ/1=-\;)<:5::G>:;!I^G#$LMFSM)?87:H964!!W.">1Q7:44 >9P?#C5
M!X-\6Z/+>6B7&K:M)J%I(A9E0;T= ^5!!RF#C/7O6G'H7BK5?%WA_7-9_LJV
MBTSSU:VM97D+>9&5W;F49.<<<8&>23@=M++'!$\LKK'&@+,[G 4#J2>PIX((
M!!R#0!Y7/X&\7KX'OO!-G/I"Z61(MM>R22>;Y98NL;(%P.3@L">.@S70W.A>
M(-*UY]7T!-.N6N[.&VO+>\E>,!XMVR1656SPQ!! Z#FNSHH IZ5%?P:5;QZI
M<QW-\$_?2Q)L1F[[1Z#I^%7*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X;XJ,\OA[3-+\QH[?
M5=7M;"Z93@^2[_,,]LXQ^-=S6-XI\.VWBKP_<:5<R/#YFUXIX_OPR*<JX]P1
M0!)?>&]'U#07T.XT^ Z:T?EB!4"J@QQMQT([$=*YJ^;4+WQC;^$-+U2YTO3[
M#2TN9IX-KSR$L41-T@;  4DG!)IDNE?$>^L#I-UJ^B00.OE2ZE;12_:63H2J
M'Y%<COGCM5N]\+:KIVN66M>'+BWEN(M/&G7$.I2.1/&IW(_F*"=X.<D@YS0!
MS&H^*_$>G>']9T]=16;5=*UJULX[QXE'G0RLA7>H&,X8@D >V#6A-%XGM/'E
MMX<7Q7=RVNHV,ES+/);P^; R, ?*PFT [@,$-@9[U/+X U*ZT*\%S>VKZOJ&
MK0:C=2*&6)1&Z8C3J2 J8!/4FNBN=!N)_'NGZ^LL0M[:PFM6C.=Y9V5@1QC'
MRGO0!PESXF\2Z?X1UJ"+4_M&I:9X@BT^"[FB3,L3-'@. ,9PY!( K?2;6_#7
MCO1-.O-=GU:RUF.X5EN8HT,,T:!]R%%&%(R,'./6L+QIX<N]+\-ZVS74:MJO
MB.UN8'C!)B#/$HR#W!7-=$?#&OZYXBMM1\13Z=%#86T\-JFGER6>9=C2-N V
MX7HHSUZT <W9>++NWUW167Q<^KSWNH_9+RUBM,6:HV['E2>6.5(7^(YYJW'/
MXGUNT\7WD?B6XL4TC4+J*S2""([O+4,!(64Y49  &#UR3QB2/P9XN_L70=/>
M[T95T">"2U2/S MUY?RYD./D.TG@ \G.:Z+2O#%U8:7XGM9)H6?5[ZYN82I.
M$65%4!N.HQSB@#%TSQ5JIUGP?>WTX_LOQ%I:J8@@"PWFP2 @XSAAN &>HK8\
M,ZKJ&M^*/$=R;@G1K.=;"TB"C#2(,S/G&3\QVCG'!KG/&-C%H/PDTW2I[R(:
MWIL=I_9_E'<\EW&5";%/)R01TZ$UVGA'0SX=\*Z?ICMOGBCW7#]=\K'=(WXL
M30!0\4ZI?Z/X@\+SQ7!73;J]:QO(MH(9I$/E-G&1AUQP?XJQ-%\6ZC-\0M12
M^N@-!G-S#8H44!'M?+$AW8R<EI#R?X*ZCQ?H4OB+PU<6%M+'#=[HYK:63.U)
M4<.I..<97\C7)ZK\.=3N?A_I&C6&H6\.KV9D:6[?=M<S)(L^,#//FL1]!0!B
M1^-M2FT[0(]6UZ;2H]8%UJ$ES%;JTL< <"&%/D8#(8$L03QUYJ#4M>U#7?#N
MG00Z@+RYL_%=K;VFH2P;/.4C<CLN%R1NP< 9V^]=]JGAB]MKG1-0\-O:1W6E
M6[6:P7>X130,%&TLH)4@HI!P>]4]:\+>)M?T*PCO-5LDU.WU:/4 \<1\J!$S
MM1>,O@X.6QG)Z<4 5)KSQ%X8\4G25U6?6UU#2[FYLUNXXU=+F+!V@HJC:VX<
M=O6E\!ZQ-JE]&1XOEU&86Y.HZ9?6Z0S6\O'**%5E4'((.1R.:NQ>&_$FI>(9
M-;U:]L+.ZM["6ST\6 :41/(03,WF 9/RCY<$>]/T_0/$-YXHTW6/$!TB-M-A
MEC1K#>7N"X"G>6 VJ,$[1GGO0!YS=:QK7B?X(VNHW^L7'VAM62*1DCC'F+]H
M4+D;?X< C&.1SFNJ\0>(GL/$T7AR^\77NFV]I8)/)>1VZ//=2NS  XC*A5"Y
M.%&<^U%I\--5M?A2?"XO;/\ M%+P7<4OS&(D2B0 \9[8Z5MS:+XIAUB+Q!8M
MH_\ :<]F+2_M97D$#;79D='"[LC<001SGM0!R[^,]2O- T*YU'5[K3-.>2Z@
MO]6L[0$L\;!8B0R-Y:N,L3MZ\<"O1?#,L\WA^VDGU:WU8MN*7T  69-QVDA>
M-V, XXR#69-9>-+>SL'M]2TR^NE21;V"ZB,4,I8Y4HR*67:/EP<Y')YJAI^F
M:QX4TW2+.VDM&EO=8>6^CAA;RTCD+NRQ#^%5P.3Z'UQ0!W->66<OBS7=,\4:
MC'XFGLVTO4;R&QAB@B*N(F) DRI)'1<#'3)SFO4Z\C\.V'BF\TWQ;::+<::M
MM>ZW?Q.]WO#VY+E69-H(;CD XP>YSP ;WAGQ7?Z[XJT8/($L[WPTNH26ZJ,"
M<RHI(/7H2.M<YXKU75-2\/>(HVG666R\4VUO9B10%10T+*IQ@D;F/OS72OX-
MU;1-2T2^\,S6,C6&E_V5+%?EU#Q@JP<% <-E>1CO5";X=ZW<^'M8LI=5M?MN
MH:U%J?VE$8! /++ +CJ"AP,GC&3UH OQ3:UX;\>:)IMYKMQJUEK45PK+<Q1J
M89HD#[DV*,*1D;3G'K7&^%]4O-%^#7C+4=/G,%W;ZI=/%(%!VG*<X((KO;30
M/$&H>+]/UKQ#+IJQZ7%*EI%8ESYDD@"L[[@,?*,!1GKUK'L_AUJ5O\-_$7AI
MKNT-UJEU-/%("VQ Y4@-QG/R]A0!*-6UG7[WPUH-OJLU@]SHRZG?7D$:&5_N
M*%7<"JY9B2<=N,58U6;7M$\,I!K7BFULS_:'E#4EB!GFMCDJJIL*^<>G"D8!
M/6I)_">LV+^']3T6XL3JNFZ>-.GCNMXAN(L+GYE&5(9<CCO4,_A7Q2XTO5I-
M2L+S6K._FNO(GWK:JDD9C\M" 6 4<@D=2: .-\0ZW>ZM\-?&MHFN7EU!I<L0
MBNI;<12W$,B+F.12@X!8\@ G [=>JUK4M9\/:[X#TJ+6+BYBO[J6.[DFCCW3
M* I4':H QG' 'O4=[X U_4K'Q9;7FHV#G7X(G\Q5<>3.@ " 8_U>% SG/'2K
M]]X4U_6M3\(:EJ,NFQ7&C7$DMRENSE74@ ;,KG/'.<4 0VC:_P",=1\07%IX
MAN=)@TZ^DL+*&WAB96>,#<\N]26!8]!C@5EV?BO7_%!\$):7_P#9O]L6=X;Y
MHHE8AHB@+(&!P<[L9R!NZ'%;I\.^)]%U'63X;N-+-GJMPUV?MOF![69E =E"
M@AP< X..:?I7@1M%O_"9M+E'M=$M+F"4OD/*TH3Y@.G56)Y[]Z ,*76_$NE6
M7B_2HM0N=0GTFXM/)O#;H\Z03!6D.Q0 [(NXCC_"ND\#WZZA'>2VGBH:_I_R
M>6TJ*MQ _.Y7VJO!X(RH(YILGAO7+;6_$NK:5J%K!<:C):26XE0NN(4VND@Q
MP&Y&5Y&<U3_LKQ!IB^(_%%R=+M]6ET\1PPV:O)%F/>P=R0"[$MC@= !S0!WE
M<'J<VNZI\3)_#]IK4VG:8FDQW<C01QF3>977"EE.,@#/!^[QC.:[2Q:=]/MG
MNE"W#1*90!C#X&?US7G^H1ZS_P +FNYM$>S,Z:#"'AO"RQR*9I/XE!*D$#G!
M[CW !DWOBWQ-9>%KFV34%EU;3O$D>E_:GB4?:(F*E=X P"0P!QCI6]J3:]8Z
MEH'A.+Q%<R7.I/<7%UJ;0QB5(HU!*(NW:,E@ <' J)OA]J<V@"*>]M&U2YUV
M/6+QU#"($,"43C. J@#-;_BCP_?ZAJ6D:UH\]O'JFEO)Y:70;RIHY%VNC%>1
MT!! .".E '*:IKVN^&X?%^COJTMY-8Z0-2T^]FC3S4!W*5?"A6PRY!QWYHO9
M_%MA?>%Y4\2R2/KS>1<PR6\9BMR8]^Z(!<Y7!QN)R<9]*T;GP3K&L6/B:ZU2
MYL5U?6+$6,*0;S!;1J&P-Q&YB68DG'T%;&H^&;J\N?"DB30J-&G$DP;/SCRF
M3Y>/4]\4 <K<^*-7\'#QK;W6HRZLNE6=O=64MTB!PTNY=K; H(W 'H.,U?O&
M\1>$+CP_>WOB*YU1+^_AL;ZVGAB5%:7(#Q;5!7:V."3D&K^J^!3K6J^*)+NX
M1;/6=/@M$V9+QLF\[B.G5@1SVJ$>&_%&LW>BQ^([G2_L.E7"7>ZS\PR74J A
M"P8 (,G<0,Y- &#X3AU*QF^(.H?VY>3R6EW<(%D2+#NL*%9#A =P  P,# Z4
M[2O%.OZSX3\#V*:DT.IZ^TQN+\1(72.(,S;5QM#$!0#CCTK=M/">MV6I>*X8
MYM/?2];:6=&8N)HY7C"8(QMVY'7.:JV7@'5--\)^%X+2\M!KGA]W>)W#&"4/
MN#H>-P!5NN.".E %:_UC7/#-WXET235Y[_RM EU6PN[B./S867<I5MJA6YVD
M9'MS33>^)-+M_".NW.OS7/\ :UY:VUW8F&,0*LRG[F%W J<<D\^PXK2E\':U
MJY\0:CK%Q8)J>H:4^EVL5L7,,$9#'+,P!8EF!/ P!WK0U+PK=WNA^%[%)X5D
MTB\L[B9F)PZPC#!>.I[9Q0!SMIKFHW/B^XL[SQ5)IFJQZBR0:1=6Z+;W%J'P
MNQBNYV9.0P;.>,8KTZN$U?PWXIUL_P!F:A=:3-I:WJ7*7I1A=HBR"14"@; P
M V;P>G.,UT.DW>IS^(-=@NS&;*WEB6T*(00#&&<$GJ<D=/6@#"^+I=?AEJAB
M ,@DMBH/0G[1'BH))=>\,>+_  _%>:]/JEIK$DEO<130QH(I0A=6BVJ"%^4C
M!)X[DUN>.?#UQXJ\'WNC6LZ6\UPT1$KYPNV5'/0'G"G'O6='X>\1:IXHTG4-
M?N--^RZ1YCP+9[]UQ*R[-[AAA  2< GD]: .>\.Z]X@?PUK/B[5-8DFM]*:]
M6*P6)%681EMI=@,YZ*,8X7/.34MS=^)?#OAW2/%5YXAGO3/-;?;[&2&(0".9
ME4B/:H92I<8))SCFNA\/^#6L?!FI>'M3ECE2^ENB[0D\),S'N.H#?G66OA'Q
M1J.G:5H.M7FEMH^GRPN\]N)//NUA(**RD;4R57<03TXH R?&GBB[TB[UN[B\
M7M'>6 #VNEVEIYL(4*"5N&\LD,W/\2X!!K;^V:OXJ\:ZCIUGK5SI-CI5I;2$
M6T<;-+-,I<%BZM\H4 8&,YJM?>"/$4]CXDT2VOM.ATK6+B>Y^TD.;@-(,^65
MQMV[@!NR3MXQGD68/#?BS2]:;6-,ET8W%_9PP:A!<-+Y:R1 A9(R!DC:<%2!
M]: .8\.ZIJ]KX?M]'M;M+;4]7\37EO-=QQAO*56=Y&16R,_+@9SC-=;=P^)/
M#NAZV;GQ/:FT5(VLM2U!5$MODXDWA5"M_L\9)."*S[3X>:M9>'[>.+4[9]:L
M=8EU.VN'1O+DWDY60#D;E8YQG!Z9JQJ/A7Q7KNGWDNIZE8+>_:+:>SLHM[6D
M9A</AR0&;>>IQQ@=: ,G3?%.J+>:]IVB:M>:^T>C-?6;7MIY<BSABNT?(F]3
ME2./;-3Z+J,^KZ5J9T_QU<WI6P=KB&>WBCNK2<8.578-JG#*0P/;!K0;PUXP
MG\1OKK:GIMM=W&G261$*,ZVN&WQLFX?O/FSNW;>#QTJQ;>&==U/7_P"UM?.E
M6\D5A-9)_9V]FE\S;EG+@<#;PO/)/- '':+=:GH7PL\+3G6]1@TRZ*_;;R&V
M25[&'RVP$ 0X4L%!9@Q&:](\(7$EUH?G'7H=<@:5OL][&%#-'QA7VX&\'(.
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M&-2U"SDOK+6HM2F*(4C6-"W[I.,G ( +=>]:FNV_B8WT<VBRZ9/:-"8IK+4
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M\0I6U?4'2VMX#Y+,FR0/!(0K?)G"9^7!'OFL_2QK6@_#7PMXBBU^[)4V41L
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M1&W D;&/#=.<=*M6=RMY96]T@(6:-9 #V!&?ZUYB/$VL_:_BHGV^3;I%NKV
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MRH.1NPN!D'K62;O5/#/BFXT-]8O-0L[O2)KRWDO-K2P31D @,JC*D,#R."*
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M_DFWAO\ [!T/_H(H Z>BN#8ZGXK\:Z]IR:W?:7I^CB"&-;$HKRRNF]F9F4\
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M7A@&G0$_O6QB9C)GE<<*..3DFH+#P_XANO$FGZOX@N=++:;#+'#]AB<-,9
M2Y8\# SM&>3UXKL*;))'#$\LKJD:*69V. H'4D]A0!2T6'4X-(MXM8NH;K4%
M!\Z:%-B,<G&!VXP*Q/&'A2X\2ZAX<N8+F*%=)U..]D#@DNJG[HQWK6N/$%A;
MZAI%D9#(^K%_LKQ89&"H9"<^FT<'O6I0 5Q>E>!Y=.^(6H>(&NXWL)O,DMK4
M*<Q32B(2OGISY7ZFNTJ*VNK>\A\ZVGCFBW,N^-PPRI*L,CN""#[B@#A?#?PX
M?1[+Q%:75^LJ:C"UG:M&IS;VW[PJO/<>8?R%1)X/\5R1>'S<ZEI0?0IHS;Q0
MQ2".9 AC9G).0VT\ <#GKGCT2B@#E?"GA2?P_JWB6\N+B*:/5[XW2(JGY%.?
ME;/7K5#P3X!E\*ZO>W=Q>I=1+$;334"D&WMC*\FPD]3E@/\ @(KN:* .(LO#
M/B?1]^E:3JUA!HC7;7$<K0,US CR&1HE!^0C)8!CT!Z&NWHK.O=;M+#6-,TN
M;S/M&I-(L&U<C,:;VR>W% '!_P#" >)1X9@\/IJVFI9:=<)<63"%]\Q27S%$
MW. .N=O).#GC!ZSP_H%SI6IZ]>W,T+MJEPDX6,'"8B5".?=2:Z&B@#S#7=)T
M_P +_!0^'-8U&'[5!:%;8Q'YY)PVZ/RU/)._;TKK? ^BSZ'X3M(+T[M1GW75
M\YZM/(=[Y^A./P%;,^G6-U=075Q96\MS!_J9I(E9X_\ =)&1^%6: .>\4^'9
MM?FT%X9XXAINJQ7[[P3O5%8%1CO\U5_$OA6XUSQ5X7U>*YBCCT>>661&!)D#
MJH 'Y5U-% 'E%],FB:EXOL[+Q3I=E8SRM=7T%U$RW-N[QC=Y62 VX $'! )[
M]#I>!?#%VNG>"M6F=8A8Z.\$D#J=Y,NQ@?; 7GZUUNO6VB06<^M:KIMK<?8(
M7G,KVZR2(J L=I(SV-:-E=Q7]A;WD.?*N(EE3<,':P!&?P- '&ZOX#GU6W\:
M0F]CC'B#R3"=I/E&.-5^;UR5[=JZC0X]4ATF&+6&LVO$&UC:!A&0.F-W.:T:
M* .2NO#>JI\0E\16%Q9&TN+)+*\@N48OL5RV4(XR0<<UB_\ "!^(4\./X/BU
M6P7PXS%!,8G^UK;EMQBZ[,X.W=Z=J[+3_$%I?:0=3FCN-.MPY0_VA'Y# YVC
M(;L21CUS4G]MVG_"2?V#^\^V_9/MGW?E\O?LZ^N>U %Z*)(84BC4*B*%51V
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M7<5XC^5*(_NNI7D$$MQW![8KMJ* *.D6U]::5!#J=\+V] )EG$8C#$DG 4=
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M .G+\>PKO** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,VJ7C->7SO\ >,TG)!]P,+_P&E\4^&+[6]8T/4]/U&.SN-)DFE0R1&0.73:
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MLX-!U!YY$#6S-<0^:2QC#;MNS<3SC."1[UW.DV3:=H]C8LX=K:WCA+@8#%5
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MEDCWB-6+RE(V#99L;2>@Z<YKI=7\%:AK%OX6%WK(N+K1]1COIYY(0#/M.2H
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M/Y+22S!F+,PY( 4 #I6/XNM=1LM5^&MMJMZM[>Q:L5DN539YG3!(]<8S[YH
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MF!'_ !YSD=:Z:S@U+Q7>>*]2.N:C:-IU]-86-O!-MA3RD7YG3H^YB<Y[=,4
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M< @$.<@<=*SHI-;M?AGH?C*3Q'JDNI;K0O$T_P"XDC>54*M'T)*MDL><YY'
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MF0V7VR\O/+S^_O)?,E?))^9N_7 ]@*NT %%%% !1110 4444 %%%% !1110
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M\';$-Y(;*DDG.<XP,"N!GG&I^'_#>B6GBVVU81:A:QV5A#;>5<A8W&3<#<2
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M]DN([NW,L4L88LIPK*0RDMSGG--;PG>32^&Y[S6'N[G2;B2XFFDB ,Y=&7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3Y.0I78,9ZYYS6W;>#]7F\2Z/KNM:_'>7&FB94BAL_)C*R)M/&XD-T)/(X
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M^[GC=M]3C/>N6UN[TS0?&6NC_A+3H*7L<<]Y;W%J"9SLV[[9R?O$#!X;D=*
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M 'SWX=BGT?\ 9YU'7;#4M2@O?G1 EY((X_\ 25&54'"D@8)')R?6N[U>QO\
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MUWDH5QC/RYSGOCWH S- AGT+XG7^@Q:C?W6GRZ3'?!+VY:<QR>:R':S$D @
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M9&^9AN)S@$X'L!7#ZW::7XV^*>CKI=Q]ICTV-CK$D)S$5217BA8]"WF*3M[
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MI]4\(Z+J%RVZ>ZL()Y"!C+-&K']36M5#0M,_L7P_INE>;YWV*UBMO,V[=^Q
MN<9.,XSC-7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *H:WK%IX?T:ZU6_9UM;5-\A1=Q SC@?C5
M^N.^*_\ R2WQ#_UZ_P#LPH ZJQO(=0T^VO;<DPW$2RQDC!VL 1Q]#4]8_A+_
M )$S0O\ L'V__HM:\W.FSZSI'C_4;K5]4633-1O/L"PWLD:P,D:N" I&>2!@
MY  XQDT >P45Y+Y-W86?@3Q+_:NH2ZGJM[:Q7I>Y<Q2I-$S%?*SL4#C& .F>
M3S5'Q?J:0)K^M:=<>)+W4+&[_=7T+M'96I1E!AV[PKJ,$,=IR2: /:**XAKV
MXT#XJ-!=74ITO7;/S(!+(2D-Q /G50>%#(=WN14WP[EO-4TN_P#$5W/.ZZO>
M//:Q2.2(;8';$ #P,@;N.NZ@#L:*\AU>^FUKQ-XE6>W\43/8S"UTYM)+B*V8
M1*Q<[6 9RS9^8'C K5T74M8L/&6@S:TUQ$OB#252:WE8A8;V%0S84\)N4MP.
MI% 'I-%>+W6NZG=:)=:ZESJ;6OB'7X[*VCLW)D2RC##,(S\K/Y;<CUS5U+C4
M+#2O%\=A9^(;'1QH<L]NVIL^^"Y57!\MV9FP05;KP0<4 >MUE)KT#^*Y?#XB
MD^T1V27IDXV%6=D ]<Y4UC?#[26MO#=CJMS?WMY?ZE902SO<3LZCY,@*IX4#
M=CCDXR<FL;4M&CUSXR7-M<W-U%:C0(6DCMIVA:7]_)@%U(;'4X!&3B@#T>BO
M)+2^\KP??Z5?ZQJQBMO$<NG6XMBTEW=1*VX0!\AN1G+9& .M4P=5ETCQE9:.
MVM6#:1]DU&PMKZX9ID.&9TSO8E&"'"EC]Z@#V>BO/K_7'\5^(O!UCI5S-%:S
M1?VW>&*0J?)4 1HV.H9VP1_LUQVGZMJNIZ/#XBL[#Q5/X@EN_/65 YLVB\W!
MA";MNSR\C.W.><T >W7$K0VTLJQ/*R(6$:?><@9P/<U7TN]DU'3(+N:RN+*2
M5<M;W  DCYQ@X)'ZU%X@D>+PWJDD;LCI9RLK*<$$(<$&O*=+N]3U+P/\-XSJ
M]]%+?7CQW,Z3MYDB;)<@MG).!P>QP1R* /9Z*X/PY;'0?B3JNA6MU>2::^F0
M7J0W-R\_ER&1T;:SDD @ GGK4_C*2;4/%/AGPW]JN+>RU W,UV;:4Q/(L2 A
M-ZX(!+ G'.!0!VM-1%C0(BA5'0*, 5YOXBT_4O"^DVVD6.NWQM-9UJVLX7=V
M:>RA<$R*LK$DYVG!/*[N_6IVLSX0\?:-IVFW=ZVGZO:72S6]S=23A)(E5UD4
MN203D@X..E 'H=%>'P6UY;_!W2_&3:SJLFMP_9Y$E:\DV;#,J;"F=I!4\D@D
MGOVKJH]);Q+\1O%MCJ&HZB-.M4LS%:V]W)"H=XCELJ0>,=.A)R0>* /1J*\3
MM]?U"[\->#]+OY-9OH;F:^%V;!F^TW"6\A1%+ AL<J6(.3M]ZN/JNMV'A^_T
MR!=:T^SO-7M++3[C4,BXAAF($@5F))VD,%))(W#T% 'KTDB11M)(P5$!9F/0
M =ZRKK7572K'4=.LKG5(+QX_+-H!D1N,B0[B/E Q[\URNM^"ETKP]X@:UU?4
MO[,DTN0O9RW4LA$R#>)%E+[ESC#*.&[^E<EJ*2Z#\'O!$NFWM]"]Y?:>\S?:
MI"3OB^91D\)P/E''M0![=17GYLO^$O\ B%XAL-2N[U;#1X[:*WMK:ZD@4O*A
MD:1BA!)Z 9.!@US0U'6+S2]%TEM8O5DMO%DVDO>)*1+- BR8W'NVW R>X!ZT
M >RT5P6@VA\/_$^^T.TN[R339M(CO?)NKEY]DOFLA*ER2,@#/-7-?N;C2?B'
MX:O#<RK87\<^GSQESY8DV^9&V.FX['&>M '8UGW6I36^KV-BFFW4T5R'+W48
M'EP;1D;\G//08!KR[P]XLOM*?7-<U&[FEM-4TV?6+&*9R5B$4KJ$0'IE&A.!
MZTZS.KZ3XM^&&F7>HWKR3V=U)>K).Q\V0Q;SOR?FVL2!GIB@#T?4O$NGZ=I.
MLZ@'-P-(1FNHXOO*50/MYXSM(_.M*TN%O+."Y0%5FC60 ]0",UXK;:+;6GA?
MXIW$<MXSP37EL@ENY'4IY*G)#,0S?[1YQQFMR73)/#A\$:M;:GJ,EY?7UO9W
MGFW3M%,DD+DCRR=J@%1@ #% 'IUW=P6%G/>74JQ6\$;2RR-T55&23] *S;GQ
M':6VM:+IH221M765X)4QM C0.<YYY!&*Q?BM;)<_#/72[2KY5LTB^7(R9('0
MX(R.>0>#7,7N@1?VU\.M,@O+Z&&6&\>2073M+@PH657)+*#TX/ )QB@#UFF/
M%'(5+HK%3E2PS@^U>0:EJ-]X1M_'>FZ9>WS06O\ 9_V/S)6GDMS<'8^PN23Z
M@$]:V/"QNK/QA:Q:9IWB:#2I[:1;W^V"[J)5VE)%9V;#'Y@0, \<4 >@WFH6
MFGK"UW.L0FF2"/=_%(QPJCW)JS7G/Q7TR"^D\(F62Y7?KUM;GRKAXQM?=D_*
M1\WRC#=1S@C-4O%4=DVJWUE'-XGU";3K"-(H=-F=$L&VDB223S%WNPP?FW'
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MK%B25]CP*U-/TO\ X3?Q!XGGU._U&.*POC864-K>20+!L129 $(RQ+9RV>E
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M2]'LM/60R"UMXX Y&-VU0N<=NE8MKX0CMM)\2V O&8:Y<W%PS^7_ *GS8PF
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M*W<Y(/3@CO5G1M#UFTU$7FK^))M2V0F&*%+<6\8R02[J"=[\#G@#G YKH:*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@OB=XKU+0]&
MFM- =5U86TEX\I4,+:WCY+D$$98X0 CN3VKO:\>\7:1XOT[PYXTO[J#1)XM0
MBE:6X^TR^<ENJD1QJOE[?E7/&>22<\T >MV<C2V-O(YR[QJS'U)%35SVDZU]
MCL=#L-<>V@U74%9((;8O(C[%W<,5&/D )SCG(&:Z&@ HHHH **** *]]#/<6
M,\-M=-:SNA6.=4#F-B.& ;@X]#7F>H1>,K/QUH_AY?'5TT5_;SS-,=.MMR&/
M& !L[YKU2N"US_DM'A/_ *\+S^2T :LVL'P?IEI;ZSJ-YK>HW4S);K#:H)YS
MC.%1,+A1R2<#U-7M!\3V7B![N"*&ZM;RS95N;2[B\N6+<,J2,D$$=""17/>+
M[B'2/B!X4UO4)%ATR-+JUDN9#B."215*%CT ;:1DTGAJZ@UOXFZ_K.F2I<:8
MEC;V?VF([HY9@SL=K#AMH8 D>M '1>+-<?PYX6U'5H[:6X>V@>14C3=R 2"W
M(^4=SZ5Q-UXXNGG\"ZG/%J%I#=M.+JV6$@W+?9LJ%0$[@78;:Z_QXC2?#WQ&
MB*69M,N % R3^[:N)L-1L-5O_A8]C=0720K-%(8G#;)%LLE3CHPXXZB@#L=/
M\<Z5>6VK2W,=WICZ2@DO(;^+RWC0@LK8!(((!Q@GI4FC>,;+6-16P:QU'3[F
M2$SP)?V_E>?&" 63D],C(.",CBN!\:V5Q?ZQX_@M$D>7^R;"3;&,LP21V8 =
MSM4\5K>'AHFJ>+])NK?QKJ.OW=M!+/%&?):.)'4*?,,<8*DY& 2#E>G% 'I)
M(4$D@ <DFN6T[Q_I6I7UK#';:A%;7LABL[Z:WVV]RPR<(V<\@'&0,XXS6[K%
MM+>:'?VL!Q--;21QG./F*D#]37DGAB+1[_3O"EC=>,=5GO8)K<KHJK"6MYH1
MDJZB/>J*5())Z=^: /1E\;:,-)U?4)Y);9-(D:*\BG3;)&PZ#&>=V1M(ZYXK
M&U/X@3V?BKP_ID.B:DT.HP23RJ;;,@ 52H4;NHS\V>G%<EXC1]=\477C'3+!
M;K1-#FBCO(E)_P")F8B2[J <-Y.<J3U((Y K=\0Z]I2?$/P-KDE_!'I<]G>>
M7=R.%C.Y$*C<> 3Z&@#H+WX@:38WUS"]OJ$EK:3""[U"*WW6UO(<?*[9SQD9
M(! SSBI=1\<6%AK-UH\=CJ5]J-M''*UO9V_F,R.#\PY P,<Y(Y(QG->:+;Z=
M!8>(]'UWQAJ6GR/J-TDNDPB$O<)+(2AC1HR[[U8<@GG/3%=OX:@6#XH>)X@6
M;RM/T] S_>( DZ_E0!#KGQ,AM]$T#4]'L;N[AU34([8_Z.2R#?MDC(R,2<,
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M,S!1L.??/.,@$C.*XYI+6Z\:7EK8>([K66O?#EY:6UW<31LDEP60^7$R*H)
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M>WC$LZHQCC9MH9L< GMDUY_H^L:?K?QJN[G3)X[FW305B^T1'<DC"?)VL.&
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M^%G:\V!D:3IXS_W\KB;B:.U\&:==SN([:V\=&6:5N%C07#Y8GL!0!Z-?>/\
M3["5XVTS6)C! D]X8;3=]C5UW 2\\'') R0*ZF&6.>&.:)@\<BAD8="",@UY
M;XEUG1+?4]4UO1/&"Z1JZVT<K0R%'M]24)F,JC??R/DW(<]J]*TNYGO-)LKJ
MY@,%Q- DDL1_Y9L5!*_@3B@#*UGQ=9Z1JD>EI97^HZ@\7GFVL(1(R1YQO;)
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MG/=:HM__ &49_)\T?8_+\PC<5S_K,]\=*72/'5GK%Y9Q1Z7JMO:W^[[%>SP
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M(E8*DAPQ4H2>H)^E:6I>+M-TKQ1I?A^X$_VS4@QB95!C3 .-YSD;MI X.2*
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M'97CV-RL=RK ^4QM@JY],D%<]>N.10!ZA!KNFW,5W+'=+Y5HS+/*RE4C*G#
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M&3C@9ZUP<'BK7CX>TN]G\/:V+B2^\B^A6V3S4&#\R+G'E;L#<>=H/<YKO:*
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M/MY99&ZLS1J23]2:V*Y_P)*DO@#P]Y;JVW3;=&P<X81J"#[@\8KH* "BBB@
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M BF5&A:*6,,#M;;(O0X.#@CBL?X9:A>:I\/-*O=0N9+FZE$IDFD.6;$K@9_
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MB=#I\DTDP6YL!).F]BS 2!P#R3@LIKI+"RATZRBM(,^7&.K=6).23[DDG\:
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M'OC&>G3- %@D $DX ZDUY[X!N87\;>.-LBGS[^-XC_ST41X)7^\,CJ*]#HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOMP.^>WK7<>&4>+PIH\<BLCK8PJRL,$$(,@B@#$F\;SMXPO?#>G:%<WMU9M
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MI:SX1TZ^U6U,%S+;QL6+HWG HI\S"\+N)/R]JP]2\2MXOT/Q'I^BZ9>36?\
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M[2S$X79$L:L2\C=@"!GDDUS7C+QH=:\#^+[,6-UIMWI M1<"1QN5GD!(!7J
M%Z@\@BI5,OA^]\"Z[>6EVUA%HIL;IHK=Y&MG9(V4LJ@M@E2.G!KG]9FN-<@^
M)LUO87*-.-,,,+Q$2L@/#%,9&0,X(R!C.* /1+;QG=MX@L=+U#P]=6"ZDDC6
M$TDR,92B[BKJ.8SMYP<UA>'_ (A:L=-\2:CK6D2_9K#49+:$1RQ$A]\<:6X
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M;*Y9N).A:/;CA@"#U/%7-.\1KJ?BG5]'@M3Y6EK$);K?PTCC=L QV7!)SWH
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MN"WVE8D$;YW$DCC' QR3GM@T =E17$W_ (]N;9]3N[309;O1=*F:&]O1<*K
MICS"D9&7"9Y.1T.,XJUJ/B^]_M6YL- T0ZNUG DUU)]J6%5#@LB)D'>Y49QP
M.1SS0!UE%4=&U6VUW1K/5;,L;>[B65-PP0".A]QT-<I-X]U.676TTKPS)>C1
MKB2&Y=KQ8E8*H;*94Y8@GY>V!SS0!W-%<?/X[%Q#H::'ICZC?:Q:_;(8'F$*
MQ0@ EI'P<<L!P#DUB^)/B!JD7@CQ'-:Z8UCKFDD0W433JPMPZY29&QAQR,#
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M!W-\IXX'3GF@#U.BJ&BZK!KNAV.JVH807D"3(&Z@,,X/N*OT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5ROQ T.^UOPY&VE!&U/3KN'4+1'.%>2)L[2>V1D?7%=510!P4OQ'FN+
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M".G!ZTS6=,U+Q!X>^(FLVNFWBQZK#;Q6,$L+)-,D"\OL/S#))P",D#I7L%%
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M6BD9"JR* 2A(X(!X./>L7P[X8BT&6]O);VYU'4KYE:YO+G:&<*,*H"@!5'.
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MZ;-!/':Q/<BWF<H0C%%_7&.OI7I=% &3XHMIKWPCK5K;QF2>>QGCC0=68QL
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MD@#1D>:IAC 9?4$@C(]* ,W4O&NN7?B3P6=#L(I+#5[:6Z$<MWY1FQ$&*O\
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M+=  NX]LG@9J*YEG\*?$/5=7N-.O[K3=7M+=1-96S3F*6+<-K*@) (8$'&*
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MO(5]WRGM[BM.\\*Z?KOA;Q-#X:\-ZE932V210W.H/,KW+!_,,:I*<@ JOS'
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M#%0V,[AV84 ==14%G<_;+*"Y\B:#SHU?RIUVR)D9PP[$=Q4] !1110 4444
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M444 %%%% !161XHUZ/PQX<N]9E@>=+8*3&AP6W,%Z_C6O0 445S^H>*H=/\
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M(]?\/W^D32O%'>0-"SH 2H88R,T >:1V[W^G?"G3OM5Q!;W-DRSB"4QF1!:
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MY'_TCPU97#1Y^4.[.20.@IR_#)HM)N-'@\2:A%I5[+))>VPCC/F[W+,%8C*
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M]_>6MI*EPZBUCA&U0J@[<<$D$<YYKMKSPI;WFD:'I[7,JII%Q;7$; #,AA&
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M/%OAFU\8>&[G0[R::&"X*%GAQN&U@PQD$=16W10!D1^'K>/Q.FO"64W"V'V
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M9(SU.[GM72Z_X5L6LO$]\UE<ZE)JUK&D]DD@7?Y2D*(SCAN<\D\@5QND:?\
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MG:=,2UTL?F7+DY+3.=SG/?YB?P KH*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *"<#)HKB?B66
MFL-!TQW9;/4]:M[2["L5WQ'<Q0D=F*@?C0!V44\4Z%X94D4'&48$9_"E$T3.
M$$B%RNX*&&2/7Z5Y]+I5AX8^*&AP:'9PV-OJ=A=I>6]L@2-A&$9'*CC=EB,]
M>:@^"V@:?;^ ])UL0*^IW$#QO<MRPC$A 0>BC:O [\]Z .[UG6K+0;%;N^D*
M1M-'"NT9)9W"#CZL,^U41XD7_A-)]">*-88M-2^^TF3^](R;<=,?+G.>]<U\
M7].L[WP]I3W5K#,R:M:QJ9$!(5Y &'T(&#ZU7D\,:->_%PZ?<:?!)IUKX?A\
MNR*#R<^?(!E.AP,X!XYSZ4 >DB1#'Y@=2F,[L\8]<T1R1S1AXG5T/1E.0:\.
M830:)_PCUG8F[T[_ (3&XM%L/.$:/"BM(L.X\!=PSCOC'>NY\$Z1J>EZ_JTC
M:!%H>D74431V<5PDB+.I8,RJF NY=N>.JT ;_B+7VT*7146W$W]I:E'8DE]O
MEAE=MW3G&SI[UKQSQ2JS1RHZJ<$JP(!KA?BG:17\'A2TG9EAG\0V\;[6*DJ8
MY01D<C(X_&L76]*L/#?C#4+/1;2*RM+_ ,,W;W-M;J$C+1D!'VCC.&(S0!ZO
MO7 .X8/0YZTTS1"41&1!(1D(6&2/I7EVID#X3^ \D<W.D >_*5%K6CP:'KFI
M:GXC\/&]L9[];J+7[24?:+)<J%5@<.JJ1C*DC'44 >D076HOKEW;S6<$>G1Q
MJT-RL^7D8_>!3'R@>N>:N^?#YJQ^:GF,-P7<,D>N*\M@_P"2N^/_ /L#0_\
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MK$TJ"1N50L,GZ"O'KS0-,T3P%X0\0Z=;HFLK<:>YO5_UL_F%5=6;JRD,1@\
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M.27;)#<$@[XV ^7&..O?K5S0O#<&AR74XO;Z^O+K;YUU>RAW8+G:HP H R>
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MMT(4AEA@E"PSHN=H=2#G&>Q%=!10!SMMX*TBV\%-X3 GDTPHZ?._[SYG+YW
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MZDD"@#F[[P)97>M7^L6^IZKI^H7P19IK.<(2JJ%"X*D8X!Y&0>A%$_@#1Y-
MTS2;:2\LETR3SK2YMIMLT;\[FW$$$MN;.1SFNIHH Y*+X=Z,HU(S37]S-J4"
M0W4\]QF1RC%E?< ,,"1C' VK@#%3V7@FSMGNY;K4M3U*XN;5K/S[V=6>.%OO
M*FU0!DX)."3@5TU% '-VO@C2K32-"TR-[G[/HMP+FU+.-Q<!A\QQR/G/IVJ[
M<>&]/N]=FU:X1Y)IK Z?)&Q!C:$L6((QU))[]*JZWXK31-=TG27TZZGEU21H
M[>2)DVY4;FW98$<>QKH1TH Y;2_ >GZ9=VTS:AJE[%:(T=I;7EQOBMU9=I"@
M $_*2H+$X%,L/A_IUC<VC/J&J7=I9$M:6-U<!X(#M*C:-H)PI(&XG -;FMZQ
M;:#I<E_=;BBLD:HOWG=V"JH^K$"HM*U*_O+R^M;_ $F2R>V9=DHD$D4ZL"<H
MV <C&""!CCK0!DZ=X!T_3KRRE_M'5;FVL'WV5E<W(>&W;!4%1@$[02!N)Q73
M7-O#>6LMM<1K+!,ACD1AD,I&"#]14M% ')6'P]TVQN;!Y-0U6\MM.<265G=W
M(>&W8#"E1M!)4' W$XK5MO#5C:>*K[Q%&TWVV]A2"4%ALVITP,=?QK8HH 0@
M,"" 0>"#7%'X8:7"9HM/U?7=,L)F+/865\4@YZX!!*@^BD5V-S<PVEM)<7$B
MQPQKN=V/ %5[F[NX=3L;:'3WGMI_,\^Z$B@6^T97*GEMQXXZ=Z ,J[\$Z)<:
M#9:/!#)8P6#K+9R6CE)+=QGYE;GDY.<YSDYS4=KX'TZ"UU:.XN[^^N=5MS;7
M-Y=2AIC$5*A5( 50-Q. .IYS7344 8D_A73[BPT.R=I_*T::&>VPXR6B0HN[
MCD8)STK/\5^'89;#Q%K%ND\NI7.AS6*Q)\P90KLH"@9+$MBNKK N?$YM?$<V
MCMI&H.5M&N8;A(P8YRHR8T.?O<CK_AD PO#?@&S&E^'KB]NM4=;*&&XCTV>;
M]Q#.$'.PC=D$G )P#T JW>?#;1[XZE'/=ZD;#4)))I; 7&(!*_WI N,YS\P!
M) ;G'%;GAW6U\0Z+%J L[FS9F>.2WN5VR1NC%6!_$&M6@#%TKPS:Z5J<FHI<
MW=Q=RVL5K))<.&++&6*DX ^;YCDUGW26/@G1+M;;3=3U,7UU-.;>W@,[/)*2
MQ!P,*N>,G@>M6=%\5IK6OZMI":==03:6Z)<22LFS+KN7;AB3Q[5T- '(_#;P
MJWA'P9;6$\:I>2L;BY56W!7;HN>^U0J_\!K?UG1[+7](N-,U&+S;6< , 2""
M#D$$="" 0?45?JEJ%W=VKV8M=/>\$UPL4Q614\B,@YD.>H&!P.>: ,G2?!MI
MINK)JEQJ.IZI>Q1&&"74)Q)Y"-C<$"JH!.!DD$G'6K^@:!9^'-/DLK(RF)YY
M+@^:P)W.Q8] .,FJL'B7S_%FH: -/F66SM$NA(77]Z&) "C/'W3U(J3PKXA7
MQ1H:ZFEJ]J#-+%Y4C!F!1RAR1Q_#0!8U_0[+Q+H5WH^H!S:W2;7\MMK#!!!!
M]00#^%4M/\)VMAJ-CJ$E_J%[>6=M);)-=RAV='8,=V%&2-H ]J??^(Q8^+-(
MT%K*5CJ23.ESO4(OEJ&(QU)Y'IUK<H YF^\#:5?C5"\MW'+J%U%>--%*%>&:
M(*$:,XX(VCKGO3+3P%IMKJ9U%KS4;BZEMWMKJ2><-]K1NTG';MMVXKJ3P.F?
M:L/PUXC7Q''J;"SEM&L+^2Q=)'#$L@7)XX_B]3TH 7PQX9@\*Z6-.M;Z_N;9
M,");N4/Y2CHJX P/SJ+6O"5KK.K0ZF+_ %&PNXX3;O)8SB,RQ$[MC9!XSD@C
M!&3S4E[XC%EXMTK0&LI2=0CFD2YWKL'E@$C'7/(].O>MB=WCMY'CB,LBJ2L8
M(!<XX&3P,T <M;?#O1;1+:*"6\6VM=3&IV]OYHV12C=\J\9V'<3C/XUHZ[X7
MM=<NK6]%Y>V%_;*R1W=C*$DV-C<AR""I(!P1U'%:>G7%Q=Z;;7%W9M9W$D8:
M2W9PYB8CE21P<59H S]%T:UT'3$L;1IG0,TCR3R%Y)'8EF9F/4DDFH[C0+.Y
M\26>NN9?MEI!)!& PV;7()R,=>!WK4HH YK5_!=GJNIS:A%J.IZ;<7,2PW1L
M+@1BX5<[=X(/(!(!&#@]:74?!&F7L.FK;37FF3Z9%Y-K<V,VR1(\ %"6!# X
M'4'I7244 <K_ ,*_T==%@T^&6]AE@N6O$OTG_P!)\]L[I"Y!R6!(.1@CC%+)
MX"TNX\-ZGHMU=7]RNIN'N[J:8-/(1MQSC  "@   8K4U;6DTZ[L+"*(37]^S
MK;0L^Q3L4LQ9L'  'H>2.*K^'];U35Y9UO\ P[=:4D0 #SRHPD?+!@H4YP,
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MS2AE;<S$=<JHZ8P.U=369XBUC_A'_#]]JQM9;I+2%IGCC902JC).2?0?_6H
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M!)PJ;%9NY8+QG//?-/MO!&GVEUHUQ%>:AYFCQ-#:[Y@V%8!6#9'.0 /;'&*
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M1=P*MN7+;<D \U?O_#%K?:G::J+JZMM4M8S"MY 4#O&3DHP*E67/."O!Y&*
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M)WFVLB;UD0N25/!! .".V:YJ'7;CP_X8\8W%HXBN)_%<MJDQ (A\QHE+\\<
MDC/&<5Z)8^'(+2[M[N>\O+^YM8FAMY;MU8PJV-V-JC). "QR>.O6J2^!-'.E
M:OIES]HNK35IVN;J.=P<RM@EU( *G*J1C@8XH PM1TN/3OBQX/,5S>2J]K?
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MS0JP .,*,D@ ;FR??DYSV\ :6_AV_P!">ZOFL;^=KB=3(NYG9MS8;;D M@T
M8_BK38;KXH^#2\MVOGQWV[R[J1,;8DQMVL-OOC&>^:9<:]?:'XJ\<W#W-Q=V
M^FZ3#>06TKY1&VRD@ = =HR>OO747?A>WO=8TS59KZ]^UZ:CK;L&0 ;P%<D;
M<$D ?TQ3D\+V*ZYJ.JO)/-+J,*V]S%(5,;Q@$!=N.@!/USSF@#@M=M'G\/>
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ME87D\L%K>VT\T)Q+'%*K,A_V@#D?C7E?C"%/#7BO6'\/V\=D\WA2ZFF2U0(
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M[>SMX[7^Q8+D0+& BR^5-\X7H#P.1W% 'J>D:M::YI5OJ-E*KPSQJX 8$KD
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M6^G?$GQK9V4$=O;".PE$,2A4#LDFX@#@$[1F@#NZ*** "BBB@ HHHH ****
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M*SM))CB);B=8RY]@3S61X8\3G5=!O-3U-[6TCMKVXMR^[8@2.0H"2QX. ,T
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M69 ^V,PKTSTSSGUVCTKL/#WAG3?"UDUGI:W"6Y;*QRW#RA!Z+N)VCV%9]_\
M#_P_J%W>73PW4-Q>ONNI+:\EB,PVA=K;6&5P!QTZ^IH \N\+G5K^+P/;V]K8
M7X@TV]>VCU.5DC.V<(&&%;+"/:!QT)KTWP'I.H:/9ZK#?#3HUEU"2>*VL)FD
MCMPRKN3E5Q\VYL8_BJ_?>#]$O]-L;%K5[>/3P!9O:S/#);\8^1U((R.#SSWJ
M[HVBV&@6 LM.A,<6]I&+.SN[L<EF9B2S'U)H X[POIUCJ_BOQO-JMI!=70OU
MML3QA]MN(D** >BG+'WKB] M[;4X_AE:Z@!/9K=ZFD*R_,)$CW>4#GJ/E7'T
M%>IZOX)T36M0DOKB.ZBN9HQ%.]I=RP>>@Z+)L8;AVYI]]X*\/ZC;Z=;SZ>%B
MTU&2S6*1H_)! &5VD8(P,'J",CF@#A=:MX-/U_XB6MA$D-K+X:$\\<2A5$VV
M4 X' )4?C6+?_P#).OA-_P!A:Q_D:]4L?!FBZ?IVI64<,TJZFI2]EGN'EEG!
M4KAI&);@$@<\42>#-"ETW1]/>S8VNCS1SV2>:_[MT^Z<YRV/?- '-Z'IFFZQ
MXU\=OK%K;W,B3P6^)T#>7!Y"D 9^Z"2QX[\URO@]XKKPGX,TVRTNUU342U_<
MVTM_.RPPQK,RL[  [V.\ <<9)R*Z?Q3I(;Q7<7L_@V]U-)K=$CGTV]\L3D9_
M=W*%U!4<8)##'!]*M>'_ (>6P\'Z)8ZTDD>HV(ED\RRN7A:(RN7= Z$$KR >
MQQ0!P5] '^'FO17,%EOM_%JQA+89BB)>'>J9&0,EN/<UU.HV>HS?%&^M]-TC
M1;N.UTF!8(-0D:-(XW>3>8U5&') !Z=!74/\/?#3:?J%@+!DL[\QM- D\@3<
M@ 5U&<*WRKDC!.!G-/NO NBWD%FDAOUFM(VBBNH[Z9)RC')5I VY@3V)- '"
MZ=HT]GKW@+0]9-E<6T3ZE-%%!(9H RX,:Y8#)168#CC'M6_X5M+*R^+/C.&Q
MCCB3[/8L\<8 57(D)P!TSD'ZDGO6_>>"= O-&L=*-FT-M8,'M&MY7BD@;GYE
M=3NR<G)SSGFI]$\*:/X>N;BYTZV>.XN41)Y9)GD:7:6(+%B23ECSU_(4 8DA
MQ\;;?/?P[+CW_P!(2N&UI8KS0O&D>[,;^++:-BC8/WH >1T/6O4]<\)Z5XAN
M;6ZO4N$NK4,L5Q:W+P2*K?>7<A!P<=*@B\#>'8-.GL(K#9:SW,=W)&LK\RIM
MVMG.?X%^O?.30!SFNV-MHWQ&\-OI-G!:R/IFH1E8(P@<(L912!U /2N1U'2]
M(_X9MM[XP0?:FABG^T[1YC3/, Y+=23E@?:O9;C2+*ZU>RU2:(M>622)!)N(
MVB0 -QG!SM'6N=D^&'A29)XI+&=K:9F?[+]KE\F-F.2R1[MJD\\@=SB@#F9K
M+5]6\?>,4@TC1-111;VQ_M.=T:.$PA@J 1M\I+.2<CGZ55_L$R>)/AII.N/;
M:AY%A=B4HWFQ3;%C*<D#<.%/(ZBO0-:\&:-KM]]LNX[F.X:+R97M;J2 S1_W
M'V,-PY/7UJV/#>DK?:7>):+'+I<+P6>QBJQ(P"E0H.#PHZT /U>UMQX;O;80
M1?9UM758M@V@!3@ =,# KR6#3+*Y^&'PWMY+:+RKK5;3SU"@>:"DF0V.N1P<
M]J]J=%D1D=0RL""#T(KFM/\  'A_3+:VMK:WN/(M;M+RWCDNY76&10P7:"W
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MC\4O&<]_9PW$D<5BBB9 X4-"=V ?7 _*KWPG&WX<Z?&/NQS74:#T5;B0 ?@
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M1])FAM;-8+[4=3G=BX$.\"-0I  5@<Y&2?QKK[_X?>'-2U.:^N;.4M/(LMQ
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MC;^*O#]UITVHP:YITEE"P26X6Y39&2< ,V< DD=?6K][?6FG6K75]=0VUNI
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M%EXHT#4=0?3[+6M/N;Q,[H(;E&<8Z\ YXI+WQ5X>TTD7NN:=;D2F$B6Z1<2
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MO](\_P"T[/.D\KSO^>GE;MF[/.<9SSUJ_J_B31- AAEU;5+2S28XB,TH7?\
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M\,VZ6"SV%M?EKI!A52+R77.,CN1C'(K7T?PIHNA&[:QM&\R[P+B2>9YWD &
M"TA)P 3QG%&G^+_#FJNB6&MV%R[R^2BQ3J2SX)P!] 3^!K:H YO3O 7AK2;^
M&]M-/99;<DVZO<221P$]3&C,53\ *U;71=/LA?BWMP@U"9I[KYF/F.RA2>3Q
MP .,5!K/B?0_#QB&KZK:632_ZM9I0I8=R!UQ[U-+KNDPV=K>2:E:+:W3!+>8
MS+LE)!("MG!X!/X4 3:;IUII&FV^GV,7DVMM&(XH]Q.U1T&3DFK55-,U2PUF
MP2^TV[BNK60D)-$VY6P2#@_4&K= !1110 4444 %%%% !1110 4444 %%%%
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MO4M5LQ-N8GR5((3D^PYZU0'@/PP-5_M(:1#]I\[S_O-Y?F_W_+SLW9YSC.:
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MDM$:+3I$EM%R?W3(I52.>P)'-9_B?P_%?Z1KT]G:*^KWNE2V2/NP7!5MJ<G
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M;QJ3=7;<*.J3D+^0 Q7LD>EV46K3:HENHO9HEADFR<LBDD#TX)-5/^$:T?\
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MZ&^ZT7VF7A_]G=MZU[G7/VO@?PU9VNH6L&DPK;:@<W,+%F1^2>%)(7DD\8H
MQM;1(_B]X3:U55G>SO5NM@Y,(5-F[VW]/?-=S6-HOA/0_#TTL^F6*Q3RJ$>5
MY'D<J.B[G)('MG%;- ' >$[B+3OB3XQTF[81WEY/%?6V\X,\)C"G;Z[2"#6W
MXA\0VR+J6AV4[/K?]F3W,<42EC'A<*6(^Z22,9ZU<U[PKH?B:.)-8TZ&Z,1S
M&YRKI_NLI##\#3M"\,:+X:ADBT?3XK42G=(RY9Y#_M,26/XF@#S75H;&/]G;
M2I+%8Q.L%E):L@&[[49$R5_VMQ;/?K70^'[*VN/BAX]EF@CD<K919=<_(T'S
M#Z' SZX%;EOX#\,6FJ)J,&D0I<)*9D&YC&DA_B6,G8K>X&:U[?2[*UU"]OX+
M=4NK[8;F0$YDV+M7/T''% 'C5M9V\'[.>D31PHLHNK:;S,?-O^UJ-V?7''TX
MKL?#EO92_%SQTTJ1O=".R4!P"1&8?FQ[$@9^@KJ1X8T4:!%H0L$_LR(J4M]S
M8!5]XYSGAAGK7-+X%MM6\9^)[W7--$EI=-;?8Y1,49@L(6091@P&0 0>#@=:
M .3\*7,O]E^&],TJRL9KIK_4IM-N;W<8K:".0@E54@L3OP.>!FJ=PAN_"/B.
MVO)+6?=XP@CF^RH4B))@#[022.<YY/.:]7O?!OA[4-.L;"XTR+[-8_\ 'JD3
M-&81C!"E2" 1U&>>]-7P3X;1I#'I4,8D:%V5"RJ6BQY9V@X!&T=NW- &+J]O
M##\6?"PBB1 ^G7L3!5 !0>60I]AD\5QDK3V&EZE\+8G99[C5%MK,@\KI\V96
M8>H55D4_45Z_<:;:3:A;ZF]L)+VTCD2!\D%0^-P'..=HZURVB:+J6J>.)O%V
MN:7'ITD-H+*QM3*LL@4L6>1V7(R<X !.!GUH [*W@BM;:*W@0)#$@1$'15 P
M!^5<CXHN;B7Q?H>G:996#ZJ(+BZCN[\.R6\8V(VU5(+,VX#J, &NRK(UOPQH
M_B(VYU6R$[6Y8Q.'9&3/!&5(.#@9'0T >*>(9'?X+^,/,EMI67Q&P+6JE8B?
M,C)V DX&23U/6NXUW_DNO@[_ +!]U_Z"U=3+X%\,S6E[:/I$(MKTQM<0JS*C
MF/ 0[0<#&!TQG'-:,VAZ;<:S::O+:JU_:1M'!.2<HK#! &<<YH T*\VU/_DX
M31/^P'+_ .AM7I-4)-$TV77(=:>U5M1AA,$<^3E4)R5QG'4F@#QYQ(/A1XI$
M/E -XFE28R [!&;I P;'.W'7VS737FDZVNM3:CJUYH,4L>BW4'V:P#K)-$0I
M!(8\JK =.F[WKK8?!OAZWO-1NH]+B$FI!EO 2Q28-RV4)V\XY('-)I?@SP_H
MJW(L-.6,W,7DRLTCR,8_[@9B2%]A@4 >;7.E6+_"#X?P-:QF.6_TXN-OWO,/
MSY^NXY^M;VO6EE+\3;ZWN9TLK2Y\)3QW$^0@1/."[B3QP">M=L?#NDMIEAIQ
MLD-G8/%):Q;CB-H_N$<YX]ZDGT73;K4'O[BSCEN7M6LV=^=T+')0CH03[4 <
M=H3:CH_B31M'UZQTNYD-I+%IFJV(*-L0*65T/W<C!R"1D5Z!6%HW@WP_X?NS
M=:9IRPSE/+#M(\A1.NU=Q.T<#@8'%;M 'G'AJ'2KJR\?'7TA:,ZO=+?&;J+=
M479D]0H3D8]\5)X26RE^)7B!X\/&FF:>NFLY)/V4HQ.TMS@MU]\9KH]5\#^&
MM;U(ZAJ.DPSW3!0[%F42!>F]00'Q_M U-K/A+0M?EAEU'3UDEA0QQRI(\3A#
M_#N0@[?;I0!Y1%:V]S8:?9F)'TL>/I$MH\9C,0$AP!TV[MW'2NNU2*-/BIJ.
MQ%7S/"KEP!]XB8@$_05UZ^'-'2ST^SCT^%+;3I5FM(D&U8G (# #O\QZ^M6&
MTJQ;5CJC6ZF]-O\ 93*<Y,6[=MQTQGF@#R_0[G;\./ &GVMA9W6H7DBFU>\+
M>5 \:.QD(7EB " /4^U4[Q[HZ-\5X[V>REN%MXO--E&R1;_((. S,<\ 'GJ*
M] 3X=>%(].;3X](1+5IA.$6:0;'&<%#NRG4_=(ZU83P1X;C2X2/2HD2YM?L<
MRHS 219SA@#R<_Q=>3S0!PVFVL%UJ'PB6>)9%31Y9%5AD;A;PX./8\_4"F:Z
MBQ2_%U(U"J=.MW( P-QMWR?J<"O2HM TN"33'BLT5M+A,%D03^Y0J%*CGGA5
M'.>E)/X>TFY;5#-9(YU2-8KW)/[Y54J >>, D<8H \VTRU@N[CX0)<1+(B:9
M-(%89&X6T1!Q['!^H%4/&H\F3XG+$-D3II33;./E9L2'\5SGVKUB'P_I5NVE
MM%9HITN)H;(@G]RA4*0.>> !SGI5?5=#B>SUJXT^QLI=2U&W$<@NPS13[5(1
M7 /W<$CCUH Y7Q=!ID7C_P"'Y@2%+D7,R1B, ?N1"W''8'&/J<5Z+7EV@^#[
MIO$>BW*^%(O#]IIKO/.QO%N'N)/+9$1""2$7<QYQ[ 5ZC0!PV@HDOQ:\8M=*
MK7"6]DEMO'(@*,6V^Q?.??%<!):P7?A[2[$HKZ4WCYHK:,?<-N6D^4?[.2PK
MU[6O"6A^(;B*XU.P66>-#&LJ2/&^T\E2R$$K['BI3X;T8V6G60T^%;;3IDGM
M(D!58I%SM8 =^3U]: -***.&,1Q1K&@Z*HP!^%/HHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM
MJ&H6>E6,M]?W,5M:PC,DLK;54?6K-<)\3A=M;>&Q:O;)G6X,M=(6B!VOLW@$
M$C?M[]<4 =#:^+= O=(N=5M]5MWLK7/VB7=CRO\ >!Y'XBH5\<^%GO+BT&NV
M7GVZ-)*ID "JOWCD\''?'2O/_%FF:G!I'C:_U75-)FO)=%2.:UT^-HR &8I(
MX9F.2"P!]!6QK^G68USX:P?9X_*BN'$:[>%"VY8?JJG\* -;7/&]E+X"US6_
M#>HV]U-80L00,[''0,IY_.M+2O&6@:I?)IEOJ]K-J6S+0(_)('S =B1SD#.,
M5YYXN4)=?%4*  VE63-CN=D@S^0K9\1K9#3/AU_9@CR-5M/LOEXSY/EMOQC^
M';U_"@#J[_QMX9TO4CIU]K5I!=*0'C=_N$] QZ+GW(JSK/B;1?#ZP'5=1@M?
MM!(B5SDOCK@#D@=SVKA/#7V+_A6/BW^TO+\W[7J7]H^9C._<WWO^ [<?A4'@
M/SO^$RT,:EG[2/!]MY'F=?\ 6?/C/\7W,]Z .E\-^-;>_N-6-_J%K]F&L?8-
M.D4@+*&B1T4$<,3N./6NHO-3LM/EM8KNYCADNY1# K'F1R,[1^ ->4Z9H5OX
MD\-?$&QTHHLJZ]-/9/'C"SHL;*5/;Y@1]#6GX6U=?B%XPTW6MO\ HNBZ:K,G
M9;V<8=?^ HI'_ J .GT+Q#;+H(O=2\0V-\C79MUNX8_*CW%L+'C)YSQFKVC^
M+- U^[FM=*U6VNYX5W/'&W.W.-P]1[CBO&-$ACN?@Y;03('BE\4QHZGHRFX4
M$5Z)X@1H_BEH36JA9VTB^12HQG!C*C\": -J3QYX5BN;JW?7K)9;7/G*9/NX
MZC/0D=P.E=%7ANI_V5_PS!:[_*W^5'Y?3=]H\WYL=]V=^?;->Y4 <(=>\8ZG
MXFUW3]#@T);72YXX=UZ9@[EHU?\ AR/XL5HZ#XT@O-)EGUL0Z9=VVH'3+A#+
MNC\\$8"MQD,"",^M<UING>(+[QYXT;1_$$6F1K>P!T>P6X+'[.G()88^E5O&
MOA>WT7P1I^GRW$M[)>^(;::]N)@ T\DDGS,0. ,8  Z "@#NO^$U\-'1?[8_
MMFU_L\RF%9]WRM(/X5[L?IFI;?Q9H%WHT^L0:K;/I]N2)IPW$1'9AU4\C@US
MVO)%'\5/!R3JBVJVUX+9<843;4QCWV9Q^-<AXYV_:_B7]EQY/]D6GVG;T\_+
M8S[[,?I0!Z=8^+_#VIZN^E66KVL]\F[,*/R=O7'9L=\9Q2Q^+O#\VJQ:7%JU
ML]_++)"D"MEB\>=XQVQ@]?2N3\3K9 ?#L:6(]PU2#[+Y>,_9_)??C_9V[<_A
M4WPPM8$?QA="-?/D\1WB-)CDJK# SZ#)/XF@#:T+Q!;1^$3J^J>(K"^MXV?S
M-0B3R8L!L 8R>1T]S1>>/?#T'A:^U^WU""YM;16#!&P3(!D1D$9!/ &1WKR+
MPP+QOA;X-%K);1Y\1MEKI"T0;][LW@$$C=C'/7%=7KVF:E!IGCN^U35-)FO)
MM"\N>UT^-D*[5DV2.&9CD@L,^BB@#L[7QYX>F\-6NNSZE;P6L^U.7SB4J"8Q
MQEB,]A5]/$^B2Z3!JJ:G;-87$BQ13A_E9R=H7V.>,5QYN[F7_A"--TN#3QJ,
MFF-<17U[&TBVZ+'&K;%5EW,V\=Q@ UQ=ZOVWP)K4-S<078D\9(DDENACC?+1
M;BJY. 23W/7- 'L&F^+_  _K$\,.G:M;7$DYD$01O]84QOV^N,CIZU??4[*/
M5(M,>YC%]+&9D@S\Q0'!;'IFN2^(]DUEHMAXCL(0+GP[<+=JD8QN@^[,@] 4
M.?\ @--\&-'XA\4Z_P"+T826SLNFZ>_8PQ<NP]FD)_[YH ZO7+^32_#^I:C$
MBO):VLLZJW0E4+ 'VXK&\/>,+:^\%Z-KNLSVMBVH*."VU-Y#' )]E)Y]*O>,
M/^1)U[_L'7'_ *+:O,;6WBNOA=\,89XUDB?6+0,C#(88EX/M0!Z39^-_#.H6
MMY<VNLVLL-D UPP8CRU/0D'G!]>E<C\/?B!-XIN=2O\ 4=;TV&VA\YDTY(=K
M11(R@2O*6Z8//'?/'2M<JJ_&Y"H +^'6W8[XN!C/YFO.=-S_ ,*$O]V?LW]M
M?Z5C_GC]I3?GVQU]LT >PZ/XP\/:_=/;:5JUM<SJN_RU;#%?[P!ZCW'%-3QG
MX;EO5LX]8M7N665A$K9.(\[R?3&UNOH:PO%WE?\ ":^!/LFS[5]LFV;,9^S^
M2V_I_#]W]*R/ MK!%X \67"1J)IK[42[XY."P SZ#^I]: .PB\=>%I[Z&RCU
MVR:>:,21KYF RE=PYZ9VG.,YQ5G1O%6A>(9+B/2=4M[M[?!E6-N5!Z'![>_2
MO,[K3K-_A%\/+=K>,Q2:AIA="O!WGY_SW'/UK;\17<&E?$S4=0EM_.B@\(3R
MRQ#CS528';^61^- '5Z=XT\-ZM>2VEAK-I<3Q(SLB/U5>I4]& ]1FL;3OB'I
M7B32=>;3=3MK*>P,RK/+^\58TP!.5X^7)Z>U<W"=3A\4?#Q;^XT>.*0RM:V-
MA;LA@C-L_&\N=R_='W1DCVJ&T(_X5/\ $<=QJ.J9_.@#T5?$6G:7X8L-3U?6
M;0Q30Q_Z8!L2X9E!RB\GYNH SQ4EMXKT&[T:?5X-5MI+"W)$TP;B(CJ&'4'D
M<&O/="V_VI\*_M6/(_L-_L^[IY_DQ?KMW8_&J/C?;]L^)GV7'D_V1:?:=O3S
M\MC/OLQ^E 'IUEXO\/:CK#Z19ZO:S7Z[LPH_)V_>QV..^,XQ6U7 ^)K6"SUG
MX?);Q+&L-^8HPHQM3[.XP/;@?E7?4 <EIWB"]UO7]<-K-%;Z+I.ZT\UDW&:Y
M R[9[(G QW.>>*LZ/XCLH/"^G7VJ^(+"Z%RSHM_&ODQ3,"YX!)QA5.>?X37.
M?#K_ ))3>E_^/@S7YG]?,\R3.?PQ7)>';>*Z^&7POAGC62,Z[DJPR#@W!&?R
MH ]=T7Q1HGB+S_[)U*"[-N0)50\IGH2#S@X//2HM,\9>'-9U)].T[6;2YNU!
M/EQODL!UVGHV/;-<-XV6=/&'B8V0(N'\&R$;.I(E<9^N.E=+IS>&!H?@UI_(
MWE(AI6T'._RN=NWMMSG/'KVH J>#/&DM_IGB*^U^Z@A@T_6IK&.3;L"H"@0'
MU.6QGWKLI]0M+:^M;*:X1+F[W^1$3S)M&6Q]!S7A=N0OPN\?,3A5\5LS'T G
M@R:]#\37$;?%+P1 DBF<+?2;,\@&' )]B0?R- #O%_Q#TG2]$UJ/2]7LVUJR
MA<I"3NQ(HR5]"1SE<YX-:RZG*WBK3[1M9M$6:Q\YM-,7[V0\_O V>%'3&.U>
M9DV/_#,-R;KR_,,4GF;\;OM/GGK_ +6ZMZ;_ )+MX<_[%]__ $)J .MG\?>%
M+:6&.;7K)&E8JN7[ABAR?X?F4CG'0U<UGQ3H?A^2&/5M4M[22?)C61N6 ZG'
MH/7I7FME:6X^!'BMQ"FZ6349'./O,LK@$_3:/RK;\+,C?$G4FO"IG_L&Q-L7
MZ^5\_F8]MV,T =WI^J6.JQ2RV%U%<QQ2M"[1-N <=1G\146KZWIF@68N]5O8
MK2 L$5I#]YCT '4GV%<?\)?L?]B:[_9^W[%_;MWY&S[OEY&W'MC&*T/%EU<G
MQ-X=TS3K:P_M*?[1-#>7T;2+;*BJ&VJI4EB' ZCC- $'C7QJ++X8ZAXF\-7M
MO<-%Y8BE WKDRJC CUP3P:;KGBG4[#Q9X&TZ!XA;ZSY_VL%,D[8T88/;EC7G
MNNR22?"7XD":ZM[F0:VN^6WC,<;-FWR54LV.<]SZUU'BG_DH'PL_[>O_ $5'
M0!ZG6'/XR\-VVM#1YM9M$U N$\DR<ACT4GH&/H3FMRO,/";:#_PJN^/B?R?)
M74+G^U/-!)\[[0V-VWYMWW,8YZ4 =IK'C#P]H%TMKJFK6UM<,N_RV;+!?[Q
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MXJT+PZ8EU;4X+1I@3&KG+,!U.!SCWZ59BUO3)KRUM(KZ!Y[J#[1;HKY\V/\
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M*:0J,#<R G ^IK1K&\(?\B5H/_8.M_\ T6M;- !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5M0TZS
MU:PEL=0MHKFUF&)(I5W*U6:JZCJ-GI%A-?ZA<QVUK"-TDLC851_GB@#.M/!_
MAZQTJ[TRVTJW2SO.+F/!/G=OF).3^)J_-I=C<3V4TMM&\EDQ:V8CF(E=I(_
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M-V"H9"&(C+?=WL!M7/'WB.M "3V)\,Z5-_PB_A^WFGED!-M'*MNA.T+N)/&
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M<++Y#<-L63^X9,; WL3F@!O_  K[PG_9T.G_ -B6WV6&5I8T^;Y&8 $@YSR
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MK$=UXSBMH=>B>&731<II?V;#D%N)O,/.,<;<5):>-O#=_K']DVNJPR7A=D5
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MY+<6$$KWL(M[DNN?-C&<*?89/YU3T;QAH'B"Z:UTS44FN%3S/*9&C8I_> 8
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MF;-K*63.-R[@-RY[C(J+3_&_AK5;@066KP32?9VN3C("QJ<%F)&%QCO@]^E
M$^D>$] T&\EN]+TNWM;B5=C2(.=N<[1G[JY[# J.+P;X<@UHZQ%H]JM_O,OF
MA>CGJX'0,?7&:71?&/A_Q#=/:Z7J4=Q.B>9LV,A9,XW+N W+G'(R.:X&#QWK
M\GPI\5Z\US'_ &AIVH306S^2N%160 $8P>&/6@#T^TTRRL9KN:UMHXI+N3S;
MAE',CXQD_@!69IO@OPWH^I?VCI^CVMO=?-MD1?N;NNT=%S[ 5)HVOVMZMA8S
M72'59=/CO7AP02C  N.,8W<<5>35K&35Y=)2X5KZ&%9I(0#E4)P"3TY(Z=:
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MPVUO&(X84$<:+T50, #\*EKG? >K7FN^!M(U2_=9+NY@#RLJA03D]AP*Z*@
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MH3W(YIA\%^&6FO9CH5@9+X$7+&!?W@)R<_4@$^XS0!@^'&4?%[QLI8!C!IY
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M]*>PT"UFNM2N[;SI7C<$A!\R@(-I)))Y-<_HTB_\(O\ "YV<;1K$J[B-HZS
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MVW!?97/.*N_# B32M<N8,&QN-=O);-E^ZT1<#*^Q8-0!LWGC;P]8ZPVD7&H
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M7UN\:';TV%\KC\,5D^(M2NKNY\:^1J&G:1;6,:VTR_8UDN+YC""-Q)'!W[%
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M=Z)K^"WCGD4QE24<<.,C!!]NE07?BW0K&34TN=12-M+$9O,JV(O,^X,XY)[
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MSP:O:IXLT31[6TN+N]!2\&ZV$$;S-,,9RJH"2,$'.,<BN.\(7NDVTOQ#%Y+
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M0>!5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M02>6L@+;3T;'I[TL-[:7%NUQ#=0RP+G,B2!E&.O(XXH ;)IUE-?PW\EI ]Y
MI6*=HP7C!ZA6Z@&K! 92K $$8(/>H8[VTFN&MXKJ%YE4.8UD!8*>AQUQ2?VA
M9?;?L?VN#[5C/D>8-^/]W.: .4\1^%Y3#IUOH_A_P_?:7:[]^EWL*QJ&8Y#Q
ML$8*<YR,<YJ7PQX1-KI^I'7K:PGN-2O1=R6T2;X(=H58T7<!G:$'.!S733WU
MG;"0SW4$0B :3S) NP'@$YZ9Q2R7MI$4$EU"A<97=(!N'J/6@!FH:;8ZM9O9
MZC9P7=L_WHIXPZGTX-16VAZ39Z4VEVVFVD6GL"K6J0J(V!ZY7&#FI+RZ*PW$
M5K/;"^$3-$DSX ;'!8#G;G&?:L[PYJE]<>&(;_7_ +';W(+B62!B(&57*JZE
MN=K  C/K0!8LO#6A:;I]Q866CV-O9W((G@C@54E!&"&&.>..:M/IUC*+426<
M#"T8-;AHP?)(& 5_NG!(XJ6WN8+N+S;:>.:/^]&X8?F*K:SK%EH.D7.J:C.L
M-K;H7=F/7V'J3T [F@"86-HMY+>"VA%S*@CDF"#>Z#.%)ZD#)X]ZIZ9X;T/1
M;B:XTO2+&RFFXDDMX%1F'7!('3VJS'J=F^G+?M<PI;%0QD:0!5SZG.*P/'7B
M"\T3P;+K6CS6KE)(1N=/,5U>54RI# 9^;.>1Q0!N?V-I?]E?V5_9UK_9V,?9
M?)7RL9SC;C'7FFW>AZ3?:C;:C=Z;:3WMK_J+B2%6>/G(VL1D<\U9NKVUL8Q)
M=W,-NA.T-+($!/IDT^6X@@MS/--''"HR9'8!0/7)XH 9:6-II\+0V=M#;QL[
M2%(D"@LQR3@=R>2:GJ**Y@GMQ<13QR0$;A(C@J1ZYZ4VUO+6^B,MI<PW$8."
M\4@<9],B@!EEIMCIJS+8V<%LLTIFE$,80.YZL<=2<#FH-1T#1]8GMY]2TNSO
M);<YA>>%7*'V)'%6!J%DTD4:WEN7FSY2B5<OCKM&><>U/AN[:XDEC@N(I7B;
M;(J.&*'T('0T 46\-Z&Y<MH]@=]R+M\VZ_-..DAX^_R?FZ\TW4/#&@ZM?1WN
MHZ-87=U'@)-/;J[ #IR15T:A9%XD%Y;EYB1$HE7+D<''/.,=J5;^S<SA+N!C
M <3 2 ^6?]KT_&@"KJWA[1=>6(:MI5G?"(YC^T0J^WZ9'%7H((;6WC@MXHX8
M8U"I'&H55 Z  =!3#>V@2-S=0[9#A#Y@PQ]O6L74_&VA:3?W%A<7,SWMN$9[
M:"VDEDPP)!"JIR, Y(X'&<9% &S%8VD%W<7<-M#'<W.WSYD0!Y=HPNX]3@<#
M/2J;^&M"EUA=7DT>Q;4E((NC;J9 1T.[&<^]8FM^*-,N?#.F:Q9>)&T^RN[N
M-(KJ*V\WSB2P\HJ5)7)!!. 1CM6CKGC+1/#UVMI?W$OVAH_.,5O;R3,D><;V
M"*=J^Y]* +6I>&M#UBZBNM3T>QO+B'B.2>!791UQDCI3]5T#1]=ACBU;3+2]
MCC.8UN(5?8?;(XJC?^--"T^TL;EKM[A;]#):K:0O.\R@ E@J G !&3VK(U_X
MDZ3I6FZ)?V9>\M]5NTA1XX)& 3=ASPN=XP?D^\2#QP: -G7=&FE\+R:9H=OI
MD6T*([6ZMP;9T!!,;*!P",C('%8'AOPE>1^(DU6_TG2=)M+:S>TMM.T]MZDR
M,#([G8HYV@8Q]:U8=:MKGQQ;6L6N3 S:6+I-):T*@H6XF+E<@]MA(^E)+\0_
M#,-\]L]](%CF^SR7(MI#;I+G&PS;=@.>.M &X=(TUM.CTYK"V-C%M\NW,2^6
MNT@KA<8&" 1Z8I'T?3);JXNI-/M6N+F+R)Y6B4M+'_<8XR5]CQ6;JGC30]'O
MY=/NKF5KZ)$D-M!;22R%6W8(55.1\ISCIWQD4UO''A\:#:ZRE\TMG=OY5OY4
M+O)(XSE1&!NW#:<C'&* );7P7X6LKJ*ZM?#FE07$3!XY8[.-61AT((&0:L3>
M&M"N=735I]'L9-10@K=/;J9 1T.[&<CL:DT;6]/U^Q^V:=.98@[1L&1D9''5
M65@"I'H16A0 UT26-HY%5T8%65AD$'J"*R+?PCX;M($@M]!TV*))Q<*BVR "
M4='''WAV/:HM6\8Z)HNH-I]Y<R_;1$LPMH;>261U8L 555.?N-TZ8YQ0GC30
M)/#@U];\?V>7\L/Y;;S)NV[-F-V_/&W&: -$:1IJZ:^FBPM18R;M]L(E\MMQ
M);*XP<DDGZU!J7AO0]9,!U/2+&\-O_J?/@5]@]!D<#VK#U/XB:1:^$]4UJU,
M\LE@I5K:2VE21)=I**Z%=R \?,1C'>K_ (?\9:5X@DM[6"25+Z2T%V8);>2(
M[,[21O49&[B@#:M+&TL$D2TMH;=9)&E=8D"AG;JQQU)]:J3>']&N=6359]*L
MI-01=JW3P*9 /][&:CTWQ+I&KRZE'8WJRMILS0W?RE?*<9R,D<]#R,C@UGR^
M/_#L=E87274\XU",RVL5O:2R2R(#@OY:J6"^Y % %'Q#X5D$&GV^C>'_  _>
MZ7;,YDTN\A6--S<AXV",%.<Y&.<U+X9\(&VL-4.OVUA/-J=V+F6UB3?!"J*J
MQHNX#.T(#G Y^E:/_":>'O["AUK^TD_L^:=;=92C?+(6V[6&,J<]<@8[U@7G
MC3^T?$'A'^Q+N4:=?WMQ#<![<IYH2(L,;U!QG!!'6@#L]0TVQU:S>SU&S@N[
M9_O13QAU/IP:BMM$TJRTLZ7;:;:0V# JULD*B-@>N5Q@Y[UG:CXDTQX-=LX-
M4:WN--M'DNKB*!I!:?*2&/!4L!\VSD\=*K6WB_1M,T#19]0UMKG[?!NM[IK=
ME:ZVJ"3L5>"<C"XR2< 9H V=)T'2=!A>+2=-M+&.0[G6WB5-Q]3@<TNJZ)I>
MN0)!JNG6M]$C;U2XB60*WJ,BJ6D^+]%UFUOKBVNFC73_ /C[2YB>!X!C=EE<
M @8!.>G%4K+XB>&+Z6UBBOI5>[E6*V$MK+'YY;."FY1N7C[PX'&>HH Z&WL+
M.T:=K>UAB-PV^8QH%\PX RV.IP /PJC=>%] O;"VL;K1=/FM+4Y@@>W4I%_N
MC&!^%:U<]J_C?0M$OY+&ZN)WN8HQ+,EM:RS^0AZ-)L4[1]: +LGAO0YEO%DT
M>Q9;U46Z!MU_?!?NAN.<=L]*NV5E:Z=9Q6=E;Q6UM$-L<42!54>@ Z5D7_C3
MP]IEG87EUJ4:VU^C/:RHK.LH5=YP5![=!U)X'/%:FG:A!JNG07UMYGDS+N3S
M(V1L>ZL 1^- !:Z;8V,US-:6<$$MR_F3O%&%,K_WF(ZGW-/DLK66\AO)+>)[
MF!66*9D!= V-P!Z@' S]*Q-?U**S\0^'[9]<DL'NII%2T6V$@O, ?*6P=F,Y
MSD9S4-_\0O#>G2W<4UY,\EG*T5RL%I+*82H!);:IPN"/FZ'G'0T ;<ND:;.+
MP3:?:R?;@%NMT2GSP!@!^/FP..:KVOAC0;$6GV71K"'[&S-;&.W4&%FX8KQP
M3W/>N(^(WC]],M]!M=#U"2!M5N8"U[%9-.%MGS\T?RE6;@?+R?;FN@7QEI&C
MZ?I]O>ZA?7UY/!YJA;"0W$B X,CQ(F4&?4"@#H8M+L(-1GU&*RMTOIU"S7*Q
M 22 8P&;J0,#\JK:AX:T+5KV*]U'1[&[NH<".:>W5V7'(Y(JK)XU\.Q:)9ZR
M^IQC3KR800S[6P7.>#QE?NG.<8QS58_$'PVMK:7#WDT:W@D-LCVDH>780&VK
MMR3EEP,9.>,T =.0",$<51_L;3/[*72_[/M?[/4 "U\E?* !R/EQC@C/UKGC
M\3?"WV%KH7EPPC9UFB2SF:6#;C<9$"[D R.2 *TM0\8:)IMC87<MT\R:@N^T
M2VA>9YUP&RJ("2 ""3CC- %G5?#>B:Z\3ZMI%E?/%_JVN(%<K[ D=/:M&**.
M")(HHUCC10J(@P% Z #L*XWQ!\2=*TKP[I^KV1>\BOKI((BL$A 'F!9-P"Y5
ME!.%."2, 5<&NVMUXPTF"+7)X?M=DT\>EO9E?.7GYV9EW(1_=..G2@#5O_#6
MA:I?Q7VH:/8W5W%CRYIK=7=<=.2.U7(K"S@O9[R*UA2ZN HFF5 'D"C"[CU.
M.V:Y^[^(7AJROI[6:]EQ;R^3/<+;2M!#)TVO*%V*<GG)X[U:U7QCH>C7_P!@
MN[J0WODK.MO#!)*[HQ8 J$4[ONMTZ 9/% %'Q1X3748M/&EV=I$RZU;:A>':
M$\T(V78X'S-CUZUM:5X>T;0VF;2M*L[%ICF0V\"QE_K@4NB:YIWB'3$U#3+C
MSK=F9,E2K*P."K*0""#V(I^KZQ8Z#ILFHZE.(+2-D5Y"I(!9@HZ#U84 0VGA
MK0K#4Y-3M-'L8+Z7.^XBMU5SGK\P&>>_K23>&="N-735IM'L9-10@K=-;J9
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M+=7$:VEN;N59K.:-C".LBJR@LON :T[SQ!I5AX>.O7-VJ:8(5G^T $@HV-I
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M8 ,& P<J>#R,4 7M-TNPT>S6STVS@L[922(H(PB@GJ<"K=%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<-\68XF\#-)*B$)>VAW,!\H\^///;BNYJ&[L[:_M9+6\MXKBWE&'BF0
M.C#T(/!H XB&YA?XP+9SB+[&-&)TU1@QE_-(FV]M_ !QS@?6IOAY!+9W7BFT
MAXTF'5Y%L5_A3*@R*GHH<D8' .:ZBYT/2KRU@MKC3;26"WQY$;PJ5BP,#:,?
M+QQQ5NWMX+2W2"VACAA082.-0JJ/0 =* .-^+>C7FN_#/5K.P1I+@*DRQ*,E
MPCAB .YP#@>HKHM!URPUW0+75;&>-K:6(/D,/D..5;T(Z$=L5J5D-X6\/O?/
M>MHFG&Y=MSRFV3<S>I..3[T <SK6IK<?$;P@)CG2+B.Y,#./D>Y &P\\9V[M
MI[[N*YSQ!IZQ'XH6\4*'21IR7'EE04CNS$Q8J.@; 5CCN0:]7OM.LM3MC;7]
MI!=0$AO+FC#KD=#@]QZU$=%TLZ>VGG3;,V3'+6Y@4QD^I7&": /-[[1=+75_
MAP5L8 ;D2).P09F4VI)#G^,$@9!SFJ&LV%G!:?%JQBM8$M88()XX%0!(Y#;9
M+!>@.0#D5ZHWA_16-L6TBP)M1BWS;)^Y'^QQ\OX5C>*_"\-YX9UNVT;2[*/4
MM3MG@:98TB+%AC+L!D@?C0!R>H:!I]E=?#[4]#MHH=4FO(EEEA'SSV[1,TQ<
M]7& .3GK[UE:E?V%QHFEWVG206]FWBN.1%GDWW+R?:")'8Y&P=?EP3MVY(SB
MO4O#VAVFF:?:L-,M;6]6!8I6B1<\8R P'0D9_P#KU(WAG0'-R6T336-TXDG)
MM4/FL#D,W')SSD]Z .+T[1M&U+XG>,1/8VES"]G9289%9&++)E\="2/XNO/O
M65I6D7&L?!#PWJ=F@FUG1XUO;$L,EC&QS']&4;<>N/2O3O["TC[3/<_V58^?
M<#;-+]G3=(/1CC)'UK,U'3]7TZ*TL/"5CH]G9R;Q<,ZF/R"0,.B(,,>O!QG
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M6\0NFC$1FV#>4!R%W=<9)./>HFTK3FM;FV:PM3;W+L\\1A7;*S=2PQAB>Y-
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M8J2J]A9QZ=IUK8PY\JVA2%,]=J@ ?RJQ0 4444 %%%% !1110 4444 %%%%
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M"M(%V!N1].^*FL+NWMOC#XJAGGBBEN-/M/)1W"F3 ?.T'K^%<V45/V9+$*H
M\JV;@=S=(2?SH ]&U?QGI.C:B=/D6]NKQ(Q-+#8VDEPT2'HS[ =HX[\U/#XK
MT:Y71WM[P3)K!9;)T4D2%5+'/'RX /7'(QUKF=#U&QT7XA^-(]6NX+2:XDMK
MF)[B0()(!"%RI/4*0P/I7(Z)+'8P^"M5N6%MIDVOZA+!)+\BI'*LOE]>@;J/
MK0!Z;K?C#3M&35483S76FVBW4L,4+.=C$A3P.F5.?0#)XI_@[Q'_ ,)3X8LM
M4-O-!++$AE22!XUWE%8[-P^9.>&&0?6N&OM0M=5\4^/WL9EN(U\.+%YD1W*S
M 39VD<'!...X([5V'P[O+6[^'OA\6UQ%,8M.MXY/+<-L<1+E3CH1Z4 8.@>(
M+^ZUWXB0:AJ4R6>F2*+=U0$VR>6Y8J,<D8SSGI6M8>,=%TSPKHEY>:Q<7<-^
M"EO=S0$/.P#-RJC@D*0!CDX Y-<=I'_(3^,'T_\ :,E5]#17\)?"<,H(^W9P
M?41RD?K0!W,?Q)T"47$:)J1O8&"R6']GR_:0",[O+VYVX_BZ=/44S6?%6DWF
M@:%JUKK]S96=]?Q1P36\&XSL=P\I@02H)!!/&,5%I*)_PN/Q(^T;AIEF,XYY
M:3/\A^5><7O'PS\) =!XP( _[;ST >G0>.XI_B'=>&!97>R&!#YWV23_ %A9
M@<G& F ,,>"<\U9L?'V@ZCJ<-E!+=8N)&AMKE[61;>X=<Y5)"-K'@]^<<9K!
M34(-.^,?B S21B:31[<P1,X5IB&?Y5SU/;BN3;6&N[#P3?W?B:VE%QJ=M<MI
MEK!#'!9J2<Y(&Y=I8+\S<DF@#N-(\?P:]?>([$P7UG%IY=8[DV<@*JL8+,Q8
M8#!B<*>2 .*N:7XKTG3_  -IVKW.L7-_;3GRX;F2 ^==.6("B-1DMP1@#MFN
M:T:[MH[OXF6;SQ+=/<RR+"7 =E^SCD+U(]ZP?#<D=CX1^%FIWK+'IMO<SI/(
MYPD;NLBQLQ[#=QD^M 'IUEXUT:]M-2FW7-O)IL)GN[>ZMGBFB3!;=L8 D$ X
M(S4%K\0O#]Y?V5K%+=!;YA';7+VDBP2R$9V+(1M+<'C/48ZUR'B:ZM]4\6^)
M[K3IH[BWM/"%Q;W,L+!E$C,61"1QG:&/XU9U=%C\ ?#M44*%U+2< #IP* /3
MZY[6O&FD:%?-9W7VR6:.(33"UM))Q!&<X>0H#M'!Z^AK6MM3LKN^O+*WN$DN
M;-E6XC'6,LNY<_4<UPWB=[>S\1ZGJ&D>*K;2=8AM(S>V=]&&@N8U#&,D-@]V
M&Y"<=.M %\_$.U;Q[:^'H+:YFMY[);A;F*UD<,79 C @8\O#'+] >,]:M77Q
M%\/6=W<122W;06TOD7%[':2-;0R9P5:4#:""0#S@=ZYC2-:AN?BEH>HWHBT\
MW_A.,I#(P0!VF5O+7/4\\#K6?I6K:9IOP-UC2=0N8$U."*^M+BU=QYK7#O)M
M&WJ2Q92/K0!W^M>.-#T'4!I]Y-.]X]NMQ'!;P/*\J%BHVA0<G*DX]!FF:GX\
MT+2;V6UN9+IC;JK74L-K))':AAE?-900F1SSVYKEO#UG+;_%318;U/\ 2[;P
M9$C[NJN)@K?CUK+*-!>>.+;4/&,>BP-?S2W%K+:Q.9()(UVN"WS,"OR@#NN.
MM 'HFK^,-)T>^M[&4W5S=SQ>>L-E;/<.(LX\PA <+GOW[50^'VN3:_8:U=R7
M?VJ%-8N8K5\# A!&P#VP:Y[PY+8>&?']W:ZCJ")&^@V*V=S=D1>;'$&5S\V,
M'."1UK2^%-Q!=:3K]S:C%O-K]Y)%QCY"P(./H10!KZMX]T'1=0GL[F2Z=K4*
M;N2"UDECM0PR#*Z@A>.>>U3:KXRTC2KJ"U)NKRZGA^T)!86SW#^5_P ]"$!P
MON>O:N3T'7-&\/?\)U;^(;FWBD75;BZE@G*[IH)$4IA3]\%1M _"I= U#3M,
M^(^MR7ACTZ&_TRQFT]+G$($*(P9 #P"I(RHZ4 =++XY\.PZ'9:T^H#^S[R?[
M/%+Y;<28;Y6&,J1M;.1U%4X_B1H$CSP!-2%["5_T%M/F%PX8$AECV[BN >>W
M?'%>?1*EUI^GWJ*&L;[X@BXM&Q\KQ'< P]BRL:[A$7_A><[[1N'AN, XY_X^
M7_P% &DWC[PXF@6>N/?%+"[G^S)(T3 K)\V59<94C8W7^M.T[QOHVI27T2F[
MMKBR@-S+!=VLD,GE<_.%8 E>.U>77$]M::#:W%W@6L/Q!D>0D<*HDD))]AU_
M"NF\07$&M_$)AI,T=VUOX<O%N&MV#@>85$:DCN2"0* .VE\4:5#H5AK+SL+*
M^,*P/Y9RQE("<=1G<.O2L;2?'D.I>.=7\/&SNHTL?+59FM9 -VUV<NQ&%7"C
M:3C=GC-<3=Z[I=Q\*/!-E!?0371GTQ##&X9T*.@;<!R ",9/<@=ZTI'$GC/X
MH:=%,B:A>Z?;):1%P'E;[*X^4=3@XZ4 =AI?CO0]7U&&SM9+D&YW?99I;62.
M*ZV\MY3L &P 3QVY%.L/'.B:IK?]D6,EQ/="66&39;OLB:/<#O;&%R58#/7'
M%<+X?AMM3LO!JW'CA;@1R036FFQ6<0=7CC.4.P;E"KN4D\>M=#\+8T2R\3NJ
M@,_B*]+'N?G H J?%3QA?:"ND:9IDM[:W%_?0QS74%DTNV%BP81DJ5,G'"\M
M[<UI:7JL'_"2Z+8/X@U:2YET]Y5LKRT$9G4,P\R3Y%*L,8QQT'%9_P 5O^/O
MP/\ ]C+:_P!:9JG_ "<'H7_8%F_]#:@"7P7XKF9?&MYKVH_Z%I>L7$4;R  0
MPKT48'/ZDUT6F^-=&U'[6-]S9O:P?:I8[ZV>W80_\] ' RO'4=.]>2)%-)X3
M^(K12-&L/BKSI75-^V-)T9FV]P -V/:NJEMM)N]3N;G6_&G]M)#HUR)XK:T0
M;;63:'8M"#Z @'G@D=Z .RT7QGI.NWHL[;[9#.T1GB6[M)(/.C! WIO W#D=
M/45T%>=>&]3N=/\ $^G:*/$-GXBTZ>SEEM[A43[1:(FS&]D.&5@0,D DBN[T
MW4K/5]/AO]/N$N+28;HY4Z,,XX_$4 8D_CS0;?57L7FN,1SBUENEMI#;QS$@
M"-I<;0V2!UX)P:34_'FB:7J%[I\AO)[VS"M-!:VDDSJK+NW84'Y0",GH,XKS
M2RLUF\(:II&K^-AIT7]H7%O=:?\ 8XGE#M.Q7;QYC%MRL"/7CI7<>%XU'Q0\
M<E@&<+IZEB.2/):@"XOQ)\,R/9F*ZN)+:[:.-+Q+60VZN^-J-)C:K'(X/3OB
MK.L^.=$T._FL[IKN22W19;IK:TDF2V0]&D900HP">>W->;1(J?LS6.U0/WT#
M<#O]N7FM3Q-K$]Y/XSB?7HM)2S7[*EC!;Q-/?%H 06+@LVXMM&T# '6@#LM4
MU>S3Q=X;MQK=Q UZLS06D,8:*\ 3.6;!QM'(Y&:S?!NM:CJ/COQO87=T\MK8
M7-NEK&0,1!E8D# [X'6N3CFCN/%OP>DBD61?[.G&Y6R,BV4$?G6[\/\ _DI?
MQ&_Z^[7_ - >@#J]8\7Z1HFI)IMT]P]])!Y\5O!;O*\J[MN%"@Y.>WH">@K*
M;XH^&18?;5EO9(4S]I\NQE8VF"5/G +^[Y!Z^G%13HK?'"S8J"5\/2D$]OWZ
MBL/38T'@OXI$(,MJ.I[N.O[E: .VU;Q=I6D&T1VN+J:[C,T,%C;O<2/&,9?:
M@.%Y')]:BN/&^AP:78:A%-/=QZAG[)':6[RRR[?O811D;>^0,=#7GFGI=P^(
MM#D'B-=#6X\+6:P3R0QNLNPDN@,G (W*V!V/M5VUT[14TW2'LO&KVVI/<WMS
MI^IO;*D4I=QYZ;6 1E+8( (SC*\"@#LY/'>A+I=I?1R75Q]KD>*&W@M9'G9T
MSO7RP-P*X.<@8_$4Z3QSH2:+;ZHLT\D=Q,;>*".V=IWF&=T?E8W;AM.01QBN
M,AU*'Q!:Z=->^(+;1M?M+R\ALM3M8P;:["E5D;#_ "D,"O&[.5)!XJ./Q7J.
MH#1K*6_TNPEEU"]@DUN*!&C?R5'S1;\J&?<03S]UL9H [F/QMH3^';K7'NG@
ML[20Q7 FA=)(I 0-C(1NW9(XQSD4W3?'&BZGJEOI<;7<&H3J[K:W5K)#(%4
MEB& P"#P>AY]#7D[WD/V35[F74VU"VM/%=A=W5S(J*9+<+&/-*J -F<8(&"
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M;*BA0MUM4#L/LS<5R.FV0N/!-SH^K>-QIZ?;I;:XTX6<3RK,;@E0./,8L2K
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M(B@#)))P /6NFMO'.CS66HW%S]KT]M.C$MU!>V[1RHASM8+_ ! X(&,\\=:
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M0!MV6CZ9IC2M8:=9VC2_ZPP0+&7^N ,TW1=)AT/1[?3;<EHX00"0!DDDDX'
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MC:5YMS+_ &;9^9=#%P_D+F8>CG'S?C7+:AXMTC4AX>O(-6U&T@N]4-M;BWC
M6Z=6*E'R#\A(/(Q3;?QW)?>+_$&@+IU[&EA"HCG^RN-K[)&8NW15.U=A[^]
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MM$+7GA^.&\ 7J\&-LR?0H2?^ UU?P]3^TUUCQ;(#NUN[+6Y88(M8OW<0QVR
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M6L$ODG='YD8;8?49Z?A0!XCI5];6VE>']0NKIFM+#Q5=&\DN,*\7F&41R2@
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M'4%>.G!J6@#Q.6]M4\&?%73GN85OCJ-[,+8N!(8RB8?;UV^]=;XI54/P^50
M%U:  #L/(DKMFTZQ>>2=[*W::5=DDAB4LZ^A..1[5*T$3^7OB1O+.Y,J#M/J
M/2@#RK1-=TG0/ GBC2M8O+>#4;>ZOA-;2N!),9&9D*J>6W!EP1UJ*TM;?2M.
MT56\5?\ "->)K/0[9)UNU7R9X@"0K*^ Q5MP)4Y&?I7JLNG64]U'=36=O)<1
M_<E>)2Z_0D9%%UI]E?;/MEG;W'EG*>=$K[3[9'% 'D=OJ5[J'B?2]:O]>_X1
M<ZGX?A*2"*+RY&21RZ S*0.'5@.N#WQ7?> K6RM_#7F:?J4VI6]S=3W NI8A
M'YC,Y+%0 !M+9(P,'/%=!=65I?0B&[M8;B('(26,. ?7!J955$"(H55&  ,
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M&(5$LX)4XP JE@^#@#!XXK?\,ZG8ZK\7/$MSI\L<\ T^U3SHCN21@S@E6'#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*HZ1K%AKNG)J&FS^?:NSJLFTKDJQ5N" >""*O4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !3617 #J&P<C(S@^M.HH :44N'*C>!@-CD"F"VMUN#<""(3L,&0(-Q'U
MZU+10!&T$+RI*\4;2)]URH)7Z'M2I%'&I5$55/)"C I]% $<%O#;)L@ACB3.
M=L:A1G\*2*V@@+F&&.,N=SE% W'U..M2T4 -1$C7:BJJ^BC IU%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPVJ6!P#QD_[.!UJ*_P# ?B*ZT?Q!X?@U'3H=*U.XN+I9]CFXW2-OV,/N[=V
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M .,XZ=JNT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP !W)KB%\=_#J774N_[0TXZA_J%OFMB!_NB<KMQU_BQ1\6'<^#HK+S&C@O\
M4+:TN74X(B>0!N?<<?C75SZ-IMSHKZ/+90G3FB\DVX7";,8P!VH N@@@$'(/
M0BEK@K^.YN/&.G>"M,U"ZTK2[/2?MDC6K_O7 ?RHXP[!B ,$D]3Q7/ZQXCU_
M1O#OBW2X]4EGOM&O[)+6]F"[VBG>,A7P "0"RDX&0: /7:*\TO;+7M/\=Z5H
MD7BO4Y+75[6>2Z>41EXFB*G,/RX3.[&,' SWP1EZAKOB#1_"/B^S@U>>XN](
MU:V@L[NXP9#'(\)VN0!G[[#/H: /6+JSM;V-8[NWBG1'615E0, RG*L,]P>0
M:GK@)!JWA;QMX>ADUZ^U.TUAIH+J*[V$)(L9=7C"J-HR",=,&N?C\2SVVLZ3
M=6WBC4]5N+K5TM+E%LW&G&.1RFV-BFT%?EP0Y)(/7- 'K](RJZE6 92,$$9!
M%>9V\6N>(KKQAN\2:A90Z;?R1V:6I12"(D;YB5)91D87CJV<\8+'Q3JZIX#U
M^]NF.GZO;K97\> $6X=<QR =B6!![<B@#T/3],L-)MOLVG65M9P9+>5;Q+&N
M?7  %4_$/B33/"^F"_U29HX6D6&-4C+O([=%51R2<&L?0]1OM9\>Z_*MRXT?
M3%CL(HA]R2XQOE?ZKE5_.N:^,VG/<?\ "+3C4+R$/KEK;^5$RA%)+GS "I.\
M= <X]J /2=.OEU+3X;Q(+F!91D1W,+12+SCYE;D=*M5Y[Y&I:KXQF\,)XAU2
M"PTFQCFEGC=!<7,LK-C<^W&U57H ,]ZPM2\3^([3PM>V<6IL^IZ9XCBTU+MT
M ,\3%2OF   G#8.,9Q0!Z_16=HFF3:3I_P!FN-3O-2E+EVN+LJ6)/8;0 !Z#
MM7GWC?6I+74M;>+Q5JD5W8VPDM+'2[-I(X&";O\ 2"(V!W'U(POYT >I45YO
M]NUCQ)XSTW3H]7N=.L;KP['?SK:;0^\R8^1F!V]1D^@QWS6<VK^([3P9KMS!
MJ=S=W'AG7&4NX7?=6D>QF23 P3M<\\?=% 'K-%<7?ZY<:QXT\-Z9H]XR6;6S
M:K>O'CYX,;8E^C,<_1:D^*&JW^B?#^_U#3)VAO(I(/+=?>9%(_$$C\: .PHK
MS+Q)>7OA9=&TB^\3:HW]K7,LUY?QP>9+&B1J3'"J(=BEBO8D#/-067B:X;P_
MX@MO^$CN[>QM+F!;76+ZS=9S%)C<BJR O("&4':>HZT >J45Y-9:_K2IXITW
M0;W5]1>#3HKJQ;4K4I<H[,ZN%#HI<84%<C&>.:DM_%<6D^&O$.KZ5XGO-6^Q
M66YK#58\7%O<9P&/RJ0O/(P1QP: /5:*\WOH];\'KX>U67Q%?ZBUY?6]IJ%O
M=;#$PFX+1J%&S:Q! !Z=:J1+KVNV7C&\;Q+J%F-*U&[BL8[8HH&Q0PWY4EEY
M "\=_7@ ]3K-OM<LM/U2PTV5G>\OV80PQKN.U1EG/HHXR3ZBHO"NI3:QX1T;
M4[G'GW=E#/)M&!N9 3C\37-^&6_M'XD^,=5G^8V/D:=;Y_Y9QA/,<#ZLV?PH
M [NBO$M/\<W5U86/B"+6]8GU6XND:325L)#:?9VDVF-3Y>,JASOW<D'KFNA\
M1^)M<\(:]<Z.DOVZ376']AO,RC[/,2JO&_\ L+N#@_5>: /3**X#4%U;^V?#
MW@U-=O8R]G+=7^H1[1/-L*J I((7+,2<#H *H^(M0UKPIIEAI.H:_</%?ZF8
MH]2B@,EU':!"Y4A4.9,C;N"G@YQQ0!Z;17C5]XMU.S\)^+5TK5=2NH;*.UFT
M^_OK9XI07D"O&2Z+NQCKCH^,\5T5]'K/ACQ)X>:7Q#?WT.L7#V5Y%-LV)(T;
M,KQ *-F"IXYXH [Z&Y@N/,\B:.7RW,;[&#;6'53CH?:L_P 0^(],\+Z9_:&J
M3-'"9%B0(A=Y';HJJ.23@UQGPFT^6&/Q%<R:G?7.-9NX#'.ZE25<?O#A0=Y[
MG./854^-&G//#X9G&H7D(?7+6#RHV4(I.\^8 5)WCH#G'M0!Z3IU\FIZ?#>)
M!<P+*"1'<PM%(O./F5N1TJ"/0-&AU)M2BTFQ2_8DFZ6W02DGK\V,UQQ@U+5/
M&,GA9/$.J06&EV$<\UQ&Z"YN997;;N?;C:JKT &>]86I^)_$5EX6U&RBU-I-
M3TOQ##I\=VZ@&:)BI7S   3AL' &<4 >OU";NW$TD'G1F:*,2/$&!=5.<$CK
M@X.#[&JFB:9/I.G_ &>XU2\U*4N7:XNRN[)[ *  OH.U<%I>FS-\8?%<K:MJ
M!6"TMY!$778X<2'8PVYVJ2< $'U)H [_ $75[37]&M=5L6=K6Z3S(RZ[21[B
MK]>'Z.FLZ'\'M$\46^OWJ26PM]MBNS[,T33*A5EVY)(8DMGKTQ6MKOBDW?B7
MQ!;R^(M7TMM-=8+"&PLGE1I/+#EY2L;!LLP&TD<#WS0!ZU165X:U*XU?PQIF
MHW<!@N;BVCDFB*E=CE1N&#R.<UJT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DZ]:ZQ<6\$FB7\-
MK=0R[REQ'OBG7!!1\?,.N00>H'6M:LW6=;M-#BM)+L2%;J[BLX_+7/[R1MJY
M]LT <E+X O[^SO[N]U"U@UVXU"#489;6$^1!+"H5/E8Y;(SN)(SN]JT]-\.Z
MS<^*+?7_ !'=V,DUG;O!9V]C&XC3>1O<ER26(4#'0#UKK** /,U^&%ZOPJU3
MPA_:-O\ :+RZ,ZW&P[5!E5\$=?X<5NZGX8U:+6+#7- O+.+48++[!/'>1LT,
M\60P^Z05(;)'UKKZ* . U7P'JVKZ'H]M>ZV+F^M-:35;B:16V$#=F*-<G:HW
M  >WO6H_AS5;;XAR>(;"[L_L=Y;1V]W!/&QD 0D@QD'&3GO75U@>(?&&F^&[
MNQLKB*\NKZ^+?9[6S@,LCA1EC@=A_GI0 >+="N=>TRV2QN(H;VSO(;VW,ZEH
MV>-LA7 YP>>E<Y>>"/$.HWFK7EYJM@TVK:1)ITZ)"X2#(;R_+Y)(!;)SR><8
MZ#L+/6%O=5NK 6&H0FW1',\]N4BDW#.$;HQ'0CL:-:UNTT&U@N+P2%)[F*U3
MRUR=\C!5S[9- &3J?A:>^TGPU9K<QJVD7MK<R,5.)!$I! ],YKD_&.G6'BOX
ME:'8:=>)-(L;KK20L&7[+'(LBI(1T)D7 '7DUZI5>VL+.R>9[6T@@>=M\K11
MA3(WJV!R?<T 6*XD^&/$NG7.I6V@ZO8VNF:A=/=%YK=GN+5I#F3R^=K9.2-P
MX)[UH6OCG3;_ %;4=/L+34KLZ<9$N)X+5FB$B#+1AN[]L=S6WIE^-4TV"]6V
MNK83+N$-U$8Y4YZ,IZ&@#+L/#\MIXTU776N%>.]M;>!8\?,ICW9)[<[JPG\
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MI(P#COS3)==TO3Y]%L8L%-4)CLC;J#'A8R_4<!=HXQ6Q0!PG_")^(C;:'?\
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MS+4FZ1!()!$K[MN 1@-MR!0!0T^UU+QKJ'B.[?7]3T]+'49=/L8;*;RTC\H
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MPKI=S:W!D*9\PQ,&;OU8Y.?>M-_#[OX[A\1_:%"1Z:]CY&WDEI%?=G/^SC%
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MDU&-Y81(;=78;%*G@_(HX[;J] &<#)R: %HHHH **** "BBB@ HHHH ****
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CB@AMU*PQ)&I8L0B@
MD\D\=S4E% !1110 4444 %%%% "$!@00"#P0:CM[:"TA$-M!'#$.B1H%4?@*
MEHH **** "BBB@".&"&WC\N")(DR3M10HR3DG ]ZDHHH *A-K;FZ%T8(C<!=
M@EV#>%],]<5-10 4444 %%%% !4<\$-S$8IXHY8VQE)%# XYZ&I** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\0^(-1T_4;+
M2M&TG^T-0NU>3,LOE0PQKC+.^#U)   R:Z*L'Q-XC.AQ6UM:6IO=7OG,=E9J
M<>8P&2S'^%%')/;\: &>%O$LVNG4;2_T_P"P:GILX@NH!+YB\J&5E; R"#GH
M#70U@>%?#TNAVEU-?7(NM5U"8W-]<*N%9\ !5'9%  'T]ZWZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KGM>\%:)XDU""_P!1BN3<P1F*.2"[
MEA(4G)'R,.]=#10!CZ#X:T[PXLZZ>;K$Y4O]HNY)^F<8WL<=3TK8HHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>josetrevejo-tarsussepara013.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**3(SC//I0 M%%% !1110 44@((R#FEH **"0!DG HZT %%%% !1129&<9Y]
M* %HHHH **** "BBB@ HHHH ***0D 9) ^M "T444 %%%% !1110 4444 %%
M%)D9QD9]* %HHHH **** "BBB@ HHHH **** "BDR,XR,^E!( R3B@!:***
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M!CCJ"1SC%):R+'^T+JDCL%1?#JL2>@'FKS7,:=>7VM_!/3?"5KHNI-J%]!'
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MJ5@23U:8G:4![@\U'=C5/#WC>S\1:E8SWL-UHZV-X^F6SR^3.C[\[!EMAW,
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M$*0<YJ_IWB,ZGXLU?1H+3]QIB1"6Z\S[TKC=L"X[+@DY[XQ7#:CIMUIOP?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%<_P"+_$K^%M+M;Q+)KPSWL-KY2-M8^8V,CU/MQ]10!T%%<?8^+-4M_$CZ
M/XCTVTLM]B]]#/:W1F78A =6RBD,,@Y'%9@^(&LQ:);^*+O0;>+PU.Z?.+LF
MYCA=@JRLFS;CD' ;(!H ]#HK@=+UOQ)<_%G6M,DAM3IEK;P?+]I;*(QD*NJ[
M,%VX!&1C Y-=+XJ\01^&/#MSJKP-</&52*!#@RR.P55SVR2.>U &N75652P#
M-]T$\GZ4ZO,KR]UR;XF>"(-<TVUM9<WLD;VEP98V'V<Y4Y52&''J#G@UM1^.
MI'^&=WXN_L]0]NL[?9O-X;RY&3[V.^W/3O0!V=-$B-(T8=2Z]5!Y'X5Q6J>-
M-73Q7'X<T;18;R\ETZ._62:Y,<:*796W?*>!@8QR2WU-0VVO6<'C_P 8Q1:+
M#'?:?80SS7@D.ZY'E[@I&. .F>: .]HKSRW^(&M-INAZY=:!;PZ)J<L$);[6
M3/&9< /LV8V;CZY(P<#I5^;QAJUQJ^KQZ/HD5YIVCR>5=S/<E)9'"AG6)-I!
M*@C[Q&3Q[T =I30ZLS*&!9?O 'D?6L?PCKS>)_"FG:TUN+<W<?F>4'W;>2.N
M!GI7%V=]KD'Q+\;P:%IEM=S;[.21[NX,,:C[. %&%8ECSZ 8Y- 'IU%<5I7Q
M 75F\+^7IYB.M27,,R/)\UM)"K%EZ?-\RD=N.:DUCQT-&O?$4,ECYB:/9P7"
ML)<&5I2RA3D84 @<\]?:@#L"0JEF(  R2>U(CK(@=&#*>A!R#7)/K&M#1]97
MQ#H-H(8M/DN%>UNC+#.NUMT3$JI!P/0@@UCZ9XT%AX0\'MI/AZ,+K#-!!91S
M[5A.UF W$=,CDXX&3SC% 'H]%<5:^-[JQGUZU\36$%G/I%FM\6M)S*DT)#?=
MW*I# J1@CFGV'BS6(=2TZ#Q!HUO8P:I&[6CV]R96C=4+^7("HPQ4$Y!(R"*
M.RHKC/#OBS7-92PU*70K=-%U!&DBGM[OS98%"EE\U-H SC'RDX)P:=X;\5:[
MKO\ 9U^^A6ZZ+J0+0SP7GF2P#!*F5=H SC'RDX)P: .P=UC4L[!5'4DX I:Y
M'XH_\DP\1?\ 7FW]*JV?BS6;35=#M=5T6"VT[5CY-K*ET7FC<(642IM &X \
M G'K0!W%%<%+XXUNYM-4UC2-!MKK1--EEC=Y;LI/<"+B1HU"$8!!QD\X[5L:
M=XNBU3Q-:Z9:P;K6ZT=-5BN"W)5GVA=N/0YSF@#I:R]?T*#Q!IRVDUQ=6S1R
MK-%/:R;)(I%Z,#R/P((KE]3^(S:;H>N:FVF[UTO6!II193F128QO''7Y^GMU
MJ>X\4^)+<Z982Z)80ZQJ<LWV>&6^/E1Q1JK$NX0DO\V-J@^N: -30_#%MHNJ
M7&H3ZE>:EJMU&L;7-ZZ%Q&I)"*JJH5<G/ ZUT->>^+?[4O/!#>(Y-._LWQ!H
M,CW42B3>I$9_> , "T;H#P0.W'%=SIU['J6F6E_#GRKF%)DS_=8 C^= %FBD
M/0UYY\$KF>Z^&MM+<3232&YG!>1BQ^^>YH ]$HK"_P"$A=/'/_".2VP1)-/^
MVP7&_P"^0^QTQCJ,J>O>L/0?B/#J^D>(M2GLOLT6DAYD_>;O/M\,4DZ<;MC<
M<]* .W,B"01EUWD9"YY(^E-\^(J["5,(<.=P^7Z^E>?V'B*'4/'_ (;2]T""
M'5+[1#=_:O-+/;J23Y0&!GW-<GI__(D?%[_L*7_\J /;U974,I!4C((.012U
MSW@+_DGGAK_L%VW_ **6LZZ\5ZW<>*=7\/Z)HUK//IZ0R-<75T8X]LBDX.%)
MW9& .G!)(Z$ [*BN$A^(<M[X=T2XL=)WZQK$\EM#8R3[5C>(L)69P#\J[">!
MDY'%-N_&.N6]KK^F76F6=OKUA8?;H?+NF:">')!=6*!@5P?E(Y..<'( .]HK
MF/A[?:MJ/@?2KO6%B\^6UB=)4F,C3*8U.]\J,,23D#/U--U7Q%JQ\02Z+X>T
MRUO+FUMTN+N2ZN3"B!RP1!A6)9MK'L ![T ;FKZ7;:UI-SIMWYGD7"%',;E&
M'N".A!YK%TKP9%8:Q!JM]K&IZO=VT316K7SH1 K8W%0BKEB  6.366_Q#GN5
M\-II6C&XN-<2Y"Q2S^7Y$L. RN<'@'=DC^[P#FG1^/YM/TWQ*^OZ=';WN@"-
MI8[68R).)%S'L8@$9/'(XH [FBN&_P"$R\0:?J^A:=K?A^VMWU>X\N.2WO#(
ML0"%BKY0?.,#ID')YXY?J/B_7=,FEO[KP_%%H,5ZMHTLER1<E6D$8F$>W&S<
MPP-V2.: .VHKD+OQ7K$_B34M+T'18+V+2EC-Y)-=&(L[KN$<0VD%MN#DD#)Q
MQUK/T[XAW>N:)HDVE:3&VIZQ)<B&"><I'%'"Y5I'8*3V7@#JV.U '?TUI$1E
M5G56;[H)P3]*Q?#6O3:S'?07UHMGJ6GW!MKJ!)/,3=M#*RM@$JRL",@'M6/X
MLU.QL_''@VTN=)AN[B[GG6WNG<AK4A5)*C'.<@?A0!VE%<%)XU\07<FOC1]
MM9DT6ZDAF>XO#&)@BAL( A^8@GK@#CDYXZ[0]5BUW0;#5H$9(KRW2=4;JH8
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MK.ESQV]WY=R2$63;LEB;;\V=PX.,<^G(!Z@TB(ZHSJ&;[H)Y/TIQ( ))P!7
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MZ+7*ZKX%M-3U*\O8M6U?3S?*JWD5E<!$G &W)!4X..,J10!7^% Q\+?#^?\
MGV_]F-9D%]J'AOQ_XNO[C0=4NM/OFM3;S65N92S)  1M'.,\9Z @YQQ7>:?8
M6VEZ=;V%E$(;6VC6**,=%4# %6: /(;+1-9\/:;X0UJZTF[GDM=0O+J^M+1/
M-EA%R'QA1UVY7.*TK=M5N/$/BW6I?"MU/9W=A:1P65TH1KF-2X<$'(W8).P_
M[(.">/3** /*-,TF58_$4/A_2=9L-#FT::,65\CJ#=G.WR4<DCY<@XXR1BG:
M#H6JV^A?#2*;3[A)+">1KM6C(, ,4@!;TY('XUZK10!YQXF\,:AKOB7Q5##
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M- 'H.BR:O+IP?6[>TM[PL?W=I(TB*O;D@9/KQBM&BB@ HHHH **** "BBB@
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M]2%&<#W- %ZBN-TC7/%SW.G3ZOI%B-,U!"Y:SD=I++Y=R^;NX8=B5Q@UD_\
M"=>)'\,OXQBTO3SX>4F06YD?[6UN&VF3/W <#=M].] 'I%85SX4L;[Q)!K=Y
M/>7,ELP>WM99LV\+A=N]4_O8SR<]3BL:Y\4Z]?>+;S0= M=.8164%XEW=L^P
M!]W!"\DG QT[Y[ X8^(GB=_!K^*AH^G1V%C(8KV!YG,LI5]DC1$<  ]-V3P?
M;(!ZE17%7OB;Q!<^,[WPYH=GIY,%G#="ZO&?8H8L""%Y).!CIWSV%4X/B#?W
M6C6L$=A:Q^(9M3ETMX9)3Y$4L0+22%NI0*,@=>0/>@#T&H9KRVMI(8Y[B&*2
M9ML2NX4R-Z*#U/TKS/Q1XN\0+X+\5VF;&WUC2XD:6XM9'V/!*IVR1'[RN"",
M$\$9STJWJFM7MA/X&@UG3-*O;V_O/+$^QG^S\##QEN0^#R: /1Z*X1O$_BG4
MM6\0V&B6&E@:1<"/SKQWQ*#&KA0%_BY.2>!\O!YQ''X\U'6K/PS%H-C:C4=:
MM7NW^UNQBMHT #9V\MEC@=/>@#OZS;+0[2PUO5-6A:4W&I>5YX9@5'EKM7:,
M<<'FL7PIXFU/6->U[2-5L(+6?23 A,+EED+JS%@3_"0 1QD9P:34O$&MW?BJ
MX\/^'+>P\VRMTGO+F^+E%+D[$54Y)(4G.< 4 =;17G-W\2+^V\,V]\-)C;4X
M];71KRT60E1)D@^6W'4;2,_WJ[;1CJYTY#KBV2WQ8[ELF8Q@9XY;G..M %JV
MO+:\61K6XAG$;F-S$X;:PZJ<="/2IJ\LT[QR=.\#^*=<LM#L;=]/UQ[4P6T>
MP3DR1(9&QC+D/U]A70VWB+Q%9>+]+TG7;+3D@U:.9K8V<CL\+QJ&*N6&&X/4
M <B@#LJ*YCQIXEOO#D>CC3[**\GU'4$LA'(Y4 LCD'(Z<J,G!XSQ6=#XKUS3
M]7U+1]=M-/\ MD6F/J5I-9L_ER*IVLC!N00<=.H/:@#N**\ZL/'FO/X-7Q1?
M:78I:W4,*6%K'*PEEGD94&XD;50L<CJ=O)]*M-XPUK2I-2LM9@TR2[BTJ;4;
M26Q=S%)Y0^:-@W(()7D'D'MB@#NZ*\ZB\;^)(--T/Q!J6F:='HFIR01ND<CF
MX@$N LAS\I&2/EZ@$<FKGB?Q3XDT-M3OXK#3(]*TY=^RZG(GO$"AG:/'"XY
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M2[R.P554#)))Z "FVUS!>6T=S:S1SP2+N26)@RL/4$<$4 >5S6'B34?A[;>
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M='\6V.H0M;#4=7O9(B2#NBDP%<8/UKL7N[:.ZBM7N(EN)59HXF<!W"XR0.I
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MJ$TSV6K7 B:*. H/+568[D88*@ =<'..:]9T^RATW3;6PM]WDVT*0Q[CD[5
M R?H*L4 <%H.FZG)\0K76I]-N+6T/AJ*T;SBN4F$Y)0@$\XY_&JR>'M5'Q#\
M;ZB;-_LE_ID4-K+D8E<1X('.>OK7HU% 'G5YX>U63X3^&M)2S<W]JVG&>'(R
MGENA?OC@ _E4MH-<\->*/$D-EHDNHP:I<K>6MQ%-&J12&-599MS!E *@Y .1
MT&:] KF=7\"Z3J^I3Z@TNH6D]U&L=T;*\>$7*@8 D"GG XSUQQ0!G_",,/A;
MHFXY.R4Y]?WK\US0\,ZW>:%XT\,MI<\$]WJD^J6-ZY3[/+^]CDC3(;(8[>>,
M#GFO4[&QM=,L(+&RA6"UMT$<4:]%4# %6* //[DZSXRUKP\D_A^]TJUTN\%_
M=RWC1X,BHRJD>UB6&6/S<# _"M3QQI>H72:-JNEVWVNZTB_6Z-L&"M-'M9'5
M2>-V&R,^E=910!YWKL'B;QQX?U>%-(_LR"/R)=-BO2HGFFCD$C;]K%54[0H[
M\YZ5--_:_C#Q'X>>;0+W2K+2KAKRYDO6CR\H0JJ1A6.X98DMP,"N^HH \Q'A
MK6/^%0^(]'^PO_:%U/>-#!N7+AY2RG.<<@YK>UG2+^Y\1>";F&V9X;":5KI@
M1^[!@91G\3CBNPHH \:T&_UMO >O:-8>'[J]DO[V_AM+F%XQ$F^1U/FEF!7:
M23T((QSUQ=N?!-OH>K6TU_X4_P"$ELCI5K9@Q11R2030*5SM<CY74CD="O->
MCZ+HMIH-B]I9!Q$\\DYWMD[G8LWX9)K1H \RU71M2L;#P;J%CX76$:9>O/=:
M7IK(3$KHP^7)52<D9P>I/;FJVH>&XK7Q%K-[>^ O[>_M1DNK.3RX6:%S&JM%
M*68; &7.1D?,:]6HH I:99I:Z+:V9L[>V5(%1K:#F./CE5X'RCD=*\R\->!=
M5DM=?TS6+8QVT&G2:-IDC,#YD+22N).#QP8A_P !KUJB@#R_1?#_ (@N?A[X
MNN=7L7C\0:S:R1"W+*6(2W\J-<@XY(8]?XJBET/6].\)_#V==(N+J?19(VO+
M2 H95'E%3C) ."?6O5:* .3\-:??0^,?%>I7-I);V^H-9O 9",MM@"L.">0>
M#3_ASIE[HW@33[#4(&@NHVF+QL02-TSL.GL0:ZFB@#Q*^\*:I/H&HV?_  AQ
MN/$"WSW4VKS"(F=!/O40N6W;B@5=O  S]#Z!X9L;Z/QCXIU2YLY;:WU#[&\'
MF[=QVP ," 3@@\'^M=;10!YI9^$[F3X(RZ)J2?8KV);B=&=@/)D6=Y8VR.G\
M)^AK2^&$5W?:'<>*=3C":AKTHN64?P1*H2)?IM&[_@5=!XA\-67B:"*VU":\
M%JI/F007#1).#CY9 OWAQT^M:T44<$*11(J1HH5$48"@<  >E '#:M'K&E_$
M\Z_;Z-<ZAIG]C+:R_9F3S _G,WRJS#=CC(ST;OC%84_AO7[C0[[7?[*D&H3>
M(H-8333(OF^1$5 0G.W>54G&?;K7K-% 'GT(U_5OB!;:\FA3V-G%I-Q;PK>N
MBN92Z,-X1FV@XP.I^4GTJGHFDSR^--,U.P\)W?AV5/,.L.7C6"X!0@*JHY#G
M>0P; X'/6O3:* /'=+\(Z]!\-[W39=.D6\D\1+=K$67)B$T;;NN,84G\*[/Q
M)HEWJGC?P[<)"S6,-I?PW,H(_=^8D87\\'\JZ^B@#R7PQX6ATX:1I=Q\.[4Z
ME9R(ESJTD<0A*)_RV1P2S.< @;0<GG&*LZQI5[JFO0S0>$+C3_$45^A&M6TB
M+ T"R#+.P8,^8Q@HRDY.*]1HH \NUK2KW5-=CE@\(7%AXCBOD*:U;2(L#0+(
M,L[!@SYC!!1E)R<5U/CS1K[5]#MI-,C6:_TZ^@OX(68*)6B;)3)X&1G&>^*Z
MBB@#A8DU3Q3XXT/59=%O=*L-&CG<F]V!YII4V;556;Y0,G)ZU<^&>E7VB> [
M*PU*W:WNHY;AFC8@D!IG8=/4$'\:ZZB@#AM7AU/0OB'_ ,)#:Z/=ZI8WFG+9
MS)9E#+%(DA93AF7*D,1UXQ7-_P#"(:YJ?AS7)-2T6-[I_$BZM'ITLB,MQ$%C
M!CW?=SMW+D\9'I7KM% 'F(T"*[\/^)UT;P(FB&?2I;:!I(XHKBXD93E-J$@+
MD+R3R:U-3T34I]/\!QQVK,^G7MO)=C(_=*L#*2>>Q('%=U10!YWXB\(W^O>(
MO%,8C\JVU'0XK2"X8C:9@[G![\97/'>HKM=?\66V@Z-<^';S3C9WEO<ZC<W#
MQ^5B$[ML15B7W,!@X&!UKTFB@#BM!T;4+73O&D<]LR/?:G=36P)'[Q&B0*1S
MW(/6L+^R98O!_A[1_$'@F;6+:#3(DW6VQI[:X PR\LI48 ^93U!SVKU*B@#R
MHZ1XDTD^ M4NM-O-3FTI+N.\B@E229!*F(P2S -M& 3GM73>%=)U"Q\1^,+J
MXMV@COKU);9V(.]1$HSP?45U]% 'B,'AC4X=$T@)X*D_MK2]1@O-2U"00M->
M%)@S>4^[<Y8?-R0 !BNDTNX\1>&K[Q3*/#%]>1ZCJ+W%EY#1YW&-!^\!8;5.
M!R,]&]L^E44 >2KX(UC3H/AI:);&?^R)WDOY$8;8BP!/?D9)''I4_P 4=/OX
MM=TJYT5U2]UR)]"N!GGRY/F$@'^QASGWKU.L2#PKIT7B1]?D>ZN;_#+";F=I
M$MU;[PB4\)GVH T["R@TW3[:QM4V6]M$L,:^BJ, ?D*L444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5E>(KO5++2C)I%M;S7;2(FZYD"10J3\TC\@E5'.!R:U:Y'X@Z5=ZIINF>
M1IS:G;6NHQW%Y8*R@W$0##&&(5L,5;:3@[: ,5_'^JV6A^*VN#I-Y?Z)!%<1
MSV6[R)ED!P"NXD$%6!^;TJ^/$OB:PUW0EU:VTQ=.UJ1H8XX _G6S^674.Q.U
M_ND' &/>N7O_  OKUQ;^,([3PNEE#K>F0K:00/"HB>,N-DF& WMN#9&1SC/%
M=KXBT>_OM0\(RVUN72PU 37)W*/+3R77/)YY('&: .4\.:OXB&C?$"^U5].O
M;>QN;U3 T<A#21Q)\H#,1Y1 ^[UY//-:=CXNOY?#'A"VT>PTZ#5-<A9XHRC+
M;6T:)N<[5.2!E0%!')ZU6M-%UZUL?B!HC:-,RZM+>W=G=K+'Y<GFQ!5CP6W!
MLCN,>]-L_#>O:-H/@;4H=--SJ&A6\D%WIZRH'9)4"MM8G:64JIQGGGF@"?Q7
MXBU[1_A[K]UK^B:7<W%C+"L>Z,O:7B,Z8;8QW C/0GJ 036A?^)=>;Q98^'=
M%M=.!N=*%\9[E7*PX<*?E4C<.0 ..3UXQ65XPL/%WC'X=>(K5]'6WFNI(!IU
M@9$\X(KH6,C;MF3@D '@#')I;ZXU'2_BOITMIILE^T7ALK/;1.BR;?.7E-Q"
MD@XX)'&?I0!IV'BOQ#=Z1K-K_9U@_B#2[Q;27$A2VVL%83G<=P4(Q)7)/'O6
M=<>+M=FT7Q98?:M'EU+3+ 7<5Y9;S"\;*^1MW$JXV-CYB.0:S[SPOKM_I^HZ
MQ>:,TCZAKD%[<:/YJ%Y+2)-@1CG86X#%<XXQ4\'AS5Y=3\2&'PU'I=GK6BFV
MMHXFB402*) !*%/WFW@Y7( X)XH FTKQ-KVG^$/"=C)/ICZIJT"M!<W&\110
M)"C%Y<MEY,D#@@$MVJQ+\0=1M=)O[:2WL+G7X-1@TZ#[.[?9IWGP8WZD@8+9
M&3RIYK+'A_4[[P_X3N=2\(&ZDT"(V=SIETT$AN(S$BF2/+%<AD! 8@GGVJW>
M^&;^\\-_;-)\)V.CW=GJMOJ%II\?EQR7"PGI*R?*&.7P,G''- $F_71\6O#4
M&N"Q>1+"\:.>R5T1P?+RI5B2",=<G.1TJ]\4I9X+'PU+:PB>X7Q!:^5$S;0[
MX? )[#.,FF01>(-;^(FBZY<Z%-IVF6EI<PD7$T9E#OLY(5CP<8&"3\ISC(K0
M^(.EZOJ=EHC:-:K<W-EK%O=LCR!%V(&)R3VY XR>>E %1?%'B'2-<NM(UZ+3
M)97TV6_LI[))$4F/[T;JS$YY!R".*EN?&-]#\/="\0K;VYN=0:R$D9#;%\YE
M#8YSQN..:J'3-8\5^+&U.]TF?2+.UTN>RA6ZDC:226; 9L(S#: O7/.:PSIO
MBV]\#Z%X:/AJ6WETJ>S%S/)<Q%)4AD7F/#9/ W'(' (Y- '0CQ1XCU#Q!JMM
MH\>CO'IET('T^=V6[F7"DR*VX*H.X[<J0<=:=;^(&_X6?X@TM=.L4:TTR.X%
MVL6)Y"<?*[9Y4>E97C#1]4UVZNK<>$1_:ZS#^S->MIHT$*9!5W;<) 5YRN"#
MCCK6A!X=U5/BEXCUAK4_8+O2H[>";>OSR #(QG(Z=QB@#-@\=>*_^$3TGQ;<
MV6DII-P\"W%LHD\_;(XC+JV[:/F.0I!XZG/32U7QAK3ZIK4>BMHR6VCD1R)?
MNWF7<H0.RIA@$ # 9(;)JI/X8UE_@IIF@+9$ZI"MF)(/,3Y=DR,WS9QP%)Z]
MJAU'PRVG>(]=G?P-:^(EU*87-I<NL!\IRBJT<AD(*KE=P*Y^\>] %Y_&VJZU
MJEI:>'6TBV,^F0ZC&NJ%R]QYN["1A6'W=O)YP2.*GOO%'B*;7X=$L(]'T_4!
MI\5W)#J3LYED<L#'&489"E>6YZCBJWB/2I9[6'2[[P';:M9):(MJVGM'']FE
MQAE!=E*+G&&7MU%5;[1]4.@Z=H_B+PB/$PBL(D2[@FC$L=P!APS.RD#A<.OO
MF@#T6QEN)M/MY;RW%M<O&K30APXC?'*[AP<'O7GW_":^*;KPQ=>,;&STHZ#"
M9)4M)!)]IEMXV(9]X.U20I(&T\=Z[/PQ97VG^%=+LM4F\^^AM4CGDW;MSA<'
MGO\ 7O7G\.E>*--\!77@*WT&29F2:S@U3SXQ;^1(S?.PW;PP5B-H4\B@"AXO
M74]<^*_@\P?V3/:SVUQ/8)=P.Z!3$"3(N[D^F,8XKT;Q7JT_ASP/JFIQ+']I
MM+-G0*OR!PN!QZ9QQZ5@7GA:_A^(7@J[M+<RZ9I-E/;SSEU&S,6U.,Y.<=@:
MZ_6]*@UW0[[2KDD0WD#PN1U4,,9'N.M ''Z)\,/#5QX>@?6M/34]3NX5EN[Z
MY8M*\C#)(;.5 )XQC&!5B[NM0\%Z+HGA[3[DZKJE[<FUM)M0)PB ,Y:0KRP1
M1CU/%5-*U7QOH&DPZ-=>$WU6ZM8Q##?6UY$D,ZJ,*S[B&0XQG@^U.U'0O%/V
M#P[K-RT.J:[I5Y)<SV\)6)7CE5E:.,G RJL,%NN.30!-_P )9KFDWVKZ3K46
MGRWUMI,FJ6EQ:(Z12JF059&8D$-CHW(/:LM_&_B^WTKPYK4NFZ5)9ZW)#;QV
MB&19DDE0F-BY)7:2,D;<@'J35FXTG6O$FK:SKD^DS:>O]AS:98VEQ)&997<E
MF9MK%5&0J@$^IXJ6[\.ZM)X/\!V*6A-SIE[I\MXF]?W2QIASG.#@^F?:@"1/
M%?B#3-3UW2M9BTV6ZL](.J6LMFDBHR@LNQU9B<[EZ@CBJ4?C7Q3;Z)HGB;4;
M+2ET6_>W2:"(2>?"LN%$FXG:1D@[<9 .,GK5GQ3I-\/$FOZQY!_L\^%9;43;
MA_K0[MMQG/0YSC%8=E;^(/$W@'POX<;0Y8;8I8RW&I&:,PFWCV."HW;]Y"J,
M%1@YYQS0!N^*O%GB/0'U*_$>BP:;8X:.VNI3]IO8P 79"K83J0 5))7MFK5[
MXD\07?C*7P_H<&GJHTZ*^%U>*[!-S,I!56&XG"X&1CDD]!7*ZSX2U>\@\7:>
M/"T-WJ6I3SRVVLW#1%1"RC8@).]6 &P#  /.<5U7A[3=4/C:36;O3I;2WET2
MWML2NA995D<LIVL>Q!STYH S8OB#JT.CV.H:A9V:)!K3Z1J[1;ML9#;%E0D\
M+NVYSGK727OB"Z7Q[IOAVRBA>-K22\OY'!)BC!"QA<'&6;/7L*Q=.\(RW7A/
MQ=H^L1"WBU/4[V:)F92!&[923@\8(!YYXJK\*DU&^T"[\5ZF@FU+442./#<-
M% FQ<$]-S!V_X$* /1Z*I:3<WMWI-M<:C8_8;R1 TUMY@D\IO3<.#]:NT %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 50.C69\0#7-C?;A:FT#;CCRRX?&/7(ZU?HH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
M"]M(K^QN+.X!,-Q$T4@!P2K#!Y^AINGV,&F:;:V%LI6WM84AB!.2%4 #GOP*
MLT4 %%%% &5KWAZQ\262V>H-=?9@V7C@N'B$@Q@J^TC<I]#6A;6T-G:Q6UM$
MD4$*!(XT&%50,  >F*EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHKCKSQK?MJ&J0Z)X=EU.WTI_*NY_M20_O H9DC
M4@[R 1UQSQ0!V-%4=&U:UUW1;/5;(L;:[B66/<,$ CH1ZCI5Z@ HHHH ****
M "BBN=\(>*X_%UGJ%Q%:/;"SOY;(JSAMQ3'S=.,YZ4 =%14%S>VMGL^U7,,&
M\X3S9 NX^@SUIT]S!:PF:XFCAB'5Y&"@?B: ):*A-W;!&<W$.U &8[QA0>A/
MUH%Y:D3$7,)$!Q*0X_=]_F]/QH FHJ*"Y@NH1-;S1S1'H\;!E/XBDMKRVO$9
MK6YAG53M8Q.& /H<4 345DZGXDTS2-3T[3[R<)<:@[)$,@!=J,Q+9/ ^4C/J
M15+2_%45WJFNVMZUO:1:;>+:QR/*%\S,:OW[_-T]J .CHJ*XNK>TA,US/%#$
M.KR.%7\S6=K7B33-!TV._O)QY$LD<<>P@ER[!01SR/F!)],T :U%0M=6Z6IN
M6GC%N%W&4L-N/7/2N5F\>6L^D^'=2TM%GM]7U&&T(D;#1*X<Y(!//R]/>@#L
M**KPWMM=QR-:7,$^PD-Y<@8 ^AQTJEH^HW4NA1WNLFPMY_F\TVUQOA4!B!AS
MCMC\: -6BF0S17$2RPR))&PRKHP(/T(K(\5>(X?"VAOJ,D#W,AD2&"VC8!II
M78*J#/?G/T!H VJ*QO"WB*W\5>'K;5K>)H?,W+) YRT4BDJR'W!%:37UHD[0
M-=0+,B[VC,@#*OJ1Z>] $]%5Y;ZT@0M-=01JJAR7D  4\ \]O>EEO;6":*&6
MYACEE_U:/( S_0=Z )Z*AN;RULU5KJYA@5CM4RN%!/H,TZ2>&(@22QID%AN8
M#(')/X4 2454.J:>+5;HWUJ+=CM67SEV$^@.<9J::Y@MH#///'%".3)(X51^
M)H EHJ,7$!BCE$T?ER$!'W##9Z8/?-1QW]G,)C%=P.(>)2L@/E_[W/'XT 6*
M*R] \0Z?XETT7^G2[X2[I@D;AM=ER0"< E21ZBEAN]0?Q%<VDD=F-/2%7C=9
MB9BYQD,F.%]\T :=%00WEK<R21P7,,KQG#K&X8J?<#I3Y)XHB!)*B$@D!F R
M!U/X4 245%;75O>0B6UGBGB)QOB<,,_44R"_L[J22.WNX)GCX=8Y Q7Z@=*
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M,],]:]4KEM0\!:9?7]Y=Q7FJ6!OCF[BL;MHH[@XQEE'<C@D8)H ?\/+RTO\
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MTT/3]=^)VE6^J6T=U:Q^$[>7[/*NY&82D LIX. QX/?GM5672[_Q%J/C,?\
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M>A^;.3S6=X+\-://\'=3U.YT^VN;R6"^'FSQAV15DDVJN>@!4-@=^>M=[:^
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MPH$5<G)P![\U:HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M41*WVC .S&.-Q[=\USEGX;T=O /Q'D?3K=VM;W4H[8O&#]G2-2R+'G[@#$G
MQR: /:JJ1ZII\M^]A'?VKWB#+6ZS*9%^JYR*J>'[DGPCI=U<.2?L$4DCGDG]
MV"37DZH1:^$-6L= T[3-/NM<MWMKEKII+Z597;)<[.=RDD@N>,>E 'L%QK.E
MVG_'SJ5G#^\,7[R=5^<=5Y/7D<>]2WFH66G0">]O+>VA) $D\JHI/IDFO--&
M\/Z5J4/Q#N;ZP@N93J=U$K3('V*(D/RY^Z<G.1Z#T%4O"<46MZ_X*MM6C2[@
M@\*"Y@CG4.IF+(A;!X)"_P Z /0=!\0R:QKWB"Q*1>1ILT,<,D9SYBO$KY/;
M^+M4MQXKTFU\40>'I;E%OIH&F +J N&4!3DYW-O! QR :YKX?6=I8>+/'%K8
MHJ6T>H0A43[J?N5)4#L 21CMC%,O=.L9_CO9/+96\C'0GF+/$I/F+,@5NGW@
M. >HH VO#GC&VU.REDU*XLK*?[?<6D,;3!3((Y"@(#'))QVK?O=3L--5&O[Z
MVM5<[4,\JH&/H,GFO(K3P_I5S\+/'%_<6$$UW]HU1UFE0,Z%&<KM)Y4 C/'<
MD]ZUN-=U2RCMM T_5=1MM$MC=W.K7!6&))02%5=CY9MK$M@< #- ';ZUXJTG
M0;G38+VY17U"<0Q?.HV@JS;VR1A?EQGU(K95E=0RD%2,@@\$5X=IUK:ZAX?^
M%C7=O;W.Z]E@)D0.&C42;5R1RHP,#VKW%55$"(H55&  , "@#G/!'BQ?&?A]
MM56S-H!<20>69-_W3C.<#K2/XJ2V\9W^D7KVMM96MA#=?:99-GS.[K@DG&/E
M'YUS7P-_Y)\__80N/_0JLMI%AJGQIU!K^TBNEAT6W*1S('0,99!NVGC.,C/N
M?6@#NOMUI]B^V_:H/LFW?Y_F#9M]=W3'O446K:;/:I=0ZA:26[N(TE292C-_
M=!!P3[5Y/I_V*#PS<:)_9*Z@&\6W5MI]@TWE0@H[. YP?W:A6.W!SQQ21^';
MK6G^(.AM:6%E>"&RN((-.D+11W 5V5AE5PQV)GB@#V">X@ME5IYHXE9@BF1@
MH+'H!GO41U.P&H"P-];"](R+?S5\S'KMSFO-[36%^(?B#P;&HS;6=I_;5\G8
M3C,<:?4/YAQ_LUS^D:/K^N^"_M5MH>C+?3WSW0UB:^*W"SK<'DCRSC&W9C=T
MH ]HU+4;72=.N+^]E6*W@0N[,0.!VY[US,GCJWN#X6GT_P F2TUJ4K*SN-T
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M9],;2+S2)K6>X,<[S7/S%1U$6W(9\]C7-_%JV2\T?P_:R%A'-K]G&Q4X.&+
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M8!\Z60*G/3D\5P.A:#I>K>/O'4NHV,%X1<P1*)T#A%-NF[ /0GC)'H/2N?\
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M$2W,BETA+@.RCJ0O4@4 >=^)M-1/%E]=S>$=7O%N(8PLNEWA$5Z5&-ERFY0
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M;V<US?6[K=7:VB;)DX8N%9CD]$S\WI6]#-%<01SP2)+%(H9)$8,K*>001U%
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M3,SO.K;M[L3EB3US6C=:-97FLZ?JTR,;NP65;=@Q 42 !LCOP!7-P>*]1O\
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M+YV2>(T5L'!P;A!UKVB;PKI,WB9/$/E31ZDJ"-GBN'19%&<!U!VMC)ZBH(/
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M]MI\;JLDAEEDEE:225S@%F=B2QX'4]J(]!TZ/Q#+KRP$ZE+ +9IF=CB,'.T
MG &>>!0!YCK.K:QHGC30O%5YX7FT;3HU&F7\K74,B&%V'EDA"2 K<YQ[5T&D
MZ?8ZO\3O&O\ :EK!=&&*S@A6= X6%HBS 9Z L6S]*[/5])L==TFYTO4H!/9W
M*[)8R2,C.>HY'(!R*X;Q+H44.OPROX1O]4M4LDMXKG3KXI*^W/[J=3(N].G)
MW=\T </I]C97WA'P;8D^?8R>*IT^9L^;'NEX)[AAP?4$UV&LV-Z/BC!9:/I&
MC3PVNB;X+:]8Q11[YF$C(JHPR<(#P.#[UL>$?!4=KX8TF+6[2-;ZTO9=12**
M0[;>5W=@HVD [0^.XK=USPOIGB"2WFO$G2YM]PAN+6X>"5 WW@'0@X.!D=*
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MQ"RN7V@]B_7\*R=*M=";XB>'+333'/HEMH]T^F@N9$$WGJK[2V<D#(]ATXH
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M&=0SV,>U2>6X[5/X^NK:V\)3QW6GIJ"W4T-M':R2&-))'D55#,.0N2"?88H
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M.,U/J%A:ZKI]Q87T*SVMQ&8Y8VZ,IZBJ.F>*=!UJ^FLM,U>SN[J$$R10RAF
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MQUH ;JG@7P[K&HRWU[8,\TP43A)Y$2?:,#S$5@K\<?,#QQ6]);PS6SVTD2-
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M>VM+R1&G@.Q+=!C$<A)/SC//3J.*T=(U[2=?MGN-)U"WO8D;:[02!MI]#Z4
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M6 \46QWNI95N@IDW[@%<E&.,'"@UN:YJZ_#WQEXAOF&+76---[;J>C7D.$*
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M2IYBR+^\<E"I)78=V5 )/"X'-:\.AZ;!9WUI%:(L%]))+<H"<2-)]\GGO[4
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MPGI%H;V.]\FSBC%S']V4!0 P]B,&@!NM>+= \.S10ZOJMO:2RC<B.WS%>F[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLKV.]O+NTG#_ &AHP=J1KC*J6.<$C'O7I=GIEEI\EU):6R0O=3&><J/]9(0
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M4=D4%';.%8'/RB@"GXRT75?%(B\-)IT$.@R21/=WKS LT:,&\M(\9#$J!N/
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MG:'IFDR/)8V<<#O%'"S+G+)&"$!/L"?SK0HH JV&G6>F6YM[*W2")I&D*(,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSW5G=R6<\EHV89&3&'3D\%2IQDXS4GCB:^M_ ^MW&G3QP7,-E+*'="PPJDD
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MTSBK] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2!?WA*_*5&T *"3U/?%:7PYTS6= TFXT35--$,5O<320W:SHZW"O(S#"CE<
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ME$_LY]&%F&W_ #>9YH;&/3 ZUK^+=*GUWPAJ^E6S(L]W:20QESA=Q4@9]LT
M>=W$.NQZC\-XTOK6XU"2*Z\J=[<HD2&W7J@8EBHSW&3CI6I+XUUGPW:^+;?6
M)K2_N=&2V>VN1%Y"R_:,JH=<D !AR0>E6].T77[O4?!EYJ&FQ61T9+B&X07*
MRY#0*BL,#N0>.U,USP1?ZUJ/C!MT,4>J6UD+.1SN'FP%F^8=ANV_AF@!?#WB
MVY/BNST6Z\1Z-KR7]O)*DNG!5:WE3!*,%=LJ0203@_*:UOB%XAO_  SX934-
M-CCDN/M<$7ER#AP[A2/8G/6F^'X=9DU99KWPUI6CVT4)#&)UEEEE..4*@!4
MW=>3D<"I/'NAWOB#P_#9V"HTR7UO.0[;1M20,WZ"@#%UKQ!KGA]=(TC4]?TB
MVU#4Y9I'U&:$1P6T**I*JK.-S;F !)[GBFZ?XQU.^T'68;;5-$GO=,NXX&U;
M>%M3"X5O.(W8W %@5W8W+U[5K^+]"O+S5-&UJPL;;49M.,J265PP0312* =K
M$$!@54C/'6LC5/#^O:IH=O.^A:5%-;ZM%>C287 $L**1LDDQM9\DMTP, <T
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M !1110 4444 %<YXST&[US3;-].DB34=.O8KZU\XD1NZ9^5B.0""PS[UT=%
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M(')4@$#W-7-=\*7,5MX<N/#R0?:O#[_Z/;SN426$Q^6Z;@#M)7&#@\BNPHH
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M);0JZ>0TJIAI,;A*%.X\X!&,5?T.VU1_C1XF9]9D:""WM283 F'C82%8\XR
MI)Y')[U4E\%>+#X2N/#,']E1VT-VUW%=&9R]X?/\Y5==GR'.,MEN@P,<UOV6
MB:_8_$*[UQ8+![+5+6WCNU-PP>W>,-G9\F''/4[?PH C^*4DLGA_3-*25XH=
M8U:VT^X=#@B)V.X ^X7'XULW_@KP[J&@-HLNDVJ6138BQ1*IC]&4XX8>M/\
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MIVJVXAN;@M%I$ENHC-N)"O,N-^_:"V>F>,5WUC9Q:?I]M90 B&WB6) ?[J@
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MP"0A#N&..1VS7,V?@KQ#HNB>#9;$6%SJ>@)-'-;R3,D<R2K@[7VD@C /(]:
M'^(_%NLZ<WC\6URJ?V/9VDMEF)3Y;.K%B<CG.!UJS)?^)M%\1>&Y-0UB.[M=
M9G:WGLA;(BV[&-G7RW'S'!7'S$Y]JI7G@CQ'J=EXV>\ET];O7[6WC@2*1O+A
M,88%22N2,%><<G/ Z5T^NZ!=ZGJ'AB>!X0FEWOGS[V()7RF3Y>.3EAUQ0!R<
M?C_5;*S^(-Y<LER-%O1!8Q% H&X[5#$8)&XC/>NFTRP\8:;JENU]K5OJUE+"
M_P!I$L"0&"4 %3'L'S*3D$-DCKDUAQ?#J\N;7QU9WUQ#'%K]UY]K)$2QCQRI
M8$#D, < _C6BFF^-M:S;:S<:?IUFMG-!(+&1I3=2.FT.=RC8JY+  YSWQ0!S
M^E^,;^+Q'HMM+XNL-8EU"Y:VO+*T@7RK<E&8-%( "P4J!\Q.<]JS]#U?5O"_
MA_Q[KT^K?;#::O/;K%-"B(\Y,,:RL5&0.0"HXP*VHO#'C!K#PU"]OHT"^'YX
MF2WBN'*W05&C+EMGR<'(&#G)R>E2#P/K4D'BW196LETW5[V34;:\61C+%,2C
M(K1[<8#("3N_GP -\,>,C)XPL='7Q;:^(X;^WE9FCA2-K:5 &XV 91@6ZY(*
M]:W_ (@ZSJ>AZ!;7.DO&MW)J%M /,4%6#R!2#Z YZCFK&B_\)7-J2R:S;Z59
MVD4)4QVDK3-/(2/GRRKL4 'CD\\GBE\9Z%=^(-+L[:S:)7AU"VN6,K$#9'(&
M;& ><#B@#FGE\86WCF/PS_PDJ30WM@UY]K:QC62VV.%8(H^4@[E^]G'/6JA\
M4>*+7P9K=Z;M;N\\.:RT-S(($4WEJFQGRH&%;:^<C'W:["?0KN3XB6>OJT7V
M2'3);1E+'?O:1&! QC&%/>H= \/OI,?B<:HUNUKJFI378&[CR7C1</D#!^4Y
M_G0!#JOB&ZNO%/AG2=$N5\J\5M0NY0@;_1%48'/3>S*,CGBK/C?7+S0]$@_L
MT1_VA?WD-A;/*NY$>5L;B.^!DX]JY;X/Z/)'97VKS7!NH=QT[3)F'6RA=@A'
MLQ)_[Y%==XQ\/S^(M$2"SGC@O[6YBO+224$H)8VW+NQS@\@_6@#'@O==\.^-
M-'TC4]8.KV>L1SJDDEM'$\$L2A^-@ *E<\$9!'6N(\,W/BG1/@U9>);/5XTM
MK")I%TPVR%)HED(;=(?F#'YB,8 X&.]=[::-K^L>+=-UO7X+&RBTJ*5;:VM+
MAIC)+( K.S%5P H( P3SUKFK/P5XRA^'T/@B9M*-G*OESWZSOOBC9]SJ$V88
M\D Y'7D<9H MQ2K/^T-#,GW9/# 9?H9LU2T[Q[KTO@;6KUIH9=3_ .$@;2;%
MWB 6,,Z*I(&,XW,?>NHC\*7D7Q5C\2(T TU-&&GA-Q\P.)-W3&,8[YKEW\%7
M.A_#S78=3U.PLISK9U6UNF9C%&=\9C#\ C)7!QG&>] &T+SQ/H?COPYHM[K*
MZE8:@ER[RO:I%(6CCSM.T8QD@C&#U!S6/;>,M0M?$&DQS>+=/U2XO-1%I=Z9
M9PJ88%;< 8Y0 Q*D+G<><G@4Z]&M:M\2O"Z:K)8PR_8[XBWT^9I1"C1!?-9B
M%^\Q  QQMZG/$D7A+Q@OA_0-,$&C1)X?N()HDCN'Q>F,XRQV?N\J2>C98]L<
M@$7A;^V+35/B!?R:U).UK<2 HUO&!(ZP+L<D#C  &!QQ4FF>,=?U;P;X,AAN
MXH]9\02R+)>M"I$4<>]G94^Z6PH SQS6M:>&=>LM8\61(EC)INMEYHYS,PDC
MD:()M*;<$9'7/3\JIV'@36=,\'>%(K::R.N^'Y7D4.[>3,K[@Z;L9&5;KC@C
MI0 ZZU[7_#E]K^C7FJ#4)(M"FU6QO7MTC=&3*E&50%;!VD<#N#FH!K'BNPL?
M"FOWFLQSPZM=6MO<:<+5%1%F'#*X^;<."><$YX XJ_+X5UW7+C7=6U9;*UOK
MO1Y-*LK6"9I$B5LDL[E1DEB.@X [U=U'PK?W?ACPKIL;P"?2KNQFG+,=I6'&
M_;QR>.,X_"@#&M?$6KW_ (NO;(^)K2POK?43%'H=W;*BSVP; 97(WLS)E@5)
M&>,8KM/%-]<:9X1UF_M'"7-M8S31,0#AU0D'!X/(KEM>\/\ BC7V.F7MOH\M
MHMZL\&J[V%Q!&L@<!8]GWP!MW!@#U-=AK>FC6- U'2S)Y8O+62WWXSMWJ5S^
MM ',ZKXAU*U\.>#[R&=5GU*_L8;IM@.])5RXQCC/MTK+COO%NN3>*S::\FGP
MZ3?2Q6VRTCD:3;&K!7W#[HSVY.X\\"D'AGQCJ-CX9L=132;:#0[VUF=H;AW:
MY$7&[E!LXR<<Y)ZC'/1:+X=O-.3Q2)GA/]JW\MS!M8G"M&BC=QP<J>F: .=M
M/%&N>*I?"^G:??+I<U]I)U2^N(X5D8 %4"('! RS$\@\"L5-?U'PI/X]N[JZ
MMFU'[?8VJ74B;8P7C1%E90>,*=Q XR#VK<L?!WB'P_#X8U#3%L+G4=-TPZ;>
M6TTS1I+&2K HX4X(9<\CD&FKX#UZ\A\2SW]W8IJ.H7EK?V;Q;FCBEA"E58$
ME05"YZD<X!XH CT/QJ[:U>Z5!XIM_$$;:9+>1720QH\$L9 *$( I4A@1D9X(
MYK9^'-UXBUK0;+7]:U5)4O;52EG';JBH1_RT+CDEL$XX SCM5VT@\4ZBE^-6
M@TRR@DM&@AM[:5IBTAZNSE5PO8* >M7/!NCW/A_P;I.DWC1M<6ENL4AB)*DC
MT) _E0!R?CBVU2X^)O@N&SUF2S2;[84"P(_E.D/+?,.=P;'/3M5+2K/7[K6?
M'+Z3K0TN.'4V=66V25I9/)3AM^0%  Z<G)Y&*Z;Q?H>LWGB'PYKNB1V<\^DO
M<;[>ZE:)9%EC"9#!6P1CTJQH7A^]TVX\3R7#0G^U+UKB$(Q.%,2)\W'!RI]:
M .6D\<ZQ<6OPYN8I(X?[<E"WR+&"'^49QG)7G/2IO^$BU>[\8:AIX\36FF7U
MO>B.UT>[ME5+J#Y<,)"-S%AN(VG@]J2+X?ZNFG_#^ RVF_P_+ON_WC888'W/
MEYZ=\5<\2^'O%'B%+G1[FWT>:QEN1);ZF[LL]K'N#8$83EQC 8,,\9[T =_7
MBNLPZ?\ $+7/%5U-J=K;KIL/]G:.9)U0BX1A(\HR>/G55R.HS7K6NIJ4NA7T
M>CM$NHO"R6[S,557(P&) /3KT[5SWA[X;>&M)\/6-C>:)I=[=0Q 3W,UHDC2
MR=68LPR>2<9[8H SO^%@RS_!X>*K1(WU'RDA,;?=6Y+B(Y'H&.<>E%Q=>+/#
MWBCPOI]YKB:E::G<O'<2-:1Q.K+$S;1M&-I.".XV]3GC.U?P(=+TKQC:)>66
MF^&[]8[VV/(%G<(5).T# 0E%/'3&,4V]N-=U'QSX%;57TM6$\TL<&G3-,)%\
MAMTQ9E&%Z #!^\>3V +6@^(/$=Y_PD6NW^J(NDZ%?7T7V-+9-URD08C<_50H
MVXQR2#FLW0_B#,VH>'Y9?%MAJDNJSI!=Z7#"B_93(I*F-A\QVMA3N)SGM77^
M'O"4UEHGB33-3>)H]6U"\G'DL3B*;H#D#YL9J/P_8>,;(:7IEZNDI86"B.6\
MB=GENT5=J@(5 C/0D[CTXH XC_A:,AL_[?\ ^$KL=WVO'_"/^4F?L_F[,;_O
M^9M^?.<=L5TDE]XJUKQ%XNL;'7$TZVTF2/[,RVL<C,6A5]IW#[N<GU.[J,<V
M=(T/Q9H,$>@Z>NE?V5%<EXK^1V,R0&0N8S%MP6P2H;=C&#C-:NE>'KRRUWQ9
M>RO"8M6EC>W"L20%A"'=QQR.V>* ..A\3>+#X4\/>,)]5A$-Y<VT4^F):KY;
M1R.(RP<_.&/WNN!G&#C);KOCZ;^UO$ B\76.COI4I@M-/FA1S=NB!F,A;Y@K
M,2HVD8QFMK_A"=4_X5EH7ASS+7[;8S6KRMO.PB.4,V#C)X''%6)=%\4:-JFL
M_P#"/Q:7/::K/]J62\E9&M)F15<[0I\Q3M# 9'.10!1C\0Z]XF\4:?8Z5J*Z
M98WOA^'5&<0)+)&SN1A=PQDY YR  >,G-<WXFU37M3^'>I6]YJV;C3?$"Z=-
M-';HOVI5EC*,1T4C<#@<'%>BVV@7T7CX:[--#)!_8Z6+$95FE$I<MMQ@+@^M
M<YJ?@/5[KPOXELH);07=]KG]J6F]VV%0T9"N<9!.P],]J ._LX+F#3XX+F\:
MYN%7#7!C5"Q]=HX%>1:!J^K^%_#'CG7I-2:_DMM8N+>.WEA15DG+QQK(2N#W
M'RCC%>N:<][+I\+ZC!#!>$?O(H)3(BG/9B 3QCL*\_7P)K%QI_B[0+IK--,U
M>]FU"UO8Y6,L<K,C(K1[<8!7).Z@"Y/=>)?"FKZ VJ:Z-6M-4NQ8W$;6L<7D
MRNK%6C*@';E<$-G@UUVN7%U:Z%?3V4UI#<QP,T<MXY2%& ^\Y'11U-<O_8WB
MCQ#JVBR>(8=,M+/2;@79^R3O*UU.JE5(!1=BC<3CD]![UM>--#N/$?A&_P!*
MM9(DGF"&/S<[&*NK[6Q_"=N#[&@#D/#OBZYD\2OI<?BF+Q!!+ILMT)UMDB,$
ML948&T ,I#=\GCK5&'Q#XPB\ Z/XTN=;B=9'MO/TY;2,))&\BQD[\;@YW;N,
M =,<9.ZVA^*[_P 3V&N7<&EP(EI/8O917#MY*/M(</L&YLK@K@ #'/6B;P7J
M<GPDL/"PDMOM]NMJ'8N?+_=RH[8.,]%..* -'3==OK?X@:SH&JSJT!MTO].<
MJ%Q#]V121UVMCKS@U+X#U;4?$&B7&LWTF;>\NY7L(]@7R[8-M3.!DDX)R?45
MS?Q:L7O9= CTN[6#7;FYDL(@.6:":,K,2/11AL]L5Z)864&FZ=;6-JFRWMHE
MAC7T51@#\A0!Y5J6FZM-\?X$BUZ2&1M&>6.06L;>5'YQ_= $8(_VCS72:;XC
MU.X\'>+]0EG4W.G7>H16S>6HV+%G8,8P<8[]:N3>&;Z3XK6_B</!]@CTDV14
ML?,\PR%LXQC&#ZUB2>%O%=M9^)M#L!IAT[6+BYN([V69Q)")A\R>6%P3G(#;
MN,YP>E &8SZUK'CGP+<G6WA>ZT9[DA;>,A6*1&3@C^+].U=)I7B+4[KPQXPO
M99U,^FWU_#:ML4;$B'R#&.<>_6JLOA77[&^\'ZCIR6%Q/I&G&QNH9IFC4[D0
M%D8*<X*GJ!V_")_"_BNTB\3:/IXTPZ=K-S<7*7LLSB6#SE^9/+"D$YS@[N,Y
MYZ4 57\0^*-3OO!NFV&IQ6DFL:+]JNKAK='*.%1BZJ>,\D =/FSCC%0:OXTN
M(M<U32Y/&MGH\FDQQ0QB:WC+7TQC#L[AA\J9(&%QWYK?TOPAJ-EK?A&\EDMS
M'I&C&QN KDDR%4&5XY'RGDX^E/N]'\2:1X@U>^\/V^F74&K%)'6\F:,VTRH$
M+<*V]2%4XX.10!O^%]9_X2+PMI>L&,1M>6R2L@Z*Q'('MG-:U064=Q#8V\=W
M,LURL:B61$V!WQR0.P)[5/0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !117(_$+Q))X=T>Q\F]2Q>
M_O8[0WCQ[_LZ$,S.%Z$X4@ \9(H ZZBO()/'-[;Z+XL@TSQ$VK?8=.6]LM1>
MW17C8DJT;#:%;!"D';T:M&_N?%^GZSX;1?$?F'7B\,\3VL?EVI\O?NBP,D@!
M@-Q.>,T >G45Y7?>(/$.@Z?X\L'UF2\GT>T@NK*\EAC$B^8K$A@%"G!7CCO5
MZXO?$WAZ\\-:G?ZXU[!JUY%9W=B;>-8X6E4E3&P&[Y2,<DYH [/3?$&F:OJ&
MI6-E<&6XTV4172;&78QR0,D8/0],UIUXUI>O-X9O/BOK,<:R2VMVCQHW0N58
M+GVR1717<WB7PE/H%]J'B"75(M0OH;&^MI;>)$1I<@/$44$;6QP2<@T >AT5
MP6D>+KK2M/\ %L'B&X\^\\/RR2^855#-;LN^$X4 9(RO ZBN:7Q;JL4NFZ1X
MC\6/HUPNF)?75Q':QF22:5F*Q %"H5% !XR3WH ]BHKR63QIXAU+P]X4;3K^
M&*]OM5ETZXN! "DH4.HE"D<<!7P,<\=*]-TVVN-.TJ*&]OY+Z:)29+J5%5GY
M)R0H ''''I0!=HKRB/5_%=[X G\?0ZZT3+')>1:5]GC-OY",?D8[=Y8JN=P8
M<FKUQJWB'Q%X^&CZ5K+:9ILNC0:@76".212SL,+N'4_+DG. IP.<T >DU6OM
M/M-2A2&]MTGC21955QD!U.5/U!&:POB%JM[HG@'6-3TZ;R+RW@WQ2;0VT[AV
M((-8EU=^)/#>L^'+R_UMKZVU>\6RNK-K>-$A>1&93$0-P *X^8G(H ]!IIDC
M618RZB1@2JD\D#K@?B/SKS*#4/%&O^%]5\766OO9K"]R]CIZV\30M'"S+B0E
M2Q+;#DAAC/%58I[_ ,1?$[POJ4.KW-I#>:%]N2!(XV$:L8B\8W*3AN,GKQP1
M0!ZS6==Z!I%_JMMJEWIUM/?6HQ!/)&&:/G/&>G)KR6?XDS&SNM?3Q0%N8KMQ
M%H(ME,;VZR;-I;;N\PJ"VX-@$@8KJUE\1>(?&WB?2K;Q!+INGZ>;8P&"WB:3
M=)"&(RRGY<Y)[G. 0!R =\\B1[=[JNYMJ[CC)]![U136K&37I-%61_MT< N&
M3RFV["0,[\;<Y/3.:\DOM0UKQ1H?P\OI]8EMKFXU1H)3!#'CS8S*@E 93SA3
MQ]WGI786.N:L/B_>>'I;TS:?!HB7*QO&BYEWJI<D#/()XZ<]* .[K,T[Q!IF
MJZGJ6G6=P9+K376.Z38R^6S D#)&#T/3-><Z=XNO(/$&B*?%\>LS7]\;6\M(
M+4"UC!5R##($!.TJ!RQSS6C\/_\ DI/Q%_Z_+;_T!Z /2**X'QSXI_LWQ!I>
MB/KAT2VG@EN;B]2(/(0I55C3<K $DDDD=%]ZP1XWUNZ\.6:Z;JL4]TOB2+2A
M?M;@+<PNN59DP,'Y@#MQRIQC- 'KE%>;1KXJ3QY/X4/BJX>UETY=1^V-;0^?
M%^\,9C3"[<$X.2IP!@=<UG-XK\4+X6M(8=1C?58O%)T5[MX%Q,@=EW,H&!VS
MC!XZT >M=!69H.OZ;XFTI-3TFX,]H[,JR%&3)4X/# 'K7,V%UK6A>/;;0M1U
MF75K+4K&6>%YX8TDAEC9=P&Q0"I#=".,5Q'@36;_ $OX/Z#::7*D-]JNL-81
M3N@<0!I'+/M/!(53@'OB@#W"BO/WE\0Z+XHA\./X@GO8]7L+AK.ZN((A+:W$
M8'/RJ%9<,#@@]*J'QQJD_P *8;N%@GB>:==)V%1E;W?Y;$KC'8OC&,4 >ET5
MX[J?C:Z6[UQ&\9?V?=Z0YMK2T-HC"[DC0%GE.P\.^0 I7 %:DFN^(O$WC'2]
M,TO56TJROO#T6IRE8$D>)FDP=NX=3E5YX !XSS0!Z=16)XJUIO#/@_4]7"B:
M6SMF=0W1WQ@9QVSC-<I=7'B;PJF@ZK?^()-2COKR"UO[26WB2-/-XW1%5##:
MQ'!)R* .JN_%^AV7B&'09KQCJ<NTBWB@DD*AC@%BJD(,D<L16Y7D7AO2=2'Q
MN\3@^(+LM!%:23-Y$.;A"H/EM\G  XRN#[YKKOB!JVK:7:Z$NC7*6]Q>ZQ!9
ML[QAUV.'SD'MD \8/'6@#KZS]9UJQT#3S?:C(\=N&5"R1-(<DX'"@FN&B7Q4
M/'5UX4/BJX>U?3TU 7K6T/VB/YV0QKA=N"0#DJ< 8'7-8^K^-/$>G_"B_OEU
M$'5M/UA].:\$*9E5)MNXJ05!(]!0![#17#:K=:]J/Q*E\/6.L/IVGC2([MWB
MAC>0.9G3Y2RG&0!G.<;>!DYKGI?'&JZ?X9:SO]8CBO$\02Z.^K/ N5B0%S+L
M V[]HV],9.: /6J*X/P+XF.I:YJND+K3:W:V\45Q;WSQ!'PQ96C?:J@D%000
M.C5WE %74M2LM(L);[4;J*UM(L;YI6VJN2 ,GZD"I;6Z@O;2&ZM9DFMYD$D<
MB'*NI&00?3%<5\8_^26:OD9^:WZ_]=XZJ>$M6A\(:9XDT+4G*Q>''>X@)/+6
M;@R1X]2/F7\ * .V@UO2[G6+C2(+^"34;9 \ULK@O&IQR1V^\/SJ_7BW@#2[
MZ#XBW$]W*T&JZOX=:_N)  3%)-<DC /'RKL&#_=K>@\<:I#\++^ZN6#^)K*9
M]*=0@^>\W[$(7&#G<K8QCK0!Z716%J6HW/AGP/<ZC>R_;;O3[ RRN0%\Z14R
M3@  98=O6N0N;WQ1X<T71O$E]X@DOEN9[9+^Q>WB6)4F(7]T54,"I88R3G'-
M '?6&KV6ISWT-I,9)+&<V]P-I&R0*&QR.>&'(XK,\47'AN0Z=HWB*.*==2N!
M';02Q,ZR2#Z# Z]ZXS0]+UW4]?\ &PTS7I-*CCU9C&88(Y#)*8D^_O!^4 +P
M,$Y//2LK4-=F\2_\*IU>Y15N+C4&\T*,#>N%8CVRIH ]6L-3TPZE<:%9#RYM
M/CCWPK R)&C %0IP%/&. >*TZ\]@\6ZC;_$#QO:W,_FZ;H]A#=06^Q1M/E;V
M^8#)R<]2:Q[W4O&>G>!=+\3GQ$99=1DM&N+8VL0CMXYG3 C^7.0&"G<3G)/!
M H ]:IIDC$HB+KYA4L$SR0.IQZ<C\Z\N\;>)[W2+W6IX_&$5M<V,0EL]*MK8
M3*P";B+@["5+'(&&7 P:>(]1U'XUZ?/'K%S;PR: +P0K'&P5#-&&BR5SM8@$
MG[WH0.* /0--UJQU::]BLY'=[*<V\X:)DVN.H!8#</<9%6[BW@N[>2WN88YH
M)5*R1R*&5@>H(/!%>6P^/=9L]#\?W\TRW4NE:L]GIZ.BJJ!G"(#M R 6!YYX
MZUL7,OB#PCK'A][_ ,03:O:ZI>+8744]O$FR1T8J\9100,KC!SP: .IT?POH
M7A]I7TC2;2R>7AVAB"EAZ$]<>U:U>3C4O%VH>$_$FOIXD>U;2+J^%M!':Q%9
M4A9B!(2N3P-HQCIDY)JQK/BJ]EU6P6]\1OX9LKK3(+BTG%LCQ3SODNKR.I "
MC;\N1G.<T >H456L#<'3;8W<D,MR8E,LD'^K9L<E?8GI7G7_  EFM_\ "A7\
M2?;?^)N(687'E)U$Q7[N-O3CI0!Z=17!W$_B#6?B#K6AVNN2:=IUK:6TP:""
M-I5=]^0I92,'&3G/W1C&36-:>*_$.I:'H.CKJ*Q:M?:M<Z?/J*0KGRX"Y9U0
MC:&(4#ICD\4 >CC5[(ZXVC"8_;UMA=&+:?\ 5%BH;.,=01C.:O5Y)=WNH>$?
M'>OW]]>MJ;V/A?SK>65%1W F8A7V  G=D9 '&.]2^'O&4H\1:%;#Q9_;AU(M
M%>VQM5C%M)L+JT9500N5VX8GJ#0!ZM17GW@"[\1^()KK5=2UMC9VE_=6L=FD
M$8$RJY 9V SQD  ?W<G.:N^,M1UN+Q1X6TC1[\6:ZG)<I<.8EDPJ1[L@,.HY
MQVSC.1Q0!VE%>=P:OKVCZIXET"ZUNWN9+73DO['4=118Q$K;E/F[  0K+G.*
MK^%_%$\GBU-*A\33:]:W.G2W!EFM%B,4J,@RA"*"C!SQSC YH ],HKS'P5J7
MBG5/ /\ PE6H^(K<2S6$HAAN84CMXF5B!-(RC/\ "20,#!QCO3?#OB^2'Q/%
M9#Q--K]E/IT]U*\MHL7E21[3F,A%!5@QXYQ@<T >H45X]?:SXT@^&'_":Q^(
M/W]TD<QLOLL7E0122 +Y9V[MP!&2Q(//&<&N@^V>(]9^)FMZ+;:VUCI=A':7
M&$@C9R64Y0$CHW))Y(V@#&30!Z#17DOBCQ?>Z+?:G>+XOBDNK.[58M(MK820
M^3N4%)7V960@DGYA@\5M--XCU[Q]XCT:VU^73=.L([5XV@MXFD#R(3@%E/RY
M!)SSTP0,T =E>ZO9:==V-K=3;)K^4PVZ[2=[A2Q&0.. >M7J\:GU?6?$$'@Y
M9;F%-9MM=NK"6Z$0VEHTD4R!.F=O..F?:MJ;5O%&@W_BC1X;^;6KFVTI-0L'
MF@02JS%U*X0 /RN0,>U 'I$L4<\3Q2HLD;J5='&0P/4$=Q7-_P!G^#/ 44FJ
M?9=+T99/W;3[%C+9YV@]>V<#TJAX&U-M3N9Y;;Q@NO67E#S(IX$BN+>;/=55
M2%(SPPR".#UK>UG3M&^U6NOZL8U_LE)'CEF?$<08 ,Q'3.!P>H[4 6=(UK3-
M>LA>:5?07EON*^9"X8 CL?0^QJ_7$^!+:2YU7Q#XF2U>TL=9GB:TA=-C,D:;
M?.*]MY.>>< $]:[:@#!G\;>&+;6/[(FUVPCO]X0P-,,AO[I[ ^W6MZO*O'UI
M8Z!X.N_#-CH-PMA> R3:K*AD@MF>0EI)&&YRP/.<8Y'(%>GVH5;. )+YRB-0
M),YWC'7/O0!-52WU2PN[^[L+>[AEN[/;]HA1@6BW#*[AVR!5#Q1KC:%HYFMX
MA/?W#K;V5O\ \]IVX4?0<DGL 37)> -%_L'QSXGLWG:XN3:6,MS<-UFF?SF=
M_P 23@=A@=J /1Z*YCQOJ$NGZ?:%=>@T2"6X"3W+('F9=I^2%2K N3CL<#)K
MB6\;:TO@O6Y-/U7[;<Z?J]M:VU[/;B-IHI&B.'3: #\[*2 ..1ZT >NU1UC5
M[+0=*N-3U&;R;.W4-)(%+;02!T )/)%<?]LUOPSXWTRRU#79=4LM2M+J61);
M>./R9(0K938 =I#$8)/U-<=XDD\1ZU\%[WQ->:VSI?Q+*^F^1&(8XFE&T(P&
M_<!@Y).>1CO0![:[K'&SNP5%!+$] *YRU^(7A"]NX;6V\1Z=+<3.(XXTF!+L
M3@ >Y-;&LI-+H>H1VZ%YVMI%C0=68J<#\Z\ZT36-6\&^&]!CU_PE%:Z;#';V
M<MXETDDL+D*@=T"\*6QT8D9_"@#U*BJ&MW$]KH5]/;7%K;SQP.T<UVV(HV X
M9S_='4UP?A3Q/-)XRM-*C\3RZ_:WEE+-(\UH(O*E0IRA"*"C!CQSC YH Z?P
MZ?"VNW=SXFT6VMY;N21K>:]\@K(67 *Y8 ]@..N*Z2O#O!^J7^D?"B6XLIY;
M6-M>ECN[N&#SGMH"WS2!<'..!T.,YQQ733>)=2L_"D;:5XEM=;?4]3@T_3M0
M,:%H?,P&\U5 4LN&(X'49% 'I=%<-!<ZSX;\;Z/H]]K4^KV.L13A6N88TDAF
MB4/D%%4%2N>".,=:L^/]7O-(L]->*^GTW3Y;K9?ZC!;B9[:/8Q!P0P +!06(
M.,T =%J.KV6DFS%[,8S>7*VL'REMTK D+P..AY/%7J\F\13:A>>'?"SV^OV>
MKO)XE@%GJ*HI!0H^#($PI93G(&,X'0YK=L+S7-&\;WN@W>MG4X)-';4()KV.
M./R9%DV$$QJ/D.0>G&* .\K"C\8Z%+8ZQ>I>$V^C2R0WS>4_[IT^\,8RV/;-
M<1X>\5W0\6:%9#Q9_;HU(2QWD8M0D,3K&7#0N$7*Y4KR3D'-8>G_ /(C_%[_
M +"=_P#RH ]GT^^M]4TZVU"SD\RVNHEFB?:1N1AD'!Y'![U9KGO ?_)//#?_
M &"[;_T4M=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !6!XLT.ZUJQLY-/FBAU'3[M+RU:8$QLZ@
M@J^.=K*S#CIG-;]4-5UBRT:.VDO9&1;FYCM8L*6S)(<*..G/>@#F=4T/Q5XC
M\+:]8:I/IEO+?6P@M+>W9VCB/.6>0J&).1P%P /<U?U/PY=WNK>%;N.6$)I$
MKO.&)RX,)3Y>/4]\<5TU% 'F7CS0;FRTCX@:W))$;?4=,@CB12=ZF(.&W<8Y
MW#&":OP^'O$FLS^'H]8FTT:5I,T=XLL#.9KJ1$(CW*1A,9R<$Y/2NK\17&EV
MGAV_N-:C233(X2URCQ[P4[Y7O5^!HW@C:(8C*@J,8XQQ0!P4/P[FG/CF#4+F
M'[-XBE#0F'):( '!8$ 9!(. 3TJ;_A'?%6MW.BP^(I=*2QTJYCNV>S>1I+N6
M,'82&4!!D[B,MR*ZNPUFUU*]O[2!9Q+8R".4R0LBDG^Z2,,..HK0H \K\9:/
M;^(/BAHMA8W2O]IMS_;4"88&VAD62/?CH2XV_0UU.KZ-KEMXH.O^'OL$LL]H
MMI=6UZ[QJP5BR.K*K'(W,"".0:UDL-%\-VVH:C;V%M9J5>YNY((0K28!8LV!
MECUID?B;3I9-'2/[0XU>(S6KK Q7;M#98XPG!'7% &-?^&=;U/\ X1:>^OK2
M:\TR_-W=NJ%%8%6&V, 'IN &<9 R>:[ @$$$9!ZTM% 'FH\%>*(/"TW@NVNM
M,&@R%XEO69_M,=NS$E/+V[2V"5#;@,=JZ*Q\+S6/CV76HWA%A_9,6GQQ G>"
MCELGC&,$=ZZBB@#C?BO_ ,DM\0_]>W_LPJ >'O$FKZMH?]MS:;_9ND3"Z1[=
MG,MU*J%4+*0 F-Q) +<UV5[96NI6<MG>V\=Q;2C;)%*H96'H0>M3@8&!TH \
MZ_X1+Q5IVD:GX:TBXTH:->R3&*YG:03VL<Q)=0@7:Y&YL'</>KESX0U/3?$?
MAW4?#[63V^FZ>=,DAO'93Y65PRE5.6^7H<5W-% '#:?H'BW0T?1])NM+31S=
MO-%=2;S<0Q/(9&C$>W:QRS ,6'!Z5LZ/H5SI_BWQ)JTLD30:HUL854G<OEQ;
M#NXQUZ8)KH** /-?^$"URS\)>&K2RGT^34]%U*2]VRNXAE5GD.W<%R#AQV[&
MM'_A#-2N?'6H:]=W%M'#?:'_ &<Z0LQ=)20689 &WK@YSTXKN:* /-(_"/C!
MM*\/6DDFBQCP_/"\$43R;;K8I3<YV?(=I.  >2<FM_PQX6O-$\6^*M6N)H'@
MU>>*6!8R2R!%8'=D =^V:ZRJ%OK%E=:S>Z3%(QO+)(Y)E*D +)G;ST/W30!C
M^(=%U5]=T_7]":T-_:PR6TL%VS)'/"Y5L;E!*D,@(X/4U3O_  YXAUK3M&.I
MWEBU[::U#J,JQ!ECCB0G]VAQEB >K8SSTKLZJZEJ$.E:=/?7 D,,";W$49=L
M>RCD_A0!D#0;D?$5O$7F1?93I(L?+R=^_P TOG&,8P?7.>U<)XE\.:AHVE6<
M NH%N;_QJM[;2*"RQB1V9-P.,D=P/SKU:UN8[RS@NH@PCFC61=ZE6P1D9!Y!
MYZ4VZL;6^\G[5;Q3>1*LT7F*#LD7HP]"/6@#E]-T+7;SQ@GB#Q =/B^R6CVM
MI;V4CR#+L"\C,RKSA0  /QK#T?X;ZIIWP\TW1S>VBZQIFH_VC:S+N:$N')"M
MP#@JQ!QZ]Z],HH Y#3M#UN]\5P>(O$9T^ V-M)!:6UE(\BJ7(WR,[*O.%
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MUBIX/N#0!P%YX%\43^'-7\-076EQ:?<W,UU%=$N9I2\AE5)!MPOS8!8$D@8
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MUIVFPZ=!<?Z*B>:'9G'RLRG ..>/X1C'-;_A'09_#NEW-I<2QRM-?7%R#'G
M620L!SW -):Z!/!X[U'7VFC,%U8PVRQC.X,C,23VQ\PH \Y_M7Q8_P -;[Q3
M+XEG6\TB66*.*.&,17"Q2[2905)+, 1P0!@<9S7:6^M7]E\2O[,O;AGTW5[
M7.GJP $4L?$L8(&3E2'YJL? M[_PK75_#'VNW^TWTMPZ2_-L422EQGC/ -9_
MQ4C2?1M(L-.O4C\3+>11Z>D9!DRX*2$CJ$V,Q)Z<"@#?\"ZIJ&OQ:MK5S<,]
MA<WSIIL6 %6",[ PXS\S!CS[5@C3+[5?BMXH@M=7N=,@%E9&62T">:QQ)M +
MJP ZD\9/'(YSWNCZ7;Z+HUEI=J,06D*0I[A1C)]SUK.T_09[/QIK>MO+&T.H
M06T21C.Y3&'R3VYW"@#S\^-]23PCHEMJ&KO:W-UJ=S8W6J16X:010,^65 I
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M91N4@\@C\17.Q:5KWAK1KR\@ELO[5U/5X9YX;6%C"BNT<;*@/.=HW%CCN>U
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M'_M'25AT2YAGLMB2#[28G!7SO[ORYX7.20<\5HCP3J3ZSXGBN)[*30_$*9G
MWBXB?RMGR_PD9YR: ,^[E\1>%]+T/Q#=>(KN_:YN;:+4+2:.,0[9B%/EA5!4
MJ6&.3G'-6;2;7]<^)WB/35UR>TTK29+.5888TW.7B#%,D9"$AB>_(P1BI4\)
M^)]2AT?2]=O],?2M,GBF,ELC^==F+[@<-\J#(!;!.<<8K<T?P]<:;XQ\2ZU)
M-&T.K?9?*1<[D\J,H=W;DGC% '(^'-:OKWQ'%!J'BFXL]<%W(+G0[RW1(7A#
M, (?E!8[=I#!FSSD5WOB*YFL_#FH7%O>VUC-' Q2ZNO]7"<?>;UQZ5S,OAKQ
M1JEYIEOK-]I5Q8Z=?)>)>1Q,+J78VY5*X"+G@,0>1GCFMWQ?H4OB3PM>:5!,
MD,TNQXWD7<NY'5P&'H2H!]C0!Q7A_P 23+XEDTVS\0ZEK%I/I4UUYM_:&)HY
MD91F,F-,J0_3G&!SS5&+4_$]O\/=#\:7'B.YEN7>U\ZR\J,6\D4DBQD$;=VX
MALEL]>@'%=(WAGQ1>^)+37+^\TL2K:3V4MK")/+2-]I#(Q&6?<O.0!C [9,D
MW@F\D^%^G^%1=0"ZM1;!IN=A\J1'..,\A3B@""V?6_%/BKQ#]FUZYTVUTB=+
M2UA@CC*22; [-+N4EAE@, C@>O-6/A&6/POT8N '(FW =CYSTLGAOQ'IOB35
M[SP_>Z:EEK#)+.+M',EO*%"%XPO#9 !P2.16KX(\/S>%?!]AHL\Z3R6OF R)
MG#;I&8=?9A0!R&L:U?)XQU"ROO%-SX?N%FC72(I;=/L=RFQ22[E?F)8L"-RD
M<8I]MI6H:M\3?&<-MK-UI<*K8EWLU3S'?R3MY=6 4<Y &3D<C'.KXE\/>*=;
M@U32!>Z3-HVHY42743>?:H0 0BJ-KD<E22""><XK6T3P[-I7BC7M3:=)(-16
MU6)>=Z^5&4.[ZYH XZU\37U_\/\ 0;K5?$O]F237,UO=W%O!NN;GRWD0") K
M<DJ"<+P,XK#\1ZW<:O\ !7QI#/>SWR6%ZEO!<W,/E2R1[X77>NU?F&\C.!G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !63XE\/6GBC0;G2;TND<P!66,X>)U.5
M=3Z@@&M:B@#@I?#WCZ^L#H][XFTU;%U\N6^MK-ENY$Z'JVQ6([@<5=OO"=_8
MZQ8ZOX:N[:*YM[$:=+#?AY$FA4Y4E@=P8'//.<UV%% ' R?#Z[N-"NHKG489
M-5O]5AU*[N!$5CS&ZD1HN20H5 !D^]=!<Z!+/XYL/$ G016UC+:F(@[F+LK
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M))7!'7G.>G2I_$6@ZK=Z[I>MZ+<V<=Y91S0-'>QLT;I)MR1M((8%!]<UT]%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?*KB-N&#' (!!!/3K6AX9U#3;/XD^/A<W$$$YEM9&,KA<QB!>>>P).?3(]:
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MQ4'PF&/AMIH'027( ]!]HDJMK4\-O\9_#KSRI$K:7=*K.P4$[DXY[T 0:/\
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M29%B4MC<6W $'&"W6L"_D2[T#QM#-J*:F6US3P\_EJ@E&8%)VKQC@C(X.,T
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MML=1MKA[J+8I\QECW*<XR,'T(KN+AF2VE=3AE0D'WQ7FFN?\EC^'G_7G=_\
MHDUZ3=_\><__ %S;^5 ' ^#OB7I=UX;T1=9U-VU*ZC1)IS;,(O.;HID5?+5C
MQQD5TNL^--"T"\^R7]W()UC\V18;>2;RH^F]RBG8O!Y.*\L2]TV;]F:"RMI8
MC=211P1P*P\PW!F! "]=V?F^G-;HBU&/QSXR4^)K+2 QMYI$NK-9?-A\A5W
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M[:O!(8R<;PK@97/&10!NT5YM\.?&[W/A2QF\17[R7=_J<UE;RM'PS _*A*C
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MS/G'EB7&W=GC&>O%+K'CO0M#OYK.[EN7DMT5[IK>UDF2V4\@RLJD(".>>W-
M'2UCW?A/PY?W4EU>:!I5Q<2'+RS6<;NQ]R1DU7U;QGHVD/;1R2SW4US#]HBB
ML;=[AS%_STP@.%]S27/C?0;?2+#4EO&N8=0.+-+6%Y99R.H5%!;(P<\<=\4
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MO>OY=JEO"\DLS\Y58P-V1@Y&.,<UH:+KEAK]B;O3Y'9$D:*1)(VC>)UZHZL
M58>AH DN=&TN]GDFNM-LYY98?(D>6!69X\YV$D<KGG'2II;*UG:!IK:&1K=M
M\)= 3&V,97/0X)&1ZU7_ +9L?^$@_L,RD:A]E^UB,H<&+=MR#TZ]NO-5M+\4
M:1K$VJ165V)&TN9H;O*E1&PSGDCD?*>1QP: ,BRT#5]2\9P^(/$"642:=%)#
MIUM:NTFTO@/*[%1R5   &!DUU]<=#XITS5?$>@26>N7:1W]K+-;V M2$ND /
MSL2N5(QD#(S7/7OQ+EU;P?XQGTZ*[LKO2S,MM,UI(H"H$&6+KM#Y8_(>0.U
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MSNU.TB6::'8?E4XP<XP?O+Q[B@"<:'I*VT]LNEV0@N%59HA;KMD"@*H88P0
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MCYZY8#)ILNB:3/?&^FTNRDO"I0W#VZ&0KC&-Q&<8XQ0!3\&_\B-X?_[!MO\
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MVMVT+7-M#,T+B2(R1AO+8=&7/0^XJ.;2M.N+Z.^GL+66[C7:D[PJTBCT#$9
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M.FZ9 \&GZ?:6D+G+QV\*QJQ]P ,TZQTVPTN%H=/LK:TB9BY2WB6-2Q[X '/
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MHVLP6T;7=I>HK07:JI*?*V">"5W(?;K7<:1J)O/#ECJ5W$+1IK2.>6-N!%E
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M7T;WLMA(566[2T<PVS,<!96QA3DC([9'J*J>'+9;;XJ:S"&:0PZ-8QB1QAB
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M0W$,<T3=4D4,I_ U)7*^/_%DW@_P\+ZWLY+F>2>.),1%T7<Z@[L$8X)QZG%
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MG)=VK11W2J,DQD]>.<$ XH WKBQM+N6*6YM8)I(3NB:2,,4/JI/0_2G"UMQ
M\ MXA"^=T>P;6SUR.AS7GO@OQ3)#!XXO]=U&5K/3=:N(T:4EO*B4C:BCKWP
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MG>6GF&38N\C;NQSCTS0!YCH/]D:OXB\/3IXXO=9N85>YM[18X"(AY95O,\M
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MS-;07,)AGACEB/5'4,I_ TDEI;2VWV:2WB># 'E,@*X'3CI0!X+K-W:/X?\
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MK-J,)LMP\[+2.0=G7;M.[.,8!/:O;*@-E:-.\YM83,Z['D,8W,OH3W% '!:
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MTEN(&#1M,3(^ PX)"GG'3-85A$\?@CX::A)JLNDV< FBEOXU0^0TB,$+;P5
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MO+ZYEN;F6)S)-,Y9V/F,.2>3P*Y;0_\ D<_BU_URM_\ T1)70_![_DE&@?\
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M!PVW Y.*\^UR^@U7PQ\2KN#+6\VI6!C+*1O7, ##/8@9'J"*[[Q$ ?BMX()
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M332T)%K)'&0PE58@R 9*\D9R!S0!I^+_ (AP2>$?$+Z7;ZM''!%-!%J\46V
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MBZY?RV-G%+>A=DDMJI7($K,_SR8&2%+$]: .Q(#*58 @\$'O2)&D8 1%4 8
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M [HV4D8;(*^F>I YIB>.S<V&M+'H>J1:KI:(TMA(L7F8<$JX._:R\$GYNQH
MZ_:!G@<]?>FO#%)&$>-&0?PLH(KR+X<>*#I_@=_$NOOX@N)IQ\TUQ,)HKEVE
M952WC#G#=!C:OY5WFD^+X[_65T>^TG4-)OY(3/!%>!,3(" 2K(S#(R,@\C-
M'1%%.<J.>O'6EP"02!D=#7'Z)\1],UVWEO8+#48=-MX99;B^N(U6*$QDY0D,
M<M@9XSP1WXJ32_'MKJ&HV5K<Z3J>FKJ",]C/>QHJ7 5=Q VL2IV\@,!Q0!U@
M !)  )Z^]#*&4JP!4C!![UR5A\0;&_N[/_B6:E!IU_-Y%EJ4L:B&=^< 8;<
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M>E:G>66FOY=_?6T2M%;M@%@<L&;:""VT'%6=2\;6]I?&TT_3-0UB5+=;J?[
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M6EZYX?\ $=WX?UC7-=NHK:W22ZDD61&1)Q*8XF"C<X"L<#.-P[FO::0  8
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M",$ CWH \HT^RL;?6?A^^FG4)+2XO]0N1)J Q*Y>&0ER,# 8_,..A%;(4_\
M"Q?&)P<'1K;!]?\ 6UW]% 'B6CV\Z_ [P9J"P2R1:5J<5]<HB%F\E)Y-Q"CD
MX!W?A74G5[#Q?\2O#=SH-RM[:Z3!=2W=S#DQIYJ*B)NZ;B<G'7BO1*0  8
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M &."2!["O:*0  8  % 'F7@WQIIVF>%M \-M;S2Z_#Y=C-IBH1+$RG:TC9&
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MJ\DAV$OY$ZM$BD=> D!_"G>(-"GT?P=\-M/,3O/%KEI+<X4DB1BSR$_\"8T
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M[KPI\/\ 5KS_ (276KQC-:?/=SJ3$!<1[MNQ5(R"0>N171Z?XS-SXBMM'O\
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M-<Q;:S#X>\->,/#E[;W+:L]U?206X@<_:(Y<LD@;&W;@\DGC!S4GA*%V\3^
MI?+8HOA,#?C@'$?>@#J[_P <M:W5S!:Z!J-\UC"DVHF Q_Z+N7=L^9AO<+SA
M<\8]:GOO&D*R6$&C:?<ZS=7UJ+V.*V9$"P'&'9G( SG '4G-<-J<&FZ/XO\
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M1'[4$QE1AR$?D<-C&><5!\.O%.I^*M*N;K4-.FMPMS,L4S&/:RB1@$ 5B<J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT1\ORU3]Q\IR6Y9MW(YQF@#TJBN/M_'%Q<:))JR^&]1^SRO"FGJ&0O>F0X!
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M77HF\7R>'?)?SDL%OO-R-NTR%-N.N<KF@#7HKC;OXB65EI]Y>R6-RT=KK/\
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M-R<MGG@<CJ>M1V'C\7DVGW$NB7EOHVI3B"RU&1T(D9L["R [E5L?*3ZC.,T
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M;+:2W\S;NV;U*YQD9QGI6+=^-%9M,AT33)]5N]0M!?1PI(D02 XP[LQP,E@
M.<G/I56?XBV46E:5>+IU[))?WCV'V50OFQ7"ALQL,XSN3;G..0<XH ZC2[+^
MS=(LK#S/,^S0)#OQC=M4#..W2K=<2WCJ]6#7+:?P]<6NL:;:+=K:/<1L)8F)
M&]7!QQM.1[8&:O\ @#6M4U[P;IVH:M:M#<2P1MYK,A%QE0?, 3[H))X.#[4
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MW<8T^^\4:A=Z%]H$YL9D5G?#[PC3'YF3=CCK@8S7;T >(PZ3I%E;ZGH.N?\
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M<*@)X'KD] #6O7'_ !#M+N2PT?4K2UFNO[)U6"^F@A7=(\2AE;:O<@-G'M0
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MNE^(C^!Q$3HLE^OB(GL(N<Q8]#.!QZ5[%0!XQX5N[W4/B9XFUC7-*D_XELR
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M %;#&-H0$XR>U>A^$89AK?C.=H)DBN;])(6DC9?,7R$Y&1Z\4 .D^($=S8Z
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MD<$HZ/@9!PPY P10!OT5RNJ>*M236[S2]"T,:I+81)+>,]T( I<$K&GRG<Y
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M/O62.XM9-CQNIR#Z$>H((-9VB>%'T[69=:U+5[G5=3> 6RS31I&L46=Q540
M#)P2>^!7"_$CQ=J=_P#";5I[.P>RFBG^Q:C_ *5A[1UEC!5<#]X&#=01PV?:
MNS\-6DGA[P7,+?P_#8RPH\J6,-V91*P4$'>5X+$8Z'\: .JHKA=6^)=KIO@O
M1?$46GO<C4PK_9TEPT2"-I)&)QSL"G/'-:NL>)H8-;AT-;/[6MQIT][.XEVB
M.)  .QSN)QU&/>@#I:*\?7Q9=6?PY\&W7A/1$L;/4-4CMQ;F\SLS.?W>YE)(
M?#9;^'/0UI)J>LV_Q1U866BI<ZC-I%FTD#702*'#2;LR;3GD@#"\]>,4 >G4
M5B>%/$(\3:(+XVCV<Z326]Q;,X<Q2QL59=PZC(ZUD6/C6^U3Q3J&CV.@EX=-
MO/(O+M[H*L:%00X!7+$Y;Y1TV]>10!V5%</:>/[J=;'4Y=":+P[?7*VUO?FY
M!D^=MJ.T6WY49L '<2,@D5/:^,=4OK^1[/PX\^CQW[6+W4=T#,&5_+9_)V_<
M#9_BSCG% '8T5PC>/-8NI];CTCPN;Q=&NI(+AWO1&'"@'Y/E.6(S\O '')S5
MIO'3:C'I">'-,_M&[U*S^W".:<0)!",#+MAN=QV@ 'D'TH [&BN-?Q^O]@VU
MS%I<SZM<7S::NF&505N5)W*7Z!0%+;L=,<<UC^*?&WB.Q\&>(7.A-IVJV$2Y
ME%QOB"."!+&^P!V4\%2!C(H ]*HK+TJ[U.X\/QW-Y81PWYB+"W6XWJQQ\OS[
M1C/';C/>O)=0\2:WK?PCUZ]UBT5(H]27RY4GWMA;Q1Y84*.% P#DYH ]NHKD
M;/Q=J2^)['1]9T'^SEU&*62SE6[64DQ@,RR* -K;3G@D=LFJEM\0+J=+/5)-
M",?AR\NEMH+_ .T@R?,^Q)&BV\(S8&=V>0<4 =S17'6GC2_U+Q;?Z%I^@-,F
MG720WET]T$6.-E!#@%<LW+?*/[O7D57A^(%S)'!JK:&5\-3W0MH]0^U#S.7\
MM93%MXC+X&=V<$'% '<T5YYHWB[6CXR\71ZK9Q0Z1I7EL[BY#?9D$)?(&T%M
MW4\C'3FK$/C[4DMM-U34O#9L]#U&6..*Z^V!Y8Q(<1M)'M&T'(Z,<9H [NBN
M>\=75G8^!]7N=0L?MUI';EI;7S#'YJY'&X<BL?\ X3$Z?!X7TS2M!:>35=.\
MZT@%SM6$(D9",Q!^4*WWNOR]"30!W-%<[X7\2W&N3ZI8ZAIW]GZEIDRQ7$*S
M"5"&4,C*V!D$'TJ'7?$>MV%_<0:5X:>_AM(!//<37'V=&SGY(R5.]L+ST R.
M>: .HK(T?08](U'6+Q)WD;4[H7+JP "$(J8'K]W-8MQXYDNGT6V\/Z7_ &C>
M:K9_;U2:?R$A@POS.VUN<L   ><US6B^*_[&N/'FMWNGSI.NH6\0L0P+M,8D
MC"!NA!;HWISCM0!ZM17F=UJ6K7?Q/\%PZQI"Z=.JWKKY5R)XW4PCC=M7##'(
MQW&">V9-XJ&G_#SQIJ7A?15T^>UU6X@G?[46/F8 :X&Y3SDK\G3WH ]?HKSS
M6-9B%]X)_P"$@\/1OJ-W>E+=DO"PM6P/WF0H#9&.".*TKGQAJMQJFIVOA[P\
M-3ATM_*N9I+P0;I=H8QQC:VX@$9S@9.* .QHKB)?B*DZ>'#H^E2W[Z]!-);H
M91&8VC"Y5\@@ 9;)[;3@'(%:GACQ+<ZU>:KINHZ:-/U+3)$2>))_.1E==R,K
M8&<C/&.,4 ='17!R^(O$(^+ZZ%%81OIJZ:)R#=!?E:4*9L;>HP5V9YZYIT_C
MW4I(-3U+2_#AO=%TV62.:Y-X(Y)?+_UC11[3N P>K#..* .ZHJI:ZC;WNDPZ
MG;%I;::!;B,HI+,A7<,#U([5S.F^,M5DU72K?6/#CZ9;:MO%G(UR'D5@A<++
M'M&PE0>,G!&#0!V-<[J?A7^V?$%K?ZAJ=S-86DJSP::$18A*HX=B!N;!Y )P
M#7.O\2-3?1M0UFS\+M-IVF3S17DC7H1L1.0QC7;\V%&XYQZ<X-=%8>+(KSQ9
M)H36QB#V$=_:3E\BXC8X;C'RE3CC)ZYXH VKNQM[Y8EN8_,6*5)D&X@!U.5/
M'7!P>>X%6*P]$\1C7-8UNTAM"MKI=PMJ+KS,B:7:"ZA<<;20.IS61<^,]5N+
M[58] \.C4K72I3!<SO>"$O*JAF2-=IW$ CJ1SQ0!V=%>::IXZU:\UWP8_AVR
M2XT_5XIIPDER(C,5B),;?*=NS(.><D8[9JOI&LZSIVO^-QI&A#4C%J9FF,ET
M(%"^3'A5.UMS'!XX XYYH ]3J&[M8;ZSGM+A2T,\;1R*&*DJ1@C(Y'![5R?_
M  G3ZA9Z)_8.EF^OM6M3>)!-.(5@B7;N9WPW\3!0 #DU!>_$>.P\,KJUQI,P
MN(]373+NS64,T,F[!VD#Y^"".F01TH [>.-(HUCC4*B *JCH .@IU9VBW>I7
MNG";5=,73KDL?]'6X$V%[$L !GVK1H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB_BG9W=YX%G%G
M:S74L5S;SF*!"[LJ2J6PHY/ )KM** .'TYY=3^*$.M0V5['8R^'S&LEQ;/%A
M_M&=I# 8; S@\XYKE=2\-WEW8ZW/<:7?3P6_BXW[6\(=)9[?RD1FB*D%OO$C
M:>=I%>Q44 >3OH^DW/ACQ;-X=\.ZQ%))I,EM'<WC7!>Y+*Q\N..4EL XYP,D
MX%:/B;09K[X>^%O-T^[N5TR2TN+JS@+I,T8B*.%"D-N&_. 0>,5Z/10!YUH6
MF:,\.O7>A:!JUOFP-NEW?O<;K@D,2B1S$M@''.!DG K&T_0]6A^$/@Z4:;=-
M>:+?Q7\UCY969D5Y RA3@[MKY [XKUZD+*I + 9.!D]: .!CN)?%OQ T?5+.
MPOX-.T>UN=\]W:O!YDLH50BJX!. I).,5DZ1X:U*^_9Y30C9RPZB;:0BVF4Q
MN669G"G.",X'YUZF'5B0K E>H!Z4Z@#S?PKI_AV?Q+97.F>&M=@N+:)Y'NM1
MENE6V<KM* 2L0[$,P^7(&,YKM= UJ/Q!I*W\5M<6P,LL1BN%"NK1NR-D9XY4
MUIU!9V=O86XM[6(1Q!F;:"3RS%F//<DD_C0!P$%Q>_#_ ,3ZX+C2;^]T+5KH
MW\-S80&=H)F $B2(O(!*@@@8_I8NKG7/'>D>(+*'2I=-TBXTZ2WM7OXS%//.
MP/S;2?EC' Y&37?44 >57U[>>*O#.B>%X=%U2VU!9[3[>;BT>.*V6%E9V\PC
M:V=GR[2<YK9T:PO(KGX@&2TG075VS6Y:,CS1]G497^\,\<=Z[MF"J68@ =2:
M7K0!Y;+I6HGX6>![06%S]IMKS36GA\IM\05AN+#&0!WSTI=&\2KX?\5>-S<:
M;J-S$^HJ8GLK5Y]\@A3*':#M/W<$X!R>>*]1K)TG0H-'O]7O(II';4KD7,@?
M&$(14P/;"T >76.C7FC:1X5T_P 2V.K2Z2ME<236NGI*^+N27>JR"+G 5F S
MQG-)IFEW\6G6FGKHE_:O;>,8;PPM"[+';N2RMOY#!1PQ!.#UZBO9U974,C!E
M/0@Y%&Y2Q7(W#DC/- ')36=R?B]9WHMY3:KH<T1GV'8',\9"[NF< G'M7&VF
MC70^)+>#?+SH=K?GQ$ISP%8?)%CT$VYL>@KUR>-Y;>6..5H7="JR* 2A(X(S
MQD>]8WAWPQ!H$E[<M>7-_J-\ZM<WMT5+R;1A5 4 *H&< #N: #QGHQ\0>#=6
MTM!F6>V;R<=I!\R'_OH+7GMO9ZU?>$+SQ?=:3>)K?]KV^H1V9A83&. )$4"8
MSRGFG'^U7K]% 'B_B/PYJS? ZW@&GW,VKWMZFH74$<3-('DE,C94#/R@@'TQ
M74:KI][)\<- OTM)VLXM+FCDN!&3&C$M@%N@/M7H%% 'G_PVT^]L=6\:O=VD
M]NMQKLTL+2QE1(A/#+GJ/<4V\OI]!^*NI:I<Z7J$NERZ5!";JVM7F"R!W(&%
M!)XZX!QQGK7H5% 'BTGAJ[O-+3Q!J&CZBUK-XCN-1EL(M\=RMK)'Y2MM0APP
MPK%1S@FNV\#:?HT5WJ5]H^B:E8Q/Y<0NM0DGWW(&3PDQ+*JD]<#.3Z5V=% '
ME.NZ)IEEX[UN_P!=TC6KRWU%();.73#<D;DC$;1,(6&&^52"W'/7BM+2-%>Q
M\8>%&M-&N-/L8-&N5:%F:46[N\;;&D.<MU[]C7HE% 'DGB;0]4O-)^)\5OI]
MS(]Y);/; 1G]^%BCW;/[V-I''<8JWK[7/B+Q)\/-3L=-U$6T%W,9S-:/&81M
M49<$?*,@X)X->H4UG5" S 9.!D]30!Y[I)N-/^(WC*UN-/O@-4\F6TN%MG:%
MU2WPV7 V@Y&,$]:Y'1O"]VOPI\'/J>D:BZZ9?S27ME$LD5P(G:5=RA2'R-RM
M@<D9KW*B@#R"_P##EEJ'A37;GPOX=U2&9)+62)[Z2?S+T0R"0JJ3$L .0.!D
MGBM:YU:X\3^/?!UW8Z-JL=A9RW+7-Q=6;PA&>!@%PPSUX)Z9( )KTFB@#B/B
M=!<OH^C7=O:7%TMAK5I=SI;1F1Q$C'<0HY.,]JHP:F?#_C;5==N--U232]>M
M+62&6&QDD>*2)64QR(H+(2"",CUKT6B@#D?A[I][:Z5JE]?6LEI+JVJ7&H+;
MRC#Q(Y 4,.S84$CMFN6&DZE_PDWQ7E_L^Z\N]L(DM7\EL3L+=P0AQ\QR0..]
M>KT4 >=ZMIM])X&\#6Z6=PTUM?Z6\\:QDM$J;=Q8=@.^>E95C9RZA\1_BG90
M &:XL+:) 3C+-;D#]37J\BL\3HKE&92 ZXRI]1FN<\,>#8/#FH:IJ3ZA=ZCJ
M6ILAN;FZV@D("% "@   T <&]_>ZMX1\':-;:#JZW6FWVG"_,UD\:PB)E5B"
M1\W(SD9 &2<5U_A>RNK?6?&DDUM-&EQJ.^%G0@2+Y"#*^HR"./2NRHH \>\.
MV>H^&+#P3KMWI=^\%OI<UA?116[/-;EF#JQC W8RI!P..*T?%M_JWB+PE#J8
MT"^AM[/7+:XAA\IC<2V\;@F0Q8R.<X7K@9KU"B@#SB:*ZU/XR>'-:@L+U=/.
MD2AII;9T",2V%;(^5O8\UDZUX=U1_&-[X7@L;AO#^NZA;ZG<7"QDQ1JH)GC9
MN@9VCCP/]JO7:1F5<;B!DX&3WH \P\3:)IUKX]O=3US2]6N]/OK.%8)M--P?
M+EC+!D98"#R"I!(QP>E=IX0L;;3_  O9PVNES:7$P:46<\K2/&68L=S$DY.<
MD9XSBMRB@#S3P[X=O[SX6>(]&DMY;:[O9]06)9T*9WLVP\]CD<^E5O"NEZ!-
MJFC+%X6UZ+4K;]Y<2WLUTL-G(J$9!D8HY). %SP<\"O5** /&+/1=57X<?$J
MU;3;P7%WJMY);1&!MTRMMPR#&6!QP15J]\/PPKX/U/6]+U2XT^+0TL;E++SU
MEMI0(V4LL1#D<.I'.#C->N;EW;=PW8SC/-+0!X_XHT*.;X*:]!X?\.:G:O>W
M4<J6LQEFN)\2QCS"K%G&53.T] ,UZY "+>,$8(09!^E244 >2>&_"U[<>);_
M $'4;&>/1=)AOH;*5XR$E6[?(VD\-M3<O'3-3^ ].UFZL-;U+6K"Y@O8=.BT
M>W6:,JSK#&2[*#U#.V0>^*]4HH \3L]*U2P^#7@HS:5?&;2]9AO+JV6W8S)$
ML\A)V8W'@@].]=QH2SW7Q'U?5A:745G=:5:>5)/ T>2&D)7Y@,,,C(ZC-=I1
M0!R/P]L[FRTO5TNK>6!I-:O94$J%2R-*2K#/4$<@U6\(Z9<IK7C<7-O-!'>:
MD3%(Z%1(AB4;E)ZC.>17;T4 >+^&O#FC6UII.B:CX6UR?6[:9(KC,UTMJNQL
M^>'W>45X# #OQBM#48T/B(W.AZ-KFD^)VU%!.L,<GV.YC\P!Y)&QY3*8\G/#
M9]Z]8HH \HT'Q+_85SXVC?2M1NC)K=P;8VEJ\PEDV(/+)4':?N\M@<]>#67!
MX-CT&/PS/XCTW4KFSCT;['<?V>TQ>VG\PR#<(2&*G>RYY&0*]5T308-#DU1X
M99)#J-\][)OQ\K,%! QV^45K4 >52:.NG:5H.OZ-X<U&VM['5Y+NXL9&>:Y>
M)T:(R[6);=C:VSKCWJYXJU+5/&?@7Q5;:?H=ZEH+55M'GA:.:Z?.YPL3 -@
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M'2*V6%E9W\PC:P.SY=I.<BO5Z* .6^)%I<7WPYUVUM();BXDM2J11(69CD<
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M=)DTT;1 TJ\JS8&YL'!P3C('% !X'T270?"-E:W7-](#<7CGJT\AWOG\3CZ
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MZB\L*I*5VB)?,)#[LL"P& .>: .@\.>)-=U>2QGO-!A@TW4(//@N;:\\XQ#
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M=@JC ]210!<HHK'\0Z^F@1Z<[V[3?;=0@L0 VW896V[O?'I0!L4444 %%%%
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MC+26_M]I6E@BT)]EY+*HV_=W97!)/'MG-9T7Q#MQ/9_VAH&MZ;9WDJQ07EW
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MI7DFXWR6UO($9HQ(I/')'!Z-BNC&AVOASXK^'+32WEAL9K&[<V?G,R(XV L
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MTH P;718O$_Q%UVWUU)7@33K&22Q\YEC\UEDR2%/)'(';G/85RM[8PZA\/\
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MEUD:1G^^&1AL*^B@#&!CWT_#V@)H-K<J;N>\NKN<W-S=3[0TLA 7.%   "J
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MZKJ7B;3M6>REE22RUS3YR3IT811@H#E &#,6VL#NYKU1TBN;=HY%2:&1<,K
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MNO#]YH&MM:.AVS"2VU +MW-O!.YQ][G# ,>M ':^*_$5OX3\,7VN743RQ6J
MF./JQ+!0/;DBI=!U#4-2TI+O4],739GY$ N!-\N 02P YY/'M7%_''3K.Z^&
M&I7D\"/<6GEF"0]8RTJ!L?4<55N/#VE/XI\,^%A9K%HDEG/J,]FI(CN9@(U&
M\9YQG..E 'H'B#5QH7AS4=7\GSQ96TEQY0;;OVJ3C.#C..N*YRX^(*V^F>#[
MW^S"W_"1S01!//Q]G\Q0<YV_-C/MFN3U2WCT2U^)/A^P!CTJ+1UNH;<,2EN[
MQR!PN>@.T''2JFH_\BO\'?\ K]L?_0%H ]K) ZG&:6O-M*T#3/&OB;Q9<^(;
M87K6E_\ 8+6.5CBWB6-3E!GY2Q8G(YK"\*:E<6<W@W7[^Z>2*>*]T6YN96SO
M6.1WA8GN?W3#- 'LU&0.M>(Z)KEUX8T_6]:N7D$FO:1)K4"N>DWFN%1?^ S0
M?E5NY\&2:):Z:=6\.W'B#2H-)B@9;:7]]93 LTLB1DC<6+ Y!W#;0!['6&OB
M,3^,'\/V=J9S;0":^N/,VK;[O]6F,'<S8)QQ@#/M5OP_/:7/AW39K&ZENK1[
M:,PSS'+R+M&&8_WO7WKB_ W[_1O&NH2<W%QK%ZKL>H5!L1?P _6@#T7(SC/-
M(2!U.*\/30;&P^$?ASQ/$KG7(GL72^,C&0!I439G/W-K;=O2NIT[0=-\9^+O
M%DWB"V%[]BNTLK6&5CMMXQ$K$H,\%BQ.[KQ0!W>H:M9Z9+8Q74I1[VX%M  "
M=TA5FQ[<*>:NY QD]:\&2QM]?TSP#_:\?VZ1=8N-/::8DM-!&90H)[_='/M6
MG>Z=-K_B#Q0C>%+O5C:3BQL9XKV*(6*K$A7RP[J0V6W;AUR.>* /9JYK6/&=
MEIWAK7=8M(S>?V/(\,\6XQYD7:2NX@_WAS@UH^'UU!O#&G1ZU'MU'[+&MVI8
M-^\V@-R"0><]*\9CT/3+#X;?$JZM;..*>+4KVT1USE85:,A/H#0![O'()(U;
MH2H.,],T_(SC//I7F-_X>T_PUXI\%WVFQO'>W=VUO>7!D8O=*T+D^9D_,<J#
M[=JYW5_LIMW\3:1HM\[_ -L1M'X@NKI!(V;A4950'<8NJ!< 8[4 >QPZM9W&
ML76E1REKRUBCEF3:<*KEMO/_  $U6\3:_;^%_#=]K5U&\D-I'O*)U8Y  'U)
M%<5X=T'2A\:?%ET+*+S[>.UGB?G*/(LF]A[GO5GXTZ=9WGPRU6YN($DFM$5X
M'/6,EU!(_"@#K/#FIZAJ^D)>ZEI:Z;))AHX1<B;*%00Q( P>3Q[5K Y&1TKR
MB30-+.K^#?#*6BPZ->6T^H7=JC$)=2I'&%W\\@9SCH<"J.OVT7A^/X@:#I@,
M.E_V&E[';JQV02MO5M@_A#;0<>U 'LN1G&:"0!D]*YGP1X?L=&T&WNK>-C>7
M]O#+>7#N6:9]N<G)X^\< < <5SNH:'8>(/C)=VNJ)]HLTT.&0VK,=DC>=( S
M =< GKQSGL* /2**\4@+6<%KI$4DAL]-\=Q6UJ&<MY<6W<(\GG +$5U^JL?^
M%L!-QQ_PC-P<9_Z;)0!WF1G&>:,C.,\UX3::%9VO[/5WKVUY-5NM+\N2Y>1B
MWEB0;4 S@ !5Z?7N:Z?5] L?"NL>#]6TH.FH7>IQV=Y/YC%KM)(W+F3)^8Y4
M-GM0!Z=D9QGDTN0*\?TWP_IWB3X?:UXIU1&?7)7O9H[TR,)+4Q.XC5#GY0H0
M<"FWEG<ZM9Z5XE\0>';CQ!IUWHEL6^RR#SK&7:6D=(R1G=N!RO(VT >Q$@=3
MB@D 9->.W+Q>(_$\5O'H=YXJTBTT:U>T22ZC3_6[LS.)&7<Y"@9ZC!Z9J:3P
M[XADT#0&UOP]-K%MIQNHI]*EO$:4H7'DR9#;)&5!MP3GGUH ]<I"0.IQFN>\
M$3:;+X6MQI)O!:1O)&(;W/FV[!SNB;/(VG*@<\ <FN8TO0-,\:>)_%ESXAMA
M>M:7WV&UCE8XMXEC4Y09^4L6)R.: .H\9>*X_"&C17QLY+R:>YCM;>W1PF^1
M\X!8]!P>:UM,GO+G3XIM0LELKI@?,MUF$H3DX^8 9XP>G>O"-;M8=9^&7A"_
MU-/M=ZFMIIQNI22\D"S2J 3WR%&3[5[M8Z58Z;IB:;9VR0V:*56%>@!))_4F
M@#$UKQK9:9X9UC6;2,WHTNX^S31;C'F0,JL,D'IN'..U=/D9(SR*\ .AZ=9?
M"[Q_<VEI'#<)K$]HDBCE8EN(]J_05V]YX?T[PQ\1/"$VE1/#-?274%Y)YC,U
MT!"7!D)/S'< <GO0!W&F7>HW4EZM_I@LEBN&CMV%PLOGQCI)@#Y<_P!T\BM
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MCOHC,"TRH$VAG0\YPI.#SR.YIVN>#O#P^,GAG3AI4'V.;3IO,BYPVQ=J9Y[
M ?A0![ K$JN\!6(Y7.<&G5Y;H?AG2O&$7BC4=;@\^[CU.YL[>5W(-G%%\J"/
MGY",;LCJ3S6%9K)XRN?AI'K,LLJ7FFWGVL;RIN @3AB.>2H)]>?6@#V[(QG(
MQZTN1D#/6O,(O"VD:E\3]4TJ[M1+I=IH]FL=DS'RN"ZJ2,\[0"!GU]<5R?\
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M/G!6($C$#'7- 'L5%8GA">PN/">G2:7/<S67E;8FNB3* "05;/.5(*_A6W0
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MJ5#QEAAAA@05(Z@CL*V#)&)!&74.PR%)Y/X51@UJRN-<N]'CD)O+6*.:5<<
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M8NM3T_6=2TBXO45+S[$R8G"C"DAU;:P'&X8.*V+_ %JRTV_TZRN9"L^H2M%
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M26=9""JE00-N #CGOFMRB@#FM"\#Z5X>\0:IK-H]PUQJ!.4D8%(07+LL8 &
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M&L<:#^%5& /R%2T4 >3^"O /]J^ ;*WU#4=6M;.XEE>\TP%5CE(F;&=R[U!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRNXK&3_K6 !SCCWS6%KVI"^^*OPZN;2=_LEY;W<R@$@.IA#*2/QH ],HHHH
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M(H)-HR2%(&<<X-=K10!YGXOUR?Q;\./%BZ?I5W]B2)([2=XW5KLY!<K&5#
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MOE4%F-O(  ,DG::\1ETO4#^S]X5M/L-S]ICU*-GA\EMZCSI#DKC(&"*]ZHH
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M80^+?"6JZ9I>O-;1/)#?7U['<NYFDA*J"KY/WL[G "C(YZXL^'_#EY+XUN]
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M\R,S'<9,F,'( WXSC/<9 -;Q%XDU?58O"$E_H$FF6]YKME+;R"Z67<I;(60
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI9SBX-J -DTB_<+GJ0IYQT)QGI6Q6%J?B,V/BG1M!@M/M$^H"621O,VBWBC
MRY&#G)(4#CFMPD $DX ZDT +17GQ^(VHG17\31^'0_AA'/\ I/VO%PT0;:9A
M%MQM[XW9QS5W4?&VH+XMD\.:-H:ZA<K:Q7:RM="*/RV)!))4XQA<8SG=VP:
M.THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]LY_*N[9T3&]E7<=HR<9/I3J ,GQ3I4FN>$]7TJ%@LMW9RPH3T#,I S[9Q7
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MOELB[VCERJX;;DY&1\IKG]$\*ZG>? JY\/36SVVHS)=!(IAM.XS.Z9ST!X_
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MQ.&9O0 D5A0'6-!T/Q1X73P_J5U=75S>26-Q%#FWDCFR5+29PI7<<CKQQG-
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M6+1W>G@G[D$H),8]D<$#V-=S7"Z#_P 3#XM^*-0BYM[.TMM/+CHTG,C#ZKN
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M -ASCKGC%=/HVC7=A\3KV<V\OV%=%MK:.X*_*[([9&?7&#0!V]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1P7
M$-S'YD$T<J9(W1L&&?3(J2O*M"\<QV'P[_MG3O#UM;JVL?8S96IVABT@4L/]
MHY_.MT>*/$UGKKZ/J6E:=]KN;":[T_[+<.ZL\>,Q/N4<_,/F'Y4 =Q17%2^/
MXE^%\7B^&V$DTT*".T#?>N&;9Y>>O#Y'T%)<^)_$EQ?7]KHVE:?.VDQ1_;O/
MN&3S9F0.8HL*>@(^9NY H [:BN%/C?4=9O=/M/#-KI[R76F)J>=1G:/*.2 B
MA026!4Y/0<50U77O%LGCOPI:V]K:V27=I/-+9SW+?>"KO5R@(.W/RXSG/.*
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MQ,5!$BG'!^N:U!XB\1HNCZ-#9Z;-KMW;/=2.\\GD0P)M&YCMW%F+ 8 ZYYH
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MO<8+.%IG"]2 ,X'N>E<I'XM\1Z=)H]UK^DV$&G:M<1VR?9KAWEM7D'[L2 J
MP)X)'0GO0!T6A:!8>%["Y6&::1II&N;J[NY=TDKD<L[<#H!Z  5KJRNBNC!E
M89!!R"*\B?5?$NHZ=\3(M2-FUG;6]Q%M29V,1%KP(P5QM/4].2>*UM'\4:]I
M.F>$VO\ 2K--&U'[-8Q%)V-S&SQ_([KMVX..@.1D4 >D45P5]XVUE(M7U>PT
MJTFT'2)Y(;@O.PN)A%Q*\8 VX4YP">=IZ5+?>,=9G\8R>'= TVSN7%E%>K<W
M,S)&L;$@YP"2?NX ]3Z4 =Q1110 4444 %%%% !1110 4444 %%%% !1110
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M\5I>(=#N]4\=Z+<+"QL$L+VWGF!&$,@0*/7G!_*N6\,>%HM._L?2[CX=VO\
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MZRM3T;6_$D/C/6#H]S9O>Z2NG:?:7!032;0S%F 8A<LV!SVK;\0Z#J=SX/\
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M=( 0XSVX)'/&<9XJQX,T=K7Q9=WVF>'[W0-&DM-DMI<LJK+<[P0Z1JS!0%W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %9UYHMI?:QINJ3!_M.G&4P8; _>+M;([\5HT4 %%%% !111
M0 4444 %%%% !5+5])L==TJXTS4H!/:3KMD0DC/.001R"" 01T(J[10!S^C>
M#M-T746U%9KZ\OO*\E;B_NGG>./.=J[CP,@5N000VT7E01)%&"6VHH49)))P
M/4DG\:DHH **** "BBB@ HHHH **** "BBB@ HHHH YC5? 6CZMJ-U>O)?VT
MEXH2\2SO'A2Y & )%4X/'&>N*Z&TM+>PLX;2UB6&W@01Q1H,!5 P /PJ:B@
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M.V10!/17.>!/%#^,O!]EKLEJMJUR9 85?>%VNR]<#^[FNB#JV<,#M.#@]#0
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MN_[+<R6LF?[Z'#8]1GO61XT\8-X5BTV*VLDO;_4KM+2"%YQ$H+?Q,V#@#Z4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*LT>-LBMC(;(R2<\^W%367@6PLM7BU87^IS:@(GAFGFG#-<HV/E?C&%P" N
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M0Z7;26D\%NG"0O+&2X4=@2H.!QS6E+X#TMM,TBTM[F^M)M(B\JSO+>8+.B8
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M 74]P&>2,@9C;Y<;.,X '.3GDTQ?AUHB^#]0\,![O^S[Z<SRGS!OW%E8X.,
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M3M2O8;.XCB >W3 &$/50 3P*]YK"TOPCI6E0:S!&DDT.L7,MS=QSL&5FD&&
MX'RX[4 </KGAS1_"VB^%-4T.SAMM0CU&SA^TPJ!)<I(0KJ[#E]P)/.:L>#-
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MX+B4:N6,%A%$=S)&Y 5\D*H(R<=P.* /::*** "BBB@ HHHH **** "BBB@
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M258':&; ([>U:FI:7JFF:1-I]]I]OI>CZOXALHS8VMSYB11/@3+D*NU690<
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MBGMWMYHDDAD4H\;J"K*1@@CH1CM7A-KI5C'\"[B2"UAMY[C5UBDGA0)(RB^
M4;ASP.GI0![G#>VMS++%!<PRR1'$B)(&*'W Z4+>VKW36JW,+7*#+0B0%P/4
MCK7GNK:3I_AKXB>&'T/3K>S>:QU".5;>,)YP2-&0-C[V&YR>:YOPSHFM:CX;
M\-:C9>&].AO!<0WSZT;\&>;<V9=X\O)WJ6!4L<<>E 'MM%%% !1110 4444
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MW;SQ@9/3N2>:(_ &AQ:5?:?&MRD=Y?'46D6<K)'<$@[T8<J1@8KJ** .:M_
MVCII^I6EY]JU+^TD6.ZFOIS))(JYVKNXVA<DC&,$YZTND^"=-TF[EO#<ZA?7
M<D!MA/?W33/'$>2B$]!G\3BNDHH YB'P%H4'A&V\-)%.+&UD\VW<3$2PR;RX
M=7'(8%C@_A3K3P-H\$6H"Z-WJ4NH0?9KF>_G,LC1<_(#QM7DGC'/-=+10!S>
MF>"=-TZ[-U-<ZAJ4H@:WC.HW)G$4;8W*H/'. "3DG'6F:5X#TG2+ZUN8I]0G
M6R#"RM[F[:2*UR-OR*>GRD@9S@=*Z>B@!KHLD;1NH9&!# ]P:Y73OA[H^FV5
MG913ZA):V5Y'>6L4UR76%TW;0N>B_,>*ZRB@#,FT&PGUW^V)8R]T;-K$ACE#
M$S!B"OU%96E> ])TB^M;F*?4)TLMWV*VN;MI(;7((^13TX) SG /%=110 UT
M61&1P"K#!![BN3LOASHMCIEOIJ3ZA)9VUY%>6T,UT76%XR64)GHN2<CO7744
M 8>N^%K+7KJTNY;B]M+NU#K'<64YB?8^-R$CJ#@?EQBL\?#GP\NG:AIZ1W*6
ME[+'.8EN&Q%*@&)(SU5^ 2<\D<UUE% '-:9X'TO3-8CU?S[^\U%(7@-S>7)E
M=T;'RG/8;> ,#D^IJ/3_  !H^FWUM/%+?O;VDAEM+&6Z9[>W<YY1#TQDXSG&
M>,5U-% $-U:P7UG-:7,:RV\\;1R1MT96&"#]0:P-)\#Z;I5]#=_:M2O7MHVB
MM4OKIIDMU88(0'U'&3DXXKI:* .6T[P!H^FWUM/%+?R06<ADM+*:Z9[>V8Y&
M40^F3C.<9XQ4=Y\.M"OK^XGD:^2VNIA<75A'=,MM<29!W/'T)) )[''-=;10
M!F66A65AKFI:O KBZU$1+.2V5Q&I5<#MP:R+KX?:-=7\]P\E^EM<SBYN+".Z
M9;::7(.YH^^2 2.A(Y!KJJ* ,*7PG82>*U\1QSWD%[Y:Q2K#.5CG5<[0Z_Q8
MS6M>V<&HV%Q8W2>9;W,30RIG&Y&!!'Y&IZ* .4C^'VDIH-OI#76IR1VDPFL[
MA[MC-:D*% C?^%0!C'3DUI:%X8L= DNIX)+FYO+LJ;B[NYC++)M&%!8] !T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/$'B#4K'4K/
M2=%TC^T+^Y1Y2TLIA@AC7 )=]IY)(  &:Z.LC5;M;F630['5UT_6);?SXF$0
MD94# %@K<'T_&@"KX6\2S:]_:-K?6'V#4]-G$%U;B7S%R5#*RM@94@YZ UT-
M<'\/5EL-8\4:+>NMWJ=K=1376I#(-WYL>5++D[2H7&T<#C%=Y0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>josetrevejo-tarsussepara014.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BD!!&00?I2T %%(2 ,DX%&1G&1GTH 6BBDR,XR,^E "T4$@#).!10 444$@
M#).!0 44=1D44 %%%% !102 ,DXHH **** "BBB@ HHI,@$#/)Z4 +1110 4
M444 %%%% !129&0,\FEH **** "BBB@ HHHH **** "BDR,XR,^E+0 44A(
MR2 />EH **** "BBB@ HHI,C.,C/I0 M%%% !112$@#)('UH 6BBB@ HHI,C
M.,\^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !103@9-)N&0
M,CGISUH 6BBB@ HHHH **0D @$C)Z4$@8R0,T +1102 ,DX% !1110 4444
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M%(F3=)YOW6!"$C!).:Z_PW975OXZ\9W,UM+'!<SVI@D="%E"VZ@E3WP>..]
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M!=@RHY.[//H*]MKQ>ZL]3'@SXA^'O[%U0WUSJ%U>6Y6T<QSQO(A78X&&8CG
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MLQ27$B#+K$H0CCIEB,F@#MZ*X:3Q_/>W6@V^A:6MXVMV#W<#33^4L17;D2$
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M ':[UW[-PWXSMSSCUIU>8W%[KT7Q846VF6DNJS>'8Q)&URPMX<7#Y)?9N(Z
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MR6"Z?)-M6*:/=YNYP#\BA2<@9((XYX .VHKA-3\=:MX?\,ZSJ&M: (;K2Y(
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MY2/KBK]S?:CXG\=>$+V#P_JMII]C+<FYEO;<Q%6>!E QUP#QNZ$D8SS7H]%
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ME[6W<D=.1F@#LKGQO#INL68U%8H-#U&S^T6>HEB%WA=[1OZ$K\P]<$=:J?\
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MKG3-4\8Z_K>I+I=WIUL= FTJV%\HC>6:4DEMH)PHP!D]<T =#?\ BR:S\/\
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MT_Q+IVGQ1:J7CMYK&=W\J55W>6X91G(!P1W'2KGC[1;S7O!]U::<JM?(\5Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *.HHHH BM[:"SMHK:VB2&")0
MD<<:X55'0 #H*EHHH **** "HKJW2[M)K:3.R9&C;;UP1@XJ6B@"EH^EV^B:
M-9:7:ES;VD*P1F0Y8JHP,GUXJ[110!FZIH=IJ]UIEQ<M*'TZY^U0[& !?:R_
M-QR,,:TJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKJ
M6HVND:9<ZC>RB*VMHS)(Y[ #]3[5:K@/&NH2R>)]+TVZT?5[K1;<"]G:RL9)
MUN)@W[N,[1C"D;R#U(6@#=\%^)Y/%N@G4I=/>PD6XE@:W=]S*4;;SP.>.E=%
M7G_PIU5+_3=9B6TOH2NK7<NZXMVC4AYF.T$_Q#N.H/6O0* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH I:9I-GH\$T-C$8TFGDN'!8MF1V
M+,>?4D\5=HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>josetrevejo-tarsussepara015.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\9+6XO?AGJ$%K;RSS-+ 1'$A9CB52>!0!I6WA8:#!>7T6O:]=N+60!+V_:5
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M\4[4DGCN+TLJRC!='MB0-F=PP /K7K8S@9ZUX_XJU+P]XMT.6.#PSJ"^+WC
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M-K9>+/#\/@SQ;J&M23W874+1]1-[$MK@[Y&))V$<8Y&2:VY]0O1\?K;3Q=W
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M7?A2^L/@KI\%O!))K6F^5JJH%)<W(?S7&.I/S.M:WP[T^['AW5M9O[6:WO\
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MMTK, RLC,W&,G=QBMCQ%I:^*?&?@.ZGT*:?2A'>M<PWEGE8=T2[!*I!"G<.
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M8WJ,J1_LU=\-7FH?#>SE\-ZGHFJ7FFV\TC:=?Z?;&X5HF8L%=5^96!)[8/\
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MQCCK7F,>B:SJGPW\&>"6L+^UBO<'59C"R?9X(V+%&)'RLQQC/ITYH ?X7O\
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M].U'6+BQT1K:Z667[>\._:B;"T@8$G..2><^]:X\6Z-@?\4+XA_\$)_PK/\
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M,Q&:Z<C&QB,':HZCH21WJGXJ\%7^A'3O%.CZAKNL:GI-RKBVN9_/:2!CME1
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M6C=\JZ_H0?:LSX?Z7XDLO'.JG7[:5A;:?#8Q7Y'R7:H[%7!]=K+GW!KT^B@
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MXU;^]DY/X'M5#Q;\-97T*2]TK6->N]7T]EO+!+S4'G7S4.0 K=R,@?6O3:*
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MCPDX]%/1OKGGBM6'QO>S3QQGP3XEC#L%+O##M7)ZG]YTJ_XZL;C4_ >NV5I
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M*5=99B7SP /-Y.<<5AR6GA*_^*WC1/%MW:Q"(V7V5;J_-N.8/GVC>N>BY_\
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MH Z^BO+/!>FR?#OQC%X8GG>6SUFR6YAD=B0;R)0)P,_WAA_PQ3?B"2/C#\/
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MX?ZO;6UK)]LN]-E2.W8C=O:,X4\XSDXKH&8*I9B !U)I/,0%1O7+?=&>OTH
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M.OI7JOVJW_Y[Q?\ ?8IZ2)(,HZL!W4YH \JU#P7JZ?"ZTLEMFN=;NM2AU'4
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MS(,'CY0B\]J;:>#=97XI".2T(\,VVH3:S%,6&&GDC0! ,Y&U][=*]2^U6_\
MSWB_[[%2 A@"""#R"* ///B'X?U76/&'@:\T^S>>WT_4#+=.I $2;HSDY/\
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MA76=1\/BV>3P\2;K3+D,"( QR\!&<\')4^AZUV2NKC*,&'3(.:"Z*P4LH8]
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MKDKZ]"*Y2[\&ZSI?Q&T@:7:^=X:.HG4CA@/L4I1ED4 G[K$AACH<UZF\T49
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M+WXD^"M3MK9I+.P-Y]IE!&(]\05<\YY/I2_%#2]0U?P8UMIEF]W<K=P2B%"
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M(/F1MC##!_G7:44 %</X^T._\67NB>'Q;2?V')<?:-4G5]H*(,K%US\S>G3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/OX/L'=F-]K@
M+'.!K-T!^0DXKH** .>_X0W3_P#G_P!=_P#!W=__ !RC_A#=/_Y_]=_\'=W_
M /'*Z&B@#GO^$-T__G_UW_P=W?\ \<H_X0W3_P#G_P!=_P#!W=__ !RNAHH
MY[_A#=/_ .?_ %W_ ,'=W_\ '*/^$-T__G_UW_P=W?\ \<KH:* .>_X0W3_^
M?_7?_!W=_P#QRC_A#=/_ .?_ %W_ ,'=W_\ '*Z&B@#GO^$-T_\ Y_\ 7?\
MP=W?_P <H_X0W3_^?_7?_!W=_P#QRNAHH Y[_A#=/_Y_]=_\'=W_ /'*/^$-
MT_\ Y_\ 7?\ P=W?_P <KH:* .>_X0W3_P#G_P!=_P#!W=__ !RC_A#=/_Y_
M]=_\'=W_ /'*Z&B@#GO^$-T__G_UW_P=W?\ \<H_X0W3_P#G_P!=_P#!W=__
M !RNAHH Y[_A#=/_ .?_ %W_ ,'=W_\ '*/^$-T__G_UW_P=W?\ \<KH:* .
M>_X0W3_^?_7?_!W=_P#QRC_A#=/_ .?_ %W_ ,'=W_\ '*Z&B@#GO^$-T_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***0LH."P!/;- "T444 %%(2!U('UI<
MC.,\T %%%% !129'/(XZTN<C(H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6&D:?8S30W]HL!+J2)X(\HI9?+ (//('/)KV.H+NRM+^$0WEK#<Q!@X2:,.
MPZ'![CUH P_#,FHO!9G5KB]>^ELA/-&80($+N6VA@OWU!"XST4''.:Z.BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXAZGX:A\L0VB;(ICG,\R_P"M53TPHQQUZGI7;T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<Q\1/^1!U;_KFO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[W!4!3P !E3@\G(XJGJ_C*UL?L$=MXR6^MY+MO-EMY;195C\IB SOB/&\#G
M/(')Z]Y!H.CVMI-:6^DV,-M-_K88[=%23M\R@8/XT^VT?3+*.)+73K2!(G+Q
MK% JA&(P2,#@D$C/O0!YY_PG5B=?6%O%$PL/LMNRR)=Z>!YA:3S/,9C\Q "9
M$><?B,SP>-H)IQYGB^RMENX[DMO:$BT*2J(]O0DF,M]XMD@$# (/HBVT"SO.
ML,8FD55>0(-S 9P">X&XX^I]:IR:!HTQNC+I-@YN\?:"ULA\[!R-_'S<\\T
M><7?Q*MDT006_B&SFGFN&9)IVC:06P91M=5 &]LG P"%Y(R,&G:>+-&\+37M
MIHFHV5O;F6X?R(5C:VC3R6:&0,OSNS,JJ1D]2,#"UZO!H^F6MFUI;Z=:0VS-
MN:&.!50GCDJ!C/ _*E_LC31>37@T^T^U3+LEF\E=\BX PS8R1@#@^E '&^%_
M'VE&"[36?$=BC+*OD&ZN[?<4**3\T>$;Y]XXZ=ZWO^$[\(_]#1HW_@='_C6E
M;:+I5G (+73+*"%6+B.*!54,1M)P!U()'TXJS%:V\&[R8(H]V,[$ S@ #IZ
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M  G?A'_H:-&_\#H_\:/^$[\(_P#0T:-_X'1_XUO[5_NC\J-J_P!T?E0!@?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4JWAU&QEC$,BKN5T9HU"@X9=N2.16WI/@1;;X7CP;?70DS#)&UQ"N,%G9U8
M]P2/RJ_HUCXL74(I=<U:PDMH(C&(;*W*_:&./GD+$XQCHO<GGM0!TE%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!4O-+T_4&C:]L+6Y:/E#-"KE?ID<5;  & , 4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% ",RHI9B%4#)). !5&PUS2-5D
M>/3M5L;QT&YEM[A)"H]2%)Q5YBH0ER H')/3%<3!%'#\6]0-E!'^ZT"(,L8
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M1+Z>8&0_52:S=?@U;3;GP?X:E=KZ.XBG>[\Z_>V%W< *=ID4$XRSL$[X [4
M>J51TS4FU'[9NL+NT^S7+VX^TQ[?."X_>)R<H<\'VKG?"^@WQ\.WVD^(#F+[
M8[6\,.H22/#"=K+&91M<X.?PQ7-P7VH:-\.?'4NF37#3V&HW<=JSR-*T2*$'
M!8D_*,GGTH ]4HKSB*WM=!\7>$8]"O[F=-4287:R7;S"XB$6X3'<2 0V/F&,
M[L5Z/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 444=* ([BWAN[>6WN(DF@E4I)'(H974C!!!Z@BJFE:'I6APO%
MI6G6ME'(VYUMX@FX^IQUJWY\/_/5/^^A1Y\/_/5/^^A0!GQ^&]#AU9M5BT>P
M346))NEMU$A)ZG=C.3ZTRZ\*^'K[4O[1NM#TZ>]R&^T26R,Y(Z$DC)(XQ6GY
M\/\ SU3_ +Z%'GP_\]4_[Z% %75-%TO6X%AU73K6]C0[E6XB5PI]1D<&I;#3
M[+2[-+33[2"TMDSMB@C"*,\G '%2^?#_ ,]4_P"^A1Y\/_/5/^^A0!)4-M:6
MUE$8K6WB@C9V<K$@4%F.6.!W)))-.\^'_GJG_?0H\^'_ )ZI_P!]"@!MK:6U
MC!Y-I;Q01;F;9$@5<L22<#N223[FL[4/"OA_5KP7FHZ)IUW<@ >;/;([$#H"
M2.:T_/A_YZI_WT*//A_YZI_WT* ([FPL[PP&ZM()S;R"6'S8PWEN.C+GH1ZB
MF:CI>GZO:&UU*RM[RW)R8KB,.N?7![U/Y\/_ #U3_OH4>?#_ ,]4_P"^A0!E
M'1#I6EBU\+1:;I3>9YA4V>Z-^,'*HR')XYSVI/#>@'0].N8KBX6ZN;RZEN[F
M01[$:20Y(5<G"@8 !)Z5K>?#_P ]4_[Z%'GP_P#/5/\ OH4 4-,\.:)HT\L^
MF:18V4LO$CV]NJ%AUP2!T]JTZC\^'_GJG_?0H\^'_GJG_?0H DHJ/SX?^>J?
M]]"CSX?^>J?]]"@"2BH_/A_YZI_WT*//A_YZI_WT* )**C\^'_GJG_?0H\^'
M_GJG_?0H DHJ/SX?^>J?]]"CSX?^>J?]]"@"2BH_/A_YZI_WT*//A_YZI_WT
M* )**C\^'_GJG_?0H\^'_GJG_?0H DHJ/SX?^>J?]]"CSX?^>J?]]"@"2BH_
M/A_YZI_WT*//A_YZI_WT* )**C\^'_GJG_?0H\^'_GJG_?0H DHJ/SX?^>J?
M]]"CSX?^>J?]]"@"2BH_/A_YZI_WT*//A_YZI_WT* )**C\^'_GJG_?0H\^'
M_GJG_?0H DHJ/SX?^>J?]]"CSX?^>J?]]"@"2BH_/A_YZI_WT*//A_YZI_WT
M* )**C\^'_GJG_?0H\^'_GJG_?0H DHJ/SX?^>J?]]"CSX?^>J?]]"@"2BH_
M/A_YZI_WT*<KJXRK!OH<T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1T6
M1&1U#(PPRL,@CT-+10!S5OX9\$7<T\-MHGAZ:6W;9,D=I"S1-Z, .#P>M._X
M13P7]L^Q_P!@:!]J\OS?)^QP[]F<;MN,XSQFO--/%SX=\0>)O&UF))(+77[B
MUU:!<G?:$1D2 ?WHV8M]":[&*XCN/C2+FV=)HY/"ZO$RM\K@W!((/H?6@#H/
M^$*\*?\ 0L:-_P" $7_Q-'_"%>%/^A8T;_P B_\ B:XO3?&FHP^)=&M+OQ/H
MNJ2ZA<M;W6FV*J?L9*,P*N&)8 J%.[U[5%-XD\8W/ASQ-KUMJ=E;PZ'?7<<=
MNUH'^TI"YX9LC;\O''.03GF@#N?^$*\*?]"QHW_@!%_\31_PA7A3_H6-&_\
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MHH PO^$*\*?]"QHW_@!%_P#$T?\ "%>%/^A8T;_P B_^)K=HH PO^$*\*?\
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M* ,+_A"O"G_0L:-_X 1?_$UHZ=I&FZ1$\>F:?:64;G<ZVT*QACZD*!DU<HH
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MMSE_X1"R';Z\D5EV'A_Q'H:RZ+I^DZ1/9&\>6#4KA\F*%Y"[*T6W+,-S 88
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%*@@G<Q7CNH:NH$,:G(C0$=PHI3&A;<47=ZXYH \&FN7^&OQVCN[VYM5T_Q
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M'.Q!V9'&[;NW8_V20*]:>*.5662-'5AA@R@Y'H:(HHX(Q'#&D<:]%10 /P%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?3I8K6%$,=VTB%9F/4*H.X8XY(&3GZF[0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>=TJHJ8Z_P 3,V!]16'IGC[Q!JOA?QO+?6%OIFIZ)#(T,<3>88SY3.NXG(+
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MZ">A?^"Z;_X_0!T-%<]]G\8_]!/0O_!=-_\ 'Z/L_C'_ *">A?\ @NF_^/T
M=#17/?9_&/\ T$]"_P#!=-_\?H^S^,?^@GH7_@NF_P#C] '0T5SWV?QC_P!!
M/0O_  73?_'Z/L_C'_H)Z%_X+IO_ (_0!T-%<]]G\8_]!/0O_!=-_P#'Z/L_
MC'_H)Z%_X+IO_C] '0T5SWV?QC_T$]"_\%TW_P ?H^S^,?\ H)Z%_P""Z;_X
M_0!T-%<]]G\8_P#03T+_ ,%TW_Q^C[/XQ_Z">A?^"Z;_ ./T =#14=N)A;1"
MY:-YP@\QHU*J6QR0"20,]LGZU)0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXY<.5,C-_>+XX)QC)ZT =+;_ !,T2YO(K5+;4E:2XA@W/;;5438\IV.>$<L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP'=^++.(W]K VT(&\O>1+Y1Y(/0Y[<XKIK:;[1:PS[=OF(KXSTR,T 2T444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KEO$GB;4]+U[3-'T?1X=1N[V&:8B6[\@(L90==K9SO_2N
MIKD/$/ARRUWQ?82-XANK"^@LY%%M93+'-)$S+EL_> RJC(_.@#;T.ZUB[M9'
MUK2X-/G#X2.&Z\\,N!SG:N.<\5J5Q7@FZOK?Q!XF\.W.HW&I6^E2P&VN;E@T
MNV5"QC9OXBI'4\\UVM !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5BZ]X4TGQ&]O+?12K<VQ/D7-O.\,L>>H#H0<'TZ5M44 9FA>'M,\.63VNF6
MYB220RRLSL[RN>K,S$EC]36G110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>josetrevejo-tarsussepara016.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D==Z,I)
M (QD'!_.EHH Y[_A#[7_ *"NO?\ @VG_ /BJ/^$/M?\ H*Z]_P"#:?\ ^*KH
M:* .>_X0^U_Z"NO?^#:?_P"*H_X0^U_Z"NO?^#:?_P"*KH:* .>_X0^U_P"@
MKKW_ (-I_P#XJC_A#[7_ *"NO?\ @VG_ /BJZ&B@#GO^$/M?^@KKW_@VG_\
MBJ/^$/M?^@KKW_@VG_\ BJZ&B@#GO^$/M?\ H*Z]_P"#:?\ ^*H_X0^U_P"@
MKKW_ (-I_P#XJNAHH Y[_A#[7_H*Z]_X-I__ (JC_A#[7_H*Z]_X-I__ (JN
MAHH Y[_A#[7_ *"NO?\ @VG_ /BJ/^$/M?\ H*Z]_P"#:?\ ^*KH:* .>_X0
M^U_Z"NO?^#:?_P"*IT7A.UBF20:GK;%&# /JDS*<>H+<CVK?HH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD R6*D97CUH ZVBN)7Q[<S:%H,]OH$TFKZVK/;:<TX7;&HR7>0C 7;M/3/S
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@O +I!XJ\<6,Y
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MT#:]O'/JT.FR$E]-BU"5;8Y.2-@/ /H#BM75?!^EZHUG(K75A/9Q&""?3YS
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MV&CVE[:VB.L5Y<2W,P9R27D.6QZ5+HNCV?A_1K72K!66UMDV1AVW$#.>OXT
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M&KZ9_:BKT'VF!<2H/=E*GZUR_B#2)])^&?A)[T?\3&_\1V]_>$CDRR[V.?<
MA?PKUCQ+X1T?Q9%:1ZO;M*MK+YL>URO.,$''53W'>IM?\.:=XEM[2#44=TM;
MI+N((Y7$B9VDXZCD\4 <=IFG6.O?%SQ>=8M(+PV%O9P6D=S&)%CC=&9RH/'+
M=ZXJ\M;:R^&/Q1M;/_CWAUAHXU!R% ,0VCV'3\*]:UCP7IFKZNNK&>_LK_RO
M)>>PNF@:6/.0K;>H_6H$^'GAV+0-4T.*VE2PU.02W$8E;)8;>03S_"/KSZT
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MEMM4NXH'6%0T2;"-JG'RCV%9C>&](C_9Q&I?8(&U#[ EP+MD!F5PPP0_48&
M #T&*],A\"Z1;:Y?:K;2WT#WY=[JWCNF$$K,I4LR=">2?KS5IO"6DMX/_P"$
M6,<G]E^0+?9YAW;!_M=: .1U$QZYXOAAM/#EIK.J6FEQ&XEU.YV6\"R$D!4V
M/EVP<D <<9KA-9@BE_9]USSK>V+6.KRQ6PC_ 'BVZ_:5!6)B =O)&<#(KV#4
M/ ^E:AJ*7_G7]K.(%MI39W;P^?$O17VGG&3SP>>M1?\ "N_#O]CZMHXMYAIN
MIR"66U$S>7&X.<QC^#D \>@H Z#3["STVS2WL;2"U@'S>7!&$7)ZG XJU6?H
MND1Z)IZV<5W>W2!LB2\N&F?MQN/;CI6A0 4444 %%%% !1110 4444 %%%%
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M,JP8Y("_*<9/2N6T;1;_ %;1/&>@VMK8V1@U>&5--$Y>UX$;O#N"C"M@@@*
M"2,4 >P17-O/"9H9XI(AGYT<%>.O(JK>7SG2+BZTMK6ZF1&,0>8+&S#L6&<"
MO-ETB'6-,U[0[#P]%X>UL_9+BYTV20?9+E%D)7:8^-K[61B #TR*K:DVGP>#
M/'%FOAP^'=5&F"2YLHW5H)$PX62/9\ISA@3@'@9Z4 >JVUVRZ5;W6HM;V\C1
M*TVV4&-6(&0&.,C/0]ZL?:(-K-YT>U0&8[AP#T)KR?3;.VUJ^^'&E:G#'<:>
MF@&[%O,H:.241Q*"RGAL!B1GUK*U?3K/2K/XM65@ EM%:6FR)3\L68V8J/0
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M1\0[+[-$UMIFMW L8V4$6P_=XV9^[C<W3U- 'M5MJME=:9%J*7$:VTB*^]W
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MEU;RSO!'/$\T?WXU<%E^H[5X&V@:9!^SA!KJ6D?]L11Q317Y7]]&PG"C:_4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M02,'TR ,^]:FH76J>,W\.Z</#^IV#VFH07NH37</EQ1B+DJC9^<EL ;<\<T
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M3>6;'S<EG8(8QG'\0D3MWJI\2M"U>[U:TGT6UEF_M2T?1[YXQ_JH7D1@[>@
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MTWP#_P DZ\-?]@NV_P#1:T =%65I'A^TT>[U&\C>:>[U";S;BXG8%VP,*HP
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M9HY(G9E_B ((*_C754 %%8&OW^OP7=M:Z'86;[T>2:\OI62&+! "X4$ECGZ
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M;TL=R6CL\8&>.6 )..O%<[XD\5ZQ8>+;'PYH^FVUU=7MF\\<EQ*R)&RL 2^
M3MQGISG [T =%I5IIFC6EOHFGF*)+6$".W#Y94'&2.O7N>I-:%<);:Y#'\4[
MK3[S2[&*\AT);J?4(\ER-ZAH\D9V \_A69=?$3Q):^$!XM;0;(Z3<E/LT8N&
M\Z-'<*CR#;MP<_PG(R.O. #TM)HGEDB25&DCQO0,"5SR,CM3Z\RM+C7T^)7C
M>'0+.REE+63R2WTK)&O[@84!022>?0#'O535?&GB'6=,\$ZAH\5M:#4M0\N:
M&6=QF5/,5HV*CF/*D^O XH ]8HKAW\4^);G5M3MM)TO3+D:2\<=U;O=,D\S%
M%=C$",!?FP"W4@]*[@'(!QCVH B6Y@>X>W6:-IHP"\88%E!Z9'45+7!0>(((
M?B#XOMHM(M$N=/T^*=KQ1B2X_=A@KGT'055@\>>(?['T+Q#=Z/81:+J,EO"Z
M+.QN(_-(428QMV[CP,YQCH>  >CT45PVO>+?$.B&^U.72+*/1+*<1L)KAA<S
MQY4&5 !MQ\W )R0#TH [FBN,NO$WB"Z\6ZMX>T33K!I+&*";[3>3.L8$@)P0
MH))R.,<8!SV!UO!_B!_$WAJWU*:V%M<%Y(9H0VX))&Y1L'N,KD?6@#8EN8(&
MC6::.-I&V1AV +MZ#/4U+7%^.M6MM,U7PG%/I5K?-=ZM'!&\XR;=C_RT3_:%
M,D\3^)=0\1:]H^A:9I[-I,D8,]Y,ZJX>-7"@*"=V2?0  =<T =O17"Z-\09-
M4N_"S2V"P66O6LI1RY+17,?WHSV((#8/4XJ35_'QTO6=>@6R$]EHME%),ZMA
MWN96Q'".W((Y[9H [:BN/LO$NN6FLPZ7XAL;"*6\M9;BTDLIF==T8!>-]P'.
M&!!'!P:P[?XA>(G\+Z9XKGT:PCT6X>%)T^T.;@!W"%U&-NT,> 3DCGC/ !W.
MEZ%:Z3?:I=V[RM)J5P+F8.00K;%7"X P,*.N:O07,%U&9+>:.9 2I:-@PR.H
MR*X32M5\2W/Q<US3Y&LSIEK;P9C\Z3Y$;S"K*N,;SP&Z=!@G%9_ASQQ;VGP_
MDU*QT&UM[B;5FL+6PMCL2:=G"@DXXSU)]J /4**Y"Q\1ZW9>)K70_$=G8))?
MP236=Q8RNR,T>"\;!@"#@YST-<_!\1?$<G@^S\7R:+81Z*S1K<1FX?[05:01
MET&-N 3P"<D#/&: /3Z**\^BU?Q(WQAOM/+V0TNWT^.1HVFD $9D;YP,8\SL
M>V .: /0:*\X/C[7V\.-XOCT>R/AM6+B,SO]K: -M\W&W;_M;<].]>BQR)+$
MDD;!D<!E([@T (DT4DDD:2HTD9 =0P)7(R,CMQ39KF"W,8GFCB,C!$WL%W,>
M@&>I]J\VL;CQ GQ$\<0Z!9V,LGG6CR2WTK(@_P!'7"@*"23SSP!COFEU/QK:
MZGX=\$:O/H=M.VJ:M# ([@[OLLNYE+H<=05.#0!Z;17$S>*?$%WK>K0:)I>G
MW5OI,ZP3P2W12ZF)56)08V@8;C<><'I7;4 %%<5)XG\1ZKJ6KQ^&M-T^:TTF
M8VTKWD[HUQ,JAF2,*"!C(&3W-4KGXCW5U!X4?0M+CN9?$,<_EQSRE/)DC49#
M$#H"6R<=%XH ]"IBS1/+)$DJ-)'C>@8$KGID=LU%8&\-A =06!;S8/.$!)C#
MXYVD\XSZUYW;W&O)\3O&<.@VEE+,R6+R2WLK)&@$1PN%!))R?88/M0!Z917!
M6OCZ]U70M ?3=.@76-7>:,0W$Q$4'DDB5F8#) (  '7<*BU+XAWVC>&M7NK_
M $V#^U-(O(+:Y@@D+1R+*4VNAP#RK]#W!% 'H5%9FA3:U/8M+KEK:6MRTA,<
M-M*T@6/ P&) ^;.<XX]*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[XBZ ^N:1I\BZ<-373[^
M.ZEL3C,\8#*ZKD@;L/D GG&*[&B@#RB[\.PWG@[Q3'H'@A](:XLO(M_,54GN
M6.2PV G"CY<$GGGBNDUG2KZXUWP/-%;.\=C/(URPZ1 V[*"?Q.*[.B@#R?QM
MIMY;P_$K4);=TM+K2K58)3T<HK[@/ID?G5^X.L>*9_"NFOH5[9C3KV&^O;N8
M+Y/[I3@1L"2^YB,<# ZX[=UK>D6VOZ)>:3>&06UW&8I#&<-@^AJY%&L,*1+G
M:BA1GT% 'E*^"M6U2/XF64ENUN-7G5K&23A92H)!^F0!^-:=]+K/C.;P]82>
M'K_3?L5_#?:A/=A!&OE9.R,ACOW-C!':N_AO+6YEFB@N899(&VRHCAC&?1@.
MA^M3T >2^/=&NV\=VVG:>0+?Q= MKJ 5L,JP,K-)^,19/RJ_XI\+V,7C,:M?
M^%9-<TR:PCMECMHED>VDC9B/D)'RLK8R.A7FNNTWPI8:=KESK)FO+S4)U,8F
MNYC(88R=WEQCHJY_E6[0!Y3JGA"%].\,ZC+X+C-G9/<?:]$MRLCQI-C#@9 9
M@44D _Q'&<5UO@C3K2SM+V:S\,+H$,TP\N)L"65% P[J,A3DM@9)Q74T4 <U
MXS59=.@@NO#;:[ILDA%U#&JO)&,':ZH<;N>#@@C.17%VGA[5_P"S=)2#3K^'
M3H?%$%W:6EW)OEM;18R"6RQ(7?N(&20"*]9J*&Y@N#*()HY3$YCD",&V,.2I
MQT/(X]Z .'\2Z/K5UXSOKS2XW1G\,7%I;W(.T+<-("BY['C.:YK3-#-KK'A/
M4],\#W5@FGS&/4)GA07,KO"R;OO9= QR6)YR, X->Q5!=7EK8QK)=W,-O&S!
M TKA 6/09/>@#RRR\-:S'X6^)ML^GS";4[Z\DLD.,SJX.TK]:[[P;:7&G^"-
M!L[N)HKF#3X(I8VZHRQ@$'Z$5JF\M5O5LS<PBZ9/,$!<;RN<;MO7&>]3T >>
M^+],:X\;6MUJ7ANYU_2?L!BMK>-$DCBN=Y)9U8@#*[1N/3!K%TK3+C3_  BF
M@Z]X&EU"PBOKHS1VR*WE[I"\;P+D$IAB,C!'''6O7** /++73KFW\*1V.M>$
MK[5M$EO9VAM)F$UW90\>3P6R?X^C;E! YYK-U7PSKUWX L;*#3K\I'XBCN;2
MTN9/,FM[,9P'.3T.3C)(! KV6B@#@W&J>&OB!KE_#HEYJ=IK,-NT;6A3,4L2
ME"K[F&T$8.[I7+^$].U._P!.\.7'V?S&MO$U[-=M$<H@_>J2#Z;CBO0M9\&V
M&KZI_::WFHZ??&(023Z?<F%I8P20K=C@DX/7GK6IH^D6.@Z3;Z9IT/DVL"X1
M,DGDY))/)))))]30!SS6-_;_ !-U'6$LY)+7^PXXHV& ))5E=M@]\$?G6]H&
MJ_VYX?L-5^SM;_:X%F\IFW%-PSC/>M!E#J58 J1@@]Q59YK#2;6")Y+:SMP5
M@A5F6->F%1>@Z#@#TH Y37[:_P!(\>6/BFVTVYU&T;3WT^ZBM &EC_>"1'"D
MC<,@@XZ5S.M>'M;UOPOX\U0:5/#=ZX+=+.P?;YWEP@*"P!(!.6.,\5ZW10!'
M;J5MHE88(0 C\*Y+Q?8W\/B'P[XDL;&6_73'GCN;:#'FM%*@&Y 2 2I4''<&
MNQHH X/3;+4=:\4ZUXEGTVYL('TQ=.LX+D!99 &9V=E!.WYF  //TK&TWPYK
M$/[.[Z#)82KJILYHQ:G&_<96('Y$5ZK10!YAK?A5IM,\%WVH: ^K0:99?9KV
MP50TB[XT&Y5) 8JR8(SG!-5]3\-O=>!KF+1?"!T@S:I;2);#:)9(DD0F1U'"
MG[W&3P*]7HH *X;QK!J%OXP\):]:Z7=ZA:Z<]VEQ'9JK2+YL052%)&1D<\UV
M2WEJUXUFMS";I$WM"'&]5]2O7'O4] 'G=A-K'@V]\0VJ>'M0U)-0OY=0L9K0
M(4+2@$I(2PV88=3Q@UT?@;0I_#7@G2M(NF5KBWA_>[3D!V)9@#W +$5T-% '
MG7BK2VN/'2W6I^&;CQ!IS6"Q64*JCQ0S[V+EU<@+D%/G(/ K(TK3)['P58Z!
MXB\#SZC9VUQ=+,+9%8QN96>-X5R"4*N1N!!&,8KURB@#RR#3;F'PI:V'B#PE
M?:QI$ES<-% [+/=V4>[]P"-V2=I89#$KP*H:EX:\077@[P];)87KBW\2QW4-
MO<2"2:VLP7VB1LGH".YP"!VKUVYN;>SMWN+J>*"!.6DE<*J_4G@5(CK(BNC!
MD895@<@CUH X1_[5\-?$#7;^'1+S4[368K=XFM"F8I8T*%7W,-H(P=W2N7\)
M:=J=]IWANY^S^8UMXFO9KMHCE$'[U20?3<<5Z%K/@VPU?5/[36\U'3[XQ""2
M;3[DPM+&"2%;L<9.#UYZUJ:/I%EH.DV^F:=#Y-K NU$R2>3DDD\DDDDGU- '
M/-97]O\ $S4M82RDEM?[#CBC8$ 22K+(VP'UP1^=;V@:K_;GA^PU7[.UO]K@
M6;RF;<4W#.,]ZT&574JP!5A@@]Q4$36=F;?3XF@A(CQ!;J0IV* /E7T''3IQ
M0!POC#3&N/&MG=:EX<N=?T@6!B@MHD61([G?DLZLP RN!N/3!K$T+P]K-K#X
M=L9=%DMCIGB&XGE\I1Y*PN)2K1D?P#<HZ#Z5Z[10!RL6FWB_%>ZU,V[BR;1(
MK=9OX3()G8K]<$'\:XWPWH=POQ,N?#Y"MH?AZZDU.W .0LEPH,<9';9F9A]1
M7JUW;_:[.:W\Z:'S4*>;"VUTR,94]B.U9_A_PY8>&[2:&S\Z22>4S7%Q<2&2
M69S_ !.QZG  ]* -:O*+:#7]#\"ZAX&A\/7US=L+FVL[V/9]F>*5F*R.Y;Y<
M!SD8SQ[UZE!<P74?F6\T<T>XKNC8,,@X(R.X/%2T ><ZIX8O[?Q-\-TM8'N+
M31HYH;F=1P@\E$4GZE:]&HHH XOP]I5_:V_C19[9T-[J=Q-; _\ +1&A101]
M2"/PKF(_#.M"'X5@Z=-G2@?MW3]Q\BCYOQ!KUNB@#RSQ!IMSJ6MM+9^$KZP\
M3I>*(-7M&"P/")!\\CAAN!C&"K*3G@5ZG14-U>6UC;M<7EQ#;P+C=),X11DX
M&2>* /-[0:YX6T76_#</AV_OI9[BY?3KFW"&!TF)9?,8L-A4L0<CMQFK.B^%
M+_1?%GA)/):6UTW0I+2>Y7[@ERG'XX.*]%!!&1R** "N1\-:9>VFK>,);BW>
M-+S4/-MV/_+1?)1<C\017744 >,6G@V2TT;PC>ZWX8FU:&TTV2RO+%45Y8&+
MAT<*2-W1@<'C=6K>>')IO#NAC2O"O]D(OB2VO'M(RI<0HV/-D X4X R 3CBO
M4J* "N0O=+O9/BQI6J);.;&+2IX7F_A5RZD+]< UU5Q<P6D#3W,T<,*XW22,
M%49..2?>I: //9?#NH77Q@U6_>VD33;KP^;,7./E\PR#Y?KC)KDM?N=<LO@V
M/#EWH-S;R6 M[>XO'9# Z),@4QD,2Q;"\8&,G/09]OKCX/AMH=O/"%FU%K""
M?[1#ICW;&UCDSN!">@;D G&>U $V@:;>6OCSQ?>SV[I;7CVAMY#TDVP[6Q]#
MQ7$Q:%K>F>"_!LK:/=SS:5K,MS=6L(!E$;238(!(SPRGKWKUYW2*-I)&5$4%
MF9C@ #J2:9;W,%Y;I<6TT<\+C*21.&5A[$<&@#S#Q=9S:W+=.O@O4X=?V#^R
MM5LV5"F5!4RR!AMVL2&4Y&!QG->HPB18(Q,P:4* [ <$XY-/HH \W30=4'Q$
M\<WYLI?LE]I<4-M+QB5Q%@@>^:6\T'5)/A-X9TM+*4WULVG&:$8W)Y;H7S],
M'\J]'HH *\1USPK?ZAI/B.TD\(2WOB.:[GF35;A$9##OW1B)R<@[ $" #!ZU
M[3!<P72%[>:.9 Q0M&P8!@<$<=P:EH X_P -VMZWCGQ%J\UC<6UK?6MCY/GJ
M Q*J^Y2 3R,@&IOA[IMYI7AA[:^MW@F-]=2!'Z[6F=E/X@@UU5% '"?$+1]1
MU76/!LMC:23QV>LQ3W#)_P LXQU8^U:/AO3;RT\8^+[NXMWC@O+FW>WD/20+
M JDCZ$$5T<]Y:VLD,=Q<PQ/,VR)9'"F1O10>I]A4] 'E=OX6U=/@YH\*64B:
M]H\XOK:!L!C(DS-M_P"!(2/Q%3+X-U+5/AAK<5U;*NN:U<MJ,MO,1PXD5HXB
M>PVHJ^V37IU0+>6KWCV:W,+72*'>$."ZJ>A*]0* . \.Z/IAU0SZ;\/WT9HK
M63?=W*+&ZR,,!(P"=P(+9;@=/6JTWA[5F^!.G:*+&4ZE&EH'MN-P*SHS?D 3
M^%>GT4 <+;0:AI?Q;U2[?2KR:QU6TMHXKN%5:.)H]VX2'((Z^AKE=#\(:_;?
M#J%?[.<:GIOB#^U8K21@IG17^Z#G )4MC/>O9** .#C74?%7CC1]6.CWVFZ?
MH\%P=U\BH\TLJA-JJ">  3GUK(;P[JY_9_AT+[!+_:BPQJ;;C<")PQ_3FO4Z
MB6Y@>XDMTFC:>,!GC# LH/0D=1G!_*@"6N"NK.^M/BO<W;Z7>W&G:II<=F+F
MW566%P[9WY((&#G/-=M=7EK8QK)=W,-NC,$#2N$!8]!D]_:IZ /)%M/$4?PW
M;P /#]ZVH>4; 7V%^R&(MCS=^[/W.=N,YXQ7JMK;K:6<%LA)6*-8P3W &*FH
MH Y7P[IMY:>-O%]Y/;O';WD]JUO(>D@6 *V/H>*X3_A%=<_X0GP!9_V;-]HT
M_7EN+J/C,48FD;<>>F"#^->RT$@ DG '>@#R[QIIT^J7]\(?"-^GB%&VZ7K-
M@X5<8&QI) P( .058'@<9S7I\8<1J)""X W$=":;;W$-U D]O-'-"XRDD;!E
M8>H(X-24 >>64NK^"]2\16R>']0U.+4+^34+&:S"LI:15S'(2PV88=3Q@U1T
M;P?JNBWWPX@D@,HTR.^:^ECY2)Y8\@9]-S$#Z5ZC10 5RNA:;>6WC_Q;?36[
MI:W8LO(E/239&P;'T)KJJ* /&HO!ERGAWPS=:MX=DU*+3;O4!=Z=M5I/+GE9
MED520&(VH<9SAJNZKX;:[\ :E#H?@\Z0;C4+9HK8;1--&DB$NZ@X7'S<9)P*
M]8HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *P/%FOS:#I]K]DABFOKZZ2SM4F?;&';)W.1
MSM"JQ./3'>M^N0^(7A^37=)T^2+3HM2.GW\=V]C)MQ<1@,KH-W&<.2,]Q0!F
M7GCK5M'TSQ%%J,&G2ZII=DM]"]JS>1/&Q*\@G*D,I!&>XI+KQ?XML=3T:*;2
M=,>+7 R6<:2N)+=]N\><QX(VY)VCL<9[Y]YX=-_X/\41:+X'BT1KFR\BV4I%
M'<7#<E@P0D*O3&3SS71:QH]_<ZYX)GAMF>+3YY&NF!'[L&!E&>>>2!Q0!F3>
M.=;TO3?%T>J6FGOJ>@P17"-;%Q#.DBDKPQW C:0>:LKXL\1V%_H<^LZ?I\>D
MZS.EM&L#N9[:1U+1A\_*V<8.,8/KWQ/&^EWMM;_$C4IH&6SN]*MD@E)&'**^
MX>O&1^=7IX]<\43^%M.GT*YLHM-O(;Z\O)7C,+^4IVB+#%FW,0>0,#K0!E^&
M];@\.:U\4M9N59XK.\24HIP6(5L*/J<#\:Z(>)O$^D76BR^(K+3%L=5N4M<6
M;2>;:RR E ^[AQD;21C!]:PT\#ZKJ2?$JRG@^S+K,ZM8RNPVR%02#QD@9Q6E
M>?V_XPG\/V-UX>N]+6POH;Z_N+EXS&6BR0D6UB7W-CG P* -G0?%YNM-UZ36
M8XK6ZT.XFCNUCSM\M1O609YPR<_G6)IOC7Q)K46G6MI::39ZC-8+J-RUX[^5
M%'(S")  <ERJY)Z#T-9GCW1;F;Q]9Z=8.H@\50+;:DBMA@ENZN9/QC+)^(K2
M\3^&+>+QD-9NO":^(-.GL4MO)CBB>2VDC9BI"N0-K*V.#QM% #KOXBZA_8F@
M7-CI<$E]J5_)ITUL\IVQS)O4X8?P[USG'W3G&:[G2O[2_LV'^U_LGV_!\W[)
MN\K.3C;NYZ8Z]ZX2?PY?/#X+:U\/V^F+::J;JZL[1EV6Z%7 )Q@$\KG&>2>M
M>CT </IWBCQ%K&J7<FG6>E3:=::B]E-:^>PNU57V-(<_*.[!3U'?-8&C7WB6
MTN?'$FA6NG-';:S//(]ZS_O3Y4?R(%Z'"]3Q\PXZU-K6DW^K:Y')#X0FL?$,
M-\ACUNVD183 L@)9V#!FS&""C*>36]H&CZA:6OC-)[9D:_U.XFM@2/WB-#&J
MD<\9((Y]* %?Q-KFJZ)HFH:'9V%O#J%H+J>ZU&4^5!D*1'A2&9B2>>!A:XOQ
M[K\GB/X7Z9>SPQQ7*:[';SI$^Y-\<CH2I[J<9'UJS:^&]0L8O"IUCPK+K=K:
MZ(MI]B'E.+:ZR,LRNP7!7C=SC%4K[PEXBE\ '0TT,QW5OXA^UA8&00M"TC/F
M/G[H! P0/I0!T5Y_R<5IW_8NM_Z.:NK\9Z[-X9\(:EK,$22RVD0=4DSM;D#G
M'UK#NM$U)_C99:XMJQTV/16MFN,C D\UCMQG/0CM6E\1=,O-9^'^LZ=I\!GN
MYX-L42D L=P/?CM0!03Q+XCL?$NBVNL6.G1V&LM)'"MN[F:V<(7 D)^5L@$'
M &#Z]Z+>,_$U]H^H^)=)T_3'T.R>;9#,[BXN8XB0[JP^5<[6P"#TK:\2Z7>W
MOB+PC<VUNTD-E>O)<,"/W:F%U!/XD#BN7MK3Q'H/@_4_!=MX>NKN21KF*QOT
MDC%N8IF9@TA+;E*[SD;3G''6@"=]>U[4_BAH:Z7<6@TFZT@WL<4ID&Z)VCW%
M@#@N/X>P!/K7H6HSW%KIMS<6EJUW<1Q,T5NK!3*P'"Y/ R>,UP/]AZEX9\7^
M%[FVTVYU*QM-%_LF22V*9C8,F'8,P^7"]JZCQO8:CJ?@K5K+2BWVV: K&%?8
M6Z94-V)&1GWH R-(\4:VGB2VT;7$TEI+RUEGA;3I&8PO'MW1R!B<\.,$8Z'B
ML*U^(7BF3P1:^-)M*TQ=' 5KFW5Y/M!3?L9T_A !R0ISD#.1G%&GZ/-;^+]"
MU;3/!#:/I<,,]I*JQPI-N=5Q)(%;E!MQG);J<<C.'H']O:Y\%=.\*VNA7#/?
MP")-1#Q_9TA,F2S?-N# 9&W;R1Q0!V\WB;Q)J/B[6=!T*TTP+I\4$HNKQGVD
M2(2%(7DDD'!XP >M<AXV\0OXF\!^&KZ>V%M=Q^)8;:Y@5MP26-I%8 ]QQD?6
MMFRU&]T3XG>+VM-'N]3MO(L$=+0H9481-MX9ERIYR0>,#CTS-1\%^()? NCP
M_8-VI2^)!JUY;QR*?(5W=B,YP=H*YQWH [[3?$5Q-XWU?PY?011-;PQ75FZ9
MS/ W#$Y[JXQ^(I?"/B&X\2V^HWS011V*7TMO9.F<S1QG:9#]6#8QZ5S'Q7BO
MM/.C^(-%*C5UE?3(T+8,JW"E0/<JX5@/8UV^@:/!X?\ #]AI%M_JK2!8@<?>
M('+?4G)_&@#CUU+Q&WQFN; 7%F--ATR.4Q,TF/+,IRP'3S.,9Z8Q4'_"<^)9
M?#,OC&WTW3F\/(6E6V9W^U/;JQ4R;ON X!;;CIWJ_>66I6?Q8.I#2;F[TW4-
M+CL6G@9,0.)6)+AF!VX.<C/TK CT[Q-:_#R7P F@7$ET8WLH]2\R,6I@9C^\
M)W;@0A^[MSD4 >JP31W-O'/$VZ.10ZGU!&17"WOB[Q%I5_!<ZC9:7!ILVH):
M"T\\F\5'D\M)3@[3DD-M Z'KFNWLK5;*PM[1"2L$2QJ3W"C']*\9_P"$6U4>
M'H;<>##)KMEJ"7=[JDGDF2[VSASY+EMQ++S@[0 ".N* .R;Q+XJU/6O$&G:)
M8Z6HTF=4$UXTF)=T:N% 7^+).3T''!R<='X4UT>)O"NFZT(?)^V0"1H\YVMT
M(SW&0:R_"NG7UKKOBJ\NK22"*_O(YK?>1EE\A%/0GH01^%2?#G3+S1OA]HVG
M:A 8+N"#;+$Q!*G<3VX[T 4(-<3_ (6OJ^E+I=DLMOI*W'VX1_OY!N'R,W=?
M;VK'@\?^*&\(Z;XOGTS3(]'F:%;B ._G[7<1EU/W0-QR%.<CN.@TH="U-?B_
MK6L&T8:?<:,MO%/N&&D# [<9SVK/E\-:PWP*L=!%B_\ :D<=L'M]RY!6=&;G
M.. ">M '4Z'XDGOO$/B'1M0BB@GTN9&B9"0)+=UW(YSWX8'''%<[9_$#5M5T
M[36L;.QBN=9N[G[ URS"-+2(_P"MDP<ECQ@#&=PI/B)X?U^?58M1\,V_F7%_
M8RZ1>D.%\N)R"LO)'W?GZ<\U)XJ\&V\:^&)8=!36=.T6-[673RJ,[1,B@.H<
MA2RE%.,\Y- "7?Q!U+3M!U![BPM9M6TW4;>SFBMW)BF64H5>,GD95^A/!!J]
M#X@\46OB>'0]5MM)$NH6<T]C);-(522/;E),\D?,/F&/I6-=^')[OPG(FE>$
M8-%,FK6DR6L0C65X8Y$)>0*=H/WC@$\>]=-JVEWMQ\1?#>I10,UG:VUXD\H(
MPC.(]H]>=I_*@#@]-\1ZS'\%]8UW6[?3M5@665HX+@/('/VE@RN&XV@XV@=
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MM#L+V(PW5O911RQD@E6"@$<<5O4 %%%% !1110 4444 %%%% !1110 4444
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M:TBSAE4("#ALEEP<XYJS%XK;_A*H_#ESI5S'>R6_VH/')&\0BSM+$E@<AN"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<M\0]*O]8\'3VVFV_VBZ2>WG6$,%+B.5'(!) S@'K74
MT4 <5J=IJVH>.?"6JKH]PEM9QW?VDF6(F'S454!^;D\<[<@=B:S(=&UI= ^(
M%JVCW FU>XN7LE\R+]X)(5C7G?QR.^.*](HH \\N-)UEX?  72+@G2G1KT>9
M%^Z A,9_CYY.>,\5!H]CXC\-WE_H@\,0ZE:RW<L]CJ9EC"(DCE\2@_-\I8]
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M"0C?LC!RS $@9+<#.<#GK@=35'6=)MM<TJ?3;MIU@F W-!*T;C!!&&'(Y H
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M0&,#[_//IGBLO4O"FMZQ-X\CCM&M#J<MI<:?-,Z%)'@5."%8D LG<=#7I]%
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M=11Z':QYAVEEVNX&02.OK5.^\(ZQ#X)EMX-/:?4+_7AJTUO%)&! IG$A7<S
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M%BM+:(Q"63'),CH=F,]!GCG/6@#<LY?&EYH#WBOHZ7MRT4MM!(D@2&(X+*[
MDL^WN,#/M765D7LFJZ=X?@_LS3TO;Z-8D,#S",8X#'<>.!D^^*UZ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** */]D61UT:UY)^WBV-IYNX_ZK=NQC..HSG&:O444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6]ETUTANFC@^QREV6,=!+G[K^H% &M15*SUC3-1EDBL=1M+J2+_6)!.KE/J
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M(>+?'LVD^*-,\.Z2VE&[NEDDGGO[G9%;A1D!MO.X]OP]: .\HIL9+1(S%22
M25.1^'M6,_BS2(_%:^''NHQ?-;^?S(H ^8*$ZYWG.0,=* -NBN5\+^,K75]'
MM[C4KJQL[RXN)X8H#,%+A)6C&T,<DG:.G>M^]U33],$9O[ZVM!(=J&>98]Q]
M!D\T 6Z* 00"#D&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYR,_,0<<9/X5<KC/BN\T'PUUBXM[FXMYX8U9)()FC8?.H(RI&002,&@#LAG
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M_>XR..,<4Z;P=HT_]E&2&<MI:&.U<7,@8(0 48ALLI  (;.<5F>-/%MUH/\
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M8Z5-8^';'3)8[E/M-U/;PF*!KF=I6C0XRJECQG R>IP,GBL?QIXR&D?#F_\
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M[*<9#$M\PXZ'('I7144 <E%\-O#,-M;6R6MSY-K<BYMD-[-B!N>$^;Y5^8Y
MZ]^@K8LO#VGV&M7NKVZ2K>7P07#&9RKA!A1M)P, G&!6K10 5FZSH6GZ]!#%
M?1,Q@E$T$L;E)(9!T96&"#6E10!C'PQIKV-_:RK/)_:"[+N5IF\V9<;<%\Y
MP2,# &3ZFKVF:;;Z1IMOI]H)!;6Z".)7D9RJ@8 RQ)P!5NB@ K#U7PEI6KZM
M;ZK,MQ#J$"&);FTN'@=HR<E&*$97/8_A6Y10!S(^'_AK^P+K1'L&DL+F8SR1
MR3NV)"<[E).5.3_#BG0^!=#AT*[T<Q7,MM> +<M+=2-+*HZ*7)W;1D\ XY/J
M:Z2B@#$D\*Z7-=:7<R"Y,VE@BS;[3)^[R-I[_-D<<YXHC\):,DVK2M;/,=6
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ML<,,\\]#TQ4-WX/T6\TZRT^2WD2VLIQ<0)%.Z$2@[@Y(.6;))R2>23UK=HH
M11M4+DG QDGFEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDK31IYTABCD.<NL1;8K<GD"M2QT>PTRYOKBSMQ%+?3>?<MN)WO@#/)XX Z4
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M<9[TZ218HGD<X1 68^@%>=>#=-N_$W@K4]=-[)8ZMXD9W%VB[GMH0Q6-%Y'
M0<<]6)H ]&R.>1QUID%Q#=0K-;S1S1/RKQL&4_0BO,SX<T?P[\0O#=CX5A:"
M^422:IY<C-OM=A&Z;)Y)?;M)YSFM;0#_ &!\2]8\.1<6%]:C5[6,=(7+[)E'
ML6PV.V30!W5%%% !1110 45POQB('PNU8LVU=]ON.<<>?'GFN0\36?PQL/#U
M[<>'=0M(];2,FP.F:@[SF?\ @"JKDG+8!XZ4 >TT5Q<_B'7Q<:3H5G;V/]M/
MIJ7M_+>NRQ1=%P O)8ON]  IJG_PGVH7=MI5I:6EA;:Q=W=Q9S"\G;R(9(/O
M@$#+;N"HXX/M0!Z!2,RHA9F"JHR23@ 5R+>)]9L;CP_9ZII=O;W>HW\MI-Y<
MN]-JHS"2,]<-M'##(S3M6UZ676M=\/F%!#!HOVL2Y.XLQD4CTQ\M '4V]Q!=
MP+/;31S0O]V2-@RGZ$5)7A6D:EKVG?"7X>KHTMO$MUJD=O(9)'4LQF<JIV_P
M':0W?IQ7M+G4O[(S&MI_:?DCABWD^9CGG&[;GVS0!*M]:/=M:+=0-<J-S0B0
M%P/4KUJ>O"/ 5WJ6@^$_%7BQM.TB>:WN;MWN&#&X>0%25W8_U?7OGVKNI/&7
MB"UT.UO[K2K'[1J]S#;Z1:),V[,@)S.<87"C<0N?3WH [VBN-MO$^M6&N2Z+
MX@M; 7,EC)>VEQ9._ER!.&1@W(89!ZX(/:L%?B)XF3PWHWB:;1+%M+OY(H3;
MQS-]HW/\H89&T*6Z Y."#D=@#U"BN1TCQ%KB^,F\.Z]::>CRV)OK>6QD=EVA
MPC(VX#)&X'(P*U?$-[K%I;VZ:+903W$TNQY;J39#;I@DN^.3T  '<T ;-%>>
M7'Q"U"Q\,:I>7-A:S:EI>HPV4T=K(6BF$ACPR$X(RLG0]Q5Z+Q'XEM/$]MHN
MKV.EH^I6L\UB]K*[!)(P"4DW 9&&'S#'TH [6BN)M_'ZO\,;CQ5<6RQ75M'(
MDUID_+<JVSR_7E\?@16GKFM:MH_@&XULV4$FIVUHMQ-;9.P$ &0 ]>!NQ]*
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MF$NA>,OQMY Y Z9ZF@#O**\]N_'>L):ZCKUK86#^'M/N7AD#S,+F9(VV22H
M-H (; /)"GD9K0G\2Z[J/BC4=+\.V>G2P:7'$;F6\E=?->1=ZI'M!Q\N,L<]
M>E '703PW,?F02QRQY(W1L&&0<$9'H:(YX9FD6*6-VB;9(%8$HW7!]#R*XOX
M22&;X?6\IC:,O=W;%&ZKFXDX-8FB7?B:/Q%XVC\/V6GR^5JIE=[V1U$A,*8C
M0*.OR\D\#(Z\X /4Z*X;2?B"VIW_ (89K-(=.U^TD,4A8EHKJ/EHR>F,!L'J
M2*V+#Q#/J/C?5=&@@C-CIEO$9KC)W&>3+!!VP$P3[D4 =#4<,\-PI:"6.558
MJ2C!@&'!''<5P6HZGXE'QDLM,M)+,:?_ &:\_E222 ,ADC5V( P9 00O;!//
M)KG] USQ)HOA3Q!J6F:?I\NGZ=J=_-/]JE=9)@LK,PCVC P.YZG/''(![#17
M&77BO5-1U6+3O#=O8&06,=]/-J$C*B+)GRXP%Y+':23T '>MSPQK@\1^'[?4
MO(-O(Y>.:$MN\N1&*.N>X#*>>XH UZ*\^O/'6L);ZGKEI86$F@:9<20RAYF%
MS,L;;99$ &T $-@'KM/3(JU/XH\07_BK5M"T"RTYS906\ZW5W(X0B12=I"C)
M)(XZ# .>PH [>BO+T^(_B&7PA;^+AHUC%H\<B17<3SL9V/F"-VCP-H 8G /)
MP>E;=UXF\17?C'5O#NB6&GEK&&";[5>2.$ <'Y2%&221QT& ?84 =?<75O:(
MKW-Q%"K,$5I'"@L>@&>]35XQXZ\0OXE^'>C7<]L+6\A\10VMU &W".6-G5@#
MW'&1]:[F_P#$.MWOBF\T+PY:V!?3X8Y;RYOW<(&DR4C54&2<#)/:@#KJ*\_7
MXB7(TO2]0N-.C@B_M9M)U93(6^RR@E RMT*[L<GLPK1\2^-?[!U^*Q6!98(-
M/N-2U"0D[HH4&$VCN6;(Y]* .OHKB=-\4Z[%JFD0Z]8Z=#;:QN6W-I,S/;R!
M#((Y,C!RH;D=QT[U2B\>ZL]C!XC:QL!X:GNEA4"9OM2Q-)Y:S$8VX)(.WK@]
M: /0Z@@OK2ZEEBM[J"62(XD2.0,4/N!TK.\4R:C%X9U"32S;BZ6%R#.S!0,'
M)!7G..GO7EGP]U"Z\)_#'3+^+2-+EN=4ECM+'R<I-<3/(X'GN5Z#D\9X% 'M
M=%<A8>(M;L_$\&@^(K6P$M[;23V=Q8N^QC'C>C*_((# YZ$5#X \4:_XPT^W
MUBZT^QM-)FA8+MD<S/*K8) Q@)PPY.<C/0T =B9X1<+;F6,3,I=8RPW%1U('
M7'(HGN(;6!I[B:.&)!EI)&"JOU)K@/$DVI1?%K1UTFW@FNY-(N$4W#E8XQYD
M9+-@$D<8P.I(Z=:@U/QC=-X$\6-KFCZ?<7NBS""XMN7MK@'8RMAN<$-T/I0!
MZ0CK(BNC!D895E.01ZBG5PLGB?59+K1M&T*UTJ"YN-*2^Q>R,D>TX41QJHR2
M/T&.*Z_2[B[NM+MI[^S-E=N@,UOY@?RV[C<."/>@"W17GG_">ZM]A/B,6-A_
MPC0NO)QYS?:C%YGE^=C&W&>=O7'>I[GQ7XFO-<\1Z9HFFZ<?[&:,F:[D<"4-
M$'"@+_%G// ''7/ !WE%>;0_$'79=&T7Q*VD646A:A/! \;3,;E/,8)O'&W:
M&Z#J1@\9P-!_$_B?4O$VOZ-H>G:;_P 2F2(&XO97"R!XPX4!1][)//  QUSP
M =G/=6]L8A<7$41E<1QB1PN]CT SU/M4U>.>*O$"^*-*^'&KB V[S>(H%DA)
MSY<BN49<]\,IKL;CQ%X@U/Q#JFF>&K/33%I6Q+B>_D<"25EW;$"#C (RQ[GI
M0!V5%<'8_$.2\;PQ<R6"P6.L32V5P6?+6UVF0$ST(9E8#\*E\1>/7T37-2M8
MK);FVTS3TN+A@V&,\K[(81V&[KD]J .WHKCK'Q+K=IK46E:_;::);NTEN+26
MQE=EW1XWQN&&<X8$$<'!XI/ 7B77O%VG6^LWFGV-II5Q!^Z"2.TS2AL$XQ@)
MPP'.> >] '94444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!%=0"YM)K<G EC9"?3(Q7G/@[4
MM4LO@SY.EV1NM=TI9;$VG&5G1RO.<= 0WN*]+K,M-"L['6[[5;;S(IKY5%Q&
MK?NW9> ^WLV.,CJ,9H X_P %W%QI!CM'\):^MW>R![[5+L0DRR'J[D2$[1V
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MU&W:WNX4<21-C*YD8CI[$5UM% '+76FWC_%'3=36!C91:5/ \W&%=I(R%_$
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M^(^J6^L6NDR^"-56^ND>2&'[3!EU3[QSOQQGN:] K@M<_P"2T>$_^O"\_DM
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M@#TIG54+LP"@9+$\8I5974,K!E(R"#D&O"K![JY\/^#-$&FMK%E]MU$-827
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MF2!*J-,ZQMZJ6 R.^*W]8TZS\.>+-8TW1K:.SL+[PQ=7%Q:0+MC$B':L@4<
MD,1QUH ]4\V,R>7YB[R-VW/./7%..0#@9/85XT_A_3=*\#^!==M;94U=KO3"
M][_RU<2;0RENI7!QMZ  "O8YO]1)_NG^5 %+1KK4+O2XIM6LHK&\8D/!%.)E
M7DXPV!G(P>E7DECDW>6ZOM.#M.<'TKP'PY;+>?!CP-;.[HDWB..-FC8JVTRR
M@X(Y!P3R*[[3='T_P[\8$M-'M(K&UNM">2:"!=J.Z3*%8@<9PQ&?>@#T(D $
MDX [TQ)8Y(_,2163^\IR/SKE_B!)9'0+>SO;6ZO!>WL,$5G;R!#<R9W"-F/
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M9QO=1Q+9QF$-\@;H23]X<_*!GB@#U^BL/P=!JMIX0TNVUO/]I0P".;+AR2O
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M/#([,S;6QC!WL,$$$=<UIZ%H$&@PW"QW-W=SW,OFSW-W)ODD;  R0
M *TQ+&9!&)$+E=P7/./7'I2^9&)1%O7S"-VS/./7% &+KOABVURYM;P7E[I]
M_:AEBN[*0)($;&Y#N!!4X!P0>1Q51? NE?9=-MI9KV>&QNFO2DTV_P"TSDD[
MY21EB"<@# SVX%=##=6]R',%Q%*$.'*.&VGT..E(+VT,T<0NH3+(NY$\P98>
MH'<4 9W_  C5BOB.XUR-IH[BZMA;7,2,!'.H^ZSKCE@"0""..*Q;3X;Z79Z
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M)?,LI1<KOM,A@50[,;2&((8-VK?T'P_;:!!<+%/<W4]S+YUQ=73AY9GP%R2
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M+P_>:/(MS<1WDWVBXN)IB9Y)<@B3>,$,"JXQC&*=8>#+"R2_,UWJ%_<7UO\
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M/8DD#. >@HO?A]I%[J5[=FXU&"*_(:]LX+HI!<MC&70>H !P0#WS0 _X;_\
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M8(XIO*%U8RH3MN(<X8'/1U;J.X(-=#7"^,_W7C[P'<1_Z_[9<0\=XVA.[\.
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MBQ'YC+(VP#RU(=MNT]1Q6%KD<]IX7^)EG/:V.G^6;"1K;3Y"\,3MMR1E5P2
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M4F 1RIW*<CD50U;P/I6L:A<7DDVH6SW2!+M+2\>%+E0, 2*IYXXSP<<5TM%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>josetrevejo-tarsussepara017.jpg
<TEXT>
begin 644 josetrevejo-tarsussepara017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417141118832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TARSUS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-4717861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15440 Laguna Canyon Road, Suite 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">418-1801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TARS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,781,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055311424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 193,705<span></span>
</td>
<td class="nump">$ 224,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">104,819<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">29,885<span></span>
</td>
<td class="nump">16,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">4,036<span></span>
</td>
<td class="nump">3,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">6,803<span></span>
</td>
<td class="nump">7,868<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">340,724<span></span>
</td>
<td class="nump">256,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,767<span></span>
</td>
<td class="nump">3,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">349,278<span></span>
</td>
<td class="nump">265,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">36,570<span></span>
</td>
<td class="nump">23,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">5,958<span></span>
</td>
<td class="nump">13,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">42,528<span></span>
</td>
<td class="nump">36,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan, net</a></td>
<td class="nump">29,933<span></span>
</td>
<td class="nump">29,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">74,067<span></span>
</td>
<td class="nump">68,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized; 37,749,468 shares issued and outstanding at March&#160;31, 2024 (unaudited); 34,211,190 shares issued and outstanding at December&#160;31, 2023</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">555,655<span></span>
</td>
<td class="nump">441,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(280,387)<span></span>
</td>
<td class="num">(244,656)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">275,211<span></span>
</td>
<td class="nump">196,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 349,278<span></span>
</td>
<td class="nump">$ 265,491<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417142116176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">37,749,468<span></span>
</td>
<td class="nump">34,211,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">37,749,468<span></span>
</td>
<td class="nump">34,211,190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417165737296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 27,614<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,066<span></span>
</td>
<td class="nump">12,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">51,578<span></span>
</td>
<td class="nump">15,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">65,298<span></span>
</td>
<td class="nump">27,452<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations before other income (expense)</a></td>
<td class="num">(37,684)<span></span>
</td>
<td class="num">(24,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">3,117<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(983)<span></span>
</td>
<td class="num">(684)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on equity investments</a></td>
<td class="num">(585)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of equity warrants issued by licensee</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,953<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(35,731)<span></span>
</td>
<td class="num">(23,419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities and cash equivalents</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (35,792)<span></span>
</td>
<td class="num">$ (23,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (usd per share)</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.88)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (usd per share)</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted Average Number of Shares Outstanding, Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (shares)</a></td>
<td class="nump">35,300,655<span></span>
</td>
<td class="nump">26,742,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (shares)</a></td>
<td class="nump">35,300,655<span></span>
</td>
<td class="nump">26,742,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 24,720<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember', window );">License fees and Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,894<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055228816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,727,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 192,900<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 301,732<span></span>
</td>
<td class="num">$ (74)<span></span>
</td>
<td class="num">$ (108,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation expense</a></td>
<td class="nump">3,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of vested stock options</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon the vesting of restricted stock units (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,800,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 173,404<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">305,651<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(132,182)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2023</a></td>
<td class="nump">34,211,190<span></span>
</td>
<td class="nump">34,211,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 196,988<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">441,641<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(244,656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(35,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation expense</a></td>
<td class="nump">5,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,281,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs of $6.7 million</a></td>
<td class="nump">98,329<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">98,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants, net of issuance costs of $0.6 million</a></td>
<td class="nump">$ 9,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options (shares)</a></td>
<td class="nump">49,310<span></span>
</td>
<td class="nump">49,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of vested stock options</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon the vesting of restricted stock units (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">$ (61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2024</a></td>
<td class="nump">37,749,468<span></span>
</td>
<td class="nump">37,749,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 275,211<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 555,655<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
<td class="num">$ (280,387)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417150346144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35,731)<span></span>
</td>
<td class="num">$ (23,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of term loan-related costs</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,519<span></span>
</td>
<td class="nump">3,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_OperatingLeaseNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on equity investments</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization/accretion on marketable securities</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(1,484)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of equity warrants issued by licensee</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized gain from transactions denominated in a foreign currency</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(13,264)<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(929)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(383)<span></span>
</td>
<td class="nump">3,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">12,335<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and benefits</a></td>
<td class="num">(7,287)<span></span>
</td>
<td class="num">(1,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(37,789)<span></span>
</td>
<td class="num">(21,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">40,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(104,550)<span></span>
</td>
<td class="num">(28,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(340)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(102,224)<span></span>
</td>
<td class="nump">11,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of paid issuance costs</a></td>
<td class="nump">98,604<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of pre-funded warrants, net of paid issuance costs</a></td>
<td class="nump">9,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of equity awards</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">108,771<span></span>
</td>
<td class="nump">5,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(31,242)<span></span>
</td>
<td class="num">(5,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents &#8212; beginning of period</a></td>
<td class="nump">224,947<span></span>
</td>
<td class="nump">71,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents &#8212; end of period</a></td>
<td class="nump">193,705<span></span>
</td>
<td class="nump">65,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest expense paid in cash</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities', window );">Offering costs included within accounts payable and accrued liabilities</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_OperatingLeaseNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Noncash Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_OperatingLeaseNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417141170848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts', window );">Issuance costs, warrants</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Payments of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417050626736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Presentation of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Presentation of Financial Statements</a></td>
<td class="text">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221; or the &#8220;Company&#8221;) is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The Company launched XDEMVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis, in August 2023, after receiving United States ("U.S.") Food and Drug Administration ("FDA") approval in July 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-On Public Offerings</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company completed a follow-on public offering under its shelf registration statement on Form S-3 (the "2021 Shelf Registration Statement") of 5,714,285 shares of common stock at a public offering price of $17.50 per share. In September 2023, the underwriters partially exercised the underwriters option to purchase additional shares resulting in the Company's issuance of an additional 355,164 shares of common stock at the public offering price of $17.50 per share. The aggregate net proceeds received by the Company were $99.3&#160;million, after deducting underwriting discounts, commissions, and other offering-related expenses.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company filed a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission ("SEC") on November 21, 2023, (the "2023 Shelf Registration Statement"), which replaced the 2021 Shelf Registration Statement, and permits the Company to offer up to $300.0&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company filed an automatic shelf registration on Form S-3 ASR (the "2024 Shelf Registration Statement"). On March 5, 2024 the Company completed an underwritten follow-on public offering under the 2024 Shelf Registration Statement of 2,812,500 shares of the Company&#8217;s common stock, par value $0.0001 per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of its common stock (the &#8220;March 2024 Public Offering&#8221;). The price to the public was $32.00 per share and $31.9999 per pre-funded warrant, which was the price to the public of each share of common stock sold in the March 2024 Public Offering, minus the $0.0001 exercise price per pre-funded warrant. The pre-funded warrants are exercisable, subject to certain beneficial ownership restrictions, at any time after their original issuance and will not expire; as of March&#160;31, 2024, 312,500 of pre-funded warrants are exercisable. The Company also granted the underwriters a 30-day option to purchase up to 468,750 additional shares of its common stock at the public offering price of $32.00 per share, which the underwriters exercised in full and was completed on March 5, 2024. The aggregate net proceeds received by the Company were $107.7&#160;million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Market Sales Agreement</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the 2023 Shelf Registration Statement, the Company concurrently filed a sales agreement prospectus covering the sale of up to $100.0&#160;million of common stock pursuant to an Open Market Sale Agreement (the "2023 ATM Prospectus") with Jefferies LLC ("Jefferies"), which replaced the November 1, 2021 Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the "2021 ATM Prospectus"). Under the terms of the 2023 ATM Prospectus, Jefferies will act as the Company's sales agent and is entitled to compensation for its services equal to 3% of the gross proceeds of any shares of common stock sold. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, there were no sales of the Company's common stock pursuant to the 2023 ATM Prospectus. During the year ended December 31, 2023, the Company sold 1,000,000 shares of common stock under the 2023 ATM Prospectus for net proceeds of $19.2&#160;million, after deducting broker commissions and offering-related expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a limited operating history, limited history of product sales and has accumulated losses and negative cash flows from operations since inception. The Company has funded its inception-to-date operations through its Initial Public Offering ("IPO"), subsequent follow-on public offerings, and the 2023 ATM Prospectus, as well as from proceeds from product sales, the development and license agreement (the "China Out-License") with LianBio Ophthalmology Limited ("LianBio"), and draws on the loan and security agreements with Hercules Capital, Inc. ("Hercules") and Silicon Valley Bank, a division of First-Citizens Bank &amp; Trust Company ("SVB") (the "Credit Facility"). The Company estimates that its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the issuance date of the accompanying Condensed Financial Statements that have been prepared on a going-concern basis. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company plans to fund its operations, capital funding and other liquidity needs using existing cash and investments and, to the extent available, cash generated from commercial operations. Management expects the Company to continue to incur operating losses for the foreseeable future and may be required to raise additional capital to fund its ongoing operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own and/or enter into collaborations and other arrangements to address its liquidity needs, which could materially and adversely affect its business and financial prospects, or even its ability to remain a going concern.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Segment  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates one reportable operating segment focused on the development and commercialization of therapeutics. To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purpose of evaluating financial performance and the allocation of capital and personnel resources. The Company&#8217;s chief operating decision-maker, its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417141032160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies and Use of Estimates</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the SEC. Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on February&#160;27, 2024.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of March&#160;31, 2024, the Condensed Statements of Operations and Comprehensive Loss, and the Condensed Statements of Stockholders&#8217; Equity for the three months ended March&#160;31, 2024 and 2023, and the Condensed Statements of Cash Flows for the three months ended March&#160;31, 2024 and 2023 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December&#160;31, 2023 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2024 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2024 or any other interim or annual period.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these Condensed Financial Statements and Notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, expected demand for inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions used in the preparation of the accompanying Condensed Financial Statements under different assumptions and conditions.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Condensed Financial Statements as of and for the three months ended March 31, 2024, reflect the Company&#8217;s estimates of the impact of the macroeconomic and geopolitical environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies and estimates that most significantly impact the presented amounts within these accompanying Condensed Financial Statements are further described below:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities and Long-Term Investments</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist primarily of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are recorded at fair value with unrealized gains and losses reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized gains and losses as well as credit losses, if any, on marketable securities identified on a specific identification basis are included in other income (expense) on the accompanying Condensed Statements of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other-than-temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company's holdings of common stock in the parent company of LianBio was included as marketable securities. As of December&#160;31, 2023, this LianBio common stock was classified as long-term investments due to the Company's intent at that time to hold these shares for longer than one year. These equity securities are designated as available-for-sale with associated unrealized gains or losses reported in other income (expense) within the Condensed Statements of Operations and Comprehensive Loss for each reported period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable generally consists of amounts due from the Company's customers, which includes pharmaceutical wholesalers and specialty pharmacy providers related to product sales of XDEMVY in the U.S. Payment terms are typically 30-60 days following delivery to customers. Accounts receivable are recorded net of discounts, chargebacks, allowances and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so it can properly assess and respond to changes in their credit profile. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company did not record a reserve for estimated credit losses during the three months ended March 31, 2024. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower-of-cost or net realizable value, with cost determined on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and adjusts the value for any excess and obsolete inventory to net realizable value in the period in which the impairment is first identified and such charges are recorded as a component of cost of sales in the Condensed Statements of Operations and Comprehensive Loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Product that may be used in clinical development programs are excluded from inventory and the costs are charged to research and development expense in the Condensed Statements of Operations and Comprehensive Loss as incurred, as long as they do not have an alternative use. Prior to FDA approval of XDEMVY in July 2023, costs related to the production of inventory were recorded as research and development expense on the Condensed Statements of Operations and Comprehensive Loss in the period incurred. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow. The carrying value of intangible assets as a result of achieving certain commercial milestones was $4.0&#160;million as of March&#160;31, 2024, and are amortized to cost of sales over their useful life of 10 years from the date of first commercial sale (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Amortization expense for the three months ended March 31, 2024 was $0.1 million; no amortization expense was recorded for the three months ended March 31, 2023.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the expected future amortization expense for the Company's intangible assets is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including intangibles, are evaluated for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in the Condensed Statements of Operations and Comprehensive Loss. There have been no impairments of intangible assets for the three months ended March 31, 2024 and 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash, cash equivalents, accounts receivable, net, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from <span style="-sec-ix-hidden:f-311">three</span> to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in circumstances of the business indicate that the asset&#8217;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Right-of-Use assets (&#8220;ROU assets&#8221;) represent the Company&#8217;s right to control an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the initial non-cancelable lease term, unless there is a renewal option that is reasonably certain to be exercised. The Company uses its incremental borrowing rate at the lease commencement date in determining the discount rate utilized to present value the future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable. The Company has lease agreements with both lease and non-lease components, which are accounted for as a single component for all asset classes. Lease expense for the Company's operating leases are recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's variable lease costs, consisting primarily of real estate taxes, insurance costs, and common area maintenance, are expensed as incurred and excluded from the reported ROU assets and lease liabilities amounts presented in the accompanying Condensed Balance Sheets. The current and noncurrent portion of the operating lease liability are included in accounts payable and other accrued liabilities and other long-term liabilities, respectively, in the accompanying Condensed Balance Sheets. Rent expense is allocated to research and development and general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration Risk </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company maintains cash held on deposit at financial institutions in the U.S., including SVB. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. The Company invests its excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. The following table summarizes the percentage of the Company's product sales from its largest customers:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, amounts due from these five customers each exceeded 10% of gross accounts receivable and accounted for approximately 100% of the accounts receivable balance on a combined basis.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Major Suppliers</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not currently own manufacturing facilities and depends on an outsourced manufacturing strategy for the production of XDEMVY for commercial use and for the production of its other product candidates for clinical trials. The Company enters into agreements with third-party manufacturers that are approved for the commercial production of XDEMVY and third-party suppliers that are approved for XDEMVY's active pharmaceutical ingredient. Although there are potential sources of supply other than the Company's existing manufacturers and suppliers, any new supplier would be required to qualify under applicable regulatory requirements. The loss of certain manufacturers and third-party suppliers could result in a temporary disruption of the Company&#8217;s commercialization efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Product Sales, Net</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes product sales, net of XDEMVY when a customer obtains control of promised goods or services, which occurs at a point in time, typically upon delivery of the Company's product to the customer. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as each performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells XDEMVY to customers in the U.S., which became available for commercial sale during the third quarter of 2023. The Company sells XDEMVY to a limited number of specialty pharmacies and distributors (i.e., its customers) who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. Revenue from product sales is primarily recognized upon physical delivery of the product (when the customer obtains control of the product), in return for agreed-upon consideration. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or the transaction price, which may include fixed or variable consideration for (i) invoice discounts for prompt payment and distribution service fees, (ii) government and private payer rebates, chargebacks, discounts and fees, (iii) product returns and (iv) costs of co-pay assistance programs for patients, as well as other incentives. Estimates of variable consideration are calculated based on the actual product sales each reporting period and the nature of the variable consideration related to those sales. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates reflect the Company&#8217;s best estimate of the amount of consideration to which the Company expects to be entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ materially from </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect product sales, net and earnings in the period such variances are adjusted. The Company categorizes product sales deduction estimates as follows:</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Service Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Pay Discounts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's customers are contractually permitted to return the product within the contractual allowable time before and after the applicable expiration date. In the initial sales period, the Company estimates its provision for returns based on industry data and adjusts the transaction price at the time of the product sale to the customer. Once sufficient history has been collected for product returns, the Company will utilize that history to inform its returns estimate. Once the product is returned, it is destroyed since it cannot be resold.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A chargeback is the difference between the Company's invoice price to the wholesaler and the wholesaler&#8217;s customer's contract price. The wholesaler tracks these sales and charges back the Company for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price and accounts receivable at the time of sale of the product to the customer.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company&#8217;s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer.</span></div><div style="margin-top:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ii) License Fees and Collaboration Revenue</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">China Out-License </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss has historically primarily related to the China Out-License that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kong, Macau, and Taiwan (the "China Territory")&#8212; see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract; (b) the contract&#8217;s transaction price for allocation (including variable consideration); (c) the stand-alone selling price for each identified performance obligation; and (d) the timing and amount of revenue recognition in each period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment; (ii) equity-based consideration; (iii) sales-based royalties; (iv) sales-based threshold milestones; (v) one-time payment for executing a drug supply agreement; (vi) development milestone payments; (vii) regulatory milestone payments; and (viii) a one-time termination payment to transition the rights to develop and commercialize TP-03 in China for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis to Xi An Grand Chang An Pharmaceutical Co., Ltd  ("GrandPharma"). Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#8217;s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Threshold Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other License Fees and Collaboration Revenue</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service. There was no revenue recognized under this arrangement for the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, freight, third-party royalties payable on the Company&#8217;s product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon FDA approval of XDEMVY in July 2023. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses in the Condensed Statements of Operations and Comprehensive Loss. Therefore, cost of sales of XDEMVY will reflect a lower average per unit cost until the related inventory is sold.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative costs consist of salaries, benefits, stock-based compensation and other personnel-related costs for the Company's executive, finance, sales and marketing, and other administrative functions. Selling, general and administrative expenses also include sales and marketing costs to support our commercial launch, consulting fees, legal services, rent and other facilities costs, patient assistance donations, and other general operating expenses not otherwise classified as research and development expenses. Advertising costs are expensed as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including the costs of salaries, payroll taxes, employee benefit and other employee-related costs (including stock-based compensation expense), license fees, materials, supplies and the cost of services provided by outside contractors to conduct nonclinical studies, clinical trials and contract manufacturing activities. All costs associated with research and development are expensed as incurred. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company's license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense in the Condensed Statements of Operations and Comprehensive Loss when paid or become payable, provided there is no alternative future use of rights in other research and development projects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company&#8217;s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's common stock on the date preceding the award grant date.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock awards granted typically have <span style="-sec-ix-hidden:f-330">one</span> to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including (a) the fair value of the Company&#8217;s common stock on the date of the option grant for all awards granted prior to the IPO, (b) the expected term of the stock option until its exercise by the recipient, (c) stock price volatility over the expected term, (d) the prevailing risk-free interest rate over the expected term, and (e) expected dividend payments over the expected term.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within cost of sales, research and development expense or selling, general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s expected term represents the period that the Company&#8217;s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain due to the Company&#8217;s historical operating performance and recorded cumulative net losses in prior fiscal periods. A valuation allowance is recorded to reduce deferred tax assets, because based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when the Company were to determine that deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase the net income in the period that such determination was made.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to net losses in all periods presented, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals diluted net loss per share.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued or Effective Accounting Standards</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Outside of the pronouncement below, other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2023-09"). ASU 2023-09 requires annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold and a disaggregation of income taxes paid, net of refunds. The standard also eliminates certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities and is effective for the Company beginning with the 2025 Annual Report on Form 10-K. Early adoption is permitted. ASU 2023-09 should be applied prospectively. Retrospective adoption is permitted. The Company is currently assessing the impact this standard will have on the Company's financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417049507568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,602&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,524&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">This balance includes cash requirements settled on a nightly basis.</span></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,578&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228,298&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">This balance includes cash requirements settled on a nightly basis.</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds and U.S. Treasury Securities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded with readily-available market prices that are publicly observable and independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper, Corporate Debt Securities and Government-related Debt Securities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper, corporate debt securities and government-related debt securities were valued using Level 2 inputs that utilized industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The Company reviews trading activity and pricing for these investments as of each measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LianBio Common Stock and Equity Warrants</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, contemporaneous with the China Out-License transaction, the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, common shares in LianBio at an exercise price equal to common stock par value, which converted into warrants of the parent company of LianBio (a pharmaceutical company focused on the Greater China and other Asian markets; Nasdaq: LIAN; any references to common stock or warrants of LianBio shall refer to common stock or warrants of the publicly-traded parent of LianBio) in connection with LianBio's previous Initial Public Offering. The first two tranches were vested exercised, and converted into 156,746 shares of LianBio common stock as of December 31, 2022 and are recognized at fair value within long-term investments in the Condensed Balance Sheets as of March&#160;31, 2024 and December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2024, LianBio announced its plan to wind down its operations. On March 14, 2024, LianBio's Board of Directors made a special cash dividend payment to the Company for $0.7&#160;million (equivalent to $4.80 per share), which was recorded to other income (expense) in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024, and cash and cash equivalents in the Condensed Balance Sheets as of March&#160;31, 2024. LianBio was delisted from NASDAQ in March 2024 and now trades on the over-the-counter markets. As of March&#160;31, 2024 and December 31, 2023, LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2024, the Company executed an agreement with LianBio to terminate the unvested third warrant tranche (the "Warrant Termination Agreement") for a cancellation payment of $0.4&#160;million (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Upon execution of the Warrant Termination Agreement the Company recorded the final change in fair value of the equity warrant to other income (expense) in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024, and removed the equity warrant from other assets in the Condensed Balance Sheet as of March&#160;31, 2024. The third tranche of the equity warrant was classified as Level 3 in the fair value hierarchy and presented within other assets in the accompanying Condensed Balance Sheets as of December&#160;31, 2023. The most significant assumptions used in the option pricing valuation model as of each balance sheet date to determine its fair value included observable and unobservable inputs: LianBio common stock volatility (based on the historical volatility of similar companies); the probability of regulatory milestone achievement for vesting; and the application of an assumed discount rate.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the equity warrants were remeasured each reporting period with adjustments reported within other income (expense) on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised, expired or terminated. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:83.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants prior to termination</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination of equity warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and available-for-sale investments by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,945&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,130)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1 ) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, substantially all available-for-sale debt securities had a maturity of 12 months or less. Four securities have a contractual maturity between <span style="-sec-ix-hidden:f-460">one</span> and two years, with an estimated fair market value of $20.6&#160;million and amortized cost of $20.6&#160;million. As of December&#160;31, 2023, all available-for-sale debt securities had a maturity of 12 months or less. As of March&#160;31, 2024 and December&#160;31, 2023, the Company had twenty-six available-for-sale debt securities and one available-for-sale debt security, respectively, in a continuous gross unrealized loss position for less than one year. As of March&#160;31, 2024 and December&#160;31, 2023, unrealized credit losses on these securities were not material. Further, the Company does not intend to sell these investments prior to maturity and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis. Accordingly, the Company did not recognize any other-than-temporary impairment losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417146719776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Detail</a></td>
<td class="text">BALANCE SHEET ACCOUNT DETAIL<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,107&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March 31, 2024 and 2023 was $0.2 million and $0.1&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Other Accrued Liabilities&#160;</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other accrued liabilities consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:68.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product sales deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055546112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Outstanding and Reserves for Future Issuance</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company had 37,749,468 shares of common stock issued and outstanding, which excludes 312,500 of pre-funded warrants that remain exercisable at period end and are reserved for future issuance. As of December&#160;31, 2023 the Company had 34,211,190 shares of common stock issued and outstanding, respectively. Each share of common stock is entitled to one vote.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,435,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,054,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,217,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,760,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,708,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,494,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,382,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per stock option</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity during the three months ended March 31, 2024 was as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,760,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127,326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,217,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable&#8212; March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,972,207&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,826&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested&#8212;March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,245,410&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of March&#160;31, 2024.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, there was approximately $33.0&#160;million of unrecognized compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average period of 2.6 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Activity</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity during the three months ended March 31, 2024 was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,708,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207,718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, there was approximately $41.0&#160;million of unrecognized compensation expense related to unvested restricted stock units, which the Company expects to recognize over a weighted average period of 3.5 years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan ("ESPP")</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to the ESPP was $0.2 million and $0.1 million, respectively, for the three months ended March 31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417146719776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,731)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,419)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding&#8212;basic and diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,300,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,742,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share&#8212;basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.01)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.88)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Weighted-average shares outstanding includes pre-funded warrants issued on March 5, 2024.</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised&#8212;vested and unvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,217,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,596,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units&#8212;unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,199,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,724,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417049624496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment &amp; Contingencies</a></td>
<td class="text">COMMITMENTS&#160;&amp; CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the ordinary course of business, the Company enters into lease agreements with unaffiliated third parties for its facilities and office equipment. On March 20, 2024, the Company executed an amendment for an additional office suite. This amendment was accounted for as a lease modification and resulted in the recognition of an operating lease right-of-use asset valued at $0.4&#160;million as of the execution date. As of March&#160;31, 2024, the Company had six active leases for adjacent office and laboratory suites in Irvine, California with a lease term through January 2027. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The below table summarizes the components of total lease expense:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company's facility leases had a remaining lease term of 2.8 years and a weighted-average incremental borrowing rate of 10%. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,698&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-License Agreements for Lotilaner</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elanco In-License Agreement for Skin and Eye Disease or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company executed a license agreement with Elanco Tiergesundheit AG (&#8220;Elanco&#8221;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, a clinical milestone was triggered to Elanco under the Eye and Derm Elanco Agreement upon enrollment of the first patient in the Phase 2a Galatea trial, evaluating the potential treatment of rosacea. The related milestone payment of $1.0&#160;million was included in research and development expense in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made cash payments to Elanco under the Eye and Derm Elanco Agreement comprised of $1.0&#160;million upfront upon contract execution in January 2019 and a total of $4.0&#160;million for three specified clinical milestone achievements in September 2020, April 2021, and March 2023, which were all recorded in research and development expense in the Condensed Statements of Operations and Comprehensive Loss. During 2023, a milestone of $4.0&#160;million was achieved and paid to Elanco upon the first commercial sale of XDEMVY in the U.S., which was recorded as an intangible asset in the Balance Sheet as of December 31, 2023. The Company is amortizing the intangible asset to cost of sales over its useful life of 10 years from the date of the first commercial sale.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make further cash payments to Elanco of $2.0 million under the Eye and Derm Elanco Agreement upon achievement of the last clinical milestone in the treatment of human skin diseases using lotilaner and a maximum of $75.0 million for various commercial and sales threshold milestones for the treatment of human skin diseases and the treatment of blepharitis in humans using lotilaner. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company received certain types of payments from its sublicensees, it was obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license, which occurred in July 2023 with FDA approval of XDEMVY. As a result of the commercialization of XDEMVY, the Company began accruing royalties payable to Elanco during the third quarter of 2023, which are recorded to cost of sales in the accompanying Condensed Statement of Operations and Comprehensive Loss for the three months ended March 31, 2024, and accounts payable and other accrued liabilities in the accompanying Condensed Balance Sheets as of March&#160;31, 2024. Royalty expense during the three months ended March 31, 2024 was $1.2 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elanco In-License Agreement for All Other Diseases or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company executed a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement"). In September 2020, the Company issued Elanco 222,460 shares of its common stock with an estimated fair value of $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash payments under the All Human Uses Elanco Agreement of $0.5 million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the potential treatment of Lyme disease. The Company is required to make further cash payments under this agreement upon the achievement of various clinical milestones up to an aggregate maximum of $4.0 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its product sales, net. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements, including severance and change in control agreements, with six of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnities and Guarantees</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities varies, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055580416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Out-License Agreements</a></td>
<td class="text">OUT-LICENSE AGREEMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License of TP-03 Commercial Rights in the China Territory in March 2021</span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into the China Out-License agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the China Territory for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis and Meibomian Gland Disease. LianBio was contractually responsible for all clinical development and commercialization activities and costs within the China Territory.</span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed this arrangement and identified the following material promises under the arrangement: (i) the exclusive license to research, develop, manufacture, commercialize, make, offer for sale, sell, and import TP-03 in the China Territory; and (ii) the research and development services in the form of clinical study materials for the respective Phase 2b/3 trial ("Saturn-1") and Phase 3 ("Saturn-2") TP-03 trials. The promises to provide research and development services for Saturn-1 and Saturn-2 clinical trials were evaluated and determined to be distinct promises in the contract and each of the two clinical trials are separate performance obligations apart from the promise to provide the license.</span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assessment of the initial transaction price for the China Out-License agreement included an analysis of amounts the Company expected to receive, which at contract inception consisted of: (i) the upfront cash payment of $15.0&#160;million; (ii) a second cash payment of $10.0&#160;million; (iii) a $10.0&#160;million milestone that was determined to be within the control of the Company; and (iv) $1.2&#160;million representing the initial fair value of the equity warrant. </span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for each performance obligation as follows: </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License</span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that this license was distinct based on an evaluation of the delivery of the functional license that was in the later stages of development, and it met the criteria for being distinct from the research and development services required under the China Out-License agreement. The Company determined the standalone selling price of this license using a discounted projected sales model and recognized as license fees and collaboration revenue the total allocated transaction price at contract inception, upon delivery of the license.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Services </span></div><div style="margin-top:12pt;text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standalone selling price of these performance obligations was determined using the adjusted market assessment approach. The Company analyzed costs expected to be incurred for each of the clinical trials through completion to estimate the price that a customer would be willing to pay for these services in order to benefit from the clinical trials. The Company determined that LianBio simultaneously benefited from the research and development services that are satisfied over time, as they were able to request and access the clinical trial data at any point through the trial completion. Therefore, the Company recognized the amounts allocated to the respective research and development performance obligations for Saturn-1 and Saturn-2 within license fees and collaboration revenue as the research and development services were provided using an input method, based on the costs incurred for each clinical trial and the total costs expected to be incurred to satisfy each performance obligation. The Company believes this method most faithfully depicted its performance in transferring the promised services during the expected period of time that each clinical trial was ongoing. The Company monitored the expected completion dates for each clinical trial and updated its estimated time to completion at each reporting period, as necessary.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2023, a specified milestone event was triggered based upon the signing of an agreement for which the Company has no ongoing obligations, resulting in $2.5&#160;million recognized as license fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023.  </span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2024, LianBio announced its plan to wind down its operations and on March 14, 2024 made a special cash dividend payment to the Company for $0.7&#160;million (equivalent to $4.80 per share - see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). On March 26, 2024, the Company executed an agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. ("GrandPharma"), a subsidiary of Grand Pharmaceutical Group Limited, and LianBio to transition the rights to develop and commercialize TP-03 in China for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis from LianBio to GrandPharma (the "Novation Agreement"). Upon execution of the Novation Agreement, the China Out-License agreement with LianBio was assigned to GrandPharma and a one-time payment of $2.5&#160;million (the "Termination Payment) was triggered and due to the Company from LianBio within fifteen days. This Termination Payment was recorded to license fees and collaboration revenue in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and to other receivables in the Condensed Balance Sheets as of March&#160;31, 2024, as the $2.5&#160;million cash payment was not yet received by the Company until April 5, 2024. The Novation Agreement amended the $15.0&#160;million future development milestone payable on China regulatory approval of the China Out-License agreement with a combined condition of patent issuance related to TP-03 in China.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the execution of the Novation Agreement, the Company entered into an agreement with LianBio to terminate the unvested third tranche of the equity warrants related to the purchase of 78,373 shares of LianBio common stock for a total cancellation payment of $0.4&#160;million (the "Warrant Cancellation Payment"). This Warrant Cancellation Payment was recorded to license fees and collaboration revenue in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and other receivables in the Condensed Balance Sheets as of March&#160;31, 2024.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March&#160;31, 2024, the Company received aggregate payments from LianBio totaling $83.2&#160;million, comprised of (i) initial consideration of $15.0&#160;million, (ii) $67.5&#160;million for the achievement of specified milestones, and (iii) $0.7&#160;million related to a special cash dividend.</span></div>As of March&#160;31, 2024 the Company is eligible to receive further consideration from GrandPharma upon the achievement of additional TP-03 events, including: (i) additional regulatory and/or patent milestones of up to an aggregate of $20.0&#160;million; (ii) China-based TP-03 sales threshold milestone payments of up to an aggregate of $100.0&#160;million; and (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055365744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility Agreement</a></td>
<td class="text">CREDIT FACILITY AGREEMENT<div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company executed the Credit Facility with Hercules and SVB that expires on February 2, 2027. As security for the obligations under the agreement, the Company granted a continuing security interest in substantially all of the Company's assets, excluding intellectual property on which there is a negative pledge. Concurrent with the execution of the Credit Facility, the Company made a $20.0&#160;million draw.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2023, the Company entered into an amendment to the loan and security agreement (the "First Amendment"). The First Amendment set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions, including an extended period for the Company to drawdown the $25.0&#160;million tranche associated with the New Drug Application ("NDA") submission from March 15, 2023 to March 15, 2024, provided at least $5.0&#160;million was drawn on or before March 15, 2023 and at least an additional $5.0&#160;million was drawn on or before September 15, 2023. The Company did not incur any lender fees as part of this First Amendment. </span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2023, the Company entered into a second amendment to the loan and security agreement (the "Second Amendment"). The Second Amendment updated the terms of the amount and proportion of the Company&#8217;s cash required to be maintained at SVB or affiliates of SVB. The Company did not incur any lender fees as part of this Second Amendment.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2023 and September 15, 2023, respectively, the Company made separate draws of $5.0&#160;million (including SVB's commitment of $1.25&#160;million) from the $25.0&#160;million tranche that became available upon submission of the NDA. On March 15, 2024, the $15.0&#160;million tranche related to the Company's NDA submission with the FDA for TP-03 in September 2022 and the $35.0&#160;million tranche related to the FDA approval of XDEMVY in July 2023 both expired and were no longer available to be drawn as of period end. As of March&#160;31, 2024, the Credit Facility provides for a remaining aggregate principal amount of up to $75.0&#160;million with tranched availability as follows: $50.0&#160;million available upon achievement of product sales, net thresholds; and $25.0&#160;million available upon lender approval.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these tranches may be drawn down in $5.0&#160;million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Amendment, the outstanding principal draws accrue interest at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus 4.45% with an aggregate cap of 11.45%, or (ii) 8.45%. At the execution date of the Credit Facility, the WSJ prime rate was 3.25% and increased to 8.50% as of March&#160;31, 2024.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay a specified fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.4 million was derived by multiplying 4.75% by the $30.0&#160;million outstanding principal balance as of March&#160;31, 2024 and is accreted to interest expense through maturity.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and 2023, the effective interest rate for the full term of the Credit Facility was 11.96% and 12.12%, respectively. The Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Credit Facility consists of principal outstanding less legal and administrative issuance costs that were recorded as a debt discount to the term loan, net and will continue to be accreted to interest expense using the effective interest method during its term. The principal balance of this Credit Facility and related accretion and amortization are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055123456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consulting Agreements</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a preexisting consulting agreement with a board member who was appointed in December 2021. During the year ended December 31, 2023, this consulting agreement provided for annual cash compensation of approximately $0.2&#160;million and option grants to purchase 45,134 shares of the Company&#8217;s common stock, with exercise prices ranging from $2.01 to $34.72 per share.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2024, this consulting agreement with the board member was amended to provide for annual cash compensation of approximately $0.4&#160;million and an additional option grant to purchase 10,000 shares of the Company&#8217;s common stock, with exercise price of $27.49 per share. This amended consulting agreement may be terminated by either party with ten days' notice and contains standard confidentiality, indemnification, and intellectual property assignment provisions in favor of the Company.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, the Company recorded $0.1&#160;million and $0.1&#160;million, respectively, of selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss related to this amended consulting agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sponsorship Activities </span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, a board member of the Company was appointed president of the American Society of Cataract and Refractive Surgery ("ASCRS"), a society dedicated to meeting the needs of anterior segment ophthalmic surgeons.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, the Company recorded $0.1&#160;million of selling, general and administrative expenses in the accompanying Condensed Statement of Operations and Comprehensive Loss for sponsorship and event-related activities associated with ASCRS.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417146632816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility with Pharmakon Advisors, LP</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2024, the Company executed a loan and security agreement (the "Pharmakon Credit Facility") with funds associated with Pharmakon Advisors, LP. The Company drew $75.0&#160;million in the initial tranche of the term loan in April 2024, a portion of which was utilized to repay all outstanding indebtedness on the existing Credit Facility term loan, resulting in total net proceeds of $39.8&#160;million. The agreement provides for three potential additional term loan tranches in principal amounts up to $25.0&#160;million, $50.0&#160;million, and $50.0&#160;million, respectively, subject to customary conditions to funding and, in the case of the last two tranches, achieving minimum net sales milestones. The three potential additional term loan tranches may be requested on or prior to December 31, 2024, June 30, 2025 and December 31, 2025, respectively. The Pharmakon Credit Facility matures on April 19, 2029.</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan bears interest at a floating rate based upon the secured overnight financing rate ("SOFR"), plus a margin of 6.75% per annum, and the SOFR is subject to a 3.75% floor. The agreement contains representations and warranties, and affirmative and negative covenants in each case. There is also no warrant coverage to the lenders and no financial covenants associated with the financing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investment in Privately-held Eye Care Company</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2024, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participated in an equity round of an early clinical-stage private eye care company. Pursuant to the terms of a Preferred Stock Purchase Agreement the Company purchased</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $3.0&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of preferred stock. Drs. Azamian and Link are board members and the Company's former director, Michael Ackermann, is an executive and board member of this private company. The Company owns a small minority of this private company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055476064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35,731)<span></span>
</td>
<td class="num">$ (23,419)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417054961280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=tars_BobakAzamianMember', window );">Bobak Azamian [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Bobak Azamian, Chief Executive Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to 291,000 shares of common stock held by Dr. Azamian between August 23, 2023 and July 24, 2024. Dr. Azamian terminated the trading plan effective January 8, 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Bobak Azamian<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">January 8, 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">291,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=tars_JoseTrevejoMember', window );">Jose Trevejo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Jose Trevejo, former Chief Medical Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to 6,107 shares of common stock held by Dr. Trevejo between August 17, 2023 and May 16, 2024. Dr. Trevejo terminated the trading plan effective January 12, 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Jose Trevejo<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">former Chief Medical Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">January 12, 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">6,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=tars_BobakAzamianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=tars_BobakAzamianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=tars_JoseTrevejoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=tars_JoseTrevejoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417053989856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segment</a></td>
<td class="text">The Company operates one reportable operating segment focused on the development and commercialization of therapeutics. To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purpose of evaluating financial performance and the allocation of capital and personnel resources. The Company&#8217;s chief operating decision-maker, its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the SEC. Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on February&#160;27, 2024.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of March&#160;31, 2024, the Condensed Statements of Operations and Comprehensive Loss, and the Condensed Statements of Stockholders&#8217; Equity for the three months ended March&#160;31, 2024 and 2023, and the Condensed Statements of Cash Flows for the three months ended March&#160;31, 2024 and 2023 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December&#160;31, 2023 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2024 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2024 or any other interim or annual period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these Condensed Financial Statements and Notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, expected demand for inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions used in the preparation of the accompanying Condensed Financial Statements under different assumptions and conditions.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Condensed Financial Statements as of and for the three months ended March 31, 2024, reflect the Company&#8217;s estimates of the impact of the macroeconomic and geopolitical environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies and estimates that most significantly impact the presented amounts within these accompanying Condensed Financial Statements are further described below:</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div>Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities and Long-Term Investments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities and Long-Term Investments</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist primarily of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are recorded at fair value with unrealized gains and losses reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized gains and losses as well as credit losses, if any, on marketable securities identified on a specific identification basis are included in other income (expense) on the accompanying Condensed Statements of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other-than-temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div>As of March&#160;31, 2024, the Company's holdings of common stock in the parent company of LianBio was included as marketable securities. As of December&#160;31, 2023, this LianBio common stock was classified as long-term investments due to the Company's intent at that time to hold these shares for longer than one year. These equity securities are designated as available-for-sale with associated unrealized gains or losses reported in other income (expense) within the Condensed Statements of Operations and Comprehensive Loss for each reported period.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div>Accounts receivable generally consists of amounts due from the Company's customers, which includes pharmaceutical wholesalers and specialty pharmacy providers related to product sales of XDEMVY in the U.S. Payment terms are typically 30-60 days following delivery to customers. Accounts receivable are recorded net of discounts, chargebacks, allowances and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so it can properly assess and respond to changes in their credit profile. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company did not record a reserve for estimated credit losses during the three months ended March 31, 2024.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div>Inventory is valued at the lower-of-cost or net realizable value, with cost determined on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and adjusts the value for any excess and obsolete inventory to net realizable value in the period in which the impairment is first identified and such charges are recorded as a component of cost of sales in the Condensed Statements of Operations and Comprehensive Loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Product that may be used in clinical development programs are excluded from inventory and the costs are charged to research and development expense in the Condensed Statements of Operations and Comprehensive Loss as incurred, as long as they do not have an alternative use. Prior to FDA approval of XDEMVY in July 2023, costs related to the production of inventory were recorded as research and development expense on the Condensed Statements of Operations and Comprehensive Loss in the period incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div>Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow. <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including intangibles, are evaluated for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in the Condensed Statements of Operations and Comprehensive Loss. There have been no impairments of intangible assets for the three months ended March 31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash, cash equivalents, accounts receivable, net, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from <span style="-sec-ix-hidden:f-311">three</span> to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in circumstances of the business indicate that the asset&#8217;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March&#160;31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Right-of-Use assets (&#8220;ROU assets&#8221;) represent the Company&#8217;s right to control an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the initial non-cancelable lease term, unless there is a renewal option that is reasonably certain to be exercised. The Company uses its incremental borrowing rate at the lease commencement date in determining the discount rate utilized to present value the future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable. The Company has lease agreements with both lease and non-lease components, which are accounted for as a single component for all asset classes. Lease expense for the Company's operating leases are recognized on a straight-line basis over the lease term.</span></div>The Company's variable lease costs, consisting primarily of real estate taxes, insurance costs, and common area maintenance, are expensed as incurred and excluded from the reported ROU assets and lease liabilities amounts presented in the accompanying Condensed Balance Sheets. The current and noncurrent portion of the operating lease liability are included in accounts payable and other accrued liabilities and other long-term liabilities, respectively, in the accompanying Condensed Balance Sheets. Rent expense is allocated to research and development and general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration Risk </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company maintains cash held on deposit at financial institutions in the U.S., including SVB. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. The Company invests its excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. The following table summarizes the percentage of the Company's product sales from its largest customers:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, amounts due from these five customers each exceeded 10% of gross accounts receivable and accounted for approximately 100% of the accounts receivable balance on a combined basis.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Major Suppliers</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not currently own manufacturing facilities and depends on an outsourced manufacturing strategy for the production of XDEMVY for commercial use and for the production of its other product candidates for clinical trials. The Company enters into agreements with third-party manufacturers that are approved for the commercial production of XDEMVY and third-party suppliers that are approved for XDEMVY's active pharmaceutical ingredient. Although there are potential sources of supply other than the Company's existing manufacturers and suppliers, any new supplier would be required to qualify under applicable regulatory requirements. The loss of certain manufacturers and third-party suppliers could result in a temporary disruption of the Company&#8217;s commercialization efforts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Product Sales, Net</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes product sales, net of XDEMVY when a customer obtains control of promised goods or services, which occurs at a point in time, typically upon delivery of the Company's product to the customer. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as each performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells XDEMVY to customers in the U.S., which became available for commercial sale during the third quarter of 2023. The Company sells XDEMVY to a limited number of specialty pharmacies and distributors (i.e., its customers) who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. Revenue from product sales is primarily recognized upon physical delivery of the product (when the customer obtains control of the product), in return for agreed-upon consideration. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or the transaction price, which may include fixed or variable consideration for (i) invoice discounts for prompt payment and distribution service fees, (ii) government and private payer rebates, chargebacks, discounts and fees, (iii) product returns and (iv) costs of co-pay assistance programs for patients, as well as other incentives. Estimates of variable consideration are calculated based on the actual product sales each reporting period and the nature of the variable consideration related to those sales. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates reflect the Company&#8217;s best estimate of the amount of consideration to which the Company expects to be entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ materially from </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect product sales, net and earnings in the period such variances are adjusted. The Company categorizes product sales deduction estimates as follows:</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Service Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Pay Discounts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's customers are contractually permitted to return the product within the contractual allowable time before and after the applicable expiration date. In the initial sales period, the Company estimates its provision for returns based on industry data and adjusts the transaction price at the time of the product sale to the customer. Once sufficient history has been collected for product returns, the Company will utilize that history to inform its returns estimate. Once the product is returned, it is destroyed since it cannot be resold.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A chargeback is the difference between the Company's invoice price to the wholesaler and the wholesaler&#8217;s customer's contract price. The wholesaler tracks these sales and charges back the Company for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price and accounts receivable at the time of sale of the product to the customer.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company&#8217;s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer.</span></div><div style="margin-top:12pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ii) License Fees and Collaboration Revenue</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">China Out-License </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss has historically primarily related to the China Out-License that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kong, Macau, and Taiwan (the "China Territory")&#8212; see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract; (b) the contract&#8217;s transaction price for allocation (including variable consideration); (c) the stand-alone selling price for each identified performance obligation; and (d) the timing and amount of revenue recognition in each period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment; (ii) equity-based consideration; (iii) sales-based royalties; (iv) sales-based threshold milestones; (v) one-time payment for executing a drug supply agreement; (vi) development milestone payments; (vii) regulatory milestone payments; and (viii) a one-time termination payment to transition the rights to develop and commercialize TP-03 in China for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Demodex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> blepharitis to Xi An Grand Chang An Pharmaceutical Co., Ltd  ("GrandPharma"). Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#8217;s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Threshold Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other License Fees and Collaboration Revenue</span></div>License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, freight, third-party royalties payable on the Company&#8217;s product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon FDA approval of XDEMVY in July 2023. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses in the Condensed Statements of Operations and Comprehensive Loss. Therefore, cost of sales of XDEMVY will reflect a lower average per unit cost until the related inventory is sold.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative costs consist of salaries, benefits, stock-based compensation and other personnel-related costs for the Company's executive, finance, sales and marketing, and other administrative functions. Selling, general and administrative expenses also include sales and marketing costs to support our commercial launch, consulting fees, legal services, rent and other facilities costs, patient assistance donations, and other general operating expenses not otherwise classified as research and development expenses. Advertising costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including the costs of salaries, payroll taxes, employee benefit and other employee-related costs (including stock-based compensation expense), license fees, materials, supplies and the cost of services provided by outside contractors to conduct nonclinical studies, clinical trials and contract manufacturing activities. All costs associated with research and development are expensed as incurred. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company's license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense in the Condensed Statements of Operations and Comprehensive Loss when paid or become payable, provided there is no alternative future use of rights in other research and development projects.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company&#8217;s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's common stock on the date preceding the award grant date.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock awards granted typically have <span style="-sec-ix-hidden:f-330">one</span> to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including (a) the fair value of the Company&#8217;s common stock on the date of the option grant for all awards granted prior to the IPO, (b) the expected term of the stock option until its exercise by the recipient, (c) stock price volatility over the expected term, (d) the prevailing risk-free interest rate over the expected term, and (e) expected dividend payments over the expected term.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within cost of sales, research and development expense or selling, general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s expected term represents the period that the Company&#8217;s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain due to the Company&#8217;s historical operating performance and recorded cumulative net losses in prior fiscal periods. A valuation allowance is recorded to reduce deferred tax assets, because based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when the Company were to determine that deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase the net income in the period that such determination was made.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to net losses in all periods presented, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals diluted net loss per share.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued or Effective Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued or Effective Accounting Standards</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Outside of the pronouncement below, other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2023-09"). ASU 2023-09 requires annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold and a disaggregation of income taxes paid, net of refunds. The standard also eliminates certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities and is effective for the Company beginning with the 2025 Annual Report on Form 10-K. Early adoption is permitted. ASU 2023-09 should be applied prospectively. Retrospective adoption is permitted. The Company is currently assessing the impact this standard will have on the Company's financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417054531008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Expected Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the expected future amortization expense for the Company's intangible assets is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Product Sales from Each of our Largest Customers</a></td>
<td class="text">The following table summarizes the percentage of the Company's product sales from its largest customers:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417141010208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Financial instruments measured at fair value</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,602&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,524&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">This balance includes cash requirements settled on a nightly basis.</span></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (for LianBio shares)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,578&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228,298&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">This balance includes cash requirements settled on a nightly basis.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in fair value of equity warrants</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the equity warrants were remeasured each reporting period with adjustments reported within other income (expense) on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised, expired or terminated. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:83.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants prior to termination</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination of equity warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value of equity warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of equity warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Summary of estimated value of cash, cash equivalents, marketable securities, and equity securities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and available-for-sale investments by major security type are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,705&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,945&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,130)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government-related debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1 ) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This balance includes cash requirements settled on a nightly basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055704208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:72pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,107&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other accrued liabilities consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:68.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product sales deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055403968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Stock details</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,435,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,054,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,859,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,217,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,760,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,708,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,494,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,382,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation assumptions of stock options</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per stock option</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity during the three months ended March 31, 2024 was as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,760,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127,326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,217,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable&#8212; March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,972,207&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,826&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested&#8212;March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,245,410&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of March&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted stock unit activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity during the three months ended March 31, 2024 was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price/Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,708,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207,718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding&#8212; March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055554384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Net (loss) income per share, basis and diluted</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net loss per share:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,731)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,419)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding&#8212;basic and diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,300,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,742,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share&#8212;basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.01)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.88)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Weighted-average shares outstanding includes pre-funded warrants issued on March 5, 2024.</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Outstanding potentially dilutive securities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised&#8212;vested and unvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,217,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,596,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units&#8212;unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,128,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,199,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,724,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417049611296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of lease cost</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The below table summarizes the components of total lease expense:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future contractual lease payments</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,698&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055552096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Summary of Interest Expense</a></td>
<td class="text">The Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Balances of Debt, Debt Issuance Costs, and Accumulated Accretion</a></td>
<td class="text">The principal balance of this Credit Facility and related accretion and amortization are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of end of term charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417152876848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Presentation of Financial Statements (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 05, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ClassOfWarrantOrRightReservedForFutureIssuance', window );">Pre-funded warrants reserved for future issuance (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tars_FollowOnPublicOfferingMember', window );">Follow-On Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Stock issued (shares) | shares</a></td>
<td class="nump">2,812,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,714,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Original issue price (usd per share) | $ / shares</a></td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ClassOfWarrantOrRightSalePrice', window );">Price per warrant (usd per share) | $ / shares</a></td>
<td class="nump">31.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (usd per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Stock issued, net proceeds | $</a></td>
<td class="nump">$ 107.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issued in warrant conversion (in shares) | shares</a></td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Stock issued (shares) | shares</a></td>
<td class="nump">468,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Original issue price (usd per share) | $ / shares</a></td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Stock issued, net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tars_A2023ShelfRegistrationStatementMember', window );">2023 Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_SaleOfStockConsiderationAmountAuthorized', window );">Authorized consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tars_A2023ATMProspectusMember', window );">2023 ATM Prospectus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Stock issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Stock issued, net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds', window );">Agent fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_SaleOfStockConsiderationAmountAuthorized', window );">Authorized consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ClassOfWarrantOrRightReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant Or Right, Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ClassOfWarrantOrRightReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ClassOfWarrantOrRightSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Sale Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ClassOfWarrantOrRightSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_SaleOfStockConsiderationAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_SaleOfStockConsiderationAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Sales Agent Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tars_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tars_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tars_A2023ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tars_A2023ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tars_A2023ATMProspectusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tars_A2023ATMProspectusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417141188704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 3,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairments of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=tars_IntangibleAssetsMilestonePaymentMember', window );">Intangible Assets, Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=tars_IntangibleAssetsMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=tars_IntangibleAssetsMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055014272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2024 (remaining nine months)</a></td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">1,867<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization</a></td>
<td class="nump">$ 3,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417054327632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Fair market value of common stock</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 27,614<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tars_LicenseAndCollaborationOtherMember', window );">License And Collaboration, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Five Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service condition period for full vesting</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service condition period for full vesting</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_LicenseAndCollaborationOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_LicenseAndCollaborationOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tars_FiveCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tars_FiveCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417142147568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates - Product Sales from Each of our Largest Customers (Details) - Revenue Benchmark - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer D</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer E</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tars_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tars_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tars_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tars_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tars_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tars_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tars_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tars_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tars_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tars_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417048564016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Instruments Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 193,705<span></span>
</td>
<td class="nump">$ 224,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants (for LianBio shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">298,524<span></span>
</td>
<td class="nump">228,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">186,744<span></span>
</td>
<td class="nump">224,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">3,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">31,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">3,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">30,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">25,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government-related debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">23,604<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants (for LianBio shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">218,602<span></span>
</td>
<td class="nump">225,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">186,744<span></span>
</td>
<td class="nump">224,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">31,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Government-related debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants (for LianBio shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">79,922<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">30,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">25,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Government-related debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">23,604<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants (for LianBio shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Government-related debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents', window );">Debt securities, available for sale and cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale And Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_EquityWarrantsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Warrants, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_EquityWarrantsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417051345584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 14, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>tranche</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>security </div>
<div>contract</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>warrant </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_WarrantAgreementNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_NumberOfVestedWarrants', window );">Number of vested warrants | warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_EquitySecuritiesFVNINumberOfShares', window );">Equity securities (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities', window );">Number of securities with contractual maturity between one and five years | security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,819<span></span>
</td>
<td class="nump">$ 2,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,945<span></span>
</td>
<td class="nump">$ 2,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of available-for-sale debt securities in gross unrealized loss position for less than one year | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ProceedsFromCancellationOfWarrants', window );">Proceeds from warrant cancellation payment</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tars_LianBioMember', window );">LianBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Special cash dividends paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Special cash dividend (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember', window );">Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Contractual maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Contractual maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Contractual maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Contractual maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_EquitySecuritiesFVNINumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_EquitySecuritiesFVNINumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_NumberOfVestedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Vested Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_NumberOfVestedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ProceedsFromCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cancellation Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ProceedsFromCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_WarrantAgreementNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Agreement, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_WarrantAgreementNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_LianBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_LianBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tars_LianBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tars_LianBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417142119072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value, beginning of period</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Remeasurement of equity warrants prior to termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (201)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Termination of equity warrants</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value, end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417152906528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">$ 224,947<span></span>
</td>
<td class="nump">$ 193,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">224,947<span></span>
</td>
<td class="nump">193,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,496<span></span>
</td>
<td class="nump">105,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1,130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">104,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNIAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized cost</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="num">(477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Estimated fair value</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">224,947<span></span>
</td>
<td class="nump">186,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">224,947<span></span>
</td>
<td class="nump">186,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government-related debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,496<span></span>
</td>
<td class="nump">23,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="nump">$ 2,495<span></span>
</td>
<td class="nump">23,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=tars_CommonStockInLianBioMember', window );">Common stock in LianBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNIAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNIAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=tars_CommonStockInLianBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=tars_CommonStockInLianBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417054346720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,533<span></span>
</td>
<td class="nump">$ 2,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">677<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 4,036<span></span>
</td>
<td class="nump">$ 3,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417165703664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 2,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">(Less): Accumulated depreciation and amortization</a></td>
<td class="num">(1,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,290)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">1,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055124016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable and other</a></td>
<td class="nump">$ 19,142<span></span>
</td>
<td class="nump">$ 18,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Accrued product sales deductions</a></td>
<td class="nump">16,382<span></span>
</td>
<td class="nump">4,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_AccruedClinicalStudiesCurrent', window );">Accrued clinical studies</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">$ 36,570<span></span>
</td>
<td class="nump">$ 23,691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AccruedClinicalStudiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Studies, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AccruedClinicalStudiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417141002832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares) | shares</a></td>
<td class="nump">37,749,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,211,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ClassOfWarrantOrRightReservedForFutureIssuance', window );">Pre-funded warrants reserved for future issuance (shares) | shares</a></td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares) | shares</a></td>
<td class="nump">37,749,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,211,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CommonStockNumberOfVotes', window );">Common stock votes | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 5,519<span></span>
</td>
<td class="nump">$ 3,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, weighted average period of recognition</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, weighted average period of recognition</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ClassOfWarrantOrRightReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant Or Right, Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ClassOfWarrantOrRightReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Number Of Votes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417166953488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Shares Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant', window );">Stock options reserved for future grant (shares)</a></td>
<td class="nump">7,435,442<span></span>
</td>
<td class="nump">7,054,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan', window );">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</a></td>
<td class="nump">2,859,434<span></span>
</td>
<td class="nump">2,859,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding', window );">Stock options issued and outstanding (shares)</a></td>
<td class="nump">5,217,617<span></span>
</td>
<td class="nump">4,760,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant', window );">Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan</a></td>
<td class="nump">1,981,673<span></span>
</td>
<td class="nump">1,708,725<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved (shares)</a></td>
<td class="nump">17,494,166<span></span>
</td>
<td class="nump">16,382,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417150346144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 5,519<span></span>
</td>
<td class="nump">$ 3,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 3,919<span></span>
</td>
<td class="nump">$ 2,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055773648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">4.08%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average volatility</a></td>
<td class="nump">71.23%<span></span>
</td>
<td class="nump">71.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per stock option (usd per share)</a></td>
<td class="nump">$ 35.09<span></span>
</td>
<td class="nump">$ 15.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417054487056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (shares)</a></td>
<td class="nump">4,760,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">633,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(49,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(127,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (shares)</a></td>
<td class="nump">5,217,617<span></span>
</td>
<td class="nump">4,760,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (shares)</a></td>
<td class="nump">2,972,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested (shares)</a></td>
<td class="nump">2,245,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (usd per share)</a></td>
<td class="nump">$ 16.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">35.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">16.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (usd per share)</a></td>
<td class="nump">18.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (usd per share)</a></td>
<td class="nump">18.83<span></span>
</td>
<td class="nump">$ 16.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (usd per share)</a></td>
<td class="nump">15.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (usd per share)</a></td>
<td class="nump">$ 23.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 5 months 15 days<span></span>
</td>
<td class="text">7 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">6 years 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm', window );">Unvested</a></td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 96,254<span></span>
</td>
<td class="nump">$ 34,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">65,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Unvested</a></td>
<td class="nump">$ 30,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055223936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Unit Activity (Details) - Restricted stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (shares) | shares</a></td>
<td class="nump">1,708,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares) | shares</a></td>
<td class="nump">596,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares) | shares</a></td>
<td class="num">(207,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares) | shares</a></td>
<td class="num">(116,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (shares) | shares</a></td>
<td class="nump">1,981,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 16.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share) | $ / shares</a></td>
<td class="nump">36.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share) | $ / shares</a></td>
<td class="nump">16.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (usd per share) | $ / shares</a></td>
<td class="nump">17.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 22.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417054171552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings Per Share, Basic [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35,731)<span></span>
</td>
<td class="num">$ (23,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (shares)</a></td>
<td class="nump">35,300,655<span></span>
</td>
<td class="nump">26,742,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (shares)</a></td>
<td class="nump">35,300,655<span></span>
</td>
<td class="nump">26,742,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (usd per share)</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (usd per share)</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.88)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055809280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">7,199,290<span></span>
</td>
<td class="nump">5,724,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options, unexercised&#8212;vested and unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">5,217,617<span></span>
</td>
<td class="nump">4,596,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember', window );">Restricted stock units&#8212;unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">1,981,673<span></span>
</td>
<td class="nump">1,128,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417048723600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Lease Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 20, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for operating lease liability | $</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_LesseeOperatingLeaseNumberOfLeaseContracts', window );">Number of leases | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Estimated incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LesseeOperatingLeaseNumberOfLeaseContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Lease Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LesseeOperatingLeaseNumberOfLeaseContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417146764768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417140886912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Summary of Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (remaining nine months)</a></td>
<td class="nump">$ 660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments, undiscounted</a></td>
<td class="nump">2,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">(Less): Imputed interest</a></td>
<td class="num">(343)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance', window );">(Less): Tenant improvement allowance</a></td>
<td class="num">(164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">2,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">$ 398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 2,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417051965024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">31 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=tars_IntangibleAssetsMilestonePaymentMember', window );">Intangible Assets, Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementFutureCashPayments', window );">Future cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for license agreement (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for license agreement, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock issued for license agreement, share price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | Clinical milestones | Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment', window );">Contractual milestone payment</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | Commercial and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | Commercial and sales milestones | Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment', window );">Contractual milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Future Cash Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementMaximumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementMaximumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=tars_IntangibleAssetsMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=tars_IntangibleAssetsMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_ElancoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_ElancoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_ClinicalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_ClinicalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_CommercialAndSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_CommercialAndSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417049728112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Employment Arrangements (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>contract</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers', window );">Number of employment arrangements with executive officers</a></td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Employment Arrangements With Executive Officers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_NumberOfEmploymentArrangementsWithExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417044447264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-License Agreements (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2024</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,066<span></span>
</td>
<td class="nump">$ 12,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tars_LianBioMember', window );">LianBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Special cash dividend (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Special cash dividends paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment', window );">Additional cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_TerminationPaymentPeriodDue', window );">Days due within</a></td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issued in warrant conversion (in shares)</a></td>
<td class="nump">78,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_ProceedsFromCancellationOfWarrants', window );">Proceeds from warrant cancellation payment</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_UpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Milestone Determined by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Milestone payments to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Milestone payments to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_ElancoMember', window );">Elanco | License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for license agreement, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_GrandpharmaMember', window );">Grandpharma | License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_GrandpharmaMember', window );">Grandpharma | License agreement | Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementMaximumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementMaximumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ProceedsFromCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cancellation Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ProceedsFromCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_RevenueRemainingPerformanceObligationAdditionalCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Additional Cash Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_RevenueRemainingPerformanceObligationAdditionalCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_TerminationPaymentPeriodDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination Payment, Period Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_TerminationPaymentPeriodDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tars_LianBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tars_LianBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_LianBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_LianBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_MilestoneDeterminedByTheCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_MilestoneDeterminedByTheCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_ElancoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_ElancoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_GrandpharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_GrandpharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417044130448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 15, 2023</div></th>
<th class="th"><div>Mar. 15, 2023</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Draw on credit facility</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_LineOfCreditFacilityDrawDownIncrements', window );">Increments to draw on credit facility at company's election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest', window );">End of term charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_LineOfCreditFacilityPeriodicPaymentInterestRate', window );">End of term charge, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Prime Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, First Amendment, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_LineOfCreditFacilityDrawDownIncrements', window );">Increments to draw on credit facility at company's election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tars_LineOfCreditSVBMember', window );">Line of Credit, SVB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Draw on credit facility</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LineOfCreditFacilityDrawDownIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Draw Down Increments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LineOfCreditFacilityDrawDownIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LineOfCreditFacilityPeriodicPaymentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Periodic Payment, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LineOfCreditFacilityPeriodicPaymentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payment applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityFirstAmendmentTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityFirstAmendmentTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tars_LineOfCreditSVBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tars_LineOfCreditSVBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417141313568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement - Summary of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense for term loan</a></td>
<td class="nump">$ 869<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of end of term charge</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense related to term loan</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417055779520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan, gross</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Debt issuance costs</a></td>
<td class="num">(875)<span></span>
</td>
<td class="num">(875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Accretion of end of term charge</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts', window );">Accumulated amortization of debt issuance costs</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan, net</a></td>
<td class="nump">$ 29,933<span></span>
</td>
<td class="nump">$ 29,819<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 835<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479359/835-30-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417054221024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,578<span></span>
</td>
<td class="nump">$ 15,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_RelatedPartyTransactionAnnualCashCompensation', window );">Related party transaction, annual cash compensation</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_RelatedPartTransactionTerminationNoticePeriod', window );">Related party transaction, termination notice, period</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">$ 27.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_RelatedPartTransactionTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Part Transaction, Termination Notice, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_RelatedPartTransactionTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_RelatedPartyTransactionAnnualCashCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Annual Cash Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_RelatedPartyTransactionAnnualCashCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140417044366944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 19, 2024 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Apr. 05, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Draw on credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Net proceeds</a></td>
<td class="nump">$ 39.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Preferred stock purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pharmakon Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtInstrumentNumberOfPotentialAdditionalTranches', window );">Potential additional tranches | contract</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements', window );">Tranches with minimum net sales milestones | contract</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pharmakon Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tars_DebtInstrumentFloorInterestRate', window );">Interest rate floor</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pharmakon Credit Facility, Tranche One | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Draw on credit facility</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pharmakon Credit Facility, Tranche Two | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pharmakon Credit Facility, Tranche Three | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pharmakon Credit Facility, Tranche Four | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DebtInstrumentFloorInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Floor Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DebtInstrumentFloorInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DebtInstrumentNumberOfPotentialAdditionalTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Potential Additional Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DebtInstrumentNumberOfPotentialAdditionalTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Tranches With Milestone Requirements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_PharmakonCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_PharmakonCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_PharmakonCreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_PharmakonCreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_PharmakonCreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_PharmakonCreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_PharmakonCreditFacilityTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_PharmakonCreditFacilityTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_PharmakonCreditFacilityTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_PharmakonCreditFacilityTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MJNUB$BK:=C'MPB0'8C6),]N!;K]^QTF:D39 F,8%V,YY7S_'.<:>[KAXE#&
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MS_4I1A2@LTR&]5OC/%?:GC4*ZF6G[IK$G,O9K,=S=5O&]K9LPAY&<:9T"IV
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MVLH SSVHE&$<1>.PY$(%:>+WYB9-=(U2*)@;9NNRY.9M"E(WDZ ?[#8>Q;I
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M8H\VX/G,VE!_(0;-GVA\^ ]02P,$%     @ D(&H6'6OA[ZO*   A84  !@
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M>FU'/S%7E*YFHOEJ7=7@QICU'GHX0L3BV>/L*$$+83;VW8EX,"82KZA!YDG
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M,X)6]D!-*"EN2/2:AK()@1@EY]&HYQ@>12V$XU)@@F)*C )"N)+MS\B6@A<
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M_LV1^KZ&-#NCAQK*Z>T])>D]O#G:<WT*AC;(3$Z_3_DH^,EC$BOE ^_JVJM
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MT<ZFY"PG^UE"V;Y<!2!2M6?.I.8=[2R-?)+]G<%CO-(A]7HE+:&59))XU%H
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M\:9-6(-,0;MH47;G=L +1E#FX9K@/7" %^PUXB"DM>; !JRBS9(K,4*0T1:
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M0&T/CA<O,8%X0?W7!0/2XT!2A6-[F-.FBYZXMVM:O=^IV2F$_#.<.Q9R8G1
MHNAUG<^U9D^3(%> UO/LW= ?ZPOZ_X6^6"0OCECQCXGGTYZB-D$_PZ1ADBM+
M=A?,>*@._2+6"M?\#)>7<10T!:0?WQ^?/MZMI\"K Z1.F)*L\I51I+Q[1YA=
M$ 2U&H4OX7KOVDWMOL$+X[A3$;=/2YYE_X:7N_Q'BPF3MWF1#VQ]/N;5+0C
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M.O[&.)YH9#7/[I=NW!*HS?$MMQ.5S+ D5DP3Z$1T,A>ZM)K15!IABP2,P9:
M;0R;<4DV\#A)G_;YG"<I44Z];*&2"*++&9QFJ*H:ITF$V7),FX$92I(3;(FH
MHF(LA9?P;!(;:'!-Y$B<UB)#1N]ZUJ>\*)3D$:F@46;HF@*C%&%+)DG$36EC
MA6BQ8J]N$._6:(5UE@A%I/G4:S/2!V(DKT4Z;PBZ+9^3+5L0OCYLG>0\%NWD
M,1(Y?3EI%@+N-;K'V$6(^^LT=EN+B4%58N?ZT^P4,4HG D")!;B*S5SKK$S&
M(M6>PZG9M"2"C%N9V7#9Z.Y3L1<W(1"80MFUF"6(!T]3II-I;F* F#DM" 3+
MV'M, #[@H!@9$%'H,1^JN3N/]E4@,,G(,<OH4.P%.;'@^1,B/Z=*U "2E#4(
MI:0G30F ]) 4LPA8 ;6!E^"KFZW#5\T2CG+N#>603,<I?]2<\C9W&RQ8U*=0
M8B_.*)JYD)6V&4+PNIJAG&#OJW+_%EF10Q>HG&MNJF_/#G$VT3)N??CH&\)L
MLJ'F,<:G2EA=G6'-3'BLJ* ,0N/99,!(LY"-4.0(U%!?FT$I0W-:"[C4PF8N
M S<!HY 9M7FWX"X0G@LV3 9 ;06"P0W;NKS">%(U<BKB:;WH'F<%-,E0(0*:
M$=:J!TUD9(HA:?/Y-U!,":!8'Y)[I '.2$.2PZ,^8^^XCOG74W;[=O3NC%ET
M3) 9N6&A-3,(JRU-6[L"L&OFO33%&.<H;=\1HC-V*;!+7H:'<G?,,GAP[_ZA
MJ7J;)X23MSDRF4C&"&3O)U  T+5@GR1*H\Q<R":4+N.!92Q:ARWVC&_6XN$?
M4DEV5 >]9>N*<38;UNN"H*%^)*5$0O^YL0>21; QE?ET'T'*5G+,$?*5)':G
MB%ZZ;?">CF1U#JY5J+3D1H'28^]S=B/&JL+AF/D#.]9;(CC/907)L!IR"ZQ"
M\4,=#+:4B]P\Q5E=&9;31II=U@_71"$LEY)(D?QAR$@J5 "(+W)0%\(PM]F]
M8U -[**P/YE\Q(KM=*3T?-7O'>-DFJ84_3W:[N$V-_95V!OV&=6Y)CC=.J,6
M< OY6Q&D,,ZBW5'PGOA6D"^[F\Z]+Y$F[N Q8>\;:XU'22DE9M0PF MV*[5N
MZ,/21&8/J+01QVLA<< BFYN+I2E_+<Q+CB5SL>DD!LP3)3/V;G3_9O1/$MMP
MJX5%CC.B235=<P-MCONXV(\0?B()1P<]L,/W8LO;GA*H,.I*PM4ZQ)@O5PT>
MF\+%%G)-S:,$-@4RT'!K"W_!4>WC-G26M)^W^+[-'@9LR#=08BG,W"IWA !%
M =]ZNW"<P?9H3,=M7.S!3258CNH%.EV#"8X((WII:E_7Z(;)0'.X1+,&:MY)
MK#YDW1Y[+&3N]%Y67>S9]59,7B+>4%Y.63;C^91V[;:?G6"Q4MS_'Z4)Z@B
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M,1PXH-I'0OMA9-5<S!MI\)IOI@6^JZBR KB_E=(</ZR"_J4V^PE02P,$%
M  @ D(&H6&[_"N0R!P  !A,  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&ULM5A;;]LX%OXKA">=30!9EJB;G28!G-2="6;;&'7;>5CL RW1ME!)])!4
M',^OGW-(25%:.VD7W1>+(GGNW[E8%SLAOZ@-YYH\E$6E+@<;K;?GHY%*-[QD
MRA5;7L')2LB2:7B5ZY':2LXR0U06(^IY\:AD>36XNC![<WEU(6I=Y!6?2Z+J
MLF1R?\T+L;L<^(-VXT.^WFC<&%U=;-F:+[C^M)U+>!MU7+*\Y)7*144D7UT.
MIO[Y=8CWS87/.=^IWIJ@)4LAON#+;78Y\% A7O!4(P<&CWM^PXL"&8$:?S4\
M!YU().RO6^YOC>U@RY(I?B.*/_-,;RX'XP')^(K5A?X@=K_SQIX(^:6B4.:7
M[.S=,!B0M%9:E TQ:%#FE7VRA\8//8*Q=X2 -@34Z&T%&2W?,,VN+J38$8FW
M@1LNC*F&&I3+*PS*0DLXS8%.7RVT2+\,K\&NC-R($F*M&+KK8J2!.]X9I0VG
M:\N)'N$4D'>BTAM%9E7&LZ?T(]"J4XVVJEW39QF^8](E@>\0ZM'P&7Y!9VI@
M^ 7'3-TPR1M3YVP/R-)D*B6KUMRL_S-=*BT!)O\]9+SE'1[FC:ESKK8LY9<#
MR W%Y3T?7/WZBQ][KY_1/.PT#Y_C_D-!>H'3Q[N;/X;7T\7L#;FY>S>?O5],
M/][>O4>V)22)D43N:JTTJ[*\6A-XD _6(D6@")"WM:XE)[=*U:Q*.9DJ(E8$
M@I5NNF@Y1&^X4955>[)A&0D2)PDG3AB/B<(X&*+4"E5&: X,P3Z4)Q[E.V2W
MR8$S?TB+.@.RP*=.Y'E(#IX>KFI$&]DQ#*16()=I*!98CH"&RS17;%EP KM;
M+G.1$5Y9(: $:4*5&<-6UK"\,<QM+'O#4UXNN6R-"[ZU+72H[SO^Q/M1V^#N
MEINZ5.Q=,F-@J.%P@ 'HK7-= !<MB*@XN1<:=/SXJ,N_5)\YX7_5N=X3!J[)
ME!'=*/><T03=*4D.G@13/4-&/3\F,\OM%NY4J"^9%ZQ2S3E<G)7;0NPY;Q T
MKP$.@%=SS;C:5OW\;Y"[Q%9P_A5D#OCYIN^!QH[O4/Z[%$^<,(B<,*2P\B((
M(*7_JSR$P\L^H,XX OP'86]E[XDMYK(Z A)R6E>0>KHYL<NS'S$U G0F3NPG
M)'22V'.".,:,UC)/D:LUMZXPYB^I\$3N07'$=R9CWXF3 %:)-W82&I&/0K/B
M6&YT'@8EPTGH^*">'SO!F$+%2,BQVD=F#[ANG#U<F@MI_P)O+NP8AC$5Z\J@
M#PH#1HREJ4T;-/!&@%D5<EAHIDT[,(K>0<U@-CKH$Y0O^09'$C#WWT+!-A;%
M O"LSB$7)02_WP6_QG@#:Z61N6(%N..$^$$$O[_^,J8^?6UJK2%"@1F'RB"V
MICWY4#PC^/7C@"Q@BC$%9,TKT+"P!2V#^2#'%F:B$3@3?T+0B4$;@&.>.@&,
M1'#Y!(F\V!25%<LEN6=%;8K1&JMK!Y86L>A9P$4.PQ&BQK@,?9O!>T=%:H4N
MQOWK@H$"BW0CT'++9;@%'.*%4F2\<(A53]@@6=?B:5YM 9#?[6,$AT&WYK(D
MIQ#S/7A5G9'8!3R:GS_-P(9ZWX,+U] ,<O5EN$+V.=@*L(1&@H:$KC<FK^ !
MF'_U+=F]*,"+!:9"XKL@^Q4^)_!XD]_G&;:;?<Z+S#)KP_RJMVI9#EN6QF]#
MX\5>& "+3_R/X8I<#\/FPS-IF[<]G&);0:7Z1<8.P;B;U;*-BC8N+:U+^2&7
M8IS[0']?FT(-$>Y4[ZVFZ[7D:U3^MH(B \F2DL_&@E/_[,EL,3Q0]!]K%)@5
MNS$4:#<*T%8H#71,?FN0& >!,QXGG1-FMMG#R2G,&8'OG5D&U"<POJ]XCD2G
M/DV<@,;F;.QZ!BBYA),V&NVSIV:[]953'LNJX34.0-$0M9[$#HW"5B&</HYP
MH,XDH0[U$AO!R =@ACZ\Q)$SIC'YU%3=AOP;:AI"!_,](*"!"_T+E$#Y@>>$
MX"AT-B8RZ\*1=^&P@(*A(F5%6A=M^IK<S5<K #^VMR77.\YM)C:S%* 0TI6W
MB=X6 BP_^INBT9N3C G):_6T]+,#HZ-[?*"4MI:S[5:*!U-TBCTY"0+7@W]&
M4!"!+Q#65:_8'VP(DEN+89#J>NN3PM8.G?U!CYN*HI"HXT\$)"QA9/=U36A&
M3="&NK$M/6Z_Y]J<_ 0]]S%/#[;D_V/"OI2(C^W;Y%'@=ZD7 <(3:J 68PY]
MMBX\!20[B3]N$L]_FGC0TKW8)F6"6?UR@CU.$@!PZD)_^D%DA/[/0(8\."K]
M1(@$;M1"Y-D)\G0P6\SG@[.7)YZ>&:@?DAG_G'@N[1R".0L;?KOQ]-^(8P;>
M[T-;\R<@< _]U1WUODV47*[-%QBL W6E[6>*;K?[R#.UWS8>K]LO1"!V#?6+
M%'P%I)Z;1 -HVN:KBWW18FN^="R%UJ(TRPUG,+#B!3A?"?C/U+R@@.[3U]4_
M4$L#!!0    ( )"!J%CX?;MOIP,   ((   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;(V5;6_;-A#'O\I!+8H&4*PG/]<VD'0>.J#-C#A;7PQ[04MG
MBPA%:B05)]]^1TI1G2T.^D;BT_WYNSORN#@J?6]*1 N/E9!F&936UO,H,GF)
M%3,#5:.DF;W2%;/4U8?(U!I9X8TJ$:5Q/(XJQF6P6OBQC5XM5&,%E[C18)JJ
M8OKI&H4Z+H,D>!ZXY8?2NH%HM:C9 ;=H_Z@WFGI1KU+P"J7A2H+&_3*X2N;7
M0[?>+_B3X]&<M,%YLE/JWG5^*Y9![(!08&Z= J/? WY&(9P08?S3:0;]EL[P
MM/VL_JOWG7S9,8.?E?C."ULN@VD !>Y9(^RM.G[!SI^1T\N5,/X+QW9M%@>0
M-\:JJC,F@HK+]L\>NSB<&$S/&:2=0>JYVXT\Y2_,LM5"JR-HMYK47,.[ZJT)
MCDN7E*W5-,O)SJYN*.]?E3&P00W;DFE<1)9TW6R4=QK7K49Z1B.#;TK:TL!:
M%EB\M(^(IX=*GZ&NTS<%OS$]@"P)(8W3X1MZ6>]DYO6R,WIKIB67AQ,GX:^K
MG;&:SL3?K_G;R@U?EW/W9&YJEN,RH(M@4#]@L/KP+AG'G]Z '?:PP[?4?S(C
M;VJ\3GBSOH.OOV^WL%G?PO;+U>T:[DJ$O1)T,RD\8-E.(!BTA@:U+<'2=*ZJ
MNK',7R&U=S> Y\!D 047C<4")/$*QUL3KW&\<]+5B"].!5!.\[)/JOMD</-L
M^AX^9J-PDB47KIEFX3"97<!W?Z6PN&0/J*E"M.H&J+882PC$_.'=-$W23_^G
M^DA2))G%<3@>C2 =AY-A&K[8M.<]*T(LR2!NH>+!='KA97\""[C,15/0((7_
M<M_X"!R9UDQ2<+DQ#?4IH&U01FU,!O])QZF>HZJ516DY$^*I):1R1MG*&\TM
MIZV.2.<:'_W&!>RUJMH$,I$WHD_@^;3!#G/6&'167 .OZ !9<.S:"UDJ^J;1
M3T!%*;^'"FVI"D_&]Y>YDA0-)]R-'U4C"B@I1J2+5'X)_;+'IO,%R,AWVIW3
M:G]*)9G/X<HXS->.R];OJVKGB@F)#!]1Y]Q@T67P 8TC<$B-[#JC,$TFX3B9
MP# <S<9TLH9P2U.:YVZZ]:61W)I.I+=,PMDT"<>3C%I).@TS:MTIRP1,PF0V
M"]-93.J3=!A.IA-X[>9')W6Y0GWPKX^A*]5(VY;H?K1_X*[:NOYC>?LZ4CP.
M7!H0N"?3># 9!:#;%Z?M6%7[*K]3EMX,WRSID4;M%M#\7M'QZ3IN@_[97_T+
M4$L#!!0    ( )"!J%BR<MH\, P  +@B   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;-5::7/C-A+]*RAE-FM7:60=/N=PE<=V)DYYCHJ=[&YM[0>(
MA"1D2((!2,O*K\_K!GA)LI69VOVP7VP=0*//UZ]!O5D:^\4ME"K$8YID[FUO
M413YJX,#%RU4*MW Y"K#-S-C4UG@K9T?N-PJ&?.F-#D8#X?'!ZG46>_\#7_V
MV9Z_,661Z$Q]ML*5:2KMZIU*S/)M;]2K/OA9SQ<%?7!P_B:7<W6GBE_RSQ;O
M#FHIL4Y5YK3)A%6SM[V+T:MWA[2>%_RJU=*U7@NR9&K,%WIS$[_M#4DAE:BH
M( D2_Q[4I4H2$@0U?@\R>_61M+']NI+^ ]L.6Z;2J4N3_$/'Q>)M[[0G8C63
M95+\;)8_JF#/$<F+3.+XKUCZM4?CGHA*5Y@T;(8&J<[\?_D8_-#:<#I\8L,X
M;!BSWOX@UO)*%O+\C35+86DUI-$+-I5W0SF=45#N"HMO-?85YY<F374!+Q?B
M>YGFK\6ER0J=S546:>7>'!0X@U8>1$'>.R]O_(2\B?@  0LGKK-8Q=W]!]"M
M5G!<*?AN_*S #](.Q&34%^/A^/ 9>9/:X G+F^PTV F9Q5U[Q95V46)<:97X
M]\74%199\Y]M7O"''&X_A"KIE<MEI-[V4"I.V0?5.__^N]'Q\/4S)AS6)AP^
M)_T;8K9#WJ</'V[N/UQ_O+^K!'[Z>'_S\?WUQ\N;ZSMQJY#VXF)NE?)^N\E$
ML5#"V%AGJ&01F=)BA9F):>D@W+D^+X"BN<Q6 IN4=4)GA1$)"Y.-L*4N%J+,
MY&RF$RT+%6.KMK'(I2TH)  >H;%N)B,LX(\H;@;K(R74[Z7.2=! ?,H$DB5:
M(%-\MJPI\:BBDL1+8 %VQ.Q DDX?Q+$FE)!))=B5NE #<;_0KK5\*?$N@KT9
M2>+-^" 8E9I88Z_T< ,=$7J  Q9J[S"K(C//^"!R%LX%N%I)L0LB+('(2S-[
M69*3G ,J/\BD)*T+\6(X. 0&) G+=R2"I'K#Z+-8DLH7_(UW154X75<L9"R<
M?@R0Z(_VCI;Q;\A:&!J\0%8D<FJ@I$&@V2D42'%C'Q#HOKB4B<;&3$L?R,H7
M"'B*,ZTIYPOQD\Q*RA-H<D(N56)*W4 4<IJHT _T'Q!,2D90TF2<&F2@*1 3
M+U,]HA4Y]0H2D#T=H%DSE_Y,Q*<UYX;]XH48G9SQWZ'X%2>S%MTEH^%$G([$
M_>;IV#<^'=/?H]%N5_^]SMM5Y69ROD0J4,=L=&-_0=9X<"I62EJ?Y' JMQ45
MOY0/,&:NX/O(<N5 ,<0%T$%"8"?7WVCXMYT.WM/[U$ET6J;A\%RN?"T:',)K
M,O6(VJ#D:)3!YVC[,VC:APP(":5LK03V<'GH-"]]OF.5<D6?-V(Q5C,09B&?
M2==961#.=E5XM262AV*O<1?^4*51Z/<1A>/C(2TY$F?'(WIQ+,[.>-.).)W0
M_U/Q_7>GX]'X=0CFUE/[ * 8T!_J>MP_/CL5>[< LOU7XF;-*+$W.9SLUU_?
MJTQZTRW<QVZ0"9PO,]3/WNCX<%]\7C=]O>SK ""M^J.ST4;J AFGG$5]D )K
M2=C1Z=%SRS*352M'_>/A<3!__>1Z1WWT3?;R%J6?=2&?P.'6%#J1&5+D&O\B
MLW4IK[S[HCT"7J\4]50^"I^C47F<90SYL4QEQMVD 8C1V5.H#57]477O\(@3
M=+G7RLZ!MUF\4+H0%^_%'@5^/'SM%_";T>M]UD\]1@DZ%=(;G#&)0;D"]*)"
MC(B4+9!M'/"$Z&,)QR&Z<!W\1/M)PU@]H,9R'W"8"MQ*E8TT /$/64%\4KLL
MM( ")>1;-\1$E(G<"&#HBCWDR'-QX[&H\A@)6+##^MQSJ"7YSO)3B8I IH_%
M'IW0(Y^30E<$*<$[=7AZ^QX?FE;@A#, B1E:>4;:4]<" #L=\H+LM2KASMRR
MN8\/YV7"?:'_A .XOW#+'E"4J^X\GF"#B$!#T"P3ZFBH*D ^=]<"<9BCSF**
M1- >00VX]*QMHH3>(!O6)(EWL6^0,VU1M3ET8HSR@?B\( ^/I7@OR39)!\ND
M+Q05J:\06I:; IO(+:W(S80U#GU2>E]6WFD,"?5,*U^,!L.Z:9.! /"D#*$C
M7&"GD$WMA*J:35"6* ?'B]2B(J(O8W%7X-RT:I4!#*BX/+$%(JD%S4_(\UOC
M7)VZ!?=/#Z)";?;/R6:.I!(E$DFW:+#JZ^-#1EA-FJ\[ILQGUE011,XS\6XQ
M&]W%B- </3D@68<M6=Y*LM#E*@(CPWE;DDU&"ZT>@OL@_T[E<.84AL #8) 7
M4#6AUR.?WNWL72XT7B^1IH3US.OL5X;TFZ,X$%>EI3RH"JDQ:=T3GJVRF3%+
MRZ7NU!5YNZF0IH"%DPF+^^?5]8=?_U7I_,O@;E ;#]FUW70.XR68@";*X:EK
MV/9.)MP,[_B6P1/7*Q5Y9V]/.2;=!@/ 'U4A;@@GH#:.:XRT#>2%)@5PYUD)
MVJ9G@1,%$H,42SUT![;TI.D;RIAIHN=^.#&HA2_85UHB1$_6!,5BW,[PK\&P
M5FY6>B:2U-Q,X\V^,O-]HM-*R"G<].M^Y"LHE8_, TG;DZ.U(GH :32E:SN'
M=GEO4X6YA4E:L-<"F%W:!#[978C8Y@N<66C7=+MUQ;F35.-:ERNLQPE1$<!\
MZB45I% GMV8E$YXCFV@%+Z:^/!:@ H*.1;+%>JY]9=*_#(G']D.-6>=PU(+2
M5&<5>RA6N>)]=7)P_I$45TX#F5'HYMJ/E1NJ!]4DQX&)/*"!AC,_!OBL())O
M6._80*IZV>CK2I0I:$ND5,P,%Q[<EEF^ F2>0R<^IFGL]"E8K0=92<+B,J)J
M>6"O-CD=S*G P43,/0,]259^'F.Z]L/514>J1QB>6F48F"O%MC(JO[X;^*F:
MTPP?1;;D8:@.,-S(%C6!CCUV^BY(UPR_HZF U_/LU<)V:54#;QM0\Q?;\G^W
M*Q_Z/A2N'QKC^#:$L8@]@&T5J=<[5>U LPO8W#UU('YF?Z[J#M;QX0Z=.;71
MZL<5L@QV#@\7Z*B?V)ZK"BZ>&1W6V_8W#0]SC+!,^5"+LC435+O^5T/!!E[V
M$=6$KL$8W) I#\0^Z75[7("#?, [>!IU/!30<T\/%'KV5*T,0ZZLJZLU<.SO
M&BDH).QR\0N=MFVHV!$*[1QE9M@Y'H_[AYC<'>!>U>!*SH*'T$NB+^$V"73>
M%3IE6)Q);9L1^L5D,*J[U=Z+$7C/<#@AB/12^QYE'FESS2&@!*<[J%U4,X#F
MJN9.62J92W+\3#& >64VZ.':%+6%'3?8N,-Y;,QP<%0;4XT3A=D^)7$0NZ,2
M]*L)%8?MFR:A2VES4\U!56H^,0#=PLPJ_3;8DJ5;6;N3+%4N(K+7Y3\>L3J=
MJB8C&PZ!H)R=A18PAQQJHAUBTZ;$5"C?QFN>%']RTLA_AITLL0)UN-GG_R(W
MV<I'JH[,NO>)GCQ%3-RW$1-26B;.;-7\_Y"AH/VD>6+\>-ZZWUJ?=_F1A;_T
M,T(U6YH'%_TPR1.X.$6WLUFX,(\6="%*#N#0FJ2SBX&-;M]#",.0^Z#"G;MU
M7$_=AR1D(S6DNBJ;"X8JK%.5J1F//U1!3N72UAVG98#W2&LRUC8J4U>0]M".
M0T+8@N%$9UX :6Q*.%661/%(A=:WWLPL/&4-#P$V7<"=;"!N41ESO['[Y.T'
M'LYTRLV6_G>K)Y5$\RA!?\-)M*:JXJ21Z)^YA,L86?!#)ZSB 4+O?&:U 6/A
M_A3T-3.(_%(VMW7LINJ()5V,^^MQ'EP+OELMF,]*9S)?&=9,JZM61G :OK"=
MT"<Q],1,L^@^I]]4J8P<78&&S@*AI@1HKNI<S31;CY8(@V*59LVSLO?@N" X
M*.J-/&]HC=^R8E0,#TC[(5L\)08<A"ALX'M[_O6U[3/97X)@:81:=?YZ)/&Q
M:E$JH%_F9.2I"T5_T0"L>J3V0[@"I8JZHEM8D,AE"!UX:9WQ!5>0;CF"\H4R
MG%2BO R'1\2?^LSW:35\JPM?QK'AN+=+C[R6:&A2GU/I67E@\^:,9/AP;MPA
MU)G4]A]?3M#YF>D0^85\4%Y0/9=X-*!,K4MI]56$?[#M:?1!Z]<$*5VJTV\F
MZ S@L_]A0?UI_;.,"_]KA&:Y_TT'9H&Y1E 3-</6X>#DJ.?OV:LWA<GYMPE3
M4Q0FY9<+!3)E:0&^GQG0C_"&#JA_K'+^)U!+ P04    " "0@:A8F>/#*6H*
M  "('0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6S56>]OV[P1_E<(
M+QL2P+$=.VF+-@F0I&E7H#^")MT[8-@'6J(MOI5%E:3B>G_]GCM2,NTX:=YA
M^S"@:"R).MX]=_?<'76Z-/:[*Y3RXN>BK-Q9K_"^?CT<NJQ0"^D&IE85GLR,
M74B/2SL?NMHJF?-+BW(X'HU>#!=25[WS4[YW8\]/3>-+7:D;*URS6$B[NE2E
M69[UCGKMC:]Z7GBZ,3P_K>5<W2K_K;ZQN!IV4G*]4)73IA)6S<YZ%T>O+X]I
M/2_XFU9+E_P69,G4F.]T\2$_ZXU((56JS),$B3_WZDJ5)0F"&C^BS%ZW);V8
M_FZEOV/;8<M4.G5ERM]T[HNSWJN>R-5,-J7_:I9_5=&>$Y*7F=+Q_V(9UXYZ
M(FN<-XOX,C18Z"K\E3\C#L]Y81Q?&+/>82/6\JWT\OS4FJ6PM!K2Z >;RF]#
M.5V14VZ]Q5.-]_SYE\8??M094%;B8FZ5 N#>G0X]9-.*81;E7 8YXT?D3,0G
M4_G"B>LJ5_GF^T/HU"DV;A6['#\I\).T S$YZHOQ:'S\A+Q)9^B$Y4T>,]3.
M9:7_)2D6^N+*5,Z4.I<A-*I<W%CE8'JX86;BG:YDE6E9BEO<#+"(?UQ,G;>(
MI'_N0B@H<+Q; <JNUZZ6F3KKU;27O5>]\[_\Z>C%Z,T3YAUWYAT_)?T/^/$7
M<K[='7[\<'7]^?9:7+S_>GW]Z?KSW:U(Q0.<NYO#T00@+A;*,D:<S$[H2OA"
MB:L"X(D[9:WVQJ[H-MR9%>3+(_$AO>J'%\RBEM5*0&=E58X7O$DDI;O+UC@D
MBB_$1RVK2VT$Z$EH:*!^9F7CD.A(S7M03LU+R<%9IVV, F&#TIT]^Z7QNI25
MLL+4A2]DN="90)PT(6A&@_')GP\>,Y(TH/L>W.AY5PA^JQ8F5S_%M%1U(;%2
M.U;FD])3LX#NXGU)UV^U4^"606?/4CIH7'&P-;(L5V! 5R-J-43Q7K@I,KA/
M9\#_U\8R_6%_Y>("!],)PMWF#,1=XA?IG,*_'"O) &ME-5?=9CK'+SW3_)R4
M*T'UNIJ#I^!."H_:PEB($ W8(<"4"'DM]O4!WUQ[KXSN1AQ0LE"\]%LK^Q!<
M-3-"QJK^AJV*GGW'_V8VPT:$DY,EKE$'RG[0=E$;ZZ/+=QO_AA?NZZA5JP#?
M39&F)(:>7=Q3C22O=VYQOLE7'0RNBQ'RI>)Z)&X*^%V,I\,)(H>PVN_=2AA6
M'1[U#@(S\8K)^L$8#X+Z_(8+ONHP!F3X?0^O/$-STJC=CU>U>ZR-")N()3)3
MJ'M9-C GCQ)A&(H2.=Z(*7)..Z^KS*^5B<BTH<RO*0F- !-GR](\V$EB(Z=J
M:;&1J)7EUJ/*P#S34L\YG+$(S[V881^6$S=,C:?;,8P"0B&*V]2DQ]C7:]Y8
M5DZ&/J&V>*?SU%,$!$O+)F<L\$^6*Z>93>3"-%0M-ICM)SD\ &55IN#ZOE@6
MFGSCU_! I*I9C8QRW=$;9K9.D*:&Q=@ZDZX0M5RUQNP=G0Q&Z _*$N^^":$K
M 2*DY#L6C[86\^J-V_17H?NH"$=H2'STP-T)?; %Z%XBL-'L-I'N#R!],.Z$
M6U6'<DLLD3IB)K45%&.JE:1^--JOL#_QA=^BI2PCI*$/N8O#:G>XP/61EMSK
M#6>FTE+SR&3FNI:'V/XVNJD-A%_(ZVU&Q*Z!-,Y5">^B(L3K65-Q9,&\CM5:
M2"-Z)3$$V )M,$=0DJJ1M+Q8*!^0!D<1G;#-4T4(=HIUZ?#KQ+<$+-7:-24_
M$>N#QY%2I'>5RY)BA6B6- I)Q  D((+:\4R2OJWCD*R_A\0@GG:"RF7)6B-+
MS!P=&^776L1,=06L+.74V%C*86+5A)SWQ@-JE$>3,5,]3.Z=&=='<F'%MO<Z
M!OF:0OHV@?2VA?3NEUA Q*.$MI5A 2NNE/GO#1,!IJ;O"(*$QF0-_!#V6VE!
M7$2XA2*?4L^44BUKK$US)EJZ3<.^L*:9%U1?ZU(Q?)  4M!4T"+KDFD<S3).
M*XBEI6G*//!#0(!(678=DE,;A=-8CC_2K5(SG03QED)/Q"#V;QLGIQ<8R-#$
MF<:A:XI"R=SGYT8PB*H0?..XL3'WI"3&T3Y%(\2L0D&4U(XQI_]H  W+!"W!
M03M,$)@W)$4?&5 ;=+D=R*%SI#5KN-E@#*F&NIRTF"2IP0$2ZTT2\F:[S7C4
MZ,?"\?'&(++^,S,RH/4,T!G.6+O;\ >_ZJINF/P*D_?7S!MJCN.98SN>MT"G
M'=>\\'1.X#+X?/54.=F,Q"D8 P:YP'5!4_ 8@@'5S!>SAKKW7-6:-Z0A)95*
M%8 (:D;-9\SXV,SD:W#RIGO8J0XIVN2<O8C+$+2[["=B,=4<X3;?5'QA*FIW
M8Q1U<I-\1[S&'O$Q8)LZEZU9+37D42&3BFJ50^E'^\V\R/IS/E6*,D;2V('I
M\)V:V@87-"!.^M3'0+,P7ZR[$@JO4$.AS'S.8V.(#J9QKDL:28*-J"6KDKZ-
M[ FM5YI4!>EA6J327.A3]()4Z#;<M3<>G"2=S']0I6+5I_:%]R;!5^C4Z-T\
M/6^ YE\ 4]OR0B!I:U5!IV+(ZH_&K8<*4(E2Y%0ZAE%T#!/G['B*,AF(+PFX
M1Y-PMM+OJ%-6%8@D:X,4@RGY$),<,M8L*[YK-M4Q[2Q_=!RDH4BA]8XNHW2C
MWC/7E-18WC:A[70?H2<+]D:#EQVJ^]2<H+&*:_>.!Z]&%"_"%43+AT@,)3X;
M3V/1 9L53Q1>M#9M]MXJ:WSLTS>/#_ZNQ05F<,O0%AA(Z1(#%Y(S4QC[*=BO
MS  8^7R "8Q7AN>] P[-9NITKF5H&(*@K???@^%K@+R@,A3:N19QPH&27X?J
M2CP9SB3P()+D@W%>K4?7T+ ]^^"!*V"R=6*,V"<)O<_F/D1J=X34 [S?**$"
MB$F;^W!M_X\=V5#NHI=!D@;B3=7A,HKH4H=,)>GPDF9?T/J.&X&@S$U8>;#%
M#%QU&O4@\%)$8EV;Z9E7BKAOQ2T'@-NQ <NGY+=YT/Z/I?[_/MN/0]T#H6&U
MC3,G=2ONH0Z7LN1:=$O'R.044F536MOV;.*_,5DNF4"]6*%'C2,N*'FU 3CZ
M%%V*"_2-I3@)DD-->AA-:&N"6;QK.M]BHJ*3GXTV8ET8H XW9:;-#ZOF#08L
M.J/C?AF\THVIOXI52:DWY2Z31FG=)D -I]$)@',-(V=5V39>F]DY$+=)0QJ$
MAFK[W'3:=33ZD,A21HG1&EKTID)KXL/1G0W#4%8\,EV[U YN1!K$@ QGOB]?
M]2<O)X&!.4#:+8F<H#?0S[Z'D\FVU2)HD 1A\DI2>#0XWDKAWX("XBI]):8:
M41"GX5.+_D_R\;^3C(1'&!NVDW1K2@@Y*.>(E3D?I@6P'I0">(MZD+U7D_4A
M#1^L(E&YX9[Q"51[2L-G4WE$YL'Q4S\</^V]>)DP10L36D!JEMM0V-'9N7Y[
M^DI"TJX@"<Y'&HS!KB\IP^3K&*KHG+\!TNDZR"A\*.ON=I\9+\+7M?7R\(T2
M<,\U8J%4,[P*W4YZH6*W%][4_*UM:CQF8?Y9*'1$EA;@^<R@:8D7M$'W\?7\
MWU!+ P04    " "0@:A8']?[F/((   8%P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6RE6&MOVS84_2N$EVX)X/DAVXG3)@&<UY9B[8HF:S<,^T!+
MM$5,$C62BIO]^IU+2K*D.%Z'?;$EBKR\]]QS'^391ND_32R$95_2)#/GO=C:
M_/5P:,)8I-P,5"XR?%DIG7*+5[T>FEP+'KE%:3(,1J/C8<IEUKLX<V,?],69
M*FPB,_%!,U.D*==/ER)1F_/>N%<-?)3KV-+ \.(LYVMQ+^PO^0>-MV$M)9*I
MR(Q4&=-B==Y;C%]?3FF^F_!)BHUI/#.R9*G4G_1R%YWW1J202$1H20+'WZ.X
M$DE"@J#&7Z7,7KTE+6P^5])OG>VP9<F-N%+)9QG9^+PW[[%(K'B1V(]J\Z,H
M[9F1O% EQOVRC9\;G/186!BKTG(Q-$AEYO_YEQ*'QH+YZ(4%0;D@<'K[C9R6
MU]SRBS.M-DS3;$BC!V>J6PWE9$9.N;<:7R76V8LK+2)IV2T/92+M$UNLM1
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MD22@C[A+A1>'B-SDNI&CM6UE%MI&8MR:;.1R0%N[X\VEE/G>%L)H."IJ=3.
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MZ=UT)28?Y.J!T<"06E=X]#>D%<R"ZS<-Q%IJ3<[^7+Z.VDX5WA'>%BF7W$*
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MK6T\95(B+NCT67GJ7;%IP)YRAZ UA[T%A13S <%D_I5)?>"06KO$_#(2X7)
M%)D +C)^<F@.GA4/TP#69Z?*_1HL.\*=-E%3MA91@>? *!5@%]I;'#D&5+5H
M *8B4#^0(YN#$H4>V,$W-RYF8;0U\L0G&=H"UW_^/ON)D//J2?8?[%D0E\+I
MT*B:?L9Y/;1Z/@1F$JR4H3=WVE,7 CR[ 3932 H0F,W$;/J9DTO7=?TD>QNA
M*FL+ S.=M8T>#7)P<9"TXR4O*,(=7@62[]IE2UEQ&+\6[,) OP8/95",0FD\
M_)<$1M;),@T"^#CIL*F: ,DDW"9+%IDFN5,"OS%H'C_)?CY$N3B>'W9BM2_1
MH]#W-46VFE;70I.IOAY?,^FKLHX9J3?>K=A]J9AC*-DD"]]W@SC!V#"6 "0*
M[ 6+;1=]B0MUT'IA7BR:0<*;7W;YGD"@AM_@1@%/]&9]8C%N-F/B@N2SLWXF
M7+7+BTUB 7WE:6D8*8==(H309"8#)Z:!Y!K4TB!;YZR[S\P?T#=A'7(Z<IPC
MC]V,"!NYI,+ )'W:>[0N@A"B@?F\07H</V[+/5);4!,G1R]$KC3V&J(T!0,1
M$!(9/$G3B^QYU#4)K408P$(8("Z+;A1#CAP9(;:$6''@GZ2]\AE*0&2&/HVM
M-;6)=,ME1=ERK$[A%RH0C\7:57H%/2#8PI-0,X8Q.B)]C"P<5;)B)O;5T=3I
MI^\Z]!0*S:-C;<<AN#G;Y#>/EB6_N?@;ZN;$9WIBO>B0C7%B<AJ1VFS]BJ4#
M**"Z1('G%^838C"\5\B#&#H39QF<#9H@Y[AD0&.0P"7; :0C!9=[L /N8B!3
M3I(HI"-52MS!J _/6$?AY9!%?6@NT;@Q;3GEDX378B\EEM)[_<"D$<*5LDH
M@! I\?E<;*C*3T3;E",KSQNV 1<'\C0G1I0QH Q4R)K45 ,8B&44.MX5N!-&
MU@%PR6 "-7)DQ")-U)Z)VFZZAP-++479LS>)(+C]$(J=L1YY%E"1G2LY8R%2
MH5I+]XZ$<6(H&:/,4.@?9"'%PH2KXV4%/SE,M)BDT\]Y,65F,=Y3L=W>$:Z3
M)E:Q(P VQMY.(,G<D\X&BI"3M!BJ/#IO5^<_1VP\)17E\OOW;W^6K^B+J^_/
M,(; K&S2(=V1OP#PB?)<VIJBS='!*-@AY@.OA@)LQ&[I8VK1'9NK!6UJ+<:!
M)*GQ$*!&: RV(DX2PD#T.VPY;&M2 ALL40\)UFP R()^FXIF767 T=$Z DU5
MF"H$_+%IF_,"^0UYYPT@%@ M<3<@^E9,1(V[1XMLQWL5B1]R9/9!.&IZ)):7
M^'%L9=#D'CA[5@5@S"6JS_>4LHF[DNWR>@XW734!WY1VE-'P^T-?L7N=,\ ,
M4 QW(J,+>-8(2+[BM"(D6(S?]VF6"$Z.BARL\5Q4*\'F-5 O.\'$RZQK%!?5
MR \]>DMBE$O0]?0G<BLWYP$*'"4+N<N4[5LH>R4+'(\),:TVS_,OM5A5K$>A
M<DU$K&EZ@1:B9AJS:&LF]Q%*<H@AD8OLTPA8%M'I*+^*U2I7Q^M,GK=P,IBV
M1OCWOO(?)WG7EPZ2/6?7//W]:M*R(%S?M1C8XFPN/RS_.<ID0ERSVF]A)R)Y
M94, DY'^.9-EVN\OULG8F$DQ#64G<UT:=N-J.CE0@5H/:T$#(MEQU0^\7E,V
M8UW!M_]XIO:LC*&1I* SX&NO7$FFY@N9YS7^3&Z*YVV' 1:"_NG)JQ>OGW.-
M#HH,EKO##D'Y/ZZ_N5Q<7EZ*:VFOT[4=>7MMRI0E++"?9*MA>543-14\1Q;7
MO$R8GI=.:ZO!^.XE0ZSJU5(?R$-%[E2&B:0XH<:!"L80LZ!4_9D&Z3WSTMX<
MBBYRE&!%P25)@?R$/@[>4M6,(OHF"F4/"50(%UP0J\'@R2(:YIJ*"Y@(!-M7
M;/.CR,2ID!EA)C!PA[S&L.B;J23)PZ0PX">MN,428C"H;\QD4]F&8# !Z'#:
M>PM#=KJ0'QT%>]7P4+!??%32R=$>)-H@?Q/%31LX<*Q6Q&=A&BHVQ+58H-'Y
M25(N^C7<O08Q.!F9."$B"#D#$/R@2BZTU!@@B[S:UB3"(&*XEP!@GU1@IDGJ
MT_AR*#*B'Z\DOY_C &6,ZY<5SG0TMT:R%:O.>">L1"D=GILX-@5/C3N6\ZC%
MKQG \$"X-:;K<KQU)D3:8Z*#Q13)4Z5S)C.#1)=7$PC3(A#=!M90<":#<XBR
M_X0S>$[5VFA5)[%GDNDE8_Q8"*L>H\=-@70D@VRWR>%T0U)?_ 'TC[ZK #LQ
MT4*%*64ZP!G\UXN7;_[QWTDE(JZ%?:>DP3!OIZ)O *S72#8*D'P]SFC\"LWX
MMAP <W &SWHE'C0@_QH5E4+W_ 0F0J/"5G2/C0H%4':377^;_2E^?I9=?V,_
M/\_@:?/Y17:5?'Z975W!YYO)6CIEP4C]J@>CWH'^R;!<UJR80<-"KR[_A$.M
MNY8M^+&HLR)05:#HF@,V<'7)(VCP>_R^QEU(EP&-::GI<957]+D==J &CM$G
M5#9)PA3*[_MFE$P/?]D2"6!IF!TB5<_ 7+G@H1R]A2I5[]:Q!E#.6NA9<$D*
M/*6"FV(&-AD[?8>JD8D5*=X @905YZK12$F9P#A- TG%3U,*$&%7GF,,96^V
MX6PY!IV(QHB"$</+GMP:<Z@XK@\G,#TFO_:55V^WT"@5L1-+72-+<<@1;FJ4
M:NN-F#443%"M+M2?8%H53JFE6B'B:KRVG\3/G.Z96(*N=D&L#L6(?F7C9E+I
M!B"E+)?57A+V<WRT(.24XB@4@?*\\9N2/H(JH["JPX5,@["0'.SH\#09+Y7O
MAIV5P@>U\0<] ]P*CJ _FA-R%>O6KHZ7G;WGLA7R44DURZ2&_\6C9*?5&7H0
M"?=O<\IC0*=BZH$6TV;$7=G%&-$34QR06RC7:Y>B7XNG@7+.VBT:OMFZQ;),
M#.NX[JXJHJ3ES#94OW/ P*JAL\"D5A"@^YTD'E+ %X4\)\/-R0#1I71!8[\Z
M!J,3OU:L#Q*?)%=E2)8$VB6E) *(C=^+A\Y+I1&&?,D,UM P4S9FQ!YL.%T-
M8;>(MRC]4 :<^][M.-N8DM$ZJK9IHU^)Y3UOX0F=YRBK3> S@KW(7"UW^A[>
MA%>#9:YO:F;GQ C$)*Q:%]P]B<YM1MA+C&;'C3E60/&LG"'/D#7 (FRL4A9O
MX]04VAL7L^#QH,G=]%KT1',DIX;CWYV-6F%,CJZH,[.][XF/G-Z=S927H;^!
M!/;T^Q0.@K\\QI!2//"NKKT2%)H<00%(S$ZFE:4KL$H\))&.91]I68D;%1B?
MQH9PN>0Q/3I_'E2]9J"B790!<TI?HNJ=5A?N@IN"A$V<P<*Y]<'0-307TE H
MUL']DKP%_ &BH18E\.=HEI58T!L':]@4A(5=N^[RK4<G/A\ *5*I+EAYXU,P
M[AIB)KO-WI-0'',5'>.4N)ME)U/\S;QQ1@7XG:.MD@*&&D)Y3M,E:'F1W6ZJ
MW8Y-K1)L@Z:LN>20PL8A["COA'+7U5"OP.#C/)?X+ P:A',.0*9:N3E49D71
M9JQ+I X/!Q:Q"+%Q-AS1-4AZ&'*Z4,GZQV91ZB'ZJ5,<9]?CO"B&^%=A#9I8
M=<@TF'!LI@'74[3=#,^@HR.F"K8N<H:8'+VB:A!8?Z\^TI0*\&WA]H"T*.*(
MQ:[1#=B$QV%A=W0^^=ZAH;[D0B\0(&"Q+//B(WR(<S(!R%@PF *'\8Q_)R:'
M 3[6@UI0=?9H(%:27ZC4PAN 74KX/^97AXQGE"-W**M>VB+$&4@Q;P\QPL0!
MGW,M:'J6Q"*YY(&JPBA!.50-2E&&4-7,G$GO!Y2S-/)%]I^LQL;BFM3^%C>X
M)G))E$U#\13#'(G8M%)'% ;*7?@,R 10:,&!IU1Z42RDLD0E\2#$AG';X4#)
M7<3D=:R9#]E:IE:^[SC7OFI*8%7=/C;5,*4$@8LMA[UR'L5BP G8N/I9HG(T
MLSN-=]A<ZVFIBG2W-+):ZL='[TXIF0V+A\2YR1H8L?5V2>MB,RCQKZ%$[CQ9
M.R-5CV%/H6]D/2JZC60@=QK:LJ249D$"V)+VJ03#&3BAU!^6'@Z3[6)L:U7?
MQ9XQ$9..E0,O*?,]5-"O1KL:'8TIFHUF:]19,1B%Y3#UF%X1\4,H63$SE'2K
MR^)@OJ1#@&1 XJ'/5'V''7.8.JT7UW01CDG=H1V6OI22-!T6>S;%@V(>9""P
ME2FNQ0DLHP2*O&LHSTCS+9DI$<'2N5(. IG:DK67*E Q.W7LBP+L%HO>E+F;
M/,$75F[<BMQX!;S^R<CIL,[76K@'ZA0,#<-W8[>;49J0D^G8CA0R61C]Y)K(
M#$9&"? #9E'C:=2VGM8$44!QRIZ8.LKNGL0^"4DKHBCK$@V#2HIP4P(+3JQ"
M_;;J)Q*E;!VQI8@I>>Q)B H%A+3;C76X14>YG^%FL0U8F(LV&HAS5)))ZOB!
M37K3'&32[34]G90<*D)L:)&SJL4%VO"HB+P#8GNAVD**..@8 DKUJ4K.N\BM
M3S5$C)D75%W0?:K5"$BH6=@R&E)Q)1\;=KT"-6,4=@O,A]EWNA*L @#Z,UI5
M5'V.'38+@)"WDZR/N]_A>)P-9Y("$C=RW#6W@HWM)J3*U<2Q;:Y9?]]RJK2V
M26 Z%U-^J.M4Y/A$@T1^QD[<D98['<%,,$H%5E+*<!&<.>]9(WPR2JLT"-XY
MJW/45-P)I!4:IY#E8FT@<]*)LH(,C.4OKFM)O1MX"ZM>7 ?&>P<84(FXX$3D
MUTV2>B&://'=E,7'0Q<F)LT.5A3A8@789"J/M9_CU#PB5KOO:<)]2W4) [;4
M00U:LNOVL4=8 9P]ML$::>H3PDN44B8-'8U:!5)_(JZKX5TJ)&05=K&5/H5A
M/=:/@.C!0-UCO(92.*K>--X@+:2D#%$U.)YD-Y8G5UX22;AC2N$2_(^HI5PB
M\:!$T1$4^_A5=)\*5+_RL?\.#<-4;P;!WSYZH:1(++Q</'Y8L(6L^M9G5M^
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MLKLV#P.#S'_"@+8&U/KM%K)>OF>&G1XKN2$*9P,:#FRHUAJ<$S46Y<HH>"O
MSIQ>&9G?'IY#7 5Y)RNHM68V7?O7;%9R?7 \,; ,3I[D+>2Y@Z1/0(;DHZS-
M4I.+NN#%8_L)N-?[2#L?S^E.P(],C4D8>(3Z--J!%_8QAQ8O?"KF)5.\C?F2
MW0/%##E3BM4+;L=_G<VT4<"7O[<%[["C[=BHH2.]8CD_&8%(-%=K/CI]\RI(
M_+<[/(]ZSZ-=Z*Y:0#K#1*FW.;?3?+MSUTMN*\_J^U\T =UJP^I"U O"OS7"
MW!.V8:K0!!X2C9G3I+4M"#0%,F],HS@16C>LSCEIH.J*"*.Q7+XUHWZ0D N'
M]@'FU*A$<EFR6K?O8>)%M2KE/>?$!7G9J'P));+3""S;]@WQ#ZP[PV9R1( 8
M^;)G!GG/<U[-8/'V28AQ5<!E;1';.%[@_(L<3[THC+THHC#RX\BCE/[L>@9*
M\'P.J)?%4U@T&HS</+E"R6H+"PNAY\,Z[C?UFFO3OG'#@_\2:NS1(/62("61
MER:^%R8)^0PP2N2(ZL)M:JSY<RX\6G?K<B3PIEG@)6D(H]3/O)3&Y%H:5G;T
MDW.2#Q/=9QB<C*:1%X![0>*%&?72*"4[=!?WNHN?U]WAS':,?- EMTEP)])V
M"3X%3_@=CCG9,.11+A>UI;^H+658GCO=8H;?2<AKC0A7AAG;R&RF/JVX8HX>
M6!14NN)+W%4AWW](#8\U4+,$0>DC<KU4P+YA__Y>9*VNM$%PS6"+(*])$,;P
M^^951@/Z%JG!K1$N6/ UB'5E&VO@14D,OT$2DBO8B,%OCRQX#1Z6=C(K8(L3
MV'PM'4)O&DP)5C'L&/!4IEX#26.8_!J-_&17T9.^Z,G.HM^PLG'@#$A=M1K#
MJ(>BVT:!G;A/=^$Y$XJL856.JRQ@0WI05R=Q9 ((2<!Y!&5F_4$N%'#?6Y%&
M(R7P^7G)(&%7^5)BI1S*X0J$BQ,J6?#2(RZ=TI'*40'?BGH%"GXQ)RZ J[8=
M&*XJL@\<O0<6Z .2C$' ]N>K/2.AWVLH^8(3)?3MX1SA!<0*R3!$82#1V,_(
M'ER@2>S]:+:6)12FQ-Z1!F-8>P^O4[B\%VL!,BC(O>!EX< Z6NX-1AWD80=I
M\W9HLS@H VCG4?Z17O'81YH%<-W96]*>9ND+]O06WQY2(:YMK/H)&%(TJF."
ML66L7!GYMC(BMX;-X,_&[J; JCY=@]'98J'X A/VH8:= !I*3FYLUO:# _)I
MT/P/M^S,#QL)I#(9)["+CN,0\PO]FV;DMY;]21AZ69;VB;^XXRH7R-?]:.J%
M@7_@ &A X)0^YP*-]@.:>B%-[+ML[%MR"@5O.@9TUX&;W:/ODO*P]UFL+ 1'
M(_1ZFG@TCCJ'\+#\! +UIBGUJ)\ZUL0!B"$*X":)O8PFY$N[-;;F/UC3"(X9
M@0\&-!S#(0.<P/5#WXL@49AL;!ZL+X?HR^%(+#3)69DW9=<R;+\0\SD(#L\@
M,VXVG#OU\S:]!%L$[YI+UWRP19L?&I5Y.$#:$-*W^O'^[+K4X[C&.Y23]<K)
M=E)^ZQ%DIX1VXFUOS+L7^?\%]IQP'LY$EO=AT$LE!D:FU%(C0<[?N#/?/C#/
M2X.L%4KP6"AP3O(3)Z(45?B\(!Z.9T!(.H8]=ULI)X-/THJKA?WP1EXTM7%?
MI_W3_MO^S'W2/DQW?PS ^@O@,RGY'$S]<0HG+.4^MMV-D2O[@3N3!CZ7[7#)
M&9PR<0*\GTMINAM<H/_'X_1?4$L#!!0    ( )"!J%AWRG]6Q@,  +,(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;(U6VV[C-A#]E8&V6,2 8MUL
MR\[:!I+M+EJ@NPV2M/M0](&6QA81BE1)*D[^OD-*T3JM[?;%YFW.G)DYY&BY
M5_K15(@6GFLAS2JHK&VNHL@4%=;,C%6#DG:V2M?,TE3O(M-H9*4WJD64QO$L
MJAF7P7KIUV[U>JE:*[C$6PVFK6NF7VY0J/TJ2(+7A3N^JZQ;B-;+ANWP'NUO
MS:VF632@E+Q&:;B2H'&["JZ3JYNI.^\/_,YQ;P[&X"+9*/7H)C^7JR!VA%!@
M81T"H[\G_(A".""B\5>/&0PNG>'A^!7]LX^=8MDP@Q^5^,9+6ZV">0 E;EDK
M[)W:_X1]/)Y@H83QO[#OSD[R (K66%7WQL2@YK+[9\]]'@X,YO$)@[0W2#WO
MSI%G^2.S;+W4:@_:G28T-_"A>FLBQZ4KRKW5M,O)SJZ_4MU_4<; +6JXKYA&
MN'A@&X%FM(PL.7#'HJ('N^G TA-@&7Q1TE8&/LD2R[?V$1$;V*6O[&[2LX!?
MF!Y#EH20QNGD#%XV1)MYO.P$WB>F)9>[PVC_N-X8JTD<?QZ+MX.;'(=S%^;*
M-*S 54 WPJ!^PF#]_ETRBS^<(3L9R$[.H?O27 BJS0BX+%2-T!!KXUB'3HG<
M ),EE%RT]I_9[MB?QW^H$+9*T+6DE(!U10>#UM"BMA58VB:O36N9OS]JZYT6
MATY!$D='\3NU*WBH-.(;)0#5L:B&0KJ?#+Z^FOX %]DTS+-DY(9I%DZ2Q0B^
M^?N$Y25[0DW/0X=N@!X68XD"<7[_;IXFZ8=_L[H@*(+,XCB<3:>0SL)\DH9O
MG Y\3X(0EV0<=Z3B\7P^\K#_@Y:KEFA+6B117&Y;GX$]TYI)2BXWIJ4Y);1+
MRK3+R?B,8*:#8*9G"_KK 8=&6926,R%>NHCH[:/J%JWFEJ,YII:SX,>U_E9"
MASEPF?P/#K!'NG_X[)-5PE:KNA,=$T4K!M&=EAILL&"M06?%-?":Z%EP^=8>
MR%*7,JU^ 7I%BT>HT5:J],SX]K)0DBKH@/OUO6I%"175E7"1^@51OQQHTYT
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M*%/V3=*V&K!S^4W*"\9A+8[@3/;PMTC/=L2M4?W'.QY5FD=/O>-CF;ME'+!
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M NKWA1#R^4MU@N85L.G_4$L#!!0    ( )"!J%@-=)OSK0(   D'   9
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M2M6#M]X8652S:R$-3L)JF>&_"I1UP.]+*<UV8\=A^_>+_P!02P,$%     @
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MPBC&5$X0SQ>$\-V-=-#\ZV#Z/U!+ P04    " "0@:A8@^TF=0D#   M"
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6RMEM]OVC 0Q_\5*ZNF5NH:
M\H, '41JJ:I-VE14VNUAVH-)#K#JV)GM0+N_?N<D9!0"Z\->2&S?]_RYR_G,
M<"W5DUX"&/*<<:%'SM*8_-)U=;*$C.H+F8/ E;E4&34X5 M7YPIH6HHR[OJ=
M3N1FE DG'I9S$Q4/96$X$S!11!=91M7+-7"Y'CF>LYFX9XNEL1-N/,SI J9@
M'O.)PI';>$E9!D(S*8B"^<BY\B['/6M?&GQCL-9;[\1&,I/RR0X^IR.G8X&
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MO(;LL, /!9#& -^OA-"[B;F+^D^/Z2]02P,$%     @ D(&H6+,:K!QD P
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M<VAE970T-"YX;6RM5FUOVC 0_BNG;)HZ:9 WWMI!)*"=M@_54*NU'Z9],.0
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MBPG2'C#OYT+HEX4UT#2MR6]02P,$%     @ D(&H6#AP4Q;U @  N0@  !D
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M*7Q;$*$-8'_)N=I.] '-UTKT&U!+ P04    " "0@:A8:,]6B#L#  !D#
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M0_CF?>#-ADQ7^=NE#ZF4:9Q_7#(Z8SP[0'T_3U.YW<@"E&]E3_\'4$L#!!0
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M7'VYY"S@6?D \?WG-"UV-\H$^XOF+?X/4$L#!!0    ( )"!J%CH=*8_6P@
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M#M4$5),HS4SJWGO\SBN3:JUOG52DQBKM,*DN'1R&LWG!L9'HPTC[T)7E4$U
M-8G2S!#2.H34&D(OGA7O,^5)C,AT&:2+YB1:D=9)1&H,JGF5MC\M</I'\U#H
MF!RJ":@F49H9S[I_Y%C?UV^(YP4)O[G?A+:1H!JKM,/=87]TM-^$-HF@&H=J
M JI)E&8&MNX4.?96D3>?J_*3(F?$%-HM@FH,JGF5=A!ZQ[D:'NY7H3TCJ"9.
M; 1UJ+D1$C6LF<"Z<^2T:1V1?\E]&D:*?#B50F@C":HQJ.9!-1^J<:@FH)I$
M:6:>ZX:2@^TH.="6$E1C4,V#:CY4XU!-0#6)TLQ UZTEQ]Y;N@VR,"/;3\$6
M[ZT^!6D8/*[4Z8D"LA=R!]58I1W-9_M'\UEHWPJJ<:@FH)I$:698Z^:58^]>
M6683^9WWP9<PVD2-H84VKJ :@VH>5/.A&H=J JI)E&8FN^YS.5?8>06TE075
M&%3SH)H/U3A4$U!-HC3S,_=UYXO:.U^MYQ5VKVVBH1JCC9TPQSF:5T"']:$:
MAVH"JDF49H:U;GY1>_/K:%YQ<,C+!?F8!O%TJ<CO<7-XH<TQJ,:@F@?5?*C&
MH9J :A*EF0FO.VN40N<7%-IC@VH,JGE0S8=J'*H)J"91FAGHNA='[;VX5WZ0
MT:ZWSC>T*P?5/*CF5YK1D3[^I!J'#BJ@FFS8!&IL@IG(NME&[<VV\R<1'Y^3
MQDQ"6W!0C4$U#ZKY4(U#-0'5)$HS$UXW\^@ .XF =O.@&H-J'E3SH1J':@*J
M291F!KKNYE%K<^75DPAH<P^J,:CF036_THSC9YLF$="N'523*,T,;MVUH_:N
M78NYQC)5S6]90/MX4(U!-0^J^5"-0S4!U21*,S->-_OH&#O;@/;XH!J#:AY4
M\Z$:AVH"JDF49@:Z[O%1^\%LKYUM0%M^4(U!-8\V'PUW^+EWZ* <J@FH)E&:
M>=JDNI?GVGMYY\\V_&23-F77/D#;[$(U!M4\J.9#-0[5!%23*,V,>-T!=!WH
M9,.%-OR@&H-J'E3SH1J':@*J291F!KIN^+GV0^E>.=FPZZWS#>W_037//3[&
MCC:<[ $Z*(=J JI)E&8&=^\DC?;&WK<G&WZ89IJ\R_?3LV)?_<V^BGW UEG&
MGLD1>RI'[+D<L2=SQ)[-$7LZQ__C,#VW[ARZ?>SD ]HHA&H,JGE0S8=J'*H)
MJ"91FAGHNE'HVH_Z Y^VQSY:Z[Q#^XA0S8-J/E3C4$U -5EI)\^?9.:X[@^Z
M]OZ@.1>Y( ^?;AOS">T#0C4&U3RHYD,U#M4$5),HS<QQW2YT1]@)!K0W"-48
M5/.@F@_5.%034$VB-#/0=6_0M1\(V.*,J.[QR1R=_ 7^P2E1SUJ*V=>J=?:@
M;3RHQJ&:@&H2I6VSU]V[,$JDTD5Y59TLGYEN8KV]1LKNT=V5>]Z5UZOIUHMO
M+_OS/D@789R1E9KGI;W+43XK2;=7TMG>T<FZO,S*8Z)U$I4WERJ8J;18(/_Y
M/$GTRYUB@-WUC";_ 5!+ P04    " "0@:A8DVXUZND"  #5!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U-BYX;6RM5=%NVC 4_14KJZ96VIJ00* =1*+0
M:GVH5)5V>YCV8)(+L>K8S+Z!=E\_VPD9A13M82^)[=QS<HY]?>]P(]6SS@&0
MO!1<Z)&7(ZXN?5^G.114G\L5"/-E(55!T4S5TM<K!31SH(+[81#$?D&9\)*A
M6[M7R5"6R)F >T5T6114O5X!EYN1U_&V"P]LF:-=\)/ABBYA!OBTNE=FYC<L
M&2M :"8%4; 8>>/.Y:1OXUW -P8;O3,FULE<RF<[N<U&7F % 8<4+0,UKS5,
M@'-+9&3\JCF]YI<6N#O>LM\X[\;+G&J82/Z=99B/O(%',EC0DN.#W'R%VD_/
M\J62:_<DFSHV\$A::I1%#38*"B:J-WVI]V$'8'C: 6$-"/<!W7< 40V(G-%*
MF;,UI4B3H9(;HFRT8;,#MS<.;=PP84]QALI\90:'R41!QI#<T)1QAJ]DO%0
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M%@9I O3[A1"X[9B#OKG7X[]02P,$%     @ D(&H6)FC%-6Z!   V!\  !D
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MSCG;(YZW5K3\H%"_B%9ZQ5G^HMQ)KN[&*DXN;VE")(W0#>'R!7WA)!.D2*%
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MQZ%C,^&XA/$2HXHA=DP;&8-K'F)FJFO?DVTO@GR89&)BRWSV_=YI'QT+8?Q
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MX\_+[Y.(\^*,<X(?9>Z_ %!+ P04    " "0@:A8%\C,&]L!  #1(@  $P
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M4$L! A0#%     @ D(&H6 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "0@:A8<ESA$N\    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" "0@:A8F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( )"!J%B;#3>I[@4  ,P?   8
M      " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" "0@:A8H.,B0C<&  !<&0  &               @($R#@  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ D(&H6&C>KL'L @  #@H  !@
M             ("!GQ0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( )"!J%@DLIRF-P8  "D=   8              " @<$7  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "0@:A8E$9+9;H&  !\
M+0  &               @($N'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ D(&H6-CQ85G[!P  MR(  !@              ("!'B4
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )"!J%B'()L2
M4 (  $L%   8              " @4\M  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " "0@:A8P[@->-@,  "N(0  &
M@('5+P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ D(&H
M6'6OA[ZO*   A84  !@              ("!XSP  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( )"!J%BJ^-UEYPH  ,8@   9
M      " @<AE  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ D(&H6&9B;<Q(!   M0D  !D              ("!YG   'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "0@:A8;O\*Y#('   &$P
M&0              @(%E=0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( )"!J%CX?;MOIP,   ((   9              " @<Y\  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ D(&H6+)RVCPP
M#   N"(  !D              ("!K(   'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " "0@:A8F>/#*6H*  "('0  &0
M@($3C0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )"!
MJ%@?U_N8\@@  !@7   9              " @;27  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ D(&H6+!?*1ZS!   > L  !D
M         ("!W:   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " "0@:A80DKX.#P%  #%"P  &0              @(''I0  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( )"!J%A1FSRB00(  )H%
M   9              " @3JK  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ D(&H6" OR8QN!   9Q(  !D              ("!LJT
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "0@:A837_Y
MS$\U   _N0  &0              @(%7L@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( )"!J%B),7]**0,  &P'   9
M  " @=WG  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
MD(&H6/)1ME@5!@  61,  !D              ("!/>L  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " "0@:A8OLXJ=.<#  #)"0  &0
M            @(&)\0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( )"!J%C0Q1E)1@8  /T0   9              " @:?U  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ D(&H6'?*?U;& P
MLP@  !D              ("!)/P  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " "0@:A8>[HG%G\#  ")"   &0              @($A
M  $ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( )"!J%@Y
M0?^GF@,  *T(   9              " @=<# 0!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ D(&H6)C 0!%9!P  *$   !D
M     ("!J <! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )"!J%C9Y2U;,0@  /9,   9              "
M@3$> 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ D(&H
M6!H?6@A[!P  \$0  !D              ("!F28! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " "0@:A8,W"W5T,#  !4"@  &0
M        @(%++@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( )"!J%@7)#'L40<   XV   9              " @<4Q 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ D(&H6 UTF_.M @  "0<
M !D              ("!33D! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " "0@:A890]V$$L$  !&&   &0              @($Q/ $
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( )"!J%B#[29U
M"0,  "T(   9              " @;-  0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ D(&H6+^H-YFM!   ,QH  !D
M ("!\T,! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "0
M@:A85!31?Q8#  "&"   &0              @('72 $ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( )"!J%BS&JP<9 ,  %H.   9
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M970T-RYX;6Q02P$"% ,4    " "0@:A8:,]6B#L#  !D#   &0
M    @(%)7P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M )"!J%BP5]<U5@,  )T*   9              " @;MB 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ D(&H6-K;'LZD @  #P<  !D
M             ("!2&8! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " "0@:A86T.#1YD#   7#@  &0              @($C:0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( )"!J%A5UA)OEP8
M *$]   9              " @?-L 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ D(&H6!GJO-(A @  :00  !D              ("!
MP7,! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " "0@:A8
MBW8#;"D)  ! ;P  &0              @($9=@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( )"!J%CH=*8_6P@  -MH   9
M      " @7E_ 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ D(&H6)-N->KI @  U0<  !D              ("!"X@! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "0@:A8*%P5!-0"  #C!P
M&0              @($KBP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( )"!J%B9HQ35N@0  -@?   9              " @3:. 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ D(&H6+:5P<]S
M!@   4(  !D              ("!)Y,! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " "0@:A8\__]S4T#  "P%0  #0
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:+GAM;%!+!08     0P!# $P2  !(IP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>191</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>75</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Description of Business and Presentation of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements</Role>
      <ShortName>Description of Business and Presentation of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Balance Sheet Account Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetail</Role>
      <ShortName>Balance Sheet Account Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitment &amp; Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingencies</Role>
      <ShortName>Commitment &amp; Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Out-License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/OutLicenseAgreements</Role>
      <ShortName>Out-License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Credit Facility Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreement</Role>
      <ShortName>Credit Facility Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Balance Sheet Account Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailTables</Role>
      <ShortName>Balance Sheet Account Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/BalanceSheetAccountDetail</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/NetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Commitment &amp; Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesTables</Role>
      <ShortName>Commitment &amp; Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/CommitmentContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Credit Facility Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementTables</Role>
      <ShortName>Credit Facility Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/CreditFacilityAgreement</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Description of Business and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails</Role>
      <ShortName>Description of Business and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Product Sales from Each of our Largest Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates - Product Sales from Each of our Largest Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails</Role>
      <ShortName>Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Balance Sheet Account Detail - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails</Role>
      <ShortName>Balance Sheet Account Detail - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails</Role>
      <ShortName>Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Stock-Based Compensation - Shares Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails</Role>
      <ShortName>Stock-Based Compensation - Shares Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/NetLossPerShareTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Commitment &amp; Contingencies - Lease Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Lease Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Commitment &amp; Contingencies - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Commitment &amp; Contingencies - Summary of Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Summary of Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails</Role>
      <ShortName>Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Commitment &amp; Contingencies - Employment Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Employment Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Out-License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/OutLicenseAgreementsDetails</Role>
      <ShortName>Out-License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/OutLicenseAgreements</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Credit Facility Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementDetails</Role>
      <ShortName>Credit Facility Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/CreditFacilityAgreementTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails</Role>
      <ShortName>Credit Facility Agreement - Summary of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails</Role>
      <ShortName>Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="tars-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SubsequentEvent</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtSecuritiesAvailableForSaleTerm, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 -  tars-20240331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="tars-20240331.htm">tars-20240331.htm</File>
    <File>tars-20240331.xsd</File>
    <File>tars-20240331_cal.xml</File>
    <File>tars-20240331_def.xml</File>
    <File>tars-20240331_lab.xml</File>
    <File>tars-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="617">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tars-20240331.htm": {
   "nsprefix": "tars",
   "nsuri": "http://tarsusrx.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "tars-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "tars-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "tars-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tars-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tars-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tars-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 299,
   "keyCustom": 41,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 37,
   "memberCustom": 36,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2023": 3,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 191,
   "entityCount": 1,
   "segmentCount": 75,
   "elementCount": 608,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 617,
    "http://xbrl.sec.gov/dei/2023": 30,
    "http://xbrl.sec.gov/ecd/2023": 15
   },
   "report": {
    "R1": {
     "role": "http://tarsusrx.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://tarsusrx.com/role/CondensedBalanceSheets",
     "longName": "0000002 - Statement - Condensed Balance Sheets",
     "shortName": "Condensed Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
     "longName": "0000003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "longName": "0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostsAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity",
     "longName": "0000005 - Statement - Condensed Statements of Stockholders' Equity",
     "shortName": "Condensed Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
     "longName": "0000006 - Statement - Condensed Statements of Cash Flows",
     "shortName": "Condensed Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquityParenthetical",
     "longName": "0000007 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Condensed Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements",
     "longName": "0000008 - Disclosure - Description of Business and Presentation of Financial Statements",
     "shortName": "Description of Business and Presentation of Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://tarsusrx.com/role/FairValueMeasurements",
     "longName": "0000010 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetail",
     "longName": "0000011 - Disclosure - Balance Sheet Account Detail",
     "shortName": "Balance Sheet Account Detail",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://tarsusrx.com/role/StockBasedCompensation",
     "longName": "0000012 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://tarsusrx.com/role/NetLossPerShare",
     "longName": "0000013 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://tarsusrx.com/role/CommitmentContingencies",
     "longName": "0000014 - Disclosure - Commitment & Contingencies",
     "shortName": "Commitment & Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://tarsusrx.com/role/OutLicenseAgreements",
     "longName": "0000015 - Disclosure - Out-License Agreements",
     "shortName": "Out-License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://tarsusrx.com/role/CreditFacilityAgreement",
     "longName": "0000016 - Disclosure - Credit Facility Agreement",
     "shortName": "Credit Facility Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://tarsusrx.com/role/RelatedPartyTransactions",
     "longName": "0000017 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://tarsusrx.com/role/SubsequentEvent",
     "longName": "0000018 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Tables)",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://tarsusrx.com/role/FairValueMeasurementsTables",
     "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailTables",
     "longName": "9954474 - Disclosure - Balance Sheet Account Detail (Tables)",
     "shortName": "Balance Sheet Account Detail (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://tarsusrx.com/role/StockBasedCompensationTables",
     "longName": "9954475 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://tarsusrx.com/role/NetLossPerShareTables",
     "longName": "9954476 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://tarsusrx.com/role/CommitmentContingenciesTables",
     "longName": "9954477 - Disclosure - Commitment & Contingencies (Tables)",
     "shortName": "Commitment & Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementTables",
     "longName": "9954478 - Disclosure - Credit Facility Agreement (Tables)",
     "shortName": "Credit Facility Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
     "longName": "9954479 - Disclosure - Description of Business and Presentation of Financial Statements (Details)",
     "shortName": "Description of Business and Presentation of Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails",
     "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details)",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates - Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails",
     "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details)",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates - Expected Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
     "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details)",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails",
     "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Product Sales from Each of our Largest Customers (Details)",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates - Product Sales from Each of our Largest Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails",
     "longName": "9954484 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "tars:EquityWarrantsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "longName": "9954485 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-96",
      "name": "tars:WarrantAgreementNumberOfTranches",
      "unitRef": "tranche",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "tars:WarrantAgreementNumberOfTranches",
      "unitRef": "tranche",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails",
     "longName": "9954486 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)",
     "shortName": "Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
     "longName": "9954487 - Disclosure - Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)",
     "shortName": "Fair Value Measurements - Estimated Value of Cash, Cash Equivalents, Marketable Securities, and Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails",
     "longName": "9954488 - Disclosure - Balance Sheet Account Detail - Inventories (Details)",
     "shortName": "Balance Sheet Account Detail - Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
     "longName": "9954489 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)",
     "shortName": "Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails",
     "longName": "9954490 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
     "longName": "9954491 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "tars:CommonStockNumberOfVotes",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails",
     "longName": "9954492 - Disclosure - Stock-Based Compensation - Shares Reserved for Issuance (Details)",
     "shortName": "Stock-Based Compensation - Shares Reserved for Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails",
     "longName": "9954493 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-115",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails",
     "longName": "9954494 - Disclosure - Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Valuation Assumptions of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails",
     "longName": "9954495 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
     "longName": "9954496 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "shortName": "Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://tarsusrx.com/role/NetLossPerShareDetails",
     "longName": "9954497 - Disclosure - Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails",
     "longName": "9954498 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)",
     "shortName": "Net Loss Per Share - Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails",
     "longName": "9954499 - Disclosure - Commitment & Contingencies - Lease Agreements (Details)",
     "shortName": "Commitment & Contingencies - Lease Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-131",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-131",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails",
     "longName": "9954500 - Disclosure - Commitment & Contingencies - Lease Cost (Details)",
     "shortName": "Commitment & Contingencies - Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails",
     "longName": "9954501 - Disclosure - Commitment & Contingencies - Summary of Minimum Lease Payments (Details)",
     "shortName": "Commitment & Contingencies - Summary of Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
     "longName": "9954502 - Disclosure - Commitment & Contingencies - In-License Agreement for Lotilaner (Details)",
     "shortName": "Commitment & Contingencies - In-License Agreement for Lotilaner (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "tars:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
     "longName": "9954503 - Disclosure - Commitment & Contingencies - Employment Arrangements (Details)",
     "shortName": "Commitment & Contingencies - Employment Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "tars:NumberOfEmploymentArrangementsWithExecutiveOfficers",
      "unitRef": "contract",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "tars:NumberOfEmploymentArrangementsWithExecutiveOfficers",
      "unitRef": "contract",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://tarsusrx.com/role/OutLicenseAgreementsDetails",
     "longName": "9954504 - Disclosure - Out-License Agreements (Details)",
     "shortName": "Out-License Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-143",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
     "longName": "9954505 - Disclosure - Credit Facility Agreement (Details)",
     "shortName": "Credit Facility Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "tars:LineOfCreditFacilityDrawDownIncrements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails",
     "longName": "9954506 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details)",
     "shortName": "Credit Facility Agreement - Summary of Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails",
     "longName": "9954507 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)",
     "shortName": "Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://tarsusrx.com/role/RelatedPartyTransactionsDetails",
     "longName": "9954508 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "tars:RelatedPartyTransactionAnnualCashCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://tarsusrx.com/role/SubsequentEventDetails",
     "longName": "9954509 - Disclosure - Subsequent Event (Details)",
     "shortName": "Subsequent Event (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-158",
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:ProceedsFromLinesOfCredit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-181",
      "name": "us-gaap:ProceedsFromRepaymentsOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tars-20240331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "tars_A2023ATMProspectusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "A2023ATMProspectusMember",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 ATM Prospectus",
        "label": "2023 ATM Prospectus [Member]",
        "documentation": "2023 ATM Prospectus"
       }
      }
     },
     "auth_ref": []
    },
    "tars_A2023ShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "A2023ShelfRegistrationStatementMember",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Shelf Registration Statement",
        "label": "2023 Shelf Registration Statement [Member]",
        "documentation": "2023 Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and other accrued liabilities",
        "totalLabel": "Accounts payable and other accrued liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payable and other",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net amortization/accretion on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "tars_AccruedClinicalStudiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "AccruedClinicalStudiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical studies",
        "label": "Accrued Clinical Studies, Current",
        "documentation": "Accrued Clinical Studies, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalesCommissionCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued product sales deductions",
        "label": "Accrued Sales Commission, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r655"
     ]
    },
    "us-gaap_AccumulatedAmortizationDeferredFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedAmortizationDeferredFinanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization of debt issuance costs",
        "label": "Accumulated Amortization, Debt Issuance Costs",
        "documentation": "Amount of accumulated amortization of debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Less): Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r166",
      "r549"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r106",
      "r171",
      "r545",
      "r568",
      "r569"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r34",
      "r440",
      "r443",
      "r475",
      "r564",
      "r565",
      "r789",
      "r790",
      "r791",
      "r796",
      "r797",
      "r798"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r685",
      "r875"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r578",
      "r796",
      "r797",
      "r798",
      "r851",
      "r878"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r379"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of pre-funded warrants, net of issuance costs of $0.6 million",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r59",
      "r133"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r718",
      "r728",
      "r753"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r756"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r722",
      "r732",
      "r749",
      "r757",
      "r761",
      "r769"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r423"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of end of term charge",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r81",
      "r114",
      "r349"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r349",
      "r463",
      "r793"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of term loan-related costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r463",
      "r674",
      "r675",
      "r793"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r52",
      "r55"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of net income (loss) per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r168",
      "r203",
      "r235",
      "r247",
      "r251",
      "r293",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r435",
      "r437",
      "r453",
      "r541",
      "r602",
      "r685",
      "r698",
      "r815",
      "r816",
      "r859"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "terseLabel": "Assets:",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r175",
      "r203",
      "r293",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r435",
      "r437",
      "r453",
      "r685",
      "r815",
      "r816",
      "r859"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "totalLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r301",
      "r540"
     ]
    },
    "tars_AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months",
        "label": "Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months [Member]",
        "documentation": "Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities:",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r301",
      "r533",
      "r802"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "tars_BobakAzamianMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "BobakAzamianMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bobak Azamian [Member]",
        "documentation": "Bobak Azamian"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Presentation of Financial Statements",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r121",
      "r122"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents:",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r163",
      "r652"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents \u2014 beginning of period",
        "periodEndLabel": "Cash and cash equivalents \u2014 end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r118",
      "r200"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r118"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per warrant (usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in warrant conversion (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "tars_ClassOfWarrantOrRightPaymentsOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ClassOfWarrantOrRightPaymentsOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs, warrants",
        "label": "Class of Warrant or Right, Payments of Issuance Costs",
        "documentation": "Class of Warrant or Right, Payments of Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "tars_ClassOfWarrantOrRightReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ClassOfWarrantOrRightReservedForFutureIssuance",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants reserved for future issuance (shares)",
        "label": "Class of Warrant Or Right, Reserved for Future Issuance",
        "documentation": "Class of Warrant Or Right, Reserved for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "tars_ClassOfWarrantOrRightSalePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ClassOfWarrantOrRightSalePrice",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per warrant (usd per share)",
        "label": "Class of Warrant or Right, Sale Price",
        "documentation": "Class of Warrant or Right, Sale Price"
       }
      }
     },
     "auth_ref": []
    },
    "tars_ClinicalMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ClinicalMilestonesMember",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical milestones",
        "label": "Clinical Milestones [Member]",
        "documentation": "Clinical Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Out-License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r150",
      "r157"
     ]
    },
    "tars_CollaborativeArrangementFutureCashPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CollaborativeArrangementFutureCashPayments",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future cash payments",
        "label": "Collaborative Arrangement, Future Cash Payments",
        "documentation": "Collaborative Arrangement, Future Cash Payments"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CollaborativeArrangementMaximumMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CollaborativeArrangementMaximumMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum milestone payments",
        "label": "Collaborative Arrangement, Maximum Milestone Payment",
        "documentation": "Collaborative Arrangement, Maximum Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CollaborativeArrangementRightsAndObligationsContractualMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsContractualMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual milestone payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "tars_CommercialAndSalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CommercialAndSalesMilestonesMember",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial and sales milestones",
        "label": "Commercial And Sales Milestones [Member]",
        "documentation": "Commercial And Sales Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r692",
      "r693",
      "r694",
      "r695"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r88",
      "r542",
      "r589"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment &amp; Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r312",
      "r313",
      "r647",
      "r812"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "calculation": {
      "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shares of common stock reserved (shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant",
     "calculation": {
      "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant",
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant",
     "calculation": {
      "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options reserved for future grant (shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant",
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding",
     "calculation": {
      "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options issued and outstanding (shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding",
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan",
     "calculation": {
      "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationSharesReservedforIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan",
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Special cash dividend (usd per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "tars_CommonStockInLianBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CommonStockInLianBioMember",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock in LianBio",
        "label": "Common Stock In LianBio [Member]",
        "documentation": "Common Stock In LianBio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r689",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r796",
      "r797",
      "r851",
      "r873",
      "r878"
     ]
    },
    "tars_CommonStockNumberOfVotes": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CommonStockNumberOfVotes",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock votes",
        "label": "Common Stock, Number Of Votes",
        "documentation": "Common Stock, Number Of Votes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, authorized (shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r590"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity",
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding (shares)",
        "periodStartLabel": "Beginning balance (shares)",
        "periodEndLabel": "Ending balance (shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r97",
      "r590",
      "r608",
      "r878",
      "r879"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 37,749,468 shares issued and outstanding at March\u00a031, 2024 (unaudited); 34,211,190 shares issued and outstanding at December\u00a031, 2023",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r544",
      "r685"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r181",
      "r183",
      "r191",
      "r535",
      "r554"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46",
      "r79",
      "r80",
      "r255",
      "r646"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46",
      "r79",
      "r80",
      "r255",
      "r570",
      "r646"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46",
      "r79",
      "r80",
      "r255",
      "r646",
      "r777"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r152"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46",
      "r79",
      "r80",
      "r255"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r46",
      "r47",
      "r79",
      "r136",
      "r646"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46",
      "r79",
      "r80",
      "r255",
      "r646"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r367"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r681",
      "r872"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r519"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Sales",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r331",
      "r359",
      "r482",
      "r659",
      "r661"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "tars_CreditFacilityFirstAmendmentTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CreditFacilityFirstAmendmentTrancheTwoMember",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility, First Amendment, Tranche Two",
        "label": "Credit Facility, First Amendment, Tranche Two [Member]",
        "documentation": "Credit Facility, First Amendment, Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CreditFacilityTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CreditFacilityTrancheFourMember",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility, Tranche Four",
        "label": "Credit Facility, Tranche Four [Member]",
        "documentation": "Credit Facility, Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CreditFacilityTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CreditFacilityTrancheOneMember",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility, Tranche One",
        "label": "Credit Facility, Tranche One [Member]",
        "documentation": "Credit Facility, Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CreditFacilityTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CreditFacilityTrancheThreeMember",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility, Tranche Three",
        "label": "Credit Facility, Tranche Three [Member]",
        "documentation": "Credit Facility, Tranche Three"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CreditFacilityTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CreditFacilityTrancheTwoMember",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility, Tranche Two",
        "label": "Credit Facility, Tranche Two [Member]",
        "documentation": "Credit Facility, Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "tars_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CustomerAMember",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer A",
        "label": "Customer A [Member]",
        "documentation": "Customer A"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CustomerBMember",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer B",
        "label": "Customer B [Member]",
        "documentation": "Customer B"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CustomerCMember",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer C",
        "label": "Customer C [Member]",
        "documentation": "Customer C"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r255"
     ]
    },
    "tars_CustomerDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CustomerDMember",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer D",
        "label": "Customer D [Member]",
        "documentation": "Customer D"
       }
      }
     },
     "auth_ref": []
    },
    "tars_CustomerEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "CustomerEMember",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer E",
        "label": "Customer E [Member]",
        "documentation": "Customer E"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility Agreement",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r202",
      "r327",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r343",
      "r350",
      "r351",
      "r353"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r94",
      "r95",
      "r138",
      "r139",
      "r208",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r464",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r794"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails",
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal outstanding",
        "verboseLabel": "Term loan, gross",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r139",
      "r354"
     ]
    },
    "tars_DebtInstrumentFloorInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "DebtInstrumentFloorInterestRate",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate floor",
        "label": "Debt Instrument, Floor Interest Rate",
        "documentation": "Debt Instrument, Floor Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r82",
      "r356",
      "r464"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r329"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r464",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r794"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r208",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r464",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r794"
     ]
    },
    "tars_DebtInstrumentNumberOfPotentialAdditionalTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "DebtInstrumentNumberOfPotentialAdditionalTranches",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential additional tranches",
        "label": "Debt Instrument, Number Of Potential Additional Tranches",
        "documentation": "Debt Instrument, Number Of Potential Additional Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "tars_DebtInstrumentNumberOfTranchesWithMilestoneRequirements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "DebtInstrumentNumberOfTranchesWithMilestoneRequirements",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranches with minimum net sales milestones",
        "label": "Debt Instrument, Number Of Tranches With Milestone Requirements",
        "documentation": "Debt Instrument, Number Of Tranches With Milestone Requirements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r63",
      "r66",
      "r81",
      "r82",
      "r85",
      "r90",
      "r131",
      "r132",
      "r208",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r464",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r794"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accretion of end of term charge",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "documentation": "Amount, after accumulated amortization, of debt discount (premium)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r818"
     ]
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "tars_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available for sale and cash and cash equivalents",
        "label": "Debt Securities, Available-For-Sale And Cash And Cash Equivalents",
        "documentation": "Debt Securities, Available-For-Sale And Cash And Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of available-for-sale debt securities in gross unrealized loss position for less than one year",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "tars_DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities with contractual maturity between one and five years",
        "label": "Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities",
        "documentation": "Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual maturity",
        "label": "Debt Securities, Available-for-Sale, Term",
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "tars_DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs included within accounts payable and accrued liabilities",
        "label": "Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities",
        "documentation": "Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r56"
     ]
    },
    "tars_DevelopmentAndRegulatoryMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "DevelopmentAndRegulatoryMilestoneMember",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and Regulatory Milestone",
        "label": "Development And Regulatory Milestone [Member]",
        "documentation": "Development And Regulatory Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r874"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r381",
      "r412",
      "r413",
      "r415",
      "r683"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Special cash dividends paid",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r223",
      "r225",
      "r227",
      "r228",
      "r229",
      "r233",
      "r447",
      "r448",
      "r536",
      "r555",
      "r665"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic [Abstract]",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r225",
      "r227",
      "r228",
      "r229",
      "r233",
      "r447",
      "r448",
      "r536",
      "r555",
      "r665"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r230",
      "r231",
      "r232"
     ]
    },
    "tars_ElancoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ElancoMember",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elanco",
        "label": "Elanco [Member]",
        "documentation": "Elanco"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of equity warrants issued by licensee",
        "negatedTerseLabel": "Change in fair value of equity warrants issued by licensee",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, weighted average period of recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails",
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options, unexercised\u2014vested and unvested",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Smaller Reporting Company",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r158",
      "r185",
      "r186",
      "r187",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r221",
      "r234",
      "r294",
      "r295",
      "r362",
      "r416",
      "r417",
      "r418",
      "r432",
      "r433",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r475",
      "r564",
      "r565",
      "r566",
      "r578",
      "r634"
     ]
    },
    "tars_EquityIncentivePlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "EquityIncentivePlan2016Member",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Plan",
        "label": "Equity Incentive Plan 2016 [Member]",
        "documentation": "Equity Incentive Plan 2016"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFVNIAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFVNIAbstract",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments:",
        "label": "Equity Securities, FV-NI [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tars_EquitySecuritiesFVNINumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "EquitySecuritiesFVNINumberOfShares",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities (in shares)",
        "label": "Equity Securities, FV-NI, Number Of Shares",
        "documentation": "Equity Securities, FV-NI, Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock in LianBio",
        "terseLabel": "Estimated fair value",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r452",
      "r539"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on equity investments",
        "negatedTerseLabel": "Unrealized loss on equity investments",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r808"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized losses",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "tars_EquityWarrantsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "EquityWarrantsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity warrants (for LianBio shares)",
        "label": "Equity Warrants, Fair Value Disclosure",
        "documentation": "Equity Warrants, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r718",
      "r728",
      "r753"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r715",
      "r725",
      "r750"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value of equity warrants",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r76"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r78"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments measured at fair value",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r450",
      "r490",
      "r491",
      "r492",
      "r672",
      "r673",
      "r679",
      "r680",
      "r681"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a01",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r369",
      "r374",
      "r450",
      "r490",
      "r679",
      "r680",
      "r681"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r369",
      "r374",
      "r450",
      "r491",
      "r672",
      "r673",
      "r679",
      "r680",
      "r681"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r450",
      "r492",
      "r672",
      "r673",
      "r679",
      "r680",
      "r681"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of equity warrants prior to termination",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Termination of equity warrants",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, beginning of period",
        "periodEndLabel": "Fair value, end of period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r490",
      "r491",
      "r492",
      "r672",
      "r673",
      "r679",
      "r680",
      "r681"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r352",
      "r360",
      "r445",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r553",
      "r670",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r804",
      "r805",
      "r806",
      "r807"
     ]
    },
    "tars_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remaining nine months)",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future amortization",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r520"
     ]
    },
    "tars_FiveCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "FiveCustomersMember",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Five Customers",
        "label": "Five Customers [Member]",
        "documentation": "Five Customers"
       }
      }
     },
     "auth_ref": []
    },
    "tars_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Follow-On Public Offering",
        "label": "Follow-On Public Offering [Member]",
        "documentation": "Follow-On Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized gain from transactions denominated in a foreign currency",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r610",
      "r696",
      "r854",
      "r855",
      "r877"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r732",
      "r757"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r732",
      "r757"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r732",
      "r757"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r732",
      "r757"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r732",
      "r757"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r613"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "tars_GrandpharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "GrandpharmaMember",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grandpharma",
        "label": "Grandpharma [Member]",
        "documentation": "Grandpharma"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairments of intangible assets",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r15"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r618"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r618"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r572"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and other accrued liabilities",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r722",
      "r732",
      "r749",
      "r757",
      "r761",
      "r769"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r773"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r773"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r773"
     ]
    },
    "tars_IntangibleAssetsMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "IntangibleAssetsMilestonePaymentMember",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Milestone Payment",
        "label": "Intangible Assets, Milestone Payment [Member]",
        "documentation": "Intangible Assets, Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r142",
      "r188",
      "r238",
      "r462",
      "r619",
      "r696",
      "r876"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense related to term loan",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r347",
      "r357",
      "r674",
      "r675"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense for term loan",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r348",
      "r674",
      "r675"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Interest Expense",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense paid in cash",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r198",
      "r199"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r656"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r653",
      "r685"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r162",
      "r172",
      "r305",
      "r306",
      "r307",
      "r518",
      "r662"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r658"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r657"
     ]
    },
    "tars_JoseTrevejoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "JoseTrevejoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jose Trevejo [Member]",
        "documentation": "Jose Trevejo"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease expense",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r684"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of lease cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future contractual lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future lease payments, undiscounted",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remaining nine months)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "tars_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Less): Tenant improvement allowance",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance",
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Less): Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "tars_LesseeOperatingLeaseNumberOfLeaseContracts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "LesseeOperatingLeaseNumberOfLeaseContracts",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of leases",
        "label": "Lessee, Operating Lease, Number Of Lease Contracts",
        "documentation": "Lessee, Operating Lease, Number Of Lease Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r203",
      "r293",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r436",
      "r437",
      "r438",
      "r453",
      "r588",
      "r666",
      "r698",
      "r815",
      "r859",
      "r860"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r140",
      "r547",
      "r685",
      "r795",
      "r809",
      "r853"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r161",
      "r203",
      "r293",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r436",
      "r437",
      "r438",
      "r453",
      "r685",
      "r815",
      "r859",
      "r860"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tars_LianBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "LianBioMember",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LianBio",
        "label": "LianBio [Member]",
        "documentation": "LianBio"
       }
      }
     },
     "auth_ref": []
    },
    "tars_LicenseAndCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "LicenseAndCollaborationMember",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fees and Collaboration",
        "label": "License And Collaboration [Member]",
        "documentation": "License And Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "tars_LicenseAndCollaborationOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "LicenseAndCollaborationOtherMember",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License And Collaboration, Other",
        "label": "License And Collaboration, Other [Member]",
        "documentation": "License And Collaboration, Other"
       }
      }
     },
     "auth_ref": []
    },
    "tars_LineOfCreditFacilityDrawDownIncrements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "LineOfCreditFacilityDrawDownIncrements",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increments to draw on credit facility at company's election",
        "label": "Line of Credit Facility, Draw Down Increments",
        "documentation": "Line of Credit Facility, Draw Down Increments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility, aggregate principal amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_LineOfCreditFacilityPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "End of term charge",
        "label": "Line of Credit Facility, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payment applied to interest."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "tars_LineOfCreditFacilityPeriodicPaymentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "LineOfCreditFacilityPeriodicPaymentInterestRate",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "End of term charge, interest rate",
        "label": "Line of Credit Facility, Periodic Payment, Interest Rate",
        "documentation": "Line of Credit Facility, Periodic Payment, Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "tars_LineOfCreditSVBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "LineOfCreditSVBMember",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit, SVB",
        "label": "Line of Credit, SVB [Member]",
        "documentation": "Line of Credit, SVB"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongLivedAssetsHeldForSaleByAssetTypeAxis",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets Held-for-Sale by Asset Type [Axis]",
        "label": "Long-Lived Assets Held-for-Sale by Asset Type [Axis]",
        "documentation": "Represents the assets held for sale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_LongLivedAssetsHeldForSaleNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongLivedAssetsHeldForSaleNameDomain",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets Held-for-Sale, Name [Domain]",
        "label": "Long-Lived Assets Held-for-Sale, Name [Domain]",
        "documentation": "A name of the assets to be disposed."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Term loan, net",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r139",
      "r340",
      "r355",
      "r672",
      "r673",
      "r869"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, net",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r58"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r678",
      "r819",
      "r870",
      "r871"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities and Long-Term Investments",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r376",
      "r517",
      "r563",
      "r580",
      "r581",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r648",
      "r649",
      "r669",
      "r676",
      "r682",
      "r687",
      "r817",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "tars_MilestoneDeterminedByTheCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "MilestoneDeterminedByTheCompanyMember",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Determined by the Company",
        "label": "Milestone Determined by the Company [Member]",
        "documentation": "Milestone Determined by the Company"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r376",
      "r517",
      "r563",
      "r580",
      "r581",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r648",
      "r649",
      "r669",
      "r676",
      "r682",
      "r687",
      "r817",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r678",
      "r819",
      "r870",
      "r871"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows From Financing Activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows From Investing Activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows From Operating Activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity",
      "http://tarsusrx.com/role/NetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income",
        "terseLabel": "Net loss",
        "netLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r120",
      "r141",
      "r159",
      "r179",
      "r182",
      "r187",
      "r203",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r226",
      "r235",
      "r246",
      "r250",
      "r252",
      "r293",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r448",
      "r453",
      "r551",
      "r611",
      "r632",
      "r633",
      "r667",
      "r696",
      "r815"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued or Effective Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r732",
      "r749",
      "r757"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosures Noncash Investing and Financing Activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tars_NumberOfEmploymentArrangementsWithExecutiveOfficers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "NumberOfEmploymentArrangementsWithExecutiveOfficers",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employment arrangements with executive officers",
        "label": "Number Of Employment Arrangements With Executive Officers",
        "documentation": "Number Of Employment Arrangements With Executive Officers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "tars_NumberOfVestedWarrants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "NumberOfVestedWarrants",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of vested warrants",
        "label": "Number Of Vested Warrants",
        "documentation": "Number Of Vested Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations before other income (expense)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r246",
      "r250",
      "r252",
      "r667"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r684"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease liability",
        "totalLabel": "Total operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails",
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "tars_OperatingLeaseNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "OperatingLeaseNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Noncash Expense",
        "documentation": "Operating Lease, Noncash Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated incremental borrowing rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r684"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r684"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain on marketable securities and cash equivalents",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r16",
      "r180",
      "r183",
      "r190",
      "r454",
      "r455",
      "r460",
      "r534",
      "r552",
      "r789",
      "r790"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherMachineryAndEquipmentMember",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Other Machinery and Equipment [Member]",
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r755"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r723",
      "r733",
      "r758"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r723",
      "r733",
      "r758"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriters' option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r193",
      "r261"
     ]
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock purchased",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r196"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "tars_PharmakonCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "PharmakonCreditFacilityMember",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmakon Credit Facility",
        "label": "Pharmakon Credit Facility [Member]",
        "documentation": "Pharmakon Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "tars_PharmakonCreditFacilityTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "PharmakonCreditFacilityTrancheFourMember",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmakon Credit Facility, Tranche Four",
        "label": "Pharmakon Credit Facility, Tranche Four [Member]",
        "documentation": "Pharmakon Credit Facility, Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "tars_PharmakonCreditFacilityTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "PharmakonCreditFacilityTrancheOneMember",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmakon Credit Facility, Tranche One",
        "label": "Pharmakon Credit Facility, Tranche One [Member]",
        "documentation": "Pharmakon Credit Facility, Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "tars_PharmakonCreditFacilityTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "PharmakonCreditFacilityTrancheThreeMember",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmakon Credit Facility, Tranche Three",
        "label": "Pharmakon Credit Facility, Tranche Three [Member]",
        "documentation": "Pharmakon Credit Facility, Tranche Three"
       }
      }
     },
     "auth_ref": []
    },
    "tars_PharmakonCreditFacilityTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "PharmakonCreditFacilityTrancheTwoMember",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmakon Credit Facility, Tranche Two",
        "label": "Pharmakon Credit Facility, Tranche Two [Member]",
        "documentation": "Pharmakon Credit Facility, Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized (shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r590"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding (shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r590",
      "r608",
      "r878",
      "r879"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r543",
      "r685"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r308",
      "r309",
      "r654"
     ]
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime Rate",
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "tars_ProceedsFromCancellationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ProceedsFromCancellationOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant cancellation payment",
        "label": "Proceeds From Cancellation Of Warrants",
        "documentation": "Proceeds From Cancellation Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net of paid issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from term loan",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r573"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of equity awards",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of pre-funded warrants, net of paid issuance costs",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Draw on credit facility",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r794"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r803"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Proceeds from (Repayments of) Debt",
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r519",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r651",
      "r677",
      "r686",
      "r778",
      "r813",
      "r814",
      "r819",
      "r870"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r519",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r651",
      "r677",
      "r686",
      "r778",
      "r813",
      "r814",
      "r819",
      "r870"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, at cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r165",
      "r550"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r538",
      "r550",
      "r685"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r153",
      "r156",
      "r548"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful lives of assets",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r368",
      "r376",
      "r407",
      "r408",
      "r409",
      "r493",
      "r517",
      "r563",
      "r580",
      "r581",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r648",
      "r649",
      "r669",
      "r676",
      "r682",
      "r687",
      "r690",
      "r811",
      "r817",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r368",
      "r376",
      "r407",
      "r408",
      "r409",
      "r493",
      "r517",
      "r563",
      "r580",
      "r581",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r648",
      "r649",
      "r669",
      "r676",
      "r682",
      "r687",
      "r690",
      "r811",
      "r817",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r715",
      "r725",
      "r750"
     ]
    },
    "tars_RelatedPartTransactionTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "RelatedPartTransactionTerminationNoticePeriod",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction, termination notice, period",
        "label": "Related Part Transaction, Termination Notice, Period",
        "documentation": "Related Part Transaction, Termination Notice, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r479",
      "r480",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r607",
      "r609",
      "r639"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r479",
      "r480",
      "r481",
      "r482",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r607",
      "r609",
      "r639"
     ]
    },
    "tars_RelatedPartyTransactionAnnualCashCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "RelatedPartyTransactionAnnualCashCompensation",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction, annual cash compensation",
        "label": "Related Party Transaction, Annual Cash Compensation",
        "documentation": "Related Party Transaction, Annual Cash Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615",
      "r618"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r479",
      "r480",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r607",
      "r609",
      "r639",
      "r858"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r480",
      "r483",
      "r575",
      "r576",
      "r577",
      "r616",
      "r617",
      "r618",
      "r637",
      "r638"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r331",
      "r359",
      "r482",
      "r660",
      "r661"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r425",
      "r867"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r716",
      "r726",
      "r751"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r717",
      "r727",
      "r752"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r724",
      "r734",
      "r759"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r133",
      "r546",
      "r567",
      "r569",
      "r574",
      "r591",
      "r685"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r221",
      "r294",
      "r295",
      "r416",
      "r417",
      "r418",
      "r432",
      "r433",
      "r439",
      "r441",
      "r442",
      "r444",
      "r446",
      "r564",
      "r566",
      "r578",
      "r878"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r245",
      "r248",
      "r249",
      "r253",
      "r254",
      "r255",
      "r365",
      "r366",
      "r519"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r650",
      "r663"
     ]
    },
    "tars_RevenueRemainingPerformanceObligationAdditionalCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "RevenueRemainingPerformanceObligationAdditionalCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional cash payment",
        "label": "Revenue, Remaining Performance Obligation, Additional Cash Payment",
        "documentation": "Revenue, Remaining Performance Obligation, Additional Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "tars_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments to be achieved",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration, Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r203",
      "r236",
      "r237",
      "r245",
      "r248",
      "r249",
      "r253",
      "r254",
      "r255",
      "r293",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r453",
      "r537",
      "r815"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAgreementsDetails",
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset obtained in exchange for operating lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r684"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty expense",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "tars_SaleOfStockConsiderationAmountAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "SaleOfStockConsiderationAmountAuthorized",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized consideration",
        "label": "Sale of Stock, Consideration Amount Authorized",
        "documentation": "Sale of Stock, Consideration Amount Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued, net proceeds",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued (shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original issue price (usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "tars_SaleOfStockSalesAgentFeePercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "SaleOfStockSalesAgentFeePercentageOfGrossProceeds",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agent fee percentage",
        "label": "Sale of Stock, Sales Agent Fee, Percentage Of Gross Proceeds",
        "documentation": "Sale of Stock, Sales Agent Fee, Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesProductSalesfromEachofourLargestCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r776"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding potentially dilutive securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balances of Debt, Debt Issuance Costs, and Accumulated Accretion",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share, basis and diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r103",
      "r104",
      "r105"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r614",
      "r615",
      "r618"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r380",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r68"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation assumptions of stock options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock unit activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock details",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r96",
      "r97",
      "r131",
      "r132",
      "r133"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expected Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Sales from Each of our Largest Customers",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r46",
      "r47",
      "r79",
      "r136"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segment",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r254",
      "r668"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service condition period for full vesting",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (shares)",
        "periodEndLabel": "Outstanding, ending balance (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (usd per share)",
        "periodEndLabel": "Outstanding, ending balance (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Value per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r380",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ]
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails",
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant-date fair value per stock option (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value",
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (shares)",
        "periodEndLabel": "Ending balance (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (usd per share)",
        "periodEndLabel": "Ending balance (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://tarsusrx.com/role/RelatedPartyTransactionsDetails",
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r385",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember",
     "presentation": [
      "http://tarsusrx.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units\u2014unvested",
        "label": "Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested [Member]",
        "documentation": "Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for license agreement, share price (usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationValuationAssumptionsofStockOptionsDetails",
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value of common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies and Use of Estimates",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r201"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r32",
      "r158",
      "r185",
      "r186",
      "r187",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r221",
      "r234",
      "r294",
      "r295",
      "r362",
      "r416",
      "r417",
      "r418",
      "r432",
      "r433",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r475",
      "r564",
      "r565",
      "r566",
      "r578",
      "r634"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r234",
      "r519",
      "r571",
      "r579",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r612",
      "r613",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r634",
      "r691"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r234",
      "r519",
      "r571",
      "r579",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r612",
      "r613",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r634",
      "r691"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r729",
      "r754"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued for license agreement (shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs (shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r96",
      "r97",
      "r133",
      "r573",
      "r634",
      "r645"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon the vesting of restricted stock units (shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r133"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity",
      "http://tarsusrx.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of vested stock options (shares)",
        "negatedTerseLabel": "Exercised (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r96",
      "r97",
      "r133",
      "r391"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued for license agreement, value",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs of $6.7 million",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r96",
      "r97",
      "r133",
      "r578",
      "r634",
      "r645",
      "r697"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of vested stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r32",
      "r133"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/CondensedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r100",
      "r101",
      "r123",
      "r592",
      "r608",
      "r635",
      "r636",
      "r685",
      "r698",
      "r795",
      "r809",
      "r853",
      "r878"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r485"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r485"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r485"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r485"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r485"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r486"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Account Detail",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "tars_TerminationPaymentPeriodDue": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "TerminationPaymentPeriodDue",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Days due within",
        "label": "Termination Payment, Period Due",
        "documentation": "Termination Payment, Period Due"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Net",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r258",
      "r259",
      "r260"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r352",
      "r360",
      "r445",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r553",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r804",
      "r805",
      "r806",
      "r807"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government-related debt securities",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsEstimatedValueofCashCashEquivalentsMarketableSecuritiesandEquitySecuritiesDetails",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r679",
      "r681",
      "r868"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of estimated value of cash, cash equivalents, marketable securities, and equity securities",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "documentation": "Tabular disclosure of unrealized gains and losses on investments."
       }
      }
     },
     "auth_ref": []
    },
    "tars_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "UpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "label": "Upfront Payment",
        "documentation": "Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r149",
      "r151",
      "r154",
      "r155"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r684"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "tars_WarrantAgreementNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tarsusrx.com/20240331",
     "localname": "WarrantAgreementNumberOfTranches",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Warrant Agreement, Number of Tranches",
        "documentation": "Warrant Agreement, Number of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding, diluted (shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r229"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://tarsusrx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding, basic (shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r229"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "835",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479359/835-30-S45-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815-15/tableOfContent"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001819790-24-000063-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001819790-24-000063-xbrl.zip
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M-4E$>"L\YR3M7!,J;)HIE#BLR67&>#9E95;H4D!G%#VJ?_ 99RFNM.0)BWB
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M3O-NXX5 PJ:Y[<\8.Q4&K17\0[SXZ>!YEK(#7IK-IUCN' D$HMK)L;$J-19
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M.N43/VJJ/MWOJW;I=UW_!5!+ P04    " "0@:A8=26S&%X(  !=)P  %
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MQ_"$(LHV[DB[D?[XOO XUD$"OD@2YFLN$KCB.@0=,O@\)Q(3$"U@S%(A-8@
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M6"*D!N'#@DBU4G :$!D1CZTT]TBHJC")O3KL9E+O=KI8:-VAB!(2I^;+=O<
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M$\?#$)AEU:PE.":6?L8:!V;ATFW:+A4..?OC&IA:V@7FW%"=Q3RZ_K/:^XL
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M@2+/#NW<&G&WI5B/MV XLF=U0+9WV)H^FVDCY)JI,"/X7R%D:-T8%:1(YY?
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MY7%1@GRI?:=,I\O:FL*)D\J/,76-T)$SC<KB7F2K" G9-!-$6@51?7/)-'2
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M/*8#&J)C<?03OW;6US?[%^B$?-G?=1FH7_]?7\6>Z"67%AX_>X70E*T;"9@
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MZP-L7\;^]*:\TDKQ]":9.I8]Q358NGKD>&9V#X%!>G--*8!!:N+>>GKS7RF
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MDK#S,E@8"D3"U\&?(X^[PG A4<<Z?>7X?[&"(1)0_;H! %UZ%JN!,8&4CD-
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M$-F#K%G0QV4/X@*ND6O5&OGJ\1T +ZA3$-?/NPZ+/VE5D369Z'SK$3]&#^Z
MP5-3!?9*7P*&G&9D[(%7.I@)78TPUGO+I5+]M$/:.8"U,\&//R RKAUX=_0K
M4S=^S;FV1S>.\5JP$D_S6F;D7 ";'-CG/M@RKCHZ=M[UTGS>E^YU]5U+_3FV
M#-"+#MM96O_.>H"YLZQ:4&#MO+5]\8A"K(.6$-B:E_Z\2W >J=T?$SRF;X<]
M[]W?A/1FY6]AV'DD]H/==W$QEQW_MWBJ;\Y+<ZF2=PORMO&43S4>)=<J%8$A
MF_4Y&U](4V)+K_B\[]+6.3CX'N>XX;.Q.FW/'5LV,%Z+YC(MYE3>0>/P\<5C
M]['CPSUVI3P0'?\_ MW)_$VQ"7_(Q'J.XZU/*F1#_F(^U=CT/@0/#Y[KN.!O
M@2:*,;;:AV#AL+'5/X1NL=D)$8=I[8=E!.#R24@Z&P$OW%X0:H]C^.ES?'N[
M:RZSFJGYZ#TTZLW$>FADZ6'QH+._L?SAT&F41(/.AX8GYW)K,6*SS)/ZM/P5
M,1W(QHD<VL,&(X8WNS3V(UW%1O*N;(*#PR7W4AQ'UO<'CO!G8Y,^S/O9/[/D
M/=J-@6UU&?>/#GS:<CU?KS1#6QG'=,,DXDIWQ%;'7'F7Y;RDE)2*],4SB:?I
M('1?$X\ZDB1&?"<Z]N@.PQ#V0:WD%5G.R\T8PK&=2]=4I9,AM5<853["C?X4
MQ4=[W.@E9ON.T(;# [YR=H#=!2)CCY>\'QE-<(4O;,N%R.5F;1@I4I@8$IZ+
M5=!-22537 K+JLT.W2<])^DC4+1G=C@]8ZY1-R$&J%:K^5KU:&G(L@GB86C?
M#N)D, 2A6Z4BYVN53[93^&SG?+95U9MX; >BWT]#M293FXZIZ>BO5#(LYY-M
M%_YRE&9U8/CP5\@&^X#,K"RSLTSDG@DTI[= Z7OJ/HP&Y#U$,LK8S'9#*+YF
MOF>:X;.A5$\&'\S2G!\]E]-Q;+\VU>A(5_5/=G#<293G$W4)O$GK$ML$<CA+
M5+[F1([K9E1!&AJE?+FQ6< ;728R+U5 3$75J,EC"AL_5BH0_FRFB3X<4Y?C
MM>[:(>%LK=@[R8:)%(I.@DF"Y?+(+B-R7 &I@X#4JY@+%[XSJBA;)BX<<GMR
M"L=#KI%KR<U:OMD0O[?UY;C&$3>UL<6MZ"H\8B,,3M"-IK<1^N%>;DO#9$AS
M,5HG^K; MJD=KX.:B?773Y*=@O87S:0XD^*D]UHF(<4POL3Z^I];C)FG\<W%
M1J]!P0C\$XQW0NP7W>0>3FE5A%0*#+"3A@9[R^Y=C1MH4=B&+4JQ^;<U@=',
ML#K&M%QXGVM)[I@Z5)J7+B%R-&HZ\-=(-XFIZBQXA%B?[7TKKA;/+-'"?UU%
M*=:K,,BIY; UKBL;6S;JK_3[FZZYXP"\2S?Z3"TM;B%#\!4]=_LM'TCGG52]
M*2AKQ41+_^)X42#T9I/0$5'JM%H?5>1RE90J#5HK*\I(JS1D9?A_BI(+;AK;
MP1RFY(46AC8E/PMD!%.\(L8;F3D(RF4$ OS6*+].M*VD&8U.1AHN": A+#S"
M%5@*(DUMO K&1(09BS2V44'^:3^+(!X?L%[ZUDC"S9_\,%/2"F/_68&Z$5 P
MH [:3_WGOO3X>_OIKMWI/@]ZG?9M/R_U[CO;)7I9NRD?J]UV3J;S<'_=O>]W
M\9"2]J![U[T?]*6'&^GAL?O4'O0>[OD))IV'N\>G[N]P9>_O7>GVH=_?.E-1
M9O;E>5Y!*OY8>R;8#LN#9VA.7J+O*L4@'TLR6;0ZI7;P:<+ZI<>?4NN7H?VM
M%06?U2WP9(9[86B8FP $,LC4H5?!']\UW9D:9':EFVR:[*;O_M-]ZX0O6,\.
MX/OXS[[.;3:+C6H9U:Z?F_!?[&OD(I#MV^;WM4:QT:B&_E0JRJ'?;WN47"Y6
M*^&W;'O4]N^K926Y0>U^U)Y\CA 5=XU(7GFX>SN?4S/*G#AZSS.K+?DHL)-4
MNH/KQH[4!?.I,<ED1?!26<ZOS/?3,',IK(^:Z12;S;B+(9'9[NN_<#'D*L=!
M?NI7$I_H*S6](T\$.QX]I^K^$6-DB;;K;PK!\FV]02S-4X$8Q*!.:-OGHVLH
M4I]LO,R<875WSC#0!;%S@S*6?N3K2G806"8"@HM [1 1V-4)0"XI%]H*0'Q+
M=JNKF-:61I0&30@A_!_Z24')YLS\7.7[<82A?B)[@.<8Y!O-BB"[ K.:_00Q
MTS@19K! /U\-::"0ZIVD[+UE,0+ 72=W^:KR-,=U7;A$R">2""S2K^=K\M%J
M-!9_4E#"_UF!UCP1T&H)J=Z3X\Q7RFOE";B0F1,YLR3NR"Z]Z/9A2C$6,%\D
M^C[%4.' /&<4Q76.^S]-I->Q'!?K-%C.,@OH#DSP(14?1K]9EL:* JG]"@&T
MT[>,B&V=EFQ&G9VK5,U"O M$T9X<6504[<Z:-1++FGU,Q!<4E,! Z7;$G?*J
M3[- ]40=RLH0,*6G@5=K6%.L5/U<6\D3#4$Y04%<KQ?D['*7*+;J;X+J5_*E
M6G:FW@4B:6^,F2"2Y!)#4CEDQWBV<')21/2I 5^^Y*47:D*$9#!-2[2);NJ.
M:[/:_LS)/E#9_L9)"A+27B'HH4*";>7D?/7X[7.9JRT>EO:HVZ2QI(#"K>9+
M35$ZN7ZR519K(QUUDO66R\^$[U'!&*%B;.J+2>R,N(S-YJIYI9GPEN7SGF]Z
MZM67RX?='FU]-.PJ;,6O4MWL5"<@["ZG,GI+<9'E.-+(MB:!VK9,1QI28"GU
M.X7JK/&@],57YAM=KN*X.1<F5;%ZEFUH\RT]R^:K.8N.C[%%K,I.C:@U-A/7
ML9M!"J'4LT.KCX;?AE8_(?Q8D[Q\,T3#BP6_RUD8#@?(0Z@"/VIQ.!(_SK5R
M'&]PGR8/UL/]9]1Q?21D.:\# ZZ CEPS,N&*K1KK8)GS\!]!4A-9FNOC J<D
MX-/ (C:EN=DB/OV9K72H4-^(?JY%VN/BG' IF"=W-T'>S+6:C6-.0<B67 7$
M143MN!T72BG7.BZDS190#X\?0K=09[8_HM9CE+RW3&LUNMX!=AG 7A+EQ+G,
M3?PX-S$^5!1Q#JW\- [ALVE3&,)_J,8.SY* Y[RC-:C+5S!C$]YG+_,2C\R&
M\SZN?:IZ-FOS>O-ZKR]H_QO139ZAW)2*<JY5;6PJT,R+3#5NHJ:Q#\=-!5?%
MSP^;3^-D=L;$?*&@-J41T6WI%<_?Q4TPOCI]([9-0)<&AV4/9Y+!&R)\LD3F
M:=3K9$@U#4]#LO575G05B,:#N?G;/77#) :W\)8V&V9GIQ:F&D*1-6T2$*KE
M6B$Y\;2>7)B:2KWU^%[**O5.$?WOB.;BY?\5MB&Q63TZ_Y]5[%T2_/9D%)*#
M'YZTE:^64P&_R]OIF++20C#UH0>+']_98:L4I[<=8;RY"ZVY3A*H )@.+TA3
M\'2N:KY>3B!(.7]_H1WA2R9:F6C%#N".$JTRGIA5SE?DILBBE4A+I>2+%+>=
M^25 _>3>H5VZ]\+7OO'<,9N.P5G67RGS9HYJ(7_NIED7W!IK[S+=%^3>5^F%
MZ":NUDV(_9/ZI^S,5PEX>UWBC%GV^15T7;:*E\B>%A2FSK(L+2Q.^Y7H!O+A
MQK+[0/'%FDU;^Y?'5U+!1#V,!N0]S !AH<0Q?EVVS)>ZA,8IX:3D6DFU(A5D
M"5!8Y=S9,*Y9JB"+9XXV-B&*82'P,:.;,D\<-$^YDRU+'&2")I2@14T<)"EH
M%3^-<$SE399&R-((HODXP2+(XE39O#0DCJ[RMH\ZGA:N'5/F<)DZ]T(TZR.U
M^\CSG:Z,LKVTAM@F4,$)'O,#@3/7GJ6%]JSN#J\2'L8U1VW80+".IQA2"W;^
MTIX/<)(RL11G:@>)93-Q>:@?)I@'#F2K?FCD6J5B8[//U_G%\O*J-%*6(?\'
M^T"U H$1D1?*G11'LCS7<<%'80U4]WHL!Q1J^>?3KWN($9S'"\AY<B+OM,>E
M=6D/.-7FC+KW)D-J/XR8Y#L/"W;Y6B!* +:D(IK'C;9W?Q-QO+ZVW!AVW!%7
M2BPW4RZ5\K7J9MB8;(G:<6!-P7I")I3;8-X\,\SEXT;\L6JDHN1:2BU?KRAY
M=L;\A0DE<P:^L55C^*^FO[9^@7^"\2X]1Z78SL#'=^N7H8TW^Y.,>EMB8B&7
M KE@3[S277B;NEM2%-Y G4I$Q1H(8LZPH:]IN? ^UY+<,74HX)!XF@Y80@!J
M6%&L22/=)*:J$P.&3US*]L$6M\[=?UU%*=:K,,BIY>B(BRN;&FR[R/<W77/'
M@> NW>CSOK2XA0P="T5NZRT?2.>=5+TIE%?IL?POCA=E26\V"1T1I4ZK]5$%
M(GQ2JC1HK:PH(ZW2D)7A_^&V*_^F\3PE.06)+@QM2GX6R BF>$6,-S)S$+M+
ME)CH9F&-\NM$VTJ:T>ADI.&"",K%/]KX"B2?VG@5C(D(,Q9I;*.>_=-^%D'T
M-V 5)M9(ZJ"*9M4DI!7&_K,"=>-<.0;40?NI_]R7'G]O/]VU.]WG0:_3ONWG
MI=Y]9[M$3XC] O!BV7=EU1,XZV0Z#_?7W?M^]UKJ#]J#[EWW?M"7'F[@TT/G
MK[\_W%YWG_KLJ*;Z=ZG[M^?>X \1%/;.*7UY#O3O5_''VC/!:%@>/$-S\A)]
M5RFNS:#3(6G$)=MG$ 50?AU78!J8_5?QE/2I0Z^"/[X'H;UNLO&QF[[[C_?M
M":K"]<@<W\=_]K5DLUEL5,NH*/V\@/]B7X<68;[?-K^OE(KU>B7TIU)1#OU^
MVZ,:15F)]Z3MWU?+2B)CJA8KC89@8ZK#DT0;4[.H-*N"C:E1K)>:XHU)WOVD
M\-581=ZQ&ALS*7>:*+41*4H-CXSF<VI&F1/7CQ\SJWJDHVH[UF0" 6S?M=2?
M$0JI]ZU$V];;>H8C5>1HPUC1NX1HZ9'H6@&,9(=,,3[+B--JJZHW\2 .A*B2
M5^.O%@S>AA0,?FXRL3S#-1WIJKZ]5=_N*5\JE5C# T8?IGO&E@$^HN,[_.Q[
MWC%HA6P'U/M<CH592CK'V*8M-@IXDC.I*>^KC[H8LK4GEK?C8-KHNO;(RRZG
M6"R<SC^(04R52L3!C-$U52GFYJ6RG)<4EDX_8-'U,H\^B;M46=JSB,/]4F8:
MCE^QP:+Q2EZ1Y;S<+"74F%.(3BVG*""/A+_4%TY%GWXZQ2YLNT9I]R:N93^,
M^UXA=>&52JZ55!/D3(1$@E(F0A%$:$]?L3 1BK?OHE+-M2H5.5^K;-;L9E*6
M25E:I2S>QD(EXH:G:"8+3[\3_."[3(XR.3J!')6/D*.8=JN.1TQ6\K7JYLD'
MF:AEHI9"48LC:963^X78Z;-9RS=#-HT(Z!=>^B:-;:TT#ZCPOI0,(%NZ4;X+
MV'CV/)7[&5\SOF9\S?B:\37CZ\='?AL.Z2EZS5:2:..<(>^RD/<1P*N64@*\
MRRF0"(?&$U6M%Y.53&*%A(-Q;F%('+8#;8)G6K#-.L$IW8<=9Y/:XYT.,\7B
M]%?)N)-Q)PW9-[FZ._VV:#3K#*Q%B3=6>/=,O[Z;51DQS=594EQ/V';:T5W:
MI_:KKM)'F(NE+6F]O^/IB+'-EYQK5?/5D!;]&1B%!&.F*C+N9-PY^[%]PNEQ
M12P]_J&K+KMZ$IP23SW'\5A1-L0;*M^]QL(.?EXF?*D'%ZB6X[+"[3\?CL'J
M.@8?R8P!\&'$%O6"T73P7='P4UO@IYQKU8J;QZQ*0#4#_EAK2_ ICKN(6TA>
MVU-(/N<2U:X]&VC!19\7E<.0V4\1.;<H*:]6<JUR7FG(>:5Z=$5Y0J<3?'"2
MZX*@%:8%:A%6]#=AQ<S($JHV348UUSJZLC,#C(" V1.#1@1,3 >DEFLU&_FR
M<G112 8ID6.5C#L9=S+N)!A)GD8;UWUM?'0\F!"B/G3U281X<&K3P@@;PVG2
M&[%M G':B<-"E]C.5<<@#@2$_^"O?+"?<'B+0/&X&)&U"M\LJDX@1DQM2BE+
M^&7<R;AS_I@F2C[65XK<UL:VJ$VPJ/ER+:D=QQFZ,MG/N)-Q1TCN?/!"V5&*
MN5822S$+?VI-=E5VRL^RL'??J:WJ#HM:7ZF#+179*J9D35&,/MD9]Q^ZZ,=^
M?.!D#M@040$N%@!K<JY5 0TH9ZM_*<%8EML5F3L?M=2V1?@W'1PEUVJ4-MN&
M9/ 1$CZ9<&?<R;AS]K@S$<U;%DGS7OH&KFW5E)(WM?" &,JB$Y@)7@#.LVOK
MZB)80:@<%JI<7I;F%*'*TYS@[++V&[&UW^S(&R:7PI5*KJ64ZOFZG%3[F"P=
M**31S+B3<2?C3L:=C#L9=U+(G4M/^_-CD]258Y..[2/W62"6Y0,R[F3<R;@C
M,G?BM4JJ1^R5Q*S&REE[B]9)]]1]& W(>U@FK9IKU1+HD)2A)I/I3\R=D[0_
M.U2D:V*(].6DQ:,<_'9';'4<G/I62>#4-_]P\S)07K,\/"H=9W1I?0/CILH;
M'W@F7*V>:Y7K^7JEF:_4$FZI?BQWSY36."=V+^7,@Z.)DTZ!#C.$C01.FZLU
MP-QEPID)9R:<R0IG\]3GE=2:N5:U6LW7J@F?%IG);R:_%RF_L<),9>,LUV-.
MR*N7P,R6$SNW*Q/13$0S$56BIH*.-[9U.==2&J5\N;'92S 3XDR(,R$^T$_>
M.#\S<<E50'+KU;PB)WS<\SG$ER6%O[D$WA;THX%_@A%/B/VBF_S5RJK@J!2(
M;@-KV+WS*?*QPO0,,G7H5?#']V"OJ&XR[K*;OON/]^==G6[FDO%]_.?O;[KF
MCJ^:S6*C6D9(^)EL_\7\5[D(:/FV^7VE5*S7*Z$_E8IRZ/?;'M4HRDJ\)VW_
MOEI6$AE3M5AI- 0;4QV>)-J8FD6E615L3(UBO=04;TSR[B?Y:TG!CX&R!A'.
M);LZV3RJCHPKJ8^Q9/5(BU1\/41B5FCKHM2Q1(/[;>OMH.5=X0FXZ(PA86N,
M0L^4_.88&3D/(:>J>A//(+@_B!<ZKBQP2[>["AT/),QG)O(O0_M;ZYJ.=%5W
M,\ >0,N!A:*.5%SVY%DU3OT[^YY[]2O$#3=7BIRXN8IP?QQW7FQ6\ 7]8U <
MB189H=L3F-Y)U<6'W_^YBI&NJ4HG0S"N?CV2DD ]TB>M.%*4#ZPXJI=S+:66
MKROU?*6:<,51VM.QGSSA^IE2JJLR=V!=4+V2:R5<5Y")D!!0RD0H@@B=?EFB
MFFN52W*^7CZZ#TLF99F4"3/O> OXE41K;&JY5KV2V/)\)DA" "H3I"B"M-&O
M\725,/5<2RXU\O4$R]DR41,"<I]5U&))6I13*X\3L 8(6%/)-TM'-S[^""F[
M]'XB]]0]NG_(A>4 C]I,+83*3VBG=<;7C*\97S.^9GS-^'JVT"]JBQMP9!8-
M,&([I<U<2RGG*_+FP:NQ.V-DR+L,Y&WL<#T%\!JEE #O<DHDPJ'Q1%7KQ63%
MG%@CP;J3%X;$H1IKMDA-A[#?Z#O^33]7R_*LWVK&G8P['Y!]V]/R),JIC*S,
MB"FNSI+>>J+_]G1'=VF?VJ^Z2OD9 4M*CYVP$=MZR;E6.=\L)=5A)0-CIBHR
M[F3<$9([1\4.@NMQ12P]?NF++MG9K<?47#?/?G9KHYQKU?*5RF:)0-:!5TB(
M9?V11>9.DB%2$@<(-BJYEIS)=DK0D\EVQIV,.V>/:1)1O%6!%.^EKWAD![>*
M'*<D=G!K P]\J.5KB?4'RQ)-0IK,C#L9=S+N9-S)N)-Q)X7<N?24?]BYK2]$
M-S]7JC_+!F3<R;B3<>?RN!.K*?C&V1N)'.W8J.=:F_T!,KP(B9=,FD7F3H)Y
M\4.%N2&.,%].)CSV6:WE,YS5>DGR$IX:+\L?V#:QT61M$QNE4KXJ)]R-ZBC6
MBMWT(WG47DH_D.,HDTXY#O-B-XZG.J"I5;.4>!_&3"8SF?RT,GE ;]1XI>)-
MW/)3PF-9SWS>5":V F$T$]OC]IJ7-QJR'M,ILJGD6O7-[EH?=9!C)ID"P3"3
MS",E\Y@>KC%-:QFK'Y6\W-B,4C/9S60WD]V8SO!&U]C$)18WBM3+^4KIZ%3M
MF<4V^LFKI2TGKR8*!O86_A&?>(4;8G5U-SX4=@H4I1)1L<R"F#.L738M%][G
M6EC0[%# "_$TW65=74P-.[EHTD@WB:GJQ(#A$Y>R;;G%.>/6:>&_KJ(4ZWA&
M[-1RV+[;*YL:Q-5?J7\TK _7I1M]GI86MY A<-!SM]_R@73>2=6;0F65'LO_
MXGA1'O1FD] 14>JT6A]5Y'*5E"H-6BLKRDBK-&1E^']*(Q?<-)X??S8E+[0P
MM"GY62 CF.(5,=[(S$%0+B,0X+=&^76B;27-:'0RTG!)  5AV6Q[]A5(-+7Q
M*A@3$68LTMA&E?BG_2RJYUH#=H2R-9(ZJ$U-K/(GK3#V?R10]R[D,)P.VD_]
MY[[T^'O[Z:[=Z3X/>IWV;3\O]>X[VP4ZRK'29YA+Y^'^NGO?[UY+_4%[T+WK
MW@_ZTL.-U&GW?Y=N;A_^T=\Z(T%F\.4Y4+9?A1]J#W>\6!X\0G.VCW8)*M4M
M2$G# >2U1K'1B'?T]+9'R>5BM1+W9.A3GQC-!A7IR.AM\4K,E>N)KFD&31JZ
MC8B%)&%^YGQ.Z3FR>GVZ6TY<!5-&I3NX;NQ(7;!P_!#;^:)]V$FKE\_E"SF
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M@8<X7DW%WI:-5U&FC**SAP,IC*9 F8"<7IN,QXLMF*8 3Y9YFBEUOU$O5*C
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MFLZOYKUCP5*_0Z'KG)Q1PD1L%9J*E;(_:&\L_&N8+!X]WP)5C'6B>W(VQ0"
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M3!<M,5\#IUG-R[MMI\6]=W ^E9S.ZIQE[GT\N24+#Y-A#C6^"J);[+J1B+%
M/?6+QXF^N]R"2>L7*>QVTF@77?3G-XD4=_II"$"J#Q;:='*0Z;'W]HP.6<NF
M=#)=NR=F[(01CU=K :97FUS_\4&BD\0S9-M1%5/CSS[;%IFBC^(]E^KLN?#\
MA<A/&F]./G^\O#AY*Y"T(BZ-%KB4_]D=M!NPUZK=C'B=YU-!"<.&PY3[3*@#
M,54U/,>-(WG<1PYG>9CP>NU<G#ES@KQB2U@GE+BKB-##6K<)N@V@ZU$*P 6
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M884F>W'ON*;Q+0J;<L:5=&Q6.@URY%.Y5Y/$7J6L5SFP2U*#^ #"S)*&EM5
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MA@H&T5#\P*O!!9F([\)@57*RJQGT5NB&*0]\9FQ26"-I:K'2T8S]-W0*-)]
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M;D>N\-%8"%4NQ\=/0]8^!(V7>,.[=_N<YQDYRF;#RH,2N;P+RJB"P$Y(IA7
M3+^HE*9';\?[RU2+*#)XEY+)0C90OM8:KXJZ)!2""$X 7]2F7.+6Z^ A;2!%
MF4A\B&Z7Q"4I6@N3< 'DMB=O2N7M=O*BE,D5?HEEN9,+4$@BJ;^5H3>JF .>
M(&\U SWF#A\]<!OL!4*&)K9@[P(3X2.@"O_.]8"RS$.=3?)A@C<^OFZ^728J
MC$15" L$F6A$1Y"G9I-WAZ8&=&@BPBP%G%II#>+72\!4 .K)1/8X+;P(2!#C
MV72/*Y95HKU@M6U1.XJ+)FAGQ4(@'H  7DM>DL!&:)2^)I+25AW7DJ^$P\49
MD<3)=F-B:F)>-*%!^V]R@GJC %$QBE84K%$X$[RA_[QW9LD$W*T]8_IFV5A2
MJ].4#$[20X[W/C3_!,OH<?VFIF]I?!=*FS]+MYCS\)(2O0HO"E%CZ=35=(VJ
M/U-:E%MT9ME_1>9D*;/O5"T22'ER- \N*>S2B9^E1Z8UITN>M/&0$:D6Q 9$
M:RJN61\UD$9B%(KWD)$A\9EAIYNB)4I:IU0O35M_1ZVA,"5*^$0YF$3AW#%9
M>979P14#+TGP1VJ\C)&K>66: BG%:R0];!1Q,HF>*_(JVKX))$N99%V?A!OW
MW?8I5BX,_@;9^I_>X##K?Z[ 02& %-X&TZR/2"0_0#PU42YQ?/=-7/7B7.<+
M/\H\2%NE?B#\"'Z';34E7V5\5TZ/"[*U*_'U4&R1!8H7G0'X/%4MCM^*+9?E
MS"+N!IS[?(A6\0NVE3>W&D6U%8KJM$9156(L-8JJ1E'5**H#0E&M@$N1,[2%
M^[-W1X%ZU\P7T3.]@80/@ AK"*(9HE[H#\3I*4M+5(?B_K#)CQ(X$")<G,(2
MN4AE&^-#3+UL9P7VJ-!A._NO6_^W-?:STH[>1\ZD)I.?J-Z20DJI=8.;!(62
M1UCY7,BUJKPN>Q+Y<<K?A"_(SQJ24B?NV\>E)!(\5N1R8O@["_@=N8Y;N3=8
MB1((OB#A<*8PJ#E('O.<2H_#*XU)3H*D0D.M84,O)2U)XY&4:RPFPBY:&&:+
MI-(=M9(AZC#2BF03A[]KMT@J2]>$5S2I-:!EWX::*I09:</"G?,='>C0=]]S
M/<Q<TIW5&BD]/40I_6'C&0\6YC(((F:%_D0W7;C?\4)@49-KX>W;X<FPFJ*C
MIFBK*9KQ%!>)S19)4I#&"=<U(Z$1 =5@!NK/^9U'<JGH8DH@0;\F %_RDM3S
M0M<+[;AUG"BU)8K$%C9D(R:VN.E2/%A,OWJ/#457,Z$2[L*98?8:QP":IRYI
M YU\Y[,:_W7N^&._H("@0J_-\OB7KJ<O)JVA(M32EI.[?#*O8+R,,GQO* (G
M6(:X/0H]DF :Q-EX@"6(EZ[Q$;:-O+48O/?Y_/J#E-H\731^+@B@]>;D_/KG
MR5OCRFO1KYOM<</8,?)H2U24CN\PWMQX"[#$I_WVVW?&Y9S(3A2O5?Q-XR,+
M:>3O%XY'RRL7]N1MR]#^J94K<J]*2XV9J>"XMR0<.[!1=]RD4FB\(#[$4GUG
MQIRE#77#AUKA,JQ)O]FBKQ*$TYX+$T7T7*8!/APVM12$@*K1(Q-@P*#,NSO?
MOE/7>:D+!<?B!DET(S4%;UG<=01"U+AAASUSZ'+%COL&J#9S\;QU?H94DCW_
M"I 8W_0$?.(B/(TR@8 H-M^IGB8(<Q5H6(5'A(T:&.>\.3]L[B7B(H/#W.BT
MF__3,C[QW9(ED/4..;YS)PR)\D#;:EA1O$6_%7>C5/SM:<W3X/%A_(>B)^I7
M2(XR=NH.2<99;!,-:O&F=H%N&,F<9MREO#-GC5^4GW!%=V9]IJN/'=S7V=<]
M)0YZK=7L+AF?3P$-8X,3Y#AX.=QJO1QNM<_GES^,/\Z__/QD?/T$\O-#)IW2
MR__D5GMJO!^6'Y@=\_H>K,#OB%$'^<D9^CAGZ..<:Z&BK E-,V?RW=6E9Y4Y
M7V./I@"PI<$UM/HNK>@]8(R"CT$'=<5@1)RL9Z&FQ&Q8%Q'V5Q.N%>%H$H^A
MTO5_4?4^Q2]+I&^R!5%T(L.'Y@T1/&02, !ZMZEC ZO,S5#4/8AOV7Z3&I N
M ON=_(_W8+47,W/YSG%IS>A'[\7#Q.4)7A90?Z*).1-I0=I6_CB^1VBU^2XA
M].'_6_+-XN,6?/1;]N^]4:O;/<W]J-WJY/Z]Z%&=7FO0&6_UJ.*_#WKY+ZD'
MM<M!=8<K'_4;219+%P@P:L+_.NF=Q!=A5"3PKKOX9722MQ%8-Y"681;?LLW1
M:)TU(AWY__ZC,VR_5\H<6LDY=3N;3(IS\_N95N;<I6DE6\PFIO=J]BZ>D["Y
M9)+Q>L:;.9:!PWM_4)OZ!0\VGG2GE%FW<<Y"SU_%LG7K97O*LO7J9=MXV6Z\
MT)QM8W"SUV*3B0UA]:IIYUEB6+BR9SS>:,;GY,:_VT1&BJ9:N/?;R,^Z=7SJ
M[^O!O<S@MM83<7W\)#W1 K9$26MG5'Y@G%:C?&_FJ^?:2\E!0GF_G61:!ZW1
M8(/QY"#[<!N;O58G)PK%R@'&BKWII!$BPAQLLXMM8Z_>YV;[]9]I@[?5#/69
M49.#*DVML.HX"JQTR?&PJ]<<-WL9B($98%]C_#^?8JQ+3IHO63KL1O.FY1$*
M$!^MZH=[*I&&:<_.:-@X[?<S)<3YD<&6AL38:J.VL(ZIU^G6M=:2(]62WDZT
M)*? 7E.0#H;(1#M0*TBM(!57D/X>%*1;*TBM((>B((-]^5F]JOE9)2546/C'
ME<BLY,L'<48IEJ@89%E\7;'=(N3J_V%KR3!?2T+3#]Y]M&_#:[6(YQ++^MGS
MKT'FA?)D=6AKA>F?G/4ZC5&G^UQ]62&WNSA5-LGZU!)VNFL)6^VS#$KS66KI
MJJ!TC?8K7<-:NHY9NL85.!U/*W8ZEG3M4'UO$AG<D7X90?SFPO:?Y$5N&D4>
MM)Z<MO=KA4='F)>HI4M)5Z<"5G@,5KC=&'5'M80=H805W,F]D/T:M&O[=<S2
M57"7]9+V:]"IF/UZ-3G)"\]'CN(P4_E=)R4+%:;@;NNES'%YUUQU4%]!Z2JX
M&'I1<]P[.>L.&OUQNY:P(Y2PG5^JK+9?_=I^';-T[?Q"90/[-:B8_7HU2<G?
ML76YB^6X34E/4(9?^3H"L?U>%@W*NRRJP_P*2E<%+HL&IV"7>XUANRK0HUK"
M2I2PT7ZO60;U-<M12U<%KED&XXK9KU>4IM3[?KO&%\=T/SA>G:0L5)<U=5RH
M!>$RUIG/#U?.!1-F@9Y<>:Y@S\K1@F'[Y*P_K$AD5<?N90K-FK*FS85FXU-[
M6%Y54RU1%92H-75 NY"H^G[DF"6J-!.5%9Q>A<ZU-9Z=9)>#@=K%(O8:OU5F
MJK5W6F&7F)AI).FBX$&TL,M\S+*X;3@B"#X$/6$/5L'R(B0[)-Z>S1A]CK,(
ML925.1H;O"ZX8 JA$HH5AWT(N#LCB+B?#2\O<2,K6@I<:V^MO65$>>5I[^#D
M['3<&'=KY:V5MU;>%PFH-U3>U1%TZ3?!M>+6BOO*%??%#EV\8Q^/&H-N69=4
M^U+>W$B^VW\VM?7+==48M+K/X&;LMD9KJ!F-W;0BVHRN^P;[I]QRDPQL>C.+
M+.Q>@[VB$FUJ0*[#&38'PR8/+CY@MN06#^DF*HI=]S?JEE#<%#'=[^.5=[,>
MU=VL*S&6NIMU_N#K;M:[FD'=S?JIW:RYQ5)>XZ7>BF9-X_4MK@^E.]"VC6I>
MI.=-;]2O!_72@QJ>=LOH#I1_77V@#7=4RU#1<R?9,N,Y*W)T'3*V;6.S)LQ\
M]1U'MNUO4Z]GN8UOZO6L.^+4'7'JP=4=<>J..'5'G)JI?;0OIO;AZ.2LV^TW
MQOW3BI0;O<!U:JTEU9G:5EI20"JRRX8?P_$15GS6"G*D"E+ B[)+!3D]1N;&
M6D&.5$$*Z$]V[F>==JKF9]7%/[LI_MG_ *OZK7KA7JK<[% 9&';$[/4J:E9'
M.^=>6NT&UA71QRQ=XYWS+FW@0R%C;*,_'M0"=H0"MG/JI=7FJR:,/6KIVGEW
MBPW,UZ!:YNO5\,66R>NU:?[GL+5E=_PGI\.3LV&O4Y$<2 F9PEIJE-2\/ W3
MZ>D1YIYKB5(2M>96?!<251.\'K-$E6:BLH(SKM+!]FHRAKQCQJ/I^R;6);T!
M39<.'I<>:<5%=<YP0T>/PB)>VG^*E7W>)?&HO$OB.KRNH!RMZE96JAS53*Y'
M+4>K^I)M($=9>>GBM7M5,BZUK.S>E7NZJ/2J)"JE,HQ6H^ZE9AC=.ZBK9DO:
M)LU9&EW2J$^FI3$X+:OU<,UU5FOO:]?><D@*-]#>LN[M:MVM=;?6W4T2^RMT
M-ZN>PU+\]EHY-Z@RKO5SW>(<C8J^V.F*5*+=4:,[WK-O7(86UVRB-9MH/IOH
MR^U@3&A'3WSGA+ -D]4,)-V8.N$K4R=\1NH$HNK[V;IN&3<^96:6QG46B;\1
M$Z/C6K"T[_ICY/O<$XMIEALB9X)QJ8%A^K9Q#[^'S9\Y(![(=?A@!R$+"?X4
MOX&VZL&&[X2^:8'0/#HABI-IP02:I@03RM<N?&<"CP[OS9!^O0#+Y$S@U]XM
MS.J!OHI/QO5:V+1H\.$#;*%%Y1!F@*2)X;TM<V4X& ,_@SF@>)N+A>^9$QQ"
M$,U@G,3/:!N3F1D$SA3TDDP_/R2P$_,-#.(Q,CKR'7$.#A;"]DU_<K_<F(*S
M,H*-^#_;GSCFS/AN+FR_85QX_@*I56T#L9^:4-/:YU2AI+YV>+*OK<&"UV"B
MUB!58D-K<+>V$L=XM$%^23@L(PK@6!/2TP616T2A$/(H=&8P3I+H* A1PT)X
M@>E;]%N6QKEGV;.@(6PR/@J.OGO\IS=G?6#U:>)98BD9M^$G>-__>.^ P"--
M:0 '#@DY*(48!6I9K%P-PP;]M'W# FL_0=V"W\/0Q+\:1N@9H.+@K(2Z^*-R
MV2 V<]BZ):C6@V,_!J3Q.%@R 0A#P)&BAN,?<6"L8@FK0?IKHX)F%/C@%$OB
M+ 3 ]IH MK@& I4A+V .3UTN73P(89.Z[6ZGP:[Q'-7%M;TH8!N/!O+BWG%-
MXUL4-K^ 77=ALT$FW(#]UP9_10@-KHM8,*3)!3TB>RZA*X9YY]LL#$)RU"]!
M)!<1# 9D'U7$*'3C\=V@%9EH.T&;<7GU.7%7)C;I7+[^BJAYOTUO^&%)F#NL
MYP2=^D?PH@/;5?Y\._;G1R=GX3T\*^/-&V)X :XG([()GZ-!LO'>!S8;5@=,
M%2PFG98&N&9@MF 5)CJ0>V$*W6P(_8=)H^=)I@:^K"!!XBR#[^/B3L2BPE_E
M2]^8Q@)&,C<G=D2.J_K2U)M$ 3N"^(C?X5@/P7;PKN.&>F1+S@-XDC!1P7OC
MR@PL\Z]WQI?+\ZOW!AN,*1A+ET[^U#30?&DCU:!+8,[H=^M^0I,3;D13."%B
MLO$#W^(JPPJY-LL,2;#X[.]$Y_S@H&1?@BS104D/-+Y-80!@S=C^31T_"(O%
M3PPJ+7[=E>(GQ>T/,)&V)2W&MD(W!J%[](I%3AQ6] XE7A9S4:?DIG!Z+*VK
M9]?.N8;6X(1_7%W*^5Z+IVT2+<<3';=/SCJ#8>,TIX>H5"=-BA)BPT=/FG2V
MJQQ9. $].#W_G;Y^)5D!Z9EY[ET3Q'^>.-"$>WGAH=5&7?D@XJOK>]M6!QX9
M4\&/R>_MTWOE:!(?];9D>1<'QJ"_M^/BFVM\MF_]R 3WIM/C^35BH^:Z7@1+
M @*&S.FP/*C2CS!LP_(>7?JK!SX9^4)!R_@F#Y]./_4HT-0/'KI.N)'DLGA^
M (;' B?)"!8V^7<4S\*:.; J: F6=*C &_4S!<^8_]PJ99NDEAFD$T(?Q0L#
M=@;(%\""J<TD?!A+>.?DK-TJ(LF O9OA2-_8J@X+9[9R)M]MGY1M]8RZ&2J0
M>!YJ;O)1.+'OIF/E:6CWY*S?&K6SZJG(\-_*$^L1E .USD>3#=/@TT1XO6_L
M7PO4J+=9%;L.X1AB]0-!^*9$AU0*=]BW[^&;$)8:7[P@4 X%G<O@;+OA?6!@
M<&D)09,Z*0PB"I#ZCWBEGZ'L+:4,.&=P]AVRQ%/?FQM7Y]<?S_\W/ENY7&P<
M7.^1@^I 'L 8E#3A/YH3[$( :R7.W!8<P9N8&<6TW<@WD1 _RSA91/+HFZR/
MB1O&'2PV:[**Z'T;'$:<)7DQ3[-I>W6"E1WJ#J5XZ"8D]F%=S7G5'0LR.G!@
M@+<4VO3;R!5G,*PLF#'I^XICVGB#WSD13H!Q(WZ*"JW<TY.W),XF""<(WFS&
M'TLK!WNTG54;Y5LU.KZ_^][$MJW@,TCIA?:V;]-<-V43X]9#XU;4,TL9MP"T
M="=IT@TBO7Q1N/)@ T<['M/*$;QM&3\7GBND+DYA&2NE)2&PL:DE7];%L_+>
M=.\P0M?56CS83I065,@^^_8<#*&5-T@RJ#Q, :E;;;)76>P;&A&JJ53/_(5!
MBZY9395%[,EWYUE,D2J1362$J<T;N3D1T1@F5=:</ 7N)$UE[D'LHN>'X#71
M?,$;0U&>>*&W8),B\CBI+)6>P9%7"0$MI45&S@-[PC;/IN- F[RX<;#2N=[(
MU?[ 6:MW^>?3@X<6:(:K_X938>)@O(?SU/,I=M6^ ^,,'-!%B)1Y#2$&>?N>
M T;?NS5OU==\^RZ"GWG@O\+WP41[+JX\;-=#G)- TPTK\IX&35NS6,RTA#*>
M [BFF"MT CJB#3^;V%IY.?(:6ZN-Z]9JE1A+W5IM"P>U I.YJENKO>K6:KW<
MUFI]A7,1K3M3+G\G'>@K$ MC6KZ*&H1O[@],W&'V\P->_?_43NE+/*3A8\^=
MP!%*X[J!-WR8P2$=._O]$\.&$&"!:^U']DH<1W6B/O25Y V8M=8M%IE5O,82
MI1LV7SYC[(ON$PBGXXE;<=/Z5R3SABHZ3KA^&=_:6^D$;NEH-T!-P#72$\#P
M(@='C1ZXC%0M<AB#[%3-^,)SM7/Z&9[C4C).&Z&)COYLYCUJ75Z>8FI?MOG?
M>-PZ;9]NV_MOU&L-VMLUCRO^^Z#7*ZTWWG#UHYY;=K5UCY>2?W\0S9W^D.8D
MI5^OJM_3Y]BPYE_,/*V/V(K2T76_>97P_.WF_EK0O<HE^AIC5/X)YW3&!PJ2
M3E#28R)_BAZ3@_L=#\HLM]T=,/]%^VGM06I^V#H.*6N4,0_F^7HF'W;I.2T.
M7Q]!T9NM;B0R-,Z8LX3_VJ&._FXZ+OK'ER)!>>E^,GT7OA)T\C07"V[:6::C
M#,_.@9 <558U]1N--=Y2S2Q1I@X64!'O0/.NJ=)@SG2R64W#VICL;>'FBE8M
M,HH**-J&OGCRUJWLTZZNHJVK:,MPXM?05Y3OQ&],TS4NG45S7W6Y>^Q94[^Z
M?O5+O3I9OECUA/1HT'M*0KH[+"TAW2TM(=U?_:@Z(5TGI"N2D.[6">DZ(;TK
M7[:[IK7S2V2DQR=GG?:S62CVG9&N5"/"RB8"GI8,K_/>N\M[5SSM#5,$\Y"M
M2ZJSWB^:C-O7K7B=C-O-RE3:@&V5C%M#:;=[!Z;?[IR<C9_=@:3$W3TN[Z9^
M=?WJ'27<?DL EK?$+_]T?=LDCAWIT'QS+^,*?2I4R*"3^^UN!CT-?\.G'RAF
M64,J$Z/!' '(2&8PP<(O\",RU<ST-4G0U9QZ?C,P9TFZGEOD"_N7YTO>HZ41
M+A<V,W<E8?JV /<B$)CV=F.0[XMG4.%P:[7Y@-LFA=H;M8;#[5*HJQ*?G7%)
MV=C>:#N@<3VH,@;5'3PG;[TZ&.YL0IA9O33R"M3 <Y9#"VPV];JJO4[G"=/\
MG)S*^@5Y'2L:NP#&'?@ S\I3U6N:6=,9^%1VO:@E+.JGG,*R?=RR[3.K<)'R
M0]\])Z7U?,%Z$D:T'MF^1_9"5S%Y%.3B$4W\_DX(23?3HRR=\T[X:0:MT> 9
ME.B]5B<G*$MPHN=PBF]YCW!D">:\&1Y-HGBX)E&,Q\.Y:^'_^10?$N?AA>G[
M6&:<@\5<VV6AW^Z=G'5&R!M91#YU@&W-:PTY' T1:.!:UJJR(;6LU;)6R]H!
MG/S/[['4;_>K=OJ7%.:S\/>J+?U%_64*P_ZC+,#<2E$R8+"7<)$')V>]1G_T
M;!6IF\57^9BO=Z?>G7IW=F^-RW!;AM6RR'O$#!WVMTK*51^$MY=NM/8D+^]@
M(?_;V)73-?7KN_'R3LFFG);5;+8"Z8):HA0TLMU>T[58HOT^>_XU2 :V=8S;
M,YU/)M$\HF:'O_M>$"2!E1]LD#3[QORU.0]"OUTZ#T(M;SN6M^V(@G8E<(CB
MU00N*UA8J[C_6J1:FO9^'I;@9W?:?"86-=TZY.1@[[02I6X%!&]>*/NU:7B@
M'96*']=%P2LMD]^'R]SIP%DS[C5.V]F>DU6KC:]9*6IU*S6@6$,%^=(!1:=;
M6D!1ZV*EQ/)5ZN*6P=:.E'%=L-7I/2_8JC6M4D+W*C5MYTYF&7%H7SJ:!],6
M0(Y 52-S.>_+<NUILTSS-.R;!K >VJZ']@H*IKY2B0>7R*OC_%E54_NN\ZE_
MOYMJIH.X(=X4#UC#@(_3O5J'IUD3QLCB^0LO"(D3:FLW"SLOC1J]_K.IHJIS
MBU3K2JTK+Y)_&Q[AA7ZM/(>C/%MES':E/6L39J<0R/>. IY0Z\;AZ,8N52-6
MBZ22;.U\C=CYZE8%@/B:*K%*P>:^"LS_.BS2SF.4,:C)::-W6A7L?UU14AWI
M*MVK[[;+OE6OQ:U*?O"NY&V=']SM@!5[CA]<2]/A&Z^R/,=NEX_$05D,[R_N
M.1YPSO["\Q>>#R8 MOXV?&X1_^N LY_NUX7L]D!?!HU!>UR12*LNEJB.=)7O
M0O:/,#%\W.*VG0NY(WE;ZT(.$!-U%*G4XY:F70I3:2[DD([$_KA=$1OUFI*/
MOWLP&!?;BC2)(=:V2O$E7T7,-7H>\OOYON0I!O*-8<ZE5IT?>NW2M:DOF96J
MT<E9G=\^$(':REO<E42M]1;'S[QXKZ7I\,U36=YBK\V'7KLJ-NIU)1SG<P]?
MZDW^Q 9S7QS3_>!X=;JQN#JPNU\?L8=E\HT2&LC7$?OQ25?I^<9>>87@M;Q5
MT(/<F<"E7,@M;1Q60C?:PVZ=D*R\N.U4VHI]S*S,]"'*?39S3 43C@= +37/
MJYS<1R?X(X-&E[DR1V-$]@P9[>%-67O0&/=+9@]XUO96F\ZCUNE:IW>HTT_.
MC/>&Y67&:RVNM?@(M7BK:/)E\,];GM>GE"_K9;$(3V76JE6\5O%C4O$=:GAI
M=T0C=+K[C5$.1NVPCFO*#/Q&L;+LQ$S_4^J^#UK==3O?+6XEW6V-UG22-HR=
MM, >;3#HD[.;>R<P;LV9Z4YLPW$GL\B"9Q.[M8_TUKZ-X*? ".PPG-F6 1)M
M&BX^8+:$WT'(UTIVPM9:CL]-_\YQ>=\%QQIG-80TL5C 1&?F(K#?R?]X+SO1
M."Z-EW[T7CQ,B%A.=VZ2&O[X_:-CA?>HD*TV*Z7('HDWBX];\-%OV;_W1JWA
M<)C[4;O5R?U[T:,ZO=:@,][J4<5_[XWZ]:!>?%#=P<I'K<E-KLY@=S+?RSGS
M)Z!_MO\R1US:9ISF'G$?[8D]O[5]H]=I&-TV%LMIQ\5S5D3SQS8],ZJ]5"I#
M!G,,PB>QWXDD^OH%>1TK&@<RQIWIN,7XVWI-G[*F,X@.5X":ZT7=>%$_!2'X
MWX@8GYJ.;SP@S>XVAO(82$ O4EU2GL7_^7S!VA4S9CVRG8ZL) CAQHJBA3#B
M$4W\O@QB]J!'7SW77HJ+86,*,PUV$C(.6J/!!N,I"G5[K4Y.7):(=9.Q8DV:
M>MQ\7:/1'CH?]9"%J-MOC/M5:8U6,]J]*@UY6A/U6M9J6:MEK9:UZLK:[D_^
M$MK1]-M5._W71"_RL@,&:A<KU6O\5KUPNUFX8\-+UZUXZRYIFYY+_3T$I/U.
M:4=2W92P4I+W*M7M:2%'+;F5VL1:<FO)K27W8"1WYRY.&9%W]W#<G+H1;#VT
M2@SM%6! ZD:P1__[.E-7ISCKA3N(;[TF.K;MR7OKZ\CCC(G&>Z:9ZV-;BT9_
M7!5&G?KFOE:5W:A*Z9QY_6/LT5$KS^$HSU:<#;O2GG4<TGWD43H*?K]:-0Y'
M-7:I&661'?2'['H]FU_L9>!@QP;.*9/,L+Z^JJ^O=AZIG984J=77QI42P5KO
M=JIWY8=]H[*[>]>:6 VA?)6:N%40N2-57!M#CI\70]9Z5BF1>Y5ZMD,U*RL@
M';1+"DAKE-3AX7WJH=4HJ5S#]<5S[YJA[<\-QWVP@W#^;+J<RJ&$7OOO7Q/T
M8L-.>'6R_U6Z5@@\#Y>Q"_7YX<K!C-W6KM3Q=>^K->(X-:+3[FVO$\DTVA;9
ML\$Q-AJL5>-P5&/+MHG/T@W,:^7I0._DK'^:K46J01$5D(\C%OU=^TF1[T-L
M>.Y:5YX[X7_D27__Y&S8RZ9S:]##"X >9GG!?-W!L6XB4Q4;\I18:U!2K%6W
M?ZHUM];</<2$PQTA*FH5KE7XF%2X"K'KZ7-CUUI%:Q4]7A6M2(P]*B7&KEX/
M13&AJV@.NS/A?^.B.FYDT@SU%AEB8_K8^B';&$)UXOM;LK&&F&8[_HEY"Y.*
MPN*?9+K]E"U[G?9&+1,_-[OM5!\+[7_O%5YF8=[9S5NP]'\VS2D,]YTY>S27
M :ZYWB31<>7CQ_T6+F)Z_H6SG$YW-DN6'] ;SZ<=?P?R:OO<QN._S,J,Q;CW
M4<G_PQF/37MJ=D_MP>FTW^D-S'9_9 ][W>[4ZH\ZW=O_"P?J#56A>%/C NT#
M963,L\+FE2\O;9DV4MR@\_S']<]KX_L_SG]\/;_X]//F\N+\RW7#N+RZV+CS
M9K91UIXF<_7MYM.U<?/-N/G')^/SY=7YU<7E^1?C^N;\YM/73U<WUY7?CC?F
M;&: L8QFIF^8<[#C86 L?#O 05D(=0COO0C>8 4-P_XUL=%8WYN^W3 6MJ__
M)YY9#0.^:+@1=5,$R5S:IA^\K?XB_'3-R')@PNF&/O2_J=-"')>]W@C.XJ)/
M^^UNL[/&WCUM3CMNWVN\/:KVO2N/^ERSXH U=F%\8SR\]G0DGP>H/5]-?W+/
MSI?H3-IO&$%T&X0F3 @4=VF@]IH2V-N<>GXS *<N30MCW)L6K-/<#/$/2WQV
MIVO,81CW\"+?F-E!T#(*G5#QH.7*=M^75Y^E*QJ"TK]+H?A3X&,\LO ]D3G[
MRJ."+_T.O@48@9M[T[UYM&</]E<:X169DV_3 H@RK/$$\[V/X%&"U5)^;3OV
M:\?@Y'B1GW%LDTOT8,,:3>*!Q>MU:X>/MNT:"5G ]S:=7\U[QP*!>0?O&;9/
MSCQ7-D4D4_A?"<\S$VL/TM[[ZE6[L?UY=NY6Y*NYBQD/P?2$CQ[;W[3[VS >
MG? >AF?8R9:.HA\;=79$&?G/[1('PT1@DIE:N?CS83Q7Y.ELMXH*'$$[9SAV
MW TST;UV]U,LIYA3FVIODZFV##8?LJUQPH+T&J7:C$)#1>M=-(+PW@:G=0Y:
MLJ37%&Z"U,9-+<]F:G3!YP&X-<G$U7=Q9'Z!J:$1ZG23!DA^OJW]&?91&^%0
M6<(A\"MKA3;8#,V6;+Y*_<-:I8&PGELNS[(!KD&PL"?HY,S@7XXK[#B/WKC#
MLC%8K41/8$/Z1SA($F:02C"), *RFD\5;>TU$]\&GU)T($9/!<0^T&D#C$?;
MMPW7"U'+P#2;LY;Q.?+A:WY21RP/OHS?<S#0LXS0@Z>@WTX/U.[DP7-W8#KP
MN=);'"R,PN$'@ FRC9GS)RP4SQ?_"/\1)M[W"(8$#CWI<JUZX2T5X,$W)TA.
M1V8"ON3X:5O+OIEQ/H&H%],[N%&)*3H6C04?=.?"[PS\JX=KT<2!-D-[OH"
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M9;A6$%7 H<4:&&9TUY<?]@<G9Z>M06_7):BUW7Z]=GNEO<ZR!Y5HL%6L)8
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MP3?X\E?AHY<\9J.S9C+'-AI!.3;Z^9%1W'R@.P[W?[)"S#M;ED1X&_G>=L?
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MZ9E5E*&=UYMT!49*,G9)1NZ=(&\IHQ:B=C.:E62<!/JRD^,E OE@!3K@\,:
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MF%#]45]5FMUMHJ/#/()<N.K!218OV:6SW=Q?C--FYY5/FFMG@)5/)DQ]U\E
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M9P)0*I$(< Y1+=#'3>1/A8\M:2YN+K_=G+S!;P?R.: 1%,],.:K]&W[!Q=[
MI QB-8X-0C@04^[:N)B%,\N9P^D4X*NQ(]RQ[<0V$OD8!7&SOHD@WI'(VDQB
MH1$2:'R-MXD[>/PLP1:(.1WT R!8NDI:$E%RANH>X_WM=[J'Z_YM-+8&AXB&
M@?AW!(MYA2L:Y'V]S4;>U]MLY'V]-[__>G/UO[]??;XUKO[@$N<'N'CYS07?
M:QZ)XS?;R =I\"MH_G/K.\SR8@P:*Y"Q:7S\^E22L#3'XAD=$!=@USE&8U D
M![DQ('(I)300^X)-01V@-*OG%)\Y298JLY(G;W@M)S#//)<7K[!LK"K',?9A
MNMO)XGZJ0=%9-\L]7WUOA*??!]^;8XIWH'*\MY;"S8TZ0TNQ"B(73:>XT;<\
MZF.(%+R/=X1WPS(06T7*\?N9#4<6:@U1""O[%Q_HU-K.P)I_'3L'B6X(B^PB
MAHYJH:<" %E2UQ!:0 F1JB2.F'#[,(ME(9=K^^9U_35]ZO6-^"94CUQ&O-EZ
M+]!).*B598W*O6#:RH4?^+0JG9MJDYN?8)FKG:SW=!;L9X)1^#+YZH5L0U_$
M+JI;V5,Y;\'#O&,+/N>Y:+;!ED?MIL!SH3ZB.\(22HN;.&,CQ$R+]N!!#=K[
MK=4\M\.VW+UF9Y.VW.:V,VKO<48;M5XW'V!I]SM[G%5OLUFE[>X@&OX+_D*2
M'$5!" >?O]2:5>-U/%W( G;'II*V(_3P2A'K6$'X3-RM6/E/.-\^V8Z  ;OB
M&S<ZS3<LWX#'^\#C]UY!J$=^"(A@-+/%'<X?M7K8*)+: ;PHP%:=/(2 )1\;
M0YM*!^G2Q#ZM\!9&^0(YN2!S$=8]&^F%0^L?D2M40*-#])F]J9-MX8?C*E4@
MN.NDH',LI:X,GLPFW;LFA@M "S]$?)VRGN'4BG)([8OCQKBDD.&^W G?Q3<:
M$P5^S/>?GMQ\^? -70+4#-PR>&T>TEF[OTVGZJTZ:_>:@Y/S;G%[UK@W.@L[
MG#3.")N6:H+!>JK9%'#V!\?S_#4-9GLMK*,NGL$$G\_J';%W'30X1F?2C.E[
M"T,?:!?SI*W)Q$:1@:8U 3)AAW3\8P3[[E*^ &RI #E 4H^^Y0OJZ^H$GN%Z
MZHWT ,9$%!:B@_X0G[\*MTGBP;!A_.:LSDZ-4!61;62AOV(@OD$%Q'<08ZF
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M)NG]7CKO)/%8J1/"3!ZZ$VX$1M00NW5@*)027L1T:6+8;QR-0E#Q@(3'<#%
M!RF<HYR+I91"> (&*/A3\<70A^\%ICZJHM\$)1GADV,8B>,MI.,O".GW*4(Z
M>/Z2D_'OZ*G0GLLPAN'8WX5CSSR/U-4@&HU@!B;VQ+@7L!7P7QPOC\PC/RB<
MHS26><S(%-24JY&LFTDJQZJ]!H4@$/JFV.Z=YX!.\=T%_8 ^&;G\;]\.OL,;
M(U?24*A6BPG$GN-6H]:,Q.#YLE4+#@"H(?#F'*<)C*%8>O@4[#F%8SQ.5,(
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MC!LKC'SWK,FWF?$OS>$O\8\-]>,$@QKR]Q20I7I*WJF!K.,R5W)I)8 -)D>
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M)"K=0%T"E1J?#G]X2W_P,^?CR+ OIS*BGICYUF:[W*UV>?M=OD@'V+HF#,'
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M'..(+67B?AA:'-GD[)#@N^TFO=F7QAV8!@@:AYB)&F0LHHW9C#86MU'E)6=
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M.>N)L_25U">*^CY2ZYBTA2F3V:K2^$U*NWD!=?P3B:Q5 ",BI4<&G<;4_<W
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M]B]0A\F-H2S&D#J2V*3@X8!3;>=Q0V6'. ^SV.X-68<,.^ Y=Y1W*8L_':7
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M^J()"LKHNS7%"[">=T#%4@F:^+1HL&7P=P"K !P/_]7?EW#%PEI2$W#9#[Y
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M(_@J;>8]I'%WYC;?N\_F1AS5\G"";1%6_),1S@9-Y0O\P8>];*AY;P*[\A0
M)B]IT5H/8;EG@O799PCF/1M9Z%'PT4NQV\Y#VU#?8<#G',K@=@SLTSIL*F4_
M$1C/4]^:5WW;5\[PH".^+;-SQ(78%:4=$Z75Z\?;NJNBM..AM$Z]\0(*Y8]
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M!2U.&1KOS!IO??QPDX!!OR9S::7\W-QN/%SVDEO^);_EQ\=PUZYQ$4WA8)+
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M3RAA:@(G$[F,J<"!*U5B9P0EW@FN,W'Q4S);,K[_5$9G;[Y\^*;BL*:Q<**
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MU*M<XL0PZ&W;[_9QI$-YQY^RO<N&]B\T_U/6)!TH7BL'W<]ZI=A71CFWE??
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MQ T1G8YN=;[XGN$,A-O+K-@*'8*E'SZ4!M.1L @)1>U;S;3CA<2=<UUR?%=
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MQ/Q*UM9>#RP1=4J..ON*;(_(I@3&EO(0:%>2U:B10C9SA->BW[VA)G,R$7)
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M6"5<F!D4E ):S$L;^A#B136 4MJT\0B!'I4<8:4Q&#HPE*2 YVF\I"N7OZM
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M^8/,N)I-6E5FI K2@9(NI=YK/S2$::Z8QA6]>#--A9JF3F@<8H]2-M]\-&_
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MC: @3%OTQ,&6\BNPEF->J4QF*$&CN1G'F90KZ>+^$TZ71:P7=2F(3"R7=2"
M,1V'X_F<ZZ1_&]TPII-KPIE2#7&Y2D;%)DUCGP[+NUR##&SD!;CXX2_?LKJZ
M% P)NI@(R$5>S.#YT(Q"TI'[W V9>RS+QX[^GU^?/?TL.%>1E"<I131UFZ]<
MCG5$/WC)RR9\^;\/.Q>HXOTBV5\<ROQ]$?/6['[O<O\41<[-A/08IY5TERLI
M-]@SB:Q@L_*-DUC($:="OCIPEM]_!KL3%AS;!QM[3SAL)Y_ZHTPNZ$T*@.HR
M0Y,''"#;;/HG*86<9N8C&? L<1^$<Y@F@?6/T.C !$6PR!WU91'*L7'V \E&
MAMC'O5^5?8OV\9N%O:?9OLO9UHF2=&-#7S> G<Y!T[T'H0,U=U+62;M;3C-S
MMV3S&\>;31%6-O6'3;)Q(F?4(#GLO\LPYE69%[N6G=[JM($^D+\;J7#\U.R8
MGK<ZF%0\S&3I(YZJ%1 N)X/SILEEZDSWZ=(981JP:K1%HRBX$-<88JI%W0R0
MA+2' S\'>=,KS5Z=SM2/M$@2='^ ;:>$,0!O)?W\46Z0$ N&1F>Z(F![AF)_
M<XQWK@^83\OA3B,;)KK5J(21M-)J9 0_HC:>HA1"[B,R^QX7;CC-UF\P6QTX
M .$1^ZVFSG 4 T5V:U.07061>>7*N\:@?DQ*^[\/FC*'6'I"PXUQ] L0%CD+
M_,[,=8XVG< X%:UH5KD*["S=#' <+34? 5BN4'F +&T7WYC3D%C4\X826-5Z
ME.@43C#J9%L7'<C-XH%OK8 !^4^ H%,V?S3\'NJ>Q,4"M%3&P;N0E*CU-^TK
M?W#X9_-SI)UTV<+JX6:,HM+FF$Q5'>)SOZOJ*X[Y^HK_6Z&0RJUDA&Z.]DNR
MGL':R52,&OIMSW*492R:(4XV] E1GP_WPG&H,S<)TM.1+9J<F#W-,$=_+)!F
M;YOZ:L2KBMN1 &P481.5@4CG>2?<A?>@:R Q$;S#4@,Q!'0)GE@7-?!=D,=T
M@F,/J=QV080+, Y4PZ#/%'HUA#_Q8I24;LN><6 48OTLQK/'9IOI+."Y_<8<
M=$.=)^8'Y(W*XAE%:>V4OF.$B?@GX,9*OK9I Y6ZRL !9'"RNHU$?T69\<,-
M6OP8O#_R%&_0QYD-YZA&J89SXI)Y;UTL[4CPTNYHWX,H%ZUE)+Q!M$V/NCUC
MT'FG_2IU,]NNPHM'& #:B0QUEBPE2@7X#44FN0 !YMR2B@MV:E%E"=;HUZP*
M:HRDTX);E$TV78> ?N[0/U+5MGT-M%PL"\3NKNN[8H6%=()U7@?K!,D9$8GP
MU.KZ,B:2D83^6Y=@K')G>KAC3C>;LS)?.G)!:$;]@P9J;)?39?P/BY*R%-3&
MNG=*-=B1U45=S9^9+?R)*T>BRZVY9C*W:@[.%]])CZ1I)I^Q,TEW^<2RE$Z5
MI?<5-T77#D!V1]%U<YV247!)J2)'A]:C-EB!['"B7_KAM'5]S"UJ?0]#Q6"R
M+;JJ=76A;<_8\(+<[AWW1,'_R?CT7M5^G?[3I=Y0;J8C<8>B*NAIBHY,D0^,
M$$L&NGV<OYBV(5$L%!=J)0TP-C9XI33:[6&W[^H=B.5]&(BZ&  SIVDX.@VO
M$"'YX7*&3D;K_>-F0:(V[MSV0',WH"6A.3H-]I'!9GD0'ZA2(H$;0AQI4V"9
M$F\H=48M6A\Q+\I\M_?!OW^B2@Q2/.DY'A9SMLBOO$>ITN2GX3^ZUO^KOJ(L
M%W/P*&<$F1N6SD J9$!]-D^\H!$F1*H((2$Q0$SZ!SD-'W+YJ;-D,8'U!Q[:
MKI;,ACY3O 8_P:1=I*:34%8R9K')A='?#W=*8C'CEEUW4!85.VPYMKR^&]MO
MT%)/&/&D7&)&[X2S/H:S?G["6=^/9[DSG/7',8.4#(>5( KY>M\]$";#>WB(
M4++<\E"QZ9,L-UF_[B)B6%&#:(APCF #^Z(C9B?_?UR3*X0VI!.B_04H%E)2
MQ6HAMQ*C^YA#X*104FRX%.5'@'C*56<3O'^:X&3LN] ?P8<:G':SO!:Y97+:
M@,1,TWV&6Z66X@:C/2C)Y@^(F?XAY-D.4?6GWA H:+W(NU0CS$<R)>39*#_L
M8E+V?: PIA]:X("DQ.<R*@FD/E'7R::X F?4=%87==TFP1;R46&HIUV*Z=%-
MG^A1K]C-#?VK :KC5W 'WJK$<!V)H#Y@H*\;.;D#_C&1LG-;)"8W$]GN^E<.
M1;)8INF2;D6=>N)SN5,^%Q8D M@_LQT 1G)^?>F7& EW#A@0;V L,K&WS$.>
MEX(_OC3^R4@!* 1 9&'7N3=N]>:,BBRQ7.;/4EJG.$.\>=\Y6CY!42FA?-46
MDZ"VM',G"-:=(O)2D "??E82##:!#,$B'/8%E@0.T'8@%^G#Z9+N&)0I<=:J
M2M3TBCI-\%U.<-)K;PA=#643]JA8!E/W.,W+G<]+3>)>(D5 ?24Y!QOY>N<G
M#)E><(!?:Y1/4W774R4!O.9Y$;.CT!3RP/MZWW.S,(3_F@-RDBF2U?\2R3F(
M!8LNE\!&PA=/<WG7<^DWEJNVW87V3C(RLS*TDP9],B3DEP9MY04=J7FQI".#
MJH8B6Z>IO=,6KGY9^H",Y<I7WDHJ^#:X,I)0X)E-6O!/IO3#;3]A<H]A;%%U
M/!?"29AZF3Q+IVFYZVF)49JEX*(]L[\XM(1Z4M%;DV%ME4H^H"YL?'AO$MD8
M^X^;R,8CI!@9&C>D>_K&+TS2-#VM\CM?Y4F67_'S9&UJ%N6%2IA*?))+("K.
M8JNZBP8P,<HFGUE#187A)I=39MS/>)K9NY[9_#(O2B/%;#/MX^SMD;[#TU3=
M<:,]$@V RDKV/"0?*G^C+I&/TF!+ZD$B;'Q+"KG3O/U&QK-Q$$B6=$5+6![9
M;51R:(G_BN.I4SOFW;=C@H:1(E/5;V)4N!2L;> S2/)WM7?5:!\Q72[^DU'H
MU_1AW5=Q%@A'L"![B-RS<>@^JI'-*G &O:U4M1."6N9/*,>2)[ JB AFK2V7
MJ;Q58*.;E/VS$GMT#\"?*"2J%SF5^]@*3C'/D91>F?1#W_#MZLKR2(&D85IE
M[%\69WK4U6>K7,IRFG:(-/FP*9HV5'RS4)"[1O=D7F%K0&EP=*(+6JWH/%8O
M-F2[%NZ]6X5M81LWH=CUKXAAIBJ7V;%DFEW\YXOO:?F_SPF$B_6(_@"KI.6'
M.%Q\P )NX+G^6]]]\_IL4Z^\*5R;39?<>O![-,C:3:2=--.J+%&=#Y#B' $
M"UVLM3F>FL"I9S>A=1S.JPV7^4FC#&<F?VD<)8O]'W)13[%&CI<-MPXG2H;\
M6[WQ\/VQZAHV54D?T(18:$*G"2S,5743>YNJA\X*^/CA<J%;F"YR@J@>@ZB^
M.$%4[\>S/#*(*HZ/?5.P$*??K90GN:2S/O)Z4/WXLEC[?[?9B/&6F.^8"(0,
MWH2K$UA!LK3R4A[$Z"VVKMXV^?Y"6KF\-:'?)$8\%4QN$^$KTTO&M+CGBU?5
M(3 M@#RJS ]JP =G%]?A$G^,X83^=Y4_W^51<SRVU?ZZ_M"F!]?S=7#.I>+Q
M8YTQQ82-)379^0K.IZU(:8=G3^.3'."+HG/D[N7K7_H6#=GYSLE1EW@ 0D$(
MRHX)9>GS&TLX?GTO/#;8SB !O:5Z']ZYS%?O:+3IO1JNQ ^]N$1I5 1.<>)3
M"R+]G#H4F[6(9AO%'O:P:.2K^6FFD1XX;FD8<7.)5N&F-'>=\.M8Q?6Z57==
M"!$ E$>47A^B(.M#UO9]:5<X<PM%6'%DW_-CYPJ8@FU9+V%G*;%&P$[O*#24
M"#^<+0]GX1],ZY/-LI]C+ZS]3 >Y16_TM)/<CGM:1S^T;(GD82C>[;=LBZV+
MR1>;J,/S[YFF:%$6K@_*,C?\:198BI8N"EKXY_#&ONX*[<NR ;DE*,1P *6=
MC@D[HWP*"K+*>YU8=H8 <295$._%? 3)#4F;FOJ?:8]-QO"T:_T>*\M?H;9\
M'+!OR3FFE)O48."IQX8%]$K1P@I;$F54J-JB"N-3(W+DB1%&#"Q3@FR5E25V
MD)8%NFVX@)/,1CM6CDHFE1L6!]0ERLJ%)42NAY!+R-"/STYC_,J:J)YOG&F[
MCV<HF*363BCM8U?D7)YHO-RN12/32)*78B^_[(MR;<-."43M#L_$GVP*.5_8
M]:EJ/Z+$)<A\&X/$VRY_YR9V^"CIYE<QE9/$70S:#927<;E?_8H.$_,IQTP0
MQZ2EP=Z#;IV)1-X<!],Q/JG4,^"GBU8M]V']+97K[T%V%V<:TF/^"J$6-*)?
MFA(GG=3#&*"5CS7AS3%JD6["C-+SCW_Z-N.YY0DB^CAS_&$YD=YFT6K?V344
M49DV]E* U&$YE\SKA_YI^588%QFD2]?H1[(,>,#$BO'12'QMW01\C:,;2F7+
M6D-_\> 8 =E;G(FCRK!YBYR=-UWK>#X]ZKPP9)G!Y&\B2P,\F&$/&_/47LM.
M2PE>[YPY].6H$YL0I.9='G[$Y+O4Y4/DN>'K#)N38Y#SB$P(2.(BS:436L.V
MZ]<<$E?T5*J";HUC(!^Z,GE: 3\2?6OR:(%V4"Y,1(US3V1+^<>?CE,!)1(8
M*&BY %DJFH1@YB)O>8NFPZ(L2%2<=I?L#\(]+ N).Y0H"/V&$@YN^]R?&YT3
M%K"5/_E)CD/PAI055G0I'"3S''Z?79!BQY736\J>G9^?FX\&N5+QR36CSHP"
MW-#%U0LJXR*_@Z>C17.^>.L],UC)])7#M?5J<3W0W<QJC$.M"S"\((8T"$/S
MFC-/Z1?\<%#]!88CAU8%C'3G[$AS/>7(=M/3XM1W?=TCC Z_N6./YB+PHPJZ
MW1]S=*#$LTP;MR.T<./GB%?1CGA5B7RE9HDCOYHW^<K #+67++ ,,7F4\:[I
MW"OS?;8H7;Z6^&M##A#H 8LV* "K1;[T+U;WK6'$E*((=1IGTT?L#9;5;-&(
M^>@ FO"_)](??TKT.VV,TYUC$Q*@D2W=>@LYL0F#D$U:@\02)P8X6(:Q(1X@
MVL/SY.R>4"\>V''8>U\;4D_>@]"9WY!*QN383!JZO$LKAG9 =,:7S%RZ2:R/
M/:=F3!&5WNJ*C4I56XLG1AY'0&KZ[/W]5.+6\+=,=#SX3E@BV2)2@"8S-+;1
MU%$G+V*);XI*QQ)IX4H.$ZB.C+AM!DWV1PG_IEQ,-+QS&BV//>O"",R!+0Y$
MO:06)W$UA.THR*Z)/TG^BK@YF@%ZUKZUO*^(LH2%..6J?LS^X+<<N,)\J.F3
M@BZ*XB#LD1X]"3JO,X?**EJT:O8H I0U@AT:+1=-P]".>Y.=V+HB)'X# >M4
MDF?2_$.[Z'1T7G=T(CADPNOH]P>Z"B"+L#>1:/*3LLK;+I*='+4$.W3<+I/C
MT%OC9,LGI]D=;+=3:?[)'UY^=BK-WX]G>7BE^5OFQ+Z[A'N J,R&]E-6&R>*
M/V^4X<9DO2:27'.E [[%[+%@<MNFR3SJD[+Y:PS,T%9<Q'.S5V%%5'5*603!
M]&9$^)#?2:6RPU*90 UD=-63LF;0M. 2:,L0<Z.U&!-\=$H^P S]W[F&XCT\
M?S^EZ; 4XVD/#+^OGUJ*XQ@^-SF9MCYC"1KIZO%;XO5A/_&5^8P+]RPYNFCJ
MW \599'<H19/_]K\*XN(((RZ]F$#U21[2B313$IB-?SW!IPYFI=  4?6=[JH
M X^.E=R-0#9ZB+H)7XTO9<;C%N^G(ZR15?"5PU;1IPL)C%27@SR]B6=HM>H_
ML7DY282"G%1<KI0J\T8;"W-\OG@5'H(21J.&C9O1>!W&V)4IRS 435XR_W[K
MW#N6[!Z]Y&WK^O?%RO^=UL(J37.$GC/(V5#\%65@M(UM0B0G:FAQM2M"W6GL
MB'E@71Y"=+BN.9BE;'TC@5V :S'Q4!, \0P)*BZ%3<VRB9@XU%).I6"I00Y%
M*_(&<J4]]>?7@W.'%42Z&$H8"4]=("U:>DN >KJ2W:7J /\6./:?!U"XO)KB
MG?9[G?@LH$AN >87_DKE86%:(5$ZPKHU:W7."SD"L[9J,K2Y+>?OJ)XLD#XN
MT6><NMB14:9\A&MBUB=!(N_R7]#?G#<[_[QT.+(0 \.#,B:6STOBZIOY#D/[
MBCKLKX/Y[*INRO45,)) 9HVH@L\7KX,QM1L8*U:/NGR5@SZ"VN/\Y[V8=*M^
MN"4]>:W <"8(*2CF!FN*2VYRE'Q9W6S]\_U32@K"XE@)IB'DJFC$1_+&*:;'
M@B@N!\7S3=V8JYGU9;4ZM2E@M-P>]8;[:<[\F81 0\3N7#)UY/96!/&\SM:G
M6R+EZ83;1G8[&YES)$\W[LK8=&2I7=+1E\6C(/ 6,8"T<9,'@>U 8\FST1*G
MK2V.%_D+%DTTV^DYSD<5UQUGYC;);_T3A@B#1UZRH((+M,^;-$%0I-O4,"#B
M$G'N0GT1<9-36%<LF#_JU9W0R YB-3V$%78@8 -.7I).%'+]2ZK>>B<=)(&Z
M$L;$J0,PQX_H8&Q<*!S(S<@^QB9A+21$)/OBNYX4O?U _:VB*?P1](2+MQT.
MH4_(Q 68.OWRR7=_2[_SY-,L.)^8;+^4T&)NNC'5O8C[X4^#OV#!B(X18B2Z
M'!J80,KI&M;NVPSBK7A,0M?*+^@^-..,A1%;C0QYV(WT(#?/4QZ$*C[ZN"SH
M2 >-CB@]U8&TCQ[U&OY1*BNZC.2H%T!QP'()9Z40"I$I''Z#)0-XT2<NRJA^
MZ>=\2WX!D0^/T=#B0)#P? %PP*QLX^!XS5"*#1&3:QDT)^<]&E#3<"I;1)'F
MZ7@Q:<(80\-C#''N]TFS51TUB&ZW(CTH8S'PJL:^E!0]"Z?*56J>(:#*QMY%
MS 8K2Z-UI<&!R9T/><B%1^K:@7T_7[R5KS 1'UF4EFA4S?P'.)0MVDW%9O7(
M.$V@3H<.$QQD5G8= J?#(Z!HTP[ J6EHT[>\.E9-7X2FRRF-WA:-,O3H,J7:
M=FC[=))3+UTI_LT[E^A,T'J)K(4P6\.U9=HT 5FD4)][>4QXRD@.>A1B[* &
M%G3@J.:HOW"FSL6VR7>WQ37>/W.39D^N4">_J0Z9S8_=5^G >U.(LT)A6<)D
M/=*V2H_C>#X.RZFVD?N;L0SAL:];B4(Y:EBB\ .*$OX@C)17KG%#)/>0HE(5
MF<>*-W3HN7R=,$[;UJ,K#6LF@*8/CFTB2 7:PDL:OFP2\2 C]CT9["3PDJF4
MEE9DH! ^#&3([6#_]I_1\%KU@#0[%G(?AHD@YKE_\4Y#NRZ$BF^89)FY:K*H
MN1]G^HJWJ^84S73:^=%ZGL\Y>@I=%<KR;S0WIB:P[CO$Z>*O,BU!2.0[K;#Y
M,_4@2F>F8N#]?,+ +?N.\'"'@=<W9&+2;+XW4PWW.FWS1K@+ A>]$M1S*,%?
M1D>9_"='%4<:2$]8@B=_>/GRA"6X'\_R\+ $1PW,*STWC-".M=^AL]<A!1//
MF>7!EO&F*=B0.!O8B#H] ^CB#=^E"#=)*K$WZU><4CN98, 9G4SC4PFM!R9G
M-:PO1E@I_;QR:M(2E 1Z,;DIXL9#DTEL-D94#&X4YF3G\DI[,:> 'CQZP2E)
M#F*YV/DB=/"9_K%QO6=R341(_G6_G1SFL/;\_ZS<VL]\BU-'PO2X9I#,!ML/
M>&@F,EF:RL!7_27)$]'ZA/FV9=)'Y^IEX;<1BWM1S"]INZFB=$AX##/#-N+G
M3M8LHE[#TP-9(A!8;?72TG;R.C$[HYC@<>"<^$U+QJV4?-IVWCA <K>GW-SY
MXLW,Z4W#B;&F>I3_+2IDNL#@(/!_\L/3?9@K [5B\F [R3RF7,T)OS;6##6<
MAYGT0^Q'OMT<8D]BK%'-.1I%*R^8#=XN6_259D+1YQ+)K?K*4&'(M SV-9"5
M0@5R'- D^\;N\S 8W$(CM6FMC2C# ]9UJ\6OZ7V=V@ 42Q-2B<G&V#0) #F6
M(C19R5(*77[2A&RO:IJOB^IXAF_VP@)/"6)"20<UDE$5LO(*7[$NY^Q4S]P+
M\(,P1[Q_9L$P1^$MLW=(<"^_!E.6+'VUO930?&!!;:A)#OK;!TT$#$1.^]D1
MS".^I777U>^)?U],&"]T\J/:@GT&6TTTS28C.S/,+G.0R_>7AH*E?S:.4#F*
MW/"9%NUFPNTS1<V#:(ELU52?=6(W?K-7EJI7L>:\*]DI+H'[<*4[BV^--A&_
MG@!2LTK$=3/+R#)7QK1[(D3U8S:CP?H/9-=A>!YMT,WY5SNK-YA)K$4X>S/8
M%9Z&L&3K.<YBAC025T"_[S)[ROCI&SH!\6B.\YN'(@@3P7I;S_D^R16'*_IA
M%KLU9?-C,,#HO5 3_<9OG*)M9>'<!LU7W$F?P?U9--_V 5RKZ!G2KAA6/,1'
M 8LC&" OJ.2CD4G1B$B,3>SXK4]94T[7D0NMH<*Z:/W8@U(LDY:B@EO)*$8@
M*<;SQ4_45)E1;%6PSQZUP0D^14PQ_E6(3(;)41I\:1*T)P4U=DO7NNB%)LTT
M3;(0>:I!CAPTG/0C+)JH=OE I/3>OU3>&)OROA,@R;@X20UXBZC_.VG I:HM
M:!!R>%M_MN1K8;XZ'&.RR::'WPR]\6#3XT##6)%UJ)=$#L)A&!44"Q081G6P
M.)+\>_\._'/J!63(O#]XR!1U 2Q!)R5Z5P-*/M 8T2)CTZ0K[WR!<C:YTK0>
MK1TC'ZBNB&D/%\>61B*)(B\*L+9Y&G;Q3VA:^4$P@V?M"D*AKR\(5_]B9+=J
M9HLA@0M&>&1R$\P%4$7YVF(0J/80FH0YB1@U25=Y>,B [WW,=H8\,V2C(+ I
MRCFT7SD=ZM?-1;'W<]]=.5?-;3;!Q+1NN&19?)A,DFS9+2L-8^>8;OL1HJ2O
M HPD'QV?"-VESX(.*?L%TC(6EQ)+G/MK)^#=2<S"9 Z*93O*527("K/,U7LD
M7!OW?,-QW+BS[@*8"\1"*=B-R_<^GD1=&]5T.),HPL;S&(UY473"50WAA=;1
M[&L@Y$"06<2$PC3$.:JFCMDI)RPTC2+B+2HS6AR_R1<PEJ\\(#9)ZG+@\ 0B
MERSKGD@T.2@D[Z(=,/,%._6H=UM:BI>BG3@^K3=WL(WLP!_F_<-Z=#1$C]'(
M=U=#IOXYRK5V(B9*Z]>VO\8&+"%304D4D"&L7)K22JB^J0Y$AX\V>'?U2=#Y
M+@6=9Z("VM:4-UDW^97)92A_C.&XFD@I7N60O@M)*8X'%$J0+Y;@/%W6[_6;
M&4[8"O2]H6\I>/N&HL^DN>C^_VG24GYU<QJF;7L7JH&E@ZOZK7=_%O\5=9Y?
M,W,P88V[CI&<#:7-O)5BM@\;:I BM&(=Z2DE<Q7?4K\K-[44,?FR[A/G]J01
M<_<:,;PVE7?"^6L>*8N<)N2.)Z2):&LZ38C))?4F3C-PES,PT^_,'C?-PE5^
M2'P[ OQ)T<HUW !R@QY(RIY2$C$D=*26-#^Y)Y#%DS^\_/P$LK@?SW)G((N3
M+;MS6X8(FEN1%;?MSYHWW_WX5BCG;64B-#4:Q;'%M@=^K>]*T8^@[ :$:-3C
M3:(K"L$30F^3+\HD6Q2<1A8SH)]<1 =4I"N:!$]'.%B$W[\++J4KI4[9"6\
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M;E*$(P[<\\4?:P.)AH, 'LD(.!&IMY*21VN6(I1V2.1 FF('SB<X&P$S$ON
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M;/Z;?;B*6G#]T8[HJ4L.:8]>JJ7PME+IDF)8@V:8+PU<AAS3)YD3-5W&'19
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MR;2F_.?JA(**<Y1^YZ)*.0_/=I2P8Y1MYSWS'DS-^+IB1W#/"B^A$BVU)3$
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M)_2ZI>=HC().MLUNK^G>)XHF?^L<A,^%6K>5?H_2MA]P*G.]-RM&Q-]=ZE%
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M8_GX4&=O67\G.="D"U+E*GK7)CEHHX0.ST8T!_*VRB/XC(5X0%.V3WP,4\[
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M7(9%P6"TV--+9YWV_O/YRPB4@S?Q4_A=$IPH4D>$!HSN6C35%HP%8]?O;MX
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M^];(\\>P!6G.?'<M.&R E*H!1*EZ=X#2'> DATRJ!KBD 2BI^KTA2=-XI-/
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M8K^.)@$9G,M44FI#ZZ4TT/D)<N\3/M[>YB4JE(VYIPOAA Y3<-B8HM?RID2
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M-#'Y8/*YD%Z#8+SJ==7O6E*?DGR)X)-@)*,T5<_= 10+-U-OG''H&*LK*=/
MLW3L=,PI9'0>PK['<\84,W%@YE!LI$4AW$B8GAE*/CJ.<#E3!,HZD^22$:V@
M_-M G/;H9#UFLT<;86K]:B<8M72<:BM"SW$KANDK_W!@89'OR=T9>Q*KR+*N
MKWP69L9L2R_DUX=(0%U)Y+)N!>3F5LE'RNQ6-X2ZN(7SC2VCGT"B/+X':K,D
M+JO77OA"W:C9ER\MI^YH(2PCOE?ZBM[1O\#=B]VM(Q>Y?#?O0' =!;EUI[]-
MB',#V7C(WCI). S>66##$@N)^"K5"7I&U2D]N1%$Q1PA :$IIN?%C,VW]4I&
MP7012Z.2+_(+S,'#1SN>,A7R\"%YS]Y3H>.@JIB.U?]_M-O3WK@_84]J Y4C
M)5(L9IFXMF9Z= @QN35F'!$ -DBH$@TKAZ[RZ\A:73CG(?$8PE77'LKU[G"Q
M"H/T":M8/N&+]TW3WEY<M[="B4A!9.M\ $I.\0ND<Y]OL,I]1YM/[0!8*^G
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ML^D=%:;K%\'::?H=!;.H;63A]9'QZ[8%-HQC43;5.31REVYKCH]%%+EQ]@Z
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M\4Z7DJ"S"#OU/276)N1&91WDG)F;;KKTS9P14\H1#.=MZKQMPW:_DI2"\?Z
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M !W-Q?=@F@I="K**G2AG.LL)8U_K*19!9:3F3XQ7(FX1?WDZ^WD@T.<U'L>
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M;@(N?:^1$P[+RR$O"2M,8B%Q5+1%3+1DIDZCI?0YH5\(OAHV0%6<EQWG4X<
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MJ:GVVH)N!/J9!QM:O4%Q.$E+9[FWH]0E=Y-G3MGO^/<.L-W79&-9L1AN=;C
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M: ,$X4A5"[O/=*B4"=V ]A\/0EJ)?V,:2\R3+?&FE3H?%UD6S8FEB#AU(G0
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M+^?B7>=:# JH*R;?C_B2,(G4LVC/&7V+<:1@7YJ*$T;(%9<NM1H5)S(BJ_I
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M-]G!;R^#S[[LU]'-@!7E0R-XCR]<M2I:3<>,^@,RL\ JA+_U C[3OHPN26L
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M1??=,39XO[&!.XH(T59VFW[+N-U%T8)_8Y-O$1]PJXK",QEDR'_K8K<OH7=
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M+[>YV1V2Z6:=%_6"Y+N2 [E!SE1I77R62RZ&S)RR96")TA_&FX5?+.8#7*:
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MH$K6*C)N(D>T"N,=3L80U"RGMUB_H?T2[LTZIH=71II_C O+4P%KXNL*1#\
MF&64!0N;-^,=:ZZ.[KB)QY(]+<$G=]W%38I8,5=":,Q)4]]P6_ZUN2H@?R L
M'?9(WF3E:\ILWMQ2>79G?2U./V!\P_YL%R3J.]%@=I6WY)G P=W$9L.!16.0
M(26<^7EIQ< NJFD:86=O-AH_%U&):2&F,J%;B'5'U2D7)Z<NBF5,;,A@^CT
M#J&*$-1+QR8=;'?8&SD-AEPPTQT @^L?+^7,;FF-&CO1V8_?*VL*U"(MBY."
M*$7);@0BIY2'0P[Z7D\Z:00XSKL[ L&O*$FTI<I 70@+=<G@/3Z6OFM,-0\
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MXH7@=P3P@Y!.OI)44:@^2<'H\UU:11BP]Z4Z[E8=3Q'H(X46?Q!X(4WU?$V
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M(*T4_5EY()N@:CKH&=J_DHG]K8YH%E='G/9=XTW\9Q2,[:O_ U!+ P04
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M(*@!Z7/]$M0):B6+M@5XEIF(K6N7U'H&B*<LG4^VQ-:^ZC:XMJ*1_>%I=*#
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MJ\=H'(+3H1Z"LC+99%QLWIIJ5XR'JKC+O63/G__E? :$#\Q)R0"YHAE(GF9
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MHRK=&L9*'2" +3WOLY_7+S$L\1]_^U]02P,$%     @ D(&H6&L6,CMX5@
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M=5AT,FTG=M'GEK83NXCQV&TG;BUA^1;5XYS)N+YCB]ILC(@JZ0*.T>:I2C!
MKKV%R$-D7)$C&%K?-MP+Z$0:4^RDZ$V<V5O@?<3.US&M"GV[@-JE2\7.^3 W
M !VV6T4/BKLS_:6%U ]&":,%1N8"2.5JY:@K$$2D:%\+61QCCOOFF2V'H\*&
M%A;'8L(NPN[G]N5L,EYX7*L2?1=3]BI2S"10U8(.#M[4]#V#.A>K4TZM?:!;
M((YPB+:_<FY?GNPAV1[JXE_DO!!B&'T(P_QV_"I\'<[#:-UX0VHL%#(!K8LB
MYVP$^,1E;<\4E$%G$5L73MP+Z"E0H)W$>WCS7Z1T?G8^JKUB-UTSKH"J& 2+
MRH!D@A8>A ,O2@03,LLVI!1S:T>Q,[@G09->--'#Z?M'G--:,:\O!U:H"A-:
M*W*63:+=C-9?S2/CH%A&I2R39"<;\^-N)$^!# UDW$N!U?7T@K?CVX<T'R>C
MT9O)](\PS0-OJD>D$;AW%$35XA!?#(/ 6>1.YJAMZRUC1X@G<>NRS_E$GRKI
MP?NXX@[=/E;E08M8BX@]IGILSP($6Q)H)8CI%HMKOH/<A^?PW.A5F9L=T_TT
MT8-3<GO5 Z>ML:J0U\P$><U"90@YT1[H12U=UT:)UE?[F\ZYGRHC]I1Z'X7>
MUS*[I=1,<2: "%A[SV0#SG$+:(2-)4F%J;4U.7*B_"&U_W!9]^!H7.:GSGZ;
M;(B?%KM6'9:PZ$].;O*BP^!')*G,AG-<M2U:YD5^Q#3YO-36/\+H' =,)>6#
M9B"MK@E,R@()KD!)+@3K+,^R==U?WVMZVO0\*4;T4#>RD-S;V>P<\^OS*=G@
M)<RE:?X5_UC\:C9P+N9L6 ;4LHY9<;4GG_1@-#?T2HJ8>.OSF6[(GC;[>M!.
M#P4@&U N^'T)TJ(T.3$#IF"LP6B"* J'P'A6@21A9.N^.)V /4L&[:&;'C*J
MNVRR_PS3:1C/ETL92)1%EL!KPB#Y"5I'""86R 6YT=8'FUJ[Y3N#?-K$ZE=G
M/>1=WKN7+G[Y_NMB\LQ/?^(T#<F:#Y@0U@2*.Z0GJ:A:N>V1HI)D4Y(RU)+.
MUE>1NZ-\VC3K66NW>>;ZM(9W Y9)!)Z" ([>4M"C/&V\M;]-L,@MH_BG>3?A
MG4$^2Y8UTMEMDOE>-[./.)M/AZFFD-8_>U'%\_.TAM>)21X4"I"U6$XY\A8]
M)XN?K$Y<UT0CVVDL2*L-;2/29TFWEMJ[XW1T[T/T+O6@ QM\=G5F!A.<DY5W
M CQ+$4J4/$?!?&Y^]](%U],F5'/-W$&?ELD^MT_^E>2R.%4 BZOC7ET$GT@8
M4GC40CDDAA_M#J;)30(/(7'F>6UA3BN4O$ H48/5(EM9%.;F_58V9LRW*@%X
MC;,T'2YLXZ2\/)\-QSBKDQL_D#0I,@C+7[P9CL,X#</H,LW^=;UG'CUH5.7>
MS]RS:*#MFEM5$ZQJ9*\?0;ZHX=?GQ=-??K_\DP_A>_W1PK)<W@87*0N2HPQ%
M6=I_=(C@!$IP7M0>BR''YAU+]T>]]WN:OF ^'^&JPN<^++--8):)VR0O)KQ4
MX*-UY! R#D$K#623HRCU#,XU/]YJ!?Y@-1*'9>DMM^LHRCZ9<HSS.!OF89A^
MKSU9WB_KG!9IQ=&[4*2P("+%R@I5 &>T@JB+]"Y+D9JW+-T(YFAE&,?AQDV&
M-M%1'YD1EW!^#6?TY6\DCEE(532KM+,N"'LJY=B.[DAU'6W4>9,D_>CB.*PQ
M 5DTDAS]4AOY6.\AF$QA@-+T&AE4W#0_^SH26[:5?AR+++NHH"%)%O,:WU
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M;EC(UEKT+3;7:P\]7,"QE]@G+636\&!C 23\>05(UDDDZQ,PQXB)!+_V2<[
M4Q%&)4PY8POE77WH(U3>@V76P]%!->GU>'=YS"]#8$FGVH"(@U*UCT"2!9PQ
MAAF>#"NMW>.KSW^2CL[>@NZA='6-97U_UP%-3_>KUY$<YR;UX9K9H.(]Q-KC
M&[Y"A;Z>@9.CH*4OE<-U,GCP( A;S)*9PLTC5/*6J\Z^=+R+-%O?6RX[/;\=
MUU*=X3>LR 3C9CW$.3#C+;>D#D;6204!/D;:M80N7FC-2NY657SO8PY_5KN/
M B:]2*^71B<+7*N*ON'L7R^_O\1Q^G(6ILM6@<XE)@T1-[(Z38XG\OEMY."<
M]%%$'[5MW^7D?DQ/VGHW54@/+9ANXUNC6[TG7?#U9..W83N.U6^KT:UT::".
M'GR#K3BS9HY3^ BNCI%0*"*$( ,P&[1$J:3#UMVZCD.7+?[#<=FRBQ9Z:N\[
M^XC?<%QG":XS=1C3!KF5D(.E[33D#)&7>NPD5=$12;'-[U+N G*,Z^*6^KJC
MKG\_8??@CZSN-6?+Y@+5FJYP\>0S5Z6 ][%V'C26<#$/7!8E9!1.F-:]CC9A
M>6(\:"+R@YB,[Q=IHARU,UP9<%%I4%DP\-QS,*&HR",Q%5NSX1XXS\TA?9 :
M^FAN=!-:!;9Z([I .Y0;>@GK9#S0AZEP&S7VE/\A-I$K$(7D1B05(2;:+U4(
MB7PJE#7^CLQJ8X5M75YT<&KL[FWVSHQ=Q-X'(\YG\\E9'6YW ^*ZQ3'G(2D7
MP.B,9$KK_:;6!K+%3-NGD<FTGFBY!=()^!L/5=]-6C24??/[Q?\SF:[QS18O
M '-)9ED[+B1%3E6A%\#)[$&9DJ,6+)AN=<M;+QEO/OE)^A,-A-RP-UU%LVR;
M?@W3BN-=0#5,S]D(Y/#).OMJ:-*7>!OG@MP#CFQ>-+2_V8Q8F^9'\"9K0.%,
M\"H%9CL=1)V6SN_)[SF,RG>0:O.10,-O>+&^E:4I+-"#@X/$ UDQY0P$420(
MHT)BT;%PL[)JTR2@VQ]^V$211C*?-!188]-,QBB?I_G[Z2><?ANFI7<JK+))
M1PYHZ^QA] X\(H<4M%*R=M7UG6Z7M[RF=SW[R9KGO07=L*'G%3RU.&:%:+9V
M0CN :FB@-P(YO('>7T>W%=Y(P(U-]&9PJ&5<V*,2+)FG:"2$RO20=:$-KQZ&
M=KJ3/BVMWV.B#Z3T7>3:VDB_(QSC&1*H*S5RD_%B#OW*!#G#M$NZ@%1>UFW-
M0.0^@]#!DSG+UC/=R69O?]9A37@CC4SZ$V<?-SUGD^E\^-]+6+=J$ <H@_&,
M$2;%R?%$Y^FKZ$"+PG1,6%AIW3[C?D1'2$#JMX"JH0)ZH,?&Q5\IAC;&>UU\
M *9-'34G+41,-25+8,W'<IA:UQ=W@/7DB-):%7TD#M2&FW%[3\YXLR?GA_-I
M^A(N9B=<'2:U;$T^,"5EI6F;9*9&487VX:BL 9&-1"5=0&S=G+F_U3PY;IZ(
MXON8^O30-K.+?SXBR7DVG./*H:!%#2>9#VCS-B'&"":(VE])(L181SERE FE
MYSFU3N?L92%/D\A'57<?\SH?^G:^"</I8H0?.2/G9XL1P[.?_JRC2#'_AM,S
M/F#9*AV] >-M74^0$$T)H)+U62@NP\TY><?;EK>NYFFR^?B*[R'G9)4P-QO$
M9+C-Y!^7Q.GIGB!XSQ&,%BH)(442K1-6U\]^<G1YD%![F%1UZU[Z<CX-'Z#(
MUC*;*1;7D;!Y7H>;DS\0K15<9"%Y\RD=]^!Y<B1H)OR&I]![6^?[]K/7PV_#
MC./\,<QQH!?UMX*\32TY66I6(/*:^I <0PJVH^'-DYS[7M23H^AIT6#CV*MC
M=]I:G6<N$LRKCGX*Z<ND3,ZG[\+T,\[F%W>+AV_)M3.TX_3NVD^"S89 W-B0
M+U\B%C!::11DKQ4Y839 4#:!=DGZE*--H?5NM1E-^QS1Q2VJX@4]+1+01%HC
M^96T1Q0%&+)'DXK-V+KYZMU(#C<HH8F^M^>"[BS>8[?EZER<Q5A$#$;3HN2B
M?;6"6(J&X@W+RD:9<_/DT1.MEFVA]EUK8W<1_S&*'+O@^ZLV]L$:W;7:\2'J
M. 9MI)2) B 'OHX/5TQ4;Y5@B\295<5KC?W7X#^&VMA>V;*+%@Y6&YN<8;2E
M1G"VCEOF4D!D"4'PH)32);C2^A3JL=3&[J2O3K6QNPC[,+TZ+HIU#$LZIDA+
M3$R"4@S!IWI($BB.9"Q)BG'[=SR.71!Y&)_C04+OX8;POBJ=+M#^*G_<484[
M%+D]1/X'+G]4EO&B<Z+MJW;S%+E S$(#PV2\DB4HUWNL<L+ECWTQ8Q>Q'Z'\
ML1CEDJC7:\HP4)F\)^]Y!./0L&)TXJIU3M6C*G_<27T[EC_N(OO^RQ\-L]J+
M4(<4.R3_*6;PA3D@$"BU339@)Y?BT90_-O0>&HBT83K&_65"74 ]FV+'G334
MJ?+M(>(]6+$C.B55-D1K1$V[6:0=1Q8.)6N>2_$"NYUQGY;.=RMV;*_R7:3:
MNHYB#>7%NF6WS2X+KL#$0JL+%*[28@T$'I(.RD@9;^SB&XHF;GSPJ10Y[B3K
M22-!-32^U["\7#?A,IF,2@R$A3P-Q;F$F!3Y'+88--IQ\DUW4MK+)Z:TAPBJ
MKS?MU;I=E@E!6>$J;2SY"8;\A)PM,/+ALA9).;N;TEX],:4]1% -CTVN87F]
M;HHOHL_"27"H/;WUA,5+5L '&P)7FFN7=U+:ZR>FM(<(JJ'K>@W+3^MY".2/
MUT:74- (4*Z>PP:A@'9H'Y@W19ENQ?LW/OC)*.TA@CI$?[:K&7W>%NV$\!!2
M34WWJO9&9[;>U:B(3)/_V'O#UZ.F4QXJW>*A0M_HY#1++[O(BOL%P^Q\NIR$
M^68X#N,T#*.WX]E\>K[XV>KW.<PO_I,]4L=:/';/M+#F*V^4\G7QD)=A1%CP
MTQ?$^<_3R?G7X?CS!;Y/\S!?0'X5EJF,E\RU*+Q2UD(*3M>BJ9J=3U^QJ)PB
MLR\HG&K\5N^+>>]QRQ?/_WX7@N4A$J*A][8D<++Z/$1'\GDD@C!!R:B+%:SY
MN.4.N Z56G907MT:K-Q:0:>2CG9E81=?_M<0IX3LR_=W^ U'BP,.[QWYU;J
MS8R\ $OQD:^CNY3@@666I(VMF^5V0W:L@][VA-C,N%:*Z>$JZ&XC= OORBGM
M K:G&^6=@![GCKD/C6\B56_J.C[';$%EK >.=02.UA1DDM\&QD8N0_2BJ-99
M+"? K2V7U*='K1VTU">EWHZ_GL]G"PGP=0-9BUD542C"M8SBF\# &?I68T%"
M)4W'^XR'$.@VG,/'E#TJ<A-E]M1"#WER=T$3ZP-CFRB$UA*D*35#5 2R[\Z
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MITB2$!2L*4)86[*2)4X08DZ6.Y5=MP:938H/GH-U:JR3/EH<[9K K@RW3F$
M9BK+A22\Y-1#+DQDIR+3]OD5'+36\[Y5!KLHZ?"D2NG\['Q4<X9_GDYF5[++
M?R99O\0RF>)OX<]!XL4$KQ6DA+7/OR!A92' .UN$%<JWKR5H ORYT:\'=1[
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MR6CT9C*M_]' ^JR"$0&D=HL340Z>10LR.>]B)F&6D^G0]: 5GB#?>PZ*3I=
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M6(O[J_U^'T?#SXNDV5E-S)R2O3Z_<L*W6LE 9Y&DBQH<JSULBT8(H@1(09#
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MM9DJLT07#_! ]\RLI:Z:M*=2:G5T[YCL61@N9G(KDLPA&9*R/_T#2$8$XV(
M")"I:K-629E!N/N/X0Z'PX]_^U_?'Y;@JZCJO"S^_4_^7[P_ 5&PDN?%W;__
MZ?.G-S#]T__ZC__Q/_[M_X'P_[SX\!:\*MGJ010->%D)T@@.ON7-/6CN!?A'
M6?V>?R7@_9(T65D]0/@?[6,OR\>G*K^[;T#@!6C]L?5OJ[\2/V XCCS(XCB"
M"*,(8C\4$ N<>;XON.^CJ[N_HC02*:8,\B#)(/*"&&(4<!BQA# /A2C(1+OH
M,B]^_ZOZ@Y): "E>4;?__/<_W3?-XU]_^>7;MV]_^4ZKY5_*ZNZ7P//"7]:?
M_E/_\>\'G_\6MI_V,<:_M+_=?+3.CWU0+NO_\G]^>_N1W8L' O.B;DC!%($Z
M_VO=_O!MR4C3HGZ6+W#R$^I?</TQJ'X$_0"&_E^^U_Q/__$_ .C@J,JE^" R
MH/[[^</-29+X%_6)7PIQI][M>U'E)?_8D*IY2ZA82N[;U9JG1_'O?ZKSA\>E
M6/_LOA+9\6675;6SJN(2*R[]6''YYU/$?KF ?4?\-H>\.F"N%?>=*Q[','WG
MC-U/TD*(Z1D>D+F8Y>X+];K@<WUW-Z0N9GUZCEU]+<J&+&?X6FS)#%A>JA^\
ME7_KR:B%1HQI2Z<WW0-6Q?=&%%QTUG)G:9#S?_^3_-M"VJ1Z\9$LQ6WVL2G9
M[^JO]?6=W 7?""'?/9-_(W?RM[]695V_KTHF!*\74<*\Q,<44C])(4)^"'&4
M21D9]?PP8B06T:+9?.,7HH"?/ZZ9:SFXA/R?#%!I3FAW)>IR5;%N7Y0L*9^@
MX_(_6OH@$P(\;CCXMU^VK#M'<_G,&"V-X%'T09F!EIDKT+(#.LPD0U=@RQ*X
MS4#+%%AS-2F,O/??6M?C&>'<X>-Y82W9#OFE\LO*:A^5DEV(2F<%U1I0.<)>
MV'EI?[9<]9>#K\9UM1:$5.S,.^@_\0LKI5?ZV,"=;W=6E0\N)&Y*%]^F[JU(
MAO\$RHJ+2IY2C@B_T8M5#>\(>5RTE*X?'RO!\O9+]D&=0>J/UQ\^_B8>J*AT
M3*_V8A-;VY8^&#( .@[ 3Y*'^F<]DZ$/S;BQG0050_MZ!A#PI>/@_[M<ZXVE
MW;H[M12W%34C-6WE[1>3<@?A+V+9U.N?*)L0MO9 G]XL)L!8_+76FS]HI^A_
M)U5.J/1>I:?XJGP@>;'P0Y($V,\@IV$($><$IIAX, IY&OMAFGB4F*C_(8F)
M]7U-$"B*X$M'\_1W61<7/;6^3%HS/384U%AI3\OB2$N/$)A5+4\+N*^'(Y^T
M4[S;KZ*Z7B[+1OEQMX]*M?OM(\$B2!/&(/<0@\BG%!*?^S!4^A<0+)63FNC?
M24H3J^%G>3"LOE6Y>O1?0=D2-E/"TQCIZ:(3R<U44I&$&YJ@(SK!?GI6-$<:
M>IK.K(IZ5MQ]?3W_@)G:"L87[\G3WVOI<:OXO(I'O\IKMBSK527>YH6X:<3#
MN8.VYBK3?3TE<?"U!@/R8$L??%$<@)8%!U]50V&/?&%KP?YR5W[]1:[4?U<9
MWWY%==>?Y8MJ*.SZZVKZF-F7MJZ:Q0?Y^L5Z9^&9[WLB@4G,!$0932!-F ?3
M-/010SA((ZV=96_=R8]OTO&MFYR1)?A-$ 5,:UO-'+M]+,85]0()38]BEL)I
MJ^$)4<;V!_G(8&^0_]HJW?YJLRC7"1'62G3JUW:.F5*ZV^QE)7C>O"$L7^;-
MTV_D>_ZP>GA15E7Y+2_N7I)'^9OF:8'"4&2A5"$FJ#PK>3Z'E&8A]%!"(S\+
M<"A2$U_-A/C$:M<Q ;*>BRM [NZJ]D8!/%9YP?)'^94E#^6J:,R\.B. ]1R]
MJ6 ST^5V]RPST"/W9H-<SPK8\ +6S+AS"&T@<.0C&I&>U6VT 67?D[1:P\[T
M?!"UD _=7Q?\E?@JEN6CV@M>?W\412T6:981FGH))%S$<O?F"&(4!5#NVC$B
M/@TBDIC8FE%J$QN7-6U "@[XEKJ9)1G'2\]T.$/!S%;L # @#'K*[@R#EH".
M+,$XK5E57TOL?5W7>\A.N6\*5DD'3[P2W7]OBMM'44GOKS4?>4.6U[1N*L*:
MA>=3'/B9RM&*I9\>Q0&D:4)@FG$A$,:$)+&)INN3GMJGN%=N6@WR I1K#@"I
M:]'4K2(L<T*5@<U%_5<S4V" KIY=F 8S,R.QY@'\M.;B9P7=AA'0<P*^K'EQ
M&&$R!\"1$3$@/*M%,0=DW[Q8K& >I?I<\&KY=/=1L%6E7)7?F_=5SL3+^^+N
MO?SV:YB-\ZO,$3E>/JEO^)H!Z4-7OXL&M%R SH[H60@-3,X'[=S!868!-)'8
MY&ZXB=KI26L5L#NS]&RQ.CT1AV$ZS2=L/?]EFPI)JN;I4T6*6MJ O"RV<67.
M6!P12F'&8P11'')(8L$@"A+I^K,T(X*;.?_C!"?W_UORH*4/!@SHQ:#M,-0]
M$+A#QO1,<!$H%B<#/4F='0[.D)OY?* G_.$10?,YVU."U"91-])5*!_$;7,O
MJ@4+,B_F@3P$1($\^*,DAB23I@")(/(C5=9!#(\#!S0F5O<U1>F]*I*FKOTA
M)+H^_$6"FCKKO8P=M2O0TG/ICY\4QIGC?4AA9@_[I(B'KO3ICUJF/-Z32KR0
M7CE_63ZH W^;;G5=5<K!4F& ^L73]C/OR9/ZV?4W4O'VCT^2ZG7!W\OOQ#OR
ML,X92CR.L4]]&'LHA0B'(4Q1@B%%/F:81X@$V"B5<@(F)];]EC!0E"U3L29Y
M,7H&Y+GA-K- )DB;)W!."(6KG,\I6)PW371"D \R2Z>D91ZV:!?]51)O7DG_
MZ@W)J[^3Y4KHQBM./#ZQ;5-T0$L(D%I=_;4< ,6"?G#BE.3GHQ(.A+:Q,%LA
MP18 -Y&',Q)9A1Q.K3E;K.&,4,,@P[F/3N3:G-+TU_^]RINGFZ)NJK;>J&X=
MK4_WI.A2ZNIW9?%5>F&"OUNU63593*(T$"G$' MY0$DR2(*(0<:"" 6Q\!,O
M6#SN%2M?O@V[XM]$<_:ET%:BVU6CZME5DX K0,5=7A0JOD?)LLW'^ZE6HAA7
MI<SVBIGO,2_)!"01":5+2SWYBA.AJ@5B&@8HEF^]?\7KFMX_\@L^7@*M^WI%
M^]\_S+MUY!4_Q]LRV\A:_F#+(!@* 092 /H$AI_K)0&M*%>@$P8,I.E._*"1
M\O2)W_45V(@D_]H*-:-+[OH]S.6G.^/[QW+>7;\.8X_>.0.6,<Z'1^G8M(GY
MV4TA;>5=3I?BNDT#>/V=+5?*9OY:EOQ;OEPN" UY@.56(U 80,23"-(@"V 8
M>B3V>)P*I'5*L*(^=5QTPTM[>L@W[/1)$8:!4B-<-4.H4Z%E&%S=L*%PVC("
M.D[ 3QM>P)J9TYNL>>C5!@1705DCVO.&:VU@.0CD6BUB9WA>"=ILJRL^B>_-
M"RG/[PONITD6< 0Y22A$,?-A2CP"@Y2F$0\H2Q*M7B-GZ$R=7+6;=@RN[RHA
MS),J3X&D9R\<B&YF&13!G1HF11.T1!U&/\^(Y4C73U&95:O/B+JOO^<^;J>I
M+\NE_&>I<J.^BH$',[AQ_4?>W'>WL.6I3_>E/BCQ.?*]# 9QP""* @0ICC 4
M(O$#>8B-46*4..V2N8EMPMN<J=150.QL@=/7H&= G@M<,ZNS0W=X:+S:R=MH
MVSMVZ1Q-"4X^-$%]\!0P.K)R3EF;U31. >J^/9V$AFT3(-*(SC-KVY#<ETOY
M<-V=%@W3J;76FC#>LR:_Z7_5,_"OZSC.%"G41D([:WRC0W/FYC<&,!PVP#%Y
MV.R+WK;6VJWL4FK&[L4G^3;6E<)8,);2(($$L0 B(1#$V/=AEK$TBG'LA[Y6
MU;06M7G/"-UN)3D +0L&O?/.HC9N%IQC8;A]C\)P?CNVP,.@=:!+7.PZ!5I^
M3<QZ >J*.=KZ[^PB\W7ZTY5GI[&?]D,35)2^+Y<Y>UJ$/O88PQ$,/<8A\M(0
M8DI\&!#"_,P/XM!S5U?:T9S8RITLKGQ9UJ9!51T$]5P@Q[B86;QS]:97H.,
M?.G_.TD8Q0"".2I2>XH_3EWJ+@1&U:E[C]HX0J?.$EVQ^V_Y4M1-68C^YF@1
M82_@)/.AA](8HC3 D 8B@3'")$Z(H+%>GT ;XA,;D'7#AH<U6?#8T35I+VR*
MIX['-!U*SN(?:^PVS*POSB>$SL2YF@Y"2U_+)92&'I@=%N,.F>&:,_IG=M+N
MNFN6:UB8XW4GYS=2BI<J>TA25E^LV^P?1!%NZD6&.$8D(S!!F?3<0AI '--(
M'E013C)&HU@OL*U);V*CNV8 J/<&OG5$ 1NPLK;"!I9$ T4-N^L6&S-3NX%%
M$0=#ZJI+^YJ^6T@,[*E;:.Q,Z(40F1E-?8%'[:3&,O.91GV9=JRAP6/F!0&_
M%8^YNEC\E#\(_J:L5$[3W\GRS9+<Z18%C"PQM0/Y[OW-\%:ZY0!D9;6;;3B>
M.6\$R;@5<XB&F?4R 0)\4;PXZCRJ(:U5-<'8NK-5%&@(-ZPJT/GX!94%]'S*
M(=U/.>P3"U]_%Q7+:]59^Q]"=;87_/JKJ,B=^"!409'JC%(6;8Q_19:?1/7@
M+U0I02I( OU4C;Q#F0=3'F$U_4B00# /!YEQ3>6\,DQL?08<662:S_PZ]8)G
M/_A+,C.*#K+/-_GE \&NP%HTT,L&-L*!@71 B><X#?UY7HW+A/29)9@_-?UY
M7M'1)/5G8L7<"?T@C_/]_;,JR+O^GM>ZSN>11Z>_]MBD.;P2<H&'O.CLBF)
MLZ'>*:G/^Y<7"FQ\GS$B*_BBJ#OR)$?DLO(@CZTWF^<X(LS08QS[F&U&9_6H
MXF9")8SV3;1R4?>WXP*+B"4\@6'&$$0^%I!03J#GD9 @SCTO-4S1'*$V=8[%
MFC;@*C>YWE WS;T< TS/:W(&@^GMP!J!-CM[2WB21$<-$9UE+H[1FCD544/L
MP]Q"G8><M;=5163OI#BKJI)VY.VVM^N"IBR6>IU"'(I 'N'DW]*0,)AYB#+J
M<^QAH[8X)L0GUOZN!G19%G=0[4K#EK87=[0]#:B>.9@*)C/K<*JK;0O<EA?P
M5@,Y%UUMST(P75_;TZ2?N[/M65 T>MN>7\/.U&S:8@P&IJB<Z,]%26M1?55G
M@YOB<=74'X1"0%+M1B<JBU?) X(\4>=U6V+6=5H)D,C2.!"0R?]U$26<Q0F4
M/XXRCP99++!YUPK7;)IHI'5SBK:ARU=%;MB;HLQ MZ*9"7/^HDCDJ\9I(0S"
M&$LW$060HI!"X6<I\84:9H1,>T\\_VLR;C$Q?$FBX#_,Z]';A9X3<+.=:MO=
MZ&IG.%-;UC-D%W3\@EV&K\"&9=#R?-65*[MJF#0UH([V/>?LS;HW3@7N_OXY
M&1V[/5;NVYL)#5V/S?58E9BDG*:(0N:I+5(>SB$.4C6< D4A3\(H2*-%4S9D
MJ6=_3U(R<M0W]+25^Y-Z!)2MUYGW+5L+85@@>1HF/5OH1'@SHS8DV?>J5>T3
M6JH.>R:<E<R1=3E-9U8S<5;<?7T__X!MG.WA(6^GGM;7!5>A<$E 2'LA3XD$
MA9@S2B'%S(.(1E0>NY$'?>RE+(U]U5O>+,IVDM;D,;8-Y3:CG0UI@Y_>E8T
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M^8NOHJ*EG<TP;I8]I&5O(OZG]Q?I$/E;4_$WX'M7\D?J_X"LFONRRO\I^-]
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M8TB9KZRT'U&/HX"H1H.JOES/-N^L;F16-S3TH\BB 3^I+B4_2P=0T32SCKM
M1#3!?HHB-7LD@2CQ.<1)G$"6QEX:$QI'9GFN]D#8=VNY1'Z"2.Q)#&#$.8&(
MRC-7&A$/\B",N?Q>I&G$%H703!<TEQYWTJ\IS"J[WJ9F_48-[T:D0!T=\).B
M=/KP:KRM')7 T8ZPN_:LQORH6/MV^/B'7(U@67BAY_'4%])Z2LU!F B8)HA
M(9(@Y6',$A^;V-%#$A,;TZX;"SL<O'+IW!7K>2O3J=BQ.2M3#E=QK&I'"#SS
M,)532C?R2<O3J9#?4,%OY>&W4.?@-WE!"I87=Q_D$?ACF56;W]P47'S_^(T\
MJM_TM1MAD,:,^Q%,>*"<'<(A)8D/O8SS((HRQ@TS^B[A9F*?H.<-;%@ &^Z
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MI;$JA#N^XFR%<*,"#0OAQC]HN^T]/%;B7IXLY;I=9[7WY3)G3]V?6Z?2\]*
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MI;C-VC 7W>_4L4?[NN#'N+EF3?Y5Y;:IH->V&W+(/)9F$8(X1!2BQ.,0HS"
M*0K"-/4BC/1:J,W![,R&!:PD*X#TK!CFI4WYSO2LU(_R)LR,W-'F2=M6-%?@
MP JJM+BCIO$*K)F?="C:'#B[RJN;DM5YT_!F /T@:V\.FA?/C'ZU$I_*O^=M
MWZ6RN,W^LWR0A\Z5/'4^O27?#!K3FJX[L77>'\@,^$JHN:L;EE1P33$%>JZ
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MN;O"G1?[2%\XC8=<:7<;>M.Y=UHD2$19%&,8Q(Q"Q.2.G0H1P< GL? 3[K/
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M13TSB^7L,G..7]&5:6_BBO9C%\[8ZWM^MO?VFQ_^9RXJ5>SWU%\L<T0X0E1
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MP1'E@G*S$0':M"=6MYX3T+("AKR8#@O01U,STCD-1H:1S9/P#"HT';?:O0
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M[TG>WBE=/S2ZP<?C3T^L2^]?WX(U5:#([MW!CCO2N@B<CTY>+KR9HETFMU'
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M'Z$QL1G9MB'(MS3-VP_L Z-I.2X3U] V;!H/W&A(:M5PX(0L#KL-[%.8O=7
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MK$BW$\,HZH&YI;UFZA\Z7-R@0[4_.G 2L%X/*GRHRCUGNM/6\$'5<5+-!U[
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MU E@YS+<VY]G2:%2DN02IY%FMGB(X"*-S1Y+.<MU3$24@<:9.] <V80M!^C
MPLVA V<_1@3]43,"W']=U.FV%P=6$LS(0^@'7I'L+G&HLF,'BM/6%KNKX*2
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MH3E3!&=))#&-39C+6"KL#&:>QZG(5>X^>.WEY!C9G^^XP2T[:,\/ZC"$+$<
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MU.I;M?CVRVKYY^:[38'SQ=.,9(1%&4MQEFEN.^HCS*G9C!.=\SB5.4]Y[F+
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M^A\4]_D5P/ #,*M=KS9V.I.=0GJW^JI6/RK13/\J\[10I8DR<\4$IBQ7F%O
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MW]!1GODL\"A.XX!@D@8:7S?"+$QR)@)1Y,*\3V"8UM0U$9HX:J@O4$T?208
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MF#(N)YP!W[>(&3^M-M(WO=L)OMI_I$PO_7Y'O[_??M_H>WE-9!EE+$[2@N"
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MCD.835C:2>G.Y29>T7=6DQ*9Y3Q'0,5M=:<C.&$5.&68UC*9F-A1J+AGX=U
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MORU_K+8[G"C#HV)!@M>B)G+Y!#&E>FATI!.B'5EMK8WEAPCJP<=J J5V;.\
M0V\6\T\?<7E2/<;5NFK8U40J+S@3&;CBQ!RF!%W0# %+KN5JR6-L[8S?048/
M_E43O!S+X@Y0LO$-SQ3G8I[.##D?#)*ZI-N7.]J$=AQ"S0<*9/SK[#1F?*CM
MY<'N^$U">O"HVFB6H]G< 5:V]$\,Z3F=F >>1 %5/&E$SA5P&;@7.7'MAWDF
M[\%Y:OC"N1<C.W"7WDQ#G,XV#QQDMV^2S#\O9L3T5;7AU]\O6(/%U,X)!M!Q
M<@-KK,"CXE!X*M$7X5QH?LOL2-NX;M3@&1:#B*@#S7-E7[>B%T4)GK,$E+4W
M4VW.$))"TJ'.YU*\+::U>W4_->.^EP\C_?LA=HPH.@#5^9/;N_"]AL6)9=M;
M.J7E*1%S:Y^3P@T/7C.($1FHL&GR$#24(K4KB1?W8!W*,4^@N]+8#0"/PL8]
M;Z.#"*H#(+X\^3);?$=\C[,Z#.R.#65K"U<R0$FUB,>0UTD[H[]&$SBY&%*;
MAYJX'8*\1XD:]RH="&IM1=$!MN[8@95.>S(](0=I06%M@(NAANJ52%%;+\5#
ME1)M;LQQPX\#H>=(9O=@XY]%-'[!N+[BJ*J0=>)2 2H3B2E%0V3.0PD8E$HY
M)='Z,>1N2KI1.@,:6,>+H .]L[FAK_#KRDY<T)C)F8%4E-G&XKU2 9@C1IGD
MC6B>CW@_-=WHH>$ U4@4'8#JRB8FQEF7414(JG"R\7BB>Y@3Z2+JE*644;1.
MF[ZR_+A/'D_MZ.W%[ YNL=H&8;J-Q]=L[\6\ONG@/-6MN&A=O>(AAD07,A>U
M>(V8$[P,#K%(TSQ>\  YXSZ%/ F.6@FC _WS (>XX-992_>Q9N1R^D!N@;:.
M_EI3:+)$H5M7 1T9Y1SLV>1)4-5(%!V ZMWYNILM;>I0)DXF[9*ON=Z&SH4)
M&;PGKT$DYH0F3[/8UB;2'62,78[81L*WDQJ/8G<7E8A7^OQL=Z!CL-S4 ^3(
MUU3DJ0+]OP?KM"K9"8&B]9/+31K&?EH9!"U',;H#Y?(LY\WK4IB]"]/\>OXB
M?)F2E34IG'Q')PPDGH@G1BL(-9YE=,*:"B[2@SU4#@IEWTW*N [80+!IP?8>
MT)/2Z<GI)A*Z<2)K^[DE?L;Y:OH5Z]S&$WRS6-6,N[?E8_@VL=ZZVDJ&G -;
M8Z-%@<N90\B2H9#9F.9AHCU)'-=O&PIM XJI Q2^QW68SC&_#,LYN0ZK*]O]
M!<LT38E[TDF>M86<?>W07VHAE$K@I4HE"$GW>^N0]N-4C>O;#82UQL+H %ZW
M&34Q*6@F780LR3=5#&O3=F7 )FOKF8DQM-9CMZD8UXD;"#Y',KN#V-)CWNW$
M\-J>UP0P=1>*L0#11PGT+:Y,2E*S 1-2[J1IW,2YIXY6'B^69C ;O&G5NXT$
M/N-ZFLB4OD;^,1VLKG_L0.VL'J#]*7M;^83U$42#S,*#XLX!(04A!\.5UUGF
M 2)WP_>VNA[G(%Z_76Z6S1L_]ATN-PV")P5=MCHY2&ESYHH&EYP&93&[@D$4
MWEI;[4;9V,&GQLAY. S51#P=V%+7=[5M0?WL=/UYL9S^-^:)448)].1X*$>[
MH6N>C$)R0:3VQ2MO0_"MC]K#%(T=LWI2D!TECD[!]7JU.JT[T5:HX,CE**C(
M)!42G/8,,FU,VDPW_(,=Y%L!:TO-V!&M$4!U@!@Z!=35AOF<9Q>+4Y QTG;(
MR0'O68)L@I/DR,;\X.C<5JC:=TS!@.&K$:!UJ$ ZP->5QX-[+W@6='!>"*CC
MH.B"IZ^\MK2E:*R7VC%F6X<:=B!K[-#5P#AK+9B^L';KGN=<6F^8@:+%QHB,
MX#D=($=<JO, ?$BM"_8>(&?LN-;38>LH0?2(J;-K7F&V3$8/TM1F"HP8%:RL
M [$C:FX\\Z7UX^$]I(P;V'IZ+!T@@!YQ=/5.3U($K;(%S2T'E7RBO?A 7\5D
M'3KE3>M2\Z,'034?\3$>H@X51==]_2_8N%J4LYX>B_DJU.S#*R^C]4WTJ)#I
M'LNT"Z$>NK=&(=7M<_(%$1>@- Y9*(I,<U9\[0IG("3M-YF<=32A-ZY]F\\[
M23G^/?#L S_68L-)S(5C21RRM99\6BLA%DT*-Z907"K9I<'"PQL*Q@V$MI#W
M[4? @SD\XFVV6JYK\[)\FM;D,>#RZS3ALV_3U43J6$R=Y$VFG095;$T.PPP%
MI3,QAHQLI^0#6N *.NAOE\BX;^U.@N0'R''1D*E]@&+S[KC=P>J7Q4F8SB>!
MC'I6F_^X(!DHF0HX)3?=5;6D"Z5D[=LAXS8!X\"CC4QO ^1(!G=@")]MY#<\
MB;B<H&+*)4P@DG>@;"S@T68(W(=0),^H!^@P>4G Z.@X5J"W.TL>R-T1H5$M
MO<D;X@#9=IORF!G]<+&UZLYV8K(NA>D$B2DRRZ.LQT9D$*K(:%U,B/(QF_7Q
M9<9Y"FN/AL8,[4!K7%RSY"W@:_IR-<$4I.(L0[)1@-+60_3!@XQ!\E)3B44>
MRBB]H**3Q]/#C8]&#.X (N_Q*\Y/<74EE2H%PC4#RY*K;0<<."%J@0NFA,9J
M:5NWJKE)0R>VZ8$RO97V>@2#.P+(1/M8+!T5<+)67'K&P%D;01;2>T+EJ$MK
MS7&^]KB .$Z"]\!A+W9V (.+!K=G/?TON:&CU=XG!<6(5-O:2%*=W$*,6BOM
MDU-JL)["-XGIY&)IHSG:L+P#[+Q8K-9O2^VH?=52^["8Y8E6P64C ^0H59TB
M0J> Q$UWL4<6A!4^M*^IOX^:<=5,(W'?"MLWX7T'*'I/XB "ZA2^7TB)SA:;
MWO]GS)I@D-YFGFDSFXPT.G+1,@V12YM==&3]MS=;'B!H7$TT#);:2: #./V*
M<^+1C/;R+)],Y]/*G_7T*YYOQ[L4D@WDVXGD065&C$J6O(3D@M8B8'"M8RR/
MD#1N=N PD&HIA0Y 5;5MU;/G/)HD&:4P2H%.G'@C/1V*^D>1M=,[=Z;H]F_4
MUVD8-_-ON%OM8#YW4 IVP97+&MN)E>C)[G?55,SD2RA;VT,Z^B,6)D2("EOG
MQMQ!1B<IR(TMZ /9W %2?E_,%]=W<8;Y2V_4<>TJ1[BQQ""K$K@:G23@VZ*"
MMMB\J?ZC1'62;=P&16U%T,$M]7I.GX6K]78SF\+_22D8HY4)A'825)("0G$9
M9++%L9*L4*V3%>X@8UP/K+&@;T^;.HKK'0'GTCK33F,D)I1$)C^1"R$[#1E1
M2,]DMKFU=7.#A''=K*<!S"'<WA\L?@N6.7ZJ&>T?V[9SO9=1DZ0,F6?"@!>D
MG971@;Q&K'T!C&$HO5=ZD):N]U(TK@$T+*(:RJ(#;;0MS_^ Z72YJ=Y_]?7W
MZ1_S)89939G_-4SG&X,/HY'6:P.ZU-1Y5]_W1,K@7.'"E%BB:XVPW2@;UT@:
M%FD#R*8'Q)U$S+GVJUE.OV[B%.<[>3N__;,ZEE0*B<A#KC,CZ8*WH3:F* FB
M0RF1;O<B5&OP[4ODN"5; ^-P4(EU ,G[M;E5QF99 G"E"RC4-7LNU+E0*F"1
M@KG4&GK'7:J#56X-"[$V$N@AU(#K*W$2S#XX@YJLS4+&0%"UP7+E$)<<#<=(
M+G5K^%PEH)-"TD8AA(-9VP$N=ND,^(YTZ"+3]Y=U_NTON/WOQ?F*02CEM:WC
M 8AW4GMP(1LP6:DZ^H;KY@FKQU/=2;EIHU#HTPJQ@YOQH1T_^QJFLYK]]VJQ
M_!!F>&FH/LO_YW0[D/>BZ27+N7BL;$=;"U8B.4AH-"ET)ET]K=FU;N;0BO:1
M,QJ>&'-[0'XP '0 _#NV?+D5HZ0U9-@64\@0D;*6D',!@BO!>(RH>.LP[P/D
MC)PD,2X\6XFI POAO*7K>0N,"_YDK9Q$$^B*BI'L:N?!LT(>E1284](RNM:C
M=NZCI9."_S:W>1.&=Z"J;N[C>5A-TX19JP2Y9*"Q/M%:H2%:YX"<,6X%(]TK
M6B<%WDG(N+=G&QD_ IS]&=XA:GZ9SD[7F"<8,)J<+.A2R-^VGA-CG ;2H2R:
M%%4(S6>=WDW*N!?;DR#G$*9W@)W_P.FGST3WLZ^X#)_P]]-:U_6VW&II<<&S
M@$:IFM9HF"<UG5" LXD!\JAM\<F9W6JT]P#5OC1VTGFDS=4VJ(!^( !N-;-W
MA0GO)8$$:^]639O3PD VV;"0G'.Y=1!W+P+'O2*'Q<J!P-Q?</VB\DS)WV[X
M@SJH6'O]9*Y8M1@BN-I>L03&K)(<BWXB7-Y'XKA7< _(;"*\'Z9;TQVS"ZYM
MX8@.3?>-16C>E>FQ/;1O;O_ 3 6KDF#1"2A2DE. QD&4SH)PTGNM@F6YM>&S
M$V&-NS3E')ETOK;GC*P&]P39*KQ 4B59LE02SZV=S9ZZ-+7'PB,]F_;A=P<7
MXP7U6X[4H-UB7D_KIB\-1D25= ''2'6K$@R0,V0A\A 95V3^#C#NYP&".L'2
M 9*^#S1'L[T##-W8PUF+$J,%1N;(&5>N5I&[ D%$<J&UD,4QYKAOGAIT%R&=
M8.9X0=^9@G8,USN SI6NFV<M:%Q,V:M(GH2HG?)EC;>8FJ1I4.=B=<JI];5\
MBXB1 Z/'"_;^WJ8'<+D#F-PS-?2\H9741!:/0'P@7S0; 3YQ61O>!&706<36
M%4(/$C1R=+0Y?-IQOP<H/3X2]&QC*@8R"I4!R00Q*@@'7I0()F26;4@IYA%F
MMNX!L<&R^ > V"!2Z0!N-Z>"GNVB,*&U(K/1)-*ZQ*]J K ZY#&C4I9)L@4:
M8^MN2L9-TF\/I ;\[@ U=[PY6,[0^=HB5,M$.\@:@D8),IMDG4*1U6#ABC==
M-K9KXG\=QN .('(S9^?U_'9\X_UB-GNU6/X9EGGB374J- +WCKA5"^M\,0P"
M9Y$[F>N@VL;XV9/$3ARU Q%QJ[AQ./%T@+X'IR7PH$6LS2H\IOHVQ ($6Q)H
M)4CQ6BRN^>5V]."*(=O$#P>$?698[".5@Q'V99-/2&=IN6YT$=X:5^RT-585
M<EV9(-=5J PAIU*'ZM4F*]HHT3H+YL"YT8-=A$^)J2,ET V2KI>H2*F9XDP
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M [[/]O9Q\2S]U^ETB?=O[1>,I"VT5E9CA-K'I::<9+JV@@3F(FD-&9-@K8V
M/4GLLO1Q,,P.*+XN7A%O;9 X2V;.^ON[69BOZ436=-8O]5<FT6<Z=\K5( 0Q
MDY.=[T5 8(F'VMU2HVM=7+$[=5W:IT^&RC9"ZR<2NCL_)T7D:&WM#:@% \62
M!\\Y_1&\$X:9PD3K:-+NU(W[)/3$J!Q(:/UZ31?E='<P,H3(O*_-_Z24Q$VN
M:(>LUG]R.GC:9BY;6Z3[4SFNTGQJKZF5N'JP*J^8TK4[)>T+B8N73=LF3,F(
M6F70)J@ZR(D.LN<1T/JH-?.LF-9J\5&BNO1VFJ'B 6_G>!%UB[FS;N>KB9?.
M%R$T9%FOCR)\G8-7XV(Z%I^,$[IUB<_#%'7IISPMV@X23K=0VS:B_&-.@GM-
MWYC7*@VR=>^N+:Z6\(I^;79:6U9>;2L]L3P%MAEKKGT=#EQJJ;LCCLB8N4$K
M$K9.&Q]T0UVZ/D\+]#&@T>TY>;.8?R)7[&03D,"LC>>8@:Z44'N.U1)[NF2\
M+M(84S#YUGG CU/5I5OTM(@]6$@=P&YW!DY2RJ[0]0),^^I/E@).V 0\(&K!
M=5*Y]7"0W:D;-V7NB6$XD- Z\,[KMNK_UZ#7US##35W'>6?^^@.Z":Y_X\IO
M;OOYW\Y .+L=7GY+G\/\$[XG5_5EH8.XGB@AN)+DCVI>.*AD)=E2#B'I8'*T
MO 3>NO+W:7<XKG8>+"K0,4Q^]$,TR1&3KB-^4ZYCHXT2X*WCX.@6D\HEGYM/
M:SR*X'$U?Y\0WTN(W4QL/F[+&*6/)M8^O#R#XB: +_7-+K/ G2.&L];FR?"X
M'2QONE/<[B/$3L91G#6LNGP:F><+0^PU\?B2K5ZSDB29?)&7^J"LR19++ $S
MGIP&RR1WK?VWG8D;-U-ZN.>#0833@=_V?OKI,W&+#/]-F<S;N [3>74"SLV7
M5XOE]<9JYXFWWR>L".-E%!"$BZ"B9-4G4, 5\S$SIG+SEI]'D#OR2\,P %J,
M(\T.@/MZ3I]%O*QS5FM?'EF"+H@6(OV'G&&R63R&0%]%S;G)B:?V2?O72!CY
M<>%) '8,U\?NUOG+V9IOR1E;GC>\?;VM)\C/3]>_+];_B>OMW-[JP]5SLU-A
MEF)"J&IL2&-J.;51$)E3=8*1R;D8QM*-D63W=/H<BL*17P,&168_HFV&[Z$G
M4=V>NO5N(\C/N)ZF,+N^GR/F4SVVSC!3J_;:7?M95K>7OX W9H\E1P[>(P<5
ME 3GBP>;4K%TP0K%6Q>*[T18JWS1LS7.'S0VAW"2E Y(WA:P&.F&R$R PXS@
MN$D%>62R_<OJ _1T,[&J$4[N2P,]6A8':[.ON(R+%O?UBUE8K2X2%MXN-\;M
MY?YN;,UIPWUAE5.*%+6R$- C8 GT#2N"P[C3';S/JMU4&#4&T[#L[_&>_ 57
M:3G=O/@ORO/3%7E-JU78=+*]^.S%^:R$,+N\;PZY+ ]?[.@;L]$^&UV;;Y>?
MPORL@S#=Y:O%;)JWQ^<Z16_OHN@"X<4;'CV9B2;42? ^&R!S,8/@*?!L-&;7
M^O&M">''7KOGXKLB4UK^>5A-Z7A>I>(CB>OYK*87AIRP%%:@&.Y .6O!!14@
ME$0>?LK)8^L,T/VI'/>*?GI,WKS"!Y9KC^KWP^G)25A^)^-]^FD^+62GS]=G
M_AEY<^](!HF\,=)3?ZQP45Z2&WE"+#](^1ZZU-&JM\D>&RG>V^M>-FTP4A?'
M(S"U2?2H;]0*-03NA8^>!]3-QXO=2\W1(X$>8O7E\5$)G47%@/M,-A)C=%J%
M#5!4C$%*+TUJK19WHVSDJ7YM4')K\$][H?2HTUZ%Z?+?P^P4?\.P.ET>;B[>
M_4%'ZZ,=Z&ND;2Y6JC,B9HNZV"62E(UH'$&'D3\*"HN F$4 #-%HEERPS8M2
M'J+GZ$;[=WSV):9UM$GGY" IGPC3A8Y-(H?)!^=YD3DQUSJWX$&"QM4OS7!Q
MJR5^,R'TJ%B>AUEUO#]\1CQ7H+_@.DP/"MS>_V%'*Y@=Z>S*E_3HI,R<#&E;
M<P2RSQ"3,N"L"%QIRZUNW6JA"U_RP^D7 DO]R#"[*K<[#Y M4==L14C6U$Z:
MKH W/D(.TAKK,QW1UIE]^]#W5_ ?]\'A+?MJ*%GVJ PWD<_;HS8/<0SO_J3C
M_;X=*&RD R\EO*DJO5CLK'_C)E2[J7^*E9SS6.X%Z*(2C,O 0=8^]"I%!4Y$
M IWBP05AF,;6^3S'47ST /==5W]^=?7+P\-34"FD!"%C'9!KZ)0JRP$QN.)C
MD:6T]I6/)'E<W?B$^+PU$/X)1=VCGOP=UW6^SSM<;G9YB(*\^1%':\8':6JD
M$E^&Y7PZ_W2QR*5_H;EV+ G0F (H)3TX71N'H=!*,5%4:MV,XSY:CIY4>.-S
M+U$;8U2\Q A,1MIDS DB"@.T]1P"EAB:MU6^EYAQ54\3'-R:'MB$\3VJB]J3
M8KH9%48V;(W/X;Q&YPY+#;K[HQID_^Q 8R,U<KG6IB/AU?4N;Y;+BRH872R/
M($6UWH-+X!5GH&WQUFJMI6V=B[H7@4<7V.RRV.5A*#;7$E4/Q BD(T:'+2AI
M(6:NO#/!6A?&8$<GJFDX;-VJJ1E.;CTJL;>GZS?35!,$GWU:XN$!^#L_YVCU
M]3AU747&%$N):Q, :X(N8<%!E X!F6<!HX[:M\[CZR(R]F(QH^\NEIL!P,]J
M+M2GS0)W'9A@#>HD&621(B@;/1!;$M3),\(I)Y)I7O*Z.WE_A;C8/BB\K?V&
MD62/JN\%T3!=OPII4]MSH6 .LM_N^:CC[;==:&P5&<.XON,R#2K7,8L1G*]/
M063O@[.V 'J+H1COK6FMU.ZFY.A(UK5/O8)CSK.09"C84KO(<,W 9^4AZ>BE
M$BRRW#HW[AY21HX\'2__6Q&E!BSO476<1<3>A>7ZZC#Q@RRG>S_K:.6Q&Y6-
MM,=]BUU>2]X$%XP'5Y.>Z5JJO>>]I]L#76;,JJA:O^L_1M/1A<'W?/Z=D/=*
M!&4*R*((\K1EB"%:*%S4*UKDQ%H7MNQ!WKB:IREV;M7[#B2D'O72A].XPO\Z
MI8]Y^?5 4^;F1S3(Z7R IE:U9=?7N)*#)U&K& UPP77M<4$"-?05*PPC-UF3
MJ=S\&?YN6HY//[C^N9>HE35<&I( 7K&J-J7&N3B01BG4&$TRK7M=W$O,R+5C
M+7!P.U>@!>/[5!<'I5N?_^ )4\LOEAPKQ?SN/0^?:FZ#2U8K >2\9X*8XA"\
MMI"9=(Q+KXOX@5+-\5/U7M_CE\7RXO._;_^\/%7,%55B22 \"KJ$E0*GR.'@
M/KJ2N'3>M7X9V(FP;A/-]\'(+>767"0=]#TYJP.ZP;);N])1%^=R <=\I%U%
M#36! 7Q Y@P&;IJ77>]&V;@ULP,A;0"A=  UNB7>7MX2DYQX,<9K<,DI8I P
MX)G@P),7RFOO5&D=2[I.P;AM3 :"SA%,[@ B9XWX;K3?^V.^O-FJ[V;OU,W)
MF)2B==$Q0+*"#D30'"*W9,EB\5(HX5QI;=T?1_&X?7 '@N 3"K$#R/X6EO_
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MM^O/N#S3D<XP[9(N()67]009B-QG$#IXTK?9>J9WNF >7VMT:!PKS<5PK.W
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MD3> F\->"H&%Z91[+'N,<RF=\TAK*A&3A%#NR=,6TPTV)*PZ^.24 Z\_734
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MV)&]G]X Q0_#$/NXW#_DN_U=Z!_-?5.7^)2&1+G4R&B )+>1(2V#038Z3>"
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M</S0\/8JK1/R)2XRRKF'RNSK#S /ETD%W#T&<Y"<TT UP@03Q)4"6!N1(*[
M+N7*NQA*1X"G45RNIGWQC:<*G$[M^/O2Y%_?/OS.BHY7?]EI6-Z $HFM3I2B
M(*E '%N.=!(:24I2XL%05GSR=S'B*\\*/Q]F=Y?#GU/]+7@3"\KO*FYIC%H9
M#=0:D[LJ.8^L%W"L!*\$UH$I6?I"^A$!K=3 GQ4$F[[ T1II $['"^Z!;7"Z
M1G;\R5[?52YI$C"<B#@_;,E#>"1&5EN/@@K68A^9*S[/O@\^*O>@/AY6FWME
M;1TW@/-WX'Y.;F-<>'M7/[, [L8)&\^4)0PEEPN@3)8LL(!4="J%*(Q2Q?L>
M[2*F\G9:'2>;#9****T!]'V)X/(,/?A$"U;^& _GLR]?_[@;G4XEUX91)#2#
MPX=+A[31$05AK/6.!<E*%_3L):ARY6)K*"RGO :0^,BD[EA(23$7!=(BY6PN
MB,DH W\$GHQ3C!I1O)'E4S(J-]IM#76G*JH!K#TKTUTB_7A?TD(Q84)*#2*3
M%G%*,/ .#E $=R<9PRSCI6= G$YU*Y7?-8.B,^N^ ;2OS=9><#:[NIG/YG8<
MAN/O YL,-<DHY+$&43(0I;5!(V44[!#:$.9+EZ[MHZ=Q/[,P-C8GCY525.U+
M\C<C.YM=I7_8++GYU?3+\/N/^:KK4W@_F;Z_R8]=/\QF-[D>;! TEXGR/&6%
M9'..B]>N!'E!!">$4[%9.+7CUORP[S;N3?:#M;[UT^)^EQF)82!EU%XQC9+-
M7:)R_SLG%4=)+R9$)B9#Z2-[!RF->Y1GWN6.4$_U#>Z!AT\WV0.^2G].YA$$
MPR2Q.#HD59[R;9E!5NB I%,Z:FP9V;RRV;65[?A"W0J,JIM6"9DWL#W=QT^P
MVPYS-?0VD7Z:C']!=!^70=SL6[X_7_]YOL'Z-)G_=X1MVT^^CW,O^+5D% B%
M:.6$5\@R =;$\E0+:Q-LX5PZK"VQQ6=ZG86QNO4=E;?.]J#SDNWI<YP.)]D=
M6OU5_CTRD-[&A)V!$RK7>$6LD-:,H-SJ/DI#* _%IT"=E<-.%B;_8V'G!M-+
M-K6'E9;_T:)F[=L/.[[;DZS3BBA"\O2XB+A*!!G"/4HJ<B*T$%J7+NBOQFPG
M U3_,<"*$&O %E^-%K^SSMBZ"-[]G?\Q#KQVABZ\84YRIE]0I"D&780DC4M,
MB%3\37XGRCJA7+]0E/>@O!:?NVZO8%U&_7?IIC29WB6:BM?G/ONEGFIT#^.P
M4)WN<FC3?0TC%XQ[H3!R1@,\HZ/(>!61XE@HK2(AHI^I6:?6T6X&^V_LSR'L
M[X]E^B1)^2ZEZ.=7:?&?+'?X]<&DRU_^+:<[!XRXZ*-(B!&_&%H%&[T*&J7<
M%8]:X=QF+^GG<S2EB6QA".=14-J5LJFJQ8;2A1WEL'['_OEFZG_ %I/O\ <6
M!(\=9WEJ2WY8! >.33HA.'&<S,.$G#LXP7@B32U,]JR!U2(ZNCQHKIOHRG=>
M9O#S6Z.U"\O  XW)>T2PD8A[B&T=,P$)AP7E(N;8]PS;[!X26Y@86GN3+:7!
MB\7QMB*Z76<.9L(EDY_C,0("$=P@8\"P<X<$JZTSF)M^(7T M2W,)JV([K[T
MVD#H?[!,!CJRX!E3R#/"(5;5#D'\Z!$.+' >)':I="'EP436O=DI@-?SJ.=R
MWN"NLAC%H_J-=7N*X?=1W\;+VJ@2\3@&I&U^>:.I1DZS"/\JE79<..)*Y\1;
M>5G;*4N\2K(MGMMO7L0L*%T6DRI,/(O>(D,M>.M")C"^0!#3TALFG0&3+UW)
MVP<C%_WB]A L[WYQ6PL6#?@$'\:PG\7[9A(?5RPNGNC!\24D<0)HS_%H=.#'
M6V)S9QSX6\.T]J5K0?:0T\K+W&I@>3+)LHSFV@7AZM&)D"X)[17B*L(?1'!D
MN=%(*DFI4%XS5OJ\VDM072 64WLW.!VA@P8 E4WL*BW:QMV_:N/!81$@-LNM
M&;1PR.)$$+4\&4(\IZYT"Z(G1#0)G&,4_"1P.47:#< E1UA P(]7X_ V_HJC
MR:(/\<J37[&$C2!6FPBRR7VF35+9R7 (1^4<"QC<CM(C]#J053>'WA^D2FND
M 9!]C2/XT???XCA.[2CWS@_7><3Y/'>&^Q57O-U9D$J110H69'-%)9<V]_)R
M#E%ML=$&>U<^NCB$P+HY\/Z UY^6&H!@&=?UXWTI"_=.VY1+63#$7!QCC:SF
M$HD0& E)6&-*/P(LS$(K+UM;"2IJ(J0! ^E87Z4H)SK1A"Q5#KCRL,%0&A$#
M_P8':B/5I3?G@L5Q_95_U 3/<95RAVCR<BKE_K2CFZ6P9[.;Z^5-[>31O6WQ
MY'KW3_:4=S^2YS92\MSFQAHT(*&ERMU_(O@1$B.CK8HB&B]U++RA5$[)WZ^\
MOXYV_>.+NJ[W=CC-JHYK:L[&[)>CGZ[)P$+,B;7RB$9PQ[B" ,%$9Y!-R1(0
M)$FA=//K_KBYZ.3\(:C>VFZC/D :\$F.+CG?)HDOP]D_WT]C_# & N-L_@7T
M.+".8@>!$7)"2L1M,,C%D%"2V&:7T419.C?6.U-U'?O:AM,,7%Z:_?PCYI87
M,;SZ%:?V>_QS OI<M/)?2$8:$VS2&%$#7BMG"F(P$A2B,ECNF4V$]'+TG(6[
MNAF?EV)1Y0#TTDSK[I!^._PU#."3+P3B+%<J]VCP/M=3$0''=, 1!<:5Y7!2
M.U<ZZ]X[4W4++%^*(9T,ETNVGU5$NZA"G7T8+[,G&UO+XH=O02KWTALD;[@C
MV",A<F(\>@9ZPQ(%S8FD.&$62M^DGYG%NL6@EVA;9X#2Y23.UM)%K_P<=I;Y
M;?G'I;N_T=>STHY<M9$+@QB".4XQ4DKFQ\L0F3MB'-(D2$P#$8R4KCIK(!=V
M@NFN/;WY,AF-WD^F^8<#Y90-2@2DO,.(<Y>067B5@5";L'2.E,XI]L/)1>?
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M%A1K7GH49P]L7&@'Y';W_U.A\G*,YMW?/X?3Q7_S( F2'/5*ICP@)^5*9(M
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MZ!//+]H1>)P6?%YP/(#8L. H.N\05\DA)ZQ#. 0CA.?"XV8:U99F_L5GL5_
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M(9A[ND>>19]-G+T=.'U[$S_!OO'MKSCZ%7\'N?^8#70*C)C\Z @G"GS"N>'
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M=S$XMZ+T2\#][" 9_",.O__(E0R_XM1^C^_^CE,_G,7/TZ&/ Q*U$40&I+@
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M7=DXL4:O4NJI.X&+DN77$V?_^>I_[/70;@U#=Q1V;_G/ZJ4H]Z6W)IUXK5.
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M,S$R-"YH=&U02P$"% ,4    " "0@:A8=26S&%X(  !=)P  %
M    @ & "   97AH:6)I=#,Q,BTS,S$R-"YH=&U02P$"% ,4    " "0@:A8
M;?>0W>T$  "D%P  %               @ $0$0  97AH:6)I=#,R,2TS,S$R
M-"YH=&U02P$"% ,4    " "0@:A8&;WU$^H$   E%P  %
M@ $O%@  97AH:6)I=#,R,BTS,S$R-"YH=&U02P$"% ,4    " "0@:A8"9/]
M>KLZ  !LQ@  '               @ %+&P  :F]S971R979E:F\M=&%R<W5S
M<V5P87)A+FAT;5!+ 0(4 Q0    ( )"!J%B$D.U'P=<" /0C&  1
M      "  4!6  !T87)S+3(P,C0P,S,Q+FAT;5!+ 0(4 Q0    ( )"!J%A)
M++RMQ1$  #S"   1              "  3 N P!T87)S+3(P,C0P,S,Q+GAS
M9%!+ 0(4 Q0    ( )"!J%B'T?@E,!\  '(O 0 5              "  21
M P!T87)S+3(P,C0P,S,Q7V-A;"YX;6Q02P$"% ,4    " "0@:A8:Q8R.WA6
M   "T0, %0              @ &'7P, =&%R<RTR,#(T,#,S,5]D968N>&UL
M4$L! A0#%     @ D(&H6'TM$F7F!@$ $F\* !4              ( !,K8#
M '1A<G,M,C R-# S,S%?;&%B+GAM;%!+ 0(4 Q0    ( )"!J%AH'K.> Z
M  6"!P 5              "  4N]! !T87)S+3(P,C0P,S,Q7W!R92YX;6Q0
52P4&      L "P#< @  @5T%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>tars-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:tars="http://tarsusrx.com/20240331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tars-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2024-05-02</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:A2023ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-21</startDate>
            <endDate>2023-11-21</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-05</startDate>
            <endDate>2024-03-05</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-05</startDate>
            <endDate>2024-03-05</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:A2023ATMProspectusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-21</startDate>
            <endDate>2023-11-21</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:A2023ATMProspectusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">tars:IntangibleAssetsMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tars:FiveCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tars:LianBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-14</startDate>
            <endDate>2024-03-14</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:CommonStockInLianBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">tars:AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:MilestoneDeterminedByTheCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tars:LianBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:GrandpharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:GrandpharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-05</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityFirstAmendmentTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-05</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-15</startDate>
            <endDate>2023-03-15</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-15</startDate>
            <endDate>2023-09-15</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tars:LineOfCreditSVBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-15</startDate>
            <endDate>2023-03-15</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tars:LineOfCreditSVBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-15</startDate>
            <endDate>2023-09-15</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-30</startDate>
            <endDate>2024-01-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-30</startDate>
            <endDate>2024-01-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-19</startDate>
            <endDate>2024-04-19</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-19</startDate>
            <endDate>2024-04-19</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-19</startDate>
            <endDate>2024-04-19</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:PharmakonCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-19</startDate>
            <endDate>2024-04-19</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">tars:BobakAzamianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">tars:BobakAzamianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">tars:JoseTrevejoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">tars:JoseTrevejoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>tars:segment</measure>
    </unit>
    <unit id="tranche">
        <measure>tars:tranche</measure>
    </unit>
    <unit id="warrant">
        <measure>tars:warrant</measure>
    </unit>
    <unit id="security">
        <measure>tars:security</measure>
    </unit>
    <unit id="contract">
        <measure>tars:contract</measure>
    </unit>
    <unit id="vote">
        <measure>tars:vote</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0001819790</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-30">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-49" id="f-311">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-59" id="f-330">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="c-104" id="f-460">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39614</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">TARSUS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">81-4717861</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">15440 Laguna Canyon Road, Suite 160</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">92618</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">(949)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">418-1801</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">TARS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-23">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">37781693</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">193705000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">224947000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">104819000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">2495000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">29885000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">16621000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">4036000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">3107000</us-gaap:InventoryNet>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">1476000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">1093000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">6803000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">7868000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">340724000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">256131000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">1338000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">1468000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">3767000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">3867000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">2132000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">1880000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">631000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">1317000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">1514000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">349278000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">265491000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">36570000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">23691000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">5958000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">13245000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">42528000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">36936000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">29933000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">29819000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">1606000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">1748000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">74067000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">68503000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-69" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-70" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-71"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-72"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-73" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-74" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-75" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-76" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-77" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-78" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-79" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-82"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-83" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-84" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-85" unitRef="shares">37749468</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-86" unitRef="shares">37749468</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-87" unitRef="shares">34211190</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-88" unitRef="shares">34211190</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-89" unitRef="usd">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">555655000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">441641000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-93" unitRef="usd">-63000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">-2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-95" unitRef="usd">-280387000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">-244656000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-97" unitRef="usd">275211000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">196988000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-99" unitRef="usd">349278000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-100" unitRef="usd">265491000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">24720000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-3" id="f-102" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-3" id="f-103" unitRef="usd">2894000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-3" id="f-104" unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">27614000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-3" id="f-106" unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">1654000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-6" decimals="-3" id="f-108" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">12066000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-9" decimals="-3" id="f-110" unitRef="usd">12356000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">51578000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-9" decimals="-3" id="f-112" unitRef="usd">15096000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-113" unitRef="usd">65298000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-9" decimals="-3" id="f-114" unitRef="usd">27452000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">-37684000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-9" decimals="-3" id="f-116" unitRef="usd">-24952000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">3117000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-9" decimals="-3" id="f-118" unitRef="usd">2293000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">983000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-9" decimals="-3" id="f-120" unitRef="usd">684000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">605000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-9" decimals="-3" id="f-122" unitRef="usd">6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">-585000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-9" decimals="-3" id="f-124" unitRef="usd">-65000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">-201000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-9" decimals="-3" id="f-126" unitRef="usd">-17000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">1953000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-9" decimals="-3" id="f-128" unitRef="usd">1533000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">-35731000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-130" unitRef="usd">-23419000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">-61000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-9" decimals="-3" id="f-132" unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">-35792000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-9" decimals="-3" id="f-134" unitRef="usd">-23415000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-135"
      unitRef="usdPerShare">-1.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-136"
      unitRef="usdPerShare">-1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-137"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-138"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-139" unitRef="shares">35300655</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="INF" id="f-140" unitRef="shares">35300655</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="INF" id="f-141" unitRef="shares">26742023</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="0" id="f-142" unitRef="shares">26742023</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-143"
      unitRef="shares">34211190</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-144" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-145" unitRef="usd">441641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-146" unitRef="usd">-2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-147" unitRef="usd">-244656000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-148" unitRef="usd">196988000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-149" unitRef="usd">-35731000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">-35731000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-151" unitRef="usd">5519000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">5519000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-5" id="f-153" unitRef="usd">6700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-16"
      decimals="INF"
      id="f-154"
      unitRef="shares">3281250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-16" decimals="-3" id="f-155" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-156" unitRef="usd">98328000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">98329000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <tars:ClassOfWarrantOrRightPaymentsOfIssuanceCosts contextRef="c-1" decimals="-5" id="f-158" unitRef="usd">600000</tars:ClassOfWarrantOrRightPaymentsOfIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-15" decimals="-3" id="f-159" unitRef="usd">9365000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">9365000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-16"
      decimals="INF"
      id="f-161"
      unitRef="shares">49310</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-3" id="f-162" unitRef="usd">802000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">802000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-16"
      decimals="INF"
      id="f-164"
      unitRef="shares">207718</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-17" decimals="-3" id="f-165" unitRef="usd">-61000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">-61000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-167"
      unitRef="shares">37749468</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-168" unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-169" unitRef="usd">555655000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-170" unitRef="usd">-63000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-171" unitRef="usd">-280387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-172" unitRef="usd">275211000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-173"
      unitRef="shares">26727458</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-174" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-175" unitRef="usd">301732000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-176" unitRef="usd">-74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-177" unitRef="usd">-108763000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-178" unitRef="usd">192900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-179" unitRef="usd">-23419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-180" unitRef="usd">-23419000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-28" decimals="-3" id="f-181" unitRef="usd">3906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-9" decimals="-3" id="f-182" unitRef="usd">3906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-29"
      decimals="INF"
      id="f-183"
      unitRef="shares">6443</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-28" decimals="-3" id="f-184" unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-9" decimals="-3" id="f-185" unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-29"
      decimals="INF"
      id="f-186"
      unitRef="shares">66611</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-30" decimals="-3" id="f-187" unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-9" decimals="-3" id="f-188" unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-31"
      decimals="INF"
      id="f-189"
      unitRef="shares">26800512</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-190" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-191" unitRef="usd">305651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-192" unitRef="usd">-70000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-193" unitRef="usd">-132182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-194" unitRef="usd">173404000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-35731000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-196" unitRef="usd">-23419000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">170000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-9" decimals="-3" id="f-198" unitRef="usd">104000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-9" decimals="-3" id="f-200" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">114000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-9" decimals="-3" id="f-202" unitRef="usd">81000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">5519000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-9" decimals="-3" id="f-204" unitRef="usd">3906000</us-gaap:ShareBasedCompensation>
    <tars:OperatingLeaseNoncashExpense contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">132000</tars:OperatingLeaseNoncashExpense>
    <tars:OperatingLeaseNoncashExpense contextRef="c-9" decimals="-3" id="f-206" unitRef="usd">151000</tars:OperatingLeaseNoncashExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">-585000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-9" decimals="-3" id="f-208" unitRef="usd">-65000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">290000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-9" decimals="-3" id="f-210" unitRef="usd">1484000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">-201000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-9" decimals="-3" id="f-212" unitRef="usd">-17000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-9" decimals="-3" id="f-214" unitRef="usd">-16000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">13264000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-9" decimals="-3" id="f-216" unitRef="usd">2500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">929000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-9" decimals="-3" id="f-218" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">383000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-9" decimals="-3" id="f-220" unitRef="usd">-3165000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">-1065000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-9" decimals="-3" id="f-222" unitRef="usd">-257000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">-106000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-9" decimals="-3" id="f-224" unitRef="usd">-38000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">12335000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-9" decimals="-3" id="f-226" unitRef="usd">-1046000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">-7287000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-9" decimals="-3" id="f-228" unitRef="usd">-1313000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">-232000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-9" decimals="-3" id="f-230" unitRef="usd">-8000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">-37789000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-9" decimals="-3" id="f-232" unitRef="usd">-21970000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">2500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-9" decimals="-3" id="f-234" unitRef="usd">40301000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">104550000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-9" decimals="-3" id="f-236" unitRef="usd">28667000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">174000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-9" decimals="-3" id="f-238" unitRef="usd">340000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">-102224000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-9" decimals="-3" id="f-240" unitRef="usd">11294000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">98604000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-9" decimals="-3" id="f-242" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">9365000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-9" decimals="-3" id="f-244" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">802000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-9" decimals="-3" id="f-246" unitRef="usd">13000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-9" decimals="-3" id="f-248" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">108771000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-9" decimals="-3" id="f-250" unitRef="usd">5013000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">-31242000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-9" decimals="-3" id="f-252" unitRef="usd">-5663000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-253" unitRef="usd">224947000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-254" unitRef="usd">71660000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-255" unitRef="usd">193705000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-35" decimals="-3" id="f-256" unitRef="usd">65997000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">384000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-9" decimals="-3" id="f-258" unitRef="usd">116000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">868000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-9" decimals="-3" id="f-260" unitRef="usd">593000</us-gaap:InterestPaidNet>
    <tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">275000</tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities>
    <tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities contextRef="c-9" decimals="-3" id="f-262" unitRef="usd">0</tars:DeferredOfferingCostsIncurredButNotYetPaidIncludedInAccountsPayableAndAccruedLiabilities>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-263">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tarsus Pharmaceuticals, Inc. (&#x201c;Tarsus&#x201d; or the &#x201c;Company&#x201d;) is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The Company launched XDEMVY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Demodex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; blepharitis, in August 2023, after receiving United States ("U.S.") Food and Drug Administration ("FDA") approval in July 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Follow-On Public Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company completed a follow-on public offering under its shelf registration statement on Form S-3 (the "2021 Shelf Registration Statement") of 5,714,285 shares of common stock at a public offering price of $17.50 per share. In September 2023, the underwriters partially exercised the underwriters option to purchase additional shares resulting in the Company's issuance of an additional 355,164 shares of common stock at the public offering price of $17.50 per share. The aggregate net proceeds received by the Company were $99.3&#160;million, after deducting underwriting discounts, commissions, and other offering-related expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Company filed a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission ("SEC") on November 21, 2023, (the "2023 Shelf Registration Statement"), which replaced the 2021 Shelf Registration Statement, and permits the Company to offer up to $300.0&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2024, the Company filed an automatic shelf registration on Form S-3 ASR (the "2024 Shelf Registration Statement"). On March 5, 2024 the Company completed an underwritten follow-on public offering under the 2024 Shelf Registration Statement of 2,812,500 shares of the Company&#x2019;s common stock, par value $0.0001 per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of its common stock (the &#x201c;March 2024 Public Offering&#x201d;). The price to the public was $32.00 per share and $31.9999 per pre-funded warrant, which was the price to the public of each share of common stock sold in the March 2024 Public Offering, minus the $0.0001 exercise price per pre-funded warrant. The pre-funded warrants are exercisable, subject to certain beneficial ownership restrictions, at any time after their original issuance and will not expire; as of March&#160;31, 2024, 312,500 of pre-funded warrants are exercisable. The Company also granted the underwriters a 30-day option to purchase up to 468,750 additional shares of its common stock at the public offering price of $32.00 per share, which the underwriters exercised in full and was completed on March 5, 2024. The aggregate net proceeds received by the Company were $107.7&#160;million, after deducting underwriting discounts, commissions, and other estimated offering-related expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Open Market Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the 2023 Shelf Registration Statement, the Company concurrently filed a sales agreement prospectus covering the sale of up to $100.0&#160;million of common stock pursuant to an Open Market Sale Agreement (the "2023 ATM Prospectus") with Jefferies LLC ("Jefferies"), which replaced the November 1, 2021 Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the "2021 ATM Prospectus"). Under the terms of the 2023 ATM Prospectus, Jefferies will act as the Company's sales agent and is entitled to compensation for its services equal to 3% of the gross proceeds of any shares of common stock sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2024, there were no sales of the Company's common stock pursuant to the 2023 ATM Prospectus. During the year ended December 31, 2023, the Company sold 1,000,000 shares of common stock under the 2023 ATM Prospectus for net proceeds of $19.2&#160;million, after deducting broker commissions and offering-related expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a limited operating history, limited history of product sales and has accumulated losses and negative cash flows from operations since inception. The Company has funded its inception-to-date operations through its Initial Public Offering ("IPO"), subsequent follow-on public offerings, and the 2023 ATM Prospectus, as well as from proceeds from product sales, the development and license agreement (the "China Out-License") with LianBio Ophthalmology Limited ("LianBio"), and draws on the loan and security agreements with Hercules Capital, Inc. ("Hercules") and Silicon Valley Bank, a division of First-Citizens Bank &amp;amp; Trust Company ("SVB") (the "Credit Facility"). The Company estimates that its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the issuance date of the accompanying Condensed Financial Statements that have been prepared on a going-concern basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company plans to fund its operations, capital funding and other liquidity needs using existing cash and investments and, to the extent available, cash generated from commercial operations. Management expects the Company to continue to incur operating losses for the foreseeable future and may be required to raise additional capital to fund its ongoing operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own and/or enter into collaborations and other arrangements to address its liquidity needs, which could materially and adversely affect its business and financial prospects, or even its ability to remain a going concern.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Segment  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates one reportable operating segment focused on the development and commercialization of therapeutics. To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purpose of evaluating financial performance and the allocation of capital and personnel resources. The Company&#x2019;s chief operating decision-maker, its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-36" decimals="0" id="f-264" unitRef="shares">5714285</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-37"
      decimals="2"
      id="f-265"
      unitRef="usdPerShare">17.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-38" decimals="0" id="f-266" unitRef="shares">355164</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-39"
      decimals="2"
      id="f-267"
      unitRef="usdPerShare">17.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-38" decimals="-5" id="f-268" unitRef="usd">99300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tars:SaleOfStockConsiderationAmountAuthorized contextRef="c-40" decimals="-5" id="f-269" unitRef="usd">300000000</tars:SaleOfStockConsiderationAmountAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-41" decimals="0" id="f-270" unitRef="shares">2812500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-42"
      decimals="INF"
      id="f-271"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-43" decimals="0" id="f-272" unitRef="shares">312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-43"
      decimals="2"
      id="f-273"
      unitRef="usdPerShare">32.00</us-gaap:SaleOfStockPricePerShare>
    <tars:ClassOfWarrantOrRightSalePrice
      contextRef="c-43"
      decimals="INF"
      id="f-274"
      unitRef="usdPerShare">31.9999</tars:ClassOfWarrantOrRightSalePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-43"
      decimals="INF"
      id="f-275"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tars:ClassOfWarrantOrRightReservedForFutureIssuance contextRef="c-3" decimals="INF" id="f-276" unitRef="shares">312500</tars:ClassOfWarrantOrRightReservedForFutureIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-44" decimals="0" id="f-277" unitRef="shares">468750</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-45"
      decimals="2"
      id="f-278"
      unitRef="usdPerShare">32.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-41" decimals="-5" id="f-279" unitRef="usd">107700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tars:SaleOfStockConsiderationAmountAuthorized contextRef="c-46" decimals="-5" id="f-280" unitRef="usd">100000000</tars:SaleOfStockConsiderationAmountAuthorized>
    <tars:SaleOfStockSalesAgentFeePercentageOfGrossProceeds contextRef="c-46" decimals="2" id="f-281" unitRef="number">0.03</tars:SaleOfStockSalesAgentFeePercentageOfGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-47" decimals="0" id="f-282" unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-47" decimals="-5" id="f-283" unitRef="usd">19200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-284">The Company operates one reportable operating segment focused on the development and commercialization of therapeutics. To date, the Company has operated, managed and organized its business and financial information on an aggregate basis for the purpose of evaluating financial performance and the allocation of capital and personnel resources. The Company&#x2019;s chief operating decision-maker, its Chief Executive Officer, reviews its operating results for the purpose of allocating resources and evaluating financial performance.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-285"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-286"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-287">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information pursuant to Form 10-Q and with the rules and regulations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the SEC. Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on February&#160;27, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Balance Sheet as of March&#160;31, 2024, the Condensed Statements of Operations and Comprehensive Loss, and the Condensed Statements of Stockholders&#x2019; Equity for the three months ended March&#160;31, 2024 and 2023, and the Condensed Statements of Cash Flows for the three months ended March&#160;31, 2024 and 2023 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December&#160;31, 2023 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2024 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2024 or any other interim or annual period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these Condensed Financial Statements and Notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, expected demand for inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions used in the preparation of the accompanying Condensed Financial Statements under different assumptions and conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Condensed Financial Statements as of and for the three months ended March 31, 2024, reflect the Company&#x2019;s estimates of the impact of the macroeconomic and geopolitical environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#x2019;s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies and estimates that most significantly impact the presented amounts within these accompanying Condensed Financial Statements are further described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities and Long-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist primarily of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are recorded at fair value with unrealized gains and losses reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized gains and losses as well as credit losses, if any, on marketable securities identified on a specific identification basis are included in other income (expense) on the accompanying Condensed Statements of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other-than-temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the Company's holdings of common stock in the parent company of LianBio was included as marketable securities. As of December&#160;31, 2023, this LianBio common stock was classified as long-term investments due to the Company's intent at that time to hold these shares for longer than one year. These equity securities are designated as available-for-sale with associated unrealized gains or losses reported in other income (expense) within the Condensed Statements of Operations and Comprehensive Loss for each reported period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable generally consists of amounts due from the Company's customers, which includes pharmaceutical wholesalers and specialty pharmacy providers related to product sales of XDEMVY in the U.S. Payment terms are typically 30-60 days following delivery to customers. Accounts receivable are recorded net of discounts, chargebacks, allowances and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so it can properly assess and respond to changes in their credit profile. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company did not record a reserve for estimated credit losses during the three months ended March 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is valued at the lower-of-cost or net realizable value, with cost determined on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and adjusts the value for any excess and obsolete inventory to net realizable value in the period in which the impairment is first identified and such charges are recorded as a component of cost of sales in the Condensed Statements of Operations and Comprehensive Loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Product that may be used in clinical development programs are excluded from inventory and the costs are charged to research and development expense in the Condensed Statements of Operations and Comprehensive Loss as incurred, as long as they do not have an alternative use. Prior to FDA approval of XDEMVY in July 2023, costs related to the production of inventory were recorded as research and development expense on the Condensed Statements of Operations and Comprehensive Loss in the period incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow. The carrying value of intangible assets as a result of achieving certain commercial milestones was $4.0&#160;million as of March&#160;31, 2024, and are amortized to cost of sales over their useful life of 10 years from the date of first commercial sale (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Amortization expense for the three months ended March 31, 2024 was $0.1 million; no amortization expense was recorded for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the expected future amortization expense for the Company's intangible assets is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including intangibles, are evaluated for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in the Condensed Statements of Operations and Comprehensive Loss. There have been no impairments of intangible assets for the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash, cash equivalents, accounts receivable, net, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from &lt;span style="-sec-ix-hidden:f-311"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;changes in circumstances of the business indicate that the asset&#x2019;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception. Right-of-Use assets (&#x201c;ROU assets&#x201d;) represent the Company&#x2019;s right to control an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the initial non-cancelable lease term, unless there is a renewal option that is reasonably certain to be exercised. The Company uses its incremental borrowing rate at the lease commencement date in determining the discount rate utilized to present value the future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable. The Company has lease agreements with both lease and non-lease components, which are accounted for as a single component for all asset classes. Lease expense for the Company's operating leases are recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's variable lease costs, consisting primarily of real estate taxes, insurance costs, and common area maintenance, are expensed as incurred and excluded from the reported ROU assets and lease liabilities amounts presented in the accompanying Condensed Balance Sheets. The current and noncurrent portion of the operating lease liability are included in accounts payable and other accrued liabilities and other long-term liabilities, respectively, in the accompanying Condensed Balance Sheets. Rent expense is allocated to research and development and general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company maintains cash held on deposit at financial institutions in the U.S., including SVB. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. The Company invests its excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. The following table summarizes the percentage of the Company's product sales from its largest customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, amounts due from these five customers each exceeded 10% of gross accounts receivable and accounted for approximately 100% of the accounts receivable balance on a combined basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Major Suppliers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not currently own manufacturing facilities and depends on an outsourced manufacturing strategy for the production of XDEMVY for commercial use and for the production of its other product candidates for clinical trials. The Company enters into agreements with third-party manufacturers that are approved for the commercial production of XDEMVY and third-party suppliers that are approved for XDEMVY's active pharmaceutical ingredient. Although there are potential sources of supply other than the Company's existing manufacturers and suppliers, any new supplier would be required to qualify under applicable regulatory requirements. The loss of certain manufacturers and third-party suppliers could result in a temporary disruption of the Company&#x2019;s commercialization efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(i) Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes product sales, net of XDEMVY when a customer obtains control of promised goods or services, which occurs at a point in time, typically upon delivery of the Company's product to the customer. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as each performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells XDEMVY to customers in the U.S., which became available for commercial sale during the third quarter of 2023. The Company sells XDEMVY to a limited number of specialty pharmacies and distributors (i.e., its customers) who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. Revenue from product sales is primarily recognized upon physical delivery of the product (when the customer obtains control of the product), in return for agreed-upon consideration. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price, or the transaction price, which may include fixed or variable consideration for (i) invoice discounts for prompt payment and distribution service fees, (ii) government and private payer rebates, chargebacks, discounts and fees, (iii) product returns and (iv) costs of co-pay assistance programs for patients, as well as other incentives. Estimates of variable consideration are calculated based on the actual product sales each reporting period and the nature of the variable consideration related to those sales. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates reflect the Company&#x2019;s best estimate of the amount of consideration to which the Company expects to be entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ materially from &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect product sales, net and earnings in the period such variances are adjusted. The Company categorizes product sales deduction estimates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Service Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prompt Pay Discounts: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's customers are contractually permitted to return the product within the contractual allowable time before and after the applicable expiration date. In the initial sales period, the Company estimates its provision for returns based on industry data and adjusts the transaction price at the time of the product sale to the customer. Once sufficient history has been collected for product returns, the Company will utilize that history to inform its returns estimate. Once the product is returned, it is destroyed since it cannot be resold.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A chargeback is the difference between the Company's invoice price to the wholesaler and the wholesaler&#x2019;s customer's contract price. The wholesaler tracks these sales and charges back the Company for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price and accounts receivable at the time of sale of the product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company&#x2019;s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(ii) License Fees and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;China Out-License &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss has historically primarily related to the China Out-License that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kong, Macau, and Taiwan (the "China Territory")&#x2014; see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract; (b) the contract&#x2019;s transaction price for allocation (including variable consideration); (c) the stand-alone selling price for each identified performance obligation; and (d) the timing and amount of revenue recognition in each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment; (ii) equity-based consideration; (iii) sales-based royalties; (iv) sales-based threshold milestones; (v) one-time payment for executing a drug supply agreement; (vi) development milestone payments; (vii) regulatory milestone payments; and (viii) a one-time termination payment to transition the rights to develop and commercialize TP-03 in China for the treatment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Demodex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; blepharitis to Xi An Grand Chang An Pharmaceutical Co., Ltd  ("GrandPharma"). Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Terms for Receipt of Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#x2019;s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual terms that establish the Company&#x2019;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Upfront License Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee&#x2019;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales Threshold Milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other License Fees and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service. There was no revenue recognized under this arrangement for the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, freight, third-party royalties payable on the Company&#x2019;s product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon FDA approval of XDEMVY in July 2023. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses in the Condensed Statements of Operations and Comprehensive Loss. Therefore, cost of sales of XDEMVY will reflect a lower average per unit cost until the related inventory is sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative costs consist of salaries, benefits, stock-based compensation and other personnel-related costs for the Company's executive, finance, sales and marketing, and other administrative functions. Selling, general and administrative expenses also include sales and marketing costs to support our commercial launch, consulting fees, legal services, rent and other facilities costs, patient assistance donations, and other general operating expenses not otherwise classified as research and development expenses. Advertising costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including the costs of salaries, payroll taxes, employee benefit and other employee-related costs (including stock-based compensation expense), license fees, materials, supplies and the cost of services provided by outside contractors to conduct nonclinical studies, clinical trials and contract manufacturing activities. All costs associated with research and development are expensed as incurred. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company's license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense in the Condensed Statements of Operations and Comprehensive Loss when paid or become payable, provided there is no alternative future use of rights in other research and development projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company&#x2019;s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's common stock on the date preceding the award grant date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock awards granted typically have &lt;span style="-sec-ix-hidden:f-330"&gt;one&lt;/span&gt; to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#x2019;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#x2019;s judgment, including (a) the fair value of the Company&#x2019;s common stock on the date of the option grant for all awards granted prior to the IPO, (b) the expected term of the stock option until its exercise by the recipient, (c) stock price volatility over the expected term, (d) the prevailing risk-free interest rate over the expected term, and (e) expected dividend payments over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within cost of sales, research and development expense or selling, general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#x2019;s judgment, including:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The fair value of the Company&#x2019;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain due to the Company&#x2019;s historical operating performance and recorded cumulative net losses in prior fiscal periods. A valuation allowance is recorded to reduce deferred tax assets, because based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when the Company were to determine that deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase the net income in the period that such determination was made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to net losses in all periods presented, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals diluted net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued or Effective Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#x2019;s financial statements have been discussed within the footnote to which each relates. Outside of the pronouncement below, other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#x2019;s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosure&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2023-09"). ASU 2023-09 requires annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold and a disaggregation of income taxes paid, net of refunds. The standard also eliminates certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities and is effective for the Company beginning with the 2025 Annual Report on Form 10-K. Early adoption is permitted. ASU 2023-09 should be applied prospectively. Retrospective adoption is permitted. The Company is currently assessing the impact this standard will have on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-288">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information pursuant to Form 10-Q and with the rules and regulations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the SEC. Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on February&#160;27, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Balance Sheet as of March&#160;31, 2024, the Condensed Statements of Operations and Comprehensive Loss, and the Condensed Statements of Stockholders&#x2019; Equity for the three months ended March&#160;31, 2024 and 2023, and the Condensed Statements of Cash Flows for the three months ended March&#160;31, 2024 and 2023 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December&#160;31, 2023 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2024 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2024 or any other interim or annual period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-289">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these Condensed Financial Statements and Notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources and involve judgments with respect to numerous factors that are difficult to predict and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, expected demand for inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions used in the preparation of the accompanying Condensed Financial Statements under different assumptions and conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Condensed Financial Statements as of and for the three months ended March 31, 2024, reflect the Company&#x2019;s estimates of the impact of the macroeconomic and geopolitical environment, including the impact of inflation, higher interest rates, and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#x2019;s assets or liabilities as of the issuance date of the accompanying Condensed Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies and estimates that most significantly impact the presented amounts within these accompanying Condensed Financial Statements are further described below:&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-290">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. The carrying amounts reported in the accompanying Condensed Balance Sheets for cash and cash equivalents are valued at cost, which approximate their fair value.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-291">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities and Long-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist primarily of short-term fixed income investments carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase, including those that have maturity dates beyond one year from the balance sheet date, are classified as current assets on the accompanying Condensed Balance Sheets due to their highly liquid nature and availability for use in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are recorded at fair value with unrealized gains and losses reported as a component of accumulated other comprehensive loss within the accompanying Condensed Statements of Stockholders' Equity until realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, as well as interest and dividends, are included in interest income. Realized gains and losses as well as credit losses, if any, on marketable securities identified on a specific identification basis are included in other income (expense) on the accompanying Condensed Statements of Operations and Comprehensive Loss. The Company evaluated the underlying credit quality and credit ratings of the issuers during the period. To date, the Company has not identified any other-than-temporary declines in fair value of its investments and no credit losses associated with credit risk have occurred or have been recorded. Interest earned on marketable securities is included in interest income within the accompanying Condensed Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;As of March&#160;31, 2024, the Company's holdings of common stock in the parent company of LianBio was included as marketable securities. As of December&#160;31, 2023, this LianBio common stock was classified as long-term investments due to the Company's intent at that time to hold these shares for longer than one year. These equity securities are designated as available-for-sale with associated unrealized gains or losses reported in other income (expense) within the Condensed Statements of Operations and Comprehensive Loss for each reported period.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-292">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/div&gt;Accounts receivable generally consists of amounts due from the Company's customers, which includes pharmaceutical wholesalers and specialty pharmacy providers related to product sales of XDEMVY in the U.S. Payment terms are typically 30-60 days following delivery to customers. Accounts receivable are recorded net of discounts, chargebacks, allowances and other adjustments. The Company monitors the financial performance and creditworthiness of its customers so it can properly assess and respond to changes in their credit profile. The Company estimates the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances. Amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company did not record a reserve for estimated credit losses during the three months ended March 31, 2024.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-293">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;Inventory is valued at the lower-of-cost or net realizable value, with cost determined on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and adjusts the value for any excess and obsolete inventory to net realizable value in the period in which the impairment is first identified and such charges are recorded as a component of cost of sales in the Condensed Statements of Operations and Comprehensive Loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Product that may be used in clinical development programs are excluded from inventory and the costs are charged to research and development expense in the Condensed Statements of Operations and Comprehensive Loss as incurred, as long as they do not have an alternative use. Prior to FDA approval of XDEMVY in July 2023, costs related to the production of inventory were recorded as research and development expense on the Condensed Statements of Operations and Comprehensive Loss in the period incurred.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c-1" id="f-294">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;Intangible assets are measured at fair value as of the acquisition date or, in the case of commercial milestone payments, the date they become due. The evaluation of intangible assets includes assessing the amortization period for which the asset is expected to contribute to the future cash flows of the Company. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis when the Company is unable to reliably estimate the pattern of cash flow. &lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including intangibles, are evaluated for impairment whenever events or changes in circumstance indicate that the carrying value of an asset might not be fully recoverable. To do so, the Company compares the carrying value of the intangible asset to the undiscounted net cash flows over its remaining useful life, and if not recoverable, will estimate the fair value of the asset. If the fair value is less than the carrying amount, an impairment loss is recognized in the Condensed Statements of Operations and Comprehensive Loss. There have been no impairments of intangible assets for the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-48" decimals="-5" id="f-295" unitRef="usd">4000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-48" id="f-296">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-297" unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-9" decimals="-5" id="f-298" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-299">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the expected future amortization expense for the Company's intangible assets is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-300" unitRef="usd">300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-3" id="f-301" unitRef="usd">400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-3" id="f-302" unitRef="usd">400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-3" id="f-303" unitRef="usd">400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-3" decimals="-3" id="f-304" unitRef="usd">400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <tars:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour contextRef="c-3" decimals="-3" id="f-305" unitRef="usd">1867000</tars:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-306" unitRef="usd">3767000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-9" decimals="-3" id="f-307" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-309">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash, cash equivalents, accounts receivable, net, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings disclosed as other assets are carried at fair value based on unobservable market inputs (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value hierarchy during the years presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-310">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are stated at historical cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from &lt;span style="-sec-ix-hidden:f-311"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining lease term or the estimated useful lives of related improvements. The Company evaluates the recoverability of its property and equipment, net whenever events or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;changes in circumstances of the business indicate that the asset&#x2019;s carrying amount may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amounts to the sum of the future undiscounted cash flows the assets are expected to generate over the remaining useful lives of the assets. If a long-lived asset fails a recoverability test, the Company measures the amount by which the carrying value of the asset exceeds its fair value. There were no impairments recognized during the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-50" id="f-312">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-313">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception. Right-of-Use assets (&#x201c;ROU assets&#x201d;) represent the Company&#x2019;s right to control an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the initial non-cancelable lease term, unless there is a renewal option that is reasonably certain to be exercised. The Company uses its incremental borrowing rate at the lease commencement date in determining the discount rate utilized to present value the future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable. The Company has lease agreements with both lease and non-lease components, which are accounted for as a single component for all asset classes. Lease expense for the Company's operating leases are recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;The Company's variable lease costs, consisting primarily of real estate taxes, insurance costs, and common area maintenance, are expensed as incurred and excluded from the reported ROU assets and lease liabilities amounts presented in the accompanying Condensed Balance Sheets. The current and noncurrent portion of the operating lease liability are included in accounts payable and other accrued liabilities and other long-term liabilities, respectively, in the accompanying Condensed Balance Sheets. Rent expense is allocated to research and development and general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-314">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company maintains cash held on deposit at financial institutions in the U.S., including SVB. These deposits are insured by the Federal Deposit Insurance Corporation ("FDIC") in an amount up to $250,000 for any depositor. To the extent the Company holds cash deposits in amounts that exceed the FDIC insurance limitation, it may incur a loss in the event of a failure of any of the financial institutions where it maintains deposits. The Company invests its excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to assess that this exposure is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S. The following table summarizes the percentage of the Company's product sales from its largest customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, amounts due from these five customers each exceeded 10% of gross accounts receivable and accounted for approximately 100% of the accounts receivable balance on a combined basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Major Suppliers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not currently own manufacturing facilities and depends on an outsourced manufacturing strategy for the production of XDEMVY for commercial use and for the production of its other product candidates for clinical trials. The Company enters into agreements with third-party manufacturers that are approved for the commercial production of XDEMVY and third-party suppliers that are approved for XDEMVY's active pharmaceutical ingredient. Although there are potential sources of supply other than the Company's existing manufacturers and suppliers, any new supplier would be required to qualify under applicable regulatory requirements. The loss of certain manufacturers and third-party suppliers could result in a temporary disruption of the Company&#x2019;s commercialization efforts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-315">The following table summarizes the percentage of the Company's product sales from its largest customers:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-51" decimals="2" id="f-316" unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-52" decimals="2" id="f-317" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-53" decimals="2" id="f-318" unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-54" decimals="2" id="f-319" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-55" decimals="2" id="f-320" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-56" decimals="2" id="f-321" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-322">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(i) Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes product sales, net of XDEMVY when a customer obtains control of promised goods or services, which occurs at a point in time, typically upon delivery of the Company's product to the customer. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are capable of being distinct; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue as each performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells XDEMVY to customers in the U.S., which became available for commercial sale during the third quarter of 2023. The Company sells XDEMVY to a limited number of specialty pharmacies and distributors (i.e., its customers) who in turn sell it directly to clinics, hospitals, pharmacies and federal healthcare programs. Revenue from product sales is primarily recognized upon physical delivery of the product (when the customer obtains control of the product), in return for agreed-upon consideration. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price, or the transaction price, which may include fixed or variable consideration for (i) invoice discounts for prompt payment and distribution service fees, (ii) government and private payer rebates, chargebacks, discounts and fees, (iii) product returns and (iv) costs of co-pay assistance programs for patients, as well as other incentives. Estimates of variable consideration are calculated based on the actual product sales each reporting period and the nature of the variable consideration related to those sales. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates reflect the Company&#x2019;s best estimate of the amount of consideration to which the Company expects to be entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ materially from &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect product sales, net and earnings in the period such variances are adjusted. The Company categorizes product sales deduction estimates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Service Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company engages with wholesalers and specialty pharmacies to distribute its products to end customers. The Company pays the wholesalers and certain specialty pharmacies a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid to the customers and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prompt Pay Discounts: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's customers are contractually permitted to return the product within the contractual allowable time before and after the applicable expiration date. In the initial sales period, the Company estimates its provision for returns based on industry data and adjusts the transaction price at the time of the product sale to the customer. Once sufficient history has been collected for product returns, the Company will utilize that history to inform its returns estimate. Once the product is returned, it is destroyed since it cannot be resold.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A chargeback is the difference between the Company's invoice price to the wholesaler and the wholesaler&#x2019;s customer's contract price. The wholesaler tracks these sales and charges back the Company for the difference between the negotiated prices paid between the wholesaler's customers and wholesaler's acquisition cost. The Company estimates the percentage of goods sold that are eligible for chargeback and adjusts the transaction price and accounts receivable at the time of sale of the product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patients who meet certain eligibility requirements may receive co-payment assistance. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accrues rebates for contractually agreed-upon discounts with commercial insurance companies and mandated discounts under government programs such as the Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Program, and other government health care programs in the U.S. The Company's estimates for expected utilization of commercial insurance rebates are based on data received from its customers. The Company's estimates for rebates under government programs are based on statutory discount rates and expected utilization as well as historical data it has accumulated since product launch. The Company&#x2019;s rebate calculations may require estimates, including estimates of customer mix, to determine which product sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to revenue in the period identified. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual rebates vary from estimates, the Company may need to adjust accruals, which would affect product sales, net in the period of adjustment. An accrued liability is recorded for unpaid rebates related to product for which control has transferred to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(ii) License Fees and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;China Out-License &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss has historically primarily related to the China Out-License that allows the third-party licensee to market the Company's TP-03 product candidate (representing functional intellectual property) in the People's Republic of China, Hong &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kong, Macau, and Taiwan (the "China Territory")&#x2014; see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract; (b) the contract&#x2019;s transaction price for allocation (including variable consideration); (c) the stand-alone selling price for each identified performance obligation; and (d) the timing and amount of revenue recognition in each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The China Out-License was analyzed under GAAP to determine whether the promised goods or services are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is not distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The China Out-License arrangement included the following forms of consideration: (i) non-refundable upfront license payment; (ii) equity-based consideration; (iii) sales-based royalties; (iv) sales-based threshold milestones; (v) one-time payment for executing a drug supply agreement; (vi) development milestone payments; (vii) regulatory milestone payments; and (viii) a one-time termination payment to transition the rights to develop and commercialize TP-03 in China for the treatment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Demodex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; blepharitis to Xi An Grand Chang An Pharmaceutical Co., Ltd  ("GrandPharma"). Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Terms for Receipt of Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#x2019;s transaction price is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual terms that establish the Company&#x2019;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Upfront License Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the China Out-License. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company utilizes the most likely amount method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be constrained until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company utilizes the most likely amount method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the sales-or-usage-based royalty exception the Company recognizes revenue based on the contractual percentage of the licensee&#x2019;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from the China Out-License.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales Threshold Milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Similar to royalties, applying the sales-or-usage-based royalty exception, the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from the China Out-License. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other License Fees and Collaboration Revenue&lt;/span&gt;&lt;/div&gt;License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:Revenues contextRef="c-57" decimals="-5" id="f-323" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-58" decimals="-5" id="f-324" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-325">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists of direct and indirect costs related to the manufacturing and distribution of XDEMVY, including raw materials, third-party manufacturing costs, packaging services, freight, third-party royalties payable on the Company&#x2019;s product sales, net and amortization of capitalized intangible assets associated with XDEMVY. Cost of sales may also include period costs related to certain inventory warehouse and distribution operations and inventory adjustment charges. The Company began capitalizing inventory costs upon FDA approval of XDEMVY in July 2023. Prior to FDA approval of XDEMVY, manufacturing and other inventory costs were recorded to research and development expenses in the Condensed Statements of Operations and Comprehensive Loss. Therefore, cost of sales of XDEMVY will reflect a lower average per unit cost until the related inventory is sold.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-326">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative costs consist of salaries, benefits, stock-based compensation and other personnel-related costs for the Company's executive, finance, sales and marketing, and other administrative functions. Selling, general and administrative expenses also include sales and marketing costs to support our commercial launch, consulting fees, legal services, rent and other facilities costs, patient assistance donations, and other general operating expenses not otherwise classified as research and development expenses. Advertising costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-327">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. Research and development expenses include internal costs directly attributable to in-development programs, including the costs of salaries, payroll taxes, employee benefit and other employee-related costs (including stock-based compensation expense), license fees, materials, supplies and the cost of services provided by outside contractors to conduct nonclinical studies, clinical trials and contract manufacturing activities. All costs associated with research and development are expensed as incurred. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with agreements established with third-party service &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;providers under the service agreements. As it relates to clinical trials, the financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Such payments are evaluated for current or long-term classification based on when they will be realized. The Company's objective is to reflect the appropriate expense in its financial statements by matching those expenses with the period in which the services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial taking into consideration discussions with applicable personnel and outside service providers. The clinical trial accrual is dependent in part upon the timely and accurate reporting of progress and efforts incurred from contract research organizations ("CROs"), contract manufacturers and other third-party vendors. Although estimates are expected to be materially consistent with actual amounts incurred, the Company's understanding of the status and timing of services performed relative to the actual status and timing of services performed can vary and may result in changes in estimates in any particular period. The Company makes significant judgments and estimates in determining the accrued liabilities balance at each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into, and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company's license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense in the Condensed Statements of Operations and Comprehensive Loss when paid or become payable, provided there is no alternative future use of rights in other research and development projects.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-328">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. Stock option awards are at an exercise price of not less than 100% of the fair market value of common stock on the respective date of grant. The grant date is the date the terms of the award are formally approved by the Company&#x2019;s Board of Directors or its designee. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing market price of the Company's common stock on the date preceding the award grant date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock awards granted typically have &lt;span style="-sec-ix-hidden:f-330"&gt;one&lt;/span&gt; to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#x2019;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#x2019;s judgment, including (a) the fair value of the Company&#x2019;s common stock on the date of the option grant for all awards granted prior to the IPO, (b) the expected term of the stock option until its exercise by the recipient, (c) stock price volatility over the expected term, (d) the prevailing risk-free interest rate over the expected term, and (e) expected dividend payments over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock-based compensation expense is reported in the accompanying Condensed Statements of Operations and Comprehensive Loss within cost of sales, research and development expense or selling, general and administrative expense, based upon the assigned department of the award recipient. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#x2019;s judgment, including:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The fair value of the Company&#x2019;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of the option grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock option awards are expected to be outstanding. Management estimates the expected term of awarded stock options utilizing the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term since the Company does not yet have sufficient exercise history.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Prior to 2023, the Company did not have sufficient trading history for its common stock to use its own historical volatility. Management estimated the expected volatility based on a designated peer-group of publicly-traded companies for a look-back period (from the date of grant) that corresponded with the expected term of the awarded stock option. Beginning in January 2023, the Company began using its own historical stock price for expected volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company estimates the risk-free interest rate based upon the U.S. Department of Treasury yield curve in effect at award grant date for the time period that corresponds with the expected term of the awarded stock option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-1" decimals="2" id="f-329" unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-60" id="f-331">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-61" id="f-332">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-333" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-334">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain due to the Company&#x2019;s historical operating performance and recorded cumulative net losses in prior fiscal periods. A valuation allowance is recorded to reduce deferred tax assets, because based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when the Company were to determine that deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase the net income in the period that such determination was made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-335">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method and if-converted method as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to net losses in all periods presented, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals diluted net loss per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents (i) net loss for the periods presented, and (ii) unrealized gains or losses on the Company's reported available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-337">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued or Effective Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#x2019;s financial statements have been discussed within the footnote to which each relates. Outside of the pronouncement below, other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#x2019;s management to have no impact, or an immaterial impact, on its current financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosure&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2023-09"). ASU 2023-09 requires annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold and a disaggregation of income taxes paid, net of refunds. The standard also eliminates certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities and is effective for the Company beginning with the 2025 Annual Report on Form 10-K. Early adoption is permitted. ASU 2023-09 should be applied prospectively. Retrospective adoption is permitted. The Company is currently assessing the impact this standard will have on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-338">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.672%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants (for LianBio shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Money Market Funds and U.S. Treasury Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded with readily-available market prices that are publicly observable and independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial Paper, Corporate Debt Securities and Government-related Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper, corporate debt securities and government-related debt securities were valued using Level 2 inputs that utilized industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The Company reviews trading activity and pricing for these investments as of each measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LianBio Common Stock and Equity Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, contemporaneous with the China Out-License transaction, the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, common shares in LianBio at an exercise price equal to common stock par value, which converted into warrants of the parent company of LianBio (a pharmaceutical company focused on the Greater China and other Asian markets; Nasdaq: LIAN; any references to common stock or warrants of LianBio shall refer to common stock or warrants of the publicly-traded parent of LianBio) in connection with LianBio's previous Initial Public Offering. The first two tranches were vested exercised, and converted into 156,746 shares of LianBio common stock as of December 31, 2022 and are recognized at fair value within long-term investments in the Condensed Balance Sheets as of March&#160;31, 2024 and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2024, LianBio announced its plan to wind down its operations. On March 14, 2024, LianBio's Board of Directors made a special cash dividend payment to the Company for $0.7&#160;million (equivalent to $4.80 per share), which was recorded to other income (expense) in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024, and cash and cash equivalents in the Condensed Balance Sheets as of March&#160;31, 2024. LianBio was delisted from NASDAQ in March 2024 and now trades on the over-the-counter markets. As of March&#160;31, 2024 and December 31, 2023, LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 26, 2024, the Company executed an agreement with LianBio to terminate the unvested third warrant tranche (the "Warrant Termination Agreement") for a cancellation payment of $0.4&#160;million (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Upon execution of the Warrant Termination Agreement the Company recorded the final change in fair value of the equity warrant to other income (expense) in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024, and removed the equity warrant from other assets in the Condensed Balance Sheet as of March&#160;31, 2024. The third tranche of the equity warrant was classified as Level 3 in the fair value hierarchy and presented within other assets in the accompanying Condensed Balance Sheets as of December&#160;31, 2023. The most significant assumptions used in the option pricing valuation model as of each balance sheet date to determine its fair value included observable and unobservable inputs: LianBio common stock volatility (based on the historical volatility of similar companies); the probability of regulatory milestone achievement for vesting; and the application of an assumed discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the equity warrants were remeasured each reporting period with adjustments reported within other income (expense) on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised, expired or terminated. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.504%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.563%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remeasurement of equity warrants prior to termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Termination of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.542%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remeasurement of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and available-for-sale investments by major security type are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1 ) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, substantially all available-for-sale debt securities had a maturity of 12 months or less. Four securities have a contractual maturity between &lt;span style="-sec-ix-hidden:f-460"&gt;one&lt;/span&gt; and two years, with an estimated fair market value of $20.6&#160;million and amortized cost of $20.6&#160;million. As of December&#160;31, 2023, all available-for-sale debt securities had a maturity of 12 months or less. As of March&#160;31, 2024 and December&#160;31, 2023, the Company had twenty-six available-for-sale debt securities and one available-for-sale debt security, respectively, in a continuous gross unrealized loss position for less than one year. As of March&#160;31, 2024 and December&#160;31, 2023, unrealized credit losses on these securities were not material. Further, the Company does not intend to sell these investments prior to maturity and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis. Accordingly, the Company did not recognize any other-than-temporary impairment losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="c-1" id="f-339">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.672%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants (for LianBio shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-62" decimals="-3" id="f-340" unitRef="usd">186744000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-341" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-342" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-343" unitRef="usd">186744000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-66" decimals="-3" id="f-344" unitRef="usd">31812000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-67" decimals="-3" id="f-345" unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-68" decimals="-3" id="f-346" unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-69" decimals="-3" id="f-347" unitRef="usd">31812000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-70" decimals="-3" id="f-348" unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-71" decimals="-3" id="f-349" unitRef="usd">30828000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-72" decimals="-3" id="f-350" unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-73" decimals="-3" id="f-351" unitRef="usd">30828000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-74" decimals="-3" id="f-352" unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-75" decimals="-3" id="f-353" unitRef="usd">25490000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-76" decimals="-3" id="f-354" unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-77" decimals="-3" id="f-355" unitRef="usd">25490000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-78" decimals="-3" id="f-356" unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-79" decimals="-3" id="f-357" unitRef="usd">23604000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-80" decimals="-3" id="f-358" unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-81" decimals="-3" id="f-359" unitRef="usd">23604000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-82" decimals="-3" id="f-360" unitRef="usd">46000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-83" decimals="-3" id="f-361" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-84" decimals="-3" id="f-362" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-363" unitRef="usd">46000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-82" decimals="-3" id="f-364" unitRef="usd">218602000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-83" decimals="-3" id="f-365" unitRef="usd">79922000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-84" decimals="-3" id="f-366" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-367" unitRef="usd">298524000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-368" unitRef="usd">224947000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-86" decimals="-3" id="f-369" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-87" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-88" decimals="-3" id="f-371" unitRef="usd">224947000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-89" decimals="-3" id="f-372" unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-90" decimals="-3" id="f-373" unitRef="usd">2495000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-91" decimals="-3" id="f-374" unitRef="usd">0</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents contextRef="c-92" decimals="-3" id="f-375" unitRef="usd">2495000</tars:DebtSecuritiesAvailableForSaleAndCashAndCashEquivalents>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-93" decimals="-3" id="f-376" unitRef="usd">631000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-94" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-95" decimals="-3" id="f-378" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-379" unitRef="usd">631000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <tars:EquityWarrantsFairValueDisclosure contextRef="c-93" decimals="-3" id="f-380" unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-381" unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure contextRef="c-95" decimals="-3" id="f-382" unitRef="usd">225000</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">225000</tars:EquityWarrantsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-93" decimals="-3" id="f-384" unitRef="usd">225578000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-385" unitRef="usd">2495000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-95" decimals="-3" id="f-386" unitRef="usd">225000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-387" unitRef="usd">228298000</us-gaap:AssetsFairValueDisclosure>
    <tars:WarrantAgreementNumberOfTranches
      contextRef="c-96"
      decimals="INF"
      id="f-388"
      unitRef="tranche">3</tars:WarrantAgreementNumberOfTranches>
    <tars:NumberOfVestedWarrants
      contextRef="c-26"
      decimals="INF"
      id="f-389"
      unitRef="warrant">2</tars:NumberOfVestedWarrants>
    <tars:EquitySecuritiesFVNINumberOfShares contextRef="c-26" decimals="0" id="f-390" unitRef="shares">156746</tars:EquitySecuritiesFVNINumberOfShares>
    <us-gaap:DividendsCommonStockCash contextRef="c-97" decimals="-5" id="f-391" unitRef="usd">700000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-97"
      decimals="2"
      id="f-392"
      unitRef="usdPerShare">4.80</us-gaap:CommonStockDividendsPerShareCashPaid>
    <tars:ProceedsFromCancellationOfWarrants contextRef="c-98" decimals="-5" id="f-393" unitRef="usd">400000</tars:ProceedsFromCancellationOfWarrants>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-394">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the equity warrants were remeasured each reporting period with adjustments reported within other income (expense) on the accompanying Condensed Statements of Operations and Comprehensive Loss, until exercised, expired or terminated. These equity warrants are valued in the accompanying Condensed Financial Statements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.504%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.563%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remeasurement of equity warrants prior to termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Termination of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.542%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remeasurement of equity warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-4" decimals="-3" id="f-395" unitRef="usd">225000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-99" decimals="-3" id="f-396" unitRef="usd">-201000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-1" decimals="-3" id="f-397" unitRef="usd">24000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-3" decimals="-3" id="f-398" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-26" decimals="-3" id="f-399" unitRef="usd">108000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-9" decimals="-3" id="f-400" unitRef="usd">-17000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-35" decimals="-3" id="f-401" unitRef="usd">91000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock contextRef="c-1" id="f-402">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and available-for-sale investments by major security type are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government-related debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1 ) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-65" decimals="-3" id="f-403" unitRef="usd">186744000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-404" unitRef="usd">186744000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-69" decimals="-3" id="f-405" unitRef="usd">3484000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-406" unitRef="usd">3484000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-73" decimals="-3" id="f-407" unitRef="usd">3478000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-100" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-100" decimals="-3" id="f-409" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-410" unitRef="usd">3477000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-411" unitRef="usd">193706000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-101" decimals="-3" id="f-412" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-101" decimals="-3" id="f-413" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-414" unitRef="usd">193705000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-69" decimals="-3" id="f-415" unitRef="usd">28341000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-69" decimals="-3" id="f-416" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-69" decimals="-3" id="f-417" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-69" decimals="-3" id="f-418" unitRef="usd">28328000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-73" decimals="-3" id="f-419" unitRef="usd">27374000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-73" decimals="-3" id="f-420" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-73" decimals="-3" id="f-421" unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-73" decimals="-3" id="f-422" unitRef="usd">27351000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-77" decimals="-3" id="f-423" unitRef="usd">25509000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-77" decimals="-3" id="f-424" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-77" decimals="-3" id="f-425" unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-77" decimals="-3" id="f-426" unitRef="usd">25490000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-81" decimals="-3" id="f-427" unitRef="usd">23613000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-81" decimals="-3" id="f-428" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-81" decimals="-3" id="f-429" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-81" decimals="-3" id="f-430" unitRef="usd">23604000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-102" decimals="-3" id="f-431" unitRef="usd">1108000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-102" decimals="-3" id="f-432" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-102" decimals="-3" id="f-433" unitRef="usd">1062000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-102" decimals="-3" id="f-434" unitRef="usd">46000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-435" unitRef="usd">105945000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-436" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-437" unitRef="usd">1130000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-438" unitRef="usd">104819000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-88" decimals="-3" id="f-439" unitRef="usd">224947000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-88" decimals="-3" id="f-440" unitRef="usd">224947000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-441" unitRef="usd">224947000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-442" unitRef="usd">224947000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-92" decimals="-3" id="f-443" unitRef="usd">2496000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-92" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-92" decimals="-3" id="f-445" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="-3" id="f-446" unitRef="usd">2495000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-447" unitRef="usd">2496000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-448" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-449" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-450" unitRef="usd">2495000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-4" decimals="-3" id="f-451" unitRef="usd">1108000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain contextRef="c-103" decimals="-3" id="f-452" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-103" decimals="-3" id="f-453" unitRef="usd">477000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-454" unitRef="usd">631000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-4" decimals="-3" id="f-455" unitRef="usd">1108000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain contextRef="c-103" decimals="-3" id="f-456" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss contextRef="c-103" decimals="-3" id="f-457" unitRef="usd">477000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-458" unitRef="usd">631000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <tars:DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities
      contextRef="c-3"
      decimals="INF"
      id="f-459"
      unitRef="security">4</tars:DebtSecuritiesAvailableForSaleContractualMaturitiesGreaterThanTwelveMonthsNumberOfSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="c-105" id="f-461">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-106" decimals="-5" id="f-462" unitRef="usd">20600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-106" decimals="-5" id="f-463" unitRef="usd">20600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c-3"
      decimals="INF"
      id="f-464"
      unitRef="contract">26</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c-4"
      decimals="INF"
      id="f-465"
      unitRef="contract">1</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-466">BALANCE SHEET ACCOUNT DETAIL&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the three months ended March 31, 2024 and 2023 was $0.2 million and $0.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable and Other Accrued Liabilities&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and other accrued liabilities consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade accounts payable and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued product sales deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-467">&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-3" decimals="-3" id="f-468" unitRef="usd">2533000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-4" decimals="-3" id="f-469" unitRef="usd">2533000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-3" decimals="-3" id="f-470" unitRef="usd">677000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-3" id="f-471" unitRef="usd">392000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-3" decimals="-3" id="f-472" unitRef="usd">826000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-3" id="f-473" unitRef="usd">182000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-474" unitRef="usd">4036000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-475" unitRef="usd">3107000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-476">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-107" decimals="-3" id="f-477" unitRef="usd">1269000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-108" decimals="-3" id="f-478" unitRef="usd">1251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-109" decimals="-3" id="f-479" unitRef="usd">681000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-110" decimals="-3" id="f-480" unitRef="usd">660000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-111" decimals="-3" id="f-481" unitRef="usd">168000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-112" decimals="-3" id="f-482" unitRef="usd">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-113" decimals="-3" id="f-483" unitRef="usd">680000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-114" decimals="-3" id="f-484" unitRef="usd">680000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-485" unitRef="usd">2798000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-486" unitRef="usd">2758000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-487" unitRef="usd">1460000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-488" unitRef="usd">1290000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-489" unitRef="usd">1338000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-490" unitRef="usd">1468000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-491" unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-9" decimals="-5" id="f-492" unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and other accrued liabilities consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade accounts payable and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued product sales deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c-3" decimals="-3" id="f-494" unitRef="usd">19142000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c-4" decimals="-3" id="f-495" unitRef="usd">18149000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedSalesCommissionCurrent contextRef="c-3" decimals="-3" id="f-496" unitRef="usd">16382000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent contextRef="c-4" decimals="-3" id="f-497" unitRef="usd">4867000</us-gaap:AccruedSalesCommissionCurrent>
    <tars:AccruedClinicalStudiesCurrent contextRef="c-3" decimals="-3" id="f-498" unitRef="usd">461000</tars:AccruedClinicalStudiesCurrent>
    <tars:AccruedClinicalStudiesCurrent contextRef="c-4" decimals="-3" id="f-499" unitRef="usd">277000</tars:AccruedClinicalStudiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-500" unitRef="usd">585000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-501" unitRef="usd">398000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-502" unitRef="usd">36570000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-503" unitRef="usd">23691000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-504">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Outstanding and Reserves for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the Company had 37,749,468 shares of common stock issued and outstanding, which excludes 312,500 of pre-funded warrants that remain exercisable at period end and are reserved for future issuance. As of December&#160;31, 2023 the Company had 34,211,190 shares of common stock issued and outstanding, respectively. Each share of common stock is entitled to one vote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,435,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,054,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,217,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,760,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,708,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,494,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,382,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.885%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.542%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per stock option&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity during the three months ended March 31, 2024 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price/Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,760,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;633,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(127,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding&#x2014; March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,217,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable&#x2014; March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,972,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested&#x2014;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,245,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock as of March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, there was approximately $33.0&#160;million of unrecognized compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average period of 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Unit Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity during the three months ended March 31, 2024 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price/Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,708,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(207,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding&#x2014; March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, there was approximately $41.0&#160;million of unrecognized compensation expense related to unvested restricted stock units, which the Company expects to recognize over a weighted average period of 3.5 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan ("ESPP")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to the ESPP was $0.2 million and $0.1 million, respectively, for the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-505" unitRef="shares">37749468</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="0" id="f-506" unitRef="shares">37749468</us-gaap:CommonStockSharesIssued>
    <tars:ClassOfWarrantOrRightReservedForFutureIssuance contextRef="c-3" decimals="INF" id="f-507" unitRef="shares">312500</tars:ClassOfWarrantOrRightReservedForFutureIssuance>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="0" id="f-508" unitRef="shares">34211190</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="0" id="f-509" unitRef="shares">34211190</us-gaap:CommonStockSharesOutstanding>
    <tars:CommonStockNumberOfVotes contextRef="c-3" decimals="INF" id="f-510" unitRef="vote">1</tars:CommonStockNumberOfVotes>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-511">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,435,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,054,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,859,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding (unvested and vested) under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,217,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,760,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,708,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,494,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,382,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant contextRef="c-3" decimals="INF" id="f-512" unitRef="shares">7435442</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant contextRef="c-4" decimals="INF" id="f-513" unitRef="shares">7054222</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan contextRef="c-3" decimals="INF" id="f-514" unitRef="shares">2859434</tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan contextRef="c-4" decimals="INF" id="f-515" unitRef="shares">2859434</tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding contextRef="c-3" decimals="INF" id="f-516" unitRef="shares">5217617</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding contextRef="c-4" decimals="INF" id="f-517" unitRef="shares">4760366</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant contextRef="c-3" decimals="INF" id="f-518" unitRef="shares">1981673</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant contextRef="c-4" decimals="INF" id="f-519" unitRef="shares">1708725</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-3" decimals="INF" id="f-520" unitRef="shares">17494166</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-4" decimals="INF" id="f-521" unitRef="shares">16382747</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-522">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was recognized in the accompanying Condensed Statements of Operations and Comprehensive Loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.885%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.542%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-115" decimals="-3" id="f-523" unitRef="usd">135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-116" decimals="-3" id="f-524" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="-3" id="f-525" unitRef="usd">1465000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-3" id="f-526" unitRef="usd">1163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-3" id="f-527" unitRef="usd">3919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="-3" id="f-528" unitRef="usd">2743000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-529" unitRef="usd">5519000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-9" decimals="-3" id="f-530" unitRef="usd">3906000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-531">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of granted stock options was estimated as of the date of grant using the Black-Scholes option-pricing model, based on the following inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per stock option&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-532">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-9" id="f-533">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-534" unitRef="number">0.0408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-9" decimals="4" id="f-535" unitRef="number">0.0420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-1" decimals="INF" id="f-536" unitRef="number">0.7123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-9" decimals="INF" id="f-537" unitRef="number">0.719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="2" id="f-538" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-9" decimals="2" id="f-539" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-540"
      unitRef="usdPerShare">35.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-9"
      decimals="2"
      id="f-541"
      unitRef="usdPerShare">15.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-542">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity during the three months ended March 31, 2024 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price/Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,760,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;633,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(127,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding&#x2014; March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,217,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable&#x2014; March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,972,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested&#x2014;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,245,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock as of March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-543" unitRef="shares">4760366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-544"
      unitRef="usdPerShare">16.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-103" id="f-545">P7Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-546" unitRef="usd">34128000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-547" unitRef="shares">633887</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-548"
      unitRef="usdPerShare">35.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-549" unitRef="shares">49310</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-550"
      unitRef="usdPerShare">16.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-551" unitRef="shares">127326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-552"
      unitRef="usdPerShare">18.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-553" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-554"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-555" unitRef="shares">5217617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">18.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-557">P7Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-558" unitRef="usd">96254000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-559" unitRef="shares">2972207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-560"
      unitRef="usdPerShare">15.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-561">P6Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-3" id="f-562" unitRef="usd">65826000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c-3" decimals="INF" id="f-563" unitRef="shares">2245410</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-3"
      decimals="2"
      id="f-564"
      unitRef="usdPerShare">23.22</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm contextRef="c-1" id="f-565">P8Y10M9D</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue contextRef="c-3" decimals="-3" id="f-566" unitRef="usd">30428000</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-5" id="f-567" unitRef="usd">33000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-121" id="f-568">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-569">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity during the three months ended March 31, 2024 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price/Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,708,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(207,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding&#x2014; March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-122" decimals="0" id="f-570" unitRef="shares">1708725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-122"
      decimals="2"
      id="f-571"
      unitRef="usdPerShare">16.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-123" decimals="0" id="f-572" unitRef="shares">596726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-123"
      decimals="2"
      id="f-573"
      unitRef="usdPerShare">36.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-123" decimals="0" id="f-574" unitRef="shares">207718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-123"
      decimals="2"
      id="f-575"
      unitRef="usdPerShare">16.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-123" decimals="0" id="f-576" unitRef="shares">116060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-123"
      decimals="2"
      id="f-577"
      unitRef="usdPerShare">17.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-124" decimals="0" id="f-578" unitRef="shares">1981673</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-124"
      decimals="2"
      id="f-579"
      unitRef="usdPerShare">22.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-124" decimals="-5" id="f-580" unitRef="usd">41000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-123" id="f-581">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-125" decimals="-5" id="f-582" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-126" decimals="-5" id="f-583" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-584">NET LOSS PER SHARE&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; table sets forth the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,300,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,742,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; Weighted-average shares outstanding includes pre-funded warrants issued on March 5, 2024.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options, unexercised&#x2014;vested and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,217,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,596,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&#x2014;unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,128,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,199,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,724,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-585">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; table sets forth the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,300,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,742,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; Weighted-average shares outstanding includes pre-funded warrants issued on March 5, 2024.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-586" unitRef="usd">-35731000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-587" unitRef="usd">-23419000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-588" unitRef="shares">35300655</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-589" unitRef="shares">35300655</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="0" id="f-590" unitRef="shares">26742023</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="0" id="f-591" unitRef="shares">26742023</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-592"
      unitRef="usdPerShare">-1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-593"
      unitRef="usdPerShare">-1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-594"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-595"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-596">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding and potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact under the treasury stock method and if-converted method would have been anti-dilutive for each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options, unexercised&#x2014;vested and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,217,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,596,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&#x2014;unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,128,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,199,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,724,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-127" decimals="0" id="f-597" unitRef="shares">5217617</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-128" decimals="0" id="f-598" unitRef="shares">4596414</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-129" decimals="0" id="f-599" unitRef="shares">1981673</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-130" decimals="0" id="f-600" unitRef="shares">1128373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-601" unitRef="shares">7199290</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-9" decimals="0" id="f-602" unitRef="shares">5724787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-603">COMMITMENTS&#160;&amp;amp; CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the ordinary course of business, the Company enters into lease agreements with unaffiliated third parties for its facilities and office equipment. On March 20, 2024, the Company executed an amendment for an additional office suite. This amendment was accounted for as a lease modification and resulted in the recognition of an operating lease right-of-use asset valued at $0.4&#160;million as of the execution date. As of March&#160;31, 2024, the Company had six active leases for adjacent office and laboratory suites in Irvine, California with a lease term through January 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The below table summarizes the components of total lease expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the Company's facility leases had a remaining lease term of 2.8 years and a weighted-average incremental borrowing rate of 10%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;In-License Agreements for Lotilaner&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Elanco In-License Agreement for Skin and Eye Disease or Conditions in Humans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2019, the Company executed a license agreement with Elanco Tiergesundheit AG (&#x201c;Elanco&#x201d;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, a clinical milestone was triggered to Elanco under the Eye and Derm Elanco Agreement upon enrollment of the first patient in the Phase 2a Galatea trial, evaluating the potential treatment of rosacea. The related milestone payment of $1.0&#160;million was included in research and development expense in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has made cash payments to Elanco under the Eye and Derm Elanco Agreement comprised of $1.0&#160;million upfront upon contract execution in January 2019 and a total of $4.0&#160;million for three specified clinical milestone achievements in September 2020, April 2021, and March 2023, which were all recorded in research and development expense in the Condensed Statements of Operations and Comprehensive Loss. During 2023, a milestone of $4.0&#160;million was achieved and paid to Elanco upon the first commercial sale of XDEMVY in the U.S., which was recorded as an intangible asset in the Balance Sheet as of December 31, 2023. The Company is amortizing the intangible asset to cost of sales over its useful life of 10 years from the date of the first commercial sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is obligated to make further cash payments to Elanco of $2.0 million under the Eye and Derm Elanco Agreement upon achievement of the last clinical milestone in the treatment of human skin diseases using lotilaner and a maximum of $75.0 million for various commercial and sales threshold milestones for the treatment of human skin diseases and the treatment of blepharitis in humans using lotilaner. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company received certain types of payments from its sublicensees, it was obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license, which occurred in July 2023 with FDA approval of XDEMVY. As a result of the commercialization of XDEMVY, the Company began accruing royalties payable to Elanco during the third quarter of 2023, which are recorded to cost of sales in the accompanying Condensed Statement of Operations and Comprehensive Loss for the three months ended March 31, 2024, and accounts payable and other accrued liabilities in the accompanying Condensed Balance Sheets as of March&#160;31, 2024. Royalty expense during the three months ended March 31, 2024 was $1.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Elanco In-License Agreement for All Other Diseases or Conditions in Humans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company executed a license agreement with Elanco granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement"). In September 2020, the Company issued Elanco 222,460 shares of its common stock with an estimated fair value of $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made cash payments under the All Human Uses Elanco Agreement of $0.5 million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the potential treatment of Lyme disease. The Company is required to make further cash payments under this agreement upon the achievement of various clinical milestones up to an aggregate maximum of $4.0 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its product sales, net. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment agreements, including severance and change in control agreements, with six of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnities and Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities varies, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-131" decimals="-5" id="f-604" unitRef="usd">400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <tars:LesseeOperatingLeaseNumberOfLeaseContracts
      contextRef="c-3"
      decimals="INF"
      id="f-605"
      unitRef="contract">6</tars:LesseeOperatingLeaseNumberOfLeaseContracts>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-606">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The below table summarizes the components of total lease expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-607" unitRef="usd">179000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-9" decimals="-3" id="f-608" unitRef="usd">170000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-609" unitRef="usd">103000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-9" decimals="-3" id="f-610" unitRef="usd">81000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-611" unitRef="usd">282000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-9" decimals="-3" id="f-612" unitRef="usd">251000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-613">P2Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="2" id="f-614" unitRef="number">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-615">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-616" unitRef="usd">660000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-617" unitRef="usd">961000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-618" unitRef="usd">994000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-619" unitRef="usd">83000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-620" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-621" unitRef="usd">2698000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-622" unitRef="usd">343000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <tars:LesseeOperatingLeaseLiabilityTenantImprovementAllowance contextRef="c-3" decimals="-3" id="f-623" unitRef="usd">164000</tars:LesseeOperatingLeaseLiabilityTenantImprovementAllowance>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-624" unitRef="usd">2191000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-625" unitRef="usd">585000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-626" unitRef="usd">1606000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-627" unitRef="usd">2191000</us-gaap:OperatingLeaseLiability>
    <tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment contextRef="c-132" decimals="-5" id="f-628" unitRef="usd">1000000</tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment>
    <tars:CollaborativeArrangementRightsAndObligationsUpfrontPayment contextRef="c-133" decimals="-5" id="f-629" unitRef="usd">1000000</tars:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment contextRef="c-134" decimals="-5" id="f-630" unitRef="usd">4000000</tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment>
    <tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment contextRef="c-135" decimals="-5" id="f-631" unitRef="usd">4000000</tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-48" id="f-632">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <tars:CollaborativeArrangementFutureCashPayments contextRef="c-136" decimals="-5" id="f-633" unitRef="usd">2000000</tars:CollaborativeArrangementFutureCashPayments>
    <tars:CollaborativeArrangementMaximumMilestonePayment contextRef="c-136" decimals="-5" id="f-634" unitRef="usd">75000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <us-gaap:RoyaltyExpense contextRef="c-137" decimals="-5" id="f-635" unitRef="usd">1200000</us-gaap:RoyaltyExpense>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-138"
      decimals="INF"
      id="f-636"
      unitRef="shares">222460</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-138" decimals="-5" id="f-637" unitRef="usd">3100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharePrice
      contextRef="c-139"
      decimals="INF"
      id="f-638"
      unitRef="usdPerShare">14.0003</us-gaap:SharePrice>
    <tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment contextRef="c-140" decimals="-5" id="f-639" unitRef="usd">500000</tars:CollaborativeArrangementRightsAndObligationsContractualMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment contextRef="c-141" decimals="-5" id="f-640" unitRef="usd">4000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment contextRef="c-142" decimals="-5" id="f-641" unitRef="usd">77000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:NumberOfEmploymentArrangementsWithExecutiveOfficers
      contextRef="c-3"
      decimals="INF"
      id="f-642"
      unitRef="contract">6</tars:NumberOfEmploymentArrangementsWithExecutiveOfficers>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-643">OUT-LICENSE AGREEMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License of TP-03 Commercial Rights in the China Territory in March 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into the China Out-License agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the China Territory for the treatment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Demodex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; blepharitis and Meibomian Gland Disease. LianBio was contractually responsible for all clinical development and commercialization activities and costs within the China Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed this arrangement and identified the following material promises under the arrangement: (i) the exclusive license to research, develop, manufacture, commercialize, make, offer for sale, sell, and import TP-03 in the China Territory; and (ii) the research and development services in the form of clinical study materials for the respective Phase 2b/3 trial ("Saturn-1") and Phase 3 ("Saturn-2") TP-03 trials. The promises to provide research and development services for Saturn-1 and Saturn-2 clinical trials were evaluated and determined to be distinct promises in the contract and each of the two clinical trials are separate performance obligations apart from the promise to provide the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assessment of the initial transaction price for the China Out-License agreement included an analysis of amounts the Company expected to receive, which at contract inception consisted of: (i) the upfront cash payment of $15.0&#160;million; (ii) a second cash payment of $10.0&#160;million; (iii) a $10.0&#160;million milestone that was determined to be within the control of the Company; and (iv) $1.2&#160;million representing the initial fair value of the equity warrant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for each performance obligation as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that this license was distinct based on an evaluation of the delivery of the functional license that was in the later stages of development, and it met the criteria for being distinct from the research and development services required under the China Out-License agreement. The Company determined the standalone selling price of this license using a discounted projected sales model and recognized as license fees and collaboration revenue the total allocated transaction price at contract inception, upon delivery of the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Services &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The standalone selling price of these performance obligations was determined using the adjusted market assessment approach. The Company analyzed costs expected to be incurred for each of the clinical trials through completion to estimate the price that a customer would be willing to pay for these services in order to benefit from the clinical trials. The Company determined that LianBio simultaneously benefited from the research and development services that are satisfied over time, as they were able to request and access the clinical trial data at any point through the trial completion. Therefore, the Company recognized the amounts allocated to the respective research and development performance obligations for Saturn-1 and Saturn-2 within license fees and collaboration revenue as the research and development services were provided using an input method, based on the costs incurred for each clinical trial and the total costs expected to be incurred to satisfy each performance obligation. The Company believes this method most faithfully depicted its performance in transferring the promised services during the expected period of time that each clinical trial was ongoing. The Company monitored the expected completion dates for each clinical trial and updated its estimated time to completion at each reporting period, as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2023, a specified milestone event was triggered based upon the signing of an agreement for which the Company has no ongoing obligations, resulting in $2.5&#160;million recognized as license fees and collaboration revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2024, LianBio announced its plan to wind down its operations and on March 14, 2024 made a special cash dividend payment to the Company for $0.7&#160;million (equivalent to $4.80 per share - see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). On March 26, 2024, the Company executed an agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. ("GrandPharma"), a subsidiary of Grand Pharmaceutical Group Limited, and LianBio to transition the rights to develop and commercialize TP-03 in China for the treatment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Demodex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; blepharitis from LianBio to GrandPharma (the "Novation Agreement"). Upon execution of the Novation Agreement, the China Out-License agreement with LianBio was assigned to GrandPharma and a one-time payment of $2.5&#160;million (the "Termination Payment) was triggered and due to the Company from LianBio within fifteen days. This Termination Payment was recorded to license fees and collaboration revenue in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and to other receivables in the Condensed Balance Sheets as of March&#160;31, 2024, as the $2.5&#160;million cash payment was not yet received by the Company until April 5, 2024. The Novation Agreement amended the $15.0&#160;million future development milestone payable on China regulatory approval of the China Out-License agreement with a combined condition of patent issuance related to TP-03 in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the execution of the Novation Agreement, the Company entered into an agreement with LianBio to terminate the unvested third tranche of the equity warrants related to the purchase of 78,373 shares of LianBio common stock for a total cancellation payment of $0.4&#160;million (the "Warrant Cancellation Payment"). This Warrant Cancellation Payment was recorded to license fees and collaboration revenue in the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and other receivables in the Condensed Balance Sheets as of March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through March&#160;31, 2024, the Company received aggregate payments from LianBio totaling $83.2&#160;million, comprised of (i) initial consideration of $15.0&#160;million, (ii) $67.5&#160;million for the achievement of specified milestones, and (iii) $0.7&#160;million related to a special cash dividend.&lt;/span&gt;&lt;/div&gt;As of March&#160;31, 2024 the Company is eligible to receive further consideration from GrandPharma upon the achievement of additional TP-03 events, including: (i) additional regulatory and/or patent milestones of up to an aggregate of $20.0&#160;million; (ii) China-based TP-03 sales threshold milestone payments of up to an aggregate of $100.0&#160;million; and (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-143" decimals="-5" id="f-644" unitRef="usd">15000000</us-gaap:ContractWithCustomerLiability>
    <tars:RevenueRemainingPerformanceObligationAdditionalCashPayment contextRef="c-143" decimals="-5" id="f-645" unitRef="usd">10000000</tars:RevenueRemainingPerformanceObligationAdditionalCashPayment>
    <tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-144" decimals="-5" id="f-646" unitRef="usd">10000000</tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-143" decimals="-5" id="f-647" unitRef="usd">1200000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-145" decimals="-5" id="f-648" unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DividendsCommonStockCash contextRef="c-97" decimals="-5" id="f-649" unitRef="usd">700000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-97"
      decimals="2"
      id="f-650"
      unitRef="usdPerShare">4.80</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-5" id="f-651" unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <tars:TerminationPaymentPeriodDue contextRef="c-98" id="f-652">P15D</tars:TerminationPaymentPeriodDue>
    <us-gaap:ContractWithCustomerLiability contextRef="c-146" decimals="-5" id="f-653" unitRef="usd">2500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-143" decimals="-5" id="f-654" unitRef="usd">15000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-147" decimals="0" id="f-655" unitRef="shares">78373</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <tars:ProceedsFromCancellationOfWarrants contextRef="c-98" decimals="-5" id="f-656" unitRef="usd">400000</tars:ProceedsFromCancellationOfWarrants>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-148" decimals="-5" id="f-657" unitRef="usd">83200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <tars:UpfrontPayment contextRef="c-149" decimals="-5" id="f-658" unitRef="usd">15000000</tars:UpfrontPayment>
    <tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-150" decimals="-5" id="f-659" unitRef="usd">67500000</tars:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <us-gaap:DividendsCommonStockCash contextRef="c-151" decimals="-5" id="f-660" unitRef="usd">700000</us-gaap:DividendsCommonStockCash>
    <tars:CollaborativeArrangementMaximumMilestonePayment contextRef="c-152" decimals="-5" id="f-661" unitRef="usd">20000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment contextRef="c-153" decimals="-5" id="f-662" unitRef="usd">100000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-663">CREDIT FACILITY AGREEMENT&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2022, the Company executed the Credit Facility with Hercules and SVB that expires on February 2, 2027. As security for the obligations under the agreement, the Company granted a continuing security interest in substantially all of the Company's assets, excluding intellectual property on which there is a negative pledge. Concurrent with the execution of the Credit Facility, the Company made a $20.0&#160;million draw.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2023, the Company entered into an amendment to the loan and security agreement (the "First Amendment"). The First Amendment set a maximum interest rate, and updated the terms of prepayment under the Credit Facility and other certain specific conditions, including an extended period for the Company to drawdown the $25.0&#160;million tranche associated with the New Drug Application ("NDA") submission from March 15, 2023 to March 15, 2024, provided at least $5.0&#160;million was drawn on or before March 15, 2023 and at least an additional $5.0&#160;million was drawn on or before September 15, 2023. The Company did not incur any lender fees as part of this First Amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 23, 2023, the Company entered into a second amendment to the loan and security agreement (the "Second Amendment"). The Second Amendment updated the terms of the amount and proportion of the Company&#x2019;s cash required to be maintained at SVB or affiliates of SVB. The Company did not incur any lender fees as part of this Second Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 15, 2023 and September 15, 2023, respectively, the Company made separate draws of $5.0&#160;million (including SVB's commitment of $1.25&#160;million) from the $25.0&#160;million tranche that became available upon submission of the NDA. On March 15, 2024, the $15.0&#160;million tranche related to the Company's NDA submission with the FDA for TP-03 in September 2022 and the $35.0&#160;million tranche related to the FDA approval of XDEMVY in July 2023 both expired and were no longer available to be drawn as of period end. As of March&#160;31, 2024, the Credit Facility provides for a remaining aggregate principal amount of up to $75.0&#160;million with tranched availability as follows: $50.0&#160;million available upon achievement of product sales, net thresholds; and $25.0&#160;million available upon lender approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these tranches may be drawn down in $5.0&#160;million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the First Amendment, the outstanding principal draws accrue interest at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus 4.45% with an aggregate cap of 11.45%, or (ii) 8.45%. At the execution date of the Credit Facility, the WSJ prime rate was 3.25% and increased to 8.50% as of March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay a specified fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.4 million was derived by multiplying 4.75% by the $30.0&#160;million outstanding principal balance as of March&#160;31, 2024 and is accreted to interest expense through maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024 and 2023, the effective interest rate for the full term of the Credit Facility was 11.96% and 12.12%, respectively. The Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense for term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of end of term charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense related to term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Credit Facility consists of principal outstanding less legal and administrative issuance costs that were recorded as a debt discount to the term loan, net and will continue to be accreted to interest expense using the effective interest method during its term. The principal balance of this Credit Facility and related accretion and amortization are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of end of term charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-154" decimals="-5" id="f-664" unitRef="usd">20000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-155" decimals="-5" id="f-665" unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <tars:LineOfCreditFacilityDrawDownIncrements contextRef="c-156" decimals="-5" id="f-666" unitRef="usd">5000000</tars:LineOfCreditFacilityDrawDownIncrements>
    <tars:LineOfCreditFacilityDrawDownIncrements contextRef="c-156" decimals="-6" id="f-667" unitRef="usd">5000000</tars:LineOfCreditFacilityDrawDownIncrements>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-157" decimals="-5" id="f-668" unitRef="usd">5000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-158" decimals="-5" id="f-669" unitRef="usd">5000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-159" decimals="-4" id="f-670" unitRef="usd">1250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-160" decimals="-4" id="f-671" unitRef="usd">1250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-155" decimals="-5" id="f-672" unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-161" decimals="-5" id="f-673" unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-162" decimals="-5" id="f-674" unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-163" decimals="-5" id="f-675" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-164" decimals="-5" id="f-676" unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-165" decimals="-5" id="f-677" unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <tars:LineOfCreditFacilityDrawDownIncrements contextRef="c-166" decimals="-5" id="f-678" unitRef="usd">5000000</tars:LineOfCreditFacilityDrawDownIncrements>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-167" decimals="4" id="f-679" unitRef="number">0.0445</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-168" decimals="4" id="f-680" unitRef="number">0.1145</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-166" decimals="4" id="f-681" unitRef="number">0.0845</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="c-154" decimals="4" id="f-682" unitRef="number">0.0325</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="c-169" decimals="4" id="f-683" unitRef="number">0.0850</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentInterest contextRef="c-169" decimals="-5" id="f-684" unitRef="usd">1400000</us-gaap:LineOfCreditFacilityPeriodicPaymentInterest>
    <tars:LineOfCreditFacilityPeriodicPaymentInterestRate contextRef="c-166" decimals="4" id="f-685" unitRef="number">0.0475</tars:LineOfCreditFacilityPeriodicPaymentInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-3" decimals="-3" id="f-686" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-163"
      decimals="INF"
      id="f-687"
      unitRef="number">0.1196</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-170"
      decimals="INF"
      id="f-688"
      unitRef="number">0.1212</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="c-1" id="f-689">The Company recognized interest expense on the accompanying Condensed Statements of Operations and Comprehensive Loss in connection with the Credit Facility as follows:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.031%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense for term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of end of term charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense related to term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-1" decimals="-3" id="f-690" unitRef="usd">869000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-9" decimals="-3" id="f-691" unitRef="usd">602000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-3" id="f-692" unitRef="usd">80000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-9" decimals="-3" id="f-693" unitRef="usd">53000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-694" unitRef="usd">34000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-9" decimals="-3" id="f-695" unitRef="usd">29000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-696" unitRef="usd">983000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-9" decimals="-3" id="f-697" unitRef="usd">684000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-698">The principal balance of this Credit Facility and related accretion and amortization are reported on a combined basis as term loan, net on the accompanying Condensed Balance Sheets as follows:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of end of term charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-3" decimals="-3" id="f-699" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-4" decimals="-3" id="f-700" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet contextRef="c-3" decimals="-3" id="f-701" unitRef="usd">875000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet contextRef="c-4" decimals="-3" id="f-702" unitRef="usd">875000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="c-3" decimals="-3" id="f-703" unitRef="usd">-517000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="c-4" decimals="-3" id="f-704" unitRef="usd">-438000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:AccumulatedAmortizationDeferredFinanceCosts contextRef="c-3" decimals="-3" id="f-705" unitRef="usd">291000</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
    <us-gaap:AccumulatedAmortizationDeferredFinanceCosts contextRef="c-4" decimals="-3" id="f-706" unitRef="usd">256000</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
    <us-gaap:LongTermDebt contextRef="c-3" decimals="-3" id="f-707" unitRef="usd">29933000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-708" unitRef="usd">29819000</us-gaap:LongTermDebt>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-709">RELATED PARTY TRANSACTIONS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consulting Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a preexisting consulting agreement with a board member who was appointed in December 2021. During the year ended December 31, 2023, this consulting agreement provided for annual cash compensation of approximately $0.2&#160;million and option grants to purchase 45,134 shares of the Company&#x2019;s common stock, with exercise prices ranging from $2.01 to $34.72 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 30, 2024, this consulting agreement with the board member was amended to provide for annual cash compensation of approximately $0.4&#160;million and an additional option grant to purchase 10,000 shares of the Company&#x2019;s common stock, with exercise price of $27.49 per share. This amended consulting agreement may be terminated by either party with ten days' notice and contains standard confidentiality, indemnification, and intellectual property assignment provisions in favor of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2024 and 2023, the Company recorded $0.1&#160;million and $0.1&#160;million, respectively, of selling, general and administrative expenses in the accompanying Condensed Statements of Operations and Comprehensive Loss related to this amended consulting agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sponsorship Activities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, a board member of the Company was appointed president of the American Society of Cataract and Refractive Surgery ("ASCRS"), a society dedicated to meeting the needs of anterior segment ophthalmic surgeons.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2024, the Company recorded $0.1&#160;million of selling, general and administrative expenses in the accompanying Condensed Statement of Operations and Comprehensive Loss for sponsorship and event-related activities associated with ASCRS.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <tars:RelatedPartyTransactionAnnualCashCompensation contextRef="c-171" decimals="-5" id="f-710" unitRef="usd">200000</tars:RelatedPartyTransactionAnnualCashCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-172"
      decimals="INF"
      id="f-711"
      unitRef="shares">45134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-173"
      decimals="2"
      id="f-712"
      unitRef="usdPerShare">2.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-174"
      decimals="2"
      id="f-713"
      unitRef="usdPerShare">34.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <tars:RelatedPartyTransactionAnnualCashCompensation contextRef="c-175" decimals="-5" id="f-714" unitRef="usd">400000</tars:RelatedPartyTransactionAnnualCashCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-176"
      decimals="INF"
      id="f-715"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-177"
      decimals="2"
      id="f-716"
      unitRef="usdPerShare">27.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <tars:RelatedPartTransactionTerminationNoticePeriod contextRef="c-176" id="f-717">P10D</tars:RelatedPartTransactionTerminationNoticePeriod>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-178" decimals="-5" id="f-718" unitRef="usd">100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-179" decimals="-5" id="f-719" unitRef="usd">100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-178" decimals="-5" id="f-720" unitRef="usd">100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-721">SUBSEQUENT EVENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility with Pharmakon Advisors, LP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 19, 2024, the Company executed a loan and security agreement (the "Pharmakon Credit Facility") with funds associated with Pharmakon Advisors, LP. The Company drew $75.0&#160;million in the initial tranche of the term loan in April 2024, a portion of which was utilized to repay all outstanding indebtedness on the existing Credit Facility term loan, resulting in total net proceeds of $39.8&#160;million. The agreement provides for three potential additional term loan tranches in principal amounts up to $25.0&#160;million, $50.0&#160;million, and $50.0&#160;million, respectively, subject to customary conditions to funding and, in the case of the last two tranches, achieving minimum net sales milestones. The three potential additional term loan tranches may be requested on or prior to December 31, 2024, June 30, 2025 and December 31, 2025, respectively. The Pharmakon Credit Facility matures on April 19, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loan bears interest at a floating rate based upon the secured overnight financing rate ("SOFR"), plus a margin of 6.75% per annum, and the SOFR is subject to a 3.75% floor. The agreement contains representations and warranties, and affirmative and negative covenants in each case. There is also no warrant coverage to the lenders and no financial covenants associated with the financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Investment in Privately-held Eye Care Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:54pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2024, the Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;participated in an equity round of an early clinical-stage private eye care company. Pursuant to the terms of a Preferred Stock Purchase Agreement the Company purchased&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $3.0&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of preferred stock. Drs. Azamian and Link are board members and the Company's former director, Michael Ackermann, is an executive and board member of this private company. The Company owns a small minority of this private company.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-180" decimals="-6" id="f-722" unitRef="usd">75000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="c-181" decimals="-5" id="f-723" unitRef="usd">39800000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <tars:DebtInstrumentNumberOfPotentialAdditionalTranches
      contextRef="c-182"
      decimals="INF"
      id="f-724"
      unitRef="contract">3</tars:DebtInstrumentNumberOfPotentialAdditionalTranches>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-183" decimals="-6" id="f-725" unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-184" decimals="-6" id="f-726" unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-185" decimals="-6" id="f-727" unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <tars:DebtInstrumentNumberOfTranchesWithMilestoneRequirements
      contextRef="c-182"
      decimals="INF"
      id="f-728"
      unitRef="contract">2</tars:DebtInstrumentNumberOfTranchesWithMilestoneRequirements>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-186" decimals="4" id="f-729" unitRef="number">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <tars:DebtInstrumentFloorInterestRate contextRef="c-186" decimals="4" id="f-730" unitRef="number">0.0375</tars:DebtInstrumentFloorInterestRate>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-187" decimals="-6" id="f-731" unitRef="usd">3000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-732">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-733">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-734">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-188" id="f-735">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, Bobak Azamian, Chief Executive Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to 291,000 shares of common stock held by Dr. Azamian between August 23, 2023 and July 24, 2024. Dr. Azamian terminated the trading plan effective January 8, 2024.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-188" id="f-736">Bobak Azamian</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-188" id="f-737">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-189"
      decimals="INF"
      id="f-738"
      unitRef="shares">291000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-188" id="f-739">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrTerminationDate contextRef="c-188" id="f-740">January 8, 2024</ecd:TrdArrTerminationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-190" id="f-741">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, Jose Trevejo, former Chief Medical Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to 6,107 shares of common stock held by Dr. Trevejo between August 17, 2023 and May 16, 2024. Dr. Trevejo terminated the trading plan effective January 12, 2024.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-190" id="f-742">Jose Trevejo</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-190" id="f-743">former Chief Medical Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-191"
      decimals="INF"
      id="f-744"
      unitRef="shares">6107</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-190" id="f-745">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrTerminationDate contextRef="c-190" id="f-746">January 12, 2024</ecd:TrdArrTerminationDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
